FINAL PROGRAM - Imo

• WHERE ALL OF OPHTHALMOLOGY MEETS • 

FINAL 

PROGRAM 

2012 JOINT MEETING: 

NOVEMBER 10 – 13 

SUBSPECIALTY DAY: NOV. 9 – 10 

AAOE PROGRAM: NOV. 10 – 13

FALL INTO THE 

WINDY CITY 

Catch the leading experts in eye care at Allergan Booth #1408 

Saturday, November 10 

9:30 am 

Treatment of Macular Edema Due to 

Retinal Vein Occlusion 

Shree Kurup, MD 

10:00 am 

Treatment of Allergic Conjunctivitis 

Rajesh Rajpal, MD 

10:30 am 

Management of the Post-operative 

Cataract Surgery Patient 

Karl Stonecipher, MD 

11:00 am 

Treatment of Hypotrichosis 

Steve Yoelin, MD 

12:00 pm 

Detecting and Managing 

Glaucoma Progression 

Louis B. Cantor, MD 

12:30 pm 

RESCUE ME!—Interactive Cases 

Robert Osher, MD 

1:00 pm 

IOP Lowering: Options for Starting or 

Replacing Therapy 

Jonathan Myers, MD 

1:30 pm 

Conquering Capsule Complications— 

Strategies for Complicated Cataracts 

David Chang, MD 

2:00 pm 



Ron Gallemore, MD, PhD 

3:00 pm 

Focus on Dry Eye Disease 

Christopher Starr, MD, FACS 

3:30 pm 

Making Social Media “Work” for 

Your Practice 

Joe Casper, MBA, COE, OCS, 

Senior Eye Care Business Advisor, 

Allergan, Inc. 

Eric Abrantes, Marketing Director, 

Advanced Eye Centers 

Sunday, November 11 

9:30 am 

Management of the Small Pupil 

in Cataract Surgery 

Eric Donnenfeld, MD, FACS 

10:30 am 

REFRESH OPTIVE Advanced 

Marguerite McDonald, MD, FACS 

11:00 am 

IOP Reduction With Adjunctive Therapy 

Nathan Radcliffe, MD 

12:00 pm 

Treatment of Hypotrichosis 

Steve Yoelin, MD 

1:00 pm 

A Versatile Option in Adjunctive 

IOP Lowering 

E. Randy Craven, MD 

1:30 pm 



Michael Singer, MD 

2:00 pm 

Healthcare Reform: What Every 

Practice Should Know 

Mike Driscoll, OCS, Eye Care 

Business Advisor, Allergan, Inc. 

Jeffrey Lemay, Director, Healthcare 

Reform Initiative, Allergan, Inc. 

3:00 pm 

Adventures in Darkness 

Tom Sullivan 

Monday, November 12 

9:30 am 

Protecting Your Practice From Theft: 

Lessons Learned 

Jill Maher, MA, OCS, Eye Care Business 

Advisor, Allergan, Inc. 

11:00 am 

Successful Strategies for Effective 

EMR Implementation 

Sherri Boston, MBA, COE, OCS, 

Eye Care Business Advisor, 


Jane T. Shuman, COT, COE, OCS, 

EyeTechs and eyebuzz ® 

Jeff Grant, President & Founder, 

Healthcare Management & Automation 

Systems, Inc. 

12:30 pm 

Why You Can’t Ignore Social Media: As 

Featured in Ophthalmology Management 

Greg Raeman, COE, CCOA, OCS, Eye 

Care Business Advisor, Allergan, Inc. 

2:00 pm 

Keys to Attracting & Managing 

Talented Employees 

Jim Rienzo, OCS, Senior Eye Care 

Business Advisor, Allergan, Inc. 

Tom Pannullo, COO, Ophthalmic 

Consultants of Long Island 

©2012 Allergan, Inc., Irvine, CA 92612 mark owned by Allergan, Inc. eyebuzz is a registered service mark owned by Eyetechs, Inc. 

www.allergan.com APC67SF12 122420 Presentation times and speakers are subject to change. This event is not affiliated with the official program of the 2012 Joint Meeting.

Table of Contents 

2012 Joint Meeting Highlights.......................................................ix 

2012 Board of Trustees.................................................................xiii 

2012 Committee of Secretaries.................................................... xix 

The Council...................................................................................xxv 

Meeting Overview.......................................................................xxix 

Meeting Directory.......................................................................xxxv 

Shuttle Schedule........................................................................xxxix 

Awards 

Academy Laureate...........................................................................1 

Special Awards................................................................................4 

Secretariat Award..........................................................................15 

Achievement Award Program........................................................17 

International Awards.....................................................................28 

Visionary Society, Corporate and Organizational Donors .............29 

Courses and Breakfasts 

Selection Committees....................................................................33 

Programs-by-Day............................................................................35 

Breakfast With the Experts............................................................51 

Instruction Course Program...........................................................59 

Skills Transfer Program 

Skills Transfer Program General Information...............................113 

Skills Transfer Course Contributors.............................................114 

Skills Transfer Program................................................................115 

Sessions and Symposia 

Opening Session & Business Meeting........................................129 

Academy Café..............................................................................130 

Academy Spotlight Sessions & Symposia...................................131 

Papers / Posters / Videos 

Original Papers.............................................................................153 

Scientific Posters.........................................................................173 

VIdeo Program..............................................................................246 

Special Meetings and Events 

Special Meetings & Events.........................................................257 

Learning Lounge...........................................................................261 

Technology Pavilion......................................................................265 

AAOE Program / Practice Management 

AAOE Program.............................................................................281 

Coding Sessions...........................................................................282 

AAOE Instruction Courses............................................................283 

AAOE Special Meetings & Events...............................................296 

Exhibit Hall, Indexes 

Informational Posters...................................................................305 

Available Academy Services in the Exhibit Hall..........................307 

Indexes.........................................................................................308 

Exhibitor List................................................................................309 

Product Index...............................................................................313 

Participant Index..........................................................................323 

Participant Financial Disclosure Index.........................................333 

CME & CE Credit..........................................................................349 

CME Credit Statement.................................................................351 

Future Annual Meeting Dates and Locations..............................352 

P.O. Box 7424, San Francisco, CA 94120-7424 | Tel: 415-561-8500 Fax: 415-561-8533 

© 2012 American Academy of Ophthalmology. All rights reserved. 

No portion may be reproduced without express consent of the American Academy of Ophthalmology. 

Academy staff are available at the Academy Resource Center (Booth 508) to answer any questions you may have. 

i

Living up to Life 

Visit Booth #2739 for our program: 

Innovations in Leica Microsystems’ 

Surgical Microscopes & Video 

Saturday: 4:00 p.m. 

Sunday: 2:00 p.m. 

Monday: 4:15 p.m. 

• The New Leica M822 Surgical Microscope 

• Innovations in Ophthalmic Surgical Video 

Seenu M. Hariprasad, MD, University of Chicago 

• Surgical Video with TrueVision 3D 

Michael Saidel, MD, University of Chicago 

Meet us at AAO 2012 in Chicago, booth #2739 to Test Drive the Leica 

M822 Ultimate Red Reflex Surgical Microscope, or call 800-248-0123 

today to arrange your free demonstration. 

www.leica-microsystems.com/testdrive 

© 2012 Leica Microsystems, Inc. BGA#AAO

DURING THE AAO-APAO JOINT MEETING 

Here is just a sampling of the presentations that showcase the latest 

technologies in ophthalmology brought to you by Alcon, booth #2808. 

Saturday, Nov. 10 

9:30 AM 

Blepharitis: The New Consensus 

Stephen V. Scoper, MD 

11:00 AM 

The LenSx® Laser: Sphere and Cylinder 

Are Not Enough 

Paul Ernest, MD 

11:30 AM 

Alcon Advances for Today’s LASIK Surgery 

Sonny Goel, MD 

Charles Moore, MD 

12:30 PM 

Advanced Optical Biometry: Using the 

LENSTAR LS 900®* Optical Biometer with 

Toric IOLs, Strategies for Success 

Warren Hill, MD 

1:00 PM 

Methods to Manage Pre-Existing 

Corneal Astigmatism with Toric IOLs 

Edward J. Holland, MD 

Samuel Masket, MD 

1:30 PM 

Rethinking the Role of IOP in the Diagnosis and 

Management of Open-angle Glaucoma 

Matthew McMenemy, MD 

2:00 PM 

The LenSx® Laser: A New Cataract Procedure 

Stephen Lane, MD 

Satish Modi, MD 

Dan Tran, MD 

3:00 PM 

Multifocal IOLs: Setting Expectations for 

Presbyopic Patients 

Randy Epstein, MD 

Cathleen McCabe, MD 

3:30 PM 

Clinical Pearls to Adopting the 

Ex-PRESS®GFD 

Steve Vold, MD 

Sunday, Nov. 11 

11:00 AM 

Maximizing Success with the 

Ex-PRESS® Glaucoma Filtration Device 

Ike Ahmed, MD 

12:30 PM 

Multifocal IOLs: Setting Expectations for 

Presbyopic Patients 

William J. Lahners, MD 

Andrew Maxwell, MD 

1:00 PM 

Alcon Advances for Today’s 

LASIK Surgery 

Vance Thompson, MD 

1:30 PM 

Integrating the LenSx® Laser into 

Our Practice 

Michael P. Jones, MD 

Christa Garner, BA, CRC 

3:00 PM 

Methods to Manage Pre-Existing Corneal 

Astigmatism with Toric IOLs 

Gary Foster, MD 

Ehsan Sadri, MD 

3:30 PM 

Blepharitis: The New Consensus 

Stephen V. Scoper, MD 

Monday, Nov. 12 

10:00 AM 

The LenSx® Laser: A New Cataract Procedure 

Jerry Hu, MD 

Robert Lehmann, MD 

12:30 PM 

Alcon Advances for Today’s LASIK Surgery 

Joseph L. Parisi, MD 

1:30 PM 

My Experience with the Ex-PRESS® Glaucoma 

Filtration Device 

Jeff Goldberg, MD 

2:00 PM 

Optically Measured Lens Thickness in 

IOL Power Calculation 

Sheridan Lam, MD 

Presentations, presenters and 

times are subject to change. 

These presentations are not 

affiliated with the official 

program of the 2012 AAO- 

APAO Joint Meeting. 

For important safety information 

about the Alcon® products 

discussed in these presentations, 

please visit the Alcon booth. 

Scan for Alcon at the 

AAO Information 

*LENSTAR® is a registered trademark of Haag-Streit 

©2012 Novartis 9/12 MIX12422JAS

VISIT US AT 

ALLERGAN BOOTH #1408 

©2012 Allergan, Inc., Irvine, CA 92612 

® 

marks owned by Allergan, Inc. APC86OM12 122086 

restasisprofessional.com

Dedicated to 

advancing the 

treatment of eye 

diseases with 

unmet medical need 

Visit us at AAO/APAO Booth #1571 

ThromboGenics , a biopharmaceutical company focused on 

developing innovative ophthalmic medicines. 

11/12 

ThromboGenics, Inc. 101 Wood Avenue South, 6th Floor, Iselin, NJ 08830 - USA ©2012 ThromboGenics, Inc. 

All rights reserved. THROMBOGENICS and the THROMBOGENICS logo are trademarks or registered trademarks 

of ThromboGenics in the United States, European Union, Japan, and other countries. 

THRCOR002 A

800.787.5426 

haag-streit-usa.com 

Your Octopus 

data will connect 

with your satellite 

office 37,000 

times faster. 


Octopus connectivity launches a new era in perimetry. One 

where doctors are always linked in real time to crucial 

patient data. Wherever you are online, your expertise can 

go to work instantly. From a satellite office, exam room, or 

somewhere more far out. 

Call 1-800-787-5426 to schedule a demo. 

Powered by 

Visit us at AAO Booth #3808. 

The Superior Practice. 

© 2012 Haag-Streit USA. All Rights Reserved.

• 2012 Joint Meeting HIGHLIGHTS • 

Kick off the 

Joint Meeting 

The Opening Session 

Sunday, Nov. 11, 8:30 a.m. – 10 a.m. 

Stephen J Ryan MD will receive the 2012 Laureate 

Award for his distinguished career and contributions 

to ophthalmology. Dr. Ryan is currently the President of 

the Doheny Eye Institute and the Distinguished Grace 

and Emery Beardsley Professor at USC. Abraham Verghese 

MD MACP will deliver the Opening Session 

keynote address about the physician-patient relationship. 

Dr. Verghese is a renowned physician, bestselling 

author and professor for the theory and practice of 

medicine at Stanford University’s School of Medicine. 

Joan W Miller MD will give the Jackson Memorial 

Lecture: AMD Revisited—Piecing the Puzzle. Dr. Miller 

is the Henry Willard Williams Professor of Ophthalmology 

& Chair, Department of Ophthalmology, Harvard 

Medical School and the Chief of Ophthalmology, Massachusetts 

Eye and Ear Infirmary and Massachusetts 

General Hospital. She is preeminent in the field of 

ocular neovascularization. 

AAO-APAO Joint Symposia 

Join us for three joint symposia with the Asia-Pacific 

Academy of Ophthalmology (APAO): 

SYM05 Sunday, Nov. 11, 10:30 a.m. - 12:00 p.m. 

Corneal Stem Cell Advances in Clinical and Laboratory Research 

- international authorities will present on the topics of 

stem cells, the diagnosis of stem cell deficiency and interventions 

in clinical practice. Techniques currently emerging from 

the laboratory will be highlighted. 

SYM21 Monday, Nov. 12, 8:30 a.m. - 10:00 a.m. 

Ethnic Variations in Glaucoma Prevalence, Detection, and 

Treatment Outcomes – experts will discuss the role of race 

and ethnicity in glaucoma incidence, treatment and screening 

practices. 

SYM39 Tuesday, Nov. 13, 8:30 a.m. - 10:00 a.m. 

Management of Diabetic Retinopathy: East-West Perspectives 

– knowledgeable panelists will review new understanding of 

the epidemiology of, and trends in the management and clinical 

approaches to diabetic retinopathy, as well as how they differ 

between East and West. 

ix

• 2012 Joint Meeting HIGHLIGHTS • 

Turning the Spotlight On Four 

Hot Topics in Ophthalmology 

Be sure to make time for the four free Spotlight Sessions 

at the 2012 Joint Meeting: 

Spotlight on Innovation in Ophthalmology: From 

Theory to Therapy 

SPO1 Sunday, Nov. 11, 10:30 a.m. – 12:00 p.m., Grand 

Ballroom S100ab. Investigate the factors driving and influencing 

innovation in ophthalmology through six 10-minute 

presentations, followed by a Q&A session. 

Spotlight on Corneal Collagen Crosslinking 

SPO2 Sunday, Nov. 11, 2:00 p.m. – 3:30 p.m., Grand Ballroom 

S100ab. Discuss surgical treatment modalities utilized 

in US clinical trials and internationally, the clinical experience 

of basic science, indications, surgical technique and complications 

encountered with several CXL treatments for indications 

following refractive surgery. Then Continue the Conversation 

in the Learning Lounge, Booth 107 at 3:30 p.m. with R Doyle 

Stulting MD PhD and A John Kanellopoulos MD. 

Spotlight on Cataracts: Clinical Decision-making 

with Cataract Complications 

SPO3 Monday, Nov. 12, 8:15 a.m. – 12:15 p.m., North Hall 

B. Start off Cataract Monday by attending the presentation of 

seven video cases about the management of intra-operative 

challenges and complications. The session will conclude with 

the 8th annual Charles Kelman Lecture. Then Continue the 

Conversation in the Learning Lounge, Booth 107 at 1:45 p.m. 

where Douglas D Koch MD and Warren E Hill MD will moderate 

an interactive discussion. 

Spotlight on Pseudoexfoliation 

SPO4, Monday, Nov. 12, 4:15 p.m. – 5:30 p.m., North Hall 

B. Conclude Cataract Monday by exploring many of the challenges 

inherent to the exfoliation syndrome from the perspective 

of cataract and glaucoma management. This symposium 

will primarily examine important decision-making strategies 

pertaining to the timing of cataract surgery in patients with 

exfoliation. Clinical pearls to avoid and manage complications 

during cataract surgery will be discussed. 

x 

Not to Miss Returning Favorites 

The Great Debate 

SYM41 Monday, Nov. 12, 10:45 a.m. – 12:00 p.m., E450 

Five pairs of debators will argue the pros and cons of five controversial 

topics. Audience voting will determine which speakers 

were most effective. 

Late Breakers Symposium 

SYM25 Monday, Nov. 12, 2 – 3:30 p.m., Grand Ballroom S100c 

Topics will cover new technology and therapies as well as important 

issues and controversies that have come up within the last 

six months in the field of ophthalmology. 

Grand Rounds: Cases and Experts From Across the 

Nation 

SYM43 Monday, Nov. 12, 3:45 – 5:00 p.m., S406a 

Real residents from different academic programs present real 

cases from real department grand rounds. Cases are presented to 

a panel of experts followed by Q&A and discussion. 

Best of the Posterior Segment Specialty Meetings 2012 

SYM03 Sunday, Nov. 11 10:30 – 11:45 a.m., S406a 

This symposium will feature best papers focusing on the posterior 

segment from the major retina, neuro-ophthalmology, uveitis, 

oculoplastics and pediatric ophthalmology specialty meetings of 

2012. Continue the Conversation in the Learning Lounge, Booth 

107 at 12:00 p.m. 

Best of the Anterior Segment Specialty Meetings 2012 

SYM44 Tuesday, Nov 13 12:15 – 1:30 p.m., S406A 

This symposium will feature best papers focusing on the anterior 

segment from the major retina, neuro-ophthalmology, uveitis, 

oculoplastics and pediatric ophthalmology specialty meetings 

of 2012. 

Interactive Learning 

Learning Lounge, Booth 107 

All Joint Meeting attendees are welcome to gather at the Learning 

Lounge for informal, small group presentations and discussions 

on the hottest topics at the Joint Meeting. See page xx 

for a schedule, check the Mobile Meeting Guide, www.aao.org/ 

mobile or stop by the Learning Lounge.

Laser Refractive Cataract Surgery is 

Now a Reality with Alcon’s LenSx ® Laser. 

Cataract Surgery Will Change 

in a Femtosecond. 

With Alcon’s LenSx ® Laser, the Possibilities Have Just Begun. 

Delivering the precision of a femtosecond laser to Refractive Cataract Surgery, the LenSx ® Laser is designed to reproducibly perform many of the 

most challenging aspects of traditional cataract surgery. Creating highly reproducible capsulotomy, lens fragmentation and all corneal incisions 

including arcuate incisions with image-guided surgeon control, Alcon’s LenSx ® Laser is Putting the Future in Motion. 

CAUTION: United States Federal Law restricts this device to sale and use by or on the order of a physician or licensed eye care practitioner. 

United States Federal Law restricts the use of this device to practitioners who have been trained in the operation of this device. 

Please see adjacent page for brief summary information. 

The LenSx® Laser is indicated for use in patients undergoing cataract surgery for removal of the crystalline lens. 

Intended uses in cataract surgery include anterior capsulotomy, phacofragmentation, and the creation of single 

plane and multiplane arc cuts/incisions in the cornea, each of which may be performed either individually or 

consecutively during the same procedure. 

For Important Safety Information and Full Directions for Use, please reference the LenSx® Laser Directions for Use. 

To learn more about LenSx ® Laser technology for Laser Refractive Cataract Surgery, visit lensxlasers.com. 

© 2011 Novartis 9/11 LSX11503JAD

2012 Board of Trustees 

Ruth D Williams MD 

Paul Sternberg Jr MD 

David W Parke II MD 

Richard L Abbott MD 

Laurie G Barber MD 

George B Bartley MD 

Cynthia A Bradford MD 

David A Durfee MD 

Alaa ElDanasoury MD 

Paul B Ginsburg PhD 

B Thomas Hutchinson MD 

J Antonio Roca MD 

Jonathan B Rubenstein MD 

Andrew P Schachat MD 

Gregory L Skuta MD 

John R Stechschulte MD 

Humphrey J F Taylor 

Linda M Tsai MD 

Russell N Van Gelder MD PhD 

Ann A Warn MD MBA 

George A Williams MD 

Charles M Zacks MD 

President 

President-Elect 

Executive Vice President/CEO 

Past President 

Trustee-at-Large 


Senior Secretary for Advocacy 

Senior Secretary for Ophthalmic Practice 

International Trustee-at-Large 

Public Trustee 

Chair, FAAO Advisory Board 

International Advisor 

Secretary for Annual Meeting 

Editor, OPHTHALMOLOGY 

Senior Secretary for Clinical Education 


Public Trustee 


Chair, The Council 

Vice Chair, The Council 







xiii

See what we’re revealing. 

Introducing world-class visualization from the leader in cataract surgery. 

Experience Alcon’s latest commitment to you, the LuxOR Ophthalmic Microscope. It’s the only one of its kind to provide: 

• Superior red reflex stability 1 

• Greater depth of focus 1 

• An improved surgeon experience 

To see how Alcon is expanding its ophthalmic surgery expertise to microscope innovation, contact your sales representative 

today or visit AlconSurgical.com. 

1. Data on file, Alcon Laboratories, Inc. 

© 2012 Novartis 7/12 DIA12005JAD AlconSurgical.com

World Ophthalmology Congress ® 2014 Tokyo 

WOC2014 

Tokyo 

XXXIV International Congress of Ophthalmology 

in conjunction with 

29th Asia-Pacific Academy of Ophthalmology Congress 

118th Annual Meeting of the Japanese Ophthalmological Society 

April 2 6, 2014 

Venue: Tokyo International Forum / Imperial Hotel, Tokyo 

President 

Tetsuro Oshika, M.D. 

Professor and Chairman, Department of Ophthalmology, Faculty of Medicine, University of Tsukuba 

WOC2014 

Tokyo | April 2–6 

Secretariat: c/o Congress Corporation 

Kōsai-kaikan Bldg., 5-1 Kojimachi, Chiyoda-ku, Tokyo 102-8481, Japan 

Phone: +81-3-5216-5551 Fax: +81-3-5216-5552 E-mail: woc2014tokyo@congre.co.jp 

www.woc2014.org

Some surfaces are worth protecting 

THE OCULAR SURFACE IS ONE. 

© 2012 Novartis 2/12 SYS11179JAD 

Surface Protection and More 

References 

1. Christensen MT, Blackie CA, Korb DR, et al. An evaluation of the performance of a novel lubricant eye drop. Poster D692 presented at: The Association for Research in Vision and Ophthalmology Annual Meeting; May 2-6, 

2010; Fort Lauderdale, FL. 2. Lane S, Paugh JR, Webb JR, Christensen MT. An evaluation of the in vivo retention time of a novel artificial tear as compared to a placebo control. Poster D923 presented at: The Association for 

Research in Vision and Ophthalmology Annual Meeting; May 3-7, 2009; Fort Lauderdale, FL. 3. Davitt WF, Bloomenstein M, Christensen M, et al. Efficacy in patients with dry eye after treatment with a new lubricant eye drop 

formulation. J Ocul Pharmacol Ther. 2010;26(4):347-353. 4. Alejandro A. Efficacy of a Novel Lubricant Eye Drops in Reducing Squamous Metaplasia in Dry Eye Subjects. Presented at the 29th Pan-American Congress of 

Ophthalmology in Buenos Aires, Argentina, July 7-9, 2011. 5. Wojtowica JC., et al. Pilot, Prospective, Randomized, Double-masked, Placebo-controlled Clinical Trial of an Omega-3 Supplement for Dry Eye. Cornea 2011:30(3) 

308-314. 6. Geerling G., et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. IOVS 2011:52(4).

2012 Committee of Secretaries 

American Academy of Ophthalmology 


Cynthia A Bradford MD 

Daniel J Briceland MD 

Louis B Cantor MD 

Anne L Coleman MD PhD 


Tamara R Fountain MD 

Jeffrey S Heier MD 

Gregory P Kwasny MD 

Robert F Melendez MD MBA 

Richard P Mills MD MPH 

Jeffery A Nerad MD 

Michael X Repka MD 

William L Rich III MD 

Philip R Rizzuto MD 


Andrew P Schachat MD 


Ronald E Smith MD 

Chair 

Senior Secretary for Advocacy 

Secretary for State Affairs 

Secretary for Ophthalmic Knowledge 

Secretary for Quality of Care 

Senior Secretary for Ophthalmic Practice 

Secretary for Member Services 

Secretary for Online Education/eLearning 

Secretary for Federal Affairs 

Editor-in-Chief, the ONE Network 

Chief Medical Editor, EyeNet Magazine 

Secretary for Knowledge Base Development 

AAO Medical Director for Governmental Affairs 

AAO Medical Director of Health Policy 

Secretary for Communications 


Editor, OPHTHALMOLOGY 

Senior Secretary for Clinical Education 

Secretary for Global Alliances 





xix

800.787.5426 


Imaging with Depth of Field. Just Dandy. 

HSImaging.com 

What if none of your slit images had blurry edges? You 

would have a Haag-Streit, of course. Invest in one and 

submerge yourself into our extreme world of depth of field. 

Visit HSImaging.com to learn about our entire range of slit 

lamps and imaging systems. 

LED Powered BQ 900 ® Slit Lamp with IM 900 ® Imaging System 




Anticipating every move. 

Now that’s smart. 

Experience the intuitively adaptive control of NEW OZil® IP. 

Featuring innovative OZil® Intelligent Phaco, the Infiniti® Vision System puts 

optimized OZil® torsional emulsification and dynamic fluidic management at 

your fingertips. With significantly enhanced capabilities, OZil® IP is always thinking 

one step ahead. For more information, contact your Alcon representative. 

© 2011 Novartis 12/11 INF546

Buy Reliance, 

and Help your Neighbor Weather the Storm. 

800.735.0357 


RelianceDurable.com 

In tough times, Americans pull together. And we become 

stronger, like Reliance equipment, manufactured in the USA 

since 1898. Yes, it’s patriotism. But our American made 

products are just better, too. More durable, and innovative. 

The qualities you value in exam chairs and stands. Are you in 

the market for new equipment? Then consider Reliance, and 

your 20,000 neighbors across the nation who help manufacture 

our products. 



© 2012 Reliance Medical Products. All Rights Reserved.

Save the Date! 

There’s strength in numbers. Lobby on Capitol Hill for 

ophthalmology’s top legislative issues including advocating for 

fair Medicare physician payment, reducing regulatory burdens 

and vision research. Meet face-to-face with your Members 

of Congress and show the might of our members at this 

important opportunity. It’s the most effective way to protect 

the interests of our profession and our patients. 

Congressional 

Advocacy Day 

April 10 – 11, 2013 

Washington, DC 

“Join hundreds of your ophthalmology 

colleagues in Washington D.C. for 

Congressional Advocacy Day. We need your 

voice! Academy members advocate for our 

patients and our profession. Join me in 

Washington D.C. in 2013.” 

Ruth D. Williams, MD 

Academy President 

Registration opens in January 2013. 

Congressional Advocacy Day is open to all 

Academy members and registration is free. 

www.aao.org/myf

The Council 

The Council serves as the advisory body to the Board of Trustees. The Council was established in accordance with section 7.01 of the 

Bylaws of the American Academy of Ophthalmology. 


Chair 

Ann A Warn MD MBA 

Vice Chair 

Councilors Representing State 

Societies 

Alabama Academy of 

Ophthalmology 

Wonsuck Kim DO 

Alaska Society of Eye Physicians 

and Surgeons 

Scott A Limstrom MD 

Arizona Ophthalmological Society 

Thomas J McPhee MD 

Arkansas Ophthalmological Society 

Morriss M Henry MD 

California Academy of Eye 

Physicians and Surgeons 

Kimberly Cockerham MD FACS 

Craig H Kliger MD 

Asa Dan Morton III MD 

Ronald Lee Morton MD FACS 

Colorado Society of Eye Physicians 

and Surgeons 

Robert A King MD 

Connecticut Society of Eye 

Physicians 

Jeffrey R Sandler MD 

Delaware Academy of 

Ophthalmology 

Odette V Callender MD 

Florida Society of Ophthalmology 

Gary B Schemmer MD 

Stephen G Schwartz MD MBA 

Michael W Stewart MD 

Georgia Society of Ophthalmology 

James Gerard Brooks Jr MD 

Hawaii Ophthalmological Society 

George Nardin MD 

Idaho Society of Ophthalmology 

Adam C Reynolds MD 

Illinois Association of 

Ophthalmology 

Richard A Quinones MD 

David K Yoo MD 

Indiana Academy of Ophthalmology 

Derek T Sprunger MD 

Iowa Academy of Ophthalmology 

Christopher L Haupert MD 

Kansas Society of Eye Physicians 

and Surgeons 

William S Clifford MD 

Kentucky Academy of Eye 


David E Jones MD 

Louisiana Ophthalmology 

Association 

Keith Kellum MD DVM 

Maine Society of Eye Physicians 

and Surgeons 

Cynthia A Self MD 

Maryland Society of Eye Physicians 

and Surgeons 

Sanjay D Goel MD 

John T Thompson MD 

Massachusetts Society of Eye 


Robert A Lytle MD 

Michael J Price MD 

Michigan Society of Eye Physicians 

and Surgeons 

Arezo Amirikia MD 

Robert Jay Granadier MD 

Minnesota Academy of 

Ophthalmology 

Eugene O Gullingsrud MD 

Mississippi Academy of Eye 


Curtis D Whittington Jr MD 

Missouri Society of Eye Physicians 

and Surgeons 

Melissa G Cable MD 

Montana Academy of 

Ophthalmology 

Brian D Sippy MD PhD 

Nebraska Academy of Eye 


David D Ingvoldstad MD 

Nevada Academy of Ophthalmology 

Steve M Friedlander MD FACS 

New Hampshire Society of Eye 


John J Dagianis MD 

New Jersey Academy of 

Ophthalmology 

Paul D Langer MD 

David M Ringel DO 

New Mexico Academy of 

Ophthalmology 

Ashok K Reddy MD 

New York State Ophthalmological 

Society 

Gary S Hirshfield MD 

Roger C Husted MD 

James A Kinsey MD 

Arnold S Prywes MD 

North Carolina Society of Eye 


Cynthia Hampton MD 

North Dakota Society of Eye 


Lance K Bergstrom MD 

Ohio Ophthalmological Society 

Anita Dash-Modi MD 

Mark S Law MD 

Oklahoma Academy of 

Ophthalmology 

Amalia Miranda MD 

Oregon Academy of Ophthalmology 

Mary P DeFrank MD 

Pennsylvania Academy of 

Ophthalmology 

James B Dickey MD 

Joanna M Fisher MD 

Karl R Olsen MD 

Puerto Rican Society of 

Ophthalmology 

Emilio A Arce-Lopez MD 

Rhode Island Society of Eye 


Robert H Janigian Jr MD 

South Carolina Society of 

Ophthalmology 

Kurt Frederick Heitman MD 

South Dakota Academy of 

Ophthalmology 

Monte Steven Dirks MD 

Tennessee Academy of 

Ophthalmology 

Erich Bryan Groos MD 

Texas Ophthalmological Association 

John R Fish MD 

Victor H Gonzalez MD 

James H Merritt MD 

Utah Ophthalmology Society 

Rachel Benator MD 

Vermont Ophthalmological Society 

Brian Y Kim MD 

Virginia Society of Eye Physicians 

and Surgeons 

Anthony J Viti MD 

Washington Academy of Eye 


Brian E Bowe MD 

Washington DC Metropolitan 

Ophthalmological Society 

Reshma Katira MD 

West Virginia Academy of Eye 


Mark D Mayle MD 

Wisconsin Academy of 

Ophthalmology 

Deborah W Bernstein MD 

Wyoming Ophthalmological Society 

Anne Elizabeth Miller MD 

Councilors representing 

Subspecialty and Specialized 

Interest Societies 

American Academy of Pediatrics, 

Section on Ophthalmology 

George S Ellis Jr MD 

American Association for Pediatric 

Ophthalmology and Strabismus 

Jane C Edmond MD 

American Association of 

Ophthalmic Oncologists and 

Pathologists 

Paul J Bryar MD 

American Board of Ophthalmology 

John E Sutphin MD 

American College of Surgeons, 

Advisory Council for Ophthalmic 

Surgery 

Vikram D Durairaj MD 

Sarwat Salim MD 

American Glaucoma Society 

James C Tsai MD MBA 

American Ophthalmological Society 

Thomas J Liesegang MD 

American Osteopathic Colleges of 

Ophthalmology and Otolaryngology 

David D Gossage DO 

American Society of Cataract and 

Refractive Surgery 

David A Goldman MD 

Thomas M Harvey MD 

American Society of Ocular Trauma 

Michael P Grant MD PhD 

American Society of Ophthalmic 

Plastic and Reconstructive Surgery 

Louise A Mawn MD 

American Society of Retina 

Specialists 

Peter K Kaiser MD 

Mathew W MacCumber MD PhD 

American Uveitis Society 

Justine R Smith MD 

Association for Research in Vision 

and Ophthalmology 

Robert B Nussenblatt MD 

Association of University Professors 

of Ophthalmology 

Joel S Schuman MD 

Association of Veterans Affairs 

Ophthalmologists 

Mary Gilbert Lawrence MD MPH 

Canadian Ophthalmological Society 

Paul E Rafuse MD PhD 

Contact Lens Association of 


Thomas L Steinemann MD 

Cornea Society 

Shahzad I Mian MD 

Eye Bank Association of America 

Alan Mark Kozarsky MD 

Macula Society 

Neil M Bressler MD 

National Medical Association, 

Ophthalmology Section 

Eydie G Miller-Ellis MD 

North American Neuro- 

Ophthalmology Society 

Matthew Dean Kay MD 

Ocular Microbiology and 

Immunology Group 

Bradley Dean Fouraker MD 

Outpatient Ophthalmic Surgery 

Society 

Y Ralph Chu MD 

Pan-American Association of 

Ophthalmology 

Stephanie Jones Marioneaux MD 

Retina Society 

Thomas M Aaberg Jr MD 

Society of Military Ophthalmologists 

Jonathan S Collins MD 

Women in Ophthalmology 

Laura J King MD MMM 

The Academy’s Council is integral to Academy relations with state, subspecialty and specialized interest ophthalmic societies. www.aao.org/council 

xxv











Welcome to the 

S OE 2013 Congress 

in Copenhagen 

Photo: Morten Jerichau/Wonderful Copenhagen 

Photo: Cees van Roeden/Wonderful Copenhagen 

Online Registration and Abstract submission 

is open from 1 November 2012. 

Please stay updated on the SOE 2013 Congress website 

www.soe2013.org 

Photo: Shutterstock

888.myLENSTAR 

(888.695.3678) 

myLENSTAR.com 

myLENSTAR.com 

Breathe deeply. The unmatched 

accuracy of the LENSTAR ® Optical 

Biometer takes the stress out of 

selecting the correct toric IOL. 

Along with LENSTAR’s perfect 

Ks come superior outcomes 

for you and your patients. Call 888.myLENSTAR for a demo. 




Meeting Overview 

For location information see the program pages that follow or access the Mobile Meeting Guide, www.aao.org/mobile. 

Thursday, Nov. 8 

Event 

Time 

Registration Attendees 4:00 - 6:00 pm 

Exhibitors 

7:30 am - 6:00 pm 

Friday, Nov. 9 

Alumni & Related Group Functions 

Registration 

Special Meetings & Events 

Event 

Attendees 

Exhibitors 

Time 

All Day 

7:00 am - 5:00 pm 

7:30 am - 6:00 pm 

7:30 am - 3:00 pm 

Subspecialty Day Meetings Refractive Surgery 8:00 am - 5:15 pm 


E-posters 

Retina 

Retina Exhibits 

7:00 am - 5:30 pm 

8:00 am - 5:00 pm 

9:30 am - 3:30 pm 


Event 

Time 

AAOE/Practice Management Coding SOS 

8:00 - 11:00 am 

AAOE/Practice Management Coding Camp 

12:30 - 3:30 pm 

AAOE/Practice Management Saturday Programs 

8:30 am - 4:30 pm 

Academy Café 

1:00 - 3:45 pm 

Alumni & Related Group Functions > 

Joint Meeting Exhibition 

9:00 am - 5:00 pm 

Learning Lounge 

12:00 - 5:00 pm 

Networking With the Experts: Knowledge and Tips for the Young Ophthalmologist 

12:00 - 1:30 pm 

Registration Attendees 7:00 am - 5:00 pm 

Exhibitors 

7:00 am - 5:00 pm 

Scientific Posters 

9:00 am - 5:00 pm 

Scientific Posters Online/Videos on Demand 

9:00 am - 5:00 pm 


9:00 am - 4:00 pm 

Subspecialty Day Meetings Cornea 8:00 am - 5:30 pm 

Glaucoma 

8:00 am - 5:30 pm 

Oculofacial Plastic Surgery 8:00 am - 5:15 pm 

Pediatric Ophthalmology 

8:00 am - 5:15 pm 


8:00 am - 5:30 pm 

Refractive Surgery E-posters 7:00 am - 5:30 pm 

Retina 

8:00 am - 5:30 pm 

Uveitis 

7:50 am - 5:20 pm 

SYMPOSIA What is Global Ophthalmology? (Global Alliances) 2:30 - 4:00 pm 


xxix



AAOE/Practice Management Courses 

AAOE/Practice Management General Session 

Academy Business Meeting 

Academy Café 

Event 

Time 

2:00 pm - 5:30 pm 

10:00 am - 12:00 pm 

10:00 - 10:30 am 

10:30 am - 3:45 pm 


Breakfast With the Experts 

Fall Council Meeting and Surgery by Surgeons Forum 

Instruction Courses 



7:30 - 8:30 am 

11:30 am - 5:30 pm 

9:00 am - 5:30 pm 

9:00 am - 5:00 pm 

10:30 am - 5:00 pm 

2013 Medicare Update 12:15 - 1:45 pm 

OMIC Forum: Top Ten Indemnity Payments of 2011 

Opening Session 

Orbital Gala 

Original Paper Sessions 

2:00 - 3:30 pm 

8:30 - 10:00 am 

6:00 - 10:00 pm 

10:15 am - 5:30 pm 


Run/Walk for Vision 5K Race 



Scientific Poster Tours 

Skills Transfer Courses 


Young Ophthalmologist (YO) Program 

Spotlight on Innovation in Ophthalmology: From Theory to Therapy 

Spotlight on Corneal Collagen Crosslinking 

SYMPOSIA 

Introduction to Refractive Surgery for Residents (ISRS) 

Exhibitors 

Vision Rehabilitation Education: Effectively Transmitting the Need for Low Vision Services to the Ophthalmic 

Community (Vision Rehabilitation Committee) 


From Metal to Molecules: The Evolution of Oculofacial Plastic Surgery (ASOPRS) 

Corneal Stem Cell: Advances in Clinical and Laboratory Research (Joint Session with APAO) 

Contagion! Epidemics in Ophthalmic History (Museum of Vision) 

Cataract Surgery: The Cutting Edge 

Preferred Practice Pattern Guidelines ® : Adding Practical Value to Daily Practice (Preferred Practice Patterns 

Committee) 

Optimizing Optics: Perspectives From Contact Lens, Intraocular Lens, and Refractive Surgery (CLAO) 

How Does It Feel? An Insider’s Perspective on Living With Anophthalmia (ASO) 

Medical and Surgical Treatment of Macular Disease (The Retina Society) 

7:30 am - 5:00 pm 

6:30 - 8:00 am 

7:30 am - 5:00 pm 

7:30 am - 5:00 pm 

12:30 - 1:30 pm 

9:00 am - 5:30 pm 

10:00 am - 5:30 pm 

10:00 am - 2:00 pm 

10:30 am - 12:00 pm 

2:00 - 3:30 pm 

8:00 - 10:00 am 

10:00 am - 12:00 pm 

10:30 - 11:45 am 

10:30 am - 12:00 pm 

10:30 am - 12:00 pm 

12:15 - 1:45 pm 

12:15 - 1:45 pm 

12:45 - 1:45 pm 

2:00 - 3:30 pm 

2:00 - 3:30 pm 

2:00 - 3:30 pm 

xxx 

Academy staff are available at the Academy Resource Center (Booth 508) to answer any questions you may have.


Sunday, Nov. 11 (cont.) 

SYMPOSIA 

Event 

Modern Technologies and Techniques for Young Ophthalmologists to Know (Young Ophthalmologist International 

Subcommittee and Young Ophthalmologists from SOE and APAO) 

Video Case Presentations of Rare Vitreoretinal Diseases (Eurolam) 

LASIK Is Safe : Prevention and Management of Laser Complications (ISRS) 

The Controversies and Dilemmas of Managing Ocular Infectious Diseases: Point-Counterpoint (OMIG) 

Controversies in Pediatric Ophthalmology and Orthoptics: A Point-Counterpoint Discussion (AOC/AACO) 

International Perspectives: Trauma of the Anterior Segment and Its Management (SCO and PAAO) 

International Opportunities for Young Ophthalmologists (Young Ophthalmologist International Subcommittee) 

Time 

2:30 - 4:00 pm 

3:45 - 5:15 pm 

3:45 - 5:15 pm 

3:45 - 5:15 pm 

3:45 - 5:15 pm 

3:45 - 5:15 pm 

4:15 - 5:15 pm 


Event 

Time 


9:00 am - 5:30 pm 

Academy Café 

9:00 - 11:45 am 



7:30 - 8:30 am 


9:00 am - 5:30 pm 


9:00 am - 5:00 pm 


9:00 am - 5:00 pm 


8:30 am - 5:30 pm 


Exhibitors 

7:30 am - 5:00 pm 


7:30 am - 5:00 pm 


7:30 am - 5:00 pm 


12:30 - 1:30 pm 

Senior Ophthalmologist (SO) Program 

2:30 - 5:00 pm 


7:30 am - 5:30 pm 


8:30 am - 5:00 pm 

Spotlight on Cataracts: Clinical Decision-making With Cataract Complications 

8:15 am - 12:15 pm 


4:15 - 5:30 pm 

Ethnic Variations in Glaucoma Prevalence, Detection, and Treatment Outcomes (Joint Session with APAO) 

8:30 - 10:00 am 

SYMPOSIA 

Pediatric Corneal Disease and Treatment (AAPOS) 

8:30 - 10:00 am 

Re-engineering the U.S. Health Care System: The Impact on Ophthalmology (AMA Ophthalmology Section Council) 8:30 - 10:30 am 

What to Do When Your Patient Sees Nothing and You See Nothing: The Neuro-Ophthalmology Workup (NANOS) 

8:30 - 10:30 am 

2012 International Forum: Addressing Diabetic Blindness, Refractive Error and the Basic Eye Exam (Global Alliances) 8:30 - 11:00 am 

Advances in the Surgical Management of Glaucoma (Prevent Blindness America, Inc.) 

10:15 - 11:45 am 

Then and Now (Senior Ophthalmologist and Young Ophthalmologist Committees) 

10:15 - 11:45 am 

Update on Pediatric Ocular Trauma (ASOT) 

10:15 - 11:45 am 


10:45 am - 12:00 pm 

Making Electronic Health Records Meaningful and Useful in Your Practice (Committee on Medical Information 

12:45 - 1:45 pm 

Technology) 


xxxi


Monday, Nov. 12 (cont.) 

SYMPOSIA 

Event 

The “Local” Challenges of International Ophthalmology (Women in Ophthalmology) 

Why Take the Risk? How to Create an Effective Risk Management Strategy With Patient Education and Informed 

Consent Documents (Patient Education Committee and OMIC) 

Crash Course in Teaching: A Primer for Faculty Development (AUPO) 

Advances in the Treatment of Diabetic Retinopathy (Macula Society) 


Femto Forum: Cataract, Cornea, Refractive, and Beyond (ASCRS) 

Non-bacterial Infectious Keratitis (Cornea Society) 

Vision Rehabilitation: What’s New for Patients With Low Vision (Vision Rehabilitation Committee) 

Quality Improvement: How Do We Improve Quality, Maintain Efficiency and Sustain the Physician-Patient Relationship? 

(Practice Improvement Committee) 

Grand Rounds: Cases and Experts From Across the Nation 

Time 

12:45 - 1:45 pm 

12:45 - 1:45 pm 

12:45 - 2:15 pm 

2:00 - 3:30 pm 

2:00 - 3:30 pm 

2:00 - 4:00 pm 

2:00 - 4:00 pm 

3:45 - 4:45 pm 

3:45 - 5:00pm 

3:45 - 5:00 pm 

Tuesday, Nov. 13 


Academy Café 

Event 

Time 

9:00 am - 3:00 pm 

10:30 - 11:45 am 







7:30 - 8:30 am 

9:00 am - 5:30 pm 

9:00 am - 3:00 pm 

9:00 am - 12:00 pm 

8:30 am - 12:00 pm 


Exhibitors 

7:30 am - 3:00 pm 


7:30 am - 3:00 pm 


7:30 am - 3:00 pm 


8:00 am - 5:30 pm 

Management of Diabetic Retinopathy: East-West Perspectives (Joint Session with APAO) 

8:30 - 10:00 am 

Ocular Tumors: Evidence-Based Rationale for Treatment (AAOOP) 

8:30 - 10:00 am 

Shifting Gears: Practical and Ethical Transitions to Retirement (Committee on Aging, Senior Ophthalmologist 

10:15 - 11:15 am 

Committee, Ethics Committee and the American Geriatrics Society) 

Workforce Issues in Ophthalmology: Eye Health Care for Baby Boomers and Beyond (NMA) 

8:30 - 10:00 am 

Clinical Applications of Ocular Imaging (ARVO) 

10:15 - 11:45 am 


12:15 - 1:30 pm 

SYMPOSIA 

Wednesday, Nov. 15 

Event 

Time 

26° Lo Mejor de la Academia en Español 2012 (The Best of the Academy in Spanish 2012) 7:00 am - 5:00 pm 

xxxii 


Discover The FUTURE Of Diagnostic Imaging 

Advanced technology at the touch of a button 

Register To Attend a Special 

AAO Symposium 

New Advances in Multi-modality Imaging 

November 10, 2012 • 5:30pm–7:30pm 

Marriott Chicago Downtown 

www.HeidelbergEngineering.com/us/AAO2012 

SPECTRALIS is a registered trademark of Heidelberg Engineering, Inc. 

© 2012 Heidelberg Engineering, Inc. All rights reserved. 2660

Meeting Directory 

All rooms are in McCormick Place North Building (N), South Building (S), Lakeside Center (E). 

Exhibition is in South Building, Level 3, Hall A. 

AAO Meetings On Demand (Subspecialty Day 

and Joint Meeting Content) 

Grand Concourse and Booth 605 

AAOE Coding Sessions (Saturday) 

Room S105 

AAOE Member Lounge South, Level 5 

AAOE Program South, Level 5 

Academy Café 

Room S406b 

Academy Resource Center Booth 508 

Bags and Programs 

Hall A 

Bistro AAO Booth 2490 


Hall A 

Business Center South, Level 2.5 

Grand Concourse Level 2.5 & 

CME Reporting/Proof-of-Attendance 

Academy Resource Center, 

Booth 508 

Coat and Bag Check 

South, Level 1 Lobby 

Executive Offices 

Room S401 

Exhibitor Locator Booth 3500 

Exhibitor Lounge (Wi-Fi available) Booth 987 

Exhibitor Registration 

Hall A 

Exhibitor Service Center/Exhibitions Office Hall A 

First Aid South, Level 2.5 

Foundation of the American Academy of 

Ophthalmology (FAAO) 

Global Alliance Office 


Booth 508 

Room S403a 

Hotel Assistance Grand Concourse, Level 2.5 

Informational Exhibits and Posters 

Hall A 

International Center Booth 4509 

Internet Access Grand Concourse & Booth 2987 

Learning Lounge Booth 107 

Lost and Found 

Room S402 

Meditation/Prayer Room 

Room SA1a 

Meeting Information 

Grand Concourse & 


Meetings Office 

Room S402 

Mobile Device Charging Stations Booth 2485 

Mobile Meeting Guide Assistance Booth 2987 

Mobile Meeting Guide Download 

www.aao.org/mobile 

Museum of Vision Booth 704 

New Orleans 2013 Grand Concourse, Level 2.5 

Newsroom 

Room N426a 

Ophthalmic Mutual Insurance Company (OMIC) Booth 1104 

Ophthalmology Job Center 

Room N426c 

OPHTHPAC/Surgical Scope 

Grand Concourse 

Grand Concourse Level 2.5 & 

Proof-of-Attendance/CME Reporting 


Booth 508 

Publishers’ Row 

Hall A 

Registration 

Hall A 

Rest Stop 

Booths 2485, 2490, 2787, 2981, 

2987 

Ribbons 

Bags & Programs, Hall A 


Hall A 


Meeting Point, Hall A 

Scientific Posters Online/Videos on Demand Booth 165 

Seated Massage Stations Booth 2787 

Senior Ophthalmologist (SO) Lounge 

Grand Concourse Lobby 

Shuttle Bus Pick-up and Drop-off: Routes 1 - 8 South, Level 1 Lobby 

Shuttle Bus Pick-up and Drop-off: Routes 9 & 10 North, Level 1, Gate 26 

Speaker Ready Room 


Subspecialty Day 

Cornea 

Glaucoma 

Oculofacial Plastic Surgery 



Refractive Surgery E-Posters 

Refractive Surgery Free Papers (Friday only) 

Retina 

Uveitis 

Grand Ballroom, S100ab 

Room E354 

Room S406a 

Grand Ballroom, S100c 

North, Hall B 

North, Hall B 

Grand Ballroom, S100ab 

Arie Crown Theater 

Room E450 

Technology Pavilion Booth 880 

The Electronic Office (IHE) Booth 114 

Ticketed Event and Tour Sales 

Hall A 

Tour Program Departures 


Videos on Demand/ Scientific Posters Online Booth 165 

Wi-Fi Access Booth 2981 

Young Ophthalmologist (YO) Lounge 






xxxv

More control at your fingertips. 

Now that’s confidence. 

Introducing automated lens placement 

with the new INTREPID ® AutoSert ® IOL Injector. 

Achieve smooth, streamlined IOL delivery for all standard incision sizes – that’s the 

power of the new INTREPID® AutoSert® IOL Injector. Optimize procedural control with 

surgeon-selectable parameters that offer greater versatility while helping to minimize 

wound disruption and trauma. 1,2 

To learn how this new innovation for the INFINITI® Vision System can help improve 

your surgical outcomes, visit infinitivision.com. 

IN 

Use your Smartphone to scan 

this QR code and learn more. 

NEW 

INTREPID ® AutoSert ® IOL Injector 

For important safety information, please see adjacent page. 

© 2012 Novartis 3/12 INF11708JADUS 

1. Johansson, C. Comparison of Motorized IOL Insertion to Traditional Manual IOL Delivery. ASCRS Presented Paper, 2011. 

2. Allen, D. Experience with Electro-Assisted IOL Injection Device. ASCRS Presented Paper, 2011. 

PANTONE 

2935 

Spot Reverse Version

Be part of an innovative and captivating debate on controversies in ophthalmology. Hear experts provide differing 

opinions and interpret clinical outcomes based on available knowledge. Vote for the best answers and winning argument. 

A Free CME Breakfast Symposium 

Monday, November 11, 7:00 a m–8:15 a m 

Hyatt Regency McCormick Place • Regency Ballroom C/D/E 

2233 South Martin L. King Drive • Chicago, IL 60616 

Faculty 

Edward J. Holland, MD 

Director, Cornea Services 

Cincinnati Eye Institute 

Professor of Ophthalmology 

University of Cincinnati 

Cincinnati, OH 

Marguerite B. McDonald, MD, FACS 

Clinical Professor of Ophthalmology 

NYU School of Medicine 

New York, NY 

Adjunct Clinical Professor of Ophthalmology 

Tulane University Health Sciences Center 

New Orleans. LA 

Jai G. Parekh, MD, MBA 

Managing Partner, Brar-Parekh Eye Associates 

Woodland Park / Edison, NJ 

Chief, Cornea & External Disease / Medical Director 

Research Institute at St. Joseph’s HealthCare System 

Paterson, NJ 

John D. Sheppard, MD, MMSc 

President, Virginia Eye Consultants 

Research Clinical Director 

Thomas R. Lee Center for Ocular Pharmacology 

Associate Professor of Ophthalmology & 

Microbiology/Molecular Cell Biology 

Eastern Virginia Medical School 

Norfolk, VA 

For more information and to register, please visit www.aao2012.strategicallyspeaking.com. 

Jointly sponsored by 

Office of Continuing Education and Strategically Speaking, Inc. Supported by an educational grant from Bausch & Lomb Incorporated. 

Presented for attendees of the American Academy of Ophthalmology 2012 Annual Meeting. This is not an official function/event of the American Academy of Ophthalmology.

Shuttle Schedule 

Continuous shuttle bus service will operate between most of the official Academy hotels and McCormick Place from Friday, Nov. 9 through 

Tuesday, Nov. 13, according to the schedule below. Times of operation and boarding locations are subject to change. Check the route list 

to determine which route serves your hotel. Routes 1-8 will drop off and pick up at South, Level 1, Transportation Lobby. Routes 9 & 10 

will drop off and pick up at North, Level 1, Gate 26. Additional shuttle information and updates will be available at your hotel and McCormick 

Place. Please note: Hotel rates include $8 to partially defray shuttle costs. 

6:30 AM 

7:00 AM 

7:30 AM 

8:00 AM 

8:30 AM 

9:00 AM 

9:30 AM 

10:00 AM 

10:30 AM 

11:00 AM 

11:30 AM 

12:00 PM 

12:30 PM 

1:00 PM 

1:30 PM 

2:00 PM 

2:30 PM 

3:00 PM 

3:30 PM 

4:00 PM 

4:30 PM 

5:00 PM 

5:30 PM 

6:00 PM 

6:30 PM 






During peak hours shuttles will run every 10 to 15 minutes. 

During non-peak hours shuttles will run every 20 to 25 minutes. 

Hotel Address in Chicago Phone Route Boarding Location 

ACME Hotel Company 15 East Ohio Street 312-894-0900 1 Embassy Suites Chicago Downtown 

Allerton Hotel Chicago 701 North Michigan Avenue 312-440-1500 7 Front Entrance on Huron Street 

Avenue Crowne Plaza Chicago 160 East Huron Street 312-787-2900 7 Allerton Hotel Chicago 

Best Western Grant Park 1100 South Michigan Avenue 312-922-2900 9 Curbside on 11th Street 

Chicago Marriott Downtown Magnificent Mile 540 North Michigan Avenue 312-836-0100 4 Corner of Ohio & Rush Streets 

Chicago’s Essex Inn 800 South Michigan Avenue 312-939-2800 9 Hilton Chicago 

Conrad Chicago 521 North Rush Street 312-645-1500 4 Corner of Ohio & Rush Streets 

Courtyard Chicago Magnificent Mile 165 East Ontario Street 312-573-0800 7 Fairfield Inn & Suites Chicago Downtown 

Courtyard Chicago River North 30 East Hubbard Street 312-329-2500 1 CTA stop SE corner Dearborn before Hubbard 

dana hotel & spa 660 North State Street 312-202-6000 1 Embassy Suites Chicago Downtown 

Doubletree Hotel Chicago Magnificent Mile 300 East Ohio Street 312-787-6100 6 Curbside on Fairbanks Court 

Drake Hotel 140 East Walton Place 312-787-2200 8 Curbside on Oak Street 

Embassy Suites Chicago Downtown 600 North State Street 312-943-3800 1 Front Entrance 

Embassy Suites Chicago Lakefront 511 North Columbus Drive 312-836-5900 6 Curbside on Columbus Drive 

Fairfield Inn & Suites Chicago Downtown 216 East Ontario Street 312-787-3777 7 Front Entrance 

Fairmont Chicago, Millennium Park 200 North Columbus Drive 312-565-8000 3 Curbside on Columbus Drive 

Four Points by Sheraton Chicago Magnificent 

Mile 

630 North Rush Street 312-981-6600 4 Corner of Ohio & Rush Streets 

Four Seasons Hotel Chicago 120 East Delaware Place 312-280-8800 8 Westin Michigan Avenue Chicago 

Hard Rock Hotel Chicago 230 North Michigan Avenue 312-345-1000 2 Curbside on Wacker Place 

Hilton Chicago 720 South Michigan Avenue 312-922-4400 9 Curbside on 8th Street 

Hilton Suites Chicago Magnificent Mile 198 East Delaware Place 312-664-1100 8 Westin Michigan Avenue Chicago 

Hotel 71 71 East Wacker Drive 312-346-7100 2 Hard Rock Hotel Chicago 

Hotel Cass – A Holiday Inn Express 640 North Wabash Avenue 312-787-4030 4 Corner of Ohio & Rush Streets 

Hotel Felix 111 West Huron Street 312-447-3440 1 Embassy Suites Chicago Downtown 

Hyatt Chicago Magnificent Mile 633 North Saint Clair Street 312-787-1234 7 Fairfield Inn & Suites Chicago 

Hyatt Regency Chicago 151 East Wacker Drive 312-565-1234 3 Curbside on Wacker Drive 

Hyatt Regency McCormick Place 2233 South Martin L King Drive 312-567-1234 walk N/A 


xxxix

Shuttle Schedule 

Hotel Address in Chicago Phone Route Boarding Location 

Inn of Chicago 162 East Ohio Street 312-787-3100 6 Curbside on Ohio Street, across street 

InterContinental Chicago Magnificent Mile 505 North Michigan Avenue 312-944-4100 4 Side Entrance on Upper Illinois Street 

James Chicago 55 East Ontario Street 312-337-1000 4 Corner of Ohio & Rush Streets 

JW Marriott Chicago 151 West Adams Street 312-660-8200 10 W Chicago City Center 

Millennium Knickerbocker Hotel Chicago 163 East Walton Place 312-751-8100 8 Westin Michigan Avenue Chicago 

Omni Chicago Hotel 676 North Michigan Avenue 312-944-6664 7 Allerton Hotel Chicago 

Palmer House Hilton 17 East Monroe Street 312-726-7500 10 Curbside on Wabash Avenue 

Peninsula Chicago 108 East Superior Street 312-337-2888 7 Allerton Hotel Chicago 

Radisson Blu Aqua Chicago Hotel 221 North Columbus Drive 312-565-5258 3 Fairmont Chicago, Millennium Park 

Renaissance Blackstone Chicago Hotel 636 South Michigan Avenue 312-447-0955 9 Hilton Chicago 

Renaissance Chicago Downtown Hotel 1 West Wacker Drive 312-372-7200 2 Curbside on Wacker Drive 

Residence Inn Chicago Magnificent Mile 201 East Walton Place 312-943-9800 8 Westin Michigan Avenue Chicago 

Residence Inn Chicago River North 410 North Dearborn Street 312-494-9301 1 CTA stop SE corner Dearborn before Hubbard 

Ritz-Carlton Chicago (A Four Seasons Hotel) 160 East Pearson Street 312-266-1000 8 Westin Michigan Avenue Chicago 

Sax Hotel Chicago 333 North Dearborn Street 312-245-0333 1 CTA stop SE corner Dearborn before Hubbard 

Sheraton Chicago Hotel & Towers 301 East North Water Street 312-464-1000 5 Curbside on Columbus Drive 

Silversmith Hotel & Suites 10 South Wabash Avenue 312-372-7696 10 Palmer House Hilton 

Sofitel Chicago Water Tower 20 East Chestnut Street 312-324-4000 8 Westin Michigan Avenue Chicago 

SpringHill Suites Chicago River North 410 North Dearborn Street 312-644-4071 1 CTA stop SE corner Dearborn before Hubbard 

Sutton Place Hotel Chicago 21 East Bellevue Place 312-266-2100 8 Westin Michigan Avenue Chicago 

Swissôtel Chicago 323 East Wacker Drive 312-565-0565 3 Hyatt Regency Chicago 

Trump International Hotel & Tower Chicago 401 North Wabash Avenue 312-588-8000 2 Hard Rock Hotel Chicago 

W Chicago City Center 172 West Adams Street 312-332-1200 10 Curbside on Adams Street 

W Chicago Lakeshore 644 North Lake Shore Drive 312-943-9200 6 Curbside on Inner Lake Shore Drive 

Westin Chicago River North 320 North Dearborn Street 312-744-1900 2 Curbside on Clark Street, across street 

Westin Michigan Avenue Chicago 909 North Michigan Avenue 312-943-7200 8 Front Entrance, Across St on Delaware Place 

xl 


mobile meeting guide 

access the 2012 Mobile Meeting Guide 

at www.aao.org/mobile. 

The Mobile Meeting Guide contains: 

• Complete program content including 

abstracts, course handouts, evaluations, 

Technology Pavilion and Learning 

Lounge schedules 

• Meeting directory & information 

• Hotel & shuttle bus information 

• Exhibitor list & hall floor plans 

• Chicago attractions, restaurants & 

transportation information 

Access the Meeting Guide on your 

smartphone or tablet. The easy to 

use wireless Web App is available for 

any web-enabled mobile device. A 

downloadable version will be available 

for iOS and Android devices. 

For assistance onsite, visit the Internet 

Access Booth #2987.

Laureate Recognition Award 

In September 2002, the Board of Trustees approved an award 

program to induct individuals as Academy Laureates—outstanding 

ophthalmologists whose significant scientific contribution to 

the field has shaped the way modern ophthalmology is practiced. 

The Laureate award program recognizes individuals from around 

the world who have made exceptional scientific contributions to 

the betterment of eye care, leading to the prevention of blindness 

and the restoration of sight worldwide. 

The Laureate Recognition Award may be given to individuals who 

have: 

• Developed new techniques now accepted worldwide 

• Designed a seminal invention or an adaptation of previous 

technology 

• Developed a new treatment modality 

• Discovered the etiology of a disease state 

• Reassessed previous findings resulting in a significant shift in 

treatment 

• Established new standards of quality care in ophthalmology 

• Made a breakthrough in genetic understanding 

• Led primary research in new pharmacological products 

• Focused on eye care for people worldwide 

On behalf of the Board of Trustees, we are pleased to announce 

the 2012 Academy Laureate. 




Academy staff are available at the Academy Resource Center (Booth 508) to answer any questions you may have. 1

Laureate Award 

2012 Laureate Award 


Stephen J Ryan MD 

The American Academy of Ophthalmology takes special pride in honoring Stephen J. 

Ryan, MD, as recipient of the Laureate Recognition Award at its 116th Joint Meeting. 

While in medical school at Johns Hopkins, Dr. Ryan was introduced to vision research 

– stimulating his lifelong passion for ophthalmology and the excitement of the pursuit 

of new knowledge and innovation in our specialty. He credits A. Edward Maumenee, 

M.D. as his mentor and role model while a resident, chief resident, and assistant and 

associate professor at Wilmer. 

Dr. Ryan’s research contributions have helped to change how vitreoretinal disorders are 

now treated. For example, his early animal model of choroidal neovascularization has 

been widely used for decades for studying the mechanisms and treatment of choroidal 

neovascularization in preclinical studies. His posterior segment penetrating trauma 

model in primates and other animals led to a better understanding of the pathogenesis 

of traumatic traction retinal detachment which influenced the timing of vitrectomy in 

patients with vitreous hemorrhage after penetrating posterior segment injuries. His 

laboratory continues to study cellular proliferation in models to elucidate molecular 

mechanisms of diseases affecting the retina, especially the macula. 

He is currently the President of the Doheny Eye Institute and the Distinguished Grace 

and Emery Beardsley Professor at USC; but in 1974, he was the first and only full-time 

faculty member as well as founding Chair of Ophthalmology at the Keck School of Medicine 

of USC. Thirty eight years later, Doheny at USC is now a top ten ophthalmology 

program in U.S. News & World Report, Ophthalmology Times, and NEI funding rankings. 

Dr. Ryan was Dean of the Keck School of Medicine of USC and Senior Vice President for 

Medical Care from 1991 to 2004, a period characterized by institutional growth and a 

change in culture to a private research university medical school striving for excellence 

and following the proven successful model of Doheny at USC. 

Dr. Ryan is a longstanding member of the Institute of Medicine of the National Academy 

of Sciences and serves as the Home Secretary for the IOM. He has also been a leader 

of numerous ophthalmological organizations. He served as president of the Association 

of University Professors of Ophthalmology and the Macula Society. He is a member of 

the International Council of Ophthalmology. He is founding President of the National 

Alliance for Eye and Vision Research/Alliance for Eye and Vision Research established 

in 1993 by the AAO, ARVO, and the AUPO to educate opinion leaders in Washington and 

to advocate for NEI vision research to Congress. 

He has published almost 300 articles in the peer-reviewed literature and has delivered 

over 40 named lectures, including the Jackson Lecture. He is the author or editor of 9 

books including RETINA which is in its 5th Edition. Some of his awards include the AAO 

Senior Honor Award and Distinguished Service Award, the ARVO Kupfer Award for Distinguished 

Public Service, the American Ophthalmological Society Lucien Howe Medal, 

and the Johns Hopkins University Society of Scholars Award and the Distinguished 

Alumnus Award. He has Honorary Degrees from Providence College and the University 

of Leipzig. He is Chairman of the Board of the Arnold and Mabel Beckman Foundation 

and serves on the boards of Allergan, Inc., Johns Hopkins Medicine, and the W. M. Keck 

Foundation. 

Dr. Ryan resides in San Marino, California with his wife, Anne. They have one daughter. 

In addition to his laboratory colleagues at Doheny, he works with the Beckman Initiative 

in Macular Research which brings together leaders from around the world in different 

disciplines – clinician scientists and basic scientists -- to focus on atrophic macular 

degeneration in a collaborative effort to develop treatments of AMD. 

Dr. Ryan is honored at this 2012 Joint Meeting for his distinguished career and contributions 

to ophthalmology. It is with great pleasure that the Academy welcomes Dr. 

Stephen J. Ryan as the 2012 Academy Laureate. 

2 



Laureate Recognition Awardees 

2011 

Alfred Sommer MD MHS 

Recognized for his remarkable career and lasting 

contributions to ophthalmology, epidemiology 

and public health worldwide through his 

discovery of the link between vitamin A deficiency 

and childhood blindness and mortality. 

2010 

Bradley R Straatsma MD JD 

Recognized for his unique contributions to the 

science of ophthalmology through innovative 

research in posterior segment pathology and 

his leadership in enhancing ophthalmic education 

institutions and organizations worldwide. 

2009 

Bernard Becker MD 

Recognized as a pioneer in ophthalmic research, 

clinical care, education and leadership. 

He is widely accepted as a world expert on the 

treatment of intraocular pressure regulation 

and neuroprotection of the optic nerve. 

2008 

Professor Alan C Bird MD 

Recognized as a pioneer in ophthalmic 

research, teaching and clinical medicine. He 

is one of the world’s experts on the treatment 

of retinal vascular disease and genetic and 

degenerative retinal disorder. 

2007 

Claes H Dohlman MD 

Recognized as the founder of modern corneal 

science and for his years of teaching and 

educating young ophthalmologists in the field 

of cornea. 

2006 

Lorenz E Zimmerman MD 

Widely recognized for his many contributions 

to our understanding of a broad spectrum 

of diseases of the eye and for his ability to 

clearly communicate his cogent observations 

to ophthalmologists in clinical practice through 

a series of seminal publications and lucid 

lectures. 

2005 

Arnall Patz MD 

A gifted teacher and clinician who saved the 

sight of an untold number of newborns when 

he suspected oxygen had a role in the alarming 

number of retrolental fibroplasia cases among 

premature infants. 

2004 

Danièle S Aron Rosa MD PhD 

Honorary Professor and Chair of Ophthalmology, 

Park University and Chair of Ophthalmology 

at Hospital Robert Debrè and Foundation 

Rothschild in Paris and inventor of the YAG 

Laser for the treatment of posterior capsule 

opacity (secondary cataract). 

J Donald M Gass MD 

Professor at both the University of Miami 

School of Medicine and Vanderbilt University 

in Nashville, well known for his research on 

diseases of the retina, macula and uvea, much 

of which was done in Miami. 

Marshall M Parks MD 

Almost single-handedly created the subspecialty 

field of pediatric ophthalmology and worldrenowned 

for his contributions to understanding 

and treating amblyopia and strabismus. 

2003 

Charles D Kelman MD 

New York Medical College clinical professor 

of ophthalmology and attending surgeon 

at the New York Eye and Ear Infirmary and 

the Manhattan Eye, Ear and Throat Hospital, 

pioneered phacoemulsification and invented 

the cryoprobe. 

Robert Machemer MD 

Former chairman of the Department of Ophthalmology, 

Duke University, Durham, N.C., 

invented the vitreous infusion suction cutter, 

which allowed surgeons to more safely remove 

vitreous from the eye. 

Charles L Schepens MD 

Harvard Medical School clinical professor 

emeritus, and president of the Eye Research 

Institute of the Retina Foundation, is the father 

of modern retinal surgery. 



3

Special Awards 

Recipients of the following awards attend the Annual Meeting as guests of the president. The Academy formally presents them 

with an award during the opening ceremonies. Each award bestowed by the Academy is described below; however, not all 

awards are presented each year. 

Guests of Honor 

Each president has the privilege of selecting individuals 

as Guests of Honor at the Annual Meeting. Individuals are 

selected in recognition of their significant contribution to 

ophthalmology and to the Academy. 

Distinguished Service Award 

The Distinguished Service Award honors an individual or 

organization for ongoing notable service to ophthalmology and 

to the Academy. The president has the honor of selecting the 

recipient of this award, who also is approved by the Board of 

Trustees. 

Special Recognition Award 

First awarded in 1991, the Special Recognition Award is 

presented to an individual or organization for outstanding 

service in a specific effort or cause that improves the quality 

of eye care. The recipient need not be an ophthalmologist. 

The president has the honor of selecting the recipient of this 

award, who also is approved by the Board of Trustees. 

Straatsma Award for Excellence in Resident Education 

Established through the Academy, the Association of University 

Professors of Ophthalmology (AUPO), and private funds, 

the Straatsma Award for Excellence in Resident Education is 

given to a program director dedicated to the principles and 

significance of residency education. 

International Blindness Prevention Award 

Established in 1992, the International Blindness Prevention 

Award honors individuals who have made significant contributions 

to the prevention of blindness or the restoration of sight 

around the world. 

Outstanding Advocate Award 

The Outstanding Advocate award was established in 2008 

to recognize Academy members’ participation in advocacyrelated 

efforts at either the state and/or federal levels. 

Nominations are reviewed and a selection is made by the 

Academy’s Awards Committee with final approval by the Board 

of Trustees. 

Outstanding Humanitarian Service Award 

First awarded in 1992, the Outstanding Humanitarian Service 

Award was established to recognize the contributions of Academy 

Fellows and Members in selflessly providing medical eye 

care. Each year this award is presented to individuals for their 

participation in charitable activities, indigent care, community 

service, or other humanitarian activities. Nominations are 

reviewed and selections are made by the Academy’s Awards 

Committee. The Board of Trustees chooses from or approves 

the recipient(s) recommended. 




4 



Guest of Honor 

Emily Y Chew MD 

Emily Chew is the Deputy Director of the Division of Epidemiology and Clinical Applications 

(DECA), at the National Eye Institute, the National Institutes of Health in Bethesda, 

Maryland. She is also the Chief of the Clinical Trials Branch in the division. Emily received 

her medical degree and her ophthalmology training at the University of Toronto, Canada. 

She completed her fellowship in medical retina at the Wilmer Eye Institute, the Johns 

Hopkins Medical Institutes and the University of Nijmegen, the Netherlands. 

Her research interest includes phase I/II clinical trials and epidemiologic studies in retinovascular 

diseases such as age-related macular degeneration, diabetic retinopathy and 

other ocular diseases. She has worked extensively in large multi-centered trials headed 

by the staff from her division, including the Early Treatment Diabetic Retinopathy Study 

(ETDRS), the Age-Related Eye Disease Study (AREDS) and the Age-Related Eye Disease 

Study 2 (AREDS2), which she chairs. She works on other clinical trials in collaboration 

with other institutes within NIH such as the Actions to Control Cardiovascular Risk in 

Diabetes (ACCORD) Trial and she chairs the ACCORD Eye Study. She directs the clinical 

portion of the international study, Macular Telangiectasia Project. 

Emily is married to Robert Murphy, MD who is in practice with the Retina Group of Washington. 

They have three daughters. 



5



Stephen C Gieser MD MPH 


Stephen C. Gieser, MD, MPH is a glaucoma consultant at the Wheaton Eye Clinic. He is a 

third-generation ophthalmologist and a fourth-generation physician. Dr. Gieser received his 

undergraduate degree from Wheaton College and his medical degree from the University 

of Illinois in Chicago. Following his ophthalmology residency at Yale, Dr. Gieser completed 

a fellowship in International Blindness Prevention at the Dana Center for Preventive 

Ophthalmology of the Wilmer Institute and received an MPH from the Johns Hopkins 

Bloomberg School of Public Health. He subsequently went to India on a Fulbright Scholarship, 

where he taught and participated in research at C.M.C. Hospital in Tamil Nadu. 

Returning from India, Dr. Gieser completed a Heed fellowship in glaucoma at the Wilmer 

Institute. He has written numerous publications in ophthalmic journals and textbooks, and 

has given over 100 lectures and presentations on glaucoma pharmacology. 

He is a Fellow of the American Academy of Ophthalmology and a Diplomate of the American 

Board of Ophthalmology. Dr. Gieser currently serves as a trustee of the Morton Arboretum 

and is a member of the Collections & Research Committee of The Field Museum. 

A horticulturalist and beekeeper, Dr. Gieser lives on a farm in suburban Chicago with his 

wife, Dr. Ruth Williams and their three teenage children. 

6 




H Dunbar Hoskins Jr MD 

H. Dunbar Hoskins Jr., MD is Executive Vice President Emeritus of the American Academy 

of Ophthalmology, a position he assumed January 1, 1993, after a distinguished career 

in private practice. He retired from that position in April 2009. As CEO of the Academy, 

he founded the ONE Network, initiated the Global Alliance Division and substantially 

increased the assets of the Foundation of the Academy. The American Academy of Ophthalmology 

is a leader in Subspecialty Societies in the area of outcomes analysis, patient 

advocacy, understanding health care delivery dilemmas, and educational and technological 

innovations 


Dr. Hoskins is an internationally recognized glaucoma specialist, having authored or coauthored 

more than 70 publications and presented more than 300 invited lectures. 

He received an Academy Honor Award in 1979 and a Senior Honor Award in 1989 and 

Distinguished Service Award in 1999. He is also a member of the Alpha Omega Alpha 

Medical Society, the Sigma Zeta Honor Society, and was listed in the March 1991 issue of 

Good Housekeeping as one of “The 400 Best Doctors in America” and is listed annually in 

the “Best Doctors in America.” 

He has held numerous other positions in ophthalmology, medicine and business. Among 

the highlights: Chairman of St. Mary’s Hospital and Medical Center in San Francisco, 

Chairman of Mercy Services Corporation, founder and Chairman of Medem Corporation, 

Founding Director of the American Glaucoma Society, founder and Director of the Foundation 

for Glaucoma Research and Secretary-Treasurer of the Pan American Association of 

Ophthalmology and Chairman of the Advisory Committee to the International Council of 

Ophthalmology. 

He is a Clinical Professor of Ophthalmology at the University of California School Of Medicine, 

San Francisco. 

Born in Virginia, Dr. Hoskins, the son of an ophthalmologist, received his medical degree 

at the Medical College of Virginia where he did his internship and residency. He was certified 

by the American Board of Ophthalmology in 1970 and did his Glaucoma Fellowship 

at the University of California School San Francisco Medical Center. While serving in the 

United States Navy, he served as Chief of Ophthalmology at the Naval Hospital in Rhode 

Island in 1968. 

The father of three, he lives with his wife, Ann, in Belvedere, located in Northern California. 


7


Distinguished Service Award 


National Alliance for Eye And Vision Research 

NAEVR is a non-profit advocacy organization comprised of a coalition of 55 professional society (ophthalmology 

and optometry), patient and consumer, and industry organizations involved in eye and vision research. Founded 

in 1997 by the American Academy of Ophthalmology, the Association of University Professors of Ophthalmology 

(AUPO), and the Association for Research in Vision and Ophthalmology (ARVO), NAEVR serves as the 

“Friends of the National Eye Institute (NEI)” and advocates for increased federal funding for vision research at 

the NEI within the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department 

of Veterans Affairs (VA). NAEVR has been commended for its advocacy by former NIH Director Elias Zerhouni, 

M.D. and, most recently in early 2012, by current NIH Director Francis Collins, M.D., Ph.D. 

NAEVR’s affiliated educational foundation, the Alliance for Eye and Vision Research (AEVR), is sponsoring The 

Decade of Vision 2010-2020 Initiative, a sustained awareness program about the power of federally funded 

vision research to benefit patients by increasing productivity, maintaining independence, and improving quality 

of life. In 2009, Congress recognized AEVR’s efforts in resolutions passed by both the House of Representatives 

and the Senate that designated 2010-2020 as the decade of vision. 

8 



Special Recognition Award 

Paul R Lichter MD 

Dr. Lichter served as Chair of the Department of Ophthalmology and Visual Sciences at 

the University of Michigan Medical School from 1978 to 2012 and is the founding Director 

of the W.K. Kellogg Eye Center, which opened in 1985. During his tenure, he expanded 

the scope of clinical practice of the Department; built on a legacy of innovation to grow a 

robust and vibrant vision research program; and brought together physicians and scientists 

to create what is today one of the most highly regarded and successful eye centers in the 

country. The center has top rankings in all areas of its mission: clinical care, research, and 

education. 


Dr. Lichter is also a respected clinician, educator, and researcher whose interests involve 

glaucoma, genetics, quality of life, ethics and medical professionalism including physicianindustry 

conflict of interest. He has more than 200 publications to his credit, including 

scientific articles, editorials, and book chapters, and he has delivered 40 named lectures, 

including the 50th Jackson Memorial Lecture in 1993. In 2008, he received the prestigious 

Howe Medal from the American Ophthalmological Society. 

In addition to serving as the 100th President of the American Academy of Ophthalmology 

in 1996, Dr. Lichter is also a Past President of the Association of University Professors of 

Ophthalmology, the American Ophthalmological Society, and the Pan American Association 

of Ophthalmology as well as a Past Chair of the American Board of Ophthalmology. 

Until recently, he served as a Director of the Heed Ophthalmic Foundation and President of 

the Society of Heed Fellows. He is currently the President of Academia Ophthalmologica 

Internationalis. Dr. Lichter is a past Editor-in-Chief of the journal Ophthalmology and serves 

as an Associate Editor of the American Journal of Ophthalmology. 

A native of Detroit, Dr. Lichter received his undergraduate, medical school, and ophthalmology 

residency education at the University of Michigan and completed a glaucoma 

fellowship under the late Robert N. Shaffer, M.D. at the University of California, San 

Francisco. He is married to Carolyn Lichter and has a daughter, Laurie Lichter, and three 

grandchildren. 


9


Outstanding Humanitarian Service 

Award 


Timothy J Kietzman MD 

Timothy J. Kietzman, MD was nominated by the Wheaton Eye Clinic to receive this year’s 

Outstanding Humanitarian Service Award. 

Dr. Kietzman fell in love with ophthalmology as a child while observing his father, Dr. 

Benjamin Kietzman, who served as a missionary ophthalmologist in northern Nigeria. After 

Dr. Kietzman completed his training and military service commitment he joined a large group 

practice in Georgia as a comprehensive ophthalmologist. Dr. Kietzman, however, wanted 

more out of life, so he began seriously contemplating the possibility of also serving as a 

missionary ophthalmologist overseas. Through Interserve USA, he became aware of the 

desperate need for an ophthalmologist in Gilgit, a city in the northern mountains of Pakistan. 

One of Dr. Kietzman’s former classmates, a family practice doctor, had pioneered the Gilgit 

Eye Hospital project 5 years earlier. To provide needed specialty expertise, Dr. Kietzman 

visited the project, and then in March 2000 moved his family to Pakistan 

Dr. Kietzman brought western standard eye care to Gilgit. He treated a wide variety of eye ailments and introduced 

state of the art cataract surgery, glaucoma procedures and diabetic eye care. He was instrumental in raising funds 

to purchase equipment for the Gilgit Eye Hospital, including two phaco machines, a YAG laser, as well as other 

needed equipment. His desire to prevent the many injuries he was treating led him to produce a radio drama 

designed to raise public awareness about safety issues. He documented a 20% decline in open globe injuries in his 

last four years in Gilgit, which he partially attributes to his public health efforts. 

Due to the diligence and commitment of Dr. Kietzman, the Gilgit Eye Hospital set the standard for quality eye care 

that is still the primary source in Northern Pakistan within twenty hours of driving in any direction. The clinic saw 

over nine thousand patients in 2010 and performed fourteen to sixteen intraocular surgeries per week. Dr. Kietzman 

performed all of these services free of charge with the clinic only charging a minimal amount on a sliding scale to 

maintain its sustainability. 

Dr. Kietzman not only provided excellent eye care but actively taught both Pakistani ophthalmologists and ophthalmic 

technicians. He spent much of his last five years in Gilgit training a Pakistani ophthalmologist, as well as five 

ophthalmic physician assistants to be able to diagnose basic eye problems and triage as necessary. Dr. Kietzman’s 

hope is that education will create a more sustained health care resource for the rural Pakistani people. 

During his tenure, Dr. Kietzman, his wife and four sons, maintained strong passion for the Pakistani people despite 

many obstacles. First, Dr. Kietzman learned to speak Urdu as well as understand the rudiments of several local 

languages. Then there were the usual difficulties such as a non-western dress code, unreliable water, electricity, 

heating and medical supplies as well as the more unusual, like several robberies, personal health problems, floods, 

earthquakes, political & sectarian unrest and a terrorist attack on their children’s boarding school. Especially tough 

on Dr. Kietzman were prolonged separations from his family after the attack when his family was evacuated. 

Dr. Kietzman’s reputation in Pakistan and from those who have visited the Gilgit Eye Hospital is second to none. 

He is known throughout the country as an ophthalmologist who provided loving, caring and excellent patient care. 

Gilgit Eye Hospital is known by the same high standard, thanks to his medical care. 

In recognition of the sacrifice that he and his family have made to provide eye care for people in a very needy area 

of the world, the Academy is priviledged to honor Dr. Kietzman with this year’s Outstanding Humanitarian Service 

Award. 

10 



Outstanding Humanitarian Service 

Award 

P Namperumalsamy MD 

P. Namperumalsamy, MD was nominated by the All India Ophthalmology Society to receive 

this year’s Outstanding Humanitarian Service Award. 

Dr. P. Namperumalsamy is one of the founding members of the Aravind Eye Care System 

(AECS). AECS was established in 1976 as a modest eleven bed hospital and has grown to 

enormous proportions. The mission of AECS was to “eliminate needless blindness by providing 

appropriate, compassionate and high quality eye care to all”. 

Over the past three decades Aravind has restored or preserved sight in over 3.5 million 

people with over 70% of them receiving care either for free or at a subsidized rate. During 

2010-2011, Aravind performed over 300,000 surgeries and handled over 2.5 million outpatient 

visits. This makes Aravind the largest provider of eye care worldwide. Through its 

network of eight eye hospitals located in Tamilnadu and Pondicherry, Aravind contributes to 

35% of the cataract surgeries performed in the state of Tamilnadu and 5% of all national surgeries. They have been 

able to achieve this scale through the principle of providing large volume, high quality and affordable services in a 

sustainable manner. 

As one of the founding members of a team of three ophthalmologists, Dr. P. Namperumalsamy played an active 

role in developing Aravind’s outreach strategies. The cornerstone of Aravind’s high volume work is their outreach 

program, encouraging active involvement from the community. Working within a large community network Aravind 

conducts over two thousand eye camps and performs around 76,000 free cataract surgeries each year. 

An innovative initiative of Dr. Namperumalsamy to extend urban eye care amenities to people was setting up of 

permanent rural vision centers in the villages and providing quality care through an unique telemedicine system. 

This service to the underserved population was started in 2004 and extended to 41 centres at present. 

Having realized that India is having the largest diabetic population, next only to China, Dr. P. Namperumalsamy has 

launched programs to fight against diabetic retinopathy in concurrence with the directive from VISION 2020 – The 

Right to Sight initiative by WHO and IAPB. Special diabetic screening outreach camps are organized utilizing 

mobile vans equipped with modern imaging systems and satellite connectivity and developing software for reading 

and grading images. 

Dr. Namperumalsamy has received numerous awards, including the Padmashree Award by the Government of India 

(1997), the Lifetime Achievement Award by the All India Ophthalmological Society, the Achievement Award from 

the American Academy of Ophthalmology and the Dr. B.C. Roy National Award (2006) in the category of Eminent 

Medical Teacher. Time Magazine honored Dr. Namperumalsamy as one of the “100 Most Influential People in the 

World” in its May 2010 issue. 

Dr. Namperumalsamy sacrificed his personal life to serve the community and underserved populations in the 

prevention of blindness. Even from the beginning he drew a meager salary for himself in order to build Aravind, a 

nonprofit organization. He has been described as a tireless worker, dedicating six or more days a week to his various 

roles at Aravind for nearly 50 years. His natural people skills, innate intelligence, and tremendous leadership 

have enabled him to succeed at a level that could not have been imagined when he and others first started Aravind. 

For his dedication and commitment to provide high quality eye care and service regardless of economic status, the 

Academy is proud to announce Dr. P. Namperumalsamy as a recipient of the Outstanding Humanitarian Service 

Award. 



11


Outstanding Advocate Award 

S William Clark III MD 


S. William Clark III, MD was nominated by the Georgia Society of Ophthalmology (GSO) to 

receive this year’s Outstanding Advocate Award. 

Dr. S. William Clark III, a solo general ophthalmologist in Waycross, Georgia, has been a 

committed advocate for ophthalmology and organized medicine at the state and federal 

levels since completing his fellowship in 1984. As a second-generation ophthalmologist, Dr. 

Clark learned the importance of being an effective political advocate from his father at an 

early age. His interest developed into a passion for patient and physician advocacy after he 

returned home to practice. 

Dr. Clark is Past President and Board member of the Medical Association of Georgia (MAG) 

and has served as Vice President and Academy Councilor representing the GSO. He has 

been active in the legislative and PAC committees of both organizations. 

Since 1988, he has served in the AMA House of Delegates, representing the AMA Young Physicians Section, AAO 

and MAG and is now Vice-Chair of the Georgia AMA Delegation. He was the AAO OphthPAC Chair from 2007 to 

2011. 

His academic appointments as Adjunct Associate Professor in Ophthalmology at Emory and Clinical Assistant 

Professor in Family Medicine at MCG have given him the platform to deliver advocacy training to residents there as 

well as at UF Shands and Yale. 

Emulating the Academy’s Leadership Development Program, the Georgia Physicians Leadership Academy (GPLA) 

was founded by Dr. Clark during his term as President of MAG as an initiative to involve more physicians in 

statewide advocacy and leadership efforts. GPLA is in its 5th year and was the driving force behind the 2012 GSO 

Advocacy Day, an inaugural program developed as his service project by GSO President and GPLA graduate, Dr. 

David Bogorad. Dr. Clark’s foresight in creating the GPLA will, without a doubt, continue to be a successful program 

and will serve as a breeding ground for state-level advocacy efforts across medical specialties, impacting all physicians 

in the state. 

During his tenure as OphthPAC Chair, our Academy achieved significant goals. The Congressional Advocacy Program 

successfully matched every member of Congress with a constituent AAO Congressional Advocate. The PAC 

first broke the two million dollar threshold and was nationally recognized for strategic expenditures. Ophthalmologists’ 

incomes were increased and our patients were protected at the federal level. 

Dr. Clark is tireless in his efforts and loyalty to organized medicine, and specifically to ophthalmology. His level 

of commitment is to be admired by his colleagues and new generations of physicians to come. The scope of his 

advocacy efforts will continue through the GPLA program, participation with organized medicine and his unwavering 

dedication to his friends in Congress. For nearly thirty years, he has put forth tremendous time and energy to 

ensure the ophthalmologists’ point of view is heard and considered when relevant legislative issues arise. This 

steady involvement has forged personal relationships and mutual esteem with federal and state legislators, further 

expanding his scope of influence on key concerns for patients and physicians. 

As one colleague states-“Bill Clark has worked tirelessly for his entire career on behalf of our specialty. His efforts 

have been highly effective at organizing and inspiring other ophthalmologists in Georgia and around the country”. 

For his commitment and devotion to all his activities in the state and federal levels, the Academy is proud to honor 

Dr. Clark with this year’s Outstanding Advocate Award. 

12 



Straatsma Award for Excellence in 

Resident Education 

Thomas A Oetting MD 

Thomas Oetting, MD is the Program Director for the Ophthalmology Residency Program and 

Professor of Clinical Ophthalmology at the University of Iowa, Iowa City and the Chief of the 

VA Eye Service, Veterans Affairs Medical Center, Iowa City. He has worked tirelessly with 

residents and faculty to improve ophthalmic education. 

Dr. Oetting wishes to thank AAO/AUPO for the honor of being associated with Dr. 

Straatsma, who has been an inspiration to all in ophthalmic education. He accepts this 

award on behalf of the program at the University of Iowa and the dedicated faculty and 

staff who do not waiver in their support of resident education. In particular, Dr. Oetting 

would like to thank program coordinator Laura Pitlick, a compassionate leader with amazing 

organizational skills. Dr. Oetting feels fortunate to be able to work with the brilliant, 

hard working residents at Iowa. 

Dr. Oetting became Residency Director in 2006 when Keith Carter took on the role of Chairman. He feels fortunate 

for the active mentorship of Dr. Carter as well as the guidance and leadership of Andrew Lee. Dr. Oetting credits 

these two great mentors as he learned the ropes of being a program director and feels that their mentorship allowed 

him to move beyond the basics to strive for excellence in resident education. 

Dr. Oetting’s great interest is in surgical education. While Chief of the VA Eye Service in Iowa City for the past 15 

years he has taken on the initial education of residents as they enter the operating room. His goal has been to 

decrease the risk to patients as residents enter their surgical career and to increase resident competence at the 

end of the program through enhancements in surgical training. Dr. Oetting feels fortunate to have many like-minded 

colleagues at Iowa who have helped him to develop curriculum enhancements. 

Dr. Gina Rogers, Dr. Oetting and others recently published a summary of the downstream impact that the enhanced 

surgical education at Iowa has had on patient safety. Dr. Rogers reported that the enhanced surgical curriculum in 

the first and second year decreased the sentinel complications of the third-year residents. This study showed that 

the enhancements in Iowa’s educational program decreased the complication rate of posterior capsular tear and vitreous 

loss by about half. The curriculum enhancements included a structured wet-lab, a formative feedback process, 

backing-in process and deliberate practice of the capsulorhexis portion of the procedure. 

Dr. Oetting and his colleagues have been very involved in wet-lab and simulator work. One of the first projects Dr. 

Oetting took on when he came to Iowa was to develop a wet-lab at the VA Hospital in Iowa City. Over the years, this 

wet-lab has developed into a very active part of the curriculum. More recently, Dr. Oetting and Dr. Emily Greenlee 

developed a structured wet lab program that first-year residents use to learn the basic skills for ophthalmic surgery. 

In addition, residents use a commercial simulator. Dr. Oetting and Dr. Chris Watts have presented data demonstrating 

some benefit with simulation in the very early learning curve in residents at Iowa. 

Dr. Oetting is also interested in using Web-based resources for education. Dr. Andrew Doan, Dr. Oetting and others 

founded EyeRounds.org (http://www.eyerounds.org) to showcase interesting cases and tutorials from residents 

at Iowa. The EyeRounds Editorial Board includes elected faculty and residents who peer review the content. In 

addition, Dr. Oetting and his son Drew Oetting developed http://facebook.com/cataract.surgery as a virtual forum 

for interesting cases. This site has been a great way to learn and has essentially extended the Iowa faculty into the 

thousands as experienced surgeons from all over the world share tips. 

Dr. Oetting looks forward to continuing to shepherd innovations in ophthalmic education with his colleagues, and 

leading talented residents as they pass through Iowa City. 



13


International Blindness Prevention 

Award 


Marilyn T Miller MD MS 

Marilyn T. Miller, MD, MS is a Professor of Ophthalmology at the University of Illinois at 

Chicago (UIC). She obtained her medical degree and clinical training in ophthalmology at UIC 

and has been on the faculty there since 1965. 

She has a longstanding participation in international ophthalmology, especially in educational 

activities in a number of developing countries including Nigeria and India, as well 

as several other Asian and South American countries. Dr. Miller has visited a clinic in rural 

Nigeria for over 25 years with a small non-governmental organization, FOCUS, Inc. Originally, 

their visits were focused on treating patients, but now the role is primarily in the area of 

teaching and lecturing. Currently, she is president of FOCUS, Inc. and continues to visit the 

eye clinic at Mercy Hospital Eye Center in Abak, Nigeria. 

Dr. Miller has been recognized for her many contributions to international service in ophthalmology, including the 

Humanitarian Award from the American Academy of Ophthalmology (AAO), and more recently the Howe Medal 

by the American Ophthalmological Society (AOS), the Park Silver Medal from the Children’s Eye Foundation of the 

American Association of Pediatric Ophthalmology and Strabismus (AAPOS) and the Dr. G. Venkataswamy Endowment 

Oration Award. The Howe Medal denotes distinguished service to ophthalmology and has had 75 recipients 

since first awarded in 1922. Dr. Miller is only the third woman to receive this honor. She also served on the AOS 

Council and served as its first woman president. Other organizations for which she has been president include the 

Chicago Ophthalmologic Society and AAPOS. 

Dr. Miller has served on a number of boards and advisory committees, including the Board of the AAO, Advisory 

Committee of the Foundation of the AAO, Medical Advisory Committee of the Division of Specialized Care for 

Children in Illinois, Smith Kettlewell Eye Research Institute, Bernadotte Foundation for Children’s Eyecare and the 

Advisory Committee of the World Health Organization. She has also participated in many of the international committees 

of the AAO chairing one of the first international committees, the Committee on International Ophthalmology. 

In addition, for many years she served as one of the AAO’s representatives to the International Agency for the 

Prevention of Blindness (IAPB). 

A current major area of interest for Dr. Miller is in training and education internationally in the field of pediatric 

ophthalmology and strabismus and she has been on the organizing committee for many international conferences 

and congresses for the pediatric ophthalmology and strabismus section. She has also been an invited lecturer 

at several national and international medical schools and hospitals. Dr. Miller has delivered a number of named 

lectures and received the Bock Award for a contribution in the field of neurodevelopment. Her research interest in 

congenital anomalies and teratogens led her to Sweden where years later she received an honorary degree from 

the University of Göteborg for her clinical research in thalidomide embryopathy. 

14 


Secretariat Award 

The Secretariat Award recognizes ophthalmologists and non-ophthalmologists for special contributions 

to the Academy and ophthalmology. Recipients are selected by the senior secretaries 

and secretaries in their respective areas and approved by the Board of Trustees. 

This annual award was developed to increase opportunities for individuals to be recognized for 

contributions that are outside the scope of the current Achievement Award program. 





Secretariat Awards 

Secretariat Awards 

Ann Louise Coleman MD PhD, Secretary for Quality 

Care, Jeffrey A Nerad MD, Secretary for Knowledge 

Base Development, Louis B Cantor MD, Secretary for 

Ophthalmic Knowledge, Jeffrey S Heier MD, Secretary 

for Online Education/eLearning, Robert F Melende 

MD, Gregory L Skuta MD, Senior Secretary for Clinical 

Education honor: 

Angela N Buffenn MD MPH Los Angeles, CA 

David F Chang MD 

Los Altos, CA 


Bethesda, MD 

George Cioffi MD 

Portland, OR 

Brad H Feldman MD 

Philadelphia, PA 

Mary Lou Jackson MD Boston, MA 

Andreas K Lauer MD 

Portland, OR 

Andrew G Lee MD 

Houston, TX 

Dale R Meyer MD 

Albany, NY 

Aaron M Miller MD 

Tomball, TX 

Kevin M Miller MD 

Los Angeles, CA 

Steven A Newman MD Charlottesville, VA 

Thomas A Oetting MD Iowa City, IA 

Mary A O’Hara MD 

Sacramento, CA 

Steven R Rusell MD 

Iowa City, IA 

Hermann D Schubert MD New York, NY 

Ingrid U Scott MD 

Hershey, PA 

Mark B Sherwood MD Gainesville, FL 

Carla J Siegfried MD 

St Louis, MO 

George A Stern MD 

Missoula, MT 

Gwen K Sterns MD 

Rochester, NY 

Tara A Uhler MD 


Daniel J Briceland MD, Secretary for State Affairs, 

Gregory P Kwasny MD, Secretary for Federal Affairs, 

William L Rich III MD, AAO Medical Directory of 

Health Policy, Cynthia Ann Bradford MD, Senior 

Secretary for Advocacy honor: 

James S Brown III MD Starkville, MS 


Los Altos, CA 

Robert A Copeland Jr MD Washington, DC 

William Ehlers MD 

Avon, CT 

Sanjay Goel MD 

Clarksville, MD 

John Haley MD 

Garland, TX 

Lawrence Halperin MD Boca Raton, FL 

John C Hoskins MD 

Knoxville, TN 

Suber S Huang MD 

Cleveland, OH 

Jeff S Maltzman MD 

Tucson, AZ 

Nancy McCann 

Fairfax, VA 

Phillip R Rizzuto MD, Secretary for Communications 

honors: 

Daniel J Briceland MD Carefree, AZ 

Ronald A Braswell MD Birmingham, AL 

Andrew G Iwach MD 

San Francisco, CA 

Rebecca J Taylor MD 

Nashville, TN 

Alan L Wagner MD 

Virginia Beach, VA 

Jonathan B Rubenstein MD, Secretary for Annual 

Meeting honors: 

Rosa Braga-Mele MD North York, Canada 

Christopher Rapuano MD Philadelphia, PA 

Andrew P Schachat MD, Ophthalmology Editor honors: 

Richard Y Hida MD 

Sao Paulo, Brazil 

Christopher Kai-shun Leung MD Hong Kong 

Gerald McGwin PhD 

Brimingham, AL 

Denis M O’Day MD 

Nashville, TN 

Joel Sugar MD 

Chicago, IL 

Tamara R Fountain MD, Secretary for Member 

Services honors: 



Jeffrey L Marx MD 

Lexington, MA 

Christie Morse MD 

Concord, NH 

David W Parke Sr MD North Branford, CT 

Jean E Ramsey MD 

Boston, MA 

Richard P Mills MD MPH, Chief Medical Editor, EyeNet 

honors: 

Steven I Rosenfeld MD Delray Beach, FL 

Ronald E Smith MD, Secretary for Global Alliance 

honors: 

Alaa M El-Danasoury MD Jeddah, Saudi Arabia 

Gabriel Van Rij MD 

Rotterdam, Netherlands 

George O Waring III MD Atlanta, GA 

16 


Achievement Award Program 

The Achievement Award program was originally developed to 

recognize individuals for their contributions to the Annual Meeting 

scientific program. In 1985 the program was expanded to include 

additional areas of contribution. In 1997 a new category, the Life 

Achievement Honor Award, was added. The Honor Award and the 

Senior Honor Award were renamed to Achievement Award and 

Senior Achievement Award in 1999. 

Categories of contribution for participation in the Annual Meeting 

include: 

• Instruction Course, Skills, or Breakfast With the Expert 

• Scientific E-Poster presentation 

• Film or Video Production 

• Scientific Exhibitor 

• Scientific Paper Presentation 

• Symposia 

• Scientific Poster Presentation 

• Subspecialty Day 

Informational Posters and Exhibits are not awarded points toward 

the Achievement Award programs. 

Other categories of contribution for Academy service include: 

• Committee Members 

• Trustees 

• State Society Presidents 

• Participants in the Academy’s Leadership Development Program 

• Representatives 

• Authors, Co-Authors, and Reviewers of Academy Educational 

Material 

• Councilors 

• Support of Advocacy Efforts 

The program is based on a cumulative point system; one point is 

awarded per category of contribution. Since 1998 an individual 

can earn a maximum of three points per year. For example, an 

individual serving on a committee and presenting two scientific 

papers, one instruction course, and one scientific poster 

during the Annual Meeting receives one point for committee 

participation, one point for the instruction course, and one point 

for the paper. The individual would not receive a fourth point for 

the poster or the additional paper. 

Individuals who earn 10 points receive the Achievement Award; 

individuals who earn 30 points receive the Senior Achievement 

Award; individuals who earn 60 points are eligible to receive the 

Life Achievement Honor Award. The Awards Committee reviews 

all nominees and submits their recommendations to the Board of 

Trustees for final approval. 

On behalf of the Board of Trustees, we are pleased to announce 

the recipients of the 2012 Achievement Award, Senior 

Achievement Award, and Life Achievement Honor Award for 

contributions to the Academy, its scientific and educational 

programs, and to the profession. 

The 2012 Awards Committee of the American Academy of 

Ophthalmology: 

Laurie Gray Barber MD – Chair 

Cynthia Ann Bradford MD 

Daniel J Briceland MD 

Mary G Lawrence MD 



Derek T Sprunger MD 





Life Achievement Honor Awards 

Life Achievement 

Honor Awards 

Susan H Day MD 


Yale L Fisher MD 

New York, NY 

Dale K Heuer MD 

Milwaukee, WI 

Edward J Holland 

Union, KY 

Thomas J Liesegang MD 

Ponte Vedra Beach, FL 

James G Ravin MD 

Toledo, OH 

Ivan R Schwab MD FACS 


George A Stern MD 

Missoula, MT 


Rochester, NY 

18 


Senior Achievement Awards 

Amar Agarwal MD 

Chennai, India 

Laurie Gray Barber MD 

Little Rock, AR 

David S Boyer MD 


Alan N Carlson MD 

Durham, NC 

Suresh R Chandra MD 

Madison, WI 

Senior Achievement 

Awards 

James Chodosh MD MPH 

Boston, MA 


Bloomington, MN 

Sophia Mihe Chung MD 

St Louis, MO 

Denise de Freitas MD 

Sao Paulo, Brazil 

John F Doane MD 

Leawood, KS 

James Philip Dunn Jr MD 

Baltimore, MD 

Jeffrey P Edelstein MD 

Chandler, AZ 

Deepak Paul Edward MD 

Baltimore, MD 

Philip J Ferrone MD 

Great Neck, NY 

Brian A Francis MD 


Brenda L Gallie MD 

Toronto, Canada 

Jay M Galst MD 

New York, NY 

Steven J Gedde MD 

Miami, FL 

Christopher A Girkin MD 

Birmingham, AL 

John M Haley MD OCS 

Garland, TX 

Morris E Hartstein MD 

Raanana, Israel 

Lawrence W Hirst, MD MBBS 

Graceville, Australia 

Michael S Ip MD 

Madison, WI 

Deborah S Jacobs MD 

Needham, MA 

Anselm Kampik MD 

Munich, Germany 




Awards 

Jemshed A Khan MD 

Overland Park, KS 

Terry Kim MD 

Durham, NC 

Mark A Latina MD 

Reading, MA 

Michael A Lawless MD 

Chatswood, Australia 

Jacqueline A Leavitt MD 

Rochester, MN 

Mark J. Lucarelli, MD FACS 

Madison, WI 

David Baker Lyon MD 

Leawood, KS 

Geva E Mannor MD MPH 

La Jolla, CA 

Robert A Mazzoli MD 

Steilacoom, WA 

Marc A Michelson MD 


Quan Dong Nguyen MD 

Baltimore, MD 

Mildred M G Olivier MD 

Hoffman Estates, IL 

Silvia D Orengo-Nania MD 

Houston, TX 

Mark Packer MD 

Eugene, OR 

Jean E Ramsey MD MPH 

Boston, MA 

Jade S Schiffman MD 

Houston, TX 

Steven D Schwartz MD 


Debra J Shetlar MD 

Houston, TX 

David G Shulman MD 

San Antonio, TX 

Rona Z Silkiss MD FACS 

Oakland, CA 

Samuel Solish MD 

Portland, ME 

Carole Gail Summers MD 

Minneapolis, MN 

Janet S Sunness MD 

Baltimore, MD 

Audrey R Talley-Rostov MD 

Seattle, WA 

Donald Tan MD FRCS FRCOphth 

Singapore, Singapore 

20 



Vance Michael Thompson MD 

Sioux Falls, SD 


Seattle, WA 

Michael S Vaphiades DO 


Abhay Raghukant Vasavada MBBS FRCS 

Ahmedabad, India 

Rudolph S Wagner MD 

Belleville, NJ 


Awards 

David K Wallace MD MPH 

Chapel Hill, NC 

Scott M Whitcup MD 

Irvine, CA 

Alan H Zalta MD 



Achievement Awards 


Madhu R Agarwal MD 

Redlands, CA 

Lama A Al-Aswad MD 

West New York, NJ 

Michael A Albert Jr MD 


Nitin Anand MD FRCS 

Halifax, England 

Donna M Applegate COT 

New Albany, IN 

Robert S Bailey Jr MD 

Wyndmoor, PA 

Roberto Bellucci MD 

Salo, Italy 

M Tariq Bhatti MD 

Durham, NC 

Carlos G Bianciotto MD 


Michael V Boland MD PhD 

Baltimore, MD 

Navaneet S C Borisuth MD PhD 

Rock Island, IL 

Francois-Xavier Borruat MD 

Lausanne, Switzerland 

Erick D Bothun MD 


Gagandeep S Brar MBBS 

Chandigarh, India 

Melissa G Cable MD 

Independence, MO 

Jorge G Camara MD 

Honolulu, HI 

Hilda Capo MD 

Miami, FL 

Albert Castillo BS 

San Antonio, TX 

Dean M Cestari MD 

Boston, MA 

Altug Cetinkaya MD 

Ankara, Turkey 

Meena Chakrabarti MBBS 

Trivandrum, India 

R V Paul Chan MD 

New York, NY 

Claus Cursiefen MD 

Koln, Germany 

Manuel B Datiles III MD 

Rockville, MD 

David A Della Rocca MD 

New York, NY 

22 



Hardeep S Dhindsa MD 

Reno, NV 

Sander Dubovy MD 

Miami, FL 

Ira Dunkel MD 

New York, NY 

Malvina B Eydelman MD 

North Potomac, MD 

Antonio Fea MD 

Torino, Italy 


Paul J Foster FRCS 

London, United Kingdom 

Anne E Fung MD 


Ron P Gallemore MD PhD 

Torrance, CA 

Dasa Gangadhar MD 

Wichita, KS 

Julian Garcia-Feijoo MD PhD 

Madrid, Spain 

Thomas A Gardner MD 

Denver, CO 

Sunir J Garg MD FACS 


Arthur Giebel, MD 

Walla Walla, WA 

Thomas A Graul MD 

Lincoln, NE 

Paul B Greenberg MD 

Providence, RI 

Satinder Pal Singh Grewal MD MBBS 

Chandigarh, India 

Dilraj Grewal MD 

Chicago, IL 

Erich Bryan Groos, MD 

Nashville, TN 

Eugene O Gullingsrud MD 

Edina, MN 

John R Guy MD 

Miami, FL 

Pedram Hamrah MD 

Cambridge, MA 

Richard A Harper MD 

Little Rock, AR 

Linda Harris 



Eau Claire, WI 

Seyed Javad Hashemian MD 

Tehran, Iran 


23



Natasha L Herz MD 

Rockville, MD 

R Nick Hogan MD PhD 

Dallas, TX 

J Jill Hopkins MD 


Osama I Ibrahim MD PhD 

Alexandria, Egypt 

Tsutomu Inatomi MD PhD 

Kyoto, Japan 

Edward K Isbey III MD 

Asheville, NC 

Hiroshi Ishikawa MD 

Pittsburgh, PA 

Natalio J Izquierdo MD 

San Juan, PR 

Johanna Jensen MD 

Nampa, ID 

Peter E Jensen MD 

Nampa, ID 

Vishal Jhanji MD 

Kowloon, Hong Kong 

Douglas A Katsev MD 

Santa Barbara, CA 

Rohit C Khanna DO 

Hyderabad, India 

Rahul Khurana MD 

Los Altos, CA 

Yoon-Duck Kim MD 

Seoul, Korea 

Aaleya F Koreishi MD 

Colleyville, TX 

Bobby S Korn MD PhD FACS 

La Jolla, CA 

Jean-Francois Korobelnik MD 

Bordeaux, France 

Alan Kozarsky, MD 

Atlanta, GA 

Pavel Kuchynka MD 

Prague, 10, Czech Republic 

Oh Woong Kwon MD 

Seoul, Korea 

Steven M Kymes PhD 

St Louis, MO 

Warren E Laurita MBA 

Cleveland, OH 

Erik Letko MD 

Littleton, CO 

Michele C Lim MD 


24 



Anthony J Lombardo MD PhD 

Indianapolis, IN 

Mauricio Maia MD 

Assis, Brazil 

Marcus M Marcet MD 

Cyberport, Hong Kong 

Alexandre S Marcon MD 

Porto Alegre, Brazil 

Harry H Mark MD FACS 

North Haven, CT 


Ian L McAllister MD 

Nedlands, Australia 

Peter J McCluskey MD 

Sydney, Australia 

Gregory J McCormick MD 

Hinesburg, VT 

Gerald McGwin PhD 


Erik L Mertens MD FEBOphthal 

Antwerp, Belgium 

No Photo 

Available 

Monte D Mills MD 


Carlos A Moreira, MD PhD 

Curitiba, Brazil 

Susan K Mosier MD 

Manhattan, KS 

Raghu Mudumbai MD 

Seattle, WA 

Francis L Munier MD 

Lausanne, Switzerland 

Tanuj Nakra MD 

Austin, TX 

Aaron L Nathenson MD 


Lisa Nijm MD JD 

Springfield, IL 

Rudy Nuijts MD 

Maastricht, Netherlands 

Rahul T Pandit MD 

Houston, TX 

Ki Ho Park MD PhD 

Seoul, Korea 

John D Peters MD 

Omaha, NE 

Paul M Phillips MD 

Sewickley, PA 

David E I Pyott CBE 

Irvine, CA 

Mujtaba A Qazi MD 

Chesterfield, MO 


25



Alireza Ramezani MD 

Tehran, Iran 

P Kumar Rao MD 

St Louis, MO 

Anthony D Realini MD 

Morgantown, WV 

Cynthia Roberts PhD 

Columbus, OH 

Karolinne M Rocha MD 

Shaker Heights, OH 

Reginald J Sanders MD 

Chevy Chase, MD 

Robert M Schwarcz MD 

New York, NY 

Vincenzo Scorcia MD 

Rome, Italy 

Stefan Seregard MD 

Stockholm, Sweden 

Diana J Shamis COMT 

Gainesville, FL 

Kimiya Shimizu MD 

Kanagawa, Japan 

Roni M Shtein MD 

Ann Arbor, MI 

Jonathan E Silbert MD 

Bethany, CT 

Annapurna Singh MD 

Cleveland, OH 

Arthur J Sit MD 

Rochester, MN 

Allan R Slomovic MD 


Lois E H Smith MD PhD 

Boston, MA 

R Theodore Smith MD 

New York, NY 

Sharon D Solomon MD 

Baltimore, MD 

Margaret Sophia Spencer MD 

Panorama City, CA 

Erin D Stahl MD 

Kansas City, MO 

Mitchell B Strominger MD 

Boston, MA 

Jeanine Suchecki MD 

Farmington, CT 

Kyung Rim Sung MD PhD 

Seoul, Korea 

Colin S Tan MBBS 

Singapore, Singapore 

26 



Shachar Tauber MD 

Springfield, MO 

Tongalp H Tezel MD 

Louisville, KY 

Christopher K Thiagarajah MD 

New York, NY 

Nancy A Tucker MD 


Harvey S Uy MD 

Makati City, Philippines 


Pravin Vaddavalli MD 

Hyderabad, India 

Gregory P Van Stavern MD 

St Louis, MO 

Deborah K VanderVeen MD 

Boston, MA 

Jan A Venter MD 

London, England 

Steven D. Vold MD 

Fayetteville, AR 

Jonathan D Walker MD 

Fort Wayne, IN 

Robert E Wiggins MD MHA 

Asheville, NC 

Edward A Wylegala MD PhD 

Katowice, Poland 

Tetsuya Yamamoto MD 

Gifu, Japan 

Roger P Zelt MD FACS 

Pittsburgh, PA 


27

2012 International Awards 

International Awards 

International Ophthalmologist Education Award Recipients 

The International Ophthalmologist Education Award was developed to recognize international Academy members who pursue lifelong education 

in ophthalmology. To qualify, international members need to earn 90 Continuing Medical Education (CME) credits over a period of three 

years. Half of these credits (45) must be from Academy-sponsored CME activities. After applying for the award, members are responsible for 

recording their Academy and non-Academy credits on their online CME transcript. 

Hugh D McGowan MD (Canada) 

Czehong Low MBBS FRCS (Singapore) 

Ali A Alrajhi MD (Saudi Arabia) 

Nicanor F Tinageros MD (Peru) 

Armando J Rivas MD (Venezuela) 

Rosario Tapia-Ramirez MD (Mexico) 

Fabrizio I Camesasca MD (Italy) 

Jorge E Valdez MD (Mexico) 

Klaus N Ditzen MD (Germany) 

Emilio M Dodds MD (Argentina) 

Adolfo Guemes MD (Argentina) 

Olivia Early MBBCh (Northern Ireland) 

Anita Panda MD MRCOPHTH (India) 

Pierre George Mardelli MD (Lebanon) 

Sawsan R. Nowilaty MD (Saudi Arabia) 

Niro Kasahara MD (Brazil) 

Jeong-Min Hwang MD (Korea Republic of) 

Arif Omar Khan MD (Saudi Arabia) 

Daniel A Badoza MD (Argentina) 

Pavel Rozsival MD (Czech Republic) 

Sajjad Haider MBBS (United Kingdom) 

Abdul Hamid Awan MBBS (Pakistan) 

Hala Mohammed Nassim MBBS (Saudi Arabia) 

Sunil Shah MD (England) 

Ashok Sharma MD (India) 

Rafael A Macias MD (Colombia) 

Ahmed R Parkar MBChB (Kenya) 

Chee-Chew Yip MBBS (Singapore) 

Juliano V Coatti MD (Brazil) 

Nagpal Manish MS DO FRCS (India) 

Roberto Murillo Limongi S Carvalho MD (Brazil) 

Eduardo Jorge MD (Brazil) 

Carmen N Demetrio MD (Argentina) 

Benjamin F Mendoza Gonzales MD (Peru) 

Sergio Hernandez-Da Mota MD (Mexico) 

Hector J Barros Bermudez MD (Colombia) 

Sidney A Somoza Cienfuegos MD (El Salvador) 

Martin Baumeister MD (Germany) 

Jae Woo Jang MD PhD (Korea Republic of) 

Colin J Vize MBBS (England) 

Jodhbir S Mehta MBBS BSc (Singapore) 

Philippe M Desmangles MD (Switzerland) 

Shadrokh Nabili MD (United Kingdom) 

Thi Ha Chau Tran MD MBBS (France) 

Marc Salle MD (France) 

Milagros E Martinez MD (Dominican Republic) 

Masako Sugai MD (Japan) 

Paul E Tesha MBChB (United Kingdom) 

Roberto Gallego-Pinazo MD (Spain) 

Balakrishna V Kumar MBBS (England) 

Gernot Petzold MD (Germany) 

Gian P Giuliari MD (Venezuela) 

Anupama P Rao MBBS DO (United Arab Emirates) 

Marcus Montello Franca MD (Brazil) 

Emmanouil Gkogkos MD (Greece) 

Saiful I Bhuiyan MBBS (Bangladesh) 

Shivanand J Sheth MBBS (India) 

Marcos D Parra Orjuela MD (Colombia) 

Nam Soo Han MD (Korea Republic of) 

Tarek A M Abdel-Fattah FRCS (Saudi Arabia) 

Andreas Kotoulas MD (Greece) 

Norinobu Kaga MD (Japan) 

Anthi Bakouli MD (Greece) 

International Scholar Award Recipients 

The International Scholar Award honors international Academy members who have demonstrated their dedication to lifelong education in 

ophthalmology. 

To qualify, international members must have already received the International Ophthalmologist Education Award. They need to earn 60 Continuing 

Medical Education (CME) credits within two years of applying and half of the credits (30) must be from AAO sponsored CME activities. They must 

also successfully complete a timed, online self-assessment test. 

Paul A Adler MBBS (Australia) 

Francesco P Bernardini MD (Italy) 

Massimo Busin MD (Italy) 

David Choy MD (Mexico) 

Abali I Chuku MBBS (Nigeria) 

Javier Cordoba Umana MD (Costa Rica) 

Mohamed L Daramy MD (England) 

Carlo De Conciliis MD (Italy) 

Hosam Ibrahim El Sheha MD (Saudi Arabia) 

Hazem A El-Sabagh MBBS (Saudi Arabia) 

Arnaldo Espaillat MD (Dominican Republic) 

Antonio Ferreras MD PhD (Spain) 

Bruno M Fontes MD (Brazil) 

Graciela Garcia-Briones MD (Mexico) 

Jose A Gegundez Fernandez MD PhD (Spain) 

Hosam A Ibrahim Elzembely MD (Egypt) 

Hadi Kjaerbo MD (Denmark) 

Salvador Gerardo A. Lopez MD (El Salvador) 

Miguel J Maldonado MD PhD (Spain) 

Eduardo F Marques MD (Portugal) 

Marcia C Martins MD (Brazil) 

Prakash Mathew MBBS (England) 

Mehdi Modarres MD (Iran Islamic Republic of) 

Alejandro Navas MD (Mexico) 

Andres Perez Casas MD (Spain) 

Emeterio Pina-Hurtado MD PhD (Spain) 

Karen Salcedo MD (Venezuela) 

Juan Salinas MD (United Kingdom) 

Daniel Horacio Scorsetti MD PhD (Argentina) 

Tarun Sharma MBBS (India) 

Gopal Lal Verma MD (India) 

Ernesto S Yapur MD (Argentina) 

Yoram Zevnovaty-Braun MD (Mexico) 

28 


Visionary Society, Corporate and Organizational Donors 

The Visionary Society 

The Academy greatly appreciates the generous support 

provided by the following corporations, 

organizations and individuals. 

2011 Corporate and 

Organizational Donors 

The Academy greatly appreciates the support provided 

by the following corporations and organizations to 

the Academy Foundation.* 

The Visionary Society recognizes those donors who have 

contributed $1 million or more to the Academy Foundation. 

Platinum Members 

(One-time contributions of $1 million 

or more in two or more fiscal years) 

Alcon, Inc. 

Pfizer Ophthalmics 

Gold Members 

(One-time contributions of $1 million 

or more in any one fiscal year) 

Alice R. McPherson, MD 

Dr. Charles R. and Judith G. Munnerlyn 

Stanley M. Truhlsen, MD 


$250,000 to $499,999 

Genentech, Inc......................................................................$310,000 

Allergan, Inc..........................................................................$285,000 

Alcon, Inc..............................................................................$277,500 

Knights Templar Eye Foundation, Inc...................................$250,000 

$50,000 to $99,999 

Retina Research Foundation...................................................$50,000 

$25,000 to $49,999 

Merck & Co., Inc.....................................................................$40,000 

International Ophthalmic Industry Society.............................$36,500 

Terminal Varreux SA...............................................................$30,000 

Abbott Medical Optics............................................................$27,500 

Santen, Inc..............................................................................$27,500 

Visionary Society 

and Donors 

Members 

(Cumulative giving of $1 million or more) 

Knights Templar Eye Foundation, Inc. 

Abbott Medical Optics, Inc. 

Eli Lilly and Company 

Genentech, Inc. 

Merck & Co., Inc. 

Industry Support 

The Academy would like to thank the following companies 

for their generous support of the 2012 Joint Meeting 

and Subspecialty Day. 

Joint Meeting Gold Support Level 

Genentech, Inc. 

Joint Meeting Bronze Support Level 

Santen, Inc. 

Glaucoma Subspecialty Day 

Merck & Co., Inc. 

Retina Subspecialty Day 

Regeneron Pharmaceuticals, Inc. 

$10,000 to $24,999 

STAAR Surgical Company......................................................$19,500 

The Allergan Foundation........................................................$15,000 

AcuFocus, Inc..........................................................................$12,500 

Bausch + Lomb........................................................................$12,500 

Up to $10,000 

Avedro, Inc................................................................................$7,500 

Freeman Company....................................................................$7,500 

Oculus Optikgeraete GMBH.....................................................$5,000 

Schepens International Society...............................................$5,000 

Eli Lilly and Company................................................................$4,000 

Columbia Valley Daybreak Rotary Club ...................................$4,000 

Rotary Club of Birmingham.......................................................$4,000 

Sea Island Rotary Club.............................................................$4,000 

Roanoke Rotary Club................................................................$2,500 

Rotary Club of Alamance..........................................................$2,500 

Brainstormer LLC......................................................................$1,000 

Dorsey & Whitney....................................................................$1,000 

* This list recognizes gifts and pledges made from January 1 – December 31, 2011, 

with cumulative support of $1,000 or greater. 

Cataract Monday 

Alcon Laboratories, Inc. 

Bausch + Lomb 


29

Invest in Your 

Academy and 

the Future of 

Ophthalmology 

For more than 30 years, the Foundation of the American 

Academy of Ophthalmology has been committed to 

funding the Academy’s priority educational, quality of care 

research and service programs. 

These programs give the gift of sight, forge new paths in 

Make a gift today! 

www.faao.org/donate 

Questions? 

Contact Karen Duke 

at kduke@aao.org 

or 415.447.0356. 

www.faao.org 

education and health policy research, and build upon 

the distinguished legacy of our profession. The Academy 

supports its members from residency through retirement, 

providing the resources needed to administer the best 

possible patient care. 

Support from members like you plays a critical part 

in helping the Foundation to advance the Academy’s 

mission — dues alone are not enough. With your 

contribution, we can continue to truly make a difference 

in our profession and in our communities.

GetEyeSmart.org 

Educating the Public | Strengthening Our Profession 

Provided by the 

American Academy of Ophthalmology to: 

> Empower consumers to protect their eye health 

> Raise awareness of eye diseases and conditions 

> Promote ophthalmologists as the leaders in 

eye care 

EyeSmart features: 

> Comprehensive, reliable, easy-to-understand 

information on everything related to eye health 

– in English and Spanish (OjosSanos.org) 

> Timely tips and news articles to help people 

keep their eyes healthy 

> Educational videos, animations and images 

> Eye health Q&As that answer common 

questions about eye diseases and conditions 

Come to the Academy Resource Center, Booth 508, at the 2012 Joint Meeting in Chicago 

to learn more about how EyeSmart can benefit your practice and your patients. 

“Like” EyeSmart on Facebook to get 

the latest eye health news for your 

patients and details on important 

awareness campaigns.

Academy Online Community 

Where all of ophthalmology goes to connect 

Are you making the most of this Academy 

member benefit? 

The Academy’s online community is a secure, 

member-only forum where you can: 

• Consult with colleagues on difficult cases 

• Discuss clinical topics in your area of 

expertise 

• Get opinions on electronic health records 

• Connect with Academy leadership through 

blog posts 

• Reconnect with classmates and colleagues 

“The Academy online community is 

a perfect setting to get ideas from 

other practitioners on how to manage 

difficult cases. It is a very positive 

environment where I can share ideas 

and techniques on patient care, keep 

updated on the politics of medicine, 

and research practice management 

tools such as electronic medical 

records.” 

Connect with your colleagues today — it’s easy! 

• Scan this QR code with your smartphone or 

visit www.aao.org/community 

• Log in with your existing Academy 

username and password 

• Browse, comment and share 

– Chad R. Bouterse, 

DO, Clarkston, Wash. 

Join the conversation! 

www.aao.org/community

ALL NEW! 

See it at: 

AAO 

Chicago 

Booth 2344 

Intuitive, 

Inspired 

Pachymetry. 

With Bluetooth ® wireless connectivity, one-button navigation, rotating color LCD 

screen and rechargeable lithium ion battery, the Reichert ® iPac ® Pachymeter 

is the most advanced handheld pachymeter available. 

Reichert ® is Pachymetry. Learn more at www.reichert.com/ipac 

An American Company • Made in the USA 

Follow us: 

@ReichertTech 

© 2012 AMETEK, Inc. All rights reserved. 09/12 Reichert, Reichert Technologies and iPac are registered trademarks of Reichert, Inc. 

“Advancing Eye Care. Preserving Sight.” is a trademark of Reichert, Inc. AMETEK is a registered trademark of AMETEK, Inc. Bluetooth is a registered trademark of Bluetooth SIG, Inc.

No daily calibration required! 

Large easy to read 

LCD display on 

both sides. 

4X longer lasting 

battery. Over 2,500 

measurements. 

Easy to use push 

button activation. 

Actual size shown. 

Uses genuine 

OCU-FILM ® + 

tip covers, for 

the most accurate 

measurement. 

Cushioned grip 

to help prevent 

slippage. 

Award-winning, 

ergonomic design, 

for left or right 

handed use. 

Your wish is our design. 

TONO-PEN AVIA ® ... 

All the features you asked for, built on 30 years of 

TONO-PEN ® accuracy, reliability and ease of use. 

Visit us at: 

AAO 

Chicago 

Booth 2344 

Reichert ® is Tonometry. See more at www.reichert.com/tonopen 

An American Company • Made in the USA 

Follow us: 

@ReichertTech 

© 2012 AMETEK, Inc. All rights reserved. 09/12 Reichert, Reichert Technologies, TONO-PEN, TONO-PEN AVIA, and OCU-FILM are registered trademarks of Reichert, Inc. 

“Advancing Eye Care. Preserving Sight.” is a trademark of Reichert, Inc. AMETEK is a registered trademark of AMETEK, Inc. All other trademarks are properties of their respective owners.

Selection Committees 


Jonathan B Rubenstein MD* 

The Annual Meeting Program Committee is responsible for the 

Annual Meeting Scientific Program, including Breakfast With the 

Experts, Instruction Courses, Symposia, and Scientific Papers, Posters 

and Videos. 

Each subcommittee has five reviewers who grade the instruction 

courses and paper/poster abstracts, and three subcommittee members 

who review the grades and select the courses and abstracts for 

presentation. The chair of the subcommittee represents the group on 

the Annual Meeting Program Committee. This peer-review selection 

process ensures the quality and integrity of Academy educational 

programs and allows broader input from Academy Members. 

The Annual Meeting Program Committee monitors the scientific program 

by reviewing evaluation data, the post-Annual Meeting survey 

and reports from independent course/symposium monitors. 

Volunteer to be a reviewer by visiting Member Services on the 

Academy’s website and completing the online volunteer form. Volunteer 

to be a course/symposium monitor by e-mailing the Meetings 

Division at meetings@aao.org. 

Associate Secretary for the Annual Meeting Program 

Cynthia Mattox MD FACS* 

Annual Meeting Program Committee 

Keith D Carter MD FACS 

Kathryn A Colby MD PhD* 

William J Fishkind MD FACS* 


Parag A Majmudar MD* 

Carla J Siegfried MD* 

John T Thompson MD* 

Terri L Young MD* 

Subcommittee for: Cataract 

Chair 


Subcommittee Members 

Steven Henry Dewey MD* 

Mitchell P Weikert MD* 

Subcommittee Reviewers 

George Beiko MD* 

Uday Devgan MD* 

Luther Fry MD* 

John A Hovanesian MD* 

Kevin M Miller MD* 

Subcommittee for: Cornea, External Disease 

Chair 



Bennie H Jeng MD* 

Terry Kim MD* 


Jessica B Ciralsky MD 

Shahzad I Mian MD* 

Robert L Schultze MD* 

Neda Shamie MD* 

Gary Alan Varley MD* 

Subcommittee for: Glaucoma 

Chair 

Carla J Siegfried MD* 


Jess Thomas Whitson MD FACS* 

Martha M Wright MD 


Steven J Gedde MD* 

Malik Y Kahook MD* 

Martha Motuz Leen MD* 

Steven R Sarkisian MD* 

Molly Walsh MD* 

Subcommittee for: Neuro-Ophthalmology, Computers/ 

Information Technology, Ethics, General Medical Care, 

International Ophthalmology, Medical Education, Ophthalmic 

History and Vision Rehabilitation 

Chair 



Sophia Mihe Chung MD* 

Michael S Lee MD* 


Madhu R Agarwal MD 

John B Kerrison MD* 

Byron L Lam MD* 

Howard D Pomeranz MD PhD 

Prem S Subramanian MD PhD* 

Subcommittee for: Ocular Tumors, Pathology, and Orbit, 

Lacrimal Plastic Surgery 

Chair 

Keith D Carter MD FACS 


Don O Kikkawa MD 

Matthew W Wilson MD 


Imtiaz A Chaudhry MD PhD 

Vikram D Durairaj MD* 

Bobby S Korn MD PhD FACS* 

Julian D Perry MD* 

Erin M Shriver MD 

Subcommittee for: Pediatric Ophthalmology, Strabismus 

Chair 

Terri L Young MD* 


Hilda Capo MD 

Michael F Chiang MD* 


Arlene V Drack MD* 

Judith E Gurland MD 

Natalie C Kerr MD 



33



Edward L Raab MD 

Martha P Schatz MD 

Subcommittee for: Refractive Surgery and Optics, Refraction, 

Contact Lenses 

Chair 

Parag A Majmudar MD* 


Karl G Stonecipher MD* 

Sonia H Yoo MD* 


David A Goldman MD* 

Rajesh K Rajpal MD* 

William B Trattler MD* 

John Allan Vukich MD* 

Elizabeth Yeu MD* 

Subcommittee for: Retina, Vitreous and Intraocular 

Inflammation, Uveitis 

Chair 



Janet Louise Davis MD* 

Srinivas R Sadda MD* 


Ron Afshari Adelman MD MPH* 

Rajendra S Apte MD PhD* 

J Fernando Arevalo MD FACS 

Sophie J Bakri MD* 

Christina J Flaxel MD 

Richard S Kaiser MD* 

Mathew W MacCumber MD PhD* 

Colin A McCannel MD* 

Dante Pieramici MD* 


Special Projects Committee 

The Special Projects Committee is responsible for developing Annual 

Meeting programs to complement those that are submitted by 

members or societies. 

Associate Secretary 

Gary S Schwartz MD 

Committee Members 

Maria M Aaron MD 

Ali R Djalilian MD 

Jill S Melicher Larson MD* 

Scott C Oliver MD* 

Douglas J Rhee MD* 

R Michael Siatkowski MD* 

Skills Transfer Advisory Committee 

The Skills Transfer Advisory Committee is responsible for selecting 

the Skills Transfer courses and labs. 

Associate Secretary 

Thomas W Samuelson MD* 


Iqbal K Ahmed MD* 

Susan R Carter MD 

Jack A Cohen MD FACS 

William Barry Lee MD* 


Julie H Tsai MD 

Asia-Pacific Academy of Ophthalmology (APAO) Planning 

Committee 

Chair 

Clement C Y Tham MBBS* 


Shigeru Kinoshita MD* 

Charles McGhee PhD FRCOphth FRANZCO* 

Tien Yin Wong MBBS* 

AAOE Program 

The AAOE Program Committee, with the AAOE Board of Directors, 

are responsible for selecting the AAOE Program and Practice Management 

Breakfast With the Experts roundtables. 

Chair 

Elise Levine MA CRC OCS* 

Board Members 

Nancy Baker 

Albert Castillo 

Tim D Couch 

Sandra Dixon Curd MBA COE COA OCS 


Rajiv R Rathod MD 

Robert E Wiggins Jr MD MHA* 


Heather Hambrick Dunn COA 

Paulette Hottle 

Warren E Laurita MBA 

Susan Stratton OCS 


Laura G Hobbs 

Maryanne Inman 

Diane McVinney CPC OCS 

Denitra Michell Miller-Ballard OCS CPC 

Mark M Prussian 

Brittney Wachter 

Ivonne R Witt 

Academy Staff 

Julia Fennell 

Sangeeta Fernandes 

Brandi Garrigus 

Susan Oslar 

Melanie Rafaty 

Michael Rhea* 

Debra Rosencrance 

Elizabeth Washburn 

34 


Programs-by-Day 

CAT - Cataract 

COM - Computers, Information Technology 

COR - Cornea, External Disease 

EHR - Electronic Health Records 

ETH - Ethics 

GEN - General Medical Care 

GLA - Glaucoma 

GO - Global Ophthalmology 

HIST - Ophthalmic History 

INTRA - Intraocular Inflammation, Uveitis 

MEDED - Medical Education 

Topic Key 

NEURO - Neuro-Ophthalmology 

NON - General Non-Medical 

OPTIC - Optics, Refraction, Contact Lenses 

PATH - Ocular Tumors, Pathology 

PEDS - Pediatric Ophthalmology, Strabismus 

PLAST - Orbit, Lacrimal, Plastic Surgery 

PRACTICE MANAGEMENT/AAOE 

PM-ASC - Ambulatory Surgery Centers 

PM-BUS - Business Operations & Finance 

PM-EHR - Electronic Health Records 

PM-HRM - Human Resources 

PM-IMT - Information Technology 

PM-MKT - Marketing & Business Development 

PM-OPT - Optical Dispensing 

PM-PROF - Professional Growth 

PM-REMB - Coding & Reimbursement 

PM-RISK - Compliance & Risk Management 

REF - Refractive Surgery 

RET - Retina, Vitreous 

VIS - Vision Rehabilitation 

Locations: All rooms are in McCormick Place, unless otherwise indicated. 

Courses designated with a plus (+) sign are part of the Academy Plus course pass. Courses designated with a dollar ($) sign are not 

included in the course pass and must be purchased separately. Sessions and events that are left blank are free. Content from courses 

with a diamond (u) will be captured and available to purchase on AAO Meetings On Demand. Product options include Subspecialty Day 

meetings and/or Joint Meeting. Courses are not sold individually. 


Time Type No. Title Topic $ Room 

On 

Demand 

7:30 AM - 3:00 PM SPE SPE01 DICOM Working Group 9 - Eye Care COM Hyatt Regency 

McCormick Place 

CC24ab 

8:00 AM - 5:00 PM SUB Retina 2012: The Winds of Change RET $ Arie Crown Theater 

(E) 

u 

SUB Refractive Surgery 2012: The Era of Lasers and Lenses REF $ Hall B (N) u 

Page 

258 

Saturday, Nov. 10 (cont.) 


On 

Demand 

Page 

7:50 AM - 5:20 PM SUB Uveitis 2012: The Challenges Continue … But the Future Is Bright INTRA $ E450 u 

8:00 - 11:00 AM SOS Coding SOS PM-REMB $ S105 282 

8:00 AM - 12:00 PM AAOESP SPE02 The Profitable Practice: Managing Your Practice’s Billing Operation PM-BUS $ S504bc 296 

8:00 AM - 5:15 PM SUB Pediatric Ophthalmology 2012: Learning from Our Past, Looking to Our PED $ S100c 

Future 

u 

SUB Oculofacial Plastic Surgery 2012: Form, Function, Finesse PLAST $ S406a u 

8:00 AM - 5:30 PM SUB Retina 2012: The Winds of Change RET $ Arie Crown u 

Theater (E) 

SUB Refractive Surgery 2012: The Era of Lasers and Lenses REF $ Hall B (N) u 

SUB 

Cornea 2012: Pushing Surgical Boundaries, Professional Development, COR $ S100ab u 

and Popular Opinion 

SUB 

Glaucoma 2012: Managing Challenging Glaucoma Problems—Merging GLA $ E354 u 

Art and Science 

9:00 AM - 12:00 PM SPE SPE03 Selling and Purchasing on eBay, Craigslist, and other Mediums: How to COM $ N227a 258 

Clean your Office with Profit 

9:00 AM - 4:00 PM AAOESP SPE04 Harnessing the Effective Leader Within: Strategies to Improve Your PM-HRM $ S503ab 296 

Leadership Skills 

12:00 - 1:30 PM SPE SPE05 Networking with the Experts - Knowledge and Tips for the Young 

GEN $ S101ab 258 

Ophthalmologist 

12:00 - 3:00 PM AAOESP SPE06 Enhancing Quality, Productivity and Profits in the 21st Century Ophthalmic PM-ASC S501 296 

ASC 

12:00 - 5:00 PM LL Learning Lounge Booth 107 261 

12:30 - 3:30 PM CAMP Coding Camp PM-REMB $ S105 282 

12:30 - 4:30 PM AAOESP SPE07 Optical Dispensing Boot Camp PM-OPT $ S502a 296 

1:00 - 2:15 PM ACADCAFE SYM45 Academy Café: Uveitis INTRA S406b u 130 

1:00 - 4:00 PM SPE SPE08 Use Blogging & Social Networking to Super Charge Your Website & 

Internet Marketing with guest presenter: Randall Wong MD 

COM $ N227a 260 


Up-to-date information is available in the Program Search on the Academy’s website: www.aao.org/2012. 

35




On 

Demand 

Page 

2:30 - 3:45 PM ACADCAFE SYM46 Academy Café: Cataract CAT S406b u 130 

2:30 - 4:00 PM SYM SYM01 What is Global Ophthalmology? GO S405 u 132 




On 

Demand 

Page 

7:30 - 8:30 AM BWE Breakfast With the Experts Roundtables $ Hall A (S) 52 

8:00 - 10:00 AM SYM SYM53 Introduction to Refractive Surgery for Residents REF S503ab 132 

8:30 - 10:00 AM OPSESS SYM54 Opening Session GEN Hall B (N) u 129 

9:00 - 10:00 AM IC 148 Using an Add-On Mirror Telescopic Intraocular Implant to Assist AMD CAT + S106b 60 

Patients: Patient Selection, Surgical Technique, and Clinical Results 

IC 149 “Big Bubble” Technique of Deep Anterior Lamellar Keratoplasty: A 

COR + S106a 68 

Simplified Approach to Successful Surgery 

9:00 - 11:15 AM SKILLS LEC150/ Management of Vitreous for the Anterior Segment Surgeon CAT + S105a 115 

150 

SKILLS LEC151/ Phacoemulsification and Advanced Techniques CAT + N427bc u 115 

151 

SKILLS LEC152/ Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve GLA + S105bc u 119 

152 Fiber Layer 

SKILLS LEC153/ 

153 

Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course PLAST + S105d 122 

SKILLS 

LEC154/ 

154 

Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense 

Pulsed Light, Radiofrequency, and Ultrasound Devices 

PLAST + S102d 123 

IC 155 Thyroid Eye Disease PLAST + S104b 93 

SKILLS LEC156/ ISRS Laser Refractive Surgery Course REF + S103bc 126 

156 

SKILLS LEC157/ Macular OCT: Mastering the Basics RET + S102abc u 127 

157 

9:00 - 11:30 AM SKILLS LAB158 Soft Contact Lens Fitting for the Practicing Ophthalmologist COR $ N227a 122 

SKILLS LAB159 Basic Oculoplastic Surgery PLAST $ N226 123 

9:30 - 11:00 AM SKILLS LAB432A 23-Gauge Vitrectomy: What, When, and How? Required: LEC432 RET $ N228 128 

9:30 - 11:30 AM SKILLS LAB160 Is It Time to Replace Gonioscopy by Anterior Segment Imaging in the GLA $ N231 120 

Diagnosis and Management of Angle-Closure Glaucoma? 

10:00 - 10:30 AM SPE SPE24 Annual Business Meeting NON Hall B (N) 258 

10:00 AM - 12:00 PM SYM SYM02 Vision Rehabilitation Education: Effectively Transmitting the Need for Low VIS S504d 132 

Vision Services to the Ophthalmic Community 

AAOESP SPE23 General Session: The 4 Disciplines of Execution PM-BUS S501 296 

10:00 AM - 2:00 PM SPE SPE09 2012 Young Ophthalmologist Program NON + S101ab 258 

10:15 - 11:15 AM IC 161 IOL Fixation With Fibrin Glue: Technique and Results CAT + N427a 60 

IC 162 Failed Graft: Never Say Die! COR + N140 68 

IC 163 Follow the Cornea: Do You Know Where Your Corneal Transplant Tissue COR + N139 68 

Comes From? 

10:15 AM - 12:00 PM OP OP01 Cataract Femtosecond Original Paper Session CAT Grand Bllrm u 154 

S100c 

OP OP02 Glaucoma Original Paper Session GLA S405 u 160 

10:15 AM - 12:30 PM IC 164 Advanced IOL Power Calculations for the Cataract and Refractive Surgeon CAT + E351 u 60 

IC 165 Learning Phaco Chop: Pearls and Pitfalls CAT + S404 u 60 

SKILLS LEC166/ Manual Extracapsular Cataract Extraction (ECCE/SICS) Surgery: Indications CAT + E352 116 

166 and Techniques 

IC 167 Phaco Pearls for the Beginner CAT + S505ab 61 

IC 168 Extreme Cornea: Diagnostic and Management Dilemmas in Your Practice COR + S103d 68 

IC 169 Herpes Simplex Keratitis: When Herpes Isn’t a Dendrite, and Vice Versa COR + N138 69 

IC 170 Interdisciplinary Approach to Kerato-prosthesis Surgery and Management, COR + N136 69 

From the Subspecialist’s Perspective 

36 

Type Key: AAOEIC = AAOE Instruction Course, AAOESP = AAOE Special Meeting, ACADCAFE = Academy Café, BWE = Breakfast with the Experts, IC = Instruction Course, 

LL = Learning Lounge, OP = Original Paper Session, OPSESS = Opening Session, PT = Poster Tour, SKILLS = Skills Transfer Course, SPE = Special Meeting, 

SPOTLIT = Spotlight Session, SUB = Subspecialty Day Meeting, SYM = Symposium




On 

Demand 

Page 

10:15 AM - 12:30 PM IC 171 Recent Developments in the Diagnosis and Management of Conjunctival COR + S403b 69 

Tumors 

IC 172 Combined Cataract Surgery With Trabeculectomy: Guidelines, Indications, GLA + S106b 80 

Methods, Techniques, and Postoperative Management 

IC 173 Tubes, Ties, and Videotape: Surgical Video of Baerveldt Glaucoma 

GLA + N135 80 

Implants and Managing Complications 

IC 174 Optic Neuropathy in Asia: Clinical Characteristics and Basic Research NEURO + N427d 89 

SKILLS LEC175/ Introduction to Nasal Anatomy and Rhinoplasty PLAST + S104a 123 

175 

IC 176 Common Asian Eyelid Surgery: A Video-Based Course PLAST + S106a 93 

IC 177 Advanced Vitreoretinal Surgical Techniques and Instrumentation RET + E350 104 

IC 178 Principles of Pediatric Retinal Surgery in Pediatric Retinal Diseases Other RET + S103a 104 

Than ROP 

IC 179 Eye Genetics for Ophthalmologists RET + N137 105 

10:30 AM - 5:00 PM LL Learning Lounge Booth 107 

10:30 - 11:45 AM SYM SYM03 Best of the Posterior Segment Specialty Meetings 2012 RET S406a u 132 

ACADCAFE SYM47 Academy Café: Combined Procedures GEN S406b u 130 

10:30 AM - 12:00 PM SPOTLIT SPO1 Spotlight on Innovation in Ophthalmology: From Theory to Therapy MEDED Grand Ballrm u 133 

S100ab 

SYM SYM04 From Metal to Molecules: The Evolution of Oculofacial Plastic Surgery PLAST E450 u 134 

SYM SYM05 Corneal Stem Cell Advances in Clinical and Laboratory Research COR Hall B (N) u 133 

11:30 AM - 12:30 PM IC 180 Anterior Segment OCT COR + N427bc u 69 

IC 181 Innovative Uses of Adhesives in Anterior Segment Surgery COR + N139 70 

IC 182 State-of-the-Art Use of the Femtosecond Laser for Keratoplasty, Cataract COR + N427a 69 

Surgery, and Astigmatic Incisions 

IC 183 Electronic Health Records: Compliance and Medicolegal Issues EHR + S105bc u 77 

IC 184 3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying Glaucoma Damage GLA + S105a 80 

and Progression 

IC 185 Emergency Neuro-Ophthalmology: Diagnosis and Management NEURO + S102abc u 89 

IC 186 Avoiding and Managing Blepharoplasty Complications PLAST + S102d 93 

IC 187 Management of Strabismus in Thyroid Eye Disease PEDS + S103bc 98 

SKILLS LEC188/ New Techniques for Strabismus Surgery PEDS + N140 126 

188 

IC 189 Understanding Small Aperture Corneal Implant Technology: From 

REF + S104b 101 

Indications to Outcomes 

IC 190 Custom Ablation 2012: How to Start and Obtain the Best From Your REF + S105d 101 

Custom Ablation 

11:30 AM - 5:30 PM SPE SPE10 Fall Council Meeting and Surgery by Surgeons Forum GEN Fairmont Chicago 

259 

Imperial Ballrm 

12:00 - 1:30 PM SKILLS LAB150A Management of Vitreous for the Anterior Segment Surgeon 

CAT $ N228 115 

Prerequisite: LEC150 

12:15 - 1:45 PM SYM SYM06 Contagion! Epidemics in Ophthalmic History HIST S405 u 134 

SYM SYM07 Cataract Surgery: The Cutting Edge CAT Hall B (N) u 134 

SPE SPE11 2013 Medicare Update GEN Grand Ballrm u 259 

S100c 

12:30 -1:30 PM PT Poster Tour: Cataract CAT Meeting Pt 

174 

Hall A 

PT Poster Tour: Glaucoma GLA Meeting Pt 

197 

Hall A 

PT Poster Tour: Refractive Surgery REF Meeting Pt 

221 

Hall A 

PT Poster Tour: Retina, Vitreous RET Meeting Pt 

225 

Hall A 

12:30 - 2:00 PM SKILLS LAB157A Macular OCT: Small Group Instruction Prerequisite: LEC157 RET $ N231 128 

12:30 - 2:30 PM SKILLS LAB154A Introduction to Aesthetic Facial Surgery by Fractional Lasers, Intense PLAST $ N230 123 

Pulsed Light, Radiofrequency, and Ultrasound Devices 


SKILLS LAB156A Laser Refractive Surgery Prerequisite: LEC156 REF $ N227b 127 

SKILLS LAB191 Enucleation and Evisceration: Theory and Practice PLAST $ N226 124 



37




On 

Demand 

Page 

12:45 - 1:45 PM SYM SYM08 Preferred Practice Pattern Guidelines: Adding Practical Value to Daily MEDED S403b 134 

Practice 

SPE SPE12 American Board of Ophthalmology: MOC Overview and Q&A with Board NON N136 259 

of Directors 

SPE SPE13 Dialogue With the FDA: Ophthalmic Initiatives Affecting You and Your NON N135 259 

Practice 

1:00 - 2:15 PM ACADCAFE SYM48 Academy Café: Oculoplastics PLAST S406b u 130 

1:30 - 1:45 PM SPE SPE14 OMIC Annual Members Meeting NON N137 259 

1:30 - 3:30 PM SKILLS LAB192A The iPhone for Ophthalmologists (Basic) COM $ N227a 117 

2:00 - 3:00 PM IC 193 Drop and Stop: The Practical Management of Fallen Fragments CAT + S403b 61 

IC 194 Resident Cataract Training Program Using the Kitaro DryLab and WetLab CAT + S104b 61 

Systems 

IC 195 Retina Pearls for the Anterior Segment Surgeon CAT + S106b 61 

IC 196 Diagnosis and Treatment Modalities in Cases of Moderate and 

COR + S106a 70 

Recalcitrant Fungal Keratitis 

IC 197 How to Avoid the Mistakes We Made in Starting Descemet-Stripping COR + S505ab 70 

Automated Endothelial Keratoplasty 

IC 198 Slay Your Dragon: Successful Implementation of Voice Recognition 

EHR + S105bc u 77 

Software Into Your Electronic Health Record 

IC 199 Medical Therapy for Open-Angle Glaucoma: A Complete Review of the GLA + N137 80 

Pharmacodynamics, Pharmacokinetics, and Toxicity of All Potentially 

Useful Drugs 

IC 200 Top 10 Pitfalls, Problem Solving, and Interpretive Strategy for Automated GLA + S105a 80 

Threshold Perimetry 

IC 201 The Vertical Diplopia Dilemma, Made Simple NEURO + N136 89 

IC 202 Current Controversies in Retinoblastoma Management PATH + N427a 91 


IC 203 A Natural Festival of Light and Color OPTIC + N135 92 

IC 204 Asian Blepharoplasty and the Eyelid Crease: Challenges and Solutions—A PLAST + N139 93 

Video-Complemented Course 

IC 205 Controversies and Advances in Pediatric Oculoplastic Surgery PLAST + S102d 93 

IC 206 Evaluation and Management of Orbital Cellulitis PLAST + N138 94 

IC 207 Update on the Current Diagnostic Workup for Infants and Children With PEDS + S105d 98 

Poor Vision 

AAOESP SPE22 The Four Disciplines of Execution: Breakout Session PM-PROF S501 296 

AAOEIC 208 Anatomy of an EHR Contract: Understanding and Negotiating the Best PM-EHR + S502a 290 

Terms 

AAOEIC 209 Diagnosing and Improving the Financial Health of Your Practice PM-BUS + S502b 283 

AAOEIC 210 Making the Most With Modifiers PM-REMB + S504d 288 

AAOEIC 211 MD/OD Relationships: Business and Compliance Concerns PM-RISK + S503ab 289 

AAOEIC 212 Ophthalmic Financial Policies for the Small Practice PM-BUS + S504a 283 

AAOEIC 213 Electronic Health Records Implementation: Overcoming Resistance to PM-EHR + S504bc 290 

Change 

IC 214 Advanced Corneal Topographic Analysis REF + E352 101 

IC 215 Update on Intrastromal Corneal Ring Segments REF + N427bc u 102 

IC 216 Medical and Surgical Therapy of Cystoid Macular Edema in Uveitis RET + N427d 105 

IC 217 Treatment of Retinal Detachment With Special Emphasis on Buckle RET + S103d 105 

Surgery 

2:00 - 3:30 PM SPOTLIT SPO2 Spotlight on Corneal Collagen Crosslinking COR Grand Ballrm u 135 

S100ab 

SYM SYM09 Optimizing Optics: Collagen Perspectives From Contact Lens, Intraocular OPTIC S406a u 136 

Lens, and Refractive Surgery 

SYM SYM10 How Does It Feel?- An Insider’s Perspective on Living With Anophthalmia PEDS Grand Ballrm u 135 

S100c 

SYM SYM11 Medical and Surgical Treatment of Macular Disease RET E450 u 135 

SPE SPE15 OMIC Forum: Top Ten Indemnity Payments NON Hall B (N) u 259 

SKILLS LAB151A Phacoemulsification and Advanced Techniques Prerequisite: LEC151 CAT $ N228 115 

2:00 - 3:40 PM OP OP03 Refractive Surgery Original Paper Session REF S405 u 168 

38 







On 

Demand 

Page 

2:00 - 4:15 PM IC 218 A Video Bouquet of Phaco Complications That Should Never Have 

CAT + S102abc u 62 

Occurred, With Tips on Damage Control and Prevention to Optimize 

Postoperative Outcome 

IC 219 Advanced Phacoemulsification: Maximizing Customized Cataract Surgery CAT + E351 u 62 

Outcomes 

IC 220 Clinical Decisions in the Management of Complications of Cataract and CAT + S103bc 62 

IOL Surgery 

IC 221 Best of the Best 2012: An Update in Cataract Surgery CAT + S404 u 62 

IC 223 Complications Following Glaucoma Filtering Surgery: Face Them Boldly, GLA + S103a 81 

Manage Them Efficiently 

IC 224 Prevention and Management of Complications in Oculoplastic Surgery PLAST + S104a 94 

IC 225 How to Interpret Fundus Fluorescein Angiography and Autofluorescence RET + E350 105 

2:30 - 3:45 PM ACADCAFE SYM49 Acadmey Café: Cornea, External Disease COR S406b u 130 

2:30 - 4:00 PM SYM SYM12 Modern Technologies and Techniques for Young Ophthalmologists to GO S101ab 136 

Know 

3:15 - 4:15 PM IC 222 The Management of Recurrent Pterygium COR + S105d 70 

AAOEIC 226 Going Lean: Tools for Efficiency and Effectiveness in the Ophthalmology PM-BUS + S504d 283 

Practice 

AAOEIC 227 How to Teach Your Staff to Get Along With Each Other PM-HRM + S504a 291 

AAOEIC 228 Marketing to Reach the Audience You Want! PM-MKT + S502b 293 

3:15 - 5:30 PM AAOEIC 229 Ophthalmology Practice Buy-In and Pay-Out Arrangements PM-BUS + S502a 284 

SKILLS 

SKILLS 

SKILLS 

LEC230/ 

230 

LEC231/ 

231 

LEC232/ 

232 

Advanced Refractive Cataract Surgery and Anterior Segment 

Reconstruction 

CAT + N427bc u 116 

Microsurgical Suturing Techniques CAT + N140 116 

Anterior Lamellar Keratoplasty: Principles and Practice COR + S102d 118 

IC 233 Electronic Health Record Incentives: A Closer Look at Meaningful Use EHR + N427d 77 

IC 234 The Consequences of Poor Decision Making in Neuro-Ophthalmology ETH + S106a 78 

(Ethics) 

SKILLS LEC235/ Glaucoma Filtration Surgery GLA + S105bc u 120 

235 

SKILLS LEC236/ Implantation of Glaucoma Drainage Devices GLA + N138 120 

236 

IC 237 Improving Success in Filtration Surgery: Intraoperative Surgical Techniques GLA + S103d 81 

and Postoperative Management of the Failing Filter 

IC 238 Update Your Anterior Chamber Angle Skills: How to Best Examine, Grade, GLA + N137 81 

and Treat 

SKILLS LEC239/ Computerized Perimetry Lecture: Visual Field Testing and Interpretation, GLA + S105a 120 

239 Emphasizing Glaucoma 

IC 240 How to Evaluate a Patient With Uveitis INTRA + E352 88 

IC 241 Diagnostic and Therapeutic Dilemmas in Neuro-Ophthalmology NEURO + S505ab 89 

SKILLS LEC242/ Fundamental Face-Lifting Techniques PLAST + N139 124 

242 

IC 243 Difficult Strabismus Problems: Diagnosis and Management 2012 PEDS + S403b 98 

AAOEIC 244 Coding and Reimbursement for Ophthalmic Diagnostic Testing PM-REMB + S504bc 288 

AAOEIC 245 Deciphering Financial Reports PM-BUS + S503ab 284 

AAOEIC 246 Surgery Billing Made Easy For All Specialties PM-REMB + S501 288 

SKILLS LEC247/ Phakic IOLs REF + N136 127 

247 

IC 248 Diabetic Macular Edema: 2012 Update on Management RET + S106b 105 

IC 249 Diagnostic Ophthalmic Ultrasonography RET + N427a 106 

IC 250 Understanding Macular Disease Through Clinicopathologic Correlation RET + N135 106 

IC 251 Management of Vitreoretinal Diseases in Pathologic Myopia RET + S104b 106 

3:30 - 5:00 PM SKILLS LAB153A Cosmetic Botulinum Toxin and Facial Fillers: An Introductory Course 


PLAST $ N229 122 



39




On 

Demand 

Page 

3:30 - 5:30 PM SKILLS LAB152A Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve GLA $ N231 119 

Fiber Layer Prerequisite: LEC152 

SKILLS LAB156B Laser Refractive Surgery for Ophthalmology Residents 

REF $ N227b 127 


SKILLS LAB188A New Techniques for Strabismus Surgery Prerequisite: LEC188 PEDS $ N230 126 

SKILLS LAB252 Oculoplastic Surgery: Anatomic Foundations, Surgical Techniques, and PLAST $ N226 124 

Enhanced Results 

3:45 - 5:15 PM SYM SYM13 Video Case Presentations of Rare Vitreoretinal Diseases RET E450 u 138 

SYM SYM14 LASIK Is Safe : Prevention and Management of Laser Complications REF Grand Ballrm u 137 

S100ab 

SYM SYM15 The Controversies and Dilemmas of Managing Ocular Infectious Diseases: 

Point–Counterpoint 

COR Hall B (N) u 138 

SYM SYM16 Controversies in Pediatric Ophthalmology and Orthoptics: A Point– 

Counterpoint Discussion 

SYM SYM17 International Perspectives: Trauma of the Anterior Segment and Its 

Management 

PEDS Grand Ballrm u 136 

S100C 

COR S406a u 137 

4:00 - 4:40 PM OP OP04 Ocular Tumors and Pathology Original Paper Session PATH S405 u 165 

4:00 - 5:30 PM SKILLS LAB166A Manual Extracapsular Cataract Extraction (ECCE/SICS) Surgery: Indications CAT $ N228 116 

and Techniques Prerequisite: LEC166 

4:15 - 5:15 PM SYM SYM18 International Opportunities for Young Ophthalmologists GO S101ab 138 

4:30 - 5:30 PM IC 253 Cliffhanger: Vitrectomy by the Anterior Segment Surgeon for the Broken CAT + S404 u 63 

Posterior Capsule, the Sinking Nucleus, and the Dangling IOL 

IC 254 Pterygium: The Outcome Measure Is Now Cosmesis, Not Recurrence COR + S103bc 70 

IC 255 Spectral Domain OCT From the Cornea to the Optic Nerve: A 

GEN + E350 79 

Comprehensive Overview 

IC 256 What’s Your Next Step? Case Studies in Glaucoma Management GLA + S102abc u 82 

IC 257 Case-Based Approach to Isolated Eye Pain NEURO + S105d 89 

AAOEIC 258 A Physician’s Guide to Avoiding Embezzlement PM-RISK + S502b 289 

AAOEIC 259 Accountable Care Organizations: A Primer for Ophthalmologists PM-BUS + S504d 284 

AAOEIC 260 EHR and Medical Professional Liability Risk PM-EHR + S504a 290 

IC 261 Children With Low Vision: Strategies and Interventions VIS + S104a 112 

4:40 - 5:30 PM OP OP05 Orbit, Lactimal, Plastic Surgery Original Paper Session PLAST S405 u 165 




On 

Demand 

Page 


7:30 - 9:00 AM SKILLS LAB306 Workshop in Techniques of Lacrimal Intubation PLAST $ N229 124 

8:00 - 9:00 AM SKILLS LAB307 An Innovative Approach to Iris Fixation of an IOL Without Capsular CAT $ N226 117 

Support: Hands-on and Practical 

8:00 - 9:30 AM SKILLS LAB235A Glaucoma Filtration Surgery Lab Prerequisite: LEC235 GLA $ N230 120 

SKILLS LAB247A Phakic IOLs Prerequisite: LEC247 REF $ N228 127 

8:00 - 10:00 AM SKILLS LAB232A Anterior Lamellar Keratoplasty: Principles and Practice 

COR $ N227b 118 


8:00 - 11:00 AM SKILLS LAB239A Computerized Perimetry Lab: Visual Field Interpretation, Emphasizing 

Glaucoma Prerequisite: LEC239 

GLA $ N231 121 

8:15 AM - 12:15 PM SPOTLIT SPO3 Spotlight on Cataracts: Clinical Decision-making with Cataract 

Complications 

CAT 

Hall B 

(N) 

u 139 

8:30 - 10:00 AM SYM SYM19 Pediatric Corneal Disease and Treatment COR Grand Ballrm u 140 

S100c 

SYM SYM20 Re-engineering the U.S. Health Care System: The Impact on 

Ophthalmology 

GEN S406a u 140 

SYM SYM21 Ethnic Variations in Glaucoma Prevalence, Detection, and Treatment 

Outcomes 

GLA 

Grand Ballrm 

S100ab 

u 139 

8:30 - 10:10 AM OP OP06 Cornea, External Disease Original Paper Session, Part I COR S405 u 157 

40 







On 

Demand 

Page 

8:30 - 10:30 AM SYM SYM40 What to Do When Your Patient Sees Nothing and You See Nothing: The NEURO E450 u 141 

Neuro-Ophthalmology Workup 

8:30 - 11:00 AM SYM SYM22 2012 International Forum: Addressing Diabetic Blindness, Refractive Error GO S101ab 141 

and the Basic Eye Exam 

9:00 - 10:00 AM IC 308 Surgical Management of Astigmatism in Cataract and Refractive Surgery CAT + E351 u 63 

IC 309 Zernike-Optimized Cataract Surgery: Pseudophakic Visual Quality Beyond CAT + S106b 63 

Emmetropia 

IC 310 Endothelial Keratoplasty in Challenging Cases COR + S403b 71 

IC 312 Medical Ethics in the Hot Seat: How Compliance With the Academy’s ETH + S106a 78 

Code of Ethics Can Turn a Good Litigation Defense Into a Great One 

IC 313 Drug-Related Adverse Effects of Clinical Importance to the 

GEN + S505ab 79 


IC 314 3-D Viewing: Nerve-Wracking Optic Nerves!! Is This Glaucoma?? GLA + S104b 82 

IC 316 The Glaucoma Horizon: Medications, Surgeries, Mechanisms, and GLA + S404 u 82 

Diagnostics 

IC 317 Top 10 Essentials of Gonioscopy: 3-D Viewing and Interpretation GLA + S105a 82 

IC 318 International (Dis)Agreement on Infectious Uveitis INTRA + S103bc 88 

IC 319 Pediatric Ocular Tumors PATH + S102d 91 

IC 320 Oculoplastic Office Procedures: Video Clips PLAST + E352 94 

IC 321 Oculoplastic Procedures for the General Ophthalmologist PLAST + E350 94 

AAOEIC 322 Can My ASC Accept that Reimbursement? A Financial Evaluation of PM-ASC + S501bc 283 

Payer Rates 

AAOEIC 323 Coding Odyssey PM-REMB + S502b 288 

AAOEIC 324 Defending the Small Practice Ophthalmologist in a Medical Malpractice PM-RISK + S504d 289 

Lawsuit 

AAOEIC 325 Human Resources and Your Practice: A Consultant’s Guide to Improved PM-HRM + S504bc 291 

Performance 

AAOEIC 326 Practice Growth and Profitability: Limiting Factors PM-BUS + S501d 284 

AAOEIC 327 Successfully Evaluating Practice Management Systems PM-EHR + S504a 290 

IC 328 Refractive Lensectomy: Indications, Lenses, Formulas, Outcomes REF + S103a 102 

IC 329 Controversies in the Management of Open-Globe Injuries Involving the RET + S103d 106 

Posterior Segment 

IC 330 Evaluation of Early-Onset Hereditary Retinal Degeneration in Infants and RET + N137 106 

Children 

9:00 - 10:15 AM ACADCAFE SYM50 Academy Café: Glaucoma GLA S406b u 130 

9:00 - 11:00 AM SKILLS LAB192B The iPhone for Ophthalmologists (Advanced) COM $ N227a 118 

9:00 - 11:15 AM IC 332 What’s New in Normal-Tension Glaucoma? GLA + N135 83 

IC 333 Dialog with the Editors of the Major General Ophthalmology Journals MEDED + N427a 88 

About the Peer Review Literature 

IC 334 Imaging Studies in Strabismus PEDS + N427d 98 

AAOEIC 335 Dissection of a Successful Web Design PM-MKT + S503ab 293 

AAOEIC 336 Medicare Postoperative Cataract Eyewear: Coding, Billing, and Supplier PM-OPT + S501a 293 

Compliance 

AAOEIC 337 Retina-Specific Panel Discussion: Ask Your Peers PM-BUS + S502a 284 

IC 338 A Step-by-Step Primer to Starting LASIK in 2012 REF + N427bc u 102 

IC 339 Diagnosis and Treatment of Central Serous Chorioretinopathy RET + S104a 107 

IC 544 OCT: Interpretation and Clinical Applications RET + S102abc u 90 

9:00 AM - 5:00 PM LL Learning Lounge Booth 107 261 

9:30 - 11:30 AM SKILLS LAB619 Workshop in Flap Techniques in Oculoplastic Surgery PLAST $ N226 126 

SKILLS LAB242A Fundamental Face-Lifting Techniques Prerequisite: LEC242 PLAST $ N229 124 

10:12 AM - 12:00 PM OP OP06 Cornea, External Disease Original Paper Session, Part II COR S405 u 158 

10:15 - 11:15 AM AAOEIC 341 Internal Controls for the Ophthalmic Practice PM-BUS + S501bc 284 

10:15 - 11:45 AM SYM SYM23 Update on Pediatric Ocular Trauma PEDS Grand Ballrm u 142 

S100c 

SYM SYM24 Advances in the Surgical Management of Glaucoma GLA Grand Ballrm u 141 

S100ab 

SYM SYM32 Then and Now HIST S406a u 142 



41





On 

Demand 

Page 

10:15 AM - 12:30 PM IC 342 A Video Symposium of Challenging Cases and the Management of CAT + S404 u 63 

Intraoperative Complications During Cataract Surgery 

SKILLS LEC343/ Astigmatism in the Cataract Patient CAT + S103bc 117 

343 

IC 344 Comprehensive Strategy for Unplanned Vitrectomy Technique for the CAT + E351 u 64 

Anterior Segment Surgeon 

IC 345 Secure Posterior Chamber IOL Placement Without Adequate Capsular or CAT + E350 64 

Zonular Support 

IC 346 Advances in Treatment of Severe Ocular Surface Disease: Views From COR + N138 71 

Experts on the Front Lines 

IC 347 Complications in Collagen Crosslinking : Diagnosis, Management, and COR + E352 71 

Prevention 

IC 348 Deep Anterior Lamellar Keratoplasty Update COR + S106b 71 

IC 349 Descemet-Stripping Automated Endothelial Keratoplasty Cliffhangers COR + N140 71 

SKILLS 

LEC350/ 

350 

Endothelial Keratoplasty Surgery: Comprehensive Overview and Surgical 

Pearls 

COR + S102d 118 

IC 351 Atypical Keratitis COR + S104b 72 

SKILLS LEC352/ Schlemm Canal Surgery GLA + N137 121 

352 

IC 353 Curbside Consultation in Neuro-Ophthalmology NEURO + S505ab 89 

SKILLS LEC354/ Blepharoplasty PLAST + S103a 124 

354 

AAOEIC 355 Content Marketing: Getting Your Web Page Ranked PM-MKT + S501d 293 

AAOEIC 356 Do I Look Like Your Mother?! Or, How to Manage the Difficult Employee PM-HRM + S502b 291 

AAOEIC 357 Health Care Fraud and Abuse Boot Camp: The Basics, Plus More PM-RISK + S504a 289 

AAOEIC 358 Let’s Make a (Practice) Deal: A Step-by-Step Approach PM-BUS + S504d 284 

AAOEIC 359 When to Use E&M and When to Use Eye Codes PM-REMB + S504bc 284 

SKILLS LEC360/ Diabetes 2012: Course on Diabetic Retinopathy RET + S105a 128 

360 

IC 361 Endoscopic-Assisted Ophthalmic Surgery: Anterior and Posterior Segment RET + S106a 107 

Techniques 

IC 362 Management of High-Risk ROP in the 21st Century: Thermal-Destructive RET + S403b 107 

vs. Pharmacologic Treatment 

IC 363 Ocular Ultrasound RET + S105d 107 

IC 364 Retinoblastoma 2012: They Live and See! RET + N136 108 

IC 365 State-of-the-Art Techniques and Technologies for Microincision 

RET + S105bc u 108 

Vitrectomy Surgery to Treat Complex Vitreoretinal Diseases 

IC 366 Systemic Therapeutic Agents and Retinal Toxicity RET + S103d 108 

10:30 - 11:45 PM ACADCAFE SYM51 Academy Café: Retina RET S406b u 130 

10:30 AM - 12:00 PM SKILLS LAB230A Advanced Refractive Cataract Surgery and Anterior Segment 

CAT $ N228 116 

Reconstruction Prerequisite: LEC230 

10:30 AM - 12:30 PM SKILLS LAB231A Microsurgical Suturing Techniques Prerequisite: LEC231 CAT $ N227b 117 

SKILLS LAB236A Implantation of Glaucoma Drainage Devices Prerequisite: LEC236 GLA $ N230 120 

10:45 AM - 12:00 PM SYM SYM41 The Great Debate RET E450 u 142 

11:30 AM - 12:30 PM IC 340 Argon Laser Peripheral Iridoplasty: All You Need to Know GLA + S102abc u 83 

IC 367 Vision and the Artist HIST + S104a 91 

IC 368 Pediatric Leukocoria: All You Need to Know PEDS + N427d 99 

IC 369 Pediatric Uveitis: What You Need to Know PEDS + N427bc u 99 

AAOEIC 370 Analyzing and Maximizing Return on Investment for Electronic Health PM-EHR + S503ab 290 

Records 

AAOEIC 371 Employment Law Basics for the Small Ophthalmology Practice PM-HRM + S501a 291 

AAOEIC 372 How to Create an Effective Dispensary Website Tab That Gets Results PM-OPT + S501bc 294 

AAOEIC 373 Managing Office Waiting Times PM-BUS + S502a 284 

IC 374 Presbyopia, the Corneal Approach: State of the Art REF + N139 102 

IC 375 Solving the High Myopia Problem With Phakic IOLs REF + N427a 102 

11:30 AM - 1:30 PM SKILLS LAB152B Computerized Scanning Imaging of the Optic Nerve and Retinal Nerve 

Fiber Layer Prerequisite: LEC152 

GLA $ N231 120 

42 







On 

Demand 

Page 

12:30 - 1:45 PM SPE SPE16 Welcome to the Real World of Ophthalmology: Reality 101 for Residents GEN N135 260 

and Fellows 

12:30 - 1:30 PM PT Poster Tour: Cornea, External Disease COR Meeting Pt Hall A 190 

PT Poster Tour: Pediatric Ophthalmology, Strabismus PEDS Meeting Pt Hall A 219 

12:30 - 2:30 PM SKILLS LAB175A Introduction to Nasal Anatomy and Rhinoplasty Prerequisite: LEC175 PLAST $ N229 123 

12:45 - 1:45 PM SKILLS LAB376 Surgical Anatomy of the Eyelids: Cadaver Demonstration PLAST $ N226 125 

SPE SPE17 Tele-health in the VA, DOD and Indian Health Service: The Right Care in GEN N427a 259 

the Right Place at the Right Time 

SPE SPE18 The Resident Hub User Group Session GEN S103d 259 

SPE SPE19 Ergonomics/Musculoskeletal Disorders in Ophthalmologists GEN N427d 259 

SYM SYM27 Shifting Gears: Practical and Ethical Transitions to Retirement ETH S406a u 148 

SYM SYM28 The “Local” Challenges of International Ophthalmology GO S403b 143 

SYM SYM29 Making Electronic Health Records Meaningful and Useful in Your Practice COM Grand Ballrm u 143 

S100c 

SYM SYM30 Why Take the Risk? How to Create an Effective Risk Management GEN S505ab 144 

Strategy With Patient Education and Informed Consent Documents 

12:45 - 2:15 PM SYM SYM26 Crash Courses in Teaching: A Primer for Faculty Development MEDED S405 u 144 

1:00 - 2:30 PM SKILLS LAB151B Phacoemulsification and Advanced Techniques Prerequisite: LEC151 CAT $ N228 115 

1:30 - 3:00 PM SKILLS LAB235B Glaucoma Surgical Lab for Ophthalmology Residents 

GLA $ N230 120 


1:30 - 3:30 PM SKILLS LAB350A Endothelial Keratoplasty Surgery: Comprehensive Overview and Surgical COR $ N227b 118 

Pearls Prerequisite: LEC350 

2:00 - 3:00 PM IC 311 Ocular Surface Diseases in Cancer Patients: Update on Clinical Spectrum COR + N136 72 

and Treatment 

IC 315 Glaucoma and Refractive Surgery GLA + S104a 83 

IC 377 Abandoned Phaco: Convert to No-Stitch Manual Small-Incision Cataract CAT + N427bc u 64 

Surgery 

IC 378 Complete and Early Vitrectomy for Postoperative Endophthalmitis (CEVE) CAT + N138 64 

IC 379 Understanding Ophthalmic Viscosurgical Devices to Optimize Their Use in CAT + N427a 64 

Cataract Surgery and Complications 

IC 380 Surgical Strategies for Recurrent Pterygium With or Without Motility COR + N135 72 

Restriction 

IC 381 Improving Patient Education and Adherence: Are You Up to Date? GLA + S104b 83 

IC 382 Understanding and Utilizing Glaucoma Imaging GLA + S106a 83 

IC 383 Needling Revision of Trabeculectomies GLA + N427d 84 

IC 384 Swollen Disks, Headache, and Vision Loss: A Case-Based Approach to NEURO + N140 90 

Pseudotumor Cerebri 

IC 385 Practical Ocular Oncology for the Comprehensive Ophthalmologist PATH + S105a 91 

IC 386 Diagnosis and Management of Essential Blepharospasm and Hemifacial PLAST + S105d 95 

Spasm 

IC 387 Enucleation, Evisceration, and Care of the Anophthalmic Socket PLAST + N137 95 

IC 388 Clinical Applications of New Concepts of Extraocular Muscle Function PEDS + S103d 99 

IC 389 Nightmares in Pediatric Cataract Surgery PEDS + S106b 99 

AAOEIC 390 A Practical Guide to Understanding and Negotiating Your First 

PM-BUS + S501d 285 

Employment Agreement 

AAOEIC 391 AAOE Book Club: Professional Growth and Development PM-PROF + S502a 294 

AAOEIC 392 Creating an Effective Lens Selection and Pricing System PM-OPT + S501bc 294 

AAOEIC 393 Electronic Health Record Conversion Challenges: Device Interfaces, PM-EHR + S503ab 290 

Existing Paper Charts, Transition Workflow, and More 

AAOEIC 394 Forecasting Staffing Needs: A Volume-Based Model PM-HRM + S504d 292 

AAOEIC 395 How to Develop a Successful In-House Technician Training Program PM-PROF + S502b 294 

AAOEIC 396 Benchmarks to Improve Your Practice PM-BUS + S504a 285 

AAOEIC 397 Social Media and the Workplace: Legal, Ethical, and Practical Issues PM-HRM + S501a 292 

Every Employer Should Consider 

IC 398 Engineering and Physics Principles: A Primer for the Vitreoretinal Surgeon RET + S102abc u 108 

IC 399 Epiretinal Membranes: Etiologies, Perioperative Management, Surgical 

Techniques, and Case Discussions 

RET + S102d 108 



43





On 

Demand 

Page 

2:00 - 3:30 PM SYM SYM31 Advances in the Treatment of Diabetic Retinopathy RET S406a u 144 

SYM SYM25 Late Breakers Symposium GEN Grand Ballrm u 145 

S100c 

2:00 - 3:40 PM OP OP07 Retina, Vitreous Original Paper Session, Part I RET S406b u 169 

2:00 - 4:00 PM SYM SYM33 Femto Forum: Cataract, Cornea, Refractive, and Beyond CAT Hall B (N) u 145 

SYM SYM34 Non-bacterial Infectious Keratitis COR Grand Ballrm u 146 

S100ab 

2:00 - 4:15 PM SKILLS LEC400/ Glaucoma Laser Therapy: Innovations and Advice From the Experts GLA + S105bc u 121 

400 

AAOEIC 401 Social Networking: Balancing Risks and Rewards PM-RISK + S504bc 289 

IC 402 Danger Zone: Refractive Surgery Nightmares and Worst-Case Scenarios: REF + S505ab 103 

A Video-Based Course 

2:30 - 4:00 PM SKILLS LAB403 Enhancing Your Presentation Using Keynote by Apple Inc. for the 

COM $ N227a 117 

Intermediate User 

OP OP08 Neuro-Ophthalmology Original Paper Session NEURO S405 u 164 

2:30 - 5:00 PM SKILLS LAB360A Diabetes 2012: Workshop on Diabetic Retinopathy Prerequisite: LEC360 RET $ N231 128 

SPE SPE21 2012 Senior Ophthalmologist Program and Reception NON S101ab 260 

3:15 - 4:15 PM AAOEIC 404 Acquiring Practices: Buying Strangers, Friends, and Enemies PM-BUS + S504a 285 

AAOEIC 405 Building Patient Loyalty: How to Over-Deliver Service PM-MKT + S501a 293 

AAOEIC 406 Electronic Health Record Search and Negotiation: Keys to Finding the PM-EHR + S502b 291 

Right EHR for the Right Price With the Right Terms 

AAOEIC 587 How to Run a Lean, Mean Refractive Practice in Today’s Tough Economic PM-BUS + S501bc 285 

Times 

3:15 - 5:30 PM IC 407 Multifocal and Accommodative IOLs: Face the Challenge CAT + N139 64 

IC 408 Management of Difficult and Challenging Cases Presented in 3-D High CAT + S404 u 65 

Definition 

IC 409 One-Stop Chop Squad CAT + E351 u 65 

IC 410 Anterior Segment Reconstruction Following Trauma COR + S104a 72 

IC 411 Descemet’s Membrane Endothelial Keratoplasty and Related Advanced COR + S103a 72 

Endothelial Keratoplasty Techniques 

SKILLS LEC412/ Endothelial Keratoplasty Techniques COR + S105a 119 

412 

IC 413 Theory and Techniques of Corneal Surgery: An Interactive Course for COR + N427a 73 

Corneal Surgeons 

IC 414 Top 12 Corneal Surgical Tips for 2012 COR + S103d 73 

IC 415 Managing Your EHR After Implementation EHR + S104b 78 

SKILLS 

LEC416/ 

416 

Trabeculotomy by Internal Approach (Trabectome) Surgery for Adult 

Open-Angle Glaucoma 

GLA + N138 122 

IC 417 Angle Closure and Angle-Closure Glaucoma GLA + S106a 84 

IC 418 Decoding the Uveitis Workup: Why, When, and What to Order INTRA + S103bc 88 

IC 419 What You Need to Know About Headache: A Pain for the Patient and a 

Pain for the Doctor 

NEURO + S105d 90 

44 






On 

Demand 

Page 

Endoscopic Forehead and Eyebrow Elevation PLAST + N140 125 


3:15 - 5:30 PM SKILLS LEC420/ 

420 

IC 421 Optimizing Outcomes and Minimizing Complications in Oculofacial Plastic PLAST + E352 95 

Procedures: A Case-Based Approach 

IC 422 Complete Guide to the Evaluation and Management of Ptosis PLAST + N427d 95 

IC 423 Lotions, Potions, Botulinum Toxin, and Fillers: Nonlaser Rejuvenation for PLAST + S106b 96 

the Ophthalmologist 

IC 424 Management of Orbital Tumors: Case Presentation and Discussion PLAST + N136 96 

IC 425 What’s New and Important in Pediatric Ophthalmology and Strabismus PEDS + S102d 99 

for 2012 

IC 426 Cataract Surgery in Children: Complicated Cases and Controversies PEDS + S403b 99 

AAOEIC 427 Compliance FAQs and NSFAQs (Not So Frequently Asked Questions) PM-RISK + S502a 289 

AAOEIC 428 Comprehensive Cataract Coding PM-REMB + S501d 288 

AAOEIC 429 Peer-to-Peer Problem Solving PM-PROF + S504d 294 

AAOEIC 430 Practice Valuations: What’s a Practice Worth Today? PM-BUS + S503ab 285 

SKILLS LEC431/ The Surgical Correction of Astigmatism REF + N135 127 

431 

SKILLS LEC432/ 23-Gauge Vitrectomy: What, When, and How? RET + S102abc u 128 

432 

IC 434 Retinal Pharmacotherapy RET + E350 109 

IC 435 Surgery of Retinal Detachment RET + N427bc u 109 

IC 436 Cutting-Edge Information on Pathologic Myopia RET + N137 109 

3:30 - 5:00 PM SKILLS LAB166B Manual Extracapsular Cataract Extraction (ECCE/SICS) Surgery: 

CAT $ N228 116 

Indications and Techniques Prerequisite: LEC166 

3:30 - 5:30 PM SKILLS LAB352A Schlemm Canal Surgery Prerequisite: LEC352 GLA $ N230 121 

SKILLS LAB354A Blepharoplasty Prerequisite: LEC354 PLAST $ N229 125 

SKILLS LAB437 Surgical Anatomy of the Orbit and Lacrimal System: Cadaver 

PLAST $ N226 125 

Demonstration 

3:42 - 5:35 PM OP OP07 Retina, Vitreous Original Paper Session, Part II RET S406b u 171 

3:45 - 4:45 PM SYM SYM35 Vision Rehabilitation: What’s New for Patients With Low Vision VIS E450 u 146 

3:45 - 5:00 PM SYM SYM36 Quality Improvement: How Do We Improve Quality, Maintain Efficiency 

and Sustain the Physician-Patient Relationship? 

GEN 

Grand Ballrm 

S100c 

u 146 

SYM SYM43 Grand Rounds: Cases and Experts From Across the Nation GEN S406a u 146 

4:00 - 5:15 PM OP OP09 Intraocular Inflammation, Uveitis Original Paper Session INTRA S405 u 162 

4:00 - 5:30 PM SKILLS LAB343A Astigmatism in the Cataract Patient Prerequisite: LEC343 CAT $ N227b 117 

4:15 - 5:30 PM SPOT SPO4 Spotlight on Pseudoexfoliation CAT Hall B (N) u 147 

4:30 - 5:30 PM IC 438 Ophthalmoscopic Evaluation of the Optic Disc and Retinal Nerve Fiber GLA + S105bc u 84 

Layer 

IC 439 Uveal Melanoma Therapies: Protons, Plaques and Eyewall Resection PATH + S505ab 91 

AAOEIC 440 ASC Guide to Managed Care Contracting PM-ASC + S504bc 283 

AAOEIC 441 Employee Physician Contract Review PM-HRM + S502b 292 

AAOEIC 442 How to Avoid an EHR Failure PM-EHR + S504a 291 

AAOEIC 443 Developing a Health Care Facility in the Aftermath of a Recession PM-BUS + S501a 285 



45



Tuesday, Nov. 13 (cont.) 


On 

Demand 

Page 


8:00 - 9:30 AM SKILLS LAB230B Advanced Refractive Cataract Surgery and Anterior Segment 

CAT $ N228 116 

Reconstruction Prerequisite: LEC230 

SKILLS LAB431A The Surgical Correction of Astigmatism Prerequisite: LEC431 REF $ N227b 127 

8:00 - 10:00 AM SKILLS LAB400A Glaucoma Laser Therapy: Innovations and Advice From the Experts GLA $ N230 121 


8:00 - 10:30 AM SKILLS LAB420A Endoscopic Forehead and Eyebrow Elevation Prerequisite: LEC420 PLAST $ N229 125 

8:00 - 11:00 AM SKILLS LAB484 Orbital Fracture Repair: Plating Workshop PLAST $ N226 125 

8:30 - 10:00 AM SYM SYM37 Ocular Tumors: Evidence-Based Rationale for Treatment PATH S406a u 148 

SYM SYM38 Workforce Issues in Ophthalmology: Eye Health Care for Baby Boomers 

and Beyond 

GEN 

Grand Ballrm 

S100c 

u 148 

SYM SYM39 Management of Diabetic Retinopathy: East-West Perspectives RET Grand Ballrm u 147 

S100ab 

8:30 - 10:15 AM OP OP10 Cataract Original Paper Session CAT S406b u 154 

OP OP11 Pediatric Ophthalmology, Strabismus Original Paper Session PEDS S405 u 166 

8:30 - 10:30 AM SKILLS LAB485 Neuroimaging in Ophthalmology NEURO $ N231 122 

9:00 - 10:00 AM IC 486 Creating an Effective Cataract Surgery Training Curriculum for Residency CAT + S104b 65 

Programs 

IC 487 Intraoperative Floppy Iris Syndrome: Pearls for Management and 

CAT + N427bc u 65 

Prevention 

IC 488 Pearls for IOL Exchange CAT + E350 65 

IC 489 Allergic Eye Disease: An Enigma for Physicians COR + S105bc u 73 

IC 490 Anterior Segment Imaging: A Practical Guide for Ophthalmologists COR + S106a 74 

IC 491 Extreme Corneal Ectasia: Battle of the Bulge COR + S105a 74 

IC 492 Next-Generation Technologies for the Diagnosis and Treatment of Dry Eye COR + S103d 74 

and Meibomian Gland Dysfunction 

IC 493 Contact Lens in Ophthalmology Practice COR + N427a 74 

IC 494 Canal, Trab, or Tube: What Should I Do? GLA + S106b 85 

IC 495 Continuous 24-Hour IOP Monitoring for Glaucoma GLA + S101ab 85 

IC 496 Glaucoma Filtration Device Mini-Shunt: Friend or Foe? GLA + N139 85 

IC 497 Management of the Conjunctiva in Glaucoma Filtration Surgery GLA + N137 85 

IC 498 Manual Small-Incision Cataract Surgery: An Alternative to 

GO + S103bc 87 

Phacoemulsification 

IC 499 Management of Patients With Eyelid Tumors: From Clinic to Pathology PATH + N140 91 

IC 500 Glaucoma in Infants and Children: What We Don’t Know Can Hurt Them! PEDS + N138 100 

AAOEIC 501 Current Trends in New Associate Employment Contracts PM-BUS + S502b 285 

AAOEIC 502 Hanging a Shingle in the 21st Century: Is a Start-up Solo Practice Possible PM-BUS + S501d 285 

in 2012? 

AAOEIC 503 Hiring an Ophthalmologist for Your Practice PM-BUS + S502a 286 

AAOEIC 504 Managing Up! PM-HRM + S501a 292 

AAOEIC 505 Mastering Patient and Staff Efficiency and Satisfaction Though Facility PM-BUS + S504d 286 

Design 

AAOEIC 506 Social Media and Social Networking in the Physician Office PM-BUS + S504a 286 

AAOEIC 507 Implementing Electronic Health Records Into an Ambulatory Surgery PM-EHR + S501bc 291 

Center 

IC 508 Corneoplastique: The Art of Premium LASIK and Cataract Surgery REF + S104a 103 

IC 509 Diagnosis and Treatment of Polypoidal Choroidal Vasculopathy RET + S103a 109 

IC 510 Retinal OCT Interpretation 101 RET + S102abc u 110 

IC 511 The Evaluation and Management of Retinal Pigment Epithelial 

RET + E351 u 110 

Detachment in AMD 

SKILLS LEC513/ 

513 

Endoscopic Transnasal Lacrimal Surgery: Principles and Practice PLAST + N136 125 

46 






On 

Demand 

Page 

Surgery for Severe Corneal and Ocular Surface Disease COR + S102d 119 


9:00 - 11:15 AM SKILLS LEC512/ 

512 

IC 514 Ophthalmic Dermatology: Periocular Skin Lesions PLAST + E352 96 

IC 515 Periocular Tumors and Techniques of Eyelid Reconstruction PLAST + S403b 96 

IC 516 Infantile Onset Esotropias PEDS + N427d 100 

IC 517 Management of Pediatric Cataracts PEDS + S505ab 100 

AAOEIC 518 CodeFest PM-REMB + S503ab 288 

AAOEIC 519 Optical Shops: Sales Strategies for Today’s Economy PM-OPT + S504bc 294 

IC 520 Update on Treatments for Diabetic Retinopathy: Clinically Relevant RET + S105d 110 

Results from the Diabetic Retinopathy Clinical Research Network 

9:00 AM - 12:00 PM LL Learning Lounge Booth 107 261 

10:00 - 11:30 AM SKILLS LAB150B Management of Vitreous for the Anterior Segment Surgeon 

CAT $ N228 115 

Prerequisite LEC150 

10:00 AM - 12:00 PM SKILLS LAB412A Endothelial Keratoplasty Techniques Prerequisite: LEC412 COR $ N227b 119 

10:15 - 11:15 AM IC 521 An Approach to Selecting Electronic Health Records in Your Practice EHR + S103a 78 

IC 522 Ophthalmologists’ Strategies for Enhancing Organizational Effectiveness GO + S103d 87 

in Developing Countries: Case Examples 

AAOEIC 523 ASC Benchmarking PM-ASC + S501a 283 

AAOEIC 524 Leading Change: Theory to Practice PM-PROF + S502a 294 

AAOEIC 525 Mitigating Legal Risks: Social Media and the Doctor’s Dilemma PM-RISK + S501d 289 

AAOEIC 526 Ophthalmic Coding Specialist (OCS) Exam Preparation PM-REMB + S504a 288 

AAOEIC 527 Selling Your Ophthalmology Practice in an Uncertain World: Nuts and PM-BUS + S504d 286 

Bolts for the Busy Practitioner 

AAOEIC 528 Smile ... Even If It Kills You: Training for Excellent Customer Service PM-MKT + S501bc 292 

10:15 - 11:45 AM SYM SYM42 Clinical Applications of Ocular Imaging RET S406a u 149 

10:15 AM - 12:30 PM IC 331 Cataract Surgery in the Setting of Ocular Comorbidities and High-Risk CAT + S102abc u 65 

Features for Intraoperative and Postoperative Complications 

IC 529 Conquering Capsule Complications: A Video Primer CAT + S404 u 66 

IC 531 Femtosecond Laser-Assisted Refractive Cataract Surgery CAT + S103bc 66 

IC 532 New and Emerging Technologies in Cataract and Refractive Surgery CAT + S106a 66 

IC 533 Tackling Weak Zonules and Using Capsular Tension Devices CAT + E350 66 

IC 534 The Surgical Management of the Malpositioned IOL CAT + E351 u 66 

IC 535 Current Topics in Cornea/ External Disease: Highlights of the Basic and COR + N139 75 

Clinical Science Course 8 

IC 536 Ocular Surface Disease Management: Moving From Adequate to Expert COR + N427bc u 75 

IC 537 Evidence-Based Guidelines in the Management of Glaucoma GLA + N140 85 

IC 538 Glaucoma Postop Care in the Office: A Video Compendium of 

GLA + N138 85 

Techniques—When and How to Intervene 

IC 539 Understanding Nystagmus: A Practical Approach for the Clinician NEURO + N137 90 

IC 540 Visual Fields in Neuro-Ophthalmology NEURO + N427a 90 

IC 541 Emerging Paradigms in Oculoplastics: The Asian Perspective PLAST + S105bc u 96 

AAOEIC 542 Financial Decision Making in the Eye Care Practice PM-BUS + S502b 286 

IC 543 Corneal Topographic Analysis and Anterior Segment Imaging: Pearls for REF + S104a 103 

Your Clinical Practice 

IC 545 Spectral Domain OCT Interpretation for the General Ophthalmologist RET + S106b 110 

IC 546 The Latest Advancements in Macular Surgery RET + S105a 110 

IC 547 Retinal and Choroidal Manifestations of Selected Systemic Diseases 2012 RET + S104b 111 

IC 548 Low Vision Rehabilitation for Ophthalmologists VIS + S101ab 112 

10:30 AM - 12:00 PM OP OP12 Glaucoma Original Paper Session GLA S405 u 160 

10:30 - 11:45 AM ACADCAFE SYM52 Academy Café: Cataract CAT S406b u 130 

11:00 AM - 12:00 PM SKILLS LAB416A Trabeculotomy by Internal Approach (Trabectome) Surgery for Adult Open- 

Angle Glaucoma Prerequisite: LEC416 

GLA $ N230 122 



47





On 

Demand 

Page 

11:30 AM - 12:30 PM IC 549 IOL Power Calculation: Problems With LASIK Eyes CAT + N135 67 

IC 550 End-stage Ocular Surface Disorders: The Expert Opinion! COR + S505ab 75 

IC 551 Anterior Segment OCT and Confocal Imaging: A Practical Approach COR + S102d 75 

IC 552 An Approach to Implementing Electronic Health Records in Your Practice EHR + S103a 78 

IC 553 What the General Ophthalmologist Needs to Know About Cancer and Its GEN + S403b 79 

Complications: From Front to Back 

IC 554 Diagnosis, Optic Neuropathy: Now What? NEURO + S105d 90 

SKILLS LEC555/ Advanced Techniques in Orbital Decompression and Expansion PLAST + N136 126 

555 

IC 556 Approach to Genetic Eye Diseases for the Comprehensive Ophthalmologist PEDS + N427d 100 

IC 557 Overview of Utilization of Bevacizumab for ROP PEDS + S103d 100 

AAOEIC 558 How to Develop a Successful Ophthalmic Ambulatory Surgery Center PM-ASC + S504bc 283 

AAOEIC 559 Leveraging Relationships for Savings and Effectiveness in Technology PM-IMT + S501a 292 

AAOEIC 560 Customizing Patient Education Using a Patient Portal PM-IMT + S504d 292 

AAOEIC 561 Negotiating Clinical Trial Agreements—and Don’t Forget About 

PM-BUS + S503ab 286 

Compliance! 

11:30 AM - 1:45 PM AAOEIC 562 Buying or Selling a Practice: 

PM-BUS + S501bc 286 

Creating Win-Win Transactions 

AAOEIC 563 Detecting and Preventing Fraud and Abuse in the Optical Dispensary and PM-BUS + S501d 287 

Medical Practice 

AAOEIC 564 Steps for Successful Retina Coding PM-REMB + S504a 289 

AAOEIC 565 Website 101: Three Steps to Creating Your First Website PM-MKT + S502a 293 

11:30 AM - 2:00 PM SKILLS LAB513A Endoscopic Transnasal Lacrimal Surgery: Principles and Practice 

PLAST $ N229 126 


12:15 - 1:30 PM SYM SYM44 Best of the Anterior Segment Specialty Meetings 2012 GEN S406a u 149 

12:30 - 1:30 PM SKILLS LAB416B Trabeculotomy by Internal Approach (Trabcetome) Surgery for Adult Open- GLA $ N230 122 

Angle Glaucoma Prerequisite: LEC416 

12:30 - 3:30 PM SKILLS LAB151C Phacoemulsification and Advanced Techniques Lab for Ophthalmology CAT $ N228 115 

Residents Prerequisite: LEC151 

12:45 - 1:45 PM AAOEIC 566 How to Benchmark for a Retina Practice PM-BUS + S501a 287 

AAOEIC 567 Starting Out on the Right Financial Foot: A Guide for Young 

PM-PROF + S502b 295 


12:45 - 3:00 PM AAOEIC 568 Three Areas of Succession Planning for Senior Physicians PM-BUS + S504bc 287 

1:00 - 2:30 PM SKILLS LAB343B Astigmatism in the Cataract Patient Prerequisite: LEC343 CAT $ N227b 117 

2:00 - 3:00 PM IC 569 Optimizing the Results of Presbyopic IOL Surgery CAT + S102abc u 67 

IC 570 Help! A Corneal Ulcer Just Walked In! What Do I Do Next? COR + E350 75 

IC 571 Pandora’s Box in Severe Ocular Chemical Injuries: The Entire Gamut of COR + S505ab 76 

Management 

IC 572 Use of Surgical Adhesives and Amniotic Membrane in Conjunctival, COR + S404 u 76 

Corneal, Cataract, and Refractive Surgery 

IC 573 Practical Use of Corneal Imaging COR + S104a 76 

IC 574 The Institutional Review Board Submission Process: Why Should I Care, ETH + S106a 79 

and What If I Don’t? 

IC 575 Cell Biology, Genetics, and Outflow Biochemistry of Glaucoma in 2012 and GLA + E352 86 

Beyond 

IC 576 Gonioscopy and Angle Imaging GLA + S104b 86 

IC 577 Help, the IOP Is 40! GLA + S105d 86 

IC 578 How to Manage Bleb Fibrosis Over the Plates of Glaucoma Drainage GLA + S103a 86 

Implants 

IC 579 Normal-Tension Glaucoma: Evaluation and Treatment GLA + E351 u 86 

IC 580 The Management of Neo-vascular Glaucoma in 2012 GLA + N136 86 

IC 581 Evolution’s Witness: How Eyes Evolved HIST + N137 92 

IC 582 Tips for Oculoplastic Surgery in Asian Patients PLAST + N427d 97 

IC 583 Oblique Muscle Surgery PEDS + N135 100 

AAOEIC 584 All I Want Is What’s Fair: Compensation Formulas for Shareholder 


PM-BUS + S501bc 287 

CANCELED 

48 







On 

Demand 

Page 

2:00 - 3:00 PM AAOEIC 585 Essential Search Engine Optimization Tools for Your Website PM-IMT + S502b 293 

AAOEIC 586 How to Join a Group Practice: Introductory Concepts PM-PROF + S502a 295 

AAOEIC 588 Partnership Pitfalls: Preparing for the Unexpected PM-BUS + S503ab 287 

AAOEIC 589 Updating Your Partnership/ Shareholder/ Buy-Sell/New Employee PM-BUS + S501a 287 

Agreements 

IC 590 FemtoLASER: Diagnosis and Management of Intraoperative and 

REF + S101ab 103 

Postoperative Complications With the Use of a Femtosecond Laser for 

LASIK Surgery 

IC 591 Modern Management of the Irregular Cornea REF + N427a 103 

IC 592 Intravitreal Injection Techniques: Minimizing Discomfort and Potential RET + S102d 111 

Complications 

IC 593 The Crowded OR: Optimizing Surgical Strategies in Cataract, Glaucoma, RET + N138 111 

and Cornea Surgery in Combination With Vitreoretinal Surgery 

IC 594 Visual Electrophysiology Testing: Principles and Clinical Applications RET + N140 111 

2:00 - 4:15 PM IC 595 Code Red: Mastering Phaco Nightmares and Worst-Case Scenarios: A CAT + S103bc 67 

Video-Based Course 

IC 596 Endothelial Keratoplasty (DSEK/DSAEK/DMEK/ DMAEK): Current 

COR + N427bc u 76 

Strategies to Improve Results and Avoid Complications 

IC 597 Examining the Optic Nerve and Evaluating the Visual Field: The Five Rs GLA + S105a 87 

IC 598 Facial Fracture Repair: Better Outcomes and Improved Technique PLAST + S106b 97 

IC 599 Stereo Anatomy of the Orbit, Eyelid, and Lacrimal System: A Surgeon’s PLAST + S103d 97 

Perspective 

IC 600 Refractive Laser Surgery (Surface and LASIK) Following Previous Surgery: REF + S105bc u 104 

A Practical Approach to Indications, Diagnostic and Treatment Techniques, 

and Possible Complications and Their Management 

IC 601 Retinaws: A Comprehensive Video-Oriented Course on Challenging Retinal RET + S403b 111 

Cases in the Operating Room 

IC 602 Scleral Buckling and Vitrectomy for Rhegmatogenous Retinal Detachment: RET + N139 111 

How to Avoid and Deal With Recurrences? 

3:00 - 5:00 PM SKILLS LAB512A Surgery for Severe Corneal Ocular Surface Disease Prerequisite: LEC512 COR $ N227b 119 

3:00 - 5:30 PM SKILLS LAB555A Advanced Techniques in Orbital Decompression and Expansion 

PLAST $ N229 126 


3:15 - 4:15 PM IC 603 Techniques and Devices for Surgical Reconstruction of Traumatic and CAT + N427d 67 

Developmental Iris Defects 

IC 604 Step-by-Step Deep Anterior Lamellar Keratoplasty Using the Big Bubble COR + S102d 76 

Technique 

IC 605 Current Techniques in Lacrimal Surgery PLAST + S105d 97 

IC 606 FemtoLASER: Current Anterior Segment Applications for a Femtosecond REF + S101ab 104 

Laser 

3:15 - 5:30 PM IC 607 Avoiding Complications in Lens Implant Surgery CAT + N427a 67 

IC 608 Step-by-Step, 3-D Instructional Course in Microcoaxial and Microbiaxial CAT + S404 u 68 

Cataract Surgery 

IC 609 The Boston Keratoprosthesis: Case-Based Presentations Highlighting the COR + S103a 77 

Essentials for Beginning and Experienced Surgeons 

IC 610 Descemet-Stripping Automated Endothelial Keratoplasty and New 

COR + S104b 77 

Refractive Surgeries 

IC 611 Managing Angle-Closure Glaucoma With Crystalline Lens Removal and GLA + N136 87 

Adjunctive Procedures 

IC 612 Glaucoma Drainage Device Surgery: All You Wanted to Know but Were GLA + N140 87 

Too Afraid to Ask 

IC 613 Medical and Surgical Therapy and Diagnosis of Uveitis INTRA + S505ab 88 

IC 614 Review of Clinical Optics OPTIC + N137 92 

IC 615 Basic Browlift: Principles and Techniques PLAST + N138 98 

IC 616 ROP Screening and Treatment: What You Wanted to Know but Were PEDS + S104a 101 

Afraid to Ask (Intermediate/Advanced) 

IC 617 Genetics and AMD: What Do I Need to Know Right Now? RET + S106a 112 

IC 618 Mystery Retina 2012: Interactive Discussion of Challenging Cases RET + S102abc u 112 



49




On 

Demand 

Page 

7:00 AM - 5:00 PM SPE SPE20 26° Lo Mejor de la Academia en Español GEN $ Sheraton Chicago 260 


50 





Sunday – Tuesday, Nov. 11 - 13 

7:30 - 8:30 AM 

Hall A 

Roundtable discussions are moderated by leading experts in 

the field. Attendees are encouraged to bring their individual 

questions and cases for discussion. 

Registration fee is $40 onsite and includes a continental breakfast. 

Breakfast With the Experts are ticketed events; they are 

not included in the Academy Plus course pass. 


Practice Management roundtables were selected by the AAOE 

Program Committee. 

The Annual Meeting Program Committee selected all other 

roundtables. 

See page 33 for committee details. 






Breakfast With 

the Experts 


Cataract 

Jointly sponsored by the Academy’s Annual Meeting Program Committee and 

the American Society of Cataract and Refractive Surgery (ASCRS) 

Roundtable B100 

Clinical Pearls for Improving Outcomes With Presbyopia- 

Correcting IOLs 

Moderator: Bonnie A Henderson MD* 


Femtosecond Laser Cataract Surgery 

Moderator: William J Fishkind MD FACS* 


Financial Considerations in Purchasing a Femtosecond Laser 

for Refractive Cataract Surgery 

Moderator: Kevin M Miller MD* 


Fuchs Endothelial Dystrophy: Preoperative Considerations for 

Cataract Surgery—Combined or Staged Surgery 

Moderator: Sumit Garg MD 


Limbal Relaxing Incisions/Presbyopia IOLs 

Moderator: R Bruce Wallace MD* 

B Roundtable 105 

Pediatric Cataract and IOL Surgery 

Moderator: M Edward Wilson Jr MD* 


Phacoemulsification Pearls 

Moderator: Stephen H Johnson MD 


Surgical Management of Cataract and Glaucoma: So Many 

Options—Which One Should I Choose? 

Moderator: Bradford J Shingleton MD* 

Cornea, External Disease 


the Cornea Society 


Acanthamoeba Keratitis 

Moderator: Kristin Hammersmith MD 


Boston Keratoprosthesis 

Moderator: Peter Zloty MD* 


Pterygium Surgery 

Moderator: Lawrence W Hirst MD MBBS MPH DO FRACO FRACS* 


the Pan-American Association of Ophthalmology (PAAO) 


Lamellar Approaches in Keratoplasty: Back to the Past? (In 

Spanish) 

Moderator: Ashley Behrens MD 

Ethics 


the Ethics Committee 


Ethical Relationships Between Physicians and Industry 

Moderator: Anthony J Aldave MD* 


Ethical Expert Witness Testimony: What You Should Know 

Moderator: Ron W Pelton MD PhD 

Glaucoma 


the American Glaucoma Society (AGS) 


Glaucoma Filtration Device Mini-shunt: Pearls and Pitfalls (Ex- 

PRESS) 

Moderator: Andrew George Iwach MD* 


Glaucoma Surgery: Intraoperative Modifications for Improved 

Results 

Moderator: Samuel Solish MD 


Women in Ophthalmology (WIO) 


Recognizing and Preventing Angle-Closure Glaucoma 

Moderator: Jody R Piltz-Seymour MD* 

Intraocular Inflammation, Uveitis 


the American Uveitis Society (AUS) 


Workup in a Patient With Uveitis 

Moderator: John J Huang MD* 


the Retina Society 


Posterior Uveitis: Workup and Management Pearls 

Moderator: David G Callanan MD* 

Medical Education 




Como publicar en Inglés (How to Publish in English) 

Moderator: Lihteh Wu MD* 

Neuro-Ophthalmology 


the North American Neuro-Ophthalmology Society (NANOS) 


Diagnosis and Management of Myasthenia Gravis 

Moderator: Mark L Moster MD* 

52 

* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. 

No asterisk indicates that the presenter has no financial interest. 

Up-to-date information is available in the Program Search on the Academy’s website: www.aao.org/2012.




What’s New in Giant Cell Arteritis? 

Moderator: Larry P Frohman MD 

Ocular Tumors and Pathology 




Update on Retinoblastoma and Melanoma for the General 


Moderator: Miguel A Materin MD 

Orbit, Lacrimal, Plastic Surgery 

Jointly sponsored by the Academy’s Annual Meeting Program Committee 

and the American Society of Ophthalmic Plastic and Reconstructive Surgery 

(ASOPRS) 


Challenging Coding Cases in Ophthalmic Plastic Surgery 

Moderator: L Neal Freeman MD MBA FACS* 


Ptosis Repair: How to Achieve the Best Results 

Moderator: Jeremiah P Tao MD* 


Workup and Management of Epiphora 

Moderator: Parag Gandhi MD* 

Pediatric Ophthalmology, Strabismus 


and the American Association for Pediatric Ophthalmology and Strabismus 

(AAPOS) 


Negotiating Your Buy-In 

Moderator: Mark D Abruzzo JD 


Strategies to Survive and Thrive in Private Practice 

Moderator: Debra L Phairas 


Tools and Tips to Build a Budget for a Dynamic Practice 

Moderator: Mark S O’Conner MBA 

Electronic Health Records 


EHR Stage 2 of Meaningful Use 

Moderator: E Joy Woodke COE OCS* 


When to Consider a New EHR System 

Moderator: Jeffrey Daigrepont 

Professional Growth 


Hospital Employment of Ophthalmologists: The New Normal? 

Moderator: Lawrence Geller MBA* 


Practical Aspects of Gearing Up for Retirement 

Moderator: Donna W Howell JD 


the Senior Ophthalmologist Committee (SO) 

SO Roundtable B138 

Transitions in Practice: Slowing Down and Its Implications 

Moderator: Allan D Jensen MD 


the Young Ophthalmologist Committee (YO) 


Complications of Eye Muscle Surgery 

Moderator: John W Simon MD 


Pediatric Pseudotumor Cerebri 

Moderator: Paul H Phillips MD 


When and How to Prescribe Glasses for Children 

Moderator: W Walker Motley MD 

Practice Management /AAOE 

Sponsored by the American Academy of Ophthalmic Executives (AAOE) 

Business Operations & Finance 


ACOs — What You Need to Know 

Moderator: Richard E Gable PhD MBA 


How to Avoid Joining the Wrong Practice: Factors to Consider 

Before Accepting an Associate Position 

Moderator: Mark E Kropiewnicki JD LLM* 

YO Roundtable B139 

Pearls for Succeeding at Your First Job 

Moderator: Purnima S Patel MD 





OCT Anterior Segment Imaging in Clinical Practice 

Moderator: Amin Ashrafzadeh MD* 


the International Society of Refractive Surgery (ISRS) Executive Committee 


Enhanced Screening for Ectasia: Why and How We Should Go 

Beyond Topography and Central Thickness 

Moderator: Renato Ambrosio Jr MD* 


IOL Calculations After Refractive Surgery 

Moderator: Warren E Hill MD* 


the Experts 



53



Retina, Vitreous 


the American Society of Retina Specialists (ASRS) 


How to Avoid Endophthalmitis After Anti-VEGF Injections 

Moderator: Thomas A Albini MD* 


Tips and Traps in Surgery for Diabetic Retinopathy! 

Moderator: Carl D Regillo MD FACS* 


the Macula Society 


Integrating Spectral Domain OCT Into a Busy Clinical Practice: 

Pearls and Pitfalls 

Moderator: Srinivas R Sadda MD* 


New Paradigms in the Treatment of Wet AMD: From Naíve to 

Resistant Cases 

Moderator: Daniel B Roth MD* 




Office-Based Vitrectomy: Experience and Advice 

Moderator: Scott J Westhouse DO 






Deep Anterior Lamellar Keratoplasty 

Moderator: William Barry Lee MD* 


Femtosecond-Assisted Keratoplasty 

Moderator: Luciene Sousa MD* 




Dos and Don’ts in Descemet-Stripping Endothelial Keratoplasty 

and Deep Anterior Lamellar Keratoplasty 

Moderator: Sophie X Deng MD PhD* 

Ethics 




Ethical Dilemmas in Emergency Ophthalmic Care 

Moderator: Gregory J McCormick MD 


Clinical Practice vs. Research: Ethical Distinctions 

Moderator: J Jill Hopkins MD* 


Practical Aspects of Ethical Comanagement 

Moderator: Charles M Zacks MD 


the Experts 

Cataract 




Management of the Broken Posterior Capsule and Advanced 

Vitrectomy Technique 

Moderator: Louis D Skip Nichamin MD* 


Strategies for Efficient Cataract Surgery 

Moderator: Priscilla Perry Arnold MD 


Toxic Anterior Segment Syndrome Following Anterior Segment 

Surgery 

Moderator: Nick Mamalis MD* 




Posterior Capsule Management: How And Why 

Moderator: Lisa B Arbisser MD 

Glaucoma 




Importance of Ocular Blood Flow in Glaucoma 

Moderator: Alon Harris PhD* 


Much More Than a Hole in the Iris: Management of Primary 

Angle-Closure Glaucoma 

Moderator: James A Savage MD* 


Ocular Imaging: Can We Improve Glaucoma Diagnosis and 

Management With These Devices? 

Moderator: Gadi Wollstein MD* 

Global Ophthalmology 


the Global Outreach Committee 

GO Roundtable B275 

The Global Epidemic of Diabetic Eye Disease: What Is the 

Ophthalmologist’s Role? 

Moderator: Fernando Barria von Bischhoffsha 

54 










Key Diagnostic Signs in Posterior Uveitis 

Moderator: Brian Berger MD* 


Medical Management of Uveitis 

Moderator: C Stephen Foster MD* 




Roundtable Roundtable B278 

I Think My Patient Has Anterior Ischemic Optic Neuropathy: 

What Do I Do Now? 

Moderator: Neil R Miller MD* 


Idiopathic Intracranial Hypertension 

Moderator: Deborah I Friedman MD* 


Pitfalls and Pearls: Radiology of Selected Orbital and 

Neurological Ophthalmic Lesions 

Moderator: Roger E Turbin MD* 




(ASOPRS) 

B281Roundtable 

Aesthetic Skin Rejuvenation 

Moderator: Julie A Woodward MD* 


Eyelid Reconstruction 

Moderator: Rona Z Silkiss MD FACS 


How to Improve Your Blepharoplasty Technique 

Moderator: Denise D Garcia MD 




(AAPOS) 


Approach to Pediatric Cataracts: When and How to Operate 

Moderator: M Edward Wilson Jr MD* 


Management of Brown and Duane Syndromes 

Moderator: Mohamad S Jaafar MD FACS 


Tips for Examining Young Children in the Office 

Moderator: Gregg T Lueder MD 

Practice Management / AAOE 


Ambulatory Surgery Centers 


ASC Benchmarking — The Path to Quality and Profit 

Management 

Moderator: Kent L Jackson* 



Are You Covered? What your Corporate Documents Need to Say 

about Governance, Buy-out, Termination, Compensation, and 

More 

Moderator: Daniel M Bernick JD* 


Financial Decision-Making in the Eye Care Practice 

Moderator: Michael D Brown* 


How to Value an Ophthalmology Practice 



The Seven Deadly Sins of Selling Your Solo Practice 

Moderator: Richard C Koval MPA CMPE* 

Coding & Reimbursement 


the Outpatient Ophthalmic Surgery Society (OOSS) 


The Ophthalmic ASC: Payment, Regulation, Policy 

Moderator: Michael A Romansky JD 

Information Technology 


EHR Stage 2 of Meaningful Use 

Moderator: Ronald Barry Sterling* 


When to Consider a New EHR System 

Moderator: Jeffrey Daigrepont 



The First Few Years of Practice: Some Key Concepts for Young 






Fellowship Match: Landing Your Top Choice 

Moderator: Azadeh Khatibi MD 


the Experts 



55



the Experts 



Go BIG! The Perks of Joining a Large Group 

Moderator: Robert F Melendez MD MBA* 


Building A Successful Portfolio Using Alternative Investments 






Corneal Inlays for Presbyopia 

Moderator: Jorge L Alio MD PhD* 


Management of Flap Complications 

Moderator: Ahmed N Sedky DO 





Diabetic Macular Edema Treatment: When to Use Anti-VEGF 

and When to Use Laser? 

Moderator: Andrew N Antoszyk MD* 




Evidence-Based Approach to the Care of Neovascular AMD 

Patients 

Moderator: Jennifer Irene Lim MD* 




Diabetic Retinopathy: Surgical Approaches in 2012 

Moderator: Thomas M Aaberg Jr MD* 


Intellectual Property and the Retina Specialist 

Moderator: David A Saperstein MD* 

Vision Rehabilitation 


the Vision Rehabilitation Committee 


“Doctor! I Can’t See _____!” Or, What to Do About Low Vision 

Moderator: Joseph L Fontenot MD 


Cataract 




A Systematic Approach to Resident Cataract Surgery 

Supervision 

Moderator: Aldo Fantin MD 


Anterior Vitrectomy for the Cataract Surgeon 

Moderator: Lisa B Arbisser MD 


Complex Axial Length Measurement and Unusual IOL Power 

Calculations 

Moderator: Warren E Hill MD* 


Fixing the Iris: Repair and Prosthesis 

Moderator: Michael E Snyder MD* 


Incorporation of High-Tech IOLs Into Your Practice 

Moderator: Marc A Michelson MD* 


Pearls for Phaco Chop 

Moderator: Marjan Farid MD 





Cataract Surgery and Fuchs Corneal Dystrophy Management: 

Considerations and Endothelial Keratoplasty Discussions 

Moderator: Kenneth M Goins MD 

Ethics 




The Ethics of Informed Consent 

Moderator: Roberto Pineda II MD 

Glaucoma 




Combined Cataract, IOL Implant, and Glaucoma Filtering 

Surgery 

Moderator: Edward J Rockwood MD* 


Getting the Best Results From Glaucoma Surgery 

Moderator: George L Spaeth MD FACS* 

56 







Pediatric Glaucoma: Clinical Update 

Moderator: Sharon F Freedman MD* 



the Global Outreach Committee 

YO GO Roundtable B455 

Start Now! Volunteering Abroad as a Young Ophthalmologist 

Moderator: Grace Sun MD 





Uveitis for Dummies: Approach to the Patient With Uveitis 

Moderator: Russell W Read MD PhD* 


When Is Ocular Imaging Useful in Uveitis? 

Moderator: Marc Dominique De Smet MD PHD FRCSC FRCOPHTH* 





Avoiding Malpractice Pitfalls When Caring for Neuro- 

Ophthalmology Patients 

Moderator: Walter M Jay MD 


Cost-effective Approach to Diplopia 

Moderator: Steven A Newman MD 

P Roundtable B460 

The Patient With Eye Pain 

Moderator: Howard R Krauss MD* 





When to Refer a Choroidal Nevus 

Moderator: Susanna S Park MD PhD* 




(ASOPRS) 


Fillers and Neurotoxins for Facial Rejuvenation 

Moderator: Wendy W Lee MD* 


When and How to Lift the Brow? 

Moderator: Christine C Annunziata MD 




(AAPOS) 


Pediatric Optic Neuropathies 

Moderator: Mays A El-Dairi MD* 


Reading Disorders in Children: What to Ask, What to Check, 

What to Tell Parents 

Moderator: William O Young MD 




Catarata pediátrica (Pediatric Cataracts) 

Moderator: Tony Aguirre MD 

Practice Management/AAOE 




The Ophthalmic ASC: Payment, Regulation Policy 

Moderator: Michael A Romansky JD 



Associate Employment Contracts: How to Avoid Signing a 

Contract You Will Regret 



Improving Operational Efficiency using Lean Six Sigma Tools 

Moderator: Dennis G McCafferty COE MBA* 


Partial Retirement In a Group Practice 

Moderator: Robert J Landau JD 



the Outpatient Ophthalmic Surgery Society (OOSS) 


ASC Benchmarking: The Path to Quality and Profit Management 

Moderator: Kent L Jackson* 


Roundtable 292 

Savvy Medicare and Social Security Planning for “Baby 

Boomer” Physicians 



the Experts 



57




Big Practice Problems: What the Experts Recommend 

Moderator: Michael D Brown* 


Charting Your Course to Financial Success in a Small 

Ophthalmology Practice 



the Senior Ophthalmologist Committee (SO) 




Satellite Office Models for the Retina Specialist 

Moderator: Dante Pieramici MD* 

SO Roundtable B475 

Stopping Surgery: When, Why, and What It Means to Your 

Practice 

Moderator: Michael W Brennan MD 




Finding Your Dream Job 

Moderator: Michael E Summerfield MD 





Laser Vision Correction After Refractive IOL Surgery 

Moderator: Sonia H Yoo MD* 




Collagen Cross-Linking for Keratoconus and Ectasia 

Moderator: Joseph Colin MD* 


Corneal Aberration: Evaluation and Treatment 

Moderator: Mark Packer MD* 





25-, 23-, 20-Gauge: Does Size Matter? 

Moderator: Kirk H Packo MD* 


the Experts 


The Treatment of Choroidal Neovascularization in 2012: Which 

Drug and Why? 

Moderator: Jeffrey S Heier MD* 




Controversies in the Management of Wet AMD 

Moderator: Judy E Kim MD* 

58 




Instruction Course Program 

Sunday – Tuesday, Nov. 11 – 13 

h 

NEW 

APAO 

EHR 

GO 

P 

SO 

YO 

Based on the 2011 Annual Meeting attendee evaluation 

data, a star indicates that the instruction course 

received an overall course grade within the top 10% of 

its subject area 

New course 

Asia-Pacific Academy of Ophthalmology 



Eligible for Pain Management credit 

Endorsed by Senior Ophthalmalogist Committee 

Endorsed by Young Ophthalmalogist Committee 

Selection Committee 

The Annual Meeting Program Committee selected all instruction 

courses in this section. 


Academy Plus Course Pass 

All courses in the Instruction Course Program are part of the 

Academy Plus course pass. 

Academy Plus offers maximum convenience, with unlimited 

access to all Academy and AAOE instruction courses. Individual 

tickets for Academy and AAOE instruction courses will 

no longer be sold. 

Note: Due to Fire Marshal regulations, seating capacities are 

limited. Seating is available on a first-come basis, so please 

plan accordingly. 







Cataract 

NEW Using an Add-On Mirror Telescopic Intraocular 

Implant to Assist AMD Patients: Patient Selection, 

Surgical Technique, and Clinical Results 

Course: 148 

Room: S106b 

Education Level: INT 

Sunday 

9:00 - 10:00 AM 

Target Audience: COMPSUB 

Synopsis: The mirror telescope can be used for phakic and pseudophakic eyes 

at any stages of the disease. Only the central field is magnified, enabling natural 

peripheral vision. Patient selection is performed by a unique patient selection 

program: surgical technique, clinical results and possible complications 

will be discussed. 

Objective: At the conclusion of this course, the attendee will be able to select 

patients suitable for implantation, use the special program for patient selection, 

understand the optical performance of the device, be able to demonstrate 

to patients the expected postop results, be familiar with the surgical technique, 

evaluate the clinical results being presented by 3 leading surgeons, and 

learn how to avoid possible complications. 

Senior Instructor(s): Isaac Lipshitz MD* 

Instructor(s): Amar Agarwal MD*, Sergio Benchimol MD, Juan-Carlos Abad MD 

Management of Vitreous for the Anterior Segment 

Surgeon 

Course: 150 

Room: S105a 


Sunday 

9:00 - 11:15 AM 


Synopsis: This course will review the anatomy, physiology, and pathophysiology 

of the vitreous and will present vitrectomy techniques for challenging 

anterior segment surgery scenarios. Topics will include management of vitreous 

loss from the anterior and posterior approach, utilizing the vitrector for 

decompression in challenging cataract cases, and visualizing the vitreous with 

triamcinolone acetonide (Kenalog). 

Objective: This course is designed to enhance the anterior segment surgeon’s 

familiarity with anterior and posterior vitrectomy techniques for challenging 

anterior segment cases. 

Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the lab, 

see the Skills Transfer section. 

Senior Instructor(s): Ron Afshari Adelman MD MPH** 

Instructor(s): Iqbal K Ahmed MD*, Rosa Braga-Mele MD*, Keith A Warren MD*, 

Baseer U Khan MD*, Thomas A Oetting MD 

Phacoemulsification and Advanced Techniques 

Course: 151 

Room: N427bc 

Education Level: ADV 

Sunday 

9:00 - 11:15 AM 


Synopsis: In the past few years noteworthy new phaco technologies have altered 

the way surgeons execute and analyze the phacoemulsification procedure. 

In this course, a faculty of experienced surgeons will present the latest 

phaco techniques and technologies that are applicable to ophthalmologists at 

every level of experience. This course will cover the steps of phacoemulsification, 

including scleral and corneal incisions, capsulorrhexis, hydrodissection, 

and various phaco techniques, with emphasis on machine principles including 

micropulse phaco, dual pump fluidics, and torsional phaco. Principles for 

safe cortex removal and implantation of IOLs, including foldable IOLs using 

forceps and injector-style delivery systems, will be demonstrated. Management 

of complications and challenging cases using capsular tension rings, 

pupil expanders, hooks, capsular staining, and related techniques will also 

be presented. This course will teach the most up-to-date phacoemulsification 

techniques to both individuals with little or no experience with the method and 

those wishing to refine or update their technique or transitioning from other 

cataract surgery methods. 

Objective: This course is designed to teach participants the principals and 

skills necessary to understand and perform phacoemulsification safely and 

efficiently. 

Note: Note: This is also the lecture portion of a Skills Transfer lab. To enroll in 

the lab, see the Skills Transfer section. 

Senior Instructor(s): Steven H Dewey MD* 

Instructor(s): Ricardo G Glikin MD, Nick Mamalis MD*, Anita Nevyas-Wallace 

MD*, Thomas A Oetting MD, Helen K Wu MD* 

IOL Fixation With Fibrin Glue: Technique and Results 

Course: 161 

Room: N427a 


Sunday 

10:15 - 11:15 AM 


Synopsis: IOL implantation is difficult in patients with absent or deficient capsular 

support. Sutured scleral-fixated IOLs and iris-fixated lenses suffer from 

inherent disadvantages and are not suitable for all cases. IOL fixation with 

fibrin glue offers a stable and secure method of IOL implantation and is suitable 

for all patients, including those with multifocal IOLs. Advantages include 

shorter surgical time, well-centered IOL with no phacodonesis, and the ability 

to use the same IOL. Various surgeons will share their surgical steps and experience 

with glued IOLs and discuss the merits and demerits of this exciting 

new technique of IOL fixation. 

Objective: At the conclusion of this course, the attendee will be able to understand 

and implement the technique of IOL fixation using fibrin glue and will 

be able to implant a posterior chamber IOL in patients with loss of capsular 

support. They will become more efficient at managing intra- and postoperative 

complications due to capsular tears without the need for anterior chamber/ 

iris-fixated suture-fixated IOLs, with better and faster visual recovery. 

Senior Instructor(s): Mahipal S Sachdev MBBS* 

Instructor(s): Amar Agarwal MD*, George Beiko MD*, Kenneth J Rosenthal MD 

FACS*, David T Vroman MD* 

H Advanced IOL Power Calculations for the Cataract 

and Refractive Surgeon 

Course: 164 

Room: E351 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: The indications for an IOL implantation following cataract or clear 

lensectomy have significantly increased. Techniques for determining the proper 

IOL and power will be presented. 

Objective: This course will provide clear methods and techniques for determining 

the proper IOL and power for complicated cases and will familiarize the 

clinician with indications and limitations of specialty lenses, such as multifocal 

and toric IOLs. 

Senior Instructor(s): Jack T Holladay MD MSEE FACS* 

Yo Learning Phaco Chop: Pearls and Pitfalls 

Course: 165 

Room: S404 


Sunday 

10:15 AM - 12:30 PM 

Target Audience: COMP 

Synopsis: Phaco chop minimizes ultrasound time and zonular stress. Pearls and 

strategies for learning this technique will be presented, based upon the instructors’ 

experience in teaching residents. Using a special projection system, 

the audience will don stereo glasses to view 3-D high-definition videos that 

60 

H Top 10% in subject area. NEW New Course. APAO Asia-Pacific Academy of Ophthalmology. Education Level Key: Bas = Basic, Int = Intermediate, Adv = Advanced 

Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist. 



uniquely illustrate the angle and depth of the instrument tips for both horizontal 

(Nagahara) and vertical (quick chop) methods of chopping. A stepwise 

game plan for converting to phaco chop will be presented, along with phacodynamic 

principles for selecting machine parameters and instrumentation. 

Objective: This course will present both variations of the phaco chop technique, 

their advantages in complicated cases, the instrumentation, machine 

parameters, and transition steps involved, and common mistakes. 

Senior Instructor(s): David F Chang MD* 

Instructor(s): Randall J Olson MD, Louis D Skip Nichamin MD*, Barry S Seibel MD* 

Manual Extracapsular Cataract Extraction (ECCE/ 

SICS) Surgery: Indications and Techniques 

Course: 166 

Room: E352 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: Although extracapsular cataract extractions by large incision (ECCE) 

and small incision (SICS) are still performed routinely throughout the world, 

phacoemulsification surgery has become the standard of care in many countries, 

and therefore ECCE/SICS is no longer being taught. However, understanding 

how to perform this surgery competently is still crucial when faced 

with complications during phacoemulsification surgery, or when an ECCE approach 

may be a better choice for the patient. 

Objective: By the conclusion of this course, the attendee will (1) have learned 

and be able to practice primary ECCE and SICS surgery, (2) have learned and 

be able to practice how to convert from a clear corneal phacoemulsification to 

either a ECCE or a SICS approach, and (3) better understand how to deal with 

complications of ECCE surgery. 



Senior Instructor(s): Bonnie A Henderson MD* 

Instructor(s): Thomas A Oetting MD, Geoffrey C Tabin MD, Maria Mendicino Aaron 

MD 

NEW Yo Phaco Pearls for the Beginner 

Course: 167 

Room: S505ab 

Education Level: BAS 

Sunday 

10:15 AM - 12:30 PM 


Synopsis: This video course will teach surgical pearls and recommend guidelines 

to fine-tune all steps in routine phaco for uncomplicated cataracts in a 

comprehensive manner. Emphasis will be on highlighting proper techniques, 

demonstrating specific strategies and maneuvers to optimize outcomes and 

to avoid iatrogenic complications. Adjunctive devices to stabilize the capsular 

bag and ensure pupillary dilatation will also be discussed. The technique of 

converting to a safer, nonphaco small-incision cataract surgery (SICS) in problematic 

situations like posterior chamber tear and impending nucleus drop will 

also be demonstrated. 

Objective: Attendees will be able to fine-tune their surgical strategy and optimize 

outcomes of all steps of phacoemulsification in uncomplicated scenarios 

on a consistent basis and will learn how to prevent common complications and 

successfully manage them should they still occur. 

Senior Instructor(s): Arup Chakrabarti MBBS 

Instructor(s): Thomas A Oetting MD, Kevin M Miller MD*, Abhay Raghukant 

Vasavada MBBS FRCS*, Warren E Hill MD*, Richard B Packard MD*, Iqbal K 

Ahmed MD*, Samar K Basak MD DNB MBBS* 

Drop and Stop: The Practical Management of Fallen 

Fragments 

Course: 193 

Room: S403b 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will present a comprehensive overview of posterior dislocation 

of nuclear fragments during cataract surgery and its management. It 

is aimed at both anterior and posterior segment specialists, allowing them 

to understand a part of the patient pathway they are not usually involved 

with. Risk factors for posterior displacement of nucleus, tips for damage control 

(should this occur), and strategies for safe completion of surgery, with 

guidelines for referral to the vitreoretinal surgeon, will all be shown. Extensive 

video footage will be used to practically demonstrate the techniques used in 

anterior segment management and the strategies for pars plana vitrectomy for 

nucleus removal; newer techniques of nucleus removal allowing a fully sutureless 

small-gauge posterior vitrectomy method will also be shown. Outcomes, 

counselling, and patient expectations will be discussed. 

Objective: At the conclusion of the course, the attendee will have gained insight 

into the complete patient journey for patients who experience the complication 

of a posteriorly displaced nuclear fragment during cataract surgery. 

Attendees will be able to enhance safety in their part of the patient’s surgical 

care by optimizing strategies, and they will better understand the basis of 

management by the team dealing with the other side of the equation. 

Senior Instructor(s): Somdutt Prasad MBBS* 

Instructor(s): Manish Nagpal MD*, Brian C Little MD* 

NEW Resident Cataract Training Program Using the 

Kitaro DryLab and WetLab Systems 

Course: 194 

Room: S104b 


Sunday 

2:00 - 3:00 PM 

Target Audience: ALL 

Synopsis: The Kitaro DryLab and WetLab systems are new tools available for 

the realistic simulation of phacoemulsification cataract surgery in a wet laboratory. 

This course will outline the steps used to implement a new Resident 

Cataract Training Program using the Kitaro DryLab and WetLab systems at the 

Flaum Eye Institute. The dry lab curriculum uses the Kitaro DryLab system to 

teach and evaluate technical competence in four cataract surgical skills: continuous 

curvilinear capsulorrhexis, nuclear segmentation, IOL insertion, and 

wound construction. The wet lab curriculum uses the Kitaro WetLab system 

to teach and evaluate technical competence in five cataract surgical skills: 

wound construction, continuous curvilinear capsulorrhexis, nucleus disassembly, 

epinucleus removal, and IOL insertion. 


how to implement a systematic and structured approach to cataract 

training using the Kitaro DryLab and WetLab systems. 

Senior Instructor(s): Yousuf M Khalifa MD* 

Instructor(s): William G Gensheimer MD, Matthew D Gearinger MD* 

NEW Retina Pearls for the Anterior Segment Surgeon 

Course: 195 

Room: S106b 


Sunday 

2:00 - 3:00 PM 


Synopsis: Many aspects of anterior segment surgery potentially involve the 

retina. Through a combination of brief talks and cases followed by expert panel 

discussions, we will discuss cataract and anterior segment surgery and the 

potential impact on the posterior segment. The course will provide case-based 

examples including lens fragment removal, dislocated natural and artificial 

lens management, multifocal IOL impact on retina surgery, cataract surgery in 

the anti-VEGF era, and other interesting circumstances. 


E Electronic Health Records GO Global Ophthalmology P Eligible for Pain Management credit. SO Endorsed by Senior Ophthalmologist Committee. 

YO Endorsed by Young Ophthalmologist committee. * The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information 

as of press date. No asterisk indicates that the presenter has no financial interest. 

61



Objective: At the conclusion of this course, the attendee will understand the 

impact of anterior segment surgery in relation to the retina, know the results 

of relevant retina literature, and understand how these studies apply 

to the anterior segment surgeon. The attendee will also better understand 

the perspective of the retina surgeon when preparing for surgery or managing 

complications. The goal is to foster discussion between anterior segment and 

retina surgeons in order to promote collegiality and to improve communication 

between specialties. 

Senior Instructor(s): Jeremy D Wolfe MD 

Instructor(s): George A Williams MD*, Kimberly A Drenser MD PhD*, Tarek S 

Hassan MD*, Maria A Woodward MD 

A Video Bouquet of Phaco Complications That Should 

Never Have Occurred, With Tips on Damage Control 

and Prevention to Optimize Postoperative Outcome 

Course: 218 

Room: S102abc 


Sunday 

2:00 - 4:15 PM 


Synopsis: This video course deals with the genesis, management, and prevention 

of unexpected surgeon- or technique-related complications in phacoemulsification 

in uncomplicated cataracts. The course will demonstrate complications 

that may be encountered during all steps of phaco (both uncomplicated 

and difficult cataracts) and will offer a stepwise strategy to prevent and manage 

them. Complications and remedial measures to be demonstrated include 

wound burns, wound length anomalies, capsulorrhexis extension and retrieval, 

two-stage rrhexis, use of microrrhexis forceps and scissors in tricky cases, incomplete/difficult 

hydrodissection, hurdles in phaco-chop, misplaced capsular 

tension ring, inappropriately used iris hook , how to convert to a safer, nonphaco 

technique in problem situations, and much more. 

Objective: At the end of the course, the attendee will have learned how to 

avoid and successfully manage certain intraoperative phaco complications 

that can not only mar the postoperative outcome in uncomplicated as well as 

complicated cataracts but can also lead to sight-threatening sequelae if not 

managed scientifically. 

Senior Instructor(s): Arup Chakrabarti MBBS 

Instructor(s): Thomas A Oetting MD, Amar Agarwal MD*, Kevin M Miller MD*, 

Abhay Raghukant Vasavada MBBS FRCS*, Samuel Masket MD*, Iqbal K Ahmed 

MD*, Khiun F Tjia MD* 

Advanced Phacoemulsification: Maximizing 

Customized Cataract Surgery Outcomes 

Course: 219 

Room: E351 


Sunday 

2:00 - 4:15 PM 


Synopsis: A panel of experienced instructors will discuss recent data and their 

experience with advanced cataract surgery to assist attendees in understanding 

and mastering both routine and challenging cases. Pearls for wound construction, 

capsulorrhexis, surgical technique, and complication prevention will 

be shared. Advancements in ultrasound delivery, fluidic design, and procedure 

customization will be demonstrated. 

Objective: Attendees of this course will learn how to apply latest-generation 

phacoemulsification technology and advanced surgical technique to manage 

routine and challenging cataract surgery cases. This will be presented around 

common complicated scenarios. 

Senior Instructor(s): Randall J Olson MD 

Instructor(s): Roger F Steinert MD*, Y Ralph Chu MD*, Steven H Dewey MD*, 


Clinical Decisions in the Management of 

Complications of Cataract and IOL Surgery 

Course: 220 

Room: S103Bc 


Sunday 

2:00 - 4:15 PM 


Synopsis: This program brings together 13 experts in cataract and IOL surgery 

to discuss common and rare problems. First, the most unusual complication 

of the year will be presented by expert ophthalmologists, who will describe 

it up to the point of the clinical decision. Then the panel and/or audience will 

discuss the problem, and finally the presenter will reveal the chosen management 

and resolution of the problem. 

Senior Instructor(s): Manus C Kraff MD* 

Instructor(s): Lisa B Arbisser MD, Alan S Crandall MD*, Kenneth J Hoffer MD 

FACS*, Sheri Rowen MD*, Geoffrey C Tabin MD, James P Gills MD*, Marc A 

Michelson MD*, Louis D Skip Nichamin MD*, Luther Fry MD FACS*, James A 

Davison MD*, Kenneth J Rosenthal MD FACS* 

Best of the Best 2012: An Update in Cataract Surgery 

Course: 221 

Room: S404 


Sunday 

2:00 - 4:15 PM 


Synopsis: This course will discuss how advances in technology, IOLs, phaco 

machines, and indications are making cataract surgery extremely similar to 

refractive surgery. The cataract surgeon must not only provide restoration of 

vision but also optimal vision quality; the ideal, and increasingly demanded, 

result of cataract surgery is plano correction. This requires accurate customization 

of IOL choice, obsessively accurate biometry, adoption of new technologies 

(microincision and premium IOLs: multifocal, toric, multifocal + toric, 

aspheric). 

Objective: This course is designed to provide attendees with key information 

in applying a refractive surgery approach to exploiting recent technological, 

surgical, organizational, and patient management advances. 

Senior Instructor(s): Matteo Piovella MD* 

Instructor(s): Fabrizio I Camesasca MD*, Richard L Lindstrom MD*, David F Chang 

MD*, Steven J Dell MD*, Roger F Steinert MD*, Stephen S Lane MD*, Steven C 

Schallhorn MD* 

Advanced Refractive Cataract Surgery and Anterior 

Segment Reconstruction 

Course: 230 

Room: N427bc 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course is designed for surgeons who (1) want to achieve a 

higher level of emmetropic results by addressing toricity through the use of 

limbal relaxing incisions, toric IOLs, and bioptics, and (2) want to expand their 

armamentarium for dealing with difficult cataract cases, dislocated IOLs, and 

traumatized eyes. 

Objective: This course will cover iris and scleral suture fixation techniques for 

IOLs, chopping techniques, capsular tension rings, artificial iris vs. primary closure 

for iris defects, pars plana vitrectomy, introduction to femtosecond cataract 

surgery, and strategies for dealing with challenging cases. 

Note: This is also the lecture portion of a Skills Transfer lab. To enroll in the 

lab, see the Skills Transfer section. 

Senior Instructor(s): Brock K Bakewell MD* 

Instructor(s): Louis D Skip Nichamin MD*, William J Fishkind MD FACS*, Samuel 

Masket MD*, Warren E Hill MD*, Steven H Dewey MD*, Lisa B Arbisser MD, 

Garry P Condon MD**, Alan S Crandall MD*, Richard S Hoffman MD*, Robert P 

Liss MD, Mark K Walsh MD 

62 





Microsurgical Suturing Techniques 

Course: 231 

Room: N140 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will cover basic microsurgical suturing techniques. In 

addition, principles, theories, and practical instruction in corneal-scleral laceration 

and corneal wound repair, management of cataract wound problems, 

including wound burns, and extension of clear corneal incisions will be demonstrated. 

Objective: This course offers basic microsurgical suturing training that is applicable 

in the management of penetrating keratoplasty suturing, corneal lacerations, 

and cataract wound problems. 



Senior Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter 

MD FACS 

H Cliffhanger: Vitrectomy by the Anterior Segment 

Surgeon for the Broken Posterior Capsule, the 

Sinking Nucleus, and the Dangling IOL 

Course: 253 

Room: S404 


Sunday 

4:30 - 5:30 PM 


Synopsis: Every anterior segment surgeon faces the problem of a broken 

posterior capsule at some time or another and should know how to perform 

vitrectomy. Also one should know how to manage a dropped nucleus or sinking 

fragments. Various techniques like the PAL technique (posterior-assisted 

levitation) and others will be taught, including how to perform bimanual vitrectomy. 

The dangling IOL and fixation of a posterior chamber IOL in eyes without 

capsule using the glued IOL technique will also be taught. The management of 

various challenges will be explained through videos. 

Objective: At the end of the course, the attendee will be able to fix an IOL in 

eyes without capsules, retrieve sinking lens fragments, and also do a thorough 

vitrectomy when required. 

Senior Instructor(s): Amar Agarwal MD* 

Instructor(s): David F Chang MD*, William F Mieler MD* 

Yo Surgical Management of Astigmatism in Cataract 

and Refractive Surgery 

Jointly Sponsored by the Academy’s Annual Meeting Program Committee 

and the International Society of Refractive Surgery (ISRS) 

Course: 308 

Monday 

Room: E351 

9:00 - 10:00 AM 



Synopsis: This course will teach strategies for minimizing surgically induced 

astigmatism, discuss surgical options for treating astigmatism during cataract 

and refractive surgery (including wound construction approaches, limbal relaxing 

incisions, toric IOLs, and corneal refractive surgical techniques), and demonstrate 

methods to treat postoperative astigmatism occurring after cataract 

and refractive surgery. 

Objective: By the conclusion of this course, the participants will be able to (1) 

identify regular and irregular astigmatism, (2) understand surgical strategies to 

minimize surgically induced astigmatism and determine treatment strategies 

for astigmatism, including complex refractive errors and eyes not amenable to 

surgical treatment, and (3) employ practical strategies for determining patient 

goals and desires for astigmatism correction. 

Senior Instructor(s): J Bradley Randleman MD 

Instructor(s): David T Vroman MD* 

NEW Zernike-Optimized Cataract Surgery: 

Pseudophakic Visual Quality Beyond Emmetropia 

Course: 309 

Room: S106b 


Monday 

9:00 - 10:00 AM 


Synopsis: This course aims to provide a simplified, step-by-step approach enabling 

the cataract surgeon to understand the optics of the eye. We present 

an overview of the diagnostic technologies available to assess corneal and internal 

aberrations. We also discuss methods of quantifying the image formed 

at the macula and the impact on postoperative visual quality due to the interaction 

of the cornea with the IOL. We use this knowledge to offer the most 

appropriate advanced technology IOL to the patient. Finally we present cases 

where this knowledge has been useful in understanding the unhappy patient 

or where customized cataract surgery has been performed. 

Objective: At the conclusion of this course, the attendee will be able to use 

commercially available equipment to screen the visual optics of patients and 

offer the most suitable IOL technology to give good postoperative visual quality 

and improve patient satisfaction after cataract surgery. 

Senior Instructor(s): Mathew Kurian MD MBBS 

Instructor(s): Omar Awad MD, Rohit Shetty MD MBBS, Nermin Serbecic PhD , 

Mukesh J Paryani MBBS, Kodatalu Puttaiah Narendra MD 

Yo A Video Symposium of Challenging Cases and the 

Management of Intraoperative Complications During 


Course: 342 

Room: S404 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will cover a spectrum of difficult cataract cases as well 

as a potpourri of intraoperative complications. The video content, which is 

updated yearly, will be discussed by the panel. 

Objective: This course will expose the surgeon to principles and techniques 

useful in operating difficult cases and in managing serious intraoperative complications. 

Senior Instructor(s): Robert H Osher MD* 

Astigmatism in the Cataract Patient 

Course: 343 

Room: S103bc 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will teach ways to control postoperative astigmatism. 

It will cover preoperative planning as well as intraoperative and postoperative 

surgical techniques used to control astigmatism. Intraoperative limbalrelaxing 

incisions will be discussed in detail, along with the use of toric IOLs 

and means by which to further enhance outcomes. 

Objective: At the conclusion of this course, participants will be able to plan and 

perform the techniques necessary to control postcataract astigmatism. 



Senior Instructor(s): Louis D “Skip” Nichamin MD* 

Instructor(s): Jonathan B Rubenstein MD* 





63



Yo Comprehensive Strategy for Unplanned 

Vitrectomy Technique for the Anterior Segment 

Surgeon 

Course: 344 

Room: E351 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will propose a strategy for prevention, early recognition, 

damage control, and specific plans for action to achieve an optimal outcome 

in cataract surgery complicated by vitreous presentation. Anterior and pars 

plana approaches will be detailed with ample video. The panel will include a 

retina-vitreous subspecialist. 

Objective: By the conclusion of this course, cataract surgeons of all levels of 

expertise will be able to describe a strategy for choosing the method and timing 

to remove residual lens material and appropriate management of vitreous, 

incision, and choice of IOL to achieve optimal outcomes in cataract surgery 

involving vitreous presentation. 

Senior Instructor(s): Lisa B Arbisser MD 

Instructor(s): Michael J Howcroft MD* 

Secure Posterior Chamber IOL Placement Without 

Adequate Capsular or Zonular Support 

Course: 345 

Room: E350 


Monday 

10:15 AM - 12:30 PM 


Synopsis: Loss of capsular support is often managed by placing an anterior 

chamber or iris-supported IOL. This is not always the best option, especially in 

eyes with compromised endothelium or angle damage. Video demonstration 

will be used to show a spectrum of techniques to securely place posterior 

chamber lenses when there is inadequate capsular support or decentered bag 

due to zonular inadequacy. Use in a “hot” setting, when unanticipated capsule 

loss occurs, and in a “cold” setting, when capsule or zonular deficiency 

are known preoperatively, will be covered. Techniques such as optic capture, 

scleral sutured rings and segments, scleral sutured IOLs, haptics glued under 

scleral flaps, and haptics placed in scleral tunnels will be shown in a step-bystep 

manner. 

Objective: At the end of the course, the attendee will have become familiar 

with a range of available techniques to allow secure posterior chamber IOL 

placement, even when there is inadequate capsular support or extensive zonular 

deficiency. 

Senior Instructor(s): Somdutt Prasad MBBS* 

Instructor(s): Amar Agarwal MD*, Kenneth J Rosenthal MD FACS*, Michael E 

Snyder MD* 

H Abandoned Phaco: Convert to No-Stitch Manual 

Small-Incision Cataract Surgery 

Course: 377 

Room: N427bc 


Monday 

2:00 - 3:00 PM 


Synopsis: Complications do occur in phacoemulsification surgery, for many 

reasons. Sometimes, the surgeons convert phaco to extracapsular cataract 

extraction (ECCE) for the patient’s safety. The closed chamber situation is then 

compromised, and problems of suturing are also there. But if the surgeon converts 

it to no-stitch manual small-incision cataract surgery (SICS), the wound 

integrity will remain and rehabilitation will be much faster. This course will 

teach the basics of an effective no-stitch manual SICS, which is crucial when 

complications are faced during phacoemulsification surgery. 

Objective: At the conclusion of this video-based course, the cataract surgeon 

will be able to understand (1) the indications of primary no-stitch manual SICS 

technique in the most difficult situations, (2) how to perform no-stitch manual 

SICS, step by step, (3) conversion of abandoned phaco to no-stitch manual 

SICS, and (4) how to deal with complications of no-stitch manual SICS if they 

occur. 

Senior Instructor(s): Samar K Basak MD DNB MBBS* 

Instructor(s): Arup Chakrabarti MBBS, Santanu Mitra MBBS 

NEW Complete and Early Vitrectomy for 

Postoperative Endophthalmitis (CEVE) 

Course: 378 

Room: N138 


Monday 

2:00 - 3:00 PM 


Synopsis: Postoperative endophthalmitis remains a serious complication 

whose incidence, in the absence of intraocular antibiotic prophylaxis, is apparently 

increasing in the era of sutureless, clear-corneal-incision phacoemulsification. 

Currently, intravitreal antibiotics are the treatment of choice, with 

vitrectomy being recommended only if vision is reduced to light perception. 

However, complete and early vitrectomy has been found to statistically significantly 

improve the anatomical and functional prognosis over other treatment 

modalities, and the complication rate of such surgery is lower than that of 

other treatment options. 

Objective: To review, using intraoperative videotapes, the rationale for and 

techniques and results of timely vitrectomy for postoperative endophthalmitis. 

Senior Instructor(s): Ferenc P Kuhn MD PhD 

Instructor(s): Giampaolo Gini MD 

NEW Understanding Ophthalmic Viscosurgical 

Devices to Optimize Their Use in Cataract Surgery 

and Complications 

Course: 379 

Room: N427a 


Monday 

2:00 - 3:00 PM 


Synopsis: This course will consist of a slide and video presentation of rheologic 

properties, classification, and varied utilization techniques for different ophthalmic 

viscosurgical device (OVD) types. New OVDs, recent discoveries, and 

principles and techniques to prevent and manage complications and postoperative 

IOP will be covered. Ample opportunity for discussion will be available. 

Objective: Attendees will gain insight into the rheological and surgical behavior, 

choice and optimal use of OVDs, which can enhance their skills in surgery 

and complications. 

Senior Instructor(s): Steve A Arshinoff MD* 

H Multifocal and Accommodative IOLs: Face the 

Challenge 

Course: 407 

Room: N139 


Monday 

3:15 - 5:30 PM 


Synopsis: We will review the state-of-the-art knowledge on presently available 

multifocal and accommodative IOLs (MAI). Their features, indications and 

contraindications, matching possibilities, and clinical results, pursuing highly 

satisfactory uncorrected distance, intermediate, and near vision, will be examined. 

New multifocal (ie, torics) will be discussed. 

64 





Objective: Attendees will receive information on how to use MAI. A structured 

approach on patient and IOL selection based on accurate matching of IOL features 

with patient needs will be provided. IOL performance in terms of contrast 

sensitivity, light distribution and loss, and management of complications and 

visual complaints with available solutions will be discussed. 


Instructor(s): David F Chang MD*, Richard L Lindstrom MD*, Jack T Holladay 

MD MSEE FACS*, Michael C Knorz MD*, Jay Stuart Pepose MD PhD*, Richard 

Tipperman MD*, Claudio Carbonara MD 

Management of Difficult and Challenging Cases 

Presented in 3-D High Definition 

Course: 408 

Room: S404 


Monday 

3:15 - 5:30 PM 


Synopsis: Management of difficult and challenging cases will be presented by 

the authors utilizing 3-D high-definition projection. 

Objective: Attendees will learn techniques for optimizing outcomes in difficult 

and challenging cataract cases, including intraoperative floppy iris syndrome, 

pseudoexfoliation syndrome, eyes status post RK, black and white cataracts, 

small pupil procedures, combined procedures, suture fixation of IOLs, refractive 

lens exchange, and piggyback IOLs. Attendees will enhance their surgical 

ability and increase their scope of practice. 

Senior Instructor(s): Mark Packer MD* 

Instructor(s): John A Hovanesian MD*, Douglas Katsev MD*, James A Katz MD*, 

Robert H Osher MD*, Christopher D Riemann MD*, Steven D Vold MD*, Robert J 

Weinstock MD*, Eric D Donnenfeld MD*, Neel R Desai MD** 

One-Stop Chop Squad 

Course: 409 

Room: E351 


Monday 

3:15 - 5:30 PM 


Synopsis: This course aims to provide a step-by-step learning plan for performing 

different phaco chop techniques. It will highlight their basic principles for 

effective, complete division, along with their rationale. The most effective 

parameters of ultrasound, vacuum, and aspiration flow rate for successful division 

will be presented. The course will encompass the application of these 

techniques in diverse grades of nuclear sclerosis. 

Objective: This course is designed to provide pearls and trouble shooters for 

performing different techniques of phaco chop and their applications in various 

case scenarios. The attendees will learn from the instructor’s demonstrations 

and from interactive discussion. 

Senior Instructor(s): Abhay Raghukant Vasavada MBBS FRCS* 

Instructor(s): Paul S Koch MD*, Alan S Crandall MD*, Robert H Osher MD*, Kevin 

M Miller MD*, Nick Mamalis MD* 

NEW Creating an Effective Cataract Surgery Training 

Curriculum for Residency Programs 

Course: 486 

Room: S104b 


Tuesday 

9:00 - 10:00 AM 


Synopsis: This course will review basic principles in designing a surgical curriculum 

for residents and highlight effective teaching methods that can be 

incorporated into the curriculum. 

Objective: At the conclusion of this course, the attendee will be able to (1) 

identify basic principles in the design of a curriculum, (2) describe effective 

methods for preparing residents for cataract surgery, including wet-lab training, 

stepwise introduction of cataract surgery, and the Massachusetts Eye and 

Ear Cataract Master, and (3) incorporate these teaching strategies into an organized 

surgical curriculum. 

Senior Instructor(s): Carolyn Kloek MD 

Instructor(s): Bonnie A Henderson MD*, John I Loewenstein MD* 

Intraoperative Floppy Iris Syndrome: Pearls for 

Management and Prevention 

Course: 487 

Room: N427bc 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Intraoperative floppy iris syndrome (IFIS) continues to challenge cataract 

surgeons. Multiple different surgical methods will be discussed in detail, 

with the goal of arming surgeons with a range of complimentary strategies. 

These include intracameral alpha agonists, ophthalmic viscosurgical device 

strategies, phaco techniques, iris retractors, and pupil expansion devices, including 

the Malyugin ring. This course will also review what is known about 

the pharmacologic basis and mechanism of IFIS. 

Objective: To update anterior segment surgeons on the latest clinical information 

about benign hyperstatic hypertrophy pharmacology, and the preoperative 

and intraoperative management of IFIS. 


Instructor(s): Steve A Arshinoff MD*, Allan J Flach MD 

Pearls for IOL Exchange 

Course: 488 

Room: E350 


Tuesday 

9:00 - 10:00 AM 


Synopsis: IOL exchange is becoming an increasingly popular procedure, perhaps 

because some patients are dissatisfied with their presbyopic IOL. Additionally, 

as our patient population is living longer, the prevalence of late-onset 

lens dislocation is also increasing. Thus a solid foundation in the techniques 

of lens exchange will help all ophthalmologists who perform cataract surgery. 

Objective: At the end of this course, participants will be familiar with the techniques 

to perform (1) lens exchange with or without an open posterior capsule, 

(2) lens exchange with anterior- or posterior-approach vitrectomy, (3) lens reposition 

surgery, and (4) suture fixation of IOLs. 

Senior Instructor(s): David A Goldman MD* 

Instructor(s): Sonia H Yoo MD*, Terrence P O’Brien MD*, John P Berdahl MD*, 

William Wiley MD* 

Cataract Surgery in the Setting of Ocular 

Comorbidities and High-Risk Features for 

Intraoperative and Postoperative Complications 

Course: 331 

Room: S102abc 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: Ocular comorbidities and high-risk characteristics for intraoperative 

and postoperative complications occur with surprising regularity in cataract 

surgery patients. Ocular comorbidities often reduce visual potential. Systemic 

comorbidities and other characteristics of the eye or patient are often associated 

with a high risk of intraoperative and postoperative complications. In this 

course, a faculty of internationally recognized experts in cataract surgery will 

discuss a variety of common comorbidities and high-risk characteristics, the 

unique problems they present, and strategies for achieving successful visual 

and surgical outcomes. 





65



Objective: At the conclusion of this course, the attendee will be able to identify 

a variety of ocular comorbidities and high-risk eye and patient characteristics 

for surgical complications at the time of cataract surgery. The attendee will 

also be able to describe strategies for obtaining optimal outcomes under these 

conditions. 

Senior Instructor(s): Kevin M Miller MD* 

Instructor(s): Iqbal K Ahmed MD*, Arup Chakrabarti MBBS, Michael Colvard MD*, 

Alan S Crandall MD*, James Philip Dunn Jr MD, Bonnie A Henderson MD*, Terry 

Kim MD*, Douglas D Koch MD*, Nick Mamalis MD*, Samuel Masket MD*, 

Thomas A Oetting MD, Randall J Olson MD, Robert H Osher MD*, Mark Packer 

MD*, Walter J Stark MD*, Abhay Raghukant Vasavada MBBS FRCS* 

H Conquering Capsule Complications: A Video 

Primer 

Course: 529 

Room: S404 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: Video cases will illustrate a spectrum of techniques for anterior and 

posterior capsule complications: trypan blue dye, vitreous tap for crowded anterior 

chamber, torn continuous curvilinear capsulorrhexis (CCC) options, secondary 

CCC enlargement, flap tear-out rescue technique, posterior CCC, rrhexis 

capture of the optic, early recognition of posterior chamber rupture, conversion 

from top/clear corneal incision to extracapsular cataract extraction, posterior 

polar cataracts, IOL fixation with torn anterior or posterior capsule, capsular 

tension ring and capsule hooks for weak zonules, small pupil/floppy iris strategies 

(hooks, Malyugin and other expansion rings, epinephrine, Healon 5), pars 

plana bimanual anterior vitrectomy (± triamcinolone), and Viscoat posteriorassisted 

levitation (PAL) + trap for descending nuclei. 

Objective: To use video cases to systematically review techniques of preventing, 

recognizing, and handling complications with either the capsulorrhexis or 

posterior capsule. 


Instructor(s): Robert H Osher MD* 

Femtosecond Laser-Assisted Refractive Cataract 

Surgery 

Course: 531 

Room: S103bc 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will feature a panel discussion regarding the most promising 

femtosecond-laser cataract surgery platforms. We will discuss improved 

safety and efficacy, differences in image guidance between platforms, and optimizing 

incision creation, capsulotomy, nuclear fragmentation, and cortical removal. 

Incorporation of this new technology into your practice, as well as keys 

to success in patient selection and optimal IOL selection, will be discussed. 

Objective: Attendees will gain a clear understanding of the improved safety 

and efficacy of femtosecond laser-assisted cataract surgery. 

Senior Instructor(s): Richard M Awdeh MD* 

Instructor(s): William B Trattler MD*, William W Culbertson MD*, Stephen G Slade 

MD FACS*, Steven J Dell MD*, Ronald R Krueger MD*, Louis D Skip Nichamin 

MD*, Aylin Kilic MD 

New and Emerging Technologies in Cataract and 


Course: 532 

Room: S106a 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course covers investigational and newly FDA-approved technologies 

and techniques: presbyopic and phakic IOLs, femtosecond cataract 

surgery, intraoperative wavefront measurements, 3-D imaging, femtosecond 

lasers for penetrating keratoplasty, endothelial and deep anterior lamellar 

keratoplasty, intracorneal lenses and multifocal excimer and intrastromal 

femtosecond laser treatments for presbyopia, transepithelial corneal collagen 

crosslinking, and minimally invasive glaucoma surgery 3-D visualization and 

guidance, new femtosecond lasers for refractive lenticule extraction and penetrating 

keratoplasty, endothelial and deep anterior lamellar keratoplasty, and 

intracorneal lenses and multifocal excimer and intrastromal femtosecond laser 

treatments for presbyopia, corneal crosslinking, and new stents for glaucoma. 

Objective: At the conclusion of this course, participants will be able to understand, 

discuss, evaluate, and anticipate emerging technologies in cataract and 

refractive surgery. 

Senior Instructor(s): Jonathan Davidorf MD* 

Instructor(s): Michael Colvard MD*, Iqbal K Ahmed MD*, Anthony J Aldave MD*, 

Daniel S Durrie MD*, Richard L Lindstrom MD*, John F Doane MD*, Mark Packer 

MD*, James J Salz MD*, Ganesha R Kandavel MD* 

Tackling Weak Zonules and Using Capsular Tension 

Devices 

Course: 533 

Room: E350 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will cover techniques, indications, and pitfalls for the 

use of capsular tension devices (rings and segments), capsular retractors, and 

other surgical techniques in patients with capsular-zonular complex pathology. 

A strategy for preoperative evaluation and intraoperative clues to unstable 

or potentially unstable zonules will be presented, and surgical approach and 

selection of capsular device(s) and techniques for implantation will be discussed. 

Strategies for avoidance and management of complications will also 

be presented. 

Objective: Participants will gain an understanding of the premise of and indications 

for capsular tension devices, the use of adjunctive devices, specific 

techniques in implantation, and potential complications. 

Senior Instructor(s): Iqbal K Ahmed MD* 

Instructor(s): Robert J Cionni MD*, Alan S Crandall MD*, Samuel Masket MD*, 

Robert H Osher MD*, Kenneth J Rosenthal MD FACS* 

H The Surgical Management of the Malpositioned 

IOL 

Course: 534 

Room: E351 


Tuesday 

10:15 AM - 12:30 PM 

Target Audience: SUB 

Synopsis: This course will cover a myriad of causes for the malpositioned IOL 

and will demonstrate corrective surgical maneuvers, such as retrieving the 

IOL from the vitreous and late reopening of the capsular bag. Explantation 

techniques for soft IOLs will be emphasized, as will new suturing techniques 

for sulcus and iris fixation. 

66 





Objective: This course is designed to review the causes of the malpositioned 

IOL, with emphasis on the principles and techniques of repositioning, explantation, 

and lens exchange. 

Senior Instructor(s): Michael E Snyder MD* 

Instructor(s): Robert H Osher MD*, Alan S Crandall MD*, Christopher D Riemann 

MD*, Lisa B Arbisser MD 

IOL Power Calculation: Problems With LASIK Eyes 

Course: 549 

Room: N135 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: This course will present the latest in IOL power calculation, from 

biometric measurements for axial length, corneal power, and anterior chamber 

depth, including the IOLMaster and LenStar, to formula usage and clinical decision 

making. Special attention will be paid to improving the accuracy of these 

parameters in clinical practice. Means for dealing with special cases, such 

as staphyloma, piggyback lenses, pediatric eyes, LASIK eyes, and silicone oil 

eyes, will be covered based on the presenter’s 38 years of experience in the 

field. How to handle power errors will also be presented. 

Objective: By the end of this course, attendees should obtain all the latest 

information to improve the accuracy of IOL power prediction for all patients 

receiving IOLs, either aphakic or phakic. They also should be able to handle 

especially difficult situations and to choose effective means to correct PO 

problems that occur. 

Senior Instructor(s): Kenneth J Hoffer MD FACS* 

Optimizing the Results of Presbyopic IOL Surgery 

Course: 569 

Room: S102Abc 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Appropriate patient selection for presbyopic IOL implantation is a 

major challenge. In this interactive panel discussion forum, we will cover the 

preoperative tests that can help improve a surgeon’s success rate. Challenging 

cases, such as patients with subtle topographic or OCT findings, will be 

discussed. In addition, pearls for handling the growing volume of patients with 

previous refractive surgery and/or dry eye will be presented, and strategies 

for troubleshooting the dissatisfied postoperative patient will be described. 

Objective: Attendees will interact with the faculty and improve their ability to 

recognize preoperative patient characteristics that reduce the success rate for 

presbyopic IOLs. Surgeons will also develop a systematic approach to treating 

the dissatisfied postoperative patient. 

Senior Instructor(s): William B Trattler MD* 

Instructor(s): Stephen G Slade MD FACS*, Steven J Dell MD*, John F Doane MD*, 

Mark Packer MD*, Y Ralph Chu MD*, Carlos Buznego MD*, Karl G Stonecipher 

MD* 

H Code Red: Mastering Phaco Nightmares and 

Worst-Case Scenarios: A Video-Based Course 

Course: 595 

Room: S103bc 


Tuesday 

2:00 - 4:15 PM 


Synopsis: “Code red” signifies danger, and it’s best to be prepared for such 

cases. Endocapsular rings for subluxated cataracts, prosthetic irides, and pupil 

expanders are secrets for mastering phaco surgery’s worst-case scenarios. Intraoperative 

floppy iris syndrome, IOL implantation in eyes with deficient capsules, 

and glued IOLs will all be explained. Vitreous loss, torn rrhexis management, 

and other complication management will also be covered. Management 

of dropped lenses, hard cataracts, posterior capsular ruptures, and the like will 

all be explained with excellent videos. From basic complications to nightmare 

situations, all will be covered in this course. Questions from the audience will 

be discussed so that attendees will be able go back to their practices and 

manage any situation. 

Objective: At the conclusion of this course, the attendee will be able to master 

difficult phaco cases and manage various complications without developing a 

heart attack. 


Instructor(s): David F Chang MD*, Robert H Osher MD*, Athiya Agarwal MD*, 

Iqbal K Ahmed MD*, Brian C Little MD* 

Techniques and Devices for Surgical Reconstruction 

of Traumatic and Developmental Iris Defects 

Course: 603 

Room: N427d 


Tuesday 

3:15 - 4:15 PM 


Synopsis: Iris reconstruction is required in cases of partial defects or total 

aniridia. This course will review all the currently available artificial iris implants 

in Europe and North America, including techniques and practical tips 

on implantation. Topics will include (1) preoperative assessment and surgical 

planning for iris defects, (2) systematic approach to iris reconstruction, (3) 

review of iris reconstruction implants currently available in the United States 

and Europe, (4) indications, (5) surgical techniques of each type (demonstrated 

with videos), and (6) complications and management. Surgical videos will be 

used extensively to demonstrate the techniques of each modality and the 

management of complications. A novel finding of multiple vacuolations in the 

optic of the Irismatch Aniridia Morcher 30B scleral sutured IOL will be also be 

discussed. 

Objective: After the course, the attendee will have gained a greater insight into 

the assessment, indications, and surgical strategies available for reconstructing 

the iris, together with management of complications in iris reconstruction. 

Senior Instructor(s): Sathish Srinivasan MBBS* 

Instructor(s): Somdutt Prasad MBBS*, Hans-Reinhard Koch MD**, Michael E 

Snyder MD*, Malhar Soni MD MS DNB FRCS 

Avoiding Complications in Lens Implant Surgery 

Course: 607 

Room: N427A 


Tuesday 

3:15 - 5:30 PM 


Synopsis: Six topics concerning lens implant surgery will be discussed: the feasibility 

of antibiotics and endophthalmitis prophylaxis, IOLs in the absence of 

capsular support, “fact or fiction” with new technology in IOLs, IOL explantation, 

refractive surgery, and IOL power calculations in special situations such 

as pediatric patients and patients with refractive surgery. The panel members 

will discuss methods to avoid complications and improve patient satisfaction 

with lens implant surgery. 

Objective: The panel will provide an overview of informed and management 

decisions in a wide variety of challenging implant situations to minimize complications, 

avoid pitfalls, and optimize results after cataract surgery. Audience 

questions and panel discussion will follow presentation of each topic. 

Senior Instructor(s): Woodford S Van Meter MD FACS 

Instructor(s): Robert S Feder MD*, M Bowes Hamill MD*, Cynthia Ann Bradford 

MD, Surendra Basti MBBS 





67



Step-by-Step, 3-D Instructional Course in 

Microcoaxial and Microbiaxial Cataract Surgery 

Course: 608 

Room: S404 


Tuesday 

3:15 - 5:30 PM 


Synopsis: This course will focus on the latest instrumentation, machine settings, 

and techniques for performing microincisional cataract surgery. A stepby-step 

approach using 3-D videos will be employed to educate surgeons on 

how to do coaxial and bimanual sub-2-mm microincisional cataract surgery. 

The procedure will be broken down into individual steps to provide a comprehensive 

course on the subject. By observing microincisional surgery in 3-D, the 

attendees will gain a better appreciation of the techniques and skills required. 

Cases employing the femtosecond cataract laser will also be shown in 3-D 

and discussed. 

Objective: At the completion of this course, participants will have a thorough 

understanding of how to perform microincisional cataract surgery. By watching 

instructional videos in 3-D, they will learn how to create wounds, perform the 

capsulorrhexis, remove the cataract, and insert the implant with microincisional 

wounds and instruments. The participating surgeons will be able return 

to their practices with all the information and skills necessary to transition 

from standard 3-mm cataract surgery to sub-2-mm surgery. 

Senior Instructor(s): Robert J Weinstock MD* 

Instructor(s): Stephen M Weinstock MD**, Neel R Desai MD**, Mark Packer MD* 


NEW “Big Bubble” Technique of Deep Anterior 

Lamellar Keratoplasty: A Simplified Approach to 

Successful Surgery 

Course: 149 

Room: S106a 


Sunday 

9:00 - 10:00 AM 


Synopsis: The big bubble technique for deep anterior lamellar keratoplasty 

(DALK) allows successful baring of the host Descemet membrane (DM). Visual 

results are comparable to penetrating keratoplasty, with no risk of endothelial 

rejection. This course will deal with basic surgical technique in detail, in a 

stepwise manner using surgical videos, along with instrumentation, patient 

selection, preoperative workup and investigations, and postoperative management. 

Both intraoperative and postoperative complications, along with their 

management, will be discussed. The role of the femtosecond laser will also 

be presented. 

Objective: At the end of the course, the attendee will have clear concept of 

case selection, surgical technique, postoperative care, and appropriate management 

of complications using the big bubble technique of DALK surgery. 

Senior Instructor(s): Rajesh Fogla MD FRCS 

Instructor(s): Mark A Terry MD*, David S Rootman MD*, Luigi Fontana MD PhD 

NEW Failed Graft: Never Say Die! 

Course: 162 

Room: N140 


Sunday 

10:15 - 11:15 AM 


Synopsis: This course describes the selection of the appropriate surgical procedure 

for the high-risk failed graft such as repeat penetrating keratoplasty (PK), 

Descemet-stripping endothelial keratoplasty (DSEK), or keratoprosthesis. Even 

endothelial keratoplasty and deep anterior lamellar keratoplasty (DALK) may 

fail and a repeat surgery may be required. Keratoprosthesis may be an answer 

for multiple failed grafts and for conditions known to have poor outcomes with 

keratoplasty. Surgical techniques and modifications required for performing 

DSEK for failed PK, repeat DSEK, and repeat DALK, postoperative immunosuppressive 

regimen, and outcomes of such surgeries will be discussed. A panel 

discussion on expert consensus on controversial issues regarding Descemet 

scoring, graft sizing for DSEK for failed PK, and multiple repeat PK/ keratoprosthesis 

will conclude the course. 

Objective: By the conclusion of this course, attendees will be familiar with the 

indications and patient selection for regrafts, surgical techniques and modifications, 

follow-up for and risks of repeat graft (PK, DSEK, DALK, and keratoprosthesis) 

for failed grafts. 

Senior Instructor(s): Jatin Naresh Ashar MD 

Instructor(s): Sonia H Yoo MD*, David S Rootman MD*, Anthony J Aldave MD*, 

Mark A Terry MD*, Pravin K Vaddavalli MD* 

NEW Follow the Cornea: Do You Know Where Your 

Corneal Transplant Tissue Comes From? 

Course: 163 

Room: N139 


Sunday 

10:15 - 11:15 AM 


Synopsis: The first steps of corneal transplant surgery take place in the eye 

bank. Through a combination of brief talks and expert panel discussions, we 

will inform the corneal surgeon about the process of eye tissue banking. We 

will (1) follow the path of tissue through recovery, evaluation, and processing 

to distribution for corneal transplantation, (2) provide the evidence-based 

standards for surgical tissue selection, (3) discuss current and upcoming trends 

in eye banking, and (4) inform corneal surgeons on ways to get involved in the 

process. 


intricacies of corneal donation and tissue processing. The attendee will know 

the results of the Cornea Donor Study and how they apply to surgeon screening 

of donor tissue. The attendee will appreciate the complexity of the work 

that is performed in the eye banks. The attendee will know ways to become 

involved locally and nationally with eye banks. The goal is to educate corneal 

surgeons in order to promote sustainability, to maintain availability of corneal 

tissue, and to broaden the surgeon’s knowledge of the vital resource of eye 

banking. 

Senior Instructor(s): Maria A Woodward MD 

Instructor(s): Bennie H Jeng MD*, Roni M Shtein MD*, Kristiana D Neff MD*, 

Mark J Mannis MD, Marian Sue Macsai-Kaplan MD*, David B Glasser MD, Monty 

Montoya 

Extreme Cornea: Diagnostic and Management 

Dilemmas in Your Practice 

Course: 168 

Room: S103d 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: The faculty of the Massachusetts Eye & Ear Infirmary Cornea Service 

will present challenging clinical and surgical cases of corneal conditions that 

often pose a dilemma in both diagnostic and treatment decision making. The 

topics will include optimal management of corneal melting disorders, early 

and end-stage autoimmune diseases, irregular corneal astigmatism, and anterior 

segment trauma. Recognition of sentinel signs of ocular surface tumors, 

innovative uses of scleral lenses and keratoprostheses, and novel techniques 

of measuring IOP in severe corneal disease with alternative devices will be 

discussed. 

Objective: At the conclusion of this course, attendees will be able to recognize 

and use innovative strategies to manage commonly encountered yet complicated 

corneal and external disease conditions. 

Senior Instructor(s): Kathryn A Colby MD PhD* 

Instructor(s): James Chodosh MD MPH*, Deborah S Jacobs MD, Roberto Pineda II 

MD, Samir A Melki MD PhD* 

68 





Herpes Simplex Keratitis: When Herpes Isn’t a 

Dendrite, and Vice Versa 

Course: 169 

Room: N138 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: Herpes simplex keratitis (HSK) is the most common cause of corneal 

blindness in developed nations. Many cases are missed because ophthalmologists 

are unaware of the nondendritic manifestations of HSK, such as geographic, 

marginal, necrotizing, endotheliitis, and interstitial keratitis. Features 

and pathophysiology of the different forms of HSK and clues to their diagnosis 

will be presented. A logical plan for treatment will be presented, including 

when and how to use antivirals, steroids, and surgery. Major literature on herpes 

simplex keratitis will also be briefly discussed. 

Objective: At the conclusion of this course, the attendees will be able to (1) 

diagnose common as well as unusual forms of HSV keratitis, (2) formulate a 

logical treatment plan based on their understanding of the pathophysiology of 

the different manifestations of herpes, and (3) get a general understanding of 

the newer treatment modalities on the horizon. 

Senior Instructor(s): Sonal S Tuli MD 

Interdisciplinary Approach to Keratoprosthesis 

Surgery and Management, From the Subspecialist’s 

Perspective 

Course: 170 

Room: N136 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: Successful keratoprosthesis surgery and long-term retention require 

a unique interaction between the corneal prosthesis and its surrounding environment. 

The requirements for success are not limited to the management of 

corneal disease but also include a team-focused effort between oculoplastic, 

vitreoretinal, and glaucoma specialists. Specific knowledge of the effect of 

keratoprosthesis management in these subspecialties makes all the difference 

in long-term visual rehabilitation. 

Objective: This course will guide the clinician in each different subspecialty 

toward a team approach for improved outcomes and will provide tips in avoiding 

complications within each field of expertise in regard to keratoprosthesis 

surgery and management. 

Senior Instructor(s): Jose J de la Cruz Napoli MD 

Instructor(s): Victor L Perez MD*, Eduardo C Alfonso MD*, Pete Setabutr MD, 

Audina Berrocal MD, Thasarat S Vajaranant MD*, Maria S Cortina MD 

H Recent Developments in the Diagnosis and 

Management of Conjunctival Tumors 

Course: 171 

Room: S403b 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: Benign and malignant tumors of the conjunctiva have a wide and 

varied spectrum of clinical manifestations. These are often misdiagnosed as 

simulating conditions, resulting in delayed, inappropriate, or inadequate treatment. 

Management without using standard treatment protocols may result in 

unacceptably high rates of local tumor recurrence. The aim of this course is to 

provide a systematic overview of the clinical manifestations of conjunctival 

tumors and to discuss recent concepts regarding their diagnosis, management, 

and prognosis. Typical and atypical manifestations of common and uncommon 

conjunctival tumors will be demonstrated with the help of well-documented 

clinical cases. Systemic associations will be highlighted and discussed. Advantages 

of anterior segment imaging techniques will be highlighted. Published 

literature elucidating clinical and histopathologic factors predictive of 

prognosis will be reviewed. Evidence-based standard treatment protocols will 

be detailed, and surgical procedures will be demonstrated with succinct video 

films. Discussion topics include indications and outcome of newer treatment 

modalities such as topical chemotherapy, and the utility of plaque brachytherapy 

when excision base has tumor infiltration. Useful techniques such as 

sutureless amniotic membrane transplantation for ocular surface reconstruction 

following tumor excision will be demonstrated. 

Objective: This course is designed to enable participants to accurately diagnose 

and appropriately manage common conjunctival tumors. 

Senior Instructor(s): Santosh G Honavar MD 

Instructor(s): Carol L Shields MD, Carol L Karp MD, Jerry A Shields MD, 

Mohammad Javed Ali MD 

NEW Anterior Segment OCT 

Course: 180 

Room: N427bc 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: Optical coherence tomography (OCT) can measure corneal and anterior 

segment anatomy with micron precision. Recent advances in speed and 

software for corneal power and pachymetry/epithelial thickness mapping 

makes this technology increasingly useful in a wide variety of diagnostic and 

surgical planning applications. 

Objective: By the conclusion of this course, the participants will be able to use 

OCT for (1) planning of LASIK other laser refractive and therapeutic procedures, 

(2) calculating and selecting IOL power for cataract surgery after previous laser 

vision correction, (3) detecting keratoconus, (4) fitting phakic IOL implants and 

following postoperative results, and (5) assessing risk for angle closure. 

Senior Instructor(s): David Huang MD PhD* 

Instructor(s): Georges D Baikoff MD*, Douglas D Koch MD* 

Innovative Uses of Adhesives in Anterior Segment 

Surgery 

Course: 181 

Room: N139 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: This course will present the use of cyanoacrylate, fibrin-based, and 

other new adhesives for corneal wounds, cataract surgery, pterygium surgery, 

LASIK complications, dislocated IOLs, limbal stem cell transplant, and glaucoma 

surgery. 


and describe the use of various adhesives for corneal disorders, cataract/ 

corneal procedures, dislocated IOL procedures, LASIK complications, and glaucoma 

procedures. 

Senior Instructor(s): Terry Kim MD* 

Instructor(s): Amar Agarwal MD*, Sadeer B Hannush MD, David R Hardten MD*, 

Robert J Noecker MD*, Christopher Rapuano MD*, David C Ritterband MD*, 

Jonathan B Rubenstein MD* 





69



State-of-the-Art Use of the Femtosecond Laser for 

Keratoplasty, Cataract Surgery, and Astigmatic 

Incisions 

Course: 182 

Room: N427a 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: This course will present worldwide experts to discuss their femtosecond 

laser surgery experiences. Femtosecond laser surgery is a dramatic 

change from standard methods. Advantages, disadvantages, revolutionary 

changes in techniques, and different femtosecond laser surgery platforms will 

be presented. 

Senior Instructor(s): Francis W Price Jr MD* 

Instructor(s): Luciene Sousa MD*, Bernie Iliakis*, Ramon Naranjo-Tackman MD*, 

Rudy Nuijts MD*, Sonia H Yoo MD*, Roberto Zaldivar MD*, William W Culbertson 

MD* 

NEW Diagnosis and Treatment Modalities in Cases of 

Moderate and Recalcitrant Fungal Keratitis 

Course: 196 

Room: S106a 


Sunday 

2:00 - 3:00 PM 


Synopsis: The epidemiology, etiopathogenesis, laboratory diagnosis, and confocal 

microscopy in fungal keratitis will be discussed. Stepwise algorithm for 

using conventional and newer topical and systemic antifungal agents in mild 

and moderate cases and the role of intracameral and intrastromal injections 

with antifungal agents in recalcitrant fungal keratitis will be elucidated. The 

indications and the caveats in preoperative, intraoperative, and postoperative 

management in collagen crosslinking, therapeutic penetrating and deep anterior 

lamellar keratoplasty will be highlighted. 

Objective: At the end of the course, the attendee will have clarity about the 

management of not only mild and moderate but also recalcitrant cases of fungal 

keratitis using the stepwise algorithm. 

Senior Instructor(s): Namrata Sharma MD MBBS 

Instructor(s): Rasik B Vajpayee MD, Vishal Jhanji MBBS, Tushar Agarwal MD 

How to Avoid the Mistakes We Made in Starting 

Descemet-Stripping Automated Endothelial 

Keratoplasty 

Course: 197 

Room: S505ab 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will discuss the process of starting Descemet-stripping 

automated endothelial keratoplasty (DSAEK) and will illustrate how to avoid 

the most common pitfalls. Beginning the task of learning to do DSAEK is 

fraught with hidden dangers. The authors will point out their own mistakes 

and provide techniques for a smooth transition for the surgeon, whether you 

are just beginning or are an experienced corneal expert unfamiliar with DSAEK 

techniques. Each instructor will present his standard DSAEK technique with 

complete video. Clinical examples will illustrate points where simple steps 

may help avoid common pitfalls. Slides and videos of case studies will be 

shown, emphasizing dangers and solutions. The handout outline will include 

steps, with references, that will lead to fewer complications and a greatly 

shortened learning curve. 

Objective: This course is designed to enable participants to learn from our 

experience and avoid complications while shortening their learning curve for 

endothelial keratoplasty. 

Senior Instructor(s): Sadeer B Hannush MD 

Instructor(s): Anthony J Aldave MD*, Henry D Perry MD* 

NEW APAO The Management of Recurrent Pterygium 

Sponsored by the Asia-Pacific Academy of Ophthalmology (APAO) 

Course: 222 

Sunday 

Room: S105d 

3:15 - 4:15 PM 



Synopsis: In order to properly manage recurrent pterygium surgically, we need 

to know several key “tips” related to the surgical procedures such as subconjunctival 

tissue dissection, treatment with Mitomycin C, amniotic membrane 

transplantation, etc. This course will cover the subjects mentioned in order to 

teach attendees how to perform the proper surgical techniques for reducing 

the recurrence rate to almost none using case presentations. The course also 

covers the treatment of primary pterygium and pseudo-pterygium. 

Objective: At the conclusion of this course, attendees will come to understand 

the key concepts related to the contemporary surgical management of recurrent 

pterygium. 

Senior Instructor(s): Shigeru Kinoshita MD* 

Instructor(s): Jodhbir S Mehta FRCS FRCOPHTH*, Vishal Jhanji MBBS, Tsutomu 

Inatomi MD PhD 

Anterior Lamellar Keratoplasty: Principles and 

Practice 

Course: 232 

Room: S102d 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will cover current and evolving practice in anterior lamellar 

keratoplasty. Topics include evolving lamellar techniques, including the 

“big bubble,” modified Melles, viscodissection, Ferrara, and automated and 

femtosecond lamellar techniques. A series of didactic lectures will be provided, 

with technique pearls (and complications) supported by video presentations 

and handouts. The lecture portion will be a prerequisite for the wet lab, 

where candidates will be guided through many of the techniques. 

Objective: The participant should leave the course with an understanding of 

the various options for performing anterior lamellar keratoplasty. The participant 

will have a thorough understanding of the indications, advantages, and 

disadvantages of each of these techniques. Additional hands-on training on 

the use of some of these procedures will be provided in the associated laboratory. 



Senior Instructor(s): Sadeer B Hannush MD 

Instructor(s): Woodford S Van Meter MD FACS, William W Culbertson MD*, Luigi 

Fontana MD PhD, Shigeto Shimmura MD, Donald Tan MD FRCS FRCOphth* 

Pterygium: The Outcome Measure Is Now Cosmesis, 

Not Recurrence 

Course: 254 

Room: S103bc 


Sunday 

4:30 - 5:30 PM 


Synopsis: The Perfect for Pterygium (Pterygium Extended Removal Followed by 

Extended Conjunctival Transplantation) procedure, which is a significant modification 

of autoconjunctival surgery, not only results in minimal recurrences (1 

recurrence in 1000 consecutive patients with primary and recurrent pterygia 

with 96% follow-up of more than 1 year) but also provides an excellent cosmetic 

result. 

Objective: At the end of the course, attendees will understand the differences 

between the Perfect for Pterygium surgical procedure and routine autoconjunctival 

surgery for pterygium. They will be prepared to treat pterygium as a 

significant disease, with detailed and “serious surgery” designed to achieve 

70 





a low recurrence rate and a cosmetic appearance at 1 year, when the site of 

surgery and pterygium will be undetectable. Attendees will be able to incorporate 

into their pterygium surgery any components of Perfect for Pterygium 

that they do not already use. They will understand the expected postoperative 

course and therapy and the complications of this surgery. Above all else, they 

will learn a new respect for this disease, which has so often been trivialized 

in the past. 

Senior Instructor(s): Lawrence W Hirst MD MBBS MPH DO FRACO FRACS* 

Instructor(s): Ivan R Schwab MD FACS, Linda Rose MD PhD* 

Endothelial Keratoplasty in Challenging Cases 

Course: 310 

Room: S403b 


Monday 

9:00 - 10:00 AM 


Synopsis: The indications for endothelial keratoplasty have rapidly expanded, 

to the point that this surgery is now appropriate for endothelial failure of almost 

any etiology. In this course the instructors will use video and case presentations 

to explain the differing techniques for challenging cases such as 

post-penetrating keratoplasty, phakia, aphakia, buphthalmos, patients with 

anterior chamber IOLs, patients with filtering glaucoma procedures/devices, 

patients with long-standing/severe corneal edema, situations in which visualization 

is particularly poor, or in patients of pediatric age. Visual outcomes and 

complications will also be discussed in detail. 

Objective: Attendees will gain information that is instrumental in choosing the 

type of surgery appropriate for patients with endothelial failure and complicating 

ocular factors. 

Senior Instructor(s): Jacqueline E Beltz MBBS 

Instructor(s): Massimo Busin MD*, Amit K Patel MBbcH, Vincenzo Scorcia MD, 

Robert C Arffa MD 

NEW Advances in Treatment of Severe Ocular 

Surface Disease: Views From Experts on the Front 

Lines 

Course: 346 

Room: N138 


Monday 

10:15 AM - 12:30 PM 


Synopsis: Exciting new treatment approaches to severe ocular surface diseases 

(Stevens-Johnson syndrome, graft versus host disease, chemical injuries, 

and others) have emerged in the past few years. In this newly developed 

course, leading experts in the field will present their own innovations as well 

as their perspectives on the latest developments. In Stevens-Johnson syndrome, 

for example, interventions in the acute disease phase, including topical 

and systemic medications, specialty contact lenses, and amniotic membrane 

application, have shown great promise in limiting devastating long-term ocular 

sequelae. For patients with chronic ocular findings, treatment with mucous 

membrane grafts, specialty devices such as prosthetic replacement of the 

ocular ecosystem (PROSE), and keratoprostheses constitute potential sightrestoring 

interventions. 

Objective: This course is designed to update general and subspecialty ophthalmologists 

on sophisticated novel treatment approaches to severe ocular 

surface disease. 

Senior Instructor(s): Jessica B Ciralsky MD 

Instructor(s): Kimberly C Sippel MD*, James Chodosh MD MPH*, C Stephen Foster 

MD*, Darren G Gregory MD*, Deborah S Jacobs MD, Stella K Kim MD*, Peter A 

D Rubin MD* 

Complications in Collagen Crosslinking : Diagnosis, 

Management, and Prevention 

Course: 347 

Room: E352 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will present a didactic approach to the clinical experience 

of complications encountered with several collagen crosslinking (CXL) 

treatments for indications such as (1) keratoconus, (2) ectasia following refractive 

surgery, (3) prophylactic CXL in LASIK and PRK, and (4) CXL in bullous 

keratopathy. Cornea scarring, infectious keratitis, delayed epithelial healing, 

regression, and endothelial decompensation were the most common complications 

encountered. Medical and surgical and treatment techniques of the 

above will be presented and discussed in detail. 

Objective: The participants will share our vast experience in CXL and the potential 

complications encountered in managing progressive keratoconus, post- 

LASIK ectasia, bullous keratopathy, prophylactic CXL in LASIK and PRK and 

lamellar grafts in order to stabilize and potentially visually rehabilitate these 

patients. 

Senior Instructor(s): A John Kanellopoulos MD* 

Instructor(s): Gregory Pamel MD**, Henry D Perry MD*, R Doyle Stulting MD 

PhD*, Eric D Donnenfeld MD*, Efekan Coskunseven MD**, Gaurav Prakash MBBS, 

Soosan Jacob FRCS 

H Deep Anterior Lamellar Keratoplasty Update 

Course: 348 

Room: S106b 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will explore the various surgical techniques of corneal 

tissue replacement through anterior lamellar keratoplasty, including deep lamellar 

dissections and automated lamellar resections, also announcing new 

applications of lamellar surgery in corneal stromal diseases with healthy endothelium. 

Each technique will be shown by video, and the current results 

supporting the technique will be discussed. 

Objective: At the conclusion of this course, attendees will recognize the indications 

for these new lamellar procedures and know the advantages and 

disadvantages of each technique. 

Senior Instructor(s): Vincenzo Sarnicola MD 

Instructor(s): Edward J Holland MD*, Sadeer B Hannush MD, Donald Tan MD FRCS 

FRCOphth*, Shigeto Shimmura MD, Rajesh Fogla MD FRCS 

NEW Descemet-Stripping Automated Endothelial 

Keratoplasty Cliffhangers 

Course: 349 

Room: N140 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will be comprised of video- and case-based presentations 

of a number of difficult situations that may arise during Descemet-stripping 

automated endothelial keratoplasty (DSAEK), both during the learning 

curve and in experienced hands. Case scenarios will include difficulties with 

tissue dissection, surgical challenges such as recurrent iris prolapse and floppy 

iris, inverted graft, loosing orientation of the lenticule, managing extensive 

synechiae, and dealing with inadequate space in the anterior chamber. The 

course will also endeavor to focus on tips to overcoming poor visualization, 

doing post-keratoplasty DSAEK, DSAEK following trabeculectomy and tube 

shunts, DSAEK in phakic and aphakic eyes, and DSAEK in children. Management 

of postoperative complications including dislocated lenticules and repeat 

DSAEK will also be dealt with briefly. The course will end with an introduction 

to Descemet membrane endothelial keratoplasty and identify common 

problems faced by surgeons converting from DSAEK to DMEK. 





71



Objective: At the end of the course, attendees will be familiar with challenging 

situations that may arise during DSAEK and maneuvers to manage and 

prevent them. 

Senior Instructor(s): Pravin K Vaddavalli MD* 

Instructor(s): Sonia H Yoo MD*, Mark A Terry MD*, Anthony J Aldave MD*, David 

S Rootman MD*, Jatin Naresh Ashar MD 

NEW Endothelial Keratoplasty Surgery: 

Comprehensive Overview and Surgical Pearls 

Course: 350 

Room: S102d 


Monday 

10:15 AM - 12:30 PM 

Target Audience:SUB 

Synopsis: Endothelial keratoplasty (EK) has become the standard of care for 

the surgical treatment of endothelial diseases of the cornea. This course will 

utilize international corneal experts to teach a comprehensive overview of a 

variety of surgical techniques and surgical pearls for EK. In addition, complication 

management and new Descemet-stripping EK and Descemet membrane 

EK techniques will be discussed. 

Objective: An international faculty will discuss the latest surgical techniques 

in endothelial keratoplasty surgery. The course will cover the most current 

DSEK and DMEK surgical methods including a variety of tissue preparation 

and insertion techniques. This course will also cover post operative management 

and complications of DSEK and DMEK surgery. 

Senior Instructor(s): Edward J Holland MD* 

Instructor(s): Francis W Price Jr MD*, Donald Tan MD FRCS FRCOphth*, Massimo 

Busin MD*, Mark J Mannis MD, David T Vroman MD*, William Barry Lee MD*, 

Keith A Walter MD* 

NEW APAO Atypical Keratitis 


Course: 351 

Monday 

Room: S104b 

10:15 AM - 12:30 PM 



Synopsis: Since many patients of corneal ulcer are managed empirically based 

on clinical features it is important to be familiar with not just the classical 

but also atypical clinical features. This course will present atypical features 

of common pathogens, clinical features of uncommon pathogens and special 

clinical situations such as infections after Laser in situ keratomileusis. The 

course will also provide pearls in establishing diagnosis of such atypical cases 

including the role of newer diagnostic modalities such as confocal microscopy 

and molecular methods. 

Objective: To make participants familiar with atypical keratitis cases and help 

acquire skills to diagnose and appropriately manage them. 



Senior Instructor(s): Prashant Garg MD* 

Instructor(s): Namrata Sharma MD MBBS, Francis S Mah MD*, M Srinivasan MD, 

Yoshitsugu Inoue MD PhD 

Ocular Surface Diseases in Cancer Patients: Update 

on Clinical Spectrum and Treatment 

Course: 311 

Room: N136 


Monday 

2:00 - 3:00 PM 


Synopsis: In this course the clinical spectrum and management of ocular surface 

diseases due to cancer treatment will be summarized. Update of new 

cancer treatments and their ocular side effects will be covered. Special surgical 

considerations in cancer patients will be discussed in an interactive format. 

Objective: This course is designed to provide an overview and update of ocular 

surface diseases that result from modern cancer treatments. At the conclusion 

of the course, the attendees will be able to recognize and treat the spectrum 

of the ocular surface diseases in cancer patients. 

Senior Instructor(s): Stella K Kim MD* 

Instructor(s): Kimberly C Sippel MD* 

Surgical Strategies for Recurrent Pterygium With or 

Without Motility Restriction 

Course: 380 

Room: N135 


Monday 

2:00 - 3:00 PM 


Synopsis: Although surgeries for primary pterygium have been successfully 

practiced by many general ophthalmologists, pterygium recurrence with or 

without motility restriction presents a puzzle and a great challenge. 

Objective: At the conclusion of this course, through interactive discussion, 

surgical video demonstration, and case presentation, the attendee will have 

learned the pathology that explains how recurrence occurs in pterygium, as 

well as the most up-to-date published surgical strategies —encompassing cicatrix 

lysis, amniotic membrane transplantation, intraoperative application of 

mitomycin C, muscle sheath recreation, and sealing the gap between conjunctiva 

and Tenon with anchoring sutures with or without additional conjunctival 

autograft or oral mucosal graft—to prevent recurrence and restore ocular motility. 

Furthermore, this new information can be used to correct other types of 

ocular surface diseases manifesting cicatricial complications with or without 

muscle involvement due to primary diseases or following surgeries for glaucoma, 

strabismus, and retinal problems. 

Senior Instructor(s): Scheffer C G Tseng MD PhD* 

NEW APAO Anterior Segment Reconstruction 

Following Trauma 


Course: 410 

Monday 

Room: S104a 

3:15 - 5:30 PM 



Synopsis: This course will cover the presentation and the primary and secondary 

management of chemical and mechanical injury of the anterior segment 

including all aspects of anterior segment reconstruction. 


the key concepts in the contemporary management of anterior segment 

repair following severe trauma. 

Senior Instructor(s): Charles McGhee PhD FRCOphth FRANZCO* 

Instructor(s): Peter Zloty MD*, Alexandra Crawford MD**, Edward J Holland 

MD*, Sue E Ormonde MBChB, Michael W Belin MD*, Helen V Danesh-Meyer MD 

MBChB**, Donald Tan MD FRCS FRCOphth* 

Descemet’s Membrane Endothelial Keratoplasty 

and Related Advanced Endothelial Keratoplasty 

Techniques. 

Course: 411 

Room: S103a 


Monday 

3:15 - 5:30 PM 


Synopsis: Descemet-stripping automated endothelial keratoplasty (DSAEK) is 

the treatment of choice for endothelial dysfunction, yet a significant proportion 

of patients without ocular comorbidity fail to achieve maximal visual potential. 

Transplantation of only the Descemet membrane and endothelium, a procedure 

known as Descemet membrane EK (DMEK), allows a significantly higher 

proportion of patients to achieve 20/25 or better vision. This course will cover 

indications and contraindications for DMEK, related techniques like Descemet 

72 





membrane automated endothelial keratoplasty, crescent DMEK , and thin cut 

DSAEK; describe the surgical techniques in detail; discuss intra- and postoperative 

complications and management; and present visual and refractive outcomes 

and endothelial cell losses. 

Objective: This course will enable participants to understand current concepts 

in DMEK and related techniques, including donor preparations, surgical implantation, 

and limitations. 

Senior Instructor(s): Francis W Price Jr MD* 

Instructor(s): Massimo Busin MD*, Art W Giebel MD, Friedrich E Kruse MD**, 

Amisha Patel MD**, Marianne O Price PhD*, Mark Soper* 


Course: 412 

Room: S105a 


Monday 

3:15 - 5:30 PM 


Synopsis: This course will explore the various surgical techniques used for 

endothelial keratoplasty (EK): Descemet-stripping EK, Descemet-stripping 

automated EK, and Descemet membrane EK. Emphasis will be placed on basic 

techniques that minimize complications and maximize donor endothelial 

survival. Methods of donor tissue preparation, insertion, unfolding, and positioning 

will be discussed. Benefits and problems with tissue injectors will be 

presented. Techniques to promote donor tissue adhesion and to avoid primary 

graft failure will be emphasized. Detailed videos and discussion of EK in complex 

and combined cases will be presented. 

Objective: At the conclusion of the course, participants will understand the 

safest methods of EK to avoid dislocation, primary graft failure, and pupillary 

block, and how to enhance faster visual rehabilitation. 



Senior Instructor(s): Mark A Terry MD*, Kenneth M Goins MD, George O D 

Rosenwasser MD* 

NEW Theory and Techniques of Corneal Surgery: An 

Interactive Course for Corneal Surgeons 

Course: 413 

Room: N427a 


Monday 

3:15 - 5:30 PM 


Synopsis: Corneal blindness is a global public health problem, second only to 

cataract in its importance. While medical treatments are emerging to restore 

sight in patients with corneal diseases, currently the treatment of choice is 

transplantation of the diseased tissue. 

Objective: This comprehensive course is intended to address various anterior 

segment problems involving the ocular surface, cornea, and lens. An interactive 

method will be utilized to transfer the skills of the participating faculty: 

first a patient case with a clinically relevant problem will be presented to the 

audience. The diagnosis, preoperative considerations, surgical techniques, 

detailed postoperative management, and handling of complications will be 

discussed through clinical pictures and videos. A detailed literature review 

will be presented regarding the recommendations of the faculty. 

Senior Instructor(s): Esen K Akpek MD* 

Instructor(s): Anthony J Aldave MD*, David R Hardten MD*, Albert S Jun MD, 

Roberto Pineda II MD, Kimberly C Sippel MD* 

Top 12 Corneal Surgical Tips for 2012 

Course: 414 

Room: S103d 


Monday 

3:15 - 5:30 PM 


Synopsis: Four experienced corneal surgeons from across North America will 

share 12 of their most innovative, novel, and useful tips for obtaining superior 

results from corneal surgical procedures that vary from simple to complex. 

Of interest to corneal specialists as well as to any ophthalmologist with an 

interest in cornea, the course provides annually updated topics that range 

from office procedures (eg, anti-VEGF injection therapy, in-office rebubbling) 

and commonly performed operations (eg, fibrin glue amniotic membrane and 

pterygium surgery, repair of Descemet detachments) to more specialized surgical 

techniques (eg, exchange PK, rotational PK, complex endokeratoplasty, 

freehand lamellar keratoplasty, deep anterior lamellar keratoplasty, and keratoprosthesis). 

Each surgical pearl will be described in detail and has been 

selected for presentation based on novelty, clinical relevance, and practice 

impact. A rapid-fire format with expert panel commentary and audience Q&A 

will promote lively discussion, and annual refreshing of topics and a guest faculty 

slot ensure that material is up to date and of interest to repeat attendees. 

Objective: Through step-by-step instructions, surgical video, and detailed 

handouts, the practitioner will gain practical, specific, and immediately applicable 

knowledge of improved techniques and approaches for common and 

challenging corneal surgical problems. 

Senior Instructor(s): David G Hwang MD 

Instructor(s): Eduardo C Alfonso MD*, Sadeer B Hannush MD, Allan Slomovic MD* 

NEW Allergic Eye Disease: An Enigma for Physicians 

Course: 489 

Room: S105bc 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Ocular allergy is a common disorder, affecting up to 20% population. 

Allergic eye diseases are important due to their chronic nature and refractory 

behavior to most therapies. They affect overall quality of life. Because of their 

varied presentations, they are often missed or may mimic other ocular surface 

pathologies and sometimes even infection. This may delay their diagnosis and 

management. In this course, we will present a series of cases that would depict 

the various common and uncommon manifestations of different types of 

allergic eye diseases. Topics include seasonal, perennial, vernal, atopic, and 

toxic keratoconjunctivitis and their complications and sequelae. A stepwise 

algorithm approach will describe management for each, including the role of 

topical steroidal and nonsteroidal formulations, cyclosporine, mast cell stabilizers 

and antihistaminics, topical and oral anti-inflammatory and immunosuppressive 

drugs, and prevention and management of complications. 

Objective: At the end of the course, attendee will be able to differentiate various 

forms of ocular allergies and formulate a logical stepwise treatment plan 

for them. 

Senior Instructor(s): Virender S Sangwan MBBS 

Instructor(s): Jatin Naresh Ashar MD, Neal P Barney MD*, Victor L Perez MD* 





73



Anterior Segment Imaging: A Practical Guide for 


Course: 490 

Room: S106a 


Tuesday 

9:00 - 10:00 AM 


Synopsis: This course will provide a comprehensive review of established and 

newer anterior segment imaging instruments and their practical clinical uses 

for evaluation of pathology of the cornea and angle. Instructors will cover anterior 

segment OCT (AS-OCT), ultrasound biomicroscopy (UBM), in vivo confocal 

microscopy (IVCM), and corneal topography. Emphasis will be on casebased 

approach to choosing when to use each imaging modality, what it adds 

to clinical practice, and how to interpret the images. 

Objective: This course will provide a practical and comprehensive review of 

anterior segment imaging techniques for comprehensive ophthalmologists and 

anterior segment specialists. At the end of the course, attendees will be able 

to choose the appropriate imaging modality to use for individual patients in 

the clinical setting. 

Senior Instructor(s): Roni M Shtein MD* 

Instructor(s): Shahzad I Mian MD*, Sayoko E Moroi MD PhD*, Maria A Woodward 

MD 

NEW Extreme Corneal Ectasia: Battle of the Bulge 

Course: 491 

Room: S105a 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Ectatic disorders of the cornea in their advanced stage may be associated 

with extreme thinning and forward protrusion of cornea. Surgical 

intervention is often necessary to restore tectonic integrity and corneal anatomy, 

besides improving eyesight. Customized grafts—D-shaped, banana or 

crescent shaped, large diameter corneoscleral grafts, epikeratoplasty, lamellar 

grafts, wedge excision, and other techniques—are used in such situations. 

This course will discuss indications, preoperative evaluation, investigations, 

surgical planning and stepwise execution, managing intraop and postop complications, 

and postoperative care. A variety of clinical cases will be presented, 

along with videos, to enable discussion and audience interaction. 

Objective: At the end of the course, the attendee will have a clear understanding 

of the various surgical options available in the management of extreme 

corneal ectasia. Application of appropriate surgical techniques will help improve 

vision as well as corneal anatomy and shape 

Senior Instructor(s): Rajesh Fogla MD FRCS 

Instructor(s): Sheraz M Daya MD*, Rasik B Vajpayee MD, Pravin K Vaddavalli MD*, 

Rishi Swarup MBBS 

NEW Next-Generation Technologies for the 

Diagnosis and Treatment of Dry Eye and Meibomian 

Gland Dysfunction 

Course: 492 

Room: S103d 


Tuesday 

9:00 - 10:00 AM 


Synopsis: While diagnostics and treatments for dry eye are advancing, the majority 

of practitioners limit their interventions to giving out artificial tears. The 

panel of experts in this course will engage members of the audience to share 

their experiences with the presented technologies. The panel will discuss new 

diagnostic devices such as the InflammaDry Detector, the Lipiview interferometer, 

and tear osmolarity measurement, as well as the use of existing devices 

such as high-resolution OCT and topography to evaluate dry eye. Newer, as 

yet not widely used therapeutic strategies will be discussed including Lipiflow, 

intense pulsed light lasers, and Maskin Meibomian ProbesTM. Finally, emerging 

therapeutics on the horizon will be discussed. 

Objective: Attendees will collaborate with faculty to both summarize and disseminate 

our growing intuitions about how to approach and successfully treat 

one of the most common problems seen in the office daily. 

Senior Instructor(s): Linda Rose MD PhD* 

Instructor(s): William B Trattler MD*, Parag A Majmudar MD*, Marguerite B 

McDonald MD*, Penny Asbell MD FACS*, Robert Sambursky MD*, Mina Massaro- 

Giordano MD*, Esen K Akpek MD* 

Yo Contact Lens in Ophthalmology Practice 


and the Contact Lens Association of Ophthalmologists (CLAO) 

Course: 493 

Tuesday 

Room: N427a 

9:00 - 10:00 AM 



Synopsis: In this course, the incentives, scope-of-practice options, and resource 

requirements for contact lens practice will be presented. Practitioners 

from various practice settings, including comprehensive solo practice, cornea 

practice, and multispecialty practice, will present their experiences in offering 

contact lens services to their patients. Both private and institutional practices 

will be represented. Useful resources will be reviewed. 

Objective: At the completion of this program, the participant will understand 

(1) the incentives for offering contact lens as part of comprehensive eye care, 

(2) options for offering a limited scope or full range of contact lens services, 

(3) resource requirements for a range of contact lens services and practice 

models, and (4) availability of resources for reference. 

Senior Instructor(s): Deborah S Jacobs MD 

Instructor(s): S Lance Forstot MD FACS*, Bruce Koffler MD*, Thomas L Steinemann 

MD* 

Surgery for Severe Corneal and Ocular Surface 

Disease 

Course: 512 

Room: S102d 


Tuesday 

9:00 - 11:15 AM 


Synopsis: This course is intended for ophthalmologists who plan to expand 

their surgical skills in the management of severe corneal and ocular surface 

disease. The topics will include amniotic membrane transplantation, limbal 

stem cell transplantations, and keratoprosthesis. 


describe the indications and apply the surgical techniques for amniotic membrane 

transplantation, (2) recognize limbal stem cell deficiency and effectively 

apply the various surgical techniques for limbal stem cell transplantation, 

(3) recognize and successfully prevent/treat limbal allograft rejection using 

systemic immunosuppression, and (4) describe the patient selection, surgical 

techniques, and postoperative management of patients with keratoprosthesis. 



Senior Instructor(s): Gunther Grabner MD* 

Instructor(s): Edward J Holland MD*, Scheffer C G Tseng MD PhD*, James 

Chodosh MD MPH*, Jose J de la Cruz Napoli MD, Ahmad Kheirkhah MD, Eduardo 

C Alfonso MD* 

74 





Current Topics in Cornea/External Disease: 

Highlights of the Basic and Clinical Science Course 8 

Course: 535 

Room: N139 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will provide an excellent review for the comprehensive 

ophthalmologist on a wide range of topics by the faculty of the Cornea and 

External Disease textbook in the Basic and Clinical Science Course series. The 

topics to be covered include the latest in diagnosis and treatment of ocular 

surface disorders, infectious disease, immune-related disorders, and surface 

neoplastic disorders. The new classification system for corneal dystrophies 

will be reviewed. The latest in surgical treatment for anterior segment disease 

will be shown, including indications and techniques for collagen crosslinking 

and corneal transplantation. 

Objective: At the conclusion of this course the participant should be able to 

diagnose and manage the patient with tear dysfunction. They should be able 

to recognize common infectious, neoplastic, and immune-related diseases and 

prescribe appropriate treatment. They should be able to differentiate the common 

corneal dystrophies. They should understand the role of collagen crosslinking, 

Descemet-stripping automated endothelial keratoplasty, Descemet 

membrane endothelial keratoplasty, deep anterior lamellar keratoplasty, and 

penetrating keratoplasty for the treatment of corneal disease. 

Senior Instructor(s): Robert W Weisenthal MD 

Instructor(s): Charles S Bouchard MD, David S Rootman MD*, Kathryn A Colby MD 

PhD*, Elmer Tu MD, Natalie A Afshari MD*, Denise de Freitas MD 

H Ocular Surface Disease Management: Moving 

From Adequate to Expert 

Course: 536 

Room: N427bc 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: Ocular surface disease encompasses several entities, including keratoconjunctivitis 

sicca and meibomian gland dysfunction, that share a common 

denominator: an inflamed and desiccated ocular surface. In this course, the 

pathogenesis, signs and symptoms, and diagnosis of specific ocular surface 

disease entities will be discussed. Case presentations will be used to help 

guide discussion of management and treatment options. Guidelines for treatment 

and for developing a differential diagnosis of the irritated, inflamed red 

eye will be stressed. 

Objective: This course will help the clinician understand and differentiate 

the pathophysiology and management of ocular surface disease from other 

inflammatory ocular surface conditions. Attendees will (1) improve the diagnostic 

skills and therapeutic techniques used with keratoconjunctivitis sicca, 

blepharitis/meibomian gland dysfunction, and atypical conjunctival diseases, 

(2) understand the pathophysiology of ocular surface disease, (3) increase their 

knowledge of drugs available to treat ocular surface disease, including keratoconjunctivitis 

sicca and meibomian gland dysfunction, and (4) have a working 

differential diagnosis of the irritated and red eye. 

Senior Instructor(s): Gregg J Berdy MD* 

Instructor(s): Joseph Tauber MD* 

NEW End-stage Ocular Surface Disorders: The Expert 

Opinion! 

Course: 550 

Room: S505ab 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: Ocular surface disorders are often recalcitrant to conventional 

therapies and are challenge for most ophthalmologists. Using video and 

case-based presentations, we will describe the physiology of the ocular surface 

(OS), pathophysiologic mechanisms of ocular surface disease, and OS 

reconstruction in extreme ocular surface disorders (OSD). Topics will include 

management options in acute and chronic phases of OSD, the role of aggressive 

immunosuppressive therapy, the scleral ocular prosthetic device, amniotic 

membrane and mucous membrane grafts, reconstruction of lids, fornices, and 

the OS, limbal transplantation, keratoplasty, keratoprosthesis (Boston and 

osteo-odonto), and other biological and biosynthetic substitutes and stem cell 

sources for end-stage ocular surface conditions such as dry eye, ocular burns, 

Stevens-Johnson syndrome, cicatricial disorders, and graft vs. host disease. 

Objective: At conclusion of this course, attendees will have a clear understanding 

of concepts and advances in OS reconstruction in end-stage OSD. 

Senior Instructor(s): Virender S Sangwan MBBS 

Instructor(s): Jatin Naresh Ashar MD, Santosh G Honavar MD, James Chodosh MD 

MPH*, Deborah S Jacobs MD, Sayan Basu MBBS 

NEW APAO Anterior Segment OCT and Confocal 

Imaging: A Practical Approach 

Sponsored by the Asia-Pacific Academy of Ophthalmology and the Asia 

Cornea Society 

Course: 551 

Tuesday 

Room: S102d 

11:30 AM - 12:30 PM 



Synopsis: Anterior segment OCT (AS-OCT) and confocal microscopy are useful 

adjunctive tools in the diagnosis and medical and surgical treatment of 

simple and more complex corneal and anterior segment disorders. Confocal 

microscopy offers real-time cellular and structural imaging of the cornea, 

which is especially useful in the diagnosis of microbial infections. AS-OCT is 

now commonly used perioperatively in a variety of lamellar procedures such 

as deep anterior lamellar keratoplasty and endothelial keratoplasty, including 

intraoperative use. This course details many case examples of how both 

technologies can enhance diagnostic and therapeutic success in the clinic and 

operating theater. 

Objective: At the conclusion of the course, the attendee will be able to have a 

better understanding of the practical uses of AS-OCT and confocal imaging to 

enhance diagnostic and management strategies for a wide variety of corneal 

and anterior segment disorders. 

Senior Instructor(s): Donald Tan MD FRCS FRCOphth* 

Instructor(s): Jodhbir S Mehta FRCS FRCOPHTH*, Charles McGhee PhD FRCOphth 

FRANZCO* 

H Help! A Corneal Ulcer Just Walked In! What Do I 

Do Next? 

Course: 570 

Room: E350 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Ophthalmologists will invariably encounter corneal ulcers in practice. 

The knee-jerk response is to treat with fourth-generation fluoroquinolones. 

However, this may be ineffective and could actually be detrimental in 

autoimmune or noninfectious keratitis. Features that help in diagnosing and 

differentiating between the various types of corneal ulceration (infectious and 

noninfectious) will be presented. The various established and experimental 





75



medical and surgical therapies to treat corneal ulceration will be described, 

along with an explanation of which therapies may be useful for which types of 

ulcers. A flow chart for formulating a therapy plan for corneal ulceration will 

also be presented. 


differentiate the various types of corneal ulceration, (2) determine which ulcers 

need emergent, urgent, or routine therapy, and (3) formulate a logical and 

stepwise medical and surgical treatment plan and decide when referral to a 

tertiary center is necessary. 

Senior Instructor(s): Sonal S Tuli MD 

NEW Pandora’s Box in Severe Ocular Chemical 

Injuries: The Entire Gamut of Management 

Course: 571 

Room: S505ab 


Tuesday 

2:00 - 3:00 PM 


Synopsis: The final outcome of severe ocular chemical injuries depends on the 

management in the acute phase. Chronic phase management includes ocular 

surface reconstruction (amniotic membrane transplantation, mucus membrane 

grafting). Glaucoma is the most common comorbid condition that defeats successful 

rehabilitation. Limbal stem cell transplant and keratoprosthesis form 

the main options for visual recovery. 

Objective: By the end of the course, the attendee will have learned issues that 

cannot be neglected in the acute phase (the i’s and e’s), possible mechanisms 

of glaucoma and ways to beat it, technique of ocular surface reconstruction, 

preferred choice of treatment for visual rehabilitation, outcome of stem cell 

transplants, and pearls of keratoprosthesis use in chemical injuries. 

Senior Instructor(s): Geetha Iyer MBBCHIR FRCS 

Instructor(s): Claes H Dohlman MD PhD*, Scheffer C G Tseng MD PhD*, Virender S 

Sangwan MBBS 

Use of Surgical Adhesives and Amniotic Membrane 

in Conjunctival, Corneal, Cataract, and Refractive 

Surgery 

Course: 572 

Room: S404 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Recently updated, this course will teach technique for using both 

fibrin adhesives and newer synthetic adhesives in the following procedures: 

pterygium/autograft and pterygium/amnionic membrane, conjunctival chalasis 

treatment, LASIK epithelial ingrowth removal, cataract surgery, secondary 

posterior chamber IOL implantation, ocular surface reconstruction with 

amnionic membrane, conjunctival chalasis (conjunctivochalasis), and lamellar 

corneal transplants. Experienced instructors will review pearls, practical tips, 

and pitfall avoidance. 

Objective: The participant will gain knowledge needed to begin using surgical 

adhesives as useful tools. 

Senior Instructor(s): John A Hovanesian MD* 

Instructor(s): David R Hardten MD*, Stephen C Kaufman MD PhD*, Amar Agarwal 

MD* 

NEW 


Course: 573 

Tuesday 

Room: S104a 

2:00 - 3:00 PM 



Synopsis: In this instruction course, the principles of Scheimpflug imaging, 

confocal microscope, and anterior segment OCT will be introduced. The indications 

and limitations of the instruments in both a refractive and corneal application 

will be discussed. The systematic interpretation of the images obtained 

using these devices will be explained for the diagnosis of corneal diseases and 

treatment planning by showing clinically important examples. 


how to use the presented corneal imaging devices as modalities 

complementary to the slitlamp examination. 

Senior Instructor(s): Naoyuki Maeda MD* 

Instructor(s): Michael W Belin MD*, Charles McGhee PhD FRCOphth FRANZCO* 

APAO Practical Use of Corneal Imaging 

Endothelial Keratoplasty (DSEK/DSAEK/DMEK/ 

DMAEK): Current Strategies to Improve Results and 

Avoid Complications 

Course: 596 

Room: N427bc 


Tuesday 

2:00 - 4:15 PM 


Synopsis: A video and slide presentation of the current surgical technique, instrumentation, 

and complications of endothelial keratoplasty (DSAEK, DMEK, 

and DMAEK) from the largest prospective series in the world (> 1500 cases) 

will be featured. Perspectives from “novice” EK surgeons on how to minimize 

the “learning curve” for both DSAEK and DMEK will be given. Current modifications 

of EK that avoid complications will be stressed. Various techniques for 

insertion (forceps, Busin glide, “pull through,” injectors) will be shown and correlated 

with their induced endothelial damage. Endothelial keratoplasty combined 

with vitrectomy, secondary IOL, and cataract surgery will be presented, 

including special care in the use of “precut” tissue. The course will emphasize 

an ethical, prospective approach to this new surgery and methods on how to 

avoid common surgical and postoperative pitfalls. 

Objective: At the conclusion of the course, the attendees will recognize the 

principles of EK surgical technique that produce low complications and excellent 

vision. 

Senior Instructor(s): Mark A Terry MD* 

Instructor(s): Michael D Straiko MD*, Neda Shamie MD* 

Step-by-Step Deep Anterior Lamellar Keratoplasty 

Using the Big Bubble Technique 

Course: 604 

Room: S102d 


Tuesday 

3:15 - 4:15 PM 


Synopsis: Deep anterior lamellar keratoplasty (DALK) using the “big bubble” 

technique allows baring of the host cornea’s Descemet membrane. This course 

will discuss case selection and preoperative workup and investigations for 

performing DALK, the instrumentation required, surgical technique for baring 

the host Descemet membrane using the big bubble technique, management of 

intraoperative host Descemet membrane perforation, donor corneal preparation, 

suturing techniques, and postoperative management. 

Objective: At the end of the course, the attendee will be able to master case 

selection, principles of surgical technique, management of intraoperative perforation, 

and postoperative management of DALK. 

Senior Instructor(s): Rasik B Vajpayee MD 

Instructor(s): Namrata Sharma MD MBBS, Vishal Jhanji MBBS 

76 





H The Boston Keratoprosthesis: Case-Based 

Presentations Highlighting the Essentials for 

Beginning and Experienced Surgeons 

Course: 609 

Room: S103a 


Tuesday 

3:15 - 5:30 PM 


Synopsis: While traditionally considered a procedure of last resort, keratoprosthesis 

(KPro) implantation is being performed with increasing frequency 

for an expanding variety of indications, including repeat corneal graft failure 

and corneal opacification combined with limbal stem cell failure. The design, 

indications and contraindications, surgical technique, and postoperative management 

of the Boston KPro will be presented. 

Objective: Attendees will learn to recognize patients in their practices who are 

good candidates for KPro implantation. Presentation of surgical videos and a 

detailed discussion of the postoperative management will familiarize attendees 

with KPro implantation, as well as with avoidance and management of 

postoperative complications. 

Senior Instructor(s): Anthony J Aldave MD* 

Instructor(s): Esen K Akpek MD*, James Aquavella MD*, Michael W Belin MD*, 

James Chodosh MD MPH*, Claes H Dohlman MD PhD*, Sadeer B Hannush MD, 


NEW APAO Descemet-Stripping Automated 

Endothelial Keratoplasty and New Refractive 

Surgeries 


Course: 610 

Tuesday 

Room: S104b 

3:15 - 5:30 PM 



Synopsis: This course will provide a comprehensive, contemporary overview 

of endothelial keratoplasty including indications, techniques, outcomes and 

complications of DSAEK and DMEK. 


the key concepts in the contemporary management of endothelial failure 

by endothelial keratoplasty. 

Senior Instructor(s): Charles McGhee PhD FRCOphth FRANZCO* 

Instructor(s): Alexandra Crawford MD**, Mark A Terry MD*, Donald Tan MD FRCS 

FRCOphth*, Sue E Ormonde MBChB, Shigeru Kinoshita MD* 


E Electronic Health Records: Compliance and 

Medicolegal Issues 


and the AAO Medical Information Technology Committee and 

AAOE EHR Subcommittee 

Course: 183 

Sunday 

Room: S105bc 

11:30 AM - 12:30 PM 



Synopsis: This course will demonstrate how electronic health records (EHRs), 

while improving the quality of medical records, can also create problems that 

can trigger serious medicolegal and compliance issues. This course will explore 

how EHRs can be used wisely or foolishly. Case studies will be presented 

to illustrate problems created by the use of EHRs. 

Objective: By the conclusion of this course, attendees will be able to (1) describe 

some strengths of EHR systems that can improve compliance with chart 

documentation requirements, (2) describe some “tricks” that could hurt documentation 

reliability and compliance, (3) identify features in EHRs that pose 

the greatest threats, and (4) modify EHR utilization to improve documentation 

reliability and compliance. 

Senior Instructor(s): David E Silverstone MD 

Instructor(s): Kevin J Corcoran*, Michele C Lim MD 

E Slay Your Dragon: Successful Implementation of 

Voice Recognition Software Into Your Electronic 

Health Record 

Course: 198 

Room: S105bc 


Sunday 

2:00 - 3:00 PM 


Synopsis: You can talk, but you can’t type! With all of its promises, data input 

into an electronic health record (EHR) remains a difficult challenge. Data input 

into an EHR is frequently cumbersome and time intensive and often reduces 

practice efficiency. Voice recognition software can be your salvation if it is 

implemented correctly. Proper use of voice recognition requires more than plug 

and play, but it is achievable. 

Objective: At the end of this course participants will have learned how to 

effectively implement voice recognition software into an EHR in order to increase 

efficiency, reduce frustration, and increase profitability. Participants 

should be on their way to being able to document in an EHR without even 

touching the keyboard or mouse. 

Senior Instructor(s): David K Coats MD* 

SO E Electronic Health Record Incentives: A Closer 

Look at Meaningful Use 




Course: 233 

Sunday 

Room: N427d 

3:15 - 5:30 PM 



Synopsis: The federal government is accelerating the adoption of electronic 

health records (EHRs) among hospitals and physicians, with significant financial 

incentives ($44,000 under Medicare and $63,750 under Medicaid) that will 

convert into penalties in 2015. The crux of successful participation is “meaningful 

use” of a federally certified EHR. This course will examine each of the 

meaningful use objectives and measures for Stage 1, offering specific tips for 

navigating the logistics of reporting. It will also offer a preview of Stage 2 

requirements. The panel will include practices and physicians who are participating 

in the EHR incentives and the Academy’s Health Policy Manager. Course 

attendees will have the opportunity to ask questions at the end of the session. 

Objective: At the conclusion of this course, attendees will have a detailed understanding 

of the meaningful use requirements for Stage 1, get a preview 

of the meaningful use requirements for Stage 2, and learn strategies for successful 

reporting. 

Senior Instructor(s): Julia Lee JD OCS 

Instructor(s): Michael F Chiang MD*, Kelsey Kurth 





77



NEW E Managing Your EHR After Implementation 




Course: 415 

Monday 

Room: S104b 

3:15 - 5:30 PM 



Synopsis: Out-of-the-box electronic health record (EHR) software doesn’t work 

well for many physicians. It’s important to alter the EHR itself to make it work 

for each provider in your group and for the practice as a whole. This timely 

session will reveal tips and tricks to help your software work for you, whether 

you are a solo practice, a small group, or part of a large organization. This 

panel session will include academicians, a private practice physician, and a 

practice administrator to cover all aspects of how to get your system to work 

for you, not against you. 

Objective: Here are just a few things to expect from this dynamic session: You 

will (1) discover tips and tricks for EHR optimization, (2) review lessons learned 

though EHR implementation, (3) learn ways to customize the software to work 

for your charting style, (4) learn how to deal with unanticipated problems, (5) 

discover how to maintain rapport with your patients despite the necessary 

computer use, (6) discuss future health information technology trends to prepare 

for now. Anyone who has implemented an EHR system, or is in the beginning 

stages of implementation, should attend this course. If you do not have 

an EHR system, you will benefit from lessons learned and future expectations. 

Senior Instructor(s): K David Epley MD* 

Instructor(s): Michele C Lim MD, Michael V Boland MD PhD* 

E An Approach to Selecting Electronic Health 

Records in Your Practice 




Course: 521 

Tuesday 

Room: S103a 

10:15 - 11:15 AM 



Synopsis: Electronic health records (EHRs) have potential to improve the quality, 

efficiency, and cost of health care. As a result, the federal government 

has established initiatives to promote their adoption. Beginning in 2011, 

physicians have been eligible to receive federal incentive payments ($44,000 

Medicare, $63,750 Medicaid) for meaningful use of certified EHR systems. 

Beginning in 2015, there will be financial penalties for failing to use EHRs. 

However, selection of systems is challenging, and includes clinical, administrative, 

technological, and financial components. This course is taught by a 

group of ophthalmologists and administrators, is sponsored by the Academy’s 

Medical Information Technology Committee and the American Academy of 

Ophthalmic Executives’ EHR Subcommittee, and is paired with a course on 

EHR implementation. 

Objective: At the conclusion of this course, the attendee will better understand 

key factors involving the entire EHR selection process: terminology, certification 

and meaningful use requirements, EHR workflow and clinical needs (e.g., 

registration, clinical care, image management, billing), and establishing “requests 

for proposals” and contracts with vendors. 

Senior Instructor(s): Michael F Chiang MD* 

Instructor(s): Michael V Boland MD PhD*, Linda L Wedemeyer MD, Brittney 

Wachter, Flora Lum MD 

E An Approach to Implementing Electronic Health 

Records in Your Practice 




Course: 552 

Tuesday 

Room: S103a 

11:30 AM - 12:30 PM 



Synopsis: This course will present a framework for implementing an electronic 

health record (EHR) system in an ophthalmic practice. We will discuss issues 

related to computer hardware and software, integration of other electronic 

systems, maintenance of the system, and strategies for successful deployment. 

These issues will all be discussed in the context of federal incentives 

to use an EHR system in your practice. Attendees will also be made aware of 

relevant resources available from the Academy. 

Objective: At the conclusion of this course, attendees will be able to (1) describe 

important hardware and software decisions related to an EHR deployment, 

(2) understand how various electronic systems might be integrated together, 

(3) describe a plan for maintaining an EHR system, and (4) understand 

the key steps in an EHR deployment. 

Senior Instructor(s): Michael V Boland MD PhD* 

Instructor(s): Paulette Hottle, Brittney Wachter, Michele C Lim MD, Flora Lum MD 

Ethics 

The Consequences of Poor Decision Making in 

Neuro-Ophthalmology (Ethics) 

Course: 234 

Room: S106a 


Sunday 

3:15 - 5:30 PM 


Synopsis: Wrong decisions in neuro-ophthalmology can have unforgiving consequences. 

Both medical and ethical considerations help direct the approach 

to the complicated patient with tough questions. This course will present and 

discuss multiple litigated cases. 

Objective: This course will review the medical and ethical principles that are 

critical when dealing with difficult neuro-ophthalmologic problems. 

Senior Instructor(s): Bradley K Farris MD 

Instructor(s): Thomas J Whittaker MD 

NEW Medical Ethics in the Hot Seat: How 

Compliance With the Academy’s Code of Ethics Can 

Turn a Good Litigation Defense Into a Great One 

Course: 312 

Room: S106a 


Monday 

9:00 - 10:00 AM 


Synopsis: By presenting a hypothetical malpractice litigation, this course will 

highlight the importance of ethical components of practice: adequate informed 

consent, adequate pretreatment assessment, appropriate postoperative care, 

and compliant advertising practices. The dramatization will demonstrate that 

compliance with the rules of the Academy’s Code of Ethics will benefit your 

patients and practice, and could prove advantageous or decisive in defense 

against allegations of negligence. As each ethical component is introduced 

by a plaintiff’s attorney in cross examination, “stop action” moments will allow 

attendees to offer their input on how testimony about each component 

may positively/negatively contribute to the case. Current federal regulatory 

guidelines and the Academy’s ethical guidelines will be referenced as part of 

each analysis. 

78 





Objective: At the conclusion of the course, attendees will be able to identify 

components of ethical practice and how these components affect not only the 

quality of care for each patient, but scrutiny of that care in the event of malpractice 

litigation. 

Senior Instructor(s): Christie L Morse MD* 

Instructor(s): Anthony J Aldave MD*, Gregory J McCormick MD, Ron W Pelton MD 

PhD, Roberto Pineda II MD, R V Paul Chan MD, Tamara R Fountain MD* 

NEW The Institutional Review Board Submission 

Process: Why Should I Care, and What If I Don’t? 

Course: 574 

Room: S106a 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will define ?research,? how/what to submit to IRBs, 

and applicability of research rules/regulations. Discussion topics will include 

existing guidelines?/ regulations for research in all settings, types of IRB review 

(full, expedited, exempt), institutional vs. private review boards, statutory 

authority of the Office for Human Research Protections (OHRP), specific 

regulations impacting all human research (prospective and retrospective), and 

special informed consent required by research. Via case studies, participants 

will discuss real-life obstacles in interactions with IRBs, including prolonged 

turnaround times impacting grant/study timelines, and multiple IRB submissions 

on one project with potentially different reviewing bodies. The potential 

consequences of not following ethical practices in IRB submission will be 

discussed. 

Objective: Attendees will be able to identify ethical dilemmas in human research, 

find the OHRP’s specific regulations, describe the special nature of 

research-based informed consent, resolve the identified ethical dilemmas, and 

ethically manage IRB interactions. 

Senior Instructor(s): Christie L Morse MD* 

Instructor(s): Anthony J Aldave MD*, Keith D Carter MD FACS, J Jill Hopkins MD*, 

Roberto Pineda II MD, R V Paul Chan MD, Carla J Siegfried MD* 

General Medical Care 

NEW Spectral Domain OCT From the Cornea to the 

Optic Nerve: A Comprehensive Overview 

Course: 255 

Room: E350 


Sunday 

4:30 - 5:30 PM 


Synopsis: First generations of optical coherence tomography (OCT) machines 

used in ophthalmology were designed to image the macular area and optic 

disc. The introduction of spectral domain OCT (SD-OCT) technology advanced 

the use of this diagnostic tool to different areas such as cornea, neuro-ophthalmology, 

glaucoma, vitreoretinal interface, and tumors. This course will provide 

knowledge on different applications of SD-OCT in ophthalmology. 

Objective: This course will serve as an overview of the applications of SD-OCT 

technology in different areas of ophthalmology. Topics of interest will be application 

of SD-OCT as an important tool (1) for cornea disease and refractive 

surgery, (2) to evaluate the anterior chamber configuration, (3) for ganglion cell 

layer and optic disk in glaucoma, (4) in diseases of the vitreoretinal interface, 

(5) in macular degeneration, macular edema, and other macular pathologies, 

(6) in a new application in neuro-ophthalmology for multiple sclerosis, and 

finally (7) in its applicability in ocular oncology. The attendee will be able to 

understand the indications, applications, and how to interpret SD-OCT in different 

fields of ophthalmology. 

Senior Instructor(s): Fernando M Penha MD* 

Instructor(s): Michel Eid Farah MD, Philip J Rosenfeld MD PhD*, William E Smiddy 

MD, Joshua Pasol MD, Andre Romano MD*, Mauro T Leite MD, Eduardo B 

Rodrigues MD, Caio V Regatieri MD, Carlos Alexandre Amorim Garcia Filho MD 

Drug-Related Adverse Effects of Clinical Importance 

to the Ophthalmologist 

Course: 313 

Room: S505ab 


Monday 

9:00 - 10:00 AM 


Synopsis: This course will describe adverse ocular reactions from topical 

ocular and systemic medications, with a focus on recently reported adverse 

events identified by the National Registry of Drug-Induced Ocular Side Effects 

(Portland, Oregon) and applying the WHO classification system. 

Objective: At the conclusion of this course, attendees will be able to recognize 

drug-related adverse ocular and systemic side effects when they occur in association 

with drugs commonly used by clinicians. Only those medications of 

clinical importance to ophthalmologists will be discussed. 

Senior Instructor(s): Rick W Fraunfelder MD 

Instructor(s): Frederick T Fraunfelder MD* 

What the General Ophthalmologist Needs to Know 

About Cancer and Its Complications: From Front to 

Back 

Course: 553 

Room: S403B 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: When patients with cancer present to the general ophthalmologist 

there is an extensive differential diagnosis of the underlying condition, 

whether tumor-related, concurrent infection, or the effect of treatment such as 

radiation and chemotherapy. This case-based course will review the scope of 

ocular manifestations related to cancer and illustrate how to sort these out in 

the office. The format will be both instructive and engaging. 

Objective: This course is designed to enable participants to acquire the knowledge 

and skills necessary for interpreting the eye findings seen in a cancer 

patient, using them in the differential diagnosis and management of these patients. 

At the conclusion of this course, the participants will be able to identify 

the major categories of underlying diagnoses, developing strategic management 

solutions to help their cancer patients. 

Senior Instructor(s): Jade Schiffman MD 

Instructor(s): Stella K Kim MD*, Dan S Gombos MD 

Glaucoma 

Computerized Scanning Imaging of the Optic Nerve 

and Retinal Nerve Fiber Layer 

Course: 152 

Room: S105bc 


Sunday 

9:00 - 11:15 AM 


Synopsis: This lecture, required for the hands-on workshop, introduces the 

participant to the principles of computerized scanning imaging. This is a basic 

course featuring current technologies. The main emphasis in this course will 

be spectral (Fourier) domain OCT, although some discussion of scanning laser 

polarimetry and topography (Heidelberg Retinal Tomography) will be included. 

Objective: By the conclusion of this course, participants will be able to (1) understand 

the scientific basis for imaging, (2) understand how scanning imaging 

may be used in clinical practice, (3) learn how imaging can be applied 

to the optic nerve head, retinal nerve fiber layer, and macula, with emphasis 





79



on glaucoma, (4) understand the relationship between structure and function, 

and (5) differentiate normal from abnormal scans through appropriate clinical 

examples. A question-and-answer session will be held at the end of the 

presentations, during which time questions will be entertained by the faculty. 



Senior Instructor(s): Neil T Choplin MD* 

Instructor(s): E Randy Craven MD*, Howard Barnebey MD* 

Combined Cataract Surgery With Trabeculectomy: 

Guidelines, Indications, Methods, Techniques, and 

Postoperative Management 

Course: 172 

Room: S106b 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: This course will provide a comprehensive review of guidelines and 

indications for cataract surgery combined with trabeculectomy based on 

severity of glaucoma, IOP control, preoperative medications, extent of optic 

nerve damage, level of visual field loss, and type of glaucoma. Preoperative 

considerations, including determination of surgical site, antimetabolite use, 

poorly dilating pupil, shallow anterior chamber, and posterior synechiae, will 

be discussed. Surgical methods, including anesthesia, single- or two-site 

surgery, cataract surgery techniques, and conjunctival preservation, will be 

explained; trabeculectomy methods from conjunctival dissection and wound 

architecture to antimetabolite use will be stressed. Anticipation, avoidance, 

and management of surgical and postsurgical complications, plus postoperative 

management of glaucoma, will be explained. 


the guidelines and indications for cataract surgery combined with 

trabeculectomy, determine which surgical method to use, be able to avoid 

complications, and manage the postoperative glaucoma course. 

Senior Instructor(s): Leon G Partamian MD* 

Instructor(s): Eve J Higginbotham MD, Marlene R Moster MD*, Cynthia Mattox 

MD FACS*, David Lee MD*, Anastasios P Costarides MD PhD*, Thomas W 

Samuelson MD* 

H Tubes, Ties, and Videotape: Surgical Video 

of Baerveldt Glaucoma Implants and Managing 

Complications 

Course: 173 

Room: N135 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: Clinical photos and history of several challenging glaucoma cases 

will be presented. Edited digital surgical videos will demonstrate surgical 

techniques and how to manage postoperative complications. 

Objective: The attendee will be able to formulate an appropriate surgical plan 

for a Baerveldt glaucoma implant and be better prepared to avoid and manage 

potential complications. 

Senior Instructor(s): Herbert P Fechter MD 

3-D Optic Disc Viewing: Top 10 Pitfalls in Identifying 

Glaucoma Damage and Progression 

Course: 184 

Room: S105a 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint 

projections of stereoscopic optic disc images. The 10 most common pitfalls 

in identifying glaucomatous disc damage will be viewed, discussed, and correlated 

with visual field loss. Optic disc swelling, optic atrophy, and optic disc 

anomalies (disc proper, peripapillary, and vascular) may confound our assessment 

of the glaucomatous disc. Classic glaucomatous disc changes will be 

stressed, including the identification of splinter disk hemorrhages, nerve fiber 

layer defects, cupping asymmetry and vertical elongation, focal neural rim excavation, 

and diffuse cup enlargement. Special emphasis will be placed on 

simultaneous viewing of serial stereoscopic images that demonstrate progressive 

glaucomatous disc damage over time, including baring of circumlinear 

vessels, laminar dot sign, progressive neural rim notching, increase in parapapillary 

chorioretinal atrophy, vessel course changes, and peripheral vessel 

displacement with bayoneting. 

Objective: While viewing stereoscopic optic disc images, physicians will learn 

to appreciate (1) the complexities of optic disc analysis, (2) the subtleties in 

identifying glaucomatous disc damage and progression, and (3) the most common 

optic disc anomalies and pathologies that confound our assessment of 

the glaucomatous disc. 

Senior Instructor(s): Alan H Zalta MD 

Medical Therapy for Open-Angle Glaucoma: A 

Complete Review of the Pharmacodynamics, 

Pharmacokinetics, and Toxicity of All Potentially 

Useful Drugs 

Course: 199 

Room: N137 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will present the pharmacodynamics, pharmacokinetics, 

and toxicity of drugs potentially useful for open-angle glaucoma (OAG) treatment, 

including parasympathomimetics, sympathomimetics, sympatholytics, 

carbonic anhydrase inhibitors, prostaglandin analogs, osmotics, neuroprotectors, 

blood flow enhancers, marijuana, ginkgo biloba, and other alternative 

therapies. 

Objective: Participants will be able to treat OAG more effectively by enhancing 

compliance and risk-benefit ratios. 

Senior Instructor(s): Allan J Flach MD 

Top 10 Pitfalls, Problem Solving, and Interpretive 

Strategy for Automated Threshold Perimetry 

Course: 200 

Room: S105a 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will teach a step-by-step interpretive strategy for automated 

threshold perimetry. This course will also teach recognition of the most 

common pitfalls encountered in central threshold field testing and problem 

solving to avoid misinterpretation, underdiagnosis, and overdiagnosis. 

Objective: Participants will learn to (1) systematically interpret central 30-degree 

threshold visual fields, (2) recognize common pitfalls, including testing 

“legally blind” eyes, low reliability message, testing children, normal gray 

scale display in the presence of early scotomas, isolated peripheral nasal 

steps, severe visual field loss, limitations of computerized interpretation, SITA 

variability, and pseudo-scotomas or pseudo-progression due to artifact (mio- 

80 





sis, ptosis, lens rim), and (3) problem solve using nonstandard parameters (eg, 

size V stimulus) or alternate strategies (eg, central 10-degree or peripheral 

30/60 degree field). This course was designed to optimize visual field evaluation 

and monitoring and to eliminate common interpretational errors. 


Instructor(s): John S Cohen MD* 

Complications Following Glaucoma Filtering Surgery: 

Face Them Boldly, Manage Them Efficiently 

Course: 223 

Room: S103a 


Sunday 

2:00 - 4:15 PM 


Synopsis: This course will review the early detection, prevention, and specific 

management strategy of the common complications that may be associated 

with glaucoma filtering surgery, such as hyphema, shallow to flat anterior 

chamber, early or late leaking bleb, encapsulated blebs, hypotony, the “wipeout” 

phenomenon, blebitis, bleb infection, and endophthalmitis. 

Objective: At the conclusion of the course, attendees will be able to face complications 

following glaucoma filtering surgery more boldly and manage them 

more efficiently. 

Senior Instructor(s): Anil K Mandal MD 

Instructor(s): Peter Andreas Netland MD PhD*, Dale K Heuer MD*, Eve J 

Higginbotham MD, Sriram Sonty MD FACS* 

Glaucoma Filtration Surgery 

Course: 235 

Room: S105bc 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course provides a comprehensive review of the techniques and 

complications of glaucoma filtration surgery. Glaucoma surgical technique 

will be stressed in this update of filtration surgery, with a heavy emphasis 

on surgical video presentations. The course will also discuss novel surgical 

techniques used in filtration surgery, such as Ex-PRESS shunts, as compared 

to conventional surgery. A panel discussion with questions and answers will 

conclude the session. 

Objective: This course will review surgical anatomy, basic trabeculectomy 

techniques, antimetabolites (including 5-fluorouracil and mitomycin C), and 

postoperative management and complications. 



Senior Instructor(s): George A Cioffi MD* 

Instructor(s): Jeffrey M Liebmann MD*, F Jane Durcan MD, Robert D Fechtner MD 

FACS*, Kuldev Singh MD MPH*, Steven L Mansberger MD*, Celso Tello MD* 

Implantation of Glaucoma Drainage Devices 

Course: 236 

Room: N138 


Sunday 

3:15 - 5:30 PM 


Synopsis: The first part of this course is didactic, covering the indications, 

pathophysiology, surgical technique, postoperative management, and complications 

of drainage devices (from anterior chamber tube to extraocular reservoir). 

The second part is hands-on, with implantation of Molteno, Krupin, 

Baerveldt, Ahmed, and Schocket devices on porcine eyes. Ex-PRESS shunt, 

Trabectome, and canaloplasty will not be covered. 

Objective: At the conclusion of this course, the attendee will be aware of principles 

and techniques of glaucoma drainage device implantation. 



Senior Instructor(s): Richard P Mills MD MPH 

Instructor(s): George Baerveldt MD*, Theodore Krupin MD, Anne Louise Coleman 

MD PhD, Frederick M Kapetansky MD, Donald L Budenz MD MPH*, Paul A Sidoti 

MD* 

Improving Success in Filtration Surgery: 

Intraoperative Surgical Techniques and 

Postoperative Management of the Failing Filter 

Course: 237 

Room: S103d 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will describe techniques for successful performance of 

trabeculectomy and nonpenetrating glaucoma procedures and will comprehensively 

review postoperative management of the failing filter. 

Objective: At the end of this course, attendees will understand the available 

techniques for enhancing glaucoma surgery success, including antimetabolite 

administration, and will understand postoperative adjuncts for dealing with 

failing filtration characterized by either high IOP or low IOP. 

Senior Instructor(s): Bradford J Shingleton MD* 

Instructor(s): Husam Ansari MD PhD** 

Update Your Anterior Chamber Angle Skills: How to 

Best Examine, Grade, and Treat 

Course: 238 

Room: N137 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course puts it all together for the comprehensive ophthalmologist: 

how to best look at the angle, distinguish normal from abnormal, indent 

crowded angles, record your findings, and treat the iris and angle with laser 

therapy. Studies show we look at the chamber angle in less than half of all initial 

glaucoma patient visits. Why? This course is about improving your chamber 

angle organizational skills to overcome chamber angle neglect. 

Objective: At the conclusion of the course, attendees will be able to better 

view the angle, improve their treatment of the angle, know when to perform 

and better record their gonioscopic findings, and be updated on the risks and 

benefits of laser peripheral iridotomy, selective laser trabeculoplasty, argon 

laser trabeculoplasty, and iridoplasty. 

Senior Instructor(s): Ronald Leigh Fellman MD OCS* 

Instructor(s): Ronald L Gross MD*, Silvia D Orengo-Nania MD*, Thomas W 

Samuelson MD*, Mark B Sherwood MD*, Steven T Simmons MD, George L 

Spaeth MD FACS*, Arvind Neelakantan MD* 

Computerized Perimetry Lecture: Visual Field Testing 

and Interpretation, Emphasizing Glaucoma 

Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee 

and the American Glaucoma Society (AGS) 

Course: 239 

Sunday 

Room: S105a 

3:15 - 5:30 PM 



Synopsis: This Academy/AGS lecture reviews computerized perimetry theory 

and application, emphasizing glaucoma and the Humphrey field analyzer as a 

basis for subsequent comparison with Octopus perimetry, which will be briefly 

introduced. Octopus perimetry then will be covered in more detail in the Skills 

Transfer lab. The stepwise interpretation of individual Humphrey visual fields 





81



(VFs) will be outlined, explaining the significance of each portion of the VF 

printout and the techniques for determining if the VF is reliable and if it is 

normal or abnormal. SITA, SWAP, frequency doubling perimetry, and the analysis 

of a series of VFs for progression (using event and trend methods) will be 

discussed. Tips for obtaining a better, more reliable VF test and for selecting 

the appropriate test for different patients will be summarized. Numerous 

case examples will be used. Most examples will be of glaucomatous VF abnormalities. 

Nonglaucomatous and hydroxychloroquine changes also will be 

briefly covered. Participants wanting (1) more information regarding Octopus 

perimetry and (2) practice reading Humphrey or Octopus VFs should take the 

supplemental lab. 

Objective: This course is designed to provide participants with the background 

knowledge necessary to be more comfortable with visual field interpretation 

and to be prepared for the separate laboratory session. 

Note: This is the lecture portion of a Skills Transfer lab. To enroll in the lab, see 

the Skills Transfer section. 

Senior Instructor(s): Julia Whiteside-de Vos MD MPH* 

What’s Your Next Step? Case Studies in Glaucoma 

Management 

Course: 256 

Room: S102abc 


Sunday 

4:30 - 5:30 PM 


Synopsis: Both challenging and everyday glaucoma cases will be presented 

and discussed in a panel format. Visual fields and OCT, among other ancillary 

tests, will be used to demonstrate the case presentations. Audience participation 

will be encouraged. 

Objective: At the conclusion of the course, the participants will have a better 

understanding of common glaucoma cases with diagnostic or interventional 

dilemmas. 

Senior Instructor(s): Prithvi S Sankar MD 

Instructor(s): Eydie G Miller MD*, Cynthia L Grosskreutz MD PhD*, Sarwat Salim 

MD* 

NEW 3-D Viewing: Nerve-Wracking Optic Nerves!! Is 

This Glaucoma?? 

Course: 314 

Room: S104b 


Monday 

9:00 - 10:00 AM 


Synopsis: This updated course will use digital stereo projection technology as 

an instruction device to demonstrate the characteristics and variations of a 

normal optic nerve, a glaucomatous optic nerve, and other forms of optic neuropathy 

that mimic glaucoma. 

Objective: At the conclusion of this course, attendees will be able to (1) recognize 

characteristics of a normal optic nerve, (2) differentiate between the 

normal and glaucomatous nerves in a systematic manner, (3) recognize and 

distinguish key clinical features of congenital and acquired optic neuropathies 

that mimic glaucoma, and (4) distinguish and effectively apply various ancillary 

testing options in diagnosing glaucomatous optic neuropathy. 

Senior Instructor(s): Jose Morales MD 

Instructor(s): Deepak Paul Edward MD, Smajo Osmanovic MD PhD, Sami Al 

Shahwan MD 

The Glaucoma Horizon: Medications, Surgeries, 

Mechanisms, and Diagnostics 

Course: 316 

Room: S404 


Monday 

9:00 - 10:00 AM 


Synopsis: What principles and mechanisms of action govern the future development 

of glaucoma diagnostics and therapies? This course will present 

evidence-based insights into the causes of glaucoma, as well as principles 

applied in the development of emerging diagnostics and treatments, including 

medications, lasers, and surgeries. Applications, advantages, disadvantages, 

and limitations of these technologies will be discussed in the context of the 

practical clinical care of patients with glaucoma. Current and new tools used in 

the diagnosis and treatment of glaucoma will be highlighted from the perspective 

of the practicing ophthalmologist committed to delivering to patients the 

standard of care in a cost-effective manner today and within the next decade. 

Objective: At the conclusion of this course, the attendee will be able to have 

a solid understanding of the different causes of glaucoma, the principles and 

mechanisms of action of new diagnostics and therapies, and clinical pearls for 

applying them clinically to optimize the treatment of glaucoma now and into 

the next decade. 

Senior Instructor(s): David Lee MD* 

Instructor(s): John R Samples MD*, Shan C Lin MD*, Leonard A Levin MD PhD* 

Top 10 Essentials of Gonioscopy: 3-D Viewing and 

Interpretation 

Course: 317 

Room: S105a 


Monday 

9:00 - 10:00 AM 


Synopsis: Participants will wear red-blue glasses to view 3-D PowerPoint 

projections of stereoscopic gonioscopy and slitlamp images. Identifying traditional 

gonioscopic anatomy, including normal angle vessels and iris processes, 

may be confounded by a variety of anterior chamber angle pathologies. The 

use of different gonioprisms and indispensable gonioscopy techniques (dynamic 

indentation and termination of the corneal light wedge) will be discussed. 

Special emphasis will be placed on the evaluation of narrow angles, 

decision making for the performance of laser iridotomy, and laser treatment 

of the angle and iris. Pathologic variations in overly deep anterior chambers, 

anomalous angle blood vessels and neovascularization, increased trabecular 

meshwork pigment and the Sampaolesi line, peripheral anterior synechiae due 

to anterior mechanisms with or without membranes and posterior mechanisms 

with or without pupillary block, and anterior chamber angle clefts will be presented. 

Objective: While viewing stereoscopic images, the attendee will learn essential 

gonioscopic anatomy, examination techniques, and categorization with 

variations in pathology. 


82 





NEW APAO What’s New in Normal-Tension 

Glaucoma? 


Course: 332 

Monday 

Room: N135 

9:00 - 11:15 AM 



Synopsis: This course covers recent advances in the pathogenesis, early diagnosis, 

risk factors, and treatment of normal-tension glaucoma (NTG). Based on 

rich clinical experience and proven study results, the authors provide current 

and new information on NTG. The recent advances in the structural and functional 

diagnostic technology, risk factors for the development and progression 

of NTG, neuroimaging issues, and current strategies for treating NTG will be 

shared with attendees. 

Objective: At the conclusion of this course, attendees will be able to assess 

and manage NTG patients with greater knowledge and confidence. 

Senior Instructor(s): Ki Ho Park MD* 

Instructor(s): Kazuhisa Sugiyama MD PHD, Makoto Aihara MD PhD*, Dexter Yu- 

Lung Leung DRCOPHTH FRCS, Tae-Woo Kim MD PHD* 

Schlemm Canal Surgery 

Course: 352 

Room: N137 


Monday 

10:15 AM - 12:30 PM 


Synopsis: Early results of nonpenetrating glaucoma surgery, an alternative approach 

in glaucoma filtering surgery, have shown comparable results with a reduction 

in overall complications. Yet this technique has a steep learning curve, 

with its own set of unique challenges. This course will present a systematic, 

multimedia, video-assisted review of the anatomy, rationale, explanation, and 

illustration of canaloplasty. 

Objective: This course will explain (1) the procedure’s method of re-establishing 

aqueous outflow, (2) the procedure’s advantages, disadvantages, risks, and 

benefits, and (3) the identification of glaucomas where the procedure would 

have highest probability of success. Recent clinical results and innovations to 

enhance the procedure will also be discussed. 



Senior Instructor(s): Richard A Lehrer MD*, Iqbal K Ahmed MD* 

Instructor(s): Alan S Crandall MD*, Robert Stegmann MD**, Clive O Peckar MD*, 

Howard Barnebey MD* 

Argon Laser Peripheral Iridoplasty: All You Need to 

Know 

Course: 340 

Room: S102Abc 


Monday 

11:30 AM - 12:30 PM 


Synopsis: This course will cover all you need to know about argon Laser peripheral 

iridoplasty (ALPI)—from indications, contraindications, techniques 

and pearls, and results to complications and their management. Slitlamp photographs 

and videos will be extensively used in the course, the handout, and 

the course DVD-ROM to illustrate the critical techniques. 

Objective: At the conclusion of this course, the attendee will be able to safely, 

effectively, and confidently perform ALPI in the appropriate patients. 

Senior Instructor(s): Clement C Y Tham MBBS* 

Instructor(s): Robert Ritch MD FACS* 

Glaucoma and Refractive Surgery 

Course: 315 

Room: S104A 


Monday 

2:00 - 3:00 PM 


Synopsis: Refractive surgery is a rapidly growing sector of ophthalmology. 

Both glaucoma suspects and glaucoma patients require vigilant screening for 

suitable intervention and meticulous postoperative surveillance to circumvent 

adverse effects. Various types of refractive procedures and mechanisms of 

secondary glaucoma will be reviewed. Post-refractive surgery management 

will be discussed, including the use of different tonometric devices (in light of 

changes in central corneal thickness) and assessment of other parameters of 

glaucoma evaluation, such as stereoscopic optic nerve assessment, nerve fiber 

analysis, and visual field testing. 

Objective: At the conclusion of the course, the attendee will be knowledgeable 

about preoperative, intraoperative, and postoperative considerations in glaucoma 

suspects and glaucoma patients undergoing refractive surgery. 

Senior Instructor(s): Sarwat Salim MD* 

Instructor(s): Balamurali K Ambati MD, Raghu Mudumbai MD, Prithvi S Sankar MD 

NEW Improving Patient Education and Adherence: 

Are You Up to Date? 

Course: 381 

Room: S104b 


Monday 

2:00 - 3:00 PM 


Synopsis: Patient understanding of glaucoma and the need for IOP-lowering 

medications is important in the treatment of glaucoma. We will provide a 

comprehensive review of patient educational materials available in various 

formats including brochures, videos, and online resources. We will review the 

advantages of each resource and how they can be used to help patients understand 

glaucoma and its treatment. 


describe various educational resources available in treatment of glaucoma 

and (2) provide the patient with tools to understand glaucoma, the need for 

treatment, and methods to aid in applying and incorporating the drops into 

their daily routine. 

Senior Instructor(s): Babak Eliassi-Rad MD 

Instructor(s): Meenakshi Chaku MD, Manishi A Desai MD 

NEW Yo Understanding and Utilizing Glaucoma 

Imaging 

Course: 382 

Room: S106a 


Monday 

2:00 - 3:00 PM 


Synopsis: Recent advances in imaging have led the way to better understanding 

of a variety of pathological mechanisms in glaucoma. We are now able to 

obtain high-resolution images of the anterior segment, iridocorneal angle, retinal 

nerve fiber layer, and optic nerve head. This has enabled the use of various 

types of imaging for the detection and monitoring of glaucoma progression, 

as well as aiding our diagnostic skills in assessing prognosis for interventions 

and when to intervene. This course will concentrate on the modalities of ultrasound 

biomicroscopy, anterior segment OCT, and a new angle imaging technique, 

Retcam. Optic nerve head evaluation techniques such as Heidelberg 

Retinal Tomography and retinal nerve fiber layer assessment by time domain 

OCT and spectral domain (high-definition) OCT will also be discussed. 





83



Objective: At the conclusion of this course, the attendee will be able to incorporate 

these insights into the diagnosis and management of glaucoma 

patients. 

Senior Instructor(s): Shamira Perera MBBS* 

Instructor(s): Tin Aung FRCS PhD*, Jocel L Chua MD**, David Goh MBBS 

NEW 


Course: 383 

Monday 

Room: N427d 

2:00 - 3:00 PM 



Synopsis: This course revisits all core issues of needling, from basic principles, 

preoperative preparations, technical tips for each step of the procedure, proper 

ways to prevent and manage complications, and finally to choosing the right 

adjunct. 

Objective: The course aims to help attendee to perform needling safely and 

with good results. 

Senior Instructor(s): Dennis S C Lam MD 

Instructor(s): Yolanda Yuen Ying Kwong MD, Chris Kai-shun Leung MD MBChB, 

Felix Chi Hung Li BMBS, Clement C Y Tham MBBS 

APAO Needling Revision of Trabeculectomies 

Glaucoma Laser Therapy: Innovations and Advice 

From the Experts 

Course: 400 

Room: S105bc 


Monday 

2:00 - 4:15 PM 


Synopsis: This course will provide a comprehensive review of standard, new, 

and emerging laser procedures used in the treatment of glaucoma. Topics 

discussed will include argon laser trabeculoplasty (ALT), selective laser trabeculoplasty 

(SLT), micropulse laser trabeculoplasty (MLT), cyclophotocoagulation 

(both endoscopic and transscleral), iridotomy (Nd:YAG, argon, diode, 

and krypton), and iridoplasty. Laser enhancement of filtering procedures will 

be covered as well, including laser suture lysis and bleb revision. Indications, 

treatment techniques, and postoperative care will be discussed in detail during 

the didactic portion of the course. During the laboratory section, participants 

will have the opportunity to perform endoscopic cyclophotocoagulation, 

transscleral cyclophotocoagulation, SLT, ALT, MLT, and iridotomies under the 

supervision of the course instructors. 

Objective: At the conclusion of this course, attendees will be able to understand 

the indications and techniques for the various laser therapies used in the 

treatment of glaucoma. After the laboratory section, they will have hands-on 

experience using these modalities on animal eyes. 



Instructor(s): Joel S Schuman MD*, Jorge A Alvarado MD, Mark A Latina MD*, 

Malik Y Kahook MD*, Brian E Flowers MD* 

Trabeculotomy by Internal Approach (Trabectome) 

Surgery for Adult Open-Angle Glaucoma 

Course: 416 

Room: N138 


Monday 

3:15 - 5:30 PM 


Synopsis: Angle-based surgery for glaucoma via an internal approach is covered 

in this course. The Trabectome, cleared for clinical use by the FDA, is a 

new instrument for surgical treatment of open-angle glaucoma. The didactic 

part of this course will describe accumulated data from an ongoing case series 

exceeding 2000 eyes, including combined cataract and glaucoma surgery. Published 

data, including case series, and comparative trials with cataract surgery 

alone, trabeculectomy, and aqueous tube shunt, will be presented. Indications, 

surgical technique, IOP outcomes, and complications will be described during 

a one-hour didactic course. Surgical tips including proper identification of 

angle structures using the gonioscopic approach will be emphasized. This may 

also be followed by a hands-on lab session using inverted corneal donor rings 

for practice. 

Objective: At the conclusion of the course, attendees will understand the indications, 

surgical technique, IOP outcomes, and complications associated with 

this device. 



Senior Instructor(s): Sameh Mosaed MD** 

Instructor(s): Nils A Loewen MD*, Iqbal K Ahmed MD* 

NEW APAO Angle Closure and Angle-Closure 

Glaucoma 

Sponsored by the Asia-Pacific Academy of Ophthalmology and the Asia- 

Pacific Glaucoma Society 

Course: 417 

Monday 

Room: S106a 

3:15 - 5:30 PM 



Synopsis: Practically and logically, our course will define and classify these 

glaucomas, outline their prevalence and incidence, outline methods of assessment, 

and discuss pathophysiological mechanisms before covering medical, 

laser, and surgical strategies of prevention and treatment and current approaches 

to management of the acute angle closure crisis. 

Objective: After the course, participants will have a deeper and broader understanding 

of the burden and current classification of angle closure and angleclosure 

glaucoma, an awareness of pathophysiological principles underlying 

choices of new treatment strategies, and a detailed update on how best to 

prevent and to manage this spectrum of the glaucomas. 

Senior Instructor(s): Ivan Goldberg MBBS FRANZCO* 

Instructor(s): Clement C Y Tham MBBS*, Tetsuya Yamamoto MD*, Paul T K Chew 

MD, Tin Aung FRCS PhD*, Ki Ho Park MD*, Prin Rojanapongpun MD*, Ning Li 

Wang MD 

Ophthalmoscopic Evaluation of the Optic Disc and 

Retinal Nerve Fiber Layer 

Course: 438 

Room: S105bc 


Monday 

4:30 - 5:30 PM 


Synopsis: This course covers the ophthalmoscopic evaluation of optic disc, 

cup, neuroretinal rim, parapapillary atrophy, disc hemorrhages, retinal nerve 

fiber layer, and retinal vessel width. 

Objective: The course will help participants to (1) understand pseudoglaucomatous 

macrocupping and pseudonormal minicupping, (2) detect early glaucomatous 

changes, (3) differentiate glaucoma types by disc morphology, (4) 

distinguish glaucomatous optic neuropathy from nonglaucomatous optic nerve 

atrophy, (5) consider ethnic differences in the disc appearance, (6) discuss 

pathogenic implications of the disc morphology for glaucoma, (7) perform the 

dynamic optic disc assessment using modified ophthalmodynamometry for 

estimation of the central retinal artery and vein pressure, the orbital tissue 

pressure, and the brain pressure, and (8) include the results of the dynamic 

optic disc examinations for the diagnosis of optic nerve, orbital, and cerebral 

diseases. 

Senior Instructor(s): Jost B Jonas MD* 

84 





NEW Canal, Trab, or Tube: What Should I Do? 

Course: 494 

Room: S106b 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Surgical options for glaucoma today include filtering surgeries and 

newer minimally invasive technologies that increase outflow through physiologic 

channels. How does a glaucoma surgeon choose from all these available 

options? A case presentation format will highlight optimal clinical scenarios to 

help a surgeon pick cases appropriate for Schlemm canal surgery or traditional 

filtering surgery. Presentations will emphasize case selection, surgical pearls, 

potential pitfalls, and postop management. 

Objective: On completion of this course, the attendees will be able to tailor 

glaucoma surgery to their individual patient, offering a customized approach 

and integrating newer minimally invasive procedures into their surgical practice. 

Senior Instructor(s): Arvind Neelakantan MD* 

Instructor(s): Ronald Leigh Fellman MD OCS*, Quang H Nguyen MD*, Davinder S 

Grover MD*, Keith Barton MD* 

NEW Continuous 24-Hour IOP Monitoring for 

Glaucoma 

Course: 495 

Room: S101ab 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Intraocular pressure (IOP), the only modifiable risk factor for glaucoma, 

is a dynamic parameter. Peak IOPs occurring outside clinic hours remain 

undetected in many glaucoma patients. Recent availability of telemetric 

devices for continuous 24-hour IOP monitoring has the potential to improve 

glaucoma care. 

Objective: This course will review (1) the nature of 24-hour IOP and its clinical 

significance and (2) the role of 24-hour IOP monitoring technologies in clinical 

practice. At the conclusion of this course, the attendees will understand the 

complexities of 24-hour IOP patterns and how to integrate current technologies 

for monitoring IOP into the clinical management of glaucoma patients. 

Senior Instructor(s): Kaweh Mansouri MD* 

Instructor(s): Syril Dorairaj MD, Christopher Kai-shun Leung MD MBChB*, Arthur J 

Sit MD*, Robert N Weinreb MD* 

Glaucoma Filitration Device Mini-shunt: Friend or 

Foe? 

Course: 496 

Room: N139 


Tuesday 

9:00 - 10:00 AM 


Synopsis: This course will provide practical tips in the use of Ex-PRESS shunts, 

including videos to demonstrate surgery to insert and remove the shunt if necessary. 

The management pearls for treatment of complications will be highlighted 

with illustrative cases. 

Objective: This course will review indications and contraindications for the 

use of Ex-PRESS shunts and practical tips for insertion. The course will also 

discuss prevention of complications and management of these, if they should 

occur. 

Senior Instructor(s): Annapurna Singh MD 

Instructor(s): Richard A Lehrer MD* 

H Management of the Conjunctiva in Glaucoma 

Filtration Surgery 

Course: 497 

Room: N137 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Many of the intra- and postoperative problems in glaucoma filtration 

surgery are attributable to the conjunctiva. In this course, didactic and video 

presentations will discuss the preoperative preparation, incision and closure, 

and intra- and postoperative problems concerning the conjunctiva for safer and 

less frustrating glaucoma filtration surgery. 

Objective: Attendees will be given tools to help them minimize intra- and postoperative 

complications attributable to the conjunctiva to maximize the success 

of their glaucoma filtration operations. 

Senior Instructor(s): James A Savage MD* 

Evidence-Based Guidelines in the Management of 

Glaucoma 

Course: 537 

Room: N140 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: Early detection and treatment of glaucoma are of paramount importance 

to reduce the burden of blindness and its economic impact on society. 

At present, our treatment strategies are directed at reducing IOP, either with 

medical therapy, laser surgery, or incisional surgery. Two important questions 

often confront a glaucoma specialist when initiating therapy: Who needs to 

be treated? And how should a patient be treated? This course will address the 

evidence-based guidelines for treating glaucoma and review the invaluable 

information from major clinical trials (Glaucoma Laser Trial, SLT/MED Study, 

Ocular Hypertension Treatment Study, European Glaucoma Prevention Study, 

Early Manifest Glaucoma Trial, Collaborative Initial Glaucoma Treatment 

Study, Advanced Glaucoma Intervention Study, etc.) that have enhanced our 

understanding of the risk factors and treatment strategies at various stages of 

the disease. Representative clinical cases will also be presented. 

Objective: At the conclusion of the course, the attendee will be knowledgeable 

about when and how to treat glaucoma patients based on evidence, including 

many of the major clinical trials that have guided clinical decision making in 

glaucoma practice. 

Senior Instructor(s): Sarwat Salim MD* 

Instructor(s): Malik Y Kahook MD*, Shan C Lin MD*, Raghu Mudumbai MD, Peter 

Andreas Netland MD PhD*, Quang H Nguyen MD*, Joel S Schuman MD*, Carla 

J Siegfried MD 

Glaucoma Postop Care in the Office: A Video 

Compendium of Techniques—When and How to 

Intervene 

Course: 538 

Room: N138 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will demonstrate strategies and techniques used during 

the postoperative period of trabeculectomy and glaucoma drainage implant 

procedures to increase surgical success. 


causes of surgical failure and early postoperative complications that require 

intervention. The strategies, timing, and techniques used to deal effectively 

with postoperative management of trabeculectomy and glaucoma implants 

will be discussed in detail and demonstrated with the use of slitlamp video 





85



footage to allow attendees to utilize these procedures in their own offices. The 

instructors, who have diverse training backgrounds, will show variations in 

technique that will allow even the seasoned glaucoma surgeon an opportunity 

for learning. 

Senior Instructor(s): Cynthia Mattox MD FACS* 

Instructor(s): Chandrasekharan Krishnan MD, Susan S Liang MD 

Cell Biology, Genetics, and Outflow Biochemistry of 

Glaucoma in 2012 and Beyond 

Course: 575 

Room: E352 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will highlight what is known about the genes and the 

phenotypic differences between the open-angle glaucomas. An overview of 

cell biology-based theories relevant to glaucoma will be presented. A very 

brief summary of the discussions of the Trabecular Meshwork Society meeting 

in December 2011 will be presented, along with other recent biological 

advances pertaining to glaucoma. Specific theories about the biological etiology 

of open-angle glaucoma will be presented and discussed, especially as it 

pertains to matrix metalloproteinases. Uniquely, the course emphasizes the 

substantial relevance of these findings and theories to clinical practice. 

Objective: This course will give the attendee the tools to discuss the pros and 

cons of genetic testing in the future. The attendee will understand how specific 

concepts in cell biology, including the cytokine-modulated responses to 

trabeculoplasty, impact clinical care of the glaucoma patient. The attendee 

will be aware of some future prospects for glaucoma therapy. After the session, 

many attendees will engage in ongoing scientific dialog about specific 

aspects of glaucoma, conducted through e-mail. Handouts consist of numerous 

articles disseminated through a large file e-mail service (Yousendit) and 

will serve as a basis for these ongoing discussions. 

Senior Instructor(s): John R Samples MD* 

Instructor(s): Murray A Johnstone MD* 

NEW Gonioscopy and Angle Imaging 

Course: 576 

Room: S104b 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Gonioscopy, like any other skill, requires a learning curve. The training 

here will concentrate on when and how best to hone this skill. This course 

will educate the comprehensive ophthalmologist on different types of gonioscopy 

lenses and techniques, correlating the information with imaging studies, 

and the clinical implications of their findings. The different grading systems 

and methods of documentation will be covered, as well as advice on interpreting 

state-of-the-art imaging. The course will utilize several high-resolution 

images of the angle. 

Objective: At the conclusion of this course, attendees will be to incorporate 

this valuable skill into their practices for the benefit of patients with various 

angle abnormalities. 

Senior Instructor(s): Shamira Perera MBBS* 

Instructor(s): Tin Aung FRCS PhD*, David Goh MBBS, Jocel L Chua MD** 

Help, the IOP Is 40! 

Course: 577 

Room: S105d 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will provide practical tips in rapid evaluation and urgent 

management of a patient with recently detected high IOP. The management 

pearls will be highlighted with illustrative cases. 

Objective: This course will review frequent etiopathogenetic mechanisms of 

acute rise of IOP and offer a practical approach to establishing the correct 

diagnosis and overall management of such cases. 

Senior Instructor(s): Annapurna Singh MD 

Instructor(s): Suber S Huang MD* 

NEW How to Manage Bleb Fibrosis Over the Plates of 

Glaucoma Drainage Implants 

Course: 578 

Room: S103a 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will discuss capsule fibrosis over the plate, the most 

common reason for failure to control IOP in glaucoma drainage device (GDD) 

implants, together with methods to control this and improve success. Understanding 

capsule development and long-term physiological changes, and also 

how the aqueous components and the patient’s tissues can affect the success 

of GDD procedures will be reviewed. Methods to reduce bleb capsule fibrosis 

resulting in improved IOP control will be presented. 

Objective: By the conclusion of this course, the attendee will have gained 

knowledge regarding the reasons glaucoma implants can fail to control IOP, 

the importance of plate capsule formation, and how to manage this problem. 

Senior Instructor(s): Jeffrey Freedman MB BMBCH PHD* 

Instructor(s): Mark B Sherwood MD* 

Normal-Tension Glaucoma: Evaluation and Treatment 

Course: 579 

Room: E351 


Tuesday 

2:00 - 3:00 PM 


Synopsis: A neuro-ophthalmologist will review neurologic conditions misdiagnosed 

as normal-tension glaucoma (NTG) and present the appropriate diagnostic 

evaluation. A glaucoma specialist will discuss the pathophysiology of 

NTG and appropriate medical and surgical therapies. 

Objective: This course will enable participants to identify NTG patients who 

deserve further neurologic evaluation and to become familiar with the appropriate 

treatment of patients with glaucoma and normal IOP. 

Senior Instructor(s): Mark L Moster MD* 

Instructor(s): Marlene R Moster MD* 

The Management of Neovascular Glaucoma in 2012 

Course: 580 

Room: N136 


CANCELED 

Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will present cases and data on various etiologies of neovascular 

glaucoma and will discuss different methods to eradicate or reduce 

rubeosis iridis/angle neovascularization and different management options 

including the use of trabeculectomy with mitomycin C, glaucoma drainage 

implants, and various cycloablative procedures. The role of intravitreal bevacizumab 

in the management of neovascular glaucoma will be stressed, and 

audience participation will be encouraged. 

Objective: At the conclusion of the course, the attendees will have gained confidence 

in managing patients with neovascular glaucoma of varied etiology. 

Senior Instructor(s): Anil K Mandal MD 

Instructor(s): Peter Andreas Netland MD PhD*, K V Chalam MD PhD 

86 





Examining the Optic Nerve and Evaluating the Visual 

Field: The Five Rs 

Course: 597 

Room: S105a 


Tuesday 

2:00 - 4:15 PM 


Synopsis: This course will provide a standardized process and technique, using 

five rules, for examination and documentation of the optic disc and retinal 

nerve fiber layer and for visual field evaluation to identify signs of glaucoma. 

Objective: At the end of the course, participants will be better able to systematically 

perform optic nerve examination and interpret visual fields to diagnose 

glaucoma earlier, correctly stage the disease, and detect glaucoma progression. 

Senior Instructor(s): Ronald L Gross MD* 

Instructor(s): George A Cioffi MD* 

Managing Angle-Closure Glaucoma With Crystalline 

Lens Removal and Adjunctive Procedures 

Course: 611 

Room: N136 


Tuesday 

3:15 - 5:30 PM 


Synopsis: Preoperative diagnostics and ample surgical video will be used to 

demonstrate a unified approach and specific techniques to safely perform 

phacoemulsification as a definitive treatment for angle-closure glaucoma. In 

addition, adjunctive procedures such as goniosynechialysis, endoscoplasty, 

pars plana vitreous tap, irido-zonulo-hyaloidectomy, and pupilloplasty will be 

demonstrated. Tools such as capsular tension rings, pupillary rings, iris hooks, 

and microinstrumentation to enhance surgical success will be presented. 

Objective: This course is designed to provide surgeons with an approach and 

tools for safely performing phacoemulsification in the management of angleclosure 

glaucoma and to introduce adjunctive procedures to further enhance 

outcomes in these cases. 

Senior Instructor(s): Devesh K Varma MD* 

Instructor(s): Iqbal K Ahmed MD*, Garry P Condon MD**, Sebastien Gagne MD** 

NEW APAo Glaucoma Drainage Device Surgery: All 

You Wanted to Know but Were Too Afraid to Ask 


Course: 612 

Tuesday 

Room: N140 

3:15 - 5:30 PM 



Synopsis: Topics of this course include indications of glaucoma drainage device 

(GDD) surgery, device differences, preventing early hypotony, postoperative 

care, management of encapsulation, tube outcomes, and GDD vs. trabeculectomy. 


understand the role GDD plays in glaucoma management, (2) recognize problems 

encountered associated with the procedure, and (3) be able to institute 

appropriate measures to resolve them. 

Senior Instructor(s): Paul T K Chew MD 

Instructor(s): Clement C Y Tham MBBS*, Prin Rojanapongpun MD*, Ki Ho Park 

MD*, Ching Lin Ho FRCS MBBS*, Maria Cecilia D Aquino MD, Ivan Goldberg 

MBBS FRANZCO*, Keith Barton MD* 


GO Manual Small-Incision Cataract Surgery: An 

Alternative to Phacoemulsification 

Course: 498 

Room: S103bc 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Manual small-incision cataract surgery (SICS) is an established, 

safe, effective, and economical procedure of cataract extraction. The technique 

is wholly dependent on surgeon skill and experience for its outcome. The 

course will feature experts who will explain how to select patients and plan 

SICS. This will be followed by videos demonstrating tunnel construction and 

nucleus delivery. The instructors will also give an overview of SICS techniques 

and how to choose between them. This will be followed by ways to avoid and 

manage intraoperative and postoperative complications of SICS, and a discussion 

of how novice surgeons could master SICS. The four instructors have a 

combined surgical experience of >245,000 SICS/phaco surgeries. 

Objective: This course is designed to present the technique of manual SICS, an 

established, safe, effective, and economical procedure of cataract extraction. 

It would be of great use to ophthalmologists the world over, wherever phaco 

machines and/or surgeons are not available or affordable. 

Senior Instructor(s): Parikshit M Gogate MS FRCS(ED) 

Instructor(s): Tatyarao P Lahane MS**, Anil N Kulkarni MS, Ragini Parikh MD** 

GO Ophthalmologists’ Strategies for Enhancing 

Organizational Effectiveness in Developing 

Countries: Case Examples 

Course: 522 

Room: S103d 


Tuesday 

10:15 - 11:15 AM 


Synopsis: Eye care services in developing countries often lack the management 

capacity and financial sustainability needed to function at full potential. 

Yet today we have clinical interventions like manual sutureless small-incision 

cataract surgery (SICS), which offer excellent outcomes. These can be made 

very affordable through appropriate organizational practices that enhance the 

number of people reached, the efficiency with which they are treated, and the 

outcomes. This course will describe how ophthalmologists and their teams can 

play a role in this process of building clinical and organizational capacity to 

create sustainable and quality eye care services. A panel followed by audience 

discussion will explore the components of an effective service, including the 

use of various cataract surgical procedures such as SICS and phaco. 

Objective: Upon completion, participants will (1) understand the components 

of a viable, organizationally and financially sustainable eye care service, (2) 

recognize how a team approach leads to enhanced efficiency and effectiveness 

even in the short term, and (3) know how to influence constructive changes 

for sustainable eye hospitals. 

Senior Instructor(s): Maura Santangelo MD 

Instructor(s): Susan Lewallen MD, Raheem Rahmathullah BS*, Chundak Tenzing 

MD MPH, Mariano Yee Melgar MD 





87




How to Evaluate a Patient With Uveitis 


and the Sociedad Panamericana de Enfermedades Inflamatorias 

Oculares -PAAO 

Course: 240 

Sunday 

Room: E352 

3:15 - 5:30 PM 



Synopsis: This course will focus on the step-by-step evaluation and differential 

diagnoses of patients with uveitis by using case presentations to illustrate 

specific uveitis entities. Each course instructor will present interesting cases 

as unknowns for discussion by the panel of instructors. Course attendees will 

also be invited to present their own mystery cases by submitting the cases in 

advance. The rationale for ordering laboratory evaluations/ancillary tests and 

for the treatment plan will be explained in detail. 

Objective: Attendees will have ample opportunity to participate in this interactive 

course and will experience how a uveitis specialist analyzes each patient. 

Presentations will include both infectious and noninfectious uveitis entities in 

patients with anterior, intermediate, posterior, and pan-uveitis. Special emphasis 

will be given to the newest treatment modalities. At the completion of 

this course, the attendee will be able to formulate a tailored laboratory evaluation 

for the entities presented. 

Senior Instructor(s): Careen Yen Lowder MD PhD* 

Instructor(s): Emilio M Dodds MD, Janet Louise Davis MD*, James Philip Dunn Jr 

MD, Debra A Goldstein MD*, Sunil K Srivastava MD* 

International (Dis)Agreement on Infectious Uveitis 


and the American Uveitis Society (AUS) 

Course: 318 

Monday 

Room: S103bc 

9:00 - 10:00 AM 



Synopsis: Infectious uveitis is estimated to be responsible for 10% to 30% of 

all uveitis cases, depending on the geographic location. In some parts of the 

world toxoplasmosis alone is responsible for up to 50% of all posterior uveitis. 

Infectious uveitis poses unique diagnostic and therapeutic challenges. Uveitis 

resulting from tuberculosis, syphilis, herpes family viruses, or toxoplasmosis 

can each masquerade as noninfectious uveitis. In many cases, the diagnosis 

may require an anterior chamber or vitreous tap that can then be tested using 

simple stain, culture, polymerase chain reaction, or ELISA, depending on the 

organism suspected. While autoimmune uveitis requires long-term immunosuppressive 

therapy, most infectious uveitides can be treated with short-term 

antimicrobial therapy. It is therefore highly desirable to identify possible infectious 

etiology in idiopathic uveitis. The instructors will present a variety of 

challenging cases from around the world, with interactive discussion sessions. 

Objective: At the end of this course, the audience will be able to develop a 

stepwise approach to diagnosing and managing infectious uveitis entities. 

Senior Instructor(s): Rubens Belfort Jr MD PhD* 

Instructor(s): Hatice N Sen MD, Robert B Nussenblatt MD, Emilio M Dodds MD, 

Narsing A Rao MD, Khalid F Tabbara MD*, Careen Yen Lowder MD PhD*, Bahram 

Bodaghi MD PhD*, Cristina Muccioli MD, Ronald E Smith MD*, Thomas A Albini 

MD*, Soon-Phaik Chee MD* 

Decoding the Uveitis Workup: Why, When, and What 

to Order 



Course: 418 

Monday 

Room: S103bc 

3:15 - 5:30 PM 



Synopsis: This course will primarily focus on the stepwise, cost-effective uveitis 

workup utilizing the history and clinical presentation. Uveitis entities will 

be classified in a fashion that simplifies and optimizes the workup and reduces 

unnecessary testing. Clinical cases will highlight important features. 

Objective: Participants will be able to (1) selectively order appropriate diagnostic 

tests based on the clinical presentation of various uveitis entities in a 

cost-effective fashion and (2) interpret the results of diagnostic tests. 

Senior Instructor(s): Sarkis H Soukiasian MD 

Instructor(s): Michael E Zegans MD*, Russell N Van Gelder MD PhD* 

Medical and Surgical Therapy and Diagnosis of 

Uveitis 

Course: 613 

Room: S505AB 


Tuesday 

3:15 - 5:30 PM 


Synopsis: Recent advances have increased our ability to identify a specific etiology 

for many cases of uveitis. Medical and surgical therapeutic advances 

have also produced dramatic improvements in our ability to care for patients 

with uveitis. This course will present our system. 

Objective: This course will enable participants to recognize, investigate, and 

treat patients with uveitis. 

Senior Instructor(s): C Stephen Foster MD* 

Instructor(s): Emil Mitchel Opremcak MD, Albert T Vitale MD* 


NEW Dialog with the Editors of the Major General 

Ophthalmology Journals About the Peer Review 

Literature 

Course: 333 

Room: N427A 


Monday 

9:00 - 11:15 AM 


Synopsis: Editors of the 3 major general ophthalmology journals will present 

hints on preparing research for publication, including the initial steps in research, 

preparation of manuscripts, and expectations of the peer review process. 

The audience will recount their experiences and concerns to the editors. 

Objective: At the conclusion of the course, the attendee will be able to understand 

how to select a journal to match a research study, identify the essential 

elements of a manuscript, and describe how the manuscript will be handled 

during the peer review process. Major portions of the course will be devoted 

to audience interaction with the editors concerning questions and concerns 

about the ophthalmic literature and the present peer review process. 

Senior Instructor(s): Thomas J Liesegang MD 

Instructor(s): Andrew P Schachat MD, Daniel M Albert MD FACS* 

88 






NEW apao Optic Neuropathy in Asia: Clinical 

Characteristics and Basic Research 

Jointly Sponsored by the Asia-Pacific Academy of Ophthalmology and the 

Asian Neuro-Ophthalmology Society (ASNOS) 

Course: 174 

Sunday 

Room: N427D 

10:15 AM - 12:30 PM 



Synopsis: This course will highlight characteristic features of a variety of optic 

neuropathies in Asia and provide a different perspective on optic nerve disorders. 

For example, Leber hereditary optic neuropathy G11778A pedigrees 

in Thailand showed some characteristics different from those of Caucasians. 

Japanese optic neuritis is characterized by the lack of ocular pain and the presence 

of optic disc swelling, which may be associated with the low risk of MS. 

Recent studies on neuromyelitis optica (NMO) with aquaporin-4 antibodies in 

Japan showed the differential effects of interferon beta on MS (beneficial) and 

NMO (potentially harmful). Speakers will present and discuss the most up-todate 

clinical and basic research works on each entity. 

Objective: One of the main of this first Asian Neuro-Ophthalmology Society 

instruction course is to bring together neuro-ophthalmologists from different 

Asian countries and present the latest review and updated knowledge 

concerning characteristic optic neuropathies and their treatment options in 

each country. At the conclusion of this course, the attendee will be able to (1) 

recognize the varied presentations of optic nerve disorders, (2) describe characteristic 

features of main optic neuropathies in Asia, (3) discuss the currently 

available evidence about the treatment options for various optic neuropathies, 

and (4) take wide views and look at optic nerve disorders from a different 

perspective. 

Senior Instructor(s): Satoshi Kashii MD 

Instructor(s): Hyosook A Ahn MD PhD, Wanicha Chuenkongkaew MD, Jesus M 

Tamesis MD, An-Guor Wang MD, Xiaojun Zhang MD, Makoto Nakamura MD, 

May-Yung Yen MD, Mohamad Sidik MD, KY Goh FRCS(ED) 

Emergency Neuro-Ophthalmology: Diagnosis and 

Management 


and the North American Neuro-Ophthalmology Society (NANOS) 

Course: 185 

Sunday 

Room: S102Abc 

11:30 AM - 12:30 PM 



Synopsis: This course will present a case-based review of the emergency management 

of acute vision loss, optic nerve swelling, pupillary disorders, and 

ocular motility defects. 

Objective: To teach participants to identify and manage patients with true 

neuro-ophthalmic emergencies, and to review the differential diagnosis and 

management of acute vision loss, anisocoria, and ophthalmoplegia. 

Senior Instructor(s): Nicholas J Volpe MD 

Instructor(s): Mark L Moster MD* 

NEW The Vertical Diplopia Dilemma, Made Simple 

Course: 201 

Room: N136 


Sunday 

2:00 - 3:00 PM 


Synopsis: In the majority of patients, the etiology of vertical diplopia can be established 

by careful history taking and clinical examination. Illustrative cases 

and discussion will identify specific features of common causes of vertical 

diplopia such as cranial nerve palsy, thyroid orbitopathy, myasthenia gravis, 

and orbital and head trauma. A systematic approach toward evaluation and 

critical management pathways will be presented. 

Objective: At the conclusion of the course, the attendee will be able to diagnose 

common causes of vertical diplopia. A systematic approach toward 

management will aid the attendee in ordering appropriate tests, identifying 

patients requiring emergent management, and making appropriate referrals 

to specialists. 

Senior Instructor(s): Madhura A Tamhankar MD 

Instructor(s): Kenneth S Shindler MD PhD*, Nicholas J Volpe MD 

Diagnostic and Therapeutic Dilemmas in Neuro- 

Ophthalmology 

Course: 241 

Room: S505AB 


Sunday 

3:15 - 5:30 PM 


Synopsis: In this course, actual diagnostic and therapeutic clinical dilemmas 

will be presented by a panel of university-based neuro-ophthalmologists, with 

members of the audience participating in the generation of differential diagnoses 

and therapeutic strategies. 

Objective: At the conclusion of the course, the attendee will be able to address 

difficult problems in the diagnosis and management of neuro-ophthalmic 

cases. 

Senior Instructor(s): Nancy J Newman MD 

Instructor(s): Neil R Miller MD*, Valerie Biousse MD, Steven L Galetta MD*, 

Andrew G Lee MD* 

P Case-Based Approach to Isolated Eye Pain 

Course: 257 

Room: S105d 


Sunday 

4:30 - 5:30 PM 


Synopsis: Patients with eye pain and a normal ophthalmologic examination 

often present to the ophthalmologist. In this course, differential diagnosis, 

pathophysiology, management, and cases of isolated eye pain will be discussed 

in an interactive fashion. 

Objective: The attendee will be able to identify common causes of isolated eye 

pain and summarize current treatment options. 

Senior Instructor(s): Michael S Lee MD* 

Instructor(s): Gregory S Kosmorsky DO 

Curbside Consultation in Neuro-Ophthalmology 

Course: 353 

Room: S505ab 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course offers brief, concise, and practical answers to those 

questions that are often left unanswered by traditional texts and references 

in neuro-ophthalmology. The presenters will use a case-based format to pose 

and answer questions of neuro-ophthalmic interest to the general ophthalmologist. 

The presentations will be given in a “curbside consult” format that 

will be educational and entertaining. 





89



Objective: At the conclusion of this course, attendees will be able to provide 

management solutions to common neuro-ophthalmic presentations, including 

papilledema, optic neuritis, neuroretinitis, anterior ischemic optic neuropathy, 

optic atrophy, common visual field defects, and ocular motor cranial neuropathies. 

Senior Instructor(s): Andrew G Lee MD* 

Instructor(s): Paul W Brazis MD 

Swollen Disks, Headache, and Vision Loss: A Case- 

Based Approach to Pseudotumor Cerebri 

Course: 384 

Room: N140 


Monday 

2:00 - 3:00 PM 


Synopsis: What do you do when a patient with bilateral disc swelling shows 

up in your office? Pseudotumor cerebri (PTC) is a likely cause, but how do you 

decide the urgency of evaluation and make the right diagnosis? We will use a 

case-based approach to guide the clinician through the initial patient evaluation 

and workup. The key features of each case presentation that determine 

the severity of the disease and define the need for rapid referral and management 

will be emphasized. The instructors will demonstrate how to interpret 

complex MRI and CT images and the crucial sequences to evaluate for pathology. 

In-office technology (FA, visual fields, OCT) and its diagnostic role also 

will be covered, helping the clinician recognize the warning signs of sightthreatening 

disease. We will discuss new options for non-medical management, 

including venous sinus stenting and the long-term consequences of PTC. 


features of optic disc swelling and accompanying clinical symptoms that 

suggest sight-threatening disease is present and will understand the evaluation 

and referral process. Attendees will be able to interpret the results of 

diagnostic imaging techniques (OCT, CT, MRI) and recognize critical findings 

of venous sinus thrombosis. They will become familiar with current strategies 

for the treatment of patients with idiopathic intracranial hypertension and 

describe the indications for medical management, surgery, and interventional 

neuroradiological procedures. 

Senior Instructor(s): Prem S Subramanian MD PhD* 

Instructor(s): Vivek R Patel MD 

P What You Need to Know About Headache: A Pain 

for the Patient and a Pain for the Doctor 



Course: 419 

Monday 

Room: S105d 

3:15 - 5:30 PM 



Synopsis: Patients often seen or are referred to the ophthalmologist because 

of headache, eye pain, or the elusive complaint of eye strain. These patients 

present a diagnostic and therapeutic challenge, as many will have no apparent 

ocular etiology for their pain. The purpose of this course is to present a simplified 

framework for diagnosis and management of these patients that will both 

streamline their evaluation and provide guidelines for potentially beneficial 

therapeutic interventions. This course will use a case-based approach to discuss 

various headache syndromes with ocular manifestations. 

Objective: At the conclusion of this course, the attendees will be able to identify 

the major categories of underlying diagnoses for headache and eye pain, 

develop a succinct strategy for history and clinical examination to confirm the 

suspected diagnosis, and develop treatment goals in order to help their patients. 

Senior Instructor(s): Peter A Quiros MD 

Instructor(s): Lynn K Gordon MD PhD* 

Understanding Nystagmus: A Practical Approach for 

the Clinician 

Course: 539 

Room: N137 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will review the clinical features of different types of 

nystagmus. By using a systematic pathophysiologic approach, clinicians will 

develop a rational decision-making process in the diagnosis and management 

of nystagmus. Numerous videos will be presented. 

Objective: To help attendees understand nystagmus using a practical approach. 

At the conclusion of this course, attendees will be able to identify the salient 

features of different types of nystagmus, their etiology and pathophysiology, 

and important diagnostic and treatment issues. This course will aid attendees 

in improving their clinical management of nystagmus. 

Senior Instructor(s): Agnes M Wong MD 

Visual Fields in Neuro-Ophthalmology 



Course: 540 

Tuesday 

Room: N427A 

10:15 AM - 12:30 PM 



Synopsis: This course will provide an overview of visual fields, with an emphasis 

on neuro-ophthalmic conditions. The role of visual fields in neuroophthalmology 

will be put in perspective. Guidelines will be suggested for 

choosing the best field technique. Some of the newest field techniques will 

be discussed. Anatomic correlations with visual fields will be comprehensively 

detailed. Reliability and artifacts in visual fields will be reviewed. Case examples 

of visual field defects will be presented, with audience participation. 

Objective: At the end of this course, participants should be able to maximize 

their use of visual fields as a component of the complete evaluation in assessment 

of neuro-ophthalmology patients. 

Senior Instructor(s): Jacqueline A Leavitt MD 

Instructor(s): Steven A Newman MD, Susan M Pepin MD 

Diagnosis, Optic Neuropathy: Now What? 

Course: 554 

Room: S105D 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: Optic neuropathies demonstrate characteristic clinical features 

regardless of the underlying etiology. Illustrative cases and discussion will 

identify specific features of common optic neuropathies, including optic neuritis, 

arteritic and nonarteritic anterior ischemic optic neuropathy (AION and 

NAION), and compressive optic neuropathies. Current recommendations for 

evaluation and treatment will be presented. 

Objective: At the conclusion of this course, the attendee will be able to diagnose 

common optic neuropathies and distinguish them from less common 

etiologies. The attendee will know when and what studies, treatments, and 

referrals to initiate for distinct diagnoses. 

Senior Instructor(s): Kenneth S Shindler MD PhD* 

Instructor(s): Gabrielle R Bonhomme MD, Madhura A Tamhankar MD, Nicholas J 

Volpe MD 

90 






Current Controversies in Retinoblastoma 

Management 

Course: 202 

Room: N427A 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will present several controversial issues regarding diagnosis, 

management, prognosis, and follow-up of children with retinoblastoma. 

Objective: To discuss the role of selective ophthalmic artery infusion chemotherapy 

as treatment for intraocular retinoblastoma, the relative impacts of 

intravenous chemotherapy vs. external beam radiation therapy as initial treatment 

for bilateral retinoblastoma, the utility of screening for retinoblastoma in 

the general population, and the effectiveness of office ophthalmic examinations 

vs. periodic ophthalmic examinations under anesthesia for screening of 

children at risk for retinoblastoma. 

Senior Instructor(s): James Augsburger MD 

Instructor(s): Zelia M Correa MD, Miguel A Materin MD 

Pediatric Ocular Tumors 

Course: 319 

Room: S102D 


Monday 

9:00 - 10:00 AM 


Synopsis: This course will cover the important ocular tumors affecting children. 

An organized presentation will be given on the recognition and management of 

tumors of the eyelid, conjunctiva, intraocular structures, and orbit. Retinoblastoma 

management will be summarized. Various cases will be presented, along 

with discussion of management. 

Objective: At the conclusion of this course, the attendee should be able to 

identify the most common ocular tumors of childhood and understand management 

strategies. 

Senior Instructor(s): Carol L Shields MD 

Instructor(s): Jerry A Shields MD 

NEW Practical Ocular Oncology for the 

Comprehensive Ophthalmologist 

Course: 385 

Room: S105A 


Monday 

2:00 - 3:00 PM 


Synopsis: This course will consist of rapid-fire presentation and discussion of 

cases of classic but distinctive fundus lesions, including choroidal melanoma, 

retinoblastoma, metastatic carcinoma, intraocular lymphoma, and ocular surface 

neoplastic lesions. The presenters will emphasize the clinical differential 

diagnostic features and expected ancillary test findings of the various lesions 

and disorders. 

Objective: At the end of this course, attendees will be able to identify the classic 

lesions that have been presented, based on ophthalmoscopy, fluorescein 

angiography, ocular ultrasonography, and other studies where indicated. 

Senior Instructor(s): Miguel A Materin MD 

Instructor(s): Zelia M Correa MD, James Augsburger MD, Jose S Pulido MD MS, 

Brian P Marr MD, Hakan Demirci MD 

NEW Uveal Melanoma Therapies: Protons, Plaques 

and Eyewall Resection 

Course: 439 

Room: S505AB 


Monday 

4:30 - 5:30 PM 


Synopsis: The course will overview the indications, contraindications, complications, 

and results with various therapies for uveal melanoma using an 

illustrative case approach with audience participation. The data set for the 

course is approximately 4000 cases managed by the author and others. Iris, 

ciliary body, and uveal tumors will be discussed and the advantages and disadvantages 

of various treatment modalities will be delineated, along with an 

approach for the surgeon on how to optimize their results. 

Objective: At the conclusion of the course, the participant should be able to 

select optimum therapy for each type of patient and determine the relative 

risks and successes of each procedure and determine how to minimize treatment 

complications. 

Senior Instructor(s): Devron H Char MD 

Instructor(s): Devron H Char MD 

Management of Patients With Eyelid Tumors: From 

Clinic to Pathology 

Course: 499 

Room: N140 


Tuesday 

9:00 - 10:00 AM 


Synopsis: This course will cover the common benign and malignant eyelid tumors, 

including inclusion papilloma, nevi, hidrocystoma, basal cell carcinoma, 

squamous cell carcinoma, malignant melanoma, and sebaceous carcinoma. 

Cases with various ophthalmic manifestations will be presented, and current 

management options will be discussed. The techniques used to biopsy and 

excise these lesions and methods of handling them in the pathology laboratory 

will be reviewed. This will be an interactive course with case presentations, 

including differential diagnosis and treatment. 

Objective: The attendees will learn the ophthalmic manifestations of common 

benign and malignant eyelid tumors and understand management strategies, 

including how to biopsy and excise these lesions. They will also learn how to 

avoid common mistakes made in submitting the specimen to the pathology 

laboratory. 

Senior Instructor(s): Hakan Demirci MD 

Instructor(s): Victor M Elner Ph D MD*, Jerry A Shields MD, Carol L Shields MD, 

Christine C Nelson MD, Brian P Marr MD 

NEW Vision and the Artist 

Course: 367 

Room: S104A 


Ophthalmic History 

Monday 

11:30 AM - 12:30 PM 


Synopsis: This course demonstrates how art can teach ophthalmology, and 

how ophthalmology can enhance the appreciation of art. Light, dark, and contrast 

underlie vision and make representation in art possible. The diagnosis of 

eye disease from art is hazardous, but eye disease that is known to have afflicted 

an artist can reveal much about the art and about the functional effects 

of failing vision. Art from all ages will be shown, with special attention to the 

question of eye disease in Rembrandt, Cassatt, Degas, Monet, and O’Keeffe. 

Finally, simulations of the artist’s own view of their work will illustrate directly 

how different disabilities have affected different artists. 





91



Objective: Attendees should gain an understanding of how visual processes 

and eye disease affect their patients, and gain new appreciation of art. 

Senior Instructor(s): Michael F Marmor MD* 

Instructor(s): James G Ravin MD 

Evolution’s Witness: How Eyes Evolved 

Course: 581 

Room: N137 


Tuesday 

2:00 - 3:00 PM 


Synopsis: With predation and carnivory as catalysts, the first known eye appeared 

in a trilobite during the Cambrian explosion approximately 543 million 

years ago. Although the journey to formed vision actually began billions 

of years before that, the Cambrian period teemed with anatomic creativity. 

This crucible of evolution spawned nearly all morphologic forms of the eye, 

followed by descent over hundreds of millions of years, providing an unimaginable 

variety of eyes with at least ten different designs. Some eyes display 

spectacular creativity, with mirror, scanning, or telephoto optics. Some of 

these ocular designs are merely curiosities, while others offer the finest visual 

potential packed into a small space, limited only by the laws of diffraction or 

physiological optics. For example, some spiders developed tiny, well-formed 

eyes with scanning optics and three visual pigments; scallops have 4000 eyes 

circling their mantle; and some birds have vision five times better than ours. 

Each animal alive today has an eye that fits its niche perfectly, demonstrating 

the intimacy of the evolutionary process as no other organ could. From initial 

photoreception 3.75 billion years ago to early spatial recognition in the first 

cupped eyespot in Euglena to fully formed camera-style eyes the size of beach 

balls in ichthyosaurs, animals have processed light to compete and survive 

in their respective niches. Vision is evolution’s greatest gift and its greatest 

triumph. This course will present the story of the evolution of eyes. 

Objective: This course is designed to stimulate curiosity about the novelties 

and the triumphs of the evolution of the eye. 

Senior Instructor(s): Ivan R Schwab MD FACS 

Optics, Refraction, Contact Lenses 

A Natural Festival of Light and Color 

Course: 203 

Room: N135 


Sunday 

2:00 - 3:00 PM 


Synopsis: The subtle splendor of the green flash, the thrill of a rainbow with 

its accompanying Alexander’s phenomenon, the lunar corona, the Specter of 

the Brocken, the fog bow, the Bishop’s ring, and the surreal Fata Morgana are 

earthly examples of refraction, diffraction, and reflection. The quiet splendor 

of an ice crystal display (refraction and reflection) across the panorama of the 

skies has been a source of reverence, awe, wonderment, and even fear. Such 

common and diverse events as the twilight wedge, the aureole, the glory (diffraction), 

ice crystal displays (reflection and refraction), mirages, and eclipse 

phenomena are all displays that are subtle and often ethereal, yet stunning 

and magnificent in their presentation. Knowing what they look like, where 

and when to find them, and a bit about how they are formed will add to your 

enjoyment and understanding. These intriguing images are the product of the 

largest known terrestrial lens, our atmosphere. The optics of these events are 

fascinating, especially to those in our profession. These astonishing natural 

events are surprisingly common and will be revealed, explained, and admired. 

Objective: This course is designed to illustrate and explain the atmospheric 

optics of the events discussed above. The attendee will be able to recognize 

each of these and describe the optics involved in each display. 

Senior Instructor(s): Ivan R Schwab MD FACS 

Yo Review of Clinical Optics 

Course: 614 

Room: N137 


Tuesday 

3:15 - 5:30 PM 


Synopsis: This review of clinical optics will prepare ophthalmology residents 

to take the Ophthalmic Knowledge Assessment Program examination and 

graduates of residency training programs to take the written qualifying examination 

of the American Board of Ophthalmology. It will also serve as a 

refresher course for those in practice. The course will be taught in a questionand-answer 

format, focusing on problem solving. Content and illustrations will 

be drawn from the American Academy of Ophthalmology’s Basic and Clinical 

Science Course book on Clinical Optics. 

Objective: At the conclusion of the course, participants will be better prepared 

to answer multiple-choice optics questions on written examinations. 

Senior Instructor(s): Kevin M Miller MD* 


Cosmetic Botulinum Toxin and Facial Fillers: An 

Introductory Course 

Course: 153 

Room: S105d 


Sunday 

9:00 - 11:15 AM 


Synopsis: Principles of aesthetic facial injection of botulinum toxin and facial 

fillers will be presented in a didactic format. 

Objective: At the conclusion of this course, the attendee will better understand 

the salient anatomy, clinical techniques (including complication avoidance), 

and pharmacological principles pertaining to aesthetic injection of these substances. 



Senior Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, 

John Joseph Martin MD* 

Introduction to Aesthetic Facial Surgery by Fractional 

Lasers, Intense Pulsed Light, Radiofrequency, and 

Ultrasound Devices 

Course: 154 

Room: S102d 


Sunday 

9:00 - 11:15 AM 


Synopsis: This course offers an introduction to the latest fractional resurfacing 

lasers, intense pulsed light (IPL), radiofrequency devices, and ultrasound “lift” 

(Ulthera) laser incisional surgery to rejuvenate skin. Laser liposuction will be 

introduced. Information on incorporating these techniques into a medical practice 

will also be introduced. 

Objective: By the conclusion of this course, attendees will be able to (1) compare 

and contrast the many different fractional laser devices on the market, 

(2) understand the principles of IPL, Thermage, incisional laser surgery, and 

ultrasound skin lifting, (3) have introductory knowledge of how to incorporate 

such new technologies into their practices, and (4) recognize and manage complications 

of these devices. 



Senior Instructor(s): Julie A Woodward MD* 

Instructor(s): Erin Holloman MD, Raminder K Saluja MD*, Usha P Reddy MD, 

Randal Pham MD FACS, Adam J Scheiner MD*, John Joseph Martin MD*, Ioannis 

P Glavas MD 

92 





Thyroid Eye Disease 


and the International Thyroid Eye Disease Society (ITEDS) 

Course: 155 

Sunday 

Room: S104B 

9:00 - 11:15 AM 



Synopsis: Thyroid eye disease (TED) presents with a variety of manifestations 

affecting the eye, adnexa, and orbit and can be challenging to evaluate and to 

manage. The purpose of this course is to provide a practical update to help the 

ophthalmologist evaluate and initiate management of the patient with TED. 

The International Thyroid Eye Disease Society (ITEDS) “VISA” standardized 

evaluation form will be utilized in the discussion of the clinical evaluation and 

management of this disorder. An overview of favored approaches for surgical 

management will also be provided. 

Objective: By the conclusion of this course, participants should understand (1) 

current concepts of pathogenesis of thyroid eye disease, (2) risk factors associated 

with disease and severity, (3) disease activity, progress, and severity, (4) 

the ITEDS-VISA classification, (5) the use of the ITEDS-VISA classification for 

clinical assessment, choice of investigations, and management planning, (6) 

management during the active phase, including conservative therapy, medical 

therapy, radiotherapy, and urgent surgery, and (7) management during the quiescent 

phase, including conservative therapy and surgical intervention. 

Senior Instructor(s): Mark J Lucarelli MD FACS 

Instructor(s): Kenneth V Cahill MD FACS, Peter J Dolman MD, Raymond Douglas 

MD PhD, Jonathan J Dutton MD PhD, Victor M Elner PhD MD*, Steven E Feldon 

MD*, Michael Kazim MD, Don Kikkawa MD, Jennifer A Sivak-Callcott MD 

Introduction to Nasal Anatomy and Rhinoplasty 

Course: 175 

Room: S104A 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: This introductory course will provide an overview of surgical nasal 

anatomy, preoperative rhinoplasty analysis, infiltrative anesthetic techniques, 

incisions, septoplasty, cartilage grafting, conchal cartilage harvesting, endonasal 

approach, external approach, removal of bony-cartilaginous hump, medial 

and lateral osteotomies, spreader grafts, placement of columellar struts, 

closure, intranasal packs, nasal splinting, and postoperative care. 

Objective: This introductory course will provide an overview of surgical nasal 

anatomy and basic rhinoplasty techniques. 



Senior Instructor(s): Robert M Schwarcz MD, Brett S Kotlus MD, William R 

Nunery MD, David E Holck MD, Joel Kopelman MD** 

NEW APAO Common Asian Eyelid Surgery: A Video- 

Based Course 


Course: 176 

Sunday 

Room: S106A 

10:15 AM - 12:30 PM 



Synopsis: This course is designed to provide the best surgical techniques for 

common eyelid surgery on Asian patients. Among the topics will be a review 

of eyelid anatomy, preoperative evaluation, and patient selection, followed by 

video presentations on anesthetic and surgical techniques for epicanthoplasty, 

epiblepharon, nonincisional (suture) and incisional upper lid blepharoplasty, levator 

surgery, frontalis suspension using silicone rods, and entropion. Notably, 

the course will place special emphasis on structural characteristics unique to 

Asian eyelids, as well as the prevention and treatment of complications. 

Objective: On the completion of this course, the attendee will have achieved 

several important learning outcomes: a better understanding of the surgical 

anatomy of Asians, a greater familiarity with the best and relevant surgical 

techniques, and greater competence in performing common eyelid procedures. 

Senior Instructor(s): Lay Leng Seah MBBS 

Instructor(s): Kelvin Kam Lung Chong MD, Kyung In Woo MD, Tomoyuki Kashima 

MD*, Jae Woo Jang MD PhD, Mohammad Moin MD, Chai-Teck Choo, Li Dongmei 

Avoiding and Managing Blepharoplasty 

Complications 

Course: 186 

Room: S102D 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: This course will discuss the management of upper and lower blepharoplasty 

complications, with particular emphasis on avoiding complications. 

Instead of presenting a list of complications and their remedies, this course 

will present a methodology that places complications in different categories. 

By understanding that complications can arise from technique errors or judgment 

errors, the blepharoplasty surgeon can better plan and execute more 

successful surgery. This course will teach the surgeon how to avoid common 

trouble spots and how to manage complications when they do arise. 

Objective: At the conclusion of this course, participants will understand why 

complications occur and will learn how to plan for successful procedures and 

how to manage blepharoplasty complications, including orbital hemorrhage, 

asymmetric lid creases, webbing, too much fat removed, lower lid retraction, 

rounded lateral canthus, and the unhappy blepharoplasty patient. 

Senior Instructor(s): Morris E Hartstein MD* 

Instructor(s): Don Kikkawa MD 

Asian Blepharoplasty and the Eyelid Crease: 

Challenges and Solutions—A Video-Complemented 

Course 

Course: 204 

Room: N139 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will cover the basic surgical techniques used in creation 

of an upper eyelid crease in Asians. The fundamental parameters, proper techniques, 

pitfalls, and complications will be presented. Video will be used to 

illustrate the steps. A general handout will be available from each instructor. 

Objective: At the end of the course, the attendee will have an understanding 

of anatomy, specific terminology, and issues relating to primary as well as revisional 

cases, and will take away a working knowledge of the steps involved 

in Asian blepharoplasty, developed by the instructors. 

Senior Instructor(s): William Pai-Dei Chen MD 

Instructor(s): Don Liu MD 

Controversies and Advances in Pediatric 

Oculoplastic Surgery 

Course: 205 

Room: S102D 


Sunday 

2:00 - 3:00 PM 


Synopsis: Presented by a panel of experienced oculoplastic, pediatric, comprehensive, 

and pediatric oculoplastic surgeons, this popular course combines (1) 

short lectures on controversial topics, each presented by both a pediatric and 

oculoplastic surgeon for differing viewpoints, and (2) common and challenging 

case presentations with interactive discussion between the audience and 

panelists. Congenital ptosis is often more challenging than adult ptosis, with 

considerations such as amblyopia, strabismus, difficult exam, age at which 





93



surgery should be performed, and recurrence. Particular topics include congenital 

ptosis with poor levator function, timing of surgery, unilateral vs. bilateral 

repair, technique (frontalis sling, levator resection, posterior approach), 

and material choice. Marcus-Gunn jaw-winking ptosis also raises questions of 

which surgical procedure should be performed, whether unilateral or bilateral 

surgery is optimal, and whether levator extirpation is necessary. Other topics 

to be presented include congenital nasolacrimal duct obstruction; timing/ 

order of repair; Pediatric Eye Disease Investigator Group (PEDIG) recommendations; 

balloon dacryoplasty as a subsequent or primary option; socket/fornix 

expansion for anophthalmia, including dermis fat grafting, static implants, and 

hydrogel dynamic expanders; periorbital hemangioma management; and advanced 

techniques. 

Objective: By the end of this course the attendee should be better equipped 

to make treatment recommendations and utilize techniques that incorporate 

the expertise of both specialties for these difficult but common pediatric oculoplastic 

problems. 

Senior Instructor(s): Cat Burkat MD 

Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, William R Katowitz 

MD, Morris E Hartstein MD*, Monte D Mills MD, Michael C Struck MD 

Evaluation and Management of Orbital Cellulitis 

Course: 206 

Room: N138 


Sunday 

2:00 - 3:00 PM 


Synopsis: Orbital cellulitis is a condition that may be associated with visionand 

life-threatening complications. Despite numerous medical advances 

in antimicrobial therapy, radiographic imaging, and surgical technique, the 

treatment of orbital cellulitis remains challenging. Successful management 

requires prompt diagnosis, aggressive medical therapy, and in some cases, 

timely surgical intervention. Through lectures, video, and panel discussions, 

participants will learn to manage these patients confidently. 

Objective: This course will familiarize participants with the clinical features, 

radiographic presentation, and current medical and surgical treatment options 

for orbital cellulitis. 

Senior Instructor(s): Michael T Yen MD 

Instructor(s): Thomas Edward Johnson MD 

NEW APAO Prevention and Management of 

Complications in Oculoplastic Surgery 


Course: 224 

Sunday 

Room: S104a 

2:00 - 4:15 PM 



Synopsis: This course will deal with various topics in oculoplastic surgery, such 

as blepharoplasty, Botox and fillers, ptosis surgery, lacrimal surgery, enucleation 

or evisceration, and orbital surgery. The first part of each topic will be 

dedicated how to prevent complications, and the second part will be focused 

on the management of complications in detail. Participants will learn how to 

manage challenging cases through lectures, video, and panel discussions. 


why complications occur and will learn how to plan for successful 

procedures and how to manage the complications effectively if they should 

occur when performing a variety of oculoplastic surgical procedures. 

Senior Instructor(s): Yoon-Duck Kim MD 

Instructor(s): Kyung In Woo MD, Timothy J Sullivan MBBS, Santosh G Honavar 

MD, Ashok K Grover MBBS, Chee-Chew Yip MBBS FRCS, Lay Leng Seah MBBS 

Fundamental Face-Lifting Techniques 


and the American Society of Ophthalmic Plastic & Reconstructive 

Surgery (ASOPRS) 

Course: 242 

Sunday 

Room: N139 

3:15 - 5:30 PM 



Synopsis: This basic course will consist of a step-by-step slide and video presentation 

of a preoperative assessment, surgical facial anatomy, fundamental 

face-lifting techniques, postoperative care, and potential complications. A 

downloadable course manual will be available to participants. 

Objective: Participants will acquire the ability to select appropriate patients, 

develop hands-on familiarity with facial surgical anatomy, perform safe surgical 

dissection, provide appropriate postoperative care, and integrate facelifting 

into their aesthetic oculofacial practice. 



Senior Instructor(s): Tanuj Nakra MD, Robert M Schwarcz MD, Bobby S Korn 

MD PhD FACS* 

Instructor(s): David E Holck MD, Joel Kopelman MD**, Allan E Wulc MD FACS*, 

Roger A Dailey MD*, Stuart R Seiff MD, Susan M Hughes MD FACS*, William R 

Nunery MD, Jill Annette Foster MD FACS*, John D Ng MD* 

Oculoplastic Office Procedures: Video Clips 

Course: 320 

Room: E352 


Monday 

9:00 - 10:00 AM 


Synopsis: Detailed instruction with emphasis on “pearls” of office eyelid and 

lacrimal surgeries will be presented with the use of video clips. The following 

procedures will be discussed: incision and drainage of a chalazion, lesion 

biopsy, lesion excisions, tarsorrhaphy (chemical and surgical), lacrimal probing 

and irrigation, punctoplasty, punctal cauterization, canaliculotomy, entropion 

repair, ectropion repair, and upper eyelid blepharoplasty. 

Objective: Participants will be shown the relevant anatomy and surgical steps 

in performing office eyelid and lacrimal procedures. 

Senior Instructor(s): Susan M Tucker MD 

Instructor(s): Nancy A Tucker MD 

Yo Oculoplastic Procedures for the General 


Course: 321 

Room: E350 


Monday 

9:00 - 10:00 AM 


Synopsis: This course will describe basic and effective procedures for the 

treatment of involutional ectropion and entropion, tarsorrhaphy, marginal eyelid 

lesions, dermatochalasis, and aponeurogenic involutional ptosis. 

Objective: At the conclusion of this course, the attendee will be able to select 

and perform the appropriate surgical technique for the treatment of common 

eyelid problems encountered in a general ophthalmology practice. 

Senior Instructor(s): Robert C Kersten MD 

Instructor(s): Francesco P Bernardini MD, Carlo de Conciliis MD, Martin H Devoto 

MD, Jose R Montes MD 

94 





Blepharoplasty 

Course: 354 

Room: S103a 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will cover the latest techniques in upper and lower eyelid 

blepharoplasty. Basic and advanced surgical techniques, eyelid anatomy, 

patient selection, preoperative evaluation, and avoidance of complications 

will be discussed. A course handbook with illustrations outlining the surgical 

techniques will be provided. 

Objective: This course will provide participants with the techniques required to 

perform successful upper and lower eyelid blepharoplasties. 



Senior Instructor(s): Keith D Carter MD FACS 

Instructor(s): Mark A Alford MD, Richard C Allen MD PhD, Adam G de la Garza MD, 

Robert C Kersten MD, Jill S Melicher Larson MD*, Jeffrey A Nerad MD 

Diagnosis and Management of Essential 

Blepharospasm and Hemifacial Spasm 

Course: 386 

Room: S105d 


Monday 

2:00 - 3:00 PM 


Synopsis: Patients with facial spasms frequently present to ophthalmologists. 

The diagnosis and treatment of essential blepharospasm and hemifacial 

spasm is straightforward and gratifying. Through lectures, video, and panel 

discussions, participants will learn to manage these patients confidently. 

Objective: This course will familiarize participants with the diagnostic features 

and current treatment options for blepharospasm, hemifacial spasm, and related 

facial dystonias. 

Senior Instructor(s): Richard L Anderson MD FACS* 

Instructor(s): Michael T Yen MD 

Enucleation, Evisceration, and Care of the 

Anophthalmic Socket 

Course: 387 

Room: N137 


Monday 

2:00 - 3:00 PM 


Synopsis: Enucleation and evisceration techniques will be reviewed along with 

the available implant materials. The indications and contraindications of each 

of the techniques and care of the subsequent anophthalmic socket will be 

discussed. 

Objective: At the conclusion of this course, the attendee will be able to discuss 

the appropriate circumstance when either an enucleation or evisceration 

would be performed, recite the surgical procedure for each of the techniques, 

and differentiate between the available implants and when each would be 

appropriately used. The attendee will also be able to formulate a plan for any 

early and late postoperative sequelae. 

Senior Instructor(s): Richard C Allen MD PhD 

Instructor(s): Erin Shriver MD, Jeffrey A Nerad MD 

Endoscopic Forehead and Eyebrow Elevation 

Course: 420 

Room: N140 


Monday 

3:15 - 5:30 PM 


Synopsis: The aesthetic evaluation of the patient with eyebrow ptosis, the 

anatomy of the eyebrow and forehead, and a description of the endoscopic 

brow and forehead elevation procedure will be discussed. A course handbook 

will be provided, detailing the surgical technique. 

Objective: This course is designed to provide an understanding of the preoperative 

patient evaluation, pertinent surgical anatomy, and technique of endoscopic 

brow and forehead elevation. 



Senior Instructor(s): Susan R Carter MD 

Instructor(s): Louis Savar MD 

H Optimizing Outcomes and Minimizing 

Complications in Oculofacial Plastic Procedures: A 

Case-Based Approach 

Course: 421 

Room: E352 


Monday 

3:15 - 5:30 PM 


Synopsis: This course will present a practical, case-based guide for the evaluation, 

planning, and surgical management of common oculofacial plastic procedures. 

The course will feature high-definition surgical videos of selected 

cases, including blepharoplasty, eyelid and brow ptosis repair, and nonsurgical 

procedures such as botulinum toxin and subcutaneous filler injections. Emphasis 

will be placed on optimizing surgical outcomes and minimizing and managing 

complications, using case-based vignettes. 

Objective: At the conclusion of this course, the attendee will be able to evaluate 

and manage common outpatient oculofacial plastic procedures in an efficient 

manner with optimal outcomes. 

Senior Instructor(s): Bobby S Korn MD PhD FACS* 

Instructor(s): Don Kikkawa MD, Michael S McCracken MD, Karim G Punja MD, 

Christine C Annunziata MD, Sang-Rog Oh MD**, Nattawut Wanumkarng MD 

Complete Guide to the Evaluation and Management 

of Ptosis 




Course: 422 

Monday 

Room: N427D 

3:15 - 5:30 PM 



Synopsis: This course will provide a comprehensive understanding of ptosis 

syndromes and surgical treatments. Surgical techniques, including Müller 

muscle resection and levator and frontalis sling surgery, will be presented in 

detail. 

Objective: Participants will gain a thorough understanding of ptosis syndromes 

and their evaluation and management. Participants will evaluate, categorize, 

and surgically plan for the ptosis patient. 

Senior Instructor(s): Morris E Hartstein MD* 

Instructor(s): Adam G Buchanan MD, Gabriela Espinoza MD, Steven M Couch MD 





95



Lotions, Potions, Botulinum Toxin, and Fillers: 

Nonlaser Rejuvenation for the Ophthalmologist 




Course: 423 

Monday 

Room: S106B 

3:15 - 5:30 PM 



Synopsis: Cosmeceuticals, botulinum toxin, chemical peels, and soft tissue fillers 

all provide nonlaser options for minimally invasive facial rejuvenation. This 

course will review facial skin analysis and therapeutic options available to 

patients. Assessment, indications, and techniques for use of botulinum toxin, 

chemical peels, and soft tissue fillers will be discussed. 

Objective: At the end of this course, attendees will be familiar with cosmeceutical 

categories and applications and will understand the indications, techniques, 

and complications (management and avoidance) for botulinum toxin, 

soft tissue fillers, and chemical peels. 

Senior Instructor(s): Christopher M DeBacker MD 

Instructor(s): Scott M Goldstein MD, Femida Kherani MD, David E Holck MD, Jill 

Annette Foster MD FACS*, Wendy W Lee MD* 

H Management of Orbital Tumors: Case Presentation 

and Discussion 




Course: 424 

Monday 

Room: N136 

3:15 - 5:30 PM 



Synopsis: This course will focus on management of orbital tumors through representative 

cases from the instructors’ orbital practices. Emphasis will be on 

clinical pictures showing initial presentation, imaging characteristics of orbital 

lesions, surgical approach, and the role of ancillary treatment options such as 

radiotherapy and/or systemic chemotherapy. 

Objective: This course is designed to enable the orbital and oculoplastic specialist 

to appropriately diagnose orbital tumors and become familiar with the 

multidisciplinary management of orbital tumors using illustrative cases and 

the collective experience of the course instructors. 

Senior Instructor(s): Bita Esmaeli MD FACS 

Instructor(s): Geoffrey E Rose FRCOphth, Timothy J Sullivan MBBS, Dale R Meyer 

MD FACS, Jonathan J Dutton MD PhD 

Endoscopic Transnasal Lacrimal Surgery: Principles 

and Practice 

Course: 513 

Room: N136 


Tuesday 

9:00 - 10:00 AM 


Synopsis: The transnasal diagnosis and treatment of lacrimal outflow disorders 

will be presented. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy 

surgical techniques, endoscopic Jones tubes placement, and endoscopic 

diagnosis and management of lacrimal disorders will be covered. 

Objective: Participants will understand transnasal endoscopic diagnosis and 

treatment of lacrimal outflow disorders. 



Senior Instructor(s): Francois Codere MD, Bruce M Massaro MD 

Instructor(s): Jennifer A Sivak-Callcott MD 

H Ophthalmic Dermatology: Periocular Skin Lesions 

Course: 514 

Room: E352 


Tuesday 

9:00 - 11:15 AM 


Synopsis: This course is a comprehensive overview of skin anatomy, physiology, 

and pathology as it pertains to the periocular area. In particular, a full 

spectrum of pediatric and adult lesions will be covered, including inflammatory, 

infectious, infiltrative, and neoplastic etiologies. Individual cases will be 

presented in an interactive manner to highlight management options. 

Objective: By the end of this course, participants should be able to recognize, 

evaluate, and treat periocular cutaneous lesions in patients of all ages. 

Senior Instructor(s): Scott M Goldstein MD 

Instructor(s): Femida Kherani MD 

Periocular Tumors and Techniques of Eyelid 

Reconstruction 




Course: 515 

Tuesday 

Room: S403b 

9:00 - 11:15 AM 



Synopsis: This course will give an overview of the most common benign and 

malignant skin lesions that involve the periocular region, will highlight the 

general features of malignancy, will provide a detailed description of the most 

common eyelid neoplasms, will describe the different biopsy techniques, and 

will provide the requisites to reconstruct the upper and lower eyelid under any 

circumstance. 

Objective: At the conclusion of this course, the attendee will be able to recognize 

malignant and benign tumors, differentiate among the various types 

of malignant lesions, safely diagnose every suspicious periocular tumor, and 

master the most useful techniques for upper and lower eyelid reconstruction. 

Senior Instructor(s): Jeffrey A Nerad MD 

Instructor(s): Francesco P Bernardini MD, Martin H Devoto MD, Robert C Kersten 

MD, Carlo de Conciliis MD 

NEW APAO Emerging Paradigms in Oculoplastics: 

The Asian Perspective 

Sponsored by the Asia-Pacific Academy of Ophthalmology and the 

Asia-Pacific Society of Ophthalmic Plastic & Reconstructive Surgery 

(APSOPRS) 

Course: 541 

Tuesday 

Room: S105bc 

10:15 AM - 12:30 PM 



Synopsis: This course gives an update on the diagnosis and treatment of common 

oculoplastic conditions in Asians. The upper face treatment modalities 

to be presented include nonendoscopic eyebrow lift and radio-frequency periorbital 

skin rejuvenation. The orbital topics will include the management of 

cavernous hemangioma and pediatric orbital tumors, complex orbital fractures 

management with a new navigational imaging system, and new options in 

correcting postoperative orbital fracture complications. Advances in the management 

of anophthalmic socket abnormalities will be taught. It is important 

to be familiar with these new trends to widen and refine one’s armamentarium 

of management options. 

96 





Objective: The attendee will be educated on emerging trends in the management 

of common oculoplastic conditions in Asians. 

Senior Instructor(s): Chee-Chew Yip MBBS FRCS 

Instructor(s): Yoon-Duck Kim MD, Ashok K Grover MBBS, Xianqun Fan, Reynaldo M 

Javate MD, Timothy J Sullivan MBBS, Nobutada Katori MD 

Advanced Techniques in Orbital Decompression and 

Expansion 

Course: 555 

Room: N136 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: This course is designed to foster creative thinking in orbital decompression. 

Staging, planning, and techniques for orbital decompression will be 

reviewed, including deep lateral, fat removal, transcaruncular, and endoscopic. 

Surgical versatility and creative decision making will be stressed. 

Objective: This course is designed to acquaint participants with a variety of 

techniques for orbital decompression and to enable them to design an individualized 

approach based on the patient’s needs and goals. 



Instructor(s): Raymond Douglas MD PhD, Norman Shorr MD, Catherine Hwang 

MD, Joseph L Lin MD 

Tips for Oculoplastic Surgery in Asian Patients 

Course: 582 

Room: N427d 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Asian people have different anatomic characteristics from non- 

Asian people and different beauty standards as well. To obtain the satisfactory 

surgical outcome, it is important to understand the distinct points in anatomy 

and surgical techniques. In addition to detailed anatomic differences, surgical 

pearls on eyelid surgery such as epiblepharon repair, blepharoptosis surgery, 

blepharoplasty, and epicanthoplasty for Asian patients will be presented. Surgical 

approaches to lacrimal surgery focused on Asian surgical anatomy will 

also be introduced. 

Objective: At the conclusion of this course, the attendee will be familiar with 

different approaches and unique surgical techniques for Asian patients in performing 

various oculoplastic procedures. 

Senior Instructor(s): Yoon-Duck Kim MD 

Instructor(s): Don Kikkawa MD, Randal Pham MD FACS, Kyung In Woo MD 

NEW Facial Fracture Repair: Better Outcomes and 

Improved Technique 

Course: 598 

Room: S106b 


Tuesday 

2:00 - 4:15 PM 


Synopsis: This course will provide a detailed discussion of valuable pearls for 

the reconstruction of common facial fractures that are often seen within the 

scope of an oculofacial practice, but not commonly taught during fellowship 

training. The content will include valuable insight regarding the management 

of zygomatic complex, naso-orbital-ethmoidal complex, and extensive multiple 

wall fractures of the orbit and roof and frontal sinus fractures. 

Objective: This course if designed to provide participants with a high-level understanding 

of the preoperative planning, nuances, and pitfalls of the most 

recent management and repair techniques of facial fractures from an orbitocentric 

perspective. In addition, participants should gain sufficient knowledge 

to improve surgical outcomes through the application of these techniques. 

Senior Instructor(s): Eli L Chang MD 

Instructor(s): Peter A D Rubin MD*, Jeremiah P Tao MD*, Vikram D Durairaj MD*, 

Hui Bae Harold Lee MD, William R Nunery MD, Alfio P Piva MD** 

Stereo Anatomy of the Orbit, Eyelid, and Lacrimal 

System: A Surgeon’s Perspective 

Course: 599 

Room: S103d 


Tuesday 

2:00 - 4:15 PM 


Synopsis: This course will provide a comprehensive review of orbital, eyelid, 

and lacrimal system anatomy using projected stereo images of meticulous 

cadaveric dissections. Surgical approaches and complications will be emphasized. 

Objective: This course will reacquaint participants with the anatomy of the 

orbit/ocular adnexa and increase their confidence when operating in these 

areas. 

Senior Instructor(s): Asa Dan Morton III MD* 

Instructor(s): David Baker Lyon MD, Charles S Su MD, Victor M Elner PhD MD* 

Current Techniques in Lacrimal Surgery 

Course: 605 

Room: S105D 


Tuesday 

3:15 - 4:15 PM 


Synopsis: This course aims to make an overview of the present techniques in 

lacrimal surgery, presenting the advantages and disadvantages of each. Also 

the newest techniques will update the oculoplastic surgeon. 

Objective: The following subjects will be developed: probing in children with 

epiphora, balloon dacryoplasty, external dacryocystorhinostomy (DCR) techniques 

of bone removal and the role of mitomycin C, endoscopic DCR with 

sutured flaps, endoscopic radiofrequency-assisted DCR (ERA DCR), endonasal 

nonendoscopic DCR, transcanalicular diode laser DCR, management 

of canalicular obstructions and canalicular lacerations, Lester-Jones tubes 

techniques, septoplasty in endoscopic endonasal DCR, and endoscopic lacrimal 

duct recanalization using microendoscope. Challenging cases and their 

management will be presented. Videos of the most modern techniques will be 

presented, as well as management of complications. Indications and contraindications 

of each technique and pearls and pitfalls about the timing of the 

surgery and the steps of each technique will be revealed. By the end of the 

course, the attendee will be familiar with current techniques of lacrimal examination 

and diagnosis, including nasal endoscopy, and will have gained an 

understanding of the evaluation and management of tearing in the absence of 

anatomic obstruction. Attendees will also acquire an in-depth knowledge of all 

the current techniques of lacrimal surgery for congenital and acquired lacrimal 

outflow obstruction presented by some of the experts in this field. 

Senior Instructor(s): Nikolaos Trakos MD 

Instructor(s): Reynaldo M Javate MD, Don Kikkawa MD, Yasser A Khan MD**, 

Geoffrey E Rose FRCOphth 





97



Basic Browlift: Principles and Techniques 

Course: 615 

Room: N138 


Tuesday 

3:15 - 5:30 PM 


Synopsis: There are many brow elevation techniques, and in general, the procedure 

should be tailored to the specific patient. This course will review the 

anatomical foundations, evaluation, patient selection, and treatment of brow 

ptosis. The techniques reviewed will include direct, mid-forehead, pretrichial, 

coronal, limited incision, and browpexy. 

Objective: At the conclusion of the course, the attendee will be able to describe 

the anatomical foundations of brow ptosis, evaluate the patient with 

brow ptosis, list the different techniques available for brow elevation, and 

select which procedure is most appropriate for the particular patient. 

Senior Instructor(s): Richard C Allen MD PhD 

Instructor(s): Jill S Melicher Larson MD*, Keith D Carter MD FACS 


NEW Management of Strabismus in Thyroid Eye 

Disease 

Course: 187 

Room: S103bc 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: The management of strabismus associated with thyroid eye disease 

is one of the more challenging types of ocular misalignments to correct. A 

variety of techniques have been described using adjustable as well as fixed sutures. 

This course will review the steps in the preoperative examination of the 

patient in the office, the gathering of necessary information to determine the 

muscles to be operated on, and the operative technique used by the instructors. 

Video clips will be used to partly transfer the necessary skills. A summary 

of the literature on the topic will also be given. 

Objective: Upon completion of the course, participants will be able to (1) list 

the clinical data necessary for management of the patient with TED and strabismus, 

(2) describe the operative steps involved in the surgical technique 

used to correct the ocular misalignment, and (3) understand the differences 

between the different surgical techniques for the correction of strabismus in 

TED and the pros and cons for each. 

Senior Instructor(s): Elias I Traboulsi MD* 

Instructor(s): Paul Joseph Rychwalski MD 

NEW New Techniques for Strabismus Surgery 

Course: 188 

Room: N140 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: Over the past several years, important surgical innovations have 

made strabismus surgery safer and more effective. This course will teach the 

use of novel strabismus surgical techniques, including grooved hook for suturing 

the muscle insertion, minimally invasive techniques (rectus central tenotomy 

and plication), and use of amniotic membrane transplant for restrictive 

strabismus. Video will be presented to help teach the techniques. Outcome 

studies of surgical procedures will be presented. 

Objective: At the conclusion of this course, the attendee will be able to use 

new strabismus surgical techniques to improve surgical outcomes and reduce 




Senior Instructor(s): Kenneth W Wright MD* 

Instructor(s): Yi Ning Strube MD, Luke W Deitz MD 

NEW Update on the Current Diagnostic Workup for 

Infants and Children With Poor Vision 

Course: 207 

Room: S105D 


Sunday 

2:00 - 3:00 PM 


Synopsis: For children suspected of having inherited retinal disease there are 

new options for diagnosis, and a better outlook for emerging treatments. This 

course focuses on the current workup for diseases in children presenting with 

reduced vision, and sometimes nystagmus. Investigational treatments for 

these conditions will be discussed. 

Objective: Upon course completion, participants will be able to (1) recognize 

distinguishing signs and symptoms of inherited retinal diseases of children, (2) 

order appropriate genetic blood tests prior to/along with more traditional diagnostic 

tests such as electroretinography or fluorescein angiography, and (3) 

understand the current clinical trials for Leber congenital amaurosis, Stargardt 

disease, albinism, and Batten disease. 

Senior Instructor(s): Arlene V Drack MD* 

Instructor(s): Elias I Traboulsi MD* 

H Difficult Strabismus Problems: Diagnosis and 

Management 2012 

Course: 243 

Room: S403B 


Sunday 

3:15 - 5:30 PM 


Synopsis: Case presentations of complex strabismus will form the basis for 

panel discussion and audience participation in this course on proper diagnosis 

and management. Diagnostic techniques such as orbital imaging, forced ductions, 

saccadic velocity, and active force generation testing will be discussed 

as they apply to specific cases. Reoperations, cranial nerve palsies, trauma, 

Duane syndrome, Brown syndrome, and thyroid ophthalmopathy are representative 

topics. 

Objective: To enhance participants’ ability to accurately diagnose and treat 

complicated strabismus patients. Surgical and nonsurgical options will be 

elaborated. 

Senior Instructor(s): Burton J Kushner MD 

Instructor(s): Edward G Buckley MD, David G Hunter MD PhD* 

NEW APAO Imaging Studies in Strabismus 


Course: 334 

Monday 

Room: N427D 

9:00 - 11:15 AM 



Synopsis: In order to recognize the mechanism of eye movement disorders, 

imaging studies of brain and orbit are essential. The most recent imaging 

studies show not only anatomical abnormalities but also functional abnormalities 

of extraocular muscles. Various types of strabismus cases are associated 

with abnormal findings of images, such as thyroid ophthalmopathy, esotropia 

with high myopia, consecutive exotropia, rupture of extraocular muscle after 

trauma, and special types of congenital strabismus. It is important for comprehensive 

ophthalmologists and strabismus specialists to be familiar with recent 

advances in imaging studies of strabismus. 

Objective: This course will show the findings of orbital and brain CT/MRI and 

strategies of the treatment of special types of strabismus. At the conclusion of 

this course, the attendee will be able to recognize the importance of imaging 

studies and the management of strabismus based on their findings. 

Senior Instructor(s): Miho Sato MD PhD 

Instructor(s): Joseph L Demer MD PhD*, Tsuranu Yokoyama, Jeong-Min Hwang 

MD*, Sonal R Farzavandi MBBS, Jonathan M Holmes MD* 

98 





Pediatric Leukocoria: All You Need to Know 

Course: 368 

Room: N427d 


Monday 

11:30 AM - 12:30 PM 


Synopsis: A panel of specialists, including a pediatric ophthalmologist, a vitreoretinal 

surgeon, and an ocular oncologist, will review the spectrum of diseases 

that can present as leukocoria in the first decade of life. Case studies 

will be used to highlight critical features helpful in distinguishing benign from 

malignant and ocular from systemic conditions, including ocular coloboma, 

retinoblastoma, Coats disease, persistent fetal vasculature, ROP, and more. 

Objective: At the conclusion of this course, the participant will be able to identify 

and distinguish the various and sometimes challenging ocular conditions 

that can present as pediatric leukocoria. 

Senior Instructor(s): Dan S Gombos MD 

Instructor(s): Evelyn A Paysse MD, G Baker Hubbard MD 

Pediatric Uveitis: What You Need to Know 



Course: 369 

Monday 

Room: N427bc 

11:30 AM - 12:30 PM 



Synopsis: This course will cover the challenging issue of pediatric uveitis 

through case presentation and interactive discussion with the audience. More 

than 10% of blindness due to uveitic conditions occurs in the pediatric population. 

Among etiologic entities, juvenile idiopathic arthritis, infectious diseases, 

and pars planitis remain predominant. 

Objective: At the conclusion of this course, the attendee will be able to diagnose 

common intraocular inflammatory conditions in children, evaluate the severity 

of disease, and propose a tailored workup. Therefore it will be possible 

to select the best therapeutic strategy in each situation and propose systemic 

immunosuppressors, when necessary. 

Senior Instructor(s): Janet Louise Davis MD* 

Instructor(s): Debra A Goldstein MD*, Bahram Bodaghi MD PhD* 

NEW Clinical Applications of New Concepts of 

Extraocular Muscle Function 

Course: 388 

Room: S103d 


Monday 

2:00 - 3:00 PM 


Synopsis: Recent discoveries using functional imaging and animal models 

have revolutionized our understanding of disorders of ocular motility, adding 

novel concepts including orbital ligament degeneration, selective pathologies 

within particular layers of extraocular muscles (EOMs), EOM path abnormalities, 

and genetically programmed misinnervation. This course will review modern 

concepts of EOMs, motor nerves, connective tissues, and therapeutic and 

diagnostic implications for eye surgeons. 

Objective: Functional MRI and biomechanical, innervational, genetic, and 

physiologic findings will be related to strabismus diagnosis and treatment, 

including novel surgical procedures involving orbital connective tissues or portions 

of EOM tendons, in addition to classical recess, resect, and transpose. 

At the end of this course, the attendee will be able to (1) describe the modern 

compartmental concepts of EOMs and connective tissues and (2) diagnose and 

treat, using an expended surgical repertoire, newly recognized connective tissue 

disorders causing common forms of strabismus. 

Senior Instructor(s): Joseph L Demer MD PhD* 

NEW Nightmares in Pediatric Cataract Surgery 

Course: 389 

Room: S106b 


Monday 

2:00 - 3:00 PM 


Synopsis: In this video- and case-based presentation, cataract surgery in children 

with association of anterior segment trauma, anterior segment dysgenesis, 

microcornea, subluxation, posterior lenticonus, persistent fetal vasculature, 

coloboma, post keratoplasty (penetrating/endothelial), post glaucoma filtering 

surgery, uveitis, and extended anterior capsulorrhexis will be discussed. 

These cases are prone to develop intraoperative complications. Modifications 

in standard surgical technique will be discussed. 

Objective: At the end of this course, the attendee will be able to identify challenging 

situations that arise in complicated pediatric cataract surgery, including 

the surgical modifications required and the optimal outcomes of surgery. 

Senior Instructor(s): Ramesh Kekunnaya MBBS MD 

Instructor(s): Pravin K Vaddavalli MD*, Muralidhar Ramappa MS, Sunita Chaurasia 

MD, Jatin Naresh Ashar MD 

NEW What’s New and Important in Pediatric 

Ophthalmology and Strabismus for 2012 


and the American Association for Pediatric Ophthalmology and 

Strabismus (AAPOS) 

Course: 425 

Monday 

Room: S102d 

3:15 - 5:30 PM 



Synopsis: Presented by the American Association for Pediatric Ophthalmology 

and Strabismus (AAPOS) Professional Education Committee, this course 

will provide a stimulating overview of important publications from a variety of 

peer-reviewed journals from 20011/2012 in the field of pediatric ophthalmology 

and strabismus. 

Objective: At the conclusion of this workshop, attendees will be able to (1) 

understand the latest research in ROP prevention and treatment as well as appropriate 

timing of screening in the NICU, (2) understand the causes of infantile 

esotropia and its cortical influences and consider reasons for implementing 

earlier surgery in order to improve cortical and motor outcomes, (3) be aware 

of the resources available for genetic testing and how to more wisely implement 

genetic testing into their practices, (4) understand trends in pediatric 

cataract and refractive surgery and implement this new information into their 

practice, and (5) understand the latest information on therapeutic treatment 

options for amblyopia. 

Senior Instructor(s): Jitka L Zobal-Ratner MD 

Instructor(s): Ajay Soni MD, Kyle A Arnoldi CO, Darron A Bacal MD*, Nisha R 

Krishan-Dave MD**, Arlene V Drack MD*, Patrick J Droste MD, Majida A Gaffar 

MD**, Ramesh Kekunnaya MBBS MD, Stacy L Pineles MD, Gill Roper-Hall CO, 

Kimberly G Yen MD, Terri L Young MD* 

Cataract Surgery in Children: Complicated Cases and 

Controversies 


and the American Society of Cataract and Refractive Surgery (ASCRS) 

Course: 426 

Monday 

Room: S403b 

3:15 - 5:30 PM 



Synopsis: This video-based course will present a diverse group of pediatric 

cataract cases and involve panel and audience discussion as each case unfolds. 

It will also discuss the ongoing Infant Aphakia Treatment Study. 





99



Objective: At the end of this course, the participant will be able to describe the 

preferred steps in the surgical treatment of childhood cataract and describe 

solutions to many of the commonly encountered complications of surgery in 

childhood. 

Senior Instructor(s): M Edward Wilson Jr MD* 

Instructor(s): Erick D Bothun MD, Edward G Buckley MD, Scott R Lambert MD*, 

David A Plager MD*, Rupal H Trivedi MBBS MS*, Abhay Raghukant Vasavada 

MBBS FRCS* 

Glaucoma in Infants and Children: What We Don’t 

Know Can Hurt Them! 

Course: 500 

Room: N138 


Tuesday 

9:00 - 10:00 AM 


Synopsis: This workshop will review basic principles in the diagnosis and treatment 

of childhood glaucoma. It will begin with an introduction of the etiologies 

of glaucoma in children. This will be followed by a discussion of approaches to 

diagnosing glaucoma in children, with attention to new devices for IOP measurement 

and updates on the utility of diagnostic and imaging technologies in 

children. Approaches to medical and surgical treatment will be discussed in 

detail, and key points will be reinforced by clinical cases and surgical video. 

Objective: At the conclusion of this workshop, the attendee will be able to 

identify primary and secondary pediatric glaucomas and to identify current 

methods for timely diagnosis and treatment. 

Senior Instructor(s): Sharon F Freedman MD* 

Instructor(s): Nandini G Gandhi MD 

NEW APAO Infantile Onset Esotropias 

Sponsored by the Asia-Pacific Academy of Ophthalmology 

Course: 516 

Tuesday 

Room: N427D 

9:00 - 11:15 AM 



Synopsis: In order to manage the infant with crossed eyes, we need to consider 

the natural history of the development of ocular alignment, differential diagnosis, 

significance of preoperative instability and measurement uncertainty, 

nonsurgical management, timing of surgery, surgical management, possible 

role of Botulinum toxin, and short- and long-term postsurgical management. 

Objective: After attending this course, the attendee will be able to confidently 

diagnose infantile esotropia, determine a treatment plan, operate in a timely 

fashion with a high expectation of success, and manage the patient long term 

to visual maturity. 

Senior Instructor(s): Glen Anthony Gole MD FRANZCO 

Instructor(s): Sonal R Farzavandi MBBS, Malcolm R Ing MD** 

NEW Management of Pediatric Cataracts 


Asia-Pacific Strabismus and Pediatric Ophthalmology Society 

Course: 517 

Tuesday 

Room: S505AB 

9:00 - 11:15 AM 



Synopsis: This course highlights the paradigms for management of pediatric 

cataracts. Adhering to these paradigms will enhance intraoperative performance 

and ensure a good technical and functional outcome. 


clinical pearls and tips for enhancing outcomes following pediatric cataract 

surgery. 

Senior Instructor(s): Abhay Raghukant Vasavada MBBS FRCS* 

Instructor(s): Rupal H Trivedi MBBS MS*, M Edward Wilson Jr MD*, Kanwal K 

Nischal MBBS*, Michael O’Keeffe MD, Deborah K VanderVeen MD, Bharti Kishore 

Nihalani Gangwani MD 

H Approach to Genetic Eye Diseases for the 

Comprehensive Ophthalmologist 

Course: 556 

Room: N427D 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: This course will focus on the comprehensive ophthalmologist’s role 

in the treatment of genetic eye diseases. The course will review the pertinent 

medical background, review the availability of diagnostic testing, including 

how to obtain them, and discuss nondirective counseling. Illustrative cases 

will be used to highlight pertinent aspects of the management of these patients. 

Objective: By the end of this course, participants will be able to understand (1) 

how to approach and evaluate a patient and family with a genetic disorder, (2) 

the principles of inheritance patterns, (3) where to find reliable information and 

laboratory diagnostics, including the eyeGENE network on genetic disorders, 

and (4) guidelines on genetic counseling. 

Senior Instructor(s): Johnny Tang MD 

Instructor(s): J Bronwyn Bateman MD, Wadih M Zein MD, Pamela C Sieving MA 

MS AHIP 

Overview of Utilization of Bevacizumab for ROP 

Course: 557 

Room: S103D 


Tuesday 

11:30 AM - 12:30 PM 


Synopsis: This course will emphasize the multiple uses of an anti-VEGF agent 

for ROP, specifically, bevacizumab (Avastin), identifying the risks and benefits 

of this therapeutic approach compared to confluent laser therapy. 

Objective: At the end of the course, participants will be expected to comprehend 

the pathogenesis of ROP as it relates to VEGF. They will understand the 

advantages of bevacizumab as monotherapy, the problem of delayed recurrence, 

and the special uses for bevacizumab: iris neovascularization, vitreous 

hemorrhage, following failed laser, and prior to vitrectomy. They will be aware 

of possible local and systemic complications. 

Senior Instructor(s): Helen Mintz-Hittner MD FACS 

Instructor(s): Michael Shapiro MD**, Mary Elizabeth Hartnett MD FACS* 

Oblique Muscle Surgery 

Course: 583 

Room: N135 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Planning and performing surgery on the superior and inferior oblique 

muscles is often more challenging than rectus muscle surgery. We will provide 

a case-based approach to preoperative and intraoperative assessment 

of oblique function, and we will present practical tips for performing successful 

oblique muscle surgery. Case presentations will range from the relatively 

straightforward to complicated reoperations. Specific topics to be covered will 

include intraoperative traction testing and surgical techniques for strengthening 

and weakening the inferior and superior oblique. Surgical indications for 

each technique will be described, and audience participation will be encouraged. 

100 





Objective: At the completion of this course, the attendee should have a greater 

understanding of and confidence in assessing oblique muscle dysfunction and 

performing surgery on the oblique muscles. 

Senior Instructor(s): Jonathan M Holmes MD* 

Instructor(s): David A Plager MD* 

ROP Screening and Treatment: What You Wanted 

to Know but Were Afraid to Ask (Intermediate/ 

Advanced) 

Course: 616 

Room: S104A 


Tuesday 

3:15 - 5:30 PM 


Synopsis: ROP can be a difficult and challenging disease to manage. This 

course is intended for established (intermediate/advanced) screeners/treaters 

already familiar with ROP management who would like to enhance their proficiency. 

This course will provide practical advice on how to safely and effectively 

screen and treat children, with an emphasis on clinical pearls designed 

to improve the approach to this condition. Topics will include updated findings 

of the Early Treatment of ROP study, the accurate diagnosis of plus disease, 

pitfalls in managing aggressive posterior ROP, the impact of oxygen on ROP, 

the appropriate time to refer for vitreoretinal surgery, medicolegal issues, 

the role of telemedicine and photodocumentation, and the use of anti-VEGF 

therapy. This will be followed by a presentation of challenging cases and how 

they were managed. 

Objective: At the conclusion of this course, the attendee will be better able 

to recognize children progressing to treatment-requiring ROP and to more effectively 

deal with the challenges of laser treatment. 

Senior Instructor(s): Thomas Lee MD* 

Instructor(s): Michael F Chiang MD*, William V Good MD, Kenneth W Wright 

MD*, G Baker Hubbard MD, R V Paul Chan MD, Anne M Menke RN PhD, Maria 

Ana Martinez-Castellanos MD 


ISRS Laser Refractive Surgery Course 



Course: 156 

Sunday 

Room: S103bc 

9:00 - 11:15 AM 



Synopsis: This course will start with the basics of how conventional and laser 

microkeratomes work and what one needs to know before performing LASIK 

and surface ablation. It will move on to cover tips, step by step, with presentations 

discussing the newest applications and developments in LASIK and surface 

ablation. The prevention and treatment of complications will be covered 

in detail. 

Objective: This course is designed to give participants the information and 

skills needed for LASIK and surface ablation, including patient selection, basic 

principles, postoperative care, and management of complications. 



Senior Instructor(s): Jason E Stahl MD 

Instructor(s): Richard L Lindstrom MD*, Jack T Holladay MD MSEE FACS* 

Understanding Small Aperture Corneal Implant 

Technology: From Indications to Outcomes 

Course: 189 

Room: S104b 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: Small aperture corneal inlays use the principle of small aperture 

optics to increase depth of field, improving near/intermediate vision without 

sacrificing distance vision. Indications, patient selection criteria, implant techniques 

and alignment, combination procedures, and patient outcomes will be 

presented. 

Objective: By the conclusion of this course, participants will be able to choose 

appropriate patients for small aperture corneal implants, have a basic understanding 

of the necessary surgical technique for inlay implantation, be aware 

of possible complications, and demonstrate knowledge of the patient outcomes 

that can be expected after the small aperture corneal inlay procedure. 

Senior Instructor(s): George O Waring MD* 

Instructor(s): Daniel S Durrie MD*, Gunther Grabner MD*, Minoru Tomita MD 

PhD*, John Allan Vukich MD* 

NEW Custom Ablation 2012: How to Start and Obtain 

the Best From Your Custom Ablation 

Course: 190 

Room: S105d 


Sunday 

11:30 AM - 12:30 PM 


Synopsis: Custom ablation (CA), either with surface ablation techniques or 

with LASIK, is part of the armamentarium of the refractive surgeon, but it remains 

controversial for extended use and may be hard to implement for the 

beginner. This course will discuss the principles of custom ablation, the use of 

aberrometers, the selection of patients who better benefit from CA, as well as 

the long-term evaluation of results. Special applications of CA, such as custom 

PTK, will also be discussed. 

Objective: At the end of the course the participants will be able to approach CA 

in an organized manner, and begin to improve their evaluation as well as their 

application of CA to refractive surgery patients. 

Senior Instructor(s): Paolo Vinciguerra MD* 

Instructor(s): Fabrizio I Camesasca MD*, Dan Z Reinstein MD*, Francesco Carones 

MD*, Damien Gatinel MD*, William B Trattler MD* 

H Advanced Corneal Topographic Analysis 



Course: 214 

Sunday 

Room: E352 

2:00 - 3:00 PM 



Synopsis: This course will discuss advanced topographic analysis in the patient 

evaluation process for the comprehensive clinician and refractive surgeon, focusing 

on understanding and recognizing normal and abnormal topographic 

patterns generated by multiple technologies, including standard Placido imaging, 

slitbeam-based imaging (Orbscan II), Scheimpflug imaging (Pentacam), 

and wavefront imaging. 

Objective: By the conclusion of this course, the participants will be able to (1) 

identify subtle abnormal topographic patterns that place patients at increased 

risk for postoperative complications, including ectasia, (2) differentiate truly 

abnormal preoperative topographies from artifactual images, and (3) effectively 

utilize topographic imaging techniques to demonstrate corneal pathology 

before keratorefractive refractive surgery. 

Senior Instructor(s): J Bradley Randleman MD 

Instructor(s): William J Dupps MD PhD* 





101



Update on Intrastromal Corneal Ring Segments 

Course: 215 

Room: N427bc 


Sunday 

2:00 - 3:00 PM 


Synopsis: Intrastromal corneal ring segments are more than just a solution for 

low myopia; they can also correct keratoconus, corneal ectasia, and high astigmatism. 

With the aid of femtosecond lasers, the surgical technique is easier 

to perform and the use of intracorneal rings is increasing. Nowadays, the principles 

of its use, the indications, the surgical technique, and the management 

of complications must be known by all ophthalmologists since it is becoming a 

frequently used technique for refractive and corneal specialists. 

Objective: By the conclusion of this course, attendees will be able to learn the 

principles, when to indicate the technique, and how to diagnose and solve 

complications in patients with intracorneal rings. They will be able to participate 

in a surgical lab and learn how to implant the intracorneal rings. 

Senior Instructor(s): Salvador Garcia-Delpech MD 

Instructor(s): Paulo Ferrara MD**, Joseph Colin MD*, Maria T Iradier MD PhD, 

Rafael I Barraquer Compte MD*, Manuel Diaz Llopis MD PhD, David Salom MD, 

Patricia Udaondo MD, Maria Garcia Pous MD 

Phakic IOLs 

Course: 247 

Room: N136 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will educate the participant on the use of phakic IOLs 

in refractive surgery. Topics of discussion will include patient selection and 

preoperative testing, IOL power calculations, postoperative care, complication 

management, surgical technique, and managing residual refractive error. Phakic 

IOLs currently available in the United States will be emphasized. 

Objective: At the course conclusion, the participant will understand indications 

for the use of phakic IOLs and key management aspects of phakic IOL 

candidates. 

Note: This is the lecture portion of a Skills Transfer lab. To enroll in the lab, see 

the Skills Transfer section. 

Senior Instructor(s): Sherman W Reeves MD MPH* 

Instructor(s): Elizabeth A Davis MD*, David R Hardten MD*, Stephen S Lane MD*, 

Jack T Holladay MD MSEE FACS*, Scott D Barnes MD*, Paul J Harton Jr MD* 

Refractive Lensectomy: Indications, Lenses, 

Formulas, Outcomes 

Course: 328 

Room: S103a 


Monday 

9:00 - 10:00 AM 


Synopsis: This course presents different approaches using refractive lensectomy 

as a refractive surgical procedure to achieve spectacle independence for 

far and near. The indications, contraindications, IOL calculation and selection 

(monofocal, multifocal, accommodative), and patient selection criteria for successful 

outcomes will be shown and discussed in a didactic format. 

Objective: At the conclusion of this course, the attendee will be able to define 

the best indications and most frequent contraindications of refractive lens 

exchange, identify the best IOL calculation method, know how to manage 

astigmatism, select the best choice for a multifocal IOL and the best cases for 

accommodative IOLs, and understand practical tips to achieve a high patient 

satisfaction rate with refractive lens exchange. 

Senior Instructor(s): Jorge L Alio MD PhD* 

Instructor(s): Warren E Hill MD*, Michael C Knorz MD*, Mark Packer MD*, Eric D 

Donnenfeld MD*, Andrzej Grzybowski MD* 

H A Step-by-Step Primer to Starting LASIK in 2012 



Course: 338 

Monday 

Room: N427bc 

9:00 - 11:15 AM 



Synopsis: LASIK has become the most commonly performed ophthalmic procedure 

in the world. The scientific basis for preoperative screening, surgical 

strategy, technology, and postoperative management of complications has 

progressed enormously in the last decade. This course will provide a solid 

overview of the principles underlying modern safe practice, as well as pearls 

of surgical technique to benefit the beginning LASIK surgeon. The technology 

overview will include wavefront sensing, excimer laser, microkeratome, femtosecond, 

and modern topographic technologies. The prevention and management 

of complications will be comprehensively covered. 

Objective: The attendee will acquire a broad understanding of the scientific 

principles underlying the various technologies involved in the practice of 

LASIK. The course will provide the foundations for patient selection, surgical 

planning, and operating technique, as well as a comprehensive overview of 

complication avoidance and management. 

Senior Instructor(s): Dan Z Reinstein MD* 

Instructor(s): Daniel S Durrie MD*, David R Hardten MD*, Jack T Holladay MD 

MSEE FACS*, Stephen G Slade MD FACS*, Gustavo E Tamayo MD* 

Presbyopia, the Corneal Approach: State of the Art 

Course: 374 

Room: N139 


Monday 

11:30 AM - 12:30 PM 


Synopsis: The course will discuss different corneal methods of correcting presbyopia, 

including Allegretto custom-Q, Visx presby-LASIK, Amaris PresbyMAX, 

Mel 80 laser blended vision, corneal inlays, and Femtec Intracor. Presbyopia 

and its adaptive optics will be demonstrated. 

Objective: Attendees will be able to design the best corneal treatment profile 

for each presbyopic patient according to age, error of refraction, and corneal 

measurements. 

Senior Instructor(s): Mounir A Khalifa MD* 

Instructor(s): Ronald R Krueger MD*, Gustavo E Tamayo MD*, Jorge L Alio MD 

PhD*, Dan Z Reinstein MD*, Tarek Abdel Wahab MD* 

Solving the High Myopia Problem With Phakic IOLs 

Course: 375 

Room: N427A 


Monday 

11:30 AM - 12:30 PM 


Synopsis: This course will present a review of state-of-the-art knowledge on 

anterior and posterior chamber phakic IOLs, with information on patient, eye, 

and IOL selection, surgical techniques, and management of intra- and postoperative 

complications. Special attention will be dedicated to diagnostic instruments 

for patient selection and follow-up. 

Objective: Participants will be able to assess phakic IOLs as a valuable tool in 

refractive surgery. Experience, imaging, and long-term follow-up will provide a 

safer approach to phakic IOLs. 


Instructor(s): Georges D Baikoff MD*, Dimitri Dementiev MD**, Luca Gualdi, 

David R Hardten MD*, Michael C Knorz MD*, Stephen G Slade MD FACS*, Paolo 

Vinciguerra MD* 

102 





Danger Zone: Refractive Surgery Nightmares and 

Worst-Case Scenarios: A Video-Based Course 



Course: 402 

Monday 

Room: S505AB 

2:00 - 4:15 PM 



Synopsis: Refractive surgery has its own danger zones. Various refractive surgery 

techniques, from surface ablation to LASIK and phakic IOLs, can have disasters 

that have to be handled with care. In this course, collagen crosslinking 

for ectasia and other conditions will be taught. Visco cannula-assisted reinversion 

of an implantable contact lens will be shown. Topics like flap complications, 

decentered ablations, and iatrogenic ectasia will be explained in detail. 

Attendees will be taught how to manage eyes with previous LASIK flaps and 

how to address problems with Kerarings and other intrastromal ring segments. 

Femtosecond laser and its problems will be taught through videos. Suction 

loss, stuck microkeratomes, and previous radial keratotomy will all be shown 

in video format. Finally, miscellaneous topics like conductive keratoplasty and 

its nightmares will also be covered. 

Objective: At the conclusion of this course, the attendee will know how to 

manage refractive surgery catastrophes, perform crosslinking, and treat iatrogenic 

keratectasia, flap complications, and femtosecond problems. This course 

will help the refractive surgeon sleep peacefully. 


Instructor(s): Ronald R Krueger MD*, Scott M MacRae MD*, Athiya Agarwal 

MD*, Jorge L Alio MD PhD*, Francesco Carones MD*, Alaa M Eldanasoury MD*, 

Marguerite B McDonald MD*, Gustavo E Tamayo MD*, Stephen G Slade MD 

FACS*, Sonia H Yoo MD*, Michael C Knorz MD*, A John Kanellopoulos MD*, 

Soosan Jacob FRCS, Theo Seiler MD PhD* 

The Surgical Correction of Astigmatism 

Course: 431 

Room: N135 


Monday 

3:15 - 5:30 PM 


Synopsis: This course will supply participants with the necessary principles, 

theories, and practical instruction in the various forms of astigmatic keratotomy 

(PRI, limbal relaxing incisions) and nonincisional astigmatism correction 

(LASIK, toric IOLs). 

Objective: Attendees will gain an understanding of techniques to evaluate and 

manage astigmatism as a primary procedure and as an adjunct to lens surgery. 



Senior Instructor(s): Hamza N Khan MD FACS* 

Instructor(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS*, Kurt A Buzard 

MD, Miles H Friedlander MD, Ronald N Gaster MD FACS*, David H Haight MD, 

Jack T Holladay MD MSEE FACS*, Douglas D Koch MD*, R Bruce Wallace MD* 

NEW Corneoplastique: The Art of Premium LASIK 

and Cataract Surgery 

Course: 508 

Room: S104A 


Tuesday 

9:00 - 10:00 AM 


Synopsis: To discuss the application of Corneoplastique as an art of refractive 

surgery using the full spectrum of lens- and laser-based techniques, including 

combinations to manipulate the optics of every eye for resultant emmetropic 

vision. 

Objective: At the end of this course, the attendees will be able to identify the 

most well-suited refractive laser, multifocal lens, and enhancing techniques 

for every premium surgery patient. 

Senior Instructor(s): Arun C Gulani MD 

Instructor(s): Amar Agarwal MD*, Uday Devgan MD*, Iqbal K Ahmed MD*, Jorge 

L Alio MD PhD* 

Corneal Topographic Analysis and Anterior Segment 

Imaging: Pearls for Your Clinical Practice 

Course: 543 

Room: S104a 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: This course will present a systematic approach to the interpretation 

of corneal topographies and anterior segment imaging studies using didactic 

instruction combined with numerous clinical examples. The course will 

highlight several imaging systems and technologies, including Placido-based 

topography, single and dual Scheimpflug imaging, OCT, and scanning slit beam 

imaging. 


different technologies used to image the anterior segment, be able to use 

the different maps and displays available on multiple devices, know the advantages 

and disadvantages of the most common topographers and imaging 

devices, and use the study results to manage common clinical situations in 

corneal, cataract, and refractive surgery. 

Senior Instructor(s): Mitchell P Weikert MD* 

Instructor(s): Douglas D Koch MD*, Thomas Kohnen MD*, Cynthia Roberts PhD*, 

Surendra Basti MBBS*, William J Dupps MD PhD* 

NEW FemtoLASER: Diagnosis and Management of 

Intraoperative and Postoperative Complications With 

the Use of a Femtosecond Laser for LASIK Surgery 

Course: 590 

Room: S101ab 


Tuesday 

2:00 - 3:00 PM 


Synopsis: We will discuss the surgical complications that occur with femtosecond 

laser flap creation: data entry errors, centration difficulties, suction loss, 

interface entry issues, vertical gas breakthrough, and flap tears. Also covered 

will be the diagnosis and management of postoperative complications: flap 

slippage, interface inflammation, how to distinguish these from diffuse lamellar 

keratitis, interface haze, transient light sensitivity, rainbow glare, etc. This 

course is recommended for those surgeons who have recently purchased or 

already use a femtosecond laser. 

Objective: This course will educate users of the potential risks associated with 

femtoLASIK flap creation. 

Senior Instructor(s): Christopher L Blanton MD* 

Instructor(s): Perry S Binder MD*, Jonathan H Talamo MD*, Kenneth A Greenberg 

MD**, Ronald R Krueger MD*, Steven E Wilson MD*, Dan B Tran MD* 

Modern Management of the Irregular Cornea 

Course: 591 

Room: N427a 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This clinical, experience-based course describes various diagnostic 

modalities of the highly aberrated cornea and its correlation with symptomatology, 

and how to create a plan for a treatment profile with different excimer 

laser platforms using topography, tomography, corneal wavefront- or ocular 

wavefront-guided techniques. Intracorneal ring segment (ICRS) implantation, 

corneal crosslinking , (CXL) and different techniques of keratoplasty will also 

be discussed. 





103



Objective: Attendees will be able to manage the irregular cornea using different 

diagnostic modalities and therapeutic techniques, including different 

excimer laser platforms, ICRS, CXL and lamellar corneal surgery. 

Senior Instructor(s): Mohamed Shafik Shaheen MD PhD 

Instructor(s): Sonia H Yoo MD*, Jose L Guell MD PhD*, Renato Ambrosio Jr MD*, 

Mounir A Khalifa MD*, Dan Z Reinstein MD* 

Refractive Laser Surgery (Surface and LASIK) 

Following Previous Surgery: A Practical Approach to 

Indications, Diagnostic and Treatment Techniques, 

and Possible Complications and Their Management 

Course: 600 

Room: S105bc 


Tuesday 

2:00 - 4:15 PM 


Synopsis: This course will present a didactic approach to laser refractive surgery 

(surface and LASIK) in eyes following previous eye surgery. This growing 

subgroup of patients offers an entirely different challenge than do new refractive 

procedures. This group includes eyes following cataract surgery (especially 

the growing number of post-multifocal and accommodating IOL cases), 

penetrating keratoplasty, retina surgery, glaucoma surgery, radial and arcuate 

keratotomy, PRK, LASEK, epi-LASIK, phakic IOL implantation, and finally LASIK 

reoperations with and without a customized approach. The preop assessment 

and measurements, indications, methodology, and technique of alternative 

treatments, as well as clinical experience pearls with challenges and complications, 

will be presented. 

Objective: The participants will share our experience and pearls of indications, 

patient selection, surgical technique, and complication management for safe 

and effective results based on our clinical work in the United States and in 

Europe. 

Senior Instructor(s): A John Kanellopoulos MD* 

Instructor(s): Gregory Pamel MD**, Eric D Donnenfeld MD*, Alaa M Eldanasoury 

MD* 

NEW FemtoLASER: Current Anterior Segment 

Applications for a Femtosecond Laser 

Course: 606 

Room: S101ab 


Tuesday 

3:15 - 4:15 PM 


Synopsis: This course is designated for surgeons who use a femtosecond laser 

primarily for LASIK surgery, but who wish to expand its surgical applications. 

We will discuss indications and risks of full, deep, and partial corneal transplant 

techniques, intracorneal rings for keratoconus and postLASIK ectasia, 

lamellar corneal surgery, and penetrating arcuate incisions for astigmatism 

correction. This course is recommended for those surgeons who all ready use 

a femtosecond laser. 

Objective: This course will present many of the on-label applications of femtosecond 

lasers. 

Senior Instructor(s): Perry S Binder MD* 

Instructor(s): Kenneth A Greenberg MD**, Sonia H Yoo MD*, Yaron S Rabinowitz 

MD, Steven C Schallhorn MD*, Christopher L Blanton MD* 


Macular OCT: Mastering the Basics 

Course: 157 

Room: S102abc 


Sunday 

9:00 - 11:15 AM 


Synopsis: This course provides basic instruction on accurate interpretation of 

OCTs of common macular pathologies, as well as instruction on how to identify 

and prevent common OCT artifacts. The course also provides a clinically meaningful 

review of indications and limitations of OCT in the diagnosis and management 

of common macular diseases such as AMD, diabetic maculopathy, 

epiretinal membrane, macular holes, vitreomacular traction, central serous 

retinopathy, vascular occlusions, and postoperative cystoid macular edema. 

Objective: Upon completion of this course, participants should be able to (1) 

accurately interpret OCTs of common macular pathologies, (2) describe the indications 

for and limitations of OCT in the diagnosis and management of macular 

diseases, and (3) identify, interpret, and correct common OCT artifacts. 



Senior Instructor(s): John S Pollack MD* 

Instructor(s): Jay S Duker MD*, Cynthia A Toth MD*, Anat Loewenstein MD*, 

Dante Pieramici MD* 

H Advanced Vitreoretinal Surgical Techniques and 

Instrumentation 

Course: 177 

Room: E350 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: This interactive, case-based course will highlight the latest developments 

in vitreoretinal surgery, with emphasis on sutureless vitrectomy. The 

panel will make extensive use of videos to discuss the most advanced approaches 

to vitreoretinal surgery, including the advantages of newer instrumentation. 

Objective: At the end of this course, attendees will be familiar with the latest 

advances in surgical instrumentation and techniques used for the treatment of 

macular diseases, retinal detachment, ocular trauma, retained lens material, 

and diabetic retinopathy. 

Senior Instructor(s): Sunir J Garg MD* 

Instructor(s): Julia A Haller MD*, Tarek S Hassan MD*, Allen C Ho MD*, Mark 

W Johnson MD*, Carl D Regillo MD FACS*, George A Williams MD*, Steven D 

Schwartz MD* 

Principles of Pediatric Retinal Surgery in Pediatric 

Retinal Diseases Other Than ROP 

Course: 178 

Room: S103A 


Sunday 

10:15 AM - 12:30 PM 


Synopsis: This course presents the management of pediatric retinal diseases 

other than retinopathy of prematurity, which are seen frequently in practices 

that are focused on pediatric vitreoretinal surgery. 

Objective: This course will deal with the surgical management of pediatric vitreous 

hemorrhage, Coats disease, familial exudative vitreoretinopathy, persistent 

fetal vasculature syndrome, Norrie disease, and congenital retinoschisis. 

It includes timing of intervention as well as surgical intervention, utilization of 

genetic testing, and analysis of angiographic data to aid in the management 

and prevention of retinal detachment. Also covered will be the management 

104 





of retinal detachment in these diseases that are often accompanied by an 

exudative response. The use of pharmacologic therapy as well as surgical 

techniques will be discussed. In addition, instrumentation and timing of intervention 

will be emphasized. 

Senior Instructor(s): Michael T Trese MD* 

Instructor(s): Philip J Ferrone MD*, Antonio Capone Jr MD*, Kimberly A Drenser 

MD PhD* 

NEW APAO Eye Genetics for Ophthalmologists 


Asia-Pacific Society of Eye Genetics 

Course: 179 

Sunday 

Room: N137 

10:15 AM - 12:30 PM 



Synopsis: Genetics is rapidly growing in research, diagnostics, and practice 

in medicine. Human genetic diseases are scripted and packed in our genome 

of 23 pairs of chromosomes, being classified into chromosomal, single gene 

disorders, mitochondrial diseases, and complex (multifactorial) disorders. In 

complex disorders, genes interface with lifestyle behavior to clinically manifest 

diseases like diabetic retinopathy. Diseases like retinoblastoma could be 

influenced by factors other than genetic mechanisms like methylation, a phenomenon 

called epigenetics. Gene therapy in clinical trials has reversed vision 

in patients with Leber congenital amaurosis. Gene therapy trials are ongoing 

in X-linked retinoschisis, Stargardt disease, and AMD. 

Objective: This course provides a primer for young clinical ophthalmologists, 

as it will cover a broad spectrum of the science of genetics in ophthalmology, 

starting from the basics. It will also touch upon recent advances in the molecular 

basis of ophthalmic diseases, including disease mechanism and gene 

therapy. It should also kindle the interest of clinicians thinking of venturing 

into research. At the conclusion of this course, the attendee will be able to 

take home an understanding of the definition of human genetics, the advances 

currently made, and its progression in alleviating human diseases, particularly 

blindness. 

Senior Instructor(s): Calvin C Pang PhD** 

Instructor(s): Lijia Chen MD, David Ta Li Liu MBChB, Haoyu Chen MD 

Medical and Surgical Therapy of Cystoid Macular 

Edema in Uveitis 

Course: 216 

Room: N427D 


Sunday 

2:00 - 3:00 PM 


Synopsis: The major cause of visual loss in uveitis, regardless of etiology, is 

cystoid macular edema (CME). In most patients, CME will resolve with control 

of inflammation through corticosteroid therapy administered topically, periocularly, 

intravitreally, and/or systemically. In patients who are intolerant or 

nonresponsive to corticosteroids, the use of corticosteroid-sparing agents (eg, 

cytotoxic or biologic drugs) may be useful. However, a subset of patients will 

have decreased vision secondary to CME regardless of the medical regimen 

employed. The role of an adherent posterior hyaloid over the macula in the 

persistence of CME in these cases has only recently been appreciated. In this 

course, the importance of OCT imaging in the diagnosis of vitreomacular traction 

and the therapeutic benefit of surgical removal of the posterior hyaloid in 

persistent CME associated with uveitis will be presented. 

Objective: At the conclusion of this course, the attendee will be able to develop 

a stepwise approach to the management of chronic CME in uveitis, including 

both medical and surgical intervention. 

Senior Instructor(s): Henry J Kaplan MD* 

Instructor(s): Tongalp H Tezel MD, Shlomit Schaal MD 

NEW Treatment of Retinal Detachment With Special 

Emphasis on Buckle Surgery 

Course: 217 

Room: S103D 


Sunday 

2:00 - 3:00 PM 


Synopsis: This course will discuss indications for vitreoretinal techniques in 

retinal detachment surgery, with special emphasis on buckle surgery. Tips, 

tricks, instrumentation, limitations, and pitfalls of buckle surgery in retinal 

detachment will be provided. 

Objective: At the conclusion of the course, the attendee will be familiar with 

the various aspects of timing in retinal detachment surgery, will know the indications 

and limitations of buckle surgery, will be able to apply the appropriate 

buckling techniques and select the suitable implants, and will be updated in 

postoperative management and indications for alternative vitreoretinal surgical 

options. 

Senior Instructor(s): Nikolaos E Bechrakis MD* 

Instructor(s): Heinrich Heimann MD* 

How to Interpret Fundus Fluorescein Angiography 

and Autofluorescence 

Course: 225 

Room: E350 


Sunday 

2:00 - 4:15 PM 


Synopsis: This course teaches how to interpret fundus fluorescein angiography 

(FA) and fundus autofluorescence images (AF). A step-by-step guide will be 

used, supported by (1) targeted review of the retinochoroidal anatomy, (2) illustrations 

to acquire a “visual”understanding of fluorescence patterns, and (3) 

numerous FA and AF images correlating these patterns with fundus findings. 

The majority of vascular, degenerative, inflammatory, hereditary, and tumoral 

chorioretinal pathologies will be reviewed, and the audience will be taught 

how to recognize these diseases based on the imagery. 

Objective: The attendee will be empowered with the know-how to recognize 

and interpret the angiographic and autofluorescent features of the majority of 

chorioretinal pathologies and to recognize these disease entities based on the 

angiographic and autofluorescence findings. 

Senior Instructor(s): Sawsan R Nowilaty MD 

Instructor(s): Emad Bishara Abboud MD, Hardeep S Dhindsa MD, Albert T Vitale 

MD* 

Diabetic Macular Edema: 2012 Update on 

Management 

Course: 248 

Room: S106b 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will summarize the molecular mechanisms, imaging 

studies, control of systemic factors, laser therapies, new pharmacotherapies, 

and surgical strategies in the management of diabetic macular edema (DME). 

Major clinical trials (Diabetes Control and Complications Trial, Epidemiology 

of Diabetes Interventions and Complications, UK Prospective Diabetes Study, 

Action to Control Cardiovascular Risk in Diabetes, Early Treatment Diabetic 

Retinopathy Study, Diabetic Retinopathy Study, and Diabetic Retinopathy 

Clinical Research) will be reviewed. There will be case presentations/discussion 

by a panel. 





105




recognize the molecular mechanisms of DME, (2) review major clinical trials on 

DME, (3) understand the role of imaging studies, and (4) manage DME patients 

based on a combination approach of control of systemic factors, laser therapy, 

pharmacotherapy (anti-VEGF and steroids), and surgical therapies. 

Senior Instructor(s): Arup Das MD PhD* 

Instructor(s): Thomas R Friberg MD*, Robert N Frank MD, Jay S Duker MD*, Lloyd 

P Aiello MD PhD*, Michael S Ip MD*, George A Williams MD* 

H Diagnostic Ophthalmic Ultrasonography 

Course: 249 

Room: N427a 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will present a slide and video demonstration of diagnostic 

ophthalmic ultrasonographic techniques. Several case presentations will 

be included to highlight the evaluation, interpretation, and differentiation of a 

wide variety of ophthalmic disorders. Ultrasonographic findings will be correlated 

with fundus photography, OCT, computed tomography, MRI, indocyanine 

green, fluorescein angiography, and histopathology. 

Objective: This course will review techniques of diagnostic ophthalmic ultrasonography, 

including B-scan, diagnostic A-scan, and ultrasound biomicroscopy. 

The course will highlight the interpretation and diagnostic features of ultrasonographic 

images using well-illustrated cases. Correlation with ancillary 

diagnostic tests will also be presented. 

Senior Instructor(s): Brandy C Hayden BS 

Instructor(s): Arun D Singh MD 

Understanding Macular Disease Through 

Clinicopathologic Correlation 

Course: 250 

Room: N135 


Sunday 

3:15 - 5:30 PM 


Synopsis: This course will correlate color fundus photography (FP), fluorescein 

angiography (FA), optical coherence tomography (OCT), and fundus autofluorescence 

(AF) with the histopathology of macular disease. Various diseases 

will be presented, including AMD, diabetic retinopathy and other retinal vascular 

diseases, hereditary retinal and macular dystrophies, and toxic maculopathy, 

and each will be extensively illustrated with the aforementioned imaging 

systems and further elucidated with the correlative histopathology. 

Objective: At the conclusion of the course, the participants will be able to identify 

the imaging and correlative histopathological characteristics of the normal 

and the diseased macula. Participants will be able to recognize and describe 

the various imaging characteristics of macular diseases such as AMD, diabetic 

retinopathy, and macular dystrophy and will be able to correlate the histopathological 

features of these diseases, which will enhance their understanding 

of the pathophysiology and the rationale for investigation and treatment 

of macular disease. 

Senior Instructor(s): David Sarraf MD* 

Instructor(s): Sander Dubovy MD, Deepak Paul Edward MD, Sandeep Grover MD*, 

Wico W Lai MD FACS* 

NEW APAO Management of Vitreoretinal Diseases in 

Pathologic Myopia 

Sponsored by the Asia-Pacific Academy of Ophthalmology and the Asia- 

Pacific Vitreo-Retina Society 

Course: 251 

Sunday 

Room: S104b 

3:15 - 5:30 PM 



Synopsis: This course will cover the epidemiology, diagnosis, and treatments 

of vitreoretinal diseases related with pathological myopia, including myopic 

foveoschisis, retinal detachment secondary to macular hole, and myopic 

choroidal neovascular membrane. Recommendations and techniques will be 

provided using slide and video presentation based on clinical data and the 

experience of the instructors. Interactive discussion between instructors and 

audiences will be encouraged. 

Objective: At the conclusion of the course, the attendee will be expected to 

have an understanding of the current concepts on pathogenesis and the management 

of various pathological conditions associated with high myopia. 

Senior Instructor(s): Masahito Ohji MD* 

Instructor(s): Tien Yin Wong MBBS*, Chi-Chun Lai MD*, Yasushi Ikuno MD, Xiaoxin 

Li MD*, Won Ki Lee MD*, Timothy Y Lai MBBS*, Andrew A Chang MBBS 

Controversies in the Management of Open-Globe 

Injuries Involving the Posterior Segment 

Course: 329 

Room: S103d 


Monday 

9:00 - 10:00 AM 


Synopsis: Controversies in the management of open-globe injuries involving 

the posterior segment will be presented and thoroughly discussed. An overview 

of the extent of the problem will be provided, followed by a detailed 

breakdown of the specific controversies for which controlled clinical data 

regarding management are incomplete or lacking. These areas include the 

timing of vitrectomy, use and route of administration for prophylactic antibiotics, 

use of prophylactic cryotherapy and scleral buckle, management of 

intraocular foreign bodies, use of silicone oil, concurrent placement of primary 

IOLs, management of hypotony, and surgery on NLP eyes. Recommendations 

for treatment will be provided, based on clinical data and the experience of 

the presenters. Several short videos will be presented, documenting select 

procedures and techniques. 

Objective: This course is designed to provide an update on the most appropriate 

clinical management of controversial issues in the setting of posterior segment 

open-globe injuries through the use of slide presentations, videotapes, 

and interactive panel discussions. A comprehensive handout will be provided. 

Senior Instructor(s): William F Mieler MD* 

Instructor(s): Ferenc P Kuhn MD PhD, Robert A Mittra MD 

Evaluation of Early-Onset Hereditary Retinal 

Degeneration in Infants and Children 

Course: 330 

Room: N137 


Monday 

9:00 - 10:00 AM 


Synopsis: Infants and children with inherited retinal degenerations can present 

with typical retinal findings. However, sometimes they may present with 

normal or near normal retinal appearance. Although retinal function testing is 

sometimes required for a definitive diagnosis, the diagnosis is often suspected 

or confirmed by ocular history, family history, and clinical examination. This 

course will provide a step-by-step approach to the diagnosis of early-onset 

retinal degenerations, with discussions of when to utilize electrophysiological 

testing, OCT, and genetic testing. This course will also discuss resources available 

at various levels for parents of affected children and ophthalmologists. 

106 





Objective: At the conclusion of the course, the pediatric and comprehensive 

ophthalmologist will be able to better diagnose and differentiate among the 

early-onset inherited retinal degenerations. 

Senior Instructor(s): Sandeep Grover MD* 

Instructor(s): Byron L Lam MD*, Craig A McKeown MD 

NEW APAO Diagnosis and Treatment of Central 

Serous Chorioretinopathy 


Course: 339 

Monday 

Room: S104A 

9:00 - 11:15 AM 



Synopsis: This course will cover the epidemiology, risk factors, differential 

diagnoses, natural history, various diagnostic imaging investigations such as 

fluorescein angiography, indocyanine green angiography, fundus autofluorescence, 

optical coherence tomography, and different treatment options for CSC. 

It aims to provide an overview on the diagnosis and treatment of CSC through 

review of the currently available literature and illustrative case examples. 

Objective: Participants will understand the epidemiology and risk factors of 

CSC, differentiating CSC from other retinal conditions mimicking CSC, with 

the applications of various diagnostic tool, as well as the current available 

treatment options for CSC. 

Senior Instructor(s): Timothy Y Lai MBBS* 

Instructor(s): Gemmy Chui Ming Cheung MBBCHIR FRCOPHTH, Andrew Chungtin 

Fok MBChB, Kenneth C S Fong MD*, Won Ki Lee MD*, Fiona O Luk MBChB, 

Tomohiro Iida MD*, Seung Young Yu MD 

OCT: Interpretation and Clinical Applications 

Course: 544 

Room: S102Abc 


Monday 

9:00 - 11:15 AM 


Synopsis: Through a series of lectures and case presentations, participants 

will become familiar with the use of OCT for a large variety of posterior pole 

disorders/pathologies. 

Objective: At the conclusion of the course, the attendee will be able to interpret 

OCT images for the diagnosis and/or management of patients with 

posterior pole disorders. 

Senior Instructor(s): Michael S Ip MD* 

Instructor(s): Carmen A Puliafito MD MBA*, Richard F Spaide MD*, Caroline R 

Baumal MD, Joel S Schuman MD*, Cynthia A Toth MD* 

Diabetes 2012: Course on Diabetic Retinopathy 

Course: 360 

Room: S105A 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will present a rational approach to the diagnosis and 

treatment of diabetic retinopathy based on first understanding results and 

recommendations of the Diabetic Retinopathy Study and Early Treatment Diabetic 

Retinopathy Study and subsequently reviewing DRCR.net publications 

that may modify some of those recommendations. Case presentations to a 

panel of experts will illustrate the role of OCT and pharmacotherapy relative 

to laser therapy. 

Objective: By the conclusion of this course, participants will be able to understand 

(1) the clinical indications for laser treatment of diabetic retinopathy and 

(2) the role of pharmacotherapy and OCT in current management of diabetic 

retinopathy. 



Senior Instructor(s): Keye Luc Wong MD* 

Instructor(s): Abdhish R Bhavsar MD*, Alexander J Brucker MD*, Emily Y Chew 

MD, Matthew D Davis MD, Harry W Flynn MD*, Arthur D Fu MD*, Justin L 

Gottlieb MD, Sam Edward Mansour MD* 

NEW Endoscopic-Assisted Ophthalmic Surgery: 

Anterior and Posterior Segment Techniques 

Course: 361 

Room: S106A 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will introduce the concept of endoscopic-assisted ophthalmic 

surgery and will showcase presentations with surgical videos of the 

various procedures that can be accomplished via this technique. These include 

cataract and IOL, glaucoma, anterior and posterior segment trauma, and retinal 

procedures (including retinal detachment in retinopathy of prematurity, familial 

exudative vitreoretinopathy and persistent fetal vasculature syndrome). 

The presenters are experienced anterior and posterior segment surgeons familiar 

with these techniques. 

Objective: To educate anterior and posterior segment surgeons on how intraocular 

endoscopy can assist them in complex surgical procedures. 

Senior Instructor(s): S Chien Wong MBBS FRCS 

Instructor(s): Brian A Francis MD*, Robert J Noecker MD*, Thomas Lee MD* 

Management of High-Risk ROP in the 21st Century: 

Thermal-Destructive vs. Pharmacologic Treatment 

Course: 362 

Room: S403B 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will describe the identification of high-risk ROP eyes and 

will present the rationale for both thermal and pharmacologic treatment. 

Objective: By the conclusion of this course, attendees will be better able to 

(1) identify aggressive posterior ROP, (2) distinguish typical stage 3 ROP from 

flat stage 3 ROP, (3) understand the rationale for both thermal (laser) and pharmacologic 

(anti-VEGF) treatment, (4) be familiar with the technique of current 

thermal laser treatment for posterior retinal disease, specifically dealing with 

flat neovascularization, and (5) be familiar with the technique of off-label pharmacologic 

management using available FDA-approved anti-VEGF drugs. 

Senior Instructor(s): Michael T Trese MD* 

Instructor(s): Antonio Capone Jr MD*, Kimberly A Drenser MD PhD*, Lois E H 

Smith MD PhD** 

Ocular Ultrasound 

Course: 363 

Room: S105D 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will cover basic principles of standardized ocular echography, 

including ultrasound instrumentation utilizing A- and B-scan, color Doppler, 

and ultrasound biomicroscopy. The topics will include basic principles 

of echography, vitreoretinal disease, optic disc pathology, intraocular tumors, 

ocular trauma, and anterior segment. 





107



Objective: At the conclusion of the course, the attendee will be expected to 

have an understanding of basic echographic exam techniques and to know the 

indications for the performance of ultrasound in various pathologic conditions. 

Senior Instructor(s): Roger P Harrie MD 

Instructor(s): Ronald L Green MD 

H Retinoblastoma 2012: They Live and See! 

Course: 364 

Room: N136 


Monday 

10:15 AM - 12:30 PM 


Synopsis: Recent advances in the diagnosis and management of retinoblastoma 

have significantly contributed to improved success in patient survival, eye 

salvage, and optimal vision salvage. The new systematic staging and grouping 

systems are now clinically validated and well accepted. The wide-field 

digital retinal camera has helped standardize documentation and accurate 

comparative assessment on follow-up visits. Modern management strategies 

such as transpupillary thermotherapy, plaque brachytherapy, chemoreduction, 

and periocular chemotherapy have been effective in improving eye and vision 

salvage. Selective intra-arterial chemotherapy has shown promise and 

is an exciting new development. Minimal manipulation enucleation has been 

further optimized to enable harvesting a long optic nerve stump and provide 

excellent cosmetic outcome. Adjuvant therapy in children with histopathologic 

high-risk characteristics identified following enucleation has reduced the risk 

of systemic metastasis. A multimodal protocol has been effective in salvaging 

patients with orbital retinoblastoma. Judicious use of intensity-modulated 

radiotherapy has helped salvage difficult situations and with minimal complications. 

Genetic studies now help in prenatal diagnosis and screening of 

siblings. The course aims to highlight practical aspects in the current standard 

of care for retinoblastoma and logically analyze recent developments. 

Objective: This course is designed to enable the participant to understand and 

incorporate into practice recent developments in the diagnosis and management 

of retinoblastoma. 

Senior Instructor(s): Santosh G Honavar MD 

Instructor(s): Ralph Eagle MD*, Brenda L Gallie MD*, Ashwin C Mallipatna MBBS, 

Carol L Shields MD, Jerry A Shields MD, Arun D Singh MD, Mohammad Javed Ali 

MD 

State-of-the-Art Techniques and Technologies for 

Microincision Vitrectomy Surgery to Treat Complex 

Vitreoretinal Diseases 

Course: 365 

Room: S105bc 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This interactive course will highlight state-of-the-art surgical techniques 

and technologies used in 23-, 25-, and 27-gauge sutureless vitrectomy 

to treat challenging vitreoretinal pathologies, such as advanced retinal detachment, 

proliferative vitreoretinopathy, proliferative diabetic retinopathy, 

subretinal hemorrhage, ocular trauma, and uveitis-related vitreoretinal complications. 

The instructors will make extensive use of videos to engage the 

attendees in the discussion of the most advanced techniques, newer instrumentation, 

and surgical adjuncts to facilitate safe and efficient approaches 

with minimizing surgical complications. 

Objective: At the end of this course, the attendees will not only be familiar 

with state-of-the-art microincision vitrectomy surgery but will also get a 

glimpse of future technological advances. 

Senior Instructor(s): Yusuke Oshima MD* 

Instructor(s): Pravin U Dugel MD*, Chi-Chun Lai MD*, Manish Nagpal MD*, Maria 

H Berrocal MD*, Carl D Regillo MD FACS*, George A Williams MD* 

Systemic Therapeutic Agents and Retinal Toxicity 

Course: 366 

Room: S103d 


Monday 

10:15 AM - 12:30 PM 


Synopsis: This course will provide a thorough review of systemic (and select 

topical/intravitreal) medications that are capable of causing various patterns 

of retinal toxicity. Examples of all of these specific types and patterns of toxicity 

will be presented, including disruption of the retinal pigment epithelium, 

retinal vascular occlusion, cystoid macular edema / retinal edema, crystalline 

deposition, uveitis, miscellaneous, and subjective visual symptoms. The 

mechanism of action, when known, will be discussed. Numerous examples 

of all conditions will be shown, and time will be allotted for questions and 

answers. A comprehensive, thoroughly referenced handout, complete with a 

variety of images, will be provided to all attendees. 

Objective: At the conclusion of the course, the attendee will be able to (1) recognize 

the various patterns of retinal toxicity induced by a variety of systemic, 

topical, and intravitreal medications, (2) recognize which specific medications 

are capable of causing subjective visual symptoms, and (3) better understand 

the situations and conditions in which retinal toxicity is most likely to occur. 


Instructor(s): George A Williams MD*, David F Williams MD*, Scott R Sneed MD 

Engineering and Physics Principles: A Primer for the 

Vitreoretinal Surgeon 

Course: 398 

Room: S102abc 


Monday 

2:00 - 3:00 PM 


Synopsis: A firm grasp of basic engineering and physics principles is necessary 

to develop solid ophthalmic surgical skills. This is especially true of vitreoretinal 

surgery and is independent of the specific surgical equipment being 

used. This course will introduce a practical, sensible, and interactive way to 

understand the basic physical principles at play in vitrectomy surgery, as well 

as why and how these principles can be leveraged to benefit the patient in 

the day-to-day practice of vitreoretinal surgery. Specific topics may include 

Ohm’s law, hydraulic capacitance, hydraulic inductance, vacuum vs. pressure, 

Laplace’s law, Bernoulli’s principle, Poiseuille’s law, pressure-driven systems 

(Venturi), flow-driven systems (peristaltic), viscosity, duty cycle, and Reynold’s 

number (laminar vs. turbulent flow). These intimidating-sounding concepts are 

really quite intuitive, and they can be easily applied for the benefit of the retinal 

patient. 

Objective: The participants will learn the basic engineering principles outlined 

above and how they relate to the practical aspects of safe and efficient vitreoretinal 

surgery. 

Senior Instructor(s): Christopher D Riemann MD* 

Instructor(s): Kirk H Packo MD* 

NEW Epiretinal Membranes: Etiologies, Perioperative 

Management, Surgical Techniques, and Case 

Discussions 

Course: 399 

Room: S102d 


Monday 

2:00 - 3:00 PM 


Synopsis: Epiretinal membranes (ERMs) are a common disorder affecting the 

aging eye. This course is organized into three presentations on the etiologies, 

perioperative management, and surgical techniques for ERMs: (1) etiologies 

of ERMs (eg, vitreous traction, posterior hyaloid remnants and internal limiting 

membrane rips), (2) the indications for surgery including functional impairments, 

progression, and anatomical damage to the retina, the pre-, intra-, 

and postoperative management concerns, including avoiding operating on 

108 





clinically insignificant ERMs and management of cataract, vitreous, peripheral 

retina, and recognition of specific problems that put patients at risk for 

less optimal outcomes, and (3) optimal surgical approaches and avoidance of 

complications. This will be followed by a question-and-answer session and 

case presentations. 

Objective: At the conclusion of this course, the attendee will know the etiologies 

and management implications of different types of ERMs, understand 

how to recognize and surgically manage the different symptoms caused by 

ERMs, and gain insight into surgical approaches to improve visual outcomes 

and reduce complications. 

Senior Instructor(s): Albert O Edwards MD PhD 

Instructor(s): Colin McCannel MD*, Mark W Johnson MD* 

23-Gauge Vitrectomy: What, When, and How? 

Course: 432 

Room: S102abc 


Monday 

3:15 - 5:30 PM 


Synopsis: This course will highlight the recent advances in small-incision vitrectomy 

surgery, with an emphasis on 23-gauge surgery. The specific technique 

(wound construction, entry, and exit) will be presented in a didactic and 

hands-on format. Tips for transitioning from 20- and 25-gauge surgery will be 

discussed. The experience of the faculty members will also be discussed, including 

new instrumentation and difficult cases, such as silicone oil. Videos 

demonstrating these principles will be shown during the lecture part of the 

course. One- and two-step systems will be on display to show differences in 

each technique. . 

Objective: This course will allow one to be familiar and comfortable with instrumentation 

for 23-gauge surgery. 



Senior Instructor(s): Gaurav K Shah MD* 

Instructor(s): Richard F Spaide MD*, Keith A Warren MD*, Jeffrey S Heier MD*, 

Richard G Lane MD, Kevin J Blinder MD*, Asheesh Tewari MD*, Philip J Ferrone 

MD*, Paul E Tornambe MD* 

Retinal Pharmacotherapy 

Course: 434 

Room: E350 


Monday 

3:15 - 5:30 PM 


Synopsis: The management of retinal diseases has changed in recent years, as 

the focus has moved into pharmacologic treatments. Several currently existing 

and upcoming drugs are being used to treat various retinal diseases. This 

course will provide an in-depth knowledge of the drugs in retinal pharmacotherapy. 

Objective: This course will serve as an overview of how various drugs may 

work in the retina. The session will present cutting-edge results of clinical 

trials, such as the Comparison of AMD Treatment Trial (CATT), as well as an 

overview of the techniques and complications in retinal pharmacotherapy. The 

most important drugs available in clinical practice, ranibizumab (Lucentis), 

bevacizumab (Avastin), and dexamethasone intravitreal implant (Ozurdex), will 

be presented in detail. At the conclusion, the attendee will be able to understand 

the indications, applications, and status of drugs available in retinal 

pharmacotherapy. 

Senior Instructor(s): Eduardo B Rodrigues MD 

Instructor(s): Andrew P Schachat MD, Michel Eid Farah MD, Quan Dong Nguyen 

MD*, Carsten H Meyer MD**, Philip J Rosenfeld MD PhD*, William F Mieler 

MD*, Fernando M Penha MD* 

Surgery of Retinal Detachment 

Course: 435 

Room: N427bc 


Monday 

3:15 - 5:30 PM 


Synopsis: This course will review the principles involved in managing rhegmatogenous 

retinal detachment. We will provide a detailed, comprehensive, 

state-of-the-art approach to techniques of scleral buckling, primary vitrectomy, 

and pneumatic retinopexy for the management of selected detachments. Principles 

of buckle placement, selection of elements, drainage, and use of gases 

and other adjutants will be described. 


discuss the advantages and disadvantages of scleral buckling, vitrectomy, and 

pneumatic retinopexy, (2) identify the indications and contraindications and 

technique of drainage of subretinal fluid, (3) select the appropriate gas for 

intraocular injections, (4) discuss postoperative management of retinal detachment 

patients, and (5) recognize alternate techniques for the management of 

different types of retinal detachments. 

Senior Instructor(s): Daniel P Joseph MD PhD 

Instructor(s): Harry W Flynn MD*, George A Williams MD*, Edwin Hurlbut Ryan 

MD* 

NEW APAO Cutting-Edge Information on Pathologic 

Myopia 


Course: 436 

Monday 

Room: N137 

3:15 - 5:30 PM 



Synopsis: This course will cover all you need to know about pathologic myopia, 

including the types and classification of myopic maculopathy, epidemiology, 

evidence-based management of various vision-threatening complications 

(mainly myopic CNV and myopic traction maculopathy), recent findings obtained 

by new imaging modalities, and newly identified macular pathologies, 

eg, dome-shaped macula. 

Objective: At the conclusion of this course, attendees will be able to understand 

the characteristics and natural progression of various lesions associated 

with myopic maculopathy. They will also be able to determine appropriate 

therapeutic strategies for managing patients with pathologic myopia and to 

describe the prognosis. 

Senior Instructor(s): Kyoko Ohno-Matsui MD 

Instructor(s): Yasushi Ikuno MD, Timothy Y Lai MBBS*, Gemmy Chui Ming Cheung 

MBBCHIR FRCOPHTH, Chi-Chun Lai MD*, Tomohiro Iida MD*, Oh Woong Kwon 

MD 

Diagnosis and Treatment of Polypoidal Choroidal 

Vasculopathy 

Course: 509 

Room: S103A 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Polypoidal choroidal vasculopathy (PCV) is a condition characterized 

by multiple, recurrent, serosanguineous pigment epithelial detachment and 

neurosensory retinal detachment due to abnormal choroidal polypoidal, aneurysmal 

lesions. PCV is particularly prevalent in Asians and occurs in up to 30% 

of cases presenting as neovascular AMD; it may pose a diagnostic challenge 

to ophthalmologists. This instruction course aims to provide an overview of 

the diagnosis and treatment of PCV through review of the currently available 

literature and illustrative case examples. 





109



Objective: By the completion of this course, participants will understand the 

epidemiology of PCV, the differences between PCV and AMD, the use of various 

diagnostic tools for PCV, the available treatment options for PCV, and the 

overall management strategy for PCV. 

Senior Instructor(s): Timothy Y Lai MBBS* 

Instructor(s): Fumi Gomi MD PhD*, Gregg T Kokame MD*, Adrian H Koh MD*, Won 

Ki Lee MD* 

H Retinal OCT Interpretation 101 

Course: 510 

Room: S102Abc 


Tuesday 

9:00 - 10:00 AM 


Synopsis: OCT is increasingly being used to diagnose and manage retinal diseases. 

This is an introductory, basic-level course for those who are not retinal 

specialists and are interested in learning about OCT and interpretation of OCT 

images. In this course, we will review the fundamentals of OCT, with emphasis 

on interpreting and recognizing OCT images obtained from various retinal conditions 

through examples, to become more proficient at differentiating normal 

from pathologic findings. 

Objective: At the conclusion of this course, the participants will be able to (1) 

discuss how OCT works and list differences between time domain and spectral 

domain OCT, (2) understand potential sources of artifacts, (3) recognize OCT 

images of common retinal diseases, and (4) learn to incorporate OCT into a 

practice. 

Senior Instructor(s): Judy E Kim MD* 

Instructor(s): Jennifer Irene Lim MD* 

The Evaluation and Management of Retinal Pigment 

Epithelial Detachment in AMD 

Course: 511 

Room: E351 


Tuesday 

9:00 - 10:00 AM 


Synopsis: Retinal pigment epithelial detachments (PED) are the most common 

form of exudative AMD and may present with a wide spectrum of morphologies. 

This course will review the various types of PEDs in AMD and will update 

the classification of PEDs using the many innovative imaging systems of the 

retina. Histopathological classification of PED will also be presented, allowing 

insight into the pathogenesis of the different types of PED. The natural history 

of the various types of PED will be compared, and the wide-ranging therapeutic 

modalities (new and old) will be discussed, as well as the potential 

complications of treatment, including retinal pigment epithelium (RPE) tears. 

Objective: At the conclusion of the course, the participants will be able to classify 

the different types of PEDs associated with AMD using traditional and 

innovative imaging systems of the retina and will be able to correlate these 

clinical analyses with histopathological findings. Participants will be able to 

compare the natural history of PEDs, determine the best therapeutic modality 

available, and identify and manage potential complications of PEDs, such as 

RPE tears. 

Senior Instructor(s): David Sarraf MD* 

Instructor(s): Sander Dubovy MD, K Bailey Freund MD*, Richard F Spaide MD* 

Update on Treatments for Diabetic Retinopathy: 

Clinically Relevant Results from the Diabetic 

Retinopathy Clinical Research Network 

Course: 520 

Room: S105D 


Tuesday 

9:00 - 11:15 AM 


Synopsis: This course will present clinically relevant results of completed Diabetic 

Retinopathy Clinical Research Network (DRCR.net) protocols. 

Objective: By the conclusion of this course, the attendee will be able to describe 

the results of recently completed DRCR.net protocols. Specifically, the 

attendee will know whether intravitreal ranibizumab with or without laser is 

more beneficial in the long-term treatment of patients with diabetic macular 

edema (DME). The attendee will also know the conversion factor between 

time domain OCT and spectral domain OCT in patients with DME. The attendee 

will know the incidence of clinically significant macular edema and 

progression of edema in patients undergoing cataract surgery. The attendee 

will have learned whether intravitreal ranibizumab is beneficial in decreasing 

the number of vitrectomies in eyes with vitreous hemorrhage secondary to 

proliferative diabetic retinopathy. Finally, the attendee will be able to apply 

these results to clinically relevant situations in daily practice. 

Senior Instructor(s): Scott M Friedman MD* 

Instructor(s): Carl W Baker MD*, Abdhish R Bhavsar MD*, Neil M Bressler MD*, 

Susan B Bressler MD*, K V Chalam MD PhD 

NEW Yo Spectral Domain OCT Interpretation for the 

General Ophthalmologist 

Course: 545 

Room: S106B 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: The purpose of this course is to provide general ophthalmologists 

with basic knowledge for incorporating spectral domain OCT (SD-OCT) into 

clinical practice. Attendees will be given an overview of scanning protocols 

on various SD-OCT systems on the market today. Lecturers will present an 

organized method for analysis of images and identification of pathology in the 

anterior segment, optic nerve, vitreous, macula, and choroid. The course will 

have a special focus on use of SD-OCT in patients with glaucoma and/or retinal 

disease. 

Objective: At the conclusion of this course, the attendee will be able select 

appropriate SD-OCT scanning protocols and analyze pathology in SD-OCTs of 

the anterior segment, optic nerve, and posterior segment, especially to detect 

pre-parametric glaucoma, progression of glaucoma, and the most common 

retinal pathology. 

Senior Instructor(s): Purnima S Patel MD 

Instructor(s): Vikas Chopra MD*, Rajeev Kumar R Pappuru MBBS MD, Srinivas R 

Sadda MD*, Alexander C Walsh MD* 

NEW APAO The Latest Advancements in Macular 

Surgery 


Course: 546 

Tuesday 

Room: S105a 

10:15 AM - 12:30 PM 



Synopsis: This course will highlight the latest diagnostic technologies and surgical 

techniques for a variety of macular diseases, such as macular pucker, 

macular hole, diabetic macular edema, submacular hemorrhage, and optic disc 

pit maculopathy. Current concepts and new insights in clinical application of 

OCT, microperimetry, and multifocal electroretinography for macular surgery 

will be fully updated. State-of-the-art surgical instrumentation, including 

small-gauge and intraoperative viewing systems for macular surgery, will also 

be introduced via video demonstrations. 

Objective: At the conclusion of this course, the attendee will be familiar with 

state-of-the-art diagnostic and surgical techniques for the management of 

macular diseases. 

Senior Instructor(s): Chi-Chun Lai MD* 

Instructor(s): Andrew A Chang MBBS, Yusuke Oshima MD*, Masahito Ohji MD*, 

Xiaoxin Li MD*, Timothy Y Lai MBBS*, Doric Wong FRCS(ED)*, Manish Nagpal 

MD* 

110 





Retinal and Choroidal Manifestations of Selected 

Systemic Diseases 2012 


and the Pan-American Retina & Vitreous Society 

Course: 547 

Tuesday 

Room: S104b 

10:15 AM - 12:30 PM 



Synopsis: This course will discuss the current state of retinal and choroidal 

manifestations of selected systemic diseases, including AIDS, gastrointestinal 

diseases, phacomatosis, lupus, diffuse unilateral subacute neuroretinitis, 

lymphoma, metastasis, tuberculosis, and retinal-choroidal toxicity of systemic 

drugs. Experts from the United States, Asia, and South America will discuss 

the impact that systemic diseases have had in the posterior pole of the eye 

worldwide. Topics are rotated every year to cover a wider variety of diseases. 

Objective: At the conclusion of this course, participants will understand the 

variety of retinal and choroidal manifestations of selected systemic diseases 

in and outside the United States. 

Senior Instructor(s): J Fernando Arevalo MD FACS 

Instructor(s): Rubens Belfort Jr MD PhD*, Carol L Shields MD, Jerry A Shields MD, 

William F Mieler MD*, Careen Yen Lowder MD PhD*, Lihteh Wu MD*, Francisco J 

Rodriguez MD*, Alay S Banker MD 

NEW Intravitreal Injection Techniques: Minimizing 

Discomfort and Potential Complications 

Course: 592 

Room: S102d 


Tuesday 

2:00 - 3:00 PM 


Synopsis: This course will review a practical, evidence-based approach to administration 

of intravitreal (IV) injections, including anesthetic and antiseptic 

methods, mask and antibiotic use, IOP monitoring, and the like, with an emphasis 

on minimizing potential risks and improving patient safety. The impact 

of compounding pharmacies on the safety of IV injections and recent endophthalmitis 

outbreaks will also be discussed. 

Objective: By the conclusion of this course, the attendee will be able to discuss 

specific strategies to reduce risks and improve patient comfort. Moreover they 

will be able to describe current standards for sterile medication compounding 

and ways of ensuring patient safety if a compounding pharmacy is utilized. 

Senior Instructor(s): Harry W Flynn MD* 

Instructor(s): Ninel Z Gregori MD, Raquel Goldhardt MD 

NEW The Crowded OR: Optimizing Surgical 

Strategies in Cataract, Glaucoma, and Cornea 

Surgery in Combination With Vitreoretinal Surgery 

Course: 593 

Room: N138 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Advancements in ophthalmic surgical procedures that address cataract, 

glaucoma, corneal, and vitreoretinal pathology have led to expanding 

indications, and consequently increased opportunity for combined surgery. 

While progress in surgical technique and technology is a cornerstone of improved 

outcomes and efficiency, such change may have significant implications 

in the context of combined procedures performed by one or more surgeons. A 

multidisciplinary panel will present recommendations for optimizing combined 

surgery, with an emphasis on microincisional vitrectomy surgery, current concepts 

in cataract extraction and IOLs, glaucoma drainage device implantation, 

corneal transplantation, and pediatric cataract and corneal surgery. 

Objective: At the conclusion of this course, the attendee will recognize the 

implications of recent surgical developments for related ophthalmic subspecialties 

and will be equipped with tactical strategies to optimize the execution 

of combined ophthalmic surgical procedures. 

Senior Instructor(s): Yannek I Leiderman MD PhD* 

Instructor(s): William F Mieler MD*, Elmer Tu MD, Aisha S Traish MD, Ahmad A 

Aref MD 

Visual Electrophysiology Testing: Principles and 

Clinical Applications 

Course: 594 

Room: N140 


Tuesday 

2:00 - 3:00 PM 


Synopsis: Visual electrophysiologic tests are diagnostic tools that are helpful 

or essential in a variety of retinal and visual disorders. This course, approved 

by the International Society for Clinical Electrophysiology of Vision (ISCEV), 

provides a comprehensive overview of clinical electrophysiologic tests with a 

focus on basic principles (including ISCEV standards) and clinical applications. 

A variety of clinical cases will be presented to illustrate the appropriateness 

and utility of visual electrophysiology testing. 


basic principles and clinical applications of full-field electroretinogram (ERG), 

multifocal ERG, electro-oculogram, and pattern visual evoked potential, enabling 

the attendee to incorporate these tests effectively in clinical practice. 

Senior Instructor(s): Byron L Lam MD* 

Instructor(s): Michael F Marmor MD*, Mitchell Brigell PhD* 

Retinaws: A Comprehensive Video-Oriented Course 

on Challenging Retinal Cases in the Operating Room 

Course: 601 

Room: S403b 


Tuesday 

2:00 - 4:15 PM 


Synopsis: Retina specialists often work in a “shark-infested” world. Unexpected 

events are a fact of life, and learning how not to get bitten is an effective 

way to practice safely and efficiently. This course consists of video presentations 

describing challenging cases and unexpected events during retinal surgery. 

Faculty will share their experience in predicting, treating, and preventing 

unexpected outcomes during retinal detachment surgery, diabetic vitrectomy 

surgery, small-gauge surgery, and complex vitreoretinal surgery. 

Objective: At the conclusion of this course, attendees will be able to predict, 

treat, and prevent unexpected events during and after vitreoretinal surgery. 

Senior Instructor(s): Kourous Rezaei MD* 

Instructor(s): Kirk H Packo MD*, Alay S Banker MD, Sjakon G Tahija MD, Peter W 

Stalmans MD PhD*, Hugo Quiroz-Mercado MD*, Peter Wiedemann MD* 

NEW Scleral Buckling and Vitrectomy for 

Rhegmatogenous Retinal Detachment: How to Avoid 

and Deal With Recurrences? 

Course: 602 

Room: N139 


Tuesday 

2:00 - 4:15 PM 


Synopsis: Despite rapidly evolving technical advances in retinal detachment 

(RD) surgery, the recurrence rate still ranges between 10% and 20%. The main 

causes of recurrences are missed breaks and proliferative vitreoretinopathy. 

This course will provide an overview on the different causes, prevention strategies, 

and management options for dealing with recurrent RD. 





111



Objective: This course will (1) review the different causes and risk factors for 

recurrence of RD, (2) provide an overview of the technical details of scleral 

buckling and vitrectomy procedures that could increase the success rate, and 

(3) cover the different approaches to dealing with recurrent RD, including rebuckling, 

combining scleral buckles with vitrectomy, performing retinectomy 

and using different tamponading agents. Audience: Residents, fellows, and 

established vitreoretinal surgeons. 

Senior Instructor(s): Mostafa A Elgohary MD FRCS(ED) 

Instructor(s): Louisa J Wickham MBBS* 

NEW SO Genetics and AMD: What Do I Need to 

Know Right Now? 

Course: 617 

Room: S106A 


Tuesday 

3:15 - 5:30 PM 


Synopsis: This course will provide a concise review of the use of genetics in 

the clinical care of patients with age-related macular degeneration (AMD). 


fundamental concepts in AMD genetics (including complex genetic 

disorders, AMD-associated polymorphisms, genome-wide association studies, 

and how to evaluate these reports), (2) evaluate and select among currently 

available commercial genetic tests (including their validity and integrating 

them into current clinical practice), (3) review the current literature regarding 

pharmacogenetic associations with various AMD treatments (including 

AREDS vitamins, photodynamic therapy, ranibizumab, bevacizumab, and intravitreal 

triamcinolone acetonide), and (4) discuss clinical case examples and 

how genetics may improve patient care (including AMD mimics, singleton vs. 

multiplex phenotypes, twin studies, and clinical sub-features of AMD). 

Senior Instructor(s): Stephen G Schwartz MD MBA* 

Instructor(s): Milam A Brantley Jr MD, Anita Agarwal MD*, Jaclyn L Kovach MD 

Mystery Retina 2012: Interactive Discussion of 

Challenging Cases 

Course: 618 

Room: S102Abc 


Tuesday 

3:15 - 5:30 PM 


Synopsis: The instructors of this course will present 20 to 25 diagnostically 

challenging “mystery retina” cases. The majority of the presentations will 

include interpretation of color photographs, fluorescein angiograms (FA), and 

OCT imaging studies. When indicated, other studies will also be shown, including 

indocyanine green (ICG) angiography, echography, autofluorescence, 

enhanced depth imaging (EDI) of the choroid, infrared images, electrophysiologic 

studies, microperimetry, CT and/or MRI, and, occasionally, cytology 

and histopathology. The cases will be presented as unknowns, and audience 

participation will be encouraged. At the completion of the case presentations, 

the attendees will receive a handout summarizing the cases, complete with 

pertinent references and an image or two. 

Objective: At the conclusion of this course, attendees will be better able to 

assess and evaluate a variety of diagnostically challenging “mystery retina” 

cases. They should also be able to establish a more complete differential diagnosis, 

know when to make the best use of ancillary diagnostic tests, and 

formulate a definitive treatment plan. 


Instructor(s): Lee M Jampol MD*, Jerry A Shields MD, Richard F Spaide MD*, 

Lawrence A Yannuzzi MD 


NEW Children With Low Vision: Strategies and 

Interventions 

Course: 261 

Room: S104A 


Sunday 

4:30 - 5:30 PM 


Synopsis: Ophthalmologists are often the first to identify a child with vision 

impairment. In the context of providing eye care, doctors are also asked to 

make recommendations regarding educational and classroom adaptations and 

driving despite lack of formal training in these areas. 

Objective: At the conclusion of this course, the attendee will be able to communicate 

about their patients with the use of standardized reporting templates, 

recommend current options for rehabilitation, and provide up-to-date 

information regarding education, technology, and driving for children and 

teens with low vision. 

Senior Instructor(s): Terry L Schwartz MD 

Instructor(s): Kelly Lusk**, Rebecca B Coakley 

Low Vision Rehabilitation for Ophthalmologists 

Course: 548 

Room: S101AB 


Tuesday 

10:15 AM - 12:30 PM 


Synopsis: As an ophthalmologist, you have the skills necessary to help low 

vision patients with vision rehabilitation. These basic, informative low vision 

testing tools will help your patients achieve their visual potential. 

Objective: After completion of this course, you will know how to use the necessary 

tools as a resident, comprehensive ophthalmologist, or retinal specialist 

to incorporate low vision rehabilitation into your practice. 

Senior Instructor(s): Robert M Christiansen MD FACS 

Instructor(s): Paul Homer MD, Gwen K Sterns MD 

112 




Only One 

System Delivers 

the Shield of 

Protection. 

DuoVisc ® Viscoelastic System offers both 

the endothelial protection of chondroitin 

sulfate in Viscoat ® OVD with the proven 

mechanical protection and space 

maintenance found in ProVisc ® OVD. 

One System. No Compromises. 

Brilliant from Beginning to End. 

Protection you can count on for every phase of cataract surgery. 

The first and only viscous dispersive, DisCoVisc® OVD provides the flexibility of both cohesive and 

dispersive properties in a single syringe. DisCoVisc® OVD combines the excellent endothelial protection of 

chondroitin sulfate with the mechanical protection of superior space maintenance and clarity. 

To see how DisCoVisc® OVD can help protect your outcomes, visit AlconOVD.com. 

Please refer to the important safety information on the adjacent page. 

© 2012 Novartis 8/12 VIS12711JAD

DUOVISC® Viscoelastic System is designed to give two viscoelastic materials with different physico-chemical properties that can be used differently and/or sequentially 

to perform specific tasks during a cataract procedure. DUOVISC® Viscoelastic System consists of VISCOAT® Ophthalmic Viscosurgical Device and PROVISC® 

Ophthalmic Viscosurgical Device. 

CAUTION: Federal law restricts this device to sale by or on the order of a physician. 

Viscoat® (Sodium Chondroitin Sulfate – Sodium Hyaluronate) Ophthalmic Viscosurgical Device 

Indications: Viscoat is indicated for use as an ophthalmic surgical aid in anterior segment procedures including cataract extraction and intraocular lens (IOL) implantation. 

Viscoat maintains a deep anterior chamber during anterior segment surgeries, enhances visualization during the surgical procedure, and protects the corneal 

endothelium and other ocular tissues. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber 

during surgery. 

Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury. 

Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin 

sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material. 

Adverse Reactions: Viscoat has been extremely well tolerated in human and animal studies. A transient rise in intraocular pressure in the early postoperative period 

may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recommended that Viscoat be removed 

from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. Do not overfill anterior chamber. 

ATTENTION: Reference the Physician Labeling/Directions for Use for a complete listing of indications, warnings and precautions. 

ProVisc® (Sodium Hyaluronate) Ophthalmic Viscosurgical Device 

Indications: ProVisc is indicated for use as an ophthalmic surgical aid in the anterior segment during cataract extraction and intraocular lens (IOL) implantation. 

Ophthalmic viscoelastics serve to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and surrounding 

ocular tissues. They help push back the vitreous face and prevent formation of a flat chamber during surgery. 

Precautions: Postoperative increases in intraocular pressure have been reported with sodium hyaluronate products. The IOP should be carefully monitored and 

appropriate therapy instituted if significant increases should occur. It is recommended that ProVisc® be removed by irrigation and/or aspiration at the close of surgery. 

Do not overfill anterior chamber. Although sodium hyaluronate is a highly purified biological polymer, the physician should be aware of the potential allergic risks 

inherent in the use of any biological material; care should be used in patients with hypersensitivity to any components in this material. Cannula assembly instructions 

should be followed to prevent patient injury. 

Adverse Reactions: Postoperative inflammatory reactions such as hypopyon and iritis have been reported with the use of ophthalmic viscoelastics, as well as incidents 

of corneal edema, corneal decompensation, and a transient rise in intraocular pressure. 


DisCoVisc® Ophthalmic Viscosurgical Device (Sodium Chondroitin Sulfate – Sodium Hyaluronate). 

Description: DisCoVisc® Ophthalmic Viscosurgical Device has an intermediate cohesive/dispersive index (CDI) and can best be described as the first viscous dispersive 

viscoelastic and is optimized for the entire surgical procedure. 

Indications: DisCoVisc® Ophthalmic Viscosurgical Device is indicated for use during surgery in the anterior segment of the eye. It is designed to create and maintain 

space, to protect the corneal endothelium and other intraocular tissues and to manipulate tissues during surgery. It may also be used to coat intraocular lenses and 

instruments during cataract extraction and IOL insertion. 

Warnings: Failure to follow assembly instructions or use of an alternate cannula may result in cannula detachment and potential patient injury. 

Precautions: Precautions are limited to those normally associated with the surgical procedure being performed. Although sodium hyaluronate and sodium chondroitin 

sulfate are highly purified biological polymers, the physician should be aware of the potential allergic risks inherent in the use of any biological material. 

Adverse Reactions: DisCoVisc® Ophthalmic Viscosurgical Device was very well tolerated in nonclinical and clinical studies. A transient rise in intraocular pressure 

in the early postoperative period may be expected due to the presence of sodium hyaluronate, which has been shown to effect such a rise. It is therefore recommended 

that DisCoVisc be removed from the anterior chamber by thorough irrigation and/or aspiration at the end of surgery to minimize postoperative IOP increases. 

Do not overfill anterior chamber. 


CAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO THE SALE BY OR ON THE ORDER OF A PHYSICIAN. 

U.S. Patent Nos. 5,273,056; 5,876,379 and 6,051,560. 

© 2012 Novartis 8/12 VIS12711JAD-PI



These hands-on courses offer intensive training in surgical 

and diagnostic techniques, with direct supervision and a low 

participant-to-instructor ratio. Attendance is limited to physicians 

only, except where noted in the course description. (The 

term physician refers to the definition in the Federal Register: 

“those individuals licensed to practice medicine and surgery or 

osteopathy.”) 

Skills Transfer courses are intended to provide instruction 

leading to new knowledge and/or skills. The Academy does 

not certify competence upon completion of Academy courses. 

Academy courses are not intended to serve as a basis for 

requesting new or expanded privileges. 

Academy Plus Course Pass 

Skills Transfer Didactic courses are included in the 

Academy Plus course pass. Academy Plus offers maximum 

convenience, with unlimited access to all Academy and AAOE 

instruction courses. Individual tickets for Academy and AAOE 

instruction courses will no longer be sold. 

Note: Due to Fire Marshal regulations, seating capacities are 

limited. Seating is available on a first-come basis, so please 

plan accordingly. 

Skills Transfer Labs are ticketed events - they are not 

included in the Academy Plus course pass and must be purchased 

separately. 

If you are registering for a Skills Transfer lab (LAB), and a 

prerequisite lecture (LEC) is indicated, you must attend both 

courses. The lecture is included with the lab - you do not 

need to purchase the Academy Plus course pass to attend the 

lecture. 

NEW 

R 

EQUIP 

W 

New course 

Lab is available to Residents only 

Participants are required to bring specific equipment 

to the course 

Participants are required to sign an infectious disease 

transmission waiver/release form 


The Skills Transfer Advisory Committee selected all Skills 

Transfer Courses. 






Skills Transfer Course Contributors 

The Academy gratefully acknowledges the following companies for their generous support of equipment and supplies used during 

the Skills Transfer Course Program: 

Medical Optics 

We would also like to thank the following companies for their contributions in the Cataract, Refractive Surgery/Cornea, Glaucoma, 

Retina, and Plastics Skills Transfer Labs: 

Durable Equipment / Instruments: 

Accurate Surgical & Scientific Instruments Corporation 

Accutome, Inc. 

Addition Technology 

Anodyne Surgical 

Black & Black Surgical 

Buffalo Filter 

Crestpoint Management 

Dutch Ophthalmic, USA 

Ellman International Inc. 

Endo Optiks, Inc. 

Epsilon Eye Care 

IRIDEX 

iScience Interventional 

JEDMED Instrument Company 

Katena Products Inc. 

Lasering USA 

Lumenis, Inc. 

Mastel Inc. 

Microaire Surgical Instruments 

MST (MicroSurgical Technology) 

NeoMedix 

New World Medical, Inc. 

Rhein Medical 

Rumex International Co 

Sciton, Inc. 

Stryker Medical 

Ziemer Group 

Disposables: 

Beaver-Visitec International Inc 

Ethicon, Inc 

FCI Ophthalmics 

IOP Inc. 

Medicis 

STAAR Surgical Company 

Tissue: 

Bio-Tissue Inc. 

Vision Share Eyebank Network 

114


Cataract 

Management of Vitreous for the Anterior Segment Surgeon 

Course Director(s): Natalie A Afshari MD* 

Prerequisite Didactic 

Course: LEC150 

Sunday, 9:00 - 11:15 AM 

Room: S105A 


EduLevel: INT 

Synopsis: This course will review the anatomy, physiology, and pathophysiology of the 

vitreous and will present vitrectomy techniques for challenging anterior segment surgery 

scenarios. Topics will include management of vitreous loss from the anterior and posterior 

approach, utilizing the vitrector for decompression in challenging cataract cases, and 

visualizing the vitreous with triamcinolone acetonide (Kenalog). 

Objective: This course is designed to enhance the anterior segment surgeon’s familiarity 

with anterior and posterior vitrectomy techniques for challenging anterior segment cases. 


Instructor(s): Iqbal K Ahmed MD*, Rosa Braga-Mele MD*, Keith A Warren MD*, Baseer U 

Khan MD*, Thomas A Oetting MD 

Labs 

Synopsis: This Skills Transfer course will present management of vitreous during complicated 

anterior segment surgery. A variety of vitrectomy techniques will be discussed. 

Topics will include anterior vitrectomy, pars plana access to the anterior vitreous, and 

effective use of small-gauge instrumentation. 

Objective: This course is designed to enhance participants’ technical skills in handling 

vitreous during complicated anterior segment surgery. 

Select one of the following 

Course: LAB150A 

Sunday, 12:00 - 1:30 PM 

Room: N228 


Fee: $280.00 

EduLevel: INT 


Instructor(s): Maria Mendicino Aaron MD, Sherleen Huang Chen MD*, Baseer U Khan 

MD*, Gary S Schwartz MD, Roberto Pineda II MD, Jack A Cohen MD FACS, Ali R Djalilian 

MD, Aryan Shayegani MD, Jerzy Nawrocki MD PhD, Francesco Boscia MD*, Shameema 

Sikder MD*, Robert B Bhisitkul MD**, Thomas A Oetting MD, Kenneth M Goins MD, 

John Kim MD, W Barry Lee MD, Shahzad Mian MD 

Course: LAB150B 

Tuesday, 10:00 - 11:30 AM 

Room: N228 


Fee: $280.00 

EduLevel: INT 


Instructor(s): Maria Mendicino Aaron MD, Sherleen Huang Chen MD*, Baseer U Khan 

MD*, Gary S Schwartz MD, Roberto Pineda II MD, Jack A Cohen MD FACS, Aryan 

Shayegani MD, Jerzy Nawrocki MD PhD, Brad H Feldman MD, Shameema Sikder MD*, 

Robert B Bhisitkul MD**, Thomas A Oetting MD, Kenneth M Goins MD, John Kim MD, W 

Barry Lee MD, Shahzad Mian MD 

Phacoemulsification and Advanced Techniques 

Course Director(s): Steven H Dewey MD* 



Sunday, 9:00 - 11:15 AM 

Room: N427BC 


EduLevel: ADV 

Synopsis: In the past few years noteworthy new phaco technologies have altered the 

way surgeons execute and analyze the phacoemulsification procedure. In this course, a 

faculty of experienced surgeons will present the latest phaco techniques and technologies 

that are applicable to ophthalmologists at every level of experience. This course will 

cover the steps of phacoemulsification, including scleral and corneal incisions, capsulorrhexis, 

hydrodissection, and various phaco techniques, with emphasis on machine principles 

including micropulse phaco, dual pump fluidics, and torsional phaco. Principles for 

safe cortex removal and implantation of IOLs, including foldable IOLs using forceps and 

injector-style delivery systems, will be demonstrated. Management of complications and 

challenging cases using capsular tension rings, pupil expanders, hooks, capsular staining, 

and related techniques will also be presented. This course will teach the most up-to-date 

phacoemulsification techniques to both individuals with little or no experience with the 

method and those wishing to refine or update their technique or transitioning from other 

cataract surgery methods. 

Objective: This course is designed to teach participants the principals and skills necessary 

to understand and perform phacoemulsification safely and efficiently. 

Instructor(s): Ricardo G Glikin MD, Nick Mamalis MD*, Anita Nevyas-Wallace MD*, 

Thomas A Oetting MD, Helen K Wu MD*, Mark H Blecher MD* 

Labs 

Synopsis: The past few years have brought the introduction of noteworthy new phaco 

technologies that have altered the way surgeons execute and analyze the procedure. In 

this course, the latest phaco techniques and technologies will be presented. The most 

topical techniques will be taught, including wound construction, capsulorrhexis, capsular 

staining, phaco chop techniques, techniques for operating the mature cataract, astigmatism 

management, capsular tension rings, and pupil expanders and hooks. New machine 

principles including micropulse phaco and torsional phaco will be assessed. Training will 

be one-on-one, allowing for customization of the techniques emphasized for each surgeon 

attendee. 

Objective: The surgeon attendee should attain the skills necessary for and understand 

the concepts influencing the latest phaco techniques and phaco machine technologies. 



Sunday, 2:00 - 3:30 PM 

Room: N228 


Fee: $280.00 

EduLevel: ADV 

Senior Instructor(s): Anita Nevyas-Wallace MD*, Gerald Roper MD* 

Instructor(s): Chi-Wah (Rudy) Yung MD, Donald J Doughman MD, Robert R Ditkoff MD, 

Linda M Tsai MD*, Marc A Michelson MD*, Steven R Sarkisian MD*, Audrey R Talley- 

Rostov MD*, David Anthony Belyea MD, John M Hahn MD, Herbert J Ingraham MD, 

Jimmy K Lee MD*, Anjali K Pathak MD*, Carolyn Y Shih MD MBA MPH, Roxana Ursea 

MD, Nan Wang MD PhD* 


Monday, 1:00 - 2:30 PM 

Room: N228 


Fee: $280.00 

EduLevel: ADV 

Senior Instructor(s): Anita Nevyas-Wallace MD*, Gerald Roper MD* 

Instructor(s): Nancy E Awender MD**, Bennett Chotiner MD*, Erik A Chotiner MD, 

Ricardo G Glikin MD, David R Hardten MD*, Michael Hater MD**, Rachel W Kuchtey MD 

PhD**, Herbert J Nevyas MD, Florentino E Palmon MD, Clark L Springs MD*, P Dee G 

Stephenson MD FACS*, Linda M Tsai MD*, Kevin M Miller MD*, James F Freeman MD*, 

Alan N Carlson MD*, Amy Lin MD, Asim R Piracha MD, Jeffrey Whitman MD OCS*, 

Robert P Rivera MD*, Daniel Tran** 

R Phacoemulsification and Advanced Techniques Lab for 

Ophthalmology Residents 

Course Director(s): Maria Mendicino Aaron MD 

Course: LAB151C 

Tuesday, 12:30 - 3:30 PM 

Room: N228 


Fee: $175.00 

EduLevel: BAS 

Senior Instructor(s): Maria Mendicino Aaron MD 

Instructor(s): Natalie A Afshari MD*, Ron Afshari Adelman MD MPH**, David B Krebs 

MD, Nina A Goyal MD, Raj K Goyal MD MPH*, Hilary A Beaver MD*, Michael H Goldstein 

MD*, Bonnie A Henderson MD*, Robert S Bailey MD, Chi-Wah (Rudy) Yung MD, C 

Diane Song MD**, Thomas A Oetting MD, Nan Wang MD PhD*, Rahul T Pandit MD*, Jill 

R Wells MD, Joung Y Kim MD, Amy Grossman Coburn MD**, Paul B Pruett MD, Maria A 

Woodward MD, Clark L Springs MD*, Emily B Graubart MD**, Preston H Blomquist MD, 

Daniel H Chang MD* 

Note: MIT discount already applied. Participants will be sharing equipment. 


* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest. 

R Lab for Residents only. EQUIP = Participants are required to bring specific equipment to the course. W = Participants are required to sign an infectious disease 

transmission waiver/release form. Education Level Key: BAS = Basic, INT = Intermediate, ADV = Advanced. Target Audience: COMP = Comprehensive Ophthalmologist, 

SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist. 

115



Manual Extracapsular Cataract Extraction (ECCE/SICS) 

Surgery: Indications and Techniques 

Course Director(s): Bonnie A Henderson MD* 



Sunday, 10:15 AM - 12:30 PM 

Room: E352 


EduLevel: INT 

Synopsis: Although extracapsular cataract extractions by large incision (ECCE) and small 

incision (SICS) are still performed routinely throughout the world, phacoemulsification 

surgery has become the standard of care in many countries, and therefore ECCE/SICS 

is no longer being taught. However, understanding how to perform this surgery competently 

is still crucial when faced with complications during phacoemulsification surgery, 

or when an ECCE approach may be a better choice for the patient. 

Objective: By the conclusion of this course, the attendee will (1) have learned and be 

able to practice primary ECCE and SICS surgery, (2) have learned and be able to practice 

how to convert from a clear corneal phacoemulsification to either a ECCE or a SICS approach, 

and (3) better understand how to deal with complications of ECCE surgery. 


Instructor(s): Thomas A Oetting MD, Geoffrey C Tabin MD, Maria Mendicino Aaron MD 

Labs 

Synopsis: Although extracapsular cataract extractions by large incision (ECCE) and small 

incision (SICS) are still performed routinely throughout the world, phacoemulsification 

surgery has become the standard of care in many countries, and therefore ECCE/SICS is 

no longer being taught. However, understanding how to perform this surgery competently 

is still crucial when faced with complications during phacoemulsification surgery or when 

an ECCE approach may be a better choice for the patient. 

Objective: By the conclusion of this course, the attendee will (1) have learned and be 

able to practice primary ECCE and SICS surgery, (2) have learned and be able to practice 

how to convert from a clear corneal phacoemulsification to either a ECCE or a SICS approach, 

and (3) better understand how to deal with complications of ECCE surgery. 



Sunday, 4:00 - 5:30 PM 

Room: N228 


Fee: $280.00 

EduLevel: INT 


Instructor(s): Thomas A Oetting MD, Eduardo C Alfonso MD*, Maria Mendicino Aaron 

MD, Geoffrey C Tabin MD, Preston H Blomquist MD, Abhay Raghukant Vasavada MBBS 

FRCS*, Amar Agarwal MD*, Dianna L Bordewick MD, Surendra Basti MBBS*, Samar 

K Basak MD DNB MBBS*, Adil Agarwal MBBS**, Ashvin Agarwal, Anosh Agarwal 

BMBS**, Athiya Agarwal MD*, Francisco J Gutierrez-Carmona MD, Jeff H Petty MD, 

Arup Chakrabati MBBS, Soosan Jacob FRCS, Neera Kanjani MBBS, Nilesh Kanjani MBBS 


Monday, 3:30 - 5:00 PM 

Room: N228 


Fee: $280.00 

EduLevel: INT 


Instructor(s): Thomas A Oetting MD, Eduardo C Alfonso MD*, Maria Mendicino Aaron 

MD, Geoffrey C Tabin MD, Preston H Blomquist MD, Abhay Raghukant Vasavada MBBS 

FRCS*, Amar Agarwal MD*, Haripriya Aravind MBBS, Dianna L Bordewick MD, Surendra 

Basti MBBS*, Samar K Basak MD DNB MBBS*, Adil Agarwal MBBS**, Ashvin Agarwal, 

Anosh Agarwal BMBS**, Athiya Agarwal MD*, Francisco J Gutierrez-Carmona MD, Jeff 

H Petty MD, Arup Chakrabati MBBS, Soosan Jacob FRCS, Neera Kanjani MBBS, Nilesh 

Kanjani MBBS 

Advanced Refractive Cataract Surgery and Anterior 

Segment Reconstruction 

Course Director(s): Brock K Bakewell MD* 



Sunday, 3:15 - 5:30 PM 

Room: N427BC 


EduLevel: INT 

Synopsis: This course is designed for surgeons who (1) want to achieve a higher level 

of emmetropic results by addressing toricity through the use of limbal relaxing incisions, 

toric IOLs, and bioptics, and (2) want to expand their armamentarium for dealing with 

difficult cataract cases, dislocated IOLs, and traumatized eyes. 

Objective: This course will cover iris and scleral suture fixation techniques for IOLs, 

chopping techniques, capsular tension rings, artificial iris vs. primary closure for iris defects, 

pars plana vitrectomy, introduction to femtosecond cataract surgery, and strategies 

for dealing with challenging cases. These techniques will be presented in the didactic 

course and will be practiced in the Skills Transfer lab. 

Senior Instructor(s): Brock K Bakewell MD* 

Instructor(s): Louis D “Skip” Nichamin MD*, William J Fishkind MD FACS*, Samuel 

Masket MD*, Warren E Hill MD*, Steven H Dewey MD*, Lisa B Arbisser MD, Garry P 

Condon MD**, Alan S Crandall MD*, Richard S Hoffman MD*, Robert P Liss MD, Mark 

K Walsh MD 

Labs 

Synopsis: This course is designed for surgeons who (1) want to achieve a higher level 

of emmetropic results by addressing toricity through the use of limbal relaxing incisions, 

toric IOLs, and bioptics, and (2) want to expand their armamentarium for dealing with 

difficult cataract cases, dislocated IOLs, and traumatized eyes. 

Objective: This course will cover iris and scleral suture fixation techniques for IOLs, 

chopping techniques, capsular tension rings, artificial iris vs. primary closure for iris defects, 

pars plana vitrectomy, introduction to femtosecond cataract surgery, and strategies 

for dealing with challenging cases. 



Monday, 10:30 AM - 12:00 PM 

Room: N228 


Fee: $280.00 

EduLevel: INT 

Senior Instructor(s): Robert P Liss MD 

Instructor(s): Louis D “Skip” Nichamin MD*, Warren E Hill MD*, Bonnie A Henderson 

MD*, Ayman Naseri MD*, Garry P Condon MD**, James A Bryan III MD, Michael G Orr 

MD*, Richard S Hoffman MD*, Roger C Furlong MD, Michele M Bloomer MD, Steven H 

Dewey MD*, Jeff S Maltzman MD, Corey A Miller MD, Bruce David Nichols MD, Lynn 

Polonski MD, Kevin Lee Waltz MD*, Christine S Ament MD**, M Todd Brown MD** 


Tuesday, 8:00 - 9:30 AM 

Room: N228 


Fee: $280.00 

EduLevel: ADV 

Senior Instructor(s): Steven H Dewey MD* 

Instructor(s): Donald Nixon MD*, Helen K Wu MD*, George Beiko MD*, William S Clifford 

MD*, Robert J Weinstock MD*, Kenneth J Rosenthal MD FACS*, Jason J Jones MD*, 

Tal Raviv MD*, Douglas Katsev MD*, Harold W Climenhaga MD, Lindsay Ong-Tone 

MD*, Robert A Kaufer MD*, Anthony J Aldave MD*, Balamurali K Ambati MD, Richard S 

Davidson MD*, James T Banta MD, Y Ralph Chu MD*, Pablo Miguel Arregui MD, Daniel 

H Chang MD* 

Microsurgical Suturing Techniques 

Course Director(s): Marian Sue Macsai-Kaplan MD* 



Sunday, 3:15 - 5:30 PM 

Room: N140 


EduLevel: BAS 

Synopsis: This course will cover basic microsurgical suturing techniques. In addition, 

principles, theories, and practical instruction in corneal-scleral laceration and corneal 

wound repair, management of cataract wound problems, including wound burns, and 

extension of clear corneal incisions will be demonstrated. 


116 



SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist.


Objective: This course offers basic microsurgical suturing training that is applicable in 

the management of penetrating keratoplasty suturing, corneal lacerations, and cataract 

wound problems. 

Senior Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter MD FACS 

Lab 

Synopsis: This course will cover basic microsurgical suturing techniques. In addition, 

principles, theories, and practical instruction in corneal-scleral laceration and corneal 

wound repair, management of cataract wound problems, including wound burns, and 

extension of clear corneal incisions will be demonstrated. 

Objective: This course will offer basic microsurgical suturing training that is applicable 

in the management of penetrating keratoplasty suturing, corneal lacerations, and cataract 

wound problems. 

Note: MIT discount already applied. 


Monday, 10:30 AM - 12:30 PM 

Room: N227B 


Fee: $140.00 

EduLevel: BAS 

Senior Instructor(s): Marian Sue Macsai-Kaplan MD*, Woodford S Van Meter MD FACS 

Instructor(s): Andrew J W Huang MD MPH*, Carol L Karp MD, Anthony J Lubniewski 

MD*, Joel Sugar MD, Angelo P Tanna MD*, Helen K Wu MD*, R Doyle Stulting MD 

PhD*, Anthony J Johnson MD, William Barry Lee MD*, Julie H Tsai MD, Charles S 

Bouchard MD, Denise de Freitas MD, Robert S Feder MD*, David B Glasser MD, Satya 

Reddy MD, Mark J Mannis MD, Aaleya F Koreishi MD*, Jennifer Y Li MD, Paras R Shah 

MD, Michael W Belin MD*, Luciene Sousa MD*, Mitul R Vakharia MD, Scott A Uttley 

MD, Andrea Kara-Jose MD, Helen K Wu MD* 

An Innovative Approach to Iris Fixation of an IOL Without 

Capsular Support: Hands-on and Practical 

Course Director(s): Paul R Rosenberg MD FACS 

Course: LAB307 

Monday, 8:00 - 9:00 AM 

Room: N226 


Fee: $65.00 

EduLevel: INT 

Synopsis: This course will present an innovative variation of a McCannel/Siepser smallincision 

retrievable suture technique for peripheral iris fixation in the absence of capsule 

support for secondary foldable IOLs and dislocated IOLs. This technique will be demonstrated 

with video, animation, and hands-on practice with a model. 

Objective: Surgeons will learn the rationale for iris fixation of a foldable implant and 

will add this technique to their arsenal of management options for IOL dislocation and 

aphakia. The practical method of suturing will be cemented by a hands-on approach. 

Note: Limited to 36 participants. 

Instructor(s): Garry P Condon MD** 

Astigmatism in the Cataract Patient 

Course Director(s): Louis D “Skip” Nichamin MD* 



Monday, 10:15 AM - 12:30 PM 

Room: S103BC 


EduLevel: INT 

Synopsis: This course will teach ways to control postoperative astigmatism. It will cover 

preoperative planning as well as intraoperative and postoperative surgical techniques 

used to control astigmatism. Intraoperative limbal-relaxing incisions will be discussed in 

detail, along with the use of toric IOLs and means by which to further enhance outcomes. 

Objective: At the conclusion of this course, participants will be able to plan and perform 

the techniques necessary to control postcataract astigmatism. 


Instructor(s): Jonathan B Rubenstein MD* 

Labs 

Synopsis: This course will teach ways to control postoperative astigmatism. It will cover 

preoperative planning as well as intraoperative and postoperative surgical techniques 

used to control astigmatism. Intraoperative limbal-relaxing incisions will be discussed in 

detail, along with the use of toric IOLs and means by which to further enhance outcomes. 

Objective: At the conclusion of this course, participants will be able to plan and perform 

the techniques necessary to control postcataract astigmatism. 



Monday, 4:00 - 5:30 PM 

Room: N227B 


Fee: $240.00 

EduLevel: INT 


Instructor(s): Brock K Bakewell MD*, Y Ralph Chu MD*, Jonathan Davidorf MD*, Steven 

J Dell MD*, Randy J Epstein MD*, William J Fishkind MD FACS*, Leslie Grosinger 

MD, James C Hays MD, Warren E Hill MD*, Richard S Hoffman MD*, Terry Kim MD*, 

Nick Mamalis MD*, Kevin M Miller MD*, Gerald Roper MD*, Kenneth J Rosenthal MD 

FACS*, Alan Victor Spigelman MD, David T Vroman MD*, R Bruce Wallace MD*, Robert 

J Weinstock MD* 


Tuesday, 1:00 - 2:30 PM 

Room: N227B 


Fee: $240.00 

EduLevel: INT 

Senior Instructor(s): Jonathan B Rubenstein MD* 

Instructor(s): Corey A Miller MD, Thomas A Deutsch MD FACS, Charles S Bouchard MD, 

Bruce David Nichols MD, Thomas D Lindquist MD PhD, Stephen S Lane MD*, Richard 

J Grostern MD, Richard F Dennis MD, Parag A Majmudar MD*, Marian Sue Macsai- 

Kaplan MD*, Robert S Feder MD*, Raj K Goyal MD MPH*, Kevin M Miller MD*, Brock K 

Bakewell MD*, Vanee V Virasch MD, James A Katz MD* 

Computers, Information Technology 

Computer Courses are open to all registrants. 

EQUIP Enhancing Your Presentation Using Keynote by Apple 

Inc. for the Intermediate User 

Course Director(s): Robert F Melendez MD MBA* 


Monday, 2:30 - 4:00 PM 

Room: N227A 


Fee: $100.00 

EduLevel: INT 

Synopsis: The purpose of this Skills Transfer course is to help enhance your keynote 

presentations. This course is intended for intermediate users who already know how to 

use Keynote software (Apple Inc.). 

Objective: At the conclusion of this course, attendees will be able to incorporate video, 

audio, and special graphics into their slide presentations. They will learn how to build 

3-D graphs and tables with special graphics, and how to build transition slides that flow 

nicely. 

Note: Each participant must bring their MAC laptops. 

Senior Instructor(s): Robert F Melendez MD MBA*, John W Kitchens MD* 

Instructor(s): Andrew A Moshfeghi MD* 

EQUIP The iPhone for Ophthalmologists (Basic) 

Course Director(s): Vinay A Shah MD 


Sunday, 1:30 - 3:30 PM 

Room: N227a 


Fee: $130.00 

EduLevel: BAS 

Synopsis: Currently, about 80% of physicians utilize a smartphone, and this number is 

expected to rise. In fact, estimates have shown the iPhone as having 50% of the smartphone 

market. Because of the iPhone’s advanced technology, ease of use, and market 

penetration, there are now numerous applications to improve a physician’s practice efficiency 

and overall patient care and experience. This course will introduce the user to 

more intermediate applications of the iPhone in the following areas: (1) office management: 

calendar integration, ICD-9 codes, and patient scheduling, (2) ophthalmic exam 

tools for the adult and pediatric patient: near vision cards, Amsler grids, color plates, optokinetic 

nystagmus drums and pupil gauges, optotypes, pediatric attention getters, and 

tools for performing external slitlamp and fundus photography, (3) patient education with 

videos and diagrams, (4) electronic medical records and patient consents, (5) marketing 

and branding through social media and a personalized doctor application, and (6) physician 

education / reference material: eye atlas, study reference guides, pharmacopoeia, 






117



and board review study material. The iPhone is a powerful electronic device with novel 

uses in ophthalmology, both in patient care and as a reference guide. 

Objective: By the conclusion of the course, attendees will understand and be able to use 

the iPhone not only as a powerful communication device and personal digital assistant 

but also for patient care, as a reference guide, for their own education, and to make their 

practices more efficient. 

Note: Each participant is required to bring their iPhone. This is the Basic 

session. For the Advanced session please see LAB192B. You do NOT need to 

attend both sessions as there will be overlap between the two labs. 

Senior Instructor(s): Rohit Krishna MD 

Instructor(s): Ron K Lord MD, Hemang K Pandya MD, Michael A Cassell MD, Theodore 

Leng MD, Robert T Chang MD, Nicholas R Binder MD, Peter N Lombard MD 

EQUIP LAB192B The iPhone for Ophthalmologists (Advanced) 

Course Director(s): Vinay A Shah MD, Ron K Lord MD 


Monday, 9:00 - 11:00 AM 

Room: Room: N227a 


Fee: $130.00 

EduLevel: ADV 

Synopsis: About 80% of physicians utilize smartphones, and this number is expected 

to rise. Recently, the iPhone has covered about 50% of the smartphone market. This 

course will introduce the user to intermediate to advanced applications of the iPhone in 

following areas: (1) office management: calendar, ICD-9 codes, schedules, etc., (2) patient 

care tools: near vision card, Amsler grid, color plates, optokinetic nystagmus drum, pupil 

gauge, patient consents, and performing external, slitlamp, and fundus photography, (3) 

patient education material: diagrams and videos, (4) physician education / reference material: 

eye atlas, study reference guides, pharmacopoeia, and board review study material, 

(5) discussing marketing and branding of one’s practice and services through social 

media and a Personalized Doctor Application, (6) use of the iPhone for personal use will 

be discussed, from making a conference call to using various handy iPhone apps. The 

iPhone is a powerful electronic device with novel uses in ophthalmology in patient care 

and as a reference guide. 

Objective: At the conclusion of the course, the attendees will understand and be able 

to use the iPhone not only as a powerful communication device and personal digital assistant 

but also for patient care, as a reference guide, for their own education, and to 

make their practices more efficient. 

Note: Each participant is required to bring their iPhone. This is the Advanced 

session. For the Basic session see LAB192A. You do NOT need to 

attend both sessions as there will be overlap between the two labs. . 

Instructor(s): Peter N Lombard MD, Rohit Krishna MD, Robert T Chang MD, Michael A 

Cassell MD, Nicholas R Binder MD, Theodore Leng MD, Hemang K Pandya MD 


Anterior Lamellar Keratoplasty: Principles and Practice 

Course Director(s): Sheraz M Daya MD*, Sadeer B Hannush MD 



Sunday, 3:15 - 5:30 PM 

Room: S102D 


EduLevel: INT 

Synopsis: This course will cover current and evolving practice in anterior lamellar keratoplasty. 

Topics include evolving lamellar techniques, including the “big bubble,” modified 

Melles, viscodissection, Ferrara, and automated and femtosecond lamellar techniques. 

A series of didactic lectures will be provided, with technique pearls (and complications) 

supported by video presentations and handouts. The lecture portion will be a prerequisite 

for the wet lab, where candidates will be guided through many of the techniques. 

Objective: The participant should leave the course with an understanding of the various 

options for performing anterior lamellar keratoplasty. The participant will have a thorough 

understanding of the indications, advantages, and disadvantages of each of these 

techniques. 

Senior Instructor(s): Sheraz M Daya MD*, Sadeer B Hannush MD 

Instructor(s): Woodford S Van Meter MD FACS, William W Culbertson MD*, Luigi Fontana 

MD PhD, Shigeto Shimmura MD, Donald Tan MD FRCS FRCOphth* 

Lab 

Synopsis: This course will cover current and evolving practice in anterior lamellar 

keratoplasty. An international faculty will cover different lamellar dissection techniques 

and will include the “big bubble,” viscodissection, modified Melles, and automated and 

femtosecond lamellar deep anterior lamellar keratoplasty. Avoiding and managing complications 

will also be discussed. Candidates will be guided through these techniques 

by expert and experienced faculty, and there will be opportunity for in-depth discussion. 

Objective: The participant should leave the lab with hands-on training on the use of 

various options for performing anterior lamellar keratoplasty. 


Monday, 8:00 - 10:00 AM 

Room: N227B 


Fee: $240.00 

EduLevel: INT 

Senior Instructor(s): Sheraz M Daya MD*, Sadeer B Hannush MD 

Instructor(s): Woodford S Van Meter MD FACS, William W Culbertson MD*, Luigi Fontana 

MD PhD, Shigeto Shimmura MD, Donald Tan MD FRCS FRCOphth*, Brandon Ayres MD*, 

Deepinder K Dhaliwal MD, Jose Gomes MD*, Nabil E Habib MD*, Samer Hamada MD, 

Damian Lake MBChB, Mayank A Nanavaty MD, Rebecca Papadopoulos MD, Irving M 

Raber MD, Konstantinos Samaras MD, Vincenzo Sarnicola MD, Mike Tappin FRCOphth**, 

Elmer Tu MD, Federico Badala MD, Rajesh Fogla MD FRCS 

NEW Endothelial Keratoplasty Surgery: Comprehensive 

Overview and Surgical Pearls 

Course Director(s): Edward J Holland MD* 



Monday, 10:15 AM - 12:30 PM 

Room: S102D 

Target Audience: 

EduLevel: 

Synopsis: Endothelial keratoplasty (EK) has become the standard of care for the surgical 

treatment of endothelial diseases of the cornea. This course will utilize international 

corneal experts to teach a comprehensive overview of a variety of surgical techniques 

and surgical pearls for EK. In addition, complication management and new Descemetstripping 

EK and Descemet membrane EK techniques will be discussed. 

Objective: An international faculty will discuss the latest surgical techniques in endothelial 

keratoplasty surgery. The course will cover the most current DSEK and DMEK 

surgical methods including a variety of tissue preparation and insertion techniques. This 

course will also cover post operative management and complications of DSEK and DMEK 

surgery. 

Instructor(s): Francis W Price Jr MD*, Donald Tan MD FRCS FRCOphth*, Massimo Busin MD*, 

Mark J Mannis MD, David T Vroman MD*, William Barry Lee MD*, Keith A Walter MD* 

Lab 

Synopsis: This laboratory course will utilize international corneal experts to teach a 

comprehensive overview of a variety of surgical techniques and surgical pearls for endothelial 

keratoplasty (EK). Attendees will receive hands-on experience with all steps 

of Descemet-stripping EK and Descemet membrane EK (DMEK), including donor tissue 

preparation, endothelial tissue insertion techniques, and experience with thin EK and 

DMEK techniques. 

Objective: An international faculty will discuss the latest surgical techniques in endothelial 

keratoplasty surgery. The course will cover the most current DSEK and DMEK 

surgical methods including a variety of tissue preparation and insertion techniques. This 

course will also cover post operative management and complications of DSEK and DMEK 

surgery. 


Monday, 1:30 - 3:30 PM 

Room: N227B 


Fee: $240.00 

EduLevel: 

Senior Instructor(s): Edward J Holland MD* 

Instructor(s): Francis W Price Jr MD*, Friedrich E Kruse MD**, Donald Tan MD FRCS 

FRCOphth*, David B Glasser MD, Massimo Busin MD*, Mark J Mannis MD, David T Vroman 

MD*, William Barry Lee MD*, Keith A Walter MD*, David D Verdier MD, Shahzad I 

Mian MD*, Richard S Davidson MD*, Clara C Chan MD*, Andrea Y Ang MBBS, Kristiana 

D Neff MD*, Heather M Skeens MD**, Mahshad Darvish-Zargar MD, Jennifer Y Li MD, J 

Brian Foster MD**, Kenneth C Mathys MD, Joseph S Tims MD, Florentino E Palmon MD, 

Joseph M Biber MD, Michael J Taravella MD, Vipul C Shah MD 


118 






Course Director(s): Mark A Terry MD* 



Monday, 3:15 - 5:30 PM 

Room: S105A 


EduLevel: INT 

Synopsis: This course will explore the various surgical techniques used for endothelial 

keratoplasty (EK): Descemet-stripping EK, Descemet-stripping automated EK, and Descemet 

membrane EK. Emphasis will be placed on basic techniques that minimize complications 

and maximize donor endothelial survival. Methods of donor tissue preparation, 

insertion, unfolding, and positioning will be discussed. Benefits and problems with tissue 

injectors will be presented. Techniques to promote donor tissue adhesion and to avoid 

primary graft failure will be emphasized. Detailed videos and discussion of EK in complex 

and combined cases will be presented. 

Objective: At the conclusion of the course, participants will understand the safest 

methods of EK to avoid dislocation, primary graft failure, and pupillary block, and how to 

enhance faster visual rehabilitation. 

Senior Instructor(s): Mark A Terry MD*, Kenneth M Goins MD, George O D Rosenwasser 

MD* 

Lab 

Synopsis: This laboratory course will allow participants to become familiar with the 

instrumentation and surgical techniques involved with various forms of endothelial keratoplasty 

(EK): Descemet-stripping EK, Descemet-stripping automated EK, and Descemet 

membrane EK. Use of the microkeratome and femtosecond laser for donor preparation 

may be available. Safe methods of donor insertion, unfolding, and positioning will be 

stressed. Techniques of promoting donor adherence and avoiding primary graft failure 

will be practiced. 

Objective: At the conclusion of this course, the participants will understand the complexity 

and required instrumentation for these various techniques of endothelial keratoplasty. 

Techniques to avoid complications and preserve donor endothelial cells will be 

understood. 


Tuesday, 10:00 AM - 12:00 PM 

Room: N227B 


Fee: $240.00 

EduLevel: INT 

Senior Instructor(s): Mark A Terry MD*, George O D Rosenwasser MD*, Kenneth M 

Goins MD 

Instructor(s): Neda Shamie MD*, Anand K Shah MD, Irving M Raber MD, Paul M Phillips 

MD, Karen L Hoar MD**, Alexandre S Marcon MD, David D Verdier MD, Mark S Gorovoy 

MD, Edwin S Chen MD, Thomas John MD*, Ann McColgin MD, Rajesh Fogla MD FRCS, 

Vincenzo Sarnicola MD, Robert L Schultze MD*, Luciene Sousa MD*, Michael D Straiko 

MD*, Anita Panda MD FAMS FICS FICO MRCOPHTH, Ashraf F Amayem MD, Colleen C 

Grace MD, Jeffrey M Goshe MD, Jennifer Y Li MD, Julia C Talajic MD 

w Surgery for Severe Corneal and Ocular Surface Disease 

Course Director(s): Ali R Djalilian MD, Gunther Grabner MD* 



Tuesday, 9:00 - 11:15 AM 

Room: S102D 


EduLevel: ADV 

Synopsis: This course is intended for ophthalmologists who plan to expand their surgical 

skills in the management of severe corneal and ocular surface disease. The topics 

will include amniotic membrane transplantation, limbal stem cell transplantations, and 

keratoprosthesis. 

Objective: At the conclusion of this course, the attendee will be able to (1) describe 

the indications and apply the surgical techniques for amniotic membrane transplantation, 

(2) recognize limbal stem cell deficiency and effectively apply the various surgical 

techniques for limbal stem cell transplantation, (3) recognize and successfully prevent/ 

treat limbal allograft rejection using systemic immunosuppression, and (4) describe the 

patient selection, surgical techniques, and postoperative management of patients with 


Instructor(s): Edward J Holland MD*, Scheffer C G Tseng MD PhD*, James Chodosh MD 

MPH*, Jose J de la Cruz Napoli MD, Ahmad Kheirkhah MD, Eduardo C Alfonso MD* 

Lab 

Synopsis: This course is intended for ophthalmologists who plan to expand their surgical 

skills in the management of severe corneal and ocular surface disease. The topics 

will include amniotic membrane transplantation, limbal stem cell transplantations, and 


Objective: At the conclusion of this course, the attendee will be able to (1) describe the 

indications and apply the surgical techniques for amniotic membrane transplantation, 

(2) recognize limbal stem cell deficiency and effectively apply the various surgical techniques 

for limbal stem cell transplantation, (3) recognize and successfully prevent/treat 

limbal allograft rejection with the use of systemic immunosuppression, and (4) describe 

the patient selection, surgical techniques, and postoperative management of patients 

with keratoprosthesis. 


Tuesday, 3:00 - 5:00 PM 

Room: N227B 


Fee: $240.00 

EduLevel: INT 

Instructor(s): Michael Nordlund MD*, Andrew J W Huang MD MPH*, Jose Gomes MD*, 

Jose J de la Cruz Napoli MD, Joung Y Kim MD, David D Verdier MD, Daniel H Scorsetti 

MD, Julie H Tsai MD, Heather M Skeens MD**, Pedram Hamrah MD*, Vadrevu K Raju 

MD FRCS FACS, Anthony J Lubniewski MD*, Ahmad Kheirkhah MD, Kristiana D Neff 

MD*, Clara C Chan MD*, Maria S Cortina MD, Aisha S Traish MD, Pejman Bakhtiari MD 

Glaucoma 

Computerized Scanning Imaging of the Optic Nerve and 

Retinal Nerve Fiber Layer 

Course Director(s): Neil T Choplin MD* 



Sunday, 9:00 - 11:15 AM 

Room: S105BC 


EduLevel: BAS 

Synopsis: This lecture, required for the hands-on workshop, introduces the participant 

to the principles of computerized scanning imaging. This is a basic course featuring current 

technologies. The main emphasis in this course will be spectral (Fourier) domain 

OCT, although some discussion of scanning laser polarimetry and topography (Heidelberg 

Retinal Tomography) will be included. 


the scientific basis for imaging, (2) understand how scanning imaging may be used in 

clinical practice, (3) learn how imaging can be applied to the optic nerve head, retinal 

nerve fiber layer, and macula, with emphasis on glaucoma, (4) understand the relationship 

between structure and function, and (5) differentiate normal from abnormal scans 

through appropriate clinical examples. A question-and-answer session will be held at the 

end of the presentations, during which time questions will be entertained by the faculty. 



Labs 

Synopsis: This workshop will familiarize participants with the clinical uses of computerized 

scanning imaging of the retina and optic nerve, with emphasis on spectral (Fourier) 

domain OCT. The main focus of the workshop will be interpretation of representative 

printouts from clinical examples. Instructors will be available to discuss scanning laser 

polarimetry (GDx) and confocal scanning tomography (Heidelberg Retinal Tomography) 

for interested participants. 


image quality control and the indications for repeating images, (2) become familiar with 

the analysis software, and (3) practice interpretation of representative cases. 



Sunday, 3:30 - 5:30 PM 

Room: N231 


Fee: $130.00 

EduLevel: BAS 








119




Room: N231 

Fee: $130.00 



Monday, 11:30 AM - 1:30 PM 


EduLevel: BAS 

NEW Is It Time to Replace Gonioscopy by Anterior Segment 

Imaging in the Diagnosis and Management of Angle-Closure 

Glaucoma? 

Course Director(s): Syril Dorairaj MD 


Sunday, 9:30 - 11:30 AM 

Room: N231 


Fee: $130.00 

EduLevel: BAS 

Synopsis: Angle-closure glaucomas (ACGs) are a group of disorders characterized by 

mechanical blockage of the trabecular meshwork by the peripheral iris, resulting from 

interactions between the structures and hydrodynamics inside the eye. Imaging of the 

anterior segment (AS) is an essential tool aiding the diagnosis and understanding the 

mechanism and management of ACG. Various imaging devices are now available, each 

one representing particular technical advantages/disadvantages over the others. Anterior 

segment imaging cannot replace the direct visualization of angle structures, but it can 

overcome some of the limitations of gonioscopy by providing a more objective means of 

obtaining a qualitative and quantitative evaluation of the angle. Recent advances in ocular 

imaging have included high-resolution techniques for visualizing the anterior segment 

and angle structures. These imaging techniques are enlightening clinicians and researchers 

about the importance of making an early diagnosis, establishing underlying causal 

mechanisms, and evaluating treatments. 

Instructor(s): Christopher Kai-shun Leung MD MBChB*, Vishal Jhanji MBBS , Paul F 

Palmberg MD, Clement C Y Tham MBBS, Tin Aung FRCS 

Glaucoma Filtration Surgery 

Course Director(s): George A Cioffi MD* 



Sunday, 3:15 - 5:30 PM 

Room: S105BC 


EduLevel: INT 

Synopsis: This course provides a comprehensive review of the techniques and complications 

of glaucoma filtration surgery. Glaucoma surgical technique will be stressed in this 

update of filtration surgery, with a heavy emphasis on surgical video presentations. The 

course will also discuss novel surgical techniques used in filtration surgery, such as Ex- 

PRESS shunts, as compared to conventional surgery. A panel discussion with questions 

and answers will conclude the session. 

Objective: This course will review surgical anatomy, basic trabeculectomy techniques, 

antimetabolites (including 5-fluorouracil and mitomycin C), and postoperative management 

and complications. 

Senior Instructor(s): George A Cioffi MD* 

Instructor(s): Jeffrey M Liebmann MD*, F Jane Durcan MD, Robert D Fechtner MD FACS*, 

Kuldev Singh MD MPH*, Steven L Mansberger MD*, Celso Tello MD* 

Lab 

Synopsis: This Skills Transfer course will offer hands-on instruction on glaucoma filtration 

surgery specifically for the general ophthalmologist. The lab session will provide 

experience with the techniques of trabeculectomy. 

Objective: Using porcine eyes and dissection microscopes (one per student), glaucoma 

surgical techniques will be performed. Surgical anatomy, scleral flap dissection, fistula 

creation, iridectomy, and closure techniques will be performed. 


Monday, 8:00 - 9:30 AM 

Room: N230 


Fee: $190.00 

EduLevel: INT 

Senior Instructor(s): John C Morrison MD 

Instructor(s): Young H Kwon MD PhD*, Paul A Sidoti MD*, Frank J Mares MD, Michael R 

Banitt MD*, Christopher J Engelman MD, Kevin P Pikey DO**, Steven D Vold MD*, Tak 

Yee Tania Tai MD 

R w Glaucoma Surgical Lab for Ophthalmology Residents 

Course Director(s): Thomas W Samuelson MD* 


Monday, 1:30 - 3:00 PM 

Room: N230 


Fee: $100.00 

EduLevel: INT 

Senior Instructor(s): Thomas W Samuelson MD* 

Instructor(s): Iqbal K Ahmed MD*, George L Spaeth MD FACS*, Mark B Sherwood MD*, 

Michael C Stiles MD*, Leslie S Jones MD, Jonathan S Myers MD*, James D Brandt 

MD*, Martha M Wright MD, Garry P Condon MD**, Julia Whiteside-de Vos MD MPH*, 

Richard Lee MD*, Steven Gedde MD*, J Brent Bond MD*, Robert P Liss MD, Patrick J 

Riedel MD, Husam Ansari MD PhD**, Amy W Gemperli MD, Davinder S Grover MD* 


Implantation of Glaucoma Drainage Devices 

Course Director(s): Richard P Mills MD MPH 



Sunday, 3:15 - 5:30 PM 

Room: N138 


EduLevel: INT 

Synopsis: The first part of this course is didactic, covering the indications, pathophysiology, 

surgical technique, postoperative management, and complications of drainage 

devices (from anterior chamber tube to extraocular reservoir). The second part is handson, 

with implantation of Molteno, Krupin, Baerveldt, Ahmed, and Schocket devices on 

porcine eyes. Ex-PRESS shunt, Trabectome, and canaloplasty will not be covered. 

Objective: At the conclusion of this course, the attendee will be aware of principles and 

techniques of glaucoma drainage device implantation. 

Senior Instructor(s): Richard P Mills MD MPH 

Instructor(s): George Baerveldt MD*, Theodore Krupin MD, Anne Louise Coleman MD 

PhD, Frederick M Kapetansky MD, Donald L Budenz MD MPH*, Paul A Sidoti MD*, 

Ronald Leigh Fellman MD OCS* 

Lab 

Synopsis: The first part of this course is didactic, covering the indications, pathophysiology, 

surgical technique, postoperative management, and complications of drainage 

devices (from anterior chamber tube to extraocular reservoir). The second part is handson, 

with implantation of Molteno, Krupin, Baerveldt, Ahmed, and Schocket devices on 

porcine eyes. Ex-PRESS shunt, Trabectome, and canaloplasty will not be covered. 

Objective: By the conclusion of this course, attendees will be able to complete a drainage 

device implantation in a fresh tissue eye. 


Monday, 10:30 AM - 12:30 PM 

Room: N230 


Fee: $240.00 

EduLevel: INT 

Senior Instructor(s): Theodore Krupin MD 

Instructor(s): Mark S Juzych MD**, Paul A Sidoti MD*, Martha Motuz Leen MD*, 

Alfred M Solish MD*, Keith Barton MD*, Ronald Leigh Fellman MD OCS*, Frederick M 

Kapetansky MD, Howard Barnebey MD*, Eugenio J Maul MD, Margaret Sophia Spencer 

MD, Marianne E Feitl MD, Simon K Law MD*, Joern B Soltau MD*, Steven Gedde MD*, 

Sameh Mosaed MD**, JoAnn A Giaconi MD* 

Computerized Perimetry Lecture: Visual Field Testing and 

Interpretation, Emphasizing Glaucoma 

Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 


Course Director(s): Julia Whiteside-de Vos MD MPH* 



Sunday, 3:15 - 5:30 PM 

Room: S105A 


EduLevel: BAS 

Synopsis: This Academy/AGS lecture reviews computerized perimetry theory and application, 

emphasizing glaucoma and the Humphrey field analyzer as a basis for subsequent 

comparison with Octopus perimetry, which will be briefly introduced. Octopus perimetry 

then will be covered in more detail in the Skills Transfer lab. The stepwise interpretation 


120 





of individual Humphrey visual fields (VFs) will be outlined, explaining the significance of 

each portion of the VF printout and the techniques for determining if the VF is reliable and 

if it is normal or abnormal. SITA, SWAP, frequency doubling perimetry, and the analysis 

of a series of VFs for progression (using event and trend methods) will be discussed. 

Tips for obtaining a better, more reliable VF test and for selecting the appropriate test 

for different patients will be summarized. Numerous case examples will be used. Most 

examples will be of glaucomatous VF abnormalities. Nonglaucomatous and hydroxychloroquine 

changes also will be briefly covered. Participants wanting (1) more information 

regarding Octopus perimetry and (2) practice reading Humphrey or Octopus VFs should 

take the supplemental lab. 

Objective: This course is designed to provide participants with the background knowledge 

necessary to be more comfortable with visual field interpretation and to be prepared 

for the separate laboratory session. 

Senior Instructor(s): Julia Whiteside-de Vos MD MPH* 

Lab 

Synopsis: This Academy/AGS lab will prepare clinicians to interpret computerized visual 

fields (VFs) and use them more effectively in the diagnosis and management of glaucoma 

patients. The first hour of the lab will be devoted to a lecture format presentation of 

more detailed information regarding Octopus perimetry. Participants subsequently will 

be able to spend two hours practicing interpreting Humphrey or Octopus unknown visual 

fields. Emphasis will be on glaucomatous VF changes. Interpretation of individual visual 

fields and of series of VFs for progression evaluation will be covered, using event and 

trend progression analysis methods corresponding to the type of perimeter the participant 

has chosen for concentration. Instructors have 15 to 20 years’ experience teaching VF 

interpretation. Laboratory participation is strongly encouraged to maximize the learning 

experience of the two-part Skills Transfer Computerized Perimetry course. 

Objective: This course is designed to enable participants to master the skills necessary 

for interpreting automated VFs and for using them in the management of glaucoma 

patients. 


Monday, 8:00 - 11:00 AM 

Room: N231 


Fee: $170.00 

EduLevel: BAS 

Senior Instructor(s): Julia Whiteside-de Vos MD MPH*, Jonathan S Myers MD* 

Instructor(s): Michael Berlin MD, E Randy Craven MD*, Marc Lieberman MD, Todd W 

Perkins MD*, Jeffrey S Schultz MD*, David E Silverstone MD, Martha M Wright MD, 

Anand V Mantravadi MD* 

w Schlemm Canal Surgery 

Course Director(s): Richard A Lehrer MD* 



Monday, 10:15 AM - 12:30 PM 

Room: N137 


EduLevel: INT 

Synopsis: Early results of nonpenetrating glaucoma surgery, an alternative approach in 

glaucoma filtering surgery, have shown comparable results with a reduction in overall 

complications. Yet this technique has a steep learning curve, with its own set of unique 

challenges. This course will present a systematic, multimedia, video-assisted review of 

the anatomy, rationale, explanation, and illustration of canaloplasty. 

Objective: This course will explain (1) the procedure’s method of re-establishing aqueous 

outflow, (2) the procedure’s advantages, disadvantages, risks, and benefits, and (3) 

the identification of glaucomas where the procedure would have highest probability of 

success. Recent clinical results and innovations to enhance the procedure will also be 

discussed. 


Instructor(s): Alan S Crandall MD*, Robert Stegmann MD**, Clive O Peckar MD*, Howard 

Barnebey MD*, John R Kearney MD 

Lab 

Synopsis: This course will demonstrate and train attendees in the procedure of viscodilation 

of the Schlemm canal. Attendees will be mentored in the procedure, with microscopic 

dissection and catheter and tension suture placement in the Schlemm canal. 

Objective: At the conclusion of this course, the attendees should have a good understanding 

of and hands-on ability to perform this procedure, from the insertion of the 

microcatheter through placement of the suture invaginating the trabecular meshwork. 

Note: Attendees should have experience with nonpenetrating glaucoma 

surgery. 


Monday, 3:30 - 5:30 PM 

Room: N230 


Fee: $240.00 

EduLevel: INT 


Instructor(s): Alan S Crandall MD*, Clive O Peckar MD*, Robert Stegmann MD**, Howard 

Barnebey MD*, John R Kearney MD, Robert P Liss MD, Baseer U Khan MD*, Sebastien 

Gagne MD** 

Glaucoma Laser Therapy: Innovations and Advice From the 

Experts 

Course Director(s): Lisa S Gamell MD, Robert J Noecker MD* 



Monday, 2:00 - 4:15 PM 

Room: S105BC 


EduLevel: INT 

Synopsis: This course will provide a comprehensive review of standard, new, and 

emerging laser procedures used in the treatment of glaucoma. Topics discussed will include 

argon laser trabeculoplasty (ALT), selective laser trabeculoplasty (SLT), micropulse 

laser trabeculoplasty (MLT), cyclophotocoagulation (both endoscopic and transscleral), 

iridotomy (Nd:YAG, argon, diode, and krypton), and iridoplasty. Laser enhancement of 

filtering procedures will be covered as well, including laser suture lysis and bleb revision. 

Indications, treatment techniques, and postoperative care will be discussed in detail during 

the didactic portion of the course. During the laboratory section, participants will have 

the opportunity to perform endoscopic cyclophotocoagulation, transscleral cyclophotocoagulation, 

SLT, ALT, MLT, and iridotomies under the supervision of the course instructors. 

Objective: At the conclusion of this course, attendees will be able to understand the 

indications and techniques for the various laser therapies used in the treatment of glaucoma. 

After the laboratory section, they will have hands-on experience using these modalities 

on animal eyes. 

Instructor(s): Joel S Schuman MD*, Jorge A Alvarado MD, Mark A Latina MD*, Malik Y 

Kahook MD*, Brian E Flowers MD* 

Lab 

Synopsis: This course provides a comprehensive review of standard, new, and emerging 

laser procedures used in the treatment of glaucoma. Topics discussed will include 

argon laser trabeculoplasty (ALT), selective laser trabeculoplasty (SLT), micropulse laser 

trabeculoplasty (MLT), cyclophotocoagulation (both endoscopic and transscleral), iridotomy 

(Nd:YAG, argon, diode, and krypton), and iridoplasty. Laser enhancement of filtering 

procedures will be covered as well, including laser suture lysis and bleb revision. During 

the laboratory section, participants will have the opportunity to perform endoscopic cyclophotocoagulation, 

transscleral cyclophotocoagulation, SLT, ALT, MLT, and iridotomies 

under the supervision of the course instructors. 

Objective: At the conclusion of this course, attendees will be able to understand the 

indications and techniques for the various laser therapies used in the treatment of glaucoma. 

After the laboratory section, they will have hands-on experience using these modalities 

on animal eyes. 

Note: Participants will be sharing equipment. 


Tuesday, 8:00 - 10:00 AM 

Room: N230 


Fee: $240.00 

EduLevel: INT 

Senior Instructor(s): Lisa S Gamell MD, Robert J Noecker MD* 

Instructor(s): Joel S Schuman MD*, Jorge A Alvarado MD, Mark A Latina MD*, Malik Y 

Kahook MD*, Brian E Flowers MD*, Martin Uram MD* 






121



w Trabeculotomy by Internal Approach Surgery for Adult 


Course Director(s): Brian A Francis MD* 



Monday, 3:15 - 5:30 PM 

Room: N138 


EduLevel: INT 

Synopsis: Angle-based surgery for glaucoma via an internal approach is covered in this 

course. The Trabectome, cleared for clinical use by the FDA, is a new instrument for surgical 

treatment of open-angle glaucoma. The didactic part of this course will describe accumulated 

data from an ongoing case series exceeding 2000 eyes, including combined cataract 

and glaucoma surgery. Published data, including case series, and comparative trials 

with cataract surgery alone, trabeculectomy, and aqueous tube shunt, will be presented. 

Indications, surgical technique, IOP outcomes, and complications will be described during 

a one-hour didactic course. Surgical tips including proper identification of angle structures 

using the gonioscopic approach will be emphasized. This may also be followed by a 

hands-on lab session using inverted corneal donor rings for practice. 

Objective: At the conclusion of the course, attendees will understand the indications, 

surgical technique, IOP outcomes, and complications associated with this device. 

Senior Instructor(s): Sameh Mosaed MD** 

Instructor(s): Nils A Loewen MD*, Iqbal K Ahmed MD* 

Labs 

Synopsis: During a one-hour lab session, attendees will practice with a Trabectome 

console and handpiece, with adjustable power level and foot-pedal control, and a tissue 

model consisting of an inverted human corneal ring, including the trabecular meshwork. 

The corneal donor ring will be pin-fixated to a rubber holding device. Practice surgery will 

be done via an operating microscope, enabling a realistic view of the instrument effects 

as the Schlemm canal is unroofed by electroablation. Simultaneous video illustrating the 

gonioscopic view and live surgeries will also be presented. 

Objective: At the course conclusion, the attendees will have had a realistic exposure to 

the surgical technique and one-on-one discussion of the advantages and disadvantages 

of the Trabectome procedure. 




Tuesday, 11:00 AM - 12:00 PM 

Room: N230 


Fee: $165.00 

EduLevel: INT 

Senior Instructor(s): Donald S Minckler MD*, Sameh Mosaed MD**, George Baerveldt 

MD* 

Instructor(s): Quang H Nguyen MD*, Douglas J Rhee MD*, Paul A Sidoti MD*, Arthur J 

Sit MD*, Michael C Stiles MD*, Steven D Vold MD*, Martha Motuz Leen MD*, Marina 

A Ramirez MD**, Edward M Barnett MD PhD*, Troy M Tanji MD, Mitsunori Watanabe 

MD**, Masahiro Maeda MD 


Tuesday, 12:30 - 1:30 PM 

Room: N230 


Fee: $165.00 

EduLevel: INT 

Senior Instructor(s): George Baerveldt MD*, Donald S Minckler MD*, Sameh Mosaed 

MD** 

Instructor(s): Carla J Siegfried MD*, Douglas J Rhee MD*, Martha Motuz Leen MD*, Paul 

A Sidoti MD*, Quang H Nguyen MD*, Arthur J Sit MD*, Masahiro Maeda MD 


Neuroimaging in Ophthalmology 



Course Director(s): Christopher C Glisson DO* 


Tuesday, 8:30 - 10:30 AM 

Room: N231 


Fee: $130.00 

EduLevel: INT 

Synopsis: This review of CT and MRI scans of the head and orbit will improve participants’ 

knowledge of anatomy and imaging analysis using illustrative cases. The course 

will be supervised by experienced neuro-ophthalmologists and will employ a hands-on 

format, and participants will gain knowledge to enhance skills used when ordering and 

evaluating imaging. 

Objective: Participants will recognize normal and pathologic structures on CT and MRI 

scans and become proficient at reviewing neuroimaging studies and recognizing the indications 

for ordering various types of imaging. 

Senior Instructor(s): Eric Eggenberger DO*, Eric L Berman MD 

Instructor(s): Jade Schiffman MD, Larry P Frohman MD, Jacqueline A Leavitt MD, Michael 

C Brodsky MD, Nicholas J Volpe MD, Michael S Vaphiades DO, Rosa A Tang MD*, Julie 

Falardeau MD, John Pula MD*, Melissa W Ko MD 


EQUIP Soft Contact Lens Fitting for the Practicing 



the Contact Lens Association of Ophthalmologists (CLAO) 

Course Director(s): Peter C Donshik MD*, William H Ehlers MD 


Sunday, 9:00 - 11:30 AM 

Room: N227A 


Fee: $130.00 

EduLevel: BAS 

Synopsis: To appropriately utilize contact lenses in practice, the Eye M.D. needs to recognize 

suitable candidates, select the most appropriate lens, and know how to fit and 

evaluate the contact lens. This course is for Eye M.D.s who want to add or expand soft 

contact lens fitting in their practices. The learning format includes PowerPoint presentations, 

videos, and interactive computer simulations to demonstrate and teach soft contact 

lens fitting skills. The attendee will utilize computer simulation to place and evaluate 

multiple soft contact lens fittings. Individual assistance will be available to attendees 

during the computer simulation training. 

Objective: This course will teach the practitioner (1) recognition of suitable candidates, 

(2) appropriate soft lens selection, (3) soft spherical and toric lens fitting, and (4) patient 

and practice management. 

Note: Each participant must bring their PC laptops (No MACS). Must have 

ability to load CD’s. Need Windows XP, Windows Vista or Windows 7. 

Senior Instructor(s): Melvin I Freeman MD FACS* 

Instructor(s): William T Driebe MD, Zoraida Fiol-Silva MD*, Michael H Goldstein MD*, 

Jeanine Suchecki MD, Bruce Koffler MD*, Peter R Kastl MD PhD, John S Massare PhD 


W Cosmetic Botulinum Toxin and Facial Fillers: An 

Introductory Course 

Course Director(s): Kathleen M Duerksen MD 



Sunday, 9:00 - 11:15 AM 

Room: S105D 


EduLevel: BAS 

Synopsis: Principles of aesthetic facial injection of botulinum toxin and facial fillers will 

be presented in a didactic format. 


122 





Objective: At the conclusion of this course, the attendee will better understand the salient 

anatomy, clinical techniques (including complication avoidance), and pharmacological 

principles pertaining to aesthetic injection of these substances. 

Senior Instructor(s): Michael S McCracken MD, Deborah D Sherman MD*, John Joseph 

Martin MD* 

Lab 

Synopsis: Taught by experienced instructors, the lab provides hands-on, personalized 

instruction in the basics of botulinum toxin and facial filler injections utilizing cadaver 

heads. 

Objective: At the completion of the lab, the participant will be able to identify the proper 

sites, doses, and indications for injection of botulinum toxin and facial fillers. The participant 

will demonstrate proper injection technique with the goal of avoiding techniquerelated 


Note: Participants are required to bring surgical loupes. 


Sunday, 3:30 - 5:00 PM 

Room: N229 


Fee: $305.00 

EduLevel: BAS 

Senior Instructor(s): Michael S McCracken MD, Deborah D Sherman MD* 

Instructor(s): Cat Burkat MD, Christopher M DeBacker MD, Jeffrey P Edelstein MD*, 

Craig Erwin Geist MD, Ioannis P Glavas MD, Morris E Hartstein MD*, Ronald W Kristan 

MD, John Joseph Martin MD*, Dale R Meyer MD FACS, Asa Dan Morton III MD*, Gary 

Borodic MD**, Rona Z Silkiss MD FACS, Charles B Slonim MD FACS*, Fred S Bodker MD, 

Julie A Woodward MD*, Kenneth David Steinsapir MD*, Janet M Neigel MD*, Dawn C 

Buckingham MD 

Introduction to Aesthetic Facial Surgery by Fractional 

Lasers, Intense Pulsed Light, Radiofrequency, and 

Ultrasound Devices 

Course Director(s): Julie A Woodward MD* 



Sunday, 9:00 - 11:15 AM 

Room: S102D 


EduLevel: BAS 

Synopsis: This course will focus primarily on ablative fractional and non-fractional laser 

resurfacing and incisional blepharoplasty because this is the only rejuvenating technology 

limited to physicians. Pre-operative, intra-operative, and post-operative care as 

well as management of complications and marketing will be covered. There will also 

be introductions to the latest in non-ablative fractional resurfacing, radiofrequency, and 

micro-focused ultrasound. 

Objective: By the conclusion of this course, attendees will be able to (1) compare and 

contrast the many different devices on the market,(2) have introductory knowledge of 

how to incorporate such new technologies into their practices, and (3) recognize and 

manage complications of these devices. 


Instructor(s): Erin Holloman MD, Raminder K Saluja MD*, Usha P Reddy MD, Randal Pham 

MD FACS, Adam J Scheiner MD*, John Joseph Martin MD*, Ioannis P Glavas MD 

Lab 

Synopsis: This course will focus primarily on ablative fractional and non-fractional laser 

resurfacing and incisional blepharoplasty because this is the only rejuvenating technology 

limited to physicians. Pre-operative, intra-operative, and post-operative care as 

well as management of complications and marketing will be covered. There will also 

be introductions to the latest in non-ablative fractional resurfacing, radiofrequency, and 

micro-focused ultrasound. 

Objective: At the completion of this course, participants will (1) understand safe application 

of rejuvenation technology, (2) learn how to manage complications, and (3) start to 

choose which devices and procedures to incorporate into their current practices. 



Sunday, 12:30 - 2:30 PM 

Room: N230 


Fee: $240.00 

EduLevel: BAS 


Instructor(s): Erin Holloman MD, Randal Pham MD FACS, Adam J Scheiner MD*, John 

Joseph Martin MD*, Ioannis P Glavas MD 

Basic Oculoplastic Surgery 

Course Director(s): Eve E Moscato MD 


Sunday, 9:00 - 11:30 AM 

Room: N226 


Fee: $245.00 

EduLevel: BAS 

Synopsis: This course is designed to refresh the ophthalmologist’s basic oculoplastics 

skills in a laboratory setting (employing porcine specimens), while simultaneously reviewing 

the fundamentals of ophthalmic plastic and reconstructive surgery knowledge. 

The basic principles involved in choosing suture materials and types of suture needle for 

various oculoplastics procedures will be reviewed. Surgical positioning and instrumentation 

will be touched upon as the course participants perform various surgical techniques 

employed in ophthalmic plastic and reconstructive surgery, with instructor assistance. 

Objective: The objective of the course is to provide participants with an opportunity to 

hone surgical skills that are employed in basic oculoplastics procedures such as eyelid 

lesion removal, eyelid margin lesion resection and reconstruction, eyelid laceration repair, 

ectropion repair, and blepharoplasty. A very basic introduction to ptosis repair will also 

be presented. 

Senior Instructor(s): Laryssa R Dragan MD 

Instructor(s): Christopher I Zoumalan MD, Shoib Myint DO, Raymond I Cho MD, Parag 

Gandhi MD*, Jonathan E Silbert MD, Alice Song MD, Lauren A Eckstein MD PhD, Julia 

Song MD, Jennifer Trew Scruggs MD, Edward Wladis MD*, Harmeet S Gill MD, Keshini 

C Parbhu MD, Bryan J Winn MD, Sarit M Patel MD, Carrie L Morris MD, Amy M Fowler 

MD*, Louis Savar MD 

W Equip Introduction to Nasal Anatomy and Rhinoplasty 

Course Director(s): Tanuj Nakra MD 



Sunday, 10:15 AM - 12:30 PM 

Room: S104A 


EduLevel: ADV 

Synopsis: This introductory course will provide an overview of surgical nasal anatomy, 

preoperative rhinoplasty analysis, infiltrative anesthetic techniques, incisions, septoplasty, 

cartilage grafting, conchal cartilage harvesting, endonasal approach, external 

approach, removal of bony-cartilaginous hump, medial and lateral osteotomies, spreader 

grafts, placement of columellar struts, closure, intranasal packs, nasal splinting, and 

postoperative care. 

Objective: This introductory course will provide an overview of surgical nasal anatomy 

and basic rhinoplasty techniques. 

Senior Instructor(s): Robert M Schwarcz MD, Brett S Kotlus MD, William R Nunery MD, 

David E Holck MD, Joel Kopelman MD** 

Lab 

Synopsis: Through lecture and video presentations, participants will be introduced 

to nasal anatomy, preoperative analysis, and surgical procedures. Cadaver dissection 

of the nose will provide hands-on exposure to surgical anatomy and basic rhinoplasty 

techniques, including infiltrative anesthetic techniques, open rhinoplasty incisions, septoplasty, 

removal of the bony and cartilaginous hump, medial and lateral osteotomies, 

placement of spreader and columellar grafts, closure, and nasal splinting. 

Objective: This course is designed to provide a basic introduction to nasal surgical 

anatomy and rhinoplasty. 



Monday, 12:30 - 2:30 PM 

Room: N229 


Fee: $410.00 

EduLevel: ADV 

Senior Instructor(s): Robert M Schwarcz MD, Brett S Kotlus MD, William R Nunery MD 

Instructor(s): Joel Kopelman MD**, Natalie A Stanciu MD, Sean Matthew Blaydon MD, 

Dustin M Heringer MD, Robert M Dryden MD 






123



NEW Enucleation and Evisceration: Theory and Practice 

Course Director(s): Parag Gandhi MD* 


Sunday, 12:30 - 2:30 PM 

Room: N226 


Fee: $200.00 

EduLevel: INT 

Synopsis: This course will cover theory and practice of enucleation and evisceration 

surgery: relevant preoperative considerations, detailed surgical steps, hands-on practical 

training, and video demonstrations. Implants will be available for attendees to handle 

and use on porcine orbits. Choice of procedure and relative merits of wrapping and pegging 

will be discussed, as well as postoperative complications and long-term care of the 

socket. 


preoperative evaluation and imaging, (2) develop an instrument set and implant options 

before surgery, (3) understand and anticipate anesthesia requirements, (4) understand 

and perform steps of enucleation and evisceration surgeries, (5) develop and implement a 

framework for deciding which procedure to choose, and when, (6) understand the history 

of orbital implants; gain facility with implants currently available and appreciate their 

advantages; (7) understand the advantages and disadvantages of wrapping and pegging 

implants, (8) gain familiarity with management of early postoperative complications, and 

(9) describe and learn how to manage late complications and post-enucleation socket 

syndrome. 

Instructor(s): Mauricio Chavez MD, Lauren A Eckstein MD PhD, Maria Kirzhner MD, Gary 

J Lelli MD, Marcus M Marcet MD, Sarit M Patel MD, Erin Shriver MD, Manoj M Thakker 

MD, M Reza Vagefi MD, Eve E Moscato MD 

EQUIP W Fundamental Face-Lifting Techniques 


and the American Society of Ophthalmic Plastic & Reconstructive Surgery 

(ASOPRS) 

Course Director(s): Brett S Kotlus MD 



Sunday, 3:15 - 5:30 PM 

Room: N139 


EduLevel: INT 

Synopsis: This basic course will consist of a step-by-step slide and video presentation of 

a preoperative assessment, surgical facial anatomy, fundamental face-lifting techniques, 

postoperative care, and potential complications. A downloadable course manual will be 

available to participants. 

Objective: Participants will acquire the ability to select appropriate patients, develop 

hands-on familiarity with facial surgical anatomy, perform safe surgical dissection, provide 

appropriate postoperative care, and integrate face-lifting into their aesthetic oculofacial 

practice. 

Senior Instructor(s): Tanuj Nakra MD, Robert M Schwarcz MD, Bobby S Korn MD PhD 

FACS* 

Instructor(s): David E Holck MD, Joel Kopelman MD**, Allan E Wulc MD FACS*, Roger A 

Dailey MD*, Stuart R Seiff MD, Susan M Hughes MD FACS*, William R Nunery MD, Jill 

Annette Foster MD FACS*, John D Ng MD* 

Lab 

Synopsis: Step-by-step cadaver dissection will demonstrate surgical anatomy, safe surgical 

planes, and fundamental face-lifting techniques, including cervical-mental restoration, 

flap and skin redraping, drain placement, and skin closure. 

Objective: Participants will acquire hands-on familiarity with the surgical anatomy and 

basic face-lifting techniques so they will be able to incorporate face-lifting procedures 

into their aesthetic practices. 



Monday, 9:30 - 11:30 AM 

Room: N229 


Fee: $410.00 

EduLevel: INT 

Senior Instructor(s): Bobby S Korn MD PhD FACS*, Robert M Schwarcz MD, Tanuj Nakra 

MD, David E Holck MD 

Instructor(s): Joel Kopelman MD**, Stuart R Seiff MD, Allan E Wulc MD FACS*, Roger A 

Dailey MD*, Kevin Ira Perman MD, Kenneth David Steinsapir MD*, Susan M Hughes MD 

FACS*, Kathleen M Duerksen MD, William R Nunery MD, Jill Annette Foster MD FACS*, 

Mikel W Lo MD, Bhupendra C Patel MD**, John D Ng MD*, Asa Dan Morton III MD*, 

Christopher M DeBacker MD, John Joseph Martin MD*, Rona Z Silkiss MD FACS, Kenneth 

E Morgenstern MD*, Adam S Hassan MD, Janet M Neigel MD*, Scott M Goldstein 

MD, Geva E Mannor MD MPH, Dustin M Heringer MD 

w Oculoplastic Surgery: Anatomic Foundations, Surgical 

Techniques, and Enhanced Results 

Course Director(s): Cat Burkat MD, Mark J Lucarelli MD FACS 


Sunday, 3:30 - 5:30 PM 

Room: N226 


Fee: $130.00 

EduLevel: INT 

Synopsis: Anatomic principles provide the cornerstone of successful oculofacial surgery. 

This course will cover the anatomic foundations to be considered when performing surgical 

procedures of the eyebrow, forehead, upper and lower eyelids, midface, and lacrimal 

system. A series of short lectures will be followed by interactive demonstration of clinically 

relevant anatomy on various cadaver prosections. 

Objective: This course is designed to provide knowledge of anatomic foundations on 

which participants can build successful oculofacial surgical procedures. 

Instructor(s): Arash Jian-Amadi MD, Richard Angrist MD, Richard K Dortzbach MD, Roberta 

Gausas MD, Shubhra Goel MD, Gregory J Griepentrog MD, Alon Kahana MD PhD, 

Don Kikkawa MD, Nancy Kim MD, Bobby S Korn MD PhD FACS*, David Baker Lyon MD, 

John J McGetrick MD FACS, Karim G Punja MD, Nicholas A Ramey MD, John G Rose Jr 

MD, Joseph P Shovlin MD, Manoj M Thakker MD, Edward Wladis MD* 

W Equip Workshop in Techniques of Lacrimal Intubation 

Course Director(s): Arthur Perry MD* 


Monday, 7:30 - 9:00 AM 

Room: N229 


Fee: $305.00 

EduLevel: INT 

Synopsis: This course will review indications for silicone intubation and will show different 

intubation systems and techniques. Participants will spend most of the course time 

actually performing the intubation procedure on cadavers. 

Objective: Participants should leave the course feeling confident that they can successfully 

intubate the lacrimal system and understand both the indications for this procedure 

and possible complications. 


Senior Instructor(s): Arthur Perry MD* 

Instructor(s): Bruce B Becker MD*, Jeffrey P Edelstein MD*, Andrew R Harrison MD*, 

Melissa L Meldrum-Aaberg MD, Bert Bowden MD, Karim G Punja MD, Scott M Goldstein 

MD, Christine C Annunziata MD, Adam S Hassan MD 

EQUIP W Blepharoplasty 

Course Director(s): Keith D Carter MD FACS 



Monday, 10:15 AM - 12:30 PM 

Room: S103A 


EduLevel: INT 

Synopsis: This course will cover the latest techniques in upper and lower eyelid blepharoplasty. 

Basic and advanced surgical techniques, eyelid anatomy, patient selection, 

preoperative evaluation, and avoidance of complications will be discussed. A course 

handbook with illustrations outlining the surgical techniques will be provided. 

Objective: This course will provide participants with the techniques required to perform 

successful upper and lower eyelid blepharoplasties. 


Instructor(s): Mark A Alford MD, Richard C Allen MD PhD, Adam G de la Garza MD, 

Robert C Kersten MD, Jill S Melicher Larson MD*, Jeffrey A Nerad MD 


124 





Lab 

Synopsis: This course is designed to provide hands-on laboratory experience with the 

techniques used in upper and lower eyelid blepharoplasty. Videos of techniques will be 

presented, along with personal assistance with cadaver dissection. 

Objective: Participants will be shown the clinically relevant anatomy as it relates to 

performing upper and lower eyelid blepharoplasties. 



Monday, 3:30 - 5:30 PM 

Room: N229 


Fee: $410.00 

EduLevel: INT 


Instructor(s): Mark A Alford MD, Richard C Allen MD PhD, Francesco P Bernardini MD, 

Adam G de la Garza MD, Carlo de Conciliis MD, Martin H Devoto MD, Robert C Kersten 

MD, Jill S Melicher Larson MD*, Jeffrey A Nerad MD, Alice Song MD 

W Surgical Anatomy of the Eyelids: Cadaver Demonstration 

Course Director(s): Edward H Bedrossian MD FACS 


Monday, 12:30 - 3:00 PM 

Room: N226 


Fee: $155.00 

EduLevel: INT 

Synopsis: Using slides, video, and cadaver prosections, this course will demonstrate 

landmarks important in the correction of brow ptosis, blepharoptosis, ectropion, entropion, 

and retraction. Included will be a precourse quiz and participant interaction. 

Objective: This course is designed to (1) review eyelid anatomy, (2) show structures in 

prosected cadavers, and (3) improve surgical technique. 

Senior Instructor(s): Edward H Bedrossian MD FACS 

Instructor(s): Robert C Della Rocca MD, Bryan Arthurs MD FRCSC 

EQUIP W Endoscopic Forehead and Eyebrow Elevation 

Course Director(s): Stuart R Seiff MD 



Monday, 3:15 - 5:30 PM 

Room: N140 


EduLevel: INT 

Synopsis: The aesthetic evaluation of the patient with eyebrow ptosis, the anatomy 

of the eyebrow and forehead, and a description of the endoscopic brow and forehead 

elevation procedure will be discussed. A course handbook will be provided, detailing the 

surgical technique. 

Objective: This course is designed to provide an understanding of the preoperative 

patient evaluation, pertinent surgical anatomy, and technique of endoscopic brow and 

forehead elevation. 


Instructor(s): Louis Savar MD 

Lab 

Synopsis: A brief lecture outlining the steps in endoscopic forehead and eyebrow elevation 

will be followed by step-by-step cadaver dissections for hands-on experience with 

the equipment and surgical technique. 

Objective: Participants will obtain a familiarity with the surgical anatomy of the brow 

and forehead, instrumentation, planes of dissection, and closure techniques in endoscopic 

forehead and eyebrow elevation. 

Note: Participants are required to bring surgical loupes. Participants will be 

sharing equipment. 


Tuesday, 8:00 - 10:30 AM 

Room: N229 


Fee: $460.00 

EduLevel: ADV 


Instructor(s): Kimberly Cockerham MD FACS*, Kathleen M Duerksen MD, Jill Annette 

Foster MD FACS*, David E Holck MD, John Bryan Holds MD*, Asa Dan Morton III MD*, 

Eve E Moscato MD, Rona Z Silkiss MD FACS, Harmeet S Gill MD, Morris E Hartstein 

MD*, Craig N Czyz DO, Louis Savar MD 

W Surgical Anatomy of the Orbit and Lacrimal System: 

Cadaver Demonstration 

Course Director(s): Robert C Della Rocca MD 


Monday, 3:30 - 5:30 PM 

Room: N226 


Fee: $130.00 

EduLevel: INT 

Synopsis: In this course, instructors will address small groups of attendees (four to five 

persons). Surgical anatomy and clinical correlation will be emphasized. Several short didactic 

lectures with slide demonstrations will present nasolacrimal surgery, orbital fracture 

repair, and anterior and medial orbitotomy. Associated neuro-anatomy correlation 

will be included. 

Objective: This course is designed to familiarize participants with surgical anatomical 

landmarks encountered in orbital and lacrimal surgery. Specific surgical techniques will 

be demonstrated. 

Senior Instructor(s): Robert C Della Rocca MD, Edward H Bedrossian MD FACS 

Instructor(s): David A Della Rocca MD, Chaneve Jeanniton MD, Meredith A Abbott MD, 

Harsha Reddy MD 

Orbital Fracture Repair: Plating Workshop 

Course Director(s): Jeremiah P Tao MD*, Eli L Chang MD 


Tuesday, 8:00 - 11:00 AM 

Room: N226 


Fee: $180.00 

EduLevel: BAS 

Synopsis: A discussion of indications and techniques for straightforward and complex 

fracture repair, including anatomy, approaches, complications, and secondary repairs, will 

be followed by a series of well-defined exercises that introduce plating systems and other 

alloplastic materials. Model skulls, sample plates, and tools will be provided. 

Objective: To provide participants with a high-level understanding of the most recent 

management and repair techniques for facial fractures from an orbitocentric perspective. 

In addition, participants should gain sufficient practical experience to ease the transition 

to intraoperative use of these techniques. 

Instructor(s): Peter A D Rubin MD*, Carlo R Bernardino MD, Patrick R Boulos MD, William 

R Nunery MD, Harold Lee MD 

EQUIP W Endoscopic Transnasal Lacrimal Surgery: 

Principles and Practice 

Course Director(s): Francois Codere MD 



Tuesday, 9:00 - 10:00 AM 

Room: N136 


EduLevel: INT 

Synopsis: The transnasal diagnosis and treatment of lacrimal outflow disorders will be 

presented. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy surgical techniques, 

endoscopic Jones tubes placement, and endoscopic diagnosis and management 

of lacrimal disorders will be covered. 

Objective: Participants will understand transnasal endoscopic diagnosis and treatment 

of lacrimal outflow disorders. 

Senior Instructor(s): Francois Codere MD, Bruce M Massaro MD 

Instructor(s): Jennifer A Sivak-Callcott MD 

Lab 

Synopsis: This course will present the transnasal diagnosis and treatment of lacrimal 

outflow disorders. Endoscopic nasal anatomy, transnasal dacryocystorhinostomy surgical 

techniques, endoscopic placement of Jones tubes, endoscope-assisted intubation, 

and use of the endoscope for diagnosis and management of lacrimal disorders will be 

covered. 

Objective: At the conclusion of this course, participants will understand transnasal endoscopic 

diagnosis and treatment of lacrimal outflow disorders. 







125




Room: N229 

Fee: $460.00 

Senior Instructor(s): Francois Codere MD 

Tuesday, 11:30 AM - 2:00 PM 


EduLevel: ADV 

Instructor(s): Bruce M Massaro MD, Jennifer A Sivak-Callcott MD, Jorge Corona MD, 

Steven C Dresner MD, Angela M Dolmetsch MD, Isabel Bleyen MD, James H Merritt MD, 

Jamie Wong MD, John T Harvey MD, Liat Attas-Fox MD 

EQUIP W Advanced Techniques in Orbital Decompression 

and Expansion 

Course Director(s): Robert A Goldberg MD 



Tuesday, 11:30 AM - 12:30 PM 

Room: N136 


EduLevel: INT 

Synopsis: This course is designed to foster creative thinking in orbital decompression. 

Staging, planning, and techniques for orbital decompression will be reviewed, including 

deep lateral, fat removal, transcaruncular, and endoscopic. Surgical versatility and 

creative decision making will be stressed. 

Objective: This course is designed to acquaint participants with a variety of techniques 

for orbital decompression and to enable them to design an individualized approach based 

on the patient’s needs and goals. 

Instructor(s): Raymond Douglas MD PhD, Norman Shorr MD, Catherine Hwang MD, 

Joseph L Lin MD 

Lab 

Synopsis: Through lectures, video presentations, and laboratory dissection, various 

techniques for orbital decompression will be reviewed, including deep lateral, fat removal, 

transcaruncular, and endoscopic. Surgical versatility and creative decision making 

will be stressed. 

Objective: This course is designed to acquaint participants with a variety of techniques 

for orbital decompression and to enable them to design an individualized approach based 

on the patient’s needs and goals. 

Note: Participants are required to bring surgical loupes and headlamps. 

Participants will be sharing equipment. 


Tuesday, 3:00 - 5:30 PM 

Room: N229 


Fee: $460.00 

EduLevel: ADV 

Senior Instructor(s): Robert A Goldberg MD 

Instructor(s): Norman Shorr MD, Michael Kazim MD, Jonathan Kim MD, Raymond 

Douglas MD PhD, Chee-Chew Yip MBBS FRCS, Kenneth A Feldman MD, Raman Malhotra 

MBChB FRCOphth, Tanuj Nakra MD, Ronald Mancini MD, Mehryar Taban MD, Catherine 

Hwang MD, Shu-Hong Chang MD, Konstantinos Papageorgiou MD, David Khoramian 

Isaacs MD, Joseph L Lin MD, Daniel B Rootman MD MSc 

Workshop in Flap Techniques in Oculoplastic Surgery 

Course Director(s): Dawn C Buckingham MD 


Monday, 9:30 - 11:30 AM 

Room: N226 


Fee: $130.00 

EduLevel: INT 

Synopsis: This course will begin with a discussion of various suturing materials and 

techniques. Basic flap techniques will then be discussed, including advancement, rotation, 

and bilobe and rhomboid flaps. Additionally, Z-plasty, Y-V plasty, and the management 

of dog ears will be covered. These techniques are crucial in achieving the best 

possible cosmetic result in periorbital reconstruction. The majority of the course will be a 

hands-on practicum, during which participants may perform these procedures under the 

supervision of experienced course instructors, utilizing pig’s feet. 

Objective: At the conclusion of this course, the participant will be more familiar with 

various suturing techniques useful in periorbital wound closure and will have a better 

understanding of the indications for and techniques utilized in flap reconstruction of periorbital 

cutaneous defects. 

Senior Instructor(s): George O Stasior MD, Suzanne K Freitag MD, Morris E Hartstein 

MD*, Cat Burkat MD, Nicholas Rameu MD 

Instructor(s): Junhee Lee MD, Sang H Hong MD 


NEW New Techniques for Strabismus Surgery 

Course Director(s): Kenneth W Wright MD* 



Sunday, 11:30 AM - 12:30 PM 

Room: N140 


EduLevel: INT 

Synopsis: Over the past several years, important surgical innovations have made strabismus 

surgery safer and more effective. This course will teach the use of novel strabismus 

surgical techniques, including grooved hook for suturing the muscle insertion, minimally 

invasive techniques (rectus central tenotomy and plication), and use of amniotic 

membrane transplant for restrictive strabismus. Video will be presented to help teach the 

techniques. Outcome studies of surgical procedures will be presented. 

Objective: At the conclusion of this course, the attendee will be able to use new strabismus 

surgical techniques to improve surgical outcomes and reduce complications. 

Instructor(s): Yi Ning Strube MD, Luke W Deitz MD 

Lab 

Synopsis: This hands-on lab will transfer the surgical skills required for the use of new 

strabismus techniques. Attendees will actually perform the procedures. Specific techniques 

will include use of the grooved hook for safe suturing of tight muscles and suturing 

of muscles during topical anesthesia surgery. Techniques for amniotic membrane transplant 

useful in the treatment of restrictive strabismus will be taught. Minimally invasive 

techniques of partial rectus tenotomy and plication will be presented. The minimally invasive 

procedures have utility for the treatment of small-angle strabismus. 

Objective: At the conclusion of the course, the attendee will be able to perform new 

strabismus surgical techniques that will improve patient care and clinical outcomes. 


Sunday, 3:30 - 5:30 PM 

Room: N230 


Fee: $200.00 

EduLevel: 

Senior Instructor(s): Yi Ning Strube MD, Lisa S Thompson MD 

Instructor(s): Luke W Deitz MD, Rebecca S Leenheer MD 


ISRS Laser Refractive Surgery Course 


the International Society of Refractive Surgery (ISRS) 

Course Director(s): Michael C Knorz MD* 



Sunday, 9:00 - 11:15 AM 

Room: S103BC 


EduLevel: INT 

Synopsis: This course will start with the basics of how conventional and laser microkeratomes 

work and what one needs to know before performing LASIK and surface ablation. 

It will move on to cover tips, step by step, with presentations discussing the newest applications 

and developments in LASIK and surface ablation. The prevention and treatment 

of complications will be covered in detail. 

Objective: This course is designed to give participants the information and skills needed 

for LASIK and surface ablation, including patient selection, basic principles, postoperative 

care, and management of complications. 


Instructor(s): Richard L Lindstrom MD*, Jack T Holladay MD MSEE FACS* 


126 





Laser Refractive Surgery 

Course Director(s): George O Waring IV MD* 

Labs 

Synopsis: Jointly Sponsored by the Academy’s Skills Transfer Advisory Committee and 

the International Society of Refractive Surgery (ISRS) The wet lab is designed for those 

interested in learning techniques in laser refractive surgery. Mechanical microkeratomes, 

femtosecond lasers, excimer lasers, and corneal inlays will be available in the lab, with 

experienced surgeons on hand to assist with questions and to demonstrate techniques. 

Objective: Participants will become acquainted with a broad array of both mechanical 

and laser microkeratomes and how they work with excimer lasers. 




Sunday, 12:30 - 2:30 PM 

Room: N227B 


Fee: $240.00 

EduLevel: BAS 


Instructor(s): David R Hardten MD*, Vance Michael Thompson MD*, Wallace Chamon 

MD*, Minoru Tomita MD PhD*, Parag A Majmudar MD*, Karolinne M Rocha MD, Sherman 

W Reeves MD MPH*, Mihai Pop MD, Elizabeth Yeu MD*, Calvin G Eshbaugh MD**, 

Duane A Wiggins MD, Raj K Goyal MD MPH*, Paul C Kang MD*, William Wiley MD*, 

John J DeStafeno MD, Thomas M Harvey MD*, John P Berdahl MD*, Brandon Ayres 

MD*, Jodhbir S Mehta FRCS FRCOPHTH*, Suphi Taneri MD* 

R Laser Refractive Surgery for Ophthalmology Residents 

Course Director(s): George O Waring MD* 


Sunday, 3:30 - 5:30 PM 

Room: N227B 


Fee: $140.00 

EduLevel: BAS 


Instructor(s): Daniel S Durrie MD*, Shachar Tauber MD*, Scott D Barnes MD*, Renato 

Ambrosio Jr MD*, John A Hovanesian MD*, David A Goldman MD*, Michael Vrabec 

MD*, Erin D Stahl MD*, James C Loden MD*, Allen Boghossian DO, Michael J Collins 

MD FACS, Ryan T Smith MD, Lisa Nijm MD, Erik Letko MD, Jeremy Z Kieval MD*, Jessica 

B Ciralsky MD, Joel D Hunter MD**, Aylin Kilic MD 


Phakic IOLs 

Course Director(s): Thomas M Harvey MD* 



Sunday, 3:15 - 5:30 PM 

Room: N136 


EduLevel: INT 

Synopsis: This course will educate the participant on the use of phakic IOLs in refractive 

surgery. Topics of discussion will include patient selection and preoperative testing, IOL 

power calculations, postoperative care, complication management, surgical technique, 

and managing residual refractive error. Phakic IOLs currently available in the United 

States will be emphasized. 

Objective: At the course conclusion, the participant will understand indications for the 

use of phakic IOLs and key management aspects of phakic IOL candidates. 

Senior Instructor(s): Sherman W Reeves MD MPH* 

Instructor(s): Elizabeth A Davis MD*, David R Hardten MD*, Stephen S Lane MD*, Jack T 

Holladay MD MSEE FACS*, Scott D Barnes MD*, Paul J Harton Jr MD* 

Lab 

Synopsis: Using pig eyes, the participant will have the opportunity to practice the insertion 

of phakic IOLs. Instructors will be available to assist and answer questions. FDAapproved 

phakic IOLs will be emphasized and available for implantation. 

Objective: This wet lab will enable the participant to practice the surgical technique of 

inserting phakic IOLs. 


Monday, 8:00 - 9:30 AM 

Room: N228 


Fee: $280.00 

EduLevel: INT 

Senior Instructor(s): David R Hardten MD*, Sherman W Reeves MD MPH* 

Instructor(s): D Rex Hamilton MD*, Scott D Barnes MD*, Thomas M Harvey MD*, Andrew 

J Velazquez MD, John P Berdahl MD*, Anthony J Lombardo MD PhD, William Wiley 

MD*, Preeya K Gupta MD*, George O Waring MD*, Gregory Pamel MD**, Andrew C 

Shatz MD*, Asim R Piracha MD, Michael Vrabec MD*, Paul J Dougherty MD*, Lisa Nijm 

MD, Paul J Harton Jr MD*, Gregory Parkhurst MD*, Scott M MacRae MD* 

The Surgical Correction of Astigmatism 

Course Director(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS* 



Monday, 3:15 - 5:30 PM 

Room: N135 


EduLevel: INT 

Synopsis: This course will supply participants with the necessary principles, theories, 

and practical instruction in the various forms of astigmatic keratotomy (PRI, limbal relaxing 

incisions) and nonincisional astigmatism correction (LASIK, toric IOLs). 

Objective: Attendees will gain an understanding of techniques to evaluate and manage 

astigmatism as a primary procedure and as an adjunct to lens surgery. 

Senior Instructor(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS* 

Instructor(s): Kurt A Buzard MD, Miles H Friedlander MD, Ronald N Gaster MD FACS*, 

David H Haight MD, Jack T Holladay MD MSEE FACS*, Douglas D Koch MD*, R Bruce 

Wallace MD* 

Lab 

Synopsis: This practical, video-based course and hands-on lab allows participants to 

improve their management of astigmatism, identify appropriate surgical candidates for 

astigmatism correction, and select the best techniques for each case, either combined 

with lens surgery or alone. Participants will learn to perform toric IOLs and corneal incisions 

(peripheral corneal relaxing incisions or limbal relaxing incisions), and will learn 

pearls and common pitfalls of each. The impact of various cataract incisions on astigmatism 

(surgically induced astigmatism) and laser vision correction will be discussed. Attendees 

will also learn to perform analysis of astigmatism, using topography and clinical 

measures as well as aggregate analysis using vector software. 

Objective: Attendees will gain an understanding of techniques to evaluate and manage 

astigmatism as a primary procedure and as an adjunct to lens surgery. 


Tuesday, 8:00 - 9:30 AM 

Room: N227B 


Fee: $190.00 

EduLevel: INT 

Senior Instructor(s): Jean-Luc Febbraro MD*, Hamza N Khan MD FACS* 

Instructor(s): Kurt A Buzard MD, Miles H Friedlander MD, Ronald N Gaster MD FACS*, 

Paul Gilwit MD FACS, David H Haight MD, R Bruce Wallace MD*, Douglas D Koch MD* 


Macular OCT: Mastering the Basics 

Course Director(s): John S Pollack MD* 



Sunday, 9:00 - 11:15 AM 

Room: S102ABC 


EduLevel: BAS 

Synopsis: This course provides basic instruction on accurate interpretation of OCTs of 

common macular pathologies, as well as instruction on how to identify and prevent common 

OCT artifacts. The course also provides a clinically meaningful review of indications 

and limitations of OCT in the diagnosis and management of common macular diseases 

such as AMD, diabetic maculopathy, epiretinal membrane, macular holes, vitreomacular 

traction, central serous retinopathy, vascular occlusions, and postoperative cystoid 

macular edema. 






127



Objective: Upon completion of this course, participants should be able to (1) accurately 

interpret OCTs of common macular pathologies, (2) describe the indications for and limitations 

of OCT in the diagnosis and management of macular diseases, and (3) identify, 

interpret, and correct common OCT artifacts. 


Instructor(s): Jay S Duker MD*, Cynthia A Toth MD*, Anat Loewenstein MD*, Dante 

Pieramici MD* 

Lab 

Synopsis: This course will provide attendees with a small-group interactive format 

(5-6 attendees per instructor) for hands-on experience reviewing and evaluating OCTs 

covering a wide range of common macular diseases, with emphasis on sharpening the 

OCT-interpretation skills of the attendees. Attendees will rotate with all instructors, covering 

a variety of topics, including but not limited to AMD, vascular occlusions, epiretinal 

membrane, vitreomacular traction, macular holes, diabetic retinopathy, and postoperative 

cystoid macular edema. Attendees are invited to bring one challenging case for discussion 

at the end of the lab, time permitting. 

Objective: Upon completion of this course, participants should be able to (1) identify the 

OCT features of normal and abnormal macular anatomy, (2) diagnose common macular 

pathologies based on specific OCT characteristics, and (3) identify, correct, and prevent 

common OCT artifacts. 


Sunday, 12:30 - 2:00 PM 

Room: N231 


Fee: $100.00 

EduLevel: BAS 


Instructor(s): Jack A Cohen MD FACS, Dafna Goldenberg*, Brandon G Busbee MD*, 

Sachin S Mudvari MD 

Diabetes 2012: Course on Diabetic Retinopathy 

Course Director(s): Keye Luc Wong MD* 



Monday, 10:15 AM - 12:30 PM 

Room: S105A 


EduLevel: INT 

Synopsis: This course will present a rational approach to the diagnosis and treatment 

of diabetic retinopathy based on first understanding results and recommendations of 

the Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study and 

subsequently reviewing DRCR.net publications that may modify some of those recommendations. 

Case presentations to a panel of experts will illustrate the role of OCT and 

pharmacotherapy relative to laser therapy. 

Objective: By the conclusion of this course, participants will be able to understand (1) 

the clinical indications for laser treatment of diabetic retinopathy and (2) the role of pharmacotherapy 

and OCT in current management of diabetic retinopathy. 

Senior Instructor(s): Keye Luc Wong MD* 

Instructor(s): Abdhish R Bhavsar MD*, Alexander J Brucker MD*, Emily Y Chew MD, 

Matthew D Davis MD, Harry W Flynn MD*, Arthur D Fu MD*, Justin L Gottlieb MD, Sam 

Edward Mansour MD* 

Lab 

Synopsis: The latest in diagnostic methods and treatment techniques will be reviewed 

in small groups using stereofundus images of actual cases of diabetic retinopathy. Panel 

discussions will highlight current treatment controversies in which DRCR.net results may 

modify DRS and ETDRS recommendations. 

Objective: By the conclusion of this course, participants will be able to understand the 

clinical indications for laser treatment of diabetic retinopathy and to know the best treatment 

techniques based on Diabetic Retinopathy Study, Early Treatment Diabetic Retinopathy 

Study, and DRCR.net clinical trial results. 


Monday, 2:30 - 5:00 PM 

Room: N231 


Fee: $150.00 

EduLevel: INT 

Senior Instructor(s): Keye Luc Wong MD*, Justin L Gottlieb MD 

Instructor(s): Gary W Abrams MD*, Michael M Altaweel MD*, Neal H Atebara MD, 

Maria H Berrocal MD*, Robert A Braunstein MD, Alexander J Brucker MD*, Suresh R 

Chandra MD, John H Drouilhet MD FACS*, Michael S Ip MD*, Richard H Johnston MD, 

James L Kinyoun MD 

23-Gauge Vitrectomy: What, When, and How? 

Course Director(s): Gaurav K Shah MD* 



Monday, 3:15 - 5:30 PM 

Room: S102ABC 


EduLevel: INT 

Synopsis: This course will highlight the recent advances in small-incision vitrectomy surgery, 

with an emphasis on 23-gauge surgery. The specific technique (wound construction, 

entry, and exit) will be presented in a didactic and hands-on format. Tips for transitioning 

from 20- and 25-gauge surgery will be discussed. The experience of the faculty members 

will also be discussed, including new instrumentation and difficult cases, such as silicone 

oil. Videos demonstrating these principles will be shown during the lecture part of the 

course. One- and two-step systems will be on display to show differences in each technique. 

Hands-on experience with the faculty members will be available during the wet 

lab portion of the course. Various vitreoretinal machines will be available for hands-on 

participation with cannulas, cutters, and light pipes. Pig eyes will be used for the wet lab 

portion of the course. 




Instructor(s): Richard F Spaide MD*, Keith A Warren MD*, Jeffrey S Heier MD*, Richard 

G Lane MD, Kevin J Blinder MD*, Asheesh Tewari MD*, Philip J Ferrone MD*, Paul E 

Tornambe MD* 

Lab 

Synopsis: This course will highlight the recent advances in small-incision vitrectomy surgery, 

with an emphasis on 23-gauge surgery. The specific technique (wound construction, 

entry, and exit) will be presented in a didactic and hands-on format. Tips for transitioning 

from 20- and 25-gauge surgery will be discussed. The experience of the faculty members 

will also be discussed, including new instrumentation and difficult cases, such as silicone 

oil. Videos demonstrating these principles will be shown during the lecture part of the 

course. One- and two-step systems will be on display to show differences in each technique. 

Hands-on experience with the faculty members will be available during the wet 

lab portion of the course. Various vitreoretinal machines will be available for hands-on 

participation with cannulas, cutters, and light pipes. Pig eyes will be used for the wet lab 

portion of the course. 





Sunday, 9:30 - 11:00 AM 

Room: N228 


Fee: $280.00 

EduLevel: INT 


Instructor(s): Keith A Warren MD*, Jeffrey S Heier MD*, Kevin J Blinder MD*, Richard G 

Lane MD, Richard F Spaide MD*, Philip J Ferrone MD*, Asheesh Tewari MD*, Peter W 

Stalmans MD PhD*, Paul E Tornambe MD* 


128 




Cover more ground 

in less time. 

{ 

Leaping over 50 times its own length, 

the rocket frog can accelerate up to twice 

the speed of gravity. 

The Integrated WaveLight ® Refractive Suite 

The fastest refractive platform in the U.S. features: 

• Unrivaled 500 Hz Excimer Laser ablation times at just 1.4 seconds per diopter * 

• Precise 200 kHz Femtosecond Laser custom flap creation in 6 seconds * 

• A 1050 Hz-type Eye Tracker, synchronized at 500 Hz, with 2 millisecond latency time * 

• A broad range of customized, patient-specific treatments available 

Ask your Alcon Sales Representative for more information. 

WaveLight ® FS200 

Femtosecond Laser 

WaveLight ® EX500 

Excimer Laser 

© 2012 Novartis 8/12 ALL12695JADUS 

*Treatment times are approximate. 

For important safety information about this product, please refer to the adjacent page.

Health Care Professional Information Sheet-All WaveLight ® Allegretto Wave ® 

EX500 System Indications 

The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer Laser System 

Caution: Federal (USA) law restricts this device to sale by, or on the order 

of a physician. 

Statements regarding the potential benefits of wavefront-guided and Wavefront 

Optimized ® laser-assisted in-situ keratomileusis (LASIK) are based upon the results 

of clinical trials. These results are indicative of not ony the WaveLight ® ALLEGRETTO 

WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer Laser System treatment but also the care 

of the clinical physicians, the control of the surgical environment by those physicians, 

the clinical trials’ treatment parameters and the clinical trials’ patient inclusion and 

exclusion criteria. Although many clinical trial patients after the wavefront-guided 

and Wavefront Optimized ® procedure saw 20/20 or better and/or had or reported 

having better vision during the day and at night, compared to their vision with 

glasses or contact lenses before the procedure, individual results may vary. You can 

find information about the clinical trials below and in the Procudure Manuals for the 

WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer Laser System. 

As with any surgical procedure, there are risks associated with the wavefront-guided 

and Wavefront Optimized ® treatment. Before treating patients with these procedures, 

you should carefully review the Procedure Manuals, complete the Physician WaveLight ® 

System Certification Course, provide your patients with the Patient Information Booklet, 

and discuss the risks associated with this procedure and questions about the procedure 

with your patients. 

Indications: The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer 

Laser System is indicated to perform LASIK treatments in patients with documented 

evidence of a stable manifest refraction defined as less than or equal to 0.50 diopters 

(D) of preoperative spherical equivalent shift over one year prior to surgery, exclusive 

of changes due to unmasking latent hyperopia in patients 18 years of age or older: for 

the reduction or elimination of myopic refractive errors up to -12.0 D of sphere with and 

without astigmatic refractive errors up to 

-6.0 D; for the reduction or elimination of hyperopic refractive errors up to +6.0 D of 

sphere with and without astigmatic refractive errors up to 5.0 D at the spectacle plane, 

with a maximum manifest refraction spherical equivalent (MRSE) of +6.0 D; and in 

patients 21 years of age or older for the reduction or elimination of naturally occurring 

mixed astigmatism of up to 6.0 D at the spectacle plane. 

LASIK is an elective procedure with the alternatives including but not limited to 

eyeglasses, contact lenses, photorefractive keratectomy (PRK), and other refractive 

surgeries. Only practitioners who are experienced in the medical management and 

surgical treatment of the cornea, who have been trained in laser refractive surgery 

including laser system calibration and operation, may use the device as approved. 

Prospective patients, as soon as they express an interest in an indicated LASIK procedure 

and prior to undergoing surgery, must be given the WaveLight ® System Patient 

Information Booklet and must be informed of the alternatives for refractive correction 

including eyeglasses, contact lenses, PRK, and other refractive surgeries. 

Clinical Data Myopia: The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q 

Excimer Laser System for LASIK treatments of myopic refractive errors up to -12.0 D of 

sphere with and without astigmatic refractive errors up to -6.0 D at the spectacle plane 

was studied in clinical trials in the United States with 901 eyes treated, of which 813 of 

866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, 

at 6 months was 91.9%, and at 12 months was 93.9%. 

The studies found that of the 844 eyes eligible for the uncorrected visual acuity (UCVA) 

analysis of effectiveness at the 3-month stability time point, 98.0% were corrected to 

20/40 or better, and 84.4% were corrected to 20/20 or better without spectacles or 

contact lenses. 

The clinical trials showed that the following subjective patient adverse events were 

reported as moderate to severe at a level at least 1% higher than baseline of the 

subjects at 3 months post-treatment: visual fluctuations (12.8% at baseline versus 

28.6% at 3 months). Long term risks of LASIK for myopia with and without astigmatism 

beyond 12 months have not been studied. 

Clinical Data Hyperopia: The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® 

Eye-Q Excimer Laser System for LASIK treatments of hyperopic refractive errors up 

to +6.0 D of sphere with and without astigmatic refractive errors up to 5.0 D with 

a maximum MRSE of +6.0 D has been studied in clinical trials in the United States 

with 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. 

Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months 

was 69.9%. 

The studies found that of the 212 eyes eligible for the UCVA analysis of effectiveness at 

the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 67.5% 

were corrected to 20/20 or better without spectacles or contact lenses. 

The study showed that the following subjective patient adverse events were reported 

as much worse by at least 1% of the subjects (in order of increasing frequency) at 

6 months post final treatment: glare from bright lights (3.0%); night driving glare 

(4.2%); light sensitivity (4.9%); visual fluctuations (6.1%); and halos (6.4%). Long 

term risks of LASIK for hyperopia with and without astigmatism beyond 12 months 

have not been studied. 

Clinical Data Mixed Astigmatism: The WaveLight ® ALLEGRETTO WAVE ® / ALLEGRETTO 

WAVE ® Eye-Q Excimer Laser System for LASIK treatments of naturally occurring mixed 

astigmatism of up to 6.0 D at the spectacle plane has been studied in clinical trials in 

the United States with 162 eyes treated, of which 111 were eligible to be followed at 

6 months. Accountability at 1 month was 99.4%, at 3 months was 96.0%, and at 6 

months was 100.0%. 

The studies found that of the 142 eyes eligible for the UCVA analysis of effectiveness at 

the 3-month stability time point, 95.8% achieved acuity of 20/40 or better, and 67.6% 

achieved acuity of 20/20 or better without spectacles or contact lenses. 



subjects at 3 months post-treatment: sensitivity to light (43.3% at baseline versus 

52.9% at 3 months); visual fluctuations (32.1% at baseline versus 43.0% at 3 months); 

and halos (37.0% at baseline versus 42.3% at 3 months). Long term risks of LASIK for 

mixed astigmatism beyond 6 months have not been studied. 

Clinical Data Wavefront-guided Treatment of Myopia: The WaveLight ® 

ALLEGRETTO WAVE ® / ALLEGRETTO WAVE ® Eye-Q Excimer Laser System used in 

conjunction with the WaveLight ® ALLEGRO Analyzer ® device. The device uses a 6.5 mm 

optical zone, a 9.0 mm ablation/treatment zone, and is indicated for wavefront-guided 

LASIK: 1) for the reduction or elimination of up to -7.0 D of spherical equivalent myopia 

or myopia with astigmatism, with up to -7.0 D of spherical component and up to 3.0 D 

of astigmatic component at the spectacle plane; 2) in patients who are 18 years of age 

or older; and 3) in patients with documentation of a stable manifest refraction defined 

as ≤0.50 D of preoperative spherical equivalent shift over one year prior to surgery was 

studied in a randomized clinical trial in the United States with 374 eyes treated; 188 

with wavefront-guided LASIK (Study Cohort) and 186 with Wavefront Optimized ® LASIK 

(Control Cohort). 178 of the Study Cohort and 180 of the Control Cohort were eligible to 

be followed at 6 months. In the Study Cohort, accountability at 1 month was 96.8%, at 

3 months was 96.8%, and at 6 months was 93.3%. In the Control Cohort, accountability 

at 1 month was 94.6%, at 3 months was 94.6%, and at 6 months was 92.2%. 

The studies found that of the 180 eyes eligible for the UCVA analysis of effectiveness 

at the 6-month stability time point in the Study Cohort, 99.4% were corrected to 

20/40 or better, and 93.4% were corrected to 20/20 or better without spectacles or 

contact lenses. In the Control Cohort, of the 176 eyes eligible for the UCVA analysis 

of effectiveness at the 6-month stability time point, 99.4% were corrected to 20/40 

or better, and 92.8% were corrected to 20/20 or better without spectacles or contact 

lenses. 



subjects at 3 months post-treatment in the Study Cohort: light sensitivity (37.2% at 

baseline versus 47.8% at 3 months); and visual fluctuations (13.8% at baseline versus 

20.0% at 3 months). In the Control Cohort: halos (36.6% at baseline versus 45.4% at 3 

months); and visual fluctuations (18.3% at baseline versus 21.9% at 3 months). Long 

term risks of wavefront-guided LASIK for myopia with and without astigmatism beyond 

6 months have not been studied. 

Contraindications: LASIK treatments using the WaveLight ® ALLEGRETTO WAVE ® 

/ ALLEGRETTO WAVE ® Eye-Q Excimer Laser System are contraindicated if any of the 

following conditions exist. Potential contraindications are not limited to those included 

in this list: pregnant or nursing women; patients with a diagnosed collagen vascular, 

autoimmune or immunodeficiency disease; patients with diagnosed keratoconus or 

any clinical pictures suggestive of keratoconus; and patients who are taking one or both 

of the following medications: isotretinoin (Accutane ® 1), amiodarone hydrochloride 

(Cordarone ® 2). 

Warnings: Any LASIK treatment with the WaveLight ® ALLEGRETTO WAVE ® / 

ALLEGRETTO WAVE ® Eye-Q Excimer Laser System is not recommended in patients 

who have: systemic diseases likely to affect wound healing, such as connective tissue 

disease, insulin dependent diabetes, severe atopic disease or an immunocompromised 

status; a history of Herpes simplex or Herpes zoster keratitis; significant dry eye that 

is unresponsive to treatment; severe allergies; and unreliable preoperative wavefront 

examination that precludes wavefront-guided treatment. The wavefront-guided LASIK 

procedure requires accurate and reliable data from the wavefront examination. Every 

step of every wavefront measurement that may be used as the basis for a wavefrontguided 

LASIK procedure must be validated by the user. Inaccurate or unreliable data 

from the wavefront examination will lead to an inaccurate treatment. 

Precautions: Safety and effectiveness of the WaveLight ® ALLEGRETTO WAVE ® / 

ALLEGRETTO WAVE ® Eye-Q Excimer Laser System have not been established for patients 

with: progressive myopia, hyperopia, astigmatism and/or mixed astigmatism; ocular 

disease; previous corneal or intraocular surgery, or trauma in the ablation zone; corneal 

abnormalities including, but not limited to, scars, irregular astigmatism and corneal 

warpage; residual corneal thickness after ablation of less than 250 microns increasing 

the risk for corneal ectasia; pupil size below 7.0 mm after mydriatics where applied for 

wavefront-guided ablation planning; history of glaucoma or ocular hypertension of 

> 23 mmHg; taking the medication sumatriptan succinate (Imitrex ® 3); under 18 years 

(21 years for mixed astigmatism) of age; over the long term (more than 12 months 

after surgery); corneal, lens and/or vitreous opacities including, but not limited to, 

cataract; iris problems including, but not limited to, coloboma and previous iris surgery 

compromising proper eyetracking; taking medications likely to affect wound healing 

including, but not limited to, antimetabolites; treatments with an optical zone below 

6.0 mm or above 6.5 mm in diameter; treatment targets different from emmetropia 

(plano) in which the wavefront-calculated defocus (spherical term) has been adjusted; 

myopia greater than – 12.0 D or astigmatism greater than 6 D; hyperopia greater than 

+ 6.0 D or astigmatism greater than 5.0 D; mixed astigmatism greater than + 6.0 D; 

and in cylinder amounts > 4.0 to < 6.0 D. 

Due to the lack of large numbers of patients in the general population, there are few 

subjects with cylinder amounts in this range to be studied. Not all complications, 

adverse events, and levels of effectiveness may have been determined. 

Pupil sizes should be evaluated under mesopic illumination conditions. Effects of 

treatment on vision under poor illumination cannot be predicted prior to surgery. Some 

patients may find it more difficult to see in such conditions as very dim light, rain, fog, 

snow and glare from bright lights. This has been shown to occur more frequently in the 

presence of residual refractive error and perhaps in patients with pupil sizes larger than 

the optical zone size. 

The refraction is determined in the spectacle plane, but treated in the corneal plane. 

In order to determine the right treatment program to achieve the right correction, 

assessment of the vertex distance during refraction testing is recommended. 

Preoperative evaluation for dry eyes should be performed. Patients should be advised 

of the potential for dry eyes post LASIK and post wavefront-guided LASIK surgery. This 

treatment can only be provided by a licensed healthcare professional. 

Adverse Events and Complications for Myopia: Certain adverse events and 

complications occurred after the LASIK surgery. Two adverse events occurred during 

the postoperative period of the clinical study: 0.2% (2/876) had a lost, misplaced, or 

misaligned flap reported at the 1 month examination. 

The following adverse events did NOT occur: corneal infiltrate or ulcer requiring 

treatment, corneal edema at 1 month or later visible in the slit lamp exam; any 

complication leading to intraocular surgery; melting of the flap of >1 mm2; epithelium 

of >1 mm2 in the interface with loss of 2 lines or more of BSCVA; uncontrolled IOP 

rise with increase of >5 mmHg or any reading above 25 mmHg; retinal detachment 

or retinal vascular accident; and decrease in BSCVA of >10 letters not due to irregular 

astigmatism as shown by hard contact lens refraction. 

The following complications occurred 3 months after LASIK during this clinical trial: 

0.8% (7/844) of eyes had a corneal epithelial defect; 0.1% (1/844) had any epithelium 

in the interface; 0.1% (1/844) had foreign body sensation; 0.2% (2/844) had pain; and 

0.7% (6/844) had ghosting or double images in the operative eye. 

The following complications did NOT occur 3 months following LASIK in this clinical 

trial: corneal edema and need for lifting and/or reseating the flap/cap. 

Adverse Events and Complications for Hyperopia: Certain adverse events and 

complications occurred after the LASIK surgery. Only one adverse event occurred during 

the clinical study: one eye (0.4%) had a retinal detachment or retinal vascular accident 

reported at the 3 month examination. 


treatment; lost, misplaced, or misaligned flap, or any flap/cap problems requiring 

surgical intervention beyond 1 month; corneal edema at 1 month or later visible in the 

slit lamp exam; any complication leading to intraocular surgery; melting of the flap of 

> 1 mm2; epithelium of > 1 mm2 in the interface with loss of 2 lines or more of BSCVA; 

uncontrolled IOP rise with increase of > 5 mmHg or any reading above 25 mmHg and 

decrease in BSCVA of > 10 letters not due to irregular astigmatism as shown by hard 

contact lens refraction. 

The following complications occurred 6 months after LASIK during this clinical trial: 

0.8% (2/262) of eyes had a corneal epithelial defect and 0.8% (2/262) had any 

epithelium in the interface. 

The following complications did NOT occur 6 months following LASIK in this clinical 

trial: corneal edema; foreign body sensation; pain, ghosting or double images; and 

need for lifting and/or reseating of the flap/cap. 

Adverse Events and Complications for Mixed Astigmatism: Certain adverse 

events and complications occurred after the LASIK surgery. No protocol defined adverse 

events occurred during the clinical study. However, two events occurred which were 

reported to the FDA as Adverse Events. 

The first event involved a patient who postoperatively was subject to blunt trauma to 

the treatment eye 6 days after surgery. The patient was found to have an intact globe 

with no rupture, inflammation or any dislodgement of the flap. The second event 

involved the treatment of an incorrect axis of astigmatism which required retreatment. 


treatment; corneal epithelial defect involving the keratectomy at 1 month or later; 

corneal edema at 1 month or later visible in the slit lamp exam; epithelium of > 1 mm2 

in the interface with loss of 2 lines or more of BSCVA; lost, misplaced, or misaligned 

flap, or any flap/cap problems requiring surgical intervention beyond 1 month; 


contact lens refraction; any complication leading to intraocular surgery; melting of 

the flap of > 1 mm2; uncontrolled IOP rise and retinal detachment or retinal vascular 

accident. 

None of the following complications occurred at 3 months after LASIK during this 

clinical trial: corneal edema; corneal epithelial defect; any epithelium in the interface; 

foreign body sensation, pain, ghosting or double images; and need for lifting and/or 

reseating of the flap/cap. 

Subjects were asked to complete a patient questionnaire preoperatively and at 

3-months, 6-months, and 1-year postoperatively. 

Adverse Events and Complications for Wavefront - guided Myopia: Certain 

adverse events and complications occurred after the wavefront-guided LASIK surgery. 

No adverse event occurred during wavefront-guided treatments during this clinical 

study. 


treatment; lost, misplaced or misaligned flap or any flap/cap problems requiring 

surgical intervention beyond 1 month; corneal edema at 1 month or later visible in the 

slit lamp exam; any complication leading to intraocular surgery; melting of the flap of 

> 1 mm2; epithelium of > 1 mm² in the interface with loss of 2 lines or more of BSCVA; 

uncontrolled IOP rise with increase of > 5 mmHg or any reading above 25 mmHg; and 


contact lens refraction. 

The following complications occurred 3 months after wavefront-guided LASIK during 

this clinical trial: corneal epithelial defect (0.6%); foreign body sensation (0.6%); and 

pain (0.6%). 

The following complications did NOT occur 3 months following wavefront-guided LASIK 

in this clinical trial: corneal edema; any epithelium in the interface; ghosting or double 

images; and need for lifting and/or reseating of the flap/cap. 

ATTENTION: The safety and effectiveness of LASIK surgery has ONLY been established 

with an optical zone of 6.0 – 6.5 mm and an ablation zone of 9.0 mm. 

Reference the Directions for Use labeling for a complete listing of indications, warnings 

and precautions. 

1. Accutane ® is a registered trademark of 

Hoffmann-La Roche Inc. 

2. Cordarone ® is a registered trademark of 

Sanofi S.A. 

3. Imitrex ® is a registered trademark of 

Glaxo Group Limited 

© 2012 Novartis 8/12 ALL12695JADUS-PI

Opening Session 


8:30 – 10:00 AM 

North Building, Hall B 

Join the Academy as we open the 2012 Joint Meeting with the Asia-Pacific Academy of Ophthalmology. This exciting 

program includes: 

2012 Laureate Award: Stephen J Ryan MD 

Dr. Ryan is recognized by the Academy for his valuable and innumerable contributions to the field of vitreoretinal 

disease and ocular trauma. His leadership has made a key impact in major national and international organizations, 

reshaping not only ophthalmology but the entire field of medicine. 

Opening Session Keynote: Abraham Verghese MD 

Dr. Verghese is a renowned physician, bestselling author and Professor for the Theory and Practice of Medicine at 

Stanford University School of Medicine. He has garnered many accolades for his advocacy efforts on behalf of patients 

and his celebrated debut novel, Cutting for Stone. Join us for a book signing at the Resource Center following 

the Opening Session. 

Jackson Memorial Lecture: Joan W Miller MD 

Dr. Miller is preeminent in the field of ocular neovascularization and an internationally recognized expert in the field 

of macular degeneration. She is the Henry Willard Williams Professor of Ophthalmology & Chair, Department of 

Ophthalmology at the Harvard Medical School. She is also the Chief of Ophthalmology with the Massachusetts Eye 

and Ear Infirmary and Massachusetts General Hospital. 

TIME TOPIC SPEAKER 

8:30 AM Opening Remarks Jonathan B Rubenstein MD 

8:32 AM APAO President’s Address Frank J Martin MD 

8:38 AM Academy President’s Address Ruth D Williams MD 

8:44 AM Academy Awards 

8:56 AM Laureate Award: Stephen J Ryan MD Paul R Lichter MD 

8:59 AM Academy’s Chief Executive Officer’s Address David W Parke II MD 

9:05 AM Academy’s President-Elect’s Address Paul Sternberg Jr MD 

9:10 AM Keynote Speaker Abraham Verghese MD 

9:30 AM Introduction of the Jackson Memorial Lecture Jonathan B Rubenstein MD 

9:32 AM Jackson Memorial Lecture: AMD Revisited – Piecing the Puzzle Joan W Miller MD 

9:57 AM Jackson Memorial Lecture Award Presentation Thomas J Liesegang MD 

9:58 AM Concluding Remarks Jonathan B Rubenstein MD 

10:00 AM End of Session 





Academy Café 

Room S406b 

Join us for free coffee and lively conversation in the Academy Café: a casual meeting place where you can benefit from discussions on 

various ophthalmologic topics. Eight moderated discussion sessions with expert panels are scheduled throughout the meeting. Bring your 

cell phone, smartphone or laptop and text message your questions to the panel. 

How to submit a question: Point the browser on your laptop or wireless mobile device to http://ai.acuport.org and login with your 

Badge ID and Password or send SMS text to 41411 with the keyword ACafe followed by a space and your question (example: “acafe Here 

is my question”). Note: For SMS, standard text messaging fees may apply based on your wireless plan. 

Saturday 

SYM45 

Uveitis 

1:00 - 2:15 PM 

Moderator: Justine R Smith MD 

Panel: Russell W Read MD PhD, Howard H Tessler MD, 

Jennifer E Thorne MD PhD, Daniel V Vasconcelos-Santos MD PhD 

SYM46 

Cataract 

2:30 - 3:45 PM 

Moderator: Bonnie A Henderson MD 

Panel: Robert J Cionni MD, Douglas J Rhee MD, Mark Packer MD, 

Susan M Pepin MD, John Allan Vukich MD 

Monday 

SYM50 

Glaucoma 

9:00 - 10:15 AM 

Moderator: Thomas W Samuelson MD 

Panel: Reay H Brown MD, Marlene Moster MD, 

Nathan M Radcliffe MD, Kuldev Singh MD MPH 

SYM41 

Retina 

10:30 - 11:45 AM 

Moderator: Thomas R Friberg MD 

Panel: Sophie J Bakri MD, Lawrence P Chong MD, 

Alan F Cruess MD, K Bailey Freund MD 

Sunday 

SYM47 

Combined Procedures 

10:30 - 11:45 AM 

Moderator: Stephen S Lane MD 

Panel: Douglas D Koch MD, Richard A Lewis MD, Keith A Warren 

MD 

SYM48 

Oculoplastics 

1:00 - 2:15 PM 

Moderator: Stuart R Seiff MD 

Panel: Suzanne K Freitag MD, Jeffrey A Nerad MD, John D Ng MD 

SYM49 


2:30 - 3:45 PM 

Moderator: Edward J Holland MD 

Panel: Clara C Chan MD, Douglas A Katsev MD, 

William Barry Lee MD, David D Verdier MD 

Tuesday 

SYM52 

Cataract 

10:30 - 11:45 AM 

Moderator: Sonia H Yoo MD 

Panel: Richard S Davidson MD, Richard S Hoffman MD, 

Christopher E Starr MD, Richard Tipperman MD 

Free Coffee. 

Your Questions. 

Expert Panels. 

Lively Conversation. 

130 


Academy Spotlight Sessions & Symposia 

Saturday - Tuesday, Nov. 10 - 13 

Spotlight Sessions and Symposia are free of charge and open to all attendees. 

APAO Sponsored by the Asia-Pacific Academy of Ophthalmology 

GO Global Ophthalmology 

SO Endorsed by Senior Ophthalmologist Committee 

YO Endorsed by Young Ophthalmologist Committee 


The Special Projects Committee developed the Spotlight on Innovation in Ophthalmology: From 

Theory to Therapy, the Spotlight on Corneal Collagen Crosslinking, the Spotlight on Pseudoexfoliation, 

the Great Debate, Best of Anterior Segment Specialty Meetings 2012, Best of Posterior 

Segment Specialty Meetings 2012, Grand Rounds: Cases and Experts From Across the Nation, 

International Perspectives: Trauma of the Anterior Segment-Evaluation and Management, Late 

Breakers Symposium, and the Academy Cafés. 

The American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology 

selected all Joint Sessions. 

The Annual Meeting Program Committee selected all other spotlight sessions and symposia. 






Spotlight Sessions & Symposia 

Spotlight Sessions 

& Symposia 


GO What is Global Ophthalmology? 

Event No: SYM01 

Room: S405 

2:30 - 4:00 PM 

Combined meeting with the Global Alliances Secretariat 

Chair(s): Linda M Lawrence MD, David H Cherwek MD*, Brad H Feldman 

MD 

This symposium on global ophthalmology will first seek to define this evolving 

subspecialty within ophthalmology, one that concerns eye health in its global 

context with particular emphasis on communities lacking or still developing 

mechanisms for medical and surgical eye care. The session will tackle the delicate 

ethical issues involved when crossing borders and cultures to offer one’s 

services abroad. Furthermore, it will address the many risks inherent in international 

medicine and how to minimize exposure to these risks. 

2:30 PM What is Global Ophthalmology? 

Linda M Lawrence MD 

2:40 PM The Ethical Role of Trainees and Medical Students in Global 

Ophthalmology and Education 

R V Paul Chan MD 

2:50 PM Developing and Maintaining a Successful, Ethical International 

Ophthalmology Program 

Anthony J Aldave MD* 

3:00 PM Panel Discussion 

3:10 PM Risk Management: What to Know Before You Go 


3:20 PM Risk Management: How to Thrive When You Arrive 

David H Cherwek MD* 


3:40 PM How is Global Ophthalmology Evolving? 


3:50 PM Q&A 

4:00 PM End of Session 


Introduction to Refractive Surgery for Residents 


8:00 - 10:00 AM 

Room: S503ab 

Sponsored by the International Society of Refractive Surgery (ISRS) 

Chair(s): Ronald R Krueger MD*, J Bradley Randleman MD 

This course will provide an overview of the most relevant topics on refractive 

surgery, including patient evaluation, topographic evaluation, a step-by-step 

surgical explanation of LASIK and surface ablation procedures, and discussion 

of surgical complication recognition and management, providing a basis upon 

which these individuals in training may begin to grow their knowledge base and 

gain comfort in practicing independently after graduation. The course will be an 

interactive didactic session led by recognized experts and international leaders 

in the field of refractive surgery, but will be specifically directed at the resident 

education level, as opposed to many of the courses at AAO directed towards 

specialists already in practice. This focus should allow the resident to gain the 

optimal learning experience. 

8:00 AM Welcome and Opening Remarks 

J Bradley Randleman MD, Ronald R Krueger MD* 

8:02 AM Basic LASIK Patient Evaluation 

Ronald R Krueger MD* 

8:20 AM Topographic Evaluation 

J Bradley Randleman MD 

8:40 AM Step-by-Step PRK and LASIK 


9:00 AM Decision Tree: When PRK and When LASIK 

Marguerite B McDonald MD* 

9:20 AM Intraoperative Complications and Management 

Amar Agarwal MD* 

9:40 AM Postoperative Complications and Management 

David R Hardten MD* 

10:00 AM Closing Remarks 

Ronald R Krueger MD*, J Bradley Randleman MD 


Vision Rehabilitation Education: Effectively Transmitting the 

Need for Low Vision Services to the Ophthalmic Community 


10:00 AM - 12:00 PM 

Room: S504d 

Combined meeting with the Vision Rehabilitation Committee 

Chair(s): Janet S Sunness MD*, Mary Lou Jackson MD 

Patients with moderate visual loss, for example patients successfully treated by 

anti-VEGF agents, may still be unable to read because they require more than 

normal magnification or lighting. Few of these patients, and others with difficulties 

in daily visual tasks whom vision rehabilitation would greatly help, are being 

referred for low vision intervention. There is a critical need to improve awareness 

of the benefits vision rehabilitation can offer. This session is designed to 

explore ways to increase this awareness. 

10:00 AM Introduction 

10:05 AM General Methods for Increasing Referrals 

Sue J Vicchrilli COT OCS 

10:20 AM Increasing Referrals for Low Vision Rehabilitation- What Can Be 

Done? 

Joseph L Fontenot MD 

10:35 AM Microperimetry and Clinical Practice: The Additional Benefit of 

Microperimetry Results for Referring Physicians 

Samuel N Markowitz MD 

10:50 AM Resident Education: Conveying the Value of Vision Rehabilitation 

Mary Lou Jackson MD 

11:05 AM BREAK 

11:10 AM Occupational Therapists and Publicizing the Importance of Vision 

Rehabilitation 

Lylas G Mogk MD* 

11:25 AM Panel Discussion 

11:40 AM The Impact of Reaching Out 

Janet S Sunness MD* 

11:50 AM Conclusion 




10:30 - 11:45 AM 

Room: S406a 

Chair(s): R Michael Siatkowski MD*, Scott C Oliver MD* 

This symposium will feature best papers focusing on the posterior segment from 

the major retina, neuro-ophthalmology, uveitis, oculoplastics and pediatric ophthalmology 

specialty meetings of 2012. 



132 

* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the 

presenter has no financial interest. Up-to-date information is available in the Mobile Meeting Guide: www.aao.org/mobile.


Sunday, Nov. 11 (con’t) 

10:32 AM Automated Quantification of Volumetric Optic Disc Swelling in 

Papilledema Using Spectral-Domain OCT 

Randy H Kardon MD PhD* 

10:39 AM Subretinal Fluid in Uveitic Macular Edema: Effect on Vision and 

Response to Therapy 

Brian P Lehpamer MD** 

10:46 AM 36-Month Efficacy and Safety Results of RISE and RIDE, 2 Phase 3 

Randomized Controlled Clinical Trials of Ranibizumab for Diabetic 

Macular Edema 

David M Brown MD* 

10:53 AM Two-Year Results From the Argus II Retinal Prosthesis System 

Clinical Trial 

Mark S Humayun MD PhD* 

11:00 AM Lean Processes in Action: From Toyota to Ophthalmic Practice 

Dennis P Han MD* 

11:07 AM Macular Edema Following Cataract Surgery in Diabetic Eyes Without 

Central-Involved Diabetic Macular Edema 

Stephen J Kim MD 

11:14 AM Percutaneous Drainage and Ablation as the First-Line Therapy for 

Macrocystic and Microcystic Orbital Lymphatic Malformations 

Kenneth V Cahill MD FACS 

11:21 AM Intravitreal Aflibercept Injection vs. Ranibizumab for Neovascular 

AMD: Two-year Results From the Phase 3 VIEW 1 and VIEW 2 

Studies 

Ursula M Schmidt-Erfurth MD* 

11:28 AM Two-Year Results From the Comparison of AMD Treatments Trials 

(CATT) 

Daniel F Martin MD 




Spotlight on Innovation in Ophthalmology: From Theory to 

Therapy 

Event No: SP01 

10:30 AM - 12:00 PM 

Room: Grand Ballroom S100ab 

Chair(s): Emmett T Cunningham Jr MD PhD MPH 

This session is intended to give clinical ophthalmologists an improved understanding 

of the factors driving and influencing innovation in ophthalmology. Following 

a brief welcome, six 10-minute presentations will be given, covering: 1) 

The role of physician innovators; 2) Innovating from Academia; 3) Innovating 

from private practice; 4) Funding innovation; 5) Team building; and 6) Mistakes 

to avoid. This will be followed by a 20-30 minute audience Q&A session with all 

participants. Participants should gain an improved understanding of the innovative 

process, including how to protect and advance their own innovations. 

10:30 AM Welcome 

Emmett T Cunningham Jr MD PhD MPH 

10:35 AM The Role of Physician Innovators 

Daniel M Schwartz MD 

10:45 AM Innovating From Academia 

Mark S Blumenkranz MD* 

10:55 AM Innovating From Private Practice 

Richard L Lindstrom MD* 

11:05 AM Funding Innovation 

Gilbert H Kliman MD** 

11:15 AM Building A Team 

William Link PhD* 

11:25 AM Mistakes I’ve Made (but Wish I Hadn’t) 

Eugene De Juan Jr MD* 

11:35 AM Panel Discussion/Q&A 


APAO Corneal Stem Cell: Advances in Clinical and 

Laboratory Research 


10:30 AM - 12:00 PM 

Room: North Hall B 

Joint Session with the Asia-Pacific Academy of Ophthalmology (APAO) 

Chair(s): Charles McGhee PhD FRCOphth FRANZCO*, Edward J Holland 

MD* 

The diagnosis and treatment of stem cell deficiency has been marked by limited 

therapeutic interventions in the past. Over the last decade we have rapidly 

gained a more detailed understanding of stem cells and stem cell-like cells in 

the epithelial, stromal and endothelial layers and advanced techniques to replenish 

these layers. Current surgical techniques include traditional limbal stem 

cell transplants for ocular surface disease and penetrating/lamellar corneal 

transplantation for cellular deficiencies, or abnormalities, in stromal and endothelial 

layers. In a series of six presentations by acknowledged international 

authorities in the field, the concepts of stem cells, the diagnosis of stem cell 

deficiency and common and advanced interventions in clinical practice will be 

discussed. Techniques currently emerging from the laboratory, that will influence 

stem cell transplantation techniques in the coming 5-10 years, will also be 

highlighted. These concepts will be illustrated by case examples. Sufficient time 

is allotted for discussion. 


10:31 AM Stem Cells: What Are They and Where Are They in the Cornea? 

Ali R Djalilian MD 


10:46 AM Defining Corneal Epithelial Stem Cell Failure in the Clinic 

Clara C Chan MD* 


11:01 AM Advances in Ocular Surface Stem Cell Transplantation 

Edward J Holland MD* 


11:16 AM Transplanting Limbal Stem Cells: Ex-Vivo Expansion and Other 

Techniques 

Stephanie L Watson BS MBBS FRANZCO PHD 


11:31 AM Will Corneal Stromal Keratocyte Transplantation Replace DALK in 10 

Years? 

Charles McGhee PhD FRCOphth FRANZCO* 


11:46 AM Restoring or Replacing the Corneal Endothelium? 

Shigeru Kinoshita MD* 




& Symposia 


presenter has no financial interest. Up-to-date information is available in the Mobile Meeting Guide: www.aao.org/mobile. 

133



& Symposia 


From Metal to Molecules: The Evolution of Oculofacial 

Plastic Surgery 


10:30 AM - 12:00 PM 

Room: E450 

Combined meeting with the American Society of Ophthalmic Plastic and 

Reconstructive Surgery (ASOPRS) 

Chair(s): Rona Z Silkiss MD FACS, Angela M Dolmetsch MD 

Oculofacial plastic surgery is evolving. As new technologies develop they are 

incorporated into the practice of oculofacial plastic surgery in innovative and 

meaningful ways. New discoveries in endoscopic and laser technology, molecular 

medicine, designer pharmaceuticals, nanotechnology and nanofabrication 

have and will continue to influence the practice of oculofacial plastic surgery. 

These innovations have had a significant impact on patient care, influencing 

outcomes in a positive way. This forum will look at several of these innovations 

and their impact on traditional oculofacial plastic surgery and patient outcomes. 


Rona Z Silkiss MD FACS 

10:32 AM Historical Overview 

Robert Graham Weatherhead MD 

10:40 AM From Selective Neurectomy to Targeted BotulinumTherapy: Toxin 

Comparison 

Jean D Carruthers MD** 

10:48 AM From Decompression to Rituximab: The Use of Novel Biologics 

Simeon A Lauer MD 

10:56 AM From Surgical Removal of Capillary Hemangiomas to Propranolol 

Francois Codere MD 

11:04 AM From External DCR to Endoscopic DCR 

Nancy A Tucker MD 

11:12 AM From Surgical Excision to Topical Therapy for Basal Cell Carcinoma 

Timothy J Sullivan MBBS 

11:20 AM From Blepharoplasty to Stem Cell Transfer: What the Future Holds 

for Cosmetic Surgery 

Robert A Goldberg MD 

WENDELL L HUGHES LECTURE 

11:28 AM Introduction of the Wendell L Hughes Lecture 

Ralph E Wesley MD FACS 

11:33 PM Wendell L Hughes Lecture: From Bench to Bedside: Genetics of 

Congenital Anophthalmia 

Christine C Nelson MD 

11:58 PM Presentation of Award 


Cataract Surgery: The Cutting Edge 



Chair(s): Robert H Osher MD* 

12:15 - 1:45 PM 

Panelists: Iqbal K Ahmed MD*, Burkhard Dick MD*, Abhay Raghukant Vasavada 

MBBS FRCS*, Boris Malyugin MD PhD*, Richard L Lindstrom MD*, David F Chang 

MD* 

To stimulate a panel discussion, this symposium will present short videos of 

novel ideas, techniques, and devices from cataract surgeons around the world. 

Expect controversy and spirited debate from the expert international panel. 

Guaranteed to keep you on the edge of your seats! 

Contagion! Epidemics in Ophthalmic History 


12:15 - 1:45 PM 

Room: S405 

Combined meeting with the Museum of Vision of the American Academy of 

Ophthalmology 

Chair(s): Michael F Marmor MD* 

Plague, pestilence and pandemic are words that have struck fear for centuries. 

Ophthalmology is not immune to their ravages and, indeed, has been at the forefront 

of the fight against some of their worst symptoms. Here we will discuss 

historic outbreaks, ophthalmic implications and the people that have worked to 

find the cause and cure of contagious diseases. 

12:15 PM Welcome 

Jenny Benjamin 

12:20 PM Contagion: Epidemics in Truth and Fiction 

Robin Cook MD** 

12:30 PM From Miasma to Antisepsis: The Quest for a Cure 

Ronald S Fishman MD 

12:40 PM The Universal Diseases: Tuberculosis and Syphilis 

Pamela S Chavis MD 

12:50 PM The Egyptian Ophthalmia: Trachoma 

Robert M Feibel MD 

1:00 PM Gonococcus: More Than an Epidemic 

James G Ravin MD 

1:10 PM Leprosy and Ethics: The Trial of Hansen 

Michael F Marmor MD* 

1:20 PM Parasites in the Eye: On the River and Elsewhere 

Hugh R Taylor MD FRACS* 

1:30 PM The Modern Plagues: AIDS and CMV 

William R Freeman MD* 

1:40 PM Closing Remarks/Questions 

Michael F Marmor MD* 


Preferred Practice Pattern Guidelines: Adding Practical 

Value to Daily Practice 


12:45 - 1:45 PM 

Room: S403b 

Combined meeting with the Preferred Practice Patterns Committee 

Chair(s): Christopher Rapuano MD* 

This symposium features the newly revised Preferred Practice Pattern ® (PPP) 

Guidelines on Refractive Errors & Refractive Surgery, Amblyopia, Esotropia & 

Exotropia, Pediatric Eye Evaluation, and Vision Rehabilitation for Adults. The 

refractive PPP includes up-to-date evidence-based treatment recommendations 

and options for patients with refractive error or presbyopia with an emphasis on 

refractive surgery and contact lenses. The pediatric ophthalmology titles provide 

up-to-date evidence-based management recommendations for amblyopia, esotropia, 

and exotropia and vision screening for children. The Vision Rehabilitation 

PPP includes evidence-based recommendations for adults with visual impairment. 

Attendees will receive a free CD-ROM containing the 18 PPP titles in PDF 

format. 

12:45 PM Preferred Practice Patterns Development Process 

Christopher Rapuano MD* 

134 





12:55 PM Highlights of the Refractive Errors and Refractive Surgery PPP 

Stephen D McLeod MD 

1:05 PM Highlights of the Pediatric Eye Evaluations PPP 

C Gail Summers MD* 

1:15 PM Highlights of the Amblyopia PPP 


1:20 PM Highlights of the Esotropia and Exotropia PPP 


1:25 PM Highlights of the Vision Rehabilitation in Adults PPP 


1:35 PM Q&A 


Spotlight on Collagen Corneal Crosslinking 


Room: Room: Grand Ballroom S100ab 

2:00 - 3:30 PM 

Chair(s): A John Kanellopoulos MD*, R Doyle Stulting MD PhD* 

This spotlight session will present a didactic approach to the clinical experience 

of basic science, indications, surgical technique and complications encountered 

with several CXL treatments for indications, such as keratoconus and ectasia 

following refractive surgery. Several surgical treatment modalities utilized in 

the US clinical trials and internationally will be presented. Long term clinical 

results and other potential indications such as infectious keratitis, LASIK and 

PRK prophylaxis, and bullous keratopathy will be presented. 

2:00 PM Introduction 

A John Kanellopoulos MD* 

2:02 PM Basic Science of Corneal Crosslinking 

Farhad Hafezi MD PhD* 

2:12 PM Clinical Indications and Patient Selection 

R Doyle Stulting MD PhD* 

2:22 PM Surgical Technique 

Theo Seiler MD PhD* 

2:32 PM Higher Fluence and Higher Riboflavin Concentration 

John Marshall PhD* 

2:42 PM Combined CXL and Other Techniques: Topography-Guided PRK, 

Intracorneal Ring Segments, and Phakic IOLs 

A John Kanellopoulos MD* 

2:52 PM Complications and Their Management 

Michelle Y Cho MD 

3:02 PM Growing Potential Indications: Infectious Keratitis, Prophylaxis in 

LASIK/PRK, and Bullous Keratopathy 

Eric D Donnenfeld MD* 

3:12 PM Panel Discussion/Q&A 


How Does It Feel?– An Insider’s Perspective on Living With 

Anophthalmia 


2:00 - 3:30 PM 

Room: Grand Ballroom S100c 

Combined meeting with the American Society of Ocularists (ASO) 

Chair(s): Brian J Miller BCO BADO, Susan Benes MD* 

Surgeons and ocularists share experience and wisdom with patients and their 

families about how to adapt visually, psychologically, emotionally, cosmetically, 

vocationally and ethically to their new anophthalmic status. Hearing from patients 

(or their parents) who have gone through the loss of an eye, and who 

are also professionals (ophthalmologists, orthoptists, ocularists), will enrich our 

understanding of this transition. These experts will help professionals who have 

not had such a loss personally to counsel their patients and ease their transitions. 


Susan Benes MD* 

2:02 PM Growing Up With Monocular Vision 

Antonio L Alcorta BCO BADO 

2:10 PM Mono Vision 101 

Anna O’Connor PhD 

2:18 PM Parenting a Child With a Prosthetic Eye 

Michael O’Neill Hughes Sr BA 

2:26 PM Informed Consent: The Patient and Enucleation 

David L Rogers MD 

2:34 PM Learning to Adapt to Monocular Vision 

Craig R Pataky BCO BA DO 

2:42 PM Performing Surgery With Monocular Vision 

George M Bohigian MD 

2:50 PM The Monocular Ocularist 

Walter J Johnson BCO BA DO 

2:58 PM The Phantom Limb, Problems After Enucleation 

Hui Bae Harold Lee MD 

RUEDEMANN LECTURE 

3:06 PM Introduction of the Ruedemann Lecturer 

Brian J Miller BCO BADO 

3:08 PM Ruedemann Lecture: How Does the Patient and/or Pediatric Parent 

Feel About Their Ocularist or Physician Experience? 

Kathy J Hetzler BCO 


Brian J Miller BCO BADO 


Medical and Surgical Treatment of Macular Disease 


2:00 - 3:30 PM 

Room: E450 

Combined meeting with The Retina Society 

Chair(s): Charles C Barr MD FACS*, Annabelle A Okada MD* 

Treatment options for macular disease currently involve both medical and surgical 

approaches. Multicenter clinical trials, which have been completed or will be 

completed in the near future, give us some guidelines, but some diseases of the 

macula still require the practitioners to use best clinical judgment. Symposium 

speakers will discuss both conventional and alternative therapeutic strategies 

in treating a variety of macular diseases. They will focus on not only the visual 

benefits to the patient, but also the economic impact of different treatment 

strategies. Understanding the benefits, as well as the risks and limitations of 

these therapeutic approaches will be of value to both vitreoretinal specialists 

and comprehensive ophthalmologists. 


Annabelle A Okada MD* 

2:01 PM The Role of Genetic Testing in AMD 

Edwin M Stone MD PhD 

2:09 PM The Current Status of Nutritional Supplements in the Treatment of 

Macular Degeneration 


2:17 PM Results of the CATT Trial and Implications for Treatment of AMD 


2:25 PM Cost-Effectiveness of VEGF- Trap vs. Ranibizumab and Bevacizumab 

in Treatment of AMD 

David F Williams MD* 


& Symposia 



135



& Symposia 


2:33 PM Emerging Treatments for Dry AMD 

Philip J Rosenfeld MD PhD* 

2:41 PM Management of Extensive Submacular Hemorrhage in AMD 

Sophie Bakri MD* 

2:49 PM Therapeutic Options for Treatment of Posterior Polypoidal Choriodal 

Vasculopathy 

Adrian H Koh MD* 

2:57 PM Management of Myopic Macular Disease 

Timothy Y Lai MBBS* 

3:05 PM Myopic Traction Maculopathy 

Mark W Johnson MD* 

3:13 PM Ocriplasmin Manipulation of the Epimacular Vitreous and 

Membranes 

Michael T Trese MD* 

3:21 PM Macular Hole Surgery 2012 


3:29 PM Closing Remarks 

Charles C Barr MD FACS* 


Optimizing Optics: Perspectives From Contact Lens, 

Intraocular Lens, and Refractive Surgery 


2:00 - 3:30 PM 

Room: S406a 

Combined meeting with the Contact Lens Association of Ophthalmologists 

(CLAO) 

Chair(s): Deborah S Jacobs MD, Warren R Fagadau MD, Michael H Goldstein 

MD* 

The goal of this symposium is to highlight advances in optics in several realms: 

contact lens, intra-ocular lens, cornea surgery, and refractive surgery. Advances 

for presbyopia and astigmatism will be covered, as well as advances related to 

the optics of IOL calculations, lamellar keratoplasty, dry eye, and treatment of 

keratoconus. Visual performance as a metric for optics will be presented. Dmitri 

Azar will give the invited Whitney Sampson Lecture on wavefront optimization 

in refractive surgery. 


2:02 PM Pearls and Pitfalls With Toric IOLs 

Bonnie A Henderson MD* 

2:10 PM Optics of Presbyopia-Correcting IOLs 

Scott M MacRae MD* 

2:18 PM IOL Calculation After Refractive Surgery 

David Huang MD PhD* 

2:26 PM Optical Aberrations and Visual Disturbances Associated With Dry 

Eye 

Kazuo Tsubota MD* 

2:34 PM Contact Lenses and the Correction of Higher Order Aberrations 

Deborah S Jacobs MD 

2:42 PM Corneal Collagen Crosslinking for Keratoconus: Impact on Optics 


2:50 PM Femtosecond Laser-assisted Keratoplasty: Impact on Optics 

Amy Lin MD 

WHITNEY G SAMPSON LECTURE 

2:58 PM Introduction of the Whitney G Sampson Lecture 

3:00 PM Whitney G Sampson Lecture: Wavefront Optimization in Refractive 

Surgery 

Dimitri T Azar MD* 



GO SO Modern Technologies and Techniques for Young 

Ophthalmologists to Know 


2:30 - 4:00 PM 

Room: S101ab 

Combined meeting with the Young Ophthalmologist International 

Subcommittee, and Young Ophthalmologists from the European Society 

of Ophthalmology (SOE) and the Asia-Pacific Academy of Ophthalmology 

(APAO) 

Chair(s): Lauren Patty Daskivich MD, Anthony P Khawaja MBBS 

The joint session with the young ophthalmologist (YO ) committees of the Academy, 

the European Society of Ophthalmology and the Asia-Pacific Academy of 

Ophthalmology will focus on particular strategies for the treatment of various 

ocular diseases that are applied internationally, but not yet universally practiced. 

Attendees will learn about clinical and surgical techniques that may be useful in 

their future practices. If applicable, appropriate disclosures will be made when 

discussing available, but non-US approved, technologies or techniques. 

2:30 PM The Expanding Indications of the Boston Keratoprosthesis Both in 

North America and Around the World 

Anthony J Aldave MD* 

2:40 PM Q&A 

2:45 PM Why DMEK Will Replace DSAEK 

Francis W Price Jr MD* 

2:55 PM Q&A 

3:00 PM Imaging of the Lamina Cribrosa: Insight Into Glaucoma Pathogenesis 

Nicholas G Strouthidis MD 

3:10 PM Q&A 

3:15 PM Stem Cell Transplantation to the Inner Retina: A Translational 

Approach 

Hari Jayaram BMBCh 

3:25 PM Q&A 

3:30 PM Visual Field Testing: Innovative Practices and Future Trends 

Elena Papageorgiou MD PHD 

3:40 PM Q&A 

3:45 PM Glued IOLs in Sticky Situations 

Amar Agarwal MD* 

3:55 PM Q&A 


Controversies in Pediatric Ophthalmology and Orthoptics: A 

Point–Counterpoint Discussion 


3:45 - 5:15 PM 


Combined meeting with the American Orthoptic Council and American 

Association of Certified Orthoptists (AACO) 

Chair(s): David G Morrison MD, Cheryl Lynn McCarus CO COMT 

The pediatric ophthalmic practice encompasses a wide range of disease processes 

and potential treatment modalities. Many clinicians have anecdotal evidence 

to support many current practice patterns. The emergence of evidencebased 

medicine and large clinical trials of common conditions have given additional 

weight to certain treatment modalities. However, a “one size fits all” approach 

may not be the best strategy for all patients. The goal of this symposium 

is to define several common clinical conditions ranging from strabismus and 

136 





amblyopia to vision therapy, and infantile hemangiomas, with evidence to support 

varied treatment strategies. Evaluation of these conditions and treatment 

dilemmas will be discussed in a point-counterpoint format. 


Cheryl Lynn McCarus CO COMT 

3:50 PM Hemangioma Treated With Propranolol: Rewards Outweigh Risks 

Kathryn M Haider MD 

3:58 PM Hemangioma: Lesions Can Be Treated With Steroid Injection or 

Surgery 

Louise A Mawn MD* 

4:06 PM Rebuttal / Introduction of Next Topic 

4:08 PM Part-time vs. Full-time Occlusion for Amblyopia: Evidence for Parttime 

Patching 

Noelle S Matta COT 

4:16 PM Full-time Occlusion: Better Compliance and Outcomes 

Jessica Kane CO 


4:26 PM Botulinum for Recurrent Esotropia: A New Treatment Option 

Scott R Lambert MD* 

4:34 PM Botulinum for Comitant or Recurrent Esotropia: Not Worth the Risk 

Sean P Donahue MD PhD* 


4:44 PM Vision Therapy and Computer Orthoptics: Evidence-Based Approach 

to Use in Your Practice 

Jennifer Lambert 

4:52 PM Vision Therapy- Are You Kidding Me? Problems With Current Studies 

Sarah Whitecross OC 


David G Morrison MD 


International Perspectives: Trauma of the Anterior 

Segment—Evaluation and Management 


3:45 - 5:15 PM 

Room: S406a 

Combined meeting with the Colombian Society of Ophthalmology (SCO) and 


Chair(s): Carlos A Restrepo Pelaez MD*, Mark J Mannis MD, M Bowes 

Hamill MD* 

This symposium will deal with the evaluation and management of anterior 

segment ophthalmic trauma. The goal of the symposium is to present to the 

attendees the most recent and practical approaches to the evaluation and 

management of anterior segment injuries. To accomplish this, experts from 

both the United States and Colombia, South America, have been selected to 

present topics of interest to the ophthalmologist faced with managing ocular 

injuries. Topics to be covered include evaluation of the injured anterior segment, 

management of injuries to the cornea, lens and iris, intraocular foreign bodies, 

pediatric eye trauma, and war trauma. The talks will stress practical and useful 

information that is geared to providing the comprehensive ophthalmologist with 

the best techniques and approaches to assist in management of these injuries. 


3:46 PM Evaluation of the Injured Anterior Segment 

Preston H Blomquist MD 

3:56 PM Foreign Bodies in the Anterior Segment 

Mauricio Velez Fernandez MD** 

4:06 PM Management of Lacerating Injuries of the Anterior Segment 

Malvin D Anders MD** 

4:16 PM Acute Management of the Injured Lens 

Surendar Dwarakanathan MD 

4:26 PM Management of the Traumatic Cataract 

Juan G Sanchez MD** 

4:36 PM Management of the Injured Iris 

M Bowes Hamill MD* 

4:46 PM Pediatric Eye Trauma 

Angela Maria Fernandez** 

4:56 PM War Trauma 

Carlos Alberto Restrepo Pelaez MD* 

5:06 PM Discussion 


LASIK Is Safe: Prevention and Management of Laser 

Complications 


3:45 - 5:15 PM 


Combined meeting with the International Society of Refractive Surgery (ISRS) 

Chair(s): Sonia H Yoo MD*, Joseph Colin MD* 

LASIK is one of the most common ophthalmic procedures performed all over the 

world because of its high rate of predictability and excellent visual outcomes. As 

new technologies are introduced, outcomes have improved and complications 

have declined. This symposium will look at the history of LASIK as well as new 

innovations in the field and will focus on strategies to avoid complications and 

improve patient outcomes. 


Joseph Colin MD* 

3:47 PM The History of LASIK 

Vikentia Katsanevaki MD 

3:55 PM Comparison Between Surface and Intrastromal Ablations 

Julian D Stevens DO* 

4:03 PM Comparison of Microkeratome and Femtolaser Flap Dissection 

Perry S Binder MD* 

4:11 PM Biomechanical Properties of the LASIK-ed Cornea 

Damien Gatinel MD* 

4:19 PM Quality of Vision and Life Following LASIK 

Steven C Schallhorn MD* 

4:27 PM How to Prevent and to Treat Flap Complications 

R Doyle Stulting MD PhD* 

4:35 PM When Are Phakic IOLs Preferable to LASIK 

John Allan Vukich MD* 

BARRAQUER LECTURE 

4:43 PM Introduction of the Barraquer Lecturer 


4:48 PM Barraquer Lecture: 30 Years of Refractive Surgery — A Critical 

Analysis With an Optimistic Outlook 

Gunther Grabner MD* 


Sonia H Yoo MD*, Joseph Colin MD* 



& Symposia 



137



& Symposia 


The Controversies and Dilemmas of Managing Ocular 

Infectious Diseases: Point–Counterpoint 


3:45 - 5:15 PM 


Combined meeting with the Ocular Microbiology and Immunology Group 

(OMIG) 

Chair(s): Darlene Miller MPH, Prashant Garg MD* 

In recent years several issues related to the management of ocular infections 

have either provoked controversies or generated new dilemmas. These include 

the efficacy of intracameral antibiotics for prophylaxis against endophthalmitis, 

of culture and corticosteroids in the management of bacterial keratitis, of oral 

antiviral therapy for viral infections of the eye, and the usefulness of advanced 

diagnostic techniques such as in vivo imaging and molecular diagnostic techniquest. 

The point-counterpoint format of this symposium will present to the audience 

the evidence for and against these controversial issues, debated by a panel 

of leading ocular disease experts, followed by a survey of audience opinion via 

invited participation and polling. 


Darlene Miller MPH 

3:48 PM Diagnosis and Treatment of Ocular Infections — Should Be Guided 

by Culture/Susceptibility Testing 

David G Hwang MD 

3:55 PM Diagnosis and Treatment of Ocular Infections — Culture/ 

Susceptibility Testing Are Unnecessary 


4:02 PM Panel Discussion and Audience Poll 

4:05 PM Topical Corticosteroid Therapy in the Management of Bacterial 

Keratitis — Is of Great Value With Proven Benefit 

M Srinivasan MD 

4:12 PM Topical Corticosteroid Therapy in the Management of Bacterial 

Keratitis — Is Dangerous and Has No Proven Benefit 

Elisabeth J Cohen MD* 


4:22 PM Prophylaxis Against Endophthalmitis in Cataract Surgery — 

Intracameral Therapy Is the Way Forward 

Steve A Arshinoff MD* 

4:29 PM Prophylaxis Against Endophthalmitis in Cataract Surgery — 

Prophylactic Antibiotic Therapy Is Unnecessary 

Wiley Andrew Chambers MD 


4:39 PM Treatment of Herpes Simplex Virus Infection — Oral Antiviral 

Therapy Is the New Standard 

James Chodosh MD MPH* 

4:46 PM Treatment of Herpes Simplex Virus Infection — Topical Antiviral 

Therapy Remains the Standard 



4:56 PM Molecular Methods in Diagnosis of Ocular Infections — The New 

Paradigm 

Regis P Kowalski MS* 

5:03 PM Molecular Methods in Diagnosis of Ocular Infections — Have 

Limited Applications 

Todd P Margolis MD PhD 


5:13 PM Concluding Remarks 

Prashant Garg MD* 


Video Case Presentations of Rare Vitreoretinal Diseases 


3:45 - 5:15 PM 

Room: E450 

Combined meeting with the European Latin America Retina Specialist Society 

(Eurolam) 

Chair(s): Stanley Chang MD*, Gisbert W Richard MD 

Using intraoperative videotapes and case presentations, a panel of internationally 

recognized experts will demonstrate their approach to various types 

of vitreoretinal diseases. Clinical evolution and diagnosis options will also be 

analyzed and the different management options employed by the panellists will 

be reviewed. 


3:46 PM Preoperative Diagnosis of Posterior Vitreous Detachment: Really? 

Ferenc P Kuhn MD PhD 

3:54 PM Surgical Techniques for Special Cases of Vitreoretinal Interface 

Disorders 

Marcio B Nehemy MD* 

4:02 PM Update in Diagnosis and Treatment of Familial Exudative 

Vitreoretinopathy 

Borja F Corcostegui MD* 

4:10 PM The Current Challenge of the Giant Retinal Tear 

Federico A Graue-Wiechers MD 

4:18 PM An Atypical Case of an Optic Nerve Pit 

George A Williams MD* 

4:26 PM Treatment of Vasproliferative Tumors 

Alain Gaudric MD* 

4:34 PM Macular Edema, Dissociation Between OCT and Angiography 

David E Pelayes MD* 

4:42 PM Current Management of Norrie Disease 

Antonio Capone Jr MD* 

4:50 PM Intraocular Tumor: Will Tissue for Diagnosis Tell the Whole Story? 

Stefan Seregard MD 

4:58 PM Discussion 

Stanley Chang MD*, Gisbert W Richard MD 


GO YO International Opportunities for Young 



4:15 - 5:15 PM 

Room: S101ab 

Combined meeting with the Young Ophthalmologist International 

Subcommittee 

Chair(s): Grace Sun MD 

Today’s residents and young ophthalmologists (YOs) must become tomorrow’s 

leaders in the global fight against eye disease. This symposium will address 

the challenges of treating eye disease in underserved parts of the world and 

will identify the organizations working toward this goal and the opportunities 

available for resident and YO involvement. The symposium will also examine 

the unique challenges of incorporating volunteer service into one’s career by 

sharing the experiences of those who have found ways to balance work abroad 

with family, clinical practice, and financial concerns at home. At the conclusion 

of the course, the attendee will have an understanding of the global burden of 

eye disease, the organizations and strategies employed to address this burden, 

the role residents and YOs play in this work, and the challenges of balancing 

domestic life with international service. 

4:15 PM Overview on Ophthalmology and Global Health 

Grace Sun MD 

4:25 PM Involving Residents in Global Health 

Devin M Gattey MD 

138 





4:35 PM YO Opportunities With the Himalayan Cataract Project 

Geoffrey C Tabin MD 

4:45 PM Building a Career in Global Volunteering as a YO 

James D Lehmann MD 

4:55 PM The Resident’s Perspective on Global Health Work 

Luxme Hariharan MD 

5:05 PM Q&A 



Spotlight on Cataracts: Clinical Decision-making With 

Cataract Complications 


8:15 AM - 12:15 PM 


Chair(s): David F Chang MD*, William J Fishkind MD FACS* 

This case-based video session will focus on cataract surgical complications. 

A series of seven video cases will provide the framework for didactic lectures 

and panel discussion regarding the management of intraoperative challenges 

and complications. Topics will include IOL exchange, mature white and brown 

lenses, anterior and posterior capsular tears, zonulopathy, small pupils, and IFIS. 

The videos will be paused at different decision points for the audience to weighin 

using response pads, and for the panelists to comment. The session will conclude 

with the 8th annual Charles Kelman Lecture. 

8:15 AM Case 1: IOL Power Surprise s/p LASIK 

8:21 AM Post-refractive IOL Calculations: The Art and Science 

Douglas D Koch MD 

8:26 AM Intraoperative Aberrometry 

Mark Packer MD* 

8:31 AM Management of IOL Power Surprise 

Warren E Hill MD* 

8:36 AM Pearls for IOL Explantation 

Bonnie A Henderson MD* 

8:41 AM Pearls for Toric IOL Implantation 

Stephen S Lane MD* 

8:46 AM Panel 

Jose L Guell MD PhD*, R Bruce Wallace MD* 

8:53 AM Case 2: Unhappy Multifocal IOL Patient 

8:58 AM Premium IOL Patient Selection: Common Mistakes 


9:03 AM Unhappy Premium IOL Patients: Managing the Eye 


9:08 AM Unhappy Premium IOL Patients: Managing the Patient 

Richard Tipperman MD* 

9:13 AM Panel 

Thomas Kohnen MD PhD FEBO*, Kerry D Solomon MD* 

9:20 AM Case 3: White Lens + Uveitis 

9:25 AM Phaco in Uveitis Patients 

James Philip Dunn Jr MD* 

9:30 AM Femtosecond Laser for Complex Cases 

Robert J Cionni MD* 

9:35 AM White Cataract: Capsulorhexis Pearls 

Brian C Little MD* 

9:40 AM Panel 

Randall J Olson MD, Robert H Osher MD* 

9:47 AM Case 4: Rock Hard Nucleus + Fixed Small Pupil 

9:52 AM Surgical Timing for One-eyed Patients 


9:57 AM Suprachoroidal Hemorrhage: Why? When? What now? 

Walter J Stark MD* 

10:02 AM Strategies for Small Pupils 

Terry Kim MD* 

10:07 AM Strategies for the Rock Hard Cataract 

Steve A Arshinoff MD* 

10:12 AM Panel 

Richard L Lindstrom MD*, Ravilla D Ravindran MD 

10:19 AM Case 5: PC Rupture with Descending Nucleus 

10:24 AM Management of Descending Nucleus: Do’s and Don’ts 

Lisa B Arbisser MD 

10:29 AM Pars Plana Anterior Vitrectomy: Do’s and Don’ts 

Steven T Charles MD* 

10:34 AM Non-capsular IOL Fixation 

Roger F Steinert MD* 


Amar Agarwal MD*, Suber S Huang MD MBA*, Louis D “Skip” 

Nichamin MD* 

10:46 AM Case 6: Traumatic Cataract and Mydriasis 

10:51 AM Strategies for Iris Defects 

Kenneth J Rosenthal MD FACS* 

10:56 AM Stabilizing the Capsular Bag 



Alan S Crandall MD*, Boris Malyugin MD PhD* 

11:08 AM Case 7: Severe IFIS 

11:13 AM IFIS: Clinical Update 

Nick Mamalis MD* 

11:18 AM Surgical Strategies for IFIS 



Rosa Braga-Mele MD*, Samuel Masket MD* 

CHARLES D KELMAN LECTURE 

11:30 AM Introducation of the Kelman Lecture 

David F Chang MD* 

11:35 AM Charles D Kelman Lecture: The Perfect IOL Calculation 

Jack T Holladay MD MSEE FACS* 


APAO Ethnic Variations in Glaucoma Prevalence, Detection, 

and Treatment Outcomes 


8:30 - 10:00 AM 



Chair(s): Prin Rojanapongpun MD*, David S Friedman MD MPH PhD*, Sarwat 

Salim MD* 

Glaucoma is the second leading cause of blindness worldwide, affecting all ethnic 

groups. There are known differences in the prevalence, incidence, and etiology 

of glaucoma among different populations. Furthermore, ethnic variations 

exist in several clinical parameters used for glaucoma diagnosis, in addition 

to treatment outcomes. This symposium will provide an overview of glaucoma 

prevalence, detection, and treatment outcomes among different ethnic groups. 


& Symposia 



139



& Symposia 

Monday, Nov. 12 (con’t) 

Knowledge of these ethnic variations will help ophthalmologists to better customize 

their approach to individual patients and to enhance therapeutic outcomes. 


Sarwat Salim MD*, Prin Rojanapongpun MD* 

8:35 AM Are There Ethnic Differences in Angle Anatomy? 

Shan C Lin MD* 

8:45 AM Are There Genetic Explanations for Glacuoma That Vary By Race/ 

Ethnic Group? 

Calvin C Pang PhD** 

8:55 AM Are There Optic Nerve Characteristics That Vary By Race/Ethnicity? 

Jost B Jonas MD* 

9:05 AM Who Is at Risk for Angle Closure Glaucoma? 

Tin Aung FRCS PhD* 

9:15 AM How Does Central Corneal Thickness Vary By Race/Etnicity, and How 

Does This Influence Management? 

James D Brandt MD* 

9:25 AM Are There Variations in Response to Medical and Surgical Therapy in 

Primary Open-Angle Glaucoma by Race/Ethnicity? 

Leon W Herndon MD* 

9:35 AM Should Screening for Primary Open-Angle Glaucoma be Conducted 

Differently in Different Racial/Ethnic Groups? 

Mingguang He MD PhD 

9:45 AM Discussion 


David S Friedman MD MPH PhD* 


Pediatric Corneal Disease and Treatment 


8:30 - 10:00 AM 


Combined meeting with the American Association of Pediatric Ophthalmology 

and Strabismus (AAPOS) 

Chair(s): Stephen P Christiansen MD, K David Epley MD* 

In children, congenital, inherited, infectious, and allergic keratopathies all vary 

dramatically in both pathophysiology and presenting signs. Each can lead to 

significant ocular morbidity and vision loss. Treatment of corneal disease is 

often more complicated in children than in adults, and vision loss from visual 

axis opacities is compounded by amblyopia. In this symposium, diagnostic and 

therapeutic challenges in the care of children with a variety of corneal diseases 

will be discussed, and advances and alternatives in the treatment of corneal 

opacities will be reviewed. 


Stephen P Christiansen MD 

8:32 AM Pediatric Allergic Eye Disease: Have We Made Any Progress? 

Stephen C Pflugfelder MD* 

8:42 AM Corneal Disease in the Developing World 

Jeremy D Keenan MD MPH 

8:52 AM HSV in Children: A Case-Based Update 


9:02 AM Point: Refractive Surgery for High Anisometropia 

Amy K Hutchinson MD 

9:07 AM Counterpoint: There Are Safe and Effective Alternatives to 

Refractive Surgery for High Anisometropia 

Sean P Donahue MD PhD* 

9:12 AM Corneal Surgery for Pediatric Cornea Opacities: PK Is Better 

Gerald W Zaidman MD FACS 

9:18 AM Corneal Surgery for Pediatric Cornea Opacities: Lamellar Surgery Is 

Better 


9:24 AM Corneal Surgery for Pediatric Cornea Opacities: Keratoprosthesis Is 

Better 

James Aquavella MD* 

MARSHALL M PARKS LECTURE 

9:30 AM Introduction of the Marshall M Parks Lecturer 

Leon-Paul Noel MD 

9:35 AM Marshall M Parks Lecture: Corneal Manifestations of Genetic 

Disease 


9:58 AM Presentation Ceremony 

Leon-Paul Noel MD 


Re-engineering the U.S. Health Care System: The Impact on 

Ophthalmology 


8:30 - 10:00 AM 

Room: S406a 

Combined meeting with the American Medical Association Ophthalmology 

Section Council 

Chair(s): Samuel Solish MD, Mathew W MacCumber MD PhD*, S William 

Clark MD 

With the ongoing implementation of the Affordable Care Act, many changes to 

the U.S. health care system are under way. New regulations will impact ophthalmologists 

in significant ways. We must be prepared to understand and react to 

the serious implications of these changes. In this symposium, thought leaders 

in ophthalmology will discuss the crucial issues and challenges of the evolving 

implementation of health system reform legislation. 



8:32 AM How Will Last Week’s Elections Affect Your Practice of 

Ophthalmology? 

Donald J Cinotti MD 

8:44 AM Re-engineering the US Health Care System: The Impact on 

Ophthalmology at the State Level 

Susan K Mosier MD 

8:56 AM Re-engineering the US Health Care System: The Impact on 

Ophthalmology at the Federal Level 

Nan A S Hayworth MD** 

9:08 AM The Academy’s Medical Director’s Plan of Action for the D.C. Office 

Michael X Repka MD MBA* 

PARKER HEATH LECTURE 

9:20 AM Introduction of the Parker Heath Lecturer 


9:22 AM Electronic Health Registries for Ophthalmology: The Big Picture 

William L Rich MD 

9:37 AM Questions and Comments of Panelists 


140 





What to Do When Your Patient Sees Nothing and You See 

Nothing: The Neuro-Ophthalmology Workup 


8:30 - 10:30 AM 

Room: E450 

Combined meeting with the North American Neuro-Ophthalmology Society 

(NANOS) 

Chair(s): Wayne T Cornblath MD, Michael S Lee MD* 

The presence of a visible ocular abnormality improves diagnostic acumen among 

patients with visual loss. However, visual loss with a grossly normal eye examination 

can result from nonorganic complaints or organic disorders anywhere 

from the retina to higher cortical function. This symposium will present strategies 

for approaching patients with unexplained visual loss and will address the 

core competencies of medical knowledge, patient care, and systems based care. 


Michael S Lee MD* 

8:32 AM Case Introduction 

8:34 AM It’s Gotta Be the Retina 

Peter A Quiros MD 

8:41 AM It’s Really Gotta Be the Retina 

Swaraj Bose MD 


8:50 AM It’s Gotta Be the Nerve 

Peter J Savino MD 


9:02 AM It’s Gotta Be the Chiasm 

Norah Lincoff MD 


9:14 AM It’s Gotta Be the Brain 

Deborah I Friedman MD* 


9:26 AM It’s Gotta Be a Functional Field 

Eric Eggenberger DO* 


9:35 AM It’s Gotta Be a Functional Acuity 

Christopher C Glisson DO* 


9:44 AM It’s None of the Above 

Janet C Rucker MD 


Wayne T Cornblath MD 

WILLIAM F HOYT LECTURE 

9:56 AM Introduction of William F Hoyt Lecturer 

Steven E Feldon MD* 

10:01 AM William F Hoyt Lecture: Are We There Yet? Has Neuro- 

Ophthalmology Reached the Paradigm Shift? 

Alfredo A Sadun MD PhD* 

10:26 AM Presentation of Award 


GO 2012 International Forum: Addressing Diabetic 

Blindness, Refractive Error and the Basic Eye Exam 


8:30 - 11:00 AM 

Room: S101ab 

Combined meeting with the AAO Global Outreach Committee 

Chair(s): Zelia M Correa MD, Linda M Lawrence MD, Fernando Pena MD*, 

Victoria M Sheffield*, Timothy P Page MD* 

At the 2012 International Forum, a panel of international experts will present 

data on diabetic retinopathy worldwide, and on screening and treatment modalities 

in resource poor countries. A second panel will discuss refractive error 

and the barriers to accessing optical services and spectacles in developing 

countries. A third panel will discuss training in a comprehensive basic eye exam 

and screening strategies in developing countries. Audience participation in Q&A 

sessions with the panelists is planned, as well as a tea and cookies break for 

informal interaction. 


Zelia M Correa MD 

8:35 AM The Emerging Threat of Diabetic Blindness in Resource Poor 

Countries 

Linda M Lawrence MD 

8:35 AM Global Data on Diabetic Retinopathy 

Ivo Kocur MD 

8:40 AM Diabetic Retinopathy Services in Urban Settings and the Use of 

Registries 

Petja I Vassileva MD PhD 

8:50 AM Diabetic Retinopathy Services in Rural Settings and Criteria for 

Referral 

Ahmed Trabelsi MD 

9:00 AM Q&A 

9:20 AM Addressing Refractive Error in Countries With Poor Access to 

Services 

Fernando Pena MD* 

9:20 AM Global Data on Refractive Error 

Ivo Kocur MD 

9:25 AM Procurement and Pricing Structures for Services 

John M Barrows MPH* 

9:35 AM Screening in Urban, Rural and School Settings 

Juan F Batlle MD* 

9:45 AM Q&A 

10:05 AM The Comprehensive Basic Eye Exam and Screening Strategies 

Victoria M Sheffield* 

10:05 AM Experiences From the Field on What Is Missed in Eye Exams 

James Standefer MD 

10:10 AM Community Screening: Planning, Executing, Referral 

Fernando Barria von Bischhoffsha 

10:20 AM Q&A 

10:35 AM Summary 

Timothy P Page MD* 

10:40 AM Tea and Cookies 


Advances in the Surgical Management of Glaucoma 


10:15 - 11:45 AM 


Combined meeting with Prevent Blindness America, Inc. 

Chair(s): Mildred M G Olivier MD*, Angelo P Tanna MD* 

Numerous novel surgical approaches have been developed to lower IOP in eyes 

with glaucoma. In this balanced symposium many of these surgical treatments 

will be addressed by experts who are implementing these procedures into their 

daily practices. Our goal is to focus on those procedures most likely to be per- 


& Symposia 



141



& Symposia 


formed by comprehensive ophthalmologists. An important aspect of this symposium 

is the plan to have one highly experienced, respected speaker provide 

on overall counterpoint discussion on each of the different surgical modalities. 


Mildred M G Olivier MD* 

10:18 AM Trabectome 

Eydie G Miller MD* 

10:26 AM ExPRESS Shunt 

Marlene R Moster MD* 

10:34 AM Update on Tube Shunt Surgery (Trabeculectomy vs. Tube Shunt, With 

a Comparison of the Devices) 

Steven Gedde MD* 

10:42 AM iStent 


10:50 AM Counterpoint: What Are the Limitations of the New Surgeries and 

Why is Trabeculectomy Better? 

Paul F Palmberg MD PhD* 

ROBERT N SHAFFER LECTURE 

10:59 AM Introduction of the Robert N Shaffer Lecturer 

Steven M Litinsky MD 

11:03 AM Robert N Shaffer Lecture: Today’s Glaucoma Challenges and What 

You Can Do About Them 

Robert L Stamper MD* 


Angelo P Tanna MD* 


SO YO Then and Now 


10:15 - 11:45 AM 

Room: S406a 

Combined meeting with the Senior Ophthalmologist Committee and Young 

Ophthalmologist Committee 

Chair(s): David W Parke MD, Martin Wand MD, Robert F Melendez MD 

MBA* , Andrew P Doan MD PhD* 

The history of ophthalmology is comprised of many chapters of an exciting 

story. It is important that senior ophthalmologists reveal the chapters that have 

evolved in their lifetime so that young ophthalmologists can better recognize 

the basis for the changes that have resulted in the chapter of our history that 

they will write. In turn, the young ophthalmologists will reveal the basis for 

new preferred practice patterns and how they are implemented. We can share 

the differences in the ways in which the average ophthalmologist learned and 

practiced, then and now. The bureaucratization of medicine with increasingly 

complex rules, codes and algorithms promoted by legislation and administrative 

directives is leaving its mark on how we have to change performance patterns 

as individual practitioners. 

10:15 AM Welcome and Introduction to the Program—SO and YO Chairs 

David W Parke MD, Martin Wand MD , Robert F Melendez MD MBA*, 

Andrew P Doan MD PhD* 

10:20 AM Cataract Surgical Approaches (SO) 

Norman B Medow MD FACS 

10:30 AM Cataract Surgical Approaches (YO) 

Uday Devgan MD* 

10:40 AM Glaucoma Diagnosis and Treatment (SO) 

M Bruce Shields MD* 

10:50 AM Glaucoma Diagnosis and Treatment (YO) 

Kouros Nouri-Mahdavi MD 

11:00 AM Cornea Surgery (SO) 

Walter J Stark MD* 

11:10 AM Cornea Surgery (YO) 

Leejee H Suh MD* 

11:20 AM The Academy’s Dual Emphasis: Education and Advocacy (SO) 


11:25 AM The Academy’s Dual Emphasis: Education and Advocacy (YO) 

Joseph T Nezgoda MD MBA 

11:30 AM The Key to Practice Success: Five Top Things to Keep Doing (SO) 


11:35 AM The Key to Practice Success: Five Top Things to Keep Doing (YO) 

Andrew P Doan MD PhD* 

11:40 AM Q&A 


Update on Pediatric Ocular Trauma 


10:15 - 11:45 AM 


Combined meeting with the American Society of Ocular Trauma (ASOT) 

Chair(s): G Philip Matthews MD PhD 

The management of pediatric ocular trauma presents unique challenges. This 

symposium will examine the epidemiology and treatment of pediatric ocular 

trauma with a focus on animal bites, non-accidental trauma, IOL calculation/ 

fixation following traumatic cataract, trauma prevention and protection from 

sports injuries using case-based presentations. Finally, the sixth Helen Keller 

lecture will be presented. 


G Philip Matthews MD PhD 

10:17 AM Epidemiology, Prevention, and Management Pearls in Pediatric 

Injuries 


10:27 AM Evaluation and Management of Animal Bites to Children 

Ron W Pelton MD PhD 

10:37 AM New Updates in the Evaluation and Management of Non-accidental 

Trauma (Shaken Baby Syndrome) 

Alex V Levin MD 

10:47 AM New Updates in IOL Calculation and Placement From Traumatic 

Cataract 

Edward G Buckley MD 

10:57 AM What’s New in Sports Trauma and Protection 

David B Granet MD* 

11:07 AM Questions and Answers 

HELEN KELLER LECTURE 

11:16 AM Introduction of the Helen Keller Lecturer 


11:19 AM Helen Keller Lecture: Primary, Secondary, and Tertiary Prevention in 

Ocular Trauma 

Wolfgang F Schrader MD* 

11:44 AM Presentation of Award 

G Philip Matthews MD PhD 




10:45 AM - 12:00 PM 

Room: E450 

Chair(s): Peter K Kaiser MD* 

This symposium will be structured as a lively, old-fashioned debate. Four groups 

of debaters will argue the pros and cons of controversial topics. Speakers will 

142 





have the opportunity to present prepared statements and then will have a 

chance to rebut those of their opponents. Audience voting will be used to determine 

which speakers were most effective in stating their arguments. 


Peter K Kaiser MD* 

What Is the Best Anti-VEGF Agent to Treat Wet AMD? 

10:50 AM Introduction of Question and Audience Voting 


10:52 AM Ranibizumab 


10:55 AM Bevacizumab 

Phillip J Rosenfeld MD PhD* 

10:58 AM Aflibercept 

Jeffrey S Heier MD* 

11:01 AM Ranibizumab Rebuttal 


11:02 AM Bevacizumab Rebuttal 

Phillip J Rosenfeld MD PhD* 

11:03 AM Aflibercept Rebuttal 

Jeffrey S Heier MD* 

11:04 AM Audience Voting 

What Is the Best Dosing Regimen for Anti-VEGF Therapy? 



11:07 AM Monthly 


11:10 AM PRN 

Anne E Fung MD* 

11:13 AM Treat and Extend 

Carl D Regillo MD FACS* 

11:16 AM Monthly Rebuttal 


11:17 AM PRN Rebuttal 

Anne E Fung MD* 

11:18 AM Treat and Extend Rebuttal 

Carl D Regillo MD FACS* 


Is a Fluorescein Angiography Necessary to Follow Patients with AMD? 



11:22 AM Yes 

Lee M Jampol MD* 

11:25 AM No, all I need is an OCT 

Jay S Duker MD* 

11:28 AM Yes Rebuttal 

Lee M Jampol MD* 

11:29 AM No Rebuttal 



What Is My Preferred Treatment for Diabetic Macular Edema? 



11:33 AM Anti-VEGF 

Neil M Bressler MD* 

11:36 AM Steroids 


11:39 AM Laser 

Darius M Moshfeghi MD* 

11:42 AM Anti-VEGF Rebuttal 

Neil M Bressler MD* 

11:43 AM Steroids Rebuttal 


11:44 AM Laser Rebuttal 

Darius M Moshfeghi MD* 


e Making Electronic Health Records Meaningful and 

Useful in Your Practice 


12:45 - 1:45 PM 


Combined meeting with the Committee on Medical Information Technology 

(CMIT) 

Chair(s): Michael F Chiang MD* 

Ophthalmology is unique in its clinical workflow. Ophthalmologists need systems 

that can be integrated into a busy workflow, provide clinical images and 

data frequently associated with patient visits and help them meet reporting 

and information exchange requirements. Payment incentives associated with 

federal “Meaningful Use” criteria are accelerating the adoption of electronic 

health records (EHRs), but it is necessary that these systems actually help ophthalmologists 

deliver care efficiently. This session will highlight the Meaningful 

Use provisions of Stage 2 and how ophthalmologists can meet these. Highlights 

of an Academy survey of members about EHR use will be presented. In 2011, 

the Academy was proactive in announcing requirements of EHR systems for 

ophthalmologists, and a similar effort to provide a list of critical features for 

PACS and imaging vendors in ophthalmology will be addressed. The culmination 

of standards and interoperability of EHRs and imaging devices, and their 

implementation into real-life clinic settings, will be described. 


12:46 PM Stage 2 Meaningful Use: How Can You Qualify for Meaningful Use 

Incentives? 

Michael X Repka MD MBA* 

12:56 PM Results of the Academy Survey on Electronic Health Records 

Michael V Boland MD PhD* 

1:06 PM Making Sure That Devices in Your Office Work With Your Electronic 

Health Records 

Michael F Chiang MD* 

1:16 PM Question and Answer Period and Panel Discussion 


go The “Local” Challenges of International Ophthalmology 


12:45 - 1:45 PM 

Room: S403b 

Combined meeting with Women in Ophthalmology (WIO) 

Chair(s): Sharon D Solomon MD, Susan M MacDonald MD* 

Despite the advances in the prevention and treatment of ocular disease, the 

worldwide social and economic burden of visual impairment remains a significant 

global public health concern. According to 2009 data from the World Health 

Organization, 314 million people worldwide are visually impaired and 45 million 

are blind. Most of the affected live in developing nations where cataract, uncorrected 

refractive error, glaucoma, and AMD, all treatable conditions in most 

developed countries, remain leading causes of blindness. Through its international 

membership of ophthalmic healthcare professionals, this Women in Ophthalmology 

symposium will discuss influential factors in ocular disease prevention 

and management on a global level, such as the development of affordable 

and specialized eye care centers, commitment to prevention and treatment by 


& Symposia 



143



& Symposia 


national leaders, partnerships between medical professionals and corporations 

to deliver care, and implementation of effective eye care strategies abroad to 

heighten local awareness and to educate affected populations. 



12:47 PM Changing the Face of Trachoma, One Lash at a Time 

Sheila W West PhD 

12:57 PM Q&A 

1:01 PM Disparities in Women’s Eye Health Around the World 

Manal Bouhaimed MBChB PhD** 

1:11 PM Q&A 

1:15 PM A Worldwide Curriculum for Ophthalmologists? 

Zelia M Correa MD 

1:25 PM Q&A 

1:29 PM Twinkling Little Eyes: A Paradigm for the Delivery of Compassionate 

Care 

Sundaram Natarajan MD 

1:39 PM Q&A 


Susan M MacDonald MD* 


Why Take the Risk? How to Create an Effective Risk 

Management Strategy With Patient Education and Informed 

Consent Documents 


12:45 - 1:45 PM 

Room: S505ab 

Combined meeting with the Patient Education Committee and Ophthalmic 

Mutual Insurance Company (OMIC) 

Chair(s): Philip R Rizzuto MD FACS, Richard L Abbott MD 

Join this discussion about the critical role that patient education and informed 

consent documents play in an ophthalmic practice’s risk management strategy. 

Through analysis of specific medico-legal cases and a survey of Ophthalmic 

Mutual Insurance Company defense counsel, learn how to minimize your risk 

of malpractice lawsuits with the effective use of ophthalmic patient education 

and informed consent tools. Discover the vital steps you can take now to save 

yourself time and money in the future. 

12:45 PM Welcome / Introduction of Panel 

Philip R Rizzuto MD FACS 

12:50 PM A Medico-Legal Case Review 

Devin A Harrison MD 

1:00 PM Role of Effective Patient Communication in Practice Risk 

Management 


1:10 PM Making Patient Education Work for Your Practice 

Philip R Rizzuto MD FACS 

1:20 PM Q&A 


Crash Courses in Teaching: A Primer for Faculty 

Development 


12:45 - 2:15 PM 

Room: S405 

Combined meeting with the Association for University Professors of 

Ophthalmology (AUPO) 

Chair(s): Andreas Lauer MD* 

The ACGME Outcomes Project emphasized the assessment of each trainee’s 

performance in core competencies as an effort to help prepare tomorrow’s physicians 

to practice, learn and teach in an ever-changing clinical environment 

where patient safety, effective clinical outcomes, practice efficiency are prized. 

While training program directors and coordinators, subspecialty academies 

and specialty medical boards have promoted competency-based curricula and 

assessment, a gap remains in many programs where engaging in competency 

based teaching is not intuitive to faculty when they have not learned in such a 

system themselves. The purpose of this symposium is to familiarize teachers 

with competency based education and instructional faculty development. While 

promoting faculty development is critical in meeting accreditation requirements, 

it also helps teachers succeed as facilitators of effective and efficient learning 

and encourages faculty to pursue teaching as scholarship. 


Andreas Lauer MD* 

12:46 PM Online Teaching Resources 

Jean Hausheer MD 

12:54 PM International Council of Ophthalmology Webinars 

Eduardo P Mayorga MD 

1:02 PM Teaching in the Clinic and the Integral Role of Feedback 

Andrew G Lee MD* 

1:10 PM Teaching and Assessing Simultaneously 

Karl C Golnik MD* 

1:18 PM Inclusion, Control and Esteem 


1:26 PM Q&A 

1:42 PM Conclusion 


STRAATSMA LECTURE 

1:45 PM Introduction of the Straatsma Lecturer 

Bartly J Mondino MD 

1:50 PM Straatsma Lecture: My Three Epiphanies 


2:14 PM Presentation of the Straatsma Award 


Advances in the Treatment of Diabetic Retinopathy 


2:00 - 3:30 PM 

Room: S406a 

Combined meeting with the Macula Society 

Chair(s): Emily Y Chew MD, Lawrence J Singerman MD* 

The incidence of diabetes has increased markedly throughout the world. The 

microvascular complication of diabetic retinopathy is one of the leading causes 

of blindness and has become a condition of significant importance in public 

health. The medical therapies, including intensive control of blood glucose and 

blood pressure and serum lipid management, remain important for preventing 

development and progression of diabetic retinopathy. The management of diabetic 

retinopathy has also changed in the era of intravitreal injections of antivascular 

endothelial growth factor (VEGF) therapies and corticosteroids. The 

updated understanding of the pathogenesis will help to provide rationale for 

144 





these therapies that target VEGF or other inflammatory components. The results 

of the controlled clinical trials for the treatment of diabetic macular edema and 

proliferative diabetic retinopathy will be presented. 


2:03 PM Mechanisms of Disease in Diabetic Retinopathy 

Lloyd P Aiello MD PhD* 

2:10 PM The Role of Fluorescein Angiography in Management of Diabetic 

Retinopathy 

Jennifer K Sun MD* 

2:17 PM Wide-Angle Fluorescein Angiography 

Fumio Shiraga MD 

2:24 PM The Role of OCT in Diagnosis and Treatment of Diabetic Macular 

Edema 

Richard Rosen MD* 

2:31 PM Medical Therapies for Diabetic Retinopathy; What Have We Learned 

from DCCT/EDIC and ACCORD? 

Robert N Frank MD 

2:38 PM Laser Photocoagulation for Diabetic Macular Edema 

Timothy Y Lai MBBS* 

2:45 PM Anti-VEGF Therapies for Diabetic Macular Edema 

Diana Do MD* 

2:52 PM Corticosteroids for the Treatment of Diabetic Macular Edema 

Mark S Blumenkranz MD* 

2:59 PM What Is the Optimum Combination Treatment for Diabetic Macular 

Edema? 

Julia A Haller MD* 

3:06 PM Scatter Laser Photocoagulation for Proliferative Diabetic Retinopathy 

Jennifer Irene Lim MD* 

3:13 PM The Role of Anti-VEGF Therapy in the Treatment of Proliferative 

Diabetic Retinopathy 

Judy E Kim MD* 

3:20 PM Vitreoretinal Surgery for Diabetic Retinopathy 

Timothy W Olsen MD* 


Lawrence J Singerman MD* 




2:00 - 3:30 PM 


Chair(s): Gary S Schwartz MD 

Topics will cover new technology and therapies as well as important topics and 

controversies that have come up within the last six months in the field of ophthalmology. 


Gary S Schwartz MD 

2:05 PM Use of the iCare Tonometer in Children 

David A Plager MD* 

2:15 PM Distinguishing Retinal Nerve Fiber Layer Injury by Optical Imaging in 

Acute Optic Nerve Head Swelling 

Mark J Kupersmith MD** 

2:25 PM Silicon Intubation for Nasolacrimal Duct Obstruction 

Stuart R Seiff MD 

2:35 PM Implantable Miniature Telescope for AMD 


2:45 PM Lifitigrast 

John D Sheppard MD 

2:55 PM Preservatives in Glaucoma Drops 

James C Tsai MD MBA* 

3:05 PM Retinal Tears for Oral Fluoroquinolone 

David A L Maberley MD** 

3:15 PM Lucentis for Diabetic Macular Edema 




Femto Forum: Cataract, Cornea, Refractive, and Beyond 


2:00 - 4:00 PM 


Combined meeting with the American Society of Cataract and Refractive 

Surgery (ASCRS) 

Chair(s): Stephen S Lane MD*, Roger F Steinert MD* 

Femtosecond lasers are a current “hot topic,” generating both enthusiasm and 

controversy. This session will explore this new technology in depth, describing 

current applications in cataract surgery, refractive surgery, and glaucoma 

surgery. The forum will expand the physician’s understanding of the potential for 

ultrashort lasers in ophthalmology while avoiding marketing hype or unfounded 

enthusiasm. 



2:05 PM Understanding Femtosecond Laser Technology: What Every Surgeon 

Should Know 

Roger F Steinert MD* 

2:13 PM Femtosecond Technology in LASIK 

Steven C Schallhorn MD* 

2:21 PM Intracorneal Inlays for Presbyopia 

Stephen G Slade MD FACS* 

2:29 PM Presbyopia-Correction Corneal Shaping 

Michael C Knorz MD* 

2:37 PM Intrastromal Astigmatic Keratotomy 

Roberto Zaldivar MD* 

2:45 PM Can Femtosecond Lasers Treat Glaucoma? 

Tibor Juhasz** 

2:53 PM Incisions for Cataract Surgery 

Perry S Binder MD* 

3:01 PM Anterior Capsulotomy 


3:09 PM Strength of Femtosecond Anterior Capsulotomy 

Gerd U Auffarth MD* 

3:17 PM Nucleus Disassembly 1 


3:25 PM Nucleus Disassembly 2 

William W Culbertson MD* 

3:33 PM Economic Considerations 





& Symposia 



145



& Symposia 


Non-bacterial Infectious Keratitis 



2:00 - 4:00 PM 

Combined meeting with the Cornea Society 

Chair(s): William Barry Lee MD*, Joel Sugar MD 

This symposium, geared toward both the general ophthalmologist and the anterior 

segment specialist, will feature management strategies for diverse, and 

often vexing, forms of keratitis. Advanced diagnostic techniques and treatment 

strategies for non-bacterial forms of infectious keratitis ranging from the very 

common (herpes simplex keratitis) to the newly described (interface infectious 

keratitis after lamellar keratoplasty) to the rare forms of keratitis (fungal and 

parasitic keratitis) will be covered. The symposium will also highlight treatment 

approaches for several challenging forms of non-infectious keratitis and 

will conclude with the Castroviejo Lecture on meibomian gland disease by Dr. 

James McCulley. 



2:04 PM Diagnostic Advances for Non-bacterial Keratitis 

Stephen C Kaufman MD PhD* 

2:14 PM A Microbial Sandwich: Interface Infectious Keratitis in Lamellar 

Keratoplasty 

Sadeer B Hannush MD 

2:24 PM Fungus Among Us? Update on Fungal Keratitis 

Donald Tan MD FRCS FRCOphth* 

2:34 PM Acanthamoeba Keratitis: Is It Safe to Go Back Into the Water? 

Elmer Tu MD 

2:44 PM Herpetic Simplex Keratitis: Pearls to Prevent Peril 

Ivan R Schwab MD FACS 

2:54 PM Eradication Strategies for Filamentary Keratitis 

Denise de Freitas MD 

3:04 PM Management Strategies for Neurotrophic Keratitis 

Richard S Davidson MD* 

3:14 PM Ocular Predictions: Systemic Disease Associations With Keratitis 

Vincent P De Luise MD FACS 

CASTROVIEJO LECTURE 

3:24 PM Introduction of Castroviejo Lecture 

Joel Sugar MD 

3:27 PM Castroviejo Lecture: Lids, Lipids, and Dry Eyes 

James P McCulley MD FACS FRCOphth* 




Vision Rehabilitation: What’s New for Patients With Low 

Vision 


3:45 - 4:45 PM 

Room: E450 

Combined meeting with the Vision Rehabilitation Committee 

Chair(s): Mary Lou Jackson MD, Joseph L Fontenot MD 

Patients who lose vision, and their families, are challenged to adapt to vision 

loss, and they are encouraged by the development of new technology. This symposium 

will outline exciting technologies that vision rehabilitation can offer to 

patients with vision loss. 


3:46 PM The School-Aged Child With Vision Loss: Technology in the School 

Setting 


3:56 PM Transition to Post-Secondary Education and Employment: How to 

Use Technology When You Have Severe Vision Loss 

Janet S Sunness MD* 

4:06 PM Working-Age Adults and Technology 

Donald Calvin Fletcher MD 

4:16 PM Retinal Prosthesis 

Mark S Humayun MD PhD* 

4:26 PM Patients with AMD: Technologies That Work 

Joseph L Fontenot MD 

4:35 PM The Oldest-Old patient- Will Granny Use a Computer? 


4:44 PM Summary: How to Identify Patients Who Will Benefit From Vision 

Rehabilitation and What to Offer Them 



Grand Rounds: Cases and Experts From Across the Nation 


3:45 - 5:00 PM 

Room: S406a 

Chair(s): Nicholas J Volpe MD 

Panelists: Alfredo A Sadun MD PhD*, Alexander J Brucker MD*, Lee M Jampol MD*, 

Raymond S Douglas MD PhD 

Real residents present real cases from real department grand rounds. Residents 

chosen from different academic programs will present cases to a panel of experts 

followed by Q&A and discussion by the panel. 

3:45 PM Introduction and Welcome Remarks 

Nicholas J Volpe MD 

3:47 PM Battle of the Two 

Michelle Y Wang MD** 

3:58 PM It Is Not Adding Up 

George N Magrath MD 

4:09 PM Itchy Eyes and Vision Loss 

Brian W Toussaint MD 

4:20 PM Retinal Hemorrhage 

John J Chen MD** 

4:31 PM Intraocular Foreign Body 

Crandall E Peeler MD** 

4:43 PM Can’t See 

Ehsan Rahimy MD 


Nicholas J Volpe MD 


Quality Improvement: How Do We Improve Quality, Maintain 

Efficiency and Sustain the Physician-Patient Relationship? 


3:45 - 5:00 PM 


Combined meeting with the Committee on Practice Improvement 

Chair(s): Joseph Caprioli MD FACS*, Anne Louise Coleman MD PhD 

Health care has become increasingly complex, with multi-step processes, interdependence 

among clinicians, and an overwhelming amount of new research 

data to integrate into daily clinical decisionmaking. Amidst this increasing complexity, 

payers and policymakers are taking the driver’s seat in asking physicians 

for evidence of quality, including efficiency in the definition of quality. Quality 

health care is defined as “the degree to which health services for individuals 

146 





and populations increase the likelihood of desired health outcomes and are 

consistent with current professional knowledge,” and six aims of health care 

are defined as effective, safe, patient-centered, timely, efficient and equitable. 

Therefore, ophthalmologists will be increasingly asked to measure quality, evaluate 

their processes and make improvements. Speakers will describe quality 

improvement initiatives and lessons learned from fields such as hospital care 

and general and vascular surgery, as well as from the Royal College of Ophthalmologists 

in the United Kingdom. The need for effective communication and 

teamwork for quality patient care will be addressed. The Academy’s Committee 

on Practice Improvement is developing activities to help members increase efficiency 

and enhance the quality of care process. These shared experiences and 

best practices will help ophthalmologist to evaluate their own care processes 

and target improvement efforts. 


3:46 PM Maintaining Efficiency: Use of Physician Extenders 


3:56 PM Quality Improvement on a Large Scale: Lessons Learned from Legacy 

Health 

George A Cioffi MD* 

4:06 PM How the Academy Can Help Members: Activities of the Committee 

on Practice Improvement 

Joseph Caprioli MD FACS* 

4:16 PM Quality Assurance Self-Testing for Ophthalmic Services: A 

Perspective from the United Kingdom 

Simon P Kelly FRCOphth* 

4:26 PM How Registry Participation Improves Quality of Care: Results From 

the Society of Thoracic Surgeons 

Fred Edwards MD 

4:36 PM Questions and Answers and Panel Discussion 



Event No: SPO4 

4:15 - 5:30PM 


Chair(s): Thomas W Samuelson MD*, Marlene R Moster MD* 

This symposium will address many of the challenges inherent to the exfoliation 

syndrome from the perspective of cataract and glaucoma management. The 

pathophysiology of exfoliation and the affect on the outflow system of the eye 

will be examined. In addition, the clinical relevance of recent genetic and epidemiological 

studies will be addressed. However, this symposium will be primarily 

clinical and will examine important decision-making strategies pertaining to the 

timing of cataract surgery in patients with exfoliation. The effect of cataract 

surgery on IOP in exfoliative glaucoma will be reviewed. Clinical pearls to avoid 

and manage complications during cataract surgery will be discussed. A panel 

of experts will debate the role of capsular tension rings, the merits of sutured 

IOLs vs anterior chamber IOLs, the role of toric and multifocal IOLs in potentially 

compromised capsules, as well as other relevant surgical dilemmas. Finally, the 

role of recently approved micro-invasive glaucoma surgery (MIGS) will also be 

debated as well as options for combined cataract and glaucoma surgery in patients 

with exfoliation. 



4:18 PM Epidemiology and Genetics of Exfoliation 

Douglas J Rhee MD* 

4:26 PM Does Exfoliation Affect the Timing of Cataract Surgery? 

Reay H Brown MD* 

4:34 PM Optimizing Outcomes With Phacoemulsification in Exfoliation 

Bradford J Shingleton MD* 

4:42 PM Panel 

Thomas W Samuelson MD*, Marlene R Moster MD* 

4:54 PM The Pathology of Exfoliation: Are the Canal and Collectors Affected? 


5:02 PM MIGS Procedures in Exfoliation: Do They Work? 


5:10 PM Combined Procedures in Exfoiation: When? Which Procedure? 

Kuldev Singh MD MPH* 

5:18 PM Panel 

Thomas W Samuelson MD*, Marlene R Moster MD* 



APAO Management of Diabetic Retinopathy: East-West 

Perspectives 


8:30 - 10:00 AM 



Chair(s): Tien Yin Wong MBBS*, Barbara Ann Blodi MD 

Diabetic retinopathy is the leading cause of blindness among working adult 

people worldwide. There are now 300 million people worldwide with diabetes, 

and half of these live in the Asia-Pacific countries. In the last 5 years, the use 

of novel intraocular injections of anti-vascular endothelial growth factor (VEGF) 

agents has resulted in major paradigm shifts in in terms of prevention and reversal 

of vision loss. Although such novel treatments have started to revolutionize 

how diabetic retinopathy is managed, questions remain about appropriate 

patient selection and the long-term efficacy, safety and cost-effectiveness of 

these new treatments compared to laser. This symposium will cover new understandings 

of the epidemiology and trends in management, comprehensively 

discuss clinical approaches to diabetic retinopathy, compare laser to intraocular 

anti-VEGF injections, and consider how clinical management and the impact of 

diabetic retinopathy differ between East and West. 


8:35 AM Trends in Epidemiology of Diabetic Retinopathy in the United States: 

A Western Perspective 

Ingrid U Scott MD MPH* 

8:45 AM Trends in Epidemiology of Diabetic Retinopathy: An Asian 

Perspective 

Tien Yin Wong MBBS* 

8:55 AM Overview of Clinical Trials on Diabetic Macular Edema 

Justin L Gottlieb MD 

9:05 AM Current Anti-VEGF Treatment Paradigms for Diabetic Macular 

Edema, Proliferative and Nonproliferative Diabetic Retinopathy 

Lloyd P Aiello MD PhD* 

9:15 AM Laser Treatment and Surgical Approaches for Proliferative Diabetic 

Retinopathy 

Raj V Azad FRCS (ED) 

9:25 AM Are There East-West Differences in the Impact of Diabetic 

Retinopathy on Quality of Life? 

Ecosse Lamoureux PhD 

9:35 AM Guidelines for Management of Diabetic Macular Edema in Asia 

Paul Mitchell MD PhD* 





& Symposia 



147



& Symposia 

Tuesday, Nov. 13 (con’t) 

Ocular Tumors: Evidence-Based Rationale for Treatment 


8:30 - 10:00 AM 

Room: S406a 

Combined meeting with the American Association of Ophthalmic Oncologists 

and Pathologists (AAOOP) 

Chair(s): Nasreen A Syed MD 

Ocular and ocular adnexal tumors are relatively rare tumors when compared 

with other types of cancer and their treatment often differs from their counterparts 

in other areas of the body. Despite the overall rarity of ocular and adnexal 

tumors, every ophthalmologist will encounter one or more of these tumors 

in their practice and will need to have some understanding of the treatment 

options. There are numerous publications in the literature describing various 

treatment options for tumors of the eye and ocular adnexa. The purpose of this 

symposium is to review the quality of the evidence in the medical literature 

as it applies to treatment of intraocular and ocular adnexal tumors using Evidence-based 

Medicine criteria. Tumors discussed will include posterior uveal 

melanoma, retinoblastoma, ocular surface squamous neoplasias, ocular adnexal 

lymphoma, and epithelial tumors of the lacrimal gland. 


Nasreen A Syed MD 

8:32 AM Introduction to Evidence-Based Medicine 

Patricia Chevez-Barrios MD 

8:37 AM The Evidence for Treatment of Posterior Uveal Melanoma 

Timothy G Murray MD MBA* 

8:45 AM The Evidence for Treatment of Retinoblastoma 

Matthew W Wilson MD 

8:53 AM The Evidence for Treatment of Ocular Surface Squamous Neoplasia 


9:00 AM The Evidence for Treatment of Ocular Adnexal Lymphoma 

Dan S Gombos MD 

9:08 AM The Evidence for Treatment of Lacrimal Epithelial Tumors 

Ezekiel Weis MD 

ZIMMERMAN LECTURE 

9:16 AM Introduction of the Zimmerman Lecturer 

Daniel M Albert MD FACS* 

9:21 AM Zimmerman Lecture: Progression of Metastatic Ocular Melanoma to 

the Liver 

Hans E Grossniklaus MD 

9:58 AM Presentation of the Zimmerman Medal 

Deepak Paul Edward MD 


Workforce Issues in Ophthalmology: Eye Health Care for 

Baby Boomers and Beyond 


8:30 - 10:00 AM 


Combined meeting with the National Medical Association Ophthalmology 

Section 

Chair(s): Everton L Arrindell MD, Robert A Copeland MD 

A growing aging U.S. population is expected to create significant demands on 

general medical care delivery over the next few decades, with specialty areas 

including ophthalmology most heavily affected. A significant shortage of ophthalmologists 

in the United States is projected over the next 20 years. To adequately 

address this need, changes in medical education and health policy, 

including the allocation and delivery of health care resources, may be necessary. 

In this symposium we will discuss the role of major organizational stakeholders 

in addressing this anticipated need. The economic impact and role of health 

policy on eye health care delivery will be explored. Additionally, a comparative 

look at eye health care delivery globally will be examined. 

8:30 AM Introduction and Welcome 

Everton L Arrindell MD 

8:32 AM The Physician Shortage in America: How Did We Get Here? A 

Historical Perspective 

Paul P Lee MD JD* 

8:40 AM The Economic Impact of Eye Health Delivery and Health Policy on 

the Physician Shortage 

William L Rich MD 

8:48 AM Training of the 21st Century Ophthalmologist: Is Expanding 

Residency Slots an Option: Pros and Cons 

Claude L Cowan Jr MD 

8:56 AM Physician Shortage and Eye Health Disparities: How Do We Prevent 

a Widening of the Gap? 

Scarlette M Wilson MD 

9:04 AM The Role of the Academy in Addressing Ophthalmology Staffing 

Issues 

David W Parke II MD* 

9:12 AM What Is the Global Perspective on Meeting Physician Shortages? 


9:20 AM The Role of Optometrists and Physician Extenders in Addressing the 

Impending Physician Shortage 


9:28 AM The Crystal Ball: What Will Ophthalmology Look Like in 20 to 30 

years? 

H Dunbar Hoskins Jr MD FACS* 

9:36 AM Q&A and Panel Discussion 

9:58 AM Closing Remarks 

Robert A Copeland MD 


so Shifting Gears: Practical and Ethical Transitions to 

Retirement 


10:15 - 11:15 AM 


Combined meeting with the Committee on Aging, Senior Ophthalmologist 

Committee, Ethics Committee, and the American Geriatrics Society 

Chair(s): Gwen K Sterns MD, Harry Zink MD* 

Many ophthalmologists decide to “slow down” as they transition their practice 

towards retirement. What are the options and choices for the experienced senior 

ophthalmologist in approaching this transition? This symposium will address the 

following questions: Is there a strategic plan for slowing down that can benefit 

both the practice and the practitioner? What are the ethical, economic, emotional 

and physical issues involved? What are the practical and ethical implications 

when a partner wants to give up surgery? What are the ethical responsibilities 

of the practice in evaluating the mental and physical competency of a partner’s 

ability to continue to practice? How have other practices solved these issues? 

The practical and ethical decisions involved with this process will be discussed. 

This symposium will include a panel of experts to address these issues. 



10:18 AM The Current State of Affairs 

Tamara R Fountain MD* 

10:26 AM Macro-economics: Demographics and Human Resource Needs: A 

Role for the Transitioning Ophthalmologist 

Paul P Lee MD JD* 

148 




10:35 AM Stopping Surgery: When, Why, How, and What Are the Personal 

Implications? 

Harry Zink MD* 

10:43 AM Ethical Issues in Evaluating the Mental and Physical Competency of 

Yourself or Your Transitioning Partner 

Christie L Morse MD* 

10:52 AM Panel Discussion: How to Transition—Success and Consequences 

Trexler Topping MD*, Michael W Brennan MD, Allan D Jensen MD 

11:07 AM Questions and Summary 



Clinical Applications of Ocular Imaging 


10:15 - 11:45 AM 

Room: S406a 

Combined meeting with the Association for Research in Vision and 

Ophthalmology (ARVO) 

Chair(s): Joel S Schuman MD*, Kyung Rim Sung MD PhD 

Ocular imaging has become integral to clinical practice in ophthalmology. From 

refractive surgery to glaucoma to retinal disease, ocular imaging helps to guide 

our practice. Imaging often provides a clear picture of the pathologies affecting 

our patients, and gives ophthalmologists objective, quantitative measures on 

which to base treatment. The field continues to evolve quickly. This symposium 

reviews the current state-of-the-art in clinical ocular imaging and looks ahead 

toward what the future might have in store. 


10:17 AM Ocular Imaging? So What? 

Anne Louise Coleman MD PhD 

10:25 AM Anterior Segment Imaging: Surgical Guidance 

David Huang MD PhD* 

10:33 AM Anterior Segment Imaging: Angle-Closure Glaucoma 

Tin Aung FRCS PhD* 

10:41 AM Structure and Function in Glaucoma 

Harry A Quigley MD* 

10:49 AM Imaging in Glaucoma: Disease Detection 

David F Garway-Heath MD FRCOphth* 

10:57 AM Identifying Progression in Glaucoma 

Gadi Wollstein MD* 

11:05 AM Retinal Imaging: Macular Degeneration 

Philip J Rosenfeld MD PhD* 

11:13 AM Retinal Imaging: Diabetic Retinopathy 


11:21 AM Retinal Imaging: The Vitreoretinal Interface 


11:29 AM Retinal Imaging in the Cataract Patient 

Carmen A Puliafito MD MBA* 

11:37 AM OCT Advances: The Next Five Years 

James Fujimoto PhD* 




12:15 - 1:30 PM 

Room: S406A 

Chair(s): Ali R Djalilian MD, Jill S Melicher Larson MD* 

This symposium will feature ten of the best papers from the major anterior segment 

specialty meetings of 2012. These papers will be in the major anterior 

segment specialty areas and are selected by the program committees of the 

respective societies from their annual specialty meetings. 


12:17 PM The Ahmed Versus Baerveldt Study: Three-Year Interim Results 

Panos George Christakis** 

12:24 PM Risk Factors for Incident Open-angle Glaucoma: The Los Angeles 

Latino Eye Study (LALES) 

Rohit Varma MD MPH* 

12:31 PM Ocular Surface Transplantation Rejection: Incidence, Characteristics, 

and Outcomes 

Andrea Y Ang MBBS 

12:38 PM The Relationship of Fuchs Dystrophy Severity to Glaucoma 

Mehul H Nagarsheth MD** 

12:45 PM Illuminated Microcatheter-Assisted 360 Trabeculotomy for Refractive 

Juvenile Open-Angle Glaucoma and Glaucoma Post-Childhood 

Cataract Removal 

Jennifer B Dao MD** 

12:52 PM A Controlled Study of Topical 0.25% Timolol Maleate Gel for the 

Treatment of Cutaneous Infantile Capillary Hemangiomas 

Christopher B Chambers MD** 

12:59 PM MICS in 3-D 

Jorge L Alio MD PhD* 

1:06 PM Crosslinking 

Theo Seiler MD PhD* 

1:13 PM Contribution of Posterior Corneal Astigmatism to Total Corneal 

Astigmatism 

Mitchell P Weikert MD* 

1:20 PM Corneal Wavefront Aberrations and Pseudoaccommodation With 

Aspheric Monofocal IOLs 

Rory A Myer MD** 




& Symposia 



149

150 

Notes

Come see the latest products and services 

at the Academy Resource Center. 

Booth 508 

• Sample products for your continuing education, 

your practice and your patients 

• Get demos of the ONE ® Network, Practicing 

Ophthalmologists Learning System, EyeWiki , 

Academy online community, and the EyeSmart ® 

and OjosSanos TM patient education websites 

• Renew your Academy, ISRS and AAOE 

membership – or join! 

• Personalize DVDs in the Video Production 

Services studio 

• Schedule free consultations with practice 

management experts 

• Get advice on coding, e-prescribing and PQRS 

• Learn about EyeCare America ® and the Academy 

Foundation 

• Report CME credits and print proof-of-attendance 

certificates 

Special Appearance – Sunday, Nov. 11 

Win an iPad! 

Meet keynote speaker Abraham 

Verghese, MD, MACP, after Sunday’s 

Opening Session. Dr. Verghese will be 

signing copies of his celebrated novel, 

Cutting for Stone. 

Get a demonstration of any product at the Academy 

Resource Center and earn entry into our iPad raffle.* 

One lucky person per day will win an iPad loaded with 

digital Academy products. Stop by each day and get 

four chances to win! 

Free Shipping! 

Get free shipping within the United States 

and Canada for product purchases at the 

Resource Center. 

* Void where prohibited by law. No purchase necessary to enter or win. Not open to 

employees, officers or trustees of the Academy and their immediate families.

Meeting 

Archives 

Materials from the Academy’s past 

Annual Meetings and Subspecialty Days 

are available to use as a resource. 

> Scientific Posters Online 

> Course Handouts 

> Videos on Demand 

> Program Searches 

> Subspecialty Day Syllabi 

> Links to order information 

presented during the 

Joint Meeting and Subspecialty Day 

www.aao.org/aao-archives 

152

Visit AAO Booth #3833 for 1 FREE Sample 

Precision Marking That Lasts 

NEW 

Wet-Field® ThermoDot Marker [Osher] 

The ThermoDot is an intraoperative bipolar instrument designed to create an ink-free, fine 

dot on the eye that can be used as a precise reference point for a variety of procedures, 

including toric intraocular lens implantation. 

Product Benefits 

• Ink-free, will not smear 

• Lasts the duration of surgery 

• Clearly visible, precise dot 

• Unique curve facilitates 

perpendicular approach 

• No additional patient 

discomfort 

ThermoDot Mark 

(precise dot) 

Ink Mark 

(smeared mark) 

While supplies last. Limited to Wet-Field® ThermoDot Marker. 

For more information, call 1.866.906.8080 or visit us at www.beaver-visitec.com 

Beaver-Visitec International, Inc. | 411 Waverley Oaks Road Waltham, MA 02452 USA | Tel: 866.906.8080 | www.beaver-visitec.com 

BVI, BVI Logo and all other trademarks (unless noted otherwise) are property of a Beaver-Visitec International (“BVI”) company © 2012 BVI

• Don’t miss the special attendee discounts 

• Over 200 hours of content captured 

• Multiple product options 

• Convenient online access for your PC, Mac 

and mobile device 

• USB Drive for offline access on select products 

AAO Subspecialty Day On Demand includes 

content presented in the following programs: 

Cornea 2012: 

Pushing Surgical Boundaries, Professional Development and Popular Opinion 

Glaucoma 2012: 

Managing Challenging Glaucoma Problems: Merging Art and Science 

Oculofacial Plastic Surgery 2012: 

Form, Function, Finesse 

Pediatric Ophthalmology 2012: 

Learning from Our Past, Looking to Our Future 

Refractive Surgery 2012: 

The Era of Lasers and Lenses 

Retina 2012: 

The Winds of Change 

Uveitis 2012: 

The Challenges Continue…But the Future Is Bright 

AAO Joint Meeting On Demand 

includes over 150 hours of content 

from the 2012 Joint Meeting 

Main Booth: 

Satellite Booth: 

Order Online: 

Order at the Meeting 

Grand Concourse ( Fri-Tues) 

Outside Arie Crown Theater, Lakeside ( Fri-Sat) 

Exhibit Hall Booth #605 (Sat-Tues) 

www.aao.org/ondemand

Original Papers 


A panel discussion, with time for audience questions, will follow each paper presentation. 

At the end of each session, the panel will select the best paper from that session. 


The Annual Meeting Program Committee selected all Original Papers. 








Cataract Femtosecond 

Moderator: William J Fishkind MD FACS 


10:15 AM - 12:00 PM 


Panel: Samuel Masket MD, Zoltan Nagy MD, R Bruce Wallace III MD FACS 

APAO PA001 

10:15 AM 

The Effect of Centration and Circularity in Manual 

Capsulorrhexis on Refractive Outcome 

Presenting Author: Mali Okada MBBS 

Co-Author(s): Dov Hersh MBBS, David vanderStraaten FRANZO 

Purpose: To determine if refractive outcome, as spherical equivalent (SE), 

was dependent on the degree of centration or circularity of the manual 

capsulorrhexis. Methods: Prospective observational study of 101 patients 

undergoing conventional cataract surgery. Slitlamp anterior segment photos 

were taken 3 weeks postoperatively. Characteristics of the capsulorrhexis 

were analyzed using computer photographic software. Results: The mean 

circularity index and decentration of the capsulorrhexis was 0.831 ± 0.018 

and 0.30 ± 0.17 mm, respectively. There was no significant association between 

either circularity (P = .447) or decentration (P = .179) with deviation 

from target SE. Conclusion: Precise and centered manual capsulorrhexis 

does not significantly change target refractive outcome. 

10:22 AM 

Panel discussion of previous paper 

PA002 

10:27 AM 

Impact of Capsulorrhexis Morphology on the Predictability 

of IOL Power Calculations 

Presenting Author: Jonathan Davidorf MD* 

Purpose: To study the impact of capsulorrhexis (CCC) morphology on predictability 

of IOL calculations. Methods: 175 random cataract surgery videos 

(acrylic IOL) were reviewed (observer masked). CCC morphology in relation to 

the IOL was graded. Haigis and SRK-T formulae were used to determine IOL 

power. Prediction errors (1-month refraction) were calculated and variances 

analyzed. Results: Mean prediction errors were +0.24 ± 0.50 D (Haigis) and 

+0.25 ± 0.47D (SRK-T). The “worst” CCC group had the lowest mean prediction 

error (P = .01). No statistically significant difference in variance was identified. 

Conclusion: Within the range of CCC morphology examined, there 

appears to be no relationship between CCC morphology and IOL calculation 

predictability. 

10:34 AM 


APAO PA003 

10:39 AM 

High-resolution Confocal Structured Images Guide 

Phacoemulsification Technique Selection During Laser- 

Assisted Cataract Surgery 

Presenting Author: Harvey S Uy MD* 

Co-Author(s): Ronald R Krueger MD* 

Purpose: To determine effectiveness of phacoemulsification (PE) technique 

selection based on high-resolution confocal structured (CS) images acquired 

during laser-assisted cataract surgery (LCS). Methods: Forty-eight eyes underwent 

LCS using a femtosecond laser (LensAR; Orlando, Flor., USA); 55 

control eyes underwent standard PE. CS images of cataract anatomy guided 

the surgeon in seleccting a nuclear dissassembly technique. Main outcome 

measures: Success of LCS and adverse events (AE). Results: All LCS eyes 

underwent successful laser capsulotomy and IOL implantation. No AE were 

observed in the LCS group, while 1 case each of a radial tear and posterior 

capsule tear developed in the control group. Conclusion: CS images may 

guide selection of surgical technique during PE. 

10:46 AM 


PA004 

10:51 AM 

Learning Curve and Initial Results in Laser Refractive 


Presenting Author: Sunil Shah MD* 

Co-Author(s): Harvey S Uy MD* 

Purpose: Assessment of the precision and predictability of a novel refractive 

cataract laser system. Methods: First 200 patients treated. Assessment included 

time under suction, time to suction, ease of opening the capsulotomy, 

and reduction in ultrasound energy compared to controls. Results: Mean 

time under suction was 250 ± 151 SD secs. On a scale of 1-10 for ease (10 

being free cap) of opening the capsulotomy, 91% scored a 10. Use of ultrasound 

energy was reduced by 56% for Grade 4 cataracts, 67% for Grade 3, 

79% for Grade 2, and 100% for Grade 1. Conclusion: The novel laser system 

for refractive cataract surgery is easy and safe to use. 

10:58 AM 


APAO PA005 

11:03 AM 

Safety and Efficacy of Laser-Assisted Cataract Surgery by a 

Single Surgeon 

Presenting Author: Michael A Lawless MD* 

Purpose: To assess safety and efficacy of a cohort undergoing laser-assisted 

cataract surgery (LCS). Methods: We retrospectively assessed the initial 

400 consecutive cases by a single surgeon across various safety parameters. 

Patients undergoing implantation of ReSTOR 3+ IOL were then compared to 

a control group with the same IOL implanted by manual technique. Results: 

No adverse complications were noted. The absolute mean difference from 

intended result was 0.28 ± 0.23 D and 0.25 ± 0.16 D for the LCS and manual 

groups (P = .216). 100% and 89.1% of patients achieved uncorrected distance 

visual acuity of 20/40 or better in the LCS and manual groups, respectively. 

Conclusion: Results indicate that LCS is a safe procedure. Comparison with 

a refined cohort of manual patients suggests that refractive results are similar. 

11:10 AM 


PA006 

11:15 AM 

Early Experience With the First 400 Cases Using a 

Femtosecond Laser for Cataract Surgery 

Presenting Author: Burkhard Dick MD* 

Co-Author(s): Ina Conrad-Hengerer MD, Tim Schultz MD** 

Purpose: To evaluate early advantages and limitations of a femtosecond 

laser for challenging cataract surgery (LCS). Methods: First 400 cases of capsulotomy 

and lens fragmentation were documented by video in a controlled 

prospective study. Docking attempts and suction breaks were noted. Patients 

were evaluated for comorbidities, free capsulotomy, effective phaco time 

(EPT), and complications. Results: 203 of 387 cases had mature cataract, 

154 





Fuchs dystrophy, cornea guttata, corneal opacity, pseudoexfoliation, glaucoma, 

intraoperative floppy iris syndrome, postvitrectomy, or small pupil. Capsulotomy 

was free in 98%, EPT was low. Two complications were observed. 

Mean docking attempt was 1.15, with 2 suction breaks. Conclusion: LCS 

provided high precision and enabled successful completion of challenging 

cases. 

11:22 AM 


PA007 

11:27 AM 

Clinical Validation Study on Cataract Surgery Without 

Astigmatic Keratotomy: The Potential of Numerical 

Simulations in Femtosecond Surgery 

Presenting Author: Harald Patrik Studer PHD* 

Co-Author(s): Philippe Büechler PhD*, Samuel W Amstutz MD**, Anita 

Nevyas-Wallace MD*, Cynthia Roberts PhD* 

Purpose: To validate finite element (FE) simulations in cataract surgery with 

a clinical study. Methods: Topography data of 13 patients’ corneas were 

acquired pre- and 30-days postop with Pentacam HR. The data were used to 

create patient-specific FE models and to compare clinical to simulated surgical 

induced change. Results: The prediction error of induced sphere and 

cylinder was 0.19 D and 0.38 D, respectively. The prediction error in surface 

elevation and curvature was below the measurement device accuracy of ±5 

µm and ±0.25 D, respectively. Conclusion: FE simulations of surgical interventions 

can predict postop topography within device accuracy. Therefore, 

simulations may prove valuable when planning incisions in femtosecond 

cataract surgery. 

11:34 AM 


PA008 

11:39 AM 

Arcuate Incision Optimization With a Femtosecond Laser for 


Presenting Author: William W Culbertson MD* 

Co-Author(s): Javier Gonzalez*, Raymond Woo*, Bruce Woodley PhD* 

Purpose: To optimize the pulse parameters of arcuate incisions in laser 

cataract surgery (LCS). Methods: Twenty-four porcine and 8 cadaver eyes 

underwent anterior penetrating and intrastromal arcuate incisions with an 

image-guided LCS system. Pulse parameters were varied, with energy of 3-10 

µJ and spot spacing of 5-50 µm. Incision location, geometry, and quality were 

assessed with OCT, microscopy, and/or blunt dissection. Endothelial cell loss 

was characterized with a dual staining technique. Results: All incisions were 

successful, at the correct location, and with the proper geometry. Anterior 

penetrating incisions were blunt dissectable. The optimized parameters resulted 

in successfully placed and precise cuts. Conclusion: OCT-guided LCS 

allows for the creation of precise arcuate incisions. 

11:46 AM 



8:30 AM - 10:15 AM 

Room: S406b 

Moderator: Steven H Dewey MD 

Panel: David R Hardten MD, Warren E Hill MD, Liliana Werner MD PhD 

PA076 

8:30 AM 

Partial Coherence Interferometry Axial Length 

Measurements Are Less Reliable After Myopic Implantable 

Collamer Lens Surgery 

Presenting Author: Miguel J Maldonado MD PhD 

Co-Author(s): Alberto Lopez Miguel, Loreto Martínez-Almeida MS**, María 

Begoña Coco-Martín MS, Maria Eugenia Mateo, Juan C Nieto DO 

Purpose: To assess axial length (AL) with partial coherence interferometry 

(PCI) in myopic eyes receiving the implantable collamer lens (ICL). Methods: 

Readings were obtained in 39 eyes before and 2 months after surgery. Highly 

myopic nonsurgical controls (25) undertook the same exams. Results: Mean 

difference between the 2 exams was 0.03 mm (P = .18) and 0.005 mm (P = .95) 

in the ICL and control groups, respectively. However, the width of limits of 

agreement was 0.66 mm and 0.16 mm for ICL and control eyes, respectively. 

ICL eyes with AL ≥ 27mm showed greater absolute differences (P = .01). Conclusion: 

After ICL implantation, PCI AL measurements are more unreliable, 

leading to possible random post-cataract refractive errors exceeding 0.75 D. 

8:37 AM 


PA077 

8:42 AM 

Main Causes of Explantation for Different Types of Phakic 

IOLs 

Presenting Author: Pilar Casas de Llera MD 

Co-Author(s): Bader T Toffaha MD, Pablo Peña MS 

Purpose: To define the main causes of explantation of phakic IOLs (P-IOLs). 

Methods: 243 eyes of 226 patients were studied and grouped according to 

their different anatomical positions (angle supported, iris fixated, and posterior 

chamber P-IOLs). Results: The main causes of explantation were cataract 

formation (53.1%), endothelial cell loss (10.7%), luxation (6.6%), endothelial 

decompensation (5.3%), and pupilar ovalization (3.7%). Conclusion: Cataract 

is the main cause for explantation of P-IOLs; endothelial cell loss is the 

second-most important cause. 

8:49 AM 


PA078 

8:54 AM 

Pathologic Comparison of Asymmetric or Sulcus Fixation of 

3-Piece IOLs With Square vs. Round Anterior Optic Edges 

Presenting Author: Liliana Werner MD PhD* 

Co-Author(s): Andrew Ollerton, Susan Strenk PhD*, Lawrence Strenk PhD*, 

Lisa Leishman MD**, Zachary Modest Bodnar MD, Jennifer Michelson, 


Purpose: To provide pathologic evidence of complications related to asymmetric 

or sulcus fixation of IOLs with square anterior optic edges. Methods: 

661 pseudophakic cadaver eyes underwent high-frequency ultrasound or MRI 

exam, gross evaluation after sectioning, and histopathology (selected eyes). 

Results: Twelve eyes had 3-piece hydrophobic acrylic IOLs with anterior and 

posterior square optic edges, and 14 eyes had 3-piece lenses with anterior 





155



round edges (13 silicone; 1 hydrophobic acrylic without symmetric in-the-bag 

fixation. Pathologic findings were more severe in the first group. Conclusion: 

IOLs with round anterior optic edges are more suitable for sulcus fixation. 

9:01 AM 


PA079 

9:06 AM 

Is the Error From Intended Refraction in First Eye Cataract 

Surgery a Predictor for Error in the Second Eye? 

Presenting Author: Mark F Brower DO 

Co-Author(s): Ryan Brower MS 

Purpose: To review the 1 month refraction of the first cataract surgery for a 

patient, and if there is an error from intended refraction (EIR), to consider the 

error (E) in selecting the IOL for the second eye. Methods: EIR in the first and 

second eye in a 102-patient population was compared. Results: Average EIR 

for the refraction was -0.044 D for the first eye and -0.014 D in the second 

eye. The difference in E between the first and second eye showed 53/102 

within 0.25 D. Twenty-three first eyes had over 0.50 D of E. Conclusion: In 

patients over 0.50 D of E in the first eye, an adjustment of 0.25 D in reverse 

direction of the EIR reduced the E in 21/23 second eyes; 0.50 D reduced E in 

21/23 eyes also, but comparing the 0.25 D vs. 0.50 D adjustment, the 0.50 D 

adjustment resulted in a lower EIR in 20/23 second eyes. 

9:13 AM 


PA080 

9:18 AM 

Visual Results 6 Months After Bilateral Implantation of a 

Toric Multifocal IOL 

Presenting Author: Thomas Kohnen MD* 

Purpose: To evaluate visual outcomes 6 months following bilateral implantation 

of the ReSTOR toric multifocal IOL (MIOL). Methods: A prospective, 

multicenter trial was conducted in 49 cataract or ametropic adult patients. 

Corneal astigmatism before surgery was > 0.75 D and < 2.5 D. Defocus curve, 

cylinder correction, and overall patient satisfaction were evaluated. Results: 

Defocused visual acuity peaked at 0 D and -2.5 D. Mean postoperative absolute 

cylinder was ≥ 0.5 D, while the corneal cylinder remained the same 

before and after surgery. Overall patient satisfaction increased after surgery. 

9:25 AM 


PA081 

9:30 AM 

NEI-RQL-42 and SVI Quality of Life and Vision Metrics After 

Bilateral Implantation of 3 Presbyopia-Correcting IOLs 

Presenting Author: Richard C Chu DO* 

Co-Author(s): Jay Stuart Pepose MD PhD*, Mujtaba A Qazi MD* 

Purpose: To compare quality of life and vision surveys following implantation 

of presbyopia-correcting IOLs. Methods: Following randomized, masked, 

bilateral implantation of Crystalens AO (n = 19), ReSTOR +3 (n = 17), or Tecnis 

Multifocal (n = 16), the NEI-RQL-42 and the Subjective Vision Score (SVI) 

were administered at 1 and 3 months. Results: There were no statistically 

significant differences for the distance subscale (P > .14). Multifocal IOLs 

had the best spectacle independence at 1 month (P < .006) but showed no 

statistical significance by 3 months (P > .4). The Crystalens AO had the lowest 

glare responses (P < .016 ), with Tecnis MF mean scores > 2x. Conclusion: 

Patient subjective responses to these instruments highlight each IOL’s inherent 

strengths and weaknesses. 

9:37 AM 


PA082 

9:42 AM 

Risk Factors for Toxic Anterior Segment Syndrome 

Presenting Author: Nick Mamalis MD* 

Co-Author(s): Zachary Modest Bodnar MD 

Purpose: To identify risk factors for toxic anterior segment syndrome (TASS). 

Methods: A questionnaire on ophthalmic instrument cleaning, products used 

during cataract surgery, and site visits were used to evaluate TASS. Results: 

Data from 130 questionnaires and 71 site visits revealed 1570 cases of TASS. 

Inadequate flushing of handpieces, ultrasonic baths, enzymatic cleaners and 

detergents, and preservative containing epinephrine increase the risk of 

TASS. There was a downward trend in the number of surveys submitted, inadequate 

handpiece flushing, and use of preserved intraocular medications. 

There was an increased use of enzymatic cleaners and ultrasound baths. 

Conclusion: We have identified practices associated with an increased risk 

of TASS. 

9:49 AM 


PA083 

9:54 AM 

Does Phacoemulsification Worsen Neovascular AMD? 

Presenting Author: Andre Grixti 

Co-Author(s): Evangelia Papavasileiou MD, Thomas Salisbury, Balakrishna V 

Kumar MBBS*, Somdutt Prasad MBBS* 

Purpose: To determine the effect of phacoemulsification on wet 

AMD. Methods: Retrospective case series of 31 subjects. Results: 

Median (range) BCVA preoperatively, postoperatively, and endpoint 

was 0.66 (0.16 to 1.32), 0.58 (-0.04 to 1.32), and 0.54 (-0.04 to 

1.4) logMAR, respectively. Median frequency of anti-VEGF injections 

per month before and after surgery was 0.33 and 0.27, respectively 

(P = .068). Median central macular thickness (OCT) measured 198 µm preoperatively 

and 231 µm postoperatively (P = .44). Conclusion: Results suggest 

phacoemulsification is not contraindicated in wet AMD, with no increased 

need of anti-VEGF injections to keep macula dry postoperatively. It improves 

vision and facilitates monitoring of disease progression. 

10:01 AM 


156 






Moderator: Bennie H Jeng MD 


8:30 - 10:10 AM 

Room: S405 

Panel: Bokkwan Jun MD PhD, Jennifer Y Li MD, Robert L Schultze MD 

PA031 

8:30 AM 

Visual Rehabilitation and Complications of the First 300 

Consecutive Descemet Membrane Endothelial Keratoplasty 

Cases 

Presenting Author: Fayyaz Musa MBBS FRCOPHTH 

Co-Author(s): Korine van Dijk OD, Lisanne Ham PhD, Isabel Dapena, Gerrit 

RJ Melles MD PhD* 

Purpose: To evaluate the visual rehabilitation and postoperative complications 

after Descemet membrane endothelial keratoplasty (DMEK). Methods: 

A prospective clinical study of 300 consecutive eyes with corneal endothelial 

failure. Results: A total of 79 eyes were excluded from BCVA analysis because 

of low visual potential, incomplete data, or nonfunctional or detached 

grafts. In the remaining 221 eyes, 87% reached ≥ 0.5 at 1 month and 96% 

at 3 months. BCVA was ≥ 0.8 in 71% at 3 months and in 79% at 6 months. 

Graft detachment occurred in 10% of eyes, ocular hypertension occurred in 

4%, and secondary cataract developed in 5% of phakic eyes. Conclusion: 

DMEK appears to be a safe and effective treatment, offering rapid and near 

complete visual rehabilitation in the management of corneal endothelial disorders. 

8:07 AM 


PA032 

8:42 AM 

Intraocular Graft Unfolding Techniques in Descemet 

Membrane Endothelial Keratoplasty 

Presenting Author: Vasilios S Liarakos MD 

Co-Author(s): Martin Dirisamer MD, Isabel Dapena, Lisanne Ham PhD, 

Korine van Dijk OD, Gerrit RJ Melles MD PhD* 

Purpose: To evaluate various Descemet-graft unfolding techniques in Descemet 

membrane endothelial keratoplasty (DMEK). Methods: In 100 consecutive 

DMEK cases, 4 different Descemet-graft unfolding techniques were 

identified and evaluated with regression analysis regarding BCVA, endothelial 

cell density (ECD), and postoperative complications at 6 months. Results: 

All DMEK surgeries could be successfully completed using 1 or more of the 4 

described techniques. None of the techniques correlated with the BCVA, ECD, 

or postoperative complication rate (P > .05). Conclusion: DMEK may be further 

facilitated by controlled unfolding techniques, either as stand-alone or 

used in various combinations, without compromising the final outcome. 

8:19 AM 


PA033 

8:54 AM 

Prevention and Management of Graft Detachment in 

Descemet Membrane Endothelial Keratoplasty 

Presenting Author: Martin Dirisamer MD 

Co-Author(s): Korine van Dijk OD, Gerrit RJ Melles MD PhD* 

Purpose: To describe the prevention and management of various types 

of graft detachment after Descemet membrane endothelial keratoplasty 

(DMEK). Methods: In 150 consecutive DMEK eyes, the incidence and type 

of graft detachment were studied. Four groups of detachments were identified: 

a partial detachment ≤ 1/3, ≥ 1/3, graft positioned upside-down and a 

“free-floating” Descemet-roll in the anterior chamber. Results: All 24 eyes 

with a partial detachment showed ?spontaneous? corneal clearance, and all 

but 6 of these eyes (75%) reached a visual acuity of ≥ 20/40. Conclusion: 

Awaiting “spontaneous” clearance may be advocated in eyes with a partial 

detachment. Minor adjustments in surgical protocol as well as careful patient 

selection may further reduce the incidence of graft detachment after DMEK 

to ≤ 4%. 

8:31 AM 


PA034 

9:06 AM 

A Retrospective Study Comparing First-Episode 

Immunologic Graft Rejection After Descemet-Stripping 

Automated Endothelial Keratoplasty and Penetrating 

Keratoplasty in Patients With Endothelial Disease 

Presenting Author: Tushar N Suthar MD 

Co-Author(s): Isaac C Ezon MD, Carolyn Y Shih MD MBA MPH, Lisa M 

Rosen MS, Ira J Udell MD* 

Purpose: To compare the incidence and risk factors for first-episode immunologic 

graft rejection in Descemet-stripping automated endothelial keratoplasty 

(DSAEK) vs. penetrating keratoplasty (PK) patients who had endothelial 

disease. Methods: A retrospective review of 171 PK and 122 DSAEK 

cases. Results: Incidence of rejection was 13.4% (23/171) for PK and 3.3% 

for DSAEK (4/122) (P < .05). Phakic patients were more likely to reject than 

pseudophakic (anterior chamber IOL P < .03 and posterior chamber IOL P < 

.01). Prior glaucoma surgery imparted a 2.63 times greater risk of rejection. 

Conclusion: DSAEK had a lower rejection rate than PK. The risk of rejection 

in both DSAEK and PK was higher in phakic and prior glaucoma surgery 

patients. 

8:43 AM 


PA035 

9:18 AM 

Theoretical, Experimental, and OCT Study of Factors 

Affecting Graft Apposition and Adhesion Strength in 

Descemet-Stripping Automated Endothelial Keratoplasty 

Presenting Author: Maninder Bhogal** 

Co-Author(s): Romesh I Angunawela MBBS, Emiliano Bilotti PhD**, Ian 

Eames PhD, Bruce Allan MD 

Purpose: To investigate the effect of air-fill pressure (AFP), duration, venting 

incisions (VI), and stromal roughening (SR) on interface fluid (IF) dispersion 

and donor adhesion in a model of Descemet-stripping automated endothelial 

keratoplasty (DSAEK). Methods: AFPs of 18 mmHg (n = 6) or 60 mmHg (n = 6) 

were used, and IF was measured by OCT before and after opening VIs (n = 6). 

Adhesion was measured by strain gauge at 60 mmHg/8 min, 60 mmHg/1 min, 

18 mmHg/8 min, 18 mmHg/1 min (n = 8 each) and after VI, and SR (n = 12). 

Results: IF diminished with time at all AFPs (P < .0001) with no difference in 

amount/rate of dispersion. VIs eliminated all IF. Adhesion was independent 

of AFP (P = .38). VIs increased adhesion (P = .0001). SR increased adhesion (P 

= .0034). Conclusion: VIs and SR aid adhesion in DSAEK. High-pressure AFP 

has no additional effect. 

8:55 AM 






157



PA036 

9:30 AM 

Sutureless Femtosecond Laser-Assisted Anterior Lamellar 

Keratoplasty vs. Deep Anterior Lamellar Keratoplasty 

Presenting Author: Mohamed F Abou Shousha MBCHB 

Co-Author(s): Victor L Perez MD*, Mervat Salah Mourad, Osama I Ibrahim 

MD PhD*, Abdallah K Hassouna MD*, Hassan El-Sayed MD PhD**, Eduardo 

C Alfonso MD*, Sonia H Yoo MD* 

Purpose: To compare the 12 months results of femtosecond laser-assisted 

anterior lamellar keratoplasty (FALK) to deep anterior lamellar keratoplasty 

(DALK). Methods: Twenty-nine eyes with anterior corneal pathologies sparing 

the endothelium were recruited. Fifteen eyes underwent FALK and 14 underwent 

big bubble DALK. Patients were followed up for 12 months. Results: 

FALK patients gained a mean of 2.5, 4, and 5 lines of BCVA at the 2-, 6-, and 

12-month visits, respectively, whereas DALK patients gained 1.3, 2.7, and 

2.7 at the same visits. Mean BCVA post-FALK was significantly better than 

post-DALK at the 6- and 12-month visits (P = .05 and P = .03). FALK patients 

had statistically significantly less astigmatism compared to DALK patients at 

all visits. Conclusion: FALK yields better BCVA and less astigmatism than 

DALK over the 12-month follow-up period. 

9:37 AM 


PA037 

9:42 AM 

Femtosecond Laser Pre-Descemet Deep Anterior Lamellar 

Dissection With a “Mini-Bubble” Technique 

Presenting Author: Roger F Steinert MD* 

Co-Author(s): Jaime Martiz MD, Zsolt Bor** 

Purpose: To develop a method of obtaining a smooth deep lamellar dissection. 

Methods: Variable laser parameters and pass patterns with a 150-kHz 

femtosecond laser were applied to human donor corneas mounted in an artificial 

anterior chamber. Results: A smooth lamellar dissection can be obtained 

utilizing very low pulse energy, wide spot spacing, and multiple raster 

pattern passes in different directions. Scanning electron microscopy showed 

no evidence of loss of endothelial cells. Conclusion: This technique, called 

“mini-bubble,” has the potential to provide a reliable method for donor preparation 

for ultrathin Descemet-stripping endothelial keratoplasty and for donor 

and host dissection in deep anterior lamellar keratoplasty. 

9:49 AM 


APAO PA038 

9:56 AM 

The Groove & Peel: A New Technique of Deep Lamellar 

Keratoplasty 

Presenting Author: Rishi Swarup FRCS 

Co-Author(s): Pravin K Vaddavalli MD* 

Purpose: To study efficacy and safety of a new technique of deep anterior lamellar 

keratoplasty (DALK):- the Groove & Peel Technique. Methods: Retrospective 

review of case records of the first 100 cases that underwent surgery 

by this technique for demographics, indication, outcome, and complications. 

Results: The most common indication was corneal scar (57%). Intraoperatively, 

Descemet membrane perforation occurred in 3 cases. All perforation 

cases could be salvaged and completed as DALK. Ninety-five percent could 

reach Descemet level dissection, whereas 5% had pre-Descemetic DALK. Final 

postop BSCVA was 20/50 or better in 78% of cases. Conclusion: Groove 

& Peel is an effective and safe technique of DALK and can be used a primary 

technique for deep lamellar keratoplasty to deliver good optical and visual 

results. 

10:03 AM 


Part II, 10:12 AM - 12:00 PM 

Moderator: Terry Kim MD 

Panel: Jessica B Ciralsky MD, William J Dupps MD PhD, Marjan Farid MD 

PA039 

10:12 AM 

Long-term Follow-up of the Athens Protocol: Combined 

Topography-Guided Partial PRK and Corneal Crosslinking in 

212 Keratoconus Eyes 

Presenting Author: A John Kanellopoulos MD* 

Purpose: To evaluate the safety and efficacy of the Athens Protocol (AP). 

Methods: 212 keratoconus (KCN) cases had the AP and were evaluated over 

a follow-up time of 6 to 48 months. Results: None of the cases showed 

further ectasia progression. Uncorrected distance VA (UDVA) improved from 

0.3 to 0.5, corrected distance VA (CDVA) from 0.5 to 0.8, attributed to mean 

improvement of the cornea index of height decentration (IHD) by 55%, SE 

from -3.8 to -1.6 D, mean K from 51.5 to 47.5. Fifty percent of cases gained 

2 lines of CDVA, 35% gained 3 lines, respectively. Minor complications were 

encountered in 12% of cases. Conclusion: The AP appeared to be safe and 

effective in halting ectasia progression and improving UDVA and CDVA by 

dramatically improving the IHD. 

10:19 AM 


PA040 

10:24 AM 

Intracorneal Ring Segments for Treating Keratoconus Based 

on Visual Impairment 

Presenting Author: Alfredo Vega 

Co-Author(s): Jorge L Alio MD PhD*, Amr M El Aswad MD, Roberto 

Fernandez Buenaga 

Purpose: To analyze outcomes of intracorneal ring segments (ICRS) for treating 

keratoconus based on preoperative visual impairment. Methods: Multicenter 

study where 611 eyes were classified according to their preoperative 

corrected visual acuity (CDVA) into 5 different grades. Refractive, topographic, 

and aberrometric data were evaluated during 6 months. Results: 

Keratometry readings significantly decreased in all grades (P < .05). Corrected 

distance VA significantly decreased in patients with milder keratoconus (P < 

.01), but significantly increased in all other grades (P < .05). Conclusion: 

ICRS implantation provides significantly better results in patients with a severe 

form of the disease. 

10:31 AM 


PA041 

10:36 AM 

AcrySof Cachet Phakic IOL in Patients With Intacs in 

Keratoconic Eyes: Analysis Over a 24-Month Period 

Presenting Author: Luis Alberto Rodriguez Torres MD 

Purpose: To evaluate outcome of AcrySof Cachet Phakic IOL (Cachet) in patients 

with intrastromal Corneal Ring (Intacs) implanted in stable keratoconus 

eyes. Methods: Study included 18 eyes. All eyes had stable refraction over 

12 months of follow-up. Cachet IOL was implanted to correct the sphere. All 

cases were followed up for more than 24 months. Results: Patients’ mean 

age was 28.2 ± 4.4 years (range: 22 to 34 years). Preoperative sphere was 

-8.7 D ± 3.3 D (-6.00 D to -14.50 D) and cylinder was -1.8 D ± 0.8 D.The BCVA 

was 0.3 ± 1.1. Postoperative UCVA was 4.3 ± 1.2. One hundred percent of 

158 





cases gained 1 line or more. No single major complication was reported. 

Conclusion: Cachet IOL is a promising is a promising solution in refractive 

correction of keratoconus after stabilizing the conditions with Intacs. 

10:43 AM 


PA042 

10:48 AM 

Toric IOLs in Cataract Surgery for Keratoconus 

Presenting Author: Pierre R Fournie MD 

Co-Author(s): Vincent Soler MD**, David Touboul MD, Jose L Guell MD 

PhD*, Joseph Colin MD*, Francois Malecaze MD** 

Purpose: To evaluate toric pseudophakic IOL implantation in patients with 

cataract and keratoconus. Methods: Twenty-nine eyes of 19 patients diagnosed 

with keratoconus and a cataract underwent toric pseudophakic IOL 

implantation with refractive outcomes analyzed primarily with at least 1-year 

follow-up. Results: The mean postoperative manifest refraction spherical 

equivalent was -0.3 ± 1.12 D. Forty-four percent of the eyes were within ± 

0.50 D of emmetropia, and 75% were within ± 1.00 D. Preoperative vectorial 

astigmatism change was 0.71 D, reduced to 0.12 D (P < .001). The magnitude 

of cylinder change was 0.85 D, and the axis of cylinder change was 61°. 

Conclusion: Implantation of a toric pseudophakic IOL is a therapeutic option 

in carefully selected patients with keratoconus and cataract. 

10:55 AM 


PA043 

11:00 AM 

Report of the Eye Bank Association of America Medical 

Advisory Board Subcommittee on Fungal Infection 

Following Corneal Transplantation 

Presenting Author: Anthony J Aldave MD* 

Purpose: To investigate the incidence of fungal infections following corneal 

transplantation. Methods: Adverse reactions reported to the Eye Bank Association 

of America from 1/1/2007 to 12/31/2010 were reviewed. Results: 

Thirty-one cases of culture-proven fungal keratitis and endophthalmitis were 

reported (1.4 cases per 10,000 transplants). Fungal infections were more 

common after Descemet-stripping endothelial keratoplasty than penetrating 

keratoplasty but the difference was not statistically significant (P = .076). 

Seventy-three percent of the fungal cultures performed on the mate corneas 

were positive, with infection developing in 67% of recipient eyes. Conclusion: 

A nonsignificant increase in the rate of fungal infection has been observed 

over the last 6 years, insufficient to compel antifungal supplementation 

of donor media. 

11:07 AM 


PA044 

11:12 AM 

A Randomized Double-Masked Placebo-Controlled 

Evaluation of Subconjunctival Bevacizumab for Recent 

Onset Corneal Neovascularization 

Presenting Author: Kamaljit S Balaggan MBBS 

Co-Author(s): Constantinos Petsoglou**, John K G Dart MD**, Catey Bunce 

MBBS PhD, Wen Xing, Robin Ali PhD**, Stephen J Tuft MD** 

Purpose: To clinically evaluate bevacizumab for recent onset corneal neovascularization 

(CoNV). Methods: Eyes were randomized to receive either 3 

monthly injections of 2.5-mg bevacizumab (n = 15) or 0.9% saline (n = 15) as 

part of a Phase 2b study. Standardized corneal photographs were obtained at 

each visit, and masked digital image processing was performed to quantify 

the change in CoNV area between the baseline and 3-month visits. Results: 

The mean area of CoNV was reduced by 36% in eyes receiving bevacizumab, 

compared with an increase of 90% in control eyes (P = .007). Conclusion: 

Bevacizumab appears more effective than placebo at inducing regression of 

CoNV. Our data suggest that a sample size of 40 patients per treatment group 

is required in a Phase 3 study to confirm this effect. 

11:19 AM 


PA045 

11:24 AM 

Evaluation of Riboflavin, UVA, and Riboflavin/UVA Effect on 

Various Ocular Pathogens 

Presenting Author: Verinder S Nirankari MD 

Co-Author(s): Jagdish Chander MD, Takeo Fukuchi MD**, Jennifer M 

Nottage MD 

Purpose: To demonstrate the antimicrobial properties of riboflavin and 

ultraviolet-A (UVA) on various ocular pathogens. Methods: Four groups of 

organisms were tested methicillin-sensitive Staphylococcus aureus (SA), 

Pseudomonas aeruginosa (PA), Candida albicans (CA) and Acanthamoeba. All 

groups were tested 6 different times with UVA light alone, riboflavin alone, 

and riboflavin with UVA. The growth inhibition zone (GIZ) was measured. Results: 

The GIZ was greater after riboflavin/UVA for PA only. The GIZ was not 

increased after any treatments on SA, CA or Acanthamoeba. Conclusion: 

Riboflavin/UVA was found to be effective against PA but ineffective on SA, 

CA, or Acanthamoeba. UVA alone and riboflavin alone were ineffective on all 

tested organisms. 

11:31 AM 


PA046 

11:36 AM 

Long-term Outcomes After Boston Type 1 Keratoprosthesis 

Presenting Author: Divya Srikumaran MD 

Co-Author(s): James Aquavella MD*, Sadeer B Hannush MD, Robert L 

Schultze MD*, Anthony J Aldave MD*, Esen K Akpek MD* 

Purpose: To assess visual and clinical outcomes of the Boston type 1 keratoprosthesis 

(KPro). Methods: Multicenter, retrospective review of patients 

who underwent surgery prior to 2007. Results: 160 eyes were operated on 

between January 2003 and December 2006. Ninety-four eyes had a minimum 

5 years of follow-up. Forty-one of 94 eyes had removal of the KPro/ 

enucleation at a mean of 21 months (range: 0.9-60 months). Of the 53 eyes 

with a retained KPro, 17% had final BCVA ≥ 20/40; 40%, ≥ 20/70; and 57%, 

≥ 20/200. Postoperative complications included retroprosthetic membrane 

48%; retinal detachment, 22%; need for glaucoma surgery, 18%; endophthalmitis, 

13%; and sterile corneal melt, 12%. Conclusion: The overall retention 

rate of KPro is 56% at 5 years. Sixty-eight percent of these eyes had improved 

final BCVA compared to preoperatively. 

11:43 AM 


APAO PA047 

11:48 AM 

Treatment of Bilateral Limbal Stem Cell Deficiency: Cell- 

Based Therapy vs. Keratoprosthesis 

Presenting Author: Sayan Basu MBBS 

Co-Author(s): Archana Singh**, Virender S Sangwan MBBS 

Purpose: To report the visual outcomes after cell-based therapies and Boston 

type 1 keratoprosthesis for bilateral limbal stem cell deficiency (LSCD). 

Methods: This was a retrospective analysis of 108 procedures performed by 





159



a single surgeon between 2001 and 2011. Results: Best postoperative visual 

acuity attained and duration for which it was maintained was significantly 

better (P < .001) in eyes undergoing Boston type 1 keratoprosthesis (n = 51) 

as compared to allogeneic limbal transplantation (n = 36) or oral mucosal 

epithelial transplantation (n = 21) with or without keratoplasty . Conclusion: 

Boston type 1 keratoprosthesis gives better and longer visual rehabilitation 

as compared to cell-based therapies for bilateral LSCD. 

11:55 AM 


Glaucoma 


10:15 AM - 12:00 PM 

Room: S405 

Moderator: Sarwat Salim MD 

Panel: Philip P Chen MD, Richard A Quinones MD, Janet B Serle MD 

APAO PA009 

10:15 AM 

Evaluation of a Sustained Release Travoprost Punctum Plug 

for IOP Reduction 

Presenting Author: Shamira Perera MBBS* 

Co-Author(s): Paul T K Chew MD, Tin Aung FRCS PhD* 

Purpose: To appraise a novel sustained-release travoprost punctum plug (TP) 

(Ocular Therapeutix; Mass., USA) for retention and IOP reduction in ocular 

hypertensive or glaucoma patients. Methods: Twenty patients (up to n = 40 

eyes) at 2 sites in Singapore were implanted with TP in either the upper or 

lower puncta and prospectively followed over 30 days. Results: The mean 

IOP reduction over 10 days was approximately 6 mmHg from 25.9 (± 2.1) to 

19.3 (± 3.4) for 7 subjects. The IOP reduction was sustained in the 2 subjects 

that exited the study after 30 days. The TP was easy to insert, and preliminary 

results suggest good retention. Conclusion: The TP achieves therapeutic 

delivery levels over 30 days. Circumventing poor compliance, the TP shows 

promise as an alternative to topical drops. 

10:22 AM 


PA010 

10:27 AM 

Corneal Hysteresis as a Risk Factor for Glaucoma 

Presenting Author: Francis Carbonaro MD PHD FRCOPHTH 

Co-Author(s): Pirro Hysi PhD, Sam Fahy PhD, Diana Kozareva, Chris 

Hammond 

Purpose: To study whether corneal hysteresis (CH) is an independent risk 

factor for glaucoma, as has been suggested. Methods CH was measured in 

1907 population-based subjects (mean age 57 years, SD 11.8 years) from the 

TwinsUK cohort, and univariate and multivariate linear regressions were performed 

against glaucoma-related endophenotypes (IOP, cup:disc ratio [CDR], 

optic disc area). Results CH was not significantly associated with disc area 

(P = .18), or CDR (P = .32), though CH reduced with age (coefficient = -0.03, 

P < .00005) and IOP (coefficient = -0.3, P < .00005). Conclusion: We found 

no relationship between CH and quantitative measures of optic disc cupping, 

suggesting that CH is not an independent risk factor for glaucoma. 

10:34 AM 


PA011 

10:39 AM 

Topical Microdroplet Administration vs. Eyedropper for 

Delivering Eye Medication 

Presenting Author: Tsontcho Ianchulev MD* 

Co-Author(s): Mark Packer MD*, Arturo S Chayet MD* 

Purpose: To compare efficacy of topical ocular medication by microdroplet 

fluid ejection device vs. eyedropper. Methods: 102 healthy volunteers received 

1 drop (26 µL) each of phenylephrine 2.5% and tropicamide 1% in one 

eye vs. µdroplet sprays of same dilating components in fellow eye. Three 

dose levels were used: 1.5 µL (n = 34), 6 µL (n = 33) and 2 X 3 µL (n = 35). 

Results: The 6 µL sprays achieved equivalent dilation to eyedropper at 10, 

20, and 60 minutes and were preferred by 90% of subjects. Dilation also 

trended faster; 70% reached 6-mm threshold at 10 minutes vs. 61% for the 

eyedropper. Conclusion: µdroplet administration achieved levels of mydriasis 

similar to conventional eyedropper at one-fourth the dosing volume of an 

eye drop. 

10:46 AM 


PA012 

10:51 AM 

In Vivo Visualization of Novel Anterior Chamber Angle 

Structures With a Newly Identified Trabecular Meshwork 

“Scoop” Using Spectral Domain OCT 

Presenting Author: Vikas Chopra MD* 

Co-Author(s): Fernanda Dominguez, Zhouyuan Zhang, Humberto Ruiz-Garcia 

MD, Muneeswar G Nittala, Brian A Francis MD*, Xiaojing Pan MD, Srinivas 

R Sadda MD* 

Purpose: To use the high-definition of the 840-nm spectral domain OCT (SD- 

OCT) Zeiss Cirrus to measure novel anterior chamber angle (ACA) parameters 

using the Schwalbe line (SL), a more easily identifiable landmark compared to 

the scleral spur (SS). Methods: The inferior and temporal angles of 208 eyes 

of open-angle glaucoma patients were imaged with SD-OCT. Results: SL 

was identified in 94% of images with calculation of a new angle metric, SLangle 

opening distance (AOD). We also newly identified the filtering region 

of the angle just posterior to SL visualized as a “scoop” containing the TM. 

Conclusion: SD-OCT permits calculation of novel angle metrics (SL-AOD and 

SL-TISA) based on location of SL instead of SS, which may provide more 

meaningful clinical measurements for angle grading and screening. 

10:58 AM 


PA013 

11:03 AM 

Definitive Surgical Repair of Traumatic Cyclodialysis Cleft 

With Sulcus-Fixated Modified Cionni Capsular Tension Ring 

Presenting Author: Shakeel R Shareef MD 

Co-Author(s): Alan S Crandall MD*, David A DiLoreto MD, Iqbal K Ahmed 

MD* 

Purpose: Several surgical procedures of varying difficulty have been described 

in closing large cyclodialysis cleft (CDC). However, there is no consensus, 

and many require more than one intervention to achieve closure. 

Methods: We describe definitive surgical repair of 5 cases of CDC 3 3 clock 

hours with chronic hypotony ranging from 6 to 45 months by suturing a modified 

Cionni capsular tension ring (MC-CTR) in the sulcus using an ab interno 

approach with a 2-year follow-up. Results: All cases had normalization of 

IOP from preop 0-7 mmHg to postop 12-18 mmHg, and improved visual acuity 

from preop count fingers - 20/200 to postop 20/40-20/60. Conclusion: We 

160 





propose that use of a MC-CTR should be the procedure of choice in repairing 

large CDC, given a 360 centrifugal force that precludes need for additional 

surgery should multiple CDC be present. 

11:10 AM 


PA014 

11:15 AM 

Efficacy and Safety of Deep Sclerectomy in Childhood 

Glaucoma in Saudi Arabia 

Presenting Author: Saleh Ali Alobeidan 

Co-Author(s): Essam E Osman MD FRCS, Ahmed Mousa AbdelRahim PHD, 

Ahmed S Dewedar MD FRCS, Philippe Kestelyn MD PhD** 

Purpose: To evaluate the efficacy and safety of deep sclerectomy in childhood 

glaucoma. Methods: A prospective cohort of children presenting with 

glaucoma to King Abdul Aziz University Hospital was subjected to nonpenetrating 

deep sclerectomy surgery (NPDS). Results: After follow-up of 35.8 

(34.5) months, NPDS procedure went smoothly in 74 eyes of 63 patients. 

The complete success rate was 79.7%, while the overall success rate was 

82.4%. Thirteen cases have failed. The probability to survive was 74.6% after 

the 12th month. The mean IOP went down to 11.5 ± 3.0 mmHg compared 

to 31.9 mmHg preoperatively. Conclusion: Deep sclerectomy in childhood 

glaucoma can effectively reduce the IOP, without the occurrence of serious 

complications that are commonly seen after trabeculotomy or combined 

trabeculotomy-trabeculectomy. 

11:22 AM 


PA015 

11:27 AM 

Does Macular Retinal Nerve Fiber Layer Thickness 

Measurement Correlate to Changes in Visual Field 

Progression in Advanced Glaucoma? 

Presenting Author: Sadhana V Kulkarni MBBS 

Co-Author(s): John Hamilton**, Stuart Glenn Coupland 

Purpose: To correlate changes in Humphrey 10-2 and SLO-Microperimetry 

(H10, SLO-MP) over 3 years to baseline macular retinal nerve fiber layer thickness. 

Methods: Decrease in macular sensitivity of 18 eyes with advanced 

glaucoma was prospectively correlated to baseline retinal nerve fiber layer 

(RNFL) thickness (µ). Decline in SLO-MP and H10 sensitivities were analyzed 

by linear regression. Results: At 3 years, baseline macular RNFL thickness 

significantly correlated with H10 and SLO-MP (P = .03). Both tests showed 

comparable overall reduction in macular RNFL sensitivity (SLO-MP P < .0001, 

H10 P = .006) Conclusion: Macular RNFL thickness measured by SLO-OCT is 

a good predictor of 3-year reduction of retinal sensitivity by H10 and SLO-MP, 

with a trend toward higher correlation with SLO-MP. 

11:34 AM 



10:30 AM - 12:00 PM 

Room: S405 

Moderator: Robert M Feldman MD 

Panel: E Randy Craven MD, Frank J Moya MD, Lisa Fran Rosenberg MD 

PA092 

10:30 AM 

Cost Comparison of the Trabectome, iStent, and Endoscopic 

Cyclophotocoagulation With Glaucoma Medication in the 

Ontario Health Insurance Plan 

Presenting Author: Yiannis Iordanous MD 

Co-Author(s): Jerrod S Kent MD, Cindy M Hutnik MD PhD*, Monali S 

Malvankar-Mehta PhD 

Purpose: To examine the projected 6-year cost of the iStent, Trabectome, 

and Endoscopic Cyclophotocoagulation (ECP) compared with topical glaucoma 

medications within the Ontario Health Insurance Plan. Methods: The 

average annual cost of glaucoma medications was determined based on 

published utilization rates and the Ontario Drug Benefit formulary. We contacted 

suppliers to determine the per-patient cost of the glaucoma devices. 

Results: At 6 years, Trabectome yielded a $242.68 cost savings over topical 

mono-therapy, ECP offered a $742.68 savings, while iStent was $57.32 more 

expensive. Conclusion: Over a projected period of 6 years, Trabectome, iStent 

and ECP may be cost-effective alternatives to glaucoma medications. 

10:37 AM 


PA093 

10:42 AM 

Comparison of Ex-PRESS Miniature Glaucoma Device 

Implanted Under Scleral Flap With Trabeculectomy 

Presenting Author: Peter Andreas Netland MD PhD* 

Co-Author(s): Iqbal K Ahmed MD*, Garry P Condon MD**, Marlene R 

Moster MD*, Sarwat Salim MD*, Steven R Sarkisian MD*, Mark B 

Sherwood MD*, Carla J Siegfried MD* 

Purpose: To compare clinical outcomes after the Ex-PRESS miniature glaucoma 

device under scleral flap with trabeculectomy. Methods: Randomized, 

prospective, multicenter clinical trial of 118 eyes (59 Ex-PRESS and 59 trabeculectomy) 

with 2 years follow-up. Results: Average IOP was significantly 

reduced compared with baseline in both groups (P < .001), with mean IOP at 1 

year after surgery of 14.6 ± 5.7 mmHg and 13.1 ± 4.6 mmHg in the Ex-PRESS 

and trabeculectomy groups, respectively (P = .118). Average IOP, number of 

medications, and success were similar in both groups at 2 years after surgery. 

Conclusion: IOP control was similar at 1 and 2 years after the Ex-PRESS 

device and trabeculectomy. 

10:49 AM 


PA094 

10:54 AM 

One-Year safety of Suprachoroidal Microstent Implantation 

to Treat Open-Angle Glaucoma in Conjunction With Cataract 

Surgery 

Presenting Author: Steven D Vold MD* 

Co-Author(s): E Randy Craven MD*, Iqbal K Ahmed MD*, David F Chang 

MD*, Tsontcho Ianchulev MD* 

Purpose: To assess safety of CyPass Micro-Stent (CM) implantation and 

cataract surgery. Methods: Prospective study of open-angle glaucoma (OAG) 

patients with CM implanted after cataract surgery. Outcomes include adverse 





161



complications and change in IOP from baseline during 12-month follow-up. 

Results: There were no major complications of endophthalmitis, suprachoroidal 

hemorrhage, retinal detachment, choroid detachment, or flat anterior 

chamber in the CM patients (n = 254). Mean IOP went down 33.4% (21 to 

16.2 mmHg) at 12 months in patients hypertensive at baseline. Conclusion: 

The CyPass Micro-Stent procedure appears effective in lowering IOP in OAG 

patients for at least 12 months. No significant adverse complications were 

observed. 

11:01 AM 


PA095 

11:06 AM 

Global Safety and Efficacy Study of Suprachoroidal 

Microstent Implantation as a Stand-alone Treatment for 


Presenting Author: Quang H Nguyen MD* 

Co-Author(s): William Flynn MD*, Steven Lee MD, Arvind Neelakantan 

MD*, Carl Erb MD**, Tsontcho Ianchulev MD* 

Purpose: To evaluate safety and efficacy of CyPass Micro-Stent (CM) implanted 

for stand-alone treatment of open-angle glaucoma (OAG). Methods: 

Prospective study of OAG patients implanted with CM. Adverse complications 

and change in IOP from medicated baseline. Results: Mean baseline 

IOP was 24.1 ± 8.5 mmHg and 2.3 ± 1.3 glaucoma meds (n = 289). No significant 

peri- or postoperative adverse complications. IOP lowered 24.3% (28.3 

± 8.5 mmHg to 20.6 ± 8.8 mmHg) from baseline at 12 months in hypertensive 

patients, and medications decreased 2.2 ± 1.4 to 1.6 ± 1.5. Conclusion: 

Clinical experience with the CM shows a beneficial safety profile, sustained 

IOP-lowering effect, and reduction in medication use through 12 months of 

follow-up. 

11:13 AM 


APAO PA096 

11:18 AM 

Safe Glaucoma Filtering Surgery Combined With Small- 

Incision Cataract Surgery in Primary Glaucoma With Hard 

Cataracts: Need of the Hour in Developing Countries 

Presenting Author: Rekha R Khandelwal MBBS FRCS 

Co-Author(s): Kanav Gupta MBBS, Dhananjay Raje PhD** 

Purpose: To evaluate surgical outcome of Moorefield Safe Glaucoma Filtering 

Surgery combined with Small Incision Cataract Surgery (SICS). Methods: 

SICS Trabeculectomy (n = 50) for primary glaucoma with hard cataract was 

compared with PhacoTrabeculectomy (n = 25) from January 2008 to December 

2009. Patients were followed up for 2 years. Result: Both groups were 

efficient in lowering IOP (P < .0001) and did not show major complications. 

Complete success (IOP < 21 mmHg without antiglaucoma medications) was 

observed in 66% in the study group compared to 52% in controls. Conclusion: 

Safe Glaucoma Filtering Surgery with SICS is easy, economical, and as 

effective as PhacoTrabeculectomy in lowering IOP. 

11:25 AM 


PA097 

11:30 AM 

Innovative, Minimally Invasive Glaucoma Surgery 

Technique: First Results of the AqueSys Aquecentesis 

Procedure 

Presenting Author: Inga Susann Kersten MD 

Co-Author(s): Burkhard Dick MD* 

Purpose: This prospective, open-label clinical study evaluated safety and 

effectiveness of Aquecentesis procedures in reducing IOP in glaucoma-patients. 

Methods: Safety parameters were evaluated using IOP and visual 

acuity. Effectiveness was assessed by comparing IOP values pre- to postoperatively 

continuing until Year 3, also calculating the change of antiglaucomatous 

medications. Results: The mean decrease of IOP with a mean 

preoperative IOP of 21.3 mmHg (n = 15) was -6.3 at Month 1 and -6.3 at 

Month 12 (-29% drop). The eyedrops were reduced from 2 preoperatively to 

0.7 postoperatively. Conclusion: The new Aquecentesis procedure proved to 

be a minimally invasive surgical approach with reduction of IOP ( ~30 % drop 

) and the number of meds after 12 months. 

11:37 AM 


PA098 

11:42 AM 

One-Year Results of an Intracanalicular Microstent for IOP 

Reduction in Primary Open-Angle Glaucoma 

Presenting Author: Thomas W Samuelson MD* 

Co-Author(s): Manfred Tetz MD**, Norbert Pfeiffer MD, Gabor Bernd 

Scharioth MD*, Salvatore Grisanti*, Clemens Vass Vass MD*, Marina A 

Ramirez MD** 

Purpose: To evaluate the ability of a nickel titanium microstent implanted ab 

interno in the Schlemm canal to lower IOP in open-angle glaucoma patients. 

Methods: Subjects diagnosed with mild to moderate open-angle glaucoma 

with visual field mean deviation ≥12dB were recruited from 6 centers in a 

prospective, international case series. Subjects were washed out of glaucoma 

medications prior to surgery and at 1 year follow up. Results: In 40 

treated subjects, mean (±SD) IOP was reduced from 23.8 ± 3.5 at baseline to 

18.0 ± 4.6 at 1 year (P < .05). Conclusion: An intracanalicular microstent may 

offer a durable alternative to medical therapy for IOP reduction. 

11:49 AM 




4:00 PM - 5:15 PM 

Room: S405 

Moderator: John H Kempen MD 

Panel: James Philip Dunn Jr MD, Debra A Goldstein MD 

APAO PA070 

4:00 PM 

Changing Pattern of Infectious Posterior Uveitis in Eastern 

India 

Presenting Author: Santanu Mandal MBBS 

Co-Author(s): Samar K Basak MD DNB MBBS*, Santanu Mitra MBBS 

Purpose: To evaluate the pattern of infectious posterior uveitis in Eastern 

India. Methods: Retrospective, noncomparative, interventional case series 

from a tertiary center. Review of all diagnosed cases to have posterior uve- 

162 





itis from April 2010 to March 2011. Cases with presumed infectious origin 

were further analyzed to find out the causative factors. Results: Out of 131 

new cases of posterior uveitis, 85 cases (64.9%) diagnosed to have proved 

infectious etiology. Tubercular origin was most common (59, 69.4%), with 

serpiginous-like choroiditis in 40.7% of cases. Toxoplasma being second in 

13 cases (15.3%); viral retinitis came in third with 12 cases (14.1%), parasite 

with a single case. Treatment modalities were also reviewed in all categories. 

Conclusion: Tuberculous posterior uveitis forms a major cause of all 

posterior uveitis in India. 

4:07 PM 


APAO PA071 

4:12 PM 

Choroidal Thickness in Behçet Uveitis: An Enhanced Depth 

Imaging OCT Study 

Presenting Author: Min Kim MD 

Co-Author(s): Hee Jung Kwon MD, Christopher S Lee MD, Sung Soo Kim 

MD PhD**, Sung-Chul Lee MD 

Purpose: To evaluate the choroidal thickness change during active and quiescent 

phases of Behçet’s posterior uveitis using enhanced depth imaging 

OCT (EDI-OCT). Methods: Choroidal thickness of 30 eyes with Behçet’s posterior 

uveitis (mean age: 47.03 ± 11.01 years) during active and quiescent 

phases was retrospectively compared. Results: Subfoveal choroidal thickness 

in the acute phase was significantly greater than that in the quiescent 

phase (398.77 ± 155.59 µm vs. 356.72 ± 141.09 µm; P = .004). It was also 

significantly greater than that of the 30 age, sex, and spherical equivalentmatched 

normal eyes. (259.96 ± 65.16 µm; P < .0001). Conclusion: Choroidal 

thickness measurement by EDI-OCT may be a useful, noninvasive. 

4:19 PM 


PA072 

4:24 PM 

Intravitreal and Subconjunctival Sirolimus in Patients With 

Noninfectious Uveitis: One-Year Outcome of the Sirolimus 

as Therapeutic Approach to Uveitis (SAVE) Study 

Presenting Author: Mohamed A Ibrahim Ahmed MBBCH 

Co-Author(s): Anthony Lamont Watters, Abeer Akhtar, Millena Gomes 

Bittencourt MD DOMS, Yasir Jamal Sepah MBBS, Joel Naor MD**, Naveed 

Shams MD PhD**, Ovais Shaikh, Henry Leder MD, James Philip Dunn Jr 

MD, Quan Dong Nguyen MD* 

Purpose: To evaluate safety and bioactivity of subconjunctival (SCJ) sirolimus 

and intravitreal (IVT) sirolimus in noninfectious uveitis. Methods: Thirty 

patients were randomized to receive sirolimus 352 µg IVT or 1320 µg SCJ. 

Sirolimus was administered at Days 0, 60, and 120, and then criteria-based 

retreatments were allowed up to 1 year. Results: At the end of 12 months, 

75% of subjects showed ≥ 2 steps or 1 step reduction to no VH (P < .05); 21% 

showed 1-step reduction in VH or no change. Forty percent gained ≥ 1 line 

of VA. Mean corticosteroid (CS) dose was reduced from 21 mg/day to 4 mg/ 

day; 35% discontinued CS completely. No statistical differences were found 

between study groups. Conclusion: Repeated SCJ/IVT sirolimus administrations 

appear to be safe and tolerable. Sirolimus has shown bioactivity in 

controlling noninfectious uveitis. 

4:31 PM 


PA073 

4:36 PM 

Vitreous Haze Grading: An Analysis of Outcomes in the 

Multicenter Uveitis Steroid Treatment Trial (MUST) 

Presenting Author: Janet Louise Davis MD* 

Co-Author(s): William J Feuer MS, Silvana A Madi MD, Michael M Altaweel 

MD*, John H Kempen MD*, Joyce C Schiffman MS* 

Purpose: To evaluate vitreous haze as an outcome marker in uveitis. Methods: 

Vitreous haze was graded clinically using the Nussenblatt scale or from 

fundus photographs. Results: There were 95 right eyes and 99 left eyes, 

with haze grading and baseline and 1-year acuity. Two-step improvement occurred 

in 33 eyes (17%) photographically and 26 (13%) clinically (kappa = 

.338). Two-step improvement photographically correlated with + 12.7 (±13.5) 

ETDRS letters vs. +10.3 (±10.3) letters clinically (P = .17); however, raw changes 

in photographic grades correlated better than clinical grades with vision 

improvement (P = .026). Conclusion: Two-step haze improvement occurred 

in few eyes and varied between photographic and clinical grading. Photographic 

grading correlated with improvements in vision. 

4:43 PM 


PA074 

4:48 PM 

Factors Affecting the Long-term Visual Prognosis in 

Birdshot Chorioretinopathy 

Presenting Author: Oren Tomkins 

Co-Author(s): Simon RJ Taylor MBBChir*, Susan L Lightman MBBS* 

Purpose: To ascertain the long-term prognosis of patients with birdshot 

chorioretinopathy. Methods: We retrospectively examined data from 36 patients 

with birdshot chorioretinopathy who were HLA-A29+. Results: Average 

logMAR visual acuity did not change significantly throughout follow-up 

of up to 10 years (0.24 ± 0.04 at baseline vs. 0.27 ± 0.06 at 10 years), but the 

visual acuity of patients on second-line immunosupression (94% mycophenolate 

mofetil) was on average 0.14 better than that of other patients. This difference 

was significant at 6 months (P < .0001), with a trend toward a better 

outcome at 1, 2, and 10 years. Conclusion: Our results suggest that visual 

acuity can be maintained long term, but patients on immunosuppression appear 

to have an improved outcome. 

4:55 PM 


PA075 

5:00 PM 

Autoimmune Retinopathy: Clinical Features and Prognosis 

Presenting Author: Monica D Dalal MD 

Co-Author(s): Lucia Lapenna MD, Yujuan Wang PhD, Robert B Nussenblatt 

MD, Chi-Chao Chan MD, Hatice N Sen MD 

Purpose: To delineate the clinical characteristics of autoimmune retinopathy 

(AIR). Methods: Retrospective review of 23 AIR cases with positive antiretinal 

antibody. Results: Mean follow-up was 30 months. Mean age was 

50 years old; 74% were female; 83% were white. Eighty-seven percent had 

bilateral disease; the most common symptom was decreased vision. All had 

reduced amplitudes on ERG, cones more than rods. Ninety-six percent demonstrated 

an abnormal visual field, 13% had macular edema, and 48% had a 

history of autoimmune disease. Sixty-five percent were treated with immunosuppressives, 

of which 67% remained stable and 27% worsened. Conclusion: 

Clinical features along with ERG and visual fields are helpful in diagnosing 

AIR. Immunosuppressive therapy can help stabilize visual function. 





163



5:07 PM 



Moderator: Sophia Mihe Chung MD 


2:30 PM - 4:00 PM 

Room: S405 

Panel: Marilyn C Kay MD, Reid A Longmuir MD, Roger E Turbin MD 

PA065 

2:30 PM 

Evaluation of Macular Ganglion Cell Complex and Retinal 

Nerve Fiber Layer Thickness Measured with Fourier Domain 

OCT in Nonarteritic Anterior Ischemic Optic Neuropathy 

Presenting Author: Saban Gonul DOMS 

Co-Author(s): Sansal Gedik MD**, Bengu Ekinci Koktekir MD, Berker Bakbak 

MD 

Purpose: To evaluate macular ganglion cell complex (GCC) and retinal nerve 

fiber layer (NFL) thickness measured with Fourier domain OCT (FD-OCT) in patients 

with nonarteritic anterior ischemic optic neuropathy (NAION). Methods: 

Eleven eyes of 10 patients with NAION and 15 eyes of 15 age-matched 

healthy subjects were enrolled in to this study. Results: Differences in RNFL 

and GCC parameters between normal and NAION eyes were significant (for 

all comparisons, P < .001). Significant correlations were found between GCC 

(Average) and RNFL (Average) (r = 0.82; P < .0001). Conclusion: Macular GCC 

thickness was comparable to RNFL thickness in NAION. 

2:37 PM 


PA066 

2:45 PM 

Recovery of Vision in Leber Hereditary Optic Neuropathy 

Despite Progressive Retinal Nerve Fiber Layer Loss 

Presenting Author: John R Guy MD 

Co-Author(s): Byron L Lam MD*, William J Feuer MS, Vittorio Porciatti, Ruth 

Vandenbroucke, Joyce C Schiffman MS* 

Purpose: To report 18-month serial data on 49 of 96 subjects with G11778A 

mtDNA in the LHON Gene Pretreatment Trial. Methods: Visual function, OCT, 

and pattern ERG were done every 6 months. Results: Acuity,fields, and pattern 

ERG remained markedly impaired in most affected subjects. In asymptomatic 

carriers only the pattern ERG dropped from 1.00 µV at entry to 0.79 µV 

(P = .001), with acuity reduced 1 line relative to unaffected eyes of the ONTT, 

P = .003. Acuity improved in 6 eyes of 5 affected subjects, with a mean 10 

ETDRS letters (20/640) baseline to 58 letters (20/70). One subject improved 

to > 20/40. Surprisingly, vision improved despite progressive retinal nerve 

fiber layer (RNFL) loss (61 µm). Conclusion: Rare spontaneous recovery in 

the face of progressive RGC loss provides hope for most affected subjects 

(mean RNFL = 54 µm, ETDRS = 10) without recovery that gene therapy may 

rescue vision. 

2:52 PM 


PA067 

3:00 PM 

Five- to 7-Year Longitudinal Data for Vision and OCT Retinal 

Nerve Fiber Layer Thickness in MS 

Presenting Author: Stephen Moster 

Co-Author(s): James Wilson, Kristin Galetta, Reiko Sakai, Steven L Galetta 

MD*, Elliot Frohman MD**, Peter Calabresi MD*, Maureen G Maguire 

PhD*, Laura J Balcer MD MSC** 

Purpose: We examined peripapillary retinal nerve fiber layer (RNFL) thickness 

up to 7 years in a multicenter collaborative MS cohort. Methods: 196 

MS patients underwent Stratus OCT measurement of RNFL thickness, lowcontrast 

acuity (2.5%, 1.25%), and visual acuity assessments at baseline and 

6-12-month intervals. Results: In MS, progressive RNFL thinning continued 

through 6-7 years of follow-up. Average thinning was 1.9 microns per year of 

follow-up (P < .001). Eyes with clinically significant visual loss showed greater 

RNFL thinning over time compared to eyes with stable vision (P ≤ .001). 

Conclusion: Progressive RNFL thinning occurs during long-term follow-up of 

patients with MS. This is observed even in the absence of ON, and is associated 

with clinically significant visual loss. 

3:07 PM 


APAO PA068 

3:15 PM 

Evaluation of Cortical Activation Patterns on Color Vision 

Using Functional MRI Among Individuals With Normal 

Vision 

Presenting Author: Sourabh Sharma Jr 

Co-Author(s): Shikha Gupta MBBS, Senthil S Kumaran MD PhD, Tanuj Dada 

MD**, Supriyo Ghose BMBS MD DOMS 

Purpose: To evaluate cortical activation patterns on color vision using functional 

MRI (fMRI) among normal individuals. Methods: Ten subjects normal 

on color vision testing were enrolled into the study. Visual stimulation (cardinal 

colors and Ishihara plates) was provided using 1.5 T MRI system. The 

outcome measures were visual functions and blood oxygen level dependent 

(BOLD) activation on fMRI. Results: Bilateral occipital BOLD activation with 

fusiform was observed on stimulation of either eye with cardinal colors. 

No activation was seen in normal subjects when they were shown Ishihara 

plates with respect to cardinal colors. Conclusion: Occipital lobes along 

with fusiform gyrus seem to be involved in color processing in normal individuals. 

3:22 PM 


APAO PA069 

3:30 PM 

Optical Aberrations: A New Trigger for Migraine? 

Presenting Author: Kareeshma N Wadia MBBS 

Co-Author(s): Rohit Shetty MD MBBS, Sharon D’Souza MD MBBS** 

Purpose: Study of the role of optical aberrations as a possible trigger for 

migraine. Methods: Light is known to be a triggering factor for migraine. Optical 

aberrations of the eye may induce scattering of light, which in turn may 

trigger a migraine in predisposed patients. Optical aberrations of 30 such patients 

were studied using Optical Path Difference III Scan, and compared with 

corresponding values in a normal group. Patients were screened for migraine 

based on a questionnaire (National Institute of Health). Results: Patients in 

the migraine cohort had increased optical aberrations as compared to normal. 

Higher-order aberrations were greater, with 59% of these patients having 

trefoil as a dominant aberration. Conclusion: Increased optical aberrations 

could be a possible trigger for light-induced migraine. 

164 





3:37 PM 



Moderator: Paul T Finger MD 


4:00 - 4:40 PM 

Room: S405 

Panel: Shahar Frenkel MD, Jonathan Kim MD, Prithvi Mruthyunjaya MD 

PA024 

4:00 PM 

Long-term Follow-up of Patients Treated With Intra-arterial 

Cytoreductive Chemotherapy for Lacrimal Gland Adenoid 

Cystic Carcinoma 

Presenting Author: Andrea N Kossler MD 

Co-Author(s): Pasquale Benedetto MD**, William J Feuer MS, David T Tse 

MD FACS* 

Purpose: To evaluate the long-term success of intra-arterial cytoreductive 

chemotherapy (IACC) as an adjunct to surgery and chemoradiation. Methods: 

A retrospective interventional case series. Results: Twenty patients 

were treated with IACC, followed by exenteration and chemoradiotherapy, 

with a follow-up range of 17-284 months (mean: 97.75 months). The carcinoma 

cause-specific survival rate was 90%. Two patients died of disease; 

however, one of these patients did not complete the treatment protocol. An 

additional patient developed metastatic disease. The longest disease-free 

survival duration since the start of IACC is 23.7 years. Conclusion: IACC is 

effective in minimizing recurrence and improving overall disease-free survival 

in lacrimal gland ACC. 

4:07 PM 


PA025 

4:12 PM 

Socioeconomic Impacts in Management of Advanced 

Intraocular Unilateral Retinoblastoma in a Developing 

Country 

Presenting Author: Sameh E Soliman MD 

Co-Author(s): Helen Dimiras MD**, Ahmed Souka MD, Brenda L Gallie MD* 

Purpose: To compare socioeconomic impacts (SIs) of trial ocular salvage for 

International Intraocular Retinoblastoma Classification (IIRC) Group C and D 

unilateral retinoblastoma (URB) to IIRC Group E eyes that are primarily enucleated. 

Methods: Records of 64 URB cases over 6 years were retrospectively 

reviewed, and data were collected on IIRC group, treatment course, 

and ocular outcome. A score was created using 6 SIs aspects (medical, financial 

burden, financial outcome, social risk, psychological risk, or cancer risk), 

and each aspect was given 0-3 levels to score. Results: Group E eyes had 

a mean score of 5/18 with 0% salvage (0/27) (P < .001). Group D eyes had a 

mean score higher than 12/18 and ocular salvage of 11.1% (3/27) (P < .001). 

Group C eyes had a mean score of 7/18 with 66.6% salvage (4/6). Conclusion: 

Primary enucleation has better SIs than trial salvage in Group D eyes. 

4:19 PM 


PA026 

4:24 PM 

Diffuse vs. Nondiffuse, Small (≤ 3 Millimeters Thickness) 

Choroidal Melanoma: Comparative Analysis in 1751 Cases 

Presenting Author: Carol L Shields MD 

Co-Author(s): Swathi Kaliki MD, Minoru Furuta MD, Jerry A Shields MD 

Purpose: To determine prognosis of diffuse vs. nondiffuse melanoma. 

Methods: Chart review. Results: Of 1751 patients with small choroidal 

melanoma (< 3 mm thickness), 297 (17%) were diffuse and 1454 (83%), nondiffuse. 

Features with statistical differences (diffuse vs. nondiffuse) included 

mean distance to optic disc (3 mm vs. 4 mm), tumor base (12 mm vs. 8 mm), 

and tumor thickness (1.9 mm vs. 2.5 mm). Using Kaplan-Meier estimates, 

melanoma-related metastasis (diffuse vs. nondiffuse) was 8% vs. 4% at 5 

years, 17% vs. 10% at 10 years, and 19% vs. 16% at 15 years (P = .0344). 

Conclusion: Diffuse melanoma showed higher probability of metastasis and 

death than nondiffuse melanoma. 

4:31 PM 




4:40 PM - 5:30 PM 

Room: S405 

Moderator: Mark A Alford MD 

Panel: Erin M Shriver MD, Julie A Woodward MD 

PA027 

4:40 PM 

Prostaglandin Analogues Induce Specific Cellular Changes 

in Orbital Fat 

Presenting Author: Edward Wladis MD* 

Co-Author(s): Hung Ngoc Le**, Dorina Avram PhD** 

Purpose: To characterize the cellular signals by which prostaglandin analogues 

(Pas) induce orbital adipocyte (OA) atrophy, sulcus deepening, and enophthalmos. 

Methods: A cell-based reporter array measured the transcriptional 

activity of 45 signaling pathways in 100,000 control Oas and 100,000 

Oas that were treated with Pas. Results: Transcriptional activity increased 

in hedgehog, interferon regulation, hepatocyte nuclear factor-4, interferong, 

and notch pathways, and decreased in heavy metal stress, Kruppel-like 

factor-4, and c-Myc pathways. Conclusion: Pas induce complex signaling 

effects in Oas. These mechanisms are novel targets in the management of 

thyroid orbitopathy, cosmesis, and the avoidance of glaucoma medication 

side effects. 

4:47 PM 


PA028 

4:52 PM 

Concomitant Autoimmune Diseases in Thyroid-Associated 

Ophthalmopathy 

Presenting Author: Katharina A Ponto MD 

Co-Author(s): Alireza Mirshahi MD*, Susanne Pitz MD**, Norbert Pfeiffer 

MD, George J Kahaly MD 

Purpose: To assess the prevalence of concomitant autoimmune diseases in 

patients with thyroid-associated ophthalmopathy (TAO). Methods: We retrospectively 

analyzed the medical records of 1091 patients with autoimmune 

thyroid diseases (AITD). Results: 334 patients (30.6%) had TAO (304 [91%] 





165



had Graves disease) and 757 (69.4%) had AITD only. Autoimmune gastritis 

and celiac disease were more prevalent in TAO than in AITD (44 [13.2%] 

vs. 11 [1.5%], P < .001; 32 [9.6%] vs. 23 [3.2%], P = .001). Conversely, type 

I diabetes, Addison disease, rheumatoid arthritis, and vitiligo were less frequent 

in patients with TAO than without (21 [6.3%] vs. 93 [12.6%], P = .002; 

1 [0.3%] vs. 21 [3%], P = .005; 0 vs. 26 [3.5%], P = .001; 0 vs. 37 [4.9%], P < 

.001). Conclusion: Screening for gastrointestinal autoimmune diseases is 

recommended in TAO. 

4:59 PM 


PA029 

5:04 PM 

Long-term Success Rate of Endoscopic Laser-Assisted 

Dacryocystorhinostomy for Treatment of Nasolacrimal Duct 

Obstruction 

Presenting Author: Jorge G Camara MD* 

Co-Author(s): John Kenneth D Lagunzad MD, Orestes Rafael Lopez Santos 

MD 

Purpose: To report the long-term success rate of endoscopic laser-assisted 

dacryocystorhinostomy (ELA-DCR) in the treatment of primary acquired nasolacrimal 

duct obstruction. Methods: Retrospective, consecutive noncomparative 

case series of 2080 ELA-DCR procedures with follow-up period of 

at least 1 year. Success was defined as absence of epiphora and/or patency 

to lacrimal irrigation. Results: 2007 cases (96.5%) had absence of epiphora 

and were patent to lacrimal irrigation. Seventy-three cases (3.5%) had symptomatic 

tearing and/or lacked patency to irrigation. Conclusion: This large 

series with long-term follow-up showed a 96.5% success rate of ELA-DCR for 

the treatment of nasolacrimal duct obstruction. 

5:11 PM 


PA030 

5:16 PM 

Surgical Outcomes of Box-Shaped Frontalis Sling With 

Prolene in French Canadians With Oculopharyngeal 

Muscular Dystrophy 

Presenting Author: Liat Attas-Fox MD 

Co-Author(s): Xi Huang MD, Evan Kalin-Hajdu MD, Francois Codere MD 

Purpose: Oculopharyngeal muscular dystrophy (OPMD) is common among 

French Canadians. Due to its progressive nature, surgical correction should 

address the pathophysiology of the disease. Methods: A retrospective chart 

review was conducted on patients who had a bilateral box-shaped frontalis 

sling with prolene for ptosis due to OPMD between 2006 and 2011. Results: 

Thirty-two patients had the procedure. The average length was 35 minutes, 

resulting in an average elevation of 3.1 mm and excellent contour. Five patients 

had minor lagophthalmos, 1 of which had severe keratitis and only 1 

required a revision for recurrent ptosis. Conclusion: This is a simple and 

effective primary technique that results in good eyelid height and contour, 

with minimal keratitis in OPMD patients. 

5:23 PM 


Pediatric Ophthalmology, 

Strabismus 


8:30 - 10:15 AM 

Room: S405 

Moderator: Terri L Young MD 

Panel: Hilda Capo MD, Michael F Chiang MD, Kenneth J Hoffer MD FACS 

APAO PA084 

8:30 AM 

Safety, Efficacy, and Adverse Events of Intravitreal 

Bevacizumab Injection Without Laser for ROP: Six-year 

Follow-up Results With Anatomical, Functional, OCT, and 

Neurodevelopmental Analysis 

Presenting Author: Alay S Banker MD 

Co-Author(s): Deepa Banker**, Khushboo Patel 

Purpose: To evaluate 6-year safety and efficacy of intravitreal bevacizumab 

(IB) in retinopathy of prematurity (ROP). Methods: Prospective study of 137 

eyes with ROP treated with IB without laser. Results: ROP regression, OCT, 

functional evaluation (electroretinogram [ERG], visual evoked potential [VEP]) 

and neurodevelopmental anlysis (developmental quotient [DQ] score) were 

performed at 6 years. Results: All eyes showed regression of ROP and normal 

macula on OCT. Eight of 137 (6%) had persistent peripheral avsacular 

retina. There was normal retinal function (normal-VEP and ERG) and normal 

neurodevelopment score (normal DQ). Conclusion: Our long-term follow-up 

study shows that IB seems to be safe and effective in treatment of ROP. 

8:37 AM 


PA085 

8:42 AM 

Angiographic Sequence of Vascular Changes in 

Spontaneously Regressed ROP Stage 2 

Presenting Author: Maria Ana Martinez-Castellanos MD 

Co-Author(s): Gerardo Garcia-Aguirre MD, Fernando Schoonewolff III, 

Virgilio Morales-Canton MD*, Jose Dalma MD* 

Purpose: To describe our findings by fluorescein angiography (FA) in spontaneously-regressed 

stage 2 ROP. Methods: Retrospective case series of Fas 

of 20 eyes (RetCam II), and macular OCT (iVUE) images. Follow-up was every 

2 weeks until reaching 52 weeks corrected age. Results: In the demarcation 

line we observed leakage, capillary free areas, vessel dilatation, and 

irregular branching. As the ROP regressed, distal vessels had tortuosity and 

perivascular leakage. No OCT abnormalities were observed in zones of angiographic 

leakage. Once the vessels reached the ora, abnormalities regressed. 

Conclusion: We were able to distinguish angiographic features of ROP regression. 

Our findings may help further the understanding of the patterns of 

retinal vascular development. 

8:49 AM 


166 





APAO PA086 

8:54 AM 

Cut and Paste for Muscle Recession in Squint Surgery 

Presenting Author: Rakesh Kumar Bansal FRCS(ED) 

Co-Author(s): Pratik Topiwala MBBS**, Pratik Topiwala MBBS**, Arun K 

Jain MD 

Purpose: To study the efficacy and safety of fibrin glue for muscle recession 

in patients undergoing squint surgery. Methods: Fibrin Glue (Baxter) was 

used for muscle recession in patients of esotropia and exotropia. The muscle 

was held with forceps and kept in contact with the sclera until reattachment 

was achieved. Resection was done as usual. Conjunctiva was closed with 

the same fibrin glue. Results: There were a total of 27 recessions (including 

bimedial recessions) in 19 patients. Eleven patients had esotropia, and 

8 had exotropia. Average time for reattachment was 1.056 minutes. After 

a minimum follow-up of 3 months, 16 patients achieved orthotropia, 2 had 

residual esotropia, and 1 patient developed consecutive extropia. There was 

no complication from use of fibrin glue. Conclusion: Fibrin glue is safe and 

effective for muscle recession. 

9:01 AM 


APAO PA087 

9:06 AM 

Secondary IOL Implantation in Children: A Decade Long 

Analysis of Safety and Visual Outcomes 

Presenting Author: Ramesh Kekunnaya MBBS MD 

Co-Author(s): Bhamy Hariprasad Shenoy, Amit Gupta MD, Virender 

Sachdeva MS DNB, Vaibhev Mittal MS 

Purpose: To study safety and visual outcome in children undergoing secondary 

IOL implantation. Methods: Retrospective, interventional case series 

including 174 eyes of 104 children. Results: 174 eyes of 104 children (M:F, 

68:36) underwent secondary IOL implantation at 6.08 ± 3.75 years, 5.6 + 2.8 

years after primary cataract surgery. Mean logMAR visual acuity improved 

from 1.08 ± 0.655 preoperatively to 0.55 ± 0.51 postoperatively (P < .0001). 

Complications included wound leak (2), hyphema (2), secondary membrane 

formation (15), glaucoma (11), IOL decenteration (10), and optic capture (15). 

Conclusion: Secondary IOL in children is a safe procedure and leads to significant 

improvement in visual acuity. 

9:13 AM 


PA088 

9:18 AM 

Comparison of IOL Calculation Formulae for Eyes of Infants 

Enrolled in the Infant Aphakia Treatment Study 

Presenting Author: Deborah K VanderVeen MD 

Co-Author(s): Rupal H Trivedi MBBS MS*, Azhar Nizam*, Michael J Lynn*, 

Scott R Lambert MD* 

Purpose: To evaluate the accuracy of common IOL calculation formulas 

for infant eyes. Methods: Forty-three eyes with in-the-bag placement of 

a SN60AT IOL were studied by entering axial length, keratometry, and IOL 

power into Holladay 1, Holladay 2 (33 eyes), Hoffer Q, SRK II, and SRK T 

formulae. Prediction error (PE: predicted - actual spherical equivalent 1 month 

postoperative refraction) was analyzed based on patient age and eye characteristics, 

using generalized linear mixed models. Results: SRK T gave the 

lowest mean absolute PE (1.4 D ± 1.1 D) and mean PE (0.3 D ± 1.8 D) (P < .05 

in all pairwise comparisons). PE within 1.0 D was obtained most often with 

Holladay 1 (45%) and SRK T (44%). Conclusion: SRK T should be considered 

for IOL power calculation in infants. 

9:25 AM 


PA089 

9:30 AM 

Recurrent Pediatric Retinal Detachment After Successful 

Initial Repair 

Presenting Author: Laura A Vickers MD 

Co-Author(s): Joseph N Martel MD, Sandra Stinnett, Prithvi Mruthyunjaya 

MD 

Purpose: To identify factors associated with redetachment after initial pediatric 

retinal detachment (RD) repair. Methods: Retrospective review of 

175 eyes of 161 pediatric patients with repair of retinal detachment (RD), 

excluding serous detachment and ROP. Results: 126, 26, and 23 eyes had 

rhegmatogenous (RRD), tractional (TRD), and combined (RRD/TRD) RD respectively. 

Repair with scleral buckle and vitrectomy (PPV) was performed in 

64, 15, and 57% of RRD, TRD, and RRD/TRD eyes. Seventy-one eyes (39%) 

re-detached at a mean 109 days. Redetachment occurred later in RRD and 

RRD/TRD, compared to TRD (P = .002). High rates of redetachment occurred 

with prior trauma or glaucoma surgery. Conclusion: Retinal redetachment in 

pediatric patients can occur later than reported in adults. RD type, trauma, 

and glaucoma surgery are risk factors. 

9:37 AM 


PA090 

9:42 AM 

Magnetic Resonance Diagnosis of Hypopituitarism in 

Children With Optic Nerve Hypoplasia 

Presenting Author: Paul H Phillips MD 

Co-Author(s): Raghu H Ramakrishnaiah MD**, Julie B Shelton MD** 

Purpose: To determine reliability of neurohypophyseal abnormalities on 

magnetic resonance imaging (MRI) for detection of hypopituitarism in children 

with optic nerve hypoplasia (ONH). Methods: Retrospective analysis of 

102 children with ONH who had MRI and endocrinologic evaluation. Results: 

Neurohypophyseal abnormalities were detected in 26 of 27 children with hypopituitarism 

(sensitivity = 96%). A normal neurohypophysis occurred in 69 of 

72 children with normal endocrine function (specificity = 92%). Conclusion: 

Neurohypophyseal abnormalities on MRI are sensitive and specific indicators 

of hypopituitarism in children with ONH. 

9:49 AM 


PA091 

9:54 AM 

Treatment of Group D Retinoblastoma With Intravenous 

Chemoreduction vs. Intra-arterial Chemotherapy 

Presenting Author: Enzo M Fulco MD 

Co-Author(s): Carolina Alarcon MD, Carlos G Bianciotto MD, Shripaad Y 

Shukla MD, Carol L Shields MD 

Purpose: To evaluate efficacy of systemic chemoreduction (CRD) vs. intraarterial 

chemotherapy (IAC) for Group D retinoblastoma. Methods: Retrospective 

study. Results: Fifty-eight patients were treated with CRD, while 8 

received IAC. Baseline features included (CRD vs. IAC): mean patient age in 

months (11.7 vs. 17.5), unilateral involvement (43.1% vs. 100%), mean tumor 

diameter in millimeters (15.3 vs. 13.1). Mean number of treatment cycles was 

6 vs. 2.6 (CRD vs. IAC). Tumor control was achieved in 94% of eyes in the CRD 

group (mean follow-up: 62 months) vs. 100% in the IAC group (mean follow 





167



up: 15 months). Conclusion: Tumor control rate was similar between the 

two groups; however, IAC required fewer treatment cycles. Longer follow-up 

for IAC is necessary to determine the treatment efficacy 

10:01 AM 




2:00 PM - 3:40 PM 

Room: S405 

Moderator: Karl G Stonecipher MD 

Panel: Rajesh K Rajpal MD, Elizabeth Yeu MD, Sonia H Yoo MD 

PA016 

2:00 PM 

Survey Study Comparing Satisfaction With LASIK and 

Contact Lenses for Vision Correction 

Presenting Author: Francis W Price Jr MD* 

Co-Author(s): Marianne O Price PhD* 

Purpose: To compare patient satisfaction with LASIK and contact lenses. 

Methods: This prospective, multicenter study surveys participants annually 

for 4 years to assess visual satisfaction, side effects, and complications. 

Baseline refraction and LASIK treatment data are recorded. Participants are 

18-60 years old, with no keratoconus, abnormal topography, or multifocal corrections. 

Results: To date, 653 subjects are enrolled in the LASIK arm and 

546 in the contact lens arm. Median age is 34 years, and median spherical 

equivalent is -3.5D (range: -11 D to +4 D). Conclusion: This study compares 

2 widely accepted methods of vision correction to set an appropriate benchmark 

for LASIK. Both treatments entail some risk but provide more functional 

and aesthetic visual correction than glasses. 

2:07 PM 


APAO PA017 

2:12 PM 

Factors Related to the Late Myopic Regression After LASIK: 

A 5-10 Year Follow-up Study 

Presenting Author: Osamu Hieda MD 

Co-Author(s): Kanae Miyamoto MD**, Shigeru Kinoshita MD* 

Purpose: To analyze factors related to long-term refractive change after 

LASIK between 5-10 years postoperatively. Methods: This retrospective 

study included 61 eyes of 35 patients who underwent myopic LASIK. Multiple 

linear regression analysis was used to examine factors associated with 

late regression, in which the independent variables were the changes in axial 

length, central corneal power, and internal higher-order aberration, between 

5-10 years postoperatively. Results: Corneal power and internal higher-order 

aberration changes showed a significant negative correlation with late regression 

(P < .001). Conclusion: Late regression is influenced not only by 

corneal curvature but also by lens change. 

2:19 PM 


PA018 

2:24 PM 

Screening for Ectasia Risk Using Placido and Tomographic 

Indices: Validation of an Artificial Intelligence Scoring 

System 

Presenting Author: Alain Saad MD* 

Co-Author(s): Damien Gatinel MD* 

Purpose: To evaluate the accuracy of a new objective method for the detection 

of forme frustre keratoconus (FFKC). Methods: 418 topographies were 

retrospectively classified as “Normal” or “FFKC” by a refractive surgeon, then 

by an objective automated system using discriminant analysis of selected 

Placido and tomography parameters. The concordance between the objective 

and the subjective classification was assessed by receiver operating 

characteristic curves. Results: The sensitivity and specificity of the scoring 

system were 96% and 97%, respectively. In 12 cases there was discordance 

between the 2 classifications. Conclusion The combination of Placido and 

tomography parameters can create an accurate artificial intelligence for the 

detection of FFKC. 

2:31 PM 


PA019 

2:36 PM 

Incidence of Microbial Keratitis Following Refractive 

Surgery 

Presenting Author: Vasudha A Panday MD 

Co-Author(s): Daniel R Lamothe MD, James R Townley MD, Matthew C 

Caldwell MD** 

Purpose: To determine the incidence and to identify trends of post-refractive 

surgery microbial keratitis at a military (USAF) laser center over the last 7 

years. Methods: Retrospective review of all refractive surgery cases completed 

from January 2005 to December 2011. A total of 24,446 total procedures, 

including both PRK and LASIK. Any diagnosis of microbial keratitis was 

identified and a chart review completed. Results: One case of Gram-positive 

bacterial, with secondary fungal, infection was identified for an incidence of 

0.0041%. Conclusion: The rate of infection reported in the literature varies 

between 0.02% and 1.5%. The rate seen in this review is significantly lower. 

Refractive surgery, whether PRK or LASIK, is a safe means of correcting refractive 

error. 

2:43 PM 


PA020 

2:48 PM 

Development of an Optimal Wavefront-Guided LASIK 

Nomogram for Myopia 

Presenting Author: Steven C Schallhorn MD* 

Co-Author(s): Jan A Venter MD 

Purpose: To develop an effective nomogram to improve outcomes. Methods: 

An iterative series of nomogram models was constructed with multiregression 

analysis from 61,543 consecutive procedures. Results: The 

most comprehensive model was estimated to improve refractive accuracy to 

87.5% (3-month MSE within 0.50 D). However, a much simpler model yielded 

similar results (87.4%) and consisted of (1) selecting a wavefront capture 

with the sphere within 0.75 D of manifest, (2) an adjustment to match the 

treatment sphere to manifest, and (3) a +5% boost. Conclusion: Through 

an iterative process using a substantial dataset of wavefront-guided procedures, 

a nomogram was developed that derived the greatest projected gain 

in outcomes with the least complicated approach. 

168 





2:55 PM 


PA021 

3:00 PM 

Better Than 20/20: A Comparison of the Speed of Visual 

Recovery Following LASIK With 5 Different Lasers 

Presenting Author: Daniel S Durrie MD* 

Co-Author(s): Jason P Brinton MD, Michele R Avila OD 

Purpose: To prospectively evaluate speed of visual recovery (SOVR) following 

LASIK. Methods: LASIK was performed on 104 eyes of 52 patients using 

femtosecond lasers from Ziemer, IntraLase, and Alcon and excimer lasers 

from AMO and Alcon. Monocular and binocular uncorrected distance visual 

acuity and contrast sensitivity (CSF) were measured immediately after surgery 

and at 30 minutes, 1, 2, and 4 hours, 1 day, and 1 month post-surgery. 

Results: At 1 day, 96% of eyes were 20/20 and 98% of patients were 20/16 

O.U. At 1 month, 100% of patients were 20/20, 92% were 20/16, and 66% 

were 20/12.5. At 1 month there was a significant improvement in CSF at 

all spatial frequencies and within each laser cohort. Conclusion: Modern 

LASIK offers rapid SOVR as well as improvement in CSF across a spectrum 

of laser platforms. 

3:07 PM 


PA022 

3:12 PM 

The Use of Point Spread Function Technology in Subjective 

Visual Assessment 

Presenting Author: Alison N Gordon MD 

Co-Author(s): David I Geffen OD* 

Purpose: To assess the initial user experience of a new refraction system 

that utilizes point spread function (PSF) technology compared to refraction 

using a standard phoropter. Methods: Standard manifest refractions were 

performed using the PSF Refractor (Vmax Vision; Maitland, Flor., USA) and 

a phoropter at 5 clinical sites. Results: 900 patients were included in the 

analysis. When compared to a standard phoropter manifest refraction, the 

PSF refractor obtained equal or better visual acuity. Results: 63% and 28%, 

respectively (P < .001). Conclusion: This new tool for subjective refraction 

provides better or equal results in terms of accuracy and reliability in refractive 

end points. 

3:19 PM 


APAO PA023 

3:24 PM 

Corneal Inlay Implantation for the Treatment of Presbyopia: 

5500 Cases 

Presenting Author: Minoru Tomita MD PhD* 

Co-Author(s): Toru Nakamura MD, Satoshi Yukawa MD 

Purpose: To evaluate use of a corneal inlay to treat presbyopia in ametropic 

and prior-LASIK patients. Methods: A corneal inlay was implanted monocularly 

in 5500 patients either with LASIK (SIM) or in a pocket interface 

below the prior LASIK flap (PL). Uncorrected (U) distance (D) and near (N) 

visual acuities (VA) were evaluated at 6 months. Results: At 6 months, mean 

UDVA and UNVA for the SIM group improved to 20/20 and J2 (P < .0001) from 

20/125 and J6 at preop. For the PL group, mean UDVA and UNVA changed 

from 20/16 and J9 to 20/20 and J2 (P < .0001) at 6 months. Conclusion: 

Implantation of a corneal inlay improves UNVA and maintains good UDVA in 

ametropic and post-LASIK presbyopes. 

3:31 PM 



Monday, Nov.12 

Part I, 2:00 PM - 3:40 PM 

Room: S406B 

Moderator: Srinivas R Sadda MD 

Panel: Sophie J Bakri MD, Mathew W MacCumber MD PhD, Carl D Regillo MD 

FACS 

PA048 

2:00 PM 

Intravitreal Aflibercept Injection for Macular Edema 

Secondary in Central Retinal Vein Occlusion: Results of the 

Phase 3 GALILEO Study 

Presenting Author: Jean-Francois Korobelnik MD* 

On behalf of GALILEO Investigators 

Purpose: To evaluate the efficacy and safety of intravitreal aflibercept (IAI) 

vs. sham. Methods: In this double-masked study, 177 patients were randomized 

to 2-mg IAI or sham every 4 weeks. Weeks 24 (primary analysis) to 

52, the IAI group received IAI or sham as needed; the sham group received 

sham every 4 weeks. Results: At Week 52, 60.2% of IAI patients vs. 32.4% 

of sham group patients gained ≥ 15 letters (P = .0004). IAI patients gained 

16.9 (mean) letters vs. 3.8 of sham group patients (P < .0001). Most common 

ocular adverse events were macular edema, increased IOP, and eye pain. 

Conclusion: Patients receiving IAI had considerable and sustained improvements 

in visual acuity after 1 year of treatment. 

2:07 PM 


PA049 

2:12 PM 

One-Year Results of the Phase 3 COPERNICUS Study: 

Intravitreal Aflibercept Injection in Central Retinal Vein 

Occlusion 

Presenting Author: David Brown MD FACS* 

On behalf of COPERNICUS Investigators 

Purpose: To assess the efficacy and safety of intravitreal aflibercept (IAI). 

Methods: Patients received 6 monthly injections of 2-mg IAI (114) or sham 

(73). From Week 24, both groups received 2 mg IAI as needed. Results: At 

Week 24, 56.1% of IAI group patients gained ≥ 15 letters vs. 12.3% of sham 

group patients (P < .001). At Week 52, 55.3% of IAI group patients gained ≥ 

15 letters vs. 30.1% of sham group patients (P < .001). At Week 52, IAI group 

gained 16.2 (mean) letters vs. 3.8 for sham (P < .001). Most common adverse 

events were conjunctival hemorrhage, visual acuity (VA) reduced, and eye 

pain. Conclusion: VA improvements at Week 24 for IAI group treated with 

2q4 were largely maintained at Week 52 with less frequent dosing. 

2:19 PM 






169



PA050 

2:24 PM 

Integrin Peptide Therapy: The Latest Human Clinical Update 

Presenting Author: Baruch D Kuppermann MD PhD* 

Co-Author(s): David S Boyer MD*, Peter A Campochiaro MD*, Hugo Quiroz- 

Mercado MD*, Vicken H Karageozian MD*, Hampar Karageozian*, John 

Park, Lisa Karageozian*, Marc Kirshbaum JD* 

Purpose: ALG-1001 inhibits integrin receptors and arrests neovascularization 

meditated by avB3, avB5 and a5B1 integrin sites. The study objective 

was to evaluate the safety of intravitreal ALG-1001 in humans with diabetic 

macular edema (DME). Methods: Fifteen subjects with advanced DME completed 

this open label study. Three monthly injections of 2.5-mg ALG-1001 

were given; subjects were followed for an additional 3 months. Results: 

There were no serious adverse effects related to study drug. Eight of 15 subjects 

reported a ≥ 3 line increase in BCVA after receiving 3 injections, with up 

to 80% reduction in central macular thickness (CMT) on OCT. Conclusion: 

ALG-1001 was well tolerated and produced a clinically significant indicator of 

efficacy, with 53% of subjects showing signficant improvement in BCVA and 

OCT CMT that lasted 90 days past the last intravitreal treatment. 

2:31 PM 


APAO PA051 

2:36 PM 

RESTORE 36-Month Extension Study: Impact of Ranibizumab 

on Patient-Reported Near and Distance Visual Function in 

Diabetic Macular Edema 

Presenting Author: Paul Mitchell MD PhD* 

Co-Author(s): Jennifer Petrillo PhD**, Cheryl Coon PHD*, Alberto Ferreira 

PhD*, Neil M Bressler MD* 

Purpose: To assess the impact of ranibizumab on patient-reported visual 

function in diabetic macular edema (DME) with visual impairment in RE- 

STORE up to 36 months. Methods: Mean National Eye Institute Visual 

Function Questionnaire (VFQ-25) change was evaluated after randomization 

to 0.5-mg ranibizumab monotherapy ® , combined 0.5-mg ranibizumab + laser 

(R+L), or laser monotherapy for 12 months followed by ranibizumab for all 

groups. Results: Month 12 improvements were maintained to Month 36 on 

subscales for near (M12, M36: 10.7, 12.2 ® , and 9.3, 7.8 [R+L]) and distance 

activities (M12, M36: 6.4, 2.6 ® , and 4.5, 4.1 [R+L]). Conclusion: Visual function 

gains from baseline to Month 12 were maintained at Month 36 in ranibizumab 

groups. 

2:43 PM 


PA052 

2:48 PM 

12-Month Preliminary Results of the READ 3 Study: 

Ranibizumab for Edema of the Macula in Diabetes 

Presenting Author: Lawrence S Halperin MD FACS 

Co-Author(s): Afsheen Khwaja MD 

Purpose: To assess BCVA and central subfield thickness (CSFT) with 6-month 

follow-up in READ 3, a phase 2, randomized trial of 2.0-mg and 0.5-mg ranibizumab 

(RBZ) in diabetic macular edema (DME). Methods: 152 study eyes 

were randomized to 2.0-mg or 0.5-mg RBZ monthly. Results: The baseline 

mean BCVA was 20/63 in the 2.0-mg RBZ group and 20/80 in the 0.5-mg RBZ 

group. CSFT was 438µm and 441µm. At Month 12, mean change in BCVA was 

+7.39 ETDRS letters and + 10.88 letters (P = .03). CSFT decreased by -175.33 

µm and -168.09 µm for the 2.0-mg and 0.5-mg groups, respectively (P = .76). 

There were no serious adverse events. Conclusion: Treatment of DME with 

0.5-mg RBZ for 12 months improves BCVA more than 2.0-mg RBZ; reduction 

in CSFT is similar to 2.0-mg RBZ. Long-term analyses of READ 3 are needed 

to determine the role of 2.0-mg RBZ in DME. 

2:55 PM 


PA053 

3:00 PM 

Ranibizumab for Diabetic Macular Edema: 36-Month Results 

From RISE and RIDE, 2 Phase III Randomized Trials 

Presenting Author: Leonard Feiner MD* 

Co-Author(s): Amy Rundle MA*, Jiameng Zhang PhD*, J Jill Hopkins MD*, 

Jason S Ehrlich MD* 

Purpose: To determine (1) if efficacy outcomes are maintained through 

Month 36 and (2) the consequences of delaying treatment. Methods: Diabetic 

macular edema patients (n = 759) were randomized to monthly 0.5-mg 

or 0.3-mg ranibizumab (RBZ) or sham. Patients in the sham group could cross 

over to 0.5-mg RBZ in Year 3. Macular laser was available to all. The primary 

efficacy outcome was the proportion of patients gaining ≥15 ETDRS letters in 

BCVA from baseline. Results: At Month 36 the primary outcome was met by 

20.6% in the sham/0.5-mg group, 44.0% in the 0.3-mg group, and 40.9% of 

patients in the 0.5-mg group. Ocular and systemic safety was generally consistent 

with the controlled Month 24 data. Conclusion: Efficacy outcomes 

with ranibizumab were sustained through Month 36. Lesser BCVA gains were 

seen with delayed treatment. 

3:07 PM 


PA054 

3:12 PM 

Effects of Intravitreal Ranibizumab on Diabetic Retinopathy 

Severity: 36-Month Data from RISE and RIDE Trials 

Presenting Author: Michael S Ip MD* 

Co-Author(s): Amitha Domalpally MBBS, Pamela Wong MPH*, J Jill Hopkins 

MD*, Jason S Ehrlich MD* 

Purpose: To evaluate the effect of intravitreal ranibizumab (RBZ) on diabetic 

retinopathy (DR) severity through 36 months. Methods: Exploratory analysis 

of ≥ 2-step and ≥ 3-step change on the Early Treatment Diabetic Retinopathy 

Study severity scale in the study eye (n = 707) in RISE and RIDE, two Phase 

3 clinical trials of monthly RBZ (0.3 or 0.5 mg) vs. sham for diabetic macular 

edema (DME). In the third year, patients in the sham group were eligible to 

cross over to 0.5-mg RBZ. Results: At Month 36, compared to sham/crossover, 

greater proportions of RBZ-treated eyes had ≥ 2 or ≥ 3 step regression 

(improvement) and fewer RBZ-treated eyes had ≥ 2 or ≥ 3-step worsening 

of DR from baseline. Conclusion: Intravitreal RBZ reduced the rate of DR 

worsening and increased rates of DR improvement in eyes with DME through 

36 months. 

3:19 PM 


PA055 

3:24 PM 

Lesions Simulating Retinoblastoma: A Retrospective Study 

of 604 cases 

Presenting Author: Shripaad Y Shukla MD 

Co-Author(s): Carol L Shields MD, Kristen M Kocher**, Elizabeth 

Schoenberg**, Swathi Kaliki MD, Jerry A Shields MD 

Purpose: To determine and classify lesions simulating retinoblastoma seen 

in a large, referral-based practice. Methods: Retrospective case series of 

604 patients. Results: Of 2775 patients referred with a diagnosis of sus- 

170 





pected retinoblastoma between 1974 and 2011, 2171 patients (78%) had 

retinoblastoma and 604 patients (22%) had simulating lesions. Of these 604 

patients, there were 27 different etiologies. The 3 most common conditions 

were Coats disease (244, 40%), persistent fetal vasculature (PFV) (158, 28%), 

and vitreous hemorrhage (27, 5%). The remainder of the patients had less 

common simulating conditions. Conclusion: Coats disease, PFV, and vitreous 

hemorrhage are the most common simulators of retinoblastoma. 

3:31 PM 


Part II, 3:42 PM - 5:35 PM 

Moderator: John T Thompson MD 

Panel: Dean Eliott MD, Harry W Flynn Jr MD, K Bailey Freund MD 

PA056 

3:42 PM 

Combining Genotype and Phenotype to Predict Progression 

to Choroidal Neovascularization 

Presenting Author: Lorah Perlee* 

Co-Author(s): Aruna T Bansal PhD*, Karen Marie Gehrs MD*, Jeffrey S 

Heier MD*, Karl G Csaky MD*, Rando Allikmets PhD**, Paul Oeth MS**, 

Toni Paladino PhD*, Daniel H Farkas PHD*, Lyle Rawlings*, Gregory S 

Hageman PhD* 

Purpose: Accuracy of prediction of CNV development was evaluated in 

patients with AMD using a model that combined baseline disease severity 

and genetic burden. Methods: An analysis was performed on 2414 AREDS 

subjects graded at baseline (AREDS simplified severity scale), surveyed 

across 13 disease-associated genetic variants and evaluated based on 10- 

year follow-up data. Results: Allowing for variation in baseline grade, the 

median predicted probability of progression was 0.2% (range: 0.04%-12%) in 

subjects with the lowest genetic load, compared to 57% (range: 26%-99%) 

in subjects with the highest genetic load. Conclusion: Evaluating patient 

genotype in combination with baseline disease improves the accuracy of CNV 

prediction. 

3:49 PM 


PA057 

3:54 PM 

Integrated 96-Week Results From the VIEW 1 & VIEW 2 

Studies: Intravitreal Aflibercept Injection in Neovascular 

AMD 

Presenting Author: Peter K Kaiser MD* 

On behalf of VIEW1 and VIEW2 Investigators 

Purpose: To assess efficacy and safety of intravitreal aflibercept (IAI) vs. 

ranibizumab (RBZ). Methods: Patients were randomized to RBZ 0.5 mg 

monthly (Rq4); IAI 2 mg monthly (2q4), 0.5 mg monthly (0.5q4), or 2 mg every 

2 months (2q8) after 3 loading doses. Weeks 52 to 96 patients were treated 

with modified quarterly dosing. Results: At Week 96, visual acuity (VA) gains 

were 7.9, 7.6, 6.6, and 7.6 letters, respectively. Most frequent ocular adverse 

events were conjunctival hemorrhage, eye pain, retinal hemorrhage, and VA 

reduced. Conclusion: VA improvements with IAI and RBZ at Week 52 were 

largely maintained through Week 96; efficacy of 2q8 IAI was similar to Rq4. 

4:01 PM 


PA058 

4:06 PM 

Anatomic Correlates of Long-term Visual Outcomes in the 

ANCHOR/MARINA Cohort of Ranibizumab-Treated AMD 

Patients 

Presenting Author: Soraya Rofagha MD 

Co-Author(s): Robert B Bhisitkul MD**, David S Boyer MD*, Kang Zhang MD 

PhD*, Srinivas R Sadda MD* 

Purpose: To report long-term visual and anatomic outcomes of ranibizumabtreated 

exudative AMD patients from the ANCHOR/MARINA trials with carryover 

into the HORIZON trial. Methods: Multicenter, uncontrolled, crosssectional 

study. Patients were evaluated with ETDRS visual acuity, biomicroscopy, 

retinal imaging, and genetic analysis. Results: Fifteen sites recruited 

65 patients with average follow-up of 7.3 years. Thirty-seven percent of eyes 

were 20/70 or better. On average, eyes lost 8.6 and 19.8 letters since entry 

and exit from MARINA/ANCHOR, respectively; 67% had CNV on fluorescein 

angiography (FA) and 68% had cystoid macular edema and/or SRF on OCT. 

Conclusion: A minority of eyes had good visual and anatomic outcomes. 

Most eyes were active by FA and OCT; visual correlates suggest that close 

follow-up and therapeutic vigilance is necessary. 

4:13 PM 


APAO PA059 

4:18 PM 

Comparison of Ranibizumab (Lucentis) and Photodynamic 

Therapy on Polypoidal Choroidal Vasculopathy (LAPTOP) 

Study 

Presenting Author: Akio Oishi MD PHD 

Co-Author(s): Hiroshi Kojima MD PhD, Michiko Mandai*, Shigeru Honda 

MD PHD, Toshiyuki Matsuoka MD PhD, Hideyasu Oh MD PHD, Mihori Kita, 

Tomoko Nagai MD, Masashi Fujihara MD PhD, Masafumi Uematsu MD, 

Yasuo Kurimoto MD PhD*, Akira Negi MD 

Purpose: To compare visual outcome between intravitreal injection of ranibizumab 

(IVR) and photodynamic therapy (PDT) in patients with polypoidal 

choroidal vasculopathy (PCV). Methods: We randomly assigned 94 patients 

with PCV to IVR or PDT. After 1 year of treatment protocol, the rate of visual 

acuity improvement or worsening as judged by 0.2 logMAR units change was 

compared. Results: After the exclusion of 6 patients who had dropped out, 

IVR and PDT groups consisted of 44 and 44 patients, respectively. Visual outcome 

was superior in IVR (improved: unchanged: worsened = 27%:66%:7% 

in IVR group and 16%:59%:25% in PDT group, P = .046). Conclusion: In 

PCV patients, IVR retained visual acuity better than PDT after 1 year of each 

treatment option. 

4:25 PM 


PA060 

4:30 PM 

The Mahalo Phase 1b Study: Multidose Safety and 

Tolerability of FCFD4514S (Antifactor D) in Geographic 

Atrophy 

Presenting Author: David F Williams MD* 

Co-Author(s): Erich C Strauss MD*, Michel Friesenhahn MD*, Alice Fong 

PharmD* 

Purpose: The Phase 1b safety run-in portion of the Mahalo study evaluated 

safety and tolerability of multiple monthly doses of a novel antibody fragment 

(FCFD4514S) in geographic atrophy patients prior to initiating the Mahalo 

Phase 2 study. Methods: Patients received a minimum of 3 monthly 10-mg 





171



intravitreal doses of anti-factor D; ocular and systemic safety and tolerability 

were evaluated. Results: Ten patients that met multidose safety run-in 

evaluable criteria were assessed; no study drug-related ocular or systemic 

adverse events were reported. Two withdrawals occurred and were unrelated 

to study drug. Conclusion: Anti-factor D was well tolerated in the 

Phase 1b study and is being evaluated further for safety and efficacy in the 

Phase 2 randomized study. 

4:37 PM 


PA061 

4:42 PM 

Antibiotic Resistance of Ocular Surface Flora After 

Continued Use of Topical Antibiotics Following Intravitreal 

Injection 

Presenting Author: Vivian T Yin MD* 

Co-Author(s): Daniel Weisbrod MD FRCSC, Kenneth T Eng MD, Carol E 

Schwartz MD*, Radha Pyari Kohly MD, Efrem D Mandelcorn MD*, Wai- 

Ching Lam MD*, Nick Daneman MD FRCP, Andrew Simor MD FRCP, Peter J 

Kertes MD* 

Purpose: To determine whether antibiotic resistance of ocular surface flora 

changes with prophylactic use of antibiotics following intravitreal injection 

for AMD. Methods: The study group received topical moxifloxacin for 3 days 

after each monthly injection. Cultures were taken at baseline and monthly 

for 3 months. Results: In the study group (n = 84), the MIC50 level increased 

(0.66 to 3.44 µg/mL; P = .011), as did the culture positive rate (25.0% to 

41.1%; P = .01) over 3 months. There was no significant change in the MIC50 

level and culture-positive rate in the control group (n = 94). Conclusion: 

Repeated use of topical moxifloxacin following intravitreal injection significantly 

increases antibiotic resistance of ocular surface flora. 

4:49 PM 


PA062 

4:54 PM 

Long-term Outcomes of a Streptococcus Endophthalmitis 

Outbreak After Intravitreal Injection of Bevacizumab 

Presenting Author: Roger A Goldberg MD 

Co-Author(s): Harry W Flynn MD*, Ryan F Isom MD, Darlene Miller MPH, 

Serafin Gonzalez PharmD, Sander Dubovy MD, Jared Matthews MD 

Purpose: To report the long-term outcomes and possible contamination 

sources of an endophthalmitis outbreak. Methods: A noncomparative case 

series; medical records and investigative reports were reviewed. Results: 

Twelve patients were affected by this outbreak: 8 (67%) underwent pars 

plana vitrectomy (PPV), and 7 (58%) underwent evisceration or enucleation. 

After 8 months, only 1 patient regained preinjection vision. DNA analysis 

confirmed microbiological testing to identify a common strain of Streptococcus. 

Issues with syringe preparation and environmental sterility were cited as 

sources of contamination at the compounding pharmacy. Conclusion: Visual 

outcomes were generally poor, and PPV did not improve outcomes. Contamination 

likely occurred at the compounding pharmacy. 

5:01 PM 


PA063 

5:06 PM 

Ocriplasmin for the Resolution of Symptomatic 

Vitreomacular Adhesion Including Macular Hole: Results of 

the MIVI-TRUST Program 

Presenting Author: Baruch D Kuppermann MD PhD* 

Purpose: To determine if ocriplasmin can be used for the pharmacologic 

resolution of symptomatic vitreomacular adhesion (VMA), including fullthickness 

macular hole (FTMH). Methods: We hypothesized that ocriplasmin 

could induce VMA resolution and FTMH closure more frequently than placebo. 

652 patients were randomized in 2 Phase 3 trials to test this hypothesis. 

Results: Pharmacologic VMA resolution was 26.5% for ocriplasmin-treated 

patients and 10.1% for placebo-treated patients (P < .001). In patients with 

FTMH at baseline, 40.6% of ocriplasmin-treated patients demonstrated nonsurgical 

FTMH closure by Day 28 compared to 10.6% (P < .001) of placebotreated 

patients. Conclusion: Ocriplasmin resulted in higher rates of VMA 

resolution and FTMH closure compared to placebo. 

5:13 PM 


PA064 

5:18 PM 

Sutureless, Small-Gauge Vitrectomy for Relief of 

Symptomatic Vitreous Floaters 

Presenting Author: John O Mason MD 

Co-Author(s): Michael G Neimkin MD, John O Mason MD, Tracy L Emond 

MS, Richard M Feist MD, Martin Lee Thomley MD, Michael A Albert MD, 

Jacob Yunker MD 

Purpose: To evaluate improvement in visual acuity and quality of life (QOL) 

following small-gauge pars plana vitrectomy (PPV) for symptomatic vitreous 

debris. Methods: Retrospective review of 175 eyes in 110 patients who underwent 

25-gauge PPV for symptomatic vitreous debris between 2008 and 

2010. Subjective QOL via a modified 9-question survey was measured preop 

and postop at 1-week and at 1-, 6-, and 12-month postop intervals. Results: 

Preoperatively, all patients complained of difficulty reading, computer use, 

or driving. Postop, 95% had stable or improved vision, 97% had complete 

resolution of floaters, and 98% had improved QOL. No major complications 

occurred. Conclusion: 25-gauge PPV improves QOL in patients with symptomatic 

vitreous debris and should be considered for patients with impaired 

QOL. 

5:25 PM 


172 






Hall A 

There will be two sessions of scientific posters, displayed as follows: 

Session 1 Saturday, Nov. 10 9:00 AM – 5:00 PM 


7:30 AM – 5:00 PM 

Session 2 Monday, Nov. 12 7:30 AM – 5:00 PM 

Tuesday, Nov. 13 7:30 AM – 3:00 PM 

Poster presenters will be at their displays during the time indicated at the beginning of each 

poster topic session. Individual hours will be indicated on a mock clock at each poster board. 

Posters indicated by a h received the highest grades by the Annual Meeting Program Committee 

and have been designated as Best Posters. 

APAO Sponsored by the Asia-Pacific Academy of Ophthalmology 

Onsite Poster Tours 

The “Meeting Point” near the Scientific Posters, Hall A 

Attend tours of highly rated posters, moderated by your mentors and colleagues. 

Subject 

Sunday, Nov. 11, 12:30-1:30 PM 

Cataract 

Glaucoma 



Monday, Nov. 12, 12:30-1:30 PM 



Tour Leaders 

Kevin M Miller MD, Mitchell P Weikert MD 

Peter Andreas Netland MD PhD, Robert L Stamper MD 

Damien Gatinel MD, A John Kanellopoulos MD 

Andrew A Moshfeghi MD MBA, Sharon D Solomon MD 

Kenneth R Kenyon MD, Jayne S Weiss MD 

Arlene V Drack M, K David Epley MD 

Scientific Posters Online 

Booth 165 

View scientific posters at your convenience at the Scientific Posters Online computer terminals. 

This service is also available on the Academy’s website, www.aao.org/2012. 







Cataract 

Cataract Poster Tour 


12:30 PM to 1:30 PM 

Session One 

Saturday and Sunday 

Presenters for Posters 1 through 39 will attend their posters on 

Sunday, Nov. 11, from 12:30 PM to 2:00 PM. 

Scientific Poster 1 

Evaluation of the EpiGlare Tester for Disability Glare 

Detection in Subjects With and Without Cataracts 

Presenting Author: Alice T Epitropoulos MD FACS* 

Purpose: To determine glare-induced changes during visual acuity testing in subjects 

with and without cataracts using the EpiGlare Tester, a new medical device for clinical 

documentation of glare disability. Methods: Prospective multicenter study: n = 66 subjects, 

26 with and 40 without cataracts. Primary endpoint was change in BCVA pre- and 

post-glare testing. Results: BCVA reduction was greater for cataract than noncataract 

group (P < .001). Seventy-six percent of patients in the cataract group had a > 4-line reduction 

in visual acuity with glare testing, compared with a 2% reduction in normal eyes. 

Conclusion: The EpiGlare Tester accurately and reliably detects change in BCVA due to 

glare in cataract patients. 


H Bacterial Susceptibility Profiles in Pseudophakic 

Endophthalmitis 

Presenting Author: Duncan A Friedman MD 

Co-Author(s): Mark L Hill MD, Gerald McGwin PhD, Richard M Feist MD 

Purpose: To examine susceptibility profiles in pseudophakic endophthalmitis. Methods: 

This was a retrospective chart review of pseudophakic endophthalmitis between 2006 and 

2010. An antibiogram was constructed. Fisher exact testing compared relations between 

older and newer fluoroquinolones (FQs). Results: A total of 108 cases of endophthalmitis 

were evaluated. Bacteria grew in 69% of endophthalmitis cultures. Gram-positive cultures 

accounted for 97% of all samples. A statistically significant association between 

newer and older generation FQs exists. Conclusion: Given the reported susceptibilities 

of endophthalmitis, prophylactic treatment of patients with newer FQ medications is an 

unnecessary cost burden to our health care system. 


H Are Topical Steroids Necessary Following 

Uncomplicated Cataract Surgery? A Prospective Evaluation 

Offering Potential Changes in the Treatment Paradigm 

Presenting Author: Hon-Vu Q Duong MD 

Co-Author(s): Kenneth C Westfield MD**, Isaac C Singleton OD FAAO** 

Purpose: To compare visual recovery, anterior chamber inflammation, and macular edema 

between 2 treatment modalities. Methods: Patients in Group I (113) received besifloxacin 

and bromfenac, while those in Group II (109) received besifloxacin and prednisolone 

acetate. Preoperative evaluation included a baseline macular OCT. Postoperative data collected 

included visual acuity and degrees of anterior segment inflammation, and macular 

OCTs were performed at 1 week, 1 month, and 2 months. Results: Visual recovery, anterior 

chamber inflammation, and foveal thickness were statistically insignificant with the P- 

value > .05 for all parameters in all studied periods. Conclusion: This study demonstrated 

efficacy between the 2 treatment modalities. 


Racial Differences in Lens Opacity Incidence and 

Progression: The Salisbury Eye Evaluation (SEE) Study 

Presenting Author: Philip Storey MPH 

Co-Author(s): Beatriz Munoz MSC, David S Friedman MD MPH PhD*, Sheila W West 

PhD 

Purpose: To evaluate racial differences in lens opacity incidence and progression over 

2 years in an older American population. Methods: 2520 people in Salisbury, Maryland, 

aged 65 to 84 years, were surveyed. Lens photographs were taken at baseline and at 2 

years and graded using the Wilmer grading scheme. Results: African Americans had lower 

rates of nuclear opacity incidence (OR: 0.52; 95% CI, 0.35-0.76) and nuclear progression 

(OR: 0.60; 95% CI, 0.38-0.92) compared to whites. African Americans had higher rates of 

cortical opacity incidence (OR: 1.90; 95% CI, 1.21-2.98) and cortical progression (OR: 1.72; 

95% CI, 1.21-2.45). Conclusion: Differences by race in the type of cataract incidence and 

progression deserve further exploration. 


Integrated Phase 3 Clinical Trials of Low-Concentration, 

Modified Bromfenac Ophthalmic Solution Dosed Once Daily 

for Cataract Surgery 

Presenting Author: Sharon M Klier MD* 

Co-Author(s): Damien Goldberg MD*, James H Peace MD**, Tom R Walters MD, 

Joseph P Gira MD*, James A Gow MD*, Timothy R McNamara PharmD 

Purpose:To evaluate the efficacy and safety of low-concentration, modified bromfenac 

solution dosed once daily (q.d.) for cataract surgery. Methods: Subjects received either 

bromfenac (n = 222) or placebo (n = 218) q.d. Dosing began 1 day before cataract surgery 

and continued through postsurgery Day 14. Primary efficacy endpoint was no ocular inflammation 

by Day 15; secondary efficacy endpoint was no ocular pain at Day 1. Results: 

Bromfenac was superior to placebo for primary and secondary efficacy endpoints (P < 

.0001). Compared to placebo, bromfenac had a lower incidence of ocular adverse events 

(P = .0001). Conclusion: Low-concentration, modified bromfenac solution dosed q.d. is 

safe and effective to treat the inflammation and pain associated with cataract surgery. 


APAO Evaluation of Role of Topical Nepafenac 0.1% in 

the Prevention of Cystoid Macular Edema in Diabetic and 

Nondiabetic Patients 

Presenting Author: Jeewan S Titiyal MD 

Co-Author(s): Sana Ilyas MD, Namrata Sharma MD MBBS, Rajesh Sinha, Radhika 

Tandon MBBS, Raj V Azad MD FRCS(ED)** 

Purpose: To evaluate role of topical nepafenac 0.1%in prophylaxis of pseudophakic cystoid 

macular edema (CME). Methods: Of 265 eyes (143 nondiabetic, 122 diabetic) with 

uneventful phacoemulsification, 133 (62 diabetic,71 nondiabetic) were randomized to receive 

nepafenac for 3 months. Results: CME was present on OCT in 6.4% of eyes. Rate of 

CME was higher in diabetics (9% vs. 4.2%, P = .1). Eyes on nepafenac had less CME (3% 

vs. 8% P = .02). Six eyes (2.2%) had clinical CME, of which 5 (3.7%) did not receive nepafenac 

(P = .1). Clinical CME developed in 4 diabetic and 1 nondiabetic eye (P = .4). BCVA 

was better with treatment (P = .02). Prolonged diabetes and insulin treatment had more 

CME (P = .001). Conclusion: Topical nepafenac decreased the rate of pseudophakic CME. 


APAO Sutureless 2-Piece, Capsular Tension Ring Segment: A 

New Design Demonstration on Cadaver Eye 

Presenting Author: Satish C Gupta MBBS 

Purpose: To demonstrate the advantages of the new design, 2-piece capsular tension ring 

(CTR) segment over the Ahmed capsular tension (Ahmed CT) Segment in an aniridia model 

of cadaver eye. Methods: A new design, 2-piece CTR segment was anchored (sutureless) 

to the sclera in an iridia model of a cadaver eye. An Ahmed CT segment was sutured in 

the other cadaver eye. The behavior of the two is demonstrated in the video. Result: In 

the new design 2-piece CTR segment, the scleral fixation arm is securely anchored to the 

sclera and hence supports the capsular bag better. It also eliminates the use of suture. 

Conclusion: The 2-piece CTR segment provided better support to the capsular bag in 

zonular dehiscence than the Ahmed CT segment. The use of suture is avoided along with 

the suture-related complications. 

174 






A Clinical Comparison of 2 Dispersive Viscoelastics 

Presenting Author: Kevin Lee Waltz MD* 

Co-Author(s): Linda Tsai MA* 

Purpose: To compare the performance of 2 dispersive ophthalmic viscosurgical devices 

(OVDs), Healon Endocoat (HE) and Viscoat (VC). Methods: This study is a multicenter, 

randomized trial with 400 eyes at 11 sites, with follow-up of 3 months postoperatively. The 

study endpoints were incidence of postop IOP spikes and postop loss of endothelial cells. 

Results: Cumulative IOP spikes as well as the mean percentage change in endothelial cell 

count for HE, from preoperative through 3 months postoperative, were noninferior to VC (P 

= .0003 and d = 13%; P < .0001 and d = 5%, respectively). The percentage of subjects with 

surgical complications was lower for the HE group (P = .0266). Visual acuity results were 

comparable. Conclusion: Healon EndoCoat was found to be noninferior to Viscoat under 

the controlled conditions of this study. 


Accuracy of Intraoperative Wavefront Aberrometry IOL 

Power Adjustment at Cataract Surgery 

Presenting Author: Samuel Masket MD* 

Co-Author(s): Nicole R Fram MD, Basak Bostanci Ceran 

Purpose: To compare intraoperative aberrometry-adjusted IOL power with preoperative 

partial coherence interferometry (PCI) for IOL power prediction. Methods: Following 

phacoemulsification, 30 eyes had IOL power adjusted (from preop PCI) according to intraoperative 

wavefront aberrometry. Results: Twenty-one of 30 eyes had a power adjustment 

of ±0.5 D; 8 eyes required a ±1 D adjustment, and 1 required a 1.5 D change. Postoperatively, 

18 of 30 eyes were emmetropic, with 27 eyes within ±0.5 D of the intended 

optical outcome. Mean optical error was -0.02 D. Conclusion: Intraoperative aberrometry 

appears to be a promising tool to minimize “optical surprises” following cataract surgery. 


Clinical Outcomes With Artificial Iris (HumanOptics) 

Prosthesis 

Presenting Author: Samuel Masket MD* 

Co-Author(s): Nicole R Fram MD 

Purpose: To assess safety and outcomes in patients with artificial iris (AI) implants. Methods: 

Nine eyes were studied retrospectively. Indications: congenital (n = 2) and acquired 

(n = 6) iris defects. Four patients had combined cataract surgery and AI. Six patients had 

secondary IOL and AI. One patient had AI alone. Postoperative aesthetics, glare, BCVA, 

IOP, corneal failure, and cystoid macular edema (CME) were evaluated. Results: Mean 

follow-up was 7.1 months (3-19). All patients had desired aesthetic result. Eight out of 9 

eyes had improvement in glare. BCVA improved in 6 eyes and was unchanged in 2 eyes. 

Ocular hypertension was noted in 6 eyes. Two eyes required glaucoma filtering surgery. 

Corneal failure occurred in 1 eye. No patients developed CME. Conclusion: AI appears 

to be safe and effective. However, monitoring of IOP and corneal clarity is warranted. 


A Phase 3 Clinical Trial of the Drug Product OMS302 

Delivered Intracamerally in BSS During IOL Replacement 

Surgery 

Presenting Author: Steve Whitaker MD* 

Co-Author(s): Alan S Crandall MD*, Gregory Demopulos MD**, Edmund Ng PhD*, 

Mark I Rosenblatt MD PhD* 

Purpose: This study evaluated effects of OMS302 on intraoperative mydriasis and postoperative 

pain in subjects undergoing IOL replacement. Methods: This 405-subject study 

was randomized, double blind, and placebo controlled. All subjects received preop mydriatics 

and anesthetics. Mydriasis and pain were measured by video and visual analogue 

scale. Results: OMS302 was superior to placebo in maintaining mydriasis (P < .0001) and 

preventing pain (P < .0001). Fewer OMS302-treated subjects experienced a pupil diameter 

< 6 mm at cortical clean-up (P < .0001) or moderate-to-severe pain (P = .006), and more 

were pain-free (P = .011). Adverse events were similar between groups. Conclusion: In 

this study, OMS302 significantly maintained mydriasis, prevented miosis, and decreased 

postop pain. 


TECMICS (Truly Endo-Capsular Micro-Incision Cataract 

Surgery) 

Presenting Author: Ahmed Mohamed Ghoneim MA** 

Co-Author(s): Hisham A Saad MD 

Purpose: Current phaco techniques cause turbulence in the entire anterior chamber 

(AC), damaging the corneal endothelium, and possibly inflaming other intraocular tissues. 

TECMICS, in theory, protects the anterior segment because the dynamic of fluidics 

is generated inside the capsular bag. Methods: Using 2 corneal incisions of 1.4 mm and 

2 microcapsulorrhexis of 1 to 1.5 mm, TECMICS was done in 30 cases before doing phacoemulsification 

as a new trend for microincision cataract surgery (MICS). Results: Changes 

in endothelial cell density and corneal K readings were statistically insignificant (P > .5) in 

all cases at 12 months after surgery. Conclusion: In standard coaxial phaco and MICS, 

turbulence in the AC can damage the corneal endothelium. TECMICS helps to achieve a 

less invasive surgery with prompt recovery and less surgically induced astigmatism. 


Performance Comparison of 21-gauge Straight and Bent 

Phaco Tips In Vitro and In Vivo During Microimplantation 


Presenting Author: Donald Nixon MD* 

Purpose: To compare cavitation pattern and operative performance of 21-gauge straight 

(ST) and bent phaco tips (BT). Methods: High-speed video of ST and BT in vitro. In vivo 

cataract surgery with ST (101) or BT (60) using the Whitestar Signature Ellips FX handpiece. 

Operative measures: mean phaco power, time, and balanced salt solution (BSS) 

were used. Results: Cavitation bubbles traveled in a relatively straight line with the ST 

compared to the BT. At each cataract density (1-5) phaco power, time, and BSS used were 

significantly lower (P < .05) with the BT compared to the ST. Conclusion: Performance 

was excellent with both 21-gauge tips, but the BT had a more complex cavitation pattern 

and better operative performance. 


Impact of Intelligent Phacoemulsification Software on 

Torsional Phacoemulsification Surgery 

Presenting Author: Silay Canturk Ugurbas MD 

Co-Author(s): Sinan Caliskan, Atilla Alpay MD**, Suat Ugurbas MD 

Purpose To study the effects of OZil intelligent phaco software(IP) on torsional phacoemulsification. 

Methods: 128 eyes were divided into 2 groups: those undergoing phacoemulsification 

using IP software (Group 1, n = 67) and those operated without IP (Group 

2, n = 61). The 2 groups were compared in terms of energy parameters, aspiration time, 

and amount of fluid used. Results: Ultrasound energy parameters were similar in the 2 

study groups. Aspiration time was shorter (P = .007), and total fluid used was less when IP 

software was used (P = .02). Conclusion: The new IP software did not cause difference in 

ultrasound energy levels. However, the new software was found to be advantageous with 

regards to fluid use and aspiration time. 


Vector Analysis of Surgically Induced Astigmatism During 

Cataract Surgery With Different Wound Sizes 

Presenting Author: Sathish Srinivasan MBBS* 

Co-Author(s): Douglas A M Lyall MBCHB 

Purpose: To compare surgically induced astigmatism (SIA) following coaxial cataract surgery 

(CS) through 1.8-mm, 2.2-mm, and 3.0-mm clear corneal wounds. Methods: Prospective 

comparative case series. Patients were randomly allocated to 3 groups. Eighty-two 

eyes had CS through a 1.8-mm wound, 15 eyes through a 2.2-mm wound, and 32 eyes 

through a 3.0-mm wound. Pre- and postoperative keratometry (at 4 weeks) was performed 

on all subjects. Surgically induced astigmatism (SIA) was calculated by vector analysis. 

Results: There were no intraoperative complications. Mean SIA in the 1.8-mm group was 

0.26 D ± 0.30 D; 0.31 D ± 0.31 D in the 2.2-mm group; and 0.39 D ± 0.29 D in the 3.00-mm 

group. SIA in the 1.8-mm group was significantly less than the 3.0-mm group (P = .04). 

Conclusion: Microincision CS through a 1.8-mm incision induces less SIA compared to 

a 3.0-mm wound. 





175




Visual and Refractive Outcomes Following Hydrophilic 

Acrylic Toric IOL Implantation in Eyes With High Corneal 

Astigmatism (> 3.00 D) 


Co-Author(s): Douglas A M Lyall MBCHB 

Purpose: To assess visual and refractive outcomes following toric IOL implantation during 

cataract surgery in eyes with corneal astigmatism greater than 3 D. Methods: Prospective 

interventional case series. Twenty-six eyes of 22 patients with more than 3 D of 

astigmatism underwent uncomplicated cataract surgery with implantation of a toric IOL. 

Results: Mean preoperative corneal astigmatism was 3.86 D ± 0.72 D. Mean postoperative 

refractive cylinder was 0.38 D ± 0.35 D. Uncorrected visual acuity improved from 0.69 

± 0.19 (logMAR) preoperatively to 0.11 ± 0.14 postoperatively. All IOLs remained stable. 

Conclusion: Use of toric IOLs during cataract surgery is effective in correcting high regular 

corneal astigmatism. 


Tamsulosin vs. Alfuzosin: Comparative Incidence and 

Severity of Intraoperative Floppy Iris Syndrome 

Presenting Author: Cedric Schweitzer MD 

Co-Author(s): John R Campbell MD, Jean-Luc Febbraro MD*, Pascal Rozot MD*, 

Thierry Amzallag MD**, Jean-Philippe Theron MD, Joseph Colin MD*, David Touboul 

MD, Rudy Drillon MD**, David F Chang MD* 

Purpose: Unlike tamsulosin, alfuzosin is a uroselective a-blocker not selective for a-1A 

receptor. Methods: We prospectively enrolled 214 patients undergoing cataract surgery 

who were taking either tamsulosin or alfuzosin (113 eyes) and a control patient for each 

case (113 eyes). Surgeries were video recorded and analyzed by 2 experienced surgeons 

masked to patient groupings. Results: 34.3% (n = 24) of tamsulosin eyes had a grade 3 of 

intraoperative floppy iris syndrome (IFIS) compared to 16.3% (n = 7) of alfusozin eyes and 

4.4% (n = 5) of control eyes (P < .001). IFIS incidence was different between cases and 

controls (P < .001) but was not between tamsulosin and alfuzosin groups (60% and 69.8%, 

respectively). Conclusion: a-blockers have different risk of IFIS; it should be considered 

for patients who are likely to need cataract surgery 


APAO Posterior Chamber Collagen Copolymer Phakic 

IOLs for Correction of Myopia, Hypermetropia and Regular 

Myopic Astigmatism 

Presenting Author: Sudarshan Khokhar 

Co-Author(s): Shikha Gupta MBBS, Animesh Jindal, Bhushan Ratansingh Wadekar 

MBBS** 

Purpose: To assess long-term results of posterior chamber collagen phakic IOLs (P-IOLs). 

Methods: Prospective assessment of uncorrected distance VA, corrected distance VA, 

refractive error, P-IOL vault, and endothelial cell density (ECD) in 3 groups: Group I, myopic 

(126 eyes); Group II, hyperopic (6); Group III, myopic astigmatism (28), over 3 years. Results: 

The mean preoperative error decreased from -11.55 ± 5.22 DS (Group I), +5 ± 2.51 

DS (Group II), 4.5 ± 2.07 DC (Group III) to -0.11 ± 0.02 DS (Group I), 0.1 ± 0.01 DS (Group 

II) and 0.53 ± 0.04 DC, respectively. There was no significant change in CDVA and mean 

vaulting at Day 1 (406.41 ± 133.44 µm) and 1 month (413.68 ± 158.4 µm). There was a 

mean decrease of 6.3% in ECD at 3 years. No patient developed cataract. Conclusion: 

P-IOL is safe for correction of all refractive errors. 


Long-term Results of Lensectomy Combined With Iris 

Sutured Posterior Chamber IOL in Extremely Subluxated 

Lens of the Pediatric Population 

Presenting Author: Osman S Arslan MD 

Co-Author(s): Eray Atalay, Mehmet Serhat Mangan**, Mustafa Unal MD, Ceyhun Arici 

MD**, lker Toker MD** 

Purpose: To evaluate long-term outcomes of lensectomy combined with iris-sutured 

posterior chamber IOLs (PC IOLs) in subluxated lens of the pediatric population. Methods: 

In this retrospective case series, 21 pediatric patients (23 eyes) with subluxated lens 

between June 1, 2006, and Oct. 30, 2010, were studied. Outcome measures were visual 

acuity and intraoperative and postoperative complications. Results: No intraoperative 

complications were observed. In all patients with a follow-up of at least 2 years (range: 

2-6 years), the visual acuity compared with preoperative visual acuity improved in all eyes. 

Conclusion: Lensectomy combined with iris-sutured PC IOL surgery is a very successful 

and effective procedure and is an alternative to conventional lens surgeries. 


APAO Indications and Outcomes of Descemetopexy With 

Isoexpansile Perfluoropropane After Cataract Surgery 

Presenting Author: Umang Mathur MD 

Co-Author(s): Jyoti Garg MS** 

Purpose: To review indications and outcomes of descemetopexy for Descemet membrane 

detachment (DMD) after cataract surgery. Methods: Sixty-seven eyes underwent descemetopexy 

by injecting isoexpansile perfluoropropane gas (14% C3F8) intracamerally. DMD 

was classified as planar / nonplanar. Results: Anatomical attachment was achieved in 

71.64% and improvement in visual acuity in 74.63% of eyes. 100% planar DMD showed 

complete attachment, and 46% of eyes with the nonplanar DMD showed partial or no 

attachment. Conclusion: Descemetopexy offers good chance of surgical outcome both 

in terms of visual acuity and resolution of corneal edema. The clinical type of DMD is an 

important factor influencing the surgical outcome. 


Loteprednol Etabonate Gel 0.5% in the Treatment of Ocular 

Inflammation and Pain Following Cataract Surgery 

Presenting Author: Rajesh K Rajpal MD* 

Co-Author(s): Raphaele Siou-Mermet MD*, Tara Erb MS 

Purpose: To evaluate loteprednol etabonate (LE) gel 0.5% pooled across 2 prospective, 

multicenter, double-masked parallel group studies. Methods: Patients (n = 813) with anterior 

chamber cell (ACC) ≥Grade 2 on the day after cataract surgery were randomized to 

LE 0.5% or vehicle q.i.d. for 14 days. Results: At Day 8, 30.8% and 15.1% of patients in 

the LE and vehicle group had complete resolution of ACC, while 74.3% and 43.8%, respectively, 

had Grade 0 (no) pain (P < .001 for both). Fewer patients treated with LE required 

rescue medication (13.9% vs. 47.0% by Day 15, P < .001), and fewer had ocular adverse 

events (17.4% vs. 25.2%, P = .006). Three patients (LE n = 2; vehicle n = 1) exhibited an 

IOP increase ≥10 mmHg. Conclusion: LE gel 0.5% was efficacious and safe in treating 

postoperative inflammation and pain in these clinical studies. 


Visual Outcomes and Foveal Thickness After Iris Suture 

Fixation IOL With No Capsular Support 

Presenting Author: Leonardo Garcia-Rojas Castillo MD 

Co-Author(s): Eduardo Chavez-Mondragon MD**, Juan Manuel Paulin Hueria MD**, 

Arturo J Ramirez-Miranda MD 

Purpose: To report visual outcomes and macular thickness by spectral domain OCT of 

iris suture fixation of foldable acrylic IOLs. Methods: We implanted an iris-fixated IOL in 

13 eyes lacking capsule support, and we report visual acuity and macular thickness. The 

mean follow-up was 4.86 months, with a minimum of 3 months. Results: Uncorrected distance 

VA and corrected distance VA significantly improved postoperatively (1.91 and 1.00 

vs. 0.66 and 0.30, respectively; P < .01). Seven cases had ocular hypertension after surgery 

due to the presence of viscoelastic in the anterior chamber. There were no cases of cystoid 

macular edema, chronic iridocyclitis, IOL subluxation, pigment dispersion, or glaucoma. 

Foveal thickness preop and postop values were 211 vs. 214 µm (P > .05). Conclusion: Iris 

fixation of 3 acrylic foldable IOLs appears to be a great option for the treatment of aphakia 

with no capsular support. 


APAO Randomized Clinical Comparison Study of 3 IOLs: 

Crystalens AO, ReSTOR +3, and Tecnis Multifocals 

Presenting Author: Robert Edward T Ang MD* 

Purpose: To compare visual outcomes associated with 3 types of presbyopia-correcting 

IOLs. Methods: Prospective, randomized study in 78 cataract patients followed for 6 

months after bilateral implantation of Crystalens AO, ReSTOR +3, or Tecnis Multifocal 

IOLs.Results: Uncorrected intermediate VA was better with Crystalens (20/20) than Re- 

STOR (20/25) or Tecnis (20/25, P < .001). Contrast sensitivity without glare was better 

with Crystalens than Tecnis or ReSTOR at 3 c/deg (P ≤ .046). Halos and starbursts were 

reduced with Crystalens vs. the multifocal IOLs (P < .001). Conclusion: Uncorrected near 

and distance vision were similar among groups. Uncorrected intermediate vision, contrast 

sensitivity, and vision quality were better with Crystalens AO. 

176 






APAO Glued IOLs: The Quick Fix Solutions for Aphakic 

PatientsóOur Experience 

Presenting Author: Bina John MBBS 

Co-Author(s): Sujatha Mohan MBBS, Mohan Rajan MD MBBS, Harsha Malkani, Sneha 

K K JR ** 

Purpose: To analyze the outcomes of glued posterior chamber IOL in patients with deficient 

capsular support. Methods: Forty-four patients with deficient capsule support had 

implantation of either a rigid or a foldable glued IOL. Preoperative visual acuity, intraoperative 

and postoperative complications and postoperative visual acuity were noted. 

Results: There was a statistically significant improvement in the visual acuity in most 

patients after the glued IOL. (P-value: 0.035). Intraoperative and postoperative complications 

included ciliary body bleeding, broken haptic, IOL tilt and vitreous hemorrhage. 

Conclusion: Glued IOLs are effective and safe for the surgical correction of aphakia. 


H American Society of Cataract and Refractive Surgery / 

European Society of Cataract and Refractive Surgery Survey 

on Foldable IOLs Requiring Explantation or Secondary 

Intervention: 2011 Update 

Presenting Author: Nick Mamalis MD* 

Co-Author(s): Zachary Modest Bodnar MD, Lisa Leishman MD**, Andrew Ollerton 

Purpose: ASCRS/ESCRS survey regarding explantation of foldable IOLs. Methods: Type 

of IOL, materials, and complications requiring explantation were evaluated. Results: Dislocation 

/ decentration was the most common complication associated with the 1-piece 

and 3-piece silicone IOLs, as well as 1-piece and 3-piece acrylic IOLs. The most common 

reason for explantation of multifocal lenses was glare/optical aberrations. Accommodating 

IOLs were new to the survey and removed due to glare/optical aberrations. Conclusion: 

The most common complications with foldable IOLs were dislocation / decentration, 

glare / optical aberrations, and incorrect lens power. 


Rotational Stability of a Glistening-Free One-Piece 

Hydrophobic Acrylic IOL 

Presenting Author: Louis D Skip Nichamin MD* 

Purpose: To evaluate the rotational stability of enVista One-Piece Hydrophobic Acrylic 

Intraocular Lens (IOL), Model MX60. Methods: Subjects receiving enVista following cataract 

surgery were randomized to one of 4 axis positions (45°, 90°, 135°, or 180°) to determine 

the rotational stability of the lens. Results:Rotational stability was evaluated on 113 

eyes. Rotation was 5° or less for 100% of the eyes, which exceeds the ANSI standard as 

well as FDA requirements of 90% subjects with 5° or less rotation at 2 consecutive visits 

3 months apart. Conclusion: enVista MX60 IOL has excellent rotational stability. 


APAO Pars Plana Fixation of Black Diaphragm IOL in 

Traumatically Aniridic Eyes 

Presenting Author: Yuping Zou MD 

Co-Author(s): Zhe Xu, Xiulan Zou MD**, Chu Zhang MD**, Chenjin Jin MD 

Purpose: To prevent corneal decompensation after black diaphragm IOL (BD-IOL) implantation 

by deepening the anterior chamber. Methods: Twenty-six cases (27 eyes) of aniridic 

patients due to eye trauma had received pars plana fixation of BD-IOL. The fixation site 

was located according to surface anatomy in 18 cases (18 eyes) and by endoscope-guiding 

in 6 cases (7 eyes). Corneal endothelial cells was monitored and the position of the IOL 

was examined postoperatively. Results: No obvious decentration or tilt of IOL and corneal 

decompensation were detected. Corneal endothelial cells decreased 1.04% at an interval 

of 43.3 ± 5.67 months. Conclusion: Pars plana fixation of BD-IOL helps to prevent postoperative 

corneal decompensation by deepening the anterior chamber in traumatically 

aniridic eyes. 


The Use of a Light-Adjustable IOL in Post-Corneal Refractive 

Surgery Cataract Patients 

Presenting Author: Lawrence A Brierley MD 

Purpose: To determine if the ability to postoperatively adjust the light adjustable lens 

(LAL) improves the refractive results in patients with previous refractive surgery. Methods: 

One-site retrospective study of 34 post-refractive patients scheduled for routine 

cataract surgery. All eyes received the standard adjustment and lock-in procedure for the 

LAL. Postoperatively, the final manifest refraction was then compared to the preop target 

refraction. Results: Manifest refractive spherical equivalent was within 0.25 D in 73.5% 

of eyes, within 0.50 D in 97.1% of eyes, and within 1.00 D in 100% of eyes. Mean absolute 

error was 0.19 D ± 0.20 D. Conclusion: Use of a light-adjustable IOL in post-corneal 

refractive surgery cataract patients is effective at reducing postoperative refractive errors. 


APAO IOL Power Calculation After Myopic LASIK Using 

Scheimpflug-Based Corneal Topographer and Double K 

Formula 

Presenting Author: Shizuka Koh MD* 

Co-Author(s): Naoyuki Maeda MD*, Yusuke Takada COT**, Teruki Fukumoto MD, 

Takeshi Ide MD PHD, Kazunori Miyata MD**, Kohji Nishida MD 

Purpose: To study the accuracy of methods of calculating IOL power after LASIK. Methods: 

Twenty LASIK patients with a monofocal IOL were enrolled. The predictive refraction 

errors (PRE) were compared among 3 methods using K readings from automated keratometry 

for the SRK/T formula (AK-SRKT) or for double-K modification of the SRK/T formula 

(AK-DK) and using the total corneal refractive power (TCRP) measured by Scheimpflugbased 

corneal topography for double-K formula (TCRP-DK). Results: The percentages of 

eyes with PREs within ± 0.5 and ± 1.0 D with AK-SRKT, AK-DK, and TCRP-DK were 10%, 

45%, and 50% and 15%, 65%, and 90%, respectively. Conclusion: The double-K formula 

using TCRP improved the accuracy of IOL power calculations after LASIK. 


Multifocal Progressive Diffractive Lens: Two-Year Followup 

Presenting Author: Barbara Kusa MD 

Purpose: OptiVis multifocal IOL combines benefits of both apodized diffractive bifocal 

and progressive refractive optics for near, distance, and intermediate vision. We present 

2-year clinical outcomes of 79 implants. Methods: OptiVis was implanted in 79 cataract 

eyes (38 bilateral) through a 2.8-mm incision. Mean age was 70.37 ± 6.25 years. Patient 

satisfaction surveys were administered to assess functional visual performance, spectacle 

independence, and unwanted visual images. Results: At 2-year follow-up, distance UCVA 

was 20/29.32 and BCVA was 20/21.84 with -0.19 ± 0.65 SE. Near binocular UCVA was 

20/38.42 at 40 cm, and 20/47.84 at 70 cm. Patients were satisfied with distance and near 

vision and referred functional intermediate vision. Conclusion: Implantation with OptiVis 

showed good functional results and patient satisfaction. 


Comparison of Through-Focus Image Sharpness Across 5 

Presbyopia-Correcting IOLs 

Presenting Author: Jay Stuart Pepose MD PhD* 

Co-Author(s): Daozhi Wang PhD**, Griffith Altmann* 

Purpose: To assess through-focus image sharpness of 5 presbyopia-correcting IOLs 

through a range of object vergences and pupil diameters. Methods: A 1951 US Air Force 

target was imaged through Crystalens AO (AO), Crystalens HD (HD), aspheric ReSTOR 4 

(R4), aspheric ReSTOR 3 (R3), and Tecnis Multifocal (TMF) in a model eye. Sharpness of 

each digital image was scored by a 2-dimensional sharpness gradient. Results: AO had 

the best distance image sharpness for all pupil diameters. At a 5-mm pupil, R4 distance 

image sharpness was similar to HD and at 6 mm the TMF was superior to HD, R3, and 

R4. TMF showed the best near image sharpness. Conclusion: Differing IOL designs are 

associated with quantifiable differences in image sharpness at varying vergences and 

pupil sizes. 


APAO Comparative Study on the Occurrence of Ptosis After 

Cataract Surgery Using Topical Anesthesia and Nadbath- 

Rehman-Ellis Akinesia 

Presenting Author: Jongwook Lee MD 

Co-Author(s): Sungjin Kim 

Purpose: To compare the effect of topical anesthesia and Nadbath-Rehman-Ellis akinesia 

on the occurrence of postoperative ptosis after cataract surgery. Methods: We examined 

marginal reflex distance 1 (MRD1) and levator function (LF) of the patients who underwent 

cataract surgery with topical anesthesia and Nadbath-Rehman-Ellis akinesia on each eye. 

Results: The mean MRD1 on eyes with topical anesthesia was significantly low 1 week 





177



and 4 weeks after surgery. Six months after surgery, the differences of MRD1 and LF 

between the 2 groups were not significant. Conclusion: In cataract surgery, Nadbath- 

Rehman-Ellis akinesia can reduce the damage of levator aponeurosis. 


H Effect of Caffeine on Fine Motor Performance on 

Simulated Anterior Segment Surgical Skills 

Presenting Author: David S Chin Yee MD 

Co-Author(s): David J Goldman MD**, Aly Sheraly MD 

Purpose: To assess the effect of caffeine intake on fine motor performance of ophthalmology 

residents using the EYESi simulator. Methods: Ophthalmology residents at Henry 

Ford completed a survey on caffeine use, then performed a series of tasks on the simulator. 

Tasks were first completed without caffeine, then 1 hour after a preselected amount 

of caffeine. Task score, timing, errors, and economy of motion were recorded. Statistical 

analysis t-tests were performed. Results: Three tasks on the simulator compared performance 

of residents’ pre- and post-caffeine intake. Each task demonstrated no significant 

difference (P > .05). Conclusion: Participants felt that caffeine intake influenced their 

surgical performance. However, the study noted that a preselected amount of caffeine did 

not improve or worsen performance. 


H Ophthalmic Surgical Developments of an Injectable 

Shape Memory Nitinol Suture 

Presenting Author: Michael Erlanger MD* 

Co-Author(s): Jeffrey L Olson MD* 

Purpose: Surgical uses of a prototype surgical device that allows the injection of a 

shape memory nitinol alloy suture were evaulated. Methods: The device was used on 

enucleated porcine or human eyes in a laboratory setting. The following procedures were 

performed: pupilloplasty, iris fixation of an IOL, scleral buckle fixation, Ahmed valve fixation, 

and Retisert fixation. Results: The pupilloplasty and IOL fixation were able to be 

performed 15 times faster than conventional suture techniques. The Retisert and scleral 

buckle were able to be fixated with preplaced sutures. Conclusion: The injectable nitinol 

suture is quicker than conventional suture techniques. The nitinol suture has a benefit of 

being able to be preplaced, and then the device can be positioned and fixated onto the 

suture. 


H Effect of Acute Sleep Deprivation on Microsurgical 

Performance on Simulated Anterior Segment Surgery 

Presenting Author: Aly Sheraly MD 

Co-Author(s): David S Chin Yee MD, David J Goldman MD** 

Purpose: To determine the effect of acute sleep deprivation (ASD) on microsurgical performance 

in ophthalmology residents. Methods: Residents completed preselected tasks 

on the EYESi ophthalmosurgical simulator while well rested and then after ASD. Task 

scores, timing, and errors were recorded. Results: Residents felt that ASD on call reduced 

the quality and quantity of sleep. No statistically significant difference was demonstrated 

in overall performance when comparing well rested to ASD states. Conclusion: With 

the increasing focus on residency program duty hours, this study demonstrates that ASD 

has a perceived negative affect on performance but did not alter simulated microsurgical 

performance. 


H Comparative Visual Outcomes Achieved With Single 

Optic and Dual Optic Models of Accommodative IOLs 

Presenting Author: Jorge L Alio MD PhD* 

Co-Author(s): Ana Belen Plaza MS, Raul Montalban MSC, Paula Ortega MS 

Purpose: To compare the visual outcomes of eyes implanted with a single-optic or a 

dual-optic accommodative IOLs (A-IOLs). Methods: Fifty-three eyes were divided into 2 

groups: Group A, 27 eyes with the single-optic A-IOL, and Group B, 26 eyes with the dualoptic 

A-IOL. Results: No differences between groups were found in near and intermediate 

visual outcomes (P ≥ .13). Ocular Strehl ratio and contrast sensitivity were better for Group 

B (P ≤ .04). Conclusion: Both IOLs have limitations in near visual outcomes. Eyes with the 

dual-optic IOL presented better ocular optical quality. 


H Cataract Surgery Improves Quality of Life in Cancer 

Patients as Measured by National Eye Institute Visual 

Function Questionnaire-25 

Presenting Author: Stella K Kim MD* 

Co-Author(s): Janhavi M Modak MD** 

Purpose: To study quality of life (QOL) of cataract surgery (CS) in cancer patients by National 

Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25). Methods: Retrospective 

study of cancer patients who had CS between 12/2008 and 3/2011. Evaluation included 

demographics, cancer and ocular history, vision, symptoms scores, and NEI-VFQ-25, 

pre- and at 1 month postop. The Student t test, Spearman correlation, and Wilcoxon 

signed rank test were used. Results: Sixty-three CE in 54 patients showed stastistically 

significant improvement in visual acuity (P < .0001), in vision-related QOL (P < .0001), 10/12 

subcategories in NEI-VFQ-25, Ocular Surface Disease Index, and symptoms scores (P < 

.0001). Conclusion: Pilot study shows CS to have a statistically significant impact on the 

vision-related quality of life in cancer patients. 


H The Effect of Dietary Lutein, Folate, and B Vitamins on 

Cataract Progression in the Age-Related Eye Disease Study 

(AREDS) 

Presenting Author: Grace Chia-Huei Shih 

Co-Author(s): Brian Toy MD, Divya Nigam, Elvira Agron MS, John Paul San Giovanni**, 


Purpose: To determine nutritional intake effects on cataract incidence and progression. 

Methods: 4757 persons (55-80 years) were assessed with lens photographs and a food 

frequency questionnaire, divided into nutrient intake quintiles (Q1-5), and followed for 

10 years. We used multivariate logistic regression models. Results: For Q5 vs. Q1 (P < 

.05), increased lutein consumption correlated with decreased cortical cataracts (OR 0.68). 

Nuclear cataracts decreased with increased intake of vitamins B2 (OR 0.59), B6 (OR 0.64), 

and B12 (OR 0.66). No associations were seen for vitamins B1, B3, and folate. Conclusion: 

Increased dietary intake of vitamins B2, B6, B12, and lutein was associated with 

decreased incidence of cataract development or progression. 


Cataract and Nutritional Factors in a Nationally 

Representative Population Sample 

Presenting Author: Sophia Ying Wang* 

Co-Author(s): Kuldev Singh MD MPH*, Shan C Lin MD* 

Purpose: To investigate potential associations between a history of cataract surgery and 

supplementation with or serum levels of vitamins and minerals. Methods: In 6790 participants 

age ≥ 40 of the National Health and Nutrition Examination Survey, we studied the 

relationship between a history of cataract surgery and dietary supplement use (2007-2008) 

and serum levels (2005-2006) of various vitamins and minerals. Results: The highest quartile 

of supplementary zinc intake was associated with greater adjusted odds of cataract 

surgery, compared to no intake (OR 2.00, 95% CI, 1.38-2.88). Other vitamins or minerals 

were not associated with cataract surgery after Bonferroni correction. Conclusion: With 

the potential exception of zinc, we did not find compelling links between cataract and 

vitamins or minerals. 

Session Two 

Monday and Tuesday 

Presenters for Posters 282 through 320 will attend their posters 

on Monday, Nov. 12, from 2:00 PM to 3:30 PM. 


APAO Biometry and Corneal Astigmatism Before 

Phacoemulsification in Southern China 

Presenting Author: Haike Guo MD 

Co-Author(s): Ying Cui MD, Qian-li Meng MD PhD 

Purpose: To present and analyze biometry data and corneal astigmatism before phacoemulsification 

in our hospital in southern China. Methods: All eyes were examined using 

the IOLMaster. The patients were divided into 5 groups according to age. Results: Of the 

4561 patients, the mean age of the patients was 70.7 ± 10.6 years. The mean values were 

as follows: AL, 24.15 ± 2.29 mm; corneal radius, 7.65 ± 0.28 mm; WTW 11.69 ± 0.46 mm; 

178 





ACD, 2.96 ± 0.52 mm. AL and ACD decreased with age. Corneal astigmatism more than 

1.0 D was 44.7%. Astigmatism was with the rule (WTR) in 29.0% of eyes, against the rule 

(ATR) in 53.1%. The amount of corneal astigmatism increased and the axis turned to ATR 

direction with age. Conclusion: The study provides data on ocular biometry in an older 

Chinese population. 


Does Anyone Really Know What the Immediate Postop 

Pressure Is? 

Presenting Author: Allison R Jarstad 

Co-Author(s): John Steven Jarstad MD 

Purpose: To evaluate the immediate postop IOP following microincisional cataract surgery 

(MICS) and determine the accuracy of immediate IOP estimation by current standards. 

Methods: IOP was estimated by palpation, then confirmed and adjusted in the O.R. 

with a Tono-Pen. Results: Immediate postoperative IOP measurements, which appeared 

to be in a safe range by palpation measured 9 mmHg to 89 mmHg. Following repeated 

verification with tonometry, surgeon accuracy improved. Conclusion: Current practice of 

checking immediate postoperative IOP by palpation can lead to underestimation or overestimation 

of actual IOP, leading to devastating retinal artery occlusion or cystoid macular 

edema. Consideration should be given to immediate postoperative IOP adjustment prior 

to case completion. 


APAO Pseudoexfoliation as a Risk Factor for Intraoperative 

Complications During Cataract Surgery 

Presenting Author: Ravilla D Ravindran MD 

Co-Author(s): Haripriya Aravind MBBS, Rengaraj Venkatesh MBBS, Alan L Robin MD* 

Purpose: To compare the intraoperative complications of phacoemulsification in eyes 

with pseudoexfoliation (PXF) to eyes without PXF. Methods: We prospectively randomized 

1000 eyes with PXF without phacodonesis into 4 groups: 3-piece and 1-piece acrylic 

IOLs with and without capsular tension rings (CTRs). We compared these to 500 eyes with 

cataracts alone randomized to 1- and 3-piece IOLs. Results: There were no significant differences 

in zonulodialysis (0.8% vs. 0.6%, P = .67), dropped nuclei (0.2% vs. 0.2%, P = 1.0), 

or PC rents (1.4% vs. 0.8%, P = .31). Conclusion: The complication rate for experienced 

cataract surgeons is no different when operating on an eye with or without PXF. 


APAO Sharps Injuries in Cataract Surgery: Safety and 

Efficacy of the Hands-Free Technique 

Presenting Author: Marcus M Marcet MD 

Co-Author(s): Ian Yu Loong Yeung MBBCHir, David SH Wong FRCOPHTH**, Keith S K 

Chan MBBS, Jimmy Shiu Ming Lai** 

Purpose: To evaluate the change in rates of sharps injuries in cataract surgery and the 

effect of the hands-free technique for instrument transfer. Methods: Comparative, retrospective 

analysis of 7723 cataract surgeries performed over a 21-month period at a multisurgeon 

center. In the last 12 months, sharp instruments were passed using the hands-free 

technique. Results: After the use of the hands-free technique, the rate of sharps injuries 

(incidents/1000 cases) decreased by a factor of 7, from 1.72 to 0.24 (P < .005; 95% CI). 

The rate of posterior capsular rupture (PCR) remained 1% during the 21-month period (P 

= .23). Conclusion: Use of the hands-free technique resulted in a 7-fold reduction in the 

rate of sharps injuries during cataract surgery. Adoption of the technique did not affect 

rates of PCR. 


APAO To Evaluate a New Device: The Glued Endocapsular 

Ring for Sutureless Transscleral Capsular Bag Fixation in 

Traumatic Subluxations 

Presenting Author: Soosan Jacob FRCS 

Co-Author(s): Athiya Agarwal MD* 

Purpose: To evaluate a new device3/4glued endocapsular ring (ECR)3/4 for sutureless 

transscleral bag fixation in traumatic subluxations. Methods: Five patients with traumatic 

subluxation underwent in-the-bag IOL implantation after stabilizing bag with glued ECR. 

Intraoperative outcome and anatomical and functional results in the postoperative period 

were studied with 7 months of follow-up. Results: Glued ECR showed good bag stabilization 

to enable procedure completion and in-the-bag IOL implantation in all cases. All 

showed good anatomical and functional results in the postoperative period. Conclusion: 

Glued ECR is safe and effective for sutureless transscleral fixation of bag in traumatic 

subluxations. It gives vertical and horizontal stability and fornix expansion. 


OCT Study of Clear Corneal Wound After Cataract Surgery 

Presenting Author: Saverio Vincenzo Luccarelli MD 

Co-Author(s): Sacchi Matteo, Edoardo Villani MD**, Francesco Bonsignore OD, Paolo 

Nucci MD 

Purpose: To evaluate OCT features and time-related changes of clear corneal wound 

after cataract surgery. Methods: Fifteen eyes were examined prospectively with anterior 

segment OCT (AS-OCT) 1 hour and 1, 7, and 30 days after cataract surgery. Results: 

One hour after surgery, we found epithelial gaping in 67% of cases, endothelial gaping 

in 100%, epithelial misalignment in 75%, endothelial misalignment in 100%, and local 

Descemet membrane detachment in 67%. At 30 days follow-up these abnormalities were 

found respectively in 0%, 92%, 0%, 75%, and 0% of cases. Conclusion: AS-OCT was 

demonstrated to be effective in providing detailed information about clear-corneal incision 

architecture and time-related changes after cataract surgery. 


Paired-Eye Comparison of Torsional and Transversal 

Handpiece Ultrasound Systems in Phacoemulsification 


Presenting Author: Kerry Assil MD* 

Co-Author(s): Lindsay Harris OD** 

Purpose: To compare performance of transversal and torsional phacoemulsification systems. 

Methods: First eye of patients (n = 25) were randomized to transversal (Ellips FX, 

[FX]) or torsional (Ozil, [OZ]) systems. Fellow eyes used the alternate system. Follow up 

took place at 1 day, 1 week, and 1 and 3 months. Results: Mean phaco time (45.7 vs. 69.7 

sec; P = .0192), power (45.2 vs. 67.1 mJ; P = .05), and BSS used (313 vs. 350.9 cc; P = .0097) 

for the FX and OZ groups, respectively. Mean differences (OZ > FX, all P < .05): endothelial 

cell loss (1 month: 243 cells), corneal edema (1 day: 24.4 µm), and macular edema (1 week: 

38.5 µm). Conclusion: FX used less phaco time, power, and BSS, which was associated 

with less endothelial cell loss and corneal and macular edema when compared to the OZ 

system. 


Refractive Outcomes in Combined Macula Surgery and 

Phacoemulsification vs. Phacoemulsification Alone 

Presenting Author: Elona Gavazi MD 

Co-Author(s): Amilia Schrier MD, Jessica Kerns, Stanley Chang MD* 

Purpose: To determine if refractive outcomes in combined phacoemulsification (phaco) 

and macula surgery are reliable. Methods: A retrospective chart review from 2004-2012 

was done: Group 1, 91 phaco eyes, and Group 2, 113 combined phaco and macula surgery 

eyes. Predicted and outcome refraction differences, mean change, and confidence 

intervals for the difference of means were calculated for each group. Results: Mean difference 

in predicted and outcome refractions was 0.05, standard deviation (SD) of 0.64, 

range (-1.5, 1.75) in Group 1 and 0.10, SD of 0.70, range (-2, 2.63) in Group 2. Difference 

in mean change for the 2 groups is 0.15 [0.05- (-0.10)], confidence interval (-0.03, 0.34), 

P-value < .001. Conclusion: Combined phaco and macula surgery yield reliable refractive 

results. 


APAO Comparison of Different Laser Pulse Widths for 

Anterior Capsulotomy and Lens Fragmentation During Laser- 

Assisted Refractive Cataract Surgery 

Presenting Author: Harvey S Uy MD* 

Co-Author(s): Simone Schneider**, Keith Edwards* 

Purpose: To compare ease of capsule opening and utilized phacoemulsification (PE) energy 

in eyes that underwent laser-assisted cataract surgery (LCS) using either a 1500-femtosecond 

(Fs) or a 10-picosecond (Ps) laser. Methods: 373 eyes underwent LCS using a Ps 

(n = 298) or Fs (n = 75) laser followed by PE. Main outcome measures: (1) ease of capsular 

opening (1 = as difficult as manual rhexis, up to 10 = no difficulty) and (2) PE energy used 

(cumulative dissipated energy, CDE). Results: The mean (SD) ease of opening was 9.4 

(1.5) and 8.6 (2.1) for Fs and Ps lasers (P < .001). The mean (SD) CDE was 13.44 (16.79) and 

7.50 (11.16) for Ps and Fs groups (P = .004). Conclusion: Lasers with shorter pulse widths 

improve the ease of capsule opening and reduce used CDE during LACS. 





179




APAO The Toric IOL in an Unusual Situation 

Presenting Author: Ritu Arora MD MBBS 

Co-Author(s): Gaurav Goyal MBBS**, Jawahar Lal Goyal MD**, Deepa Gupta MBBS, 

Aditi Abhay Manudhane MBBS, Yashpal Goel MBBS 

We hereby report 3 unusual conditions where toric IOL is helpful for better visual outcome. 

Case 1: Cataract extraction and toric IOL implantation was done in a patient of 

complicated cataract and 4 D of astigmatism secondary to twice-operated scleral patch 

graft for necrotizing scleritis. Case 2: C-shaped compression keratoplasty was performed 

followed by a penetrating keratoplasty after 8 weeks in a patient of pellucid marginal 

degeneration. Subsequent cataract and 6 D of astigmatism was managed with toric IOL 

implantation. Case 3: Toric IOL implantation for management of cataract and astigmatism 

in patients of operated pterygium. Postoperative unaided visual acuity was better than 

20/30 in all cases. 


Anterior Segment Reconstruction After Extensive Fusarium 

Corneal Abscess 1 Month Following LASIK Surgery 

Presenting Author: Nada S Jabbur MD* 

Co-Author(s): Mohamad Bachir Abiad MD, Elias L Warrak MD 

A 25-year-old woman presented with bare light perception O.D. 1 month after LASIK 

surgery. Initially, she had a corneal abrasion followed by an infected LASIK flap which 

required amputation. Cultures were negative, and she did not respond to antimicrobials. 

Exam showed a full-thickness corneal abscess extending to sclera, and B-scan showed a 

flat retina. A full-thickness corneal abscess excision with scleral rim and extracapsular 

lens extraction was done due to corneolenticular adhesions. A donor corneoscleral rim 

was sutured in place. The patient remained aphakic and cultures grew Fusarium sensitive 

to voriconazole. Nine months postop, her BSCVA was 20/40. She had no signs of infection 

or rejection. 


APAO Good Results in Posterior Capsule Rupture Cases 

Managed by a Combined Anterior-Posterior Segment 

Surgeon 

Presenting Author: Shishir Agrawal MS DNB FRCS 

Purpose: To report the results of posterior capsule-vitreous management and IOL placement 

in inadvertent posterior capsule rupture cases. Methods: Fifty referred cases of 

inadvertent posterior capsular rupture were managed meticulously by vitrectomy and IOL 

placement 3/4in the bag, sulcus, or anterior chamber3/4 by a combined anterior-posterior 

segment surgeon. Results: Good visual and anatomical results were attained in the majority 

of cases. Conclusion: A good management of posterior capsular tear cases by a 

posterior segment surgeon gives invariably a good postoperative result. 


APAO Anatomical and Visual Outcomes of Descemetopexy 

in Post-Cataract Surgery Descemet Membrane Detachment 

Presenting Author: Rajat Jain MBBS MS 

Co-Author(s): Somasheila I Murthy MD 

Purpose:To study anatomical and visual outcomes of descemetopexy in post-cataract 

surgery Descemet detachment (PC-DMD). Methods: Retrospective review of 60 PC-DMD 

patients (2006-2011), grouped based on intervention (Air/C3F8 injection) and timing (≤ 8/> 

8 days). Results: Groups were comparable in age, sex, cataract, DMD severity, and BCVA. 

On comparing time and mode of intervention at 1 month, results were comparable within 

subgroups for BCVA (P = .39, .24), DM attachment (P = .3, .2), BCVA 3 20/40 (P = .17, .13), 

and need for Descemet-stripping automated endothelial keratoplasty (P = .3, .44). Pupillary 

block seen in 19.5% with C3F8 and none in air (P = .02). Conclusion:Early or late reattachment 

of DMD with air and C3F8 is equally effective. However, air is safer, with fewer 

complications, such as pupillary block. 


Iris Sutured IOL Repositioning of Dislocated IOLs 

Presenting Author: David R Lally MD 

Co-Author(s): Marc J Spirn MD, Richard S Kaiser MD*, Mitchell S Fineman MD* 

Purpose: To compare outcomes of iris-sutured IOL repositioning of dislocated IOLs to 

anterior chamber IOL (AC-IOL) exchange. Methods: Retrospective consecutive case series 

of 20 patients with iris-sutured IOL repositioning and 26 patients with AC-IOL exchange for 

dislocated IOLs by retina surgeons. Main outcomes: visual acuity (VA), intra/postoperative 

complications. Results: Paired t test analysis: Iris-sutured IOLs: mean VA prior to dislocation 

0.48 ± 0.52 (20/60) not statistically different to best mean VA post-surgery 0.50 ± 

0.58 (20/64) ( P = .96, Snellen logMAR equivalent). AC-IOL exchanges: mean VA prior to 

dislocation 0.57 ± 0.47 (20/76) statistically different to best mean VA post-surgery 0.72 ± 

0.56 (20/105) (P = .03). Mean follow-up was 267 and 63 days, respectively. Conclusion: 

Repositioning dislocated IOLs through iris suturing is an effective solution. 


Role of Anterior Segment OCT in Diagnosis and 

Management of Descemet Detachment in Opaque Cornea 

Presenting Author: Ravikrishna Nrusimhadevara MBBS 

Co-Author(s): Vasudha Erraguntla MBBS**, Vikas Sharma MBBS 

Purpose: To highlight the importance of anterior segment OCT in diagnosing Descemet 

detachment in a case of opaque cornea. Methods: Seventy-one-year-old gentleman underwent 

cataract surgery for very dense cataract. Postoperatively he developed corneal 

edema, which failed to resolve in 2 weeks, resulting in vision of counting fingers at 1 

foot. Pseudophakic bullous keratopathy was suspected. Slitlamp examination showed 

edematous cornea with no view beyond stroma. Anterior segment OCT showed Descemet 

detachment. Patient underwent SF6 tamponade intracamerally. Immediately after, OCT 

confirmed apposition of Descemet membrane. Results: Vision improved to 20/30 with 

complete resolution of edema in 2 weeks. Conclusion: Anterior segment OCT can help 

identify Descemet detachment in opaque corneas. 


Prognostic Factors for Visual Acuity Outcome Following 

Vitreous Loss During Cataract Surgery 

Presenting Author: Michal Schaap-Fogler MD 

Co-Author(s): Philip J Polkinghorne MD*, Nadeem Ahmad MBBS, Rita Ehrlich MD 

Purpose: To determine prognostic factors for visual outcome following vitreous loss 

during cataract surgery Methods: Retrospective study on vitreous loss during cataract 

surgery cases. Data collected included age, gender, preoperative and postoperative visual 

acuity, surgeon experience, complications, axial length, and comorbidity. Results: 179 

patients followed for 12 ± 13 months. Visual acuity worse than 6/12 was associated with 

postoperative complications (OR 6.25, 95% CI, 1.378-30.9) and presence of ocular comorbidities 

(OR 4.45, 95% CI, 1.1-18.00). Secondary vitrectomy and aged patients were not 

significantly associated (P ≥ .05) Conclusion: Poor visual acuity function was associated 

with postoperative complications and comorbidity. 


Viscoelastic-Induced Interlamellar Stromal Keratopathy 

Presenting Author: Rosalind C Vo MD 

Co-Author(s): Julio Narvaez MD 

The authors report a case describing a new clinical entity: viscoelastic-induced interlamellar 

stromal keratopathy that developed during cataract surgery on a patient with a 

history of LASIK. The LASIK flap edge was lifted and the viscoelastic removed by interface 

irrigation. The keratopathy improved at the postoperative Day 1 visit with UCVA of 20/60 

from count fingers. BCVA 2 weeks later was 20/40. Interlamellar stromal keratopathy after 

LASIK has been described as a result of high IOP. We present the first case of viscoelasticinduced 

interlamellar stromal keratopathy (VISK) occurring during cataract surgery in a 

patient with a history of LASIK. This new entity requires recognition in order to undertake 

appropriate management. 


Zonular Capture Haptic 

Presenting Author: Paul Beer MD* 

Co-Author(s): Paul L Kaufman MD*, Mary Ann Croft MS*, Alexander Katz MD**, Gregg 

Heatley MD, Jarred McDonald** 

Purpose: To test a zonular capture haptic (ZCH), a first stage for an “out of the bag” 

accommodative-disaccommodative IOL. Methods: A ZCH was implanted in a surgically 

aniridic eye of 2 rhesus monkeys (Macaca mulatta). Haptic activation surgery was completed 

5 weeks later. Fifty-six days following implantation, haptic function was assessed 

with goniovideography, ultrasound biomicroscopy, and a plano perfusion lens. Supramaximal 

accommodation was induced by stimulation with 40% carbachol. Results: Prior to 

surgery, supramaximal accommodation reduced the diameter of the ciliary ring and capsular 

bag 1.87 mm and 0.99 mm, respectively. Postimplantation ciliary ring diameter was 

180 





reduced by 1.38 ± 0.085 mm, capsular bag diameter by 1.62 ± 0.1 mm, and the ZCH by 1.06 

± 0.57 mm. Conclusion: Both ZCHs were secure at 56 days and responded appropriately 

to zonular tension. 


Impact of Microvacuoles on Optical Performance of 

Hydrophobic Acrylic IOLs 

Presenting Author: George Beiko MD* 

Purpose: To assess image quality in hydrophobic acrylic IOLs with microvacuoles. Methods: 

Microvacuole formation was induced using an in vitro process by immersion in saline. 

The microvacuoles were analyzed using dark field photos and a confocal microscope. 

Modulation transfer function (MTF) and straylight scatter were measured on an optical 

bench. Results: Confocal images will be presented. Microvacuoles had no effect on MTF. 

All lenses without microvacuoles have straylight levels lower than a 20-year-old healthy 

human lens; lenses with glistenings have straylight levels greater than a 20-year-old lens. 

Multifocal lenses with glistenings have straylight levels approaching that for a 70-year-old 

human lens. Conclusion: Microvacuoles in hydrophobic acrylic IOLs increase straylight 

levels and can impact adversely on visual performance. 


Spherical Aberration at Different Pupil Diameters Before 

and After Aspheric IOL Implantation 

Presenting Author: Fabrizio I Camesasca MD* 

Co-Author(s): Massimo Vitali**, Mario R Romano MD* 

Purpose: To evaluate prospectively internal ocular spherical aberration (SA) at different 

pupil diameters before and after implantation of an aspheric IOL (SN60WF) with a mean 

Z(4,0) of -0.20 µ. Methods: Sixty-three cataract surgery eyes received an aspheric IOL 

(mean power +20.38 ± 4.03 D). SA was evaluated (Nidek OPD aberrometer) preoperatively 

and postoperatively for a 3-, 4-, and 5-mm pupil. Results: Mean follow-up was 19.90 ± 

9.40 days. Internal SA decreased significantly (P < .05) for a 3-mm pupil (from 0.04 ± 0.03 µ 

to 0.03 ± 0.02 µ), a 4-mm pupil (from 0.13 ± 0.16 µ to 0.08 ± 0.06 µ), and a 5-mm pupil (from 

0.28 ± 0.23 µ to 0.26 ± 0.24 µ). Conclusion: Aspheric IOL provided efficient reduction of 

internal SA at different pupil diameters. 


Multifocal Toric IOL Compared to Multifocal IOL Combined 

With Limbal Relaxing Incisions for Correction of Moderate 

Astigmatism During Cataract Surgery 

Presenting Author: Vinod U Gangwani MBBS 

Co-Author(s): Nino Hirnschall MD, Oliver Findl MD*, Vincenzo Maurino MRCOPHTH* 

Purpose To compare the multifocal toric IOL with a multifocal lens combined with limbal 

relaxing incisions (LRI). Methods Thirty patients with corneal astigmatism between 1.0 

and 2.5 D received a multifocal-toric IOL in one eye and a standard multifocal IOL combined 

with LRI in the other eye. Results Preoperative astigmatism was 1.85 D in the toric 

IOL eyes and 1.67 D in the LRI eyes. At 3 months, the mean distance vision in the toric IOL 

and LRI eyes was 0.12 and 0.17 (P = .10), respectively, and the near vision was 0.41 and 

0.37 (P = .12), respectively. The mean manifest residual cylinder was 0.41 D and 0.79 D, 

respectively (P = .002). Conclusion:The multifocal-toric IOL had a better performance. 


APAO Early Clinical Experience of a New Hydrophobic IOL 

Presenting Author: Peter C Heiner MBBS* 

Purpose: To evaluate the visual, refractive, and keratometric performance of the enVista 

IOL (B + L). Methods: Cataract surgery was performed on 46 eyes. Unaided vision (UVA), 

subjective refraction, corrected visual acuity (BCVA), and keratometry were recorded preand 

postoperatively to 3 months. Results: At 3 months postoperatively, 82% of eyes had 

a Snellen UVA of 6/9 or better and 100% of eyes had a BCVA of 6/9 or better. Mean 

spherical equivalent (SE) refraction at 3 months was -0.15 ± 0.51 (expected -0.31 ± 0.33) 

where 80% and 100% of eyes had a SE refraction within 0.50 D and 0.75 D, respectively. 

Mean surgically induced astigmatism was 0.39 D. Conclusion: Preliminary analysis of 

the enVista IOL shows promising results in terms of visual and refractive postoperative 

outcomes. 


Comparison of the Efficacy and Rotational Stability of Alcon 

AcrySof Toric IOL and Abbott Tecnis Toric IOL 

Presenting Author: Sergio G Monteiro MD 

Co-Author(s): Mariana Sa Cardoso MD**, Joana Pires MD**, Manuel S Mariano MD** 

Purpose: To compare the efficacy and rotational stability of 2 toric IOLs, Alcon AcrySof 

Toric and Abbot Tecnis Toric. Methods: Thirty-two eyes with cataract and topographic 

corneal astigmatism higher than 1.00 D and lower than 3.00 D; 16 received an Alcon AcrySof 

Toric IOL and 16 received an Abbott Tecnis Toric IOL. Outcomes of visual acuity and 

IOL rotation were evaluated 1 day and 1, 3, and 6 months after surgery. Results: Results 

showed a UCVA of 20/30 or better in all patients, and the mean rotation was < 6° for both 

toric IOLs. Conclusion: Short-term follow-up showed a favorable efficacy, rotational stability, 

and safety results supporting the use of these toric IOLs for patients with cataracts 

and corneal astigmatism. 


A New IOL for Microincision Cataract Surgery 

Presenting Author: Dimitra M Portaliou MD 

Co-Author(s): Ioannis G Pallikaris MD* 

Purpose: This in vitro study explores the possibility of insertion of a new foldable multicomponent 

IOL through incisions less than 1.8 mm. Methods: The IVO, MC-IOL allows 

surgeons to provide a customized adjustable refractive implant combining all degrees of 

sphere, cylinder, and multifocality with a small inventory of parts. Results: The IVO, MC- 

IOL lens, by dividing its total dioptric power, allows the development of thinner lenses that 

can be injected through smaller incisions, facilitating micro-incision surgery. The use of 

the IVO, MC-IOL could decrease the incision size to approximately 1.3 mm. Conclusion: 

The recent development of IOL technology can lead to smaller incision size. 


Multifocal IOL Calculations in the Post-LASIK Cataract 

Eye: A Comparison of the American Society of Cataract and 

Refractive Surgery IOL Calculator and Holladay II 

Presenting Author: Navaneet S C Borisuth MD PhD* 

Co-Author(s): Darshan S Hullon, Cheryl L Swanson COA, Sahiba K Chailertborisuth**, 

Susan Eaker 

Purpose: To compare the accuracy of Holladay II and the ASCRS IOL Calculator for multifocal 

IOL (mIOL) power calculations in post-LASIK cataract eyes. Methods: Postoperative 

refractive data were used to compare back-calculated optimum IOL powers (BCI) to those 

predicted by Holladay II and the ASCRS IOL Calculator in 11 eyes of 10 patients undergoing 

diffractive mIOL implantation after myopic LASIK (n = 6) or hyperopic LASIK (n = 5). Results: 

BCI correlated highly with Masket (r = 0.972), Haigis-L (r = 0.967), ASCRS average 

IOL power (r = 0.963), modified Masket (r = 0.960), and Holladay II (r = 0.956). Conclusion: 

The Masket and Haigis-L formulae most effectively predicted postoperative refractive outcomes 

in mIOL implantation of post-LASIK cataract eyes. 


Intraocular Surgical Options to Correct Postkeratoplastic 

Astigmatism 

Presenting Author: Patrizia Busatto MD 

Co-Author(s): Giobatta Driussi MD, Giorgio Beltrame MD** 

Forty eyes of 30 patients with penetrating keratoplasty (PK) and stable refraction following 

suture removal for almost 6 months underwent astigmatism correction using pseudophakic 

or phakic (T ICL or T Artiflex) toric lenses (T-IOL). We evaluated pre- and postop UCVA, 

BCVA, efficacy and safety indexes, complications, and changes from the expected axis 

of the lenses. The follow-up time was 6 to 18 months. In every group of T-IOL there was 

an improvement from pre- to postop visual acuity and good efficacy and safety index. No 

significative changes in lenses axis position were detected: 90% of T-IOL were within 5 

degrees from the expected position. In the T Artiflex group the endothelial cell loss was 

8.3% after 12 months of follow-up. Every one of the previous procedures is effective in 

correcting intraocular post-PK astigmatism and anisometropia. 





181




APAO Higher-Order Aberrations Produced by Dual Aspheric 

IOL Complexes 

Presenting Author: YiWei Goh MBBS 

Co-Author(s): James McKelvie MD PHD, Brian McArdle, Ellen Wang, Charles McGhee 

PhD FRCOphth FRANZCO* 

Purpose: To characterize higher-order aberrations (HOA) resulting from combined primary 

aspheric and supplementary IOL complexes. Methods: HOAs were compared between 3 

aspheric primary IOL models alone and in combination with an aspheric supplementary 

IOL. HOAs were assessed by repeated measurements (n = 60) of multiple IOLs (n = 9) 

using an aberrometer and a model eye. Results: All IOLs demonstrated consistent HOAs 

individually and as a complex. Negative spherical aberration was less than manufacturerstated 

values for the primary IOLs and was positive for all supplementary IOLs. Conclusion: 

Dual IOL HOA characterization may assist in IOL selection to minimize postoperative 

total HOA and improve visual outcomes. 


Clinical Outcomes of Tecnis Multifocal ZMB00 Implantation 

in Post-LASIK Cataract Eyes 

Presenting Author: Darshan S Hullon 

Co-Author(s): Cheryl L Swanson COA, Susan Eaker, Sahiba K Chailertborisuth**, 

Navaneet S C Borisuth MD PhD* 

Purpose: To evaluate refractive outcomes of post-LASIK cataract eyes undergoing phacoemulsification 

(PE) with Tecnis Multifocal ZMB00 implantation. Methods: Ten eyes of 

9 patients underwent PE with ZMB00 implantation using the ASCRS IOL calculator to 

optimize IOL powers. We analyzed the postoperative MRSE, uncorrected near VA (UNVA), 

and the rate of excimer laser enhancement (ELE) to obtain the best UNVA. Results: After 

PE, the MRSE was -0.05 ± 1.09 D. UNVA significantly improved from 0.50 ± 0.10 to 0.05 ± 

0.08 (P < .001). Forty percent of eyes were within ± 0.5 D of target outcomes, and 100% 

were within ± 1.5 D. ELE was performed in 5 eyes because of residual myopia (n = 3) 

or hyperopia (n = 2). Conclusion: Implantation of the Tecnis 1-piece multifocal lens in 

post-LASIK cataract eyes results in excellent UNVA but is associated with a high rate of 

excimer laser enhancement. 


Visual Function and Mobility After Multifocal vs. Monofocal 

Lens Implantation 

Presenting Author: Mary Gerard Lynch MD 

Co-Author(s): Courtney D Hall PhD, Audrey H Gutherie PhD, Casey Bowden, Donna N 

Loupe CO COMT 

Purpose: To assess visual function and mobility in patients with monofocal IOLs vs. multifocal 

IOLs. Methods: Twenty adults with monofocal IOLs and 14 adults with multifocal 

IOLs were evaluated by fall history and confidence questionnaires, vision, contrast and 

glare sensitivities, depth perception, balance, dynamic gait index, gait speed, and way 

finding in a virtual environment. Results: Vision, depth perception, and way finding were 

similar between groups. Contrast sensitivity was better with monofocal IOLs and less 

affected by glare (P = .02). Multifocal patients had fewer falls and higher confidence (P < 

.004), better gait speed (P = .03) and dynamic gait index (P = .02). Conclusion: Multifocal 

IOLS may have some advantage over monofocal IOLS in terms of mobility and fall risk. 


Optical Quality Analysis System Visual Quality After 

Implantation of Presbyopic IOLs 

Presenting Author: Mujtaba A Qazi MD* 

Co-Author(s): Richard C Chu DO*, Jay Stuart Pepose MD PhD* 

Purpose: To compare Optical Quality Analysis System (OQAS) visual quality metrics 

following bilateral implantation of 3 presbyopia-correcting IOLs. OQAS evaluation was 

performed 1 month postop in a prospective, randomized study of 3 presbyopia-correcting 

IOLs: Crystalens AO (n = 33), ReSTOR D1(n = 29), and Tecnis ZMA00 (n = 29).The mean Objective 

Scatter Index for the Crystalens AO (1.1) was about 50% less (P < .03) than for both 

Tecnis (1.8) and ReSTOR (1.8). This correlated with a narrower PSF for Crystalens AO than 

ReSTOR. The MTF cut-off of the Tecnis was not statistically different from the Crystalens 

AO, but greater than for the ReSTOR (P = .04).The OQAS provides objective measurement 

of visual quality after presbyopia-correcting IOL implantation, with the Crystalens 

AO showing the least scatter and ReSTOR the lowest MTF and Strehl. 


APAO Effect of Intravenous Sedation on Visual Experience 

and Fear in Patients Undergoing Phacoemulsification: A 

Randomized Controlled Trial 

Presenting Author: Tiakumzuk Sangtam MBBS 

Co-Author(s): Kah Guan Au Eong MBBS FRCS**, Joselo Delute Macachor MBBS FRCS, 

Chee-Chew Yip MBBS FRCS, Benjamin C M Chang MBBCh, Uma Shridhar Iyer MBBS 

FRCS, Kwong Fah Koh MBBS FRCS 

Purpose: To study the effect of intravenous midazolam on visual experience and fear 

during phacoemulsification under local anesthesia. Methods: 209 patients were randomized 

to midazolam (MZ = 109) or normal saline (NS = 100) groups. Postoperative interview 

with a standardized questionnaire about their intraoperative visual experiences, including 

perception of light, colors, movements, and fear, was performed. Results: Patients from 

both the groups reported perception of light (MZ = 51.03%, NS = 48.97%), colors (MZ = 

51.63%, NS = 48.37%), and movements (MZ = 46.79%, NS = 59%). Mean fear score was 

0.83 and 1.56 for MZ and NS group, respectively (P = .003). Conclusion: Results suggest 

that intravenous midazolam reduces fear. 


APAO The Effect of Binaural Beat Audio on Operative 

Anxiety in Patients Undergoing Local Anesthesia for 

Ophthalmic Surgery 

Presenting Author: Pornpattana Vichitvejpaisal MD 

Purpose: To investigate anxiolytic effects of binaural beat (BB) and musical interventions 

(MI) during cataract surgery. Methods: Prospective randomized controlled study. Randomly 

assigned to BB, MI, or Control group. Vital sign measurement and anxiety level assessment. 

Results: Anxiety level showed statistically significant decreased in MI (P < .001) 

and BB (P < .001) groups and decreased systolic blood pressure in MI (P = .04) and BB (P 

< .043) groups when compared to Control group. Conclusion: BB and MI during cataract 

surgery could significantly reduce patient anxiety levels and lower systolic blood pressure. 


A Novel Classification for Grading Ectopia Lentis 

Presenting Author: Aman Chandra MRCSED FRCOPHTH 

Co-Author(s): Philip James Banerjee BMBS FRCOPHTH, David G Charteris MD MBChB 

Purpose: To devise and validate a novel grading system for ectopia lentis (EL). Methods: 

The GEL system describes the direction and extent of lens displacement. Fifty-five images 

of EL were graded independently by 2 ophthalmologists and 1 physician and repeated 

after 8 weeks. Five patients (11%) were assessed clinically in addition to their images. 

Cohen Kappa coefficient was calculated. Results: Inter-ophthalmologist agreement was 

high at both assessments (k = 0.91 and 0.93, P < .0001). There was significant intra-rater 

agreement (k = 0.89, 0.82, P < .0001). Analysis between ophthalmologist and physician 

revealed k = 0.77 (P < .0001). Agreement between clinical appearances and photographs 

was complete (k = 1). Conclusion: This novel grading system is reproducible and simple 

and may have widespread application among those who manage and research EL. 


Efficacy of Toric IOL in Cataract With Cornea Astigmatism: 

Resident Experience 

Presenting Author: Dongmei Chen MD 

Co-Author(s): Lingo Y Lai MD, Jason Ou MD**, Amy M Waddell MD, Jennifer L 

Eikenberry MD, Yang Sun MD, Chi-Wah (Rudy) Yung MD 

Purpose: To evaluate the outcomes of toric IOL in cataract with cornea astigmatism, 

performed by residents in Indiana University. Methods: Retrospective consecutive case 

series. Patients with visually significant cataract, ≥ 1.00 D regular corneal astigmatism, 

uncomplicated phaco, and IOL implant. Toric IOL group: 13 patients, 16 eyes, AcrySof Toric 

SN6AT3/4/5. Control group: 28 patients, 30 eyes, AcrySof SN60WF IOL. Results: (1) 53% 

and 87% of patients achieved ≤ 0.50 D or ≤ 1.00 D of residual cylinder in Toric group, 

compared to 40% and 20%, respectively, in Control group. (2) 46% and 100% of Toric 

patients achieved UCVA of ≥ 20/25, ≥ 20/40. (3) 69% of Toric lens were within 10 degrees 

of intended axis. Conclusion: Toric IOL performed by PGY-4 residents effectively improve 

visual outcome, comparable to Alcon clinical data. 

182 






Unpredictability of Femtosecond LASIK Enhancement 

Following Femtosecond Intrastromal Arcuate Incision With 


Presenting Author: James C Loden MD* 

Purpose: To report adverse event of iatrogenic astigmatism induction of over 6 D after 

uncomplicated femtosecond LASIK. Methods: Retrospective case review with video of 

LASIK enhancement procedure and intrastromal incision gape. Result: LASIK enhancement 

resulted in iatrogenic astigmatism induction of greater than 6 D with the axis being 

flipped and a loss of 1 line of BCVA. Conclusion: This case suggests PRK may be preferable 

to LASIK enhancements after intrastromal arcuate incisions as the overlying intact 

Bowman membrane provides significant incision stability. 


eCME and Ophthalmology: The Toronto Visiting Professors 

Rounds Series 

Presenting Author: Zaid Mammo MD* 

Co-Author(s): Wai-Ching Lam MD* 

Purpose: To assess how the Toronto Visiting Professors Rounds Series (TVPRS) influences 

the knowledge, perceptions, and practice patterns of Canadian ophthalmologists. Methods: 

Online surveys, utilizing multiple choice and reflection questions, were administered 

before and after online viewing of the University of Toronto Ophthalmology grand rounds 

as screencasts. Results: At 6 months, 124 users registered and watched 429 screencasts. 

Most participants found TVPRS to be organized and user friendly. Mean pre-screencast 

knowledge score was 65% vs. 89% post-screencast (P = .002). Post-screencast, 73% replied 

in favor of changing future practice. Conclusion: TVPRS was well received, with 

demonstrated knowledge gain and practice change. The long-term applicability of the 

results requires more research. 


APAO Central Retinal Thickness and Refractive Power After 

Epiretinal Membrane Surgery 

Presenting Author: Mao Kusano MD PHD 

Co-Author(s): Kiyoshi Suzuma MD, Eiko Tsuiki DOMS, Masafumi Uematsu MD, Takashi 

Kitaoka MD** 

Purpose: To evaluate central retinal thickness (CRT) and refractive power following 

epiretinal membrane (ERM) surgery. Methods: In this prospective study, CRT and refractive 

power were evaluated in 20 eyes after cataract surgery with simultaneous vitreous 

surgery for ERM. Results: The mean CRT before surgery was 410.5 ± 80.9 µm and decreased 

after surgery. The mean difference between the predicted and actual postoperative 

refractive power within 2 weeks after surgery was -0.17 ± 0.55 D, and a gradual 

decrease in myopic shift was observed. A positive correlation was observed between CRT 

before surgery and postoperative refractive power within 2 weeks after surgery (P < .05). 

Conclusion: These findings suggest that CRT before surgery is a useful prognostic indicator 

for refractive power after ERM surgery. 


APAO Anterior Vitrectomy at the Time of Cataract 

Surgery: A Whole-Population Study of the Incidence and 

Consequences 

Presenting Author: Jonathon Q Ng MBBS* 

Co-Author(s): Antony Clark MBBS, Nigel Morlet MBBS* 

Purpose: To determine the incidence and long-term outcomes of anterior vitrectomy at 

the time of cataract surgery. Methods: Data linkage identified all cataract operations requiring 

anterior vitrectomy and occurrence of sight-threatening complications. Cases were 

validated using hospital medical record. Results: Of 129,982 cataract operations, 1342 

(10%) required anterior vitrectomy. There were 2 peaks in incidence, the early 1980s and 

early 1990s. A sight-threatening complication occurred in 11% of cataract operations requiring 

anterior vitrectomy. Conclusion: Sight-threatening complications are more likely 

after operations requiring anterior vitrectomy. Anterior vitrectomy rates mirror learning 

curves associated with the adoption of new surgical techniques. 


Calculation of Intraocular Lens Power After Laser Vision 

Correction Using a New Clinical Method Compared to Other 

No-History Methods 

Presenting Author: Andrea I Zambrano MD 

Co-Author(s): John G Ladas MD, Alisa Kim MD, Kimberly Pratzer COT, Oliver Douglas 

Schein MD*, Kyle Huyn, Beatriz Munoz MSC, Walter J Stark MD*, John D Gottsch 

MD, Yassine J Daoud MD 

Purpose: Evaluation of a new method for IOL power calculation after LASIK/PRK for 

myopia in the absence of clinical history. Methods: Seventy-eight eyes of 60 patients 

with cataract surgery between 2002 and 2011. Flattest Km and a target refraction of -1.2 

D were used for IOL calculation. Mean predicted refractive error (MPRE) and mean predicted 

IOL power error (MPIPE) were calculated and compared to Shammas and Haigis-L. 

Results: MPRE for the Flattest Km methods was -0.06 ± 1.2; Haigis-L, 0.3 ± 0.9; and 

Shammas, -0.01 ± 0.9 (P < .001). MPIPE were -0.1 ± 1.5, 0.5 ± 1.2, and 0.08 ± 1.2 (P < 

.001), respectively. Conclusion: Mean refractive errors were within 1 D. The flattest Km 

methods resulted in less risk of hyperopia; hence it provides a possible alternative to the 

existing formulas. 

Computers, Information Technology 

Session One 


Presenters for Posters 40 and 41 will attend their posters on 

Sunday, Nov. 11, from 11:00 AM to 12:30 PM. 


H Digital Devices Are Not Always Helpful Tools 

Presenting Author: Javier A Jardon MD 

Co-Author(s): Maria C Fernandez, Omar García MBBS, Luis A Serrano MD 

Purpose: We evaluated the accuracy and precision of cell phone digital color tests. 

Methods: Fifty eyes with vision of 20/200 or better were tested using Ishihara plates 

from Ishihara’s Test for Colour Deficiency, concise edition, 2001, and 2 digital media applications 

(appA and appB) installed to an iPhone4G. Results: When the book was compared 

to the digital appA no differences were found among answers (P = .315); in contrast, 

differences were found when the book was compared to the appB (P = .0026). When both 

digital tests were compared, differences among answers were found to be statistically 

significant (P = .027). Conclusion: Our study showed that appA has accuracy and precision 

comparable to the book, but appB was neither accurate nor precise. Portable devices 

are not always reliable methods of testing color vision. 


APAO Application of Computational Means to Develop 

Acoustic Approach to Aid the Visually Impaired 

Presenting Author: Pavan Kumar MS 

Co-Author(s): Durgesh Kumar MBBS, Pankhuri Johari MBBS MS 

Purpose: To develop an algorithm-based acoustic system. Methods: To utilize the stored 

information pattern of an event stored in destination neuron of brain. A head-mounted 

stereo camera, radar based technique was employed to identify moving and static objects. 

The common objects identified by interpreter and other things made their sense via characteristic 

acoustic signal. Multistaged information processing was done by artificial intelligence, 

ANN, and GA. A temporal distribution of audio bit pattern is to support stereoacoustic 

approach. Results: Stereo-acoustic imaging approach is capable of reproducing 

3-D stereo-acoustic frame. Conclusion: Two-way object recognition-interpretation via 

speaking device and acoustic signal provide firm steps to user. 





183



Session Two 



Monday, Nov. 12, from 11:00 AM to 12:30 PM. 


Implementation of Electronic Health Record Systems in 

Ophthalmology: Impact on Clinical Documentation 

Presenting Author: David Sebastian Sanders 

Co-Author(s): Sarah Read-Brown, Daniel C Tu MD*, Thomas Hwang MD, John C 

Morrison MD, Thomas Yackel MD MPH, Michael F Chiang MD* 

Purpose: To evaluate differences in ophthalmology documentation between paper vs. 

EHR systems in an institution that implemented an EHR (Epic; Madison, Wisc., USA) in 

2006. Methods: Database queries were performed to identify and compare 50 charts with 

the same clinical findings documented by the same providers in the same patients, using 

both paper and EHR on different dates. Results: In paper charts, 41/50 included drawings 

and 43/50 utilized checkbox templates. All EHR charts included text-based interpretations 

of clinical findings, but none had drawings. All EHR notes were longer than corresponding 

paper notes. Example cases will be presented. Conclusion: There were fundamental differences 

in the nature of paper vs. EHR documentation in these cases. 


APAO A Novel, Integrated Computer Tool for Identifying 

Digital Fundus Images With Diabetic Retinopathy 

Presenting Author: Augustinus Laude MBChB 

Co-Author(s): Muthu Krishnan**, Chua Kuang Chua PhD**, Lim Choo Min PhD**, Eddie 

Ng, Rajendra U Acharya PhD** 

Purpose: To describe an automated classifier of normal and abnormal diabetic retinopathy 

(DR) digital fundal images. Methods: Using local binary pattern, entropies, and invariant 

moments to extract the salient features (eg, exudates, hemorrhages) within a digital 

image, we propose a novel integrated index called the diabetic retinopathy index (DRI) 

as a measure of texture variation. Results: Using 50 normal and 120 images with DR 

graded by experienced ophthalmologists, we successfully categorized the images and 

found significant difference in the DRI of normal 3.27 ± 0.000157 vs/ images with DR 2.94 

± 0.000559 (P < .0001). Conclusion: The DRI derived from our tool can aid in identifying 

normal and images with DR that may have application in fundus photography-based 

screening programs. 


Session One 





APAO Visual Rehabilitation with Rose-K2 IC and Rose-K2 

Post Graft Contact Lenses in Irregular Corneas 

Presenting Author: Umang Mathur MD 

Co-Author(s): Manisha Acharya MS**, Shyama Devi OD**, Abhilekh Arneja OD** 

Purpose: To evaluate the role of Rose K2 irregular cornea (IC) and post-graft (PG) contact 

lenses in improving the visual outcome in patients with irregular corneas. Methods: 

Forty-four eyes were fitted with rose K2 IC and PG contact lenses, and vision obtained 

was compared with spectacles. Results: BCVA of 20/60 or better was achieved in 4 eyes 

(10.52%) with spectacles and in 37 eyes (97.36%) with rose K2 IC and PG contact lenses, 

with minimum improvement of 3 lines over spectacles. Conclusion: Rose K2 IC and PG 

contact lenses, with their unique design, provide improved visual function in irregular corneal 

profiles of myriad etiologies. 


Intravenous Immunoglobulin in the Treatment of Refractory 

Ocular Cicatricial Pemphigoid 

Presenting Author: Peter Y Chang MD 

Co-Author(s): Sana S Siddique MD, Siddharth S Pujari MBBS**, Ujwala Baheti 

MBBS, John Mauro DO, Shigeyasu Kazama MD**, C Michael A Samson MD*, Abdul 

Razzaque Ahmed MD**, C Stephen Foster MD* 

Purpose: To examine the treatment outcomes of intravenous immunoglobulin (IVIg) in 

patients with ocular cicatricial pemphigoid (OCP) refractory to other immunomodulatory 

therapies. Methods: Retrospective case series. Results: A total of 21 patients with refractory 

OCP were included. Mean age of disease onset was 67 years. Mean duration of 

IVIg was 34 months. Mean follow-up time was 58 months. Nine patients (43%) achieved 

disease control and maintained vision while continuing IVIg at last follow-up visit. Six 

patients (29%) remained in remission after stopping IVIg. IVIg was aborted in 1 patient 

(4.5%) due to severe pancytopenia. Five patients (24%) failed to respond to IVIg: 3 had 

disease progression and became blind in both eyes, while 2 others required addition of 

rituximab for OCP control. Conclusion: IVIg therapy may be considered in refractory OCP. 


Topical Treatment With Tacrolimus 0.03% Ointment 

for Subepithelial Infiltrates Secondary to Adenoviral 

Keratoconjunctivitis 

Presenting Author: Eliya S Levinger MD 

Purpose: To evaluate treatment with topical tacrolimus 0.03% ointment in patients with 

subepithelial corneal infiltrates (SEIs). Methods: A prospective case study. All patients 

were treated with topical corticosteroids previously or stopped the medication secondary 

to IOP elevation. Results: Eleven eyes were included. Mean follow-up was 6 ± 2 months. 

The mean BCVA improved statistically significantly after treatment from 0.67 ± 0.29 to 

0.98 ± 0.20. Seventy-seven percent of patients reported no foreign body sensation, glare, 

or side effects with treatment. Conclusion: Tacrolimus ointment is good alternative treatment 

in patients who do not respond or have unwanted side effects from topical steroids. 


APAO Mooren Ulcer: Two Decades of Experience at a 

Tertiary Care Center in South India 

Presenting Author: Anurag Mathur MBBS 

Co-Author(s): Jatin Naresh Ashar MD, Virender S Sangwan MBBS 

Purpose: To describe clinicoepidemiological features of Mooren ulcer (MU). Methods: 

Retrospective analysis (1987 to 2009). Results: 145 patients of MU (M:F, 125:20; 51.7 + 

20.3 years) had unilateral (UL) (66, 43.7 + 20.9 years) bilateral (BL) (79, 58.3 + 17.3 years; 

P = .001) disease of 1 to 156 weeks. Prior trauma, 33, and cataract surgery, 21. Visual 

acuity: no light perception to 20/20. > 6 hrs of peripheral involvement, 118 (UL, 6.6 + 2.8 

hrs, and BL, 7.9 + 2.7 hrs, P = .01). Mean stromal thinning: 75.5%. Mean follow-up: 52.8 

weeks. Therapy was topical steroids, oral steroids, 66; IV methyl prednisolone, and cyclophosphamide, 

16; conjunctival resection, 104; AMG, 1; keratoplasty, 19. Complications: 

infection, 26; reactivation, 16. Seventy-nine healed. Conclusion: MU needs aggressive 

immunosuppression for healing. 


Keratitis in Autoimmune Polyglandular Syndrome Type 1 

Presenting Author: Khalid F Tabbara MD* 

Co-Author(s): Nazri Omar MD, Frida Dalin MD, Olle Kampe MD PhD 

Purpose: The main objective of this study is to report tyrosine hydroxylase (TH) autoantibodies 

in cases of severe keratitis in patients with autoimmune polyglandular syndrome 

type 1 (APS-1). Methods: Sixteen patients with APS-1 were included. All cases underwent 

biomicroscopy and blood samples were tested for a panel of autoantibodies and 

AIRE gene mutations. Results: There were 10 females and 6 males, with an age range of 

8-42 years and a mean age of 17.5 years. Six out of 7 patients (86%) with severe keratitis 

had TH autoantibodies compared to none (0%) of 9 cases with mild keratitis (P < .05). Conclusion: 

TH autoantibodies are detected in severe keratitis with APS-1. TH is localized in 

the corneal nerves and may explain the photophobia in patients with APS-1. 

184 






Infectious Keratitis Progressing to Endophthalmitis: A 

15-Year-Study of Microbiology, Risk Factors, and Clinical 

Outcomes 

Presenting Author: Christopher R Henry MD 

Co-Author(s): Harry W Flynn MD*, Darlene Miller MPH, Richard K Forster MD, Eduardo 

C Alfonso MD* 

Purpose: To describe the incidence, risk factors, and outcomes of patients with infectious 

keratitis progressing to endophthalmitis. Methods: Retrospective case series of patients 

with positive corneal and intraocular cultures between 1/1/95 and 12/31/09. Results: 

9934 corneal cultures were performed for keratitis. Forty-nine eyes (0.5%) progressed to 

endophthalmitis. Risk factors included topical steroids (37/49 [76%]), prior surgery (30/49 

[61%]), and fungal etiology (26/49 [53%]). Vision ≥ 20/50 was achieved in 7/49 patients 

(14%). Fifteen of 49 patients (31%) underwent enucleation. Conclusion: Progression of 

keratitis to endophthalmitis is uncommon but is associated with poor visual acuity outcomes 

and a high rate of enucleation. 


Intrastromal Injection of Voriconazole for the Management 

of Refractory Fungal Keratitis 

Presenting Author: Mehdi Mazloumi MD 

Co-Author(s): Pejman Bakhtiari MD, Reza Ghaffary MD**, Hamid Riaziesfahani, 

Fatemeh Bazvand** 

Purpose: To study intrastroml voriconazole injection in patients with recalcitrant fungal 

keratitis. Methods: Twenty-four patients with fungal keratitis who failed to respond to 

the topical voriconazole and amphotericin B underwent intrastromal voriconazole injection 

at the concentration of 100 micrograms in 0.1 ml. Results: Dramatic therapeutic response 

was observed in 17 eyes (71%) after single intrastromal injection, in terms of decrease in 

size of infiltration. Seven unresponsive eyes (29%) underwent second intrastromal injection 

7 days after injection; 5 of these eyes underwent therapeutic penetrating keratoplasty. 

Conclusion: Intrastromal injection of voriconazole was shown to be an effective 

and safe option for the treatment of refractory fungal keratitis. 


APAO Ocular Manifestations of Herpes Zoster Ophthalmicus: 

Prospective Evaluation at a Tertiary Care Center 

Presenting Author: Shivani Pahuja MBBS 

Co-Author(s): Prashant Garg MD* 

Purpose: To describe clinical manifestations of herpes zoster ophthalmicus (HZO) at a 

tertiary care center. Methods: Prospective evaluation of HZO patients (May 2010 - December 

2011) for epidemiological features, clinical manifestations, and outcome on medical 

/ surgical therapy. Results: Seventy-nine patients; M:F 62:17; 44.88 + 17.41 (6-73) 

years; 48 acute, 31 chronic; 19 HIV positive. Keratouveitis (38%), punctate keratitis (35%), 

anterior stromal infiltrates (15%), neurotrophic keratitis (14%), and microbial keratitis (6%) 

seen in acute phase, and vascularized corneal scar (10%) seen in chronic phase. Tarsorrhaphy 

most common intervention (38% patients). Conclusion: Keratouveitis and punctate 

keratitis in the acute phase and corneal scar in the chronic phase are the most common 

presentations in HZO. 


Multidrug Resistance in MRSA/MRSE Colonization of 

Refractive Surgery Seeking Patients 

Presenting Author: Edward W Trudo MD 

Purpose: To report coexisting drug resistance of MRSA and MRSE organisms that were 

found to be colonized in refractive surgery-seeking patients. Methods: Retrospective review 

of records of 99 patients who underwent ocular and nasal cultures to detect MRSA 

or MRSE carrier status. Results: Seven nasal cultures and 1 eyelid culture were positive 

for either MRSA or MRSE. Resistance was seen to ciproflxicin (4/8 cultures), levofloxacin 

(3/8), moxifloxicin (2/6), and trimethoprim/sulfamethoxazole (1/8). Conclusion: MRSA 

and MRSE exhibit resistance to many currently prescribed ophthalmic and systemic medications 

in addition to methicillin. 


APAO Mucosal Complications Following Osteo-Odonto 

Keratoprosthesis Surgery in Stevens-Johnson Syndrome 

Presenting Author: Sayan Basu MBBS 

Co-Author(s): Vinay S Pillai MS, Virender S Sangwan MBBS 

Purpose: To report the outcomes of surgical management of mucosal complications 

following osteo-odonto keratoprosthesis (OOKP). Methods: This was a retrospective 

study of 25 eyes undergoing OOKP surgery between 2009 and 2012 for bilateral corneal 

blindness following Stevens-Johnson syndrome (SJS). Results: Mucosal necrosis with 

exposure of OOKP lamina occurred in 11 eyes. This was non-vision threatening and successfully 

treated by tarso-conjunctival flaps in 9 eyes. Free mucosal grafts failed in all but 

2 eyes. Recurrent mucosal overgrowth with transient visual diminution occurred in 3 eyes, 

needing repeated mucosal debulking. Conclusion: Mucosal complications after OOKP in 

SJS are common but treatable and infrequently lead to visual problems. 


Lipid Layer Thickness and Its Correlation With Osmolarity 

and Tear Film Stability 

Presenting Author: Richard C Chu DO* 

Co-Author(s): Jay Stuart Pepose MD PhD*, Mujtaba A Qazi MD* 

Purpose: To study the relationship of lipid layer thickness measurements with osmolarity 

and objective tear film stability over time. Methods: Ocular Surface Disease Index (OSDI), 

Standard Patient Evaluation of Eye Dryness (SPEED), tear interferometer (ICU), tear osmolarity 

(OSM), and optical scatter over time (OSI-T) were measured (n = 52), then analyzed 

for correlation. Results: High correlation was found between OSDI and SPEED scores (r 

= 0.79). Weak correlations were found between OSM and OSI-T and SPEED (r^2 = 0.2). 

OSM showed no correlation with ICU in all stratification analysis. Conclusion: Lipid layer 

thickness appears to be independent of OSM and tear film quality dynamics in both dry 

eye and non-dry eye patients. 


Depression, Post Traumatic Stress Disorder, and Dry Eye 

Syndrome 

Presenting Author: Anat Galor MD* 

Co-Author(s): William J Feuer MS, David J Lee PhD, Victor L Perez MD* 

Purpose: To evaluate the relationship between psychiatric diagnoses and dry eye syndrome 

(DES). Methods: Patients seen in a Veterans Affairs (VA) eye clinic (2006-2011). 

Case-control study. Results: 2,454,458 patients were identified as a DES case (n = 

462,641) or control (n = 1,991,817). Nineteen percent of males and 22% of females had 

a diagnosis of DES. Conditions found to increase DES risk included PTSD (OR 1.92) and 

depression (OR 1.92). Systemic medications found to increase DES risk included antidepressants 

(OR 1.97) and anxiolitics (OR 1.74). Multivariable analysis revealed that both 

the diagnosis and medications remained significant risk factors when considered concomitantly, 

although the magnitude of each association decreased. Conclusion: DES is 

associated with depression and PTSD and is prevalent among men and women veterans 

receiving eye care services. 


Topical Amnion Membrane Extract for the Treatment 

of Corneal Persistent Epithelial Defects: Results of the 

European Clinical Trial 

Presenting Author: Kenneth Kenyon MD* 

Co-Author(s): Emiliano Ghinelli MD** 

Purpose: To evaluate topical application of lyophylized extract of amnion membrane extract 

(AMX) for treatment of corneal persistent epithelial defects (PEDs). Methods: Following 

the Treviso (Italy) Tissue Bank protocol, 42 eyes of 37 patients with PEDs from 6 

European eye clinics underwent open label treatment with AMX, applied every 2 hours 

while awake for 4 weeks or until PED healed. Results: In all eyes, no adverse reactions 

occurred. Symptoms improved in 40/42 eyes (95%). Conjunctival inflammation decreased 

in 41/42 (98%). PED healing was complete in 40/42 (95%), averaging 21 days (range: 

7-28 days). Conclusion: Topically applied AMX demonstrated safety (100%) and efficacy 

(95%) in promoting the healing of corneal PEDs. 





185




Donor Site Complications in Autolimbal and Living-Related 

Allolimbal Transplantation 

Presenting Author: Ammar Miri MRCS 

Co-Author(s): Dalia Said**, Harminder S Dua MBBS** 

Purpose: To study the long-term changes of donor eyes used for harvesting tissue for 

limbal transplants. Methods: Fifty donor sites of limbal tissue were examined. The eyes 

were examined by slitlamp biomicroscopy and in vivo confocal microscopy (IVCM). Results: 

Mean follow-up was 41 ± 38 months. Observed complications were filamentary 

keratitis and subconjunctival hemorrhage in 4 eyes. IVCM confirmed that the central corneal 

epithelium remained normal in all eyes. The re-epithelialized donor site was covered 

with conjunctival epithelium in 17 sites and with corneal epithelium in 7 sites. Conclusion: 

Limbal donation of 2 clock-hours of the superior and inferior limbus with 3×3 mm of 

adjacent conjunctiva was a safe procedure in this group of patients during the follow-up 

period. 


Symptomatic, Clinical, and Imaging Response Following 

Anti-inflammatory Therapy for Meibomian Gland 

Dysfunction 

Presenting Author: Yureeda Qazi MBBS 

Co-Author(s): Bernardo Menelau Cavalcanti MD, Andrea C Cruzat MD, Monique 

Trinidad**, Candice Williams**, Caroline Blackie OD, Donald K Korb OD, Pedram 

Hamrah MD* 

Purpose: To compare the effects of anti-inflammatory treatment (AIT) on signs and symptoms 

in meibomian gland dysfunction (MGD). Methods: Twenty-two eyes with MGD and 

10 healthy eyes were assessed using the Ocular Surface Disease Index (OSDI) questionnaire, 

ocular surface examination, and in vivo confocal microscopy. Results: At the first 

follow-up, tear breakup time improved from 5 ± 2 sec. to 8 ± 1 sec. (P = .01), with 72% 

reduction in conjunctival epithelial inflammation (P = .003), comparable to normal eyes (P = 

.46). OSDI improved from 40 ± 13 to 34 ± 27 (first follow-up) to 28 ± 22 (second follow-up). 

Conclusion: There was prompt and significant improvement in clinical and imaging parameters, 

but patient-reported symptomatic relief lagged, indicating early sign-symptom 

disconnect and need for patient counseling to ensure compliance. 


APAO Simple Limbal Epithelial Transplantation for Unilateral 

Limbal Stem Cell Deficiency 

Presenting Author: Virender S Sangwan MBBS 

Co-Author(s): Sayan Basu MBBS 

Purpose: To report the results of a novel and simple technique of limbal transplantation. 

Methods: In this retrospective study, 15 eyes each underwent either autologous simple 

limbal epithelial transplantation (SLET) or ex vivo cultivated limbal epithelial transplantation 

(CLET) between 2010 and 2011 for the treatment of unilateral limbal stem cell deficiency 

(LSCD). In SLET a 2-mm strip of donor limbus was divided and directly transplanted 

onto the recipient ocular surface.Results: At 1 year, successful restoration of the ocular 

surface was seen in 66% of eyes after CLET and 75% of eyes after SLET (P = .23). Visual 

recovery > 20/60 (P = .27) and graft survival rate (P = .1) were similar in both groups. 

Conclusion: SLET is an easier and equally viable alternative to CLET for the treatment 

of unilateral LSCD. 


Anterior Segment OCT for Imaging of Ocular Surface 

Lesions 

Presenting Author: Fouad El Sayyad MBBch 

Co-Author(s): Carol L Karp MD, Patrick Rafael Oellers MD**, Leejee H Suh MD*, 

Sander Dubovy MD, Richard Lee MD* 

Purpose: To assess the feasibility of a commercially available OCT as an optical biopsy. 

Methods: OCT images were captured of various ocular surface lesions using the RTVue 

spectral domain OCT. Fifty-five ocular surface lesions were imaged: 20 ocular surface 

squamous neoplasia, 12 pigmented conjuctival lesions, 2 lymphomas, 10 corneal dystrophies, 

10 pterygia, and a case with ocular amyloidosis. These scans were then correlated 

to clinical photos and available histopatholology. Results: The OCT images provided a 

high correlation with the clinical images and histopathology. The RTVue OCT images provided 

optical signs, which were helpful in the differential diagnosis of lesions. It is also 

useful in following tumor resolution with topical chemotherapy. Conclusion: OCT is a 

useful, noninvasive technique for diagnosing ocular surface lesions. 


Ocular Graft vs. Host Disease Onset in Allogeneic Unrelated 

and Related Matched Donor Hematopoietic Cell Transplant 

Recipients 

Presenting Author: Hasanain T Shikari MD* 

Co-Author(s): Francisco Amparo MD*, Reza Dana MD MSc MPH* 

Purpose: To assess time to onset of ocular graft vs. host disease (oGVHD) in recipients 

of allogeneic hematopoietic cell transplant (HCT) from matched donors (unrelated vs. 

related). Methods: Retrospective review of 111 patients with dry eye presenting after 

HCT. Results: Of 86 patients with allogeneic transplants, 60% received unrelated and 

40% received related HCT. Post-HCT, oGVHD developed after 550 days in unrelated and 

after 955.8 days in related transplant recipients (P = .04). Conclusion: Matched unrelated 

donor recipients present with oGVHD considerably earlier than related recipients. Patients 

undergoing HCT, particularly from unrelated donors, will benefit from focused ocular exam 

and strict follow-up pre- and post-HCT. 


APAO Etiologic Features of Stevens-Johnson Syndrome and 

Toxic Epidermal Necrolysis With Ocular Involvement 

Presenting Author: Chie Sotozono MD 

Co-Author(s): Mayumi Ueta MD PhD, Shigeru Kinoshita MD*, Amane Kitami MD PhD, 

Masafumi Iijima MD PhD, Michiko Aihara MD PhD, Zenro Ikezawa MD PhD, Yoko 

Kano MD PhD, Tetsuo Shiohara MD PhD, Yuji Shirakata MD PhD, Satomi Sakabayashi, 

Yoshihiro Matsubara PhD, Koji Hashimoto MD PhD 

Purpose: To identify the correlation of ocular severity to specific etiologic factors of 

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Methods: This 

study involved 135 cases (87 SJS, 48 TEN) obtained from a nationwide epidemiological 

study in Japan. Ocular severity at disease onset was compared to the patient’s age, sex, 

causative drugs, and systemic findings. Results: The patient’s age and nonsteroidal antiinflammatory 

drugs (NSAIDs) as the causative drug were significantly related to ocular 

severity (logistic regression analysis: P = .0151 and P = .0126, respectively). Conclusion: 

At the onset of SJS/TEN, strict attention should be paid to ocular involvement in young 

patients when NSAIDs are the causative drugs. 


Amniotic Membrane Transplantation: Long-term Experience 

Presenting Author: Dorota Tarnawska MD 

Co-Author(s): Ewa Wroblewska-Czajka, Adrian P Smedowski MD 

Purpose: To present the outcomes of 10-year experience of amniotic membrane transplantation 

(AMT) in own material. Material: 1110 eyes. The indication for AMT: persistent 

ulceration, 42.2%; painful bullous keratopathy, 20.2%; pterygium, 16.8%; burn, 

10.4%; corneal perforation, 5.5%; band-shaped keratopathy, 3.5%; acute corneal hydrops 

in Down syndrome 0.5%; fornix reconstruction, 0.45%. Methods: The retrospective 

analysis of the percentage of resurgery earlier than 1 year after AMT. Results: Resurgery 

was required in cases of persistent corneal ulceration, 71.8%; painful bullous keratopathy, 

46.6%; pterygium, 36.8%; eye burns, 91.0%; perforation of the cornea, 83.8%; band 

keratopathy, 30.7%; acute corneal hydrops in Down syndrome, 16%; fornix reconstruction, 

60%. Conclusion: AMT is a useful adjunctive surgical procedure for selected diseases 

of the ocular surface. 


APAO Histopathological Evaluation of Corneas With 

Pseudophakic Bullous Keratopathy Following Corneal 

Collagen Crosslinking 

Presenting Author: Aditi Abhay Manudhane MBBS 

Co-Author(s): Yashpal Goel MBBS, Ritu Arora MD MBBS, Ravindra Kumar Saran MD, 

Jawahar Lal Goyal MD**, Deepa Gupta MBBS, Gaurav Goyal MBBS** 

Purpose: To evaluate the histopathological effect of corneal collagen crosslinking (CXL) 

in pseudophakic bullous keratopathy (PBK). Methods: Twelve patients underwent keratoplasty 

at 1 month post-CXL, while another 12 patients underwent keratoplasty 3 months 

post-CXL. The corneal buttons were evaluated for stromal organization using anti-type1 

collagen antibody and chromogen tagged secondary antibody. Results: Anterior stromal 

compaction was seen in 7 out of 12 patients (58.3%) 1 month post-CXL and in 5 out of 12 

patients (41.6%) 3 months post-CXL. All patients with moderate disease showed stromal 

compaction. The effect was less evident at 3 months post-CXL. Conclusion: CXL induces 

anterior stromal compaction and reduces corneal edema in PBK. The effect depends upon 

disease severity and decreases with time. 

186 






Prospective Evaluation of the International Boston 

Keratoprosthesis Project in Ethiopia 

Presenting Author: Andrea C Cruzat MD 

Co-Author(s): Roberto Pineda II MD, Irmgard Behlau MD, Yonas Tilahun MD**, Jared 

Ament**, Claes H Dohlman MD PhD* 

Purpose: To evaluate the use of the Type I Boston keratoprosthesis (KPro) in Ethiopia. 

Methods: Twenty patients underwent surgery with the Boston KPro. Locally available 

topical antibiotics were used. Results: Fresh allografts, gamma-irradiated allografts, or 

autologous corneas were used as KPro carriers. After a follow-up time of 19 ± 14 months, 

from a baseline of light perception or hand motion (HM), all patients had improved visual 

acuity ranging from HM to 20/40. Conclusion: The Boston KPro may be a viable ophthalmic 

device in the developing world; however, widespread medical expertise and improved 

patient compliance is needed in this setting. 


APAO Outcomes of Keratoplasty by Using Pediatric Donor 

Cornea Less Than 3 Years of Age 

Presenting Author: Magie Mathew MD FRCS 

Co-Author(s): Muralidhar Ramappa MS 

Purpose: To report the outcomes of keratoplasty using pediatric donor cornea. Methods: 

Medical records of 21 eyes were analyzed in two groups: Group 1, penetrating keratoplasty 

(PK), and Group 2, endothelial keratoplasty (EK). In all, donor corneas of less than 

3 years of age were used. Results: Mean recipient age was 16.86 ± 22.85 years; mean 

follow-up was 15.26 ± 11.77 months. Indication for EK was pseudophakic bullous keratoplasty 

(57%), and for PK, Peters anomaly (35%). Mean donor age was 23.63 ± 13.98 

months. Mean endothelial cell density was 4104.42 ± 1242.58 cells/mm2.The cumulative 

probability of graft survival in PK was 25% at 2 years and 10% at 5 years. Conclusion: 

Pediatric donor cornea can be considered for keratoplasty. Poor postoperative follow-up 

and pre-existing ocular comorbidities contribute to poorer visual outcomes. 


Acute Endophthalmitis Following Penetrating Keratoplasty 


Co-Author(s): Mark Jones, W John Armitage PhD, Stephen B Kaye MBBCH MD** 

Purpose: To analyze the incidence of acute endophthalmitis (AE) following penetrating 

keratoplasty (PK) in the United Kingdom (UK). Methods: Patients registered on the UK 

National Transplant Database (NTD) undergoing PK between 1999 and 2006 were included. 

Reported cases of AE were collected for up to 5 years, including data on organism 

isolated, treatment, and outcome. Logistic regression analysis was used to identify risk 

factors. Results: Of 11,320 primary PKs registered with NTD, 0.67% (76) were treated 

as presumed endophthalmitis, and 0.14% (16) as confirmed (organism isolated). Cause 

of death (infection), high risk (P < .01) and nonvisual indication (P < .01) were significant 

risk factors. Conclusion: Prophylactic measures need to be considered in the presence of 

identified AE-associated risk factors. 


Femtosecond Laser-Assisted Penetrating Keratoplasty 

Results in Low Astigmatism in Keratoconus Patients 

Presenting Author: Dariusz Dobrowolski MD 

Co-Author(s): Edward A Wylegala MD PhD, Michal Pawel Milka MD 

Purpose: To compare efficacy of femtosecond laser-assisted 110°-cut penetrating keratoplasty 

(FLPK) with conventional penetrating keratoplasty (PK). Methods: Sixty-two keratoconus 

patients were divided into 2 groups: FLPK, 32 patients, and PK, 30 patients. Postoperative 

astigmatism, BCVA, and endothelial cell loss were evaluated. Results: Follow-up 

was at least 6 months. Postoperative astigmatism was lower in the FLPK group (2.1 ± 0.5 

D vs. 4.19 ± 1.7 D in the PK group, P < .05). BCVA was, respectively, 0.59 ± 0.1 and 0.55 ± 

0.1; and endothelial cell loss was 30.4 ± 8.3% and 34.1 ± 7.8%, respectively. Conclusion: 

Femtosecond laser-assisted surgery results in lower astigmatism levels. 


Lamellar vs. Penetrating Keratoplasty in the Same Patient: 

Series of 22 Eyes, 7 Years’ Follow-Up 

Presenting Author: Arturo I Maldonado-Junyent MD** 

Co-Author(s): Ana G Maldonado-Junyent MD 

Purpose: To compare endothelial cell loss (ECL) and BCVA after penetrating keratoplasty 

(PK) and deep anterior lamellar keratoplasty (DALK). Methods: In 11 patients with keratoconus, 

PK was performed in one eye and DALK in the other. Follow-up was 9 years in 

the PK group and 7 years in the DALK group. Endothelial loss and BCVA were studied. 

Results: Average endothelial cell count was 1263 in PK, while it was 2158 in DALK. ECL 

was remarkably higher (41.48%) after PK compared to DALK. There were no significant 

differences in BCVA: PK, 0.5; DALK, 0.48. Conclusion: DALK provided better endothelial 

cell preservation in the same patient (ie, with the same immunity). 


APAO Intraoperative High-Resolution OCT during Anterior 

Lamellar Corneal Surgery 

Presenting Author: Jodhbir S Mehta FRCS FRCOPHTH* 

Co-Author(s): Laura de Benito-Llopis MD, Romesh I Angunawela MBBS, Han Nian 

Marcus Ang MBBS, Donald Tan MD FRCS FRCOphth* 

Purpose: To assess usefulness of anterior segment OCT (AS-OCT) during deep anterior 

lamellar keratoplasty (DALK). Methods: The high-definition AS-OCT iVue 100-2 (Optovue; 

Fremont, Calif., USA) was used during 8 DALK cases. Results: Images showed the 

trephination depth, the depth of different layers of manual dissection, the big bubble, a 

small localized bubble in a case with no big bubble achieved, an inadvertent intrastromal 

viscodissection, and an intrastromal retention of fluid not identified under the operating 

microscope due to diffuse scarring. Conclusion: AS-OCT obtained good quality images 

of the cornea during DALK and proved extremely useful in helping the surgeon decide on 

various surgical steps. 


APAO Deep Anterior Lamellar Keratoplasty in Children of 

Amblyogenic Age Group: Indications, Surgical Challenges, 

and Outcomes 

Presenting Author: Sunita Chaurasia MD 

Co-Author(s): Muralidhar Ramappa MS 

Purpose: To determine functional success of deep anterior lamellar keratoplasty (DALK) 

in children under 8 years of age. Methods: Retrospective case series of 22 eyes of 22 

children with anterior stromal pathologies that underwent DALK in 2007-2012. Results: 

Median age, 3 years (1-9 years), M:F = 11:11, corneal opacity due to keratitis (7), trauma 

(4), unknown (3), keloid (5),storage disorder (1), and dermoids (2) underwent DALK using 

either big bubble or manual dissection. Followed up for 30 days to 5 years. BCVA ranged 

from counting fingers to 20/20. Complications were graft infiltrate (2), HSV recurrence 

(1), graft dehiscence (3), and graft failure due to Descemet detachment (1). Conclusion: 

DALK is a viable option in children with nonectatic stromal corneal pathology, with good 

visual outcomes. 


Descemet-Stripping Automated Endothelial Keratoplasty in 

Aphakic Eyes 

Presenting Author: Cristina Bovone MD 

Co-Author(s): Leila Mattioli MD**, Lucia Lapenna MD 

Purpose: To evaluate the outcomes of Descemet-stripping automated endothelial keratoplasty 

(DSAEK) performed in aphakic eyes with endothelial decompensation. Methods: 

DSAEK with venting incisions was performed in 41 aphakic eyes (transcorneal fixation 

suture in 14 eyes). Before, as well as 1, 6, 12, and 24 months after DSAEK, BCVA, manifest 

refraction, and endothelial cell count were assessed in all eyes. Results: Comorbidities 

were present in 36 of 41 eyes. With an average follow-up of 10 ± 8.7 months, postoperative 

BCVA was ≥ 20/200 in 34 (84%) and ≥ 20/40 in 11 (27%) eyes. Complications 

included graft detachment (n = 3) and graft failure (primary, n = 1; late, n = 1). Conclusion: 

DSAEK can be successfully performed in aphakic eyes, although comorbidities can limit 

final BCVA. 





187




In Vitro Effect of Massage and Venting Incisions on 

Donor Adhesion During Descemet-Stripping Automated 

Endothelial Keratoplasty 

Presenting Author: Ana P Fraga Santini Canto MD 

Co-Author(s): Pravin K Vaddavalli MD*, Sonia H Yoo MD*, Michael R Banitt MD*, 

Marco Ruggeri PhD*, Jean-Marie Parel PhD* 

Purpose: In vitro estimation of the effect of corneal massage and venting incisions on 

donor adhesion during Descemet-stripping automated endothelial keratoplasty (DSAEK). 

Methods: Serial high-resolution spectral domain OCT imaging was performed before and 

after corneal massage and venting incisions in 10 in vitro DSAEK surgeries, and areas of 

donor nonadhesion were measured. Results: Corneal surface massage did not seem to 

improve adhesion, but venting incisions followed by surface massage resulted in better 

donor adhesion. Discussion: Corneal massage might be useful in improving donor adhesion 

only after venting incisions and may not have a role by itself. 


APAO Three-Year Incidence and Risk Factors for Ocular 

Hypertension Following Descemet-Stripping Automated 


Presenting Author: Errol W Chan MBBS MMED 

Co-Author(s): Tina T Wong PHD FRCOPHTH, Hla Myint Htoon PhD, Ching Lin Ho FRCS 

MBBS*, Donald Tan MD FRCS FRCOphth*, Jodhbir S Mehta FRCS FRCOPHTH* 

Purpose: To evaluate the 3-year incidence and risk factors of post- Descemet-stripping 

automated endothelial keratoplasty (DSAEK) ocular hypertension (OHT). Methods: In 107 

Fuchs dystrophy and pseudophakic bullous keratopathy eyes without pre-existing glaucoma 

and ≥3 years follow-up, Kaplan-Meier survival and multivariate Cox proportional 

hazards analyses were performed. Results: Cumulative OHT incidence rates at 1, 2, and 

3 years were 36.1%, 47.2%, and 47.2%. Risk factors were age < 60 years (HR 2.4, P = 

.016), fellow eye glaucoma (HR 3.2, P = .004), concurrent goniosynechiolysis (HR 3.3, P = 

.021), and post-DSAEK complications or procedures (HR 2.9, P = .006). Conclusion: OHT 

is a significant post-DSAEK complication, and its development plateaus after the first 2 

post-DSAEK years. Predictors of OHT may be useful to identify high-risk eyes for closer 

monitoring. 


Cost Comparison of Surgeon-Cut vs. Eye Bank-Cut Donor 

Corneal Tissue for Endothelial Keratoplasty 

Presenting Author: Michael C Chen MD 

Co-Author(s): Bennie H Jeng MD* 

Purpose: To determine under which circumstances it would be more cost-effective for 

the surgeon or the eye-bank to cut donor tissue. Methods: A model was constructed 

to calculate the cost of surgeon-cut tissue, for comparison with the cost of eye bank-cut 

tissue. Results: The cost per surgeon-cut donor cornea is $301.90, $376.90, $526.90, and 

$826.90 if the number of cases performed per year are 104, 52, 26, and 13, respectively. 

The processing fee of an eye bank to cut the donor tissue is approximately $750. Conclusion: 

Cost per surgeon-cut donor corneal tissue decreases as the number of cases performed 

increases. The eye bank processing fee is equivalent to the cost associated with a 

surgeon-cut cornea if the surgeon were to perform 15 cases per year. 


The Risk of Allograft Immunologic Rejection After Ultrathin 


Presenting Author: Massimo Busin MD* 

Co-Author(s): Silvana A Madi MD, Paolo Santorum MD, Cataldo Russo** 

Purpose: To report the incidence of immunologic rejection after ultrathin Descemetstripping 

automated endothelial keratoplasty (UT-DSAEK). Methods: To determine the 

cumulative probability of a rejection episode 1 and 2 years after surgery, we performed 

Kaplan-Meier survival analysis for 162 eyes that had undergone UT-DSAEK. Results: The 

risk for immunologic rejection was low in 140 eyes and high in 22 eyes. Endothelial rejection 

was documented in 4 eyes (2.47%), of which only 1 was a high-risk eye. All rejection 

episodes were reversed with corticosteroids. Kaplan-Meier cumulative probability of a rejection 

episode at Year 1 and 2 was 3% and 3%, respectively. Conclusion: Immunologic 

rejection is very rare after UT-DSAEK. 


Standardized “No-Touch” Preparation for Deep Anterior 

Lamellar Keratoplasty and Descemet Membrane Endothelial 

Keratoplasty: Creating 2 Transplants From 1 Donor Cornea 

Presenting Author: John Parker MD 

Co-Author(s): Esther Groeneveld MS, Jessica Lie PhD, Jacqueline van der Wees PhD, 

Marieke Bruinsma PhD, Gerrit RJ Melles MD PhD* 

Purpose: To describe a standardized “no-touch” technique whereby one donor cornea 

may be sectioned into anterior and posterior grafts for deep anterior lamellar keratoplasty 

(DALK) and Descemet membrane endothelial keratoplasty (DMEK). Methods: We compared 

the endothelial cell loss following Descemet membrane (DM) stripping with our 

new technique (n = 31) against that of our former harvesting methods (n = 31). Results: 

Cell loss was not significantly different between the two techniques (P = .61). All 62 DM 

and 31 anterior grafts were functional at 6 months postoperatively. Conclusion: The new 

no-touch technique succeeds at producing undamaged DMEK and DALK grafts, effectively 

doubling the pool of transplantable tissue. 


Are We Overestimating the Endothelial Cell “Loss” After 

Descemet Membrane Endothelial Keratoplasty? 

Presenting Author: John Parker MD 

Co-Author(s): Mary Ruth Macaraeg Quilendrino, Helmut Höhn, Isabel Dapena, Lisanne 

Ham PhD, Silke Oellerich PhD, Gerrit RJ Melles MD PhD* 

Purpose: To evaluate the margin of error in in vivo endothelial cell density (ECD) measurements 

after Descemet membrane endothelial keratoplasty (DMEK). Methods: In 25 

DMEK eyes, central corneal thickness (CCT) and ECD were measured. We used a mathematical 

model to estimate “apparent” cell loss attributed to morphometric changes due to 

corneal dehydration. Results: While the mean ECD decreased 34% (±17%), the mean CCT 

decreased 267 (±39) µm, which induced an 8.6% increase in total posterior corneal surface 

area. The associated stretching of the endothelial cell layer may result in an apparent cell 

“loss” that may explain ± 25% of the reported cell loss. Conclusion: The observed decrease 

in ECD after DMEK may be overestimated by about 8% due to corneal deswelling. 


APAO Comparative Outcomes of Endothelial Keratoplasty 

With or Without Stripping Descemet Membrane 

Presenting Author: Anil Raj MD** 

Co-Author(s): Magie Mathew MD FRCS 

Purpose: To compare outcomes of non-Descemet-stripping endothelial keratoplasty 

(nDSEK) with Descemet-stripping endothelial keratoplasty (DSEK) in cases of pseudophakic 

bullous keratopathy (PBK). Methods: We prospectively analyzed 20 eyes of EK subjects 

divided into 2 groups based on surgical technique: Group 1 includes DSEK whereas 

Group 2 constitutes nDSEK. Results: The BCVA in Group 1 was 0.538 logMAR and in 

Group 2 was 0.513 (P = .96), statistically not significant, at a mean follow-up of 7.5 months. 

During the early postoperative period, 1 patient in each group had lenticule detachment 

managed by rebubbling. All grafts were remained clear in either group when last seen. 

Conclusion: Outcomes of nDSEK and DSEK in PBK are comparable. 


Vital Dye Staining of Endothelial Cells Following Ultrathin 

Graft Preparation for Descemet-Stripping Endothelial 

Keratoplasty 

Presenting Author: Duna A Raoof-Daneshvar MD 

Co-Author(s): Maria A Woodward MD, Victor M Elner Ph D MD*, Roni M Shtein MD* 

Purpose: To quantify endothelial cell integrity in ultrathin tissue prepared for Descemetstripping 

endothelial keratoplasty (DSEK) over time. Methods: Following double-pass 

automated microkeratome sectioning, 8 corneas were stained with 0.2% alizarin red after 

12, 24, 48, or 72 hours of storage in Optisol. The percentages of cells exhibiting polygonal 

alizarin red staining patterns were calculated using Adobe Photoshop software. Results: 

The mean percentages of endothelial cells with normal polygonal morphology were 

78.14% at 12 hours, 80.44% at 24 hours, 84.07% at 48 hours, and 85.32% at 72 hours. 

Conclusion: Ultrathin corneal grafts prepared for DSEK may be stored up to 72 hours with 

no substantial change in endothelial cell morphology. 

188 






Replacement of Descemet-Stripping Automated Endothelial 

Keratoplasty Grafts for Late Endothelial Failure 

Presenting Author: Michael D Straiko MD* 

Co-Author(s): Mark A Terry MD*, Mark Greiner MD, Julia C Talajic MD 

Purpose: To examine causes of late endothelial failure (LEF) in Descemet-stripping automated 

endothelial keratoplasty (DSAEK). Methods: 758 DSAEK surgeries with at least 

6 months of follow-up were reviewed for the preoperative diagnosis. Results: Twentyone 

DSAEK surgeries were completed for LEF. Of the 21 eyes, 8 had active treatment of 

glaucoma (1 medical, 7 surgical). Of the remaining 13, 4 had known surgical trauma at the 

time of the initial surgery, and 1 had a history of both surgical trauma and a diagnosis of 

glaucoma. None of the replaced grafts experienced a dislocation or primary graft failure 

(PGF). Conclusion: A history of surgical trauma at the time of initial DSAEK surgery or 

a history of glaucoma surgery are frequently associated with LEF. Grafts with LEF can be 

replaced and have a low rate of dislocation or PGF with our technique. 


Factors Influencing the Stability of Keraflex Treatments for 

Keratoconus 

Presenting Author: Arthur B Cummings MD* 

Purpose: To study the role of timing of corneal crosslinking (CXL) following Keraflex. 

Methods: Twenty-four eyes underwent Keraflex followed by CXL or accelerated crosslinking 

(KXL). Four groups were determined depending on the timing of CXL. Group I had 

CXL within 4-7 days, Group II had simultaneous KXL, Group III had KXL 4-5 hours later, and 

Group IV had KXL or CXL at any interval that was deemed to be ideal. Results: Keraflex 

flattens the cornea. Rebound of the corneal shape then occurs. CXL applied after Keraflex 

had a stabilizing effect if it was administered more than 4-5 hours later. The simultaneous 

treatments (Group II) failed at 3 months while the other groups retained their corneal 

shape better, although there was a general trend toward corneal steepening with time. 

Conclusion: The timing of CXL impacts the stability of the Keraflex results. 


Long-term Results of Corneal Collagen Crosslinking for 

Progressive Keratoconus 

Presenting Author: Maddalena De Bernardo MD 

Co-Author(s): Nicola Rosa MD, Michele Lanza MD, Luigi Capasso MD, Achille Tortori 

MD** 

Purpose: To evaluate long-term keratoconus stability after corneal crosslinking with riboflavin 

(CXL). Methods: Thirty-eight eyes with progressive keratoconus were examined 

with a Pentacam before and during a 24-month follow-up after CXL. Results: Twenty-four 

months after CXL, corneal pachymetry at the thinnest point decreased in 22 eyes (58%), 

was stable in 15 eyes (39%), and increased in 1 eye (3%). Keratometry at the keratoconus 

apex decreased in 28 eyes (74%), was stable in 8 eyes (21%), and increased in 2 eyes 

(5%). Conclusion: According to our results CXL not only stabilizes most of the patients 

with progressive keratoconus but could improve some of them, suggesting the possibility 

to treat also patients with nonprogressive keratoconus. 


APAO Is Accelerated Corneal Collagen Crosslinking a Safe 

Procedure? Early Results 

Presenting Author: Sharon D’Souza MD MBBS** 

Co-Author(s): Rohit Shetty MD MBBS, Himanshu Matalia MD, Kareeshma N Wadia 

MBBS 

Purpose: Accelerated collagen crosslinking (ACXL) using the Avedro, Inc.’s KXL system 

reduces UVA radiation exposure time to 3 minutes but increases power to 30 mW/cm2. 

This study evaluates the safety profile of ACXL. Methods: Twenty-five eyes of 25 patients 

underwent ACXL. Visual acuity, corneal endothelium (specular microscopy), stromal scarring, 

and corneal biomechanical changes on the Ocular Response Analyzer and CorVis ST 

were measured. Results: No statistically significant change in corneal endothelium was 

noted. Stromal haze was initially high but reduced by 1 month post-procedure. No intra- or 

postoperative complications were noted. Conclusion: ACXL appears to be a safe procedure, 

but larger sample size and longer follow-up are needed to confirm these results. 


Topometric and Tomographic Parameters for the Diagnosis 

of Keratoconus 

Presenting Author: Fernando Faria Correia MD 

Co-Author(s): Isaac O Ramos MD, Bernardo Lopes**, Marcella Quaresma Salomao MD, 

Allan Luz MD, Rosane De Oliveira Correa, Renato Ambrosio Jr MD* 

Purpose: To compare topometric (front surface curvature) and tomographic (3-D corneal 

shape) indices for diagnosing keratoconus. Methods: Pentacam data from 1 eye randomly 

selected of 200 normal subjects (N) and 177 keratoconus subjects (KC) were analyzed. 

Tomographic and topometric indices were tested. ROC curves were calculated, along with 

pairwise comparisons. Results: All tested variables had significant differences among N 

and KC (Mann-Whitney, P < .001). Most accurate tomographic indices had higher area under 

the curve (AUC) than best topometric ones (DeLong, P < .05). Belin-Ambrosio D (BAD-D) 

had AUC of 1.00 (sensitivity 100.0%; specificity 99.5%). Conclusion: Tomographic data 

was superior to topometric data in detecting keratoconus. The BAD-D was an enhanced 

approach for detecting keratoconus. 


Combinations of Parameters From Corneal Tomography and 

Biomechanics for Enhanced Ectasia Detection 

Presenting Author: Fernando Faria Correia MD 

Co-Author(s): Isaac O Ramos MD, Bernardo Lopes**, Allan Luz MD, João Marcelo Lyra 

MD PhD**, Aydano Machado PhD, Renato Ambrosio Jr MD* 

Purpose: To combine corneal tomography and biomechanics to distinguish normal from 

ectatic corneas. Methods: Pentacam HR and Corvis ST (Oculus; Germany) data from 1 

eye randomly selected from 119 normal subjects (N) and 59 keratoconus subjects(KC), and 

from 15 eyes with normal topography (FFKC) of patients with keratoconus in the fellow 

eye. Fisher discriminant analysis was performed. Results: Discriminant analysis of Pentacam 

data for detecting KC and FFKC had area under the curve (AUC) of 1.000 and 0.946, 

respectively. Combination of Pentacam and Corvis data for detecting KC and FFKC had 

AUC of 1 and 0.985, respectively (sensitivity 100%/93.33%; specificity 100%/92.44%). 

Conclusion: A combination of data from Scheimpflug-based corneal tomography and 

biomechanics enhances the detection of mild forms of ectasia, namely FFKC cases. 


Continuous Corneal Intrastromal Ring Implantation for 

Treatment of Keratoconus 

Presenting Author: Mahmoud Jabbarvand Behrooz MD 

Co-Author(s): Hesam Hashemian MD, Ahmad Salamat Rad**, Mehdi Khodaparast 

MD**, Hamid Riaziesfahani, Elias Khalilipour MD 

Purpose: To evaluate the efficacy and safety of mechanical implantation of continuous 

intrastromal ring in keratoconus. Methods: Ninety-five keratoconic eyes were implanted 

by the MyoRing (Dioptex GmbH) with follow-up of at least 12 months. Results: A significant 

improvement in uncorrected distance VA was observed 1 month after surgery, which 

was consistent with the significant reduction in sphere (5.74 D) and cylinder (3.02 D). No 

significant changes were detected in these parameters afterward. Furthermore, a significant 

corneal flattening of a mean value of 9.78 D was found. Both spherical myopia and 

astigmatism underwent reduction, but reduction in myopia was greater than astigmatism. 

Conclusion: MyoRing implantation is a safe and effective treatment for keratoconus. 


APAO Corneal Topographic Changes After Corneal Collagen 

Crosslinking for Keratoconus 

Presenting Author: Anurag Mathur MBBS 

Co-Author(s): Jatin Naresh Ashar MD, Mukesh Taneja DO MBBS, Pravin K Vaddavalli 

MD*, Somasheila I Murthy MD, Varsha Rathi DO**, Virender S Sangwan MBBS 

Purpose: To evaluate the topographic changes after corneal collagen crosslinking (CXL) 

for keratoconus. Methods: Thirty-one eyes / 22 progressive keratoconus (>0.5 D sim K 

change/6 months; age 18.90 + 5.03 years) patients had standard CXL. Orbscan was evaluated 

at 1 week, 3 months, 6 months, and 1 year after surgery. Results: In the first week 

after collagen crosslinking, there was worsening of all the parameters on Orbscan, followed 

by nonstatistically significant decrease in the sim K value and 3- and 5-mm zone 

irregularity, which continued for 1 year. Conclusion: The immediate post-CXL topographic 

picture should not be confused with progression. Stabilization of central astigmatism, decrease 

in irregularity in paracental area, and regularization of the corneal shape continues 

until 1year after CXL. 





189




Anterior Segment OCT as a Tool for Boston Keratoprosthesis 

Serial Assessment 

Presenting Author: Norma Allemann MD* 

Co-Author(s): Joann J Kang MD, Jose J de la Cruz Napoli MD, Maria S Cortina MD 

Purpose: To identify critical anterior segment OCT (AS-OCT) findings in eyes with keratoprosthesis. 

Methods: Visante-OCT was performed in 54 eyes with Boston KPro type 1: 

44 aphakic, 10 pseudophakic; 20 primary, 34 secondary; follow-up = 19.6 months. Most 

common preoperative diagnoses were previous penetrating keratoplasty failure (35) and 

chemical burn (6). Evaluation included anatomical and functional anterior chamber depth 

(ACD), synechiae, retroprosthetic membranes (RPM), corneal melt. Results: Mean anatomical 

ACD = 2.00 mm; functional ACD = 0.23 mm; 6.74 clock-hours of angle closure; 

significant RPM (> 0.30 mm) 16 eyes; corneal melt, 7. Conclusion: Detailed anatomy in 

KPro eyes with AS-OCT allowed identification of the need for intervention. 


Scleral Pressure Measurement Pre- and Post- 

Keratoprosthesis Implantation in Cadaver Eyes 

Presenting Author: Aiyin Chen MD 

Co-Author(s): Charles C Lin MD**, Michael C Chen MD, Bennie H Jeng MD*, Yvonne 

Ou MD*, Ying Han MD PhD 

Purpose: To correlate scleral pressure to IOP using pneumotonometry in cadaver eyes 

before and after Boston type I keratoprosthesis (KPro). Methods: Central corneal IOP and 

scleral IOP were measured using pneumotonometry in 6 cadaver eyes cannulated with an 

infusion line with IOP held at 20, 30, 40, and 50 mmHg. Measurements were repeated after 

the KPro was implanted. Results: Scleral IOP has a positive and linear correlation with 

assigned IOP before KPro (P < .00001), and this correlation is highly preserved after KPro 

implantation (P < .00001). Conclusion: Scleral IOP by pneumotonometry may be used to 

estimate IOP in cadaver eyes with and without keratoprosthesis. 


Corneal Pathology in the Boston Type 1 Keratoprosthesis via 

High-resolution Anterior Segment OCT 

Presenting Author: Dennis E Cortes MD 

Co-Author(s): Mark J Mannis MD, Brett L Shapiro MD, Eric Chin MD, Jennifer Y Li MD, 

John S Werner PhD, Ellen Fiona Redenbo 

Purpose: To report our experience using high-resolution, anterior segment OCT (AS-OCT) 

in patients who had previously undergone Boston Type 1 keratoprosthesis (KPro) surgery. 

Methods: A retrospective, comparative study of patients in whom we implanted the KPro. 

Twenty-six eyes of 23 patients were examined with the Spectralis AS-OCT. Results: We 

identified epithelial ingrowth behind the front plate in 65%, periprosthetic gaps and melting 

in the carrier corneal graft in 31%, and retroprosthetic membranes in 77% of KPro 

eyes. Conclusion: AS-OCT is a useful modality in patients with a KPro and provides the 

ability to identify changes that are difficult to appreciate by routine clinical evaluation. 


APAO Study of Corneal Biomechanics in Normal and 

Keratoconic Eyes: Comparison Between CorVis ST and 

Ocular Response Analyzer 

Presenting Author: Sharon D’Souza MD MBBS** 

Co-Author(s): Rohit Shetty MD MBBS, Sarika Ramachandran MBBS, Himanshu Matalia 

MD 

Purpose: The Ocular Response Analyzer (ORA) and Corneal Visualization with Scheimpflug 

Technology (CorVis ST) both measure corneal biomechanics. This study compares the 

2 methods in normal and keratoconic eyes. Methods: Measures of corneal biomechanics; 

corneal hysteresis (CH), and corneal resistance factor (CRF) measured on ORA were 

compared to deformation amplitude (Def amp) on CorVis ST in 60 normal eyes and 60 

keratoconic eyes. IOP from the 2 machines was also compared. Results: Corneal biomechanics 

and IOP measured in both groups showed no correlation between the machines. 

Conclusion: CorVis ST and ORA do not correlate in measurement of corneal biomechanics 

or IOP; hence, they cannot be used interchangeably. 


Boston Keratoprosthesis in Egypt: Two-Year Follow-up 

Presenting Author: Ihab S Othman MD 

Purpose: To review 2-year results of Boston type 1 keratoprosthesis (KPro) in Egypt. 

Methods: Twenty-eight patients managed by the Boston KPro since October 2010. Results: 

Diagnosis included repeated graft failure in 18 cases, severe dry eye in 4 cases, and 

autoimmune disorders in 6 cases. Age range was 12-72 years. KPro insertion was associated 

with cataract extraction, IOL removal in 18 cases, pars plana vitrectomy in 6 cases, 

and anterior segment reconstruction in 10 cases. Vision improved in 22 cases. Repeated 

intervention was necessary to manage retroprosthetic membrane in 6 cases, secondary 

glaucoma in 4 cases, and corneal melting in 3 cases. Conclusion: Boston keratoprosthesis 

is a solution for high-risk corneal graft failure. Of particular use is the recurrent graft 

failure. Autoimmune disorders carry a worse prognosis. 

Cornea, External Disease Poster Tour 


12:30 PM to 1:30 PM 

Session Two 





APAO Rose-K vs. Soper Contact Lens in Keratoconus: A 

Randomized Comparative Trial 

Presenting Author: Rajesh Sinha 

Co-Author(s): Raghav Gupta MD**, Radhika Tandon MBBS, Jeewan S Titiyal MD 

Purpose: A comparative evaluation of Rose K and Soper contact lenses in keratoconus. 

Methods: A randomized comparative clinical trial was performed in which Rose K (Group 

1; n = 60) and Soper (Group 2; n = 60) contact lenses were fitted in keratoconus, and visual 

parameters and comfort score were evaluated. Results: The improvement in visual acuity 

and glare acuity were comparable. Contrast sensitivity improved significantly better in 

Group 1 at 1 and 3 months (P = .001 and .002). Comfort score was significantly better 

in Group 1 at 1 and 3 months (P = .006 and P < .001). The trial lenses required for fitting 

Rose K were significantly less (P < .001). Conclusion: Although visual improvement is 

comparable, Rose K provides more comfort and better quality of vision and requires less 

chair time and hence may have greater acceptability. 


APAO Immunosuppression for Mooren Ulcer: Topical, Oral, 

and Intravenous Step-Ladder Approach 

Presenting Author: Jatin Naresh Ashar MD 

Co-Author(s): Anurag Mathur MBBS, Virender S Sangwan MBBS 

Purpose: To evaluate a severity-based approach for immunosuppression for Mooren 

ulcer (MU). Methods: Retrospective analysis of records of MU for outcomes of immunosuppression 

regimen, 2000-2010. Results: 148 cases of MU, 51.1 ± 20.5 years; 68 were 

unilateral (UL) and 80 were bilateral (BL); > 2 quadrant (Q) thinning seen in 42.5%, > 50% 

corneal thinning in 64.8%. Topical steroid given to all. < 2 Q/UL, only topical steroids (n = 

62), 76% healed. BL/> 2 Q, oral steroids (n = 66), 78% healed. < 50 years/BL/> 2 Q, oral 

methotrexate (n = 14), 78.5% healed. BL/> 3 Q/one eyed, intravenous pulse methyl prednisolone 

(IVMP) (n = 7), 71.4% healed. BL/perforation/> 3 Q, IVMP+ pulse cyclophosphamide 

(n = 15), 73.3% healed. Conclusion: Severity-based immunosuppression regimen 

has good outcomes in MU. 


Acanthamoeba Keratitis: A Case-Control Investigation, 2008- 

2011 

Presenting Author: Allison Cory Brown PhD 

Co-Author(s): Jonathan Ross MD, Dan B Jones MD, Tracy Ayers MS, Jonathan Yoder 

MSW, Sharon L Roy MD MPH, Michael Beach PhD 

Purpose: Despite recall of an implicated lens solution after a 2007 outbreak, diagnosed 

Acanthamoeba keratitis (AK) cases did not decrease. We conducted a case-control investigation 

to identify risk factors contributing to persistence of AK. Methods: Cases 

190 





were US residents with a laboratory diagnosis of AK after January 1, 2008. Controls were 

contact lens (CL) wearers with no history of AK. All were interviewed using a standardized 

questionnaire and matched by state and CL wear status at time of interest. Results: CL 

hygiene behaviors, including topping off (mOR 4.54; CI, 2.27-9.80), recent CL adoption 

(3.22; 1.60-6.81), water storage (5.37; 1.91-18.78), and handling with wet hands (2.17; 

1.10-4.52), were significant risk factors. Conclusion: To prevent infection, CL wearers 

should observe recommended lens care practices. 


Vancomycin MIC Creep Among Ocular Staphylococcus 

aureus Isolates 

Presenting Author: Ana Hofling-Lima MD MBA 

Co-Author(s): Antonio Carlos Campos Pignatari MD PhD**, Paulo José Martins Bispo 

MS 

Purpose: To determine the emergence of S. aureus with reduced vancomycin susceptibility 

over time (MIC creep) isolates from keratitis and endophthalmitis. Methods: Vancomycin 

minimal inhibitory concentration (MIC) was determined using reference broth 

microdilution for 186 S. aureus isolates from 2002 to 2010. Results: The percentage of 

isolates inhibited at vancomycin MIC of ≤ 0.5, 1, and 2 µg/ml was 20.5%, 65.6%, and 

5.9%, respectively. From 2007 to 2010 there was a linear increase in the isolates with MIC 

= 1 µg/ml (43.6% to 81%) and 2 µg/ml (7.7% to 14.3%). Consequently, isolates presenting 

MIC ≤ 0.5 µg/ml decreased substantially from 2007 (48.7%) to 2010 (4.7%). Conclusion: 

Vancomycin MIC creep was found among ocular S. aureus isolates over a 4-year period. 


Multidrug Resistance in Bacterial Conjunctivitis Studies 

With Besifloxacin Ophthalmic Suspension, 0.6% 

Presenting Author: Marguerite B McDonald MD* 

Co-Author(s): Lynne S Gearinger**, Timothy W Morris* 

Purpose: To evaluate the prevalence and susceptibility of multidrug resistant (MDR) 

strains among 1820 ocular surface isolates from 4 clinical studies. Methods: Species 

were identified at a central laboratory, and minimum inhibitory concentrations (MICs) were 

determined for various antibiotics including B-lactams, fluoroquinolones, and macrolides. 

Results: 9.4% of S. aureus isolates and 17.9 % of S. epidermidis isolates were both ciprofloxacin 

and methicillin resistant. Besifloxacin MIC90 values against these MDR strains 

were 8- to 128-fold lower (better) than comparator fluoroquinolones and similar to vancomycin. 

Conclusion: The prevalence of MDR staphylococci was significant. Besifloxacin 

had potent activity against these isolates, comparable to that of vancomycin. 


APAO Evolution of Treatment of Resistant Deep 

Keratomycosis: A 7-Year Perspective 

Presenting Author: Ashok Sharma MD 

Co-Author(s): Jennifer M Nottage MD, Verinder S Nirankari MD 

Purpose: To describe the evolution of intrastromal injections of amphotericin B or voriconazole 

in treatment of resistant deep keratomycosis over 7 years. Methods: Intrastromal 

amphotericin B or voriconazole was given to patients with keratomycosis not responding 

to topical and systemic antifungals. Results: The addition of intrastromal amphotericin 

B was successful in 10/12 eyes (83%), and voriconazole was successful in 12/14 eyes 

(86%) with resolution of infection and scar formation. Two eyes in each group failed treatment 

and had therapeutic penetrating keratoplasty. The only complications were stromal 

haze and vascularization. Conclusion: The addition of intrastromal amphotericin B or 

voriconazole should be considered in resistant deep keratomycosis before resorting to 

surgical therapy. 


APAO Scleral Patch-Augmented Cyanoacrylate Tissue 

Adhesive for the Treatment of Corneal Perforations Greater 

Than 3.0 mm 

Presenting Author: Ashok Sharma MD 

Co-Author(s): Jennifer M Nottage MD, Verinder S Nirankari MD 

Purpose: To describe a technique of scleral tissue-augmented cyanoacrylate tissue adhesive 

(CTA) application and to evaluate its efficacy in sealing corneal perforations of 

3-4.5 mm. Methods: Prospective study of corneal perforation greater than 3 mm that 

were treated with a partial-thickness scleral patch and CTA. Sealing of the perforation 

and complete healing were evaluated. Results: Sixteen eyes were treated. The corneal 

perforations healed in 14 eyes (87.5%) in a mean of 5.65 weeks (range: 5-7), but 3 eyes 

(18.8%) required reapplication. It was unsuccessful in 2 eyes (12.5%) that then underwent 

tectonic penetrating keratoplasty. Conclusion: Scleral patch-augmented CTA is a successful 

alternative treatment method for corneal perforations greater than 3 mm. 


Efficacy of Alcaftadine 0.25% and Olopatadine 0.2% in 

Prevention of Ocular Itching at 16 and 24 Hours Post-Dosing 

in a CAC Model 

Presenting Author: Stacey L Ackerman MD* 

Co-Author(s): Francis D’Ambrosio Jr MD, Jack Volker Greiner DO PhD, Linda Villanueva 

COT*, David Hollander MD* 

Purpose: To evaluate q.d. dosed ocular antiallergics. Methods: A 3-arm (alcaftadine 

0.25%, olopatadine 0.2%, placebo) study utilizing the standard Conjunctival Allergen 

Challenge (CAC) model. The primary efficacy measure was subject-evaluated ocular itching 

at 3, 5, and 7 minutes post-challenge at 16 and 24 hours post-dosing. Results: 127 

subjects were enrolled and 115 completed. Both actives exhibited significantly lower 

mean ocular itching vs. placebo at 16 and 24 hours post-dosing (P < .0001). Alcaftadine 

achieved statistically significant lower mean itching vs. olopatadine at 3 minutes (16 

hours) (P = .0263). Conclusion: Both actives were effective at 16 and 24 hours vs. placebo. 

Alcaftadine demonstrated greater efficacy compared to olopatadine in the earliest 

time point measured in a CAC model. 


APAO Use of Autologous Serum Eye Drops Combined With 

Silicone Hydrogen Contact Lenses for the Treatment of 

Persistent Epithelial Defects 

Presenting Author: Yan-Ming Chen MD 

Co-Author(s): Wei-Li Chen MD**, Fung-Rong Hu MD, Hsiu-Fen Lin MD, Huan-Chen Hsu 

MD** 

Purpose: To evaluate the effect of combination of 20% autologous serum eye drops and 

a silicone-hydrogel contact lens (CL) in the treatment of recalcitrant persistent epithelial 

defects (PEDs). Methods: Ten eyes of 10 patients were treated with serum combined 

with CLs. Patients were divided into 2 groups: continued use or non-use of serum for 2 

weeks after total re-epithelialization and CL removal. Results: The PEDs all healed within 

3 weeks. However, recurrence of epithelial defect was noted in Group 2 without continued 

use of serum (40%). No recurrence of epithelial breakdown was noted in Group 1 during 

the 6-month follow-up. Conclusion: Combination of CLs and autologous serum with continued 

use of serum can be successfully used in the treatment of PEDs. 


Cultivating Oral Mucosa Epithelial Transplantation 

Followed by Penetrating Keratoplasty improves Vision in 

Ocular Burns 

Presenting Author: Dariusz Dobrowolski MD 

Co-Author(s): Bogumil Wowra, Boguslawa Orzechowska-Wylegala MD PhD, Edward A 

Wylegala MD PhD 

Purpose: Efficacy of cultivating oral mucosa epithelial transplantation (COMET) and 

subsequent penetrating keratoplasty (PK) in patients with limbal insufficiency combined 

with stromal corneal haze. Methods: Fifteen patients (16 eyes) with vascular conjunctival 

pannus and stromal involvement underwent autologous cultivated oral mucosa epithelial 

transplantation. Cultures were carried out on denuded amniotic membrane in the presence 

of 3T3 fibroblasts. At least 12 months after epithelium restoration, patients underwent 

PK. Corneal surface and visual acuity were evaluated. Results: Six months after surgery, 

68.7% of eyes had transparent cornea without revascularization, 31.2% of eyes developed 

vascular pannus again. In 62.5% of eyes, visual acuity increased from mean 0.01 to 0.3. 

Conclusion: COMET combined with PK effectively improves vision. 


Corneal Stromal Stem Cells: A Mesenchymal Epithelial 

Transition 

Presenting Author: Khurram Hashmani MBBS 

Co-Author(s): Matthew James Branch**, Permesh Dhillon, Andrew Hopkinson PhD**, 

Harminder S Dua MBBS** 

Purpose: To investigate the stem cell properties of corneal stromal cells (CSCs). Methods: 

CSCs were assessed against criteria set by the International Society for Cellular 

Therapy (ISCT). These cells were sorted based on their marker profiles and were also as- 





191



sessed. Sorted populations were also analyzed for their potential to differentiate into corneal 

epithelial cells (CECs). Results: CSCs fulfilled the ISCT criteria. Three subpopulations 

were isolated and demonstrated significant differences in their expression and trilineage 

potential. They also demonstrated the capacity to differentiate into CECs and progenitor 

lineages. Conclusion: This is the first study to show mesenchymal-epithelial transition in 

ophthalmology. CSCs have potential of being prelimbal stem cell and can be a source for 

generating CECs for various ocular diseases. 


APAO Reverse Conjunctival Autograft: Adieu to Recurrence 

Presenting Author: Somen Ghosh MBBS 

Co-Author(s): R K Ghosh 

Purpose: To evaluate the efficacy and safety of a reverse conjunctival autograft after 

excision of primary and recurrent pterygium. Methods: 200 eyes of 158 patients with 

primary and recurrent pterygium were divided into 2 equal groups. Group I had reverse 

graft - grafts placed with epithelial side down. Fine fenestrations were made in the graft 

for better and quicker fixation to the sclera. Group II had regular autografts. Results: 

Postoperative complications were mainly conjunctival congestion (83%), and loose autograft 

was seen more in Group I (7%). Mean follow-up period was 16 months. Group 

I showed recurrences in 2 eyes (failure rate 2%), while in Group II, failure rate was 8%. 

Conclusion: Reverse conjunctival autograft resulted in better success rates than normal 

autograft and is a cost-effective technique. 


H Long-term (3 Year) Effects of a Single LipiFlow Thermal 

Pulsation System Treatment on Meibomian Gland Function 

and Dry Eye Symptoms 

Presenting Author: Jack Volker Greiner DO PhD 

Purpose: To determine long-term effects of a LipiFlow (LTPS) treatment on dry eye patients 

with meibomian gland dysfunction (MGD). Methods: Meibomian gland scores 

(MGS), tear breakup time (TBUT), Ocular Surface Disease Index (OSDI), and Standard 

Patient Evaluation for Eye Dryness (SPEED) questionnaires were measured in 18 patients 

at baseline (BL), 1 and 9 months, and 1 and 3 years post-LTPS treatment. Results: MGS 

increased from BL (4.8 ± 3.7) to 1 month (11.4 ± 4.6; P < .001) and persisted at 9 months 

without reduction at 1 and 3 years. TBUT increased from BL (4.1 ± 1.9) to 1 month (8.3 

± 6.7; P < .012) and persisted at 9 months (P < .05), returning to BL at 1 year. SPEED 

decreased from BL (13.1 ± 4.6) to 1 month (6.2 ± 5.5; P < .001) and persisted at 3 years. 

Conclusion: A single LTPS treatment of MGD patients improves MGS and SPEED scores 

for 3 years, a long-term result surpassing all current dry eye treatments. 


Long-term Outcome of Autologous Serum Tears for 

Treatment of Dry Eye Disease 

Presenting Author: Munira T Hussain MS 

Co-Author(s): Roni M Shtein MD*, Alan Sugar MD, H Kaz Soong MD, Maria A 

Woodward MD, Shahzad I Mian MD* 

Purpose: To evaluate the safety and efficacy of long-term use of autologous serum (AS) 

for treatment of dry eye disease. Methods: Chart review of 97 eyes of 49 patients (mean 

age: 59 ± 11 years) treated with 50% AS eye drops q.i.d. was conducted. Indications 

included dry eye disease (61%), graft-vs.-host disease (28%), Sjúgren syndrome (7%), 

and Stevens-Johnson syndrome (4%). Clinical history, fluorescein staining, Schirmer, and 

Ocular Surface Disease Index (OSDI) were reviewed at baseline, 1 month, and then every 

3 months. Results: The mean follow-up was 8.7 (± 9.7, range: 1 to 43) months. OSDI 

improved at 3, 6, and 12 months (P = .0004, .0052, and .0009, respectively). Fluorescein 

staining improved at 1 and 6 months (P = .0092 and .0008, respectively). No serious adverse 

events were observed in any of the patients. Conclusion: AS eye drops are safe 

and effective for long-term treatment of dry eye disease. 


In Vivo Confocal Evaluation of Corneal Nerves in Patients 

With Diabetes Mellitus 

Presenting Author: Munira T Hussain MS 

Co-Author(s): Nilesh Raval, Rodica Pop-Busui MD, Roni M Shtein MD* 

Purpose: To compare the sub-basal corneal nerves in patients with diabetic neuropathy 

(DN) and healthy controls (HC). Methods: In vivo confocal microscopy images of 34 

subjects: 10 with severe DN, 15 with mild or no DN, and 9 HC, were analyzed. Results: 

Patients with severe DN had fewer nerves (P < .001) and less branching (P < .001) than 

HC. They also had fewer nerves (P < .001) and less branching than those with diabetes 

with mild or no neuropathy (P = .004). There was a trend toward reduced corneal sensation 

in patients with severe DN compared to HC (P = .052). Further, there was a moderate 

correlation (r = 0.45) between the number of primary nerve trunks and corneal sensation. 

Conclusion: Patients with severe DN have fewer nerves and less branching than those 

with diabetes with mild or no neuropathy and HC. 


APAO Keratoprosthesis: The Journey After ...! Analysis of 

Surgical Interventions Following Keratoprosthesis 

Presenting Author: Geetha Iyer MBBCHIR FRCS 

Co-Author(s): Bhaskar Srinivasan MBBS, Dr Shweta Agarwal, Tarun Sharma MBBS, 

Pukhraj Rishi** 

Purpose: To review the need for subsequent surgical interventions following keratoprosthesis 

surgery (Modified osteo-odonto keratoprosthesis, MOOKP) 80 eyes and Boston type 

1 KPro, 28 eyes) for functional / anatomic reasons. Methods: Retrospective review since 

March 2003. Results: A total of 77 procedures (intra- and extraocular) were performed 

ranging from 2 weeks to 5 years following keratoprosthesis surgery for mucus membrane, 

corneal graft, and lamina-related complications as well as for vitreoretinal procedures, 

glaucoma, and endophthalmitis. Vision could be maintained in all but 13 eyes. Conclusion: 

Keratoprosthesis surgery by itself is not the last step to visual rehabilitation. Further 

surgical interventions are required to maintain visual and anatomical outcome. Lifelong 

follow-up is mandatory. 


APAO Is Ocular Demodicosis a Potential Cause of 

Chalazion? 

Presenting Author: Lingyi Liang MD 

Co-Author(s): Scheffer C G Tseng MD PhD* 

Purpose: To report Demodex infestation in chalazion. Methods: Demodex counts of 47 

eyes of 47 pediatric chalazia cases and 44 eyes of 44 adult chalazia cases were compared 

with pediatric and adult controls. Eight multiple recurrent chalazion pediatric cases, 

whose previous recurrences occurred 4 (1-7) months postoperatively, received tea tree 

oil (TTO) lid hygiene. Results: Demodex mite infestation was higher in chalazia than in 

controls (70.2% vs. 10% in pediatric, 68% vs. 27% in adult, both P = 0.00). Demodex count 

was higher in multiple than in single chalazia (P = .03). During 6 (4-12) months of follow-up, 

2 out of 8 cases had 1 recurrence each after TTO treatment. Conclusion: Ocular demodicosis 

may be a potential cause of chalazion. 


Role of Transdermal Androgen Patches in Evaporative Dry 

Eye Syndrome: Case Series 

Presenting Author: Mayank A Nanavaty MD 

Co-Author(s): Matthew Gerard Long MBBS MD, Raman Malhotra MBChB FRCOphth 

Purpose: To report the effect of transdermal androgen patch therapy as an adjunct to 

conventional therapy for evaporative dry eye (EDE) and low androgen levels. Methods: 

Fourteen females with EDE and low serum testosterone were included. The Ocular Surface 

Disease Index (OSDI) questionnaire, tear film breakup time (TFBUT), Schirmer test, 

serum testosterone, and sex-hormone binding globulin (SHBG) were assessed at baseline 

and post-patching. Results: Post-patching, TFBUT, Schirmer test, and total OSDI scores 

improved significantly (P < .05) and increased after patch-free interval (P < .05). Conclusion: 

In patients with androgen deficiency, transdermal androgen patches appears to be 

effective in subjective and objective improvement of evaporative dry eye syndrome as an 

adjunct to conventional therapy. 


Treatment of Ocular Graft-vs.-Host Disease With Topical 

Loteprednol Etabonate 0.5% 

Presenting Author: Duna A Raoof-Daneshvar MD 

Co-Author(s): Munira T Hussain MS, Maria A Woodward MD, Roni M Shtein MD*, H 

Kaz Soong MD, Alan Sugar MD, Shahzad I Mian MD* 

Purpose: To evaluate the safety and efficacy of topical loteprednol etabonate 0.5% (LE) 

compared to cyclosporine-A 0.05% (CsA) for dry eye after bone marrow transplant (BMT). 

Methods: Ninety-six eyes of 48 patients were randomized to LE or CsA pre-BMT. Lissamine 

green and fluorescein staining, tear osmolarity, Schirmer test (Sch), and Ocular 

Surface Disease Index were obtained at screen and 3 months post-BMT. Results: At 3 

months, there was no change in any parameter compared to pre-BMT. There was a trend 

toward reduced ocular surface staining, higher Sch, and global physician assessment 

192 





scores in the LE group compared to the CsA group. No patients in the LE group developed 

ocular hypertension. Conclusion: Incidence of dry eye disease is low early after BMT. 

Pre-BMT initiation of LE or CsA is safe and may reduce risk of dry eye after BMT. 


APAO The Safety of Long-term Topical Tacrolimus Treatment 

in Severe Ocular Allergic Disease 

Presenting Author: Yoshiyuki Satake MD PHD 

Co-Author(s): Murato Dogru MD, Kazumi Fukagawa MD PhD, Jun Shimazaki MD, 

Hiroshi Fujishima MD* 

Purpose: To assess the safety of long-term continuous use of topical tacrolimus. Methods: 

We investigated the adverse events associated with the continuous use of topical tacrolimus 

for more than 2 years in 72 eyes of 36 cases with vernal/atopic keratoconjunctivitis. 

Results: The associated ocular comorbidities in tacrolimus users were steroid-related 

IOP elevation and chalazion. IOP elevation improved rapidly after tapering or stopping 

topical steroids. Chalazia resolved completely during topical tacrolimus use. Conclusion: 

Long-term tacrolimus use was not associated with any adverse events in severe ocular 

allergic disease. 


Primary Type I Boston Keratoprosthesis in Nonautoimmune 

Corneal Diseases 

Presenting Author: Han-Ying Peggy Chang MD 

Co-Author(s): Zhonghui Luo MD, James Chodosh MD MPH*, Claes H Dohlman MD 

PhD*, Kathryn A Colby MD PhD* 

Purpose: To report outcomes of Type I Boston KPro as primary corneal surgery in nonautoimmune 

corneal blindness. Methods: Retrospective, observational, large single-center 

series. Results: Forty-five eyes (39 patients) were followed for an average of 38 months 

(2 months to 6 years). Vision was ≥ 20/200 at 1 year in 75% of eyes. Complications included 

corneal melt (15%), glaucoma progression (42%), retroprosthetic membrane formation 

(51%), and sterile vitritis (11%). Conclusion: In a large series with long follow-up, 

primary Boston KPro effectively restored vision. Close follow-up is needed to manage the 

known complications following Boston KPro. 


Penetrating Keratoplasty vs. Lamellar Corneal Grafts: Is PK 

Really Doing Worse? 

Presenting Author: Laura de Benito-Llopis MD 

Co-Author(s): Jodhbir S Mehta FRCS FRCOPHTH*, Stephanie S Lang MS**, Donald Tan 

MD FRCS FRCOphth* 

Purpose: To compare penetrating keratoplasty (PK) and lamellar surgeries. Methods: We 

reviewed all primary keratoplasties performed in 2000-2009, and compared PK, anterior 

lamellar (ALK), and endothelial keratoplasties (Descemet-stripping automated endothelial 

keratoplasty). Results: 933 grafts were analyzed. Survival after DSAEK for pseudophakic 

bullous keratopathy (PBK) was significantly better than after PK in low-risk cases. There 

was no difference for Fuchs dystrophy, or between PK and ALK for keratoconus and corneal 

scarring. Incidence of rejection was highest in PK, lowest after ALK. Conclusion: PK 

achieved similar 5-year survival rates for Fuchs dystrophy, keratoconus, and corneal scarring 

than lamellar techniques, but these carried a lower incidence of rejection. 


Surgeon Characteristics of Eye Bank Distributed Corneal 

Tissue 

Presenting Author: Shahzad I Mian MD* 

Co-Author(s): Kevin W Ross**, Bradley Bruce Tennant, Roni M Shtein MD*, Maria A 

Woodward MD, Munira T Hussain MS, Alan Sugar MD 

Purpose: To assess surgeon characteristics of eye bank distribution of tissue for corneal 

transplantation between 2007 and 2012. Methods: Review of tissue distribution by 

Mid West Eye Banks by surgeon, type of surgery, and donor tissue parameters. Results: 

20,594 corneal tissues were distributed to 206 surgeons between April 2007 and January 

2012. The most common procedure was penetrating keratoplasty (66%), followed by 

endothelial keratoplasty (33%), which increased from 26.9% in 2007 to 36.4% in 2011. 

The mean number of grafts per surgeon was 14.0 ± 25.5 per year, while the median was 

4.3 per year. Twelve surgeons (5.8%) accounted for 41.2% of all corneal grafts performed 

annually. Conclusion: Corneal transplants are performed by a large number of surgeons; 

however, a few surgeons account for the majority of cases being performed. 


APAO Long-term Outcomes of Deep Anterior Lamellar vs. 

Penetrating Keratoplasty in Australian Keratoconus Patients 

Presenting Author: Sing-Pey Chow MBBS 

Co-Author(s): Ross B MacIntyre MD**, Elsie Chan MBBS, Alexander C Poon MBBS 

FRACS FRACO 

Purpose: To compare long-term visual outcomes following deep anterior lamellar keratoplasty 

(DALK) and penetrating keratoplasty (PK) for keratoconus. Methods: Singlesurgeon 

retrospective review. Results: Thirty-one DALK and 42 PK were included; mean 

follow-up was 3.9 years (SD 2.9) and 4.4 years (2.5), respectively. DALK vs. PK cases with 

postoperative suture-out logMAR BCVA 0.2 or better was not significantly different (P = 

.16), but PK cases were significantly more likely to achieve BCVA 0.0 (P < .05). Cases with 

postop astigmatism ≥ 5 D were similar (P = .24). Complications (rejection, cataract, glaucoma) 

were significantly higher in PK cases (P < .05). Conclusion: Visual outcomes for 

DALK vs. PK were not significantly different, but complications were significantly higher 

in the PK group. 


Gamma-Irradiated Donor Corneas for Therapeutic 

Penetrating Keratoplasty, Anterior Lamellar Keratectomy, 

and Glaucoma Patch Surgery 

Presenting Author: Jennifer M Nottage MD 

Co-Author(s): Takeo Fukuchi MD**, Verinder S Nirankari MD 

Purpose: To report the use of gamma-irradiated donor corneas (GIDC) for therapeutic 

penetrating keratoplasty (TPK), deep anterior lamellar keratectomy (DALK), and glaucoma 

patch graft surgery (GPG). Methods: A prospective noncomparative study of GIDC. Epithelialization, 

tissue clarity, corneal melt, rejection, infection, and adverse effects were evaluated. 

Results: Twenty-six eyes had GIDC (11 TPK, 9 DALK, 6 GPG). Mean follow-up was 

5.2 ± 3.8 months. Corneal epithelium healed in 5.4 ± 2.8 days. Graft clarity was achieved 

in all DALK eyes. Corneal melt occurred in 1 eye. There were no incidences of rejection 

or infection. Conclusion: GIDC is a promising treatment option for TPK, DALK, and GPG, 

with good epithelialization time and tissue clarity. 


Outcomes of Penetrating Keratoplasty and Deep Anterior 

Lamellar Keratoplasty in Patients With Keratoconus 

Presenting Author: Alireza Ziaei MD 

Co-Author(s): Mohammad R Sedghipour MD, Behzad Fallahi MD 

Purpose: To compare the outcomes of penetrating keratoplasty (PK) and deep anterior 

lamellar keratoplasty (DALK). Methods: 106 eyes of 106 patients with keratoconus who 

underwent PK or DALK were evaluated. Main outcome measures were BCVA, refraction, 

and contrast sensitivity. Results: Mean postoperative logMAR BCVAs were 0.28 ± 0.04 

and 0.03 ± 0.05 in PK and DALK groups, respectively (P = .99). Mean postoperative spherical 

equivalent refraction was -2.74 ± 0.58 D in the PK group and 3.46 ± 0.52 D in the DALK 

group (P = .36). Contrast sensitivity was significantly lower in the DALK group than in the 

PK group in all frequencies. Conclusion: Both techniques of keratoplasty (PK and DALK) 

are effective in patients with keratoconus. 


Endothelial Keratoplasty: The Relationship Between 

Recipient Anterior Chamber Depth and Donor Endothelial 

Survival 

Presenting Author: Asem A Alqudah MD 

Co-Author(s): Mark A Terry MD*, Mark Greiner MD, Michael D Straiko MD*, David Lee 

Davis-Boozer MPH* 

Purpose: To determine the relationship between anterior chamber depth (ACD) and percent 

endothelial cell loss (ECL) after endothelial keratoplasty (EK). Methods: In 76 eyes 

receiving EK, ACD was measured at preop with IOLMaster and ECL was calculated at 1, 

2, 3, and 4 years with specular microscopy. ACD and ECL were compared using correlation 

analysis and t-test. Results: Mean ACD was 2.95 ± 0.42 mm. Mean ECL was 27.7%, 

29.1%, 32.5%, and 37.2% at 1, 2, 3, and 4 years. No significant correlation was observed 

at any time point (P > .05). At 4 years, mean ECL was 43.0 ± 23.2 in eyes with ACD < 3 

mm and 29.6 ± 18.2 in eyes with ACD ≥ 3 mm (P = .008). Conclusion: ACD and ECL were 

not directly correlated; however, there may be a threshold ACD above which long-term 

ECL is reduced. 





193




Corneal Flattening Following Descemet-Stripping 

Automated Endothelial Keratoplasty for Congenital 

Hereditary Endothelial Keratoplasty 

Presenting Author: Ali A AlRajhi MD 

Purpose: To report cornea topographic changes following Descemet-stripping automated 

endothelial keratoplasty (DSAEK) for congenital hereditary endothelial keratoplasty 

(CHED). Methods: A total of 24 eyes of 17 patients (age range: 3-25 years) with CHED 

underwent DSAEK, and 20 eyes had preoperative and postoperative corneal topography 

and corneal thickness measurements. Results: There was a clear flattening of the cornea 

following DSAEK in CHED with a mean of preoperative keratometric reading (KR) from 

43.4 to a mean of postoperative KR 35.7 during the follow-up period of 2 years. Conclusion: 

DSAEK in CHED is associated with corneal flattening effect as evidenced by 

topographic changes. 


H APAO One-Year Outcomes of Pediatric Lamellar 

Keratoplasty: Endothelial and Deep Anterior Lamellar 

Keratoplasty—A Comparison With Penetrating Keratoplasty 

Presenting Author: Jatin Naresh Ashar MD 

Co-Author(s): Shivani Pahuja MBBS, Pravin K Vaddavalli MD*, Muralidhar Ramappa 

MS, Sunita Chaurasia MD 

Purpose: To analyze outcome of pediatric endothelial keratoplasty (EK) and deep anterior 

lamellar keratoplasty (DALK) and to compare with historical penetrating keratoplasty (PK) 

data. Methods: Retrospective analysis of indication, visual acuity (VA), refraction, graft 

survival of pediatric EK and DALK at 1 year was done and compared to PK. Results: 

Fifteen eyes (7.48 + 4.59 years, VA < 20/400) had EK (most common failed graft 5, CHED 

5). Fourteen (8.13 + 4.72 years, VA < 20/400) had DALK (most common keratoconus 5, 

scar- viral 6, non viral 2). One year VA > 20/80 was in 33%, 50%, 36%; refractive error 

was -0.7 D, 3.4 D, 4.75 D; graft survival was 86%, 57%, 62% in EK, DALK, and PK. Most 

common cause of DALK and PK failure was infection. Conclusion: Despite similar visual 

outcomes, EK has highest graft survival rates of these 3 pediatric keratoplasty techniques. 


H First Series of Descemet Membrane Endothelial Transfer 

Presenting Author: Martin Dirisamer MD 

Co-Author(s): Ru-Yin Yeh, Gerrit RJ Melles MD PhD* 

Purpose: To describe corneal clearance after re-endothelialization of the recipient posterior 

stroma, through Descemet membrane endothelial transferral (DMET), ie, a “freefloating” 

donor Descemet-graft in the recipient anterior chamber after descemetorrhexis. 

Methods: Twelve eyes enrolled in our study (7 suffering from Fuchs endothelial dystrophy; 

5 had bullous keratopathy). Results: All eyes operated on for Fuchs endothelial dystrophy 

showed corneal clearance with re-endothelialization of the denuded recipient posterior 

stroma, with an average endothelial cell density of 797 (±743) cells/mm2 6 months after 

surgery. In contrast, none of the bullous keratopathy eyes showed any improvement 

throughout the follow-up period. Conclusion: DMET may be effective in the management 

of Fuchs endothelial dystrophy. 


H A Multicenter Study of the Incidence of Descemet- 

Stripping Endothelial Keratoplasty Rejection 

Presenting Author: Christina Giannikas MD 

Co-Author(s): Ira J Udell MD*, Carolyn Y Shih MD MBA MPH, George J Florakis MD, 

Sadeer B Hannush MD, Christopher Rapuano MD*, Mark S Gorovoy MD, Robert W 

Weisenthal MD, Gerald W Zaidman MD FACS, George O D Rosenwasser MD*, Lara 

Rosenwasser, Michael B Raizman MD*, David D Verdier MD, Stephen E Orlin MD*, 

Sudeep Pramanik MD MBA 

Purpose: To determine the incidence of Descemet-stripping endothelial keratoplasty 

(DSEK) rejection at ≥ 2 years in a large surgical cohort from 13 surgeons. Methods: Retrospective 

review of all DSEK surgeries performed by 13 surgeons. More than 2 years 

follow-up was required. Results: The rejection rate was 2% (surgeons’ range: 1.3%- 

9.5%) in a total of 2454 surgeries. Eighty-seven percent of the rejections were reversed 

with topical steroids. Eight grafts (13%) failed following rejection. Conclusion: In this 

case series, where most patients were maintained on low-dose topical steroids for years 

after DSEK, the incidence of rejection at ≥ 2 years was 2%, lower than has been reported 

by other major studies. Most rejections were reversed with increased steroid dosages. 


Diffuse Interface Reticular Turbidity (DIRT) Following 


Presenting Author: Keunsoo Kim MD PhD 

Co-Author(s): Kim Jiramongkolchai MD**, Alan N Carlson MD*, Natalie A Afshari 

MD*, Anthony N Kuo MD*, Brian D Alder MD, Terry Kim MD* 

Purpose:To describe 7 cases of diffuse interface reticular haze (DIRH) following Descemet-stripping 

automated endothelial keratoplasty (DSAEK). Methods: Pre- and postoperative 

visual acuity, donor information, surgical technique, pathology, anterior OCT, and 

outcomes were reviewed retrospectively. Results: The occurrence of DIRH ranged from 

postoperative Day 1 to 7 weeks. Four cases improved spontaneously, with BCVA better 

than 20/40, and 2 cases required repeat DSAEK for persistent decreased vision worse 

than 20/50 and nonclearing DIRH. Histopathology showed no inflammation, deposits, or 

fibrosis. Conclusion: Etiologic factors for the occurrence of DIRH are not clear, and repeat 

DSAEK may be an effective treatment option for DIRH. 


H Endothelial Cell Density After Descemet Membrane 

Endothelial Keratoplasty: Five-Year Follow-up 

Presenting Author: Fayyaz Musa MBBS FRCOPHTH 

Co-Author(s): Lisanne Ham PhD, John Parker MD, Martin Dirisamer MD, Miguel L 

Naveiras Torres-Quiroga MD*, Korine van Dijk OD, Gerrit RJ Melles MD PhD* 

Purpose: To determine the rate of decline in endothelial cell density (ECD) up to 5 years 

after Descemet membrane endothelial keratoplasty (DMEK). Methods: In a group of 300 

consecutive patients who underwent DMEK for Fuchs endothelial dystrophy or pseudophakic 

bullous keratopathy, ECD measurements were taken at 6, 12, 24, 36, 48, and 60 

months. Results: The ECD averaged 2560 (± 200) cells/mm2 before surgery and 1670 (± 

520) cells/mm2, 1580 (± 540) cells/mm2, 1470 (± 500) cells/mm2, 1390 (± 530) cells/mm2, 

1300 (± 470) cells/mm2 and 1250 (± 390) cells/mm2 at 6, 12, 24, 36, 48, and 60 months, respectively, 

postoperatively. Conclusion: The rate of endothelial cell loss in patients up to 

5 years after DMEK closely resembles that after earlier types of endothelial keratoplasty. 


H Five-Year Endothelial Cell Density Loss After Descemet- 

Stripping Automated Endothelial Keratoplasty: Comparison 

of Fellow vs. Attending Surgery 

Presenting Author: Julia C Talajic MD 

Co-Author(s): Mark Greiner MD, Mark A Terry MD*, Asem A Alqudah MD, David Lee 

Davis-Boozer MPH* 

Purpose: To compare long-term endothelial cell density (ECD) loss of fellow-performed 

Descemet-stripping automated endothelial keratoplasty (DSAEK) to one experienced surgeon. 

Methods: Retrospective review of 589 eyes (7 fellows = 265 eyes, 1 attending = 

324 eyes) with Fuchs dystrophy that underwent DSAEK using the same technique (5-mm 

scleral tunnel, forceps insertion). Results: Fellow vs. attending ECD losses at 6 months 

(23.8% vs. 23.5%, P = .812), 1 year (24.7% vs. 24.4%, P = .882), 2 years (25.8% vs. 26.0%, 

P = .935), 3 years (28.7% vs. 32.4%, P = .151), 4 years (33.9% vs. 38.7%, P = .251) and 5 

years (35.6% vs. 49.6%, P = .063) were compared. Conclusion: No significant difference 

in long-term ECD loss exists between fellow- and attending-performed DSAEK surgery, 

indicating a robust technique that achieves comparable results for novice and expert surgeons. 


Descemet-Stripping Automated Endothelial Keratoplasty: 

Endothelial Cell Loss Over 5 Years in a Large Prospective 

Study Using the Same Technique 

Presenting Author: Mark A Terry MD* 

Co-Author(s): Julia C Talajic MD, Michael D Straiko MD*, Asem A Alqudah MD, David 

Lee Davis-Boozer MPH* 

Purpose: To document cell loss over 5 years with Descemet-stripping automated endothelial 

keratoplasty (DSAEK) using a single technique. Methods: DSAEK was performed 

with forceps insertion in 673 eyes with Fuchs dystrophy or pseudophakic bullous keratopathy. 

Results: Endothelial cell loss at 6 months, 1, 2, 3, 4, and 5 years was 25% (n 

= 673), 25% (n = 575), 27% (n = 407), 34% (n = 271), 38% (n = 139), and 45% (n = 47), 

respectively. Grafts with both 1-year and 5-year data (n = 41) had only a 12% further cell 

loss from 1 year to 5 years, which was significant (P = .001). Conclusion: After 6 months, 

194 





the progressive cell loss with forceps-insertion DSAEK is mild and better than PK. The cell 

loss from DSAEK in this study at 5 years is less than that of PK and less than all previous 

DSAEK studies. 


H APAO In Vitro Estimation of Optimal IOP and Duration 

Required for Donor Adhesion During Descemet-Stripping 


Presenting Author: Pravin K Vaddavalli MD* 

Co-Author(s): Ana P Fraga Santini Canto MD, Sonia H Yoo MD*, Michael R Banitt MD*, 

Marco Ruggeri PhD*, Jean-Marie Parel PhD* 

Purpose: In vitro estimation of the minimum IOP required for optimal donor adhesion during 

Descemet-stripping automated endothelial keratoplasty (DSAEK). Methods: Graded 

increase in IOP with an air bubble was performed in 10 in vitro DSAEK surgeries. Areas 

of donor nonadhesion were measured on serial high-resolution spectral domain OCT. Results: 

An air bubble with IOP at 30 mmHg for 5 minutes achieved optimal adhesion, which 

improved over an hour, compared to reducing the pressure to 10 mmHg or by an air-fluid 

exchange. Discussion: IOP of 30 mmHg with a full chamber air bubble for an hour resulted 

in the least areas of nonadhesion and optimal donor adhesion in DSAEK. 


APAO Evaluation of Clinical Outcome of Corneal Collagen 

Crosslinking in Pseudophakic Bullous Keratopathy 

Presenting Author: Yashpal Goel MBBS 

Co-Author(s): Jawahar Lal Goyal MD**, Ritu Arora MD MBBS, Aditi Abhay Manudhane 

MBBS, Gaurav Goyal MBBS**, Deepa Gupta MBBS, Ravindra Kumar Saran MD 

Purpose: To assess the clinical effect of corneal collagen crosslinking (CXL) in pseudophakic 

bullous keratopathy (PBK). Methods: Twenty-four patients of PBK underwent CXL. 

Twelve patients were followed up for 1 month, and 12 patients were followed up for 3 

months after CXL. Visual acuity (VA), ocular discomfort on the visual analogue scale (VAS), 

and central corneal thickness (CCT) were recorded serially. Results: Mean VA improved 

from 1.92 to 1.70 at 1 month in 24 patients, with a fall to 1.75 at 3 months in 12 patients. 

Mean CCT reduced from 846.46 µ to 781 µ at 1 month and increased to 805.08 µ at 3 

months. VAS score decreased from 4.75 to 2 at 1 month and 2.67 at 3 months. CCT and 

VAS score improved significantly at 1 month, with a worsening trend at 3 months. Conclusion: 

CXL reduces corneal edema and gives symptomatic relief in PBK. The effect is 

temporary and decreases with time. 


Topography-Guided Photorefractive Keratectomy for 

Keratoconus Combined With Collagen Crosslinking 

Presenting Author: Simon P Holland MD* 

Co-Author(s): David Lin MD 

Purpose: To evaluate safety and efficacy of simultaneous topography-guided photorefractive 

keratectomy (TG-PRK) with collagen crosslinking (CXL). Methods: 112 eyes of 

73 patients with KC underwent TG-PRK with simultaneous crosslinking using Allegretto 

WaveLight laser. Symptoms, UCVA, and BSCVA were evaluated at 1 year. Results: Fiftyseven 

eyes completed 1 year of follow-up. Symptoms improved in 52, 28 (49%) had UCVA 

of ≥ 20/40, 31 improved BSCVA, 3 lost > 2 lines, astigmatism decreased 2.7 D to 1.1. 

Conclusion: Simultaneous TG-PRK with CXL improved symptoms, vision, and both UCVA 

and BSCVA in most keratoconus patients, with reasonable efficacy, safety, and stability 

at 1 year. 


Topography-guided Photorefractive Keratectomy With 

Collagen Crosslinking for Post-LASIK Ectasia 

Presenting Author: Simon P Holland MD* 

Co-Author(s): David Lin MD 

Purpose: To evaluate topography-guided photorefractive keratectomy (TG-PRK) with collagen 

crosslinking (CXL) in post-LASIK ectasia. Methods: Evaluation at 1 year after TG- 

PRK with CXL using the Allegretto WaveLight laser of symptoms, UCVA, BSCVA, manifest 

refraction (MR), predictability, and safety. Results: UCVA improved to ≥ 20/40 in 14/24, 

compared to 4/24 before. Most (13/24) gained ≥ 2 lines of BSCVA. Mean reduction in 

astigmatism (MR) was 1.9 D. All but 2 patients had improved symptoms. Conclusion: 

Early results demonstrate that TG-PRK with CXL may be effective and safe for post-LASIK 

ectasia. Most patients had improved symptoms and uncorrected and corrected vision. 


Combined Transepithelial Phototherapeutic Keratectomy 

and Corneal Crosslinking for Progressive Keratoconus 

Presenting Author: George D Kymionis MD PhD 

Co-Author(s): Michael Grentzelos MD, George A Kounis, Vasilios F Diakonis MD, Aliki 

N Limnopoulou MD, Sophia Panagopoulou PhD, Ioannis G Pallikaris MD* 

Purpose: To compare the outcomes of corneal crosslinking (CXL) using 2 different techniques 

for epithelial removal: transepithelial phototherapeutic keratectomy (t-PTK) and 

mechanical epithelial debridement. Methods: In this prospective, comparative study, 34 

patients (38 eyes) with progressive keratoconus underwent uneventful CXL; 16 patients 

(19 eyes) underwent epithelial removal with t-PTK (Group 1) and 18 patients (19 eyes) 

underwent mechanical epithelial debridement (Group 2). Results: In Group 1, mean uncorrected 

distance VA (UDVA) and mean corrected distance VA (CDVA) improved from 0.99 

± 0.71 and 0.30 ± 0.26 preop to 0.63 ± 0.42 (P = .02) and 0.19 ± 0.18 (P = .008) 12 months 

postop, respectively. In Group 2, neither mean UDVA nor mean CDVA demonstrated a 

significant improvement 12 months postop (P > .05). Conclusion: T-PTK during CXL results 

in better visual and refractive outcomes in comparison with mechanical epithelial 

debridement. 


H Evaluation of Epithelial-On Corneal Collagen 

Crosslinking 

Presenting Author: Roy Scott Rubinfeld MD* 

Co-Author(s): William B Trattler MD*, S Lance Forstot MD FACS*, Neil F Martin MD, 

Charles J Kaiser MD**, Jonathan H Talamo MD* 

Purpose: To evaluate the safety, efficacy, and outcomes of epithelial-on corneal collagen 

crosslinking (CXL) in patients diagnosed with ectatic corneal disease. Methods: Eyes with 

preop diagnoses of corneal ectatic disease that had epithelial-on CXL were evaluated. 

Outcomes included UCVA, BSCVA, astigmatism measures, and Pentacam and topography 

data. Results: 155 eyes were evaluated. Forty-four percent and 49% of eyes had improvements 

in UCVA and BSCVA, respectively. Sixty-eight percent, 61%, and 69% of eyes had 

a reduction of 0.5 D or more in astigmatism, spherical equivalent, and 2-mm astigmatism, 

respectively; 43% and 56% of eyes experienced reduction in Holladay mean K and Magellan 

mean K, respectively. Conclusion: Epithelial-on CXL is proven safe and effective for 

patients diagnosed with corneal ectatic disease. 


H Comparing Conventional and Transepithelial Corneal 

Collagen Crosslinking in Keratoconus 

Presenting Author: David Touboul MD 

Co-Author(s): Antoine Robinet-perrin MD, Nicolas Mesplie MD, Delphine Praud, 

Caroline Garra**, Florence E Malet MD, Joseph Colin MD* 

Purpose: To compare transepithelial collagen corneal crosslinking (TE-CXL), a new alternative 

for keratoconus management, with conventional epithelium-off corneal crosslinking 

(C-CXL). Methods: Two groups of progressive keratoconus cases, of 50 eyes each with 

mild severity, were retrospectively included in a comparative study. Keratometric readings, 

visual outcomes, and safety concerns were observed at 1 year of follow-up. Results: At 1 

year, progressive cases were still 11% in the C-CXL group and 23% in the TE-CXL group. 

Adverse corneal effects were reported in 3.5% in the C-CXL group and not a case in the 

TE-CXL group. Conclusion: TE-CXL has shown more safety but less efficacy than C-CXL 

1 year after the surgery. 


Comparison of Epithelial-On Crosslinking for the Treatment 

of Mild, Moderate, and Severe Keratoconus 

Presenting Author: William B Trattler MD* 

Co-Author(s): Gaston O Lacayo MD, Gabriela Perez, Sandy T Feldman MD**, Parag A 

Majmudar MD*, Ranjan P Malhotra MD* 

Purpose: To evaluate the efficacy of corneal collagen crosslinking (CXL) in patients with 

varying grades of ectatic corneal disease. Methods: Patients that received epithelial-on 

CXL were evaluated and classified into mild, moderate, or severe keratoconus based on 

preop steep K values. Outcome measures included UCVA, BSCVA, astigmatism, steep K, 

and spherical equivalent. Results: 149 eyes met inclusion criteria. Forty-five percent of 

moderate eyes and 31% of severe eyes improved in UCVA, while 48% of mild eyes, 60% 

of moderate eyes, and 37% of severe eyes improved in BSCVA. Twenty-six percent of mild 





195



eyes, 51% of moderate eyes, and 45% of severe eyes experienced 1 D or more reduction 

in steep K. Conclusion: Epithelial-on CXL is proven safe and effective for patients classified 

as having mild, moderate, or severe corneal ectatic diseases. 


Evaluation of Patients With a Strong Response to Epithelial- 

On Corneal Collagen Crosslinking 

Presenting Author: William B Trattler MD* 

Co-Author(s): Carlos Buznego MD*, Jodi Luchs MD*, Marwa Adi MD FACS**, Roy 

Scott Rubinfeld MD*, Gregg J Berdy MD*, Gabriela Perez 

Purpose: To evaluate patients that experienced a strong response to epithelial-on corneal 

collagen crosslinking (CXL). Methods: Patients who underwent epithelial-on CXL for corneal 

ectatic disease. Eyes considered to have a strong response experienced 2+ lines of 

improvement in UCVA and/or BSCVA postoperatively. Results: 211 eyes underwent epithelial-on 

CXL. Fifty-three percent at 1 week, 47% at 3 months, and 44% at 6 months were 

strong responders. Three or more lines of improvement in UCVA was seen in 18% of eyes, 

13% of eyes, and 11% of eyes at 1 week, 3 months, and 6 months, respectively. Three or 

more lines of improvement in BSCVA was seen in 10% eyes and 8% at 3 and 6 months, 

respectively. Conclusion: Epithelial-on CXL can result in significant visual improvement 

as well as improvement in corneal shape and corneal strength in some patients. 


H Early Complications After Crosslinking for Keratoconus 

Presenting Author: Denise Wajnsztajn MD 

Co-Author(s): Shahar Frenkel MD, Joseph Frucht-Pery MD** 

Purpose:To report early complications post crosslinking (CXL) treatment for keratoconus 

(KC). Methods: Retrospective study (2007 to 2012) of ocular complications, within first 

month of CXL, in 206 eyes (180 patients), using Dresden protocol and JMP software 7.0 

(SAS; Carry, NC, USA). Results: Twenty-three eyes (11.2%) of 22 patients had 28 ocular 

complications, including delay of epithelial healing up to 30 days in 4 eyes, hypertrophic 

epithelial healing in 4 eyes, marked superficial punctate keratopathies (> 30 days) in 11 

eyes, corneal sterile infiltrates in 4 eyes, microbial keratitis in 4 eyes (positive cultures in 

2 eyes), and marked corneal edema with scarring in 1 eye. More complications occurred in 

thinner corneas (P = .002, Pearson test) and steeper Kmax (P < .0001, ANOVA). BCVA loss 

of 3 2 lines (3 eyes). Conclusion: Remarkable early complications may occur following 

CXL, more frequently in advanced KC. 


Crosslinking in Advanced Keratoconus With Thin Corneas 

Presenting Author: Denise Wajnsztajn MD 

Co-Author(s): Eyal Strassman MD**, Shahar Frenkel MD, David Landau MD, Joseph 

Frucht-Pery MD** 

Purpose: To report 1-year outcome following corneal collagen crosslinking (CXL) treatment 

for very advanced keratoconus (KC). Methods: Retrospective study (2007 to 2012) of 

CXL in 25 eyes (26 patients) with corneas thinner than 400 µm, using hypotonic riboflavin 

(Dresden protocol) and matched pairs t-test. Results: Mean pachymetry was 371.9 ± 

19.7 µm (332 to 399 µm). After using hypotonic riboflavin, mean pachymetry increased to 

438.7 ± 38 µm (380 to 521 µm). After 1 year the Kmax decreased from 62.8 ± 7 D to 58.5 

± 5.4 D (P = .013), but BCVA of 0.59 ± 0.24 (Snellen) didn’t change and was 0.56 ± 0.18 

(P = .658). Complications included delay of epithelial healing in 5 eyes, sterile infiltrate 

and microbial keratitis (1 eye each), and stromal haze in 2 eyes. Three eyes lost 2 lines of 

BCVA. Conclusion: In advanced KC with thin corneas, CXL is an efficacious treatment but 

complications are common. 


Reliability of Ocular Response Analyzer Corneal 

Biomechanical Readings After the Instillation of Topical 

Anesthetics 

Presenting Author: Juan C Nieto DO 

Co-Author(s): Miguel J Maldonado MD PhD, Alberto Lopez Miguel, Maria E Correa 

Perez MD 

Purpose: To analyze the repeatability of the ORA corneal resistance factor (CRF) and hysteresis 

(CH) after the instillation of different topical anesthetics (TAs). Methods: Normal 

eyes (60) received in a random order fashion 1 drop of tetracaine 0.5% (T), proparacaine 

0.5% (P), and oxibuprocaine 0.4% (O), and the fellow eyes balanced-salt solution (BSS). 

Consecutive ORA readings (3) were obtained 5 minutes after instillation. Results: Repeatability 

and intraclass correlation coefficients were as follows—CRF: 2.365 and 0.797 (O), 

2.364 and 0.825 (P), 2.011 and 0.844 (T), 2.097 and 0.829 (BSS); CH: 2.872 and 0.656 (O), 

2.738 and 0.619 (P), 2.454 and 0.697 (T), 2.064 and 0.782 (BSS). Conclusion: CRF and CH 

ORA readings should be obtained before the instillation of some TAs, particularly O and P. 


Foldable Artificial Cornea for Treatment of Cornea Blindness 

Presenting Author: Jose M Vargas MD* 

Co-Author(s): Yichieh Shiuey MD* 

Purpose: To evaluate the safety and effectiveness of a foldable artificial cornea for the 

treatment of corneal blindness. Methods: Nineteen patients with corneal blindness due 

to failed grafts, burns, scars, dystrophies, and keratoconus had KeraKlear artificial corneas 

implanted into a corneal pocket using a nonpenetrating technique. Results: 100% 

of these patients had improvement in vision. Preop vision ranged from 20/200 to handmotions. 

Postop vision ranged from 20/30 to 20/100. These results remained stable between 

9 and 19 months of follow-up. There were no significant complications. Conclusion: The 

initial results of the KeraKlear artificial cornea show that this device can improve vision 

rapidly in cornea blind patients and may be used as an alternative to penetrating keratoplasty 

as a primary procedure. 


A Review of Corneal Manifestations and Surgical Outcomes 

in Iridocorneal Endothelial Syndrome 

Presenting Author: Monisha Mandalaywala Vora MD 

Co-Author(s): Carolyn Y Shih MD MBA MPH, Khurram Mahmood Chaudhary MD, Ira J 

Udell MD* 

Purpose: To describe corneal findings and surgical outcomes of patients with iridocorneal 

endothelial syndrome (ICE). Methods: Retrospective case review of 12 ICE patients seen 

from 2002 to 2012 at North Shore-LIJ. Results: Corneal findings included persistent epithelial 

defect (17%), band keratopathy (17%), stromal scarring (17%), and corneal edema 

(75%). Sixty-six percent of patients had peripheral anterior synechiae, 25% had corectopia. 

Four of 12 patients had penetrating keratoplasty (PK), 2/12 had Descemet-stripping 

automated endothelial keratoplasty (DSAEK). Five of 6 patients had an average gain of 7 

Snellen lines over 41.8 months post-transplant follow-up. One of the 4 PKs had nonimmunologic 

graft failure 9 months postop; the other 3 have remained clear an average of 

59 months postop. Two of the 2 DSAEK grafts were clear an average of 16 months postop. 

Conclusion: ICE patients with corneal scarring/edema may benefit from PK or DSAEK. 

General Medical Care 

Session One 





H APAO Study of Oculodepressor Reflex in Humans 

Presenting Author: Indu Khurana MD MBBS** 

Co-Author(s): Aruj Kumar Khurana**, Ashok Kumar Khurana MBBS MD 

Purpose: To demonstrate the occurrence of oculodepressor reflex (ODR) in human beings. 

Methods: In 20 eyes of 20 patients undergoing squint surgery under general anesthesia, 

the effects of mechanical traction of the medial rectus muscle on heart rate (HR) and mean 

arterial pressure (MAP) were recorded. Changes were compared after giving intravenous 

atropine (Group 1) or retrobulbar anesthesia (Group 2) in 10 patients each. Results: MAP 

fall was 7.11% and 5.14% and HR fall was 18.28% and22.26% in Group 1 and Group 

2, respectively. Prior intravenous atropine could abolish fall in HR but not in MAP (P < 

.01), whereas retrobulbar anesthesia abolished the fall in both HR and MAP. Conclusion: 

This confirms the presence of ODR in human beings and shows that it is independent of 

oculocardiac reflex (OCR). 

196 






APAO Characteristic Changes of Spontaneous Blinks in 

Patients With Parkinson Disease 

Presenting Author: Naoko Kimura MD 

Co-Author(s): Akihide Watanabe MD, Kazutaka Suzuki, Haruyoshi Toyoda PhD, 

Naotoshi Hakamata**, Shigeru Kinoshita MD* 

Purpose: To investigate the characteristic changes in Parkinson disease (PD)-related 

spontaneous blinks. Methods: Spontaneous blinks of 23 PD patients and 18 age-matched 

healthy controls were measured by use of an intelligent vision sensor camera prototype. 

Results: Five PD patients (22%) exhibited an extremely high (more than 75 times/80 sec) 

spontaneous blink frequency and 3 PD patients (17%) exhibited an extremely low (less 

than 3 times/80 sec) frequency. Small blink-waves (100-200 millisecond) prior to blink onset 

existed in 43% of the PD patients and in 0% of the controls. Conclusion: Our findings 

showed the existence of characteristic changes in PD-related spontaneous blinks, which 

might possibly prove useful for the diagnosis of PD. 

Session Two 

Sunday and Monday 




Red Eyes and Primary Polycythemia 

Presenting Author: David Y Poon MD 

Co-Author(s): David J Ramsey MD, Richard J Kolker MD, Robert S Weinberg MD 

Purpose: To describe the presenting ocular signs of primary polycythemia. Methods: 

Three patients presented with bilateral eye redness and were initially diagnosed and 

treated for dry eye, blepharitis, and rosacea. Despite treatment and unremarkable past 

medical histories, the patients continued to have a plethoric complexion, conjunctival 

hyperemia, and persistent redness: signs suggestive of a possible systemic etiology. Results: 

When initial treatment failed, each patient had a hematocrit checked that was 

compatible with primary polycythemia (54.5 ± 2.1%). A hematologist treated the patients 

for primary polycythemia with periodic phlebotomy, which subsequently eliminated the 

eye redness. Conclusion: When managing a patient with recalcitrant eye redness, ophthalmologists 

should consider obtaining a hematocrit to rule out primary polycythemia. 


APAO Antibiotic Susceptibility of Ocular Bacterial Isolates 

in an Asian Tertiary Eye Center: A 5-year Retrospective 

Review 

Presenting Author: Yanping Xu MBBS 

Co-Author(s): Tat-Keong Chan MD FRCS FRCOphth*, Eunice Tse Ching Loh RN 

Purpose: To investigate the microbial spectrum and antimicrobial susceptibilities of 

ocular isolates. Methods: Retrospective review of 596 ocular bacterial isolates from 

2004-2008 at a tertiary eye center. Data included origin of ocular isolates and sensitivities 

to commonly used antibiotics. Results: Sensitivities of gram-positive bacteria were: 

cephalothin (58.7%), tobramycin (59.4%), ciprofloxacin (70%), levofloxacin (73.6%), and 

chloramphenicol (86.1%). Sensitivities of gram-negative bacteria were: chloramphenicol 

(32.4%), tobramycin (74.1%), levofloxacin (79.7%), and ciprofloxacin (86.2%). Conclusion: 

A large proportion of organisms tested were sensitive to the commercially available 

antibiotics levofloxacin, ciprofloxacin, and tobramycin. 

Glaucoma 

Glaucoma Poster Tour 


12:30 PM to 1:30 PM 

Session One 





Long-term Evaluation of Efficacy and Safety of Deep 

Sclerectomy in Uveitic Glaucoma 

Presenting Author: Saleh Ali Alobeidan 

Co-Author(s): Essam E Osman MD FRCS, Ahmed Mousa AbdelRahim PHD, 

Abdulrahman M Al Muammar MBBS, Ahmed M Abu El-Asrar MD** 

Purpose: To investigate the efficacy and safety of nonpenetrating glaucoma surgery in 

controlling IOP in uveitic glaucoma. Methods: Patients with uveitic glaucoma underwent 

nonpenetrating deep sclerectomy. All patients received anti-inflammatory medications 

before and after surgery. Results: The mean (SD) follow-up was 33.21 (±19.83). IOP 

was reduced from 37.66 to 15.07 mmHg (P < .0001). Complete success was obtained in 

20/29 eyes (69%); qualified success was achieved in 7 eyes (24.14%), while 2 eyes (6.9%) 

failed. Conclusion: Nonpenetrating deep sclerectomy is an effective and safe procedure 

in uveitic glaucoma with a relatively reasonable success rate and considerably low rate of 

complications. Goniopuncture increases the success rate. 


Ab Interno Trabeculectomy Using a Novel Investigational 

Device 

Presenting Author: Jeffrey R SooHoo MD 

Co-Author(s): Leonard K Seibold MD, David Ammar*, Malik Y Kahook MD* 

Purpose: To evaluate the effects of a novel ab interno trabeculectomy device on human 

trabecular meshwork (TM). Methods: This was a preclinical study using human cadaveric 

corneal rim tissue. The TM was incised using 3 instruments: (1) a novel dual blade 

device, (2) MVR blade, and (3) the Trabectome. Results: The dual blade device achieved 

complete removal of TM without injury to surrounding tissues. Tissue cut with the MVR 

blade exhibited minimal removal of TM and obvious injury to the adjacent sclera. The 

Trabectome removed a large portion of the central TM, but leaflets of residual tissue remained 

and thermal injury was noted in all samples. Conclusion: The novel dual blade 

device demonstrated complete removal of TM without residual TM leaflets or damage to 

surrounding tissues. 


APAO Bleb Excision and Free Conjunctival Autografts for 

Leaking and Overfiltering Blebs 

Presenting Author: Manish Panday MBBS 

Co-Author(s): Shantha Acharya MS**, Ronnie Jacob George MD*, Vijaya Lingam MD 

MBBS**, Lingam Gopal MBBS 

Purpose: Outcomes of free autologous conjunctival patch graft for bleb leak and overfiltration 

following trabeculectomy. Methods: Retrospective case series (January 1996-December 

2011). Hypotony was defined as IOP < 6 mmHg. Results: Sixty-four eyes were 

included (bleb leaks, 56; hypotony, 8). Median follow-up was 72 weeks. IOP (mmHg, median) 

increased from 4 at baseline to 11.5 at 6 weeks (P < .001) and 13 at final follow-up 

(P < .001). Visual acuity (logMAR, median) increased from 0.60 at baseline to 0.30 at 6 

weeks (P < .001) and 0.48 at final follow-up (P = .902). Failures (12 eyes) included 2 repeat 

patch grafts, 1 repeat trabeculecomy, and 1 case of endophthalmitis. Conclusion: Free 

patch graft is a safe and effective means of restoring bleb function and improving visual 

outcomes. 


APAO Six-Year Incidence of Ocular Hypertension in a 

Population-Based Study 

Presenting Author: Manish Panday MBBS 

Co-Author(s): Rashima Asokan MD, Ronnie Jacob George MD*, Lingam Gopal MBBS, 

Vijaya Lingam MD MBBS** 

Purpose: To report the 6-year incidence and risk factors for ocular hypertension (OHT) in 

a population-based study. Methods: Prospective cohort study. Inclusion criteria: phakics, 

≥ 40 years with baseline IOP < 22 mmHg and no evidence of glaucoma. OHT was defined 

as an IOP ≥ 22 mmHg at the 6-year follow-up with no evidence of glaucoma and without 

disc or field changes. Results: Incidence of OHT over 6 years seen in 2.53% (74/2924 





197



participants; 95% CI, 1.96-3.09). Higher baseline IOP and increasing age were associated 

with conversion. Conclusion: A significant proportion of this normal population converted 

to ocular hypertension. 


Laser and Incisional Surgery for Patients with Newly 

Diagnosed Open-Angle Glaucoma 

Presenting Author: Joshua D Stein MD MS 

Co-Author(s): Steven M Kymes PhD*, Leslie M Niziol MS, Colleen Peters MS*, Paul P 

Lee MD JD*, David C Musch PhD* 

Purpose: To understand the frequency, timing, risk factors, and costs associated with 

laser trabeculoplasty (LTP) and trabeculectomy for patients with incident open-angle glaucoma 

(OAG). Methods: A nationwide cohort of managed care enrollees with incident OAG 

were followed up to 8 years (2001-2009) in the i3 InVision DataMart database to identify 

need for LTP and trabeculectomy. Results: Among the 17,071 incident OAG patients, 1959 

(11.5%) had ≥ 1 LTP and 251 (1.5%) had ≥ 1 trabeculectomy. The median timing to first 

LTP and to first trabeculectomy was 0.96 and 1.36 years after diagnosis, respectively. The 

median cost for an episode involving LTP or trabeculectomy was $2797 and $10,128, respectively. 

Discussion: A small subset of patients with incident OAG require surgery, but 

for those who do, it is very costly. 


H One-year Follow-up of a Novel, Minimally Invasive 

Drainage Implant: MIDI Arrow 

Presenting Author: Juan F Batlle MD* 

Co-Author(s): Francisco E Fantes MD**, Rachel Alburquerque Montes De Oca MD, 

Adalgisa Corona MD, Richard Parrish II MD*, Jean-Marie Parel PhD* 

Purpose: To evaluate the IOP-lowering effects of the MIDI Arrow used either alone or 

in combination with phacoemulsification. Methods: Single-site, prospective, nonrandomized 

study of 23 eyes in 23 patients; 9 MIDI Arrows alone and 14 combined with 

phacoemulsification. All eyes received intraoperative mitomycin C. Results: The mean IOP 

decreased 50% to 11.1 ± 3.0 mmHg (MIDI Arrow alone) and 60% to 9.6 ± 2.6 mmHg (MIDI 

Arrow with phacoemulsification) at 1 year. Two patients developed transient choroidal 

effusions. All eyes with lowered IOP had filtering blebs. No serious adverse events occurred. 

Conclusion: The MIDI Arrow effectively lowered IOP when implanted alone or in 

combination with phacoemulsification without serious long-term adverse events. 


Retrobulbar Extension Implant for Encapsulated Tube 

Shunts 

Presenting Author: William Eric Sponsel MD* 

Co-Author(s): Sylvia Groth 

Purpose: To evaluate efficacy of a new retrobulbar seton for redirecting aqueous from encapsulated 

blebs. Methods: Nine eyes with bleb encapsulation underwent implantation 

of an retrobulbar extension implant (REI) silicone retrobulbar seton. IOP and antiglaucoma 

medications were compared with preop levels 0.2, 1, 2, 4, 6, 8, 10, 12, 14, and16 months 

postop. Results: 6 M/3 F; 57 ± 6.5 years; mean preop IOP 31.8 ± 3.3 mmHg on 2.6 ± 0.3 

meds. Mean IOP at the 10 postop intervals was 12.8, 15.0, 15.3, 17.7, 14.8, 15.7, 13.3, 

15.2, 16.0, and 13.2 (mean : -14.9 mmHg (-47%); P < .0001) using 0, 0, 0, 0.1, 0.6, 0.1, 0.9, 

1.3, 0.8, and 0.5 meds (mean : -2.2 meds (-85%); P < .0001). Viscoelastic reformations 

and tube flush maneuvers were required in several eyes. Conclusion: With appropriate 

postoperative measures the REI was highly effective in reducing IOP and medications. 


Hypertensive Phase and Early Complications After Ahmed 

Glaucoma Valve Implantation With and Without Subtenon 

Triamcinolone Acetonide 

Presenting Author: Angela V Turalba MD 

Co-Author(s): Louis R Pasquale MD* 

Purpose: To evaluate subtenon triamcinolone acetonide (TA) as an adjunct to Ahmed 

glaucoma valve (AGV) implantation. Methods: To test our hypothesis that TA improves the 

hypertensive phase (HP) after AGV implantation, we retrospectively reviewed 42 consecutive 

adult cases of AGV with and without subtenon TA injection and analyzed 6-month 

postoperative data. Results: Five out of 19 TA cases (26%), and 12 out of 23 controls 

(52%) developed a HP (P = .08). Early tube erosion and bacterial endophthalmitis were 

noted with TA, but not with controls. Conclusion: Subtenon TA injection during AGV 

implantation may decrease occurrence of the HP but may pose increased risk of serious 

complications within the first 6 months of surgery. 


H Lens Surgery in Patients at Risk for Narrow-Angle 

Glaucoma: Three-Year Follow-up 

Presenting Author: Barbara Kusa MD 

Purpose: To evaluate inclusion criteria and long-term results of lens removal for refractive 

purposes and glaucoma prevention. Methods: We performed anterior chamber (AC) OCT 

on 74 eyes with AC depth ≤ 2.4 mm, AC angle ≤ 15° (age above 50 years) before and 3 

years after lens extraction and IOL implantation. Results: Preoperative SE refraction was 

+2.59 D ± 2.84 D; IOP, 16.79 ± 5.17 mmHg; AC depth, 2.18 ± 0.18 mm; angle width, 12.84° ± 

5.79°. Surgery was uncomplicated. Three years postoperatively, IOP decreased by 5.38%, 

AC depth increased by 70.18%, endothelial cell count decreased by 16.02%, and AC angle 

increased by 204.36%. No eye showed angle-closure glaucoma. Conclusion: Three-year 

data show that early lens extraction in eyes with shallow AC depth and narrow angle apparently 

provides efficient glaucoma prevention and fewer surgical complications. 


APAO Trabeculotomy From Below for Exfoliation Glaucoma 

Presenting Author: Mineo Ozaki MD 

Co-Author(s): Noriko Toyokawa MD, Atsuko Fukumoto MD, Takanori Mizoguchi MD, 

Shigeyasu Kazama MD**, Shinichiro Kuroda MD 

Purpose: To evaluate the surgical outcomes of phacotrabeculotomy (PLOT) from below 

for exfoliation glaucoma (XFG). Methods: 140 eyes with XFG and 183 eyes with primary 

open-angle glaucoma that underwent trabeculotomy alone or PLOT from either above or 

below from 1998 to 2010 were retrospectively analyzed. Surgical failure was defined as 

IOP ≥ 18 mmHg. The follow-up period was from 12 to 60 months. Results: IOP was reduced 

from 24.8 ± 6 to 15.3 ± 3.2 mmHg at 60 months in XFG with PLOT from below. Success 

rate at 5 years for PLOT from above and from below for XFG was 76.5% and 92.3%, 

respectively (P = .4690 ). Conclusion: Phacotrabeculotomy from below for XFG appears to 

be effective, safe, and preserves upper conjunctiva. 


H One-Year Results of an Intracanalicular Microstent 

Combined With Cataract Surgery for IOP Reduction 

Presenting Author: Thomas W Samuelson MD* 

Co-Author(s): Manfred Tetz MD**, Norbert Pfeiffer MD, Gabor Bernd Scharioth MD*, 

Salvatore Grisanti*, Clemens Vass Vass MD*, Marina A Ramirez MD** 

Purpose:To evaluate the ability of the Hydrus microstent to lower intraocular pressure 

(IOP) in POAG patients when combined with cataract surgery. Methods: Subjects diagnosed 

with open angle glaucoma with visual field mean deviation ≥-12dB and an age 

related cataract were recruited from 6 centers in a prospective case series. Subjects were 

washed out of glaucoma medications prior to surgery and at 1 year. Microstent implantation 

in Schlemm’s canal was done following cataract surgery. Results: In 29 treated 

subjects, medication-free mean (± SDI) IOP was reduced from 24.6 ± 5.3 at baseline to 

15.5 ± 3.3 at 1 year (P < 0.05). Conclusion: An intracanalicular microstent may offer a 

continuous, durable alternative to medical therapy for IOP reduction. 


H Baseline Predictive Factors Affecting Efficacy of 

Selective Laser Trabeculoplasty 

Presenting Author: James Lin 

Co-Author(s): Larissa Habib MD, Tamara Berezina, Barry A Maltzman MD, Robert D 

Fechtner MD FACS*, Albert S Khouri MD* 

Purpose: To study predictors of selective laser trabeculoplasty (SLT) efficacy. Methods: 

Review of patients with 360° SLT for IOP reduction was conducted. Data at 1, 4, 8, and 12 

months were collected. Multivariate logistic regression was performed using covariates 

(baseline IOP, diabetes (DM), and class of topical glaucoma medication), with an endpoint 

of > 20% IOP decrease from baseline. Results: Sixty-three patients (93 eyes) were included. 

Only positive predictor was baseline IOP > 20 mmHg (at 8 months: odds ratio (OR) 

= 13.2, P < .001; at 12 months: OR = 3.8, P = .03). Negative predictors were DM (8 months: 

OR = 0.21, P = .03), and topical carbonic anhydrase inhibitors (TCAI) (8 months: OR = 0.15, 

P = .01). Conclusion: Higher baseline IOP positively predicted SLT efficacy, while negative 

predictors included DM and TCAI. 

198 






Does Prostaglandin Use Limit Selective Laser 

Trabeculoplasty Efficacy? 

Presenting Author: James Lin 

Co-Author(s): Larissa Habib MD, Tamara Berezina, Barry A Maltzman MD, Robert D 

Fechtner MD FACS*, Albert S Khouri MD* 

Purpose: To determine how baseline topical prostaglandin (PG) use affects IOP reduction 

after SLT. Methods: Review of subjects with 360° SLT for IOP reduction was conducted. 

Data at 1, 4, 8, and 12 months were collected. Chi-squared analysis used to compare 

proportion of > 20% IOP decrease from baseline between PG and non-PG treated patients. 

Results: Fifty-three patients (74 eyes) were included (46 PG and 28 non-PG). At baseline, 

there were no differences in mean IOP (PG = 19.3 mmHg, non-PG = 20.5 mmHg, P = .21) or 

number of medications (P = .07) between groups. Differences in achieving IOP decrease > 

20% between PG vs. non-PG treated groups were insignificant at all follow-up times (P = 

0.1 at 1 month; 0.7 at 4 months; 0.7 at 8 months; 0.7 at 12 months). Conclusion: Treatment 

using PG does not influence the ability of SLT to lower IOP. 


The Incidence and Amount of Anterior Chamber Bleeding 

After Laser Peripheral Iridotomy 

Presenting Author: Gabi Shemesh DOMS 

Co-Author(s): Shimon Kurtz MD**, Shani Golan 

Purpose: To determine the incidence of anterior chamber bleeding after laser peripheral 

iridotomy (LPI) in patients with antiplatelet/anticoagulant treatment. Methods: The right 

eye underwent LPI without stopping their treatment. The medications were discontinued 

for 2 weeks before the fellow left eye underwent LPI. The LPI-associated complications 

were evaluated. Results: A total 216 eyes were included. The bleeding did not differ 

significantly when the patient was on and off antiplatelet / anticoagulant treatment. The 

type of antiplatelet/anticoagulants, the laser power, age, gender, or iris color were not 

risk factors for increased bleeding. Conclusion: There is no indication for discontinuing 

antiplatelet / anticoagulant medications before an LPI. 


Prostaglandin-Associated Periorbitopathy in Patients Using 

Bimatoprost, Latanoprost, and Travoprost 

Presenting Author: Atilla Bayer MD 

Co-Author(s): Murat Kucukevcilioglu, Yusuf Uysal MD**, Halil Ibrahim Altinsoy** 

Purpose: To investigate whether rates of prostaglandin-associated periorbitopathy (PAP) 

differ between bimatoprost (B), latanoprost (L), and travoprost (T) users. Methods: Sixty 

consecutive cases with glaucoma using one of the prostaglandins in one eye were evaluated 

for presence of components of PAP (enophthalmos, ptosis, upper eyelid sulcus deepening, 

involution of dermatochalasis, loss of periorbital fat pad). The contralateral eye 

was used as a control. Results: PAP was seen in 29 cases (48%). It was most frequent 

in patients using B (9/10), followed by T (9/12), and was less common in patients using 

L (11/38) (P = .00). Conclusion: PAP is more common in cases using B and T. This side 

effect seems to be worth considering, and patients should be informed when these drugs 

are prescribed. 


A Cross-Sectional Survey of the Association Between 

Bilateral Topical Prostaglandin Analogue Use and Ocular 

Adnexal Features 

Presenting Author: Mamta Vinit Shah 

Co-Author(s): Grace Lee MD**, Daniel R Lefebvre MD, Benjamin P Kronberg MD, 

Stephanie J Loomis MPH*, Stacey C Brauner MD, Angela V Turalba MD, Douglas J 

Rhee MD*, Suzanne K Freitag MD, Louis R Pasquale MD* 

Purpose: We studied the relationship between prostaglandin analogue (PGA) use and 

ocular adnexal features. Methods: 343 patients without prior conditions affecting ocular 

adnexal anatomy underwent external digital photography. Masked readers assessed 

photos for upper lid dermatochalasis (D) and lower lid steatochalasis (S). Another masked 

observer assessed upper lid ptosis (P) and levator muscle dysfunction (L). We used unpaired 

t-tests to analyze the data. Results: There was less D (P = 5.89E-05) and less S (P 

= 4.35E-07) among current bimatoprost users vs. nonusers. All the PGAs were significantly 

associated with P and L. Conclusion: PGA use has distinct associations with ocular adnexal 

features. 


Comparison of Haag-Streit AT900 Mechanical Applanation 

Tonometer and Huvitz HT5000 Electronic Applanation 

Tonometer 

Presenting Author: Assaf Kratz MD* 

Co-Author(s): Ahed Amtirat MD, Ronit Yagev MD**, Jaime Levy MD, Tova Lifshitz MD 

Purpose: To study the relationship between IOP measurements by the gold standard 

Goldmannn mechanical applanation tonometer and a recently introduced Huvitz HT5000 

digital applanation tonometer. Methods: Twenty-eight patients underwent complete 

ocular examination including IOP measurements with both Haag-Streit AT900 mechanical 

applanation tonometer and the recently introduced Huvitz HT5000 digital applanation tonometer. 

Results: The mean IOP for AT900 and HT5000 tonometers was similar (P = .47). 

A strong, significant correlation was found for paired measurements. No proportional bias 

was observed. Conclusion: IOP measurements by GAT AT900 and HT5000 tonometers 

are comparable and interchangeable. 


Comparison of 3 Different Methods of IOP Measurements: 

Goldmann Applanation Tonometer, Ultrahigh-Speed 

Scheimpflug Technology, and Rebound Tonometer 

Presenting Author: Adrian P Smedowski MD 

Co-Author(s): Beata Weglarz MD, Edward A Wylegala MD PhD 

Purpose: A comparative trial to check different IOP measurement techniques. Methods: 

We made IOP and corneal thickness (CT) measurements of 192 eyes (63 females, 33 

males; mean age: 59.3 ± 19.9). Measurements were carried out using 3 methods: Goldmann 

Applanantion Tonometer (GAT), ultrahigh-speed Scheimpflug technology (UHS ST), 

and a rebound tonometer (RT). Results: There was no significance difference between 

values measured with GAT and RT but there was a difference between AT, RT, and UHS 

ST (P < .0001). Conclusion: The applanation tonometer and rebound tonometer can be 

equal methods of IOP measurement, in contrast to ultrahigh-speed Scheimpflug technology, 

which gives significantly different values. 


Regression Modeling for Pointwise Visual Field Analysis in 

Glaucoma 

Presenting Author: Parham Azarbod MBBS 

Co-Author(s): Fei Yu PhD, Esteban Morales, Abdelmonem Afifi PhD, Elena Bitrian MD, 

Dennis Mock MS**, Kouros Nouri-Mahdavi MD, Anne Louise Coleman MD PhD, 

Joseph Caprioli MD FACS* 

Purpose: To compare the accuracy of 4 pointwise regression models to measure the rate 

of glaucomatous visual field worsening. Methods: The regression models compared by 

using the Akaike information criteria were (1) linear, (2) non-decay exponential (y = B0 + 

B1ex), (3) decay exponential (y = eB0 + B1x), and (4) Tobit linear. Results: A total of 798 

open-angle glaucoma eyes (MD range: +2 to -27 dB) were divided into 10 groups of severity 

and analyzed. Overall and within each group, compared to the other models, the decay 

exponential regression provided the best fit (88.1% overall) for serial pointwise decay 

graphs. Conclusion: The pointwise decay exponential regression was found to be the 

most suitable method for serial threshold sensitivity analysis. 


H APAO Investigation of the Relationship Between Car 

Accidents Caused by Glaucoma Drivers and Their Visual 

Field Loss 

Presenting Author: Shiho Kunimatsu MD 

Co-Author(s): Yuki Aoki MD**, Takeshi Hara MD**, Hidetoshi Kawashima MD PhD, 

Aiko Iwase MD PhD, Toru Nakazawa MD, Hiroshi Ono**, Makoto Araie MD** 

Purpose: To investigate correlation between car accidents caused by glaucoma drivers 

and visual field loss. Methods: Thirty-six patients with mean deviation < -12 dB in both 

eyes with Humphrey visual fields analyzer 24-2 SITA-S program (HFA24-2) and 36 agematched 

normals received a driving simulator (Honda Motor Co.; Tokyo) where people/ 

vehicles suddenly appear in front of testee’s car under controlled conditions. HFA24-2, 

binocular integrated-visual field (IVF) and Esterman visual field testing was studied in relationship 

to accident frequency. Results: Number of accidents correlated with sensitivities 

in fovea, 10° lower hemifield in IVF and Esterman score (P < .01). Conclusion: The lower 

10° hemifield is crucial for glaucoma drivers to avoid these accidents. 





199




APAO Glaucoma Detection Ability of Ganglion Cell-Inner 

Plexiform Layer and Retinal Nerve Fiber Layer Thickness in 

High Myopia 

Presenting Author: Yun Jeong Choi MD 

Co-Author(s): MiJeung Kim MD, Kyoungnam Kim MD, Jin Wook Jeoung MD, Joon Mo 

Kim MD, Dong Myung Kim MD, Ki Ho Park MD* 

Purpose: To compare the glaucoma detection ability of ganglion cell-inner plexiform layer 

(GCIPL) thickness with that of retinal nerve fiber layer (RNFL) thickness in high myopia. 

Methods: In 46 high myopic and 58 non-high myopic patients along with 48 healthy myopic 

subjects, spectral domain OCT imaging was done. Results: In the high myopic group, 

the area under the receiver operating characteristic curve of the average GCIPL thickness 

did not differ significantly from that of the average RNFL thickness (0.772 vs. 0.873; P = 

.28). The best parameters were the inferior RNFL (0.884) and inferotemporal GCIPL (0.883) 

thickeness. Conclusion: In high myopia, the glaucoma detection ability of GCIPL thickness 

was comparable to that of RNFL thickness. 


APAO Rates of Macular and Retinal Nerve Fiber Layer 

Progression Determined by OCT in Glaucomatous Eyes 

Presenting Author: Sophia Kim MD 

Co-Author(s): Jung Hwa Na MD, Seung-Hee Baek PhD, Kyung Rim Sung MD PhD 

Purpose: To evaluate macular (MA) and circumpapillary retinal nerve fiber layer (cRNFL) 

progression rate using spectral domain OCT in preperimetric (PPG, 87 eyes) and perimetric 

glaucomatous eyes (PG, 40 eyes). Methods: Linear mixed effects models were used to 

evaluate the rates of changes in 2 parameters (mean follow-up: 2.5 years). Results: Sixo’clock 

(-2.33 µm/year, cRNFL) and inferior outer sector (-2.88 µm/year, MA) showed the 

highest progression rates. PG eyes showed higher progression rates in the fovea and the 

inferior inner sector of the MA than PPG eyes did. None of the progression rates of the 

cRNFL parameter differed between the 2 groups. Conclusion: PG and PPG eyes showed 

different progression rates in MA thickness. 


APAO Determination of Reference Standard for OCT 

Progression Detection in Glaucoma 

Presenting Author: Jongrak Lee MD 

Co-Author(s): Seung-Hee Baek PhD, Jung Hwa Na MD, Kyung Rim Sung MD PhD 

Purpose: To determine the preferred methods for detecting spectral domain OCT progression 

in glaucoma using various criteria. Methods: 280 glaucomatous eyes with at least 

4 OCT exams (mean follow up: 2.9 years) were enrolled. Rim area (RA), retinal nerve fiber 

layer thickness (RNFLT) slope (RNFLS), change of RNFLT normative classification (RNFLN), 

macular thickness (MT), slope (MS), and change of MT normative classification (MN) were 

compared by latent class regression model. Results: Sensitivity and specificity were RA: 

0.35, 0.92; RNFLS: 0.41, 0.85; RNFLN: 0.25, 0.98; MS: 0.60, 0.84; MN: 28, 0.93. Conclusion: 

Five methods showed decent glaucoma detection capability, while MS was the most 

sensitive method. 


APAO Glaucoma Progression in Eyes With a Previous 

History of Refractive Corneal Surgery 


Co-Author(s): Yoon Jeon Kim MD**, Sung-Cheol Yun DO PhD**, Jung Hwa Na MD, 

Kyung Rim Sung MD PhD 

Purpose: To evaluate the glaucoma progression of patients with a history of refractive 

corneal surgery (RCS). Methods: Progression was determined either by experts’ serial 

optic disc/retinal nerve fiber layer assessment or visual field data analysis in both RCS (34 

eyes) and non-RCS groups (279 eyes; mean follow-up: 2.7 years). Cox proportional hazards 

models were used to determine the associations between risk factors and progression. 

Results: Ten eyes (29.4%) of the RCS group and 77 eyes (27.6%) of the non-RCS group 

showed glaucoma progression. The prevalence was not different between the 2 groups 

(P = .48). RCS history was not a significant risk factor for glaucoma progression (P = .45). 

Conclusion: RCS history may not be related to glaucoma progression. 

CANCELED 


APAO Macular Diagnostic Abilities of RTVue-100 and Cirrus 

HD Spectral Domain OCT in Early Glaucoma 


Co-Author(s): Kyoungsub Lee MD**, Young Rok Lee MD**, Michael Scott Kook MD** 

Purpose: To compare glaucoma diagnostic abilities between RTVue-100 inner macular 

thickness (IMT) and Cirrus HD OCT full macular thickness (FMT). Methods: 119 glaucoma 

subjects and 51 healthy subjects were assessed by RTVue-100 and Cirrus HD OCT. Areas 

under receiver operating characteristic curves (AUCs) of retinal nerve fiber layer thickness 

(RNFLT), IMT, and FMT were compared between 2 OCTs in any stage of glaucoma. Results: 

Overall, RTVue-100 OCT did not show better glaucoma diagnostic ability than Cirrus 

HD OCT in RNFLT (AUC = 0.974 vs. 0.967, P = .37), but IMT demonstrated significantly higher 

AUCs than FMT in early glaucoma (AUC = 0.925 vs. 0.851, P = .02). Conclusion: In early 

glaucoma, RTVue-100 OCT showed better macular diagnostic ability than Cirrus HD OCT. 


APAO Relationship Among Nocturnal Dip, Disc Area, and 

Visual Field Progression in Open-Angle Glaucoma 

Presenting Author: Sae Heun Rho MD 

Co-Author(s): Hong Ryung Seo MD, Ji Young Suh**, Hye Mi Jung MD 

Purpose: To investigate the relationship among nocturnal dip, disc area, and visual field 

progression in open-angle glaucoma (OAG). Methods: A total of 190 OAG patients (380 

eyes) were recruited. Twenty-four-hour blood pressure monitoring, disc spectral domain 

OCT, and visual field test were performed and their correlations were analyzed. Results: 

In OAG patients with over-dip (nocturnal dip over 10%) and small disc size, the probability 

of visual field progression was higher than in those with a larger disc size. Also, when 

patients were subdivided into normal-tension glaucoma (NTG) and primary OAG, this was 

true only in the NTG group. Conclusion: In OAG, especially in NTG, small disc area is 

thought to contribute to visual field progression in patients with over-dip. 


APAO Analysis of Retinal Nerve Fiber Layer Thickness in 

Keratoconus: Impact of Rigid Gas Permeable Contact Lenses 

Presenting Author: Vishal Jhanji MBBS 

Co-Author(s): Elaine To, Marco Yu, Gilda Lai**, Cong Ye MBBS, Christopher Kai-shun 

Leung MD MBChB* 

Purpose: To measure intraclass correlation coefficient (ICC) for retinal nerve fiber layer 

(RNFL) analysis with and without rigid gas permeable (RGP) contact lenses in keratoconus 

patients. Methods: Cirrus HD-OCT imaging was performed in 14 keratoconus eyes. 

Results: Adequate reliability was found in cup/disc ratio and cup volume measurements 

(ICC ≥ 0.990) and in temporal and superior quadrant RNFL thickness (ICC ≥ 0.932). Good 

reliability was observed in rim area, disc area, and average RNFL thickness (ICC ≥ 0.845). 

Signal strength had poor reliability (ICC = 0.341). Conclusion: Use of RGP lenses during 

RNFL analysis in keratoconus patients may not have significant impact on the reliability 

of measurements. 


Effect of Silicone Oil on the Nerve Fiber Layer Thickness in 

Vitrectomized Eyes 

Presenting Author: Mia Zoric Geber MD* 

Co-Author(s): Goran Bencic*, Zoran Vatavuk MD**, Renata Ivekovic MD PhD**, 

Thomas R Friberg MD* 

Purpose: To evaluate the effect of silicone oil on retinal nerve fiber layer thickness (RNFL). 

Methods: Sixty patients with silicone oil tamponade were prospectivelly enrolled and 

divided into the Normal and Raised IOP subgroups (IOP > 22 mmHg). RNFL thickness was 

measured with a Cirrus HD-OCT at 7, 30, 90, and 180 days postoperatively. Results: Significant 

thickening of RNFL was recorded at follow-up visits (χ2 = 12.20, P = .007). No 

significant difference in average RNFL thickness was found between subgroups. There 

was a statistically significant increase of RNFL thickening in Normal IOP subgroup over 

the course of the study (χ2 = 12.14, P = .007), as opposed to the Raised IOP subgroup (χ2 

= 2.69, P = .441). Conclusion: Silicone oil is associated with RNFL thickening, which is 

dependent on duration of the silicone oil tamponade. 

200 






APAO Comparison of Retinal Vascular Changes in 

Glaucomatous and Nonglaucomatous Eyes With Unilateral 

Retinal Vein Occlusion in the Fellow Eye 

Presenting Author: Sophia Kim MD 

Co-Author(s): Kyung Rim Sung MD PhD, Jee-Taek Kim MD, Dong Hoon Lee MD**, Soo 

Geun Joe, Joo Yong Lee MD*, June-Gone Kim MD PHD, Young Hee Yoon MD* 

Purpose: To evaluate and compare the retinal vascular changes in glaucomatous (GL, 

26 eyes) and nonglaucomatous eyes (NGL, 25 eyes) with unilateral retinal vein occlusion 

(RVO) in the fellow eye. Methods: Fluorescein angiographic images were independently 

assessed in both GL and NGL groups with unilateral RVO in the fellow eye by 3 retina 

specialists.Results: Nine eyes in NGL and 11 eyes in GL groups showed focal leakage (P 

= .041). Nonperfusion and collateral vessels were found only in GL groups (3 and 4 eyes, 

respectively). Conclusion: GL eyes with unilateral RVO in the fellow eye showed vascular 

abnormalities more frequently than NGL eyes did, which may suggest common underlying 

vascular pathogenesis between the 2 diseases, glaucoma and RVO. 


APAO Risk Factors for Normal-Tension Glaucoma in a Young 

Population 

Presenting Author: Moonjung Kim MD 

Co-Author(s): MiJeung Kim MD, Ho Soong Kim**, Ki Ho Park MD* 

Purpose: To identify risk factors associated with normal-tension glaucoma (NTG) in a 

young Korean population. Methods: A population-based, cross-sectional study on Koreans 

aged 19 to 39 years was conducted from July 2008 to December 2010. Eighty (80) NTG 

patients and 4006 controls were included in the analysis. Results: Multivariate analysis 

with logistic regression demonstrated that negative refractive error (OR, 0.87 [95% CI, 

0.81-0.94]), fasting capillary blood glucose (FCG) level ≥ 200 mmol/L (OR, 12.41 [95% CI, 

2.84-54.35]), and lower HDL cholesterol level (OR, 0.97 [95% CI, 0.94-0.99]) were associated 

with an increased risk of NTG. Conclusion: Myopic refractive error, FCG level ≥ 200 

mmol/L and low HDL cholesterol level were significant risk factors for NTG in a young 

population. 


APAO Increased Iris Thickness and Association With 

Appositional Closure in Japanese Subjects With Angle 

Closure 

Presenting Author: Takanori Mizoguchi MD 

Co-Author(s): Mineo Ozaki MD, Harumi Wakiyama MD**, Nobuchika Ogino MD PhD** 

Purpose: To investigate the relationship between the iris parameters and appositional 

closure (AC) in Japanese subjects with PAC and PACG after laser peripheral iridotomy 

(LPI). Methods: Thirty-three eyes with AC in ≥ 2 quadrants (AC+ Group) and 46 eyes with 

AC in ≤ 1 quadrant (AC- Group) were prospectively recruited. IT500, IT750, maximum IT, 

and iris-area were measured using anterior segment OCT.Results: IT500 and IT750 were 

significantly greater in the AC+ Group than in the AC- Group (P < .05). After multivariate 

analysis adjusted for age, gender, ACD, and pupil size, increased IT 500 and 750 were significantly 

associated with AC (OR, 1.9; 95% CI, 1.0-3.3, 2.0; 95% CI, 1.1-3.6, respectively), 

but no association was found for maximum IT or iris-area. Conclusion: Increased iris 

thickness is associated with AC after LPI. 


Prognostic Significance of b-Zone Parapapillary Atrophy 

During the Ocular Hypertension Treatment Study (OHTS) 

Presenting Author: Eleonore Savatovsky MD 

Co-Author(s): Donald L Budenz MD MPH*, Jean-Claude Mwanza MD, Douglas R 

Anderson MD*, Joyce C Schiffman MS*, William J Feuer MS, Ruth Vandenbroucke, 

Jagadeesh Bandi MD MPH** 

Purpose: To determine if enlargement of parapapillary atrophy (PPA) predicts the development 

of primary open-angle glaucoma (POAG). Methods: 275 case/control pairs matched 

on age and follow-up time had initial and last disc photos analyzed. Disc, a and b-zone 

PPA were traced by 2 trained readers and areas were measured. Results: Readers had 

good agreement on disc area (ICC = 0.97) and b-zone (ICC = 0.82), but not a-zone (ICC 

= 0.48). The b-zone, as a percent of disc area, increased in size (P < .001) in eyes with 

incident POAG (mean = 10.6%, SD = 22.6%) and controls (mean = 10.1%, SD = 33.9), 

over follow-up (mean = 12.3 years). The increase in size did not differ between cases and 

controls (P = .82). Conclusion: b-zone enlarges both in case and control subjects during 

follow-up, but this was not associated with the onset of POAG. 


H Glaucoma and Intake of the Oxidants Calcium and Iron 

in a U.S. Population Sample 

Presenting Author: Sophia Ying Wang* 

Co-Author(s): Kuldev Singh MD MPH*, Shan C Lin MD* 

Purpose: To investigate the relationship between glaucoma and total intake of calcium 

and iron. Methods: This cross-sectional study included 3598 participants in the 2007- 

2008 National Health and Nutrition Examination Survey, age ≥ 40 years, who self-reported 

glaucoma status. Usual total intakes of calcium and iron were modeled from two 24- 

hour recall interviews. Results: Adjusted odds of glaucoma increased with higher quintile 

(Q) intakes of calcium (P-trend < .0001; Q3: OR 1.58, 95% CI, 1.32-1.89; Q4: 1.21, 1.03-1.43) 

and iron (P-trend < .0001; Q4: 1.58, 1.36-1.83; Q5: 2.95, 2.52-3.45) compared with the lowest 

quintile intake. Conclusion: Higher total intake of calcium and iron may be associated 

with increased presence of glaucoma. 


APAO Evaluation of Optic Disc Morphology With HRT-II of 

Middle-Age or Older Japanese Subjects With Normal Vision 

Presenting Author: Yoko Ikeda MD 

Co-Author(s): Kazuhiko Mori MD*, Morio Ueno MD, Haruna Yoshikawa MD, Yuko 

Maruyama MD, Shigeru Kinoshita MD* 

Purpose: To evaluate optic disc morphology of normal Japanese subjects. Methods: Of 

1861 Japanese volunteers > 40 years of age, we enrolled 838 subjects diagnosed as normal 

by glaucoma specialists and performed a Heidelberg Retina Tomograph II (HRT-II) for 

both eyes. Their refractive error was within ±12 D, and HRT-II SD was less than 50. They 

were divided into 4 age groups (40s, 50s, 60s, and over 70s), and right-eye disc area (DA) 

and rim area (RA) data were then compared. Results: In the 4 age groups, DA/RA was 

1.9 ± 0.5/1.4 ± 0.3, 1.9 ± 0.4/1.4 ± 0.3, 1.9 ± 0.4/1.4 ± 0.3, and 1.9 ± 0.4/1.5 ± 0.3 mm2, 

respectively, and no significant difference was found among generations. Conclusion: 

In normal subjects, glaucoma prevalence increased by age, yet DA/RA remained stable. 


CYP1B1, MYOC, and LTBP2 Mutations in Primary Congenital 

Glaucoma Patients in the United States 

Presenting Author: SingHui Lim 

Co-Author(s): Khanh-Nhat Tran-Viet MHA, Tammy L Yanovitch MD, Sharon F Freedman 

MD*, Thomas Klemm MS, Whitney Call, Caldwell Powell, Ajay Ravichandran, 

Ravikanth Metlapally PhD, Erica Nading MS, Steve Rozen PhD, Terri L Young MD* 

Purpose: To screen primary congenital glaucoma (PCG) patient DNA samples for mutations 

in known PCG genes CYP1B1, LTBP2, and MYOC. Methods: Whole exome sequencing 

(WES) was performed on affected members of 3 families, and variants were confirmed 

by Sanger sequencing. Sanger sequencing was performed on additional 44 PCG families. 

Results: Twelve patients (21.1%) carried CYP1B1 mutations: 1 nonsense and 6 compound 

heterozygous mutations. There were no pathogenic LTBP2 and MYOC mutations. Conclusion: 

This is the largest U.S. PCG cohort study analyzing genetic mutations using WES and 

Sanger sequencing. Five compound heterozygous CYP1B1 mutations were novel. The low 

percentage mutation rate in the 3 genes indicates other genes are implicated with PCG. 

WES may be a powerful tool to identify novel PCG genes. 


Comparing Visual and IOP Outcomes Between Descemet- 

Stripping Automated Endothelial Keratoplasty and 

Penetrating Keratoplasty 

Presenting Author: Meenakshi Chaku MD 

Co-Author(s): Sophia K Mirza MD, Peter Andreas Netland MD PhD*, Leslie A 

Olsakovsky MD 

Purpose: To compare visual acuity (VA) and IOP after Descemet-stripping automated 

endothelial keratoplasty (DSAEK) and penetrating keratoplasty (PK). Methods: Retrospective 

comparative study of 42 DSAEK and 30 PK eyes. Results: Visual acuity at 1 year 

was significantly better after DSAEK (20/40) than PK (20/80), P < .001. Initial IOP was not 

significantly different between DSAEK (16.5 mmHg) and PK (16.3 mmHg). Both groups had 

significant increased IOP at 6 months compared with baseline (P < .001). IOP at 1 year was 





201



not significantly different between DSAEK (17.8 mmHg) and PK (16.9 mmHg). Conclusion: 

Visual outcomes were significantly better after DSAEK than PK. There was not a 

significant difference in IOP between DSAEK and PK. 

Session Two 



on Monday, Nov. 12, from 11:00 AM to 12:30 PM. 


Excimer Laser Trabeculostomy Combined With Phaco + IOL 

Implantation: Five-Year Postop Observations 

Presenting Author: Michael Berlin MD 

Co-Author(s): Ulrich F Giers MD**, Lea Kleineberg MD**, Richard Stodtmeister MD, 

Lutz E Pillunat MD** 

Purpose: To evaluate the long-term IOP-lowering efficacy of excimer laser trabeculostomy 

(ELT). Methods: Ab interno ELT (fiberoptic delivery 308 nm) was used to ablate 10 

openings in the trabecular meshwork (TM) and inner wall of Schlemm canal following 

Phaco+IOL. Thirty-seven eyes of 37 patients with open-angle glaucoma participated in this 

prospective study. IOP was measured preoperatively and 1 day and 1- 60 months postop. 

Procedure: Following Phaco+IOL, the ELT probe traverses the anterior chamber to contact 

TM and excise ten 200-µm openings into the Schlemm canal in the lower nasal quadrant. 

Results: IOP—preop: 23.3 ± 5.9 mmHg; 60 months: 14.3 ± 2.6 mmHg. At each time point 

the IOP readings were significantly lower than preop (a < 0.001). Conclusion: Significant 

IOP reduction following ELT has been documented to remain stable in these patients for 

at least 5 years postop. 


Primary Deep Sclerectomy Augmented With Bevacizumab: 

A Comparative Case Control Study 

Presenting Author: Juan Carlos Mesa Gutierrez MD 

Purpose: To assess the comparative efficacy of enhancing primary deep sclerectomy 

(DS) with subconjunctival bevacizumab or intraoperative mitomycin C (MMC) application. 

Methods: Retrospective comparative case-control study (53 eyes): 27 eyes with MMC 

and 26 eyes with bevacizumab. IOP changes after DS were compared with ANOVA for 

repeated measures, and survival curves were calculated for every group. Mean follow-up 

was 60 months. Results: Complete success and partial success rates were 70% and 83% 

at 12 months in the bevacizumab group and 70% and 77% in the MMC group. Conclusion: 

Augmentation of primary DS with a single intraoperative subconjunctival injection 

of bevacizumab may be as effective in lowering IOP as intraoperative MMC augmentation. 


Differential Inner Macular Thinning in Glaucoma With 

Hemifield Visual Loss, a Fourier-Domain OCT Study 


Purpose: To correlate changes in Fourier domain OCT (FD-OCT) inner macular layer thinning 

to peripapillary nerve fiber layer (PNFL) thinning in eyes with glaucoma and visual 

field (VF) loss limited to one hemisphere. Methods: Case-control study. Sixty-four eyes 

with VF loss on perimetry were examined with FD-OCT. PNFL and inner macular (ganglion 

cell complex [GCC]) thicknesses were assessed. PNFL and GCC thickness were compared 

by Student t-test with noninvolved hemisphere. Results: GCC was thinner in the hemisphere 

corresponding to VF loss in 63 eyes (98.4%) and PNFL in 60 eyes (93.8%) (P < .001). 

Conclusion: In eyes with VF loss restricted to one hemisphere there is a significant correlation 

of VF loss to PNFL and GCC thinning in that hemisphere. 


Outcomes With the Ex-PRESS Mini Shunt Using Mitomycin 

C, Ologen With 5-Fluorouracil, and Ologen Alone 

Presenting Author: Shivali Menda MD 

Co-Author(s): Robert L Stamper MD*, Ayman Naseri MD*, Michel Risnic Rubin MD, 

Ying Han MD PhD 

Purpose: To compare the efficacy of the Ex-PRESS with mitomycin C (MMC), ologen with 

5-fluorouracil (5-FU), or ologen collagen matrix alone. Methods: All uncontrolled glaucoma 

patients who had the Ex-PRESS from 2009 to 2011, for a total of 38 eyes of 31 patients, 

were studied. Results: At 6 months, IOPs were 14.7 mmHg, 13.4 mmHg, and 21.2 mmHg 

in the MMC, ologen with 5-FU, and ologen-only groups, respectively (P = .05). At 1 year, 

IOPs were 12.0 mmHg in the MMC group, 12.2 mmHg in the ologen with 5-FU group, and 

19.4 mmHg in the ologen-only group (P = .012). Endophthalmitis only occurred in the MMC 

group. Conclusion: Ologen may reduce severe complications but appears less effective 

at lowering the IOP when used as an adjunctive agent alone with the Ex-PRESS. 


Use of Vascular Endothelial Growth Factor Inhibitor, 

Bevacizumab, in Trabeculectomy Surgery 

Presenting Author: Anuradha Mishra MD 

Co-Author(s): Majed M Alotaibi MD**, Marcelo T Nicolela MD*, Paul D Artes PhD, 

Miriam Stanfield**, Lesya M Shuba MD* 

Purpose: To investigate the effects of intraoperative injection of bevacizumab on the 

outcomes of trabeculectomy. Methods: A prospective, randomized trial comparing the 

outcomes of trabeculectomy with mitomycin C 0.4 mg/ml (1) without (n = 14, IOP 21 ± 7.1 

mmHg ) and (2) with intraoperative subtenon injection of 1.25-mg bevacizumab (n = 18, 

IOP 19.5 ± 6.2 mmHg). The primary outcome was IOP reduction of ≥ 30% at 12 months 

without glaucoma medications. Results: At 12 months, 5/14 patients (36%) in the control 

group and 13/18 patients (72%) in the bevacizumab group had a ≥ 30% reduction from 

preoperative IOP (P = .039) without glaucoma medications. There were no major ocular or 

systemic complications in either group. Conclusion: Intraoperative bevacizumab appears 

to improve the outcomes of trabeculectomy. 


Implantation of Glaucoma Drainage Devices via a Modified 

Scleral Tunnel Technique Yields Reduced Rates of 

Postoperative Tube Exposure 

Presenting Author: Brian E Flowers MD* 

Co-Author(s): Unni K Nair MD 

Purpose: To compare postoperative tube exposure rates in glaucoma drainage devices 

(GDD) where the tube was covered by a patch graft or with a modified scleral tunnel 

technique. Methods: Retrospective chart review was performed on 156 patients (189 

eyes) who underwent GDD implantation between September 1998 and December 2011. 

Demographic and outcome measures were analyzed. Results: Tube exposure occurred in 

9.5% (4/42) of GDD procedures in which patch grafts were used vs. 0.7% of procedures 

(1/147) where the tube was covered by a modified scleral tunnel (P = .0015, two sample 

test of proportions). Mean follow-up time was 39.1 months. Conclusion: A scleral tunnel 

technique had lower rates of tube exposure than patch grafts for GDD implantation. 


APAO Architectural Analysis of Post-trabeculectomy Blebs 

Using Spectral Domain OCT 

Presenting Author: Sonu Goel MBBS 

Co-Author(s): nabanita barua Jr MBBS DMS**, Chitra Sitaraman SR MD**, Sonai 

Mmukherje JR MBBS 

Purpose: A prospective and descriptive study analyzing 60 eyes that had earlier undergone 

trabeculectomy. Methods: Bleb was assessed by slitlamp biomicroscopy and spectral 

domain OCT. The time span was between first day and 1 year. No resurgery or previous 

conjunctival disease. Results: The IOPs were significantly correlated with the bleb height, 

wall thickness, internal cavity height. Internal cavity parameters and bleb reflectivity correlated 

well with the IOP of a functional bleb. Conclusion: The in vivo architecture of 

filtering blebs can be objectively described using OCT according to quantitative and qualitative 

parameters. 


Phacoemulsification and Endoscopic 

Cyclophotocoagulation in Advanced Glaucoma: One-Year 

Results 

Presenting Author: Sami Al Odhayb MD 

Co-Author(s): Sami Al Shahwan MD, Deepak Paul Edward MD, Massaoud Al Qahtani 

MD, Faisal Al Mobarak MD, Jose Morales MD 

Purpose: To determine IOP outcomes following phacoemulsification and endoscopic 

cyclophotocoagulation (Ph/ECP) in advanced glaucoma. Methods: 109 patients with advanced 

glaucomatous disc damage underwent Ph/ECP (180-270 degrees) with minimum 

1 year follow-up. IOP-related outcome measures: complete success (IOP ≤ 15 without 

medications), qualified success (IOP ≤ 15 with medications), and failure (IOP > 15 with 

medications). Results: IOP decreased from mean of 18.3 (± 7.2) to 15.2 (± 4.6) mmHg at 1 

year and number of medications from mean of 3.0 (± 1.0) to 2.0 (± 1.2). At 1 year, survival 

analysis demonstrated 21% complete success, 52% qualified success, and 29% failure. 

202 





No catastrophic complications were noted. Conclusion: In advanced glaucoma, Ph/ECP 

provided reasonable IOP control at 1 year with medications, but a noticeable failure rate 

was noted. 


APAO Effects of Phacoemulsification vs. Trabeculectomy 

and Adjunctive Mitomycin C Chemotherapy on Drainage 

Angle Status in Medically Uncontrolled Chronic Angle 

Closure Glaucoma Without Visually Significant Cataract 

Presenting Author: Xiaofei Man MD 

Co-Author(s): Clement C Y Tham MBBS* 

Purpose: To document anatomical effects of phacoemulsification vs. trabeculectomy on 

drainage angle status in chronic angle-closure glaucoma (CACG) without cataract. Methods: 

Indentation gonioscopy and ultrasound biomicroscopy were performed preoperatively, 

and then postoperatively at 1 year. Results: Fifty CACG eyes of 50 patients were 

included in this study. Phacoemulsification resulted in significantly greater postoperative 

AOD500 (P < .001), TCPD (P < .001), and ACD (P < .001) than trabeculectomy. Conclusion: 

Phacoemulsification resulted in greater opening of drainage angle and greater deepening 

of anterior chamber than trabeculectomy postoperatively in CACG eyes. 


APAO Comparing IOPs Between Both Eyes in Patients With 

Sequential Cataract Extractions 

Presenting Author: Wei Kiong Ngo MBBS 

Co-Author(s): Colin S Tan MBBS 

Purpose: To evaluate the effects of cataract extraction on IOP. Methods: We performed 

matched comparisons of IOP in a review of 128 patients with sequential cataract extractions 

in both eyes before and up to 4 years after surgery. Results: IOP (preoperative mean: 

15.3 mmHg) decreased at all postoperative periods up to 2 years (range: 12.8-13.8 mmHg, 

P ≤ .001). IOP in the first operated eye was lower than IOP in the contralateral nonoperated 

eye (P < .05). After surgery to the second eye, its IOP decreased to a value similar to the 

first operated eye. There was no difference in the IOP-lowering effect of phacoemulsification 

compared to extracapsular cataract extraction. Conclusion: Cataract extraction 

causes IOP decrease via local mechanism. 


Comparison of Dorzolamide/ Timolol vs. Brimonidine/ 

Timolol Fixed Combination Therapy in the Management of 

Steroid-Induced Ocular Hypertension 

Presenting Author: Goktug Seymenoglu MD 

Co-Author(s): Esin Fatma Baser MD, Bilge Öztürk MD**, Ceren Gülhan MD** 

Purpose: To compare efficacy of dorzolamide/timolol (FCDT) and brimonidine/timolol 

(FCBT) in patients with IOP elevations after intravitreal triamcinolone (IVTA) injections. 

Methods: Patients who had IOP of 24 mmHg or higher after IVTA were included. Sixty 

patients were randomized to receive FCBT or FCDT. Mean diurnal IOP (MDIOP) was measured 

on Week 4 and 12. Results: Postinjection MDIOP was 31.9 ± 7.3 mmHg and 29.8 ± 

5.1 mmHg in FCBT and FCDT groups, respectively (P = .23). After 4 weeks, MDIOP was 17.1 

± 3.6 mmHg in FCBT and 18.9 ± 3.3 mmHg in FCDT groups (P = .63). After 12 weeks, these 

values were 16.3 ± 2.7 mmHg and 18.4 ± 2.8 mmHg, respectively (P = .01). Conclusion: 

FCBT is superior to FCDT in reducing IOP after IVTA injections. 


Intravitreal Bevacizumab vs. Ranibizumab for Rubeosis 

Iridis 

Presenting Author: Joao J Nassaralla MD PhD 

Co-Author(s): Belquiz A Nassaralla MD PhD 

Purpose: Bevacizumab (B) and ranibizumab (R) are anti-VEGF recombinant humanized 

monoclonal IgG1 antibodies. To determine and compare whether B or R decreases rubeosis 

iridis (RI). Methods: The study included 72 eyes with secondary neovascular glaucoma. 

All patients received an intraocular injection of B or R, which was performed in 

the anterior chamber or intravitreally. RI was investigated prospectively by biomicroscopy. 

Results: RI decreased significantly (P < .01) within 1 week after application of both drugs. 

Was maintained for at least 4 weeks. The inflammatory response was observed in 3 eyes. 

The cost differences for those receiving treatment are major at about $40 (B) and $2,000 

(R). Conclusion: The 2 drugs are about equal in their effectiveness. B or R provide an 

additional strategy to the treatment of RI. 


APAO Effect of Lateral Decubitus Position on IOP in Normal- 

Tension Glaucoma Patients With Asymmetric Visual Field 

Loss 

Presenting Author: Kyoungnam Kim MD 

Co-Author(s): Yun Jeong Choi MD, Ho Soong Kim**, Jin Wook Jeoung MD, Dong 

Myung Kim MD, Ki Ho Park MD* 

Purpose: To investigate the effect of lateral decubitus position (LDP) on IOP in normaltension 

glaucoma (NTG) with asymmetric visual field (VF) loss. Methods: In 36 eyes of 

18 consecutive NTG patients with asymmetric VF by mean deviation (-12.62 vs. -3.07 dB; 

P = 0.000), IOP was measured by rebound tonometer in sitting, supine, and both LDPs. 

Results: IOP was higher in supine position than in sitting position (16.41 vs. 13.75 mmHg; 

P = 0.000). In the LDP with the worse eye on the lower side, IOP of the worse eye was 

higher than IOP of the better eye (19.82 vs. 16.57 mmHg; P = 0.000) and IOP of the worse 

eye in supine position (17.67 mmHg; P = .006). Conclusion: Our results suggest that the 

IOP discrepancy in LDPs may be associated with asymmetric optic nerve damage in NTG. 


APAO Improving Multifocal Objective Pupillographic 

Perimetry for Glaucoma 

Presenting Author: Ted Maddess PhD* 

Co-Author(s): Maria Kolic*, Corinne Francis Carle PhD, Rohan W Essex MBBS, Andrew 

Charles James PhD* 

Purpose: To compare 2 new variants of noncontact objective visual field tests with the 

current best-performing multifocal pupillographic objective perimetry (mfPOP) methods for 

the management of glaucoma. Methods: The 2 newer methods added of red/green contrast 

(R/G) and or a new test sequence. Twenty-four normal controls and 22 open-angle 

glaucoma patients (age- and sex-matched) were tested twice, 2 weeks apart. Results: 

The new luminance methods areas under ROC plots for the new luminance methods were 

best at 0.89 ± 0.33 for moderate and severe fields combined, and 1.0 ± 0.00 for severe 

fields. The R/G was best for mild fields (0.68 ± 0.07). Reproducibility was between that 

for the HFA and Matrix perimeters. Conclusion: Performance was excellent for a test 

measuring both eyes concurrently in under 7 minutes. The new methods improve on the 

previous FDA-cleared methods. 


24-Hour IOP Pattern in Ocular Hypertensive patients Who 

Converted to Glaucoma vs. Nonconverters 

Presenting Author: Nazlee Zebardast MS 

Co-Author(s): John HK Liu PhD, Tomas M Grippo MD, Taylor B Arnold MS, Grant H 

Moore MD, Robert N Weinreb MD* 

Purpose: To characterize the 24-hour IOP pattern in ocular hypertension (OHTN) glaucoma 

converters (Cs) and nonconverters (NCs) and compare with healthy (HC) and glaucoma (GL) 

groups. Methods: 15 OHTN patients who underwent a baseline 24-hour IOP study were 

followed for progression to glaucoma. We compared the 24-hour IOP pattern of Cs and 

NCs to HC and GL groups. Results: Thirty-three percent of OHTNs developed glaucoma 

during a mean of 4.3 ± 3.8 years. Similar to the GL group, IOP curve phase delay, IOP 

variation, diurnal to nocturnal IOP fluctuation and IOP change upon awakening of the Cs 

were significantly different from HC (P < .05). There were no differences between NCs and 

other groups. Conclusion: Contrary to the NCs, the 24-hour IOP pattern of Cs was similar 

to that of GL patients. This may help identify OHTN patients at higher risk of developing 

glaucoma. 


Relationship Between Heidelberg Edge Perimetry and 

Heidelberg Retina Tomograph in Glaucoma Patients 

Presenting Author: Blanca Monsalve MD 

Co-Author(s): Antonio Ferreras MD PhD*, Ana Belen Pajarin MD PhD**, Sofia Otin MD, 

Pilar Calvo MD PHD, Jose L Urcelay MD**, Luis E Pablo MD 

Purpose: To evaluate the association between Heidelberg Edge perimetry (HEP) and optic 

nerve head parameters measured by Heidelberg Retina Tomograph (HRT). Methods: Seventy-eight 

eyes with glaucomatous optic neuropathy underwent imaging with the HRT3 

and HEP (24-2 ASTA Standard). Pearson correlations were calculated between HRT and 

HEP parameters. Results: Mean deviation (MD) of HEP was -5.96 ± 5.5 dB. Mild to moderate 

correlations were observed for some HRT parameters. The strongest correlations were 

found between MD of HEP and rim area (0.455) and rim volume (0.440). Conclusion: HEP 

indices correlated moderately well with HRT3 global stereometric parameters. 





203




Reproducibility of the Spaeth/ Richman Contrast Sensitivity 

Test 

Presenting Author: George L Spaeth MD FACS* 

Co-Author(s): Jesse Richman MD* 

Purpose: To present the reproducibility of a new method of testing contrast sensitivity. 

Methods: We selected 136 eyes of 91 patients with glaucoma or ocular hypertension 

from the Wills Eye Institute. Patients were tested with the Spaeth/Richman contrast sensitivity 

test (SPARCS) and the Pelli-Robson contrast sensitivity chart. Monocular testing 

was performed on each test twice. Test-retest repeatability of SPARCS and Pelli-Robson 

was assessed by the intraclass correlation coefficient (ICC) and the coefficient of repeatability 

(COR). Results: The ICC was 0.97 for SPARCS and 0.98 for Pelli-Robson. The COR 

for SPARCS was ± 7.13% of its score range, while the COR for Pelli-Robson was ± 6.36% 

of its score range. Conclusion: The reliability of both SPARCS and Pelli-Robson was excellent. 


Glaucoma and the Whole Patient 

Presenting Author: George L Spaeth MD FACS* 

Co-Author(s): Alice Williams MD, John Lackey MD, Srinivas Gatla, Sheryl S Wizov 

COA, Robert C Sergott MD*, Thomas Tao Ming Chia, Song Lai MD** 

Purpose: To present findings showing that glaucoma is associated with changes in 

brain morphology and to put this in the context of the “eye-body” relationship. Methods: 

Twenty patients with varying stages of glaucoma and matched controls had MRI 

brain scans with automated voxel-based morphometry. A search of literature related to 

the relationship between the eye and the body was performed. Results: Glaucoma is 

associated with a decrease of brain volume in localized areas in the occipital lobe and 

increases in brain volume in selected other areas. There have been many other reports on 

relationships between eye diseases and other illnesses; few withstand scientific scrutiny. 

Conclusion: Duke Elder’s comment that “glaucoma is a sick eye in a sick body” is often 

true. The implications of this for patients and those wishing to understand the causes of 

disease are important. 


Artificial Neural Network for Glaucoma Diagnosis Using 

Spectral Domain OCT 

Presenting Author: Antonio Ferreras MD PhD* 

Co-Author(s): Ana Belen Pajarin MD PhD**, Blanca Monsalve MD, Luis E Pablo MD, 

Paolo Fogagnolo**, Michele Figus MD, Paolo Frezzotti MD, Michele Lester MD* 

Purpose: To design and evaluate the diagnostic performance of a neural network model 

based on spectral domain OCT parameters for discriminating glaucoma patients. Methods: 

196 controls and 154 glaucoma patients underwent imaging with Cirrus OCT. Retinal 

nerve fiber layer and optic nerve head parameters were included in the neural network 

model. Results: In the validating set, the neural network yielded a 95% sensitivity and 

98.3% specificity. Compared with OCT-provided parameters, the neural network had the 

largest area under the ROC curve (0.995). Conclusion: The artificial neural network improved 

the diagnostic ability of isolated OCT parameters. 


APAO Focal Relationship Between Structure and Function 

Within Central 10 Degrees in Glaucoma 

Presenting Author: Shinji Ohkubo MD PhD* 

Co-Author(s): Tomomi Higashide MD PhD, Sachiko Udagawa**, Kazuhisa Sugiyama 

MD PHD, Masanori Hangai MD*, Chihiro Mayama MD PhD, Atsuo Tomidokoro MD**, 

Makoto Araie MD**, Aiko Iwase MD PhD, Takashi Fujimura** 

Purpose: To correlate visual sensitivity and each macular layer thickness by OCT. Methods: 

To compare sensitivity of each test point of 10-2 automated perimetry with corresponding 

thickness of nerve fiber layer (NFL), ganglion cell layer (GCL), GCL+ inner plexiform 

layer (IPL), and NFL+GCL+IPL (GCC) for 60 glaucoma patients with adjusting for retinal 

ganglion cell (RGC) displacement. Results: RGC displacement significantly improved the 

correlation between sensitivity and GCL, GCL+IPL, and GCC in central 4 points (r = from 

0.19 to 0.44, P < .01). All 68 point sensitivities of 10-2 significantly correlated with corresponding 

GCC adjusting for RGC displacement (r = 0.3-0.7, P < .05). Conclusion: GCC is 

the most useful to evaluate structure and function. 


Assessment of Optic Nerve Head Drusen Using Enhanced 

Depth Imaging OCT 

Presenting Author: Timothy Sullivan MD 

Co-Author(s): Daniel Su, Rudrani Banik MD, Christopher C Teng MD, Jeffrey M 

Liebmann MD*, Robert Ritch MD FACS* 

Purpose: To assess enhanced depth imaging OCT (EDI-OCT) for evaluating optic nerve 

head drusen (ONHD) compared to conventional tests. Methods: EDI-OCT, spectral domain 

OCT, ultrasonography, disc photography, and perimetry were performed in patients with 

and without ONHD. Results: Based on disc photography, 68 eyes (34 ONHD patients) 

were classified as definite ONHD (30), suspected ONHD (27), and normal-appearing fellow 

eyes (11). EDI-OCT showed ONHD with greater detail than other tests, as hyper-reflective 

bands or signal-poor regions surrounded by the bands. No such signs were found in 80 

control eyes. ONHD detection rate by EDI-OCT was better than other tests in suspected 

ONHD eyes (67% vs. 7%-33%) and normal-appearing fellow eyes (45% vs. 9%-18%). 

Conclusion: EDI-OCT is more useful in detecting and monitoring ONHD than conventional 

tests. 


APAO Pointwise Relationship Between Visual Field 

Sensitivity and Macular Thickness in Various Locations 

Determined by Spectral Domain OCT 

Presenting Author: Youngcheol Yoo MD 

Co-Author(s): Joon Mo Kim MD, Kyung Rim Sung MD PhD 

Purpose: To evaluate relationship between the visual field sensitivity (VFS) and the 

macular thickness in glaucoma patients. Methods: 106 subjects had standard automated 

perimetry and spectral domain OCT (SD-OCT) scans. VFS of 16 central test points were 

recorded. Macular thickness values of 4 square cells were averaged on a mean retinal 

thickness (MRT) value. In each poInt, linear regression analyses of the VFS and the MRT 

were performed. Results: The VFS of each of the 16 test points showed a significant relationship 

with the corresponding MRT values (r = 0.364 to 0.619, all P < .001). Conclusion: 

Although the VFS showed a significant relationship with MRT in each test poInt, the level 

of relationship was variable among different locations. 

CANCELED 


APAO Macular Ganglion Cell-Inner Plexiform Layer 

Measurements by Spectral Domain OCT in Healthy Asian 

Eyes 

Presenting Author: Changho Yoon MBCB 

Co-Author(s): Jin Wook Jeoung MD, MiJeung Kim MD, Yun Jeong Choi MD, 

Kyoungnam Kim MD, Dong Myung Kim MD 

Purpose: To evaluate the profiles of the ganglion cell-inner plexiform layer (GC-IPL) thickness 

measured with spectral domain OCT (SD-OCT) in Asian healthy eyes. Methods: 

Ninety eyes of 90 healthy Asian subjects underwent macular and optic disc scanning with 

Cirrus SD-OCT. Results: The mean and minimum GC-IPL were 81.6 ± 5.8 µm and 79.0 ± 6.7 

µm, respectively. The mean GC-IPL was correlated with age (b = -0.102, P = .047), mean 

retinal nerve fiber layer (RNFL) thickness (b = 0.430, P < .001), and rim area (b = 12.516, P < 

.001). Conclusion: The independent factors associated with thinner GC-IPL include older 

age, thinner RNFL, and smaller rim area. These variables should be taken into account 

when evaluating and following-up glaucoma patients. 


APAO Clinical Profile of Normotensive Pseudoexfoliation 

Glaucoma 

Presenting Author: Susanta Shatterjee Sr DMS FRCS MBBS 

Co-Author(s): Mahasweta Chowdhury MBBS, Amarendra Amar MD**, Aparna Rao 

DOMS 

Purpose: To evaluate the clinical profile of patients with a new phenotype of pseudoexfoliation 

glaucoma. Methods: Patients with pseudoexfoliation over iris and/or lens, glaucomatous 

optic nerve, and visual field changes and IOP < 21 mm Hg and < 24 mmHg at any 

visit were evaluated. Results: The mean diurnal minimum and maximum IOP ranged from 

12-24 mmHg and 10-21 mmHg in 38 eyes of 20 patients with a mean corneal thickness of 

506 ± 34.9 microns and mean deviation of -15 ± 8.4 dB. Linear regression failed to demonstrate 

the influence of IOP on the mean deviation. Conclusion: Optic nerve damage in 

normotensive pseudoexfoliative glaucoma was found to be IOP independent. 

204 






Hypothyroidism and Glaucoma in the United States 

Presenting Author: Toshimitsu Kasuga MD 

Co-Author(s): Sophia Ying Wang*, Kuldev Singh MD MPH*, Shan C Lin MD* 

Purpose: To investigate the association between hypothyroidism and glaucomatous disease. 

Methods: All subjects above the age of 40 from 2 nationwide surveys: the 2008 National 

Health Interview Survey (NHIS) and the National Health and Nutrition Examination 

Survey (NHANES) for 2007 and 2008 including 13,599 and 3752 participants, respectively, 

were ascertained for the self-diagnoses of glaucoma and hypothyroidism. Results: Multivariate 

logistic regression analysis adjusted for age, gender, and race showed no association 

between self-reported glaucoma and hypothyroidism in either survey (P = .503 for 

NHIS, and P = .663 for NHANES). Conclusion: A previously reported association between 

hypothyroidism and glaucomatous disease was not confirmed. 


APAO Diagnostic Accuracy of Ganglion Cell Analysis 

Algorithm With Spectral Domain OCT in Preperimetric 

Glaucoma 

Presenting Author: MiJeung Kim MD 

Co-Author(s): Jin Wook Jeoung MD, Ki Ho Park MD*, Joon Mo Kim MD, Yun Jeong 

Choi MD, Kyoungnam Kim MD, Dong Myung Kim MD 

Purpose: To compare the diagnostic accuracies of ganglion cell-inner plexiform layer (GC- 

IPL), retinal nerve fiber layer (RNFL), and optic nerve head (ONH) parameters in preperimetric 

glaucoma. Methods: The GC-IPL, RNFL, and ONH parameters were measured by Cirrus 

HD-OCT in 92 eyes with preperimetric glaucoma and 92 age-matched normal control eyes. 

Results: There were no significant differences in the AUROCs for the best parameters of 

GC-IPL (inferotemporal, 0.823), RNFL (7 o’clock sector, 0.764) and ONH (rim area, 0.767) (all 

P > .05). With a criterion of abnormal at the < 5% level, the sensitivity of GC-IPL parameters 

ranged from 27.9% to 79.3% (specificity: 84.8%-100%). Conclusion: The GCIPL, 

RNFL, and ONH parameters have similar diagnostic power in preperimetric glaucoma. 


A Comparison of Glaucoma Patients With and Without 

Obstructive Sleep Apnea 

Presenting Author: Shaam Mahasneh* 

Co-Author(s): Jacob K Thomas MD, Jess Thomas Whitson MD FACS* 

Purpose: To compare the features of primary open-angle glaucoma (POAG) and glaucoma 

suspects (GS) among obstructive sleep apnea (OSA) patients. Methods: Retrospective 

review of 28 POAG and 68 GS eyes of patients with OSA. Compared with matched control 

groups with POAG and GS without OSA. Statistical analysis included the t-test and 

Fisher exact test. Results: Greater diabetes prevalence among OSA patients with POAG 

(P = .0001) and GS (P = .04). Greater pseudophakia among POAG patients with OSA (P = 

.040). Greater pattern standard deviations (PSD) among those with OSA and GS (P = .024). 

Conclusion: OSA patients had an increased prevalence of diabetes, pseudophakia, and 

PSD defects. 


The Association Between Hormone Replacement Therapy 

and Open-Angle Glaucoma 

Presenting Author: Paula Anne Newman-Casey MD 

Co-Author(s): Nidhi Talwar MS, Bin Nan PhD, David C Musch PhD*, Louis R Pasquale 

MD*, Joshua D Stein MD MS 

Purpose: To determine whether the use of hormone replacement therapy (HRT) affects 

the risk of developing open-angle glaucoma (OAG). Methods: Managed care claims data 

from 2001-2009 were used to identify and quantify exposure to HRT. Adjusted multivariable 

Cox regression assessed whether exposure to HRT over 4 years affected the risk of 

development of OAG. Results: Of 153,293 women included, the rate of OAG among women 

using HRT (2.98%) was significantly lower compared to those never on HRT (3.66%), P 

< .0001. Adjusted multivariable analysis showed no significant association between HRT 

use duration and OAG. Conclusion: After accounting for ocular and medical comorbidities 

and sociodemographics, there was no association between HRT use and OAG risk. 


Glaucoma Severity and Medication Adherence in a County 

Hospital Population 

Presenting Author: Cindy Ung 

Co-Author(s): Yohko Murakami MD, Elisa Zhang, Tatyana Alfaro, Michael I Seider MD, 

Kuldev Singh MD MPH*, Shan C Lin MD* 

Purpose: To assess the association between adherence with glaucoma medications and 

disease severity in a county hospital population. Methods: Pharmacy refill data were 

obtained for 126 subjects who had completed an oral questionnaire regarding adherence 

with glaucoma therapy. The medication possession ratio was measured using this refill 

data. Glaucoma severity was classified according to American Academy of Ophthalmology 

Preferred Practice Pattern guidelines. Results: Subjects with mild/moderate glaucoma 

were more likely to be nonadherent to their prescribed glaucoma medications than those 

with severe disease (adj. OR, 1.54 [1.03-2.31]; P = .04). Conclusion: Patients with more 

severe glaucoma were more likely to be adherent to their medication regimen than those 

patients with less severe glaucoma. 


Assessment of Eye Drop Administration in Patients With 

Glaucoma or Ocular Hypertension 

Presenting Author: Gail F Schwartz MD* 

Co-Author(s): Julia M Williams*, David Hollander MD* 

Purpose: To evaluate patients’ ability to administer drops properly. Methods: Sixteencenter 

study, drop administration observed in 159 patients while instilling artificial tears 

at 2 visits (Baseline, Month 3). Outcomes: Difficulty with administration defined as bottle 

touching eye/adnexa, drop missing, or excess drops. Results: Prior use of IOP-lowering 

meds was > 1 year for 80.7% of patients. At baseline, 88.6% of patients denied difficulty 

with drop administration. Difficulty instilling drops was observed in 42.1% of patients on 

at least 1 visit. Most common difficulty was bottle touching eye/adnexa (18% baseline, 

18% Month 3). Conclusion: Even patients chronically using glaucoma meds have difficulty 

with administration. Patients enrolled in trials may represent best scenario in drop 

technique. 


APAO Primary Acute Angle Closure: A 10-Year Visual, 

Pressure, and Treatment Trend in Hong Kong Chinese 

Presenting Author: Jacky W Y Lee MBBS 

Co-Author(s): Jimmy S M Lai MD**, Doris Wai Fong Yick MBChB, Yat Hin Ian Wong 

MBBS*, Can Y F Yuen MD 

Purpose: To investigate long-term visual acuity (VA), IOP, and treatment trends in acute 

angle closure (AAC). Methods: Ten-year retrospective review of AAC in Hong Kong to 

document demographics, treatments, and pre- and post-AAC IOP and VA. The year of 

attack was correlated with timing of laser; last VA and IOP; and glaucoma eye drops. 

Results: In 210 eyes (200 patients), 10% had a simultaneous bilateral AAC; 68.6% of 

eyes had improved VA, with 11.4% blinded. At 3.7 ± 2.4 years, 49.5% had IOP < 21 mmHg, 

41.9% needed glaucoma eye drops, and 13.8% had trabeculectomy. The older the attack, 

the poorer the VA (P = .03) and the longer the laser wait time (P < .0001). Conclusion: 

VA and laser promptness in AAC has improved. At 4 years, 50% had normal IOP, 69% had 

improved VA, but 11% were blinded. 


APAO Secondary Glaucoma Following Descemet-Stripping 


Presenting Author: Samar K Basak MD DNB MBBS* 

Co-Author(s): Sumit Chowdhury, Suchanda Sar MS** 

Purpose: To report the causal factors for secondary glaucoma following Descemetstripping 

endothelial keratoplasty (DSEK) with management. Methods: Retrospective 

review of 520 eyes in last 6 years performed by single surgeon. Patients with secondary 

glaucoma were divided into early (< 3 weeks) and late postoperative groups. Results: 

Causes in early period: pupillary block, 18 (3.5%); and toxic anterior segment syndrome, 

4 eyes. In late period: steroid responders, 44 cases (8.6%); previous glaucoma, 17 (3.7%); 

synechial closure, 6; and known iridocorneal endothelial syndrome, 4 eyes. Cases were 

managed medically; or surgically: trabeculectomy with MMC, 7; drainage valve, 2; and 

cyclocryopexy, 2 eyes. Re-DSEK required in 6 eyes (1.2%). Conclusion: Secondary glaucoma 

following DSEK is a significant problem and most of the cases can be managed. A 

close postoperative IOP monitoring is warranted in all DSEK eyes. 





205




APAO Comparison of Cytomegalovirus-Positive and 

Negative Eyes in Posner-Schlossman Syndrome 

Presenting Author: Miho Nozaki MD 

Co-Author(s): Munenori Yoshida MD, Yuichiro Ogura MD PhD* 

Purpose: To distinguish the characteristics of cytomegalovirus (CMV)-positive eyes with 

presumed Posner-Schlossman syndrome (PSS). Methods: Retrospective interventional 

case series. Twelve eyes of 12 patients with presumed PSS, seen at Nagoya City University 

Hospital from 2009 to 2011, underwent aqueous analysis for CMV by PCR. Results: 

Twelve eyes with presumed PSS were tapped, of which 6 (50%) were CMV-positive. Significant 

corneal endothelial cell loss was noted in CMV-positive patients (P < .001). Conclusion: 

There is a significant correlation between CMV infection and corneal endothelial 

cell loss in presumed PSS. From our results, marked corneal endothelial cell loss might 

indicate CMV infection in presumed PSS patients. 


APAO Diabetes Mellitus and Systemic Associations as Risk 

Factors for Glaucoma 

Presenting Author: Vidya J Chelerkar MBBS 

Co-Author(s): Rahul D Deshpande MBBS**, Shilpa A Joshi MBBS, Kavita Lohiya 

MBBS, Madan Deshpande MD** 

Purpose: To evaluate glaucoma in patients with diabetes mellitus (DM) and other associated 

systemic risk factors. Methods: 849 patients with DM were examined and followed 

up for 2 years for presence of glaucoma. Results: 120/849 patients were found to have 

glaucoma (14.11%). Important associations on univariate analysis were age > 65 years (P 

= .0057), duration of DM > 5 years (P = .0036), uncontrolled DM (P = .0225), serum cholesterol 

(P = 0.0000), serum triglycerides (P = 0.0000), and serum low density lipids (LDL) (P 

= 0.0000). Multiple logistic regression analysis showed total cholesterol and serum LDL 

as independent risk factors for glaucoma. Conclusion: Increasing age, longer duration of 

diabetes, high blood sugar, and lipid levels were found to be risk factors for glaucoma in 

diabetic patients. 


The Gold Shunt: An Alternative to Trabeculectomy 

Presenting Author: Robert J Mitchell MD 

Purpose: To evaluate the safety and efficacy of the Gold Shunt as a potential alternative 

to trabeculectomy. Methods: Sixteen patients with glaucoma underwent surgical 

implantation of a Gold Shunt in the affected eye. The pre- and postoperative state of each 

eye were compared over 1 year. Measurements of visual acuity, IOP, visual fields, and 

changes to glaucoma medications were tracked. Results: The surgery proved to be no 

more difficult than trabeculectomy. There were few transient postoperative complications. 

At 1 year postoperatively IOP was reduced by 7.8 mmHg on average (15.6 vs. 23.4) and 

patients required 0.6 fewer glaucoma medications (1.8 vs. 2.4). Conclusion: The Gold 

Shunt proved to be safe and efficacious in both refractory and nonrefractory glaucoma 

patients, making it an excellent alternative to trabeculectomy. 


Session One 





APAO Epidemiology of Open Globe Injuries in Hong Kong: An 

Asian Perspective 

Presenting Author: Man Kit Tong MBBS 

Co-Author(s): Ka Hung Lau MBBS, Kenneth K W Li MBCHB 

Purpose: To evaluate the characteristics of all open globe injuries presented to a tertiary 

eye centre in Hong Kong. Methods: Retrospective study of all consecutive cases over a 

10-year period was conducted. Results: 102 cases were included. The mean age was 

51.7. Work-related (32.3%) and projectiles (46.5%) were the major causes. Linear regression 

analysis showed an increase of male-related injuries over the study period. The final 

visual acuity was worse than 0.1 in 52 cases (51%). No cases of sympathetic ophthalmia 

were encountered. Conclusion: The most prevalent trauma etiology was work-related 

projectiles. A bimodal distribution of open globe injury was observed, with a lower rate of 

endophthalmitis and sympathetic ophthalmia compared to other studies. 


H APAO Demographic and Clinical Profile of Ocular 

Chemical Injuries in Children 

Presenting Author: Rasik B Vajpayee MD 

Co-Author(s): Himanshu Shekhar, Namrata Sharma MD MBBS 

Purpose: To review the pattern, risk factors, and visual outcomes of pediatric chemical 

eye injuries. Methods: Retrospective study of pediatric patients with ocular burns over 

a 5-year period at a tertiary eye center. Results: Of the 134 children, the majority were 

male (63.3%). The mean age at time of injury was 8.95 ± 4.89 years. Severe ocular burns 

(grade 4 to 6) were seen in 70% of children, with bilateral involvement seen in 18% of the 

cases. The majority of these were caused by lime kept at home for use as an additive by 

an adult tobacco chewer. Surgical intervention was required in 85% of eyes. Overall visual 

outcome was poor, and median visual acuity at final follow-up (mean: 537 ± 354 days) 

was 3/60. Conclusion: Tobacco chewing in adults poses a major ocular health hazard for 

children resulting in significant ocular morbidity. 

Session Two 





APAO Barriers to Follow-up for Pediatric Cataract Surgery in 

Maharashtra, India: How Regular Follow-up Is Important for 

Good Outcome 

Presenting Author: Parikshit M Gogate MS FRCS(ED) 

Co-Author(s): Anil N Kulkarni MS, Shailbala Patil MD, Ashok Mahadik MD**, Joan 

McLeod PhD MBA 

Purpose: To study the regularity of follow-up after cataract surgery in children. Methods: 

Demographic data were collected, visual acuity was estimated, and ocular examination 

was performed. Results: 262 children (393 cataracts) who underwent cataract surgery in 

2004-2008 were traced and re-examined in 2010-2011. Only 53 (20.6%) had been regularly 

following up with any hospital. Follow-up was poor with older age group (P < .001), less 

education of mother (P = .012), father’s occupation (P = .031), money spent on travel (P = 

.033), and if it was free surgery (P = .001). The average visual acuity improved in 150 eyes 

(38.8%) > 1 line with regular follow-up. Conclusion: Regular follow-up is important and 

improves vision; special efforts are needed to ensure better follow-up. 


APAO Hospital Cornea Retrieval Program: A Noble Concept 

in Eye Banking in India 

Presenting Author: Samar K Basak MD DNB MBBS* 

Co-Author(s): Santanu Mandal MBBS, Bani Biswas DO, Santanu Mitra MBBS, Soham 

Basak 

Purpose: To share the paradigm shift in eye banking through a hospital cornea retrieval 

program (HCRP) in India. Methods: Retrospective review of eye bank data from a tertiary 

eye hospital over last 7 years. Collection, donor age, tissue quality, and utilization data via 

HCRP were compared with voluntary donation data. Results: Since starting of HCRP in 

2005, total collection increased by 612%, from 156 in 2004 to 1112 in 2011 (P < .0001), and 

utilization percentage increased from 30 in 2004 to 80.5% in 2011 (P < .005). In the last 7 

years, donor age ≤ 60 years in HCRP was 31.8% vs. 11.3% in voluntary (P < .01). Quality 

of tissue was significantly higher in HCRP collection (P < .01). Conclusion: HCRP plays 

a crucial role in eye banking in India. It helps both in quantitative and qualitative cornea 

collection, with maximum utilization of tissue. 

206 






APAO Setting Priorities for Cataract Surgery: The Swedish 

Experience 

Presenting Author: Jonathon Q Ng MBBS* 

Co-Author(s): Mats H Lundstrom MD** 

Purpose: To examine changes in waiting times and outcomes from cataract surgery following 

adoption of national indications (NIKE) for surgery. Methods: The Swedish National 

Cataract Surgery Register was used to examine waiting times and quality-of-life 

changes for all cataract surgeries in Sweden (2009-2011). Results: There were 141,070 

operations. Waiting times fell 23% for those most needing cataract surgery (NIKE Group 

1). These patients were 1.7 times more likely to have surgery within the 3-month Government 

Guarantee period than patients not given an indication group. Postoperatively all 

patients achieved the same level of quality of life, but NIKE 1 patients had the greatest 

improvement. Conclusion: Patients with the most need for surgery are waiting less and 

benefiting more from cataract surgery. 


Session One 



on Sunday, Nov. 11, from 12:30 PM to 2:00 PM. 


H Effects of Benzalkonium Chloride on the Blood-Aqueous 

and Blood-Retinal Barriers of Pseudophakic Eyes 

Presenting Author: Ricardo Abe MD 

Co-Author(s): Rafael S Zacchia MD, Priscila Santana, Vital Paulino Costa MD* 

Purpose: To evaluate the effects of benzalkonium chloride (BAK) on the blood-aqueous 

barrier (BAB) and blood-retinal barrier (BRB) of pseudophakic eyes. Methods: Forty-four 

eyes of 44 pseudophakic patients were randomized to the use of artificial tears with or 

without BAK q.i.d. for 30 days. Laser flare meter (LFM) and OCT measurements of macular 

thickness were made by a masked observer at baseline and 15 and 30 days after 

randomization. Results: BAK-preserved artificial tears (n = 22) resulted in a statistically 

significant increase in flare measurements on Days 15 (P = .017) and 30 (P = .043). No 

change was observed in the group using nonpreserved artificial tears (n = 22, P > .05). No 

significant differences were found in OCT measurements. Conclusion: Short-term use of 

BAK-preserved drops may cause disruption of the BAB in pseudophakic eyes. 


A Comparison Between the Fluocinolone Acetonide 

(Retisert) and Dexamethasone (Ozurdex) Implants in Uveitis 

Presenting Author: Cheryl Myla A Acinue MD 

Co-Author(s): Olga M Ceron MD, C Stephen Foster MD* 

Purpose: Comparison of efficacy and safety of fluocinolone acetonide (FA) and dexamethasone 

(Dexa) implants in uveitis. Methods: Chart review of 27 eyes with FA (n = 16) 

or Dexa (n = 11) implant with a 2-year follow-up. Primary outcome was recurrence rate. 

Results: No significant differences in recurrence rate and improvement in inflammation 

and BCVA were found between the 2 groups. FA-implanted eyes had a higher rate of 

needing more glaucoma medications, surgery and/or laser (P = .02) and were 4.7 times 

more at risk of cataract progression (P = .04). Conclusion: Dexa and FA seem comparable 

in preventing uveitis recurrence and in improving inflammation and BCVA. However, the 

FA implant had higher rates of cataract progression and need for glaucoma medications, 

laser, and/or surgery. 


Clinical Outcomes of Vogt-Koyanagi-Harada Disease at a 

Tertiary Center in 194 patients: A Uveitis Survey Study Group 

Presenting Author: J Fernando Arevalo MD FACS 

Co-Author(s): Andrés Francisco Lasave MD, Hanan Nasser Al Shamsi, Sulaiman 

Mohammad Alsulaiman MBBCHIR, Abdul Aziz Al Rushood MD, Yahya A Al-Zahrani, 

Hassan A Al-Dhibi MD 

Purpose: To describe ocular clinical characteristics, complications, management, and 

surgical outcomes among patients with Vogt-Koyanagi-Harada (VKH) disease. Methods: 

We retrospectively analyzed 194 patients (382 eyes). Results: The most common form of 

presentation was panuveitis in 151 eyes (77.8%). Exudative retinal detachment (ERD) was 

diagnosed in 143 eyes (87.2%). More common complications were glaucoma in 135 eyes 

(35.3%), cataract in 25 eyes (6.5%), and choroidal neovascularization in 21 eyes (5.5%). 

Conclusion: Bilateral panuveitis is the most common ocular manifestation of VKH in 

Saudi Arabia. At presentation, ERD is present in 87.2% of eyes. More than 60% of eyes 

maintain a visual acuity of 20/50 or better. 


APAO Dexamethasone Sustained-Release Intravitreal 

Implant in Noninfectious Uveitis 

Presenting Author: Alay S Banker MD 

Purpose: To study efficacy of the dexamethasone sustained-release intravitreal implant 

(Ozurdex) implant in noninfectious uveitis. Methods: Prospective, noncontrolled case series 

of 14 eyes injected with Ozurdex implant (10 pars planitis, 2 serpiginous choroiditis, 

2 Vogt-Koyanagi-Harada syndrome). Vitreous haze,visual acuity, OCT, and adverse events 

were assessed. Results: All eyes showed reduction in vitreous haze, reduction of macular 

edema (347.50 µ vs. 396.125 µ at baseline, P < .05) up to 24 weeks in all but 3 eyes 

which required a second implant at end of 4 months. Mean visual acuity improved to 0.550 

logMAR from 0.575 at baseline. No significant increase in IOP was observed (17.42 vs. 

20.66). Conclusion: In patients with noninfectious uveitis, the Ozurdex implant reduces 

vitreous inflammation and macular edema, improves visual acuity, and reduces the need 

for systemic therapy. 


APAO Polymerase Chain Reaction Outcomes in Clinically 

Predicted Tubercular Uveitis 

Presenting Author: Soumyava Basu MS 

Co-Author(s): Praveen Kumar Balne**, Savitri Sharma MD, Tapas Ranjan Padhi**, 

Taraprasad Das MD 

Purpose: To validate ocular signs predictive of tubercular uveitis by polymerase chain reaction 

(PCR). Methods: We tested aqueous humor of 64 patients with clinically suspected 

tubercular uveitis and one or more of following clinical signs: broad-based anterior synechiae, 

retinal vasculitis with/without choroiditis and serpiginous-like choroiditis, by multiplex 

PCR for Mycobacterium tuberculosis. Thirty postoperative endophthalmitis samples 

were used as controls. Results: Ninety-two percent (92%; n = 59) of tested samples were 

PCR-positive compared to 7% (n = 2) controls (P < .0005). Conclusion: PCR validated the 

role of clinical signs in diagnosis of tubercular uveitis. 


Prevalence of Pediatric Noninfectious Uveitis in the United 

Kingdom and the United States 

Presenting Author: Oscar E Cuzzani MD DSC* 

Co-Author(s): Avani D Joshi PhD, Sumati A Rao PhD, Mary A Cifaldi PhD**, Oscar A 

Hayes PhD**, Shivaji Manthena PhD**, Andrew D Dick MD* 

Purpose: To estimate the prevalence of pediatric noninfectious uveitis in the United Kingdom 

(UK) and the United States (USA). Methods: Retrospective (1 Jan. – 31 Dec. 2010) 

analysis of pediatric uveitis patients (< 18 years). In the UK, General Practice Research 

Database (GPRD) comprises medical records of general practitioners. In the USA, MarketScan 

database captures patients treated by specialists (rheumatologists/ophthalmologists). 

Results: Sixty-three uveitis cases in GPRD; estimated prevalence of noninfectious 

uveitis (n = 47) was 4.4 per 100,000. 1513 uveitis cases in MarketScan; estimated prevalence 

of noninfectious uveitis (n = 1266) was 60.0 per 100,000. Conclusion: The UK GPRD 

may underestimate the prevalence of pediatric noninfectious uveitis, as it does not include 

patients treated by specialists. 


The Efficacy and Safety of Adalimumab in Ocular 

Inflammation 

Presenting Author: Khayyam Durrani MD 

Co-Author(s): Pichaporn Artornsombudh MD, Cheryl Myla A Acinue MD, Alaa E 

Radwan FRCS DO, Ravi Parikh MD**, Ana Marina Suelves-Cogollos MD, Sana S 

Siddique MD, Ian Chang MD**, Charles Stephen Foster MD** 

Purpose: To evaluate the efficacy and safety of adalimumab in the management of ocular 

inflammation at our institution. Methods: We performed a review of all patients with active 

ocular inflammation treated with adalimumab at our institution. Results: Sixty-eight 

eyes of 48 patients were reviewed. The mean duration of follow-up was 19.6 months. 

At 1 year of follow-up, adalimumab was effective in achieving quiescence in 33 eyes 

(48.5%). The most common side effects were injection-site reactions, arthralgias, and 





207



nausea, occurring in 2 patients each. Adalimumab was discontinued due to side effects in 

12 patients. Conclusion: These results suggest that adalimumab is a moderately effective 

and safe therapeutic modality in ocular inflammation. 


APAO Ocular Manifestations of Rickettsial Disease in India 

Presenting Author: Kanav Gupta MBBS 

Co-Author(s): Padmamalini Mahendradas MBBS DO DNB, Kavitha Avadhani, Naresh 

Kumar Yadav MBBS, Rekha R Khandelwal MBBS FRCS 

Purpose: To report ocular manifestations of Rickettsial retinitis in India. Methods: Retrospective 

observational case series of 6 patients, with history of fever and rash. They 

underwent detailed systemic and ophthalmic evaluation. Results: Anterior segment was 

normal. Fundus revealed whitish retinal lesions, retinal hemorrhages, and multiple cotton 

wool spots in both eyes. Weil Felix test was positive in all cases. All were treated 

with Tab. doxycycline and systemic steroids, which resulted in resolution of retinitis with 

improvement in visual acuity. Conclusion: Rickettsial retinitis is to be considered when 

patients present with fever and rash associated with retinitis in India. Pupillary miosis 

occurred during fundus fluorescein angiography due to Type I hypersensitivity reaction 

in 1 patient. 

Session Two 





APAO A Case Series of Scleral Tuberculosis Resistant to 

Conventional Treatment 

Presenting Author: Yashpal Goel MBBS 

Co-Author(s): Ritu Arora MD MBBS, Aditi Abhay Manudhane MBBS, G R Sethi MD**, 

Gaurav Goyal MBBS**, Deepa Gupta MBBS, Arushi Garg MBBS 

Purpose: To report cases of resistant scleral tuberculosis (TB). Methods: Five patients in 

the age group of 7-50 years presented with scleral nodules / diffuse scleritis / scleral perforation. 

Immunological testing for collagen vascular diseases was negative. All patients 

had a past history of receiving antituberculosis treatment (ATT) for systemic TB. Patients 

were given a trial of ATT. Results: Scleral lesions did not respond to the 4-drug regimen 

(earlier called Category 1). Patients were shifted to the 5-drug regimen (Category 2), which 

included streptomycin. The lesions resolved, and 1 patient underwent scleral graft. Conclusion: 

Resistant tuberculosis should be considered as an important etiological factor 

while treating patients with scleritis. 


APAO Phacoemulsification Cataract Extraction and IOL 

Implantation in Patients With Uveitis 

Presenting Author: Takatoshi Kobayashi MD 

Co-Author(s): Koichi Maruyama MD**, Nanae Takai MD**, Rei Tada MD**, Sayako 

Takeda MD PhD**, Tsunehiko Ikeda MD 

Purpose: To analyze the outcomes of phacoemulsification cataract extraction and IOL 

implantation in patients with uveitis. Methods:The records of 79 patients (110 eyes) with 

uveitis who underwent surgery between January 2005 and March 2012 were retrospectively 

examined. Their postoperative visual outcomes and complications were analyzed. 

Results: At the final follow-up examination, 87 eyes (79.1%) showed improved visual 

acuity. In 26 eyes (23.6%), relapse of intraocular inflammation occurred within 6 months 

after surgery. In cases with a quiescent period of less than 3 months, the relapse rate 

was significantly higher. Conclusion: The outcomes of cataract surgery in patients with 

uveitis were satisfactory. 


Characteristics, Complications, and Surgical Outcomes of 

Panuveitis in 400 patients Over 25 Years: A Uveitis Survey 

Study Group 

Presenting Author: Andrés Francisco Lasave MD 

Co-Author(s): Hanan Nasser Al Shamsi, Sulaiman Mohammad Alsulaiman MBBCHIR, 

Abdul Aziz Al Rushood MD, Yahya A Al-Zahrani, Hassan A Al-Dhibi MD, J Fernando 

Arevalo MD FACS 

Purpose: To describe clinical characteristics, complications, and surgical outcomes of 

panuveitis in a tertiary center over a 25-year period. Methods: Retrospective chart review 

study. Four-hundred patients (727 eyes) with panuveitis were evaluated. Results: Clinical 

diagnosis included Vogt-Koyanagi-Harada syndrome (VKH) in 151 patients (37.8%), Behcet 

disease in 104 patients (26%), presumed-intraocular tuberculosis in 21 patients (5.3%), 

and chronic postoperative panuveitis in 12 patients (3%). 181 patients (45.3%) underwent 

surgical procedures secondary to complications. Mean final visit logMAR BCVA in 

both eyes was 20/100 (0.7 ± 0.92). Conclusion: VHK and Behcet disease are the leading 

causes of panuveitis in Saudi Arabia. 


Antitumor Necrosis Factor Agents in the Treatment of 

Noninfectious Uveitis in a Single Institution 

Presenting Author: Michelle P Lin MPH 

Co-Author(s): Maria Choudhary MD**, Rula Hajj-Ali MD, Sunil K Srivastava MD*, 

Careen Yen Lowder MD PhD* 

Purpose: To evaluate safety and efficacy of anti-tumor necrosis factor agents (anti-TNFs) 

in noninfectious uveitis. Methods: Retrospective review. Results: 161 patients (70% 

female; 80% Caucasian) of median age 38 years (3-79) and follow-up of 40 months (0.5- 

119) were included. Thirty-four percent had juvenile idiopathic arthritis; 19%, spondylitis; 

11%, sarcoidosis; 11%, idiopathic; 8%, inflammatory bowel disease; 17%, others. Fortyeight 

percent received infliximab; 26%, adalimumab; 26%, etanercept. Eighty-four percent 

achieved steroid-sparing remission (12% per person-year relapse). Complications: 14%, 

infusion-reaction; 12%, infection; 4.4%, malignancy; 3.8%, demyelination. Conclusion: 

Anti-TNFs are effective in the treatment of noninfectious uveitis but are associated with 



Uveitic Glaucoma at a Tertiary Care Center in the Middle 

East (KKESH) 

Presenting Author: Jose Morales MD 

Co-Author(s): Sami Al Odhayb MD, Dhafer Saad Alqahtani Sr, Hassan A Al-Dhibi MD, 

Sami Al Shahwan MD, Ibrahim A Aljadaan MD, Deepak Paul Edward MD 

Purpose: To determine the incidence of uveitic glaucoma, uveitic etiology, and risk factors 

at KKESH. Methods: Review of 888 uveitis patients. Incidence and association of uveitis 

type with IOP elevation (≥ 25 mmHg) and possible risk factors were evaluated. Results: 

IOP elevation occurred in 28%; 18% required medical treatment, and 9% required glaucoma 

surgery. Most common uveitic etiologies: Vogt-Koyanagi-Harada syndrome (VKH) 

(23%), and Behcet (16 %). Fuchs cyclitis, herpes and VKH were most likely to develop glaucoma 

(Odds ratio [OR] 2.5; 1.7; and 1.3 respectively). Fuchs and VKH patients were most 

likely to undergo glaucoma surgery [OR] 6.7 and 2.4. Conclusion: IOP elevation etiology 

differed from that reported. Fuchs and herpes had the highest risk of developing glaucoma, 

and Fuchs and VKH had the highest risk of requiring glaucoma surgery. 


Retinal Angiography and Color Doppler of Retrobulbar 

Vessels in Takayasu’ Arteritis 

Presenting Author: Cristina Muccioli MD 

Co-Author(s): Tiago E Arantes MD, Alexandre Wagner Silva Souza MD**, Maria 

Helena M Carvalhaes**, Norma Allemann MD* 

Purpose: To evaluate and describe the ocular manifestations of Takayasu asteritis. 

Methods: Twenty-one patients were evaluated by fluorescein, indocyanine green angiography, 

and color Doppler ultrasound. Results: A statistical correlation was found between 

peak systolic velocity in the ophthalmic artery (OA) and Heidelberg retina angiograph exam 

(P = .006), and resistivity index (RI) in the OA was abnormal in patients with long vs. short 

onset time of the disease (P = .035). RI in the central retinal artery (CRA) was abnormal in 

patients with a long time of disease onset vs. those with a short time of onset (P = .006). 

208 





Conclusion: The longer the onset of the disease, the more commonly the RI showed 

changes in the OA and CRA. Doppler blood flow evaluation and HRA angiography should 

be performed in all patients with Takayasu asteritis as part of monitoring. 


APAO Loop-Mediated Isothermal Amplification for Rapid 

Diagnosis of Intraocular Tuberculosis 

Presenting Author: Kusum Sharma MD 

Co-Author(s): Reema Bansal MBBS, Aman Sharma MD, Vishali Gupta MBBS, Amod K 

Gupta MBBS 

Purpose: To report loop-mediated isothermal amplification (LAMP) in presumed intraocular 

tuberculosis (PIOTB). Methods: LAMP using 6 primers specific for Mycobacterium tuberculosis 

was performed on intraocular fluid samples of PIOTB (8), disease controls (10), 

and nonuveitic vitrectomy samples (10). Results: LAMP was positive in 6 of 8 samples 

from PIOTB and negative in all normal and disease controls. LAMP had sensitivity and 

specificity of 75% and 100%, respectively. Conclusion: LAMP is a simple, sensitive, and 

specific test for rapid diagnosis of intraocular tuberculosis. 


APAO Therapy of Non-necrotizing Scleritis With Retrobulbar 

Injection of Triamcinolone 

Presenting Author: Yukako Taketani MD 

Co-Author(s): Kazuya Inamochi MD**, Kiyoto Totsuka MD**, Hirobumi Shibui MD**, 

Yuichi Fukuzawa MD**, Makoto Aihara MD PhD*, Yohei Nomoto MD** 

Purpose: To evaluate the efficacy and adverse effects of retrobulbar injection of triamcinolone 

(RIT) in treating nonnecrotizing scleritis. Methods: Retrospective review of all 

patients who came to our clinic from 2007 to 2011 who did not response to topical corticosteroid 

and were treated with RIT for nonnecrotizing scleritis. All cases were observed 

for over 3 months after RIT. Results: All patients (6 cases) had relief of their symptoms 

with clinical improvement in inflammation. Average period from first RIT to remission was 

10.3 ± 3.5 days. During the observation, no complication was seen. Conclusion: RIT is 

highly effective for nonnecrotizing scleritis. It should be considered as alternative, valid 

treatment for eyes that fail topical corticosteroid and patients intolerant of systemic corticosteroid 

use. 


Session Two 





Implementation of a Structured Semiannual Review in an 

Ophthalmology Residency Program: Does It Alter Resident 

Development? 

Presenting Author: Katie Marie Keck 

Co-Author(s): Andreas Lauer MD* 

Purpose: Residency programs seek to develop well-rounded residents in the nonclinical 

areas of research, teaching, and service. Methods: The files of 40 graduates of one 

ophthalmology residency program were retrospectively reviewed to determine the number 

of research, teaching, and service activities reported. We compared data before (2002- 

2007) and after (2008-2011) implementation of a structured semiannual review. Results: 

Residents completing the semiannual review reported a mean of 20.7 activities, compared 

with a mean of 6.9 activities among those finishing residency prior to its implementation (P 

= .0001). Conclusion: A structured semiannual review was significantly associated with 

increased participation in resident development activities. 


Research Experience of U.S. Medical Students Interested in 

Ophthalmology 

Presenting Author: Lauren Sielert** 

Co-Author(s): Evan Allan MD, Yoonsang Kim PhD**, Vinay A Shah MD* 

Purpose: To determine the amount and type of research that medical students (MS) with 

an interest in ophthalmology perform. Methods: E-mail survey to all US MS. Results: Of 

1444 respondents, 399 MS-III and 53 MS-IVs were interested in ophthalmology. Fifty-eight 

percent of interested MS-IIIs and 81% of MS-IVs had opportunities for ophthalmology 

research; 39% of MS-IIIs and 15% of MS-IVs did not know if such opportunities existed. 

Eighty-seven percent of MSI-IIIs and 38% of MS-IVs had not initiated ophthalmology research; 

19% of MS-IVs had published/presented ophthalmology research; 43% of interested 

MS-IVs chose clinical research and 25% chose basic science. Conclusion: The 

majority of MSI-III students interested in ophthalmology have not performed research. 

Only a portion of MS-IVs have published and presented research, while the majority of 

MSIIIs have not performed research of any kind. Research should be initiated early in US 

medical schools. 


Session One 





Intravitreal Injection of a Rho-kinase Inhibitor (Fasudil) 

for Recent Onset Nonarteritic Anterior Ischemic Optic 

Neuropathy 

Presenting Author: Hamid Ahmadieh MD 

Co-Author(s): Mohammad Pakravan MD, Ali Hafezi-Moghadam MD PhD, Ramin 

Nourinia MD, Nasrin Sanjari, Souska Zandi MD PhD, Shintaro Nakao MD PhD**, 

Mohammadhassan Shah-Heidari, Mehdi Yaseri MD 

Purpose: To evaluate the effect of intravitreal injection of a rho-kinase inhibitor, Fasudil, 

in nonarteritic anterior ischemic optic neuropathy (NAION). Methods: In this pilot comparative 

study, intravitreal injection of Fasudil (0.025 mg/0.05 ml) was performed within 

2 weeks of the insult (6 eyes) and compared with placebo in control eyes (21) of another 

parallel study. Results: Visual improvement was significant 1 month after intravitreal Fasudil 

(P = .04) and was more significant than controls (P = .01). Mean deviation changes in 

perimetry were not significantly different between the groups (P = .70). Conclusion: Intravitreal 

Fasudil demonstrated short-term efficacy in management of recent-onset NAION, 

warranting larger trials with longer follow-up. 


Combination of Lateral Tarsal Strip and Gold Weight Implant 

in the Treatment of Ocular Complications of Facial Nerve 

Paralysis 

Presenting Author: Imtiaz Chaudhry MD PhD 

Co-Author(s): Osama H Al-Sheikh MD, Waleed A Al Rashed, Farrukh A Shamsi PhD, 

Yonca O Arat MD**, Milton Boniuk MD** 

Purpose: To study the effectiveness of lateral tarsal strip (LTS) along with gold weight 

implant (GWI) in the management of ocular complications (OC) of facial nerve paralysis 

(FNP). Methods: Noncomparative, case series of FNP patients requiring surgical or nonsurgical 

intervention studied for the effectiveness of LTS+GWI and compared with LTS 

or GWI. Results: Among the 160 FNP patients (112 male, 48 female; average age: 62.4 

years), 36 required LTS along with GWI, 44 required GWI alone, and 42 required LTS alone. 

Patients having LTS and GWI had faster recovery and experienced fewer ocular complications 

compared with LTS, GWI, or no treatment (P < .05). Conclusion: LTS along with GWI 

may be more effective in the management of OC associated with FNP. 


H Recovery of Ocular Motor Cranial Nerve Palsy 

Following Herpes Zoster Trigeminal Nerve Involvement 

Presenting Author: Manpreet S Chhabra MD 

Co-Author(s): Karl C Golnik MD* 

Purpose: To report the course of ocular motor cranial nerve palsy due to herpes zoster. 

Methods: A retrospective chart review identified patients with ocular motor cranial nerve 

palsy occurring at the time of herpes zoster trigeminal nerve involvement. Patients were 

seen by a single neuro-ophthalmologist from 1994 to 2012. Results: Twenty-one patients 

were identified; 3 were excluded because of incomplete follow-up. Nine (50%) had complete 

recovery and 8 (44%) had partial recovery but no diplopia in primary gaze (mean 

time = 10 weeks). One patient with complete ophthalmoplegia had persistent diplopia in 

primary position. Conclusion: Ophthalmoplegia secondary to herpes zoster has excellent 

long-term prognosis. 





209




Fundus Autofluorescence and OCT Changes in Multiple 

Sclerosis Patients 

Presenting Author: Krystian J Kisza MD 

Co-Author(s): Elizabeth L Affel MS, Robert C Sergott MD* 

Purpose: To characterize fundus autofluorescence (FAF) and OCT findings in patients with 

primary progressive (PPMS) and relapsing/remitting (RRMS) multiple sclerosis. Methods: 

Fifty eyes of MS patients underwent FAF and OCT imaging with Spectralis spectral domain 

OCT. Results: The following patterns were noted: normal foveal dimensions with 

increased hyperfluorescence, enlarged foveola area with a combined hypo- and hyperflourescence, 

and smaller than normal hypofluorescent macular area with more hyperfluorescence, 

especially in the temporal extramacular region. Conclusion: MS patients 

demonstrated abnormal FAF patterns within the fovea, macula, and extramacular area. 

The FAF abnormalities appear to be independent of intrinsic changes within the retina. The 

RRMS patients had normal and PPMS patients had abnormal macular OCT. 


Retinal Nerve Fiber Layer and Brain Atrophy in Relapsing 

Remitting Multiple Sclerosis: A Longitudinal Correlation 

Study 

Presenting Author: Michele Lanza MD 

Co-Author(s): Antonio Gallo MD*, Rosaria Sacco MD, Alvino Bisecco MD**, Luigi 

Lavorgna MD**, Mario Cirillo MD, Simona Bonavita MD, Gioacchino Tedeschi MD 

Purpose: To assess the longitudinal correlation between brain atrophy (BA) and retinal 

nerve fiber layer thickness (RNFLt) in relapsing remitting multiple sclerosis (RRMS). Methods: 

Whole brain (WB) and grey matter (GM) volumes have been measured with 3T-MRI, 

and RNFLt has been evaluated with scanning laser polarimeter (SLP) in 19 RRMS. All 

measurements were obtained at baseline and after a mean follow-up of 20 ± 5 months. A 

correlation analysis was run using the Pearson index. Results: Nasal RNFLt differences 

showed a significant correlation with both WB (R = 0.46, P < .05) and GM (R = 0.37, P < .05) 

progressive volume reductions. Conclusion: Nasal RNFLt change detected by SLP seems 

to be longitudinally correlated to BA evolution in a midterm follow-up in RRMS. 


APAO Retinal Ganglion Cell Function in Neuromyelitis 

Optica-IgG Positive and Negative Optic Neuritis Patients: 

Correlation With Retinal Structure 

Presenting Author: Yoshimichi Matsunaga MD 

Co-Author(s): Takeshi Kezuka MD PhD, Yoshihiko Usui MD, Saori Numata MD**, 

Hiroshi Goto MD 

Purpose: Photopic negative response (PhNR) gained from focal macular electroretinogram 

reflects retinal ganglion cell (RGC) function. We assessed the relationship of PhNR 

and retinal structure in neuromyelitis optica (NMO)-IgG positive and negative optic neuritis 

patients. Methods: Retrospective chart review was done for 23 eyes, 14 cases of optic 

neuritis patients. Retinal thickness from OCT and PhNR was evaluated. Results: Negative 

correlation between PhNR response and average macular retinal thickness (Spearman r = 

-0.8117, P < .0031) in NMO IgG-positive group was obtained. Conclusion: In NMO IgGpositive 

optic neuritis, RGC layer damage may be strongly associated with retinal thinning. 


King-Devick Test of Rapid Eye Movements: Correlate of 

Disability and Quality of Life in Multiple Sclerosis 

Presenting Author: Stephen Moster 

Co-Author(s): Steven L Galetta MD*, Maureen G Maguire PhD*, Laura J Balcer MD 

MSC** 

Purpose: To examine the potential for the King-Devick (K-D) test as a measure in MS. 

Methods: Forty MS patients and 20 controls completed the K-D test at a single study 

visit. Patients were also evaluated with low (2.5%, 1.25%) and high-contrast visual acuity, 

spectral domain OCT, and National Eye Institute Visual Function Questionnaire (NEI- 

VFQ-25), and MS Functional Composite. Results: MS cohort scores were higher than 

controls (55.3 ± 17.8 vs. 41.2 ± 7.2 seconds, P = .008). Higher K-D scores were associated 

with worse scores on NEI-VFQ-25 (P = .001), binocular low-contrast acuity (2.5%, P = .02), 

and high-contrast visual acuity (P = .03). Conclusion: The K-D test correlates well with 

binocular visual function, disability, and vision-specific QOL in MS. The K-D test should be 

considered for inclusion in MS trials as a rapid efferent visual function test. 

Session Two 





APAO Prevalence of Congenital Optic Disc Anomalies in the 

South Indian Population 

Presenting Author: Shikha Talwar Bassi MBBS 

Co-Author(s): Lingam Vajaya MD, Lingam Gopal MBBS, Swarnali Sen**, Ronnie Jacob 

George MD* 

Purpose: To determine the prevalence of congenital optic disc anomalies in the rural and 

urban South Indian population. Methods: This is a population-based cross-sectional study 

of 6013 subjects (12,026 eyes). Result: Optic disc anomalies were found in 81 eyes of 66 

subjects (1.09%). The prevalence of each anomaly was myelinated nerve fiber (0.28%), 

tilted disc (0.09%), hypoplastic disc (0.04%), Bergmisters papilla (0.03%), optic disc pit 

(0.04%), optic disc coloboma (0.08%), optic disc pit and coloboma (0.01%), optic disc pigmentation 

(0.03%), optic nerve head drusen (0.03%), anomalous disc vessels (0.16%), and 

glial tissue on the optic disc (0.28%). Conclusion: The prevalence of congenital optic 

disc anomalies is 1.09% in the South Indian population. 


Evolution of Visual Function and Retinal Nerve Fiber Layer 

in Neuromyelitis Optica: A Longitudinal Comparative Study 

Presenting Author: Rabih Hage SR MD 

Co-Author(s): Philippe Cabre MD**, Severine Jeannin MD**, Raymond Richer MD, 

Angelique Donnio, Harold R Merle MD 

Purpose: To determine how visual function evolves in the absence of optic neuritis in 

neuromyelitis optica (NMO) and to assess its relation with retinal nerve fiber layer (RNFL) 

thickness. Methods: Patients underwent low-contrast visual acuity (LCVA) and measurement 

of RNFL and visual field by frequency doubling technology (FDT) at baseline and after 

2 years of follow-up. Results: Sixteen patients with NMO and 27 patients with multiple 

sclerosis (MS) were included. Over a relapse-free period of 2 years, RNFL decreased in the 

MS group (-4.26 µm; P < .0001), while RNFL in NMO did not change (+0.845; P = .63). The 

same significative results were found in LCVA and FDT. Conclusion: Results suggest that 

there is no subclinical axonal loss in NMO. 


Chromatic Pupillometry to Quantify Rod and Cone Function 

in Retinal Dystrophies 

Presenting Author: Birgit Lorenz MD PhD 

Co-Author(s): Elisabeth Strohmayr DVM**, Steffen Zahn MS, Christoph Friedburg MD, 

Markus Preising PhD**, Knut Stieger 

Purpose: To quantify rod and cone function in patients with retinal dystrophies using 

chromatic pupillometry as objective testing. Methods. Twenty patients with retinal 

dystrophies and 32 healthy probands were tested using a custom-made binocular pupillometer. 

Results were correlated with visual field (VF), BCVA, and full-field stimulus test 

(FST). Results: Significant rod- or cone-weighted pupil response reduction (P < .05) corresponded 

well with clinical parameters. Conclusion: Chromatic pupillometry represents 

a highly sensitive objective test to quantify rod and cone function in retinal dystrophies. 


Clinical Outcomes of Transverse Venous Sinus Stenting in 

Idiopathic Intracranial Hypertension 

Presenting Author: George N Magrath MD 

Co-Author(s): Stephen Potter, Pamela S Chavis MD, Vibhor Krishna MD, Imran 

Chaudry*, Aquilla Turk MD**, Raymond Turner MD* 

Purpose: To present the first description of detailed ophthalmic and clinical outcomes in 

idiopathic intracranial hypertension (IIH) patients treated with transverse venous sinus 

stenting (TVSS) for sinus stenosis. Methods: Nine IIH patients received TVSS if there was 

a significant pressure gradient across the stenosis. Retrospective chart review analyzed vision, 

diuretic use, headache severity, and concomitant weight loss and papilledema grade. 

Results: Nine females ranged from 28-49 years (mean: 38); follow-up ranged from 4-24 

months (mean: 10.6; 1 lost to follow-up); papilledema and headaches improved in 5; 7 

210 





were able to maintain or decrease diuretic use. Timing of resolution of papilledema to 

stenting was observed. No patients had worsening of papilledema / headaches. Conclusion: 

Some patients with IIH can be adequately managed with TVSS. 


Campimetric Lesions Characteristics During Neuromyelitis 

Optica 

Presenting Author: Harold R Merle MD 

Co-Author(s): Stephane Olindo MD, Rabih Hage SR MD, Angelique Donnio, Raymond 

Richer MD, Philippe Cabre MD** 

Purpose: To analyze the visual field (VF) anomalies observed throughout the neuromyelitis 

optica (NMO). Methods: Twenty-seven cases of NMO and 27 cases of multiple sclerosis 

were selected. Visual field anomalies were classified using the Optic Neuritis Treatment 

Trial system. Results: After an optic neuritis (ON), 40% of the NMO group’s eyes showed 

a total loss of the VF (P = .01) and 27% fascicular anomalies, among which 12% were 

altitudinal. In presence of total VF loss, the positive predictive value in favor of NMO was 

92.8% and the negative was 47.3%. Conclusion: Visual field alterations of the NMO are 

different from the multiple sclerosis. An ON, blinding from the first attack, must suggest 

an NMO. Altitudinal deficits suggest a vascular mechanism. 


Perimetry Before and After Cerebral Shunting in Patients 

With Idiopathic Intracranial Hypertension 

Presenting Author: Jennifer L Rizzo MD 

Co-Author(s): Khoa Lam, Michael Wall MD, Machelle D Wilson PhD, John L Keltner 

MD 

Purpose: Patients with uncontrolled idiopathic intracranial hypertension (IIH) are treated 

with cerebral shunting to alleviate symptoms and improve visual function. Methods: We 

retrospectively reviewed all cases of IIH with cerebral shunting at our institution between 

2005 and 2011. Perimetry was performed before and after surgery in 19 patients. Results: 

Eighteen of the IIH patients were female and 1 male; their age was 33.9 ± 12.7 years. 

Independent analyses of the right and left eyes before and after shunting showed significant 

improvement O.D. of 4.6 dB (P < .001) and of 6.1 dB O.S. (P < .001). Conclusion: Our 

results suggest that cerebral shunting results in significant improvement in visual field 

function in patients with IIH. 


H Neural Canal Crowding at the Lamina Cribrosa in 

Nonarteritic Anterior Ischemic Optic Neuropathy 

Presenting Author: Kevin I Rosenberg MD 

Co-Author(s): Daniel Su, Rudrani Banik MD, Jeffrey M Liebmann MD*, Robert Ritch 

MD FACS* 

Purpose: To compare neural canal dimensions between nonarteritic anterior ischemic optic 

neuropathy (NAION) and healthy subjects using enhanced depth imaging OCT. Methods: 

Horizontal and vertical diameters of the optic disc, Bruch membrane opening, lamina 

cribrosa, and narrowest neural canal opening were compared between the 2 groups. Results: 

Twenty-seven NAION eyes (27 subjects) and 43 healthy eyes (43 controls) were 

included. Mean horizontal (1575 vs. 1854 µm) and vertical (1666 vs. 1932 µm) diameters 

of the lamina cribrosa were significantly smaller in NAION eyes than in healthy eyes, 

both before and after controlling for age and gender (all P < .001). The other parameters 

were similar between the 2 groups (all P > .1). Conclusion: Neural canal crowding at the 

lamina cribrosa level may predispose to NAION. 


APAO Methyl Alcohol Poisoning: Laboratory Tests as 

Predictors of Visual Outcomes 

Presenting Author: Tejas H Desai MBBS 

Co-Author(s): Aditya A Sudhalkar MS, Bakulesh Mafatlal Khamar 

Purpose: To determine if biochemical analysis at presentation can predict final visual acuity 

(VA) in methyl alcohol poisoning. Methods: Retrospective analysis of 122 methyl alcohol 

poisoning patients of a cluster outbreak in July 2009. Data collected included demographics, 

complete ocular and systemic examination, biochemical analysis, and treatment 

records. Appropriate statistical analysis was done. Results: Final VA correlated inversely 

with pH (r = -0.59), anion (r = -0.62), osmolal gap (r = -0.68), and methanol levels (r = -0.50) 

and positively with bicarbonate (r = 0.37), time to presentation (r = 0.67), and potassium (r 

= 0.29). Only pH was found to have significant influence (P < .001) on VA (multiple linear regression 

analysis). Conclusion: Acidosis affects final VA adversely despite early therapy. 


Session One 





Choroidal Evaluation Using Ultrawide-Field Enhanced 

Depth Imaging Spectral Domain OCT in Choroidal Tumors 

Presenting Author: Juan David Arias MD 

Co-Author(s): Sandor Ferenczy JR CRA, Sarah A Harmon CRA, Enzo M Fulco MD, 

Carolina Alarcon MD, Jerry A Shields MD, Carol L Shields MD 

Purpose: To describe a technique that permits ultrawide-field enhanced depth imagingoptical 

coherence tomography (EDI-OCT). Methods: Eight eyes with choroidal tumors 

were imaged with ultrawide-field EDI-OCT. Results: To achieve wide-field imaging, we 

captured several EDI-OCTs in sequential order, which together provided a field of 9 to 14 

mm at the posterior segment. Motion artifacts image were minimalized. The cross correlation 

between adjacent 2-D resolution artifacts of displacement were resolved. We present 

unique wide-field images of retinal and choroidal anatomic structure and intralesional information 

of various choroidal tumors. Conclusion: Ultrawide-field EDI-OCT can provide 

panoramic anatomic cross-sectional viewing of choroidal tumors. 


Timing of Intraocular Blood Breakdown 

Presenting Author: Amanda C Maltry MD 

Co-Author(s): Nasreen A Syed MD 

Purpose: To determine the natural history of blood breakdown in human ocular tissues 

using hemosiderin as a marker, potentially applicable in pediatric cases of nonaccidental 

trauma. Methods: We reviewed the pathology of 49 eyes enucleated due to recent traumatic 

injury and known timing from injury to enucleation. Iron staining was performed on 

archived tissue. Results: Time from injury to enucleation ranged 0 to 64 days. Hemosiderin 

was detected in 42 of 49 eyes, earliest at 4 days. Three of 8 eyes (38%) were positive 

within 4 days of injury, 14 of 21 eyes (66%) within 7 days, and all eyes within 8 to 64 days. 

Conclusion: Hemosiderin can be identified as early as 4 days after traumatic intraocular 

hemorrhage. Its presence can establish only a minimum age of the hemorrhage. 


APAO Prognostic Biomarkers in Adenoid Cystic Carcinoma 

of the Lacrimal Gland 

Presenting Author: Kaustubh Bharat Mulay BMBS MD 

Co-Author(s): Fairooz Puthiyapurayil Manjandavida MBBS, Santosh G Honavar MD 

Purpose: To identify the potential role of biomarkers as prognostic indicators of adenoid 

cystic carcinoma (ACC) and to study the potential role of hormonal therapy. Methods: IHC 

staining was performed for Ki67, Survivin, p53, and Bcl2 on 55 cases of ACC of the lacrimal 

gland. ER and PR staining was performed on every third case. Results: Thirteen cases 

(26%) had a significant basaloid pattern. p53 (median 79%) and bcl2 (median 94%) were 

expressed in all cases. Ki 67 was low (median 22.9%). Thirty-three cases (60%) expressed 

nuclear Survivin, while 43 cases (78.1%) expressed cytoplasmic Survivin. None of the 18 

cases expressed ER and PR. Conclusion: Ki67, Bcl2, p53, and nuclear Survivin expression 

have a prognostic impact in ACCs of the lacrimal gland. ER and PR nonexpression make 

the role of hormonal therapy doubtful. 


Clinical Spectrum and Prognosis of Uveal Melanoma Based 

on Age at Presentation in 8033 Cases 


Co-Author(s): Swathi Kaliki MD, Minoru Furuta MD, Arman Mashayekhi MD, Jerry A 

Shields MD 

Purpose: To evaluate prognosis of uveal melanoma based on age. Methods: Chart review. 

Results: Of 8033 patients with uveal melanoma, 106 were young (≤ 20 years), 4287 

in mid-adults (21 to 60 years), and 3640 in older adults (beyond 60 years). Based on age 

(young, mid-adults, older adults), tumor locations was iris (21%, 4%, 2%), tumor diameter 

(10.2, 10.8, 11.5 mm) and thickness (5.0, 5.3, 5.7 mm) increased (P < .0001). Kaplan-Meier 





211



metastasis at 10 and 20 years were 9% and 20% in young (P < .011); 23% and 34% in 

mid-adults (P < .0001); and 28% and 39% in older adults. Conclusion: Young patients 

showed lower melanoma metastasis. 


Choroidal Lymphoid Neoplasia: Association With Systemic 

Lymphoma 

Presenting Author: Shripaad Y Shukla MD 

Co-Author(s): Arman Mashayekhi MD, Jerry A Shields MD, Carol L Shields MD 

Purpose: To determine the association of choroidal lymphoid neoplasia (CLN) with systemic 

lymphoma. Methods: Noncomparative series of 68 eyes of 55 patients. Results: 

Twelve patients (22%) had systemic non-Hodgkins lymphoma (SNHL) at presentation. Over 

a mean follow-up of 19 months, 3 additional patients (5%) developed SNHL. All SNHLs 

were low-grade, except 3 patients that had aggressive types (2 with diffuse large B-cell 

lymphoma and 1 with plasmablastic lymphoma). All 3 cases of aggressive SNHL were 

associated with aggressive types of CLN and required enucleation for management. Conclusion: 

Most SNHLs associated with CLN were low-grade, but 5% were aggressive. 

CLN associated with aggressive systemic NHL had a poor prognosis. 


APAO Novel Immunophenotypic Profiles for Distinguishing 

Orbital MALT Lymphoma From Benign Orbital 

Lymphoproliferative Tumors 

Presenting Author: Yoshihiko Usui MD 

Co-Author(s): Shunichiro Ueda MD, Hiroshi Goto MD 

Purpose: To evaluate the immunophenotypic profiles of orbital lymphoproliferative tumors 

as an aid in distinguishing orbital mucosa-associated lymphoid tissue lymphoma 

(MALT) from benign tumors such as IgG4-related lymphoproliferative disease (IgG4) or reactive 

lymphoid hyperplasia (RLH). Methods: The immunophenotypic profiles of 40 orbital 

tumors comprising MALT (n = 20), IgG4 (n = 14), and RLH (n = 6) were analyzed.Results: 

Expression of CD25 was higher in patients with MALT compared to IgG4 or RLH (P < .001). 

In contrast, expression of CD23 was higher in patients with orbital IgG4 or RLH compared 

to MALT (P < .001). Conclusion: These results demonstrate the applicability of CD23 and 

CD25 as useful markers in distinguishing MALT from IgG4 or RLH. 

Session Two 





H Hemodynamic Modeling of Super Selective 

Intraophthalmic Artery Chemotherapy for the Treatment of 

Retinoblastoma 

Presenting Author: Lauren C Ditta MD 

Co-Author(s): Eric Chin MD, Asim F Choudhri MD**, Matthew W Wilson MD 

Purpose: Super selective intraophthalmic artery chemotherapy (SSIOAC) is currently being 

used to treat retinoblastoma. We performed computer modeling of ophthalmic artery 

(OA) flow to determine the impact of cannulation. Methods: MATLAB computer simulation 

of flow was created with input functions as OA diameter, endovascular catheter 

diameter, distance of catheter tip from ostium, mean arterial pressure, and central venous 

pressure. Results: OA flow decreases with degree of cannulation in a nonlinear manner. 

A 1.5 French microcatheter reduces flow by 15%-30% when the catheter tip is between 

2 mm and 4 mm from OA ostium, independent from displacement by infusant. Conclusion: 

SSIOAC has potential to significantly impair OA blood flow due to luminal occlusion. 


Indocyanine Green-Enhanced Transpupillary Thermotherapy 

for Retinoblastoma 

Presenting Author: Jasmine H Francis MD 

Co-Author(s): Brian P Marr MD, Scott Brodie MD PhD, David Abramson MD FACS 

Purpose: To review the experience in the use of indocyanine green (ICG)-guided transpupillary 

thermotherapy (TTT) in retinoblastomas so thick or devoid of pigment that TTT alone 

is usually ineffective. Methods: Retrospective single-center experience; retinoblastoma 

patients treated with TTT via indirect ophthalmoscope: 22 treatments of 16 eyes, with 

a mean follow-up of 12.1 months (range: 3-35 months). Results: Treatment resulted in 

significant tumor regression, with a mean reduction in apical height of 2.9 mm (± 2.3 mm, 

P = .02) in those measurable by ultrasonography. Conclusion: ICG-enhanced TTT can 

effectively treat retinoblastoma devoid of pigment and too thick for standard TTT alone. 


Clinical and Ultrasound Biomicroscopy Features Associated 

With Growth in Iris Melanocytic Lesions 

Presenting Author: Gian P Giuliari MD 

Co-Author(s): Hatem A Krema MBBS**, Hugh D McGowan MD, Charles J Pavlin MD 

FRCS, E Rand Simpson MD** 

Purpose: To determine the clinical and ultrasound biomicroscopic (UBM) features associated 

with growth in iris melanocytic lesions (IML). Methods: Clinical features such as iris 

color, largest base diameter (LBD), radial location, pigmentation, intrinsic vascularity, and 

the impact on the pupil were analyzed. UBM features included thickness, surface plaque, 

internal structure, and internal reflectivity. Results: Twenty-three percent of the 44 IML 

included showed growth. Clinical features associated with growth were a large LBD at 

baseline and an inferior location of the lesion. UBM features associated with growth were 

a greater thickness and an irregular internal structure. Conclusion: Presence of these 

features should alert the physician to a possibly more aggressive course that would require 

closer monitoring. 


Ocular Adnexal Lymphoma Staging and Treatment: 

American Joint Committee on Cancer vs. Ann Arbor 

Presenting Author: Gerardo F Graue-Moreno MD 

Co-Author(s): Paul Finger MD*, Tatyana Milman MD, Elizabeth A Maher MD, David A 

Della Rocca MD, Robert C Della Rocca MD, Gary J Lelli MD 

Purpose: To evaluate the prognostic utility of the American Joint Committee on Cancer 

(AJCC) staging system for Ocular Adnexal Lymphoma (OAL). Methods: Retrospective observational 

case series of 83 patients. Results: Ann Arbor clinical stages were IE (76%), 

IIE (17%), and IIIE (7%). Pathology upstaged 13 to IV. AJCC clinical stages were cT1NOMO 

(21.7%), cT2NOMO (44.6%), cT3N0M0 (5%), and cT4NOMO (2.4%). Local control was 

achieved in 75% of treated patients. There were 19 local recurrences, 14 belonging to 

nonradiation treatment groups. Lower-risk groups had longer disease-free survival than 

higher-risk groups. Overall mean follow-up was 43.3 months. Conclusion: Recurrence 

and disease-free survival were related to treatment and histopathology rather than tumor 

size or site-specific location. 


H Prediction of High-risk Retinoblastoma Based on 

International Classification of Retinoblastoma 

Presenting Author: Swathi Kaliki MD 

Co-Author(s): Duangnate Rojanaporn MD, Saad Abdullah Al-Dahmash MBBS, Ralph 

Eagle MD*, Carol L Shields MD 

Purpose: To determine the correlation of International Classification of Retinoblastoma 

(ICRB) and histopathologic high-risk retinoblastoma (RB). Methods: Retrospective study. 

Results: Of 519 primarily enucleated eyes, 17% were group D and 83% were group E 

eyes based on ICRB. High-risk RB was identified in 23% of enucleated eyes, including 

17% of group D and 24% of group E. On logistic regression analysis, massive posterior 

uveal invasion > 3 mm was more common in group D eyes (P = .0442), and postlaminar 

optic nerve invasion was more common in group E eyes (P = .0390). Conclusion: The 

International Classification of Retinoblastoma can predict high-risk retinoblastoma. In this 

study, high-risk retinoblastoma was noted in 17% of group D and 24% of group E eyes. 


H Histopathology of Streptococcal Endophthalmitis 

Following Intravitreal Injection of Bevacizumab: A Series of 

Seven Cases 

Presenting Author: Jared Matthews MD 

Co-Author(s): Sander Dubovy MD, Roger A Goldberg MD, Harry W Flynn MD* 

Purpose: To report the histopathologic findings from an outbreak of streptococcal endophthalmitis 

after intravitreal injection of bevacizumab from a single compounding pharmacy. 

Methods: Retrospective review of medical records and histopathologic specimens. 

Results: Seven of 12 cases of S. mitis/oralis endophthalmitis resulted in globe loss via 

enucleation (5) or evisceration (2). All globes displayed retinal detachment, cyclitic membrane 

formation, rubeosis iridis, and secondary angle closure. All specimens displayed 

212 





choroidal inflammation, and 6 of 7 had foci of retinal necrosis. Conclusion: Streptococcal 

endophthalmitis is a devastating complication of intravitreal bevacizumab associated with 

severe pathologic tissue changes and a high rate of globe loss. 

Ophthalmic History 

Session Two 





APAO DA VINCI Code 

Presenting Author: Somen Ghosh MBBS 

Co-Author(s): R K Ghosh 

Leonardo Da Vinci was one of the greatest inventor-scientists of recorded history. His 

genius was unbounded by time and technology. His works in ophthalmology have been 

colossus, a fact which mostly was not appreciated during his era and thus was lost to 

history. My researches of his notebook have revealed his immense contribution to ophthalmology. 

To name a few: He was the first to compare the eye with a pin-hole camera 

(camera obscura); he invented a new embedding technique to dissect the eye without 

spilling its contents; stereopsis; accommodation; correction of presbyopia; the optic pathway; 

pupillary reflex; night vision; the contact lens3/4and the list goes on. This poster is 

a humble attempt to give our tribute to the maestro, maybe the Greatest (FORGOTTEN) 

contributor in ophthalmology. 


H Ophthalmic Procedures in the Early Ottoman Period 

Presenting Author: Halit Oguz MD 

In 1465 Serefeddin Sabuncuoglu wrote a book entitled Cerrahiyyetü’ l-Haniyye, which 

means “Imperial Surgery. The book consists of all the fields of surgery, including ophthalmology. 

Cerrahiyyetü’ l-Haniyye is concerned with the ophthalmologic procedures that 

were studied at the time. Treatment methods are mentioned in the text, with previous 

distinguished scientists. Sabuncuoglu himself illustrated in colored miniatures nearly all 

of the surgical procedures and instruments pictured in the book. He combined Greek, Roman, 

Arabic, and Turkish surgery and influenced the development of European surgery. A 

number of Sabuncuoglu’s procedures regarding the eye are still compatible with modern 

ophthalmology. The fine natures of the instruments that are illustrated in the ophthalmologic 

sections of this book are remarkable. 


Session One 



on Sunday, Nov. 11, from 12:30 PM to 2:00 PM 


Orientation of Astigmatism in the Refractive Surgery 

Population 

Presenting Author: Louis Probst MD* 

Co-Author(s): Jack T Holladay MD MSEE FACS* 

Purpose: To evaluate astigmatism in the refractive surgery population. Methods: A 

retrospective analysis of 183,917 evaluations performed at a corporate LASIK provider 

between 2000 and 2009. Results: As the spherical equivalent (SE) myopia increased from 

-1 D to -10 D, the amount of astigmatism increased for with-the-rule (WTR) and oblique 

(0.42 to 1.29 D, 0.79 to 1.08 D, respectively) and percentage orientation of the astigmatism 

increased for WTR (29.7% to 55.1%) and decreased for against-the-rule (ATR) (44.7% to 

12.7%). As the magnitude of the astigmatism increased from 1 to 5 D, the percentage of 

WTR almost doubled, while ATR and oblique astigmatism decreased (37% to 66%, 21% 

to 12%, 42% to 23%, respectively). Conclusion: WTR and oblique astigmatism increased 

with increasing myopia. WTR astigmatism increased with increasing astigmatism. 


H Myopia and Level of Education 

Presenting Author: Alireza Mirshahi MD* 

Co-Author(s): Katharina A Ponto MD, Rene Hoehn MD, Isabella Zwiener PhD**, 

Dagmar Laubert-Reh PhD, Norbert Pfeiffer MD 

Purpose: To assess the association between myopia and education level. Methods: We 

analyzed refractive data and levels of school and vocational training of 5000 Caucasian 

participants in a population-based study. Results: Myopia (mean ±SD of spherical equivalent 

[SE]) was higher and more prevalent in individuals having left school after 13 years 

(-1.08 ± 2.5; 60.3% SE ≤-0.13 and 19.2% SE ≤ -3) than those who left after 9 years (0.24 

± 2.3, 37.5% ≤ -0.13 and 6.7% ≤ -3; P < .001, respectively). The same applies to university 

graduates (-1.19 ± 2.6; 61.9% ≤ -0.13 and 20.6% ≤ -3) vs. secondary (-0.34 ± 2.3; 45.7% 

≤ -0.13 and 11.3% ≤ -3) and primary vocational school degree holders (0.16 ± 2.5; 46.4% 

≤ -0.13 and 9.9% ≤ -3), P < .001, respectively. Conclusion: Prevalence and magnitude of 

myopia increase with the levels of school and vocational education. 


H Perceptual Training on Mobile Devices Is Effective for 

Overcoming the Effects of Aging on the Human Eye 

Presenting Author: Tova Ma-Naim MD 

Co-Author(s): Oren Yehezkel MS, Anna Sterkin PhD, Maria Lev MS**, Uri Polat PHD* 

Purpose: In presbyopia, uncorrected near visual acuity (UCNVA) results in blurred image. 

We showed that perceptual training (on PC, 30 min/session) improved the UCNVA 

(81%, 2.57 ETDRS lines) and enabled glasses-free reading without optical changes. Here 

we tested the training efficacy on mobile devices (Mob). Methods: Two groups (young, 

presbyopes) were trained on Mob (iPhone, etc.) from a distance of 40 cm (only 15 min/session, 

3 times/week). Results: The improvement of the UCNVA of presbyopes on Mob was 

similar to the results on PC (P > .05), whereas their contrast sensitivity was better on Mob 

(P < .01). Conclusion: Perceptual training on Mob is an effective solution for improving 

near vision in presbyopia by enhancing image processing in the brain. 

Session Two 





APAO Spatial Resolution to Moving Optotypes as a Sensitive 

Parameter to Functional Outcome After Cataract Surgery 

Presenting Author: Mingxin Ao MBCB 

Co-Author(s): Wei Wang MD, Xuemin Li MD PhD**, Zhiqiang Hou MD**, Chen Huang 

MD** 

Purpose: Complete evaluation of functional vision after cataract surgery demands assessment 

of resolution to moving targets. Methods: Postoperative resolution to moving 

targets might increase more obviously. Binocular visual acuity to static and moving optotypes 

at 4 speed levels was tested before and 1 month after surgery in 21 senile cataract 

patients. Results: Increment of visual acuity was 0.274 ± 0.207 at a speed of 15 degrees 

per second (dps), 0.330 ± 0.204 at 30 dps, 0.408 ± 0.190 at 60 dps, and 0.414 ± 0.172 at 90 

dps, all significantly higher than 0.164 ± 0.241 under static conditions (P ≤ .003). Conclusion: 

Postoperative outcome in terms of resolution to moving optotypes was more obvious 

in senile cataract patients. 


APAO The Reproducibility of Optical Quality Parameters 

Measured at Objective and Subjective Best Focuses in a 

Double-Pass System 

Presenting Author: Liya Qiao OCS 

Co-Author(s): Ye Zhang MD**, Xiao gu Cai Sr MD, Jiaxuan Tan**, Lei Li**, Xiuhua Wan 

MD PhD**, Ning Li Wang MD 

Purpose: To evaluate repeatability and reproducibility of Optical Quality Analysis System 

(OQAS) parameters measured at objective and subjective best focuses. Methods: 

Thirty randomizing eyes of 30 subjects were enrolled. Three consecutive measurements 

were made at objective and subjective best focus respectively. MTFcutoff, Strehl2D ratio, 

OV100%, 20%, 9%, and objective scatter index (OSI) were analyzed. Results: The PLs and 

CORs of 2 conditions were 8.4%~15.1% and 10.8%~16.3%, 8.3%~14.8%, and 10.6%~ 





213



15.9%. ICC and Bland-Altman plots showed a poor agreement of 2 conditions. Conclusion: 

Measurements provided by OQAS with either method showed a good repeatability. 

It might be best to use the best focus as chosen automatically by the instrument. 


Session One 





Nontuberculous Mycobacterial Infection as a Cause of 

Chronic Socket Discharge and Orbital Implant Exposure 

Presenting Author: Waleed A Al Rashed 

Co-Author(s): Imtiaz Chaudhry MD PhD, Hind M Alkatan MBBS**, Osama H Al-Sheikh 

MD, Yonca O Arat MD** 

Purpose: To report nontuberculous mycobacterial (NTM) infection as the cause of anophthalmic 

socket complications. Methods: A noncomparative, interventional, retrospective 

case series of 20 patients with NTM-caused socket infection studied over a 2-year 

period for their complications. Results: Among the 20 patients (12 male; average age, 

42.2 years), all had chronic discharge from their sockets, and despite therapy, 12 showed 

evidence of orbital implant exposures. Presence of NTM was confirmed by culture results. 

All patients required treatment with antibiotics, and 10 required surgical intervention in 

the form of implant removal, exchange, or dermis fat graft. Conclusion: NTM infection 

should be considered in patients with chronic discharge and exposed/extruded orbital 

implants. 


Orbital Exenteration Under Local Anesthesia in Patients 

With Significant Contraindications for General Anesthesia 

Presenting Author: Imtiaz Chaudhry MD PhD 

Co-Author(s): Massa Mateger MD, Abdul-Zahoor Khan MD, Nauman Ahmad MD, 

Osama H Al-Sheikh MD, Ayman Al-Ayoubi MD**, Waleed A Al Rashed, Yonca O Arat 

MD**, Milton Boniuk MD** 

Purpose: To report our experience with orbital exenteration (OE) for periocular malignant 

tumors under local anesthesia (LA). Methods: Over a 2-year period, 12 patients (8 male; 

average age, 77.6 years (range: 57 to 95) with significant medical conditions contraindicated 

for general anesthesia underwent OE for malignant tumors under local anesthesia 

(LA) at King Khaled Eye Specialist Hospital. Results: Average surgical time, 113 minutes 

(range: 50 to 300), estimated blood loss, 256 ml (range: 50 to 1200), and the amount of 

LA used was 15.6 ml (range: 6.5 to 24). All patients tolerated the procedure well and 

recovered completely from their surgery. Conclusion: Orbital exenteration can be accomplished 

safely under LA in patients with significant cardiac or medical risks contraindicated 

for general anesthesia. 


H The Use of Hyaluronic Acid Gel Plugs in the Treatment 

of Dry Eyes 

Presenting Author: John P Fezza MD* 

Purpose: There are potential complications from current punctal plugs such as extrusion, 

rubbing, submersion, or infection. Hyaluronic acid (HA) is a natural component in 

our bodies and is present in the tear film, joints, and skin. A new HA gel canalicular plug 

was assessed for dry eye therapy. Methods: IRB approval was achieved to place the 

HA plug in the canaliculus of 80 patients. The gel plug is inserted into the canaliculus 

with syringe and lacrimal irrigator. Patients were followed for 6 months. Results: The HA 

plug was easy to insert, and a majority of patients had a significant improvement in dry 

eye symptoms. Slitlamp confirmed improvement of corneal lubrication, and Schirmer tests 

demonstrated improved wetness. No complications were noted. Conclusion: This HA 

plug appears to be a new, safe, and effective method to treat dry eyes. 


APAO The Impact of Levator Aponeurosis Advancement on 

Spontaneous Blinks and Tear Volume in Blepharoptosis 

Presenting Author: Akihide Watanabe MD 

Co-Author(s): Naoko Kimura MD, Norihiko Yokoi MD PhD*, Shigeru Kinoshita MD* 

Purpose: To investigate the impact of blepharoptosis surgery on spontaneous blinks and 

tear volume. Methods: Twenty-five sides of 17 patients underwent levator aponeurosis 

advancement, and we examined pre- and 1.5-month postoperative spontaneous blinks by 

an intelligent vision system camera and assessed tear volume by measuring the tear meniscus 

radius (R) by meniscometry. Results: Postoperative up- and down-phase upper lid 

movement distance and up-phase maximum velocities were statistically superior. Mean 

preoperative R (0.26 mm) was significantly decreased (0.19). Higher R with longer upper 

lid down-phase movement distance tended to decrease. Conclusion: Blepharoptosis surgery 

affects spontaneous blinks, thus changing tear volume. 


Persistence of Enophthalmos and Diplopia After 

Transconjunctival vs. Endonasal Repair of Orbital Blowout 

Fractures 

Presenting Author: Hajirah N Saeed MD 

Co-Author(s): Shivani S Kamat MD, Bruce I Gaynes OD PHARMD**, Geeta N Belsare 

MD 

Purpose: To compare the postoperative persistence of enophthalmos and diplopia 

in transconjunctival (TC) vs. endonasal (EN) repairs of orbital blowout fractures (OBF). 

Methods: Meta-analysis of 13 retrospective studies describing postoperative diplopia or 

enophthalmos following EN or TC repair. Results: The odds of persistent enophthalmos 

were 0.162 and 0.189 for TC and EN repairs, respectively. The difference between the 2 

approaches was not statistically significant (Fisher exact test, P = .795). However, the odds 

of persistent diplopia were 0.052 and 0.169 for TC and EN repairs, respectively, and was 

statistically significant (P = .005). Conclusion: Transconjunctival repair of OBF appears 

to result in statistically significant reduced odds of persistent diplopia as compared to 

endonasal repair. 


Is Orbital Decompression in Thyroid Orbitopathy 

Predictable? Experience With 154 Orbits 

Presenting Author: Barbara Berasategui Fernandez MD 

Co-Author(s): Roberto F Hermida MD PhD, miriam duque MD**, Ana Orive DOMS, 

Begona Arana MBCB CMPE, Nerea Martinez Alday MD 

Purpose: To examine the asymmetry of exophthalmos before and after orbital decompression 

(OD) and its influence on the onset of consecutive diplopia in Graves orbitopathy 

(GO). Methods: A retrospective case series of 92 patients and 154 orbits that underwent 

OD for GO between January 1999 and March 2012. Results: The average preoperative 

asymmetry was 1.91 mm (0-8 mm), and 0.66 mm (0-2 mm) postoperatively. The mean 

exophthalmos reduction was 2.38 mm per wall. Only 2 patients (2.2%) suffered from new 

onset primary-gaze diplopia. One resolved spontaneously. Conclusion: OD developed by 

a skilled surgeon is a reliable and reproducible technique to correct exophthalmos caused 

by thyroid eye disease, with good symmetric results. 


Lid Contour Abnormalities After Graves Upper Eyelid 

Retraction Surgery 

Presenting Author: Sara Filipa Teixeira Ribeiro MD 

Co-Author(s): Gherusa Helena Milbratz, Denny Marcos Garcia MD**, Martin H Devoto 

MD, Guilherme Herzog Neto , Ricardo Morschbacher MD, Filipe Jose Pereira**, 

Antonio A V Cruz MD PhD 

Purpose: To analyze mathematically the upper eyelid contour abnormalities of Graves 

patients who had undergone lid surgery for retraction correction. Methods: The pre- and 

postoperative upper lid contour of 62 eyes of 43 patients was quantified with a custommade 

software which measured multiple midpupil lid distances (MPLDs) in the temporal 

and nasal sectors of the palpebral fissure. Results: The mean ratio between the temporal 

and nasal MPLDs of the lids with postoperative good contour was 1.10. Lids were found to 

be unpleasant when there was a marked deviation of this pattern, usually due to a central 

or medial overcorrection. Conclusion: Postoperative surgical contour abnormality can be 

objectively measured by comparing the temporal and nasal MPLDs. 

214 






Alleviating Pain in Oculoplastic Procedures by Reducing 

the Rate of Injection of Local Anesthetic 

Presenting Author: Aditi Gupta MBBS 

Co-Author(s): Paul J Tomlins MBChB, Tristan T Reuser MD 

Purpose: To investigate whether rate of infiltration of local anesthetic influences pain or 

efficacy of local anesthesia in oculoplastic surgery. Methods: Prospective observational 

study. An observer recorded the rate of injection of local anesthetic during each procedure. 

Patients rated pain of both injection and surgery using a visual analog score scale (VAS). 

Chi-square was used to test for significance. Results: Fifty-seven consecutive patients 

were observed. Statistically significant correlation was found between rate of injection 

and VAS score from both injection (P < .0001) and procedure (P = .0014). Significant correlation 

was found between injection VAS score and procedure VAS score (P < .0001). 

Conclusion: Slowing the rate of injection is an effective way of alleviating pain. 


Sinus Mucoceles: Is Endoscopic Sinus Surgery Enough? 

Presenting Author: Ami Ashvin Shah MD 

Co-Author(s): Mark R Melson MD 

Purpose: To clarify the surgical role of the ophthalmologist, determine whether primary 

orbital reconstruction is advantageous, and review the surgical outcomes of endoscopic 

sinus surgery (ESS) on patients with intraorbital extension (IOE) from sinus mucoceles. 

Methods: Retrospective review of all adults found with mucocele IOE from January 2000 

to January 2011. Results: Ten patients underwent operative repair to address mucoceles 

with IOE. Four patients had combined ESS and orbitotomy; 1 required primary orbital reconstruction; 

4 recurred. Conclusion: Mucoceles recur more often than currently quoted 

in the literature, and this has specific implications on patient expectations and surgical 

outcomes. Orbital reconstruction may be delayed in most cases. Orbital surgeons should 

be readily available for the operating room. 


H Risk of Ocular Blood Splatter During Oculoplastic 

Surgery 

Presenting Author: Andrew W Stacey MD 

Co-Author(s): Craig N Czyz DO, Srinivas Sai Kondapalli MD, Robert H Hill MD**, Kelly R 

Everman MD, Kenneth V Cahill MD FACS, Jill Annette Foster MD FACS* 

Purpose: To assess intraoperative blood splatter to ocular surface and adnexa. Methods: 

Five surgeons and multiple assistants wore 183 eye shields during 72 surgeries. Postoperatively, 

a luminol blood detection system was used to identify blood splatter. Results: 

Blood was detected on 55% of eye shields. Surgeons (59%) were splattered more often 

than resident/fellows (55%) and scrubs (51%). Shields worn during orbitotomy were most 

likely to be splattered (82%). Surgeon ability was “negatively affected” by shields in 42% 

of cases. Conclusion: Mucocutaneous transmission of HIV and hepatitis has been documented 

in the literature. These results suggest that oculoplastic surgeons should consider 

eye protection with patients having known blood-borne disease. 


Methicillin Resistant Staphylococcus Aureus Orbital 

Cellulitis Less Likely Associated With Sinusitis 

Presenting Author: Daniel G Straka MD 

Co-Author(s): Ami Ashvin Shah MD, Ruth Hill Yeilding MD, Chun Li PhD, Louise A 

Mawn MD* 

Purpose: To determine if sinusitis is associated with MRSA orbital cellulitis. Methods: 

Retrospective review of 274 children presenting from July 1, 1999, to June 30, 2009, with 

orbital or preseptal cellulitis. Results: 101 cases of pediatric orbital cellulitis were identified. 

Thirty-four patients had pathogens identified; 28 of these were non-MRSA infections. 

All of the non-MRSA infections had traditional historical features such as sinus disease 

(26) or trauma (2). One of the 6 MRSA infections was associated with sinusitis; however, 

the abscess was not (P < .000022). Conclusion: Results suggest the absence of adjacent 

sinusitis in a child with orbital cellulitis should alert the ophthalmologist to the possibility 

of MRSA. 


H Acute Idiopathic Orbital Inflammation: A Superantigen 

Response? 

Presenting Author: Omaya H Youssef MD 

Co-Author(s): Derron Alves DVM**, Teresa Krakauer PhD 

Purpose: To identify whether the bacterial superantigen (SAg) Staphylococcus aureus 

toxic shock syndrome toxin-1 (TSST-1) produces clinical and histopathological features 

of acute idiopathic orbital inflammation (IOI). Methods: New Zealand white rabbits received 

TSST-1 or lipopolysaccharide (LPS) injections in specific orbital tissues. Results: 

Gross orbital inflammation was present in all rabbits. Histologically, the tissue response 

in TSST-1 was primarily lymphocytic with fewer neutrophils. The LPS-induced inflammatory 

response was composed of neutrophils with fewer lymphocytes, plasma cells, and 

macrophages. Conclusion: TSST-1 and LPS produced clinically observable orbital inflammation, 

but only S aureus SAg TSST-1 produced histolopathologic features seen in the 

acute stage of IOI. 

Session Two 





Comparison of Long-term Outcomes in 1185 Hydroxyapatite 

Orbital Implants Based on Wrap or Coating 

Presenting Author: Sanket Shah MD 

Co-Author(s): Arthur Au MD**, Noel Perez Soto MD, Masood Naseripour MD**, Raza 

M Shah MD, Sara E Lally MD, Carol L Shields MD 

Purpose: To compare hydroxyapatite orbital implants (HOI) based on wrap or coating. 

Methods: Retrospective study of 1185 unpegged HOIs over 20 years. Results: Three 

groups included A: uncoated unwrapped (7%), B: uncoated sclera-wrapped (63%) and C: 

polymer coated unwrapped (30%). Mean follow-up was 46 months. Rates of exposure 

(1%), conjunctival thinning (< 1%) and infection (< 1%) were similar in the 3 groups. Ptosis 

(P < .001), superior sulcus defect (P < .001), and conjunctival cyst (P = .002) were more 

frequent in Group A. Large angle prosthesis motility was better (P < .001) in Group B. 

Conclusion: Rates of most outcomes in HOIs are independent of wrap or coating. 


APAO 18-gauge Needle: A Simple, Inexpensive Tool for 

Frontalis Surgery 

Presenting Author: Shubhra Goel MD 

Co-Author(s): Cat Burkat MD 

Purpose: To introduce the 18-gauge hypodermic needle as a tool in frontalis sling surgery. 

Methods: Case series: 64 patients (82 sides) with poor levator function congenital ptosis 

underwent frontalis closed-incision pentagon surgery with silicone rod inserted via 1.5- 

inch 18-gauge needle guide. Results: Fifty-six of 64 patients (88%) were age 1-18 years. 

Seventy-two percent had unilateral surgery. In 2.4%, the sharp needle tip cut the silicone 

during passage. Surgical time was 15 mins. for unilateral (30 mins = bilateral) cases. Main 

advantages: small incisions allowed for less operative time/bleeding, easy maneuverability 

and needle control during tissue passage, smooth threading of the silicone, and large 

decrease in material cost. Conclusion: The 18-gauge needle is a simple, cost-effective 

alternative needle for frontalis surgery, particularly useful in large medical eye camps. 


APAO Evaluation of Different Suspensory Materials in 

Frontalis Suspension for Congenital Ptosis 

Presenting Author: Kengo Hayashi MD PHD 

Co-Author(s): Nobutada Katori MD, Ken-ichiro Kasai MD**, Taro Kamisasanuki MD 

Purpose: To compare nylon suture with polytetrafluoroethylene (PTFE: Gore-tex) sheet 

that was used in frontalis suspension for correction of congenital ptosis. Methods: The 

medical records of patients with a minimum follow-up of 1 year after the surgery were 

retrospectively examined. Results: Eighteen eyelids of 26 patients with nylon, and 34 

eyelids of 33 patients with PTFE were evaluated. The recurrence rate was 73% in nylon, 

3% in PTFE (P < .001). There were no complications using nylon. Infection and granuloma 

formation occurred in 6% using PTFE. Conclusion: PTFE sheet significantly achieved a 

lower percentage of recurrence than nylon suture. 





215




APAO The Effect of Applying Temperature-Sensitive Guardix 

SG With Adhesiolysis in Experimentally Induced Lid 

Adhesion in Rabbits 

Presenting Author: Hye Mi Jung MD 

Co-Author(s): Hee Bae Ahn MD PhD, Hong Ryung Seo MD 

Purpose: To evaluate the effect of Guardix SG following adhesiolysis for preventing postoperative 

adhesion. Methods: The rabbits were categorized into 2 groups: adhesiolysis 

alone in left eyelids (Control Group) and adhesiolysis with Guardix SG in right eyelids 

(Guardix SG Group). The experimental lid adhesion was achieved by blepharoplasty with 

NaOH. Then adhesiolysis was done with or without Guardix SG. The degree of adhesion 

was evaluated microscopically. Results: Within 2 weeks after surgery, the shape of the 

eyelids had recovered completely in both groups. The Guardix SG Group showed less inflammation 

and fibrosis than the Control Group, microscopically. Conclusion: Guardix SG 

is an effective adjunctive method for reducing postoperative adhesion. 


APAO Classification and Surgical Outcome of Asian 

Blepharoptosis 

Presenting Author: Byeong Jae Son MD 

Co-Author(s): Young Ji Lee MD, Chang Yeom Kim MD, Jin S Yoon MD, Sae Heun Rho 

MD, Sang Y Lee MD 

Purpose: To classify blepharoptosis in Asian patients and investigate the type and outcome 

of surgery used. Methods: A total of 1930 patients who underwent surgery for 

blepharoptosis from 1991 to 2011 were investigated. Results: 1449 patients (75%) were 

congenital type, and 1580 (81.9%) were myogenic. 55.2% of eyes underwent frontalis 

suspension. 57.2% of congenital type were poor levator function, and 9.8% of acquired 

type. The incidences of poor surgical outcome in congenital type (17.8%), neurogenic type 

(31.2%), and frontalis suspension (17.7%) were higher than the others (P < .05). Conclusion: 

In this study, some values were different from Western studies. This is probably due 

to difference of anatomical structure and the influence of socioeconomic levels. 


Crossed Lateral Tarsal Strip: A Modified Technique for 

Paralytic Ectropion 


Purpose: To present a technique that combines properties of lateral tarsal strip (lid shortening) 

to those of tarsorrhaphy (lasting lift) for the treatment of paralytic ectropion. Methods: 

Sixty patients (noncomparative case series) were operated on with a combination of 

tarsorrhaphy and strip: a tarsal strip shortens margin and gives temporary lateral static 

lift, whereas a minitarsorrhaphy transfers dynamic upper lid lift. Mean follow-up was 60 

months. Results: Outcomes were “excellent” in 56 patients (93.3%), “good” in 2 patients 

(3.3%), and 2 failed (3.3%) (P < .0001). Complications were 1 suture granuloma and 1 fistula 

at lateral canthus. Conclusion: Crossed lateral tarsal strip offers lid shortening, lasting 

dynamic lift, and intact lateral canthal tendon, which should be respected as irreplaceable. 


Mandible Fractures in Oculofacial Plastic Trauma: A Case 

Series of Type and Management 

Presenting Author: Mithra O Gonzalez MD 

Co-Author(s): Brian J Willoughby MD** 

Purpose: To present mandible fractures primarily managed by an oculofacial plastics service. 

Methods: Retrospective consecutive case series. Results: Twenty-five mandible 

fractures were identified. Mechanism of injury included intentional violence, falls, motor 

vehicle accidents, sporting accidents, and other. Types of fractures encountered include 

symphysis, ramus, condylar, angle, dentoalveolar, and body. Concurrent orbital fractures 

were seen in 12% of patients. Management included open reduction internal fixation, 

maxillomandibular fixation (MMF)/functioning stabilization, open-reduction and rigid internal 

fixation (ORIF) + MMF. A total of 8% had complications that required additional 

surgery. Conclusion: This case series demonstrates that mandible fractures may be successfully 

managed primarily by oculofacial plastic surgeons. 


APAO Histopathologic Findings of Unilateral Idiopathic 

Persistent Eyelid Swelling 

Presenting Author: Junghoon Kim MD 

Co-Author(s): Yeon-lim Suh MD PhD**, Yoon-Duck Kim MD, Kyung In Woo MD 

Purpose: To evaluate histopathologic properties in persistent upper eyelid swelling. 

Methods: This is a retrospective study of 6 patients (6 males; mean age: 50.8 years) with 

unilateral idiopathic eyelid swelling who did not respond to steroid. In a control group, the 

specimens were collected from 5 patients with dermatochalasis. They were examined 

with light microscopy, immunohistochemistry with lymphatic marker D2-40. Results: The 

specimens of eyelid swelling showed increased lymphatic density (lymphatics/100x field), 

angulation, aggregation, and papillary projection of lymphatics (P < .05). Conclusion: 

Abnormal configuration of lymphatics in unilateral eyelid swelling patients implies that 

changes in lymphatics remain the primary predisposition of unilateral persistent eyelid 

swelling. 


APAO Imaging Analysis of Orbital Cavernous Hemangioma 

Presenting Author: Jung Hye Lee MD 

Co-Author(s): Yoon-Duck Kim MD, Kyung In Woo MD 

Purpose: To describe radiologic features of orbital cavernous hemangioma (CH) on contrast 

CT/Gd-enhanced MRI. Methods: Retrospective review of CT/MRI findings in 66 

patients diagnosed as CH. Results: CT showed late inhomogenous contrast filling (85%), 

started from one, small point (58%) in early phase. On MRI, enhancement started from 

multiple (92%), patchy (96%) areas, and progressed to late homogenous filling (50%). Two 

cases with rapid blood circulation revealed early diffuse enhancement on MRI, whereas 

they showed early focal enhancement on CT. Conclusion: Progressive contrast filling is 

a pathognomonic sign of CH. However, its hemodynamic difference results in variable enhancement 

pattern. Since time consumption of CT scan is shorter than MRI, CT can detect 

typical progressive filling of CH with rapid blood flow from an earlier phase. 


APAO Neoadjuvant Chemotherapy in Advanced Sebaceous 

Gland Carcinoma 

Presenting Author: Fairooz Puthiyapurayil Manjandavida MBBS 

Co-Author(s): Santosh G Honavar MD, Milind N Naik MBBS**, Mohammad Javed Ali 

MD, Vijay Anand P Reddy MD 

Purpose: To present outcome in advanced sebaceous gland carcinoma (SGC) following 

neoadjuvant chemotherapy. Methods: Consecutive case series including 13 patients with 

advanced SGC. Results: Four were diffuse but preseptal, while 9 had orbital invasion; 3 

had regional lymph node metastasis. TNM staging was T3a N0 M0 in 3, T3a N1 M0 in 4, 

and T3b N1 M0 in 6. Neoadjuvant chemotherapy (cisplatin + 5-fluorouracil) was followed 

by surgery in all (local tumor excision in 7, orbital exenteration in 6), radical neck dissection 

in 3, and external beam radiotherapy in 7. At a median follow-up of 18 months (range: 15- 

60), none had local or regional tumor recurrence, while 2 developed systemic metastasis. 

Conclusion: Neoadjuvant chemotherapy in advanced sebaceous gland carcinoma can 

augment local-regional tumor control and reduce the risk of systemic metastasis. 


The Value of Optic Nerve Sheath Biopsy at the Time of 

Fenestration 

Presenting Author: Rachel K Sobel MD 

Co-Author(s): Nasreen A Syed MD, Keith D Carter MD FACS, Richard C Allen MD PhD 

Purpose: To investigate the findings of optic nerve sheath biopsy at the time of fenestration. 

Methods: A retrospective review was performed of patients who had optic 

nerve sheath fenestrations at a tertiary care center from 1998 to 2011. Results: Sixtythree 

patients underwent fenestration, for a total of 75 biopsies. Forty-nine patients were 

diagnosed with idiopathic intracranial hypertension (IIH) preoperatively. The rest carried 

other diagnoses. There was no unexpected diagnostic abnormality found on any biopsy. 

Conclusion: Optic nerve sheath biopsy has limited diagnostic value. In the absence of 

any evidence to suggest a diagnosis other than IIH, the usefulness of biopsy during fenestration 

is low. This has implications for preferred surgical approach. 

216 






Session One 



on Sunday, Nov. 11, from 11:00 AM to 12:30 PM. 


APAO Macular and Nerve Fiber Layer Thickness in 

Deprivational Amblyopia 

Presenting Author: Yong-Woo Kim MD 

Co-Author(s): Seong-Joon Kim MD PHD**, Young Suk Yu MD 

Purpose: To evaluate the difference of macular and retinal nerve fiber layer (RNFL) thickness 

between amblyopic and the fellow eye in patients with deprivational amblyopia. 

Methods: Seventeen patients who underwent IOL implantation by a single surgeon after 

the diagnosis of congenital cataract were recruited for OCT scans performed by Cirrus HD- 

OCT (Carl-Zeiss Meditec; Dublin, Calif., USA). Results: No interocular differences were 

found in the final spherical equivalents and the axial lengths. The macular thickness was 

significantly greater in amblyopic eyes (P < .05), but the RNFL thickness was not. Conclusion: 

Results suggest that the light deprivation may influence on the macular thickness. 


Comparison of the iScreen to the MTI Photoscreener for the 

Detection of Amblyopia Risk Factors in Children 

Presenting Author: Noelle S Matta COT 

Co-Author(s): David I Silbert MD* 

Purpose: To evaluate the iScreen (IP) vs. the MTI photoscreener in detecting American 

Association for Pediatric Ophthalmology and Strabismus (AAPOS)amblyopia risk factors 

in children under age 7. Methods: Retrospective chart review of children with IP, MTI, 

acuity, alignment, and cycloplegic refraction performed by one pediatric ophthalmologist. 

Results: Of 150 children, 60% were found to have AAPOS amblyopia risk factors. Sensitivity 

and specificity of IP were 84% and 78%; of MTI, were 78% and 78%. With newly 

proposed revisions to AAPOS referral criteria, IP sensitivity and specificity were 86% and 

75%; of MTI, were 80% and 80%. Conclusion: Both the iScreen and MTI are accurate in 

the detection of amblyopia risk factors in children under the age of 7 and perform similarly. 

Both perform well with proposed revisions to the AAPOS referral criteria. 


APAO Outcomes of Secondary IOL Implantation in Aphakic 

Children: A 5-Year Experience at a Tertiary Eye Care Center 

Presenting Author: Muralidhar Ramappa MS 

Co-Author(s): Archana Singh**, Sunita Chaurasia MD 

Purpose: To report the results of secondary IOL implantation in eyes that underwent prior 

cataract surgery during early infancy. Methods: Retrospectively analyzed 121 eyes of 71 

children who had secondary IOL implantation between 2005 and 2011. Results: 67.63 ± 

36.18 months; M:F: 47:24. Mean follow-up, 23 months; BCVA of ≥20/40 in 28% of cases, 

≥ 20/41 and ≤ 20/100 in 31%, > 20/100 and ≤ 20/200 in 12%; better than 20/200 and ≤ 

20/400 in 6%; < 20/400 in 23%. Major complications included endophthalmitis in 1 case 

and glaucoma in 3 eyes. Conclusion: Secondary IOL implantation is a safe and effective 

means of rehabilitating pediatric aphakia. 


APAO Longitudinal Assessment of Central Corneal 

Thickness in Aphakic and Pseudophakic Pediatric Eyes 

Under 2 Years of Age: Randomized Trial 

Presenting Author: Abhay Raghukant Vasavada MBBS FRCS* 

Co-Author(s): Mamidipudi Praveen DO**, Sajani K Shah MD, Vaishali Abhay Vasavada 

MS**, Viraj A Vasavada MD*, Mayuri Khamar**, Rupal H Trivedi MBBS MS* 

Purpose: Comparative evaluation of central corneal thickness (CCT) with/without IOL implantation 

after bilateral cataract surgery at 4 years follow-up. Methods: A randomized 

clinical trial of 60 children assigned to either contact lens/spectacle correction (aphakia, n 

= 30) or IOL implantation (pseudophakia, n = 30) to assess CCT. Results: Mean CCT with 

aphakia was significantly thicker than pseudophakia at 4 years (P < .001). In presence of 

glaucoma, mean CCT in aphakia was significantly thicker (P < .01) while there was no 

difference in pseudophakia at 4 years (P = .155). Conclusion: Eyes remaining aphakic 

showed a larger increase in CCT than those receiving a primary IOL after cataract removal. 


Comparison of Postoperative Complications in Infants 

Undergoing Bilateral Simultaneous, Bilateral Sequential, 

and Unilateral Intraocular Surgery 

Presenting Author: Michael B Yang MD 

Co-Author(s): Sheela L Masifi MS, Elizabeth D Agabegi MD 

Purpose: We compared the incidence of postoperative complications after bilateral simultaneous 

(BSI), bilateral sequential (BSEQ), or unilateral (UNI) intraocular surgery in 

infants < 12 months of age. Methods: Twenty-one infants (42 eyes), 10 infants (20 eyes), 

and 19 infants (19 eyes) had BSI, BSEQ, and UNI intraocular surgery, respectively. Results: 

No eyes developed endophthalmitis. Both eyes of a single BSI cataract patient, no eyes 

of any BSEQ patients, and 1 eye each of 2 UNI cataract patients developed pupillary block 

glaucoma (P = .59). Retinal detachment occurred in the second eye of a BSI glaucoma 

patient (P = .20). Conclusion: Bilateral PBG is a serious complication that should be considered 

when contemplating BSI surgery. 


The Predictive Value of Clinical Risk Index for Babies 

Illness Severity Score for Severe ROP in Different Gender 

and Racial Populations 

Presenting Author: Michael B Yang MD 

Purpose: We previously showed that race, gender, and Clinical Risk Index for Babies 

subscore (CRIBSUB), in addition to birth weight, gestational age, and multiple birth status, 

were independent predictors for ROP warranting surgery (ROPWS). Methods: We hypothesized 

that CRIBSUB would continue as an independent predictor of ROPWS when analyzed 

in subcategories of male-, female-, black-, or non-black-only infants and performed 

multiple logistic regression on 357 infants. Results: CRIBSUB was an independent predictor 

for ROPWS in eyes of non-black or male infants but not for black or female infants. 

Conclusion: Black or female infants may have protective factors that lessen the impact 

of illness severity on the development of ROPWS. 


Long-term Outcome of Ahmed Glaucoma Valve Implantation 

in Primary Congenital Glaucoma 

Presenting Author: Walid Barakat MD** 

Co-Author(s): Deepak Paul Edward MD, Sami Al Shahwan MD 

Purpose:To evaluate long-term IOP reduction following Ahmed glaucoma valve implantation 

(AGVI) in primary congenital glaucoma (PCG). Methods: Retrospective review. Primary 

outcome measure was cumulative probability of success defined as IOP > 5 mmHg and 

< 23 mmHg without serious complications and no additional glaucoma surgery. Results: 

Fifty-eight eyes with PCG with previous glaucoma surgery underwent AGVI at 3.98 ± 3.12 

years, with a preoperative IOP of 33 ± 5.63 mmHg, and follow-up of 62.5 ± 53.0 months. 

The cumulative probability of success was 69% at 6 months, 62% at 1 year, and 56% at 

2 years. Medication use remained unchanged (3.3 preoop to 2.56 at 2 years). Major complications 

included encapsulation (10.3%), tube-cornea issues (10%), and hypotony (7%). 

Conclusion: AGVI in PCG showed decreasing success over time with need for glaucoma 

medications. 


Quality of Life in Children With Glaucoma 

Presenting Author: Benjamin L Freedman 

Co-Author(s): Alice A Lin MD, Sarah K Jones, Sandra Stinnett, Kelly Walton Muir MD 

Purpose: The evaluation of pediatric glaucoma therapies requires an understanding of 

the factors influencing vision-related quality of life (VRQoL) as reported by children with 

glaucoma. Methods: Fifty children with glaucoma were prospectively enrolled in an observational 

study including VRQoL assessment. Results: Seven patients with mental disabilities 

were unable to complete the VRQoL; of 43 children aged 5-17 years, mean VRQoL 

was 24.9 ± 12.9 (scale 0-96, lower=better VRQoL) and was associated with visual acuity 

in the better seeing eye (P = .03), not number of surgeries, number of eye drops, or specific 

diagnosis (P = 0.6-0.9). The association was consistent across age groups. Conclusion: 

VRQoL as reported by the child can be assessed across a wide age range of most children 

with glaucoma and is influenced by visual acuity in the better-seeing eye. 





217




APAO Visual Field Defects in Children With Primary 

Congenital Glaucoma 

Presenting Author: Anil K Mandal MD 

Co-Author(s): Paaraj Rajendra Dave, Harsha BL Rao MD* 

Purpose: To characterize the visual field (VF) defects in children operated for primary 

congenital glaucoma (PCG). Methods: VFs (24-2 SITA standard program) of 33 eyes of 22 

children with PCG were retrospectively reviewed. Results: The mean age at VF examination 

was 11 ± 3.8 years. The most common field defect was the arcuate defect (65% eyes), 

followed by paracentral scotoma (15% eyes). Twenty percent of the eyes had advanced 

loss with just the central island remaining. Sixty-five percent of the defects involved both 

the superior and the inferior hemifields, while 35% involved the superior hemifield only. 

Conclusion: VF defects in children with PCG resemble those of adult patients. 


High Magnitude With-the-Rule Astigmatism Is Associated 

With Higher Myopic Refractive Change in Children 

Presenting Author: Ta Chen Chang MD 

Co-Author(s): Wei Shi MS, William J Feuer MS, Joyce C Schiffman MS*, Sean P 

Donahue MD PhD* 

Purpose: To determine if high magnitude with-the-rule astigmatism (HWTRA, 3 2 D cyl) 

is a risk factor for myopic progression in children. Methods: We performed a retrospective 

chart review. Patients with a history of ocular pathologies or procedures, presence of 

pathologic myopia (magnitude 3 8 D) were excluded. Results: 202 eyes of 101 patients 

were enrolled; 24 eyes (11.9%) had initial refraction with HWTRA, which had a significantly 

higher rate of myopic change (-0.24 ± 0.21 D/year) than the rest of the cohort (-0.13 

± 0.13 D/year, P = .027) when followed > 5 years. Conclusion: HWTRA may be a risk 

factor for myopic progression in children. 


APAO Diminished Ciliary Body Movement on 

Accommodation in Myopia 

Presenting Author: Sohee Jeon MD 

Co-Author(s): Hakyoung H Kim MD, Won Ki Lee MD* 

Purpose: To evaluate the relationship between ciliary body (CB) characteristics and 

myopia. Methods: The relationship between axial length and CB parameters detected 

by ultrasound biomicroscope were evaluated in 31 young volunteers. Results: A positive 

correlation was found between axial length and CB length at scleral side, CB thickness 

at 2 and 3 mm (P = .037, .048, .044), while changes in thickness at the thickest part, and 

apical angle were inversely related (P = .006, .008). Changes in thickness at the thickest 

part (P = .006) was independently associated with axial length. Conclusion: Diminished 

CB movement during accommodation and myopia were related. 


APAO Changes in Refractive Errors Related to Spectacle 

Correction of Hyperopia 

Presenting Author: Jeong-Min Hwang MD* 

Co-Author(s): Hee Kyung Yang MD, Jungyeon Choi MD 

Purpose: To evaluate the effect of spectacle correction on the change in hyperopia. 

Methods: The following 4 groups of 120 children under 12 years of age were matched 

by age and refractive errors: esotropia with full correction of hyperopia, exotropia with 

undercorrection of hyperopia, orthotropia with full correction of hyperopia, and orthotropia 

with undercorrection of hyperopia. Changes in refractive errors were determined after 2 

years. Results: The decrease in hyperopia was more rapid in patients receiving undercorrection 

compared to full correction of hyperopia, regardless of the presence of strabismus. 

There was a positive correlation between the amount of undercorrection and change in 

hyperopia. Conclusion: Full correction of hyperopia may inhibit hyperopic reduction during 

childhood. 


APAO Comparison of Outcomes of Vitrectomy for Stage 4A 

ROP With or Without Preoperative Bevacizumab 

Presenting Author: Shunji Kusaka MD* 

Co-Author(s): Kazuki Kuniyoshi MD, Chiharu Shima MD, Kosuke Abe MD, Yoshikazu 

Shimomura MD 

Purpose: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) on the 

visual outcomes for stage 4A retinopathy of prematurity (ROP). Methods: The postoperative 

retinal status and the frequency of reoperations due to vitreous hemorrhage and/or 

reproliferation were compared between 25 consecutive eyes with IVB and 21 consecutive 

eyes without IVB. Results: The retinas were reattached in 100% of the eyes with IVB and 

95.2% without IVB. Reoperations were performed due to vitreous hemorrhage in 24.0% 

of the eyes with IVB and 19.0% without IVB. Reproliferation developed in 0% of the eyes 

with IVB and 19.0% without IVB (P = .037). Conclusion: Preoperative IVB can reduce 

postoperative reproliferation following vitrectomy for stage 4A ROP. 


APAO Comparative Analysis of 4 Horizontal Muscle 

Recession vs. 4 Muscle Tenotomy and Reattachment 

Procedures in Patients With Infantile Nystagmus Syndrome 

Presenting Author: Professor Kamlesh MS** 

Co-Author(s): Ashraya Nayaka T E MBBS, Monika Kapoor MBBS, Shilpa Goel MBBS**, 

Yuvika Bansal SR** 

Purpose: To study results of tenotomy and reattachment (T&R) in comparison with horizontal 

muscle recession in terms of improvement of postoperative nystagmus waveform 

and visual acuity. Methods: Rotational chair testing (RCT) on 20 patients (10 each in 

Group A and B) of infantile nystagmus syndrome (INS) without AHP abnormal head posture 

(or < 10° AHP). An 8-mm medial rectus recession and 10-mm lateral rectus recession was 

done in Group A, and Group B underwent disinsertion and reattachment at the same site. 

Results: Visual acuity improvement was seen in a range of 0%-50%. However, difference 

between the groups was not statistically significant, either in terms of waveform and 

visual acuity improvement. Conclusion: T&R may be an upcoming procedure to dampen 

nystagmus in patients of INS, considering the ease of the procedure and the decreased 

chance of postoperative heterotropia. 


An Effective and Novel Modification of Rectus Muscle 

Tucking Surgery 

Presenting Author: Birsen Gokyigit MD 

Co-Author(s): Serpil Akar MD, Ebru Demet Aygt MD**, Ahmet Demirok MD 

Purpose: To introduce the modified technique of rectus muscle tucking operation and 

its effectiveness. Methods: The technique was performed in 8 eyes. Tucking between 

4 and 14 mm was applied on muscles of 4 lateral, 3 medial, and 1 inferior rectus. During 

the surgery, the desired amount of the muscle folded under the remaining portion of the 

rectus muscle and 5/0 nonabsorbable suture was used for the operation. There were no 

visible parts of muscle beyond the insertion. Results: Our results shows us median 2.9 

PD (between 2 and 5 PD) decrease of squint per mm of plicated muscle in the third month 

of follow-up. There is no visible swelling in any of the cases due to tucking under the 

conjunctiva. Conclusion: This modified tucking operation is an effective procedure for 

preserving the blood supply and having cosmetically good results. 


APAO Comparison of the Surgical Response to Medial 

Rectus Recession in Esotropes With and Without Cerebral 

Palsy 

Presenting Author: Jeong-Min Hwang MD* 

Co-Author(s): DaeJoong Ma MD, Hee Kyung Yang MD 

Purpose: To compare the surgical outcomes of medial rectus muscle recession in esotropes 

with and without cerebral palsy (CP). Methods: Thirty esotropes with CP and 60 

age-matched esotropes without CP who underwent unilateral / bilateral medial rectus 

muscle recession were included. Success rates and factors affecting surgical responses 

were evaluated. Results: The rate of early and late overcorrection was significantly higher 

in patients with CP (P = .002). Patients with CP showed a larger surgical response than 

patients without CP, about 1 prism diopter per millimeter of recession (P < .001). Conclu- 

218 





sion: Patients with CP showed a larger surgical response than patients without CP. The 

surgical dosage of medial rectus muscle recession should be reduced to prevent overcorrection. 


Preoperative Assessment of Strabismus Surgery: A Tool for 

the Evaluation of Trainees and Surgeons 

Presenting Author: Ian M MacDonald MD* 

Co-Author(s): Heather K Burnett MD, Garry T Drummond MD 

Purpose: To present a tool for the assessment of competency in strabismus surgical planning. 

Methods: A daily operative card (DOC) was developed after consulting experienced 

strabismus surgeons and resident trainees, then validated for use. Preoperative choices 

were made after review of patients’ charts, recorded prior to surgery and then reviewed 

on the day of surgery. Results: The DOC allowed review of choices of particular tendons, 

unilateral vs. bilateral surgery, adjustable surgery, tendon offset, advancement of tendons, 

and others. Conclusion: A standardized DOC provides the qualitative assessment 

of preoperative strabismus surgery decision making and an opportunity for discussion and 

formative evaluation of trainees and surgeons. 


APAO Bilateral Harada Ito Procedure for Extorsion and V 

Eso Shift in Traumatic Acquired Bilateral Superior Oblique 

Palsies 

Co-Author(s): Bhawna Khurana MBBS, Anupam Singh Sr DOMS**, Sanjeev Sharma**, 

Meenakshi Chandel MBBS** 

Purpose: To report the effect of bilateral Harada Ito (BLHI) sugery on extorsion > 10° 

and esotropia in down gaze in traumatic bilateral superior oblique (SO) palsies (BLSOP). 

Methods: Five patients of BLSOP class IV were evaluated for ocular deviation and subjective 

and objective extorsion. BLHI procedure (Fell’s modification) was done. Anterior 

one-third of SO tendon was put 6-8 mm posteriorly along the superior border of lateral 

rectus insertion as per the eso shift. Results: Preoperative extorsion ranged from 10-22°, 

eso in down gaze ranged from 12-28 PD. At 6 weeks postoperatively, subjective extorsion 

of 4° and 6° were seen in 2. Eso of 5 and 8 PD were seen in 2. Conclusion: Modified 

BLHI procedure is effective in simultaneously treating extorsion >10° and eso shift >10 

PD in traumatic BLSOP. 


APAO Oral Propranolol for Treatment of Infantile Orbital 

Capillary Hemangiomas 

Presenting Author: Vishaal R Bhambhwani MBBS 

Co-Author(s): Usha K Raina MD**, Neha Goel MBBS, Anisha Seth MS**, Basudeb 

Ghosh** 

Purpose: To evaluate safety and efficacy of oral propranolol in infantile orbital capillary 

hemangiomas. Methods: Six patients received oral propranolol 0.5 mg/kg for 1 week, 1 

mg/kg for 1 week, and 2 mg/kg for 4 weeks after comprehensive evaluation by a multidisciplinary 

team. Pre- and post-treatment contrast enhanced CT scan was performed with 

refraction at each visit. Results: Reduction in volume of hemangiomas clinically and on 

imaging was noted in all eyes in 6 weeks, with reduction in astigmatism due to globe 

displacement. Mean reduction in volume and astigmatism was statistically significant (P 

< .01). There were no side effects of treatment. Conclusion: Oral propranolol in a gradually 

escalating dose proved safe and effective for the treatment of orbital hemangiomas, 

which can cause amblyopia. 

Pediatric Ophthalmology, Strabismus Poster Tour 


12:30 PM to 1:30 PM 

Session Two 





A Fresh Look at the PlusoptiX Photoscreener Utilizing 

the Newly Proposed Revised American Association for 

Pediatric Ophthalmology and Strabismus Referral Criteria 

Presenting Author: Prucilla Shady 

Co-Author(s): Noelle S Matta COT, David I Silbert MD*, Eric L Singman MD PhD 

Purpose: To evaluate the Plusoptix photoscreener (PP) in detecting amblyopia risk factors 

in children using the current and proposed AAPOS referral criteria. Methods: Retrospective 

chart review of children evaluated by the PP and for acuity, alignment, and refractive 

error by a pediatric ophthalmologist. Results: 109 children were examined. Under the 

current guidelines, the PP had a sensitivity and specificity of 98% and 88%, respectively. 

Using the proposed AAPOS referral criteria, the sensitivity and specificity were 98% and 

93%, respectively. Conclusion: The PP is a fast, user-friendly, automated, and portable 

tool for the reliable detection of amblyopia risk factors in children. Its sensitivity and specificity 

improve using the newly revised AAPOS referral criteria. 


Performance of the Spot Vision Screener for the Detection 

of Amblyopia Risk Factors in Children 

Presenting Author: David I Silbert MD* 

Co-Author(s): Noelle S Matta COT 

Purpose: To evaluate the Spot photoscreener (SP) in detecting amblyopia risk factors 

in children using the American Association for Pediatric Ophthalmology and Strabismus 

(AAPOS) referral criteria and recent revision to these criteria. Methods: Retrospective 

chart review; SP acuity, alignment, and cycloplegic refraction was performed by 1 pediatric 

ophthalmologist. Results: 105 children were examined; 70% were found to have 

amblyopia risk factors based on current AAPOS guidelines. The SP had a sensitivity and 

specificity of 80% and 74%. With the proposed revisions to the AAPOS referral criteria, 

the sensitivity and specificity were 82% and 70%. Conclusion: The SP is an accurate, 

fast, user-friendly, and portable tool for the detection of amblyopia risk factors in children 

and performs similarly to other photoscreening devices. 


APAO Long-term Outcomes of Bilateral Congenital and 

Developmental Cataracts Operated in Maharashtra, India 


Co-Author(s): Anil N Kulkarni MS, Shailbala Patil MD, Mitali Shah MD**, Mohini 

Sahasrabudhe MD**, Rupal H Trivedi MBBS MS* 

Purpose: To study 3-7 year outcomes of bilateral congenital and developmental cataract 

surgery. Methods: 258 pediatric cataract-operated eyes of 129 children who underwent 

pediatric cataract surgery in 2004-2008 were traced and examined prospectively in 2010- 

2011. Results: 109 (42.2%) had BCVA 3 6/18, while 149 (57.8%) had BCVA < 6/18. 157 

(60.9%) had BCVA 3 6/60, while 101 (39.1%) had BCVA < 6/60. Visual outcome (as a 

cut-off point of 6/18) depended on type of cataract (P = .004), type of cataract surgery 

(P < .001), type of intraocular lens (P = .05), age at surgery (P = .003), absence of postoperative 

uveitis (P = .041), and preoperative vision (P < .001). Conclusion: Developmental 

cataract, use of phacoemulsification, older children, and better preoperative vision had 

better outcomes. 


APAO Causes, Epidemiology, and Long-term Outcome of 

Traumatic Cataracts in Children in Rural India 


Co-Author(s): Anil N Kulkarni MS 

Purpose: To describe preoperative factors and 3-7 years postoperative outcome of 

traumatic cataracts in children in rural India. Methods: Eighty-two traumatic cataracts 

operated in 2004-2008 were re-examined prospectively in 2010-2011 using standardized 

technique. Results: Average age at time of surgery was 10.4 ± 4.43 years (1.03 to 18); 

average follow-up was 4.35 ± 1.54 years. Fifty (61.7%) were boys. Most common cause 

was wooden stick, 23 (28.0%) and sharp thorn, 14 (17.1%). The mean preoperative visual 





219



acuity was 0.059 ± 0.073, and mean postoperative visual acuity was 0.483 ± 0.417 (P 

6/18). Visual outcome depended on type of surgery (P = .002), gender (P = .028), and type 

of injury (P = .07). Conclusion: The visual acuity outcomes were poor in sharp injuries and 

with nonuse of phacoemulsification. 


H IOL Power Calculation in Short Pediatric Eyes 

Presenting Author: Bharti Kishore Nihalani Gangwani MD 

Co-Author(s): Deborah K VanderVeen MD 

Purpose: To evaluate accuracy of IOL power calculation formulae in short pediatric eyes 

(axial length [AL] < 22 mm). Methods: SRK II, SRK/T, Holladay 1, and Hoffer Q were 

evaluated in eyes with AL < 22 mm, when early postop refraction was available. Results: 

Ninety-seven eyes of 75 children (mean age: 3.3 years) were analyzed; mean AL was 20.7 

mm. Overall mean absolute prediction error (PE) for AL < 22 mm was 1.5, 1.0, 0.9, and 0.7 

D, and for AL < 20.0 mm (n = 18) 2.1, 1.0, 0.9, and 0.8 D, respectively. In eyes with AL < 

22 mm, Hoffer Q gave minimum PE in 67% compared to 10.3% with SRK II, 12.4% with 

SRK/T, and 10.3% with Holladay. In eyes with AL < 20 mm, Hoffer Q gave minimum PE 

in 56% compared to 0%, 11%, and 33%, respectively. Conclusion: Hoffer Q was more 

predictable in short eyes, with little difference in mean PE between Holladay and SRK/T. 


Selection of an Initial Aphakic Contact Lens Power for 

Infants 

Presenting Author: Rupal H Trivedi MBBS MS* 

Co-Author(s): M Edward Wilson Jr MD* 

Purpose: To provide guidelines for selection of contact lens (CL) power based on the 

preop data. Methods: Inclusion: age at surgery < 1 year. One eye was selected for bilateral 

cases. Results: N = 50, age: 2.4 (SD 1.7) months. Postop refraction within 1 month. 

CL power = 84.4-3.2 x axial length (AL) (R-sq 0.82, P < .001). Age and preop K did not add 

in a model containing AL. A-constant of 112.18 was obtained when IOL power calculation 

formula was used to estimate CL power. Refraction at the corneal plane was 29.6 

± 4.4 D. Estimated CL power based on regression was 30 ± 4.4 D (correlation, 0.90). If a 

CL power of 32 D had been used, 44% of eyes would have needed a replacement of CL. 

Conclusion: Using linear regression, we made use of the relationship between AL and 

CL power for future patients undergoing cataract surgery. The IOL power calculator can 

help estimate CL power. 


Long-term Longitudinal Change in Keratometry After 

Pediatric Cataract Surgery 

Presenting Author: Rupal H Trivedi MBBS MS* 

Co-Author(s): M Edward Wilson Jr MD*, Dipankar Bandyopadhyay PhD 

Purpose: To report longitudinal change in keratometry values after pediatric cataract 

surgery. Methods: Statistical analysis was performed using GEE using Proc GENMOD, 

which takes care of clustering as well as repeated measures for eyes within subjects. Results: 

N = 251 patients; number of postop K measurements: 781; age at surgery: 2.8 years; 

follow-up: 3.9 years; difference in preop and postop K: 1.3 D (P < .001). Eyes with unilateral 

cataract flattened more than eyes with bilateral cataract (not significant). Unilateral 

cataract eye: 1.42. Fellow eye with clear lens: 1.29. Postop K can be predicted by preop K, 

follow-up, laterality of cataract and AL. Conclusion: Keratometry values changed significantly 

after pediatric cataract surgery and postop K can be predicted by preop parameters. 


The Juvenile Cataract Phenotype Caused by Recessive 

Mutation in a Lens Cytoskeletal Protein (BFSP2) 

Presenting Author: Arif O Khan MD 

Co-Author(s): Mohammed A Aldahmesh PhD**, Jawahir Y Mohamed**, Fowzan S 

Alkuraya MD 

Purpose: To document the juvenile cataract phenotype from recessive mutation in the 

lens cytoskeletal protein BFSP2 in an inbred family. Methods: Report of 3 affected sisters 

harboring p.Ala201GlyfsX6 BFSP2 mutation identified following homozygosity analysis. 

Results: Each developed visual symptoms at 12 years old. The lens showed a unique 

pattern of diffuse cortical haze with scattered lens opacities (flecks). Conclusion: The 

juvenile cataract phenotype in this family is unique and may be specific for recessive null 

mutations in the lens cytoskeletal protein BPSP2. 


Evaluation of Corneal Hysteresis and Corneal Resistance in 

the Pediatric Population 

Presenting Author: Marc Comaratta MD** 

Co-Author(s): Victor A Neamtu MD, Airaj F Fasiuddin MD 

Purpose: We evaluate corneal hysteresis (CH) and corneal resistance factor (CRF) based 

on age, race, gender, and refractive error in the pediatric population. Methods: We used 

the Reichert Ocular Response Analyzer to obtain CH and CRF values. We enrolled 152 eyes 

from 79 patients aged 3-17. Results: Mean CH was lower in the age 3-6 group than ages 

7-10 (P = .003) and 11-14 (P = .0045). Mean CH and CRF was lower in African Americans 

(AA) than in whites (P = .0008 and P = .0065, respectively). Discussion: Results suggest 

there is an increase in CH values from young to older children. The finding of lower CH 

and CRF in AA children is noteworthy given that other studies have shown lower CH to be 

found in primary open-angle glaucoma (POAG) eyes and that AAs have a higher incidence 

of POAG. 


H OCT in the Evaluation of Preterm Nonglaucomatous 

Cupping 

Presenting Author: Lora R Dagi Glass MD 

Co-Author(s): Dana Blumberg MD 

Purpose: To characterize peripapillary retinal nerve fiber layer (RNFL) in children with 

nonglaucomatous cupping and a history of birth at < 37 weeks. Methods: We enrolled 

a consecutive series of 4 children with cup:disc ratio ≥ 0.5, a history of prematurity, and 

otherwise normal corneas, IOP, and gonioscopy. RNFL was examined using Cirrus HD-OCT 

optic cube 200x200 global average and quadrant analysis. Results: OCT showed diffuse 

RNFL loss. Conclusion: Results suggest that children with nonglaucomatous cupping and 

a history of prematurity have diffusely thin RNFL. This pattern is more consistent with 

theories of optic atrophy associated with prematurity. Thus, OCT may be helpful in differentiating 

optic nerve atrophy from optic nerve glaucomatous cupping. 


H Headache and Refractive Errors in Children 

Presenting Author: Zachary J Roth MD 

Co-Author(s): John W Simon MD, Jitka L Zobal-Ratner MD, Katie Pandolfo MS 

Purpose: Refractive errors are often suspected to cause headaches in children. Methods: 

We retrospectively reviewed 158 patients from a pediatric ophthalmology practice, 

characterizing headaches and tabulating refractions. Those who received new or altered 

spectacle correction were compared to those who did not. Results: 75.3% of patients 

had normal or unchanged eye examinations, including refractions. Headaches improved in 

76.4% of all patients, whether with (71.9%) or without (78.2%) refractive correction. The 

difference between these two groups was not significant (P = .38). Conclusion: Headaches 

in children are uncommonly based on refractive errors. The prognosis for improvement 

is favorable, whether with or without new glasses. 


APAO The Change of Accommodational Ability Influencing 

Asthenopia With Viewing 3-D Displays 

Presenting Author: Sung-wook Wee MD 

Co-Author(s): NamJoo Moon 

Purpose: To identify the change of accommodation affecting visual asthenopia with 3-D 

display. Methods: Fifteen normal adults watched the same 3-D display for 30 minutes. 

Objective accommodational points were measured by OQAS. Near point of accommodation 

(NPA) was measured. A survey for subjective symptoms after watching the 3-D display 

was done. The same experiments were done equally with a 2-D display. Results: 

Objective accommodation and NPA were decreased significantly with the 3-D display (P < 

.05), and these 2 methods had significant correlation. Among subjective symptoms, pain, 

tearing, and dryness were significantly increased with the 3-D display, but no significant 

change was observed with the 2-D display. Conclusion: Decreased ability of accommodation 

may contribute to visual asthenopia with 3-D display. 

220 






APAO Effect of Intravitreal Injection of Bevacizumab 

Combined With Laser Photocoagulation for Zone 1 ROP 

Presenting Author: Hwan Heo MD 

Co-Author(s): Inyoung Jeong**, Sang Woo Park MD 

Purpose: To evaluate the efficacy of intravitreal injection of bevacizumab (IVB) combined 

with laser photocoagulation for zone I ROP. Methods: We performed a retrospective analysis 

of the records of 12 eyes of 7 premature infants with zone I ROP who were treated 

with IVB combined with laser photocoagulation and followed up for at least 12 months. 

Results: Eleven eyes had aggressive posterior ROP (AP-ROP). Plus signs disappeared at 

10.1 ± 2.4 postoperative days in all 12 eyes. Eleven eyes (91.7%) had favorable outcomes. 

One eye developed total retinal detachment 4 months after treatment. No local or systemic 

complications were observed. Conclusion: IVB combined with laser photocoagulation 

is effective for treatment of zone I ROP. 


APAO Surgical Outcomes in Intermittent Exotropia With 

Large Early Overcorrection After Symmetric and Asymmetric 

Surgery 

Presenting Author: Hwan Heo MD 

Co-Author(s): Inyoung Jeong**, Sang Woo Park MD 

Purpose: To evaluate the outcomes in intermittent exotropia [X(T)] with overcorrection 

more than 20 prism diopters (PD) on postoperative day 1 (POD1) and compared the results 

of bilateral rectus recession (BLR) and unilateral lateral rectus recession-medial rectus 

resection group (RR). Methods: Among 319 patients who underwent an operation for X(T), 

14 in BLR and 20 in RR met the inclusion criteria and were reviewed. Results: The mean 

follow-up was 12.6 ± 4.3 months. All 34 patients did not need surgery for consecutive 

esotropia. Mean duration from the surgery to esotropia below 10 PD was 2.9 ± 1.1 weeks 

in BLR and 7.4 ± 6.5 weeks in RR (P = .031). Conclusion: In X(T), large overcorrection on 

POD1 resolved faster in BLR than RR, and the operation for consecutive esotropia was 

not needed. 


APAO Aggressive Posterior ROP in Large Preterm Babies 

Presenting Author: Narendran Venkatapathy MBBS 

Co-Author(s): Parag K Shah MBCHB MS 

Purpose: To describe aggressive posterior ROP (AP-ROP) in babies with gestational age 

(GA) ≥ 28 weeks and birth weight (BW) ≥ 1000 g. Methods: Ninety-nine babies having 

AP-ROP between July 2002 and October 2010 were reviewed. Fundus fluorescein angiography 

(FFA) was carried out in 19. Results: Mean GA was 31.7 weeks and mean BW was 

1572 g. All babies received supplemental unblended oxygen 3 days or longer after birth. 

Of the 52 babies who had an eye exam prior to discharge, 39 had loss of vascularized 

retina. FFA revealed large areas of vaso-obliteration posterior to the shunt vessels within 

vascularized retina. Conclusion: Features of severe capillary bed loss in the vascularized 

retina were seen in our cases. Oxygen could be a precipitating factor in causing this ROP 

in large babies. 


APAO Postoperative Lateral Incomitance After Surgical 

Treatment for Exodeviation 

Presenting Author: Changho Yoon MBCB 

Co-Author(s): Soh-youn Suh MD, Seong-Joon Kim MD PHD** 

Purpose: To evaluate the relationship between postoperative lateral incomitance (PLI), 

surgery types and outcome in exodeviation. Methods: Fifty patients who had undergone 

bilateral rectus recession (BLR, n = 25), unilateral rectus recession (ULR, n = 16) or unilateral 

recession-resection (RR, n = 9) were retrospectively reviewed. Mean follow-up period 

was 28 ± 13 (range: 12-82) months. Results: PLI was higher for ULR (81.3%) than for BLR 

(44.0%, P = .025) and RR (33.3%, P = .031). Satisfactory results (not more than 10 PD, BLR 

= 68.0%, ULR = 68.8%, RR = 55.6%) saw no differences between the groups and were 

negatively correlated with PLI (P = .036). Conclusion: In surgery for exodeviation, PLI is 

regarded as a negative predictor for satisfactory results. 


Why Mothers Say, “Look At Me When I’m Talking To 

You”: The Effect of Amblyopia on Visual-Auditory Speech 

Perception 

Presenting Author: Rajen U Desai MD 

Co-Author(s): Robert Burgmeier**, Yana Kiesau MD, Bahram Rahmani MD, Hawke H 

Yoon MD, Janice L Zeid MD**, Nicholas J Volpe MD, Marilyn B Mets MD* 

Purpose: To determine if amblyopia affects speech perception. Methods: Amblyopes 

had 20/20 acuity in the better-seeing eye at the time of testing. Controls had 20/20 acuity 

O.U. and 40 sec stereo. None in either arm had sensorineural auditory deficits or other 

neurological pathology. Patients were presented a video of a person silently mouthing 

“Ka” while an audio track played the sound “Pa.” Normal audio-visual fusion hears “Ta.” 

Subjects viewed the stimulus binocularly, and reported what sound was heard. Results: 

Among the 50 trials of controls and 110 trials of amblyopes, “Ta” was heard by 66% and 

19%, respectively (P < .001). Conclusion: Amblyopic children, even if they are 20/20 

in their better seeing eye and are tested binocularly, have impaired visual-audio speech 

perception. 


APAO Ocular Manifestations of Childhood Acute Leukemia 

Presenting Author: Deepak Khadka MD 

Co-Author(s): Brice J Williams MD, Ananda Kumar Sharma MD**, Jeevan Kumar 

Shrestha MD 

Purpose: To determine ocular manifestation and associated visual morbidity in leukemia 

children. Methods: Children with acute leukemia attending to BP Koirala Lions Centre 

for Ophthalmic Studies from January 2006 to July 2007 were included in the study, and 

detailed ocular evaluation was carried out. Results: Out of 71 cases with childhood acute 

leukemia examined, only 15% had ocular symptoms; however, 46% had ocular signs. Direct 

ocular involvements were seen in 17% and secondary involvements in 41%. Most 

common signs were retinal hemorrhage, seen in 32%. Visual acuity was less than 6/60 in 

22 eyes. Conclusion: Given the asymptomatic nature and significant visual morbidity of 

acute childhood leukemia, we recommend ophthalmic examination as a part of the routine 

evaluation in all cases of childhood acute leukemia. 


H Long-term Outcomes of Early Photocoagulation for 

Ischemic Retinopathy in Incontinentia Pigmenti 

Presenting Author: Natalia Pastora MD 

Co-Author(s): Jesus Peralta MD PhD, Marta Feito MD**, Jose Luis Vallejo Garcia MD, 

Anna Grabowska MD, Felix Armada MD**, Jose Abelairas MD** 

Purpose: To report the long-term outcomes of early detection and treatment of ischemic 

retinopathy in incontinentia pigmenti (IP). Methods: Retrospective interventional case 

series. Results: Laser photocoagulation was applied at a mean age of 6 weeks in 5 eyes 

(3 patients) with significant vascular retinal abnormalities. A proper regression of these lesions 

was noted in all cases (mean follow-up: 40 months). Conclusion: Early treatment of 

retinopathy at a preproliferative stage can prevent the potentially blinding consequences 

of vitreoretinal fibrovascular proliferation in females with IP. 


Refractive Surgery Poster Tour 


12:30 PM to 1:30 PM 

Session One 





Comparative Study of Cornea and Anterior Segment 

Biometric Features Between Scanning Slit Beam 





221



Technology, Placido Disk Topography, and 3 Scheimpflug 

Imaging Systems 

Presenting Author: Arturo J Ramirez-Miranda MD 

Co-Author(s): Alejandro Navas MD, Angie De La Mota MD, Mauricio Rivera-Narvaez, 

Aida Jimenez, Tito Ramirez-Luquin MD**, Enrique O Graue Hernandez MD 

Purpose: To compare 5 anterior segment biometric features (K-readings, anterior/posterior 

corneal elevations, pachymetry, and anterior chamber depth) by 6 different topography 

systems. Methods: Eighty-four eyes were examined with scanning-slit technology, 3 

scheimpflug imaging systems, Placido disk/OCT, and IOLMaster, 2 times by 2 independent 

observers, and the reliability coefficient was calculated with Cronbach alpha-test. Results: 

Intra/interobserver and inter-device comparison (using the Pentacam as a reference) 

showed a very good reliability coefficient (> 0.90) for all features, except for the 

IOLMaster (less than 0.50). Conclusion: Measurements with several systems can be 

used interchangeably in normal corneas. 


Ocular Higher-Order Aberration Changes After Implantable 

Collamer Lens Implantation for High Myopia and High 

Myopic Astigmatism 

Presenting Author: Seyed Javad Hashemian MD 

Purpose: To investigate the changes in higher-order aberrations (HOAs) induced by implantation 

of implantable collamer lenses (ICLs) and toric ICLs in eyes with high myopic 

astigmatism. Methods: We investigated 33 eyes with SE errors of -6.0 to -21.0 D and 

cylindrical errors of -0.5 to -4.75 D. Before and 5 days and 2 and 6 months after surgery, 

UCVA, BSCVA, defocus, and adverse events were assessed. Ocular HOAs also were evaluated 

by Hartmann-Shack aberrometry. Results: At 6.0 months postoperation the UCVA 

and BCVA were ≥ 20/20 in 40% and 66.7% of eyes, respectively. Mean defocus refraction 

and astigmatism reduced to -0.66 and 0.65 D. Six-mm pupil HOAs were not significantly 

changed. Conclusion: This study showed the ICL and toric ICL performed well in correcting 

high myopic astigmatism without significant changes in HOAs during a 6.0-month 

follow-up. 


H Refractive Outcomes of Implantable Collamer Lens 

Implantation: A Decade of Experience With Spheric ICL and 

a Lustrum With Toric ICL 

Presenting Author: Alejandro Navas MD 

Co-Author(s): Martha Jaimes MD, Arturo J Ramirez-Miranda MD, Enrique O Graue 

Hernandez MD, Tito Ramirez-Luquin MD**, Arturo Gomez Bastar MD 

Purpose: To describe the refractive outcomes of phakic posterior chamber ICL implantation. 

Methods: Cohort study. All patients before 2005 were treated with spheric model. 

After 2005 patients received toric and spheric models as needed for correction of astigmatic 

error. Results: 349 eyes with mean follow-up of 47 ± 31 months (3 to 127). Mean 

age 29 ± 6.7 years. Paired t-test was used. Preoperative spherical equivalent -11.6 ± 5.12 

D (+7.875 to -25.625), postoperative -0.52 ± 1.03 (+2.25 to -6.75) P < .001. Preoperative 

UDVA 1.72 ± 0.49 (20/1050 Snellen), postoperative 0.23 ± 0.22 (20/34 Snellen) P < .001. 

Seven eyes presented complications (2%); most resolved favorably. Conclusion: While 

complications can occur, ICL surgery is a safe and effective refractive procedure. 


H APAO Results of Posterior Chamber Toric Implantable 

Collamer Lens Implantation in Patients With Keratoconus 

and High Myopia 

Presenting Author: Indumathy T Ramachandran MS** 

Co-Author(s): Ajay Shankar Kar MBBS MD, Rajesh Fogla MD FRCS 

Purpose: To evaluate outcome of posterior chamber toric implantable collamer lens 

implantation (TICL) in patients with keratoconus and high myopia. Methods: Keratoconus 

patients with astigmatism < 6 D and BSCVA of 3 20/40 were included in the study. 

Results: Thirty-six eyes of 24 patients (mean age: 26.9 years). Mean UCVA and BSCVA 

improved from 20/200 and 20/40 preoperatively to 20/40+ and 20/25+ postoperatively. 

Mean spherical equivalent and astigmatism (refraction) were -0.08 and -0.92 D postoperatively. 

None of the patients lost any line of BSCVA (mean follow-up: 13.7 months). 

Conclusion: Implantation of posterior chamber TICL in patients with keratoconus with 

high myopia appears to be safe and effective procedure. 


Comparison of the Ratio of Keratometric Change to 

Refractive Change Induced by Myopic LASIK and PRK 

Presenting Author: Steven M Christiansen 

Co-Author(s): Gene Kim MD**, Majid Moshirfar MD** 

Purpose: To compare the ratio of change in keratometry (K) to change in spherical equivalent 

(SE) induced by myopic LASIK and PRK. Methods: The charts of 3733 eyes that underwent 

LASIK or PRK from 2007 to 2010 were reviewed, and the ratio K/SE measured at 

3 months postop was compared between eyes with low SE (0.00 to 2.99 D), moderate SE 

(3.00 to 5.99 D), and high SE (6.00 to 8.99 D). Results: Significant differences were found 

in the ratio K/SE between eyes with low SE, moderate SE, and high SE, and the variability 

in the ratio decreased with higher SE. Conclusion: The change in simulated K required 

to achieve a diopter of myopic refractive correction decreases as the amount of refractive 

change increases, is less variable with higher amounts of correction, and follows a 

nonlinear relationship. 


APAO Efficacy of LASIK in Anisometropic Hypermetropic 

Amblyopia in Adults 

Presenting Author: Ekta Kumari MBBS 

Co-Author(s): Subhash C Dadeya MD, Jawahar Lal Goyal MD** 

Purpose: To find out the effect of LASIK on visual acuity, spherical equivalent (SE), and 

stereopsis in anisometropic amblyopia in adults. Methods: Prospective interventional 

study was done on 11 anisohypermetropic amblyopes. Results were analyzed before and 

3 months after LASIK. Results: Mean age of the patients was 22.91 ± 4.59 (range: 19- 

32 years). The BCVA improved from a mean of 0.32 ± 0.13 preoperatively to 0.46 ± 0.20 

postoperatively (P-value < .05 ). The spherical equivalent decreased from a mean of +3.53 

± 0.97 before to +1.19 ± 0.49 after LASIK (P-value < .05 ). However, there was nonsignificant 

change in stereopsis. Conclusion: LASIK not only corrects refractive error but 

also improves BCVA in anisometropic amblyopia. It is an effective surgical treatment for 

anisometropic amblyopia. 


APAO Stereoacuity Changes After LASIK 

Presenting Author: Digvijay Singh BMBS 

Co-Author(s): Rohit Saxena MD, Vimala Menon MBBS, Rajesh Sinha, Shikha Gupta 

MBBS 

Purpose: To study changes in near and distance stereoacuity (nSA and dSA) after LASIK. 

Methods: A prospective study of patients who underwent LASIK for myopic correction 

and got unaided vision of ≥20/30 in each eye. SA was tested before (with contact lens 

correction) and 3 months after LASIK by near and distance Randot tests. Results: Forty 

patients (80 eyes) had mean pre-LASIK refractive error (RE) of -4.70 ± 1.72 DS O.D., -4.59 ± 

1.58 DS O.S., and anisometropia of 0.55 ± 0.51 DS. The median pre-LASIK nSA was 70”arc 

(20-960) and dSA 200”arc (60-960) and improved to 30”arc and 60”arc, respectively (P < 

.001, both). RE was not associated with SA but anisometropia of ≥1 D had significantly 

worse dSA (pre- and post-LASIK). The post-LASIK nSA and dSA were strongly associated 

(r = 0.706, P < .001), unlike change in SA. Conclusion: SA improved significantly after 

LASIK. 


H Combined LASIK and Accelerated Corneal Crosslinking: 

Refractive Outcome and In Vivo Confocal Microscopy 

Evaluation 

Presenting Author: Dario A Victoria Moreno MD 

Co-Author(s): Maria C Arbelaez MD*, Juan G Gaviria MD, Sanak Roy Choudhury DO** 

Purpose: To evaluate the refractive outcome and stromal modifications by confocal microscopy 

(CM) of eyes treated with LASIK and accelerated corneal crosslinking (ACXL). 

Methods: Refraction, visual acuity (VA), and CM were done before surgery and after 3 

months. Results: Fifty eyes were evaluated. The mean spherical equivalent (SE) was 

-4.43 D ± 2.91 D (-10.00 to 3.50). After 3 months, mean SE was -0.30 D ± 0.39 D (-1.63 to 

0.38). Eighty percent had UDVA > 20/25. On CM, there was keratocyte apoptosis (89.5%), 

stromal hypereflectivity (94.7%), and activated keratocytes (52.6%). The maximal depth of 

changes was 125.5µ. Stromal changes below flap were at 28.25µ. Conclusion: Results 

were safe in terms of VA and refractive outcome. Cross-linking effect was detected in the 

anterior stroma without any complications. 

222 






APAO Prospective Clinical Study to Evaluate the Safety and 

Efficacy of a Presbyopic LASIK Treatment in Pseudophakic 

Patients 

Presenting Author: Robert Edward T Ang MD* 

Purpose: To evaluate the visual and refractive outcomes of pseudophakic patients who 

underwent the Supracor presbyopic LASIK treatment to improve their near vision. Methods: 

In this prospective study, 35 patients implanted with a monofocal IOL underwent a 

monolateral Supracor procedure. Results: Mean patient age was 69.3 years. Six patients 

reached the 6-month follow-up. Mean SE was -0.56 D. All patients had monocular uncorrected 

distance and near visual acuity (UDVA and UNVA) of 0.8, vs. preoperative monocular 

UDVA of 0.8 in 61.5% and UNVA of 0.63 in 15.4% of eyes, respectively. Conclusion: 

Early results indicate that the Supracor LASIK procedure is a safe and effective presbyopia 

treatment in pseudophakic patients implanted with a monofocal IOL. 


Oblique Corneal Astigmatism Shifts With Corneal Refractive 

Surgery as Measured by Topography 

Presenting Author: Michael Karon MD 

Co-Author(s): James G Chelnis MD, Olivia Dryjski, Hoon C Jung MD** 

Purpose: To measure refractive outcomes in patients with oblique astigmatism undergoing 

corneal refractive surgery. Methods: A retrospective analysis of 1074 eyes with 

oblique astigmatism and 2753 eyes with nonoblique astigmatism using pre- and postoperative 

refractive error and corneal topography by OrbScan IIz was performed. Results: 

296 eyes (27.6%) had remaining oblique astigmatism after surgery. The average oblique 

astigmatism was -0.77 D (SD 0.65) preoperatively and -0.34 D (SD 0.32) postoperatively. 

For nonoblique astigmatism the average astigmatism was -0.76 D (SD 0.80) preoperatively 

and -0.34 D (SD 0.31) postoperatively. Conclusion: Refractive surgery is equally effective 

in reducing oblique and nonoblique astigmatism. 


H Wavefront Optimized vs. Wavefront-Guided 

Photorefractive Keratectomy: A Retrospective Database 

Comparison of Six-Month Outcomes 

Presenting Author: Jason N Crosson MD 

Co-Author(s): Joshua Roe MS, Vasudha A Panday MD, Matthew C Caldwell MD**, 

James R Townley MD, Doug Apsey OD** 

Purpose: To determine which laser platform for PRK is better: wavefront guided or 

wavefront optimized. Methods: 481 eyes status post wavefront-optimized PRK were age 

matched with 481 eyes status post wavefront-guided PRK. Eyes were stratified according 

to refractive error and age. The BSCVA, low contrast VA, and the percentage of patients 

achieving better than 20/20 VA (“super vision”) were compared. Results: Low contrast VA 

and super vision were significantly better with wavefront guided PRK in the over-40 age 

group. Conclusion: Wavefront-guided treatments account for aberrations induced by the 

aging eye and may offer better results in older patients. 


H Eighteen-Year Follow-up of Excimer Laser 

Photorefractive Keratectomy 

Presenting Author: Zaid Shalchi MBBS 

Co-Author(s): David P O’Brart MD MBBS, Parul Patel 

Purpose: To evaluate the long-term refractive and topographic stability of excimer laser 

photorefractive keratectomy (PRK). Methods: Fifty eyes (37 patients) underwent clinical 

assessment 18 years after myopic PRK with 6-mm optical zone. The preoperative mean 

spherical equivalent (MSE) was -4.7 D (range: -2.5 to -7.4 D) with mean programmed correction 

-4.3 D (range: -2.0 to -6.0 D). Results: At 18 years, the MSE was -0.6 D (range: -4.6 

to +1.5 D), with 36% of eyes within 0.5 D and 66% within 1.0 D of intended correction. 

There was no difference in MSE between 1 and 18 years (P > .3). The efficacy index was 

0.65 and the safety index was 1.01. All corneas were clear at 18 years, with no evidence 

of ectasia. Conclusion: Excimer laser PRK was stable between 1 and 18 years. The procedure 

was safe, with no long-term sight-threatening complications. 


Laser PRK for Co Scars: Back to 20/20 

Presenting Author: Arun C Gulani MD 

Purpose: To report the outcomes of refractive excimer PRK surgery in patients with corneal 

scars and irregular astigmatism. Methods: Fifty eyes with anterior corneal scars 

and topographical irregularities were subjected to laser PRK surgery in a refractive mode. 

Follow-up ranged from 1 month to 7 years postop. Results: Outcomes of 20/20 unaided 

vision were possible in these cases, which otherwise would have headed for more interventional 

surgeries. 100% of the patients were satisfied. Conclusion: Anterior corneal 

scars and surface irregularities can be adequately addressed and visual expectations 

of 20/20 achieved without glasses in a majority of cases with excimer laser PRK. This 

technique therefore addresses corneal disease, dystrophy, and LASIK complications with 

excellent outcomes. 


APAO Dry Eye and Corneal Sensation of Small Incision 

Lenticule Extraction for Myopia 

Presenting Author: Meiyan Li MBCB 

Co-Author(s): Jing Zhao MD**, Yang Shen MBCB, Tao Li**, Hailin Xu MD**, Li He 

MD**, Xingtao Zhou MD PhD** 

Purpose: To investigate the changes of dry eye and corneal sensation of small-incision 

lenticule extraction (SMILE) for myopia. Methods: The study involved a total of 55 eyes 

of 55 patients, with 28 eyes in the SMILE group and 27 eyes in the femtosecond LASIK 

(femto-LASIK) group. Dry eye parameters, including Ocular Surface Disease Index (OSDI), 

tear breakup time (TBUT), Schirmer test, and corneal sensation, were assessed before and 

at 1 day, 1 week, and 1 month after surgery. Results: In the SMILE group, the OSDI and 

TBUT values were getting worse after surgery. The loss of corneal sensation was smaller 

when compared to the femto-LASIK group at any postoperative time point. Conclusion: 

SMILE patients have mild dry eye and decreased corneal sensation after surgery. 


H Corneal Crosslinking and Refractive Surface Ablation 

(PRK) in Patients With Asymmetric Corneal Topography 

Presenting Author: Joao B Malta MD 

Co-Author(s): Mauro S Campos MD* 

Purpose: To evaluate safety and efficacy of corneal crosslinking (CXL) and refractive 

surface ablation (PRK) for refractive correction in patients with bilateral asymmetric 

topography. Methods: Prospective, randomized trial of 44 patients (88 eyes). CXL with 

subsequent PRK after 6 months was performed in one eye (study group), and PRK alone 

was performed in contralateral eyes (control group). Results: After 1.5 years of follow-up 

a mean undercorrection of -0.50 DE was observed in both groups. Study group presented 

more corneal haze (P < .05), and none of the patients developed cornea ectasia. Conclusion: 

Both groups achieved good outcomes with a low rate of complications. 

Session Two 





Anterior and Posterior Cornea Evaluation in Children 

Presenting Author: Emilia Cantera MD 

Co-Author(s): Magdalena Cortes 

Purpose: Corneal shape and anterior and posterior corneal indices have been evaluated 

within the pediatric population. Methods: 300 eyes of 300 children, ages 10 to 18 years, 

have been examined using the Sirius corneal topographer (CSO), a combination between 

a rotating Scheimpflug camera and a Placido disk. Corneal asphericity, simulated keratometry 

(SimK), anterior and posterior corneal meridian readings at 3-5-7 mm, pachymetry and 

other corneal indices have been reported. Results: Examined corneas showed a prolate 

profile. Anterior mean SimK average was 7.751 (SD 0.81); anterior mean meridian average 

3 mm was 7.79 (SD 0.86); posterior mean meridian average was 6.499 (SD 0.45); 

pachymetry mean was 547.59. Three corneas showed a pattern compatible with early 

keratoconus. Conclusion: Examined corneas had a prolate profile; 1% probably had an 

early keratoconus. 





223




APAO Repeatability of Keratometry Readings Obtained From 

2 Scheimpflug Devices 

Presenting Author: Yoshiaki Kanaya MD 

Co-Author(s): Yuichi Hori MD*, Yuzo Deguchi MD, Takatoshi Maeno MD 

Purpose: To evaluate the repeatability of keratometry (K) readings measured by 2 

Scheimpflug devices, Galilei (Ziemer) and Pentacam (Oculus). Methods: The power of the 

whole cornea and simulated keratometry (SimK) were measured by Galilei and Pentacam 

in 30 normal eyes. The repeatability of 3 measurements from each device was evaluated 

by coefficient of variation (COV) and intraclass correlation coefficients (ICCs). Agreement 

was assessed using Bland-Altman plots. Results: The COVs of the power of the whole 

cornea and SimK measured by Galilei and Pentacam were 0.26% and 0.19%, and 0.40% 

and 0.12%, respectively; the ICCs were 0.983 and 0.984 and 0.972 and 0.996, respectively. 

Conclusion: All K readings using the 2 Scheimpflug devices were highly repeatable. 


APAO Effect of Crystalline Lens Rise on Vaulting After ICL 

Implantation 

Presenting Author: Aeyoung Kwak MD 

Co-Author(s): Jinu Han MD, Ik-Hee Ryu MD MS, Byoung Jin Ha MD, Tae-Im Kim 

Purpose: To evaluate the parameters affecting vaulting and the correlation between crystalline 

lens rise (CLR) and vaulting. Methods: Fifty-nine eyes with ICL implantation were 

reviewed. CLR (distance between the line connecting 3 to 9 o’clock angle recess to crystalline 

lens anterior pole), white-to-white (WTW), anterior chamber depth (ACD), and postop 

vaulting were evaluated using anterior segment OCT. Results: Mean preop CLR was -110 

± 220 µm, and mean vaulting at 6 months was 560 ± 190 µm. Preop WTW (P < .05) and 

ACD (P < .001), CLR (P < .001) showed significant correlation with vaulting. In a subgroup of 

12.0-mm-sized ICLs, ACD and CLR were related with vaulting (P < .05). Conclusion: CLR 

that reflects the forward protrusion of the crystalline lens effects on vaulting and should 

be considered as a new criterion for estimating vaulting. 


Efficacy of Punctal Occlusion in the Management of Dry 

Eyes After Myopic LASIK 

Presenting Author: Abdullah Alfawaz MD 

Co-Author(s): Saeed Al-Gehedan MD, Samir M Al-Mansouri MD**, Sabah Jastaneiah 

MD, Abdullah Al-Assiri MD 

Purpose: To evaluate the effect of punctal plug after myopic LASIK. Methods: In this 

prospective study on 39 patients, punctal plug was inserted in the lower punctum of one 

eye, while the other eye served as control. They were evaluated for dry eye manifestations 

at 1, 2, and 6 months post-surgery. Results: A statistically significant difference was 

observed in the Ocular Surface Disease Index questionnaire (OSDI) between both eyes in 

all follow-ups. An improvement of ocular surface parameters of both eyes was observed 

as well. Conclusion: Patients were more satisfied with occluded eyes, which needed 

less lubrication. 


The Impact of LASIK on Tear Film Osmolarity 

Presenting Author: Robert A Eden MD* 

Co-Author(s): Robert L Schultze MD*, Kamil San BA COA, Bryan Abessi MD 

Purpose: To determine the effect of LASIK on tear film osmolarity. Methods: We evaluated 

50 consecutive eyes with preoperative myopia between -1.00 D and -5.00 D that 

underwent LASIK surgery. Tear film osmolarity was measured using the TearLab system 

pre- and postoperatively at Days 30 and 90. Results: Mean tear osmolarity (To) for the 

preoperative group was 299.97 mOsms/L, while postoperative readings were 299.27 and 

296.20 mOsms/L at 30 and 90 days postop, respectively. Analysis of variance and Tukey 

test (alpha = 0.05) demonstrated no statistically significant difference between pre- and 

postoperative groups. Conclusion: Results suggest that tear film osmolarity does not 

change significantly as a result of LASIK. 


Topography-Guided LASIK for Hyperopia and Hyperopic 

Astigmatism 

Presenting Author: A John Kanellopoulos MD* 

Purpose: To evaluate the safety and efficacy of topography-guided LASIK (TGL) for hyperopia. 

Methods: 328 consecutive TGL cases; mean preoperative sphere was +3.29 

D (+0.75 to +8.25), and mean cylinder was -1.95 (0 to -6.00). Flaps were created with 

femtosecond lasers. Results: Mean follow-up was 36 months: uncorrected distance VA 

improved from 0.55 to 0.82; 78% of the eyes were in between ± 0.50 D range, 84% were 

in the ± 1.00 D range of the goal. SE: improved from +3.29 to +0.19 and cyl from -1.95 

to -0.75. No significant complications were encountered in this limited group. Conclusion: 

TGL appears to be safe and effective in the correction of hyperopia and/or hyperopic 

astigmatism. 


Evaluation of the Efficacy of Visx Enhancement Performed 

Postphacoemulsification With a Multifocal IOL 

Presenting Author: Joseph Anthony Khell MD 

Co-Author(s): William B Trattler MD*, Gabriela Perez, Eric Liss 

Purpose: To evaluate visual outcomes in patients who received Visx laser enhancement 

(PRK or LASIK) following phacoemulsification with a multifocal IOL. Methods: Eyes that 

received Tecnis Multifocal or ReSTOR IOL followed by laser enhancement (PRK or LASIK) 

were included. Outcome measures included UCVA and astigmatism. Results: Seventyfour 

eyes with multifocal IOLs that had enhancements were evaluated; 8% of eyes that 

had an enhancement had ≥ 1 D of astigmatism pre-enhancement, compared to 14.2% of 

eyes post-enhancement. 18.9% eyes had uncorrected distance VA (UCDVA) of 20/30 or 

better pre-enhancement. 75.7% eyes had UCDVA of 20/30 or better post-enhancement. 

Conclusion: Visx laser enhancement can effectively improve visual acuity following 

phacoemulsification with a multifocal IOL. 


APAO Comparison of IntraLase FS60 and Ziemer Femto LDV 

Femtosecond Laser for Flap Creation 

Presenting Author: Jing Zhang MD 

Co-Author(s): Yue Hua Zhou**, Changbin Zhai** 

Purpose: To compare flaps created by IntraLase and Ziemer femtosecond laser. Methods: 

RTVue OCT was used to measure 816 LASIK flaps of 408 consecutive patients (Intra- 

Lase 408 flaps and Ziemer 408 flaps) 1 week postoperatively. Nominal flap thickness was 

110 µm. Results:The mean flap in the Ziemer group (105.37 ± 4.56 µm) was significantly 

thinner than that in the IntraLase group (110.29 ± 6.95 µm) (P < .001). Corneal flaps in both 

groups were uniform and regular, showing an almost-planar configuration. IntraLase and 

Ziemer had similar predictability, and the average deviation of flap thickness was 6.59 µm 

in IntraLase and 6.56 µm in Ziemer(P = .877). Conclusion: The flaps made by IntraLase are 

thicker than those created by Ziemer femtosecond laser. IntraLase and Ziemer had similar 

predictability and uniformity in flap creation. 


APAO Endothelial Cell Density After Femtosecond LASIK 

With 500 KHz Femtosecond Laser 

Presenting Author: Alok Sati MS 

Co-Author(s): Somasheila I Murthy MD, Varsha M Rathi, Mukesh Taneja DO MBBS 

Purpose: To assess effects of LASIK with femtosecond (Fs) laser on corneal endothelium. 

Methods: Prospective study of patients who had LASIK with 500-kHz Fs (Visumax, Carl 

Zeiss, 120-micron flap) for myopia was done. Pre- and 1-month postoperative specular 

microscopy (fixed frame analysis) was done. Results: Twenty-eight eyes (14 patients; 

mean age: 22) had preoperative endothelial cell density (ECD) of 2844 ± 231 cells/mm2, 

mean coefficient of variation, percentage of hexagonal cells was 32.82 and 52.32% and 

postoperatively, 2803 ± 237 cells/mm2, 34.93 and 47.03%, respectively. Decrease in hexagonality 

of cells was statistically significant in noncontact lens (CL) wear compared to CL 

(P = .0029). Conclusion: There was statistically significant hexagonality loss at 1 month. 


Refinement of Scleral Spacing Procedure for Presbyopia 

Presenting Author: Barrie D Soloway MD* 

Purpose: To discuss novel advancements of the PresView Scleral Implant (PSI) device, 

instrumentation, and technique used in the clinical trial for presbyopia. Methods: Since 

the 3/2000 start of PSI clinical trials, an evolution of the device, instrumentation, and 

technique has occurred. Changes to a 2-piece locking PSI device, Oculock and Dock instrument 

location of the PSI position, and shuttle placement of the PSI have all standardized 

the surgery. Results: 384 eyes of 205 patients have had the scleral spacing procedure 

(SSP) with the locking PSI. To date no slipping has been seen and efficacy continues to 

improve, with 100% at Snellen 20/40 or better at 24 months. Conclusion: Improvements 

in PSI stability, positioning, and subsequent facilitation of surgical technique has resulted 

in earlier and longer-lasting improvement in near acuity after SSP with PSI. 

224 






Six-Month Outcomes in High Myopia Patients Who 

Underwent Trans-PRK Treatments 

Presenting Author: Erika N Eskina MD 

Co-Author(s): Olga I Riabenko MD, Viktoria Parshina** 

Purpose: To evaluate clinical outcomes: refraction, visual acuity (VA), and contrast sensitivity 

among eyes that underwent a surface treatment with laser epithelial removal. 

Methods: Trans-PRK treatments were planned with CAM software and performed by the 

Amaris excimer laser (both Schwind eye-tech-solutions). Clinical outcomes were evaluated 

in terms of predictability, refraction, safety, and contrast sensitivity. Results: Sixmonth 

postoperative of the 54 eyes achieved UCVA 1.0 ± 0.03. Eighty-nine percent of eyes 

were within ± 0.25 D, and 100% were within ± 0.50 D. Postoperative contrast sensitivity at 

moderate spatial frequency was better than preoperatively. Conclusion: Transepithelial 

surface treatments yield superior outcomes with minimized discomfort through the efficient 

one-step epithelial removal and refractive correction. 


The Effect of Alcohol-Assisted vs. Mechanical Epithelial 

Debridement on Corneal Endothelial Cells in Photorefractive 

Keratectomy 

Presenting Author: 

Co-Author(s): Sied Morteza Entezari MD, Nariman Nassiri MD, Sare Safi MS**, 

Kourosh Sheibani 

Purpose: To compare the effects of alcohol-assisted to mechanical epithelial debridement 

on corneal endothelium after photorefractive keratectomy.Methods: Mechanical 

and alcohol-assisted epithelial debridement were compared in 88 eyes from 44 patients 

with spherical equivalent refraction < -6.00 D. Results: Three months postoperatively, 

mean endothelial cell density (P = .965), endothelial cell polymegathism (P = .892), endothelial 

cell hexagonality (P = .501), and endothelial cell area (P = .315) did not show 

statistically significant difference between the 2 groups. Conclusion: The adverse effect 

of mechanical epithelial debridement methods on the corneal endothelium is comparable 

to alcohol-assisted methods. 


Eye Rubbing in Refractive Surgery Patients: Incidence and 

Relationship to Corneal Topography 

Presenting Author: Lewis R Groden MD* 

Co-Author(s): Anh Q Bui MD, David P Simon MD FACS 

Purpose: To determine the incidence of eye rubbing in refractive surgery patients (RSP), 

and its relationship to corneal topography. Methods: Retrospective chart review of 214 

RSP. Data collected included history of eye rubbing and Orbscan corneal topography. Incidence 

of eye rubbing and its relationship to normal topography (NT) vs. abnormal topography 

(AT) were analyzed. Results: Eighty-one of 214 RSP (38%) rubbed their eyes at 

least daily. Of these 81 patients, 72 (89%) had NT, 9 (11%) had AT. Of 133 non-eye rubbing 

patients, 120 (90%) had NT, 13 (10%) had AT. The incidence of AT in these 2 cohorts of 

patients is not significantly different (P = .81). Conclusion: A history of eye rubbing is 

common in RSP, occurring in 38% of patients. A positive history of eye rubbing is not 

associated with AT. 


Patients’ Verdict: Laser Monovision Correction or Multifocal 

IOL Implantation (A Long-term Follow-up) 

Presenting Author: Tasneem Khatib MBBCH 

Co-Author(s): Rupinder Chana MBBS, Humayun A Khatib MD 

Purpose: To compare patient satisfaction with laser monovision correction (LMC) and 

multifocal IOL (M-IOL) implantation. Methods: Retrospective study comparing LMC 

(170 patients) with M-IOL implantation (394 patients) to reduce dependence on glasses 

between 2002 and 2012. All procedures were undertaken by 1 surgeon, and patients 

completed postoperative questionnaires. Results: Seventy-seven percent of those who 

returned questionnaires in the M-IOL group reported their vision to be as good or better 

than expected, compared to 71% in the LMC group. Fifty-three percent of the M-IOL group 

experienced haloes at night, compared to 23% in the LMC group. Conclusion: Both M- 

IOL implantation and laser LMC are effective for reducing dependence on glasses in the 

longer term. 


Comparing Early Visual Recovery and Aberrations in ReLEx 

With LASIK 

Presenting Author: Dan Z Reinstein MD* 

Co-Author(s): Glenn Ian Carp MBBCh, Kishore Pradhan MD, Timothy J Archer MS, 

Marine Gobbe PhD 

Purpose: To compare Day 1 uncorrected distance VA (UDVA) and spherical aberration (SA) 

between ReLEx and LASIK. Methods: Nonaspheric ReLEx (femtoLASIK) and aspherically 

optimized LASIK eyes were matched exactly for sphere, cylinder, CDVA, and age. Day 1 

UDVA was compared. SA induction was compared using corneal wavefront data. Results: 

Mean SEQ was -6.28 D, mean cylinder was 0.72. Preop CDVA was ≤ 20/20 in 92% of 

eyes. Day 1 UDVA was ≤ 20/20 in 77% of ReLEx eyes and 81% of LASIK eyes (P = .13). SA 

induction was similar in ReLEx and LASIK (P > .2). Conclusion: Early visual recovery was 

similar between ReLEx and LASIK. ReLEx, though minimally aspheric, produces similar 

SA induction to aspheric LASIK, indicating that biomechanical factors of the flapless procedure 

result in less SA induction than expected compared to nonaspheric conventional 

excimer myopic profiles. 


Retina, Vitreous Poster Tour 


12:30 PM to 1:30 PM 

Session One 





Evaluation of a Telemedicine Model for Exudative AMD 

Follow-up 

Presenting Author: Jose Andonegui MD* 

Co-Author(s): Daniel Aliseda MD*, Luis A Serrano MD, Aitor Eguzkiza MS* 

Purpose: Retina specialists are challenged by the burdensome follow-up of patients 

with exudative AMD, and new approaches are needed. Methods: We compared both 

the results of office and telemedicine examinations of 142 patients with exudative AMD 

and the time spent during both examinations. Results: Considering conventional office 

examination as the gold standard, the sensitivity and specificity of telemedicine evaluation 

were 94% and 86%, respectively. The median telemedicine evaluation lasted 1.62 

minutes compared with 10 minutes for an office examination (P < .00001). Conclusion: 

Telemedicine is a useful alternative for exudative AMD follow-up. 


Visual and Anatomic Outcomes of Anti-VEGF Therapy in 

Exudative AMD and Vitreomacular Interface Disease 

Presenting Author: Sophie Bakri MD* 

Co-Author(s): Amy E Green-Simms MD, Blake M Fechtel, Zubin Agarwal** 

Purpose: To describe outcomes of eyes with and without vitreomacular interface disease 

(VMID) treated with anti-VEGF injections for wet AMD. Methods: Retrospective series 

of 32 eyes with VMID and 146 eyes without. Results: Eyes with VMID received more 

injections (mean 14.7) over 4 years than eyes without VMID (mean 9.5) (P = .0224). BCVA 

was similar in both groups at baseline (P = .8013) and years 1-4 (P = .5417, .6275, .4574, 

and .0570, respectively). Central foveal thickness was similar to eyes without traction at 

baseline and years 1-3, and declined over time in eyes with VMID. Conclusion: Eyes with 

VMID and AMD receiving anti-VEGF therapy had improved BCVA and decreased central 

foveal thickness despite continued VMID, but required more injections than eyes without 

VMID. 





225




Inner Retinal Migration of Spectral Domain OCT 

Hyperreflective Foci and Progression of Intermediate AMD 

Presenting Author: Francisco A Folgar MD 

Co-Author(s): Joseph G Christenbury, Sina Farsiu PhD*, Cynthia A Toth MD* 

Purpose: To evaluate change in spectral domain OCT (SD-OCT) hyperreflective foci (HF) 

over time in eyes with intermediate AMD. Methods: In eyes with baseline and 1-year 

SD-OCT from the prospective A2A SD-OCT study, 1-year inner retinal HF migration was 

determined by weighted axial distribution score (AxD). AxD change in paired eyes and correlation 

with AMD progression were evaluated with signed rank tests and logistic regression. 

Results: In 296 eligible eyes (296 subjects), AxD 1-year increase (P < .001) reflected 

a shift to inner retinal layers. Eyes with geographic atrophy at 1-year were correlated with 

greater baseline HF (P < .001, OR = 1.48 per HF) and greater baseline AxD (P < .001, OR = 

1.14 per AxD point). Conclusion: Inner retinal HF migration on SD-OCT may serve as a 

biomarker for AMD progression. 


Response of Neovascular AMD Patients Is Altered by 

Variations in Sequences of the ARMS2 Gene but Not by 

Different Anti-VEGF Treatments 

Presenting Author: Alan J Franklin MD PhD* 

Co-Author(s): Magdalena F Shuler MD PhD, John P Myers MD**, Wright Lauten MD, 

Sunil Gupta MD* 

Purpose: To determine hereditary genetic predictors and response of different anti-VEGF 

therapy for wet AMD. Methods: Following 1 year of anti-VEGF treatment, we measured 

the change of visual acuity, macular thickness, injection number, and relation to the insertion/deletion 

in the ARMS2 gene. Results: Patients with at least one insertion/deletion 

within the ARMS2 gene had a significant average improvement in vision compared to 

those with the ancestral genotype (P = .0262). Treatment outcome was not dependent 

upon the type of anti-VEGF agent used. Conclusion: These data corroborate that observed 

in the CATT trial and support the use of hereditary genetics along with clinical data 

to predict the outcome of anti-VEGF treatment for AMD. 


APAO Adaptive Optics Follow-up Study of Geographic 

Atrophy 

Presenting Author: Kiyoko Gocho-Nakashima MD PHD 

Co-Author(s): Mustapha Benchaboune MD**, Jose A Sahel MD*, Michel Paques 

Purpose: To explore the microscopic changes that occur over time in retinas suffering 

from geographic atrophy (GA). Methods: Eight eyes from 7 patients underwent repeated 

adaptive optics (AO) imaging sessions using an infrared AO camera (rtx1, Imagine Eyes; 

France), and infrared SLO, autofluorescence SLO, and OCT.Results:The most relevant 

microscopic structures visible in AO were cone photoreceptors and clumps of melanin 

pigment. At follow-up visits, GA progression was observed in all eyes. Pigment clumps 

showed various degrees of mobility between visits. Conclusion: Infrared AO imaging 

could detect signs of GA progression within a time as short as 2 weeks. This study suggests 

that widespread melanin clumping precedes the onset of atrophy. 


APAO Interventional Outcomes of 55 Consecutive Eyes With 

Massive Subretinal Hemorrhage Secondary to AMD 

Presenting Author: So Goto MD 

Co-Author(s): Yusuke Oshima MD*, Nagakazu Matsumura, Fumi Gomi MD PhD*, 

Motohiro Kamei MD 

Purpose: To evaluate interventional outcomes of massive subretinal hemorrhage (SRH) 

due to AMD. Methods: Retrospective chart review was conducted in 55 consecutive eyes 

treated by pneumatic displacement (PD) alone or combined with vitrectomy and subretinal 

tPA (PPV/tPA) for massive SRHs. Results: SRH was displaced from the macula in all eyes; 

27 (49%) with PD alone and 28 (51%) needed PPV/tPA including 12 (22%) with bullous 

retinal detachment. Visual recovery was significantly related to the size (P = .020) and 

recurrence (P = .021) of SRH, and to the presence of polypoidal lesions (P < .001). Conclusion: 

Massive SRH can be successfully treated by either PD alone or combined PPV/tPA 

with visual recovery. 


IOP in Patients With Neovascular AMD Receiving 

Intravitreal Aflibercept or Ranibizumab Injection 

Presenting Author: Quan V Hoang MD 

Co-Author(s): K Bailey Freund MD*, VIEW 1 and VIEW 2 Investigators 

Purpose: To assess for change in IOP in neovascular AMD patients receiving intravitreal 

aflibercept (IAI) or ranibizumab (RBZ) in VIEW 1 and 2 studies. Methods: Patients were 

randomized to IAI 2 mg every 4 weeks, 0.5 mg every 4 weeks, 2 mg every 8 weeks (after 

3 loading doses), or RBZ 0.5 mg every 4 weeks. Results: At Week 96, % of patients with 

an increase on 2 consecutive monthly visits of 3 10 mmHg in IOP were 2.9%, 3.8%, 3.1%, 

and 6.4%, and IOP > 21 mmHg were 14.2%, 12.5%, 12.1%, and 20.2%, respectively. IAI 

groups, compared with RBZ every 4 weeks, had a lower incidence of sustained IOP > 21 

mmHg by 62%, 67%, and 50%. Conclusion: Incidences of IOP increase among IAI groups 

were lower than among the RBZ group. 


Stereotactic Radiotherapy for Neovascular AMD: A 

Randomized, Double-Masked, Dose-Ranging, Clinical Trial 

Presenting Author: Peter K Kaiser MD*, on behalf of INTREPID Investigators 

Purpose: To assess the safety and efficacy of low-voltage stereotactic radiotherapy (SRT) 

at 2 dose levels for the treatment of choroidal neovascularization (CNV) secondary to 

AMD. Methods: The INTREPID study is a double-masked, sham-controlled, dose-ranging 

clinical trial of 226 patients randomized (2:1:2:1) to 16 Gy SRT (IRay; Oraya Therapeutics, 

Inc.) + as required (p.r.n.) ranibizumab: sham 16 Gy SRT + p.r.n. ranibizumab: 24 Gy SRT 

+ p.r.n. ranibizumab: sham 24 Gy SRT + p.r.n. ranibizumab for 2 years. The primary endpoint 

was the number of ranibizumab injections during Year 1. Results: Twelve-month 

endpoints and safety will be presented. Conclusion: The use of the IRay System in the 

management of neovascular AMD will be discussed. 


Abnormal Sleep Patterns May Be Associated With 

Neovascular AMD 

Presenting Author: Rahul Khurana MD* 

Co-Author(s): Travis Porco PhD, Edwin E Boldrey MD, James D Palmer MD, J Luigi 

Borrillo MD, Mark R Wieland MD** 

Purpose: To investigate the relationship between sleep duration and AMD. Methods: 

1003 consecutive patients in a retina practice were prospectively surveyed regarding 

sleep histories. Each patient then had an ophthalmic exam and was graded on the Wisconsin 

Age-Related Maculopathy System. Results: After controlling for age, gender, and 

smoking, sleep deviation (either too much or too little sleep) was associated with neovascular 

AMD or geographic AMD (P < .01). Sleeping greater than 9 hours was 

associated with neovascular AMD or geographic AMD (age adjusted OR, 6.17; 95% CI, 

1.34-28.5; P < .01). Conclusion: Sleep deviations are associated with both neovascular 

AMD and geographic atrophy. Abnormal sleep patterns may be related to advanced AMD. 


Anterior Migration of Ozurdex Implants: Risk Factors and 

Management Strategies 

Presenting Author: Rahul Khurana MD* 

Co-Author(s): Suri N Appa MD, Farzin Avaz MD**, Walter H Stern MD 

Purpose: To describe the migration of a sustained dexamethasone implant (Ozurdex) into 

the anterior chamber. Methods: Four patients with spontaneous migration of an Ozurdex 

implant into the anterior chamber were retrospectively reviewed. Results: Each patient 

had a prior vitrectomy and absence of the posterior capsule. Two patients were aphakic, 

while 2 had an IOL. All 4 developed symptomatic corneal edema. In 2 cases the implant 

was externalized in its entirety, while the implant disintegrated upon grasping with a forceps 

and automated aspiration of the particles was required for the other 2. Conclusion: 

Absence of the posterior lens capsule is the main risk factor for anterior migration of an 

Ozurdex implant. Implant removal is necessary to reduce the risk of chronic corneal edema. 


Light Exposure and the Risk for Cataract Extraction and 

AMD: The ALIENOR Study 

Presenting Author: Jean-Francois Korobelnik MD* 

Co-Author(s): Audrey Cougnard-Grégoire PhD**, Isabelle Carriere PhD, Marie-Noelle 

Delyfer MD PHD*, Marie-Benedicte Rougier MD*, Melanie Le Goff PhD**, Jean- 

226 





Francois Dartigues PhD*, Pascale Barberger-Gateau PhD*, Joseph Colin MD*, Cecile 

Delcourt PhD* 

Purpose: We report the associations of solar radiation with the risk for cataract extraction 

and AMD in elderly French subjects. Methods: The ALIENOR study is a populationbased 

study. Exposure to ambient solar radiation was estimated from residential history 

in 837 participants. Results: After multivariate adjustment, subjects exposed to high 

ambient solar radiation were at increased risk for cataract extraction (OR = 1.7; P = .003) 

and for early AMD2 (2.9, P = .002). Subjects exposed to low ambient solar radiation were 

also at increased risk for early AMD2 (2.7, P = .006). Conclusion: This study confirms 

the increased risk for cataract extraction in subjects exposed to high solar radiation, and 

suggests that risk for early AMD2 is increased in subjects exposed to high and low solar 

radiation. 


APAO Prognostic Implication of Choroidal Thickness in 

Ranibizumab-Treated Eyes With Neovascular AMD 

Presenting Author: Hee Jung Kwon MD 

Co-Author(s): Young Ji Lee MD, Jeong-Ho Yi, Christopher S Lee MD, Sung-Chul Lee MD 

Purpose: To evaluate prognostic factors in newly diagnosed neovascular AMD. Methods: 

Forty eyes of 37 patients with neovascular AMD received 0.5 mg of intravitreal 

ranibizumab (IVR) monthly. One month after the third IVR, responders were defined as patients 

having improved visual acuity without retinal fluid. Results: Twenty-two eyes (55%) 

were responders. Multivariate logistic regression identified thicker subfoveal choroidal 

thickness (SFCT) (P = .049) and smaller choroidal neovascularization (P = .043) as predictive 

factors for responders. SFCT was significantly thicker in responders (257 vs. 167 µm) even 

after adjusting for age and spherical equivalence (P = .024). Conclusion: Thinner choroidal 

thickness is a negative prognostic factor for response to IVR in neovascular AMD. 


APAO Drop in Choroidal Thickness and Chorioretinal 

Blood Flow After Intravitreal Ranibizumab for Choroidal 

Neovascularization 

Presenting Author: Yuki Maekawa MD 

Co-Author(s): Kiyoshi Suzuma MD, Yoshihisa Yamada, Eiko Tsuiki DOMS, Harumi 

Wakiyama MD**, Takashi Kitaoka MD** 

Purpose: To evaluate the changes of subfoveal choroidal thickness (SFCT) and chorioretinal 

blood flow (CBF) after intravitreal ranibizumab (IVR) for choroidal neovascularization 

(CNV). Methods: Nineteen eyes of 19 patients with naïve CNV were measured for relative 

CBF, expressed as macular mean blur rate (MMBR), by laser speckle flowgraphy and for 

SFCT by enhanced depth imaging-OCT before and 1 month after the first IVR. Results: 

After IVR, the mean SFCT fell markedly from 226 ± 100 µm to 219 ± 102 µm (P < .05), while 

the MMBR was reduced to 93.6 ± 13.6% compared to before IVR (P < .05). There was a 

positive correlation between changes in SFCT and MMBR (r = 0.56, P < .05). Conclusion: 

The decrease in SFCT may be linked with the reduction in CBF after IVR. 


APAO Two-Year Follow-up of Ranibizumab Combined 

With Photodynamic Therapy for Polypoidal Choroidal 

Vasculopathy 

Presenting Author: Rei Nemoto MD 

Co-Author(s): Masahiro Miura MD, Takuya Iwasaki**, Hiroshi Goto MD, Hiroshi Goto 

MD 

Purpose: To evaluate the 2-year efficacy of combination intravitreal ranibizumab (IVR) 

and photodynamic therapy (PDT) for treatment-naïve polypoidal choroidal vasculopathy 

(PCV). Methods: 20 eyes of 20 patients with PCV were reviewed. Results: Mean changes 

from baseline visual acuity improved by 2.0 letters and 0.2 letters at 12 and 24 months, 

respectively. Three eyes showed severe deterioration of visual acuity by extensive subretinal 

hemorrhage. Mean central retinal thickness significantly decreased by 109 µm and 

113 µm at 12 and 24 months (P < .05), respectively. The average number of IVRs and PDTs 

were 7.1 and 1.6, respectively. Conclusion: Visual acuity improved during Year 1, but the 

benefit decreased in Year 2. 


HARBOR Study: Baseline Predictors of Visual Outcomes at 

Month 12 in Patients With Subfoveal Neovascular AMD 

Presenting Author: Carl D Regillo MD FACS* 

Co-Author(s): Linda Yau*, Phillip C Lai MD* 

Purpose: To determine baseline predictors of visual acuity (VA) at Month 12 in patients 

with wet AMD. Methods: Patients ≥ 50 years of age were randomized to receive intravitreal 

injections of ranibizumab 0.5 mg or 2.0 mg on a monthly or as-needed basis after 

3 monthly loading doses. This analysis included only the 0.5-mg arms (n = 500). Baseline 

predictors of VA at Month 12 were examined by stepwise logistic regression models. 

Results: Patients with higher BCVA (OR = 1.1 per letter increase), smaller total area of 

CNV leakage (OR = 1.2 per DA decrease), and presence of SRF (OR = 2.3) at baseline were 

more likely to achieve a vision of 20/40 or better at Month 12. Conclusion: Baseline 

characteristics, such as BCVA, total area of CNV leakage, and SRF, were predictive of VA 

at Month 12. 


Genetic Analysis of Concordant vs. Discordant AMD 

Presenting Author: Stephen G Schwartz MD MBA* 

Co-Author(s): Lana M Olson MS, Anita Agarwal MD*, Jaclyn L Kovach MD, William 

Cade PhD**, Gaofeng Wang PhD, William Scott PhD*, Jonathan L Haines PhD**, 

Margaret A Pericak-Vance PhD* 

Purpose: To investigate genetic correlations in patients with concordant (same grade 

each eye) vs. discordant (different grade each eye) AMD. Methods: Series of 1432 patients. 

Results: Older age (79 vs. 78, P = .0293), CFH Y402H risk allele H (86% vs. 79%, 

P = .0475), and ARMS2 A69S risk allele S (76% vs. 58%, P < .001) were more common 

in patients with bilateral choroidal neovascularization (CNV) than with unilateral CNV. 

No other significant associations were found. Conclusion: CFH Y402H risk allele H and 

ARMS2 A69S risk allele S were more common in patients with bilateral CNV than with 

unilateral CNV. These results confirm and extend earlier reports and may have prognostic 

and therapeutic implications. 


Choroidal Atrophy in Patients With Non-Neovascular AMD 

Presenting Author: Sumit Sharma MD 

Co-Author(s): Hani Rayess, David Xu, Gina Smith, Peter K Kaiser MD*, Justis P Ehlers 

MD 

Purpose: To determine if there is a correlation of choroidal thickness (CT) to visual acuity 

in non-neovascular AMD (NNV AMD). Methods: Retrospective evaluation of consecutive 

patients with NNV AMD who were imaged with an oversampling scan protocol to image 

the choroid, comparing visual acuity to manual measurements of retinal thickness and 

subfoveal CT. Results: Seventy-six eyes from 76 patients with NNV AMD without other 

macular pathology. Spearman correlation coefficients were calculated comparing logMAR 

visual acuity to the measured OCT parameters and were found to be significant for CT 

-0.374 (P-value 0.002). None of the other variables were found to be significant. Conclusion: 

Visual acuity was found to correlate to the measurement of CT with a thinner 

choroid associated with worse vision. 


Phase 1 Trial Targeting Tissue Factor for the Treatment of 

Neovascular AMD 

Presenting Author: John A Wells III MD* 

Co-Author(s): Christine R Gonzales MD*, Brian D Sippy MD PhD*, Victor H Gonzalez 

MD*, Brian Berger MD*, David L Johnson MD 

Purpose: To evaluate the safety of binding tissue factor with hI-con1 in eyes with active 

neovascular AMD. Methods: Prospective, multicenter, dose-escalating study of a single 

intravitreal injection of 60, 150, or 300 µg of hI-con1 in 18 eyes with active CNV and BCVA 

= 20/63 to count fingers. Anti-VEGF retreatment was allowed. Follow-up was to Week 24. 

Results: No ocular or systemic dose-limiting toxicities were identified. hI-con1 injection 

showed dose-related biologic effects including improved BCVA, CNV regression, and OCT 

fluid reduction. At Week 24, mean BCVA and OCT were +2.7 letters and -120 µm (n = 18) 

in the 300-µg group, +6.8 letters and -195 µm (n = 6). Conclusion: A single injection of 

hI-con1 showed no dose-limiting toxicities. Evidence of biologic effects were observed. 





227




Local Retinal Sensitivity Changes Associated With Reticular 

Drusen in Eyes With AMD 

Presenting Author: Mei Zhou 

Co-Author(s): Divya Nigam, Brett Jeffrey PhD, Wai T Wong MD PhD, Catherine A 

Cukras MD PhD, Elvira Agron MS, Emily Y Chew MD 

Purpose: To assess the influence of reticular drusen (RetD) on local retinal sensitivity in 

AMD eyes. Methods: Retinal sensitivity in 36 eyes (23 patients) with different stages of 

AMD and containing RetD were evaluated with the MP-1 microperimeter (Nidek). Testing 

loci located in areas of RetD were matched with control loci in areas without RetD of equal 

eccentricity from the horizontal raphe. Loci within advanced AMD lesions were excluded. 

Results: Age-adjusted repeated measures regression of 243 RetD loci to 243 spatially 

matched control loci demonstrated a statistically significant (P < .001) decrease in retinal 

sensitivity of 3.21 ± 0.38 dB. Conclusion: RetD are associated with local decreases in 

retinal sensitivity, indicating their negative impact on local retinal function. 


H Impact of Concomitant Glitazone or Fenofibrate Therapy 

on Outcomes of Diabetic Macular Edema Patients Treated 

With Ranibizumab 

Presenting Author: Diana Do MD* 

Co-Author(s): Yasir Jamal Sepah MBBS, Howard Shapiro PhD*, Lisa Tuomi**, DA VINCI 

Study Investigators 

Purpose: To compare efficacy outcomes at 24 months in ranibizumab (RBZ)-treated diabetic 

macular edema (DME) patients from RIDE and RISE (0.3-mg RBZ, n = 249; 0.5-mg 

RBZ, n = 248) who did/did not receive concomitant glitazone (GT) or fenofibrate (FF). Methods: 

BCVA, OCT, and diabetic retinopathy (DR) worsening at 24 months were compared 

between patients who did/did not receive concomitant GT or FF therapy at any time during 

the 24-month trials. Results: BCVA, OCT, and DR worsening did not differ significantly 

between patients taking a GT (n = 126) or FF (n = 27) and patients who did not across RBZtreated 

groups at 24 months (all P ≥ .05). Conclusion: Use of GT or FF did not appear to 

impact positive treatment outcomes in RBZ-treated DME patients. 


H Microperimetry Assessment of Retinal Sensitivity in 

Patients With Diabetic Macular Edema in the DA VINCI 

Study 

Presenting Author: Diana Do MD* 

Purpose: To compare retinal sensitivity after intravitreal aflibercept injection (IAI) and 

laser photocoagulation. Methods: Retinal sensitivity was assessed by microperimetry in 

a subset of 43 patients randomized to laser or IAI 0.5-mg or 2-mg regimens. Results: 

Mean change from baseline in visual acuity in the pooled IAI groups vs. laser was 11.5 vs. 

-1.3 letters (P < .0001) at Week 52 in the total cohort. In the microperimetry study, mean 

changes in retinal sensitivity from baseline were IAI, 2.0 dB (P < .001) and laser, -0.8 dB (P 

= .50). Conclusion: IAI-treated patients had improved retinal sensitivity in an exploratory 

study of DME patients. 


APAO Systemic Factors for Intraocular Levels of Vascular 

Endothelial Growth Factor and Interleukin-6 in Diabetic 

Retinopathy 

Presenting Author: Sohee Jeon MD 

Co-Author(s): Hakyoung H Kim MD, Won Ki Lee MD*, So-Hyang Chung 

Purpose: To evaluate the relationship between systemic factors and intraocular interleukin-6 

(IL-6) / VEGF in diabetic retinopathy (DR). Methods: Observational cross-sectional 

study from 42 eyes with DR was done. The correlation between various systemic factors 

and aqueous humor levels of IL-6/VEGF were analyzed. Results: In the adjusted multivariate 

analysis, smoking and HOMA-IR showed significant relationship with IL-6 after 

adjustment (P = .002 and P = .003, respectively), while Lp-A was associated with VEGF 

level (P = .032). Conclusion: The evaluation of relationship between systemic factors and 

intraocular level of various cytokines can help us to understand the complex pathophysiologic 

mechanism of DR. 


APAO Differences in Choroidal Thickness in Relation to the 

Severity of Retinopathy Among Type II Diabetics 

Presenting Author: Jee-Taek Kim MD 

Co-Author(s): Dong Hoon Lee MD**, Soo Geun Joe, June-Gone Kim MD PHD, Young 

Hee Yoon MD* 

Purpose: To assess the changes in subfoveal choroidal thickness (SFCT) among diabetics. 

Methods: Only treatment-naive patients were included. Enhanced-depth imaging was 

used to measure SFCT. Results: Among 145 patients, mean age was 62.6. SFCT increased 

as the retinopathy progressed; 262.3 ± 68.4 µm in no diabetic retinopathy (DR) (40 eyes), 

244.6 ± 77.1 µm in mild/moderate nonproliferative DR (NPDR) (47), 287.6 ± 109.0 µm in 

severe NPDR (72), and 376.8 ± 77.4 µm in proliferative DR (PDR) (36) (P < .05). Among 

diabetic macular edema (DME) subtypes, subretinal-fluid type (350.8 ± 82.6 µm) was significantly 

higher than cystoid or diffuse type (P < .05). Conclusion: SFCT increased as the 

retinopathy progressed to severe NPDR or PDR, especially when associated with DME of 

subretinal-fluid type. 


Screening for Diabetic Retinopathy Helped by Automatic 

Software 

Presenting Author: Amparo Navea-Tejerina MD 

Co-Author(s): Enrique Soto-Pedre MD MSc MPH, Jesus Morales MD**, Saray Millan- 

Velasco, Concepcion Hernaez Ortega, Pablo Perez**, Carmen M Desco-Esteban MD 

PhD 

Purpose: To assess the safety and usefulness of automated grading for diabetic retinopathy 

(DR) within a systematic screening program. Methods: A single central field image 

per eye was obtained from 5517 patients of a DR screening program in Valencia, Spain. 

Images were evaluated both manual and automatically. The sensitivity and specificity of 

an automated system operating as “> 1 microaneurysm detection for disease presence” 

grader were determined relative to a manual grading as gold standard. Results: The 

software classified 44.5% of the patients as having no retinopathy and 25.9% as having 

ungradeable images, with a 94.5% sensitivity (95% CI, 92.6-96.5) and a 69.1% specificity 

(95% CI, 67.6-70.6). Conclusion: This automated grading of DR seems to be adequate not 

only in terms of workload reduction but also in terms of safety. 


Enhanced Depth Imaging OCT Shows Thicker Choroid in 

Patients With Diabetic Macular Edema and Proliferative 

Diabetic Retinopathy 

Presenting Author: Robert Prinzi MD 

Co-Author(s): Domenic A Turco MD, Ausra Selvadurai MD 

Purpose: To compare subfoveal choroidal thickness (SFCT) in diabetic retinopathy. Methods: 

Retrospective chart review of 46 eyes from 24 patients with diabetic retinopathy 

using enhanced depth imaging OCT (Heidelberg Spectralis). Groups were analyzed based 

on presence of various pathologies including diabetic macular edema (DME), proliferative 

diabetic retinopathy (PDR), and nonproliferative diabetic retinopathy (NPDR). Results: 

Eyes with DME had significantly thicker SFCT than those without DME (mean SFCT, 303.83 

vs. 200.45, P < .0001). Eyes with PDR had thicker SFCT than eyes with NPDR (269.2 vs. 

215.57, P = .02)). Conclusion: Results suggest that DME and PDR are associated with 

thicker choroidal measurements. 


APAO Intraocular VEGF Level as a Risk Factor for 

Postoperative Complications After Vitrectomy for 

Proliferative Diabetic Retinopathy 

Presenting Author: Yoshihiko Usui MD 

Co-Author(s): Yoshihiro Wakabayashi MD PhD, Yoko Okunuki MD, Yoshimichi 

Matsunaga MD, Daisuke Muramatsu MD PHD**, Takeshi Kezuka MD PhD, Hiroshi 

Goto MD 

Purpose: To investigate whether intraocular concentrations of VEGF predict postoperative 

complications after vitrectomy for proliferative diabetic retinopathy (PDR). Methods: 

Sixty eyes of 52 consecutive patients with PDR who underwent primary vitrectomy were 

compared with respect to intraocular levels of VEGF and clinical data. Results: Multivariate 

logistic regression analysis showed that high vitreous VEGF level was associated with 

228 





a risk of early vitreous hemorrhage after vitrectomy for PDR (odds ratio: 12.3, P = .009). 

Conclusion: High intraocular VEGF level at the time of primary vitrectomy in patients with 

PDR was identified as a significant risk factor for early postoperative vitreous hemorrhage. 


APAO PAX2 Mutations in Japanese Patients With Renal 

Coloboma Syndrome 

Presenting Author: Tomomi Higashide MD PhD 

Co-Author(s): Kengo Furuichi MD PhD, Mayumi Sakurai MS, Shinji Ohkubo MD PhD*, 

Takashi Wada MD PhD**, Kazuhisa Sugiyama MD PHD 

Purpose: To explore PAX2 mutations in Japanese patients with renal coloboma syndrome 

(RCS). Methods: The PAX2 gene was screened for mutations in 26 patients with kidney 

dysfunction or morphological abnormality and colobomatous optic disc anomaly, which 

was rated from 0 (normal) to 4 (severe). Results: Four heterozygous mutations were found 

in 10 patients; R71T and Y341X were previously reported from Japan, while 662-3del2 

and G63S were new. Patients with PAX2 mutations had significantly higher disc anomaly 

scores than those without mutations (scores of both eyes: 4.0 ± 1.6 vs. 1.6 ± 1.3, P < .001). 

Conclusion: Japanese patients with RCS had unique PAX2 mutations. The patients with 

PAX2 mutations had more prominent disc anomaly scores than those without mutations. 


Ocular and Systemic Features of Familial Retinal Arterial 

Macroaneurysms With IGFBP7 Mutation 

Presenting Author: Emad Bishara Abboud MD 

Co-Author(s): Hisham Sami Alkuraya MBBS, Sawsan R Nowilaty MD, Mohammed 

Alghamdi MD FRCP, Fowzan S Alkuraya MD, Leen Abu Safieh PHD 

Purpose: To describe the features and clinical course of familial retinal arterial macroaneurysms 

(FRAM). Methods: Retrospective review of 22 patients (8 families) with FRAM 

and IGFBP7 mutation. Results: Age at presentation was 1-34 (mean: 10) years. Retinal 

features included bilateral arterial beading (100%) and macroaneurysms (95%) along major 

trunks, Coats-like features (36%), submacular gliosis (23%), and exudative RD (18%). 

Supravalvular pulmonic stenosis existed in 73% of cases. During follow-up (2-14, mean: 

9 years), recurrent visually significant bleeding and exudation occurred, 31% of patients 

required valve surgery, and 2 (9%) died from the disease. Conclusion: Retinal arterial 

beading and macroaneurysms are hallmarks of FRAM, a condition that can be sight- and 

life-threatening. 


The Interphotoreceptor Matrix Proteoglycan 2 or IMPG2: 

A Third Causal Gene in Autosomal Dominant Vitelliform 

Macular Dystrophy 

Presenting Author: Isabelle A Meunier MD 

Co-Author(s): Béatrice Bocquet PhD, Bernard Puech MD, Robert Verdet, Martine 

Mauget-Faysse MD*, Sabine Defoort MD, Claire Marie Dhaenens MD, Gaël Manes 

PhD, Carl F Arndt**, Xavier Zanlonghi MD, Christian Hamel 

Purpose: To evaluate the possible involvement of IMPG2 in autosomal dominant vitelliform 

macular dystrophy (VMD), considering its occurrence in cases of recessive retinitis 

pigmentosa with frequent macular lesions as well as in 1 case of recessive macular 

dystrophy. Methods: The IMPG2 gene was screened in 44 unrelated patients (18 with 

juvenile VMD and 26 with adult-onset VMD) with no mutations in BEST1 or PRPH2. Results: 

One asymptomatic patient with adult-onset VMD and a normal Arden ratio had a 

heterozygous missense mutation (p.C1077F) in a conserved amino-acid of the EGF-like 

domain. Conclusion: This is the first report of a mutation in a gene other than BEST1 or 

PRPH2 in adult-onset vitelliform macular dystrophy. 


New Macular Dystrophy Associated With Loose Anagen 

Hair Syndrome: A 10-Year Follow-up 

Presenting Author: Mario T Sato MD 

Co-Author(s): Aline Shiokawa SR MD, Ana Veiga, Naoye Shiokawa, Luiz Lima MD, 

Stephen H Tsang MD PhD 

Purpose: Report of 10-year follow-up of a family with a new association of macular dystrophy 

(MD) with loose anagen hair syndrome. Methods: Seven members were submitted 

to OCT and eletrophysiological tests 10 years after diagnosis. Results: There was an 

increase in pigmentary dispersions in the retina’s posterior pole in adult male patients and 

in macular coloboma in adult female patients all heading to the periphery, as well as an 

increase of short implicit time, becoming long implicit time in the scotopic phase at full 

field eletroretinography. Conclusion: These findings show delayed implicit time after 10 

years, suggesting that this disease behaves like other macular dystropies. 


Eliminating Antibiotic Prophylaxis for Intravitreal Injections: 

A Consecutive Series of 15,029 Injections by a Single 

Surgeon 

Presenting Author: Abdhish R Bhavsar MD* 

Purpose: To assess endophthalmitis risk in a consecutive series of 15,029 intravitreous 

injections without topical antibiotic prophylaxis. Methods: Data from 15,029 consecutive 

intravitreous injections performed by a single surgeon were retrospectively analyzed. All 

injections were given with povidone iodine, but without topical antibiotics prior to, during, 

or after injections. Results: 3269 patients were treated with 15,029 intravitreous injections 

of bevacizumab, ranibizumab, triamcinolone, pegaptanib sodium, dexamethasone 

implant, ganciclovir, and triesence. There was 1 case of endophthalmitis. Conclusion: 

Intravitreous injections may be given safely with a very low risk of endophthalmitis with 

povidone iodine but without antibiotic prophylaxis. 


APAO Proteomic Analysis of Aqueous Humor in Monitoring 

Treatment for Cytomegalovirus Retinitis 

Presenting Author: Jayant Venkatramani Iyer MBBS 

Co-Author(s): Stephen C Teoh MBBS FRCS* 

Purpose: To analyze ocular proteomic composition changes in patients with cytomegalovirus 

retinitis (CMVR) after treatment with intravitreal ganciclovir. Methods: Twentyfive 

aqueous humor samples were obtained from 22 CMVR patients receiving intravitreal 

ganciclovir therapy at various stages of treatment and analyzed for levels of 42 cytokines, 

chemokines, and growth factors with the Luminex (Bio-Plex 200) platform. Results: A 

common signature of infection was revealed in patients with CMVR dominated by the 

expression of fractalkine, IP-10, MCP-1, IL1-alpha, EGF and FLT3-ligand. Conclusion: Proteomic 

profiling of aqueous humor in patients with CMVR has revealed a unique proteomic 

immune signature, with varying levels detected through the course of treatment. 


A Prospective Case Series of Ranibizumab for the Treatment 

of Inflammatory and Idiopathic Choroidal Neovascular 

Membranes 

Presenting Author: Tanya N Moutray MBBCH 

Co-Author(s): Narendra Dhingra MBBS*, Adam Ross, Rajeev Chalassani MBBCh, Clare 

Bailey MD FRCOPHTH* 

Purpose: To assess the efficacy of treatment for choroidal neovascular membranes 

(CNVM) secondary to posterior segment intraocular inflammation. Methods: Prospective 

case series of new patients (n = 13) with active idiopathic/inflammatory CNVM; 73-24 

letters vision; CNVM diameter ≤ 5400 microns. Treatment: 3 loading doses of ranibizumab 

followed by a p.r.n. regime. Results: Mean BCVA gain at 4 months was 15 letters. By 

month 12, 42% required further injections beyond the loading phase (mean total number: 

4 per patient); 100% of patients had lost < 15 letters; 50% had gained > 5 letters, and 

33% had gained > 15 letters. Conclusion: We have shown that ranibizumab achieves 

good clinical outcomes for inflammatory CNVM, with a low need for retreatment after the 

initial loading phase. 


H Enhanced Depth Imaging Spectral Domain OCT of 

Eyes Treated With Iodine-125 Brachytherapy for Choroidal 

Melanoma 

Presenting Author: Robert M Beardsley MD 

Co-Author(s): Carolyn K Pan MD, Tara A McCannel MD** 

Purpose: To report the effect of plaque brachytherapy on choroidal thickness and to correlate 

to clinical radiation maculopathy in eyes with choroidal melanoma (CMM). Methods: 

Fifty-seven consecutive patients with CMM were evaluated with enhanced depth imaging 

spectral domain OCT (EDI SD-OCT) for choroidal thickness. The results were correlated 

to ophthalmoscopy, SD-OCT, and ultrasound findings. Results: Choroidal thickness decreased 

over time after radiation treatment (regression slope = -0.579) independent of 

age. In the presence of CME, the choroidal thickness was increased compared to eyes 

without CME at all timepoints after treatment. Conclusion: Plaque brachytherapy is associated 

with subfoveal choroidal thinning over time. 





229




Retinal Astrocytic Hamartomas: A Spectral Domain OCT 

Classification and Its Importance in Clinical Evaluation of 

Tuberous Sclerosis Complex 

Presenting Author: Paolo Nucci MD 

Co-Author(s): Francesco Pichi MD, Antonio P Ciardella MD, Gian P Giuliari MD 

Purpose: To propose a new classification of retinal astrocytic hamartomas (RAHs) secondary 

to tuberous sclerosis complex (TSC) based on OCT images. Methods: Review of 

OCT images of patients with RAH. All spectral domain OCT scans were performed with a 

scan rate of 40,000. Results: Ninety-eight lesions of 86 eyes with RAHs were included. 

Lesions were classified in 4 different types. Type I appeared as flat lesions without retinal 

traction. Type II were slightly elevated and presented retinal traction. Type III presented 

inner calcifications and a mulberry-like appearance. Type IV were dome-shaped, with an 

optically empty cavity. Conclusion: OCT proved to be valuable tool in the monitor and 

classification of these lesions. 


APAO Changes of Optical Densities of Subretinal Fluid in 

Central Serous Chorioretinopathy 

Presenting Author: Masayuki Hata MD 

Co-Author(s): Takanori Kameda MD, Hiroshi Kojima MD PhD, Noriko Miyamoto MD 

PhD, Michiko Mandai*, Yasuo Kurimoto MD PhD* 

Purpose: To investigate the changes in density of subretinal fluid (SRF) in central serous 

chorioretinopathy (CSC) using spectral domain OCT (SD-OCT). Methods: We retrospectively 

reviewed 53 eyes with CSC. The ratio of optical density of SRF to that of vitreous, 

or optical density ratio (ODR) and outer nuclear layer thickness (ONLT) were obtained with 

SD-OCT. We analyzed ODR, ONLT, visual acuity (VA), and estimated duration of the disease 

(EDD). Results: Eyes with EDD of 1-6 months showed greater ODR without significant VA 

deterioration than those with EDD of less than 1 month (P = .01). ODR significantly correlated 

with EDD (r = 0.63, P < .001), ONLT (r = -0.58, P < .001), and VA (r = 0.32, P = .018). 

Conclusion: In eyes with CSC, ODR increased with the duration of presence of SRF and 

possibly with progressive photoreceptor damage. 


APAO Choroidal Thickness and Retinal Detachment in Vogt- 

Koyanagi-Harada Disease 

Presenting Author: Yutaka Imamura MD PhD 

Co-Author(s): Kouhei Hashizume MD, Takamitsu Fujiwara MD, Shigeki Machida MD**, 

Masahiro Ishida MD, Daijiro Kurosaka 

Purpose: To investigate the correlation between subfoveal choroidal thickness and the 

height of retinal detachment in Vogt-Koyanagi-Harada disease (VKH). Methods: Enhanced 

depth imaging OCT was used to measure choroidal thickness. Results: Forty-two 

eyes of 21 patients with VKH (13 females, mean age: 49 years) were studied. Choroidal 

thickness before high-dose steroid therapy was 884 ± 193 µm (mean ± SD) and decreased 

to 358 ± 120 µm with disappearance of retinal detachment after treatment. The height of 

retinal detachment was significantly correlated with choroidal thickness during treatment 

(Wilcoxon signed-rank test, P < .0001). Conclusion: Retinal detachment in VKH improves 

with decreasing choroidal thickness. 


APAO Dissociated Optic Nerve Fiber Layer Appearance 

Analyzed by Spectral Domain Optical Coherence After Pars 

Plana Vitrectomy for Idiopathic Macular Hole 

Presenting Author: Hyung Woo Kwak MD PhD 

Co-Author(s): Namsuk Cho MD, Seung-Won Lee MD, Seung Young Yu MD 

Purpose: To investigate characteristics of a dissociated optic nerve fiber layer (DONFL) 

appearance in eyes with surgically closed full-thickness macular hole using spectral 

domain OCT (SD-OCT). Methods: This is a retrospective study including 52 eyes in 49 

patients. Based on SD-OCT, Group A with no defects of retinal nerve fiber layer (RNFL), 

Group B (n = 31 eyes) with defects of only RNFL, and Group C (n = 16 eyes) with defects 

of RNFL and IPL. Results: The DONFL was found in 36 eyes by fundus photographs and 

in 46 eyes by SD-OCT. There was no significant difference of BCVA between the 3 groups 

and no changes of FAF in area of the DONFL. Conclusion: The DOFNL occurred in 88.5% 

by SD-OCT after PPV. The DONFL is exhibited by defects not limited to the RNFL thickness 

and exhibited progressively. 


H Macular Leakage and Peripheral Vascular Leakage and 

Nonperfusion on Ultrawide-Field Fluorescein Angiography 

Presenting Author: Ella H Leung MD 

Co-Author(s): Gennady Landa**, Richard Rosen MD* 

Purpose:To determine the relationship between leakage in the macula and leakage and 

nonperfusion in the posterior retina (central 75 degrees) and far peripheral / anterior retina 

(up to 200 degrees). Methods: Retrospective case-control study of the ultrawide-field 

fluorescein angiograms of 125 eyes with macular leakage and 125 controls. Results: 

Compared to patients with no macular edema, those with macular leakage were more 

likely to have leakage in the posterior retina (95% vs. 64%, P < .05) and far periphery (84% 

vs. 65%, P < .05), and nonperfusion in the posterior retina (72% vs. 64%, P = .36) and far 

periphery (86% vs. 68%, P < .05). Conclusion: Macular leakage is associated with other 

retinal vascular leakage and nonperfusion in the far peripheral retina. 


Comparison of Spectral Domain OCT and Fluorescein 

Angiography Conversion Rates in Fellow Eyes of HARBOR 

Patients 

Presenting Author: Brandon J Lujan MD* 

Co-Author(s): Zhengrong Li**, J Jill Hopkins MD* 

Purpose: To evaluate the development of CNV in fellow eyes of HARBOR patients (N = 

1097) and compare fluorescein angiography (FA) and spectral domain OCT (SD-OCT) indicators 

of neovascular AMD at Month 12. Methods: The development of CNV in fellow 

eyes was evaluated by CNV leakage on FA, evidence of any fluid on SD-OCT, evidence of 

intraretinal fluid (IRF) on SD-OCT, and evidence of pigment epithelial detachment (PED) on 

SD-OCT. Results: CNV development in fellow eyes (n = 684) was observed in 12.1% (FA 

criteria; n = 83), 50.6% (any fluid on SD-OCT; n = 346), 28.7% (IRF on SD-OCT; n = 196), 

and 18.4% (PED on SD-OCT; n = 126) of patients. Conclusion: The rate of detection of 

any fluid on SD-OCT was much higher than the rate of FA conversion in the HARBOR study 

fellow eyes. SD-OCT features predictive of FA conversion will be discussed. 


APAO Retinal Blood Flow Levels Measured by Laser 

Speckle Flowgraphy Before and After Vitrectomy for 

Diabetic Macular Edema 

Presenting Author: Makiko Matsumoto MBCB MD DOMS 

Co-Author(s): Kiyoshi Suzuma MD, Yoshihisa Yamada, Michi Liu MD**, Eiko Tsuiki 

DOMS, Azusa Fujikawa MD PhD**, Takashi Kitaoka MD** 

Purpose: To report retinal blood flow levels in refractory diabetic macular edema patients 

undergoing vitrectomy. Methods: The mean blur rates (MBR) which represent retinal 

blood flow of the major optic disc vessels were measured by laser speckle flowgraphy 

(LSFG), and central retinal thickness (CRT) was measured by OCT in 10 vitrectomy patients 

(13 eyes). Results: In all 13 eyes with successful vitrectomy, macular edema resolved 

within 3 months after surgery, mean CRT was significantly decreased (P < .01), and MBR 

significantly increased (114%, P < .01) as compared to before surgery. Conclusion: Vitreous 

surgery may improve retinal blood flow levels in diabetic macular edema patients. 


APAO Association Between Retinoschisis in Highly Myopic 

Eyes and Posterior Pole Curvature Map 

Presenting Author: Masahiro Miyake MBCB DOMS 

Co-Author(s): Kenji Yamashiro MD PhD, Yumiko Akagi-Kurashige MD, Akio Oishi MD 

PHD, Akitaka Tsujikawa MD PhD*, Masanori Hangai MD* 

Purpose: To analyze the association between retinoschisis and ocular shape of highly 

myopic eyes using posterior pole curvature map. Methods: The curvature of Bruch membrane 

line was measured at 1-µm intervals for 12 ◊ 9-mm radial OCT images and reflected 

into a color map. Of the 181 highly myopic eyes evaluated, 47 eyes had retinoschisis. 

Results: The curvature map clearly visualized the edge and the shape of staphyloma. 

Of the 129 eyes with staphyloma, the map indicated smooth staphyloma in 112 eyes, 

while 17 eyes showed a highly undulated surface. At the center of smooth staphyloma, 

44 eyes showed an elevated pattern of color map, and these eyes had significantly higher 

rate of retinoschisis (P = .011). Conclusion: The curvature map may be useful to predict 

retinoschisis. 

230 






The Posterior Pole in Posterior Microphthalmos: Novel 

Spectral Domain Optical Coherence Tomography Findings 

Presenting Author: Sawsan R Nowilaty MD 

Co-Author(s): Nicola G Ghazi MD, Ahmed Mousa AbdelRahim PHD 

Purpose: To analyze macular spectral domain OCT (SD-OCT) findings in posterior microphthalmos 

(PM) in relation to axial length (AL) and macular fold (MF) features. Methods: 

Prospective SD-OCT in 20 PM cases (40 eyes) and 20 controls. Analysis included MF features 

and “posterior pole curvature index (PPCI),” a new parameter. PPCI was correlated 

to MF height and AL and compared to control PPCI. Results: All MFs were horizontal and 

partial thickness, sparing the photoreceptors. Vertical PPCI was notably larger than horizontal 

PPCI and than that of controls (mean: 164, 116, and 17 µm; Ps < .0001). PPCI strongly 

correlated with MF height and inverse AL (Rís > 0.71, Ps < .0001). Conclusion: In PM, the 

vertical posterior pole curvature is steep and inversely related to AL. This may play a role 

in MF morphology and pathogenesis. 


Natural History of Melanin in Vitelliform Lesions 

Presenting Author: Francesco Pichi MD 

Co-Author(s): Lucia Vitale MD, Maria Chiara Morara MD, Antonio P Ciardella MD, 

Paolo Nucci MD, Francesco Bonsignore OD, Elisa Restelli OD 

Purpose: To evaluate natural hystory of melanin in acquired vitelliform lesions (AVLs) 

using near-infrared autofluorescence (NIA) at 787 nm. Methods: NIA images obtained 

in 85 eyes with various AVLs (15 cuticular drusen, 13 subretinal drusenoid deposits, 34 

soft drusen, 23 adult-onset vitelliform lesions) at 6, 12, 18, and 24 months. Results: At 

baseline, 56.5% of eyes with early AVLs showed spots of increased NIA, which at Month 

12 increased and coalesced in 87%. At Month 24 in 32.9% of eyes NIA decreased and 

became dot-like. Conclusion: In early stages of AVLs, melanin granules are displaced toward 

the apex by basal lipofuscin accumulation. As the AVL evolve, an increase of melanin 

content occurs as a response to increased phagocytosis of degenerative photoreceptors. 

In late stages, this pigmented material may migrate into the neurosensory retina. 


APAO High-resolution Photoreceptor Imaging of Macular 

Microholes Using Adaptive Optics Scanning Laser 

Ophthalmoscopy 

Presenting Author: Sotaro Ooto MD 

Co-Author(s): Masanori Hangai MD*, Kohei Takayama MD, Naoko Ueda-Arakawa MD, 

Masaaki Hanebuchi*, Nagahisa Yoshimura MD PhD* 

Purpose: To assess the pathologic changes in the cone photoreceptors of patients with 

macular microholes using adaptive optics scanning laser ophthalmoscopy (AO-SLO). 

Methods: Twelve patients (14 eyes) with macular microholes underwent AO-SLO and 

spectral-domain OCT. The patients were followed up for more than 12 months. Results: 

AO-SLO showed foveal cone loss (13 eyes, round or oval; 1 eye, T-shaped) in all the eyes. 

Cone loss area (mean, 15711 µm2) correlated with worse visual acuity (P = .007). The cone 

loss area increased in 3 eyes, was stable in 6 eyes, and decreased in 5 eyes during the 

follow-up period. Conclusion: AO-SLO showed that cone loss area associated with visual 

acuity may change in macular microholes. 


Area of Peripheral Retinal Nonperfusion in Branch and 

Central Retinal Vein Occlusion and Its Effect on Treatment 

Response 

Presenting Author: Michael A Singer MD* 

Co-Author(s): Colin S Tan MBBS, Darren J Bell MD*, Joe Pollard MD**, Srinivas R 

Sadda MD* 

Purpose: To evaluate peripheral retinal nonperfusion in branch or central retinal vein 

occlusion (BRVO and CRVO) and its effect on treatment response. Methods: Patients with 

BRVO or CRVO underwent widefield fluorescein angiography. Areas of ischemia were calculated 

as a percentage of the total retinal area. Results: The area of retinal ischemia 

(mean: 13.4%) was larger with macular edema present (14.8% vs. 10.3%, P < .001). Those 

with ischemia > 10% showed more improvement in central subfield thickness (289.4 µm 

vs. 177.8 µm, P = .05) had worse visual acuity (VA) at the start (54.6 letters vs. 69.7) 

and greater gain in VA with treatment (12.6 letters vs. 1.6). Conclusion: The peripheral 

retinal nonperfusion in BRVO and CRVO affects changes in retinal thickness and VA with 

treatment. 


APAO Choroidal Thickness in Irvine-Gass Syndrome 

Presenting Author: Vivien Cherng Hui Yip MBBS 

Co-Author(s): Augustinus Laude MBChB 

Purpose: To correlate choroidal thickness (CT) in Irvine-Gass syndrome (IGS). Methods: 

Retrospective analysis of CT in 11 patients with IGS with enhanced depth imaging OCT 

(EDI-OCT), with the fellow, normal eye as control. The correlations between age, axial 

length (AXL), and refraction with CT were also evaluated.Results: EDI-OCT images were 

acquired at a mean of 3.0 (± 2.1 SD) months after surgery. There was a significant correlation 

between CT of affected eyes and age (P = .003). Eyes with IGS had a lower mean CT 

compared to fellow eyes. However, the difference in mean CT was not significant (194.9 

µm vs. 229.2 µm, P = .181). There was no correlation with AXL. Conclusion: Results suggest 

that CT is influenced by age but does not appear to be significantly affected in IGS. 

We suggest that IGS is not a choroidal-driven disease. 


High-resolution 3-D Structure of Nonexudative AMD Using 

Motion-Corrected, Ultrahigh-Speed, Ultrahigh-Resolution 

OCT 

Presenting Author: Jason Zhang MD 

Co-Author(s): Jonathan Liu, Martin F Kraus MS**, WooJhon Choi MS, Bernhard 

Baumann PhD**, Benjamin Potsaid PhD*, Joachim Hornegger PhD**, James Fujimoto 

PhD*, Jay S Duker MD* 

Purpose: To characterize 3-D features of nonexudative AMD using ultrahigh-speed 

(91,000 A-scans/sec), ultrahigh-resolution (3.2 µm) OCT (UHR-OCT), and image registration 

motion correction. Methods: Twenty eyes of 16 patients with nonexudative AMD 

were imaged to generate motion-corrected 3-D datasets with 4 times more data and ~2 

times finer resolution than commercial OCT. Results: 3-D OCT data were free of eye motion 

artifacts, and fine outer retinal pathology, including retinal pigment epithelial (RPE) 

and photoreceptor outer segment disruption, could be visualized, enabling assessment of 

drusen substructure and associated features of photoreceptor and RPE loss. Conclusion: 

3-D UHR-OCT imaging may be an important tool for assessing nonexudative AMD progression 

and response to therapy. 


Baseline Characteristics in Patients With Branch Retinal 

Vein Occlusion or Central Retinal Vein Occlusion Treated 

With Ranibizumab That Predict Visual Outcome 

Presenting Author: Raafay Sophie MBBCHIR MD 

Co-Author(s): Peter A Campochiaro MD*, Yan Zheng MS, Linda Yau*, Roman G Rubio 

MD MBA** 

Purpose: Identification of characteristics predictive of visual outcomes in ranibizumab 

(RBZ)-treated retinal vein occlusion (RVO) patients. Methods: Analysis of data of patients 

who completed Month 12 of HORIZON RVO trial. Results: Significant predictors of final 

BCVA ≥ 20/40 at Month 12 of HORIZON RVO were RBZ treatment from BRAVO or CRUISE 

baseline, fewer injections during BRAVO or CRUISE, better BRAVO or CRUISE baseline 

BCVA, and younger age at baseline. Significant predictors of final BCVA ≤ 20/200 were 

lower baseline BCVA in both BRVO and CRVO patients, delayed treatment with 0.5-mg 

RBZ, and older age at baseline in CRVO patients only. Conclusion: Younger patients and 

those who start RBZ treatment early in the disease process have better visual outcomes. 


Detection and Re-treatment of Diabetic Macular Edema in 

the READ-3 Study Using Time Domain and Spectral Domain 

OCT 

Presenting Author: Yasir Jamal Sepah MBBS 

Co-Author(s): Abeer Akhtar, Roomasa Channa MD, Raafay Sophie MBBCHIR MD, 

Afsheen Khwaja MD, Rachel Annam MD MPH, Mohamed A Ibrahim Ahmed MBBCH, 

Hyun S Jang, Diana Do MD* 

Purpose: To investigate the presence of diabetic macular edema (DME), detected on 

spectral domain OCT (SD-OCT), which may impact retreatment decisions in eyes with DME 

from the READ-3 Study. Methods: Analysis was performed on patient visits from Month 6 

to Month 24 inclusive to determine the frequency of retreatment. Results: Patients were 

retreated at 1267 visits. IRF or SRF was observed at 1254 patient visits based on SD-OCT, 

at which time 1244 were treated. Patients were retreated (FTh ≤ 250 µm on time domain 

[OCT (TD-OCT]) at 703 visits, at which time 687 visits patients were treated. Treatment 





231



frequency, if based on FTH, would be 32% (578/1786) compared to 70% (1244/1786) when 

SRF/IRF was detected on SD-OCT (P < .001). Conclusion: SD-OCT can show presence of 

IRF/SRF, which may impact treatments, in cases where FTh is ≤ 250 µm on TD-OCT. 


H African Americans at Highest Risk of Diabetic Macular 

Edema Compared with Non-Hispanic Whites and Hispanics 

Presenting Author: Rohit Varma MD MPH* 

Co-Author(s): Neil M Bressler MD*, Quan Doan PharmD**, Michelle Gleeson PhD*, 

Paul P Lee MD JD*, Mark Danese PhD*, Chantal M Dolan PhD**, Jennifer Fine*, 

Jason S Ehrlich MD*, Shoshana Colman PhD*, Adam Turpcu PhD** 

Purpose: To estimate prevalence of and identify factors associated with diabetic macular 

edema (DME) in the National Health and Nutrition Examination Survey (NHANES). Methods: 

5391 subjects in NHANES had exams and fundus photographs from 2005 to 2008. 

Race-specific prevalences and risk factors for DME were calculated using frequency distributions 

and regression analyses. Results: Prevalence of DME: 2.2% in non-Hispanic 

whites; 4.9% in Hispanics; 8.2% in African Americans (AAs). High HgbA1C (OR = 1.5), ≥ 

10 years of diabetes (OR = 10.9), and AA race (OR = 2.8) were associated with DME (P < 

.05). Conclusion: Given recent advances in DME treatment, screening, and intervention 

programs targeted at African Americans, [even] patients with high HgbA1C and long duration 

of diabetes may see a reduction in the burden of diabetic vision loss. 


Retinal Function by Microperimetry Correlates With 

Macular Volume by Spectral Domain OCT 

Presenting Author: Sandeep Grover MD* 

Co-Author(s): Michelle L Diaz MD, Lee Ferguson MD PhD**, K V Chalam MD PhD 

Purpose: To evaluate the correlation between the macular structure and function in 

various retinal diseases. Methods: Sixty-four eyes of 35 patients with various macular 

diseases were included in this retrospective study. The structure was measured using 

macular volume of the central 1-mm and 3-mm zone by spectral-domain OCT (Spectralis). 

The macular function was measured by microperimetry (Nidek) by averaging the retinal 

thresholds in similar areas. Results: The 3-mm macular volume correlated with retinal 

thresholds better than the 1-mm volume. Conclusion: Macular volume by OCT maybe an 

excellent tool for monitoring macular diseases. 


APAO Half Fluence Photodynamic Therapy Compared 

to Intravitreal Bevacizumab for Chronic Central Serous 

Chorioretinopathy 

Presenting Author: Tae-Gon Lee MD 

Co-Author(s): Judy E Kim MD*, Chulgu Kim MD**, Sung Won Cho MD PHD, Su Jin Yoo 

MD**, Jeong Il Han MD PhD, Moon Jeong Choi MD**, Young-Ju Lew MD**, Young 

Seok Jang MD**, Joo Yeon Kim, Young Hoon Lee**, Myeong Sook Ha MD, Seon 

Young Jin MD 

Purpose: To compare half fluence photodynamic therapy (hf-PDT) and intravitreal bevacizumab 

(IVB) for the management of chronic central serous chorioretinopathy (CSC). Methods: 

Retrospective review of 40 consecutive cases of chronic CSC treated with hf-PDT 

or IVB. Results: Resolution of subretinal fluid was achieved in 17 of 19 eyes (89.5%) in 

the hf-PDT group and in 6 of 21 eyes (28.6%) in the IVB group (P < 0.000). Central sensory 

retinal thinning (SRT) occurred in all cases of the hf-PDT group and in 13 of 21 eyes (62.0%) 

of the IVB group at the last follow-up (P = .004). LogMAR visual acuity at 6 and 12 months 

was 0.52 and 0.41 for the hf-PDT group, and 0.10 and 0.18 for the IVB group (P = .026 and 

P = .043, respectively). Conclusion: hf-PDT may be more effective than IVB for chronic 

CSC, but central SRT was more common. 


APAO VEGF Polymorphism Influences the Response to Anti- 

VEGF Treatment for Choroidal Neovascularization in High 

Myopia 

Presenting Author: Kenji Yamashiro MD PhD 

Co-Author(s): Masahiro Miyake MBCB DOMS, Isao Nakata MD, Kyoko Kumagai MD, 

Yumiko Akagi-Kurashige MD, Hideo Nakanishi, Sotaro Ooto MD, Hiroshi Tamura MD, 

Akio Oishi MD PHD 

Purpose: To evaluate whether VEGF gene polymorphism affects the response to anti- 

VEGF therapy for myopic choroidal neovascularization (mCNV). Methods: We studied 84 

eyes with mCNV that received anti-VEGF therapy for the first time and were followed 

up for 52 weeks or more. Visual acuity (VA) and mCNV recurrence were evaluated in association 

with VEGF single nucleotide polymorphism rs2010963 that has been shown to 

be associated with the size of mCNV in our previous study. Results: Rs2010963 was 

significantly associated with visual prognosis while not with the recurrence. The C allele 

significantly contributed to VA deterioration even after an adjustment for age, sex, and 

mCNV size (P = .017). Conclusion: VEGF polymorphism may affect the response to anti- 

VEGF therapy for mCNV. 


Epiretinal Membrane and Cystoid Macular Edema After 

Retinal Detachment Repair With Pars Plana Vitrectomy 

Presenting Author: Tanuj Banker MBCB 

Co-Author(s): Gayatri S Reilly MD, Eric D Weichel MD, Eric D Weichel MD , The Retinal 

Detachment Study Group 

Purpose: To evaluate incidence of epiretinal membrane/cystoid macular edema (ERM/ 

CME) after primary 23-/25-gauge retinal detachment (RD) repair. Methods: A consecutive 

interventional case series from 2002 to 2012 (N = 597) of RD repairs with 23-/25-gauge 

pars plana vitrectomy (PPV) or PPV with scleral buckle (SB). ERM/CME were confirmed by 

OCT/fluorescein angiography. Cases with proliferative vitreoretinopathy, redetachment, 

or macular disease were excluded. Results: 597 eyes with a mean follow-up of 404 days 

had 31% ERM and 14% CME rates. The rate of ERM following PPV/SB (n = 141) was 46%, 

compared to 27% following PPV (n = 456; P < .0001). There was no statistical difference 

in CME or visual acuity between PPV/SB and PPV. Conclusion: ERM and CME are common 

after RD repair. Results suggest SB use may be a factor in the development of ERM. 


Progressive Improvement in Vision 1 Year After Macula-Off 

Retinal Detachment 

Presenting Author: Danny Mitry MBBS 

Co-Author(s): Muhammad Amer R Awan MBBS, Shyamanga Borooah*, Andreas 

Syrogiannis MD**, Charles Lim-Fat MD, Harry Campbell MD, Alan Wright PhD**, 

Brian W Fleck MBChB*, David G Charteris MD MBChB, David B Yorston MD, Jas Singh 

MBBS FRCOphth** 

Purpose: To report long-term visual outcome of a multicenter cohort of macula-off rhegmatogenous 

retinal detachments (RRD). Methods: The Scottish RRD study was a 2-year 

prospective study that recruited all incident RRDs in Scotland. Patients were invited for 

examination at 6 weeks, 3 and 6 months, and 1 year after surgery. Using parametric testing 

we analyzed visual outcome. Results: 291 patients had successful repair with 1 operation. 

Mean visual acuity (VA) increased from 0.8 at 6 weeks to 0.57 logMAR at 1 year. 

Sixty-five percent achieved a final VA of 0.48 logMAR. Macula-off RRD of ≤ 10 days’ 

duration and those with poor initial VA (> 1.0 logMAR) had an improvement in VA at each 

visit. Conclusion: Macula-off RRD of ≤ 10 days’ duration and those with poor initial VA 

demonstrate a progressive long-term improvement. 


Triamcinolone Acetonide-Assisted Internal Limiting 

Membrane Peeling During Primary Rhegmatogenous Retinal 

Detachment Repair to Reduce Postoperative Macular 

Pucker Formation 

Presenting Author: Rajesh C Rao MD 

Co-Author(s): Kevin J Blinder MD*, Bradley T Smith MD, Gaurav K Shah MD* 

Purpose: Assessment of triamcinolone acetonide (TA)-assisted peeling of the internal 

limiting membrane (ILM) during primary rhegmatogenous retinal detachment (RRD) repair 

to reduce postoperative macular pucker (MP). Methods: MP following RRD repair, 

assessed by biomicroscopy, was compared between 30 patients (32 eyes) without ILM 

peeling (Group 1) and 30 patients (30 eyes) with ILM peeling (Group 2). Results: In Groups 

1 and 2, 11 of 32 eyes (34.4%) and 1 of 30 eyes (3.3%) developed MP, respectively. Three 

of 32 eyes (9.4%) in Group 1 and no eyes in Group 2 underwent subsequent surgery for 

MP, respectively. Conclusion: TA-assisted ILM peeling during primary RRD repair reduced 

postoperative MP and eliminated the need for subsequent MP surgery. 

232 






0.5 mg vs. 2.0 mg Ranibizumab for Macular Edema 

Secondary to Perfused Central Retinal Vein Occlusion 

Presenting Author: Alessandro A Castellarin MD* 

Co-Author(s): Dante Pieramici MD*, Ma’an A Nasir MD, Robert F See MD**, Stephen 

S Couvillion MD*, Nathan C Steinle MD, Melvin D Rabena MD*, Jessica Basefsky**, 

Lisha Wan**, Matthew J Giust MD**, Robert L Avery MD* 

Purpose: To compare the efficacy of 0.5-mg and 2.0-mg ranibizumab (RBZ) in patients 

with macular edema (ME) due to perfused central retinal vein occlusion (CRVO). Methods: 

Twenty subjects were randomized 1:1 to receive 3 monthly injections of 0.5-mg (n = 10) or 

2.0-mg (n = 10) RBZ. Starting at Month 3, retreatment was based on evidence of disease 

activity on spectral domain OCT. Results: At 6 months, mean visual acuity (VA) improved 

by +13.7 letters and +17.8 letters; central retinal thickness decreased by -347 µm and -339 

µm; and the mean number of injections was 5.5 and 4.2 in the 0.5-mg and 2.0-mg groups, 

respectively. Conclusion: In this small pilot trial, 0.5-mg and 2.0-mg RBZ treatment resulted 

in similar visual and anatomic outcomes. Patients treated with 2.0-mg RBZ may 

require slightly fewer treatments. 


APAO Baseline Characteristics and Risk Factors of Retinal 

Vein Occlusion: Korean RVO Study 

Presenting Author: Joo Yong Lee MD* 

Co-Author(s): Young Hee Yoon MD*, Hakyoung H Kim MD, Hee S Yoon MD, Se Woong 

Kang MD PHD**, June-Gone Kim MD PHD, Kyu-Hyung Park MD*, Young Joon Jo MD 

Purpose: To investigate the demographic characteristics of Korean patients with naïve 

retinal vein occlusion (RVO). Methods: This retrospective, multicenter, cross-sectional 

study was performed as a nationwide survey. Results: A total of 556 patients with newonset 

RVO presented. 176 patients (31.7%) were diagnosed with central RVO (CRVO), 

whereas 380 patients (68.3%) were diagnosed with branch RVO (BRVO). There were no 

significant differences in terms of gender or age distribution between groups. Comparison 

between the 2 groups showed that the prevalence of diabetes mellitus was significantly 

higher in CRVO and hypertension was significantly higher in BRVO (P = .018 and .001, respectively). 

Conclusion: As this was the first nationwide study performed by the Korean 

Retinal Society, the results of this study can be applied to future studies on RVO. 


Ozurdex for Refractory Macular Edema From Retinal Vein 

Occlusions Previously Treated With Anti-VEGF Agents 

Presenting Author: Evangelia Papavasileiou MD 

Co-Author(s): Andre Grixti, Balakrishna V Kumar MBBS*, Somdutt Prasad MBBS* 

Purpose: To report the outcome of combined therapy in macular edema due to retinal 

vein occlusions. Methods: Interventional case series of 31 subjects. Results: Mean time 

interval between diagnosis and treatment with Ozurdex was 20 months. Mean number of 

intravitreal anti-VEGF injections pre- and post-Ozurdex was 2.32 and 0.13, respectively. 

Mean OCT thickness decreased by -73 µm with combined treatment, whereas it increased 

by +97.74 µm on bevacizumab (Avastin) monotherapy. Conclusion: Combination of anti- 

VEGF agents and Ozurdex is effective in treating refractory macular edema due to retinal 

vascular occlusions. Moreover, combined therapy is synergistic, providing sustained increase 

in visual acuity, as well as reduction in central retinal thickness. 


H APAO Iatrogenic Retinal Artery Occlusion Caused by 

Cosmetic Facial Filler Injections 

Presenting Author: SungWook Park MBCB 

Co-Author(s): Se Joon Woo MD, Kyu-Hyung Park MD*, Jang Won Huh** 

Purpose: To investigate the clinical manifestations of retinal artery occlusion by cosmetic 

facial filler injections. Methods: Twelve patients with retinal artery occlusion (RAO) 

caused by cosmetic facial filler injections were studied. Results: Seven, 2, and 3 patients 

had ophthalmic (OAO), central (CRAO), and branch retinal artery occlusions, respectively. 

Injected autologous fat (7) was associated with worse BCVA than hyaluronic acid (4), and 

collagen (1). All patients with OAO had ocular pain and no BCVA improvement. Brain infarction 

developed in 2 cases of CRAO and OAO. Conclusion: Cosmetic facial filler injections 

can cause RAO. Iatrogenic OAO is associated with painful blindness, particularly by 

autologous fat. Clinical evaluation should be performed in patients with ocular pain after 

such injections. 


Noninvasive Visualization of 3-D Retinal Microcapillary 

Network Using OCT 

Presenting Author: Bartosz L Sikorski MD 

Co-Author(s): Maciej Szkulmowski MSC, Grazyna Malukiewicz-Wisniewska MD, 

Andrzej Kowalczyk PhD**, Maciej Wojtkowski PhD 

Purpose: To present a novel method for noninvasive visualization of 3-D retinal microcapillary 

network (RMN) using OCT reflectivity maps and to validate its clinical usefulness in 

vascular retinal diseases. Methods: OCT imaging was applied to 47 patients with diabetic 

retinopathy, central retinal vein occlusion, and branch retinal vein occlusion, and in 13 

healthy subjects. OCT maps of RMN from different retinal layers were reconstructed and 

compared with fluorescein angiography. Results: OCT showed the RMN of 20 microns 

in diameter, revealed vascular nonperfusion, and identified microexudates that were not 

visible on clinical examination and fundus photography. Conclusion: OCT is capable of 

precisely detecting the RMN and can be used for noninvasive diagnosis and monitoring of 

early stages of retinal vascular diseases. 


Water Soluble Antioxidants in the Vitreous Humor and 

Plasma in Retinal Ischemia 

Presenting Author: Louisa J Wickham MBBS* 

Co-Author(s): Abdul-Kadir Karim MBBS**, Mostafa A Elgohary MD FRCS(ED), Kamaljit 

S Balaggan MBBS, Raymond F Moss**, Maria Firth PhD**, Gary Firth MD FRCP**, 

Graham M Thompson MBBS 

Purpose: To estimate the levels of ascorbate and uric acid in patients with and without 

retinal ischemia. Methods: 104 vitreous and blood samples were obtained during vitrectomy 

of patients who had retinal ischemia, including proliferative diabetic retinopathy and 

retinal vein occlusions (n = 47) and those with no retinal ischemia, including macular hole 

and epiretinal membrane (n = 57). Results: Ascorbate level was significantly decreased 

and uric acid level increased in the vitreous (P < .001 and < .001) and plasma (P < .001 

and .04) of the ischemic group. No significant difference was found in the proportion of 

patients taking ascorbate (P = .3). Conclusion: Retinal ischemia appears to be associated 

with decreased levels of ascorbate and increased levels of uric acid in the vitreous and 

plasma. 


Predictive Value of the Ocular Trauma Score in Open Globe 

Injuries After Secondary Retinal Detachment Repair 

Presenting Author: Gareth M Lema MD 

Co-Author(s): Pradeepa Yoganathan MD 

Purpose: To determine if secondary retinal detachment (RD) repair improves visual outcomes 

vs. those predicted by the Ocular Trauma Score (OTS) in open globe (OG) injuries. 

Methods: Retrospective review of consecutive OG injuries over 3 years. Results: Thirtyseven 

eyes with OG trauma were categorized by the OTS. Initial visual acuity (VA) ranged 

from 20/20 to no light perception. Eyes with RD, afferent pupillary defect, or rupture had 

VA of 20/100 or less. When RD was repaired, visual acuity improved in all cases (final 

BCVA: 20/25 ñ hand motions). Conclusion: Final VA was better than predicted by the 

OTS in all categories, which we hypothesize is due to improvements in intraocular surgery. 


Role of Intravitreal Anti-VEGF Injections in Choroidal 

Osteomas 

Presenting Author: Ahmad M Mansour MD 

Co-Author(s): J Fernando Arevalo MD FACS, Hernando Zegarra MD, Emad Bishara 

Abboud MD, Rajiv Anand MD, Salman Mirza FRCS MBBS, Samuray Tuncer MD, 

Amparo Navea-Tejerina MD, Eman Said Kahtani MD, Jorge Mataix MD PhD**, 

Francisco J Ascaso MD, Jose S Pulido MD MS, Rainer Guthoff MD*, Winfried Goebel 

MD**, Young Jung Roh MD, Alay S Banker MD, Ronald C Gentile MD, Isabel Alonso 

Martinez MD**, Rodney J Morris MD**, Neeraj Pandey, Jungmin Park MD, Nicola G 

Ghazi MD, Vicky Antoun Massoud MD 

Purpose: To report effect of anti-VEGF in choroidal neovascularization (CNV) associated 

with choroida osteoma. Methods: Interventional case series with intravitreal anti-VEGF 

for CNV in a multicenter collaborative study. Results: Nineteen patients had mean age of 

30 years with majority of white women. The osteoma was subfoveal in 12 and peripapillary 

in 4 cases. Eight cases presented with subretinal hemorrhage, and 11 with subretinal 

fluid. The CNV was subfoveal in 11, juxtafoveal in 2, extrafoveal in 4, peripapillary in 2. 

Mean number of injections was 5, with mean follow-up of 24.6 months. LogMAR visual 





233



acuity improved from 0.78 to 0.55 at 6 months after therapy with 2.3 lines of improvement 

(P = .03). Conclusion: Anti-VEGF therapy prevents visual loss in a majority of eyes with 

CNV and choroidal osteoma. 


Real-time Ophthalmic and Fluorescein Angiographic 

Findings During 3 Consecutive Bilateral Super-Selective 

Intraophthalmic Artery Chemotherapy Treatments for 


Presenting Author: Rosanne Superstein MD 

Co-Author(s): David E Lederer MD*, Josee Dubois MD, Anne- Sophie Carret MD, 

Patrick Hamel MD, Sonia Adriana Callejo MD PhD** 

Purpose: To describe the real-time ophthalmic and fluorescein angiographic (FA) findings 

of super-selective intraophthalmic artery chemotherapy (SSIOAC) in retinoblastoma. 

Methods: Three bilateral SSIOAC melphalan treatments were performed 1 month apart. 

Retcam photographs and FA were done in real time. Results: Intra-arterial retinal precipates 

were noticed with increased frequency and duration during each successive treatment, 

lasting between 4 to 11 minutes. FA showed delayed choroidal filling lasting up to 2 

minutes. The retinal arteries demonstrated arrested flow. Conclusion: Acute vaso-occlusive 

disease was detected during treatment and confirmed on FA. Real-time funduscopic 

observation should be considered in SSIOAC to better understand and titrate treatment. 


Intraoperative OCT Analysis of Intrasurgical Macular Hole 

Dynamics 

Presenting Author: Justis P Ehlers MD 

Co-Author(s): David Xu, Peter K Kaiser MD*, Sunil K Srivastava MD* 

Purpose: To evaluate the intrasurgical microarchitectural changes of macular hole (MH) 

anatomy with intraoperative OCT (iOCT). Methods: Thirteen consecutive eyes with MH 

were analyzed with iOCT at key surgical milestones with a microscope-mounted iOCT 

system utilizing a novel automated volumetric segmentation algorithm. Results: All eyes 

were successfully imaged with iOCT. Following internal limiting membrane peeling, there 

was a significant increase in MH volume (P < .04) and base area (P < .005) with a reduction 

in the apical area (P < .005). Conclusion: Significant alterations in MH architecture are 

identified with iOCT and may help to identify MH features that impact surgical outcomes. 


PIONEER: A Prospective Study of Intraoperative OCT for 

Ophthalmic Surgery–Six-Month Posterior Segment Results 

Presenting Author: Justis P Ehlers MD 

Co-Author(s): Peter K Kaiser MD*, Alex Yuan MD, Sunil K Srivastava MD* 

Purpose: To evaluate intraoperative OCT (iOCT) in vitreoretinal surgical diseases. Methods: 

A prospective study was initiated utilizing a custom microscope-mount iOCT system 

and a standard imaging protocol following key surgical milestones. Results: Fifty-six subjects 

were enrolled. Common surgical indications included epiretinal membrane (n = 16), 

retinal detachment (n = 13), macular hole (n = 12), and proliferative diabetic retinopathy 

(n = 10). Novel iOCT findings included alterations in foveal architecture, increased hyporeflectivity 

in the sub-inner segment/outer segment space, and occult macular hole formation. 

Conclusion: Significant subclinical architectural alterations are identified with iOCT 

following surgical maneuvers. 


Blood-Aqueous Barrier Breakdown and Retinal Detachment 

Surgery: Comparison Between Scleral Buckling and Pars 

Plana Vitrectomy 

Presenting Author: Salim Ben Yahia MD* 

Co-Author(s): Rim Kahloun MD, Ghassen Ladhari, Sonia Zaouali MD**, Messaoud 

Riadh, Moncef Khairallah MD 

Purpose: To evaluate blood-aqueous barrier (BAB) breakdown after scleral buckling (SB) 

and pars plana vitrectomy (PPV) for uncomplicated rhegmatogenous retinal detachment 

surgery. Methods: Laser flare photometry was performed for 39 patients treated with SB 

and 16 patients treated with PPV. Results: There was no significant difference between 

the 2 groups regarding mean initial aqueous flare (P = .14). A significant increase in mean 

flare was found in the PPV group at Day 1 (P = .014), Day 30 (P = .01), and Day 90 (P = 

.022). Three-month anatomic success was slightly higher in the SB group (75% vs. 82%; 

P = .157). Conclusion: PPV significantly exacerbates BAB breakdown compared to SB. 


Pars Plana Vitrectomy in Eyes With Diabetic Macular 

Edema: A Systematic Review and Meta-analysis 

Presenting Author: Yannek I Leiderman MD PhD* 

Co-Author(s): Sherif Dawood MD 

Purpose: To assess pars plana vitrectomy (PPV) performed for diabetic macular edema 

(DME). Methods: Systematic review including subgroup analyses by pathology (DME ± 

vitreomacular traction, epiretinal membrane, posterior hyaloid status) and surgical procedure. 

Results: 1776 eyes of 69 cohorts were included. The weighted mean logMAR 

preoperative and final visual acuities (VA) were 0.81 (20/125) (range: 0.30-1.35), and 0.61 

(20/80) (range: 0.20-1.18). The proportion (%) of study eyes that remained stable, gained, 

or lost ≥ 10 letters was 52, 46, and 2, respectively. Conclusion: There is wide variability 

of interventions and VA outcomes among and within studies of PPV in DME. Most eyes 

exhibit stable or improved acuity following surgical intervention. 


H The Feasibility of Air Travel for Patients With Scleral 

Buckles and Intraocular Gas 

Presenting Author: Jason Noble MD 

Co-Author(s): Navapol Kanchanaranya MD, Robert G Devenyi MD, Wai-Ching Lam MD* 

Purpose: To evaluate the effect of scleral buckles on IOP change in eyes with intravitreal 

gas during simulated air travel. Methods: Patients were placed in a hypobaric chamber 

that was depressurized to an altitude of 8000 feet. IOP change was measured in eyes with 

intravitreal gas following vitrectomy / scleral buckling and was compared to eyes without 

buckles. Results: Six patients with and 10 without buckles were tested. Eyes with buckles 

had lower peak IOPs than eyes without buckles (20 ± 5 vs. 31 ± 7 mmHg, P = .003, t-test) 

as well as lower absolute IOP increases (7 ± 1 vs. 16 ± 6 mmHg, P = .002, t-test). Conclusion: 

Scleral buckles limit the magnitude of IOP increase in eyes with intravitreal gas 

during simulated air travel. 


Alternative New Dyes for Vitreoretinal Surgery: In Vitro 

Study of Cytotoxicity and Apoptosis in Human Retinal 

Pigmented Cell Culture 

Presenting Author: Fernando M Penha MD* 

Co-Author(s): Eduardo B Rodrigues MD, Elaine Fiod Costa MD, Mauricio Maia MD, 

Michel Eid Farah MD 

Purpose: To evaluate the safety of vital dyes on retinal pigment epithelial (RPE) cells. 

Methods: A RPE-19 cell line was exposed to indocyanine green (ICG), brillant blue (BriB), 

methyl blue (MetB), aniline blue (AnB) and acid violet (AcV). Five concentrations (1 to 0.005 

mg/mL) and 2 exposure times (3 and 30 min.) were tested. MTS viability assay and BAX 

protein expression were performed. Results: ICG significantly reduced cell viability in all 

concentrations. The other dyes were safe in concentrations up to 0.5 after 3 min. and 0.05 

after 30 min. Expression of BAX was significantly higher in ICG, and similar as control in 

other dyes. Conclusion: ICG showed toxicity to RPE cells in all tested concentrations. 

BriB, MetB, AcV, and AnB had the safest profile. The only dye that induced apoptosis 

was ICG. 


APAO Diagnosis and Management of Posterior Segment 

Complications in Eyes With Permanent Keratoprosthesis 

Presenting Author: Pukhraj Rishi** 

Co-Author(s): Tarun Sharma MBBS, Gaurav Mathur MS, Geetha Iyer MBBCHIR FRCS, 

Bhaskar Srinivasan MBBS 

Purpose: To describe vitreoretinal complications following permanent keratoprosthesis 

(KP) and their management. Methods: Eyes developing these complications (13/80 following 

modified osteo-odonto KP [MOOKP] and 7/25 after Boston KPro [BKP] were included. 

Results: Complications (MOOKP vs. BKP) included retinal detachment (7 vs. 1), 

vitritis (6 vs. 3), retroprosthetic membrane (3 vs. 5), and vitreous hemorrhage (1 vs. 2). 

Vitreous surgery was done in 19 eyes (12 MOOKP, 7 BKP); mean visual acuity was 6/120 

(19/20 eyes) at 6 months, in both groups. Conclusion: The most common complication 

was retinal detachment after MOOKP and retroprosthetic membrane after BKP; ambulatory 

vision was attained in most eyes. 

234 






APAO Idiopathic Macular Hole Vitrectomy With or Without 

Postoperative Prone Positioning and Spectral Domain OCT 

Imaging in Gas-Filled Eyes 

Presenting Author: Fumihiko Yagi MD 

Co-Author(s): Seiji Takagi MD**, Goji Tomita MD* 

Purpose: To evaluate whether spectral domain OCT (SD-OCT) can be used to determine 

closure of a macular hole (MH) in gas-filled eyes after vitrectomy with or without prone positioning. 

Methods: We studied 36 eyes of 36 vitrectomy cases, and SF6 gas tamponade 

was performed for MH without prone positioning (Group 0: 19 eyes), or with 1 day prone 

positioning (Group 1: 17 eyes). MHs of all patients were evaluated by SD-OCT before and 

at 3 hours and every day after surgery until confirming the MH status . Results: All of the 

MHs initially closed. Closure occurred in 1.7 days (average) in Group 0 and in 2.1 days in 

Group 1. Conclusion: If SD-OCT images through gas reveal the absence of MH closure 

after surgery, prone positioning should be used so that residual gas in the vitreous cavity 

can close the MH. 


Complications of Laser Vitreolysis 

Presenting Author: Scott L Geller MD 

Co-Author(s): SJ Feike Gerbrandy MD* 

Purpose: To determine the complications of laser vitreolysis performed by 3 experienced 

ophthalmic surgeons. Methods: Retrospective analysis of medical records of 1301 laser 

vitreolysis procedures performed on 542 eyes of 506 patients from Jan. 1 to Dec. 31, 2011. 

Results: Six patients had elevated IOP treated medically, 1 requiring surgical intervention. 

One lens opacity, 2 retinal strikes, and 1 retinal tear with detachment were documented. 

Conclusion: No patient had severe vision loss. Laser vitreolysis performed by experienced 

surgeons has a low complication rate. 


APAO Internal Limiting Membrane: Transmission Electron 

Microscope Evaluation 

Presenting Author: Shri Kant MBBS 

Co-Author(s): Sandeep Sharma MS, Amit Mittal MS**, Gajendra Singh MD**, 

Abhishek Chandra MBBS 

Purpose: To evaluate the effect of various dyes on internal limiting membrane (ILM) by 

transmission electron microscopic. Methods: Macular hole surgery with ILM peeling was 

performed in 10 patients with idiopathic macular hole. Indocyanine green (ICG), trypan 

blue, and brilliant blue dyes were used to stain the ILM. Transmission electron microscopy 

(TEM) of peeled ILM was performed to see the effect of these dyes on ILM. Results: On 

TEM there was disruption of foot end plates of normal Mueller cells and irregularity of 

intracellular components such as cell nuclei and mitochondria in ILM stained with ICG 

and trypan blue, while there were no changes seen with brilliant blue dye. Conclusion: 

Staining of ILM with brilliant blue does not adversely affect the retina. 


APAO Clinical Outcome of Cataract Surgery for Highly 

Myopic Retinoschisis 

Presenting Author: Wu Qiang MD 

Co-Author(s): Shi-wei Li, Shan-shan Du MD**, Bin Lu MS**, Wen-qing Wang CMA**, 

Jian Fang MS**, Shi-wei Li, Xinhua Du 

Purpose: To evaluate retinal changes after cataract surgery in highly myopic retinoschisis. 

Methods: Thirty-five eyes with highly myopic retinoschisis received phacoemulsification. 

The minimal foveal thickness (MFT) and maximum neuroretinal thickness (MNRT) were 

measured by OCT. Results: BCVA improved after surgery (P < .05). MFT and MNRT were 

not significantly different from the preoperative level at each postoperative visit (P > .05). 

Eyes with nonfoveal retinoschisis had significantly better BCVA than those with foveal 

retinoschisis postoperatively (P < .05). The postoperative BCVA of foveal retinoschisis eyes 

without macular holes was positively correlated with MFT after surgery (P < .05). Conclusion: 

BCVA improved, and retinal morphology remained stable after surgery for retinoschisis. 

Postoperative BCVA depended mainly on the location and degree of retinoschisis. 


The Incidence of Noninfectious Intraocular Inflammation 

After Intravitreal Aflibercept Injection 

Presenting Author: Daniel B Roth MD* 

Co-Author(s): Jonathan Prenner MD*, Howard F Fine MD MHS*, Stuart N Green MD, 

David L Yarian MD, David L Yarian MD 

Purpose: To evaluate the incidence of intraocular inflammation after intravitreal aflibercept 

injection (IAI). Methods: All eyes were evaluated within 1 week of receiving IAI for 

the presence of inflammation. Results: 477 eyes in 372 patients were treated. Three eyes 

(0.6% of injections, 0.8% of patients) presented with noninfectious intraocular inflammation. 

The first patient reported pain and distortion with mild anterior chamber (AC) reaction 

but no change in visual acuity (VA). Two patients presented with moderate AC inflammation, 

vitritis, and intraretinal hemorrhages. VA was reduced from 20/40 to 20/80 and 

from 20/200 to HM, respectively. Conclusion: Symptomatic noninfectious inflammation 

occurred in 0.6% of injections or 0.8% of patients in our early series of aflibercept use. 

Session Two 





Aqueous Interleukin-6 Is Superior to VEGF as Biomarker 

in Monitoring Therapeutic Response in Wet Macular 

Degeneration 

Presenting Author: Shailesh K Gupta MD** 

Co-Author(s): Sankarathi Balaiya PhD, K V Chalam MD PhD 

Purpose: To study the concentration of cytokines in the aqueous before and after intravitreal 

injection (IVI) of bevacizumab in wet AMD. Methods: In this prospective study, 

1.25 mg of bevacizumab was injected intravitreally (N = 64). Aqueous samples (AS) were 

obtained before IVI and 1 month later. The cytokines were measured with luminex bead 

assay. Degree of CNV and BCVA were measured. Results: IL-6, VEGF levels decreased 

from 17.3 ± 22,826 ± 125 pg/ml prior to IVA to 16.1 ± 12,162 ± 32 pg/ml (P < .001) at 30 

days. Partial to complete regression of CNV was noted in all eyes at 30 days. Degree of 

regression of CNV and extent of leakage correlated better with IL-6 (R = 0.90) than VEGF (R 

= 0.72) (P < .01). Conclusion: Measurement of aqueous IL-6 levels may refine the necessary 

dosage for this effect. 


Modified Portable Digital Camera (Pictor) Is as Effective 

as Traditional Nonmydriatic Fundus Camera for Teleretinal 

Screening of Retinal Disorders 

Presenting Author: K V Chalam MD PhD 

Co-Author(s): Donald Davis**, Sandeep Grover MD* 

Purpose: To compare the efficacy of a modified portable digital camera (MPDC) to nonmydriatic 

fundus camera (NMFC) in screening of diabetic retinopathy (DR). Methods: 204 

patients underwent one-field, NMFC photography prior to MPDC photography followed 

by ophthalmoscopy by an ophthalmologist. The main outcome measure was detection of 

referable DR. Results: For MPDC, the sensitivity was 98.2%, specificity was 94%, and 

technical failure rate was 1.2%. For nonmydriatic photography, the sensitivity was 92.0%, 

specificity was 89.7%, and technical failure rate was 11.7%. Conclusion: Portable digital 

camera-assisted retinal photography is a cheap, effective method of screening for DR and 

superior to nonmydriatic digital photography (P < .01). 


Photoreceptor Outer Segment Length on Ultrahigh- 

Resolution Spectral Domain OCT Accurately Predicts Visual 

Acuity Recovery After Macular Surgery 

Presenting Author: Shailesh K Gupta MD** 

Co-Author(s): Sandeep Grover MD*, K V Chalam MD PhD 

Purpose: To study the correlation of final visual acuity with photoreceptor outer segment 

length (PROS) after macular surgery with multivariate analysis. Methods: Eighty-six eyes 

with successful macular surgery were evaluated for PROS and foveal thickness, as well 

as segmental analysis of various layers, to define best predictor of BCVA 6 months after 

surgery. Results: PROS on spectral domain OCT was 61.1 ± 26.8 µm. Foveal thickness 





235



(R. 0.834, P < .024), as well as PROS (R .0.891, P < .0001), showed close correlation with 

BCVA. Of the 86 eyes, 76 showed a continuous inner segment/outer segment (IS/OS) line 

in the fovea. BCVA in eyes with normal PROS in the fovea was significantly better (P < 

.0001) than with interrupted line. Conclusion: PROS length was superior to integrity of 

IS-OS line in predicting BCVA after macular surgery (P < .01). 


Change in Macular Volume (Spectral Domain OCT) Is 

Superior to Macular Thickness in Predicting Functional 

Recovery in Diabetic Macular Edema After Anti-VEGF 

Therapy 

Presenting Author: K V Chalam MD PhD 

Co-Author(s): Ravi Keshavamurthy MD, Shailesh K Gupta MD** 

Purpose: To evaluate the relationship between BCVA, macular volume (MV), and central 

foveal thickness (CFT) in patients of diabetic macular edema (DME) after treatment with 

anti-VEGF therapy (AVT). Methods: 142 eyes from 80 patients with DME were treated 

with AVT. BCVA, MV, and CFT were recorded before and 90 days after treatment. Number 

of improved letters (ETDRS) was the outcome variable in multivariate analysis of predictive 

value of spectral domain OCT variables. Results: Eighty-four of 142 eyes showed 

improvement in BCVA (7 letters). Decrease in both volume (12.83+2.75 to 9.82+1.2) and 

CFT (432+24 to 347+34) was observed. Decrease in MV (R = 0.82) correlated better than 

CSTG (R = 0.71) with BCVA (P < .01). Conclusion: MV change is superior to CFT in predicting 

improvement in BCVA after AVT for DME. 


The Effect of Eylea (Aflibercept) in Exudative AMD Patients 

Recalcitrant to Ranibizumab and Bevacizumab 

Presenting Author: Vincent S Hau MD 

Co-Author(s): Tom S Chang MD, Michael A Samuel MD*, Michael J Davis MD*, Kevin 

K Suk MD, Camille M Harrison MD, Rizwan A Bhatti MD** 

Purpose: To investigate visual acuity (VA) and macular thickness with intravitreal injections 

of 2.0-mg aflibercept in eyes unresponsive to 1.25-mg bevacizumab and/or 0.5-mg 

ranibizumab in wet AMD. Methods: Twenty patients with recalcitrant wet AMD and 

choroidal neovascular membrane activity were treated with aflibercept for 2 months and 

followed with clinical exam, Snellen VA, and OCTs with periodic fluorescein angiography 

and indocyanine green. Results: Baseline median VA was 20/40, mean central foveal 

thickness (CFT) was 332.8 µm, and mean total volume (TV) was 8.63 mm3. Mean log- 

MAR VA improved from 0.42 to 0.372 at 1 month, and 0.329 at 2 months. Mean CFT 

and TV improvement was 21.82 µm and 0.49 mm3, at 1 month, and 60.25 µm and 0.53 

mm3 at 2 months, respectively. Conclusion: Anatomic and VA improvement were seen 

in recalcitrant patients given aflibercept, supporting the use of aflibercept for wet AMD 

unresponsive to anti-VEGFs. 


Vitamin D Deficiency in Advanced vs. Non-neovascular 

AMD 

Presenting Author: Sujit Itty MD 

Co-Author(s): Lejla Mutapcic MD, Shelley Day MD*, Kenneth W Lyles MD, Prithvi 

Mruthyunjaya MD 

Purpose: We assess vitamin D deficiency as a risk factor for advanced AMD (NV-AMD) 

and geographic atrophy (GA) vs. non-neovascular AMD (nNV-AMD). Methods: Medical 

records of patients diagnosed with AMD (ICD-9 codes 362.50, 362.51, 262.52) and 

tested for serum vitamin D level at a single medical center were retrospectively reviewed. 

Results: Ninety-three patients with nNV-AMD, 96 with NV-AMD, and 31 with GA were 

included. Mean levels of 25OH vitamin D were 33.5, 31.5, and 29.1 ng/ml in the nNV- 

AMD, NV-AMD, and GA groups, respectively (P = .07); vitamin D deficiency (< 20 ng/mL) 

was more prevalent in the NV-AMD (20%) and advanced AMD (21%) groups, compared 

to nNV-AMD (9.7%) patients (P = .04). Conclusion: In this first study to compare vitamin 

D levels in different forms of AMD, results suggest that vitamin D deficiency may be more 

associated with advanced AMD vs. nNV-AMD. 


APAO The Relationship Between Clinical Characteristics of 

Polypoidal Choroidal Vasculopathy and Choroidal Vascular 

Hyperpermeability 

Presenting Author: Hideki Koizumi MD 

Co-Author(s): Tetsuya Yamagishi, Taizo Yamazaki, Shigeru Kinoshita MD* 

Purpose: To investigate the relationship between the clinical characteristics of polypoidal 

choroidal vasculopathy (PCV) and choroidal vascular hyperpermeability (CVH) seen 

on indocyanine green angiography. Methods: We reviewed the medical records and 

angiograms of 89 consecutive patients with PCV. Results: The patients with CVH more 

frequently demonstrated bilateral PCV lesions (P = .009), a history of central serous chorioretinopathy 

(P = .01), thickened choroid detected by enhanced depth imaging OCT (P < 

.001), and poor responses to ranibizumab therapy (P = .01) than did those without CVH. 

Conclusion: PCV associated with CVH may have different clinical characteristics from 

that without CVH. 


Genetic Risk Factors in African Americans With AMD 

Presenting Author: Jaclyn L Kovach MD 

Co-Author(s): Brent Walter Zanke* 

Purpose: To determine the prevalence of established genetic AMD risk factors among 

African Americans with AMD. Methods: We analyzed genetic testing records of selfdeclared 

Caucasians (8493) and African Americans (2226) and compared global AMD risk 

scores derived from CFH, ARMS2, and C3 genotypes controlling for AMD phenotype. Results: 

African Americans are much less likely to have high genetic AMD risk scores than 

Caucasians with similar phenotypes despite similar population-risk allele prevalence. The 

OR for high genetic risk for AREDS 2 disease was 0.303 (P = .0001); for AREDS 3, was 

0.326 (P = .0057); and for AREDS 4, was 0.086 (P = .0033). Conclusion: AMD genetics for 

African Americans differs from that for Caucasians. Caution should be used when assessing 

genetic risk for AMD progression in non-Caucasians. 


Macular Pigment Optical Density in Dry AMD Patients on 

Different Treatment Regimens 

Presenting Author: Alla B Lisochkina MD PhD 

Co-Author(s): Yuri S Astakhov MD, Pavel A Nechiporenko MD PhD, Anastasiya N 

Telezhina MD** 

Purpose: To assess the correlation between the treatment regimen and the macular pigment 

optical density (MPOD) level in dry AMD patients. Methods: MPOD was measured 

with QuantifEYE (ZeaVision; USA) in 62 dry AMD patients (101 eyes) treated by Ocuvite 

Lutein (Bausch + Lomb; USA) courses for 2 years. Results: In patients with AMD AREDS 1 

stage treated for 1 month 3 times/year, MPOD was 0.42 ± 0.03. In AREDS 2 stage treated 

for 4 months 2 times/year, MPOD was 0.36 ± 0.04. In AREDS 3 stage on continuous treatment, 

MPOD level was the highest: 0.43 ± 0.03. In 28 healthy nontreated controls, MPOD 

was the lowest: 0.35 ± 0.02. Conclusion: MPOD level in dry AMD treatment depends on 

therapy regimen and could be suggested as its efficacy criterion. 


APAO Prevalence of AMD in the Japanese 

Presenting Author: Isao Nakata MD 

Co-Author(s): Kenji Yamashiro MD PhD, Hideo Nakanishi, Yumiko Akagi-Kurashige MD, 

Masahiro Miyake MBCB DOMS, Fumihiko Matsuda PHD**, Nagahisa Yoshimura MD 

PhD* 

Purpose: To assess AMD prevalence in the Japanese. Methods: Retina specialists used 

the Age-Related Eye Disease Study severity scale to grade fundus photographs of 6065 

Japanese (age ≥ 50 years) of a new cohort comprising 10,072 participants (2008-2010). 

Results: Gradable photographs for 5595 subjects (women, 65%) were assessed. Early 

and late AMD prevalence increased from 16.1% and 0.27% at 50-59 years to 31.2% and 

0.97%, respectively, at 70-75 years. Smoking was associated with all AMD stages and 

retinal pigment abnormalities (PAs, P < .0001), but not with drusen (P = .267). PA prevalence 

was higher in men (P < .0001) but did not differ by sex for large drusen (P = .264). 

Conclusion: The Japanese may have higher early AMD prevalence than that reported, 

with differing backgrounds for drusen and PAs. 

236 






APAO Multifactorial Analyses of the Systemic Risk of AMD 

in the Japanese 

Presenting Author: Isao Nakata MD 

Co-Author(s): Kenji Yamashiro MD PhD, Hideo Nakanishi, Yumiko Akagi-Kurashige MD, 

Masahiro Miyake MBCB DOMS, Akitaka Tsujikawa MD PhD*, Takahisa Kawaguchi**, 

Ryo Yamada MD PhD, Fumihiko Matsuda PHD** 

Purpose: To assess age-related macular degeneration (AMD) risk factors. Methods: 

AMD signs were graded for 5595 individuals (age ≥ 50 years; women, 65%) of 10,072 

Japanese cohort subjects (2008-2010) from retinal photographs; age- and sex-adjusted 

logistic regression analysis was used for 85 systemic factors (e.g., blood tests). Results: 

Chlamydia pneumoniae (C. pn) infection and a1-antitrypsin (A1AT, SERPINA1) expression 

showed the greatest association with early AMD (P = .0146 and .0165, respectively). C. 

pn infection was associated with soft and large drusen and retinal pigment abnormalities 

(PAs, P < .05); A1AT expression was associated with large drusen (P < .0001) but not PAs 

(P = .240). Conclusion: C. pn and A1AT may play significant roles in AMD and drusen, 

respectively, in the Japanese. 


Association of VEGF Genotypes With Response of 

Neovascular AMD to Intravitreal Ranibizumab 

Presenting Author: Marcio B Nehemy MD* 

Co-Author(s): Carlos Veloso, Luciana Almeida MD, Franco M Recchia MD*, Luis A 

Demarco MD PhD 

Purpose: To investigate the role of VEGF rs1413711 gene polymorphism on the outcome 

of ranibizumab therapy for neovascular AMD. Methods: BCVA and central macular thickness 

(CMT) of 95 eyes of 95 patients were measured before and 1, 3, and 6 months after 

starting the loading dose. Results: Patients with TT genotype showed greater mean VA 

improvement at the first and third month (P < .05). There was no difference when the mean 

CMT improvement was compared among the VEGF genotypes (P > .05). Conclusion: For 

the VEGF rs1413711 gene polymorphism, patients with TT genotype showed better shortterm 

functional response to ranibizumab for neovascular AMD. 


APAO Characteristics of OCT and Fundus Autofluorescence 

Before Onset of Retinal Angiomatous Proliferation 

Presenting Author: Tetsuju Sekiryu MD 

Co-Author(s): Masaaki Saito MD, Ichiro Maruko MD, Tomohiro Iida MD* 

Purpose: To evaluate the characteristics of the retina before onset of retinal angiomatous 

proliferation (RAP). Methods: We retrospectively studied the fundus characteristics of 6 

eyes that developed RAP during the follow-up period in patients with unilateral exudative 

AMD, placing special focus on OCT and fundus autofluorescence findings. Results: RAP 

lesions appeared on the sites that showed abnormal fundus autofluorescence in all 6 eyes. 

Disruption of the outer nuclear layer was observed at the lesion where developed intraretinal 

neovascularization in 5 of 6 eyes. Conclusion: Retinal and choroidal neovascular 

tissue may form toward the damaged photoreceptor cells. 


Change in Abnormal Retinal Pigment Epithelium-Drusen 

Complex Volume in AMD vs. Control Eyes 

Presenting Author: Cynthia A Toth MD* 

Co-Author(s): Rachelle V O’Connell BS, Francisco A Folgar MD, Stephanie Chiu*, Sina 

Farsiu PhD* 

Purpose: To characterize 1-year change in drusen volume using the measure of ARDV in 

eyes with intermediate AMD from the prospective AREDS2 Spectral Domain OCT Study. 

Methods: Retinal pigment epithelium-drusen complex (RPEDC) was delineated with custom 

semiautomated software. We computed overall ARDV for each eye (volume of RPEDC 

exceeding the mean + 3 SD in control eyes at each position) at baseline and 1-year ARDV 

change within a 5-mm ring centered on the fovea (rank sum). Results: In 186 AMD eyes, 

ARDV, a measure of drusen volume, was greater at baseline (4x10^-3 vs, 3x10^-5 mm^3, P 

< .001) and increased by a mean of 8x10^-4 mm^3 in volume at 1 year, compared to 2x10^- 

5 mm^3 in 97 control eyes (P < .001). Conclusion: ARDV and its increase are distinguishing 

features of intermediate AMD and warrant long-term follow-up. 


APAO Effects of Vitreomacular Adhesion on Antivascular 

Endothelial Growth Factor Treatment for Polypoidal 

Choroidal Vasculopathy 

Presenting Author: HanJoo Cho DOMS 

Co-Author(s): Sung Won Cho MD PHD, Chulgu Kim MD**, Jung Woo Kim MD**, Jae 

Woo Jang MD PhD 

Purpose: To evaluate the effect of posterior vitreomacular adhesion (VMA) on the outcome 

of antivascular endothelial growth factor (VEGF) treatment for polypoidal choroidal 

vasculopathy (PCV). Methods: We retrospectively reviewed medical records of 102 

patients with PCV and categorized them into 2 subgroups: VMA(+) Group (24 eyes) and 

VMA(-) Group (81 eyes). BCVA and central macular thickness (CMT) after anti-VEGF treatment 

were compared between the 2 groups. Results: There was no statistically significant 

difference in BCVA improvement achieved, CMT improvement achieved, and polyp 

regression rate between groups. Conclusion: Posterior VMA was not associated with a 

visual outcome after intravitreal anti-VEGF for PCV. 


VEGFA Gene Polymorphism and Response to Intravitreal 

Anti-VEGF Therapy in Neovascular AMD 

Presenting Author: Kang Zhang MD PhD* 

Co-Author(s): Robert L Avery MD*, Alan E Kimura MD*, Henry A Ferreyra MD, Seanna 

Grob MD, Dante Pieramici MD*, Ling Zhao PhD, Melvin D Rabena MD*, Michael 

Goldbaum MD, Igor Kozak MD 

Purpose: To investigate whether VEGFA is associated with the response to anti-VEGF 

therapy for exudative AMD. Methods: This prospective cohort study consisted of 223 

eyes with wet AMD treated with bevacizumab or ranibizumab for 12 months. VEGFArs943080 

was genotyped using the SNAPshot method, and logistic regression analysis 

and chi-square test were used to analyze the results. Responders gained at least 1 line on 

the ETDRS chart and had resolution of fluid on OCT. Results: The nonresponder group had 

a higher frequency of the risk (T) allele (allelic P = 0.019) and TT genotype (P = .002 under 

a recessive model) than the responder group. Conclusion: VEGFA-rs943080 is associated 

with the response to anti-VEGF treatment. 


APAO Change of Retinal Vessel Diameters in Type 2 Diabetic 

Patients Without Retinopathy 

Presenting Author: Hyoju Jang MD 

Co-Author(s): Jeong Hun Bae MD, Joon Mo Kim MD, Sung-Chul Lee MD 

Purpose: To determine the change of retinal vessel diameters in type 2 diabetic patients 

without retinopathy. Methods: Retrospective review of 70 patients and 77 age- and sexmatched 

healthy subjects as a control. The diameters of all retinal vessels passing through 

an area 0.5 to 1 disc diameter around the optic disc were measured using computer software 

(Zeiss AV ratio). Results: The mean arteriovenous ratio (AVR) was 0.801 ± 0.068 

in the patients compared to 0.762 ± 0.054 in the control group (P < .001), and correlated 

significantly with the blood HbA1c (r = .288, P = .017). Conclusion: The rise in AVR seems 

to be an early feature of diabetic retinal circulation and is associated with an elevated 

blood sugar level. 


Matched Pairs Analysis of Retinal Navigated Laser vs. 

Conventional Laser 

Presenting Author: Marcus Kernt MD* 

Co-Author(s): Raffael Liegl MD, Igor Kozak MD, Christos Haritoglou MD*, Michael W 

Ulbig MD*, William R Freeman MD*, Anselm Kampik MD, Aljoscha S Neubauer** 

Purpose: To compare outcomes for a novel navigated laser with those of a conventional 

laser in clinically significant macular edema (CSME). Methods: Focal laser in 46 patients 

from 2 centers was digitally planned and performed utilizing retina navigation (Navilas 

OD-OS; Germany). Clinical follow-up was compared with a propensity score matched 

group out of 119 conventional laser patients. Results: Matched for age, gender, baseline 

visual acuity, and number of laser spots, 28 control patients had similar baseline visual 

acuity (0.43 ± 0.36 vs. 0.48 ± 0.37 logMAR). Laser retreatments on Kaplan-Meier analysis 

showed differences after 2 months, reaching a 6-month cumulative retreatment rate of 

18% (Navilas) vs. 31% (P = .02). Conclusion: Lower retreatment rates were observed 

with navigated laser treatment in the first 6 months. 





237




APAO Comparison of Intravitreal Bevacizumab Alone or 

Combined With Triamcinolone vs. Triamcinolone in Diabetic 

Macular Edema 

Presenting Author: Jiwon Lim MD 

Purpose: To compare the effect of an intravitreal bevacizumab or combined with triamcinolone 

to that of triamcinolone in patients with diabetic macular edema (DME). Methods: 

Eligible eyes were assigned randomly to 1 of the 3 study arms: (1) the IVB Group, 

twice injections of bevacizumab (1.25 mg), (2) the IVB/IVT Group, bevacizumab (1.25 mg) 

with triamcinolone (2 mg), (3) and the IVT Group, triamcinolone (2 mg). Results: The IVB/ 

IVT group and the IVT group showed better visual acuity and reduced central macular 

thickness at 6 weeks and 3 months, compared with the IVB group (P < .05). However, no 

significant difference was observed between the 3 groups at 12 months. Conclusion: IVT 

± IVB showed more pronounced effects during the earlier postinjection period, and there 

is no benefit of addition of IVT over IVB. 

CANCELED 


RAGE T-374A Polymorphism as a Protective Genetic Factor 

for Diabetic Retinopathy and Macular Edema 

Presenting Author: Peter M B Pego MD 

Co-Author(s): Fernanda Azancoth MS**, Filipe Silva, Graca Barbas Pires MD**, Manuel 

Bicho MD PhD**, Constanca Coelho PhD 

Purpose: Identification of genetic polymorphisms associated with diabetic retinopathy 

(DR) and macular edema (ME) allows early identification of susceptible patients. Methods: 

Eighty-six type II diabetes (T2D) patients with and without DR and ME were studied. 

Polymorphism was assessed by polymerase chain reaction-restriction fragment length 

polymorphism. Results: The RAGE (receptor for advanced glycation end products) T-374A 

polymorphism A allele was more frequent in patients without DR or ME than in patients 

with DR or ME (45.3% vs. 16.3% for DR, P = .001; and 53.5% vs. 8.1% for ME, P = .008, 

respectively). Conclusion: Results suggest that in patients with T2D, the RAGE A allele 

has a protective effect against DR and ME. 


APAO Ultrawide Field Retinal Imaging Increases 

Identification of Significant Diabetic Retinopathy Lesions 

Presenting Author: Paolo Antonio S Silva MD 

Co-Author(s): Jerry D Cavallerano PhD, Jennifer K Sun MD*, Lloyd M Aiello MD, Lloyd 

P Aiello MD PhD* 

Purpose: To determine the extent and significance of diabetic retinopathy (DR) lesions 

identified by mydriatic ultrawide-field fundus imaging but not observed with ETDRS 7 

standard field fundus photography (photos). Methods: Dilated 200° imaging (Optos, D200) 

and photos were compared for DR lesions by masked graders. Results: In 206 eyes with 

varying levels of DR (none to proliferative DR) agreement for DR between D200 and ETDRS 

was exact in 82% of eyes and within 1 level in 94% (Kw = 0.85]. When D200 did not match 

photos (n = 38), D200 was deemed more accurate in 55% of eyes. One-third of DR lesions 

were located outside areas imaged by ETDRS with a more severe DR than evident on 

photos. Conclusion: D200 imaging may identify more DR lesions than photos, which has 

potential implications for assessing overall severity of DR . 


APAO Effect of Dexamethasone Intravitreal Implant 

(Ozurdex) on Macular Thickness in Diabetic Macular 

Edema 

Presenting Author: Poooja Bansal MBBS 

Co-Author(s): Vishali Gupta MBBS, Nikhil Beke 

Purpose: To report the effect of dexamethasone intravitreal implant (Ozurdex) on macular 

thickness in diabetic macular edema (DME). Methods: Retrospective study of patients 

with DME who received intravitreal Ozurdex with minimum 6 months of follow-up. Primary 

outcome measure was change in central macular thickness (CMT) on spectral domain 

OCT. Results: In 78 eyes of 61 patients, mean CMT (µm) decreased from 514 ± 177.87 at 

baseline to 394 ± 152.29 (P = .007), 301 ± 93.07 (P = 0.000), 316 ± 115.66 (P = .000), and 

396 ± 86.32 (P = .031) at 1, 6, 12, and 24 weeks. Conclusion: CMT decreased maximally 

at 6 weeks (41.24%). The effect lasted up to 12 weeks. 


Senior Loken Syndrome: Portuguese Case Series 

Presenting Author: Ana Rocha Cardoso MD 

Co-Author(s): Ines Carvalho Lains MD, Diana Garcia Beselga MD**, Joao Cardoso 

MD**, Eduardo D Silva MD 

Purpose: To report 6 patients with Senior-Loken syndrome (SLS), their phenotypic variability, 

and molecular characterization. Methods: We identified 6 patients with SLS. 

These patients underwent a thorough phenotypic and molecular analysis, including fundus 

photography, electroretinogram (ERG), multifocal ERG (MF-ERG), spectral domain OCT, and 

autofluorescence. Results: Patients had a clinical picture ranging from a Leber congenital 

amaurosis phenotype to retinitis pigmentosa or rod-cone dystrophy associated with identification 

of sonographic renal cysts and laboratory-proven renal dysfunction. Conclusion: 

Childhood and adolescence-onset retinal dystrophies should prompt a renal workup. The 

ophthalmologist may be responsible for the identification of early manifestations of kidney 

disease, allowing a swifter multidisciplinary approach and modification of the vital 

prognosis and management. 


The CABP4-Associated Retinal Phenotype 

Presenting Author: Arif O Khan MD 

Co-Author(s): May Alrashed MS, Fowzan S Alkuraya MD 

Purpose: Although CABP4 mutations have been associated with night blindness, the lack 

of reported clinical cases limits genotype-phenotype correlation. We characterize a series 

of affected patients. Methods: Retrospective review. Results: All 11 patients (age 2-26 

years; 4 families) harbored homozygous c.81_82ins1 CABP4 mutation. All had congenital 

nystagmus, stable low vision, photophobia, and a normal or near normal fundus appearance. 

None had night blindness. Seven had hyperopic cycloplegic refractions (3 +1.00 D). 

Electroretinogram showed an electronegative waveform to scotopic bright flash, nearnormal 

to subnormal rod function, and delayed and/or decreased cone responses or was 

nonrecordable. Conclusion: This clinical phenotype is not characterized by night blindness 

and is best uniformly termed “congenital cone-rod synaptic disorder. 


Progressive Expansion of the Hyperautofluorescent Ring in 

Cone-Rod Dystrophy 

Presenting Author: Luiz Lima MD 

Co-Author(s): Vivienne C Greenstein PhD*, Stephen H Tsang MD PhD 

Purpose: To evaluate the expansion of the hyperautofluorescent ring in cone-rod dystrophy 

(CRD). Methods: Forty eyes of 40 CRD patients were studied. Ring expansion was 

evaluated by measurements of its external and internal boundaries at baseline and 12 

and 24 months. Spectral domain OCT (SD-OCT) was obtained, and the horizontal extent of 

the inner segment/outer segment (IS/OS) junction was measured. Results: The external 

boundaries of the ring were identified in all study eyes. Internal boundaries were identified 

in 34 eyes. Expansion of the ring was demonstrated in all patients. SD-OCT measurements 

showed a decrease in the IS/OS junction length. Conclusion: Progressive expansion of 

the ring and a concordant decrease in the IS/OS junction length were observed over time 

in CRD patients. 


APAO Wide-field Fundus Autofluorescence Patterns in 

Retinitis Pigmentosa Patients and Their Association With 

Visual Function 

Presenting Author: Akio Oishi MD PHD 

Co-Author(s): Ken Ogino MD, Yukiko Makiyama MD, Satoko Nakagawa MD**, 

Masafumi Kurimoto MD, Nagahisa Yoshimura MD PhD* 

Purpose: To evaluate clinical values of widefield fundus autofluorescence (FAF) pattern in 

patients with retinitis pigmentosa (RP). Methods: We examined 44 RP patients with the 

Optos 200TX and identified abnormal FAF patterns such as patchy and reticular hypofluorescence. 

Bone spicule pigmentation also showed hypofluorescence. We measured the 

areas of abnormal FAF and compared them with visual field area or clinical characteristics. 

Results: Total area of abnormal FAF was correlated with visual field area (R = -0.50, P = 

.008). The area of patchy hypofluorescence was correlated with age (R = 0.59, P = .001). 

Conclusion: Objective measurement of widefield FAF can be an indicator of visual function 

or duration of the disease in patients with RP. 

238 






OCT in Retinitis Pigmentosa Patient Study: Five-Year 

Follow-up 

Presenting Author: Douglas Yanai MD 

Co-Author(s): Luiz Lima MD, Adriana Berezovsky MD**, Mauricio Maia MD, Michel Eid 

Farah MD, Juliana M F Sallum MD** 

Purpose: To study OCT data (retinal nerve fiber layer [RNFL] and retinal thickness) and 

visual acuity (VA) in retinitis pigmentosa (RP) eyes. Methods: Twenty-nine eyes were 

examined. Twenty-five eyes had VA better than 20/800. OCT scans (fast RNFL thickness 

scan, 3.4 mm) were performed. After 5 years, 7 eyes were re-examined. Results: There 

was a reverse correlation between VA and retinal thickness in the temporal quadrant, 

considering eyes with VA better than 20/800 (r = 0.64; P < .001). The 5-year follow-up 

showed that retinal thickness increases over time (P = .05). Conclusion: RP eyes showed 

thicker retina in the temporal quadrant as VA decreases. The retina becomes thicker over 

time. The data suggest that as the degeneration progresses the retina becomes thicker. 


Outbreak of Fusarium Endophthalmitis Following Brilliant 

Blue G dye-Assisted Vitrectomy Procedures 

Presenting Author: Michael J Davis MD* 

Co-Author(s): Kristie L Lin MD*, Tom S Chang MD, Michael A Samuel MD*, Rizwan A 

Bhatti MD**, Steve M Friedlander MD FACS, Nishita Patel MD**, Pravin U Dugel MD* 

Purpose: To review cases of Fusarium endophthalmitis. Methods: Case review of patients 

with fungal endophthalmitis after vitrectomy with brilliant blue G (BBG) dye. Results: 

Patients had vitrectomy with BBG dye from a single pharmacy. Fusarium cultured 

from unused vials. Presented with insidious inflammation weeks after the procedure 

and treated as noninfectious and infectious endophthalmitis. Patients required further 

surgery, intravitreal injections, and systemic antifungal medication. Conclusion: Fungal 

endophthalmitis presents as a diagnostic and treatment dilemma. This should be in the 

differential diagnosis of a patient with inflammation weeks after surgery. The presentation 

is atypical of infectious endophthalmitis and the treatment regimen is both arduous 

and lengthy. 


APAO Salvaging Acute Retinal Necrosis: A Retrospective 

Case Series 

Presenting Author: Santanu Mandal MBBS 

Co-Author(s): Santanu Mitra MBBS 

Purpose: To evaluate the outcome of management of cases with acute retinal necrosis 

(ARN) with oral valacyclovir. Methods: Retrospective, noncomparative, interventional 

case series. Reviews of records of ARN cases with a minimum follow-up of 3 years, between 

January 2005 and December 2008 were included. Results: Out of 11 cases, 9 

presented early with involvement anterior to equator. Another 2 presented late with posterior 

involvement. All were treated with oral valacyclovir and oral steroids, followed by 

barrage laser. Extensively involved cases required vitrectomy with silicone oil tamponade 

for rhegmatogenous retinal detachment. All early cases had at least 3 lines visual gain, 

whereas the late cases had poor visual outcome. Conclusion: Oral valacyclovir in early 

intervention of ARN achieves marked visual improvements. 


APAO Acute Posterior Multifocal Placoid Pigment 

Epitheliopathy: South Asian Variant 

Presenting Author: Hemanth Murthy MD 

Co-Author(s): Naveenam S Muralidhar MD MBBS, Kavitha Shekhar Rao MD 

Purpose: To study the clinical picture and the atypical features of acute posterior multifocal 

placoid pigment epitheliopathy (APMPPE) in South Asian eyes. Material and Methods: 

Retrospective analysis of 45 consecutive patients with fundus picture of multifocal 

placoid lesions and typical FFA. Results: Eighty-four eyes of 45 patients were studied. 

Median age was 30 years. Presenting vision was 20/60 or worse in 75% of patients. Atypical 

picture of headache in 26.6%, fever in 11.1% of patients, hyperemic discs in 14.2%, 

and serous retinal detachment in 20.2% of patients. Eighty-seven percent achieved 20/20 

vision. Mean follow-up was 28 months. No patients had scarring or pigmentation after 

recovery. Conclusion: APMPPE in the South Asian population showed atypical features 

of serous detachment, disc hyperemia, and disc edema. On recovery, scarring and pigmentation 

was not seen. 


APAO S. maltophilia Endophthalmitis: Clinicomicrobiologic 

Profile and Outcomes at a Tertiary Center in India 

Presenting Author: Aditya A Sudhalkar MS 

Co-Author(s): Ajit B Majji MD**, Guru Prasad Manderwad**, Nidhi Relhan MS**, 

Rajeev Kumar R Pappuru MBBS MD, Annie Mathai MBBS, Subhadra Jalali MS* 

Purpose: To determine the S. maltophilia endophthalmitis (SME) profile and its outcomes 

in India. Methods: Retrospective review of SME cases reported between 1991 and 2012. 

Data collected included demographics and a complete ocular, systemic, and microbiological 

history and examination, as well as treatment given. Results: Ten cases of SME were 

identified: 8 endogenous and 2 traumatic, with no gender inequality. All patients worked in 

a rural setting, and their age was less than 40 years. Fifty percent regained a visual acuity 

of ≥ 0.09 logMAR. Two patients developed retinal detachment 1 month after surgery. All 

were sensitive to fluoroquinolones and chloramphenicol . Conclusion: SME appears to 

have a different clinical and sensitivity profile in India. 


APAO Pantoea agglomerans Endophthalmitis: 

Clinicomicrobiologic Profiles and Outcomes 

Presenting Author: Aditya A Sudhalkar MS 

Co-Author(s): Ajit B Majji MD**, Guru Prasad Manderwad**, Swapna Reddy 

Motukupally 

Purpose: To determine the P. agglomerans endophthalmitis (PAE) profile and its outcomes 

in India. Methods: Retrospective review of PAE cases reported between 1991 and 2012. 

Data collected included demographics and a complete ocular, systemic, and microbiological 

history and examination, as well as treatment given. Results: Five cases, 4 traumatic 

and 1 postoperative, all males. Early presentation resulted in good outcomes. Anatomic 

outcomes and final visual acuity was variable; all isolates were uniformly sensitive to 

most commonly used antibiotics. Conclusion: Pantoea is a very rare cause of endophthalmitis 

and should be kept in mind while treating a patient of traumatic (vegetative) 

endophthalmitis. 


APAO A Novel, Low-Cost, Reusable Microincision 

Vitrectomy Surgery Trocar 

Presenting Author: Ajay Aurora MBBS 

Co-Author(s): Satinder Pal Singh Grewal MD MBBS 

Purpose: To describe a novel device, the autoclavable Aurora Needle Trocar (ANT), using 

a disposable hypodermic needle as a trocar, and to compare it with the Alcon 23-gauge 

(AT) trocar. Methods: The ANT was prospectively compared in 210 eyes to the AT in 204 

eyes with a single surgeon over 2 years. A penetration analysis was performed on 0.4-mm 

polyurethane film. Results: The ANT was easy to insert, needed 18% sclerotomies to 

be sutured vs. 16% with the AT. The maximum penetration force for ANT was 0.75-0.79 

Newton (N) and resistance 0.12-0.20 N, while with the AT the maximum penetration force 

was 0.87-.79 N and resistance was 0.67 to 1.42 N. Conclusion: The ANT system is efficient, 

cost-effective, and adaptable to all gauges, and it offers significantly low penetration 

force and resistance. 


Analysis of Choroidal Thickness in Branch Retinal Vein 

Occlusions Treated With Anti-VEGF Therapy Using Spectral 

Domain OCT 

Presenting Author: Hyung Cho MD 

Co-Author(s): Ahmad A Alwassia MD**, Caio V Regiatieri MD**, Jason Zhang MD, 

Jay S Duker MD*, Nadia Khalida Waheed MD 

Purpose: To study the relationship between choroidal thickness (CT) in patients with 

branch retinal vein occlusion (BRVO) using spectral domain OCT (SD-OCT), and to evaluate 

the effect of anti-VEGF agents on CT. Methods: Twenty-two eyes of 22 patients 

with BRVO were scanned using SD-OCT at baseline and on follow-up visits at 1, 3, and 6 

months, and 1 year. Results: The average subfoveal CT at baseline in the BRVO eyes was 

less than in age-matched normal eyes (208.8 vs. 255.8 µm, P = .0000835). The average CT 

in eyes that received anti-VEGF therapy decreased compared to baseline: 196.1 µm (baseline), 

187.0 µm (1 month, P = .042), 156.5 µm (3 months, P = .00033), 168.1 µm (6 months, P 

= .00026), and 174.5 µm (1 year, P = .0017). Conclusion: The choroid is thinner in patients 

with BRVO prior to the onset of anti-VEGF therapy. Anti-VEGF therapy is associated with 

further thinning of the choroid over 1 year. 





239




Evaluation of Choroidal Metastasis With OCT-Enhanced 

Depth Imaging 

Presenting Author: Hakan Demirci MD 

Purpose: To evaluate the imaging features of choroidal metastasis with OCT enhanced 

depth imaging (OCT-EDI). Methods: Retrospective analysis of 13 patients with choroidal 

metastasis. Results: On OCT-EDI, irregular thickening of retina pigment epithelium was 

observed in 8 patients (62%), and hyperreflective speckles in the subretinal fluid was observed 

in 9 (69%). In all patients, choroidal metastatic tumor originated from the outer 

layer (lamina vasculosa) of the choroid. In 3 cases that underwent treatment, the choroidal 

metastasis became hyperreflective scar tissue. Conclusion: On OCT-EDI, choroidal metastasis 

seems to develop in the outer layer of choroid that contains large, fenestrated 

vessels. OCT-EDI might be used in the follow-up of thin choroidal metastatic tumor. 


APAO Correlation Between the Repair of Cone Outer 

Segment Tips and Visual Recovery After Epiretinal 

Membrane Surgery 

Presenting Author: Yuji Itoh MD 

Co-Author(s): Makoto Inoue MD*, Tong-Sheng Lee MD, Akito Hirakata MD* 

Purpose: To compare the recovery of photoreceptor cone outer segment tips (COST) line 

and visual outcomes after epiretinal membrane (ERM) surgery. Methods: The diameter 

of COST line defect was calculated by spectral domain OCT and compared with BCVA 

after ERM surgery in 46 eyes. Prognostic factors to determine visual recovery were also 

evaluated. Results: The smaller COST line defect was correlated with better BCVA in 

all postoperative periods (P < .001). BCVA at 12 months after surgery was significantly 

correlated with preoperative COST line defect (P < .01) and preoperative BCVA (P < .05). 

Conclusion: Recovery of COST line may be related to visual recovery after ERM surgery. 


En Face Imaging of Active and Quiescent Central Serous 

Chorioretinopathy: A New Concept 

Presenting Author: Mathieu Lehmann MD 

Co-Author(s): Benjamin Wolff MD, Vivien Vasseur, Martine Mauget-Faysse MD*, Jose 

A Sahel MD* 

Purpose: To describe retinal and choroidal changes in acute and quiescent central serous 

chorioretinopathy (CSC) observed with en face spectral domain OCT (SD-OCT). Methods: 

Twenty-nine eyes with a diagnosis of CSC were prospectively scanned using en face SD- 

OCT combined with EDI. Results: Seventy-nine percent had serous retinal detachment, 

and 62% had pigment epithelial detachment. Subretinal hyperreflective deposits were 

observed in 19 patients (65%). The mean choroidal thickness was 491 µm. 100% of the 

patients demonstrated choroidal dilatation with en face OCT. Twenty percent had multiple 

hyperreflective points located in the choriocapillary layer, and 2 patients had choroidal 

cavitations. Conclusion: En face imaging using SD-OCT is an effective tool to understand 

choroidal changes in active and quiescent CSC. 


Correlation of Peripapillary Atrophy and Reticular Macular 

Disease in Patients With Primary Geographic Atrophy 

Resulting From AMD 

Presenting Author: Marcela Marsiglia MD PHD 

Co-Author(s): Sucharita Boddu, Srilaxmi Bearelly MD*, K Bailey Freund MD*, Lawrence 

A Yannuzzi MD, R Theodore Smith MD** 

Purpose: To correlate peripapillary atrophy (PPA) in AMD patients with geographic atrophy 

(GA) with peripapillary reticular macular disease (RMD), aka reticular pseudodrusen. 

Methods: Infrared imaging was used in 72 eyes of 57 patients with documented GA to 

detect peripapillary RMD and/or PPA. Results: PPA was detected in 63 of 72 eyes (87.5%) 

and peripapillary RMD was detected in 58 (80.5%). A significant correlation was found 

between these entities (P = .011, Fisher exact test). Conclusion: The high concordance 

between PPA and peripapillary RMD in AMD suggests a common disease mechanism, 

consistent with impairment of posterior ciliary circulation around the optic nerve. 


Comparing Indocyanine Green Angiography With Other 

Imaging Modalities in Detecting Reticular Macular Disease 

Presenting Author: Marcela Marsiglia MD PHD 

Co-Author(s): Sucharita Boddu, Ana Rita B M Santos MS**, Rufino Silva MD MSC*, 

Maria Da Luz Cachulo Damasceno MD, Jose G Cunha-Vaz MD PhD*, R Theodore Smith 

MD**, Srilaxmi Bearelly MD* 

Purpose: To compare indocyanine green angiography (ICG) with other scanning laser 

ophthalmoscopy (SLO) imaging modalities in detecting reticular macular disease (RMD), 

aka reticular pseudodrusen. Methods: Fellow eyes of 52 patients with unilateral CNV 

were imaged with ICG, autofluorescence (AF), and infrared (IR) for presence and extent 

of RMD. Results: ICG, AF, and IR detected RMD in 50.9%, 44.0%, and 35.5% of eyes, 

and average areas of RMD detected were 27.9%, 17.4%, and 18.6%, respectively. ICG 

and AF agreement was 90.0%, and between ICG and IR was 84.1%. Conclusion: ICG, 

AF, and IR are highly concordant in detecting RMD, with high ICG sensitivity suggesting 

choroidal involvement. 


APAO Swept Source OCT Findings in Chronic Phase of Vogt- 

Koyanagi-Harada Disease 

Presenting Author: Ichiro Maruko MD 

Co-Author(s): Yukinori Sugano MD**, Hiroshi Oyamada MD**, Tetsuju Sekiryu MD, 

Tomohiro Iida MD* 

Purpose: To evaluate choroidal and scleral thickness in chronic phase of Vogt-Koyanagi- 

Harada disease (VKH) using swept source OCT. Methods: Choroidal and scleral thickness 

was measured using OCT. Results: Fourteen eyes of 7 patients with chronic VKH were 

examined. All eyes at the last examination had no subfoveal detachment and showed the 

sunset glow fundus. Mean subfoveal choroidal and scleral thickness was 276 µm and 498 

µm, respectively. Eight eyes with peripapillary atrophy (PPA) had thinner choroid compared 

with 6 eyes without PPA (183 µm and 401 µm, P < .01). Conclusion: Although the choroid 

in chronic VKH was thinner than in acute VKH, the sclera was restored. The choroidal thinning 

might be associated with choroidal circulation because the cases with PPA especially 

had thinner choroid. 


APAO Retinal Blood Flow in Patients With Diabetic 

Retinopathy Treated With Panretinal Photocoagulation 

Presenting Author: Naoko Onizuka MD 

Co-Author(s): Kiyoshi Suzuma MD, Yoshihisa Yamada, Masafumi Uematsu MD, Takashi 

Kitaoka MD** 

Purpose: To evaluate the retinal blood flow before and after panretinal photocoagulation 

for diabetic retinopathy (DR). Methods: This study was conducted on 22 eyes of 

15 patients. The retinal blood velocity at optic disc was evaluated as mean blur rate by 

laser speckle flowgraphy, and photocoagulation was undergone by pattern scanning laser 

(PASCAL). We compared the blood velocity before and after panretinal photocoagulation. 

Results: The mean blood velocity significantly decreased to 71.2 ± 15% (P < .001) after 

panretinal photocoagulation. The number of laser spots were significantly correlated with 

decreases in mean blood velocity (R = 0.31, P = .021). Conclusion: The mean blood velocity 

measured by laser speckle flowgraphy may be useful to examine an adequate number 

of laser spots for DR. 


Evaluation of Retinal Neurodegeneration With Spectral 

Domain OCT in Multiple Sclerosis 

Presenting Author: George J Parlitsis MD** 

Co-Author(s): Aalya Fatoo MD, Susan A Gauthier DO*, Szilard Kiss MD* 

Purpose: To evaluate retinal nerve fiber layer (RNFL) thickness, macular thickness (MT), 

and macular volume (MV) in a large cohort of multiple sclerosis (MS) patients. Methods: 

140 eyes of MS patients were prospectively evaluated using spectral domain OCT (SD- 

OCT). Clinical data were correlated with RNFL and macular thickness. Results: MS eyes 

showed peripapillary RNFL thinning compared with controls (91.7 µm vs. 152.8 µm, P < 

.01), with more thinning in eyes with prior optic neuritis (P < .05). Nasal MT in MS eyes 

was thinner than controls; however, global MT and MV were not significantly decreased 

over an average follow-up period of 479 days. Conclusion: SD-OCT retinal neuronal layer 

measurements may be an objective, quantifiable biomarker of neurodegeneration in MS 

and optic neuritis. 

240 






Association of Macular Pigment Density With Foveal 

Retinal Thickness: The ALIENOR Study 

Presenting Author: Marie-Benedicte Rougier MD* 

Co-Author(s): Marie-Noelle Delyfer MD PHD*, Jean-Francois Korobelnik MD*, Claire 

Marine Puaud MD**, Joseph Colin MD*, Florence E Malet MD, Melanie Le Goff 

PhD**, Jean-Francois Dartigues PhD*, Pascale Barberger-Gateau PhD*, Cecile Delcourt 

PhD* 

Purpose: To assess the association of macular pigment density with retinal thickness in 

elderly subjects. Methods: Within the population-based ALIENOR Study, 187 subjects 

aged 75 years or older, without retinal diseases, had an autofluorescence measurement 

of macular pigment density (modified HRA; Heidelberg, Germany) and retinal thickness 

using spectral domain OCT (Spectralis; Heidelberg, Germany). Results: Macular pigment 

density within 0.5° correlated significantly with foveal retinal thickness (within 1 mm): r 

= 0.20, P = .009, but not with parafoveal retinal thickness. Macular pigment at 1° and 2° 

did not significantly correlate with foveal or parafoveal retinal thickness. Conclusion: 

Macular pigment density increases with foveal retinal thickness. 


Pathological Myopia: A New Perspective on Tilted Discs 

Using Spectral Domain-Enhanced Depth Imaging OCT 

Presenting Author: Danielle S Strauss MD 

Co-Author(s): Sri Krishna Mukkamala MD, Richard F Spaide MD*, Lawrence A Yannuzzi 

MD 

Purpose: To study the tilt of the optic nerve in pathological myopia using spectral domainenhanced 

depth imaging OCT (SD EDI-OCT). Methods: Twenty-six tilted discs were evaluated 

with fundus photography, EDI-OCT, ImageJ, and Heidelberg software. Results: Mean 

vertical diameter of disc was 1.8 ± 0.5 mm (range: 1.2-3.3 mm). Fourteen discs (53%) 

were oriented infero-temporally; 10 (38%), infero-nasal; 1 (3%), supero-nasal; and 1 (3%), 

supero-temporal. Mean index of tilt was 0.6 ± 0.1 (range: 0.2-0.75), mean torsion was 39.6 

± 15.4 degrees (range: 7.8-69.2). Seventeen (65%) displayed situs inversus. Twelve eyes 

(46%) had papillo-macular staphyloma. Choroidal thickness on conus side was 46.0 ± 23.2 

µm (range: 11-95 µm), vs. nerve tuft side: 99.3 ± 32.5 µm (range: 41-190 µm), P < .001. 

Conclusion: EDI-OCT is useful to show variation on the tilted disc syndrome. 


Association of Retinal Point Sensitivity and Inner/ Outer 

Segment Junction Status in Diabetic Macular Edema 

Presenting Author: Jithin Yohannan MPH 

Co-Author(s): Millena Gomes Bittencourt MD DOMS, Yasir Jamal Sepah MBBS, Elham 

Hatef Naimi MD, Raafay Sophie MBBCHIR MD, Ahmadreza Moradi MD, Hongting Liu, 

Mohamed A Ibrahim Ahmed MBBCH, Elizabeth Coulantuoni PhD, Quan Dong Nguyen 

MD* 

Purpose: To study the association of retinal point sensitivity (RPS) and inner-outer segment 

(IS/OS) junction status in diabetic macular edema (DME). Methods: We conducted 

a cross-sectional study and obtained simultaneous fundus microperimetry (MP) and OCT 

in DME patients using a combined MP / OCT system. The device recorded RPS and we 

analyzed the integrity of IS/OS junction at each MP point. Results: Twenty-five patients 

(37 eyes) and 1036 MP points were analyzed. Mean RPS was 10.51 dB. IS/OS junction was 

disrupted in 243 points (23.5%). Multilevel linear modeling revealed that IS/OS junction 

disruption was associated with a 3.28-dB decrease in RPS (P < .01). Conclusion: The 

index study demonstrates that IS/OS junction disruption is associated with significant 

decrease in RPS in DME. 


APAO Intraoperative Dexamethasone Implant (Ozurdex) 

Improves Outcome of Cataract Surgery in Patients With 

Diabetes 

Presenting Author: Aniruddha K Agarwal MBBS 

Co-Author(s): Vishali Gupta MBBS, Jagat Ram MBBS** 

Purpose: To determine efficacy of intravitreal dexamethasone implant (Ozurdex) in improving 

cataract surgery outcome in diabetics. Methods: In a prospective randomized 

pilot interventional study, 10 patients with nonproliferative diabetic retinopathy + macular 

edema and cataract were randomized to receive intraoperative Ozurdex in Group A (6 

eyes) vs. control in Group B (6 eyes). Results: In Group A, mean decrease in central macular 

thickness was 77.83 µm, 25.83 µm, and 24.83 µm at 6, 12, and 24 weeks, respectively. 

In Group B, CMT was significantly higher at every visit (P < .001). Group A had significant 

gain in ETDRS letters compared to Group B at all visits (P < .018) at all visits. Conclusion: 

Intraoperative injection Ozurdex improves outcome of cataract surgery in diabetics. 


Clinical Response to Intravitreal High-dose (2.0 mg) 

Ranibizumab for Radiation Maculopathy 

Presenting Author: Paul Finger MD* 

Purpose: To investigate intravitreal 2.0-mg ranibizumab for persistent radiation maculopathy 

(RM). Methods: Ten patients with RM related to uveal melanoma plaque brachytherapy 

(n = 8) or external beam radiation therapy (n = 2) were prospectively studied. 

All failed standard-dose intravitreal anti-VEGF therapy. Monthly high-dose ranibizumab 

was evaluated for safety, tolerability, and effect. Results: Vision was stable (n = 3), improved 

(n = 6), or decreased (n = 1) for a mean improvement 2.5 ETDRS letters. Foveal OCT 

thickness was stable or improved in 80% (mean 19% improvement). No adverse events 

were noted. Conclusion: High-dose ranibizumab was well-tolerated, diminished retinal 

thickness, and preserved acuity. This suggests the VEGF level was higher than could be 

managed by standard anti-VEGF doses. 


APAO Three-Year Safety and Efficacy of Ranibizumab in 

Patients With Visual Impairment Due to Diabetic Macular 

Edema: The RESTORE Extension Study 

Presenting Author: Paul Mitchell MD PhD* 

Purpose: To assess long-term safety and efficacy of ranibizumab 0.5 mg (RBZ) in patients 

with visual impairment due to diabetic macular edema (DME). Methods: Patients treated 

with RBZ (R), RBZ+laser (R+L), or laser (L) in RESTORE core phase continued in an openlabel 

extension study using p.r.n. RBZ treatment from Month 12 through Month 36 (N = 

240). Results: No new/increased ocular/non-ocular safety findings were identified. Mean 

BCVA gain from core baseline at Month 12 (R: 7.9, R+L: 7.1, L: 2.3 letters) was either 

maintained (R: 8.0 letters, n = 83; R+L: 6.7 letters, n = 83) or improved (L: 6.0 letters, n = 

74) at Month 36 with a mean of 6.8 (R), 6.0 (R+L), and 6.5 (L) injections (Months 12-35). 

Conclusion: RBZ p.r.n. treatment in DME was well tolerated and efficacious over 3 years. 


Single Intravitreal Diclofenac vs. Bevacizumab in Naive 

Diabetic Macular Edema: A Randomized, Double-Masked 

Clinical Trial 

Presenting Author: Masoud Soheilian MD 

Co-Author(s): Alireza Ramezani MD, Talieh Montahai MD, Saeed Karimi**, Mehdi 

Yaseri MD 

Purpose: To compare single injection of intravitreal diclofenac (IVD) with bevacizumab 

(IVB) in the primary treatment of diabetic macular edema (DME). Methods: Fifty-seven 

eyes were randomly assigned to received either 500-mg IVD (30 eyes) or 1.25-mg IVB (27 

eyes). Result: BCVA improved significantly more in the IVD group than in IVB groups (P = 

.033): from 0.57 ± 0.25 to 0.49 ± 0.31 vs. 0.58 ± 0.21 to 0.59 ± 0.27 logMAR at 12 weeks, 

respectively. However, the difference of macular thickness changes (18 microns) was in 

favor of IVB but not to a significant level. Conclusion: Single IVD injection might be a 

promising alternative treatment in DME. 


APAO Vitreous Estrogen Levels in Patients With an 

Idiopathic Macular Hole 

Presenting Author: Tsunehiko Ikeda MD 

Co-Author(s): Naoki Inokuchi MD, Kimitoshi Nakamura MD**, Seita Morishita MD** 

Purpose: Estrogen activates collagenase and might be associated with the pathogenesis 

of vitreoretinal disease. The purpose of this study was to investigate the vitreous levels 

of estrone (E1) and estradiol (E2) in subjects with idiopathic macular hole (IMH). Methods: 

Vitreous samples were obtained from 9 females with IMH and from 9 females with 

other retinal diseases (6 with rhegmatogenous retinal detachment and 3 with AMD) as a 

control. E1 and E2 levels in the vitreous were determined by ELISA. Results:The mean 

vitreous levels of E1 and E2 in the IMH were 1.23 ± 1.97 pg/ml and 4.64 ± 4.18 pg/ml, 

respectively, whereas in the control they were 1.45 ± 0.63 pg/ml and 0.42 ± 0.44 pg/ml. 

The vitreous E2 levels in the IMH were significantly higher than in the controls (P < .005). 

Conclusion: The findings of this study suggest that E2 might be associated with the 

pathogenesis of IMH. 





241




APAO A Novel Angiographic Classification of Polypoidal 

Choroidal Vasculopathy Predicts Its Five-Year Clinical 

Outcomes 

Presenting Author: Colin S Tan MBBS 

Co-Author(s): Wei Kiong Ngo MBBS, Louis Lim MD**, Tock H Lim MBBS FRCSE* 

Purpose: To describe a novel classification system for polypoidal choroidal vasculopathy 

(PCV) and correlate it with 5-year clinical outcomes. Methods: In a 5-year study of 107 

consecutive patients with PCV, 3 subtypes were identified based on indocyanine green 

(ICG) features. Results: Visual outcomes varied with the ICG subtypes (I to III). The highest 

rate of moderate visual loss occurred in Type III PCV, followed by Types II and I (41.2% vs. 

11.1% vs. 0% at 5 years). Good visual outcomes (≥ 20/40) were highest in Type I, compared 

to Types II and III (83.3% vs. 62.5% vs. 20%, P = .034). Independent risk factors for 

visual outcomes were PCV subtype (odds ratio [OR] 7.6, P = .003) and age (OR 1.1, P = .022). 

Conclusion: A novel classification system for PCV predicts its long-term visual outcomes. 


APAO Phase 2 Clinical Trial of Intravenous Fosbretabulin in 

the Treatment of Polypoidal Choroidal Vasculopathy 

Presenting Author: Timothy Y Lai MBBS* 

Co-Author(s): Won Ki Lee MD*, Se Woong Kang MD PHD**, Hyoung J Koh MD, Young 

Hee Yoon MD*, Gemmy Chui Ming Cheung MBBCHIR FRCOPHTH, Nikolle WH Tan 

MBBS* 

Purpose: To evaluate the efficacy and safety of fosbretabulin in polypoidal choroidal 

vasculopathy (PCV). Methods: Twenty PCV patients were randomized to 4 different dosages 

of intravenous fosbretabulin (15-45 mg/kg) and placebo. Results: At 28 days, no 

significant difference in visual acuity, number of polyps on indocyanine green angiography 

(ICGA), and retinal thickness on OCT was observed. A higher proportion of patients had 

improved or stabilized qualitative changes on ICGA and OCT in the fosbretabulin group 

compared to placebo (P = .032). No drug-related serious adverse event was observed in 

the study. Conclusion: A single intravenous fosbretabulin infusion might cause transient 

reduction in polyp activity in PCV. 


APAO Endoillumination-Assisted Scleral Buckling: The 

Future Approach to Retinal Detachment Surgery 

Presenting Author: Varun Gogia MBBS 

Co-Author(s): Pradeep Venkatesh**, Satpal Garg MD**, Rajpal Vohra BMBS MD, 

Ashish Kakkar** 

Purpose: To evaluate the surgical outcomes of endoillumination-assisted scleral buckling 

(EASB) in rhegmatogenous retinal detachment (RRD). Methods: Fifteen eyes of 15 

patients with RRD where no preoperative break could be localized underwent 25-gauge 

endoilluminator-assisted break localization and cryopexy followed by standard scleral 

buckling. Anatomical outcomes were evaluated at 6 months. Results: Median age was 

52 years (range: 18-65). Four patients were pseudophakic and 2 were aphakic. Anatomical 

success (attachment of retina) was achieved in 14 eyes (93.3%). Significant improvement 

in mean visual acuity was achieved (P < .05). Conclusion: EASB can be considered an 

effective alternative to vitreoretinal surgery in simple retinal detachment cases. 


Intraoperative OCT Imaging of Retinal Changes During 

Repair of Rhegmatogenous Retinal Detachment 

Presenting Author: Matthew P Ohr MD 

Co-Author(s): Sunil K Srivastava MD*, Peter K Kaiser MD*, Justis P Ehlers MD 

Purpose: To evaluate changes to retinal anatomy with intraoperative OCT (iOCT) during 

surgical repair of retinal detachment (RD). Methods: Imaging data for 11 consecutive 

patients undergoing iOCT and repair of RD were retrospectively analyzed. Results: Microarchitectural 

alterations were found in 100% of patients. Group 1 (n = 4) revealed isolated 

subfoveal hyporeflectivity, group 2 (n = 5) showed prominent subfoveal hyporeflectivity 

with retinal thinning and indeterminate macular hole (MH), and group 3 (n = 2) showed 

a definitive MH. Conclusion: Significant alterations of retinal anatomy are seen with 

iOCT during repair of RD, which may have implications for MH development and visual 

outcomes following RD. 


Outcomes of Patients Initially Treated With Intravitreal 

Bevacizumab for Central Retinal Vein Occlusion: A Longterm, 

Real-World Follow Up 

Presenting Author: Jasmina Bajric 

Co-Author(s): Nihal Hamouda MD, Sophie Bakri MD* 

Purpose: To assess outcomes of visual acuity (VA) and retinal thickness (RT) in patients 

with macular edema secondary to central retinal vein occlusion (CRVO) who were initially 

treated with bevacizumab and followed for up to 4 years. Methods: In this retrospective 

case series, 60 patients with CRVO who had initial treatment with bevacizumab were included. 

Patients received additional treatments at the discretion of the treating physician. 

Results: VA improved from 20/235 at baseline to 20/121 at 1 year (P < .0001), and this 

improvement was maintained at 4 years. RT improved from 586.6 µm to 338.8 µm at 1 year 

(P = .0027), and this was maintained at 3 years. Conclusion: Patients who receive bevacizumab 

as initial therapy for CRVO can maintain VA and RT improvement up to 4 years. 


APAO Measurement of Retinal Vessel Caliber in Healthy 

Eyes by Using OCT 

Presenting Author: Kyoko Kumagai MD 

Co-Author(s): Yuki Muraoka MD, Akitaka Tsujikawa MD PhD*, Tomoaki Murakami MD, 

Ken Ogino MD, Kazuaki Miyamoto MD** 

Purpose: To study the reproducibility of retinal vessel caliber measurement with OCT. 

Methods: Vertical vessel calibers measured by circle scanning around optic discs of 53 

healthy eyes were compared to horizontal calibers measured by a semiautomated program 

(IVAN) on color fundus photographs. Result: Circle scanning provided clear sectional 

images of retinal vessels and enabled measurement of vertical vessel calibers. The 

intervisit-, interexaminer-, and intraexaminer-correlation coefficients of the calibers were 

0.987, 0.991, and 0.994, respectively, and correlated well with those measured by IVAN 

(R = 0.860, P < .001). Conclusion: Circle scanning of OCT has potential for retinal vessel 

caliber measurement. 


APAO Spectral Domain OCT Analysis of Retinal Vasculature 

Changes in Branch Retinal Vein Occlusion 

Presenting Author: Yuki Muraoka MD 

Co-Author(s): Akitaka Tsujikawa MD PhD*, Tomoaki Murakami MD, Ken Ogino 

MD, Kyoko Kumagai MD, Kazuaki Miyamoto MD**, Akihito Uji MD PhD, Nagahisa 

Yoshimura MD PhD* 

Purpose: To study retinal vasculature in branch retinal vein occlusion (BRVO). Methods: 

Twenty-five eyes with BRVO were examined by sequential ultrathin sectioning with OCT. 

Results: When the artery was over the vein at the affected crossing, the vein seemed to 

run deep under the artery, and the venous lumen often seemed to be preserved. When the 

vein was over the artery at the crossing, the vein seemed to be compressed and choked 

between the internal limiting membrane and the arterial wall at the crossing. Intravenous 

thrombi were seen in 84% of eyes and were significantly associated with retinal ischemia 

(P = .036). Conclusion: BRVO may occur by 2 mechanisms, depending on the relative 

anatomical positions of crossing vessels. 


Restoration of the Blood Flow and Vision in Nonarteritic 

Central Retinal Artery Occlusion With Early Vitrectomy 

Presenting Author: Shlomit Schaal MD 

Co-Author(s): Motasem M Al-Latayfeh MD, Yoreh Barak MD, Tongalp H Tezel MD 

Purpose: To determine efficacy of 25-gauge vitrectomy in restoring perfusion and sight 

in retinal artery occlusion (RAO). Methods: Seven eyes with RAO underwent 25-gauge 

vitrectomy within 48.1 ± 36.8 hours from onset of symptoms. During vitrectomy, embolus 

was manually dislodged. Angiographic intraoperative assessment of retinal perfusion and 

change in visual acuity were recorded. Results: Intraoperative restoration of retinal perfusion 

was achieved in all patients. Visual acuity peaked at 20/63 ± 20/42 postoperatively. 

Visual gain was inversely correlated with initial visual acuity and duration of symptoms. 

Conclusion: Immediate vitrectomy and manual dislodging of embolus may result in restoration 

of retinal blood flow and recovery of the foveal vision in patients with RAO. 

242 






APAO Significant Correlation Between Visual Acuity and 

Choroidal Thickness in Bevacizumab-Treated Central 


Presenting Author: Ryotaro Ueki MBCB 

Co-Author(s): Kiyoshi Suzuma MD, Eiko Tsuiki DOMS, Yuki Maekawa MD, Takashi 

Kitaoka MD** 

Purpose: To evaluate the subfoveal choroidal thickness (SCT) in central retinal vein occlusion 

(CRVO) patients treated with intravitreal bevacizumab injection (IVB). Methods: 

We measured SCT in 20 patients with unilateral CRVO using enhanced depth imaging 

OCT. Results: The mean SCT of CRVO eyes was 226 ± 84 µm, which was significantly 

thicker than that of fellow eyes (207 ± 75) (P = .02). The mean SCT after IVB was 218 ± 

72, which was significantly thinner than that before IVB (228 ± 85) (P = .007). The change 

of visual acuity had a negative correlation with the change of choroidal thickness (r = 

-0.57, P = .0019). Conclusion: IVB may have effects on visual function via a decrease of 

SCT in CRVO. 


APAO Early Treatment Enhances Visual Outcome in Patients 

With Macular Edema Secondary to Retinal Vein Occlusion: 

Six-Month Results of Korean-RVO Study 

Presenting Author: Young Hee Yoon MD* 

Co-Author(s): Hakyoung H Kim MD, Hee S Yoon MD, Se Woong Kang MD PHD**, 

June-Gone Kim MD PHD, Kyu-Hyung Park MD*, Young Joon Jo MD, Joo Yong Lee 

MD* 

Purpose: To assess the effect of prompt treatment on visual outcome in retinal vein occlusion 

(RVO) patients with macular edema (ME). Methods: Retrospective, cross-sectional 

study from 41 sites nationwide. Treatment-naïve patients were included. Results: Among 

156 BRVO patients, neither mean BCVA nor central retinal thickness was different at baseline 

among 5 groups (duration of ME: ≤ 2 weeks, 2-4 weeks, 1-2 months, 2-3 months, 3-6 

months) (P > .05). At 6 months, patients with earlier treatment achieved the better visual 

outcome, in terms of mean BCVA improvement (P = .002) or the percentage of 3-line gainer 

(P = .019). Neither parameter showed a difference among 93 CRVO patients. Conclusion: 

Earlier treatment (as early as in 2 weeks) maximized final visual outcome in BRVO patients 

with ME. 


Risk Factors Associated With Retinal Hemorrhages in 

Suspected Nonaccidental Trauma 

Presenting Author: Zachary N Burkhart MD 

Co-Author(s): Clinton Thurber, Alice Z Chuang PhD*, Judianne Kellaway MD**, Garvin 

H Davis MD** 

Purpose: To determine risk factors for retinal hemorrhage in pediatric nonaccidental trauma 

(NAT) suspects. Methods: Records were reviewed for NAT suspects (January 2007 to 

November 2011) at Children’s Memorial Hermann Hospital, Houston, Tex., USA. Case (n 

= 103) and control (n = 65) groups were created based on presence of retinal hemorrhage 

(RH). Statistical analysis was performed to identify risk factors for RH. Results: Lethargy 

(P < .0001) and subdural hemorrhage (P < .0001) were risk factors for RH. Fracture without 

intracranial hemorrhage was never associated with RH (P < .0001). Conclusion: This is 

the first case/control study in this area. Findings suggest that abuse suspects with fracture 

but no intracranial bleed may not need dilated exam. 


Bevacizumab (Avastin) for Prevention of Macular Edema 

After Plaque Radiotherapy for Uveal Melanoma 


Co-Author(s): Carlos G Bianciotto MD, Juan C Iturralde MD, Josep Badal Lafulla MD, 

Emil Anthony T Say MD, Saad Abdullah Al-Dahmash MBBS, Sanket Shah MD, Jerry A 

Shields MD 

Purpose: To evaluate bevacizumab (Avastin) for prevention of macular edema (ME) after 

plaque radiotherapy for uveal melanoma. Methods: Study subjects randomized into 

2 groups: Avastin, 6 injections every 4 months after plaque vs. controls. Main outcome 

measure: OCT-evident ME. Results: 321 patients were included in the Avastin group and 

136 as controls. Median radiation dose to the fovea was 4024 cGy (Avastin) and 3938 

cGy (controls) (P = .40). At a mean follow-up of 20 months, occurrence of ME (Avastin vs. 

controls) was 29% vs. 42% (P = .0097); clinical radiation maculopathy, 16% vs. 30% (P = 

.0008); moderate vision loss, 35% vs. 59% (P < .001); and severe vision loss, 17% vs. 28% 

(P = .01). No difference in radiation papillopathy was found. Conclusion: The Avastin 

group had statistically lower rates of ME and vision loss. 


Vasoproliferative Tumors of the Ocular Fundus In 295 Eyes: 

Clinical Features of Primary and Secondary Tumors 

Presenting Author: Swathi Kaliki MD 

Co-Author(s): Carol L Shields MD, Saad Abdullah Al-Dahmash MBBS, Duangnate 

Rojanaporn MD, Shripaad Y Shukla MD, Brad Reilly**, Jerry A Shields MD 

Purpose: To compare primary and secondary vasoproliferative tumors (VPT) of the retina. 

Methods: Retrospective study. Results: Of 275 patients with VPT, 80% had primary and 

20% had secondary VPT. Secondary VPT presented at an earlier age (46 vs. 38 years; P = 

.0052), often bilateral (20% vs. 4%; P < .0001), with poor visual acuity < 20/60 (56% vs. 

34%; P = .0039), larger tumor base (7 vs. 6 mm; P = .0319), and multiple tumors (15% vs. 

5%; P = .0112) compared to primary VPT. Conclusion: Primary VPT is more common than 

secondary VPT. Secondary VPT is more often bilateral, multiple, and occurs at an earlier 

age compared to primary VPT. 


APAO Postenucleation Adjuvant Chemotherapy in 

Retinoblastoma With Histopathological High-risk Features 

Presenting Author: Fairooz Puthiyapurayil Manjandavida MBBS 

Co-Author(s): Santosh G Honavar MD, Mohammad Javed Ali MD, Kaustubh Bharat 

Mulay BMBS MD, Geeta K Vemuganti MD, Vijay Anand P Reddy MD 

Purpose: To assess the efficacy of postenucleation adjuvant chemotherapy in preventing 

metastasis in retinoblastoma (Rb) with histopathological high-risk features (HRF). Methods: 

Our noncomparative case series included 133 consecutive patients who underwent 

adjuvant chemotherapy (vincristine + carboplatin + etoposide) following enucleation for 

Rb with HRF. Results: Choroidal invasion 3 3 mm in 65 (48%) and retrolaminar optic nerve 

invasion in 54 (40%) were the most common HRF. There was no serious complication of 

chemotherapy. Median follow-up was 24 months (range: 12-161 months). Two patients 

(1.5%) with invasion to optic nerve transaction developed CNS metastasis. Conclusion: 

Postenucleation chemotherapy is safe and effective in reducing the risk of metastasis in 

Rb with HRF. 


Clinical Course of von Hippel-Lindau Disease-Associated 

Juxtapapillary Retinal Capillary Hemangioblastomas 

Presenting Author: Stanley Park 

Co-Author(s): Brian Toy MD, Wai T Wong MD PhD, Emily Y Chew MD 

Purpose: To report the clinical course of juxtapapillary retinal capillary hemangioblastomas 

(RCHs). Methods: Retrospective case series of 243 patients with von Hippel-Lindau 

(VHL) disease and RCH from one institution. Results: Review of clinical and photographic 

records showed 30 patients (12.3%) with juxtapapillary RCH. With mean follow-up (± SD) 

of 5.6 ± 2.0 years, 15 grew to > 1.5 mm in the greatest linear dimension. Eight of these 15 

had visual acuity (VA) of 20/200 or worse, and 5 of the 8 had marked exudation and resistance 

to conventional therapy. The remaining 15 were < 1.5 mm with a mean VA of 20/26, 

and 13 of these had no tumor growth. Conclusion: A subset of VHL patients develops 

juxtapapillary RCH. Their growth, size, and location contribute to exudation, leading to 

visual morbidity and treatment limitations. 


Fluorescein Angiographic Findings of Retinocytoma vs. 


Presenting Author: Sanket Shah MD 

Co-Author(s): Ahmet M Sarici MD, Bhavna Chawla MD, Carol L Shields MD 

Purpose: To compare fluorescein angiography (FA) in retinocytoma (RCT) and retinoblastoma 

(RB). Methods: We studied FA findings in treatment-naïve cases of RCT (n = 11) and 

RB (n = 14) after matching tumors for maximal diameter, thickness, and subretinal fluid. 

Results: RCT had lack of intratumor capillary hyperfluorescence (HF) in all phases (P < 

.003), less intense HF of lesion in venous (P = .010), and late venous (P = .001) phases, lack 

of HF foci in venous (P = .002), lack of double circulation (P < .001), and late phase mottled 

HF (P = .017) compared to RB. Conclusion: FA may help differentiate RCT from RB. 





243




Recurrent Epimacular Membranes After Internal Limiting 

Membrane Peel With Indocyanine Green 

Presenting Author: Gabriel A Benitez-Bajandas MD 

Co-Author(s): Miguel A Busquets MD**, Brian H Jewart MD, Martin A Boscarino MD 

Purpose: To compare the recurrence rates of epimacular membranes (EMM) after internal 

limiting membrane (ILM) peeling with and without indocyanine green (ICG) stain. Methods: 

Retrospective review of 148 consecutive EMM peels classified into 2 groups: ICG and 

non-ICG (no stain or triamcinolone). Groups were followed to 12 months postoperatively. 

A second surgical EMM peel was classified as a recurrence. Visual acuity was followed 

for all patients. Results: Nine of 148 total cases (6%) had recurrent EMM (at an average 

of 7 months postop). Recurrence rates were 0.8% in the ICG group vs. 30% in the non-ICG 

group. The mean change in visual acuity in the ICG group was 3 lines of improvement 

vs. 1 line in the non-ICG group. Conclusion: ILM peel with ICG may reduce epimacular 

membrane recurrences. 


Retinal Nerve Fiber Layer Thickness Modifications After 

Internal Limiting Membrane Peeling 

Presenting Author: Antonio P Ciardella MD 

Co-Author(s): Nicole Balducci, Francesco Pichi MD, Maria Chiara Morara MD, Chiara 

Veronese**, Carlo Torrazza MD**, Tommaso Perossini MD 

Purpose: To identify retinal nerve fiber layer thickness (RNFLT) changes after internal 

limiting membrane peeling (ILMP) for macular hole (MH) and epiretinal membrane (ERM). 

Methods: Spectralis OCT of the peripapillary RNFL was performed before and 1, 3, and 

6 months after surgery on 30 patients (73.5 ± 6.6 years). Results: Postoperative logMAR 

visual acuity (VA) improved (0.51 ± 0.29 vs. 0.14 ± 0.16, P < .001). RNFLT increased in all 

the sectors but the temporal one at Month 1, and returned to basal values at Month 3. At 

Month 6 RNFLT was lower than basal values in the superotemporal, inferotemporal, and 

temporal sectors (114.6 ± 19 µm vs. 130.2 ± 24.7 µm, P < .001; 125.5 ± 23.8 µm vs. 136.2 ± 

17.5 µm, P < .05 and 70.2 ± 17.4 µm vs. 98.5 ± 27.7 µm, P < .001). Conclusion: ILMP led 

to a sixth-month reduction of the RNFLT, limited to the sectors where the ILM was peeled. 


Anterior Segment Complications of Combined Phaco- 

Vitrectomy Surgery 

Presenting Author: Roxane Jo Hillier FRCOPHTH 

Co-Author(s): John Doris, Rita McLauchlan, Felipe E Dhawahir-Scala FRCOphth*, Paulo 

E Stanga MD**, George Turner MBBS*, Stephen Charles MD MBBS, Niall Patton 

MBChB* 

Purpose: To determine the incidence of anterior segment complications associated with 

phaco-vitrectomy and to identify factors that influence these. Methods: A prospective observational 

study of 102 patients. Data were captured at time points up to 12 weeks after 

phaco-vitrectomy. Results: IOL displacement/iris capture occurred in 8.8%. Use of AcrySof 

MA60 IOL (P = .0027) and large capsulorrhexis size (P = .0117) were associated with 

increased incidence of IOL displacement/iris capture. Other complications were posterior 

synechiae (5.9%), posterior capsule rupture (3.9%), and iris prolapse (2.9%). Conclusion: 

Haptic design and capsulorrhexis size play an important role in IOL positional stability 

following phaco-vitrectomy. 


APAO Foveolar Müller Cell Cone Preservation in Internal 

Limiting Membrane Peeling of Myopic Foveoschisis 

Surgery: A Long-term Follow-up 

Presenting Author: Tzyy-Chang Ho MD 

Co-Author(s): Muh-Shy Chen MD, Fong Lin Huang MD, Yu-Shuang Huang MD 

Purpose: To report the long-term results of a novel vitrectomy technique to preserve the 

foveolar Müller cell cone without peeling off the foveolar internal limiting membrane (ILM) 

during ILM peeling in myopic foveoschisis. Methods: Eighteen eyes with foveoschisis underwent 

vitrectomy. Results: A donut-shaped ILM was peeled off, leaving a 400 µ diameter 

ILM over foveola in all eyes. All eyes restored foveal contour, and logMar VA improved 

from 1.77 to 0.96. No eyes (0%) developed a macular hole during the 36-month follow-up 

period. Conclusion: Preservation of the integrity of the foveolar Müller cell cone by a 

donut peel of ILM restores normal foveal contour and successfully saves the fovea from 

the development of full-thickness macular hole after long-term follow-up. 


APAO Evaluation of Wound Closure Morphology of 

Sclerotomy Sites Using Anterior Segment Spectral Domain 

OCT 

Presenting Author: Manish Nagpal MD* 

Co-Author(s): Gaurav S Paranjpe 

Purpose: To evaluate the wound morphology in eyes undergoing sutureless vitrectomy. 

Methods: Scleral ports of 20 eyes were evaluated using anterior segment OCT on Day 1, 

15, and 30. Ten eyes each were assigned to Group A (23-gauge sclerotomies) and Group B 

(25-gauge sclerotomies). Results: On Day 1 the mean outer and inner incision diameters 

in Group A were 236.6 microns and 146 microns and those for Group B were 118.6 microns 

and 90 microns. A significant decrease (P < .0001) in both the port sizes was observed during 

both groups follow-up. Conclusion: In both groups the sclerotomy incisions showed 

good healing at 1 month duration, and 25-gauge sclerotomies showed better healing characteristics 

as compared to 23-gauge. 


Outpatient Fluid-Gas Exchange Following Unsuccessful 

Idiopathic Macular Hole surgery 

Presenting Author: Xi Rao MD 

Co-Author(s): Nan-Kai Wang MD, Yih Shiou Hwang MD, Yen-Po Chen MD, Lan-Hsin 

Chuang MD, Ling Yeung MD, I-Chia Liang MD**, Kuan-Jen Chen MD, An-Ning Chao 

MD, Wei-Chi Wu MD, Tun-Lu Chen MD**, Chi-Chun Lai MD* 

Purpose: To report the effectiveness of fluid-gas exchange after primary failed macular 

hole surgery. Methods: Fluid-gas exchange within 6 months with 15% C3F8 or 20% SF6 

was performed on 30 patients, who did not achieve anatomic closure after the primary 

vitrectomy. Results: Ninety percent of eyes achieved anatomic success. Sixteen (53%) 

achieved the type 1 closure; eleven (36%) achieved the type 2 closure; three cases (10%) 

did not close finally. After a follow-up of 12 months, the BCVA for the type 1 closure improved 

from logMAR 1.604 to 0.747 (SD: 0.336-0.417); for the type 2 closure from logMAR 

1.689 to 1.474 (SD: 0.336-0417). Conclusion: Fluid-gas exchange is an effective option 

for eyes with open holes following unsuccessful primary surgery. 


APAO Comparison Between 2 Types of Scleral Tucked Glued 

Posterior Chamber IOL With or Without Complete Vitrectomy 

With Base Excision 

Presenting Author: Tushar K Sinha MBBS 

Purpose: The aim of this study is to compare safety and efficacy of two types of scleral 

tucked glued posterior chamber IOL (PC-IOL) with or without complete vitrectomy in cases 

of subluxated lens or dislocated PC-IOL. Methods: Forty-five eyes with subluxated lens 

due to Marfans syndrome or trauma, and 5 cases of posteriorly dislocated PC-IOL were 

included in this study. Group A: 25 eyes operated with 23-gauge complete vitrectomy 

with scleral tucked glued PC-IOL. Group B: 25 eyes operated with phacoemulsification and 

anterior vitrectomy with same type glued PC-IOL implantation. Followed up at 2 weeks, 

4 weeks, 3 months, and 6 months. Results: Two cases of endophthalmitis and 1 case 

of retinal detachment were noted in Group B. Conclusion: Scleral tucked glued PC-IOL 

implantation with complete vitrectomy is the safest choice for subluxated lens or dislocated 

PC-IOL. 


APAO Sutureless 27-gauge Needle-Guided Intrascleral 

Posterior IOL Fixation With Lamellar Scleral Dissection 

Presenting Author: Shin Yamane MD 

Co-Author(s): Maiko Inoue MD, Akira Arakawa MD, Kazuaki Kadonosono MD 

Purpose: To report a new technique for sutureless intrascleral fixation of a posterior 

chamber IOL. Methods: The haptics of the IOLs were externalized with a 27-gauge needle 

through the ciliary sulcus and fixed in the scleral tunnel via lamellar scleral dissection. 

Results: The IOLs were fixed with exact centration and axial stability. No wound leakage 

was seen without any suture. Conclusion: This technique provides good IOL fixation with 

reliable wound closure without any suture. 

244 






Electroretinogram Changes Following Retinal Reattachment 

Surgery 

Presenting Author: Mohsen Azarmina MD 

Co-Author(s): Masoud Soheilian MD, Siamak Moradian MD, Hossein Azarmina MD** 

Purpose: To compare functional recovery of rod and cone cells before and after retinal 

detachment (RD) surgery. Methods: In 20 eyes of 20 patients, scotopic and photopic electroretinograms 

(ERGs) with BCVAs were compared before and 1, 3, and 6 months after 

scleral buckling in eyes with RD. Results: Retinal reattachment was achieved in all eyes. 

A- and b-wave amplitude of dark adapted ERGs and mean BCVAs increased at 3 months 

postoperatively, significantly relative to preoperative measures (P < .001). Conclusion: 

Scotopic ERG recovered greater than the photopic response after RD surgery. In this way 

the rod system recovered faster than the cone system. 


Postoperative Posterior Segment Complications in Eyes 

Treated With the Boston Type I Keratoprosthesis 

Presenting Author: Darin R Goldman MD 

Co-Author(s): Jean-Pierre Hubschman MD*, Anthony J Aldave MD*, Allen Chiang MD, 

Jennifer Huang MD, Steven D Schwartz MD* 

Purpose: To describe posterior segment complications occurring after implantation of the 

Boston type I keratoprosthesis (KPro). Methods: A retrospective chart review was conducted 

of consecutive KPros implanted over a 6-year period by a single surgeon (6-month 

follow-up minimum). Results: Eighty-three eyes (93 KPro procedures) were included, with 

a mean follow-up of 28.2 months. The most common complications were retinal detachment, 

choroidal detachment, and sterile vitritis. Visual acuity was worse among eyes that 

experienced posterior segment complications compared to eyes that did not at last followup 

(P = .003). Conclusion: Posterior segment complications occur in many patients following 

KPro surgery, resulting in persistent visual acuity reductions. 


Vitreoretinal Events in Eyes Receiving Pediatric Type I 

Dohlman (Boston) Keratoprosthesis 

Presenting Author: Amit Sangave MD 

Co-Author(s): Rajeev S Ramchandran MD, James Aquavella MD*, Mina Chung MD* 

Purpose: To report vitreoretinal (VR) pathology in pediatric eyes receiving type I Dohlman 

keratoprosthesis (KPro). Methods: Retrospective chart review of 40 patients (53 eyes) under 

the age of 18. VR pathology was recorded before, during, and after KPro implantation. 

Results: Existing VR pathology was identified in 25% of patients (13/53 eyes). New VR 

events were observed after KPro in 55% of patients (29/53 eyes). Retroprosthetic membrane 

formation (49%) and retinal detachment (34%) were most common. Conclusion: A 

minority of patients had pre-existing VR pathology. Sight-threatening, post-KPro VR events 

from either disease progression or complications are common. VR specialists should be 

involved in the longitudinal care of these patients. 


Telemedicine Diabetic Retinopathy Assessment as Part of a 

Medicare Quality Improvement Program 

Presenting Author: Ingrid E Zimmer-Galler MD* 

Purpose: To incorporate telemedicine diabetic retinopathy (DR) surveillance into the Centers 

for Medicare and Medicaid Services (CMS) Quality Improvement Organization (QIO) 

initiative “Every Diabetic Counts.” Methods: The QIO invited primary care practices with 

underserved populations to use remote retinal imaging for DR assessment. Number of 

encounters, patients referred, and change in DR assessment rate after implementation 

were evaluated. Results: To date, 725 imaging encounters were performed. Ninety-six 

patients (13%) were referred for evaluation; an additional 29 (4%) were referred urgently 

with sight-threatening disease. Conclusion: CMS acknowledges telemedicine technology 

as an effective adjunct to facilitate health care access in disparate populations and 

increase DR assessment. 


Session One 





Electronic Reading Devices Increase Reading Speed and 

Comfort in Patients With Moderate Vision Loss 

Presenting Author: Daniel B Roth MD* 

Co-Author(s): Henry Feng, Anthony Fernandes, William J Feuer MS, Howard F Fine MD 

MHS*, Jonathan Prenner MD* 

Purpose: To evaluate the ability of electronic reading devices to enhance reading speed. 

Methods: Patients were assigned newspaper, prInt, and iPad versions of text with similar 

font size to read. Increased magnification was tested; iPad and Kindle were compared. 

Results: Printed material was read more quickly than newspaper (P = .02), but iPad was 

read more quickly than either newspaper or print (P < .001). Poor visual acuity was correlated 

with slower reading speed. Patients’ reading speed increased on the iPad when font 

was magnified to 18 point (P < .001). The iPad 12 point resulted in improved reading speed 

when compared to the Kindle at 12 point and at 18 point (P < .001). Conclusion: Back-illuminated 

devices may offer a significant advantage to patients with reduced visual acuity. 


Chronic Visual Dysfunction After Blast-Related Mild 

Traumatic Brain Injury Without Direct Trauma to the Eye 

Presenting Author: Teresa Magone De Quadros Costa MD PhD 

Co-Author(s): Soo Young Shin MD 

Purpose: To detect visual dysfunction in war-injured veterans after traumatic brain injury 

(TBI) without eye trauma. Methods: Retrospective chart review of veterans who presented 

for eye exams in 2011 with documented TBI at least 12 months prior to the clinic 

visit. Results: Preliminary data show that 86% of patients were symptomatic. Fifty-eight 

percent (58%) of the patients had convergence insufficiency, 23% had accommodative 

insufficiency, and 17.6% had persistent photophobia. Mean BCVA was 20/25. Conclusion: 

Patients with TBI without direct eye injury have a high incidence of long-term visual 

problems despite good vision. Accommodation and convergence testing should be part of 

the eye exam in this patient population. 





245

Video Program 

Saturday – Tuesday, Nov. 10 - 13 

Best of Show Videos 

This year’s Video Program comprises 66 videos. The “Best of Show” award winners are indicated 

by a h . 

Videos on Demand 

Hall A, Booth 165 

All videos are available to view at your convenience at the Videos on Demand computer terminals. 

You may also enjoy this service from your laptop by accessing the Academy’s website, 

www.aao.org/2012. 



Monday, Nov. 12, 9 am - 12 pm 

Meet the producers at the Learning Lounge. You will have the opportunity to talk to select 

authors of scientific videos. 


The Annual Meeting Program Committee selected all videos. See page 33 for committee 

details. 




246 


Video Program 

Video #1 

Moonlight Phacoemulsification in a Case of Corneal Haze 

Due to Stromal Dystrophy 

Sr. Producer: Anil Raj MD** 

Co-Producer(s): Muralidhar Ramappa MS, Sunita Chaurasia MD, Shobha Mocherla, 

Deepti Chauhan MBBS** 

This surgical video is comprised of regular phacoemulsification surgery 

performed by combining it with the chandelier illumination system for better 

visualization in a case of corneal haze attributed to stromal dystrophy 

in a 64-year-old male. This video illustrates that good outcomes can be 

achieved for cataract surgery despite the presence of corneal haze, without 

requiring the surgeon to first perform a penetrating keratoplasty. 

Video #2 

Femtosecond Laser-Assisted Cataract Surgery in a Case of 

Weill-Marchesani Syndrome and Subluxated Cataract 

Sr. Producer: Samuel Masket MD* 

Co-Producer(s): Nicole R Fram MD 

This video demonstrates the use of femtosecond laser in a patient with 

Weill-Marchesani syndrome and subluxated cataract. Clinical presentation 

included brachymorphia and micro-spherophakia with zonulopathy, 

inducing inferior subluxation and tilting of bilateral cataracts. The femtosecond 

laser was used to create an anterior capsulotomy, enabling successful 

use of a toric IOL and necessary sutured capsule support devices. 

The laser was programmed to perform the anterior capsulotomy and 

corneal incisions; lens fragmentation was not included. This case demonstrates 

that femtosecond laser can be used for the creation and centration 

of anterior capsulotomy in the setting of subluxated cataracts. The patient 

had an uneventful recovery from surgery. 

Video #3 

Longest Day 

Sr. Producer: Amar Agarwal MD* 

Purpose: To show the management of a case of coloboma of a lens with 

subluxation and cataract. Methods: An endocapsular ring is implanted, 

followed by phaco and posterior chamber IOL implantation. But things 

go wrong and a glued IOL has to be done. Results: The end result 1 year 

postop is 20/20 visual acuity. Conclusion: Glued IOL can help one get 

out of disasters. 

Video #4 

Misadventures in the Anterior Chamber 

Sr. Producer: Arup Chakrabarti MBBS 

Co-Producer(s): Sonia Rani John MS**, Meena Chakrabarti MBBS 

Purpose: To demonstrate the outcomes and secondary surgical management 

of inappropriate IOLs in the anterior chamber (AC). Methods: This 

video presents cases of inappropriate use of AC and posterior chamber 

(PC) IOLs in the AC. Complications are frequent and the majority of them 

needed surgical correction. Proper surgical techniques are demonstrated 

to avoid such complications. Result: Inappropriate IOLs (both AC and PC) 

are associated with poor outcomes and should be avoided. Conclusion: 

AC IOLs and PC IOLs should be properly handled. Mishandling can aggravate 

the outcomes in a complicated cataract surgery. 

h Video #5 

In Search of New Solutions 

Sr. Producer: Robert H Osher MD* 

The cataract surgeon must deal with the occasional patient who presents 

with a history of pre-existing diplopia requiring prisms or strabismus surgery 

to avoid double vision. This video introduces an innovative intraocular 

solution aimed at eliminating the diplopia after cataract surgery. 

Video #6 

Management of Posterior Polar Cataract and Dropped 

Nucleus 

Sr. Producer: Arup Chakrabarti MBBS 

Co-Producer(s): Sonia Rani John MS**, Meena Chakrabarti MBBS 

Purpose: This video demonstrates a management strategy for hard 

posterior polar cataract (PPC) complications, including dropped nucleus. 

Methods: An innovative technique (hydrofree dissection, no hydrosteps, 

and nonrotational nucleus chopping) evolved by the surgeon was followed 

to manage 2 cases of hard PPCs with definite preoperative evidences 

of congenital posterior capusular dehiscence. Triamcinolone acetonideassisted 

anterior vitrectomy and appropriate posterior segment surgery 

were performed to optimize outcomes. Results: Posterior chamber rent 

occurred in both the cases with nucleus drop in one, which was managed 

using a fragmatome. The 3-piece hydrophobic acrylic posterior chamber 

IOLs were implanted in the sulcus with posterior optic capture through the 

rhexis margin, which have stayed well centered with full visual recovery. 

Conclusion: The complications were scientifically managed with focus 

on damage control. 

Video #7 

Lights, Camera, Action! 

Sr. Producer: Abhay Raghukant Vasavada MBBS FRCS* 

Co-Producer(s): Samaresh Srivastava BMBS MS, Viraj A Vasavada MD*, Lajja Shastri 

MD**, Vaishali Abhay Vasavada MS, Shetal Raj MD** 

High-speed photography allows a detailed and frame-by-frame understanding 

of any procedure or process. This film utilizes real-time highspeed 

imaging in a clinical operating room scenario to understand the 

finer nuances of cataract surgery. It also explores various applications of 

high-speed imaging that can help an ophthalmologist. 

Video #8 

Ophthalmology Behind the Iron Curtain: Cataract Surgery in 

North Korea 

Sr. Producer: Gerd U Auffarth MD* 

Co-Producer(s): Florian T A Kretz MD*, Tanja M Rabsilber MD* 

Purpose: North Korea is known as a very restricted and isolated country. 

Not much is known about its health care and medical infrastructure. 

Methods: The film gives a first report on charity cataract and other 

ophthalmic surgeries in this country. Results: Poor economy, health care, 

and infrastructure have led to a lot of problems and improvisations in 

North Korea; however, once adapted to these special surroundings, teaching 

and clinical work can be very effective and satisfying for doctors and 

patients. Conclusion: Ophthalmic surgery in developing countries can be 

challenging, but is worth doing in many ways. 

Video Program 




247

Video Program 

Video Program 

Video #9 

Rigid Gas-Permeable Contact Lens-Assisted Cataract 

Surgery in Patients With Severe Keratoconus 

Sr. Producer: Yoshinori Oie MD PhD 

Co-Producer(s): Motohiro Kamei MD, Nagakazu Matsumara MD**, Takeshi Nakao 

MD**, Takeshi Soma MD, Shizuka Koh MD*, Motokazu Tsujikawa MD PhD, Naoyuki 

Maeda MD*, Kohji Nishida MD 

Purpose: Intraocular images can get distorted because of irregular 

corneal astigmatism in cases with severe keratoconus. Poor visibility can 

lead to complications, including posterior capsule rupture. To overcome 

this impediment, we employed rigid gas-permeable contact lens-assisted 

cataract surgery in patients with severe keratoconus. Methods: Rigid 

gas-permeable contact lens was set on the cornea to reduce intraocular 

image distortion during surgery for 2 cases. Results: Strain was remarkably 

reduced, and intraocular manipulation such as irrigation and 

aspiration was safely performed. Conclusion: This technique provides 

excellent visualization during cataract surgery in patients with severe 

keratoconus. 

Video #10 

The Shakes! 

Sr. Producer: Somdutt Prasad MBBS* 

The video describes the visual phenomenon that arises from pseudophacodonesis, 

from the patient?s perspective, and its management. After 

routine phaco with IOL in the bag, a female patient vividly complained of a 

?judder in her vision,” describing a sensation of things shaking and fluttering. 

Vision was 20/10 and the IOL was well centered in the bag. A second 

opinion was obtained, which diagnosed pseudo-phacodonesis. Following 

much discussion, surgery to stabilize the bag with insertion of 2 capsular 

tension segments with sutures in scleral packets was undertaken. Symptoms 

resolved and the patient was happy. Patients with apparently excellent 

outcomes may be unusually sensitive to “minor” problems. Dealing 

with these at face value and addressing them surgically leads to great 

outcomes. 

Video #11 

Pretreatment of Mature Cataracts With a Femtosecond 

Laser for Cataract Surgery 

Sr. Producer: Juan F Batlle MD* 

Co-Producer(s): Rafael Feliz MD*, William W Culbertson MD* 

Successful laser cataract surgery of grade 4+ brunescent and soft white 

cataracts was performed. Capsulotomy and fragmentation were performed 

with a liquid interface and OCT guidance. Footage of laser and OR 

procedures are shown. Capsulotomy and fragmentation was effective in 

brunescent cataract. The posterior capsule was imaged successfully with 

OCT. The lens splitting was facile with segmentation propagating through 

the posterior lens. Capsulotomy in soft, white cataract proved effective in 

alleviating intracapsular pressure and avoiding radial tears. Capsulotomy 

in white cataract resulted in free floating anterior capsule. 

Video #13 

Handshake Technique for Glued IOL’s 

Sr. Producer: Athiya Agarwal MD* 

Purpose: Handshake technique helps one externalize the haptics properly 

in glued IOL surgery. Methods: Problems of externalization and their correct 

management is shown. Results: The results are good and the haptics 

dont break. Conclusion: Handshake technique makes life easy in glued 

IOL surgery. 

Video #14 

The Ks Puzzle 

Sr. Producer: Ronaldo M Badaro MD 

This video highlights the use of the toric IOL in the successful management 

of high astigmatism with coexistent cataract and keratoconus. 

Video #15 

Glued Endocapsular Hemi-ring Segment 

Sr. Producer: Soosan Jacob FRCS 

Co-Producer(s): Amar Agarwal MD* 

Purpose: To show a new device for subluxated cataracts and IOLs: glued 

endocapsular hemi-ring segment. Methods: Various cases of subluxation 

are managed with this new device. Results: The results are good and the 

lens is stable. Conclusion: The device helps patients with subluxation. 

Video #16 

The IOL Scaffold Technique 

Sr. Producer: Athiya Agarwal MD* 

Purpose: To show a new technique: the IOL scaffold technique to manage 

nuclear pieces during a posterior capsule rupture. Methods: Various 

cases of capsular rupture and their management are shown. Results: 

The results of this method for preventing a dropped nucleus are good. 

Conclusion: The technique is good. 

Video #17 

Posterior Capsular Opacification Can Be Beaten 

Sr. Producer: Sydney R K Sebiloane MBChB 

Purpose: To illustrate surgical techniques that prevent posterior capsular 

opacification (PCO). Methods: Three surgical techniques are shown: (1) 

IOL in-the-bag and shrink-wrap effect on IOL optic by edge of anterior 

circular curvilinear capsulorrhexis (CCC) and posterior capsule, (2) IOL 

haptics in-the-bag and optic capture through posterior CCC, (3) bag-inlens 

technique using anterior and posterior capsules as a membrane. 

Follow-up cases of these techniques are shown. Results: Three surgical 

techniques were successfully performed to eliminate PCO. In addition, 

follow-up cases provide proof of these concepts. Conclusion: Techniques 

using orientation of anterior and posterior capsules in relation to IOL optic 

can successfully prevent PCO. These must be complemented by meticulous 

surgery. 

Video #12 

Retrolenticular Illumination 

Sr. Producer: Hideharu Fukasaku MD 

Purpose: To enhance the observation light for cataract surgery. Methods: 

The chandelier light is used to light up the surgical place from behind 

the lens. Results: Even though the light red reflex is not enough because 

of the opacity of dense cataract, vitreous, or cornea, the retrolenticular 

illumination can help the surgeon to see the surgical maneuver well. Conclusion: 

Retrolenticular illumination is very useful for cataract surgery, if 

the light red reflex through the pupil is not enough. 

248 




Video Program 

Video #18 

Descemet-Stripping Endothelial Keratoplasty in Patients 

With Disrupted Iris-Lens Diaphragm 

Sr. Producer: Jagadesh C Reddy MD 

Co-Producer(s): Brandon Ayres MD* 

Descemet-stripping endothelial keratoplasty (DSEK) is selective replacement 

of diseased corneal endothelium by donor posterior corneal button. 

The most common complication is graft detachment or dislocation. 

Tamponade with intracameral air bubble facilitates initial attachment 

of the graft. In cases with breach in the iris-lens diaphragm, air escapes 

into the vitreous cavity causing graft detachment or dislocation. Various 

methods have been used to improve the adherence of the donor graft in 

patients with disruption of iris-lens diaphragm, like transcorneal suture 

fixation, viscoelastic, and aphakic iris-fixated IOL. In this video we would 

like to demonstrate DSEK combined with techniques to restore iris-lens 

diaphragm. 

Video #19 

Big Bubble? No Trouble! 

Sr. Producer: Rajesh Fogla MD FRCS 

The big bubble technique of deep anterior lamellar keratoplasty (DALK) 

helps retain the healthy host endothelium with good visual outcome 

comparable to penetrating keratoplasty without the risk of endothelial 

rejection. Anwar’s original technique using a sharp needle is difficult to 

master and often frustrating to the learning surgeon. Newer instruments 

designed to simplify the technique, minimize complications, and make the 

procedure reproducible will be presented in this video. A novice surgeon 

will be able to ?perform big bubble with no trouble? after reviewing this 

video presentation, which describes the procedure in a stepwise manner. 

Video #20 

Volcanic Explosion 

Sr. Producer: Namrata Sharma MD MBBS 

Co-Producer(s): Tushar Agarwal MD, Jeewan S Titiyal MD, Rasik B Vajpayee MD 

We describe the novel use of glycerin-preserved eyes in the management 

of expulsive hemorrhage in a case of bilateral autopenetrating keratoplasty. 

Following open sky cataract surgery in a left donor eye, expulsive hemorrhage 

with spontaneous expulsion of lens, vitreous, retina, and choroid 

occurred. Trephined opening was tamponaded with a glycerin-preserved 

cornea. Cataract surgery and IOL implantation was done was done in the 

right eye and autograft harvested from fellow eye was secured. Postoperatively 

corrected distance visual acuity was 6/12 in the sighted eye 

(recipient eye) and absent perception of light in the blind eye (donor eye). 

This video highlights diagnosis, management, and preventive strategies 

for expulsive hemorrhage in cases undergoing penetrating keratoplasty 

and discusses the use of glycerin-preserved eyes for this complication. 

Video #21 

Evaluation of Cornea Topography, Astigmatism With the 

Use of Tissue Adhesive in Sutureless Descemet-Stripping 


Sr. Producer: Gregory Pamel MD** 

Co-Producer(s): A John Kanellopoulos MD* 

Purpose: To view the technique used to evaluate the safety and efficacy 

of the use of tissue adhesive (TA) (ReSure Adherent Ocular Bandage, 

Ocular Therapeutix; Bedford, Mass., USA) in Descemet-stripping automated 

endothelial keratoplasty. Methods: Twenty-three consecutive 

cases were randomly assigned. In Group A, sutures were used to close 

the cornea, and in Group B, the TA was used. All cases were evaluated for 

age, sex, uncorrected distance visual acuity (VA), corrected distance VA, 

IOP, and weekly changes in refraction and topographic cylinder as well as 

possible complications perioperatively. The follow-up time was 8 to 21 

months (9.5). Results: Cylinder change: 2.2 D for Group A and 1.1 D for 

Group B. Two repositionings in Group A only. Conclusions: TA may be a 

valuable adjunct in clear-cornea cataract surgery in reducing astigmatic 

change, reducing graft dislocation, and potentially reducing the risk of 

endophthalmitis due to early wound ingress. 

h Video #22 

Innovative Surgical Management of End-stage Keratoglobus 

Sr. Producer: Mauricio Pérez 

Co-Producer(s): Michael E Snyder MD* 

This video presents a novel stem cell-sparing surgical approach to a case 

of profound keratoglobus using a limbal-conjunctival lamellar dissection 

followed by sclerocorneal keratoplasty with episcleral overlay. 

Video #23 


and Relaxing Incisions: A Two-Step Technique for Fast 

Visual Rehabilitation of Eyes With Failed Full-Thickness 

Corneal Grafts and High-degree Astigmatism 

Sr. Producer: Jacqueline E Beltz MBBS 

Co-Producer(s): Paolo Santorum MD, Massimo Busin MD* 

Descemet-stripping automated endothelial keratoplasty (DSAEK) is an 

effective technique for the management of endothelial failure following 

penetrating keratoplasty (PK). Relative contraindication exists for patients 

with high astigmatism (HA) resulting from the PK. This video describes 

a 2-step technique: first, DSAEK and second, full-thickness relaxing incisions 

through the original PK wound performed as early as 1 month post- 

DSAEK. This technique is effective for restoring clarity of the PK and reducing 

overall HA, leading to much faster visual rehabilitation than would 

be expected after repeat PK. This new technique removes this relative 

contraindication for post-PK DSAEK, providing an alternative approach for 

the failed PK with HA. 

Video Program 




249

Video Program 

Video Program 

Video #24 

Stevens-Johnson Syndrome: Dare to Dream? 

Sr. Producer: Geetha Iyer MBBCHIR FRCS 

Co-Producer(s): Bhaskar Srinivasan MBBS, Shweta Agarwal Tarun Sharma MBBS, 

Prema Padmanabhan 

The ocular discomfort and associated visual loss in Stevens-Johnson 

syndrome leads to considerable deterioration in quality of life. The goal 

of treatment is to reduce ocular surface inflammation caused by dry eye, 

lid margin keratinization, adnexal disorders, and fornix obliteration to not 

only improve symptoms but better the outcomes for visual rehabilitation 

by reducing the hostility of the ocular surface. A comprehensive approach, 

including punctal cautery, mucus membrane grafting, and fornix 

reconstruction, as well as visual rehabilitative surgeries such as cataract 

extraction, penetrating keratoplasty, Boston Type 1 keratoprosthesis, and 

modified osteo-odonto-keratoprosthesis, has been illustrated with the 

help of anecdotal cases and surgical videos. This significantly improves 

the quality of life in these patients. 

Video #25 

Mushroom-Shaped Keratoplasty: Manual Technique 

Sr. Producer: Yathish Shivanna** 

Co-Producer(s): K S Thungappa**, Rohit Shetty MD MBBS, Kareeshma N Wadia 

MBBS 

It is proven that the results of femtosecond laser-enabled keratoplasty 

with regard to faster rehabilitation, stronger wound healing, and lesser 

astigmatism are better than conventional manual keratoplasty. However, 

the cost factor is a drawback and not every center can possess the expensive 

femtosecond laser. We depict a surgery done manually, which gives 

the same results as with a femtosecond machine, thereby obviating the 

need for this expensive machine. (There is no financial interest involved in 

any of the procedures or equipment mentioned herein.) 

Video #26 

Tenon Patch Graft for Corneal Perforation 

Sr. Producer: Rasik B Vajpayee MD 

Co-Producer(s): Namrata Sharma MD MBBS, Prafulla Maharana MD**, Elsie Chan 

MBBS, Vishal Jhanji MBBS, Jacqueline E Beltz MBBS, Dermot Thomas Cassidy** 

We describe a novel technique of a Tenon patch graft for small to medium 

sized corneal perforations. Necrotic edges of perforation are dried and a 

stromal pocket extending 1 mm all around the perforation is created. A 

Tenon patch 3 to 5 mm diameter is harvested from the superotemporal 

fornix, folded on itself, and positioned over the perforation. The edges are 

tucked into the previously created stromal pocket and secured with either 

fibrin glue or sutures, depending on its size. The Tenon patch graft was 

successfully done in 5 eyes with no intraoperative problems. Time to healing 

and fibrosis was 7.8 + 3.5 days. Postoperatively, mild corneal haze was 

present and BCVA was 6/36 to 6/6. The autologous Tenon patch graft is a 

simple technique, and unlike amniotic membrane and donor patch graft, it 

is readily available with no risk of transmission of diseases or expense in 

harvesting the tissue. 

Video #27 

Ultrathin Descemet-Stripping Automated Endothelial 

Keratoplasty 

Sr. Producer: Ana Rocha Cardoso MD 

Co-Producer(s): Sérgio Brito MD, Andreia Martins Rosa MD, Maria Joáo Quadrado 

MD, Esmeralda Costa, Joaquim N Murta MD PhD 

Descemet-stripping automated endothelial keratoplasty (DSAEK) is the 

preferred method for the treatment of endothelial dysfunction. An important 

limitation of DSAEK is that some eyes do not achieve good vision despite 

a clear cornea and minimal residual astigmatism. The thickness and 

regularity of the stromal lamella seem to influence the final visual acuity: 

better results seem to be achieved with thinner grafts. This video presents 

2 methods for obtaining thin lenticules, aiming for a final thickness of 

120 microns: (1) femtosecond laser and microkeratome used sequentially, 

a technique developed by us and (2) a double-pass technique using 2 

different microkeratome heads. Consistently thin and regular grafts are 

obtained, with faster visual recovery and a small refractive shift. 

Video #28 

P.E.R.F.E.C.T. for PTERYGIUM 

Sr. Producer: Lawrence W Hirst MD MBBS MPH DO FRACO FRACS* 

In this video, the surgical techniques required to successfully undertake 

P.E.R.F.E.C.T. for PTERYGIUM are illustrated in animation and live surgical 

clips. The surgery is segmented into its logical three components of pterygium 

and extensive Tenon removal, retrieval of a very large and very thin 

graft, and finally the reconstruction of the pterygium site, including a new 

semilunar fold to obtain the optimal cosmetic result. The results of 1000 

consecutive surgeries with a 1/1000 recurrence rate and the complications 

are presented, together with the cosmetic results. 

Video #29 

Tube Tribulations 

Sr. Producer: Soosan Jacob FRCS 

Co-Producer(s): Amar Agarwal MD* 

Purpose: To show the management of Ahmad valve in glaucomatous 

cases. Methods: Various cases are shown in which the placement of the 

tube and its problems are depicted. Results: The results are good when 

the surgery is done well. Conclusion: Tube tribulations show various 

factors of tube placement. 

Video #30 

Goniosynechialysis for Refractory Angle-Closure Glaucoma 

With Synechial Angle Closure 

Sr. Producer: Ji Woong Lee MD 

Co-Producer(s): Ik-Soo Byon**, HeeYoung Choi MD PhD, Jong Soo Lee MD PhD, Boo 

Sup Oum MD**, Pak Kangyeun MD 

Purpose: To describe 3 patients with synechial angle closures who were 

successfully treated with goniosynechialysis. Methods: All 3 patients 

failed to respond to conventional therapy. Goniosynechialysis and silicon 

oil removal were performed in a 45-year-old man with secondary 

angle-closure glaucoma (ACG) after retinal surgery. Goniosynechialysis 

with phacoemulsification was performed in a 56-year-old woman with 

primary angle-closure glaucoma and in a 79-year-old woman with chronic 

primary ACG without history of acute attack. Result: After follow-up 

of 6 months, IOP has remained below 21 mmHg in all 3 patients. Mean 

extent of peripheral anterior synechiae (PAS) was reduced from 330? to 

50?. Mean number of antiglaucoma medications decreased from 3.3 to 

1.3. Mean logMAR visual acuity improved from 1.34 to 0.47. Conclusion: 

Goniosynechialysis was effective in reducing IOP and PAS in various type 

of ACG. 

250 




Video Program 

Video #31 

Reimplantation of Ahmed Glaucoma Valve in a Case of 

Ahmed Glaucoma Valve Extrusion 

Sr. Producer: Avik Kumar Roy MBBS** 

Co-Producer(s): Senthil Sirisha, Paaraj Rajendra Dave, Chandra Shekhar Garudadri 

MD* 

Glaucoma drainage devices (GDDs) are very good alternatives in managing 

refractory glaucomas. Adequate conjunctival closure is a must to 

ensure that the implant is not exposed or extruded. In the presence of 

extreme conjunctival scarring following multiple intraocular procedures, 

placement of GDD can be a big challenge. However, proper preoperative 

planning and meticulous surgical technique using a free conjunctival autograft 

along with GDD can be a solution to this relative contraindication. 

We present to you a procedure of inferior Ahmed glaucoma valve (AGV) 

implantation with primary scleral and conjunctival autograft in the presence 

of severely scarred conjunctiva in a 45-year-old, one-eyed, aphakic, 

highly myopic woman, status post vitreoretinal surgery for retinal detachment 

with previous extruded AGV and uncontrolled IOP. 

Video #32 

Amniotic Membrane and Tenon Advancement for Repeated 

Shunt Tube Exposure 

Sr. Producer: Hosam Ibrahim El Sheha MD* 

Co-Producer(s): Scheffer C G Tseng MD PhD* 

Purpose: To describe the use of amniotic membrane graft (AM) with Tenon 

advancement for repair of repeated shunt tube exposure. Methods: A 

75-year-old female with a history of dry eye, multiple corneal transplants, 

and repeated tube exposure in the right eye. Tube exposure occurred 12 

months after Ahmed valve implantation with scleral graft, and 6 months 

after revision with pericardium. A thick AM was secured over the tube 

using 8/0 vicryl suture, and the Tenon capsule was dissected to cover the 

graft and then covered with the conjunctiva. Results: There was no epithelial 

breakdown over the AM-Tenon baitlayer, with no re-exposure, no 

graft thinning, and no ocular infection during 12 months follow-up. Conclusion: 

AM with Tenon advancement is an effective alternative method 

for repair of tube exposure. 

Video #33 

A Better Way to Detect an Afferent Pupillary Defect 

Sr. Producer: Mohsin Ali BS 

Co-Producer(s): M Reza Razeghinejad MD, Lan Lu MD, George L Spaeth MD FACS* 

Testing for a relative afferent pupillary defect (APD) is a way of comparing 

the health of the right and left optic nerves. The swinging flashlight method 

is the conventional method of detecting an APD. In this video, a new, 

more sensitive method for detecting subtle APDs is described in detail: 

the magnifier-assisted swinging flashlight method (MA-SFM) using a +20 

D lens. After a general discussion of the APD and the light reflex pathway, 

cases of positive APDs are illustrated: an APD that is easily detectable 

by the conventional swinging flashlight method and cases of subtle APDs 

more easily detectable by the MA-SFM. Viewers will appreciate the clinical 

usefulness of the MA-SFM and learn how to better detect APDs using 

this method. 

Video #34 

The Role of Releasable Sutures With Trabeculectomy 

Sr. Producer: George L Spaeth MD FACS* 

Co-Producer(s): L Jay Katz MD*, Marlene R Moster MD*, Valerie Trubnik MD, Nont 

Rutnin MD 

The goal of trabeculectomy (or guarded filtration procedure) is to lower 

IOP as safely as possible to a predetermined level. However, excessive 

filtration and its consequences still occur, as commonly reported. Using 

releasable sutures can minimize excessive filtration and allow titration 

of IOP. We describe the theory and practice of releasable sutures: their 

advantages and disadvantages, especially in comparison to laser suture 

lysis; how to place them; how to evaluate the amount of filtration at surgery; 

and when and how to remove the sutures. Three different, proven 

techniques of releasable suture placement are demonstrated, each having 

is own advantages and disadvantages. 

Video #35 

Boston Type 1 Keratoprosthesis With Glaucoma Drainage 

Device 

Sr. Producer: Samar K Basak MD DNB MBBS* 

The Boston type 1 keratoprosthesis (KPro) is the most commonly implanted 

keratoprosthesis worldwide. One of the main challenges with the 

Boston KPro is treating concurrent glaucoma. Also, in many cases secondary 

glaucoma is a major complication that is very difficult to control. Ultimately, 

there is permanent visual loss due to glaucomatous optic atrophy 

in spite of a very well retained and successful Boston KPro. Thus in many 

cases, it is advisable to combine the procedure with a glaucoma drainage 

device to prevent this long-term complication. This video demonstrates a 

step-by-step approach to this combined procedure by a corneal surgeon. 

It starts with conjunctival dissection, valve priming and fixation, then 

Boston KPro assembly and suturing, placement of the tube, and ultimately 

conjunctival closure. 

Video #36 

Tube Extender for Retracted Tube in a Child With Aniridia 

Sr. Producer: Paaraj Rajendra Dave 

Co-Producer(s): Senthil Sirisha, Chandra Shekhar Garudadri MD* 

Glaucoma associated with aniridia is refractory to conventional surgical 

treatment, and better results are obtained with glaucoma drainage devices. 

In children, ocular growth causing tube retraction is one of the causes 

of failure of the procedure. Tube extenders may be used successfully in 

these cases to salvage the retracted drainage implant. A 1-year-old aniridic 

child, post-keratoplasty and lens aspiration with posterior chamber 

IOL, presented with secondary glaucoma and 2 failed filtering procedures. 

Ahmed valve implantation resulted in well controlled IOP until the tube retracted 

6 months later. A tube extender was used successfully to salvage 

the implant and stabilize IOP. The video shows a tube extender implantation 

technique in simple steps that can be quickly and easily learned. 

Video Program 




251

Video Program 

Video Program 

Video #37 

Combined Glaucoma, Vitreoretinal, and Keratoprosthesis 

Surgery: Pearls for a Successful Patient Outcome 

Sr. Producer: Ahmad A Aref MD 

Co-Producer(s): Maria S Cortina MD, Felix Y Chau MD, Thasarat S Vajaranant MD*, 

Jose J de la Cruz Napoli MD 

Glaucoma drainage implant surgery is often combined with vitreoretinal 

and keratoprosthesis surgeries for control of elevated IOP. This approach 

may be fraught with long-term complications, including tube/implant 

exposure, tube obstruction, and retinal tear / detachment. This video 

highlights surgical pearls for decreasing the risk of such complications. 

Surgical pearls include proper patient selection, posterior placement of 

the glaucoma implant, placement of a temporary keratoprosthesis, posterior 

tube entry site, needle entry parallel to the iris plane, utilization of 

a clear corneal patch graft, and placement of a postoperative bandage 

contact lens. 

Video #38 

Management of the Leaking Filtering Bleb 

This video illustrates cases of leaking filtering bleb, showing different 

surgical techniques for management, including autologous blood injection, 

cryo, and surgical excision and repair. 

Sr. Producer: Ibrahim A Aljadaan MD 

Video #39 

Neuroradiologic Aspects in Neuro-Ophthalmology 

Sr. Producer: Jose N Vargas Galveia MD 

Co-Producer(s): Ana Laura O Almeida MD, Tania Lampreia, Ana Luisa Mendonca 

Imaging of the central nervous system has undergone tremendous development 

in the last few decades, and today it is a fundamental tool in the 

evaluation of the optic pathways. With this video we try to illustrate the 

aspects of neuroradiology that are relevant for the ophthalmologist. We 

start by presenting the normal anatomy of the optic pathways via computed 

tomography and MRI. Following this brief review we will present 

some cases of lesions with functional repercussions on the optic pathway. 

These include thyroid ophthalmopathy, meningioma, pituitary adenoma, 

craniopharyngioma, and glioma. 

Video #40 

The Surgical Technique of Partial Lamellar 

Scleroiridocyclectomy 

Sr. Producer: Swathi Kaliki MD 

Co-Producer(s): Sandor Ferenczy Jr CRA, Sarah A Harmon CRA, Carol L Shields MD, 

Jerry A Shields MD 

Partial lamellar scleroiridocyclectomy is the removal of an intraocular 

tumor involving iris and/or ciliary body with an attempt to leave the outer 

sclera and retina/vitreous intact. Iridociliary tumors occupying 3 clock 

hours or less of pars plicata can be excised by partial lamellar scleroiridocyclectomy. 

This technique is useful for the management of iridociliary 

malignant melanoma, melanocytoma, leiomyoma, adenoma / adenocarcinoma 

of the ciliary epithelium, and ciliary body medulloepithelioma. In 

this video, we demonstrate the steps and the challenges of partial lamellar 

scleroiridocyclectomy. 

Video #41 

Ocular Surface Squamous Neoplasia: Cut ... Freeze ... and 

Paste! 

Sr. Producer: Samir Mohapatra MS 

Co-Producer(s): Suryasnata Rath MS FRCS, Sujata Das MBBS, Deepti Chauhan 

MBBS** 

Ocular surface squamous neoplasia (OSSN) is a slow-growing tumor 

with varied clinical spectrum. Complete surgical excision is the primary 

treatment of choice. Alcohol keratoepitheliectomy of corneal lesions and 

excision edge cryotherapy in addition are essential to prevent recurrences. 

This video is an overview of the clinical and treatment aspects of OSSN. 

Its goal is to familiarize the general ophthalmologist and the residentin-training 

about the importance of meticulous tissue dissection, with 

tumor-free margins, and proper orientation of tissues for histopathological 

evaluation, and the pearls of ocular surface reconstruction. 

h Video #42 

Surgical Correction of High Lid Crease After Asian 

Blepharoplasty 

Sr. Producer: Junghoon Kim MD 

Co-Producer(s): Kyung In Woo MD, Yoon-Duck Kim MD 

Asian blepharoplasty, the so-called double eyelid operation, has been the 

most popular cosmetic procedure performed in East Asia. Postoperative 

asymmetry and high lid crease are among the most frequent complications 

that require surgical correction after Asian blepharoplasty. Lowering 

the eyelid crease is challenging and sometimes unsuccessful because 

of the presence of extensive scarring, adhesions, and distortion of the 

anatomy from previous surgery. In this video, we introduce the simple 

surgical technique to lower the eyelid crease. The surgical procedure is 

composed of careful release of all scar adhesions and preaponeurotic fat 

advancement to prevent readhesion. In most cases, a successful outcome 

was achieved with this simple technique. 

Video #43 

Making the Transition From External to Endoscopic 

Dacryocystorhinostomy 

Sr. Producer: Katherine M Whipple MD 

Co-Producer(s): Bobby S Korn MD PhD FACS*, Don Kikkawa MD 

External dacryocystorhinostomy (DCR) has historically been the gold standard 

for treatment of nasolacrimal duct obstruction. However, endoscopic 

DCR is gaining popularity for many reasons, including rapid recovery, 

absence of a skin incision, and faster operative times. In this video, we 

describe a simplified approach to make the conversion from external to 

endonasal DCR. 

252 




Video Program 

Video #44 

Balloon Sinus Dilatation for Treatment of Silent Sinus 

Syndrome 

Sr. Producer: Joseph L Lin MD 

Co-Producer(s): David Khoramian Isaacs, Jocelyne C Kohn MD, Robert A Goldberg MD 

Maxillary sinus atelectasis, or “silent sinus syndrome,” is characterized 

by unilateral spontaneous enophthalmos and hypoglobus due to increased 

orbital volume and retraction of the orbital floor-maxillary sinus roof. 

Here we describe a single-staged surgical treatment with balloon sinus 

dilatation to revolumize the maxillary sinus and augment sinus drainage. 

A transconjunctival orbital floor approach is combined with a nasal endoscopic 

approach to access the maxillary sinus. Anterior-to-posterior slats 

are cut into the orbital floor allowing for adjustable remodeling of bone. A 

modified Foley balloon catheter is inserted into the maxillary sinus via the 

nose to support the orbital floor. The balloon is removed in approximately 

2 weeks after adequate fibrosis and remodeling of the orbital floor. 

Video #45 

Retrieving a “Lost” Extraocular Muscle 

Sr. Producer: Joseph L Lin MD 

Co-Producer(s): Jocelyne C Kohn MD, Robert A Goldberg MD 

A “lost” rectus muscle is a severe complication of strabismus or sinus 

surgery, and commonly thought to be irretrievable. Here we describe a 

technique to retrieve a slipped medial rectus muscle via an extraconal approach. 

This approach allows for the most straightforward visualization of 

the muscle in the posterior orbit. The muscle can be identified in virtually 

every case because the muscle lies immediately adjacent to the periorbita 

in the posterior half of the orbit. Through a transcaruncular approach, the 

medial rectus muscle is identified in the extraconal space adjacent to the 

periosteum, and a suture is placed through the muscle. Sutures are then 

passed from the extraconal space to the subtenon space for attachment 

to the globe. 

Video #46 

Repair of Orbital Floor Fracture: Bridge or Wedge? 

Sr. Producer: Fairooz Puthiyapurayil Manjandavida MBBS 

Co-Producer(s): Santosh G Honavar MD 

Orbital floor fracture is the most common type of fracture of the orbital 

walls, the thin bone being most vulnerable to a blowout in the event of a 

blunt trauma. Managing an orbital floor fracture and simultaneously addressing 

cosmetic as well as functional implications can be challenging. 

Successful orbital floor reconstruction involves good clinical evaluation, 

imaging, optimal timing, planning, meticulous dissection, and choice of 

an implant. This video illustrates the clinical evaluation, diagnosis, timing, 

and simplified surgical repair of an orbital floor fracture. Whether 

the choice of a floor implant is a bridge or a wedge, the aim is to restore 

appearance and alleviate diplopia. Minimal access surgery by the conjunctival 

approach and use of tissue adhesive to stabilize the implant are 

the recent advances which are shown in this video. 

Video #47 

18-gauge Needle: A Simple and Inexpensive Tool for 

Frontalis Surgery 

Sr. Producer: Shubhra Goel MD 

Co-Producer(s): Cat Burkat MD 

Purpose: To introduce the 18-gauge hypodermic needle as a tool in 

frontalis sling surgery. Methods: Case series: 64 patients (82 sides) with 

poor levator function congenital ptosis underwent frontalis closed-incision 

pentagon surgery with silicone rod inserted via 1.5 inch 18-gauge needle 

guide. Results: Fifty-six of 64 patients (88%) were age 1-18 years; 72% 

had unilateral surgery. In 2.4%, the sharp needle tip cut the silicone 

during passage. Surgical time was 15 minutes for unilateral cases (30 

minutes for bilateral cases). Main advantages: small incisions allowed 

for less operative time/bleeding, easy maneuverability and needle control 

during tissue passage, smooth threading of the silicone, and large 

decrease in material cost. Conclusion: 18-gauge needle is a simple, 

cost-effective alternative needle for frontalis surgery, particularly useful in 

large medical eye camps. 

Video #48 

Intra-arterial Chemotherapy for Retinoblastoma: A New 

Era of Minimal Systemic Exposure With a Single Agent 

Treatment 

Sr. Producer: Enzo M Fulco MD 

Co-Producer(s): Carol L Shields MD, Pascal Jabbour MD, Sarah A Harmon CRA, 

Sandor Ferenczy Jr CRA, Carlos G Bianciotto MD, Carolina Alarcon MD, Juan David 

Arias MD, Jerry A Shields MD 

A new chapter on the treatment of retinoblastoma has been written with 

the introduction of intra-arterial chemotherapy (IAC). Recent information 

on IAC indicates that it is a powerful method for retinoblastoma therapy 

with outstanding control of groups C, D, and some E eyes. Minimal systemic 

toxicities are achieved, but occasional vision-threatening ocular 

vascular toxicities occur. Systemic events such as stroke and death have 

not been observed. Recurrent retinoblastoma after failure of chemoreduction 

(CRD) can also be treated with this new technique. The exact role of 

IAC, as single or combined approach with CRD, awaits further definition. 

Video #49 

Novel Surgical Pearls for Secondary IOL Placement 

Following Pediatric Aphakia 

Sr. Producer: Dilraj Singh Grewal MBBS 

Co-Producer(s): Surendra Basti MBBS* 

We describe a series of surgical maneuvers for synechiolysis of iridocapsular 

adhesions (ICA) while minimizing zonular stress, and evacuation of 

Soemmerring ring (SR), in pediatric aphakia. Greishaber iris hooks (IH) 

are placed to estimate the ICA and augment pupil dilation. For broad ICA, 

cohesive ophthalmic viscosurgical device is injected between the anterior 

capsule and iris to define the extent of ICA. Synechiae are placed under 

traction by repositioning IH adjacent to ICA and cut with Greishaber scissors. 

SR is removed using visco-expression, manual division of SR and 

slow-motion phacoaspiration. These techniques allow synechiolysis without 

zonular stress and permit secondary in-the-bag IOL implantation. 

Video Program 




253

Video Program 

Video Program 

Video #50 

Management of Challenging Pediatric Cataracts: Pearls and 

Pitfalls 

Sr. Producer: Bhamy Hariprasad Shenoy 

Co-Producer(s): Ramesh Kekunnaya MBBS MD, Amit Gupta MD, Anthony Arokia Vipin 

Das 

Pediatric cataract surgery poses a great challenge to ophthalmologists, 

particularly when associated with difficult situations like cataract associated 

with persistent fetal vasculature syndrome, retinoblastoma, microcornea, 

posterior lenticonus, traumatic cataract, etc. Pearls and pitfalls in 

the management of these cases have been explained with a special emphasis 

on wound construction, viscosurgical procedures, anterior capsular 

management, multiquadrant hydrodissection, lens substance aspiration, 

posterior capsulotomy, anterior vitrectomy, and IOL implantation. We have 

demonstrated practical techniques for the management of difficult cases 

of pediatric cataract. Knowledge about these pearls and pitfalls will avoid 

undue complications. 

Video #51 

Nystagmus: Unraveling the Dancing Eye 

Sr. Producer: Bhamy Hariprasad Shenoy 

Co-Producer(s): Ramesh Kekunnaya MBBS MD, Amit Gupta MD 

?Dancing eye? is a fanciful term used by the layperson to refer to nystagmus. 

Nystagmus is an involuntary rhythmic to-and-fro movement of the 

eyes, independent of normal eye movements. This video provides an overview 

of the common types of nystagmus encountered in clinical practice. 

The special emphasis is on the common presentation and characteristic 

features of each type. 

Video #52 

Corneal Crosslinking and Long-term Hyperopic 

Femtosecond LASIK Stability: Initial Clinical Findings in a 

Contralateral Eye Study 

Sr. Producer: A John Kanellopoulos MD* 

Purpose: To evaluate intrastromal corneal crosslinking (CXL) in hyperopic 

LASIK.? Methods: Twenty-seven hyperopic topo-guided LASIK patients 

received 1 minute of 30 mW/cm2 CXL after in-the-flap administration of a 

single drop of 0.1% sodium phosphate riboflavin. Preoperative refractive 

error, OCT, keratometric, topographic, and topometric data were evaluated. 

Results: Mean sphere was +3.25 D, Cyl: -1.75 D. The CXL cases 

demonstrated mean regression of +0.22 D, the non-CXL cases: + 0.72 D, 

showing a strong statistically significant difference. Conclusions: Our 

data suggest that the combination of CXL in hyperopic LASIK may offer 

significant synergy in efficacy, suggesting that hyperopic LASIK long-term 

regression may be more related to a cornea biomechanical change and 

less to latent hyperopia. 

h Video #53 

Excimer Laser Phototherapeutic Keratectomy: Case-Based 

Scenarios for Better Understanding 

Sr. Producer: Jagadesh C Reddy MD 

Co-Producer(s): Christopher Rapuano MD* 

Various corneal conditions cause opacity (eg, corneal dystrophies, corneal 

scars) and irregularity (eg, Salzmann nodules, keratoconus nodules), 

resulting in poor vision, recurrent erosions, or difficulty in contact lenses 

fitting. The goal of excimer laser phototherapeutic keratectomy (PTK) is to 

create a clearer and/or smoother corneal surface to improve vision and 

comfort. PTK is a minimally aggressive, safe, often repeatable procedure 

with relatively rapid visual recovery. It helps in delaying or avoiding the 

need for anterior lamellar or penetrating keratoplasty for anterior corneal 

pathology. This video provides an overview of preoperative evaluation, 

surgical technique, postoperative management, and outcomes of PTK for 

various anterior corneal pathologies. 

Video #54 

Intraocular Foreign Body Extraction via Sclerocorneal 

Tunnel in Conjunction With Pars Plana Vitrectomy: A Safe 

Passage 

Sr. Producer: Yannek I Leiderman MD PhD* 

Co-Producer(s): Rajiv R Rathod MD 

Large and/or jagged intraocular foreign bodies (IOFB) may pose a significant 

risk for iatrogenic injury during surgical extraction, either via direct 

mechanical injury or from the effects of wide fluctuations in infusion flow 

rates and low IOP in the setting of a large patent surgical wound to facilitate 

foreign body removal. Our surgical video demonstrates the execution 

and utilization of a multiplanar sclerocorneal wound that minimizes iatrogenic 

mechanical injury while maintaining adequate outflow resistance 

and IOP during extraction of a large glass IOFB. 

Video #55 

Sub-silicon Detachments: A Slippery Terrain 

Sr. Producer: Manish Nagpal MD* 

Co-Producer(s): Rituraj Videkar MS, Gaurav S Paranjpe 

Silicon oil is an important adjunct as a long-term tamponade during 

vitrectomy for retinal detachment (RD) with proliferative vitreoretinopathy 

(PVR). Recurrence of PVR could lead to redetachments under oil. Subsilicon 

detachments present peculiar challenges related to its surgical 

management. This video presents an assortment of such complex cases 

and discusses various intraoperative steps, such as epiretinal membrane 

removal, endodrainage, endolaser, etc., done under oil. Cases with extensive 

retinal contraction need removal of existing oil, following which 

further steps, including retinectomy, could be carried out with eventual 

reinjection of silicon oil. 

Video #56 

Endoscopic Vitrectomy in Pediatric Vitreoretinal Diseases: 

Improving Visualization and Outcomes 

Sr. Producer: S Chien Wong MBBS FRCS 

Co-Producer(s): Thomas Lee MD* 

Complex pediatric retinal diseases such as ROP, familial exudative vitreoretinopathy, 

and persistent fetal vasculature syndrome pose some common 

surgical challenges. Differentiating folds of retina from fibrovascular 

membranes and hypercellular vitreous is critical to avoiding iatrogenic 

retinal breaks, which typically lead to adverse outcomes. This video illustrates 

how the unique intraocular perspective of the endoscope can 

improve visualization and appreciation of complex retinal pathology, enabling 

safer manipulation of surgical planes. 

254 




Video Program 

Video #57 

The Use of Different Types of Temporary Keratoprosthesis: 

What to Choose? 

Sr. Producer: Cesare Forlini MD 

Co-Producer(s): Adriana Bratu MD, Matteo Forlini MD, Paolo Rossini MD 

Purpose: To show the use of temporary keratoprosthesis (TKP) for the 

visualization of intraocular structures during pars plana vitrectomy in eyes 

with corneal and retinal pathologies. Methods: We reviewed 35 eyes 

with anterior and posterior segment injuries. Rigid/flexible TKP was used 

for intraoperative replacement of the opaque cornea. We performed corneal 

trephination, anterior segment reconstruction, open sky vitrectomy, 

extensive laser treatment in the periphery, and silicone oil tamponade. 

The TKP was removed and corneal graft was placed. Results: The functional 

improvement in injured eyes is usually low. Conclusions: The use 

of TKP allows one to manage the penetrating keratoplasty and the vitrectomy 

in the same surgical procedure. 

Video #58 

Spectral Domain OCT-Integrated Navigated Retinal Laser 

Photocoagulation for Diabetic Macular Edema 

Sr. Producer: Jay K Chhablani MD 

Co-Producer(s): Igor Kozak MD, Giulio Barteselli MD**, Sharif Y El Emam MD, 

William R Freeman MD* 

Purpose: To describe spectral domain OCT (SD-OCT) integration for 

treatment planning using a retinal navigation approach. Methods: Fifteen 

eyes underwent focal/grid laser photocoagulation (LP) for diabetic 

macular edema (DME). LP treatment planning was performed after integration 

of all 3 types of images: color photo, fluorescein angiograph, and 

SD-OCT thickness map on the same instrument. Results: Multimodal 

planning improved the assessment of area of leakage, especially in recurrent 

/ nonresponding eyes. Conclusions: Integration of multimodal 

retinal imaging results in more efficient treatment plan and LP. 

Video #59 

Challenges in Vitreoretinal Surgery in Eyes With Permanent 

Keratoprosthesis 

Sr. Producer: Pukhraj P Rishi MBBS 

Co-Producer(s): Tarun Sharma MBBS 

Purpose: To describe surgical steps of vitreous surgery in eyes with permanent 

keratoprosthesis (KP). Methods: Surgical steps include reflection 

of mucous membrane graft (limited or hinged), identifying the correct location 

for sclerotomies, removal of retroprosthetic membrane, wide-angle 

visualization to achieve goals such as membrane peeling, foreign body 

removal, and retinal reattachment. Results: This video demonstrates the 

difference in approach in eyes with modified osteo-odonto KP (13 eyes) vs. 

Boston KP (7 eyes). Conclusion: Performing vitreous surgery is a feasible 

option in eyes with permanent KP. 

Video #60 

Subretinal Cysticercus: A Rare Ocular Infection 

Sr. Producer: Julio E Espejo MD 

Co-Producer(s): Luis Miguel Castillo SR MD, Camilo Andres Tobon SR MD, Luis 

Geldres SR MD, Freddy Ticona SR MD, Dante Aliaga Diaz, Josel Montalvo MD 

Human ocular cysticercosis is rare zoonotic disease; cysticercosis is 

caused by the human ingestion of Taenia solium (pork tapeworm) eggs. 

The embryos invade the intestinal wall and are disseminated widely by 

the circulatory system to various tissues of the body, including the eye. 

We report a case of subretinal cysticercosis in a 50-year-old woman from 

northern Peru who presented at the National Ophthalmology Institute in 

August 2011 with blurred vision, opacity of the crystalline lens, and the 

vitreous showing severe inflammation with posterior vitreous separation. 

We surgically removed it, by pars plana vitrectomy, previous lensectomy, 

and retinotomy. 

Video #61 

Partial-Thickness Sclerectomies for the Surgical Treatment 

of Idiopathic Uveal Effusion Syndrome 

Sr. Producer: Kamaljit S Balaggan MBBS 

Co-Producer(s): Hadi J Zambarakji MD MBChB 

Purpose: To demonstrate the surgical technique of nonpenetrating deep 

sclerectomies in a patient with idiopathic uveal effusion syndrome (IUES). 

Methods: Interventional video case report: A 360-degree conjunctival 

peritomy was performed. Horizontal and vertical recti were slung. Four 

deep, partial-thickness, square-shaped sclerectomies were fashioned in 

each quadrant, with their anterior borders 9 mm posterior to the limbus. 

Scleral dissection was continued progressively deeper until bluish choroidal 

coloration was visible. No further dissection was performed. Results: 

Complete resolution of subretinal fluid occurred by 3 months after surgery. 

Conclusions: Nonpenetrating deep sclerectomies were effective in resolving 

this case and may offer an alternative to full-thickness procedures 

for IUES. 

Video #62 

Many Faces of the Anterior Vitreous: Season 2 

Sr. Producer: Abhay Raghukant Vasavada MBBS FRCS* 

Co-Producer(s): Shetal Raj MD**, Mamidipudi Praveen DO**, Samaresh Srivastava 

BMBS MS, Viraj A Vasavada MD*, Vaishali Abhay Vasavada MS** 

This film describes and highlights the events occurring in the anterior vitreous 

face and the posterior segment during phacoemulsification that are 

invisible to and unnoticed by cataract surgeons. Further, it also discusses 

the potential impact of these changes, and suggests remedial measures 

to prevent or minimize them.. 

Video Program 




255

Video Program 

Video Program 

Video #63 

The Road to Success in Diabetic Vitrectomies 

Sr. Producer: Meena Chakrabarti MBBS 

Co-Producer(s): Arup Chakrabarti MBBS, Sonia Rani John MS** 

Purpose: To reinforce pertinent surgical steps that will optimize 

anatomical and visual outcomes after diabetic vitrectomies. Methods: 

This video presentation covers all aspects of management of diabetic 

retinopathy that will assist a vitreoretinal surgeon in evidence-based 

decision making, including indications for surgery, timing of surgery, use 

of pharmacological adjuvants, lens management, choice of vitrectomy 

gauge, membrane dissection, bimanual surgery, and use of tamponade. 

The role of vitrectomy in diabetic macular edema and the effect of anti- 

VEGF administration before surgery will be discussed. This video provides 

step-by-step guidance in performing diabetic vitrectomy for all indications 

and managing postoperative complications and offers valuable pearls for 

optimizing outcomes. 

Video #64 

Densiron Infusion Sandwich Technique: Dual Intraocular 

Tamponade 

Sr. Producer: Sundaram Natarajan MD 

Co-Producer(s): Shachi Desai MS, Navendu Raj MS**, Vinay Prasad 

Important causes of recurrent retinal detachment in silicone oil-filled 

eyes are proliferative vitreoretinopathic (PVR) changes. Management of 

recurrent complicated inferior retinal detachment in already vitrectomized 

silicone oil-filled eyes is a challenge for the retina surgeon. Handling the 

retinal pathology like peeling of PVR under silicone oil gives more stability 

to the retina. In our surgical technique we start the case with Densiron 

infusion instead of BSS, utilizing the luxury of dual mode viscous fluid 

injection / extraction. This novel surgical technique is less traumatic to 

the eye, provides stability to the retina, reduces chances of intraoperative 

detachment, and saves surgical time. With silicone oil providing support 

to the superior retina and Densiron providing the inferior retina, this sandwich 

works well in preventing further inferior detachments. 

Video #65 

Transscleral Drainage of Massive Subretinal Hemorrhage 

Complicated by Polypoidal Choroidal Vasculopathy 

Sr. Producer: Ji Eun Lee MD 

Co-Producer(s): Sungwho Park MD, Sangjoon Lee MD , Boo Sup Oum MD** 

This video presents a surgical technique to drain subretinal hemorrhage 

transsclerally. A 65-year-old woman presented with massive subretinal 

hemorrhage secondary to polypoidal choroidal vasculopathy. Before 

photodynamic therapy, breakthrough vitreous hemorrhage developed with 

visual acuity of 20/500. During vitrectomy, subretinal hemorrhage was 

drained transsclerally using a subretinal fluid drainage technique of buckle 

surgery. Heavy liquid was used to facilitate the drainage. Silicone oil and 

bevacizumab were injected. After 1 month, silicone oil was removed and 

bevacizumab was injected again. Visual acuity improved to 20/50 at 6 

months. Subretinal hemorrhage resolved completely at 1 year. 

Video #66 

Endoresection of a Vasoproliferative Tumor via 

Transconjunctival Sutureless 25-gauge Vitrectomy 

Sr. Producer: Jonathan M Smith MBBS 

Co-Producer(s): David R W Steel MBBS* 

This video presents the technique used to endoresect a vasoproliferative 

tumor using a sutureless transconjunctival 25-gauge vitrectomy system. 

Along with a step-by-step description of the endoresection technique, the 

video also shows the associated pathology that can occur as sequelae 

to the vasoproliferative tumor and how to manage them at the time of 

surgery. 

256 




Where All of Ophthalmology Meets 

New Orleans 

Save the Date! 

2013 Annual Meeting November 16 – 19 

Subspecialty Day November 15 – 16 

AAOE Program November 16 – 19 

www.aao.org/2013 

The American Academy of Ophthalmology is accredited by the Accredidation Council for 

Continuing Medical Education to provide continuing medical education for physicians.


Friday - Wednesday, Nov. 9 - 14 

Special Meetings & Events are free of charge, unless otherwise noted. They are not eligible for 

CME credit. 

SO Endorsed by Senior Ophthalmologist Committee 

YO Endorsed by Young Ophthalmologist Committee 








Special Meetings 

& Events 

DICOM Working Group 9 - Eye Care 

Event No: SPE01 

7:30 AM - 3:00 PM 

Fee: FREE 

Room: Hyatt Regency McCormick Place, Conf. Center Room 24ab 

DICOM is a standard for integrating different imaging data sources so that 

they can be readily transferred, stored and exchanged. Working Group 9, a 

DICOM committee sponsored by the Academy, focuses on digital imaging 

standards for eye care (e.g., fundus imaging, ophthalmic tomography, biometry, 

visual fields and macular thickness mapping). This meeting is open 

to vendors and ophthalmologists, administrators, ophthalmic photographers 

and ophthalmic technicians interested in advancing digital imaging. 


SO Selling and Purchasing on eBay, Craigslist, and 

other Mediums: How to Clean your office with Profit 


9:00 AM - 12:00 PM 

Fee: $150.00 

Room: N227a 

This course, with speaker Andrew P Doan MD PhD, will offer an overview 

of how to shop, sell and make money on the Internet, as well as how to 

protect yourself from fraud and phishing schemes. By the conclusion of 

this course, participants will (1) have an understanding of how to purchase 

goods and services online safely, (2) learn how to sell personal or 

professional goods and services on the Internet, (3) learn how to receive 

money safely from buyers and (4) learn how to avoid fraud and phishing 

schemes. For more information visit: http://www.aao.org/so/meeting_activities.cfm. 

Note: All attendees must bring their own laptop to this course. 

YO Networking with the Experts - Knowledge and Tips 

for the Young Ophthalmologist 


12:00 - 1:30 PM 

Fee: $20.00 , lunch included 

Room: S101ab 

At this lunchtime session, four panelists and Moderator, Sanjay Kedha 

MD will cover the following topics: Benefits of Networking by Sonny Goel 

MD; Mistakes to Avoid when Signing your First Contract by Michael Parshall; 

Financial Planning by Derek Preece MBA; and Insurance by Denise 

Chamblee MD. For more information, go to: http://www.aao.org/yo/annual_meeting.cfm 

SO Use Blogging & Social Networking to Super 

Charge Your Website & Internet Marketing with guest 

presenter: Randall Wong MD 


1:00 - 4:00 PM 

Fee: $150.00 

Room: N227a 

This course, with speaker Andrew P Doan MD PhD and guest presenter 

Randall Wong MD, will offer an overview of how to blog, publish, and 

share your ideas on the Internet. This instruction provides a hands-on, 

step-by-step construction of your Internet blog and how to publish articles 

to use the power of search engines to attract people to your practice, 

website, or business. For more information, go to: http://www.aao.org/ 

so/meeting_activities.cfm. 

Note: All attendees must bring their own laptop to this course. 

27th Annual Run for Vision 


6:30 - 8:30 AM 

Fee: $50, tax deductible 

Grant Park, Chicago 

Run/Walk for Vision 5k Bausch + Lomb and the Eye Bank Association 

of America invite you to participate in the 27th annual Run for Vision 5k 

benefit run/walk. The $50 registration fee is tax deductible as a charitable 

contribution and benefits the Eye Bank Association of America. Register 

online at https://www.signmeup.com/85661 by noon Nov. 9 or onsite Nov. 

10 at the Bausch + Lomb booth (#3126). The run is limited to the first 350 

participants. 

Yo 2012 Young Ophthalmologist Program 


10:00 AM - 2:00 PM 

Fee: Included in Academy Plus course pass 

Room: S101ab 

New ophthalmologists are faced with a multitude of choices in the transition 

from training to practice. Members of the Young Ophthalmologist 

(YO) Committee, along with select consultants, will share their own experience 

and expertise. This program addresses important topics of interest 

to all new ophthalmologists, such as starting a practice, contracts, 

buy-ins, coding and insurance. You will have an opportunity to network 

with other residents and physicians in their first five years of practice. 

2012 YO Program will feature Academy President Ruth D Williams MD 

and include speakers: Rob Melendez MD MBA, Lindsay A Rhodes MD, 

Sue Vicchrilli, Randall V Wong MD, Larry Geller, Purnima Patel MD. The 

YO Program Panel Discussion will be moderated by William C Lloyd III MD, 

and include: Natasha L Herz MD, Janice Law MD, Sherman Reeves MD 

and Eliza Hoskins MD. For more information, go to: http://www.aao.org/ 

yo/yo_program.cfm 

Note: Attendees must show a YO Ribbon for entrance. 

Annual Business Meeting 


Fee: FREE 

10:00 - 10:30 AM 


Fall Council Meeting and Surgery by Surgeons Forum 


11:30 AM - 5:30 PM 

Fee: FREE 

Room: Fairmont Chicago, Imperial Ballroom 

The Academy’s Council, an advisory body to the Board of Trustees, and 

ophthalmic state and subspecialty society leaders will discuss the latest 

on the Surgery by Surgeons campaign, along with updates on Academy 

activities and strategic issues effecting the profession. Key advocacy issues 

related to state and federal affairs will be addressed. During the Surgery 

by Surgeons Forum topics will include: an overview of the threats and 

challenges to ophthalmology in the legislative and regulatory arena; Truth 

in Advertising; and Action Items for Patient Safety. The Honorable Dean 

Cannon, Speaker, Florida House of Representatives, will be the guest 

speaker. The Council will also meet by region to discuss issues common 

to certain areas of the country. Requires separate registration. For more 

information, go to: www.aao.org/council. 

2013 Medicare Update 


12:15 - 1:45 PM 

Fee: FREE 


This program will provide vital information and updates on the important 

Medicare issues impacting your practice. Hear about changes that will 

impact payments and the latest on Medicare’s Physician Quality Reporting 

258 






System and eRx programs. What other new regulations and/or requirements 

will your practice need to focus on? Attend this session to hear all 

the latest updates that will impact ophthalmology in 2013. 

American Board of Ophthalmology: MOC Overview 

and Q&A with Board of Directors 


12:45 - 1:45 PM 

Fee: FREE 

Room: N136 

Maintenance of Certification (MOC) is a lifelong learning and practice improvement 

process designed to help you stay up to date in knowledge, 

skills and practice. MOC is a continuous process designed by practicing 

ophthalmologists and is completed in four main parts over the course of 

10 years. This course will provide an overview of MOC, a Q&A session 

featuring a panel of current board directors and an opportunity for informal 

discussion between the board members and the audience. 

Dialogue With the FDA: Ophthalmic Initiatives 

Affecting You and Your Practice 


12:45 - 1:45 PM 

Fee: FREE 

Room: N135 

Interested in the latest on the drugs and devices you use in your practice? 

Want to know more about the latest studies that will affect you and your 

patients? Have questions for drug and device experts? In this free session, 

the FDA’s ophthalmic drug and device experts will provide insight and updates 

on the FDA’s TASS Program, the LASIK Quality of Life Collaboration 

Project, its contact lens research program and more. A Q&A period will allow 

audience members to engage in direct dialogue with agency officials. 

OMIC Annual Members Meeting 


1:30 - 1:45 PM 

Fee: FREE 

Room: N137 

The annual meeting of the members of the Ophthalmic Mutual Insurance 

Company (a Risk Retention Group) will be held in order to elect the directors 

of the company and to transact such other business as may come 

before the meeting. OMIC President and CEO Timothy J Padovese will 

report on the company’s latest results. 

OMIC Forum: Top Ten Indemnity Payments of 2011 


2:00 - 3:30 PM 

Fee: FREE 


Medical malpractice claims are measured in two ways. Frequency tracks 

the number of claims that have been made against ophthalmologists, 

while severity indicates the amount of money required to settle claims. 

This year’s Forum will present the cases that resulted in the top indemnity 

payments made on behalf of OMIC policyholders. Physicians who attend 

the Forum will learn more about the litigation and settlement process, 

ways to reduce their liability, and promote patient safety. 


Yo Welcome to the Real World of Ophthalmology: 

Reality 101 for Residents and Fellows 


12:30 - 1:45 PM 

Fee: FREE 

Room: N135 

Residents and fellows will learn about nonmedical aspects of practicing 

ophthalmology and get their burning questions answered in this interactive 

forum. Panelists will discuss their personal experiences and highlight 

various practice options, networking and referrals, advantages/disadvantages 

of fellowship training and resources to assist them. Learn how 

membership and active involvement within state ophthalmology societies 

and the national American Academy of Ophthalmology can benefit you. 

Moderated by K David Epley MD, the session panelists include Susan K 

Burden MD, Mark R Melson MD and Arvind Saini MD. 

Tele-health in the VA, DOD and Indian Health Service: 

The Right Care in the Right Place at the Right Time 


12:45 - 1:45 PM 

Fee: FREE 

Room: N427a 

Ophthalmologists from the Department of Veterans Affairs (VA), the Department 

of Defense (DOD), and the Indian Health Service (IHS) will review 

applications of tele-health technologies being employed in these federal 

health care systems. The DOD relies heavily on tele-health to provide care 

to its deployed service members and providers. The VA has established 

a national model for diabetic retinopathy screening in the primary care 

setting, screening more than 500,000 patients since 2006. The IHS provides 

remote surveillance of diabetic retinopathy to American Indian and 

Alaska Native communities using validated teleophthalmology services. 

Q&A period will follow. 

The Resident Hub User Group Session 


12:45 - 1:45 PM 

Fee: FREE 

Room: S103d 

The Resident Hub is a new application on the ONE Network that provides 

tools for the management of online learning for residency programs. This 

session will include a brief demonstration of The Resident Hub functions 

and features, followed by a user group. The Resident Hub users are encouraged 

to attend this meeting to discuss questions they have about using 

the application, to brainstorm desired content additions, and to get 

assistance from The Resident Hub managers. 

Ergonomics/Musculoskeletal Disorders in 



12:45 - 1:45 PM 

Fee: FREE 

Room: N427d 

Musculoskeletal disorder (MSD) symptoms in the prior month have been 

self-reported by up to 50 percent of ophthalmologists. In a recent study 

performed at Mayo Clinic and the University of Iowa, ophthalmologists 

had a significantly increased rate of MSD symptoms in comparison to a 

family medicine physician control group. Identification of risk factors and 

modification of these activities will decrease the risk MSDs. 


& Events 




259



& Events 


SO 2012 Senior Ophthalmologist Special Program 

& Reception 


2:30 - 5:00 PM 

Fee: FREE 

Room: S101ab 

Come hear two dynamic local speakers, Lynn Osmond Hon AIE CAE President 

and CEO of the Chicago Architecture Foundation and Lance Grande 

PhD, Senior Vice President of Collections and Research at The Field Museum, 

who will discuss Chicago’s Architectural Legacy and Snapshots 

from deep time: Paleontological work in the 52-million year old fossil-rich 

limestone’s of Southwestern Wyoming. The Academy’s YO Committee 

will then present the 2012 EnergEyes Award to an ophthalmologist who 

has motivated and energized the next generation. For more information, 

go to: http://www.aao.org/so/meeting_activities.cfm. 


26° Lo Mejor de la Academia en Español 


7:00 AM - 5:00 PM 

Fee: See below 

Sheraton Chicago Hotel & Towers, 

Sheraton I/II/III Ballrooms 

La Academia Americana de Oftalmología (AAO) y la Asociación Panamericana 

de Oftalmología (PAAO) auspiciarán una reunión de un día en la cual 

se presentarán y discutirán, por oftalmólogos de habla hispana, los aspectos 

más importantes en 2012 ya sean en oftalmología general o en las diversas 

subespecialidades. Nueva literatura e instrumentos oftalmológicos 

serán evaluados en forma objectiva. Debido al espacio limitado se sugiere 

que hagan reservaciones por anticipado. El sitio (on site), la inscripcion 

sera de $40 para Miembros Titulares PAAO/AAO, y $50 para Asociados/ 

No Socios, y $25 para Residentes/Fellows. 

The American Academy of Ophthalmology (AAO) and the Pan-American 

Association of Ophthalmology (PAAO) will sponsor a one-day meeting 

which will summarize the important presentations in general ophthalmology 

and all subspecialty fields at the 2012 Annual Meeting. New ophthalmic 

literature and instruments will also be objectively evaluated. The 

presenting panels will be composed of Spanish-speaking ophthalmologists. 

Please note that panel topics and/or times may change. Advance 

registration is requested due to the limited space. A registration fee will 

be charged. Onsite: PAAO/Academy Active Members $40; Associate/Non 

Members $50; Residents/Fellows $25 (with letter or appropriate Annual 

Meeting badge). Register online at www.paao.org keyword “Lo Mejor”. 

260 







Visit the Learning Lounge to participate in informal, small group facilitated discussions led by 

experts in the field and continue the conversation with your colleagues. 

Float among groups, new topics begin every 15 minutes. For the most up-to-date schedule visit: 

www.aao.org/mobile. 







12:00 

12:15 

12:30 

12:45 

1:00 

1:15 

Theater 1 Theater 2 Theater 3 

Femtosecond Laser Cataract Surgery 

Richard L Lindstrom MD 

Laser Refractive Surgery 

Financial Considerators in Purchasing a 

Femtosecond Laser 


Femtosecond Limbal Relaxing Incision 

Eric D Donnenfeld MD 

1:45 

2:00 

2:15 

2:30 

2:45 

Refractive Cataract Surgery 

Warren E Hill MD 

Enhancing Refractive Outcomes 

IOL Exchange 

Alan S Crandall MD 

Samuel Masket MD 

The Complicated Cataract 

Robert J Weinstock MD 

3:00 


4:00 

4:15 

4:30 

4:45 

5:00 

Rotary Guests 



Volunteer Experiences 

Michael W Brennan MD 

Mildred MG Olivier MD 

Baxter F McLendon MD 

Volunteer Experiences 

William H Dean MD 

Matthew S Oliva MD 

Linda Lawrence MD 


10:30 

10:45 

11:00 

11:15 

11:30 

11:45 

Controversies in the Management 

of Wet AMD 

Judy E Kim MD 

AMD 

Evidence-Based Approach to the Care of 

the Neovascular AMD Patients 

Jennifer Irene Lim MD 

The Current Status of Nutritional 

Supplements in the Treatment of 

Macular Degeneration 


12:00 

12:15 

12:30 

12:45 

1:00 

1:15 

Continue the Conversation 

Best of the Posterior Segment 

Specialty Meetings 

Retinal Pharmacotherapy for the Anterior Segment Surgeon 

Diabetic Retinopathy: A New Paradigm 

for Treatment and Pharmacologic 

Vitreolysis for the Anterior Segment 

Surgeon 

William F Mieler MD 

AMD: Evolving Strategies 

Timothy W Olsen MD 

2:00 

2:15 

2:30 

2:45 

3:00 

2013 - A Fundamental Shift in 

Medicare Payment Policy Begins 

Michael X Repka MD MBA 

Trexler M Topping MD 

Health Care Policy 


The Long-term Forecast for 

Ophthalmology Under New Medicare 

Payment Structure 

What are the Immediate Impacts on Eye 

Care Services 

Stephen A Kamenetzky MD OCS 

Gregory P Kwasny MD OCS 

262



3:30 

3:45 

4:00 

4:15 

4:30 

4:45 

5:00 



Spotlight on Corneal Collagen 

Cross-linking 

A John Kanellopoulos MD 

R Doyle Stulting MD PhD 

Corneal Crosslinking 

Role of Ectasia Risk Scoring System 

Jay Stuart Pepose MD PhD 

How Young is Too Young for CXL 

William J Dupps MD PhD 


9:00 

9:15 

9:30 

9:45 

10:00 

10:15 

10:30 

10:45 

11:00 

11:15 

11:30 

11:45 

12:00 

12:15 

12:30 

12:45 

1:00 

1:15 

1:30 


Neuroradiological Aspects in 

Neuro-ophthalmology 

Jose N Vargas Galveia MD 

A Better Way to Detect an 

Afferent Pupillary Defect 

Mohsin Ali BS 

George L Spaeth MD FACS 

Longest Day 

Soosan Jacob FRCS 

Management of Posterior Polar 

Cataract and Dropped Nucleus 

Arup Chakrabarti MBBS 


What to Do When Your Patient Sees 

Nothing and You See Nothing: The 

Neuro-Ophthalmology Workup 

Wayne T Cornblath MD 

Meet the Producers 

Stevens-Johnson Syndrome: 

Dare to Dream? 

Geetha K Iyer MBBS 

Descemet-Stripping Endothelial 

Keratoplasty in Patients With 

Disrupted Iris-Lens Diaphragm 

Jagadesh C Reddy MD 

Lights, Camera, Action! 

Abhay Raghukant Vasavada MBBS FRCS 

Excimer Laser Phototherapeutic 

Keratectomy: Case-based Scenarios for 

Better Understanding 

Jagadesh C Reddy MD 



William F Hoyt Lecture: Are We There 

Yet? Has Neuro-Ophthalmology Reached 

the Paradign Shift? 

Alfredo A Sadun MD PhD 

Corneal Cross-linking and Long-term 

Hyperopic Femto LASIK Stability: 

Initial Clinical Findings in a 

Contralateral Eye Study 


Femtosecond Laser-Assisted Cataract 

Surgery in a Case of Weill-Marchesani 

Syndrome and Subluxated Cataracts 


The Use of Different 

Types of Temporary 

Keratoprosthesis: What to Choose? 

Cesare Forlini MD 

Intraocular Foreign Body Extraction via 

Sclero-corneal Tunnel in Conjunction 

with Pars Plana Vitrectomy: 

A SafePassage 

Yannek I Leiderman MD PhD 

Avoiding Malpractice in 


Peter J Savino MD 


263




1:45 

2:00 

2:15 

2:30 

2:45 

3:00 

Post-Refractive IOL Calculations: 

The Art and Science 


Management of IOL Power Surprises 



Clinical Decision-making with Cataract Complications 

Strategies for Small Pupils 

Terry Kim MD 

PC Rupture With Descending Nucleus– 

Management of the Descending 

Nucleus: Do’s and Don’ts 

Lisa B Arbisser MD 

Steven T Charles MD 

Severe IFIS: Clincial Updates and 

Surgical Strategies 

Nick Mamalis MD 

3:30 

3:45 

4:00 

4:15 

Framing the Question and Designing 

Research 

Graham E Quinn MD 

How to Get a Paper Published 

Data Collection and Analysis 

Dean M Cestari MD 

Writing an Interesting Paper 



4:30 

4:45 

5:00 


9:00 

9:15 

9:30 

9:45 

10:00 

10:15 


Incisions for Cataract Surgery 

Perry S Binder MD 


Femto Forum 

Anterior Capsulotomy 

Stephen S Lane MD 

Nucleus Disassembly 

Steven H Dewey MD 

10:30 

10:45 

11:00 

11:15 

11:30 

11:45 

12:00 

E-Learning Methods, 

Guidelines and Software 

Karl C Golnik MD 

Eduardo P Mayorga MD 

Webinar/E-Learning 

Tips on Teaching Eye Surgery to 

Residents 

Cynthia Ann Bradford MD 

Tips on Teaching Eye Surgery to 

Physicians in Medium and Poorly 

Developed Nations 

Navendra M Patel MD MPH 

264

Technology Pavilion 



Academy members and independent consultants offer user-friendly instruction on all things hightech 

for business, clinical and academic applications. Stop by for presentations on: 

• The latest in hardware, from mobile devices to wireless computing 

• Internet, social networking, productivity and mobile software topics 

• Software for medical records, presentations, image manipulations and more 

• Information on e-prescribing and ICD-10 






Technology Pavilion Daily Schedule 

9:00 

9:30 

10:00 

10:30 

11:00 

11:30 

12:00 

12:30 

1:00 

1:30 

2:00 

2:30 

3:00 

3:30 

4:00 

4:30 

5:00 

Saturday Sunday Monday Tuesday 

9:00-10:00 

Microsoft Office 2013 Preview 

9:30-10:30 

Mobile OS Latest Developments 

11:00-12:30 

AAO ONE ® and The Resident Hub 

(90-minute session) 

1:00-2:00 

Social Media Pearls for the 


2:30-3:30 

Explore Windows 8 

4:00-5:00 

Rehab Your Online Reputation 

* Indicates IHE session 

10:30-11:30 

Supercharge Your Online Marketing 

12:00-1:30 

Smartphones: An Update 


2:00-3:00 

Physicians + ICD-10 

3:30-5:00* 

EHR 101 


9:30-10:30 

EHR Implementation Mistakes 

11:00-12:00 

PowerPoint 2010: Ask the Expert 

12:30-1:30 

Coping with Increasing Distraction in a 

Connected World: Panel Discussion 

2:00-3:30* 

Cloud Computing 


4:00-5:00 

Internet and Gaming Addiction 

9:30-10:30 

Video Editing Tips for Presenting & 

Sharing 

11:00-12:00 

VPN and Wireless Security Best Practices 

12:30-1:30 

Protect Your Identity Online 

1:45-2:45 

Microsoft Office: Ask the Expert 



9:30AM – 10:30AM 

Mobile OS Latest Developments 

Darwin J Liao MD MPH 

The Mobile market has changed greatly in the past decade. The 

current leaders are Apple’s iOS and Google’s Android, but RIM 

BlackBerry is still in the mix and joined by Microsoft’s Windows 8 

RT. How do they stack up in terms of ease of use, features, security, 

connectivity, expandability and availability of useful medical applications? 

This session will examine where the latest operating systems 

are similar and where they diverge, as well as what new features 

lay on the horizon. 

11:00AM – 12:30PM 

ONE ® Network Updates and The Resident Hub 

Robert F Melendez MD MBA, Editor-in-Chief of the ONE Network 

Dale Fajardo EdD, Director of Online Education and the ONE Network at 

the American Academy of Ophthalmology 

Sarah Page MA, E-Learning Project Manager at the American Academy 

of Ophthalmology 

The Ophthalmic News and Education (ONE ® ) Network is a comprehensive 

educational resource, which provides members and subscribers 

the ability to quickly and effectively access relevant clinical 

information from an extensive, up-to-date knowledge base. This 

presentation will provide an update on the ONE ® Network, including 

a review of new features and a preview of upcoming enhancements. 

We will also demonstrate The Resident Hub, a powerful 

online tool, used by ophthalmology residency programs to facilitate, 

measure and track ophthalmic resident education. The session will 

conclude with a discussion and audience questions. 

1:00PM –2:00PM 

Social Media Pearls for the Ophthalmology Practice 

Robert F Melendez MD MBA 

This session explores the latest ways to harness Social Media, such 

as Facebook and Twitter, to benefit both the ophthalmologist and 

patient. Topics covered include best practices and important caveats 

in dealing with online interactions. 

2:30PM – 3:30PM 

Explore Windows 8 

Jude Brown, Senior Instructor, Digital Acumen, Inc. 

Learn about the new look and features of Microsoft’s next major 

release in the Windows Family.Windows 8 sports the entirely new 

“Metro” user interface, includes the addition of Internet Explorer 10 

and the new Windows Store for downloadable Apps. This session 

will provide an overview of the product, differentiation of the 

release versions, technical requirements and discussion of the pros 

and cons of upgrading. 

266



4:00PM – 5:00PM 

Reputation Rehab: Prescription for Improving Your 

Online Presence 

Tamara R Fountain MD, Secretary for Member Services for the American 

Academy of Ophthalmology 

Polly Wood, Senior Team Lead, Reputation.com 

Patients are turning to the Internet for medical and health related 

information at an exponential rate. Currently more than 20% of 

health-related searches are for a specific provider (source: Pew 

Internet & American Life Project). What do your patients see when 

they “Google” you? This session will help physicians to not only be 

aware of the threats they face online but to also give them the tools 

to create and grow a positive reputation online. 


9:00AM – 10:00AM 

Microsoft Office 2013 Preview 


Microsoft Office 2013 for Windows, set for release early next year, 

is brimming with new features such as better integration with Office 

365 Cloud Services, clean-up with Windows 8’s new Metro look and 

feel and native PDF editing. Get an early look at Microsoft’s latest 

Office version in action and determine whether it has been worth 

the wait since Office 2010. 

10:30AM – 11:30AM 

Supercharge Your Online Marketing 

Andrew Doan MD PhD, Deputy Editor, AAO ONE Network 

Protect your online reputation and supercharge your practice’s 

promotional efforts on the Internet and improve patient satisfaction 

in your practice. This lecture will cover the costs associated with 

Internet advertising for your practice and methods to attract new 

patients. The topics covered include, Google Adwords advertising 

and “Page Rank”, protecting your online reputation and low-cost 

and no-cost ways to promote your practice using Internet tools and 

social network websites. 

12:00PM – 1:30PM 

Smartphones (Mobile Technology): An Update 

Vinay A Shah MD, Dean McGee Eye Institute, University of Oklahoma, 

Oklahoma City 

Rohit Krishna MD, University of Missouri - Kansas City, Kansas City, MO 

R Ken Lord MD, Retina Associates of Southern Utah - St. George, UT 

Learn about smartphone trends and how you can put the mobile 

power of smartphones and tablets to work to simplify your life and 

maximize productivity in your practice. Topics include the current 

state and developments in the mobile computing industry as well as 

effective medical and personal use Apps. The session will conclude 

with a discussion and audience questions. 

2:00PM – 3:00PM 

Physicians + ICD-10: What Can’t Be Delegated 

Sue Vicchrilli COT OCS; Academy Coding Executive 

You’ve heard of coding to the 5th digit? ICD-10 will introduce coding 

to the 7th digit. With the dramatic increase in diagnosis code 

options, the time is now to learn what physicians must document 

differently to assure correct claims submission and prompt payment. 

3:30PM – 5:00PM * 

EHR 101 

Colin A McCannel MD FACS, Associate Professor of Clinical Ophthalmology, 

Jules Stein Eye Institute UCLA 

David Silverstone MD, Clinical Professor of Ophthalmology, Yale School 

of Medicine 

This session will provide the knowledge framework about EHR 

systems relevant to the purchase, implementation, maintenance and 

utilization of an EHR system. A wide range of topics will be covered, 

including characteristics of good EHR systems, selection criteria 

that should be considered, possible impact on the practice and work 

flow, information technology considerations and the importance of 

EHR standards. 

*Presentation is related to The Electronic Office: Integrating the Healthcare 

Enterprise (IHE) Booth 114. 


9:30AM – 10:30AM 

EHR Implementation Mistakes and How to Avoid Them 

H Jay Wisnicki MD, Medical Director, Union Square Eye Care; Professor 

of Clinical Ophthalmology & Visual Sciences and Pediatrics; Albert 

Einstein College of Medicine 

Stephanie Kraft, Practice Administrator, Union Square Eye Care, New 

York, NY 

Rainer Waedlich, President IOTA (International Ophthalmic Technology 

Association) 

Lon Dowell, Director, U.S. Clinical Informatics / Data Management, Carl 

Zeiss Meditec Inc. 

Learn from a seasoned technology adopter ophthalmologist and an 

experienced EHR/EMR vendor as they review common EHR system 

selection and implementation mistakes and how to avoid them. 

Image data management and EMR integration will be presented. 

Questions on the stimulus requirements for government EHR reimbursement 

will also be discussed. 

11:00AM – 12:00PM 

Microsoft PowerPoint 2010: Ask the Expert 


Microsoft PowerPoint 2010 gives you more ways to create and 

share dynamic presentations with your audience than ever before. 

Extensive audio and visual tools help you tell a crisp, cinematic story 

that is as easy to create as it is powerful to watch. In addition, 

PowerPoint 2010 enables you to work simultaneously with other 

people or post your presentation online and access it from virtually 


267





anywhere using the Internet or your smartphone. As always, our 

expert will also field “how to” questions from the audience. 

12:30PM – 1:30PM 

Coping with Increasing Distraction in a Connected 

World: Panel Discussion 

Darwin J Liao MD MPH 

H Jay Wisnicki MD, Medical Director, Union Square Eye Care; Professor 

of Clinical Ophthalmology & Visual Sciences and Pediatrics; Albert 

Einstein College of Medicine 

Additional Panelist TBD 

With the ubiquity of technology, there is the increasing potential 

danger of focusing on the screen and not the patient. “Device 

distraction” can lead to reduced quality of care, or worse, medical 

errors. Our panel will discuss their experience dealing with the 

benefits and risks of ever-present technology in their practice and 

private lives and how to keep it all in perspective. Audience input is 

encouraged. 

2:00PM – 3:30PM * 

Cloud Computing 

David Silverstone MD, Clinical Professor of Ophthalmology, Yale School 

of Medicine 

Cloud computing is Internet-based computing where shared software 

and information is provided to computers on demand. This is a 

paradigm shift in the delivery model from the client-server configuration 

to the over-the-Internet provision of services. Dr. Silverstone 

will provide an overview of what cloud computing is, software as a 

service, security issues, what to ask a vendor and how it can help 

you in your practice. 

*Presentation is related to The Electronic Office: Integrating the Healthcare 

Enterprise (IHE) Booth 114. 

4:00PM – 5:00PM 

Internet and Gaming Addiction: An Ophthalmologist’s 

Odyssey 

Andrew Doan MD PhD, Deputy Editor, AAO ONE Network 

The multi-billion dollar Internet and video game industries are in 

the business of creating fun and enticing interactivity that can be 

addictive. Dr. Doan, with a research background in neuroscience, 

battled his own addictions with video games and shares his journey 

into gaming and Internet addiction providing insight into this new 

addiction that is infiltrating our youth, students and employees. 

9:30AM – 10:30AM 

Video Editing Tips for Presenting and Sharing 


Learn step-by-step how to use powerful, but inexpensive software 

to acquire, edit and professionally polish your own videos. Topics 

include adding transitions, effects and mixing music as well as 

best practices for exporting to other formats. In particular, importing 

video for use in PowerPoint and uploading for sharing on the 

Internet will be demonstrated. 

11:00AM – 12:00PM 

VPN and Wireless Security Best Practices 

Jonathon Santilli, Senior Network Engineer, Digital Acumen, Inc. 

You can connect to your email, the Internet or your office EHR 

anywhere with a Wi-Fi hotspot. What steps can you take to protect 

your wireless connections? This session will review best-practice 

procedures you can use to secure your network connections at 

home, how to set up “Virtual Private Networking” (VPN) between 

home and office and what questions you should ask your IT department 

at work to minimize the chances of someone intercepting your 

private information. 

12:30PM – 1:30PM 

How to Protect Your Online Identity and Make Online 

Purchases with Confidence 


The FBI states that identity theft is one of the fastest growing 

crimes in America and around the world. Learn simple steps to help 

avoid identity theft, scams and phishing. Additional topics include 

tips for online banking, credit card and PayPal purchases, choosing 

and keeping passwords safe, as well as spotting scams and 

fraudulent websites. 

1:45PM – 2:45PM 

Microsoft Office Overview: Ask the Expert 


This interactive session provides an audience-driven overview of 

Office 365, PowerPoint 2010 and Video Editing. Ask our Expert any 

questions that remain unanswered, or about solving a particular 

problem you have had. 

268

Museum 

of Vision 

Visit us at Booth #704 

or on-line at www.museumofvision.org 

Ophthalmodouleia by George Bartisch, 1583 (reproduction)

270 

Notes

INTERNATIONAL CENTER 

Your Place at the Joint Meeting 

McCormick Place, Level 3 

Hall A, Booth #4509 

International attendees are encouraged to visit the International Center, and ideal place to: 

• Check your e-mail 

• Enjoy light refreshments 

• Meet or leave messages for your colleagues 

• Receive assistance regarding the Joint Meeting and your stay in Chicago 

• Receive assistance from a Spanish and Portuguese interpreter 

• Learn more about AAO programs 

Admittance is by attendee badge 

Booth 

#4509 

Saturday, 10 November................... 09:00 to 17:00 

Sunday, 11 November...................... 09:00 to 17:00 

Monday, 12 November..................... 09:00 to 17:00 

Tuesday, 13 November.................... 09:00 to 15:00

272 

Notes



Booth 508 















Foundation 


certificates 


Win an iPad! 

















274 

Notes

International Society of Refractive Surgery 

A Partner of the American Academy of Ophthalmology 

Join ISRS in Chicago 

Schedule of Clinical Sessions 

While in Chicago, keep up with the latest in clinical and research developments in refractive, 

cataract, cornea and lens-based surgery with the International Society of Refractive Surgery 

(ISRS), a partner of the American Academy of Ophthalmology. 

Refractive Surgery Subspecialty Day 2012: 


The ISRS Annual Meeting 

Friday, 09 November | 08:00 to 17:15 

Saturday, 10 November | 08:00 to 17:30 

McCormick Place, North, Hall B 

Free Papers (Friday only) 

McCormick Place, Grand Ballroom S100ab 

ISRS Special Sessions 

Introduction to Refractive Surgery 

for Residents (SYM53) 

Sunday, 11 November | 08:00 to 10:00 

McCormick Place, S503AB 

LASIK Is Safe: Prevention and Management of 

Laser Complications (SYM14) 


McCormick Place, Grand Ballroom S100AB 

ISRS Rountables* 

Sunday, 11 November through 

Tuesday, 13 November 

07:30 to 08:30 

McCormick Place, Hall A 

ISRS Instruction Courses* 

ISRS Laser Refractive Surgery 

Course (156, LEC156) 


McCormick Place, S103BC 

Laser Refractive Surgery (LAB156A) 

12:30 to 14:30 | N227B 

Laser Refractive Surgery for Ophthalmology 

Residents (LAB156B) 

15:30 to 17:30 | N227B 

Advanced Corneal Topographic Analysis (214) 


McCormick Place, E352 

A Step-by-Step Primer to Starting 

LASIK in 2012 (338) 

Monday, 12, November | 09:00 to 11:15 

McCormick Place, N427BC 

Surgical Management of Astigmatism in Cataract 

and Refractive Surgery (308) 




Worst-Case Scenarios: A Video-Based Course (402) 



For more information on ISRS or to become a member, visit Member Services in the Academy 

Resource Center (Booth 508) or www.isrs.org 

*onsite fee applies

276 

Notes



Join the Leading Worldwide 

Organization for Refractive Surgeons 

ISRS is a truly global society with membership 

from more than 80 countries around the 

world. The Journal, Multimedia Library, 

newsletter and multiple meetings provide 

our global family of members with easy 

and personalized access to the most 

cutting-edge information. We are more 

than a society, we are a 

specialty-oriented family. 

— Ron Krueger 

To become a member, visit the Membership Booth in the 

Academy Resource Center, Booth 508, or visit www.isrs.org.

278 

Notes

The Electronic Office – IHE Eye Care, Booth 114 

McCormick Place Exhibit Hall 

YOUR Information Systems 

and YOUR Devices 

all Working Together 

Visit Academy-sponsored Electronic Office for Information on Meaningful 

Use Incentives and a FREE Demonstration and a FREE USB Drive. 

Find out more information about The Electronic Office 

at www.iheeyecare.org or contact flum@aao.org.

Meeting 

Archives 

Materials from the Academy’s past 

Annual Meetings and Subspecialty Days 

are available to use as a resource. 

> Scientific Posters Online 

> Course Handouts 

> Videos on Demand 

> Program Searches 

> Subspecialty Day Syllabi 

> Links to order information 

presented during the 

Joint Meeting and Subspecialty Day 

www.aao.org/aao-archives 

280

Discover Perfect Vision 

 

operating microscope Hi-R NEO 900 

Booth # 3808 

Haag-Streit Surgical GmbH 

Rosengarten 10 

D-22880 Wedel, Germany 

Phone +49-4103-709 04 

www.haag-streit-surgical.com 

HAAG-STREIT 

SURGICAL

GetEyeSmart.org 

Educating the Public | Strengthening Our Profession 

Provided by the 

American Academy of Ophthalmology to: 

> Empower consumers to protect their eye health 

> Raise awareness of eye diseases and conditions 

> Promote ophthalmologists as the leaders in 

eye care 

EyeSmart features: 

> Comprehensive, reliable, easy-to-understand 

information on everything related to eye health 

– in English and Spanish (OjosSanos.org) 

> Timely tips and news articles to help people 

keep their eyes healthy 

> Educational videos, animations and images 

> Eye health Q&As that answer common 

questions about eye diseases and conditions 

Come to the Academy Resource Center, Booth 508, at the 2012 Joint Meeting in Chicago 

to learn more about how EyeSmart can benefit your practice and your patients. 

“Like” EyeSmart on Facebook to get 

the latest eye health news for your 

patients and details on important 

awareness campaigns.

AAOE Program / Practice Management 


South, Level 5 

Locations: All rooms are in McCormick Place unless otherwise indicated. 

AAOE is the Academy’s practice management resource, dedicated to meeting the educational 

needs of those responsible for managing the business side of ophthalmic practice. 

Nonmembers may join AAOE at a discounted rate during the Meeting by visiting the Academy 

Resource Center, Booth 508. 

AAOE General Session - The 4 Disciplines of Execution 

Keynote address by Franklin Covey’s Global Practice Leader, Chris McChesney on The 4 Disciplines 

of Execution. 


10:00 AM to 12:00 PM 

McCormick Place, S501 

Event Code: SPE23 

Sponsored by Genentech, Inc. 

Welcome Reception 


6 to 7:30 PM 

Hyatt Regency Chicago, Ballroom A 

Sponsored by CareCredit SM 

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical 

education for physicians. 





AAOE Coding Sessions 



Room S105 

The following coding sessions take place concurrently with the Academy’s Joint Meeting as part of the AAOE program. These intensive 

sessions are designed to enhance participants’ knowledge of appropriate coding and documentation in order to receive proper reimbursement. 

Separate registration is required to attend these events, they are not included in the Academy Plus course pass. Members and 

nonmembers can register for the AAOE Coding Sessions without registering for the 2012 Joint Meeting. 

Coding SOS 

Introducing the first ophthalmic specific ICD-10 hands-on workshop. 

Registration includes the newly published ICD-10 for Ophthalmology 

book. 

Instructors: Elizabeth Cottle CPC, OCS and Kim Ross, OCS, CPC 

Moderator: Sue Vicchrilli, COT OCS 

Those new to practice as well as those with experience will benefit 

from hands-on ICD-10 training for proper code selection on the 

most frequently submitted services for every specialty in ophthalmology. 

Correct ICD-10 diagnosis code linkage will be imperative to 

successful claims submission, in addition to core coding confidence 

identifying: 

• CPT 

• Modifiers 

• CCI edits 

• Coverage policies 

• Bilateral and multiple procedure rules 

• Frequency edits 

Those signed up for the course are invited to email coding quandaries 

prior to the Joint Meeting to 

svicchrilli@aao.org. List Coding SOS in the subject line. 

Time: Saturday, Nov. 10 

8:00 AM - 11:00 AM 

Fee: $330 

Coding Camp 

Offered in collaboration with the Joint Commission on Allied 

Health Personnel in Ophthalmology (JCAHPO) 

Discover the hot coding issues, coding challenges and new procedures 

for each specialty in ophthalmology. 

Instructors: Elizabeth Cottle CPC, OCS, Stephen Kamenetzky, MD 

OSC and Joy Woodke, COE, OCS 

Special presentation: Michael X Repka, MD, MBA, AAO Medical 

Director for Governmental Affairs 

Moderator: Sue Vicchrilli, COT OCS 

During this three hour intermediate/advanced coding course you 

will: 

• Identify what is missed in office visit documentation - whether 

paper or EHR; 

• Recognize how MUEs impact the way you submit claims; 

• Take the modifier challenge; 

• Code multiple testing services in the same session correctly; and 

• Maximize your surgical coding. 

Time: Saturday, Nov. 10 

12:30 PM - 3:30 PM 

Fee: $270 


The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical 

education for physicians. 

282

AAOE / Practice Management Instruction Courses 


NEW Can My ASC Accept that Reimbursement? A Financial 

Evaluation of Payer Rates 

Course: 322 

Monday 

Room: S501bc 

9:00 - 10:00 AM 



Synopsis: This course provides a financial evaluation model known as contribution analysis 

in combination with qualitative considerations to help managers and owners evaluate 

acceptable reimbursement rates for the ASC. It is designed for people who do not have an 

accounting or financial background. 

Objective: Upon completion, attendees will be able to (1) identify fixed and variable expenses 

on their financial statements, (2) conduct a break-even analysis and contribution 

analysis, (3) ask important strategic questions to evaluate contract opportunities, and (4) 

make decisions regarding the feasibility of various reimbursement rates. 

Senior Instructor(s): Maureen Waddle MBA* 

NEW ASC Guide to Managed Care Contracting 

Course: 440 

Monday 

Room: S504bc 

4:30 - 5:30 PM 



Synopsis: The course will provide attendees with an overview of the ASC industry 

contracting trends and detailed discussion covering the various reimbursement methodologies. 

It will also address the surgery center contract language issues that need to be 

successfully negotiated to ensure a win-win working relationship with the health plans. 

Objective: The course will provide attendees with all the tools and know-how to negotiate 

profitable surgery center contracts. 

Senior Instructor(s): Richard E Gable PhD MBA 

NEW ASC Benchmarking 

Course: 523 

Tuesday 

Room: S501a 

10:15 - 11:15 AM 



Synopsis: This course will provide an overview of benchmarking for the ophthalmic ASC, 

including a brief history, reasons for benchmarking, processes involved, and highlights 

from the 2012 Outpatient Ophthalmic Surgery Society Benchmarking Survey. Presenters 

will introduce examples based on case studies and engage the audience in hands-on discussion 

of how to gather and apply key benchmarks to their facilities. 

Objective: To provide ASC staff with a compelling rationale for benchmarking and a 

hands-on introduction to the process. 

Senior Instructor(s): Kent L Jackson* 

Instructor(s): Albert Castillo, Maureen Wadde MBA 

How to Develop a Successful Ophthalmic Ambulatory Surgery 

Center 

Course: 558 

Tuesday 

Room: S504bc 

11:30 AM - 12:30 PM 



Synopsis: This course will show the difficulties of developing a successful ophthalmic 

ASC, from A to Z. It will discuss the various development options and pitfalls to avoid. 

Everything will be covered , from revenue generation to the costs of rent, equipment, staffing, 

supplies and other expenses. The pearls of helping develop over 350 ASCs will be 

thoroughly discussed. 

Senior Instructor(s): John A Marasco* 


NEW SO Diagnosing and Improving the Financial Health of Your 

Practice 

Course: 209 

Sunday 

Room: S502b 

2:00 - 3:00 PM 


Target Audience: ADM 

Synopsis: This session will help you to know where you have been financially, to understand 

where you are financially, and to identify the changes you will need to make to get to 

where you want to be through benchmarking data and analysis. Participants will learn how 

to understand key financial measures in their practices and what they mean. They will be 

provided with an overview of ancillary services that they can offer within their practices, 

along with “Practice Builder” ideas to help them keep their eye on the cashflow ball. 

Objective: By the conclusion of this course, participants will be able to identify, with data, 

the cost drivers in their practices, provide the tools to analyze and compare the financial 

heart of their practices, and understand the steps they will need to take to reach their 

desired financial results. 

Senior Instructor(s): Charles A Hoch 

NEW H Ophthalmic Financial Policies for the Small Practice 

Course: 212 

Sunday 

Room: S504a 

2:00 - 3:00 PM 



Synopsis: In times of increasing costs and decreasing reimbursement, it is crucial that 

physician owners and administrators keep a finger on the pulse of a practice’s finances. 

This course will share a financial policy written to help small practice physicians, administrators, 

and staff in understanding, monitoring, and following all the various financial 

flows in today’s practices. 

Objective: Upon completion of this course, the participants will understand the revenue 

cycle process of an ophthalmic practice, have the tools and knowledge to write their own 

financial policies, and have an understanding and knowledge of what is important in making 

financial information transparent, available, and understandable. 

Senior Instructor(s): Albert Castillo 

NEW Going Lean: Tools for Efficiency and Effectiveness in the 


Course: 226 

Sunday 

Room: S504d 

3:15 - 4:15 PM 



Synopsis: Concerns about health care quality and cost have moved to the forefront in 

discussions on the evolution of the U.S. health care system. It is no longer a question of 

whether health care organizations should focus on these issues, but rather how to do so 

in order to ensure their survival. The purpose of this course is to introduce participants to 

a specific approach to quality improvement and efficiency that can be undertaken in an 

ophthalmology practice: Lean Healthcare. Specific concepts and tools that can be readily 

applied in an ophthalmology practice will be introduced, and examples will be given to 

demonstrate the value of this methodology in improving both quality and efficiency. 

Objective: At the conclusion of this course, the participant should have an understanding 

of Lean Healthcare and tools that can be applied in an ophthalmology practice to improve 

both quality and efficiency. 

Senior Instructor(s): Robert E Wiggins MD MHA* 

Instructor(s): Denise C Fridl COT COE, Susie Winterling 

AAOE / Practice Management 


A American Society of Ophthalmic Administrators. C American Academy of Professional Coders. J JCAHPO. E Electronic Health Records. 

sO Endorsed by Senior Ophthalmologist Committee. YO Endorsed by Young Ophthalmologists committee. * The presenter has a financial interest. ** The presenter has not submitted 

financial interest disclosure information as of press date. No asterisk indicates that the presenter has no financial interest. 

283




NEW SO Yo Ophthalmology Practice Buy-In and Pay-Out 

Arrangements 

Course: 229 

Sunday 

Room: S502a 

3:15 - 5:30 PM 



Synopsis: Learn how to structure fair and reasonable financial and legal arrangements for 

buy-ins and pay-outs from attorneys/consultants who have more than 50 collective years 

of experience and have done hundreds of buy-ins and pay-outs. This course describes and 

explains appropriate buy-in arrangements for associates as well as customary pay-out 

arrangements for owners leaving a practice. This course covers the valuation of the ophthalmology 

practice as well as the factors affecting the entry or exit of an ophthalmologist 

from a practice. 

Objective: The course will explain how to accomplish a buy-in and co-ownership for 

associates, how to structure pay-outs for departing practice owners, avoid unforeseen 

problems, and fairly compensate practice owners for their interests in the practice. Participants 

will learn how to structure buy-in/pay-out arrangements that are fair and reasonable 

both to practice owners and to joining or departing ophthalmologists. Participants will 

also gain an understanding of ophthalmology practice values and learn about the practical 

considerations, limitations, and protections needed when establishing buy-in/pay-out 

arrangements. 

Senior Instructor(s): Mark E Kropiewnicki JD LLM* 

Instructor(s): Daniel M Bernick JD* 

Deciphering Financial Reports 

Course: 245 

Sunday 

Room: S503ab 

3:15 - 5:30 PM 



Synopsis: You spend 20 years in training to give sight to the sightless, but your eyes swim 

when you’re asked to evaluate a practice opportunity such as a buy-in or an opportunity 

to invest in an ambulatory surgery center, optical shop, or practice real estate. You are not 

alone, and help is on the way. This course will present and demystify the basic financial 

reports you will run into when evaluating practice opportunities—profit and loss statements, 

balance sheets, accounts receivables reports, and tax returns—and then help you 

understand how they all relate, and why they are important. 

Objective: This course is designed to get participants grounded in the financial reports 

they must be familiar with in practice, without having to get a degree in accounting! 

Senior Instructor(s): Robert A Wade JD 

Instructor(s): Mark D Abruzzo JD 

NEW SO Accountable Care Organizations: A Primer for 


Course: 259 

Sunday 

Room: S504d 

4:30 - 5:30 PM 



Synopsis: This course was developed to help educate Academy members on issues related 

to Accountable Care Organizations (ACOs). 

Objective: The goal of the course is to help ophthalmologists/administrators understand 

and prepare for the changes that lie ahead as our health-care system undergoes fundamental 

reform related to the financing and delivery of care. 

Senior Instructor(s): Richard E Gable PhD MBA 

NEW Practice Growth and Profitability: Limiting Factors 

Course: 326 

Monday 

Room: S501d 

9:00 - 10:00 AM 



Synopsis: This course will describe the six factors that limit practice growth and profitability. 

The course will describe how to identify these limiting factors and how to create 

documented, efficient processes. 

Objective: Attendees will (1) understand the six limiting factors, (2) understand the importance 

of having documented, efficient processes, and (3) understand how to create 

processes and how to enforce adherence to the processes. 

Senior Instructor(s): Jeff Grant* 

Retina-Specific Panel Discussion: Ask Your Peers 

Course: 337 

Monday 

Room: S502a 

9:00 - 11:15 AM 



Synopsis: This course will highlight targeted areas of interest specific to retina practices. 

A panel of experienced administrators from retina practices will provide answers to questions 

that participants present, as well as questions asked by the panel to generate discussion 

and share values. 

Objective: At the conclusion of this course, attendees will know retina-specific data for 

practice management of retina-specific operational functions. 

Senior Instructor(s): Warren E Laurita MBA 

Instructor(s): Angela Chambers RN MBA*, Jefferey T Brockette*, Deborah Curran, 

Elizabeth Hesford Cifers CPC OCS 

NEW H Internal Controls for the Ophthalmic Practice 

Course: 341 

Monday 

Room: S501bc 

10:15 - 11:15 AM 



Synopsis: It may be difficult for small practices to have internal controls and separation of 

financial duties because of limited staff. Internal controls are the methods and procedures 

used by any business to prevent or detect errors, safeguard assets (especially cash) from 

being misappropriated, and encourage staff adherence to prescribed managerial policies. 

Internal controls in a medical practice differ depending on the size and complexity of the 

practice. The key, however, is that they prevent or detect errors and efforts to circumvent 

the established policies and procedures of the organization. How good are the internal 

controls in your group practice? 

Objective: To provide tips on developing financial and control systems to decrease theft 

and financial mistakes. 

Senior Instructor(s): Albert Castillo 

Instructor(s): Traci Fritz COE OCS 

SO Let’s Make a (Practice) Deal: A Step-by-Step Approach 

Course: 358 

Monday 

Room: S504d 

10:15 AM - 12:30 PM 



Synopsis: Many ophthalmologists fail to sell their practices because they do not know 

how to go about a practice sale, or because they believe that there are no buyers. This 

course teaches a proven method developed over 20 years that has resulted in many practice 

sales. 

Objective: At the conclusion of this course, participants will understand the process involved 

in successful practice sales, what information to provide, how to attract qualified 

buyers, buyers’ motivations and fears, valuation methods, and the different types of transactions. 

They will come away with an understanding of common terms and conditions, 

negotiation tactics, and most importantly, what to say and what not say to bring a sale 

to closure. 

Senior Instructor(s): Michael J Parshall* 

NEW Managing Office Waiting Times 

Course: 373 

Monday 

Room: S502a 

11:30 AM - 12:30 PM 



Synopsis: Surveys repeatedly show that extended waiting times are a major source of 

patient dissatisfaction with their ophthalmologists. This course will analyze the factors 

that determine office waiting times and will demonstrate how practitioners can use these 

insights to minimize waits, maximize patient satisfaction, and understand the costs of 

the various strategies available. Subjects covered will include cumulative capacity and 

appointment availability, randomness of patient arrivals and duration of office encounters, 

estimates of waiting times, and the likelihood of outliers. 

Objective: By the conclusion of this course, attendees will be able to identify the causes 

of prolonged patient waiting times and to understand the strategies that can minimize 

patient waits, and their costs. 

Senior Instructor(s): Scott Brodie MD PhD 

284 

h Top 10% in subject area. NEW New Course. Education Level Key: Bas = Basic, Int = Intermediate, Adv = Advanced 

Target Audience: COMP = Comprehensive Ophthalmologist, SUB = Subspecialist, COMPSUB = Comprehensive & Subspecialist, ADMIN = Administrators 



Yo A Practical Guide to Understanding and Negotiating Your 

First Employment Agreement 

Course: 390 

Monday 

Room: S501d 

2:00 - 3:00 PM 



Synopsis: This course addresses the various practical, business, and legal aspects of reviewing 

and negotiating an initial employment agreement. Issues covered in the course 

include understanding the business and legal terms of the proposed employment arrangement, 

the fundamentals of a contract, and tips on how to negotiate the deal with the 

prospective employer. 

Objective: This course will leave attendees with an understanding of the entire employment 

and contracting process so that they approach their first contract experience with 

knowledge and confidence. 

Senior Instructor(s): Robert J Landau JD 

NEW Yo Benchmarks to Improve Your Practice 

Course: 396 

Monday 

Room: S504a 

2:00 - 3:00 PM 



Synopsis: The course will describe the key practice performance and financial indicators 

that every practice owner or administrator should understand. The course will describe 

how these indicators should be tracked/monitored, how to use the benchmarks to improve 

performance, and how to compare an individual practice with others. 

Objective: Attendees will (1) understand the most critical performance and financial 

benchmarks, such as profit margin, return on equity, facilities expense ratio, practice expense 

ration, and many others, (2) understand how to record and monitor each benchmark 

and how to use the benchmarks to improve the performance of their practice, (3) understand 

the “healthy range” for each benchmark and how to compare themselves to these 

“health ranges,” and (4) understand how to use key performance indicators to improve 

their practice, spot problem areas, and create strategic plans. 

Senior Instructor(s): Derek A Preece MBA* 

Acquiring Practices: Buying Strangers, Friends, and Enemies 

Course: 404 

Monday 

Room: S504a 

3:15 - 4:15 PM 



Synopsis: This course will describe how to acquire an ophthalmology practice, including 

both legal and business considerations. The target audience includes group practices 

seeking to acquire a competitor (whether for cash or stock), as well as the newly trained or 

relocating physician seeking to establish his or her own practice in a new market. 

Objective: Participants will learn how to evaluate potential practice targets, structure 

the transaction, negotiate the important terms, and perform due diligence. Valuation principles 

and tax issues will also be discussed, as will the seller’s employment arrangements 

with the buyer. 

Senior Instructor(s): Daniel M Bernick JD* 

Instructor(s): Mark E Kropiewnicki JD LLM* 

SO Practice Valuations: What’s a Practice Worth Today? 

Course: 430 

Monday 

Room: S503ab 

3:15 - 5:30 PM 



Synopsis: This course will describe the process of determining and assigning economic 

value to ophthalmic practices (and practice-related entities, such as optical shops and 

outpatient surgery facilities) for buy-in, buy-out, and purchase/sale transactions. It will 

also describe the various considerations that influence “goodwill” value, including but not 

limited to health care reform, the recession, and Medicare cuts. 

Objective: To provide the attendee with an understanding of (1) the components of value 

comprised in an ophthalmology practice, (2) the methods used by qualified appraisers to 

determine practice values in the present climate (including the various factors that influence 

practice goodwill value), and (3) how practice values translate to purchase prices in 

buy-in, buy-out, and practice sale scenarios. 

Senior Instructor(s): Mark D Abruzzo JD 

Instructor(s): Richard C Koval MPA CMPE* 

NEW How to Run a Lean, Mean Refractive Practice in Today’s 

Tough Economic Times 

Course: 587 

Monday 

Room: S501bc 

3:15 - 4:15 PM 



Synopsis: In this course you will learn whether to buy your own equipment or take advantage 

of the lease options available. You will learn how to price yourself in the marketplace 

today. We will discuss what your retained earnings after market share calculation should 

be. We will discuss what you should be paying for your full-time equivalents. You will find 

out if you are competitive in the marketplace. 

Objective: This course will help you to (1) make sure your practice is competitive, (2) make 

sure you are getting the most profit you can out of your refractive practice, and (3) make 

sure you are making the right business decisions. 

Senior Instructor(s): Michael D Brown* 

NEW Developing a Health Care Facility in the Aftermath of a 

Recession 

Course: 443 

Monday 

Room: S501a 

4:30 - 5:30 PM 



Synopsis: This course will discuss why now is actually a once-in-a-lifetime opportunity 

to garner huge financing, design, and development savings. Whether you’re looking to 

develop an existing or a new facility and whether you are looking to lease or own, now is 

not the time to put the brakes on. 


NEW Current Trends in New Associate Employment Contracts 

Course: 501 

Tuesday 

Room: S502b 

9:00 - 10:00 AM 



Synopsis: What are the current “normal” employment agreement terms for an associate 

joining your practice? The employment contract you present to potential candidates is important. 

Quality candidates often have multiple offers, so you need to make sure your offer 

is competitive. You also need to protect your practice in case the associate does not work 

out or tries to leave and compete. The employment contract often will also need to outline 

future buy-in arrangements to address the associate’s long-term concerns. Learn how to 

structure fair, reasonable, legal, and protective new associate employment arrangements 

from experienced attorneys/consultants with more than 50 years combined experience 

who have done thousands of new associate employment contracts. 

Objective: This course will provide participants with the range of terms presently needed 

to attract quality candidates in a competitive marketplace while also protecting your practice. 

Learn national “norms” for salary, incentive bonus, benefits and business expenses, 

as well as standard terms to protect the practice. Also learn what currently needs to be 

said about future buy-in and “partnership”. 

Senior Instructor(s): Mark E Kropiewnicki JD LLM* 

Instructor(s): Daniel M Bernick JD* 

NEW Yo Hanging a Shingle in the 21st Century: Is a Start-up 

Solo Practice Possible in 2012? 

Course: 502 

Tuesday 

Room: S501d 

9:00 - 10:00 AM 



Synopsis: This course will detail the challenges faced by physicians wishing to open a 

solo practice in the 21st century and how these challenges can be overcome. The presenters, 

who have all opened solo practices in highly competitive markets, will share their 

experiences, from strategy to tactical execution of planning, financing, building, credentialing, 

opening, and growing a practice built from scratch. 

Objective: Attendees will understand the hurdles involved in starting a solo practice from 

scratch and walk away with a road map of how this can be done today. 

Senior Instructor(s): Edwin S Chen MD 

Instructor(s): Ajit Nemi MD, Ravi D Patel MD 






285




SO Hiring an Ophthalmologist for Your Practice 

Course: 503 

Tuesday 

Room: S502a 

9:00 - 10:00 AM 



Synopsis: This course is designed for practices considering the addition of an associate 

ophthalmologist in the near future. Topics of discussion include feasibility analysis, recruitment 

processes, contract and compensation norms, future co-ownership provisions, and 

transition of the new associate into the practice. 

Objective: This course is designed to provide practices with the critical information needed 

for making informed decisions as they pursue the addition of a new ophthalmologist. 

Senior Instructor(s): Richard C Koval MPA CMPE* 

Mastering Patient and Staff Efficiency and Satisfaction Though 

Facility Design 

Course: 505 

Tuesday 

Room: S504d 

9:00 - 10:00 AM 



Synopsis: This presentation will show its attendees how to best address the key services 

of clinic, optical, laser vision correction, and ambulatory surgery in a state-of-the-art 

ophthalmic facility. Design methodologies that enhance patient and staff efficiency and 

satisfaction will be discussed in detail. The course will also show how to best incorporate 

key subspecialties like pediatrics, retina, oculoplastics, and even hearing services. 


NEW Yo Social Media and Social Networking in the Physician 

Office 

Course: 506 

Tuesday 

Room: S504a 

9:00 - 10:00 AM 



Synopsis: More than a billion people around the world use social media daily. It is imperative 

that providers and business managers learn how to manage this communication 

channel, particularly as it relates to protected health information, confidentiality, and reputation 

of the practice and providers. This course will discuss the use of social media in the 

physician practice and whether a practice should have a social media policy, reputation 

monitoring and what a practice should do from a customer service and legal standpoInt, 

and the legalities of monitoring these networks for conducting employee background 

checks. 

Objective: Participants will leave this session understanding social media networks — 

their positives and negatives for a physician practices. Participants will explore the need 

for and drafting of an effective policy. Participants will be prepared to monitor the Internet 

for reputation management and will know what to do if there is a false or misleading 

statement about the practice or a provider. 

Senior Instructor(s): Brenda Laigaie JD 

Instructor(s): Nathaniel C Guest** 

NEW SO Selling Your Ophthalmology Practice in an Uncertain 

World: Nuts and Bolts for the Busy Practitioner 

Course: 527 

Tuesday 

Room: S504d 

10:15 - 11:15 AM 



Synopsis: With electronic health records requirements, reimbursement threats, and other 

marketplace changes, many baby boom generation ophthalmologists are concerned about 

the future and are considering retirement and sale of their practices. Interested practitioners 

need to understand valuation and pricing, together with core legal strategies (stock 

versus assets), payment plans/collateral, and tax ramifications. Careful attention also 

needs to be paid to the terms of a seller’s post-sale employment agreement, if the seller 

intends to work for the buyer. 

Objective: At the conclusion of this course, the attendee will be able to understand the 

basic legal and business considerations involved in a medical practice sale. Participants 

will learn about typical values paid for ophthalmology practices, asset purchase versus 

stock sale considerations, tax allocation, security for the purchase price, payment terms, 

and postsale employment arrangements. Discussion of negotiating tricks and traps will 

be included. 



NEW Financial Decision Making in the Eye Care Practice 

Course: 542 

Tuesday 

Room: S502b 

10:15 AM - 12:30 PM 



Synopsis: In this course attendees will have a chance to see accounting basics, ration 

analysis and benchmarking, overhead and expense management, cost analysis and contracting 

and accounts receivable management. We will cover the different accounting 

methods. Critical financial statements will be discussed. We will cover benchmarks for 

your practice. This course will cover all of the financial areas of your practice to help you 

run as lean, mean, and effective as possible. 

Objective: This course is designed to help you (1) obtain benchmarks and ratios to compare 

your practice to other practices, (2) make sure you are operating efficiently and effectively, 

(3) ensure you understand your financial statements, (4) make sure your accounts 

receivables are where they should be. 


NEW Negotiating Clinical Trial Agreements — and Don’t Forget 

About Compliance! 

Course: 561 

Tuesday 

Room: S503ab 

11:30 AM - 12:30 PM 



Synopsis: Investigators are often given boiler plate or master clinical trial agreements 

(CTA) and told by the sponsor to sign it. But CTA’s are negotiable and require understanding, 

thought, and legal knowledge. The interests of the sponsors and investigators need to 

be considered in reaching agreement. Both parties must also consider the applicable fraud 

and abuse laws and rules. 

Objective: Participants will leave this course with a better understanding of the CTA: its 

terms and clauses that require negotiation. Further, participants will understand the applicability 

of the fraud and abuse statutes and their impact on the CTA. 


Instructor(s): Michele Formoso** 

SO Buying or Selling a Practice: Creating Win-Win Transactions 

Course: 562 

Tuesday 

Room: S501bc 

11:30 AM - 1:45 PM 



Synopsis: This course presents the prospective buyer and seller of a practice with a rubric 

ensuring that each gets what they need. The course will look at where to find sellers and 

buyers, how to price a practice, what’s included in the sale, and the art of negotiating, as 

well as crafting letters of intent, exclusivity or “no-shop” clauses, and the salient deal 

points and legal issues to be covered in a practice sale/purchase. Also to be covered are 

due diligence, financing, post-sale transition, employment of the seller, office staff, patient 

notifications, and restrictive covenants. 

Objective: Through lecture and Q&A, participants will learn how to craft “win-win” practice 

sales and purchases. 


Instructor(s): Mark D Abruzzo JD 

286 





NEW Detecting and Preventing Fraud and Abuse in the Optical 

Dispensary and Medical Practice 

Course: 563 

Tuesday 

Room: S501d 

11:30 AM - 1:45 PM 



Synopsis: Is fraud and abuse occurring in your medical business practice? In your optical 

dispensary? Learn the methods of detection and prevention before fraud and abuse 

happen. Find out how to set up systems of accounting and financial management with 

the right system of checks and balances. Topics covered in this course include identifying 

types of fraud in the business practice and optical dispensary, the warning signs that fraud 

exists, steps to take to combat fraud and abuse, what to do if you suspect employee theft, 

software security, establishing operational protocols, and security systems and methods 

to deter external theft in the optical. 

Objective: By the end of this course, attendees will have become aware of the internal 

and external signals that can mean fraud and abuse are occurring in their medical practice 

or optical dispensary. They will have learned the steps to take to correctly handle the situation 

if fraud and abuse do occur, and how to set up policies, procedures, and protocols 

that will prevent fraud and abuse from happening in the optical dispensary and medical 

business practice. 

Senior Instructor(s): Pamela Fritz 

Instructor(s): Patrick Boys Smith 

NEW How to Benchmark for a Retina Practice 

Course: 566 

Tuesday 

Room: S501a 

12:45 - 1:45 PM 



Synopsis: This course reviews the reasons for benchmarking and the importance of participating 

in the benchmarking process for retina activities. Changes in practice patterns 

for retina specialists over the past 10 years have increased the need for measuring efficiency 

and create unique challenges for those trying to create benchmarking standards. 

Recommendations for common benchmarks to use and healthy ranges will be given. Case 

study examples will be provided. 

Objective: Upon completion, attendees will be able to (1) define benchmarking and understand 

how to use standards to set goals for their practices, (2) understand the evolution 

of retina practices, (3) have a working knowledge of market trends that will impact retina 

practices, (4) bring common benchmark ranges to their practices for comparison, and (5) 

use standard tools to create goals and action plans. 


Instructor(s): Andrew Maller MBA* 

NEW SO Three Areas of Succession Planning for Senior 

Physicians 

Course: 568 

Tuesday 

Room: S504bc 

12:45 - 3:00 PM 



Synopsis: This course will be a panel presentation by three experts who will look at succession 

planning from an attorney’s viewpoInt, an optical shop owner’s viewpoInt, and a 

practice management consultant’s viewpoint. Areas covered will include the exit strategy 

from a legal standpoInt, how the optical shop can impact the value of a practice and the 

sale (an optical shop should represent 30% of revenue for the practice). We will cover the 

various methodologies for determining value. We will look at the various exit strategy 

scenarios and what key documents will need to be in place. 

Objective: Attendees will have the opportunity to attend a panel presentation by three 

professionals who will discuss succession planning from different points of view. Attendees 

will learn what steps need to be taken and when. You will learn what documents will 

need to be developed. You will learn what the timelines are for succession. 


Instructor(s): Arthur L De Gennaro, Mark E Kropiewnicki JD LLM* 

NEW All I Want Is What’s Fair: Compensation Formulas for 

Shareholder Ophthalmologists 

Course: 584 

Tuesday 

Room: S501bc 

2:00 - 3:00 PM 



Synopsis: This course will explore the various models used to compensate shareholder/ 

partner ophthalmologists in private practice. We will go through the basic mechanics of 

each model and consider the pros and cons of each. Does a formula reward/incentivize 

work effort, rainmaking, management, and team orientation? Does it fairly allocate 

overhead? How will doctor production be measured? Does the model fairly accommodate 

multiple subspecialties within the same practice? Should there be separate corporations 

for optical or refractive surgery? Should there be a management fee for the doctor who 

handles administration? Should ASC dividends to the medical practice be handled specially? 

These and other concerns will be addressed. 

Objective: At the conclusion of this course, the attendee will be familiar with the most 

common shareholder compensation formulas used in private ophthalmic practices. They 

will become conversant with the benefits and drawbacks of each approach. They will have 

the basic building blocks to begin creating a compensation plan for their practice that is 

fair, reasonable, effective, and legal. 



NEW Yo Partnership Pitfalls: Preparing for the Unexpected 

Course: 588 

Tuesday 

Room: S503ab 

2:00 - 3:00 PM 



Synopsis: Are your corporate, partnership, or LLC agreements as thorough and comprehensive 

as they need to be? This course will highlight various issues and circumstances 

typically overlooked in a group practice’s co-ownership agreements, and will address how 

to effectively prepare for such situations before they occur. 

Objective: This course will help attendees assess whether their current partnership, 

corporate, or LLC arrangements are as comprehensive and effective as they ought to be 

and will equip them with valuable information to improve their co-ownership agreements. 

Senior Instructor(s): Robert J Landau JD 

Instructor(s): Robert A Wade JD 

SO Updating Your Partnership/Shareholder/Buy-Sell/New 

Employee Agreements 

Course: 589 

Tuesday 

Room: S501a 

2:00 - 3:00 PM 



Synopsis: How long has it been since your partnership or group practice reviewed your 

agreement to ensure it reflects current trends and issues in the medical environment? As 

consultants, we are frequently called in when a crisis occurs, for example sudden death, 

disability, or departure of a physician. The agreement the doctors signed many years ago 

may be vague, or it may contain outdated values (or none at all) for buy-ins/buy-outs. 

Key person insurance may be missing, income distribution formulas may be sowing seeds 

of discontent, or the group is suddenly faced with an untimely departure of a revenueproducing 

doctor and also a steep buy-out. 

Objective: At the conclusion of this course, physicians and administrators will have 

learned the elements that need to be included in partnership/shareholder/buy-sell agreements 

in this decade and will be able to identify issues and current trends, particularly the 

differences between junior/senior members, to ensure that the current agreement reflects 

what the partnership/shareholders intend. 

Senior Instructor(s): Debra L Phairas 






287





C J Making the Most With Modifiers 

Course: 210 

Sunday 

Room: S504d 

2:00 - 3:00 PM 



Synopsis: Understanding modifiers and their appropriate use impacts reimbursement 

significantly. This course will walk you through some common everyday scenarios to help 

you understand the concepts of modifiers and apply this understanding in your practice. 

Senior Instructor(s): Elizabeth D Cottle CPC OCS* 

NEW C J Coding and Reimbursement for Ophthalmic 

Diagnostic Testing 

Course: 244 

Sunday 

Room: S504bc 

3:15 - 5:30 PM 



Synopsis: Coding and billing for diagnostic testing is a major part of an ophthalmic practice 

in general, but more so in some of the subspecialties such as retina, cornea, and 

glaucoma. Many practices are not sufficiently aware of Medicare’s regulations that guide 

the reimbursement of these tests. This course will provide the details for each test identified 

in Current Procedural Terminology (CPT) with a Level 1 code or Category III code. The 

presentation will include documentation requirements, unilateral vs. bilateral payment, 

recognition of which tests can be billed together on the same day, diagnosis coverage, 

and supervision rules. 

Objective: Upon completion of this course, the participant should be able to (1) identify 

proper code selection for each test performed, (2) recognize documentation requirements, 

including what is meant by “interpretation and report,” (3) understand the impact of the 

Correct Coding Initiative, (4) learn that common sense doesn’t always equal a covered 

diagnosis, and (5) identify situations where an Advance Beneficiary Notice should be used. 

Senior Instructor(s): Kim M Ross OCS CPC 

Instructor(s): E Joy Woodke COE OCS*, Michell Miller-Ballard 

NEW C J Yo Surgery Billing Made Easy For All Specialties 

Course: 246 

Sunday 

Room: S501 

3:15 - 5:30 PM 



Synopsis: Most of the revenue generated by the ophthalmic practice is from surgery. Accurate 

surgery coding and understanding of the various rules is essential. 

Objective: Attendees will learn the various aspects of surgical coding and how to access 

correct tools to be reimbursed correctly. 


C J Coding Odyssey 

Course: 323 

Monday 

Room: S502b 

9:00 - 10:00 AM 



Synopsis: This session will cover important topics to help you prepare for what’s new in 

coding and documentation in 2013. Topics include (1) audit status from commercial and 

federal payers, (2) Physician Quality Reporting System (PQRS) and E-Prescribing, (3) costly 

coding errors, and (4) transition to ICD-10 what you should be doing now. 

Objective: Upon completion of this course, the participant should be able to (1) identify 

changes to CPT and the significant changes to ICD-9, (2) discover most common coding 

errors that result in poor audit outcome and loss of revenue, (3) understand the latest 

changes to PQRS and E-Prescribing, and the bonus and/or penalties associated with these 

programs, and (4) recognize ICD-10 implementation timelines. 

Senior Instructor(s): Sue J Vicchrilli COT OCS 

C J When to Use E&M and When to Use Eye Codes 

Course: 359 

Monday 

Room: S504bc 

10:15 AM - 12:30 PM 



Synopsis: End the confusion about when to use an E&M code and when to use an eye 

code for your office visits. This course will present typical patient encounters and proper 

code selection to assist the ophthalmic practice in appropriately maximizing reimbursement. 

A review of E&M and eye code documentation requirements will be presented. 

Prerequisite: Knowledge of E&M documentation guidelines, Current Procedural Terminology 

(CPT) eye code guidelines, and state Medicare eye code guidelines is recommended. 

Objective: Upon completion of this course, the participant should be able to (1) distinguish 

the differences between Medicare and non-Medicare payer rules, (2) develop a 

method of obtaining fee schedules for each payer, and (3) understand the financial impact 

of the appropriate selection of code. 


Instructor(s): E Joy Woodke COE OCS* 

NEW C J Comprehensive Cataract Coding 

Course: 428 

Monday 

Room: S501d 

3:15 - 5:30 PM 



Synopsis: What are visual acuity requirements (if any)? What makes the surgery complex? 

Is the postop complication separately billable even when performed in my office? 

What is the impact of CCI edits on combined cataract, retina, cornea, and/or glaucoma 

cases? End the confusion about pre-, intra-, and postoperative care for the number 1 surgery 

performed in the United States. 

Objective: Upon completion of this course, the participant should be able to (1) distinguish 

between Medicare and non-Medicare payer documentation rules prior to surgery, 

(2) understand what makes the surgery complex , (3) code correctly for combined cataract, 

retina, cornea, and/or glaucoma cases, and (4) recognize which complications are separately 

billable and which are considered postop. 


NEW J CodeFest 

Course: 518 

Tuesday 

Room: S503ab 

9:00 - 11:15 AM 



Synopsis: Join your physician, technician, administrator, billers and coder colleagues in 

the first ever live coding challenge. Two teams will compete not only with each other but 

with the audience through an automated response system. In game format, two teams 

of four people will be selected: a physician, an administrator, a technician and a biller/ 

coder. The moderator will present the pre-written coding questions with multiple answer 

options. Through an automated response system, audience members can play against the 

two teams. 

Objective: Upon completion of this course, the participant should be able to (1) Determine 

the appropriate level of history, exam, and medical decision making for exams, (2) Identify 

the correct modifier in exam, tests, and surgical cases ophthalmology practices face daily. 


J Ophthalmic Coding Specialist (OCS) Exam Preparation 

Course: 526 

Tuesday 

Room: S504a 

10:15 - 11:15 AM 



Synopsis: Demonstrate your coding competency by passing the Ophthalmic Coding Specialist 

exam. This one-hour course will prepare physicians, technicians, administrators, 

and billers to test in 18 content areas of ophthalmic coding. The OCS exam is an openbook, 

100 question, multiple choice, online exam. Everyone in the office who is involved in 

chart documentation and claim submission should demonstrate their coding competency. 

This is the best way to learn and subsequently appropriately code for proper reimbursement. 

Senior Instructor(s): Kim M Ross OCS CPC 

288 





NEW C J Steps for Successful Retina Coding 

Course: 564 

Tuesday 

Room: S504a 

11:30 AM - 1:45 PM 



Synopsis: The revenue cycle of the retina practice can be quite complex. Multiple factors 

impact a successful practice. This course will teach attendees what impacts their reimbursement 

the most and how to apply tools in their own practices for success. 


Compliance and Risk Management 

SO MD/OD Relationships: Business and Compliance Concerns 

Course: 211 

Sunday 

Room: S503ab 

2:00 - 3:00 PM 



Synopsis: Ophthalmologists and optometrists will work together. The only question is 

“how?” Will they be independent and refer patients to one another? Will there be comanagement? 

Will one employ the other? Can an OD employ an MD? Will they be “partners”? 

Can they be partners? Each kind of relationship has its benefits and pitfalls. In an 

enforcement environment where the government, and your employees, are incentivized to 

catch you unawares, it makes sense to know the perils as well as the rewards of structuring 

MD/OD relationships properly. 

Objective: Participants will learn the variety of ways MDs and ODs can legally structure 

their relationships, how to structure compensation, and what the compliance (and other) 

risks are. 


Instructor(s): Robert J Landau JD 

A Physician’s Guide to Avoiding Embezzlement 

Course: 258 

Sunday 

Room: S502b 

4:30 - 5:30 PM 



Synopsis: It has been estimated that one in six doctors will experience embezzlement at 

some time during their practice years. A busy doctor is an easy target for embezzlement, 

and in a down economy, a doctor may be even more at risk. The importance of education, 

credit checks, and drug screening will be covered, as well as practice policies and procedures 

implementation. Savvy embezzlers can fool even the most experienced employers, 

so learn how to protect yourself. Real-life case examples will be discussed. 

Objective: At the conclusion of this course, physicians will have learned how to protect 

their practices from employee embezzlement by instituting accounting controls and effective 

screening and management techniques. 


NEW Defending the Small Practice Ophthalmologist in a 

Medical Malpractice Lawsuit 

Course: 324 

Monday 

Room: S504d 

9:00 - 10:00 AM 



Synopsis: This course will provide an overview of medical malpractice cases specific to 

ophthalmology. Topics include malpractice litigation statistics and terms important to an 

understanding of malpractice, a review of the malpractice lawsuit process, and common 

theories of liability against ophthalmologists. Informed consent, the role of the expert witness, 

and the importance of preparation will be highlighted. 

Objective: The current medical malpractice crisis presents ever-increasing challenges to 

the ophthalmologist. At the conclusion of this course, the physician will be both educated 

in and presented with effective approaches to minimize liability and maximize an effective 

defense. 

Senior Instructor(s): Kenneth R Larywon JD 

Instructor(s): Thomas A Mobilia JD, Robert Ritch MD FACS* 

NEW Health Care Fraud and Abuse Boot Camp: The Basics, Plus 

More 

Course: 357 

Monday 

Room: S504a 

10:15 AM - 12:30 PM 



Synopsis: The health care industry is heavily regulated by complex federal and state regulations 

that limit what providers can do in business and in payment arrangements. These 

rules are highly technical and are being enforced with increased vigor and little forgiveness 

for even inadvertent mistakes. This course focuses on three leading federal authorities: 

the Medicare and Medicaid Anti-Kickback Statute, the Stark Law (including Stark I, II, 

and III), and the False Claims Act. In addition, this course will highlight the changes in the 

fraud and abuse laws since Health Reform and provide an overview of recent government 

enforcement activities. The course will conclude with a discussion on structuring an effective 

compliance program and structuring compliant health-care transactions. 

Objective: Participants will leave the course with an understanding of the fraud and 

abuse laws, including similarities and differences among the laws. They will learn about 

recent trends in government enforcement activity since Health Reform, and participants 

will leave the course knowing how to structure compliance initiatives and programs effectively. 


Instructor(s): Nathaniel C Guest** 

NEW Social Networking: Balancing Risks and Rewards 

Course: 401 

Monday 

Room: S504bc 

2:00 - 4:15 PM 



Synopsis: This course will discuss the risks and rewards associated with social networking 

as it relates to the health care regulatory environment. Attendees will learn how to 

balance the delicate risks and rewards of patient confidentiality and HIPAA regulations, 

staff operational procedures, malpractice insurance, measuring and comparing return on 

investment for social media compared to traditional Web marketing, and more. 

Objective: This course is designed to enable participants to understand social networking 

and the associated risks and rewards. 

Senior Instructor(s): David Swink* 

H Compliance FAQs and NSFAQs (Not So Frequently Asked 

Questions) 

Course: 427 

Monday 

Room: S502a 

3:15 - 5:30 PM 



Synopsis: Government efforts to get money back from providers (or even avoid paying it 

out) is a good way to close budget gaps. Recently loosened rules concerning what constitutes 

a false claim, who can bring whistleblower actions, and knowledge requirements for 

liability, plus even more aggressive data mining before payments are made, should make 

compliance a huge concern for all practices. This course will review the basic areas of 

concern, highlight recent changes in the law, and hone in on how to avoid getting caught 

in the crosshairs of an investigation and what to do if investigated. 

Objective: Participants will leave this course knowing the basic areas of concern with 

regard to compliance, how recent changes in the law increase the need for stepped-up 

compliance efforts, and strategies to employ to stay out of trouble. 


Instructor(s): Brenda Laigaie JD 

NEW Yo Mitigating Legal Risks: Social Media and the Doctor’s 

Dilemma 

Course: 525 

Tuesday 

Room: S501d 

10:15 - 11:15 AM 



Synopsis: Physicians need to know how to promote themselves while also maintaining 

their professionalism and adhering to the ethics rules pertaining to confidentiality, privacy, 

and advertising. This course will discuss social media and specific ways in which it relates 

to physicians and poses risks to them. Areas of potential liability include whether a social 






289




media interaction establishes a physician-patient relationship and thereby potential abandonment, 

unlicensed practice of medicine (if the physician is not licensed in the patient’s 

state), and medical malpractice. Specific safeguards will be discussed to mitigate any 

potential liabilities. 

Senior Instructor(s): Amy Wong* 


NEW H E Anatomy of an EHR Contract: Understanding and 

Negotiating the Best Terms 

Course: 208 

Sunday 

Room: S502a 

2:00 - 3:00 PM 



Synopsis: Migration to electronic health records (EHR) means entering into a long-term 

business relationship with an EHR vendor. The legal document intended to govern that 

relationship, however, is typically long, highly technical, and drafted with the vendor’s 

interests in mind. It is therefore crucial that physicians and their administrators be able to 

understand EHR contract language and negotiate the best possible terms. 

Objective: At the conclusion of this course, attendees will have an understanding of typical 

EHR contract provisions, common pitfalls, and how best to negotiate more favorable 

terms. 


Instructor(s): Jeffrey Daigrepont 

NEW E Electronic Health Records Implementation: Overcoming 

Resistance to Change 


and the AAO Medical Information Technology Committee and AAOE EHR 

Subcommittee 

Course: 213 

Sunday 

Room: S504bc 

2:00 - 3:00 PM 



Synopsis: Several barriers to the adoption of electronic health records (EHRs) exist. The 

resistance to change from those who will use the EHR system is one obstacle facing ophthalmic 

practices during transition periods. In addition, the opposition often arises from 

those with various perspectives and roles. In reviewing the process of change and recognizing 

the factors that contribute to resistance, leaders can develop tools to manage and 

minimize this potential barrier. This course will review how personnel from various generations 

may respond to change, and how their technological preferences may contribute to 

your successful transition. The instructors are ophthalmologists and an administrator with 

personal experience in change management during an EHR implementation. 

Objective: At the conclusion of this course, the attendee will (1) be able to recognize common 

difficulties associated with EHR implementation and related to resistance to change, 

(2) understand some effective change management techniques, (3) recognize phases of 

change and their effect on personnel, and (4) appreciate generation-specific skills and 

perspectives and how they impact and can be beneficial to transition. 

Senior Instructor(s): E Joy Woodke COE OCS* 

Instructor(s): Michele C Lim MD, Colin McCannel MD* 

NEW E EHR and Medical Professional Liability Risk 

Course: 260 

Sunday 

Room: S504a 

4:30 - 5:30 PM 



Synopsis: The transition to electronic health records (EHR) exposes ophthalmology practices 

to more medical professional liability (MPL) risks due to a number of product, implementation, 

and usage issues. Providers must be aware of the MPL risk issues associated 

with the use of EHRs, as well as be prepared to develop and use risk mitigation strategies, 

including the following: (1) discuss the role of selection, implementation, and use on MPL 

risk, (2) examine EHR design issues that create or control risk, (3) review controllable risk 

issues and mitigation strategies, and (4) present strategies to influence EHR use and mitigate 

MPL risk. 

Objective: What you will learn in this course: (1) EHR product factors and MPL risk, (2) 

key MPL risk issues associated with EHRs, and (3) MPL risk assessment strategies related 

to EHR use. 

Senior Instructor(s): Ronald Barry Sterling* 

NEW E Successfully Evaluating Practice Management Systems 

Course: 327 

Monday 

Room: S504a 

9:00 - 10:00 AM 



Synopsis: Attendees will understand the necessary steps that are vital to any group 

evaluating practice management systems. 

Objective: At the conclusion of this course, attendees will be able to assess current office 

efficiencies as well as improve office efficiencies, understand how to look at clinical, 

administrative, and business functions that are required to run a successful practice, 

streamline these functions using a practice management system, review necessary reporting 

measures and comprehend what exactly they need a practice management system 

to provide from a reporting perspective, decipher the “bells and whistles” of a practice 

management system and understand the basic product they are purchasing, and understand 

the importance of looking ahead to integrating an EHR with a practice management 

system. Check lists will be provided at the conclusion of course to use when evaluating 

practice management systems. 

Senior Instructor(s): Kimberly C Costello 

E Analyzing and Maximizing Return on Investment for Electronic 

Health Records 

Course: 370 

Monday 

Room: S503ab 

11:30 AM - 12:30 PM 



Synopsis: As with any major expenditure, a return on investment (ROI) analysis should 

be performed before an electronic health records (EHR) system is purchased. In the first 

hour, a workshop will introduce participants to the basic concepts necessary to evaluate a 

ROI for any large expenditure project in an ophthalmology practice. In the second hour, the 

speakers will apply these concepts to a case study showing the actual results for the first 

five years of their own practice, emphasizing factors that contributed both positively and 

negatively to the ROI for EHR. Tips for maximizing and realistically forecasting an organization’s 

ROI for EHR will be discussed. 

Objective: At the conclusion of this course, the participants will have an understanding 

of the information required to conduct a ROI analysis prior to the purchase of EHR and to 

follow the results after the system is implemented. The participants will be able to state 

the benefits and limitations of such an analysis, understand the key factors that will enable 

maximization of ROI in their own organizations, and be provided a spreadsheet for their 

use. While the course uses the specific example of ROI for EHR, participants will be able 

to utilize this information when considering any major expenditure. 


Instructor(s): Denise C Fridl COT COE, Susie Winterling 

E Electronic Health Record Conversion Challenges: Device 

Interfaces, Existing Paper Charts, Transition Workflow, and More 

Course: 393 

Monday 

Room: S503ab 

2:00 - 3:00 PM 



Synopsis: Migration to electronic health records (EHR) requires careful thought and planning 

by physician practices. Given the complexities involved, this course focuses on those 

aspects of EHR conversion that may be particularly challenging, such as ophthalmic device 

interfaces, managing existing paper charts, and the transitional workflow necessary to 

handle the paper-chart-to-EHR limbo. Both small and large practice considerations will 

be addressed. 

Objective: At the conclusion of this course, attendees will have an understanding of 

potential trouble spots in the EHR conversion process and have practical options for addressing 

those challenges. 


Instructor(s): E Joy Woodke COE OCS* 

290 





E Electronic Health Record Search and Negotiation: Keys to 

Finding the Right EHR for the Right Price With the Right Terms 

Course: 406 

Monday 

Room: S502b 

3:15 - 4:15 PM 



Synopsis: This course will present critical guidance for physicians and administrators in 

the search and negotiation phases of the electronic health record (EHR) adoption process. 

Topics will include what makes the right fit between a practice, an EHR, and a vendor. 

Objective: This course is designed to help participants develop an understanding and 

knowledge of how to choose the right EHR and ensure that the necessary elements are 

present in agreements made between practice and vendor. 

Senior Instructor(s): Jeffrey Daigrepont 

NEW E How to Avoid an EHR Failure 

Course: 442 

Monday 

Room: S504a 

4:30 - 5:30 PM 



Synopsis: Buying and implementing an electronic health record (EHR) system is one of 

the biggest decisions a practice will ever make. Depending on the qualifications of the 

vendor and the methods of implementing the system, EHR system can have both positive 

and negative impact on the operations of a practice. Not all failures are caused by 

vendors, however. Some practices find it extremely difficult to implement change; others 

just have buyer’s remorse and regret their decision to purchase an EHR system. It can also 

be difficult to adjust to an EHR when the system does not meet the unique needs and 

requirements of an ophthalmology practice. This session will address vital topics such as 

the most common reasons to seek replacement; taking ownership of the problem without 

placing fault; assessing the process or product; cost, reselection, data migration, and process 

design/optimization; and the cost of indecision. 

Objective: By the conclusion of this course, participants will be able to (1) understand the 

current landscape for EHR adoption/replacement, (2) discover why EHR implementations 

typically fail, (3) determine whether to replace their EHR, (4) learn the steps for moving 

forward, (5) hear EHR replacement and/or optimization benefits, and (6) discern how to 

prevent future failures. 

Senior Instructor(s): Jeffrey Daigrepont 

NEW E Implementing Electronic Health Records Into an 

Ambulatory Surgery Center 


and the AAO Medical Information Technology Committee and AAOE EHR 

Subcommittee 

Course: 507 

Tuesday 

Room: S501bc 

9:00 - 10:00 AM 



Synopsis: The evolution of the electronic health record (EHR) continues to evolve, and the 

adoption of EHR in an ambulatory surgery center (ASC) is an opportunity for improvement 

for those looking to capitalize on the quality and efficiency gained with electronic documentation. 

Despite unique challenges, many ASCs have successfully implemented EHRs. 

This course will present firsthand case studies from the perspective of an ophthalmic 

surgeon, a registered nurse, and practice administrators who use different EHR systems. 

Objective: At the conclusion of this course, the attendee will (1) recognize electronic solutions 

for ASC processes, (2) discover alternative methods for implementing EHRs into an 

ASC, (3) identify key planning techniques for conversion, including workflow changes and 

training and hardware considerations, (4) review advantages to electronic documentation 

in an ASC, and (5) gain perspective from various ASC personnel using EHRs. 

Senior Instructor(s): E Joy Woodke COE OCS* 

Instructor(s): Michele C Lim MD, Susie Winterling 

Human Resources 

NEW How to Teach Your Staff to Get Along With Each Other 

Course: 227 

Sunday 

Room: S504a 

3:15 - 4:15 PM 



Synopsis: This course is designed to teach administrators and doctors a straightforward 

method that they can use to help employees improve relationships with their peers within 

the office. The concepts of the adult, parent, and child states of mind will be explained 

and applied to ophthalmic practice situations. Techniques for responding to peers in an 

appropriate mindset will be taught as a way of reducing contention between employees 

so that productivity and morale are enhanced. 

Objective: At the end of this course, attendees will be able to train their staff members to 

recognize their approach with their co-workers and to maintain adult-to-adult relationships 

so that unnecessary office conflict is eliminated. 

Senior Instructor(s): Derek A Preece MBA* 

Human Resources and Your Practice: A Consultant’s Guide to 

Improved Performance 

Course: 325 

Monday 

Room: S504bc 

9:00 - 10:00 AM 



Synopsis: Nearly everyone agrees that human resources are the most important asset 

a practice possesses. Yet many practices do not have a rational human resource plan 

that can deliver consistent, excellent patient care and financial performance. This course 

presents a consultant’s view of an HR program. It focuses on hiring right, training right, and 

managing for performance. Practical solutions are emphasized throughout. 

Objective: At the completion of this course, the attendee will be able to (1) outline Art’s 

HR formula for success, (2) detail the eight major points of the HR process, (3) set work 

standards, (4) recruit and hire the “right” people, (5) train, train, train, (6) measure and drive 

for performance, (7) evaluate, (8) compensate, (9) discipline or replace, and (10) repeat, 

repeat, repeat. 

Senior Instructor(s): Arthur L De Gennaro 

H Do I Look Like Your Mother?! Or, How to Manage the Difficult 

Employee 

Course: 356 

Monday 

Room: S502b 

10:15 AM - 12:30 PM 



Synopsis: The course is a humorous guide to dealing with noncompliant, subversive, or 

passive-aggressive employees, emphasizing the importance of a strong and clear employee 

manual as well as a policy and procedure manual. 

Objective: The attendee should be able to leave the course with a list of tools and strategies 

to better address the problems of managing difficult employees. They should be able 

to set limits and clearly defined rules and codes of conduct for their practices, giving them 

more confidence in their own authority. Highlights will include addressing the “pot stirrers,” 

passive-aggressive employees, the “skaters” around the edge of compliance, and 

the unique challenge of “inherited” employees. We will emphasize the importance of clear 

and complete documentation, knowledge of relevant state labor laws, having a complete 

employee manual reviewed by an attorney, as well as current policy and procedure manuals 

and job descriptions and understanding the difference between them. 

Senior Instructor(s): Nancy Baker 

Instructor(s): Elise Levine MA CRC OCS*, Nancy L LaVergne OCS CPC 

H Employment Law Basics for the Small Ophthalmology Practice 

Course: 371 

Monday 

Room: S501a 

11:30 AM - 12:30 PM 



Synopsis: Large practices often have access to expertise on human resources issues that 

small practices may not. However, being a small practice or solo practitioner, with fewer 

than 30-35 employees, does not exempt you from employment laws. Because of their fiscal 

restraints, small practices will often simply adopt, without modification, policies and 

procedures that don’t make sense given their size. Using a simple employee manual as 






291




a guide, this course will identify the most common employment law issues facing small 

practices today and clarify how to minimize exposure in areas like employment discrimination, 

wage and hour violations (especially overtime), paid time off, drug and alcohol use, 

confidentiality, privacy, and e-mail, Internet, and social media use. 

Objective: Participants will learn the issues they face as employers, the laws governing 

those issues, and as a result, what kinds of provisions they should (or shouldn’t) put into 

their employee manuals. 


Instructor(s): Jill S Garabedian JD, Brenda Laigaie JD 

NEW Forecasting Staffing Needs: A Volume-Based Model 

Course: 394 

Monday 

Room: S504d 

2:00 - 3:00 PM 



Synopsis: This course introduces a tool to help owners and managers answer one of 

the most common questions: “Do I have the right number of staff members?” The course 

provides an overview of industry staffing benchmarks and the pros and cons of that information. 

It discusses the importance of time and flow studies to help improve operational 

efficiency and to predict staffing needs. After giving background on the development of 

the Microsoft Excel Workbook, the tool will be reviewed using a case study. All attendees 

of the course will receive a copy of the Microsoft Excel Workbook to use in their own 

practices. 

Objective: Upon completion of this course attendees will be able to (1) understand the 

challenges of predicting staffing needs, (2) develop measures and benchmarks that are 

customized to their practices, (3) create a quantitative formula for predicting staff needs, 

(4) forecast when to add staff count according to volume/demand. 


NEW Social Media and the Workplace: Legal, Ethical, and 

Practical Issues Every Employer Should Consider 

Course: 397 

Monday 

Room: S501a 

2:00 - 3:00 PM 



Synopsis: This course will delve into the legal implications of social media as it relates to 

the employer/employee relationship. Employment practices and policies will be examined 

to incorporate recent precedent-setting cases. Topics include adverse employment decisions 

and the intersection of federal and state laws as they relate to social media. 

Senior Instructor(s): Amy Wong* 

NEW SO Employee Physician Contract Review 

Course: 441 

Monday 

Room: S502b 

4:30 - 5:30 PM 



Synopsis: Attendees will understand proper contract parameters. We will cover the various 

financial models for when to hire a physician. We will look at incentive programs. This 

course will show attendees the critical items needed in an employment contract. 

Objective: This course is designed (1) to give attendees knowledge of the critical items 

in an employment agreement, (2) to help attendees understand how to negotiate if the 

contract is not in their favor, (3) to help attendees make sure their contract is both employee- 

and employer-friendly, and (4) to teach attendees how to make sure employee and 

employer are both protected. 


NEW H Managing Up! 

Course: 504 

Tuesday 

Room: S501a 

9:00 - 10:00 AM 



Synopsis: Managers in middle management positions need to successfully learn to supervise 

staff, or “manage down,” and to achieve results by successfully presenting recommendations 

to their physician bosses by “managing up.” 

Objective: At the conclusion of this course, managers will have a better working relationship 

with their physicians based on clear expectations and agreed upon, defined goals and 

performance measurements. 


Smile ... Even If It Kills You: Training for Excellent Customer 

Service 

Course: 528 

Tuesday 

Room: S501bc 

10:15 - 11:15 AM 



Synopsis: This course is geared toward training the entire staff for five-star, excellent 

customer service with a goal of creating a good work environment, a happy customer base, 

and a busy, healthy practice. 

Objective: This course is designed to help participants to identify the strengths and 

weaknesses existing in their practices as well as ways to change a problematic culture. 

Attendees will also be able to identify a practice’s mission statement and learn how the 

entire team can improve by changing a few common yet undermining attitudes and habits. 

Senior Instructor(s): Nancy Baker 


NEW Leveraging Relationships for Savings and Effectiveness in 

Technology 

Course: 559 

Tuesday 

Room: S501a 

11:30 AM - 12:30 PM 



Synopsis: The two largest private ophthalmology practices in Michigan have worked together 

on projects over many years. Faced with the daunting prospect of implementing 

new information technology (practice management/electronic health records) and the associated 

costs, they jointly investigated software and negotiated a contract with Nextgen. 

They established a joint central system of redundant servers and jointly employed an IT 

manager, server administrator, and project coordinator. This project demonstrates ways 

in which medical groups can work effectively with like-minded organizations for mutual 

benefit. Doing so helped both practices to manage and share costs. Systems for both are 

enhanced as each benefits from the experiences of the other. 

Objective: By the conclusion of this course, attendees will be able to (1) apply a model 

of joint venturing to technology projects, which will help to control overhead and increase 

effectiveness, (2) understand ways in which key organizational personnel (doctors and 

administrators) can facilitate relationships between practices, and (3) understand the key 

factors allowing the establishment of a central computer processing system for use by 

multiple practices. 

Senior Instructor(s): Robert Wolford 

Instructor(s): Charles Dobis, Janet Lander MBA 

NEW Customizing Patient Education Using a Patient Portal 

Course: 560 

Tuesday 

Room: S504d 

11:30 AM - 12:30 PM 



Synopsis: Getting patient education right is critical to clinical outcomes as well as sales 

and marketing. A patient portal can facilitate systematically getting patient-specific material 

delivered at a time when patients are paying attention. 

Objective: In this presentation, I will review why patient educational efforts often fail. 

There are too many competing demands on today’s patient’s attention. Success requires 

presenting material specific to their condition, delivered when they are paying attention. 

I will discuss a new paradigm for patient portal driven education. Participants will learn 

how a portal can mine information from the practice’s data systems to match each patient 

with the most appropriate educational material and then deliver it prior to the patient’s 

encounter, when these issues are top of mind and the patient is more receptive. Lastly, 

by performing all of this electronically, execution can be maximized and measured. At 

the conclusion, participants will have a better understanding of how this mass customized 

approach to education can improve clinical outcomes as well as sales and marketing 

initiatives. 

Senior Instructor(s): Paul Christian Seel MD MBA* 

292 





NEW Essential Search Engine Optimization Tools for Your 

Website 

Course: 585 

Tuesday 

Room: S502b 

2:00 - 3:00 PM 



Synopsis: Three essential search engine optimization (SEO) tools for every website are 

a website sitemap, analytics, and Google Webmaster Tools. After starting your website, 

these three simple tools will help ensure that your website gets indexed and ranked! To 

market your website effectively, these basic SEO tools are essential to your online marketing 

presence. 

Objective: At the conclusion of this course, the attendee will be able to create a sitemap, 

install and access Google analytics, and index a website via Webmaster tools. The attendee 

will be able to understand how a sitemap allows a website to be indexed, how analytics 

improves content marketing, and how to register (index) a site on Webmaster Tools. 

Senior Instructor(s): Randall V Wong MD* 

Instructor(s): Amy Wong* 

Marketing & Business Develop 

NEW Marketing to Reach the Audience You Want! 

Course: 228 

Sunday 

Room: S502b 

3:15 - 4:15 PM 



Synopsis: Attendees will learn how to effectively market their practices to make them 

stand out from the rest. We will discuss the various methods of marketing. We will talk 

about being the “purple cow” and how to differentiate yourself from the crowd. We will 

discuss the importance of surveying your patients to make sure you are fulfilling your patients’ 

needs. 

Objective: This course will provide participants with tips to (1) market yourself in a competitive 

environment today, (2) to make yourself stand out from the competition, (3) to 

make the most out of your marketing dollars, and (4) to be the “purple cow” and be the 

best practice out there. 


NEW Dissection of a Successful Web Design 

Course: 335 

Monday 

Room: S503ab 

9:00 - 11:15 AM 



Synopsis: This interactive course will provide attendees with a hands-on opportunity to 

learn the key differences that make a website design successful. Attendees will learn 

how to evaluate the HTML code for search engine optimization (SEO) elements, use a 

content management tool to update and maintain a site, apply basic photo editing, perform 

domain name research and registration, use Google for competitive research, evaluate 

traffic, and more. This basic course will discuss upcoming technologies that will change 

website design. 

Objective: By the completion of this course, attendees will understand the basic technical 

components of a successful website and how to evaluate a successful site design 

versus a poorly implemented site. 

Senior Instructor(s): David Swink* 

Content Marketing: Getting Your Web Page Ranked 

Course: 355 

Monday 

Room: S501d 

10:15 AM - 12:30 PM 



Synopsis: The only way to achieve, and maintain, high rankings for your Web page is 

to use the strategy of content marketing. Using search engine optimization (SEO) techniques, 

the content of your website will boost your SERP rankings. Social media, e-mail 

campaigns, banner ads, Adsense/Adwords are not sustainable methods and are of little 

use to your medical practice. 

Objective: At the conclusion of this course, the attendee will be able to understand the 

concepts behind blogging, SEO, and content marketing and their unique ability to achieve 

high Web page rankings. 



NEW Building Patient Loyalty: How to Over-Deliver Service 

Course: 405 

Monday 

Room: S501a 

3:15 - 4:15 PM 



Synopsis: In today’s competitive environment, it simply isn’t enough to meet the expectations 

of patients. You have to exceed expectations. The goal of this workshop is to learn 

how to create a patient for life! 

Objective: Those taking this course will better understand their role in patient retention 

and practice growth. Proactive problem solving and the cultivation of customer relationships 

will be addressed in detail. 

Senior Instructor(s): Mary E Schmidt 

NEW Yo Website 101: Three Steps to Creating Your First 

Website 

Course: 565 

Tuesday 

Room: S502a 

11:30 AM - 1:45 PM 



Synopsis: While creating a website may seem an overwhelming task for the first-timer, 

this course will simplify the process of choosing a URL (domain name), hosting, and choosing 

software. Creating and hosting your own website can be simple, inexpensive, and fun, 

and it is a great way to market yourself, or your practice, build relationships with your 

patients, attract new patients, and provide patient education. 

Objective: At the conclusion of the course, attendees will be able to choose a domain 

name and hosting service and prepare to launch their first website. The attendee will also 

learn to avoid the most common mistakes made by the first-timer. 



Optical Dispensing 

Medicare Postoperative Cataract Eyewear: Coding, Billing, and 

Supplier Compliance 

Course: 336 

Monday 

Room: S501a 

9:00 - 11:15 AM 



Synopsis: Medicare post-cataract eyewear durable medical equipment (DME) suppliers 

are faced with constant changes. The instructor, who serves on the Provider Outreach 

and Education Advisory Committees of three Centers for Medicare and Medicaid Services 

DME contractors, can provide up-to-date answers for suppliers. Areas covered in this 

course include Supplier Enrollment, Provider Enrollment, Chain and Ownership System 

(PECOS) updates, surety bonds, electronic funds transfer, Par Provider Agreement, Provider 

Transaction Access Number (PTAN) and National Provider Identifier (NPI) compliance, V 

codes, required patient documentation (ABN, etc.), modifiers, and re-enrollment or reactivation 

forms and processes. Common Electronic Data Interchange (CEDI) processing tips 

will be included. An exercise includes tips on filling out the 1500 form. This is a thorough 

course for every DME supplier. 

Objective: Attendees will learn how to code and file for Medicare postop eyewear. They 

will be informed on how to make their practice DME Medicare compliant. They will learn 

the correct patient paperwork and record keeping and how to work with CEDI and electronic 

filing. Participants will be better able to ensure patient satisfaction, Medicare DME 

compliancy, and proper billing, coding, and reimbursement to the practice. 

Senior Instructor(s): Pamela Fritz 






293




NEW How to Create an Effective Dispensary Website Tab That 

Gets Results 

Course: 372 

Monday 

Room: S501bc 

11:30 AM - 12:30 PM 



Synopsis: Most ophthalmology websites devote woefully little space to their optical 

dispensaries, yet those dispensaries will generate about 30% of practice revenues. By 

contrast, the nation’s largest optical retailers devote as many as 40 website pages to eyeglass 

and contact lens issues. This course looks at the Web pages that every dispensing 

ophthalmology practice should consider adding to their website and discusses why most 

ophthalmology practices should consider building them. 

Objective: At the end of this course, the attendee will be able to (1) describe why their 

dispensing ophthalmology practice should have a robust optical dispensary tab and a comprehensive 

series of pages devoted to dispensing, (2) name the most important pages the 

practice should consider having on its website, and (3) describe why adding the recommended 

pages will encourage dispensary sales and increase dispensary customer satisfaction. 


NEW Creating an Effective Lens Selection and Pricing System 

Course: 392 

Monday 

Room: S501bc 

2:00 - 3:00 PM 



Synopsis: Besides frames, optical dispensaries provide lenses for their patients. In order 

to be successful it is necessary to offer a wide selection of lens styles and materials. Recent 

developments in the optical marketplace have made this process more difficult. Some 

practices have struggled. In addition, creating an effective pricing strategy has become 

more difficult, as the standard markup model is no longer practical. This course will help. 

Objective: At the completion of this course, the attendee will be able to (1) identify the 

major lens style and material groups, (2) know how and why to create a “good, better, 

best” lens selection, (3) describe why the standard markup model is no longer effective, 

and (4) know how to use a gross profit model to arrive at everyday retail prices. 


NEW SO Optical Shops: Sales Strategies for Today’s Economy 

Course: 519 

Tuesday 

Room: S504bc 

9:00 - 11:15 AM 



Synopsis: Today’s consumers have more information at their disposal than ever before. 

The purchasing options for prescription eyewear are limitless and include the doctor’s 

office, the mall, discount and wholesale chains, and now the Internet. Because of ubiquitous 

advertising from retail chains, private optical offices frequently must overcome 

preconceived opinions about price, quality, and service. Advertisements promoting deep 

discounts are intensifying the perception that the private optical is more expensive. The 

sales training, techniques, and strategies pervasive in the private sector have not been updated 

in decades, nor have they been modified to meet today’s current economic climate. 

This course will review sales strategies and techniques designed to entice and encourage 

patients to purchase from the private optical office. 

Objective: This course will enable participants to initiate new sales techniques designed 

to uncover the patient’s top priorities, establish low-cost package options as an added 

offering, and implement internal marketing strategies to promote the optical business. 

Senior Instructor(s): Carolyn Salvato* 


NEW AAOE Book Club: Professional Growth and Development 

Course: 391 

Monday 

Room: S502a 

2:00 - 3:00 PM 



Synopsis: As a practice administrator or ophthalmologist, it is easy to get caught up in 

the day-to-day tasks of running a practice. Often not enough time is given to personal and 

professional development. One way to nurture our own development is through reading, 

but many busy professionals lack the time to sort through or read the business literature 

like The Seven Habits of Highly Successful People, Good to Great, and other books of this 

type. But help is on the way! In this course, a panel of six speakers who are leaders across 

the spectrum of the field of ophthalmology will summarize the key points of books that will 

help participants grow their organizations or careers. Commitments have been obtained 

from two ophthalmologists, two practice administrators, a practice management consultant, 

and a CEO of an ophthalmology-allied organization, each of whom has been a leader 

and actively involved with the Academy/American Academy of Ophthalmic Executives, to 

participate on the discussion panel. 

Objective: At the conclusion of this course, the participant will have actionable ideas 

from top business books that can be applied to his or her professional development. 


NEW How to Develop a Successful In-House Technician Training 

Program 

Course: 395 

Monday 

Room: S502b 

2:00 - 3:00 PM 



Synopsis: With a decrease in the number of formal ophthalmic training programs, it is 

more important than ever that technicians receive standardized in-house training. This 

course is designed to present an overview of how to develop and run an in-house training 

program for technicians to increase their efficiency and knowledge. We will discuss skill 

testing to designate various levels of technical staff, as well as ways to improve office flow 

using doctor-specific, complaint-specific protocols to produce complete workups. 

Objective: At the conclusion of this course the participants should have an understanding 

and many ideas and suggestions for what is needed to develop a technical staff training 

program. 

Senior Instructor(s): Sharon Brown 

Instructor(s): Lisa Miller 

H Peer-to-Peer Problem Solving 

Course: 429 

Monday 

Room: S504d 

3:15 - 5:30 PM 



Synopsis: This is an interactive workshop to brainstorm, discuss, pose questions, and 

make connections with your peers. This discussion will be lead by a panel of highly experienced 

administrators who have found solutions for many of the issues involved in practice 

management, including those in human resources, business and finance operations, etc. 

Most importantly, this course will provide an opportunity for you to network with your 

peers and learn from them. 

Objective: Participants will have an opportunity to bring individual problems to the table, 

to learn from peers about how they solved problems that maybe relevant to them, and to 

build a network of resources that they can rely on throughout the year. 

Senior Instructor(s): Traci Fritz COE OCS 

Instructor(s): Elise Levine MA CRC OCS*, Nancy Baker 

NEW Leading Change: Theory to Practice 

Course: 524 

Tuesday 

Room: S502a 

10:15 - 11:15 AM 



Synopsis: As the saying goes, change is the only constant. As leaders, we promote it, 

deal with it, fight it, live it. Ever feel like you are drowning in constant change? If you are 

you implementing an EMR, creating a call center, changing your scheduling system, or 

hiring new staff or doctors, you are likely leading a change process. Whether it was your 

idea or you are implementing someone else’s idea, it’s a process that can be very emotional 

and personal and one you will be asked to make happen successfully. By practicing 

to define change management plans, we can improve our effectiveness by communicating 

the stages and tactics of a change process successfully using theoretical concepts in 

case study application. This course is designed to allow participants to dive into theory of 

change leadership and management in action. 

Objective: At the conclusion of this course, the attendee with have experienced the application 

of change theory to health-care management practice and further developed their 

change leadership skills, which will translate into their day-to-day work with the changes 

in our health-care environment. 

Senior Instructor(s): Danielle Johnson 

294 





NEW Yo Starting Out on the Right Financial Foot: A Guide for 

Young Ophthalmologists 

Course: 567 

Tuesday 

Room: S502b 

12:45 - 1:45 PM 



Synopsis: This course will address the practical aspects of starting a professional career 

in ophthalmology, whether by starting a solo practice or being hired by an existing practice. 

Learn the key components of each career path and how to minimize the likelihood of making 

a mistake at the start of your career. Additionally, we will explore the financial realities 

every young doctor faces. Some of the areas we will cover include balancing student loan 

repayment with other expenditures, life and disability insurance needs, home ownership, 

educational savings for children, and funding retirement (it is never too soon to start). An 

overview of basic investments will be given, as well as advice on avoidance of common 

financial mistakes. 

Objective: This course will provide residents, fellows, and practicing ophthalmologists 

with the key issues and insights to evaluate whether to start a practice or join an existing 

practice. Additionally, participants will learn how to manage their financial life now that 

they are generating significant income, putting them on the right path to financial success. 

Senior Instructor(s): Donna W Howell JD 

NEW Yo How to Join a Group Practice: Introductory Concepts 

Course: 586 

Tuesday 

Room: S502a 

2:00 - 3:00 PM 



Synopsis: This course provides practical advice on evaluating employment opportunities 

with a group practice. With the continued decline in solo practice, more physicians will 

join groups. But how do you know if a group is right for you and if you are a good fit for 

a group? 

Objective: This course is designed to provide residents, fellows, and practicing ophthalmologists 

with an framework for evaluating employment opportunities with a group 

practice. 

Senior Instructor(s): Lawrence Geller MBA* 






295

AAOE Special Meetings & Events 

Special Meetings and Events are free of charge unless otherwise specified. You do not need to register for free meetings and events. 

AAOE Special Meetings 

& Events 

Saturday, November 10 

A The Profitable Practice: Managing Your Practice’s 

Billing Operation 


8:00 AM - 12:00 PM 

Fee: $345.00 

Room: S504bc 

Senior Instructor: Ron Rosenberg PA MPH* 

Instructor(s): Curt P Hill BS, Donna Connolly** 

This is a course on managing an ophthalmology billing operation. Attendees will (1) 

learn all of the steps of successful billing and receivables management, (2) learn how 

to monitor the collection performance of the billing operation, (3) learn how to deploy 

and manage billing staff, (4) learn how to aggressively manage accounts receivable, 

(5) learn how to identify and correct operational problems that cause rejected and/or 

delayed claims and (6) obtain benchmarks for staffing and cost of billing. 

A Harnessing the Effective Leader Within: Strategies to 

Improve Your Leadership Skills 


9:00 AM - 4:00 PM 

Fee: $495.00 (Lunch included) 

Room: S503ab 

Senior Instructor: Martha Young*, Tim D Couch 

As administrators, we are expected to consistently demonstrate good leadership 

traits and strong communication skills in our interaction with physicians, associates 

and especially with patients. This experiential workshop is about leadership success 

and professional growth through expansion of “self”. You will grow by pushing your 

limits “personally, professionally and organizationally” through an understanding of 

why we act or react the way we do and how we can alter the outcome. This new 

awareness will become a useful tool in changing your attitudes, knowledge and behaviors 

in your professional and personal life. 

a Enhancing Quality, Productivity and Profits in the 21st 

Century Ophthalmic ASC 


12:00 - 3:00 PM 

Fee: FREE (Lunch included) 

Room: S501 

A symposium for the community of ASC owner/surgeon ophthalmologists, director’s 

of nursing and other clinical personnel, and administrators who practice in, or are 

contemplating practicing within, both single-specialty ophthalmic and multi-specialty 

ASCs that provide surgical eye care. Complimentary registration open to all 

Joint Meeting attendees. 

A Optical Dispensing Boot Camp 


12:30 - 4:30 PM 

Fee: $345.00 

Room: S502a 

Senior Instructor: Arthur L De Gennaro 

It is well known that ophthalmologists’ dispensaries significantly underperform compared 

with their counterparts in optometry and the commercial optical world. This 

interactive Boot Camp explores the factors that contribute to improved dispensary 

sales and profits. It is designed for ophthalmologists who want to open a new dispensary 

or to create a plan of action for the growth or improvement of an existing 

dispensary. 

Sunday, November 11 

AAOE General Session: The Four Disciplines of Execution 


10:00 AM - 12:00 PM 

Fee: FREE 

Room: S501 

Senior Instructor: Chris McChesney** 

Keynote address by Franklin Covey’s Global Practice Leader, Chris McChesney on The 

4 Disciplines of Execution, Franklin Covey’s newest book! 

Grab Hold of Performance! The 4 Disciplines exist for one reason: to execute on a 

plan in the midst of the whirlwind of distractions. As administrators and managers 

most of you are so busy just maintaining the business of running the practice 

– let alone execute on your most important priorities. The 4 Disciplines focuses your 

team’s energy on a winnable game in the midst of distraction. All AAOE attendees 

will receive a complimentary copy of The 4 Disciplines of Execution at the AAOE 

General Sessions. 

The 4 Disciplines of Execution: Breakout Session 


2:00 - 3:00 PM 

Fee: FREE 

Room: S501 

Senior Instructor: Chris McChesney** 

This interactive session is based on the keynote address of the AAOE General Sessions: 

The 4 Disciplines of Execution. 

The 4 Disciplines exist for one reason: to execute on a plan in the midst of the whirlwind 

of distractions. As administrators and managers most of you are so busy just 

maintaining the business of running the practice – let alone execute on your most 

important priorities. This interactive session will focus on providing you with tips to 

help you implement The 4 Disciplines to achieve the results you want. 

296 

* The presenter has a financial interest. ** The presenter has not submitted financial interest disclosure information as of press date. No asterisk indicates that the presenter has no 

financial interest. Up-to-date information is available in the Program Search on the Academy’s website: www.aao.org/2012.

The Electronic Office – IHE Eye Care, Booth 114 

McCormick Place Exhibit Hall 

YOUR Information Systems 

and YOUR Devices 

all Working Together 

Visit Academy-sponsored Electronic Office for Information on Meaningful 

Use Incentives and a FREE Demonstration and a FREE USB Drive. 

Find out more information about The Electronic Office 

at www.iheeyecare.org or contact flum@aao.org.

298 

Notes

Academy Online Community 

Where all of ophthalmology goes to connect 

Are you making the most of this Academy 

member benefit? 

The Academy’s online community is a secure, 

member-only forum where you can: 

• Consult with colleagues on difficult cases 

• Discuss clinical topics in your area of 

expertise 

• Get opinions on electronic health records 

• Connect with Academy leadership through 

blog posts 

• Reconnect with classmates and colleagues 

“The Academy online community is 

a perfect setting to get ideas from 

other practitioners on how to manage 

difficult cases. It is a very positive 

environment where I can share ideas 

and techniques on patient care, keep 

updated on the politics of medicine, 

and research practice management 

tools such as electronic medical 

records.” 

Connect with your colleagues today — it’s easy! 

• Scan this QR code with your smartphone or 

visit www.aao.org/community 

• Log in with your existing Academy 

username and password 

• Browse, comment and share 

– Chad R. Bouterse, 

DO, Clarkston, Wash. 

Join the conversation! 

www.aao.org/community

300 

Notes

Invest in Your 

Academy and 

the Future of 

Ophthalmology 

For more than 30 years, the Foundation of the American 

Academy of Ophthalmology has been committed to 

funding the Academy’s priority educational, quality of care 

research and service programs. 

These programs give the gift of sight, forge new paths in 

Make a gift today! 

www.faao.org/donate 

Questions? 

Contact Karen Duke 

at kduke@aao.org 

or 415.447.0356. 

www.faao.org 

education and health policy research, and build upon 

the distinguished legacy of our profession. The Academy 

supports its members from residency through retirement, 

providing the resources needed to administer the best 

possible patient care. 

Support from members like you plays a critical part 

in helping the Foundation to advance the Academy’s 

mission — dues alone are not enough. With your 

contribution, we can continue to truly make a difference 

in our profession and in our communities.

302 

Notes



Join ISRS in Chicago 

Schedule of Clinical Sessions 

While in Chicago, keep up with the latest in clinical and research developments in refractive, 

cataract, cornea and lens-based surgery with the International Society of Refractive Surgery 

(ISRS), a partner of the American Academy of Ophthalmology. 

Refractive Surgery Subspecialty Day 2012: 


The ISRS Annual Meeting 

Friday, 09 November | 08:00 to 17:15 

Saturday, 10 November | 08:00 to 17:30 

McCormick Place, North, Hall B 

Free Papers (Friday only) 

McCormick Place, Grand Ballroom S100ab 

ISRS Special Sessions 

Introduction to Refractive Surgery 

for Residents (SYM53) 



LASIK Is Safe: Prevention and Management of 

Laser Complications (SYM14) 


McCormick Place, Grand Ballroom S100AB 

ISRS Rountables* 

Sunday, 11 November through 

Tuesday, 13 November 

07:30 to 08:30 

McCormick Place, Hall A 

ISRS Instruction Courses* 

ISRS Laser Refractive Surgery 

Course (156, LEC156) 


McCormick Place, S103BC 

Laser Refractive Surgery (LAB156A) 

12:30 to 14:30 | N227B 

Laser Refractive Surgery for Ophthalmology 

Residents (LAB156B) 

15:30 to 17:30 | N227B 

Advanced Corneal Topographic Analysis (214) 



A Step-by-Step Primer to Starting 

LASIK in 2012 (338) 


McCormick Place, N427BC 

Surgical Management of Astigmatism in Cataract 

and Refractive Surgery (308) 




Worst-Case Scenarios: A Video-Based Course (402) 



For more information on ISRS or to become a member, visit Member Services in the Academy 

Resource Center (Booth 508) or www.isrs.org 

*onsite fee applies

Museum 

of Vision 

Visit us at Booth #704 

or on-line at www.museumofvision.org 

Ophthalmodouleia by George Bartisch, 1583 (reproduction)













Booth 508 















Foundation 


certificates 


Win an iPad! 

















Informational Posters 

Saturday – Tuesday, Nov. 10 – 13 

Hall A 

Informational Posters, presented by organizations that serve allied health and ophthalmological 

societies and the visually impaired, will be displayed Saturday through Tuesday during exhibit 

hall hours. 







Informational Poster 01 

The Glaucoma Foundation 

Describes grants currently funded, organizational outreach 

programs, members of governing board of directors and scientific 

advisory board. 


Mahatme Eye Bank & Hospital 

Hands-on surgical training in India. Free ICO fellowships, with over 

1000 surgeons trained so far. 


Chinese American Ophthalmological Society, Inc. 

Advances medical knowledge and scientific research in ophthalmology 

and assists in the training of ophthalmologists of Chinese 

descent. 


Combat Blindness Foundation 

Dedicated to eradicating preventable blindness in developing 

countries. 


Volunteer Eye Surgeons International 

Sends volunteer eye surgeons to developing countries such as 

Afghanistan, Vietnam and Bangladesh to restore sight surgically, 

treat severe eye diseases and teach the latest techniques. 


Lighthouse for Christ Mission and 

Eye Centre 

A faith-based eye mission hospital- Mombasa, Kenya is in need 

of volunteer sub-specialty eye doctors to serve two (2) weeks 

throughout the year. 


Mission Cataract USA 

Encourages ophthalmologists to provide free cataract surgery to 

indigent patients in their own community. 


Christian Ophthalmology Society 

Describes the Society’s annual continuing medical education meeting 

and its involvement with ophthalmologic missions worldwide. 


Retinitis Pigmentosa International 

Restoring vision and making the world accessible through 

TheatreVision Description, Adult Stem Cell Transplants, information 

hotlines and education. 


Pediatric Keratoplasty Association 

Addresses the issues associated with management of corneal 

diseases in infants and children. Meetings and newsletters disseminate 

information on these clinical issues. 


LIGA International 

LIGA Flying Doctors of Mercy supports mission eye surgery in 

El Fuerte Mexico, Nov. – March. 


New Mexico Eye Injury Registry 

Reports on traumatic eye injuries in New Mexico and compares 

them to the rest of the United States. 


Deseret International Foundation 

Partners with the local professionals of twenty-five (25) countries 

to increase their capacity to provide sustainable/high-quality relief 

to those with cataracts. 


American Society of Ocularists 

Presenting on the conditions requiring prosthetic eyes and scleral 

shell and the prosthetic results achieved. Membership information 

will be available. 


Himalayan Cataract Project 

Showcases their programmatic efforts throughout the developing 

world to alleviate needless blindness. 


Eye Foundation of America 

Since its inception in 1977, its goal has been to improve eye care 

around the world. 


Prevent Blindness America 

Founded in 1908, Chicago-based Prevent Blindness America is 

the nation’s leading volunteer eye health and safety organization 

dedicated to fighting blindness and saving sight. 


International Symposium on Ocular 

Pharmacology and Therapeutics (ISOPT) 

The place for updates and discussions on the most current treatment 

algorithms and those soon to be available in your practice. 

www.isopt.net 

306 


Available Academy Services in the Exhibit Hall 

New! Rest Stop 

Reconnect. Refuel. Relax. Recharge. 

Booths 2485, 2490, 2787, 2981, & 2987 

Looking for internet access, a comfortable place to meet colleagues 

or just a spot to take a break? Drop by the Rest Stop and find it all 

on the exhibition floor: 

• Wi-Fi Access - bring your own laptop, tablet computer 

or other web-enabled device and access free Wi-Fi at 

Booth 2981. 

• Internet Access - Use one of the computers at Booth 2987 to 

access the Virtual Exhibition, view course handouts or print your 

boarding pass. 

• Recharge your mobile device at Booth 2485. 

• Meet for lunch at Bistro AAO, Booth 2490. 

• Take time-out and enjoy a complimentary seated massage provided 

by a certified massage therapist at Booth 2787. 

Find additional computer terminals at the Internet Access area in the 

Grand Concourse. 

Mobile Meeting Guide 

www.aao.org/mobile 

For download assistance: Booth 2987 

The Mobile Meeting Guide is an easy-to-use wireless Web app for 

any web-enabled mobile device. A downloadable version is available 

for iOS and Android devices. 

• Complete program content including abstracts and course 

handouts 

• Learning Lounge and Technology Pavilion schedules 

• Course room and exhibit hall floor plans 

• Hotel and shuttle bus information 

• Exhibitor list 

• Chicago area information 

Supported by Carl Zeiss Meditec 

Posters Online & Videos on Demand 

Booth 165 

Review scientific posters and watch surgical videos at your convenience 

on dedicated computer terminals conveniently located in the 

exhibit hall. You can also access these resources during the meeting 

at www.aao.org/mobile or online at www.aao.org/2012. 


The Academy brings you the latest news-you-can-use in technology. 

The Electronic Office: Integrating the Healthcare 

Enterprise (IHE) Eye Care 

Brought to you by the American Academy of Ophthalmology 

Booth 114 

Physicians can earn up to $44,000 over five years for demonstrating 

meaningful use and interoperability with electronic health record 

systems. Visit IHE to: 

• Experience how integrating your EHR systems can improve efficiency 

and accuracy in your practice. 

• Receive a USB drive once you complete the demonstration. 

• Discuss your EHR-related questions with Academy staff. 


Booth 880 

Presentations showcase the very latest technology trends that can 

benefit medical practices. See page 265 for a schedule and course 

descriptions. 

Academy Resource Center 

Booth 508 

Find the latest information and resources: 

• Sample and purchase the best in clinical reference, patient 

education and practice management/coding products. 

• See demonstrations of the ONE® Network, Academy Online 

Community, EyeWiki , EyeSmart ® and Ojos-Sanos , the new 

Spanish-language patient education website. 

• Join or pay dues for the Academy, ISRS and AAOE. 

• Find business resources on practice efficiency, financial management 

and human resources. 

• Get your coding/reimbursement and PQRS/e-prescribing questions 

answered. 

• Find information on advocacy efforts. 

• Film a personalized patient education video. 

• Use the Resource Router to e-mail information to yourself or to 

contact Academy departments. 





Indexes 

The following indices are provided: 

• Exhibitor List, with booth number locations, page 309 

• Product Index, cross-listing exhibitors with the product categories and medical specialties they 

relate to, page 313 

• Participant Index, listing individual names and Final Program location information, page 323 

• Participant Financial Disclosure Index, page 333 




308 


Exhibitor List 

1-800-DOCTORS NEW!....................................................255 

66 Vision Tech Co., Ltd......................................................951 

A 

A Fashion Hayvin, Inc......................................................2874 

AA Vision, Inc..................................................................1804 

AAO Meetings On Demand..............................................605 

Aaren Scientific, Inc........................................................2013 

Abbott Medical Optics...............................................3244 

AccuLens, Inc...................................................................4539 

Accurate Manufacturing, Inc. NEW!.............................3073 

Accutome H....................................................................4221 

ACIGI Relaxation/FUJIIRYOKI.........................................4456 

Addition Technology, Inc.................................................3135 

ADP AdvancedMD...........................................................1679 

Aeon Astron Europe B.V..................................................4544 

AIT Industries...................................................................2835 

Ajinomoto Trading, Inc....................................................1131 

Akorn Pharmaceuticals H...............................................3800 

AKtive Srl NEW!..............................................................2575 

AL.CHI.MI.A. S.r.l.............................................................4200 

Alcon Laboratories, Inc. H........................................2808 

Alimera Sciences........................................................4414 

Allergan H.....................................................................1408 

Allscripts..........................................................................2852 

Almic Co., Ltd. NEW!.....................................................3177 

Althoraya Company For Import & Export NEW!............1579 

Ambler Surgical...............................................................2337 

American Academy of Ophthalmology (AAO)..................508 

American Express OPEN.................................................1574 

American Optisurgical, Inc..............................................3100 

American Society of Cataract & Refractive 

Surgery (ASCRS)........................................................3262 

American Society of Ophthalmic Registered Nurses 

(ASORN).....................................................................2782 

Anadolu Tip A.S.................................................................772 

Angie’s List NEW!..........................................................2576 

Angiotech H.................................................................1151 

Annidis Health Systems..................................................1776 

Anodyne Surgical............................................................2550 

AO Lab - American Ophthalmic Lab...............................2700 

Appasamy Associates.......................................................557 

Apramed Medical Devices..............................................4337 

ARCADOPHTA .................................................................1949 

ArcticDx, Inc.....................................................................2076 

Are You a Donor? NEW!...................................................126 

Army Medical Recruiting................................................2276 

Art Optical Contact Lens, Inc. NEW!.............................2075 

Asia-Pacific Academy of Ophthalmology (APAO)...........1200 

ASICO, LLC H..................................................................3300 

Association for Research in Vision 

and Ophthalmology (ARVO).......................................2046 

Audio Digest......................................................................245 

Aumed Group Corp............................................................433 

Aurolab............................................................................3276 

Aurora Surgical, LLC........................................................3170 

Avada Hearing Care Centers NEW!..............................2777 

Avedro, Inc.......................................................................2571 

B 

Bank of America Practice Solutions.................................133 

Bausch+LombH...........................................................3126 

Bayer Healthcare Pharmaceuticals...................................153 

Beaver - Visitec International H.....................................3833 

Beijing Sonop Technology Co., Ltd. NEW!....................1172 

Bell Ophthalmic Technology............................................2104 

Belrose Refracting Equipment Company H...................2800 

Benign Essential Blepharospasm 

Research Foundation.................................................2880 

Bioptigen, Inc.....................................................................434 

Bistro AAO..............................................................................2490 

Biosyntrx, Inc...................................................................2830 

BioTech Vision Care Pvt., Ltd..........................................2952 

Bio-Tissue, Inc..................................................................4340 

BJB Medical Associates...................................................159 

Brevium............................................................................3104 

Bruder Healthcare Company...........................................1774 

Brumaba USA, Inc...........................................................4527 

Brymill Cryogenic Systems..............................................2776 

Bryn Mawr Communications LLC.....................................662 

C 

C.S.O. srl..........................................................................3156 

Calhoun Vision, Inc. Cancelled 

Cambrian Medical, Inc....................................................2450 

Canon US Inc. H.............................................................2009 

CapitalSource NEW!......................................................4622 

CareCredit..........................................................................545 

Carl Zeiss Meditec H...................................................534 

Castle Biosciences, Inc....................................................2534 

Ceatus Media Group.......................................................3102 

Centers For Medicare & Medicaid Services NEW!......1675 

Chace and Associates.....................................................4071 

Charmant Inc. NEW!........................................................228 

Chona Surgical Co...........................................................4536 

Chongqing Sunkingdom Medical 

Instruments Co., Ltd. NEW!........................................462 

Cilita, Ltd............................................................................231 

CIMA Technology, Inc. .............................................2836 

Clarity Medical Systems, Inc..........................................1020 

ClientTell, Inc...................................................................2535 

Cloud Nine Development, LLC........................................3120 

Comlite Systems..............................................................2435 

Complete Medical Solutions, LLC.....................................332 

Compulink Business Systems, Inc..................................2315 

Conestoga Equipment Finance Corp. NEW!..................1674 

Consultronix S.A..............................................................2769 

Crestpoint Management, Ltd..........................................2726 

Croma - Pharma.................................................................726 

D 

DavLong Business Solutions...........................................3872 

Delta Life Science, LLC....................................................4550 

Demandforce.....................................................................236 

DermaMed International.................................................1272 

Designs For Vision, Inc. H................................................562 

Device Optical..................................................................2433 

Dexta Corporation H.......................................................2926 

DGH Technology, Inc. H..................................................3535 

Diagnosys LLC...................................................................526 

Diamatrix Ltd...................................................................1946 

DigiSight Technologies, Inc.............................................4549 

Dioptics Medical Products, Inc.......................................3219 

Doctor’s Advantage Products, LLC..................................4316 

Doctorsoft Corporation....................................................4365 

DORC International, bv....................................................1026 

Dove Medical Press NEW!..............................................263 

DSS, Inc...........................................................................3119 

DualAlign, LLC.................................................................2079 





Exhibitors 

Exhibitors 

Duckworth & Kent...........................................................2726 

Dutch Ophthalmic, USA..............................................1026 

DXDT Engineering and Research NEW!........................4457 

E 

Eagle Labs........................................................................2640 

Eagle Vision, Inc. H.........................................................3845 

Eidolon Optical...................................................................136 

Electro-Diagnostic Imaging, Inc........................................665 

Ellex..................................................................................3804 

Ellman International H...................................................3335 

Elsevier H........................................................................1500 

Emory Genetics Laboratory NEW!.................................1977 

Emtron..............................................................................4162 

Endo Optiks, Inc...............................................................1700 

Endure Medical, Inc.........................................................2808 

Enhanced Vision .............................................................2650 

Epsilon EyeCare, USA.....................................................2803 

Eschenbach Optik............................................................3123 

European Society of Cataract & Refractive 

Surgeons (ESCRS)......................................................2704 

European Society of Ophthalmology (SOE)....................1100 

European Society of Retina Specialists (EURETINA).....2703 

EVER - European Association For Vision and 

Eye Research..............................................................2882 

Everyday Health, Inc. NEW!...........................................4458 

Exhibitor Locator - American Academy of 

Ophthalmology................................................................3500 

Expeditor Systems, Inc....................................................1950 

Eye Care and Cure...........................................................2438 

Eye Designs, LLC H.........................................................3837 

Eye Med Management Solutions NEW!.........................362 

Eye Photo Systems, Inc...................................................4216 

EyeCanHear, LLC..............................................................4533 

Eyedetec Medical, Inc.....................................................3273 

Eyefinity.............................................................................344 

EyeIC, Inc.........................................................................2001 

EyeKon Medical ..........................................................121 

Eyekor, LLC NEW!...........................................................2077 

Eyemaginations...............................................................2949 

EyeMD EMR Healthcare Systems, Inc.............................357 

EyeNet - American Academy of Ophthalmology........3572 

Eye-Novation NEW!.......................................................3275 

EYEOL UK LIMITED..........................................................1273 

EyeQuick, LLC.....................................................................256 

EyeSys Vision...................................................................2936 

EyeTechCare....................................................................2669 

Eyevertise, Inc..................................................................2301 

Eyewitness Limited NEW!.............................................2275 

F 

Fallon Wellness Pharmacy NEW!..................................1871 

Fashion Optical Displays...................................................137 

FCI Ophthalmics...............................................................1504 

Feather Safety Razor Co., Ltd..........................................2604 

Fera Pharmaceuticals......................................................3077 

Finite Square mBh NEW!...............................................3375 

First Insight Corporation..................................................4417 

Fischer Pharmaceuticals, Ltd. NEW!.............................1874 

Fischer Surgical, Inc........................................................3072 

Florida Eye Equipment.....................................................4165 

Fortifeye Vitamins.............................................................131 

Fortrad Eye Instruments H Cancelled 

Frastema S.R.L.................................................................1749 

Freedom Ophthalmic Pvt., Ltd.........................................2477 

Fresnel Prism & Lens Co.................................................2150 

Fundus Photo...................................................................1850 

G 

GE Healthcare..................................................................1676 

GeneDx............................................................................1976 

GENENTECH..................................................................4300 

Geuder AG.......................................................................2726 

Glaucoma Research Foundation.....................................2781 

Glaukos Corporation........................................................4331 

Global Sight Alliance NEW!..........................................2883 

Good-Lite.........................................................................2504 

Greycoat Publishing, Ltd ..................................................150 

Gulden Ophthalmics........................................................2353 

H 

H.S. International Corporation........................................2352 

Haag-Streit AG H...........................................................3808 

Haag-Streit Group H...................................................3808 

HAI Laboratories, Inc.........................................................731 

Hausted Patient Handling Systems, LLC........................3475 

Heidelberg Engineering.............................................2326 

Heine ...............................................................................3552 

Henan Universe IOL R&M Co., Ltd..................................2668 

Highlights of Ophthalmology H.....................................3573 

HIMS, Inc. NEW!..............................................................563 

Hong Kong Feat In Technology Company.......................2174 

Howard Instruments, Inc. .........................................2905 

Hoya Surgical Optics, Inc................................................4149 

HRA Healthcare Research & Analytics............................257 

Huaian Frimen Co., Ltd....................................................1276 

HUCO...............................................................................2929 

Hurricane Medical...........................................................3405 

Huvitz Co., Ltd..................................................................4068 

I 

i2eye Diagnostics Limited...............................................2973 

Icare USA...........................................................................969 

ifa Systems AG................................................................3862 

imatters..............................................................................258 

I-MED Pharma.................................................................2855 

iMedicWare, Inc..............................................................2969 

ImmersiveTouch, Inc. NEW!...........................................2175 

Imperial Medical Technologies, Inc..................................162 

Inami & Co., Ltd...............................................................1900 

Infinite Therapeutics........................................................2877 

Innovative Visual Systems..............................................2751 

Insight Instruments, Inc...................................................3856 

Insightful Solutions, LLC..................................................2775 

Integrated Orbital Implants, Inc........................................130 

Integrity Digital Solutions, LLC.......................................4353 

International Agency for the Prevention of 

Blindness (IAPB).........................................................2976 

International Center - American Academy of 

Ophthalmology................................................................4509 

International Council of Ophthalmology (ICO)..................144 

International Eye Foundation..........................................2785 

International Sight Restoration.......................................2339 

Internet Access....................................................................2987 

IO Practiceware...............................................................3868 

IOP Ophthalmics..............................................................1835 

i-Optics.............................................................................1471 

IRIDEX..............................................................................2319 

iScience.............................................................................347 

Iscon Surgicals, Ltd.........................................................3373 

iVIS Technologies S.r.L....................................................3105 

J 

Jaggi Ophthalmic Instrument Co....................................1705 

JAMA Network...............................................................3570 

JANIX CRO.......................................................................2733 

Jaypee-Highlights Medical Publishers H......................3573 

JCAHPO - Joint Commission on Allied Health 

Personnel in Ophthalmology.......................................430 

JEDMED Instrument Company H..................................2921 

Jingming Science & Technology Co., Ltd.......................2677 

K 

KAI Industries, Ltd...........................................................2652 

Katalyst Surgical, Inc.......................................................2304 

Katena Products, Inc. H....................................................521 

Keeler Instruments, Inc. H.............................................1436 

Keiser Computers..............................................................158 

KeyMedical Software, Inc.................................................152 

Khosla Surgical IndustriesH...........................................2149 

King Khaled Eye Specialist Hospital...............................1277 

Kirwan Surgical Products LLC ..................................3222 

Konan Medical USA........................................................2145 

Koryo Eyetech Co., Ltd.....................................................2274 

Kowa Optimed, Inc. H....................................................3039 

Krebs Instruments H.......................................................2540 

Kugler Publications ...................................................3675 

L 

L3 Healthcare Design Architects....................................4529 

Labtician Ophthalmics, Inc..............................................2100 

LacriSciences, LLC.............................................................664 

Latham & Phillips Ophthalmic........................................3400 

LCA Pharmaceutical........................................................2755 

Learning Lounge - American Academy of 

Ophthalmology..................................................................107 

Leica Microsystems H....................................................2739 

Leiter’s Pharmacy.............................................................2750 

LensAR.............................................................................4156 

Lenstec, Inc......................................................................1169 

310 

= Exhibitors celebrating 25 years of participation, H = Exhibitors with more than 25 years of participation. 

Bold text = Ophthalmic Business Council (OBC) Members. List accurate as of September 25, 2012.

Exhibitors 

Leoni Fiber Optics, Inc.....................................................1176 

Lianyungang Weidir Impex Trading Co., Ltd...................2869 

LIGHTMED Corporation.....................................................962 

Lippincott Williams & Wilkins/ 

Wolters Kluwer Health H.........................................4104 

Live Eyewear, Inc.............................................................2434 

LKC Technologies, Inc. H................................................3026 

Lombart Instrument H....................................................3840 

Lumenis Vision H............................................................3438 

Lutein Pharmaceutical Co., Ltd. China............................1876 

M 

M&S Technologies, Inc...................................................2731 

Madhu Instruments.........................................................2574 

Major Surgical & Engineering Works.............................4620 

ManagementPlus............................................................4131 

MANI...............................................................................2730 

Marasco & Associates, Healthcare 

Architects & Consultants..........................................3005 

Marco H..........................................................................3319 

Mastel Precision Surgical Instruments, Inc....................2100 

Mayo Clinic......................................................................2884 

MDIntellesys....................................................................1971 

MDoffice, Inc...................................................................4034 

Meccanottica Mazza S.r.L...............................................2440 

Meda Co., Ltd..................................................................2701 

MedDev Corporation.......................................................2135 

MedEdicus.......................................................................3376 

Medennium, Inc...............................................................3028 

Medflow, Inc....................................................................3152 

Medi Instruments, Inc.......................................................330 

Medi-All...........................................................................1077 

Medical Ministry International.......................................2881 

Medical Planning, Inc. H................................................3605 

Medicel AG........................................................................751 

Medicure Instruments.....................................................4526 

Medinformatix, Inc............................................................337 

Mediphacos.....................................................................4545 

MediSURG Research & Management Corp...................4559 

Med-Logics, Inc...............................................................2532 

MedNet Technologies.....................................................2638 

MedOne Surgical, Inc......................................................2831 

MEDVISION NEW!.........................................................4621 

Menicon America Cancelled 

Merck & Co. H.............................................................3826 

Mercoframes Optical Corp................................................564 

Merge Healthcare H.......................................................3849 

Merrill Lynch....................................................................2928 

Metrovision......................................................................2653 

Micro Medical Devices, Inc..............................................431 

MicroVision, Inc...............................................................2374 

MID Labs, Inc...................................................................2900 

Middle East Africa Council of Ophthalmology 

(MEACO).......................................................................244 

Miraflex NEW!................................................................1773 

Mobile Device Charging Stations....................................2485 

Mobius Therapeutics, LLC NEW!...................................3370 

Modernizing Medicine....................................................2771 

Moller-Wedel GmbH H..................................................3808 

Montefiore Medical Center NEW!................................3175 

Morcher GmbH................................................................2049 

MORIA H.........................................................................1449 

Moss Vision Inc., Ltd.......................................................4551 

MSI Precision Instruments..............................................2605 

MST (MicroSurgical Technology)......................................626 

MTBC NEW!...................................................................2176 

MTI.....................................................................................350 

Museum of Vision - Foundation of the American 

Academy of Ophthalmology .........................................704 

N 

Nadia International, Inc...................................................2241 

National Library of Medicine NEW!..............................3474 

Nature Publishing Group.................................................3569 

Neitz Instruments Co., Ltd...............................................2737 

NeoMedix Corporation...............................................2536 

Neotech Medical Pvt., Ltd...............................................2300 

NeurOptics NEW!...........................................................1173 

New World Medical, Inc...................................................340 

New York Research Cancelled 

NexTech...........................................................................2757 

NextGen Healthcare........................................................3456 

Nidek, Inc. H...................................................................2308 

Noir Laser H....................................................................2902 

Notal Vision.....................................................................2171 

Novamed Ceramisys Limited NEW!..............................1075 

NUMEDIS, Inc..................................................................1872 

O 

OA Systems, Inc................................................................134 

OASIS Medical, Inc. .................................................2615 

Ocular Instruments, Inc. H.............................................2719 

Ocular Surgery News (OSN) H.......................................3669 

Ocular Systems, Inc.........................................................1601 

Ocular Therapeutix, Inc...................................................2238 

Oculus, Inc. H...............................................................3814 

OCuSOFT, Inc...................................................................2362 

OD-OS GmbH...................................................................4347 

ODOS, LLC........................................................................2077 

Odyssey Medical, Inc......................................................2632 

Oertli Instrumente AG.......................................................326 

OFCOR..............................................................................2834 

OIS H...............................................................................3849 

OMIC - Ophthalmic Mutual Insurance Company ....1104 

Omni Lens Pvt., Ltd............................................................238 

OPHMED Co., Ltd.............................................................2975 

OPHTEC............................................................................4037 

Ophthalmic Instrument Co., Inc .....................................2044 

Ophthalmic Photographers’ Society...............................3503 

Ophthalmologist Protector Plan......................................3176 

Ophthalmology International............................................150 

Ophthalmology Journal...................................................3572 

Ophthalmology Management...........................................528 

Ophthalmology Times H.................................................2335 

OphthalmologyWeb.........................................................2136 

OptiCall, Inc.....................................................................2475 

Optikon 2000 SPA............................................................3562 

OptiMedica......................................................................4044 

Optimetrics, Inc ..............................................................1749 

Optivision 2020, Inc.........................................................2674 

Optos, Inc.........................................................................720 

OPTOTEK d.o.o.................................................................4350 

Optovue, Inc....................................................................754 

Oraya Therapeutics, Inc .................................................2476 

ORBIS International.........................................................4100 

Oxford University Press...................................................3571 

P 

Pacific Ophthalmic Supply...............................................2302 

Pan-American Association of 

Ophthalmology (PAAO)..............................................1102 

Partners In Vision.............................................................4540 

Patient Education Concepts............................................2235 

Pelion Surgical H............................................................2000 

Penn Medical Informatics Systems..................................931 

Peregrine Surgical...........................................................3403 

PeriOptix, Inc....................................................................2237 

Peschke Meditrade GmbH..............................................2376 

PHAKOS...........................................................................2240 

Pharma Vision NEW!......................................................4556 

PHSI - Physician Hearing Services, Inc...........................2137 

PhysIOL sa NEW!..............................................................972 

PinPoint Optics.................................................................4623 

Plusoptix, Inc....................................................................2551 

PM Medical Billing Corp.................................................3173 

PNC Bank NEW!.............................................................1979 

Practice Authority............................................................1581 

Practice Flow Solutions...................................................2734 

Practice Insight................................................................1975 

Precision Vision, Inc .......................................................3220 

Premier Ophthalmic Services, Inc...................................4314 

Prescott’s, Inc...................................................................2249 

PRN - Physician Recommended Nutriceuticals..............2875 

Professional Data Systems NEW!.................................3274 

PST...................................................................................3200 

Q 

Qioptiq.............................................................................1704 

Quantel Medical .............................................................2945 

Quest Medical, Inc..........................................................1177 

QuickView Medical Records, Inc....................................2371 

R 

R.E.T., Inc..........................................................................1849 

Rapid Pathogen Screening, Inc.......................................2735 

Ray Vision International Corporation..............................3075 

Rayner Intraocular Lenses Ltd.........................................2933 

Regeneron Pharmaceuticals......................................353 

Reichert Technologies H................................................2344 

Exhibitors 

= Exhibitors celebrating 25 years of participation, * = Exhibitors with more than 25 years of participation. 

Bold text = Ophthalmic Business Council (OBC) Members. List accurate as of September 25, 2012. 

311

Exhibitors 

Exhibitors 

Reliance Medical Products H.........................................3808 

REST STOP 

Bistro AAO - Refuel........................................................2490 

Internet Access - Reconnect......................................2981 

Mobile Device Charging Stations - Recharge.......2485 

Seated Massage Stations - Relax.............................2787 

Wi-Fi Access - Reconnect...........................................2981 

Review of Ophthalmology...............................................2350 

RGP, Inc............................................................................2833 

Rhein Medical, Inc...........................................................1904 

Richmond Products, Inc.....................................................548 

Rose Micro Solutions NEW!..........................................2452 

Rumex International Co...................................................1644 

S 

S4Optik, LLC NEW!..........................................................865 

San Diego Eye Bank........................................................3202 

Santen............................................................................1839 

Scarf King..........................................................................463 

Seated Massage Stations.................................................2787 

SCHWIND eye-tech-solutions........................................2962 

SciCan, Inc.......................................................................4153 

ScienceBased Health......................................................2936 

Scientific Posters Online / Videos On Demand - 

American Academy of Ophthalmology......................165 

sea-change, inc...............................................................3122 

SEGAL Instruments Exports............................................2432 

SensoMotoric Instruments GmbH..................................2675 

Sensor Medical Technology NEW!.................................680 

Sequenom Center For Molecular Medicine LLC..............232 

Shamsi Surgical.................................................................977 

Shanghai EDER Medical Equipment Co., Ltd. NEW!....1873 

Shanghai Mediworks Precision Instruments Co., Ltd....2854 

Shanghai New Eyes Technology Co., Ltd.......................2474 

Shanghai Xiaolai Science and Trade Co. NEW!............2977 

SightLife NEW!.................................................................226 

SLACK, Incorporated H..................................................3669 

SMR Ophthalmic.............................................................2753 

Soderberg Instruments H...............................................2340 

Solutionreach...................................................................3402 

Sonogage, Inc. H............................................................2500 

Sonomed Escalon...........................................................3238 

Sontec Instruments, Inc .................................................2051 

Sony Electronics................................................................335 

SOOFT iTALiA SpA..........................................................1771 

Southern Eye Bank..........................................................4538 

Southwest Medical Books NEW!..................................2177 

Specs4Us NEW!...............................................................504 

Speedway Surgical Co....................................................2453 

Springer...........................................................................3673 

SRSsoft............................................................................3367 

STAAR Surgical Co. H....................................................3821 

Stephens Instruments H......................................2744, 2850 

Stereo Optical Company, Inc. H.....................................2634 

Sterimedix........................................................................2726 

Sterling Institutional Review Board NEW!....................4537 

Stryker H...........................................................................604 

Sucampo Pharma Americas, Inc.....................................3874 

Super Systems Optical/Fast Grind..................................2972 

SURGI EDGE....................................................................4202 

Surgical Eye Expeditions (SEE) International.................2780 

Surgistar, Inc....................................................................1162 

Suzhou Kangjie Medical, Inc.............................................262 

Synemed, Inc...................................................................2332 

Synergetics, Inc...............................................................4208 

SynergEyes, Inc.................................................................253 

T 

Takagi Seiko Co., Ltd.......................................................3352 

TBI - Tissue Banks International.....................................2903 

TearLab Corp....................................................................4344 

TearScience.....................................................................4362 

Technolas Perfect Vision, Inc..........................................4226 

Technology Pavilion - American Academy of 


Tekia, Inc............................................................................437 

TeleVox.............................................................................3566 

TelScreen.........................................................................2045 

The Electronic Office - American Academy of 


The Eye Group.................................................................1951 

The Lebanon Corporation..................................................151 

Thea.................................................................................2662 

ThromboGenics................................................................1571 

Tianjin Jingming New Technology 

Development Co., Ltd................................................2774 

Tianjin Suowei Electronic Technology Co., Ltd...............1476 

Titan Surgical...................................................................1600 

Tomey Corporation..........................................................1445 

Topcon Medical Systems H........................................744 

Tracey Technologies........................................................2204 

TransMotion Medical, Inc...............................................2002 

Trial Runners....................................................................1879 

Truevision Systems, Inc...................................................1576 

TruForm Optics, Inc............................................................333 

TTI Medical........................................................................147 

Tulip Surgicals USA, Inc....................................................250 

Tura, Inc..............................................................................234 

Turkish Ophthalmology Society (TOS)...............................505 

U 

UFSK - International OSYS, GmbH.................................4218 

Ultimate Creations, Inc......................................................334 

UMI..................................................................................1877 

University Hospitals/Case Western Reserve Eye 

Image Reading Centers NEW!................................4535 

US IOL, Inc. H........................................................2744, 2850 

V 

Valeant Ophthalmics.......................................................3076 

Valon Lasers Oy...............................................................3167 

Varitronics H.....................................................................321 

VectorVision, Inc..............................................................3003 

VersaSuite........................................................................1065 

Viewlight, LLC....................................................................551 

Viewpoint International Corp..........................................2637 

Vimetrics, LLC....................................................................156 

Virtual Officeware, Inc.....................................................1676 

Viscot Medical, LLC.........................................................1805 

Visicom...............................................................................230 

Visiometrics, S.L................................................................436 

Vision Assessment Corporation......................................1174 

Vision Associates............................................................2552 

Vision Quest Surgical, Inc...............................................2802 

Vision Share - Eye Bank Network...................................3603 

Vision Surgical NEW!.....................................................2752 

Visionary Medical Supplies..............................................155 

VisionCare Devices, Inc...................................................2754 

VisionCare Ophthalmic Technologies.............................2665 

Visionix H..........................................................................140 

VisionScience Software..................................................4530 

Vmax Vision.....................................................................2436 

Volk Optical, Inc. H.........................................................1436 

VRmagic, Inc......................................................................762 

VSY Biotechnology............................................................769 

VueCare Media................................................................4334 

W 

Walcott RX Products.......................................................3473 

Walman Instrument Group H.........................................2340 

Wasatch Ophthalmic Instruments..................................4214 

WaveTec Vision...............................................................2367 

Welch Allyn, Inc. H.........................................................1944 

Western Surgical Corporation........................................2768 

Wexler Surgical...............................................................2400 

Wi-Fi Access..........................................................................2981 

Wills Eye Institute...........................................................2635 

Wilson Ophthalmic Corp./Hilco......................................3000 

WinFame USA, Inc..........................................................1475 

WJSupply........................................................................4547 

Woodlyn, Inc. H..............................................................2139 

World Glaucoma Association.........................................3674 

World Ophthalmology Congress 2014 (WOC)................1202 

Wuhan Strong Electronics Co., Ltd...................................251 

Wuxi KangMing Medical Device Co., Ltd......................2577 

XL Precision Technologies, LLC.........................................235 

Y 

Yodle..................................................................................132 

Z 

Zabby’s...............................................................................975 

Ziemer Ophthalmics........................................................2355 

ZyDoc MediSapien..........................................................2451 

312 

= Exhibitors celebrating 25 years of participation, H = Exhibitors with more than 25 years of participation. 

Bold text = Ophthalmic Business Council (OBC) Members. List accurate as of September 25, 2012.

Product Index 

Adhesive/Bandages 

Ocular Therapeutix, Inc........................................2238 

Advertising 

Accurate Manufacturing, Inc...............................3073 

Cloud Nine Development, LLC.............................3120 

Eyevertise, Inc.......................................................2301 

Partners In Vision..................................................4540 

Patient Education Concepts.................................2235 

VueCare Media.....................................................4334 

Anterior Segment 

Accutome..............................................................4221 

Aeon Astron Europe B.V.......................................4544 

American Academy of Ophthalmology..................508 

Anodyne Surgical.................................................2550 

Charmant, Inc..........................................................228 

Duckworth & Kent................................................2726 

Ellex.......................................................................3804 

Eyewitness Limited..............................................2275 

Fundus Photo........................................................1850 

Geuder..................................................................2726 

HAI Laboratories, Inc..............................................731 

Inami & Co., Ltd....................................................1900 

Kowa Optimed, Inc...............................................3039 

Mastel Precision Surgical Instruments, Inc.........2100 

Meda Co., Ltd.......................................................2701 

NeoMedix Corporation.........................................2536 

Oculus, Inc............................................................3814 

Optovue, Inc............................................................754 

Pharma Vision.......................................................4556 

TelScreen..............................................................2045 

Thea......................................................................2662 

Tulip Surgicals USA, Inc.........................................250 

University Hospitals/Case Western 

Reserve Eye Image Reading Centers..............4535 

Vision Share - Eye Bank Network........................3603 

VisionCare Devices, Inc........................................2754 

VisionCare Ophthalmic Technologies..................2665 

WJSupply.............................................................4547 

Billing/Coding 


Eye Med Management Solutions..........................362 

ifa Systems AG.....................................................3862 

Integrity Digital Solutions, LLC............................4353 

IO Practiceware....................................................3868 

KeyMedical Software, Inc......................................152 

ManagementPlus.................................................4131 

SRSsoft.................................................................3367 

VersaSuite.............................................................1065 

Virtual Officeware, Inc..........................................1676 

Bimanual Surgical Techniques 

Hurricane Medical................................................3405 

Medicel AG.............................................................751 

MSI Precision Instruments...................................2605 

SURGI EDGE.........................................................4202 


Books and Publications 



Registered Nurses ..........................................2782 

Audio Digest...........................................................245 

Elsevier.................................................................1500 

JAMA Network....................................................3570 

Kugler Publications...............................................3675 

OMIC-Ophthalmic Mutual 

Insurance Company.........................................1104 

Ophthalmology Management................................528 

Richmond Products, Inc..........................................548 

SLACK, Incorporated............................................3669 

Springer................................................................3673 

Cameras and Accessories 

Endo Optiks, Inc....................................................1700 


Fundus Photo........................................................1850 

Ophthalmic Photographers’ Society....................3503 

Takagi Seiko Co., Ltd............................................3352 

TelScreen..............................................................2045 

Volk Optical, Inc. 

Capsular Dye 

DORC International, bv/ 

Dutch Ophthalmic, USA..................................1026 

Capsular Tension Rings 

Abbott Medical Optics.........................................3244 

Aurolab.................................................................3276 

Cambrian Medical, Inc.........................................2450 

FCI Ophthalmics....................................................1504 

Lenstec, Inc...........................................................1169 

Madhu Instruments..............................................2574 

Morcher GmbH.....................................................2049 

OPHTEC.................................................................4037 

Capsulorhexis 

Althoraya..............................................................1579 

Ambler Surgical....................................................2337 


Aurolab.................................................................3276 

Aurora Surgical, LLC.............................................3170 


Finite Square mBh................................................3375 

Fischer Surgical, Inc.............................................3072 

Hong Kong Feat In Technology Company............2174 


LCA Pharmaceutical.............................................2755 


Medisurg Research & Management Corp..........4559 

MORIA..................................................................1449 


OFCOR...................................................................2834 

PhysIOL SA..............................................................972 

Rhein Medical, Inc................................................1904 

Rumex International Co........................................1644 


WJSupply.............................................................4547 

Care/Handing Surgical Equipment 



Meda Co., Ltd.......................................................2701 

Cataract/IOL 


Alcon Laboratories, Inc.........................................2808 



Anadolu Tip A.S......................................................772 


Aurolab.................................................................3276 


Charmant, Inc..........................................................228 

Crestpoint Management, Ltd...............................2726 

DGH Technology, Inc.............................................3535 

Dioptics Medical Products, Inc............................3219 

Doctor’s Advantage Products, LLC.......................4316 

Duckworth & Kent 

Ellex.......................................................................3804 

European Society of Ophthalmology (SOE).........1100 

Eye Care and Cure................................................2438 

Feather Safety Razor Co., Ltd...............................2604 




Inami & Co., Ltd....................................................1900 

International Society of Refractive Surgery..........508 



Meda Co., Ltd.......................................................2701 

Medicel AG.............................................................751 


Montefiore Medical Center..................................3175 

Morcher GmbH.....................................................2049 





Product Index 

Product Index 


Ocular Therapeutix, Inc........................................2238 

OPHTEC.................................................................4037 

OptiCall, Inc..........................................................2475 

OptiMedica...........................................................4044 


Pharma Vision.......................................................4556 

PhysIOL SA..............................................................972 

Rayner Intraocular Lenses Ltd..............................2933 




STAAR Surgical Co...............................................3821 

SURGI EDGE.........................................................4202 

Surgistar, Inc.........................................................1162 

Suzhou Kangjie Medical, Inc..................................262 


Development Co., Ltd......................................2774 

Visiometrics, S.L.....................................................436 

WaveTec Vision....................................................2367 

WJSupply.............................................................4547 

Chairs/Instrument Stands 

AIT Industries........................................................2835 

Belrose Refracting Equipment Company.............2800 

Brumaba USA, Inc................................................4527 

JEDMED Instrument Company............................2921 

Neotech Medical Pvt., Ltd....................................2300 

Optimetrics, Inc ...................................................1749 

Reichert Technologies..........................................2344 

S4Optik, LLC............................................................865 


Topcon Medical Systems.......................................744 

Viewlight, LLC.........................................................551 

Woodlyn................................................................2139 

Charitable Organization 

San Diego Eye Bank.............................................3202 

Cleaning/Sterilization Systems 




Wilson Ophthalmic Corp./Hilco...........................3000 

Coaxial Surgery 

Medicel AG.............................................................751 

Communications/Electronic, Telephone, 

Internet 

ClientTell, Inc........................................................2535 


OptiCall, Inc..........................................................2475 

Comprehensive Ophthalmology 



Apramed Medical Devices...................................4337 

EyeIC, Inc..............................................................2001 

Fallon Wellness Pharmacy...................................1871 

iMedicWare, Inc...................................................2969 

IRIDEX...................................................................2319 


Optovue, Inc............................................................754 

Pharma Vision.......................................................4556 


VersaSuite.............................................................1065 

VueCare Media.....................................................4334 

Computer Systems - Clinical 

Allscripts...............................................................2852 

Compulink Business Systems, Inc.......................2315 

DavLong Business Solutions................................3872 

EyeIC, Inc..............................................................2001 

Eyekor, LLC............................................................2077 

EyeMD EMR Healthcare Systems, Inc..................357 

ifa Systems AG.....................................................3862 






Medflow, Inc.........................................................3152 

NexTech................................................................2757 

NextGen Healthcare.............................................3456 

SRSsoft.................................................................3367 

The Electronic Office..............................................114 


VersaSuite.............................................................1065 


Computer Systems - Office Management 

Allscripts...............................................................2852 






First Insight Corporation.......................................4417 

ifa Systems AG.....................................................3862 






Medflow, Inc.........................................................3152 

Medinformatix, Inc.................................................337 

NexTech................................................................2757 


OptiCall, Inc..........................................................2475 


SRSsoft.................................................................3367 


VersaSuite.............................................................1065 


Vision Associates.................................................2552 

Conjunctival/Lids 




OFCOR...................................................................2834 


Development Co., Ltd......................................2774 

Contact Lens/Accessories/Solutions 


OCuSOFT, Inc........................................................2362 

Contact Lenses (diagnostic, laser, 

surgical) 


Haag-Streit Group................................................3808 


Ocular Instruments, Inc........................................2719 

Odyssey Medical, Inc...........................................2632 

Contact Lenses (hard, soft, disposable) 


Continuing Education 








Cornea/External Disease 


Allergan................................................................1408 











Surgistar, Inc.........................................................1162 

TearScience..........................................................4362 


Development Co..............................................2774 



WJSupply.............................................................4547 

Corneal and InterCorneal Rings 

Addition Technology, Inc......................................3135 

Corneal Topography 



Oculus, Inc............................................................3814 

S4Optik, LLC............................................................865 

SCHWIND eye-tech-solutions.............................2962 


Tracey Technologies.............................................2204 

Woodlyn................................................................2139 

Cosmetics/Skin Care 

OCuSOFT, Inc........................................................2362 

Cross Linking 

Accutome..............................................................4221 

Aurolab.................................................................3276 

Oculus, Inc............................................................3814 

Optos, Inc................................................................720 


Cryosurgical Systems 

Brymill Cryogenic Sys...........................................2776 



Diagnostic Equipment 


Conestoga Equipment Finance Corp....................1674 


DXDT Engineering and Research.........................4457 

Ellex.......................................................................3804 


314

Product Index 

EyeIC, Inc..............................................................2001 


Fundus Photo........................................................1850 



ifa Systems AG.....................................................3862 

Inami & Co., Ltd....................................................1900 

International Eye Foundation...............................2785 



Meda Co., Ltd.......................................................2701 

Metrovision...........................................................2653 

Neotech Medical Pvt., Ltd....................................2300 

NeurOptics............................................................1173 


OCuSOFT, Inc........................................................2362 


Optos, Inc................................................................720 

Optovue, Inc............................................................754 

PHSI-Physician Hearing Services, Inc..................2137 


S4Optik, LLC............................................................865 


Stereo Optical Company......................................2634 


TearScience..........................................................4362 

TelScreen..............................................................2045 

The Electronic Office..............................................114 





TTI Medical.............................................................147 

Viewlight, LLC.........................................................551 


Volk Optical, Inc....................................................1436 



Woodlyn................................................................2139 

Digital Video Systems 



Clarity Medical Systems, Inc...............................1020 


Fundus Photo........................................................1850 



HIMS, Inc................................................................563 

Inami & Co., Ltd....................................................1900 


NeurOptics............................................................1173 

S4Optik, LLC............................................................865 

TearScience..........................................................4362 

TelScreen..............................................................2045 

TTI Medical.............................................................147 

VueCare Media.....................................................4334 

Dispensing Aids/Equipment/Furniture 

Eye Designs, LLC..................................................3837 

Fashion Optical Displays........................................137 

HIMS, Inc................................................................563 


SPECS4US...............................................................504 





Disposable Surgical Instrument 


Althoraya..............................................................1579 




Diamatrix Ltd........................................................1946 



Geuder..................................................................2726 




MANI....................................................................2730 

Medicel AG.............................................................751 

MORIA..................................................................1449 

OASIS Medical, Inc..............................................2615 


OCuSOFT, Inc........................................................2362 


Sterimedix.............................................................2726 

Surgistar, Inc.........................................................1162 

The Lebanon Corporation.......................................151 



Viscot Medical, LLC..............................................1805 



WJSupply.............................................................4547 

Disposables/Drapes, Gloves, Sponges 

Althoraya..............................................................1579 



OCuSOFT, Inc........................................................2362 

SURGI EDGE.........................................................4202 


Varitronics...............................................................321 


Electronic Medical Records 

Allscripts...............................................................2852 








ifa Systems AG.....................................................3862 






Medflow, Inc.........................................................3152 


NexTech................................................................2757 


OptiCall, Inc..........................................................2475 

Optos, Inc................................................................720 

SRSsoft.................................................................3367 

VersaSuite.............................................................1065 


Endothelial Cell Counter 




Equipment Financing/Leasing 


Merrill Lynch.........................................................2928 


Woodlyn................................................................2139 

Equipment/Supplies 






Hausted Patient Handling Systems, LLC.............3475 


Metrovision...........................................................2653 

Mobius Therapeutics, LLC....................................3370 


Super Systems/Fast Grind Intl.............................2972 

Viewlight, LLC.........................................................551 

Vision Quest Surgical, Inc....................................2802 

Woodlyn................................................................2139 

Evoked Potential Systems 

Metrovision...........................................................2653 

Examining Units 





NeurOptics............................................................1173 

Optovue, Inc............................................................754 

S4Optik, LLC............................................................865 



Viewlight, LLC.........................................................551 


Eye Bank Products 

AL.CHI.MI.A. S.r.l..................................................4200 



Surgistar, Inc.........................................................1162 


Eye Models, Charts, Anatomical Model 




Eyelid Closure Products 


Labtician Ophthalmics, Inc...................................2100 

MedDev Corporation............................................3004 

Facility Design/Furnishng/Planning 

Eye Designs, LLC..................................................3837 

Fashion Optical Displays........................................137 

Femto Lasers and Instruments 


Accutome..............................................................4221 

Product Index 

315

Product Index 

Product Index 



OptiMedica...........................................................4044 

Femtosecond 





OptiMedica...........................................................4044 


Filing/Recall Systems 


SRSsoft.................................................................3367 

VersaSuite.............................................................1065 

Finance and Credit 

Bank of America Practice Solutions......................133 

CareCredit...............................................................545 


Merrill Lynch.........................................................2928 

Finance and Investment 



Merrill Lynch.........................................................2928 


Finance and Leasing 



Merrill Lynch.........................................................2928 

Fixation Devices 

Charmant, Inc..........................................................228 






Varitronics...............................................................321 


Frames, Glasses, Sunglasses 


Live Eyewear, Inc..................................................2434 

OCuSOFT, Inc........................................................2362 


Pharma Vision.......................................................4556 

SPECS4US...............................................................504 



Glasses, Operating Room Goggles 



Glaucoma 



Allergan................................................................1408 


Aurolab.................................................................3276 



Ellex.......................................................................3804 




EyeIC, Inc..............................................................2001 

EyeTechCare.........................................................2669 




Fundus Photo........................................................1850 


IRIDEX...................................................................2319 


Meda Co., Ltd.......................................................2701 


Metrovision...........................................................2653 



Optovue, Inc............................................................754 




Thea......................................................................2662 

Valeant Ophthalmics............................................3076 

Glaucoma Implants 





Glaucoma Pressure 

EyeTechCare.........................................................2669 



Oculus, Inc............................................................3814 

Handheld Instruments 

Accutome..............................................................4221 






Diamatrix Ltd........................................................1946 




Geuder..................................................................2726 



HIMS, Inc................................................................563 



IRIDEX...................................................................2319 


LacriSciences, LLC..................................................664 

MANI....................................................................2730 


MORIA..................................................................1449 








Sterimedix.............................................................2726 





WJSupply.............................................................4547 

Health Care Management 

Allscripts...............................................................2852 



DigiSight Technologies, Inc..................................4549 





SRSsoft.................................................................3367 

VersaSuite.............................................................1065 

Hearing Systems 

Avada Hearing Care Centers................................2777 

Meda Co., Ltd.......................................................2701 


Imaging Systems 




Ellex.......................................................................3804 


EyeIC, Inc..............................................................2001 


Fundus Photo........................................................1850 



HIMS, Inc................................................................563 

ifa Systems AG.....................................................3862 




Oculus, Inc............................................................3814 



Optos, Inc................................................................720 


TearScience..........................................................4362 

TelScreen..............................................................2045 

TTI Medical.............................................................147 

VersaSuite.............................................................1065 


Implants, Glaucoma 







Implants, IOL 

AA Vision, Inc.......................................................1804 

Aurolab.................................................................3276 

I-MED Pharma......................................................2855 



Morcher GmbH.....................................................2049 

PhysIOL SA..............................................................972 




316

Product Index 


Implants, Ocular, Enucleation, 

Evisceration 



PhysIOL SA..............................................................972 



Informational Exhibits 



Registered Nurses (ASORN)...........................2782 

Benign Essential Blepharospasm 

Research Foundation.......................................2880 

EVER - European Association For 

Vision and Eye Research.................................2882 


Glaucoma Research Foundation..........................2781 

Global Sight Alliance............................................2883 


Mayo Clinic...........................................................2884 

Medical Ministry International............................2881 

Southern Eye Bank...............................................4538 

Surgical Eye Expeditions (SEE) International......2780 

Turkish Ophthalmology Society (TOS)....................505 

In-home Postop Cataract Care 


Pharma Vision.......................................................4556 

In-office Lens Production/Finishing 


Instrument Maintenance/Repair 

Althoraya..............................................................1579 




Diamatrix Ltd........................................................1946 



Geuder..................................................................2726 




Synergetics, Inc....................................................4208 

Instruments, Disposable 

Althoraya..............................................................1579 




Diamatrix Ltd........................................................1946 

DORC International, bv/Dutch 

Ophthalmic, USA.............................................1026 






I-MED Pharma......................................................2855 

IRIDEX...................................................................2319 



MANI....................................................................2730 

MORIA..................................................................1449 



OPHTEC.................................................................4037 


Sterimedix.............................................................2726 

SURGI EDGE.........................................................4202 

Surgistar, Inc.........................................................1162 



Instruments, Reusable 

Althoraya..............................................................1579 




Charmant, Inc..........................................................228 


Diamatrix Ltd........................................................1946 









Geuder..................................................................2726 


I-MED Pharma......................................................2855 

Inami & Co., Ltd....................................................1900 




MORIA..................................................................1449 



OPHTEC.................................................................4037 


SURGI EDGE.........................................................4202 





WJSupply.............................................................4547 

Insurance 


Merrill Lynch.........................................................2928 



Inter-office Communication Systems 

Expeditor Systems, Inc.........................................1950 

Intraocular Lenses 

AA Vision, Inc.......................................................1804 


Aurolab.................................................................3276 


I-MED Pharma......................................................2855 



Lenstec, Inc...........................................................1169 


Morcher GmbH.....................................................2049 

OPHTEC.................................................................4037 

PhysIOL SA..............................................................972 



Tekia, Inc.................................................................437 

Irrigation/Aspiration 

Althoraya..............................................................1579 






Geuder..................................................................2726 





OFCOR...................................................................2834 

Sterimedix.............................................................2726 

SURGI EDGE.........................................................4202 





Keratometers/Ophthalmometers 

AA Vision, Inc.......................................................1804 


Oculus, Inc............................................................3814 


S4Optik, LLC............................................................865 



Varitronics...............................................................321 

Woodlyn................................................................2139 

Knives, Diamond 

Accutome..............................................................4221 




Diamatrix Ltd........................................................1946 








SURGI EDGE.........................................................4202 

Knives, Disposable 

Accutome..............................................................4221 

Aurolab.................................................................3276 




Diamatrix Ltd........................................................1946 



MANI....................................................................2730 




SURGI EDGE.........................................................4202 

Surgistar, Inc.........................................................1162 

Product Index 

317

Product Index 

Product Index 



Lacrimal Products 

AA Vision, Inc.......................................................1804 






LacriSciences, LLC..................................................664 




SURGI EDGE.........................................................4202 

Surgistar, Inc.........................................................1162 

Thea......................................................................2662 

Laser Accessories 


Emtron...................................................................4162 



Laser Phaco 


Meda Co., Ltd.......................................................2701 


Viewpoint International Corp...............................2637 

Lasers - Demonstrated 




Ellex.......................................................................3804 

IRIDEX...................................................................2319 

OptiMedica...........................................................4044 



Lasers - Display Only 



OptiMedica...........................................................4044 

Optos, Inc................................................................720 

Latex Free Products 



Medicel AG.............................................................751 



Lens Manufacturing Equipment 




Lenses (aspheric, filter, progressive) 








Volk Optical, Inc. 

Lensmeters 



S4Optik, LLC............................................................865 

Viewlight, LLC.........................................................551 


Woodlyn................................................................2139 

Low Vision Aids/Screening 



Enhanced Vision...................................................2650 

Eschenbach Optik.................................................3123 



Metrovision...........................................................2653 

OCuSOFT, Inc........................................................2362 




Low Vision Rehabilitation 


Eschenbach Optik.................................................3123 

HIMS, Inc................................................................563 

Market Research 




Medical Records, Electronic 

Allscripts...............................................................2852 







ifa Systems AG.....................................................3862 




Keiser Computers, Inc............................................158 



SRSsoft.................................................................3367 

VersaSuite.............................................................1065 


Medical Retina 

AL.CHI.MI.A. S.r.l..................................................4200 




EyeIC, Inc..............................................................2001 


Fundus Photo........................................................1850 

IRIDEX...................................................................2319 


NeurOptics............................................................1173 

Optovue, Inc............................................................754 



Medical Society, Association 


JAMA Network....................................................3570 

Microkeratome 

MORIA..................................................................1449 



Microscopes 



Inami & Co., Ltd....................................................1900 



Leica Microsystems..............................................2739 

Meda Co., Ltd.......................................................2701 

TTI Medical.............................................................147 



Viewlight, LLC.........................................................551 


Microsurgical Equipment/ 

Instrumentation 

AA Vision, Inc.......................................................1804 


Diamatrix Ltd........................................................1946 






Medicel AG.............................................................751 


MORIA..................................................................1449 



SURGI EDGE.........................................................4202 






i2eye diagnostics limited.....................................2973 

Metrovision...........................................................2653 


NeurOptics............................................................1173 

Oculus, Inc............................................................3814 



New Exhibitor 

1-800-DOCTORS.....................................................255 

AAO Meetings On Demand...................................605 


AKtive Srl..............................................................2575 

Almic Co., Ltd........................................................3177 

Althoraya Company For Import & Export.............1579 

Angie’s List............................................................2576 

Are You a Donor?....................................................126 

Art Optical Contact Lens, Inc...............................2075 

Avada Hearing Care Centers................................2777 

Beijing Sonop Technology Co., Ltd.......................1172 

CapitalSource.......................................................4622 

Centers For Medicare & Medicaid Services.......1675 

Charmant Inc...........................................................228 

Chongqing Sunkingdom Medical 

Instruments Co., Ltd..........................................462 


318

Product Index 

Dove Medical Press, Ltd........................................263 


Emory Genetics Laboratory..................................1977 

European Society of Retina Specialists 

(EURETINA)......................................................2703 

Everyday Health, Inc.............................................4458 

Eyekor, LLC............................................................2077 


Eye-Novation........................................................3275 




Fischer Pharmaceuticals, Ltd...............................1874 

Global Sight Alliance............................................2883 

HIMS, Inc................................................................563 

ImmersiveTouch, Inc.............................................2175 

MEDVISION..........................................................4621 

Miraflex.................................................................1773 



MTBC....................................................................2176 

NeurOptics............................................................1173 

Novamed Ceramisys Limited...............................1075 

Pharma Vision.......................................................4556 

PhysIOL sa...............................................................972 

PNC Bank..............................................................1979 

Professional Data Systems..................................3274 

Rose Micro Solutions...........................................2452 

Sensor Medical Technology...................................680 

Shanghai EDER Medical Equipment Co., Ltd......1873 

Shanghai Xiaolai Science and Trade Co..............2977 

SightLife..................................................................226 

Southwest Medical Books...................................2177 

Specs4Us................................................................504 

Sterling Institutional Review Board.....................4537 

University Hosptials/Case Western 


Vision Surgical......................................................2752 

New Product 



Medicel AG.............................................................751 


Optovue, Inc............................................................754 

SPECS4US...............................................................504 

TelScreen..............................................................2045 

VRmagic, Inc...........................................................762 

Non-FDA 


EyeTechCare.........................................................2669 


Geuder..................................................................2726 



Thea......................................................................2662 

Nutraceuticals 

Biosyntrx, Inc........................................................2830 


OCuSOFT, Inc........................................................2362 

ScienceBased Health...........................................2936 

Nutritional Supplements 

Biosyntrx, Inc........................................................2830 


OCuSOFT, Inc........................................................2362 

ScienceBased Health...........................................2936 

Thea......................................................................2662 

Ocular Implants 



Aurolab.................................................................3276 

MedDev Corporation............................................3004 


OPHTEC.................................................................4037 


SURGI EDGE.........................................................4202 



Ocular Prosthetics 




Online Services 



VueCare Media.....................................................4334 

Ophthalmic Pathology 


Thea......................................................................2662 



Ophthalmic Surgery 

Accutome..............................................................4221 


AL.CHI.MI.A. S.r.l..................................................4200 

Althoraya..............................................................1579 





Charmant, Inc..........................................................228 






EyeTechCare.........................................................2669 



Geuder..................................................................2726 


Inami & Co., Ltd....................................................1900 

IRIDEX...................................................................2319 


MANI....................................................................2730 

Meda Co., Ltd.......................................................2701 




MORIA..................................................................1449 


Ocular Systems, Inc..............................................1601 

Pharma Vision.......................................................4556 

PhysIOL SA..............................................................972 


Sterimedix.............................................................2726 

Surgistar, Inc.........................................................1162 


Thea......................................................................2662 



TTI Medical.............................................................147 






VRmagic, Inc...........................................................762 

WJSupply.............................................................4547 

Ophthalmoscopes 





VRmagic, Inc...........................................................762 

Woodlyn................................................................2139 

Optical Coherent Tomography 



Optos, Inc................................................................720 

Optovue, Inc............................................................754 


Optical Lab Equipment 


Consultronix S.A...................................................2769 



Viewlight, LLC.........................................................551 


Optics/Refraction 










Organizations 



Registered Nurses..........................................2782 


Outcomes Management 



ifa Systems AG.....................................................3862 



SRSsoft.................................................................3367 

Patient Education Materials 



Eyemaginations....................................................2949 


Product Index 

319

Product Index 

Product Index 







VueCare Media.....................................................4334 

Patient Engagement 





EyeIC, Inc..............................................................2001 


OptiCall, Inc..........................................................2475 

SRSsoft.................................................................3367 

VueCare Media.....................................................4334 

Patient Flow 


Expeditor Systems, Inc.........................................1950 



SRSsoft.................................................................3367 

VersaSuite.............................................................1065 

VueCare Media.....................................................4334 









Metrovision...........................................................2653 


MORIA..................................................................1449 


OPHTEC.................................................................4037 


SPECS4US...............................................................504 

Thea......................................................................2662 

Pediatrics 






SPECS4US...............................................................504 


Perimeters/Field Testing 




Metrovision...........................................................2653 

Oculus, Inc............................................................3814 




Woodlyn................................................................2139 

Phacoemulsification 



Geuder..................................................................2726 

Medicel AG.............................................................751 

OPHTEC.................................................................4037 






Pharmaceuticals 

Accutome..............................................................4221 


Allergan................................................................1408 

Bayer Healthcare Pharmaceuticals........................153 

Biosyntrx, Inc........................................................2830 





OCuSOFT, Inc........................................................2362 

Pharma Vision.......................................................4556 

Regeneron Pharmaceuticals..................................353 



Photographic Products 


EyeIC, Inc..............................................................2001 

Fundus Photo........................................................1850 

NeurOptics............................................................1173 



Physician Education Materials 


Are You a Donor?....................................................126 



VRmagic, Inc...........................................................762 

Physician Recruitment 


BJB Medical Associates........................................159 

The Eye Group......................................................1951 


Plastics/Reconstructive 




Posterior Segment 

AL.CHI.MI.A. S.r.l..................................................4200 






EyeIC, Inc..............................................................2001 


Fundus Photo........................................................1850 

IRIDEX...................................................................2319 




TTI Medical.............................................................147 


Post-op Treatment 




Pharma Vision.......................................................4556 

Practice Management/Marketing 

Services 


Allscripts...............................................................2852 

Ceatus Media Group............................................3102 





ifa Systems AG.....................................................3862 





NexTech................................................................2757 


OptiCall, Inc..........................................................2475 




SRSsoft.................................................................3367 

Varitronics...............................................................321 

VersaSuite.............................................................1065 


VueCare Media.....................................................4334 

Preowned Equipment 


TelScreen..............................................................2045 


Protective Eyewear 



PeriOptix, Inc.........................................................2237 

Recruitment 


BJB Medical Associates........................................159 



The Eye Group......................................................1951 



Refracting Systems 




OPHTEC.................................................................4037 



S4Optik, LLC............................................................865 



Viewlight, LLC.........................................................551 







320

Product Index 





Metrovision...........................................................2653 


MORIA..................................................................1449 


OPHTEC.................................................................4037 

OptiCall, Inc..........................................................2475 


PhysIOL SA..............................................................972 



SURGI EDGE.........................................................4202 

Surgistar, Inc.........................................................1162 

TTI Medical.............................................................147 


Research and Development Services 

Eyekor, LLC............................................................2077 


Sterling Institutional Review Board.....................4537 



Retina/Vitreous Surgery 

AL.CHI.MI.A. S.r.l..................................................4200 

Allergan................................................................1408 



Diamatrix Ltd........................................................1946 




Ellex.......................................................................3804 







Fundus Photo........................................................1850 


IRIDEX...................................................................2319 



Meda Co., Ltd.......................................................2701 

MedOne Surgical, Inc...........................................2831 


Oculus, Inc............................................................3814 

Optos, Inc................................................................720 


Surgistar, Inc.........................................................1162 









VRmagic, Inc...........................................................762 

WJSupply.............................................................4547 

Retinal Specialties 

AL.CHI.MI.A. S.r.l..................................................4200 

Alimera Sciences..................................................4414 


Aurolab.................................................................3276 







EyeIC, Inc..............................................................2001 


Fundus Photo........................................................1850 

Geuder..................................................................2726 

IRIDEX...................................................................2319 



Optos, Inc................................................................720 

Optovue, Inc............................................................754 



Slit Lamp Instruments 




Fundus Photo........................................................1850 



Oculus, Inc............................................................3814 


TelScreen..............................................................2045 

TTI Medical.............................................................147 


Slit Lamps 

AA Vision, Inc.......................................................1804 








Inami & Co., Ltd....................................................1900 





S4Optik, LLC............................................................865 



TelScreen..............................................................2045 


TTI Medical.............................................................147 

Viewlight, LLC.........................................................551 

Woodlyn................................................................2139 

Small Incision Surgery 


Charmant, Inc..........................................................228 

Diamatrix Ltd........................................................1946 

Medicel AG.............................................................751 



WJSupply.............................................................4547 

Smartphone 





Sodium Hyaluronate 

Thea......................................................................2662 

Staff/Assistant Training 



OptiCall, Inc..........................................................2475 

The Eye Group......................................................1951 

VueCare Media.....................................................4334 

Strabismus 



Metrovision...........................................................2653 

OFCOR...................................................................2834 


SPECS4US...............................................................504 

Surgery Centers 


Surgery Simulator 

VRmagic, Inc...........................................................762 

Surgical Instruments, Disposable 

AA Vision, Inc.......................................................1804 

Accutome..............................................................4221 

Althoraya..............................................................1579 



Diamatrix Ltd........................................................1946 









IRIDEX...................................................................2319 


MANI....................................................................2730 

Medicel AG.............................................................751 

MORIA..................................................................1449 




OCuSOFT, Inc........................................................2362 


Sterimedix.............................................................2726 

Surgistar, Inc.........................................................1162 







WJSupply.............................................................4547 

Surgical Instruments, Reusable 

AA Vision, Inc.......................................................1804 

Accutome..............................................................4221 

Product Index 

321

Product Index 

Product Index 

Althoraya..............................................................1579 




Charmant, Inc..........................................................228 


Diamatrix Ltd........................................................1946 









Geuder..................................................................2726 






Medicel AG.............................................................751 

MORIA..................................................................1449 



OCuSOFT, Inc........................................................2362 

OFCOR...................................................................2834 










WJSupply.............................................................4547 

Surgical Lights 

Designs For Vision, Inc...........................................562 


PeriOptix, Inc.........................................................2237 

Surgical Loupes 

Designs For Vision, Inc...........................................562 


PeriOptix, Inc.........................................................2237 


Surgical Tables/Stools/Stretchers 

Brumaba USA, Inc................................................4527 



Hausted Patient Handling Systems, LLC.............3475 

UFSK-International OSYS, GmbH........................4218 

Varitronics...............................................................321 

Sutures 

AA Vision, Inc.......................................................1804 

Aurolab.................................................................3276 


MANI....................................................................2730 

Tissue Grafts/Biologics 





Toric 




OPHTEC.................................................................4037 

PhysIOL SA..............................................................972 





Trial Frames/Trial Lens Sets 

AA Vision, Inc.......................................................1804 



Oculus, Inc............................................................3814 


S4Optik, LLC............................................................865 


Viewlight, LLC.........................................................551 


Woodlyn................................................................2139 

Ultrasound 

Accutome..............................................................4221 


Ellex.......................................................................3804 

EyeTechCare.........................................................2669 


Meda Co., Ltd.......................................................2701 


Optos, Inc................................................................720 


Used Equipment 





TelScreen..............................................................2045 


Uveitis/Immunology 



Thea......................................................................2662 

Video, Digital Systems 




HIMS, Inc................................................................563 



TearScience..........................................................4362 

TelScreen..............................................................2045 

TTI Medical.............................................................147 

Viewlight, LLC.........................................................551 


VueCare Media.....................................................4334 

Video, Production 




Viscoelastics 

AA Vision, Inc.......................................................1804 


Aurolab.................................................................3276 


I-MED Pharma......................................................2855 


Lenstec, Inc...........................................................1169 


OPHTEC.................................................................4037 




Vision Screening/Training 


Metrovision...........................................................2653 

Oculus, Inc............................................................3814 


Vitrectomy 

AA Vision, Inc.......................................................1804 

AL.CHI.MI.A. S.r.l..................................................4200 





Geuder..................................................................2726 

IRIDEX...................................................................2319 


Meda Co., Ltd.......................................................2701 

Medicel AG.............................................................751 






Website Design/Marketing 

Ceatus Media Group............................................3102 




ifa Systems AG.....................................................3862 


VueCare Media.....................................................4334 

322

Participant Index 

A 

Aaberg Jr, TM xxv, 56 

Aaron, MM 34, 61, 115, 116 

Abad, J 60 

Abbott, MA 125 

Abbott, RL xiii, 142, 144 

Abboud, E 105, 229, 233 

Abdel-Fattah, TAM 28 

AbdelRahim, AM 161, 197, 231 

Abdel Wahab, T 102 

Abe, K 218 

Abelairas, J 221 

Abe, R 207 

Abessi, B 224 

Abiad, MB 180 

Abou Shousha, MF 158 

Abrams, GW 128 

Abramson, D 212 

Abruzzo, MD 53, 284, 285, 286 

Abu El-Asrar, AM 197 

Acharya, M 184 

Acharya, RU 184 

Acharya, S 197 

Acinue, CA 207 

Ackerman, SL 191 

Adelman, RA 34, 60, 115 

Adi, M 196 

Adler, PA 28 

Affel, EL 210 

Afifi, A 199 

Afshari, NA 75, 115, 194 

Agabegi, ED 217 

Agarwal, A 19, 60, 62, 63, 64, 67, 

69, 76, 103, 112, 116, 132, 136, 

139, 179, 227, 247, 248, 250 

Agarwal, AK 241 

Agarwal, D 192, 250 

Agarwal, MR 22, 33 

Agarwal, T 70, 249 

Agarwal, Z 225 

Agrawal, S 180 

Agron, E 178, 228 

Aguirre, T 57 

Ahmadieh, H 209 

Ahmad, N 180, 214 

Ahmed, AR 184 

Ahmed, IK 34, 60, 61, 62, 66, 67, 83, 

84, 87, 103, 115, 120, 121, 122, 

134, 139, 147, 160, 161 

Ahn, HA 89 

Ahn, HB 216 

Aiello, L 106, 238 

Aiello, LM 238 

Aiello, LP 145, 147 

Aihara, M 83, 186, 209 

Akagi-Kurashige, Y 230, 232, 

236, 237 

Akar, S 218 

Akhtar, A 163, 231 

Akpek, EK 73, 74, 77, 159 

Alarcon, C 167, 211, 253 

Al-Assiri, A 224 

Al-Aswad, LA 22 

Al-Ayoubi, A 214 

Albert, DM 88 

Albert Jr, MA 22 

Albert, MA 172 

Albini, TA 54, 88 

Alburquerque Montes De Oca, 

R 198 

Alcorta, AL 135 

Al-Dahmash, SA 212, 243 

Aldahmesh, MA 220 

Aldave, AJ 52, 66, 68, 70, 72, 73, 

77, 79, 116, 132, 136, 159, 245 

Alder, BD 194 

Al-Dhibi, HA 207, 208 

Alfaro, T 205 

Alfawaz, A 224 

Alfonso, EC 69, 73, 74, 116, 119, 

158, 185 

Alford, MA 95, 124, 125, 165 

Al-Gehedan, S 224 

Alghamdi, M 229 

Aliaga Diaz, D 255 

Ali, M 251, 263 

Ali, MJ 69, 108, 216, 243 

Alio, JL 56, 102, 103, 149, 158, 178 

Ali, R 159 

Aliseda, D 225 

Aljadaan, IA 208, 252 

Alkatan, HM 214 

Alkuraya, FS 220, 229, 238 

Alkuraya, HS 229 

Allan, B 157 

Allan, E 209 

Al-Latayfeh, MM 242 

Allemann, N 190, 208 

Allen, RC 95, 98, 124, 125, 216 

Allikmets, R 171 

Al-Mansouri, SM 224 

Almeida, AO 252 

Almeida, L 237 

Al Mobarak, F 202 

Al Muammar, AM 197 

Alobeidan, SA 161, 197 

Al Odhayb, S 202, 208 

Alotaibi, MM 202 

Alpay, A 175 

Al Qahtani, M 202 

Alqahtani Sr, DS 208 

Alqudah, AA 193, 194 

Alrajhi, AA 28 

AlRajhi, AA 194 

Alrashed, M 238 

Al Rashed, WA 209, 214 

Al Rushood, A 207, 208 

Al Shahwan, S 82, 202, 208, 217 

Al Shamsi, HN 207, 208 

Al-Sheikh, OH 209, 214 

Alsulaiman, SM 207, 208 

Altaweel, MM 128, 163 

Altinsoy, HI 199 

Altmann, G 177 

Alvarado, JA 84, 121 

Alves, D 215 

Alwassia, AA 239 

Al-Zahrani, YA 207, 208 

Amar, A 204 

Amayem, AF 119 

Ambati, BK 83, 116 

Ambrosio Jr, R 53, 104, 127, 189 

Ament, CS 116 

Ament, J 187 

Amirikia, A xxv 

Ammar, D 197 

Amparo, F 186 

Amstutz, SW 155 

Amtirat, A 199 

Amzallag, T 176 

Anand, N 22 

Anand, R 233 

Anders, MD 137 

Anderson, DR 201 

Anderson, RL 95 

Andonegui, J 225 

Ang, AY 118, 149 

Ang, H 187 

Angrist, R 124 

Ang, RT 176, 223 

Angunawela, RI 157, 187 

Annam, R 231 

Annunziata, CC 57, 95, 124 

Ansari, H 81, 120 

Antoszyk, AN 56 

Aoki, Y 199 

Ao, M 213 

Appa, SN 226 

Applegate, DM 22 

Apsey, D 223 

Apte, RS 34 

Aquavella, J 77, 140, 159, 245 

Aquino, MD 87 

Araie, M 199, 204 

Arakawa, A 244 

Arana, B 214 

Arantes, TE 208 

Arat, YO 209, 214 

Aravind, H 116, 179 

Arbelaez, MC 222 

Arbisser, LB 54, 56, 62, 64, 67, 116, 

139, 264 

Arce-Lopez, EA xxv 

Archer, TJ 225 

Aref, AA 111, 252 

Arevalo, J 111, 207, 208, 233 

Arevalo, JF 34 

Arffa, RC 71 

Arias, JD 211, 253 

Arici, C 176 

Armada, F 221 

Armitage, WJ 187 

Arndt, CF 229 

Arneja, A 184 

Arnoldi, KA 99 

Arnold, PP 54 

Arnold, TB 203 

Aron Rosa, DS 3 

Arora, R 180, 186, 195, 208 

Arregui, P 116 

Arrindell, EL 148 

Arshinoff, SA 64, 65, 138, 139 

Arslan, OS 176 

Artes, PD 202 

Arthurs, B 125 

Artornsombudh, P 207 

Asbell, P 74 

Ascaso, FJ 233 

Ashar, JN 68, 72, 73, 75, 99, 184, 

189, 190, 194 

Ashrafzadeh, A 53 

Asokan, R 197 

Assil, K 179 

Astakhov, YS 236 

Atalay, E 176 

Atebara, NH 128 

Attas-Fox, L 126, 166 

Au, A 215 

Au Eong, K 182 

Auffarth, GU 145, 247 

Augsburger, J 91 

Aung, T 84, 86, 120, 140, 149, 160 

Aurora, A 239 

Avadhani, K 208 

Avaz, F 226 

Avery, RL 233, 237 

Avila, MR 169 

Avram, D 165 

Awad, O 63 

Awan, AH 28 

Awan, MR 232 

Awdeh, RM 66 

Awender, NE 115 

Ayers, T 190 

Aygt, ED 218 

Ayres, B 118, 127, 249 

Azad, RV 147, 174 

Azancoth, F 238 

Azarbod, P 199 

Azar, DT 136 

Azarmina, H 245 

Azarmina, M 245 

B 

Bacal, DA 99 

Badala, F 118 

Badal Lafulla, J 243 

Badaro, RM 248 

Badoza, DA 28 

Bae, J 237 

Baek, S 200 

Baerveldt, G 81, 120, 122 

Baheti, U 184 

Baikoff, GD 69, 102 

Bailey, C 229 

Bailey Jr, RS 22 

Bailey, RS 115 

Bajric, J 242 

Bakbak, B 164 

Baker, CW 110 

Baker, N 34, 291, 292, 294 

Bakewell, BK 62, 116, 117 

Bakhtiari, P 119, 185 

Bakouli, A 28 

Bakri, S 136, 225, 242 

Bakri, SJ 34, 130, 143, 169 

Balaggan, KS 159, 233, 255 

Balaiya, S 235 

Balcer, LJ 164, 210 

Balducci, N 244 

Balne, PK 207 

Bandi, J 201 

Bandyopadhyay, D 220 

Banerjee, PJ 182 

Banik, R 204, 211 

Banitt, MR 120, 188, 195 

Banker, AS 111, 166, 207, 233 

Banker, D 166 

Banker, T 232 

Bansal, AT 171 

Bansal, P 238 

Bansal, R 209 

Bansal, RK 167 

Bansal SR, Y 218 

Banta, JT 116 

Barakat, W 217 

Barak, Y 242 

Barbas Pires, G 238 

Barberger-Gateau, P 227, 241 

Barber, LG xiii, 17, 19 

Barnebey, H 80, 83, 119, 120, 121 

Barnes, SD 102, 127 

Barnett, EM 122 

Barney, NP 73 

Barraquer Compte, RI 102 

Barr, CC 135, 136 

Barria von Bischhoffsha, F 54 

Barrows, JM 141 

Barteselli, G 255 

Bartley, GB xiii 

Barton, K 85, 87, 120 

barua Jr, n 202 

Basak, S 206 

Basak, SK 61, 64, 116, 162, 205, 

206, 251 

Basefsky, J 233 

Baser, EF 203 

Bassi, ST 210 

Basti, S 103, 116, 253 

Basu, S 75, 159, 185, 186, 207 

Bateman, JB 100 

Batlle, JF 141, 198, 248 

Baumal, CR 107 

Baumann, B 231 

Baumeister, M 28 

Bayer, A 199 

Bazvand, F 185 

Beach, M 190 

Beardsley, RM 229 

Bearelly, S 240 

Beaver, HA 115 

Bechrakis, NE 105 

Becker, B 3 

Becker, BB 124 

Bedrossian, EH 125 

Beer, P 180 

Behlau, I 187 

Behrens, A 52 

Beiko, G 33, 60, 116, 181 

Beke, N 238 

Belfort Jr, R 88, 111 

Belin, MW 72, 76, 77, 117 

Bell, DJ 231 

Bellucci, R 22 

Belsare, GN 214 

Beltrame, G 181 

Beltz, JE 71, 249, 250 

Belyea, D 115 

Benator, R xxv 

Benchaboune, M 226 

Benchimol, S 60 

Bencic, G 200 

Benedetto, P 165 







Benes, S 135 

Benitez-Bajandas, GA 244 

Benjamin, J 134 

Ben Yahia, S 234 

Berasategui Fernandez, B 214 

Berdahl, JP 65, 127 

Berdy, GJ 75, 196 

Berezina, T 198, 199 

Berezovsky, A 239 

Berger, B 55, 227 

Bergstrom, LK xxv 

Berlin, M 121, 202 

Berman, EL 122 

Bermudez, HJB 28 

Bernardini, FP 28, 94, 96, 125 

Bernardino, CR 125 

Bernick, DM 55, 284, 285, 286, 287 

Bernstein, DW xxv 

Berrocal, A 69 

Berrocal, MH 108, 128 

Beselga, DG 238 

Bhambhwani, VR 219 

Bhatti, MT 22 

Bhatti, RA 236, 239 

Bhavsar, AR 107, 110, 128, 229 

Bhisitkul, RB 115, 171 

Bhogal, M 157 

Bhuiyan, SI 28 

Bianciotto, CG 22, 167, 243, 253 

Biber, JM 118 

Bicho, M 238 

Bilotti, E 157 

Binder, NR 118 

Binder, PS 103, 104, 137, 145, 264 

Biousse, V 89 

Bird, AC 3 

Bisecco, A 210 

Bispo, PJ 191 

Biswas, B 206 

Bitrian, E 199 

Bittencourt, MG 163, 241 

Blackie, C 186 

Blanton, CL 103, 104 

Blaydon, SM 123 

Blecher, MH 115 

Bleyen, I 126 

Blinder, KJ 109, 128, 232 

Blodi, B 147 

Blomquist, PH 115, 116, 137 

Bloomer, MM 116 

Blumberg, D 220 

Blumenkranz, MS 133, 145 

Bocquet, B 229 

Bodaghi, B 88, 99 

Boddu, S 240 

Bodker, FS 123 

Bodnar, ZM 155, 156, 177 

Boghossian, A 127 

Bohigian, GM 135 

Boland, MV 22, 78, 143 

Boldrey, EE 226 

Bonavita, S 210 

Bond, J 120 

Bonhomme, GR 90 

Boniuk, M 209, 214 

Bonsignore, F 179, 231 

Bordewick, DL 116 

Borisuth, NC 181, 182 

Borisuth, NSC 22 

Borodic, G 123 

Borooah, S 232 

Borrillo, J 226 

Borruat, FX 22 

Bor, Z 158 

Boscarino, MA 244 

Boscia, F 115 

Bose, S 141 

Bostanci Ceran, B 175 

Bothun, ED 22, 100 

Bouchard, CS 75, 117 

Bouhaimed, M 144 

Boulos, PR 125 

Bovone, C 187 

Bowden, B 124 

Bowden, C 182 

Bowe, BE xxv 

Boyer, DS 19, 170, 171 

Boys Smith, P 287 

Bradford, C 67 

Bradford, CA xiii, xix, 16, 17, 264 

Braga-Mele, R 16, 60, 115, 139 

Branch, MJ 191 

Brandt, JD 120, 140 

Brantley Jr, MA 112 

Brar, GS 22 

Braswell, RA 16 

Bratu, A 255 

Brauner, SC 199 

Braunstein, RA 128 

Brazis, PW 90 

Brennan, MW 58, 149 

Brennen, MW 262 

Bressler, NM xxv, 110, 143, 170, 232 

Bressler, SB 110 

Briceland, DJ xix, 16, 17 

Brierley, LA 177 

Brigell, M 111 

Brinton, JP 169 

Brito, S 250 

Brockette, JT 284 

Brodie, S 212, 284 

Brodsky, MC 122 

Brooks Jr, JG xxv 

Brower, MF 156 

Brower, R 156 

Brown, AC 190 

Brown, D 169 

Brown, DM 133, 143, 145 

Brown III, JS 16 

Brown, J 266, 267, 268 

Brown, M 116 

Brown, MD 55, 58, 285, 286, 287, 

292, 293 

Brown, RH 130, 147 

Brown, S 294 

Brucker, A. J. 146 

Brucker, AJ 107, 128 

Bruinsma, M 188 

Bryan III, JA 116 

Bryar, PJ xxv 

Buchanan, AG 95 

Buckingham, DC 123, 126 

Buckley, EG 98, 100, 142 

Budenz, DL 81, 120, 201 

Büechler, P 155 

Buffenn, AN 16 

Bui, AQ 225 

Bunce, C 159 

Burden, SK 259 

Burgmeier, R 221 

Burkat, C 94, 123, 124, 126, 215, 253 

Burkhart, ZN 243 

Burnett, HK 219 

Busatto, P 181 

Busbee, BG 128 

Busin, M 28, 71, 72, 73, 118, 188, 249 

Busquets, MA 244 

Buzard, KA 103, 127 

Buznego, C 67, 196 

Byon, I 250 

C 

Cable, MG xxv, 22 

Cabre, P 210, 211 

Cade, W 227 

Cahill, KV 93, 133, 215 

Cai Sr, Xg 213 

Calabresi, P 164 

Caldwell, MC 168, 223 

Caliskan, S 175 

Callanan, DG 52 

Callejo, SA 234 

Callender, OV xxv 

Call, W 201 

Calvo, P 203 

Camara, JG 22, 166 

Camesasca, FI 28, 62, 101, 181 

Campbell, H 232 

Campbell, JR 176 

Campochiaro, PA 170, 231 

Campos, MS 223 

Cannon, D 258 

Cantera, E 223 

Cantor, LB xix, 16 

Capasso, L 189 

Capo, H 22, 33, 166 

Capone Jr, A 105, 107, 138 

Caprioli, J 146, 147, 199 

Carbonara, C 65 

Carbonaro, F 160 

Cardoso, J 238 

Cardoso, MS 181 

Carle, CF 203 

Carlson, AN 19, 115, 194 

Carones, F 101, 103 

Carp, GI 225 

Carret, A 234 

Carriere, I 226 

Carruthers, JD 134 

Carter, KD 33, 79, 95, 98, 124, 125, 216 

Carter, SR 34, 95, 125 

Carvalhaes, M 208 

Carvalho, RMLS 28 

Casas, AP 28 

Casas de Llera, P 155 

Cassell, MA 118 

Cassidy, DT 250 

Castellarin, AA 233 

Castillo, A 22, 283, 284 

Castillo SR, LM 255 

Cavalcanti, BM 186 

Cavallerano, JD 238 

Ceron, OM 207 

Cestari, DM 22, 264 

Cetinkaya, A 22 

Chailertborisuth, SK 181, 182 

Chakrabarti, A 61, 62, 64, 66, 247, 

256, 263 

Chakrabarti, M 22, 247, 256 

Chakrabati, A 116 

Chaku, M 83, 201 

Chalam, KV 86, 110, 232, 235, 236 

Chalassani, R 229 

Chambers, A 284 

Chambers, WA 138 

Chamon, W 127 

Chana, R 225 

Chan, C 163 

Chan, CC 118, 119, 130, 133 

Chandel, M 219 

Chander, J 159 

Chandra, A 182, 235 

Chandra, SR 19, 128 

Chan, E 193, 250 

Chan, EW 188 

Chang, AA 106, 110 

Chang, BC 182 

Chang, DF 16, 61, 62, 63, 65, 66, 67, 

134, 139, 161, 176 

Chang, DH 115, 116 

Chang, EL 97, 125 

Chang, HP 193 

Chang, I 207 

Chang, PY 184 

Chang, RT 118 

Chang, S 126, 138, 179 

Chang, TC 218 

Chang, TS 236, 239 

Chan, KS 179 

Channa, R 231 

Chan, RP 79, 101 

Chan, RVP 22, 132 

Chan, T 197 

Chao, A 244 

Char, DH 91 

Charles, S 244 

Charles, ST 139, 264 

Charteris, DG 182, 232 

Chaudhary, KM 196 

Chaudhry, I 209, 214 

Chaudhry, IA 33 

Chaudry, I 210 

Chau, FY 252 

Chauhan, D 247, 252 

Chaurasia, S 99, 187, 194, 217, 247 

Chavez, M 124 

Chavez-Mondragon, E 176 

Chavis, PS 134, 210 

Chawla, B 243 

Chayet, AS 160 

Chee, S 88 

Chelerkar, VJ 206 

Chelnis, JG 223 

Chen, A 190 

Chen, D 182 

Chen, ES 119, 285 

Chen, H 105 

Chen, JJ 146 

Chen, K 244 

Chen, L 105 

Chen, M 244 

Chen, MC 188, 190 

Chen, S 115 

Chen, T 244 

Chen, W 93, 191 

Chen, Y 191, 244 

Cherwek, DH 132 

Cheung, GC 107, 109, 242 

Chew, EY 5, 16, 107, 128, 135, 144, 

178, 228, 243, 262 

Chew, PK 84, 87, 160 

Chhablani, JK 255 

Chhabra, MS 209 

Chiang, A 245 

Chiang, MF 33, 77, 78, 101, 143, 

166, 184 

Chia, TT 204 

Chin, E 190, 212 

Chin Yee, DS 178 

Chiu, S 237 

Chodosh, J 19, 68, 71, 74, 75, 77, 119, 

138, 193 

Cho, H 237, 239 

Choi, H 250 

Choi, J 218 

Choi, M 232 

Choi, W 231 

Choi, Y 200, 203, 204, 205 

Cho, MY 135 

Cho, N 230 

Chong, K 93 

Chong, LP 130 

Choo, C 93 

Choplin, NT 80, 119, 120 

Chopra, V 110, 160 

Cho, RI 123 

Cho, S 232, 237 

Chotiner, B 115 

Chotiner, EA 115 

Choudhary, M 208 

Choudhri, AF 212 

Chowdhury, M 204 

Chowdhury, S 205 

Chow, S 193 

Choy, D 28 

Christakis, PG 149 

Christenbury, JG 226 

Christiansen, RM 112 

Christiansen, SM 222 

Christiansen, SP 140 

Chua, CK 184 

Chua, JL 84, 86 

Chuang, AZ 243 

Chuang, L 244 

Chuenkongkaew, W 89 

Chuku, AI 28 

Chung, M 245 

Chung, S 228 

Chung, SM 19, 33, 164 

Chu, RC 156, 182, 185 

Chu, Y 62, 67, 116, 117 

Chu, YR xxv, 19 

Ciardella, AP 230, 231, 244 

Cienfuegos, SAS 28 

Cifaldi, MA 207 

Cifers, EH 284 

Cinotti, DJ 140 

Cioffi, G 16 

Cioffi, GA 81, 87, 120, 147 

Cionni, RJ 66, 130, 139 

Ciralsky, JB 33, 71, 127 

Cirillo, M 210 

Clark, A 183 

Clark III, SW 12 

Clark, S 140 

Clifford, WS xxv, 116 

Climenhaga, HW 116 

Coakley, RB 112 

Coats, DK 77 

Coatti, JV 28 

Coburn, A 115 

Cockerham, K xxv, 125 

Coco-Martín, M 155 

Codere, F 96, 125, 126, 134, 166 

Coelho, C 238 

Cohen, EJ 138 

Cohen, JA 34, 115, 128 

Cohen, JS 81 

Colby, KA 33, 68, 75, 77, 136, 140, 193 

Coleman, A 81, 120, 146, 199 

Coleman, AL xix, 16, 149 

Colin, J 58, 102, 137, 159, 176, 195, 

227, 241 

Collins, JS xxv 

Collins, MJ 127 

Colman, S 232 

Colvard, M 66 

Comaratta, M 220 

Condon, GP 62, 87, 116, 117, 120, 161 

Connolly, D 296 

Conrad-Hengerer, I 154 

Cook, R 134 

Coon, C 170 

Copeland Jr, RA 16 

Copeland, RA 148 

Corcoran, KJ 77 

Corcostegui, BF 138 

Cornblath, WT 141, 263 

Corona, A 198 

Corona, J 126 

Correa Perez, ME 196 

Correa, RD 189 

Correa, ZM 91, 141, 144 

Cortes, DE 190 

Cortes, M 223 

Cortina, MS 69, 119, 190, 252 

Coskunseven, E 71 

Costa, E 250 

Costa, EF 234 

Costarides, AP 80 

Costa, V 207 

Costello, KC 290 

Cottle, E 282 

Cottle, ED 288, 289 

Couch, SM 95 

Couch, TD 34, 296 

Cougnard-Grégoire, A 226 

Coulantuoni, E 241 

Coupland, SG 161 

Couvillion, SS 233 

Cowan Jr, CL 148 

Crandall, AS 62, 65, 66, 67, 83, 116, 

121, 139, 160, 175, 262 

Craven, E 80, 119, 120, 121, 161 

Craven, ER 161 

Crawford, A 72, 77 

Croft, MA 180 

Crosson, JN 223 

Cruess, AF 130 

Cruzat, AC 186, 187 

Cruz, AV 214 

Csaky, KG 171 

Cui, Y 178 

Cukras, CA 228 

Culbertson, WW 66, 70, 118, 145, 

155, 248 

Cummings, AB 189 

Cunha-Vaz, JG 240 

Cunningham Jr, ET 133 

Curd, SD 34 

Curran, D 284 

Cursiefen, C 22 

Cuzzani, OE 207 

Czyz, CN 125, 215 

324


D 

Da Luz Cachulo Damasceno, M 240 

Dada, T 164 

Dadeya, SC 222 

Dagianis, JJ xxv 

Dagi Glass, LR 220 

Daigrepont, J 53, 55, 290, 291 

Dailey, RA 94, 124 

Dalal, MD 163 

Dalin, F 184 

Dalma, J 166 

D’Ambrosio Jr, F 191 

Dana, R 186 

Daneman, N 172 

Danese, M 232 

Danesh-Meyer, HV 72 

Dao, JB 149 

Daoud, YJ 183 

Dapena, I 157, 188 

Daramy, ML 28 

Dartigues, J 227, 241 

Dart, JG 159 

Darvish-Zargar, M 118 

Das, A 106 

Das, AA 254 

Dash-Modi, A xxv 

Das, S 252 

Das, T 207 

Datiles III, MB 22 

Dave, PR 218, 251 

Davidorf, J 66, 117, 154 

Davidson, RS 116, 118, 130, 146 

Davis-Boozer, DL 193, 194 

Davis, D 235 

Davis, EA 102, 127 

Davis, GH 243 

Davis, J 88, 99, 163 

Davis, JL 34 

Davis, MD 107, 128 

Davis, MJ 236, 239 

Davison, JA 62 

Dawood, S 234 

Daya, SM 74, 118 

Day, S 236 

Day, SH 18 

Dean, WH 262 

DeBacker, CM 96, 123, 124 

de Benito-Llopis, L 187, 193 

De Bernardo, M 189 

de Conciliis, C 94, 96, 125 

De Conciliis, C 28 

Defoort, S 229 

DeFrank, MP xxv 

de Freitas, D 19, 75, 117, 146 

De Gennaro, AL 287, 291, 294, 296 

Deguchi, Y 224 

Deitz, LW 98, 126 

De Juan Jr, E 133 

de la Cruz Napoli, JJ 69, 74, 119, 

190, 252 

de la Garza, AG 95, 124, 125 

De La Mota, A 222 

Delcourt, C 227, 241 

Della Rocca, DA 22, 125, 212 

Della Rocca, RC 125, 212 

Dell, SJ 62, 66, 67, 117 

De Luise, VP 146 

Delyfer, M 226, 241 

Demarco, LA 237 

Dementiev, D 102 

Demer, JL 98, 99 

Demetrio, CN 28 

Demirci, H 91, 240 

Demirok, A 218 

Demopulos, G 175 

Deng, SX 54 

Dennis, RF 117 

Desai, MA 83 

Desai, NR 65, 68 

Desai, RU 221 

Desai, S 256 

Desai, TH 211 

Desco-Esteban, CM 228 

Deshpande, M 206 

Deshpande, RD 206 

Desmangles, PM 28 

De Smet, M 57 

DeStafeno, JJ 127 

Deutsch, TA 117 

Devenyi, RG 234 

Devgan, U 33, 103, 142 

Devi, S 184 

Devoto, MH 94, 96, 125, 214 

Dewedar, AS 161 

Dewey, SH 33, 60, 62, 115, 116, 264 

Dhaenens, C 229 

Dhaliwal, DK 118 

Dhawahir-Scala, FE 244 

Dhillon, P 191 

Dhindsa, HS 23, 105 

Dhingra, N 229 

Diakonis, VF 195 

Diaz Llopis, M 102 

Diaz, ML 232 

Dick, AD 207 

Dick, B 134, 154, 162 

Dickey, JB xxv 

DiLoreto, DA 160 

Dimiras, H 165 

Dirisamer, M 157, 194 

Dirks, MS xxv 

Ditkoff, RR 115 

Ditta, LC 212 

Ditzen, KN 28 

Djalilian, A. R. 149 

Djalilian, AR 34, 115, 119, 133 

Doan, A 267, 268 

Doan, AP 142, 258 

Doane, JF 19, 66, 67 

Doan, Q 232 

Dobis, C 292 

Dobrowolski, D 187, 191 

Do, D 145, 228, 231 

Dodds, EM 28, 88 

Dogru, M 193 

Dohlman, CH 3, 76, 77, 187, 193 

Dolan, CM 232 

Dolman, PJ 93 

Dolmetsch, AM 126, 134 

Domalpally, A 170 

Dominguez, F 160 

Donahue, SP 137, 140, 218 

Dongmei, L 93 

Donnenfeld, ED 65, 71, 102, 104, 135, 

138, 139, 262 

Donnio, A 210, 211 

Donshik, PC 122 

Dorairaj, S 85, 120 

Doris, J 244 

Dortzbach, RK 124 

Dougherty, PJ 127 

Doughman, DJ 115 

Douglas, R 93, 97, 126 

Douglas, R. S. 146 

Dowell, L 267 

Drack, AV 33, 98, 99, 173 

Dragan, LR 123 

Drenser, KA 62, 105, 107 

Dresner, SC 126 

Driebe, WT 122 

Drillon, R 176 

Driussi, G 181 

Droste, PJ 99 

Drouilhet, JH 128 

Drummond, GT 219 

Dryden, RM 123 

Dryjski, O 223 

D’Souza, S 164, 189, 190 

Dua, HS 186, 191 

Dubois, J 234 

Dubovy, S 23, 106, 110, 172, 186, 212 

Duerksen, KM 122, 124, 125 

Dugel, PU 108, 239 

Duker, JS 104, 106, 128, 143, 149, 

231, 239 

Dunkel, I 23 

Dunn, HH 34 

Dunn Jr, J 66, 88, 163 

Dunn Jr, JP 19, 162 

Duong, HQ 174 

Dupps, WJ 101, 103, 263 

duque, m 214 

Durairaj, VD xxv, 33, 97 

Durcan, F 81, 120 

Durfee, DA xiii, xix, 34, 142, 147, 148 

Durrani, K 207 

Durrie, DS 66, 101, 102, 127, 169 

Du, S 235 

Dutton, JJ 93, 96 

Du, X 235 

Dwarakanathan, S 137 

E 

Eagle, R 108, 212 

Eaker, S 181, 182 

Eames, I 157 

Early, O 28 

Eckstein, LA 123, 124 

Edelstein, JP 19, 123, 124 

Eden, RA 224 

Edmond, JC xxv 

Edward, D 82, 106, 202, 208, 217 

Edward, DP 19 

Edwards, AO 109 

Edwards, F 147 

Edwards, K 179 

Eggenberger, E 122, 141 

Eguzkiza, A 225 

Ehlers, JP 227, 234, 242 

Ehlers, W 16 

Ehlers, WH 122 

Ehrlich, JS 170, 232 

Ehrlich, R 180 

Eikenberry, JL 182 

Ekinci Koktekir, B 164 

El Aswad, AM 158 

El-Dairi, MA 57 

ElDanasoury, A xiii 

Eldanasoury, AM 103, 104 

El-Danasoury, AM 16 

El Emam, SY 255 

Elgohary, MA 112, 233 

Eliassi-Rad, B 83 

Eliott, D 171 

Ellis Jr, GS xxv 

Elner Ph D , VM 188 

Elner, VM 91, 93, 97 

El-Sabagh, HA 28 

El-Sayed, H 158 

El Sayyad, F 186 

El Sheha, HI 28, 251 

Elzembely, HAI 28 

Emond, T 172 

Engelman, CJ 120 

Eng, KT 172 

Entezari, S 225 

Epitropoulos, AT 174 

Epley, D 173 

Epley, K 78, 140 

Epley, KD 259 

Epstein, RJ 117 

Erb, C 162 

Erb, T 176 

Erlanger, M 178 

Erraguntla, V 180 

Eshbaugh, CG 127 

Eskina, EN 225 

Esmaeli, B 96 

Espaillat, A 28 

Espejo, JE 255 

Espinoza, G 95 

Essex, RW 203 

Everman, KR 215 

Eydelman, MB 23 

Ezon, IC 157 

Fagadau, WR 136 

Fahy, S 160 

Fajardo, D 266 

Falardeau, J 122 

Fallahi, B 193 

Fang, J 235 

F 

Fantes, FE 198 

Fantin, A 56 

Fan, X 97 

Farah, M 79, 109, 234, 239 

Faria Correia, F 189 

Farid, M 56 

Farkas, DH 171 

Farris, BK 78 

Farsiu, S 226, 237 

Farzavandi, SR 98, 100 

Fasiuddin, AF 220 

Fatoo, A 240 

Fea, A 23 

Febbraro, J 103, 127, 176 

Fechtel, BM 225 

Fechter, HP 80 

Fechtner, RD 81, 120, 198, 199 

Feder, RS 67, 117 

Feibel, RM 134 

Feiner, L 170 

Feist, RM 172, 174 

Feitl, ME 120 

Feito, M 221 

Feldman, BH 16, 115, 132 

Feldman, KA 126 

Feldman, RM 161 

Feldman, ST 195 

Feldon, SE 93, 141 

Feliz, R 248 

Fellman, R 81, 85, 120 

Feng, H 245 

Fennell, J 34 

Ferenczy JR, S 211, 252, 253 

Ferguson, L 232 

Fernandes, A 245 

Fernandes, S 34 

Fernandez, AM 137 

Fernandez Buenaga, R 158 

Fernandez, JAG 28 

Fernandez, MC 183 

Fernandez, MV 137 

Ferrara, P 102 

Ferreira, A 170 

Ferreras, A 28, 203, 204 

Ferreyra, HA 237 

Ferrone, PJ 19, 105, 109, 128 

Feuer, WJ 163, 164, 165, 185, 201, 

218, 245 

Fezza, JP 214 

Figus, M 204 

Findl, O 181 

Fine, HF 235, 245 

Fine, J 232 

Fineman, MS 180 

Finger, P 212, 241 

Finger, PT 165 

Fiol-Silva, Z 122 

Firth, G 233 

Firth, M 233 

Fisher, JM xxv 

Fisher, YL 18 

Fish, JR xxv 

Fishkind, WJ 33, 52, 62, 116, 117, 139, 

145, 154 

Fishman, RS 134 

Flach, AJ 65, 80 

Flaxel, CJ 34 

Fleck, BW 232 

Fletcher, DC 146 

Florakis, GJ 194 

Flowers, BE 84, 121, 202 

Flynn, HW 107, 109, 111, 128, 171, 

172, 185, 212 

Flynn, W 162 

Fogagnolo, P 204 

Fogla, R 68, 71, 74, 118, 119, 222, 249 

Fok, A 107 

Folgar, FA 226, 237 

Fong, A 171 

Fong, KC 107 

Fontana, L 68, 70, 118 

Fontenot, JL 56, 132, 146 

Fontes, BM 28 

Forlini, C 255, 263 

Forlini, M 255 

Formoso, M 286 

Forster, RK 185 

Forstot, S 74, 195 

Foster, C 55, 71, 88 

Foster, CS 184, 207 

Foster, J 94, 96, 118, 124, 125, 215 

Foster, PJ 23 

Fountain, TR xix, 16, 79, 148, 267 

Fouraker, BD xxv 

Fournie, PR 159 

Fowler, AM 123 

Fraga Santini Canto, AP 188, 195 

Fram, NR 175, 247 

Franca, MM 28 

Francis, BA 19, 107, 122, 160 

Francis, JH 212 

Franklin, AJ 226 

Frank, RN 106, 145 

Fraunfelder, FT 79 

Fraunfelder, RW 79 

Freedman, BL 217 

Freedman, J 86 

Freedman, SF 57, 100, 201 

Freeman, JF 115 

Freeman, L 53 

Freeman, MI 122 

Freeman, WR 134, 237, 255 

Freitag, SK 126, 130, 199 

Frenkel, S 165, 196 

Freund, K 110, 226, 240 

Freund, KB 130, 171 

Frezzotti, P 204 

Friberg, TR 106, 130, 200 

Fridl, DC 283, 290 

Friedburg, C 210 

Friedlander, MH 103, 127 

Friedlander, SM xxv, 239 

Friedman, DA 174 

Friedman, DI 55, 141 

Friedman, DS 139, 140, 174 

Friedman, SM 110 

Friesenhahn, M 171 

Fritz, P 287, 293 

Fritz, T 284, 294 

Frohman, E 164 

Frohman, LP 53, 122 

Frucht-Pery, J 196 

Fry, L 33, 62 

Fu, AD 107, 128 

Fujihara, M 171 

Fujikawa, A 230 

Fujimoto, J 149, 231 

Fujimura, T 204 

Fujishima, H 193 

Fujiwara, T 230 

Fukagawa, K 193 

Fukasaku, H 248 

Fukuchi, T 159, 193 

Fukumoto, A 198 

Fukumoto, T 177 

Fukuzawa, Y 209 

Fulco, EM 167, 211, 253 

Fung, AE 23, 143 

Furlong, RC 116 

Furuichi, K 229 

Furuta, M 165, 211 

G 

Gable, RE 53, 283, 284 

Gaffar, MA 99 

Gagne, S 87, 121 

Galetta, K 164 

Galetta, SL 89, 164, 210 

Gallego-Pinazo, R 28 

Gallemore, RP 23 

Gallie, BL 19, 108, 165 

Gallo, A 210 

Galor, A 185 

Galst, JM 19 

Galveia, JNV 263 

Gamell, LS 121 

Gandhi, NG 100 

Gandhi, P 53, 123, 124 

Gangadhar, D. 23 

Gangwani, VU 181 


325



Garabedian, JS 292 

Garcia-Aguirre, G 166 

Garcia-Briones, G 28 

Garcia, DD 55 

Garcia-Delpech, S 102 

Garcia, DM 214 

Garcia-Feijoo, J 23 

Garcia Filho, CA 79 

García, O 183 

Garcia Pous, M 102 

Garcia-Rojas Castillo, L 176 

Gardner, TA 23 

Garg, A 208 

Garg, J 176 

Garg, P 72, 138, 185 

Garg, S 52, 242 

Garg, SJ 23, 104 

Garra, C 195 

Garrigus, B 34 

Garudadri, C 251 

Garway-Heath, DF 149 

Gass, JDM 3 

Gaster, RN 103, 127 

Gatinel, D 101, 137, 168, 173 

Gatla, S 204 

Gattey, DM 138 

Gaudric, A 138 

Gausas, R 124 

Gauthier, SA 240 

Gavazi, E 179 

Gaviria, JG 222 

Gaynes, BI 214 

Gearinger, LS 191 

Gearinger, MD 61 

Gedde, S 120, 142 

Gedde, SJ 19, 33 

Gedik, S 164 

Geffen, DI 169 

Gehrs, K 171 

Geist, C 123 

Geldres SR, L 255 

Geller, L 53, 55, 58, 258, 295 

Geller, SL 235 

Gemperli, AW 120 

Gensheimer, WG 61 

Gentile, RC 233 

George, RJ 197, 210 

Gerbrandy, S 235 

Ghaffary, R 185 

Ghazi, NG 231, 233 

Ghinelli, E 185 

Ghoneim, AM 175 

Ghose, S 164 

Ghosh, B 219 

Ghosh, R 192, 213 

Ghosh, S 192, 213 

Giaconi, JA 120 

Giannikas, C 194 

Giebel, A 23 

Giebel, AW 73 

Giers, UF 202 

Gieser, SC 6 

Gill, HS 123, 125 

Gills, JP 62 

Gilwit, P 127 

Gini, G 64 

Ginsburg, PB xiii 

Gira, JP 174 

Girkin, CA 19 

Giuliari, GP 28, 212, 230 

Giust, MJ 233 

Gkogkos, E 28 

Glasser, DB 68, 117, 118 

Glavas, IP 92, 123 

Gleeson, M 232 

Glikin, RG 60, 115 

Glisson, CC 122, 141 

Gobbe, M 225 

Gocho-Nakashima, K 226 

Goebel, W 233 

Goel, N 219 

Goel, S 16, 124, 202, 215, 218, 253 

Goel, SD xxv 

Goel, Y 180, 186, 195, 208 

Gogate, PM 87, 206, 219 

Gogia, V 242 

Goh, D 84, 86 

Goh, K 89 

Goh, Y 182 

Goins, KM 56, 73, 115, 119 

Gokyigit, B 218 

Golan, S 199 

Goldbaum, M 237 

Goldberg, D 174 

Goldberg, I 84, 87 

Goldberg, RA 126, 134, 172, 212, 253 

Goldenberg, D 128 

Goldhardt, R 111 

Goldman, DA xxv, 34, 65, 127 

Goldman, DJ 178 

Goldman, DR 245 

Goldstein, DA 88, 99, 162 

Goldstein, MH 115, 122, 136 

Goldstein, SM 96, 124 

Gole, G 100 

Golnik, KC 144, 209, 264 

Gombos, DS 79, 99 

Gomes, J 118, 119 

Gomez Bastar, A 222 

Gomi, F 110, 226 

Gonul, S 164 

Gonzales, BFM 28 

Gonzales, CR 227 

Gonzalez, J 155 

Gonzalez, MO 216 

Gonzalez, S 172 

Gonzalez, VH xxv, 227 

Good, WV 101 

Gopal, L 197, 210 

Gordon, AN 169 

Gordon, LK 90 

Gorovoy, MS 119, 194 

Goshe, JM 119 

Gossage, DD xxv 

Goto, H 210, 212, 227, 228 

Goto, S 226 

Gottlieb, JL 107, 128, 147 

Gottsch, JD 183 

Gow, JA 174 

Goyal, G 180, 186, 195, 208 

Goyal, JL 180, 186, 195, 222 

Goyal, NA 115 

Goyal, RK 115, 117, 127 

Grabner, G 74, 101, 119, 137 

Grabowska, A 221 

Grace, CC 119 

Granadier, RJ xxv 

Grande, L 260 

Granet, DB 142 

Grant, J 284 

Grant, MP xxv 

Graubart, EB 115 

Graue Hernandez, EO 222 

Graue-Moreno, GF 212 

Graue-Wiechers, FA 138 

Graul, TA 23 

Greenberg, KA 103, 104 

Greenberg, PB 23 

Green, RL 108 

Green-Simms, AE 225 

Green, SN 235 

Greenstein, VC 238 

Gregori, NZ 111 

Gregory, DG 71 

Greiner, J 191, 192 

Greiner, M 189, 193, 194 

Grentzelos, M 195 

Grewal, D 23 

Grewal, DS 253 

Grewal, SP 239 

Grewal, SPS 23 

Griepentrog, GJ 124 

Grippo, TM 203 

Grisanti, S 162, 198 

Grixti, A 156, 233 

Grob, S 237 

Groden, LR 225 

Groeneveld, E 188 

Groos, EB xxv, 23 

Grosinger, L 117 

Grosskreutz, CL 82 

Gross, RL 81, 87 

Grostern, RJ 117 

Groth, S 198 

Grover, AK 94, 97 

Grover, DS 85, 120 

Grover, S 106, 107, 232, 235 

Grzybowski, A 102 

Gualdi, L 102 

Guell, JL 104, 139, 159 

Guemes, A 28 

Guest, NC 286, 289 

Gulani, AC 103, 223 

Gülhan, C 203 

Gullingsrud, EO xxv, 23 

Guo, H 178 

Gupta, A 167, 215, 254 

Gupta, AK 209 

Gupta, D 180, 186, 195, 208 

Gupta, K 162, 208 

Gupta, PK 127 

Gupta, R 190 

Gupta, S 164, 176, 222, 226 

Gupta, SC 174 

Gupta, SK 235, 236 

Gupta, V 209, 238, 241 

Gurland, JE 33 

Gutherie, AH 182 

Guthoff, R 233 

Gutierrez-Carmona, FJ 116 

Guy, JR 23, 164 

H 

Ha, B 224 

Habib, L 198, 199 

Habib, NE 118 

Hafezi, F 135 

Hafezi-Moghadam, A 209 

Hageman, GS 171 

Hage SR, R 210, 211 

Hahn, JM 115 

Haider, KM 137 

Haider, S 28 

Haight, DH 103, 127 

Haines, JL 227 

Hajj-Ali, R 208 

Hakamata, N 197 

Haley, J 16 

Haley, JM 19 

Hall, CD 182 

Haller, JA 104, 145 

Halperin, L 16 

Halperin, LS 170 

Ha, M 232 

Hamada, S 118 

Hamel, C 229 

Hamel, P 234 

Hamill, M 67 

Hamill, MB 137 

Hamilton, DR 127 

Hamilton, J 161 

Ham, L 157, 188, 194 

Hammersmith, K 52 

Hammond, C 160 

Hamouda, N 242 

Hampton, C xxv 

Hamrah, P 23, 119, 186 

Han, DP 133 

Hanebuchi, M 231 

Hangai, M 204, 230, 231 

Han, J 224, 232 

Han, NS 28 

Hannush, SB 69, 70, 71, 73, 77, 118, 

146, 159, 194 

Han, Y 190, 202 

Hara, T 199 

Hardten, DR 69, 73, 76, 102, 115, 

127, 132 

Hariharan, L 139 

Haritoglou, C 237 

Harmon, SA 211, 252, 253 

Harper, RA 23 

Harrie, RP 108 

Harris, A 54 

Harris, L 23, 179 

Harrison, AR 124 

Harrison, CM 236 

Harrison, DA 144 

Hartnett, M 100 

Harton Jr, PJ 102, 127 

Hartstein, ME 19, 93, 94, 95, 123, 

125, 126 

Harvey, JT 126 

Harvey, TM xxv, 23, 127 

Hashemian, H 189 

Hashemian, S 222 

Hashemian, SJ 23 

Hashimoto, K 186 

Hashizume, K 230 

Hashmani, K 191 

Hassan, AS 124 

Hassan, TS 62, 104 

Hassouna, AK 158 

Hata, M 230 

Hatef Naimi, E 241 

Hater, M 115 

Haupert, CL xxv 

Hausheer, J 144 

Hau, VS 236 

Hayashi, K 215 

Hayden, BC 106 

Hayes, OA 207 

Hays, JC 117 

Hayworth, NAS 140 

Heatley, G 180 

Heier, JS xix, 16, 58, 109, 128, 143, 171 

Heimann, H 105 

Heiner, PC 181 

Heitman, FK xxv 

He, L 223 

He, M 140 

Henderson, B 52, 61, 65, 66, 115, 116 

Henderson, BA 130, 136, 139 

Henry, CR 185 

Henry, MM xxv 

Heo, H 221 

Heringer, DM 123, 124 

Hermida, RF 214 

Hernaez Ortega, C 228 

Herndon, LW 140 

Hersh, D 154 

Herz, NL 24, 258 

Hetzler, KJ 135 

Heuer, DK 18, 81 

Hida, RY 16 

Hieda, O 168 

Higashide, T 204, 229 

Higginbotham, EJ 80, 81 

Hill, CP 296 

Hillier, RJ 244 

Hill, ML 174 

Hill, RH 215 

Hill, WE 53, 56, 61, 62, 102, 116, 117, 

139, 262, 264 

Hirakata, A 240 

Hirnschall, N 181 

Hirshfield, GS xxv 

Hirst, LW 19, 52, 71, 250 

Ho, AC 104 

Hoang, QV 226 

Hoar, KL 119 

Hobbs, LG 34 

Ho, C 87, 188 

Hoch, CA 283 

Hoehn, R 213 

Hoffer, KJ 62, 67, 166 

Hoffman, RS 62, 116, 117, 130 

Hofling-Lima, A 191 

Hogan, RN 24 

Höhn, H 188 

Holck, DE 93, 94, 96, 123, 124, 125 

Holds, JB 125 

Holladay, JT 60, 65, 101, 102, 103, 126, 

127, 139, 213 

Holland, EJ 18, 71, 72, 74, 118, 119, 

130, 133, 138, 139, 140 

Hollander, D 191, 205 

Holland, SP 195 

Holloman, E 92, 123 

Holmes, JM 98, 101 

Homer, P 112 

Honavar, SG 69, 75, 94, 108, 211, 216, 

243, 253 

Honda, S 171 

Hong, SH 126 

Hopkins, J 54, 79, 170, 230 

Hopkins, JJ 24 

Hopkinson, A 191 

Hori, Y 224 

Hornegger, J 231 

Hoskins, E 258 

Hoskins, JC 16 

Hoskins Jr, HD 7, 148 

Ho, T 244 

Hottle, P 34, 78 

Hou, Z 213 

Hovanesian, JA 33, 65, 76, 127 

Howcroft, MJ 64 

Howell, DW 53, 56, 57, 295 

Hsu, H 191 

Htoon, HM 188 

Huang, AW 117, 119 

Huang, C 213 

Huang, D 69, 136, 149 

Huang, F 244 

Huang, J 245 

Huang, JJ 52 

Huang, SS 16, 86, 139 

Huang, X 166 

Huang, Y 244 

Hubbard, G 99, 101 

Hubschman, J 245 

Hu, F 191 

Hughes, SM 94, 124 

Hughes Sr, MO 135 

Huh, J 233 

Hullon, DS 181, 182 

Humayun, MS 133, 146 

Hunter, DG 98 

Hunter, JD 127 

Hussain, MT 192, 193 

Husted, RC xxv 

Hutchinson, AK 140 

Hutchinson, BT xiii 

Hutnik, CM 161 

Huyn, K 183 

Hwang, C 97, 126 

Hwang, DG 73, 138 

Hwang, J 98, 218 

Hwang, JM 28 

Hwang, T 184 

Hwang, YS 244 

Hysi, P 160 

I 

Ianchulev, T 160, 161, 162 

Ibrahim Ahmed, MA 163, 231, 241 

Ibrahim, OI 24, 158 

Ide, T 177 

Iida, T 107, 109, 237, 240 

Iijima, M 186 

Ikeda, T 208, 241 

Ikeda, Y 201 

Ikezawa, Z 186 

Ikuno, Y 106, 109 

Iliakis, B 70 

Ilyas, S 174 

Imamura, Y 230 

Inamochi, K 209 

Inatomi, 24 

Inatomi, T 70 

Ing, MR 100 

Ingraham, HJ 115 

Ingvoldstad, DD xxv 

Inman, M 34 

Inokuchi, N 241 

Inoue, M 240, 244 

Inoue, Y 72 

Iordanous, Y 161 

Ip, MS 19, 106, 107, 128, 170 

Iradier, MT 102 

Isaacs, DK 126, 253 

Isbey, EK 24 

Ishida, M 230 

Ishikawa, H 24 

326


Isom, RF 172 

Itoh, Y 240 

Itty, S 236 

Iturralde, JC 243 

Ivekovic, R 200 

Iwach, AG 16, 52 

Iwasaki, T 227 

Iwase, A 199, 204 

Iyer, G 76, 192, 234, 250 

Iyer, GK 263 

Iyer, JV 229 

Iyer, U 182 

Izquierdo, NJ 24 

J 

Jaafar, MS 55 

Jabbarvand Behrooz, M 189 

Jabbour, P 253 

Jabbur, NS 180 

Jackson, KL 55, 57, 283 

Jackson, ML 16, 132, 135, 146 

Jacob, S 71, 103, 116, 179, 248, 

250, 263 

Jacobs, DS 19, 68, 71, 74, 75, 136 

Jaimes, M 222 

Jain, AK 167 

Jain, R 180 

Jalali, S 239 

James, AC 203 

Jampol, L. M. 146 

Jampol, LM 112, 143 

Jang, H 237 

Jang, HS 231 

Jang, J 93, 237 

Jang, JW 28 

Jang, Y 232 

Janigian Jr, RH xxv 

Jardon, JA 183 

Jarstad, AR 179 

Jarstad, J 179 

Jastaneiah, S 224 

Javate, RM 97 

Jayaram, H 136 

Jay, WM 57 

Jeannin, S 210 

Jeanniton, C 125 

Jeffrey, B 228 

Jeng, BH 33, 68, 188, 190 

Jensen, AD 53, 149 

Jensen, J 24 

Jensen, PE 24 

Jeong, I 221 

Jeon, S 218, 228 

Jeoung, J 200, 203, 204, 205 

Jewart, BH 244 

Jhanji, V 24, 70, 76, 120, 200, 250 

Jian-Amadi, A 124 

Jimenez, A 222 

Jin, C 177 

Jindal, A 176 

Jin, S 232 

Jiramongkolchai, K 194 

Joe, S 201, 228 

Johari, P 183 

John, B 177 

Johnson, AJ 117 

Johnson, D 294 

Johnson, DL 227 

Johnson, MW 104, 109, 136 

Johnson, SH 52 

Johnson, T 94 

Johnson, WJ 135 

John, SR 247, 256 

Johnstone, MA 86 

Johnston, RH 128 

John, T 119 

Jonas, JB 84, 140 

Jones, DB 190 

Jones, DE xxv 

Jones, JJ 116 

Jones, LS 120 

Jones, M 187 

Jones, SK 217 

Jorge, E 28 

Joseph, DP 109 

Joshi, AD 207 

Joshi, SA 206 

Jo, Y 233, 243 

Juhasz, T 145 

Jun, AS 73 

Jung, H 200, 216 

Jung, HC 223 

Juzych, MS 120 

K 

Kadonosono, K 244 

Kaga, N 28 

Kahaly, GJ 165 

Kahana, A 124 

Kahloun, R 234 

Kahook, MY 33, 84, 85, 121, 197 

Kahtani, ES 233 

Kaiser, CJ 195 

Kaiser, PK xxv, 142, 143, 149, 171, 226, 

227, 234, 242 

Kaiser, RS 34, 180 

Kakkar, A 242 

Kaliki, S 165, 170, 211, 212, 243, 252 

Kalin-Hajdu, E 166 

Kamat, SS 214 

Kameda, T 230 

Kamei, M 226, 248 

Kamenetzky, S 282 

Kamenetzky, SA 262 

Kamisasanuki, T 215 

Kamlesh, P 218 

Kampe, O 184 

Kampik, A 19, 237 

Kanaya, Y 224 

Kanchanaranya, N 234 

Kandavel, GR 66 

Kane, J 137 

Kanellopoulos, AJ 71, 103, 104, 135, 

158, 173, 224, 249, 254, 263 

Kang, JJ 190 

Kang, PC 127 

Kang, SW 233, 242, 243 

Kangyeun, P 250 

Kanjani, N 116 

Kano, Y 186 

Kant, S 235 

Kapetansky, FM 81, 120 

Kaplan, HJ 105 

Kapoor, M 218 

Karageozian, H 170 

Karageozian, L 170 

Karageozian, VH 170 

Kara-Jose, A 117 

Kar, AS 222 

Kardon, RH 133 

Karim, A 233 

Karimi, S 241 

Karon, M 223 

Karp, CL 69, 117, 186 

Kasahara, N 28 

Kasai, K 215 

Kashii, S 89 

Kashima, T 93 

Kastl, PR 122 

Kasuga, T 205 

Katira, R xxv 

Katori, N 97, 215 

Katowitz, JA 149 

Katowitz, WR 94 

Katsanevaki, V 137 

Katsev, D 65, 116 

Katsev, DA 24, 130 

Katz, A 180 

Katz, JA 65, 117 

Katz, L 251 

Kaufer, RA 116 

Kaufman, PL 180 

Kaufman, SC 76, 146 

Kawaguchi, T 237 

Kawashima, H 199 

Kaye, SB 187 

Kay, MC 164 

Kay, MD xxv 

Kazama, S 184, 198 

Kazim, M 93, 126 

Kearney, JR 121 

Keck, KM 209 

Keenan, JD 140 

Kekunnaya, R 99, 167, 254 

Kellaway, J 243 

Kellum, K xxv 

Kelly, SP 147 

Kelman, CD 3 

Keltner, JL 211 

Kempen, JH 162, 163 

Kent, JS 161 

Kenyon, K 185 

Kenyon, KR 173 

Kerns, J 179 

Kernt, M 237 

Kerrison, JB 33 

Kerr, NC 33 

Kersten, IS 162 

Kersten, RC 94, 95, 96, 124, 125 

Kertes, PJ 172 

Keshavamurthy, R 236 

Kestelyn, P 161 

Kezuka, T 210, 228 

Khadka, D 221 

Khairallah, M 234 

Khalifa, MA 102, 104 

Khalifa, YM 61 

Khalilipour, E 189 

Khamar, BM 211 

Khamar, M 217 

Khan, A 214 

Khan, AO 28, 220, 238 

Khan, BU 60, 115, 121 

Khandelwal, RR 162, 208 

Khan, HN 103, 127 

Khan, JA 20 

Khanna, RC 24 

Khan, YA 97 

Khatib, HA 225 

Khatibi, A 55 

Khatib, T 225 

Khawaja, AP 136 

Kheirkhah, A 74, 119 

Khell, JA 224 

Kherani, F 96 

Khodaparast, M 189 

Khokhar, S 176 

Khouri, AS 198, 199 

Khurana, AK 196 

Khurana, B 219 

Khurana, I 196 

Khurana, R 24, 226 

Khwaja, A 170, 231 

Kiesau, Y 221 

Kietzman, TJ 10 

Kieval, JZ 127 

Kikkawa, D 93, 95, 97, 124, 252 

Kikkawa, DO 33 

Kilic, A 66, 127 

Kim, 115 

Kim, A 183 

Kim, BY xxv 

Kim, C 216, 232, 237 

Kim, D 200, 203, 204, 205 

Kim, G 222 

Kim, H 201, 203 

Kim, HH 218, 228, 233, 243 

Kim, J 126, 165, 200, 201, 204, 205, 

216, 228, 232, 233, 237, 243, 252 

Kim, JE 58, 110, 145, 232, 262 

Kim, JY 115, 119 

Kim, K 194, 200, 203, 204, 205 

Kim, M 163, 200, 201, 204, 205 

Kim, N 124 

Kim, S 163, 177, 200, 201, 217, 221 

Kim, SJ 133 

Kim, SK 71, 72, 79, 178 

Kim, T 20, 33, 66, 69, 83, 117, 139, 

194, 224, 264 

Kimura, AE 237 

Kimura, N 197, 214 

Kim, W xxv 

Kim, Y 94, 97, 200, 209, 216, 217, 252 

Kim, YD 24 

King, LJ xxv 

King, RA xxv 

Kinoshita, S 34, 70, 77, 133, 168, 186, 

197, 201, 214, 236 

Kinsey, JA xxv 

Kinyoun, JL 128 

Kirshbaum, M 170 

Kirzhner, M 124 

Kiss, S 240 

Kisza, KJ 210 

Kita, M 171 

Kitami, A 186 

Kitaoka, T 183, 227, 230, 240, 243 

Kitchens, JW 117 

Kjaerbo, H 28 

K K JR , S 177 

Kleineberg, L 202 

Klemm, T 201 

Klier, SM 174 

Kliger, CH xxv 

Kliman, GH 133 

Kloek, C 65 

Knorz, MC 65, 102, 103, 126, 145 

Kobayashi, T 208 

Koch, DD 66, 69, 103, 127, 130, 

139, 264 

Kocher, KM 170 

Koch, H 67 

Koch, PS 65 

Kocur, I 141 

Koffler, B 74, 122 

Koh, AH 110, 136 

Koh, HJ 242 

Koh, K 182 

Kohly, RP 172 

Kohnen, T 103, 139, 156 

Kohn, JC 253 

Koh, S 177, 248 

Koizumi, H 236 

Kojima, H 171, 230 

Kokame, GT 110 

Kolic, M 203 

Kolker, RJ 197 

Ko, MW 122 

Kondapalli MD, S 215 

Kook, M 200 

Kopelman, J 93, 94, 123, 124 

Korb, DK 186 

Koreishi, AF 24, 117 

Korn, BS 24, 33, 94, 95, 124, 252 

Korobelnik, J 169, 226, 241 

Korobelnik, JF 24 

Kosmorsky, GS 89 

Kossler, AN 165 

Kotlus, BS 93, 123, 124 

Kotoulas, A 28 

Kounis, G 195 

Kovach, JL 112, 227, 236 

Koval, RC 55, 285, 286 

Kowalczyk, A 233 

Kowalski, RP 138 

Kozak, I 237, 255 

Kozareva, D 160 

Kozarsky, A 24 

Kozarsky, AM xxv 

Kraff, MC 62 

Kraft, S 267 

Krakauer, T 215 

Kratz, A 199 

Kraus, MF 231 

Krauss, HR 57 

Krebs, DB 115 

Krema, HA 212 

Kretz, FT 247 

Krishan-Dave, NR 99 

Krishnan, C 86 

Krishnan, M 184 

Krishna, R 118, 267 

Krishna, V 210 

Kristan, RW 123 

Kronberg, BP 199 

Kropiewnicki, ME 53, 55, 57, 284, 285, 

286, 287 

Krueger, RR 66, 102, 103, 132, 154 

Krupin, T 81, 120 

Kruse, FE 73, 118 

Kuchtey, RW 115 

Kuchynka, P 24 

Kucukevcilioglu, M 199 

Kuhn, FP 64, 106, 138, 142 

Kulkarni, AN 87, 206, 219 

Kulkarni, SV 161 

Kumagai, K 232, 242 

Kumaran, SS 164 

Kumar, BV 28, 156, 233 

Kumar, D 183 

Kumari, E 222 

Kumar, P 183 

Kunimatsu, S 199 

Kuniyoshi, K 218 

Kuo, AN 194 

Kupersmith, MJ 145 

Kuppermann, BD 170, 172 

Kurian, M 63 

Kurimoto, M 238 

Kurimoto, Y 171, 230 

Kuroda, S 198 

Kurosaka, D 230 

Kurth, K 77 

Kurtz, S 199 

Kusa, B 177, 198 

Kusaka, S 218 

Kusano, M 183 

Kushner, BJ 98 

Kwak, A 224 

Kwak, H 230 

Kwasny, GP xix, 16, 262 

Kwong, YYY 84 

Kwon, H 163, 227 

Kwon, O 109 

Kwon, OW 24 

Kwon, YH 120 

Kymes, SM 24, 198 

Kymionis, GD 195 

L 

Lacayo, GO 195 

Lackey, J 204 

Ladas, JG 183 

Ladhari, G 234 

Lagunzad, JD 166 

Lahane, TP 87 

Lai, C 106, 108, 109, 110, 244 

Lai, G 200 

Laigaie, B 286, 289, 292 

Lai, J 179 

Lai, JS 205 

Lai, LY 182 

Lains, IC 238 

Lai, PC 227 

Lai, S 204 

Lai, TY 106, 107, 109, 110, 136, 

145, 242 

Lai, WW 106 

Lake, D 118 

Lally, DR 180 

Lally, SE 215 

Lambert, J 137 

Lambert, SR 100, 137, 167 

Lam, BL 33, 107, 111, 164 

Lam, DC 84 

Lam, K 211 

Lamothe, DR 168 

Lamoureux, E 147 

Lampreia, T 252 

Lam, W 172, 183, 234 

Landa, G 230 

Landau, D 196 

Landau, RJ 57, 285, 287, 289 

Lander, J 292 

Lane, RG 109, 128 

Lane, SS 62, 102, 117, 127, 130, 139, 

145, 264 

Langer, PD xxv 

Lang, SS 193 

Lanza, M 189, 210 

Lapenna, L 163, 187 

Larson, J. S. M. 149 


327



Larywon, KR 289 

Lasave, AF 207, 208 

Latina, MA 20, 84, 121 

Laubert-Reh, D 213 

Laude, A 184, 231 

Lauer, A 144, 209 

Lauer, AK 16 

Lauer, SA 134 

Lau, K 206 

Laurita, WE 24, 34, 284 

Lauten, W 226 

LaVergne, NL 291 

Lavorgna, L 210 

Law, J 258 

Lawless, MA 20, 154 

Law, MS xxv 

Lawrence, L 262 

Lawrence, LM 132, 141 

Lawrence, MG xxv, 17 

Law, SK 120 

Leavitt, JA 20, 33, 90, 122 

Lederer, DE 234 

Leder, H 163 

Lee, AG 16, 89, 90, 144, 264 

Lee, CS 163, 227 

Lee, D 80, 82, 201, 228 

Lee, DJ 185 

Lee, G 199 

Lee, H 125 

Lee, HBH 135 

Lee, HH 97 

Lee, J 77, 126, 177, 200, 201, 216, 233, 

243, 250, 256, 290 

Lee, JK 115 

Lee, JW 205 

Lee, K 200 

Lee, MS 33, 89, 141 

Leenheer, RS 126 

Leen, M 120, 122 

Leen, MM 33 

Lee, PP 148, 198, 232 

Lee, R 120, 186 

Lee, S 162, 163, 227, 230, 237, 256 

Lee, SY 216 

Lee, T 101, 107, 232, 240, 254 

Lee, W 106, 107, 110, 218, 228, 242 

Lee, WB 34, 54, 72, 115, 117, 118, 

130, 146 

Lee, WW 57, 96 

Lee, YH 232 

Lee, YJ 216, 227 

Lee, YR 200 

Lefebvre, DR 199 

Le Goff, M 226, 241 

Lehmann, JD 139 

Lehmann, M 240 

Le, HN 165 

Lehpamer, BP 133 

Lehrer, RA 83, 85, 121 

Leiderman, YI 111, 234, 254, 263 

Leishman, L 155, 177 

Leite, MT 79 

Lelli, GJ 124, 212 

Lema, GM 233 

Leng, T 118 

Lester, M 204 

Letko, E 24, 127 

Leung, CK 16, 84, 85, 120, 200 

Leung, DY 83 

Leung, EH 230 

Levin, AV 142 

Levine, E 34, 291, 294 

Levinger, ES 184 

Levin, LA 82 

Lev, M 213 

Levy, J 199 

Lewallen, S 87 

Lewis, RA 130 

Lew, Y 232 

Liang, I 244 

Liang, L 192 

Liang, SS 86 

Liao, DJ 266, 268 

Liarakos, VS 157 

Li, C 215 

Lichter, PR 9, 129 

Lieberman, M 121 

Liebmann, JM 81, 120, 204, 211 

Liegl, R 237 

Lie, J 188 

Liesegang, TJ xxv, 18, 88, 129 

Li, FCH 84 

Lifshitz, T 199 

Lightman, SL 163 

Li, JY 117, 118, 119, 190 

Li, K 206 

Li, L 213 

Li, M 223 

Lima, L 229, 238, 239 

Lim-Fat, C 232 

Lim, J 56, 110, 238 

Lim, JI 145, 262 

Lim, L 242 

Lim, MC 24, 77, 78, 290, 291 

Limnopoulou, AN 195 

Lim, S 201 

Limstrom, SA xxv 

Lim, TH 242 

Lin, A 115, 136 

Lin, AA 217 

Lin, CC 190 

Lincoff, N 141 

Lin, D 195 

Lindquist, TD 117 

Lindstrom, RL 62, 65, 66, 101, 126, 133, 

134, 139, 262 

Lingam, V 197 

Lin, H 191 

Lin, J 198, 199 

Lin, JL 97, 126, 253 

Lin, KL 239 

Link, W 133 

Lin, MP 208 

Lin, SC 82, 85, 140, 178, 201, 205 

Lipshitz, I 60 

Li, S 235 

Lisochkina, AB 236 

Liss, E 224 

Liss, RP 62, 116, 120, 121 

Li, T 223 

Litinsky, SM 142 

Little, BC 61, 67, 139 

Liu, D 93 

Liu, DT 105 

Liu, H 241 

Liu, J 231 

Liu, JH 203 

Liu, M 230 

Li, X 106, 110, 213 

Li, Z 230 

Lloyd III, WC 258 

Loden, JC 127, 183 

Loewen, NA 84, 122 

Loewenstein, A 104, 128 

Loewenstein, JI 65 

Loh, E 197 

Lohiya, K 206 

Lombardo, AJ 25, 127 

Lombard, PN 118 

Lo, MW 124 

Long, MG 192 

Longmuir, RA 164 

Loomis, SJ 199 

Lopes, B 189 

Lopez Miguel, A 155, 196 

Lopez, SGA 28 

Lord, RK 118, 267 

Lorenz, B 210 

Loupe, DN 182 

Low, C 28 

Lowder, C 88, 111, 208 

Lu, B 235 

Lubniewski, AJ 117, 119 

Lucarelli, MJ 20, 93, 124 

Luccarelli, SV 179 

Luchs, J 196 

Lueder, GT 55 

Lujan, BJ 230 

Luk, FO 107 

Lu, L 251 

Lum, F 78 

Lundstrom, MH 207 

Luo, Z 193 

Lusk, K 112 

Luz, A 189 

Lyall, DA 175, 176 

Lyles, KW 236 

Lynch, M 182 

Lynn, MJ 167 

Lyon, D 97, 124 

Lyon, DB 20 

Lytle, RA xxv 

M 

Maberley, DAL 145 

Macachor, J 182 

MacCumber, MW 34, 140, 169 

MacCumber. MW xxv 

MacDonald, IM 219 

MacDonald, SM 143, 144 

Machado, A 189 

Machemer, R 3 

Machida, S 230 

Macias, RA 28 

MacIntyre, RB 193 

MacRae, SM 103, 127, 136 

Macsai-Kaplan, M 63, 68, 116, 117 

Ma, D 218 

Maddess, T 203 

Madi, SA 163, 188 

Maeda, M 122 

Maeda, N 76, 177, 248 

Maekawa, Y 227, 243 

Maeno, T 224 

Magone De Quadros Costa, T 245 

Magrath, GN 146, 210 

Maguire, MG 164, 210 

Mahadik, A 206 

Maharana, P 250 

Mahasneh, S 205 

Mahendradas, P 208 

Maher, EA 212 

Mah, FS 72 

Maia, M 25, 234, 239 

Majji, AB 239 

Majmudar, PA 33, 34, 74, 117, 127, 195 

Makiyama, Y 238 

Maldonado-Junyent, AG 187 

Maldonado-Junyent, AI 187 

Maldonado, MJ 28, 155, 196 

Malecaze, F 159 

Malet, FE 195, 241 

Malhotra, R 126, 192 

Malhotra, RP 195 

Malkani, H 177 

Maller, A 287 

Mallipatna, AC 108 

Malta, JB 223 

Maltry, AC 211 

Maltzman, BA 198, 199 

Maltzman, JS 16, 116 

Malukiewicz-Wisniewska, G 233 

Malvankar-Mehta, MS 161 

Malyugin, B 134, 139 

Mamalis, N 54, 60, 65, 66, 115, 117, 

139, 147, 155, 156, 177, 264 

Mammo, Z 183 

Ma-Naim, T 213 

Mancini, R 126 

Mandai, M 171, 230 

Mandal, AK 81, 86, 218 

Mandal, S 162, 206, 239 

Mandelcorn, ED 172 

Manderwad, G 239 

Manes, G 229 

Mangan, MS 176 

Manish, N 28 

Mannis, MJ 68, 72, 117, 118, 137, 190 

Mannor, GE 20, 124 

Mansberger, SL 81, 120 

Mansour, AM 233 

Mansouri, K 85 

Mansour, S 107, 128 

Manthena, S 207 

Mantravadi, AV 121 

Manudhane, AA 180, 186, 195, 208 

Man, X 203 

Marasco, JA 283, 285, 286 

Marcelo-Lyra, J 189 

Marcet, MM 25, 124, 179 

Marcon, AS 25, 119 

Mardelli, PG 28 

Mares, FJ 120 

Margolis, TP 138 

Mariano, MS 181 

Marioneaux, SJ xxv 

Mark, HH 25 

Markowitz, SN 132 

Marmor, MF 92, 111, 134 

Marques, EF 28 

Marr, BP 91, 212 

Marshall, J 135 

Marsiglia, M 240 

Martel, JN 167 

Martin, DF 133, 135, 143 

Martinez Alday, N 214 

Martínez-Almeida, L 155 

Martinez-Castellanos, MA 101, 166 

Martinez, IA 233 

Martinez, ME 28 

Martin, FJ 129 

Martin, J 92, 123, 124 

Martin, NF 195 

Martins, MC 28 

Martiz, J 158 

Maruko, I 237, 240 

Maruyama, K 208 

Maruyama, Y 201 

Marx, JL 16 

Mashayekhi, A 211, 212 

Masifi, SL 217 

Masket, S 62, 66, 116, 139, 154, 175, 

247, 262, 263 

Mason, JO 172 

Massare, JS 122 

Massaro, BM 96, 125, 126 

Massaro-Giordano, M 74 

Massoud, VA 233 

Mataix, J 233 

Matalia, H 189, 190 

Mateger, M 214 

Mateo, ME 155 

Materin, MA 53, 91 

Mathai, A 239 

Mathew, M 187, 188 

Mathew, P 28 

Mathur, A 184, 189, 190 

Mathur, G 234 

Mathur, U 176, 184 

Mathys, KC 118 

Matsubara, Y 186 

Matsuda, F 236, 237 

Matsumara, N 248 

Matsumoto, M 230 

Matsumura, N 226 

Matsunaga, Y 210, 228 

Matsuoka, T 171 

Matta, NS 137, 217, 219 

Matteo, S 179 

Matthews, G 142 

Matthews, GP 142 

Matthews, J 172, 212 

Mattioli, L 187 

Mattox, C 33, 80, 86 

Mauget-Faysse, M 229, 240 

Maul, EJ 120 

Maurino, V 181 

Mauro, J 184 

Mawn, LA xxv, 215 

Mawn. LA 137 

Mayama, C 204 

Mayle, MD xxv 

Mayorga, EP 144, 264 

Mazloumi, M 185 

Mazzoli, RA 20 

McAllister, IL 25 

McArdle, B 182 

McCafferty, DG 57 

McCannel, C 109, 290 

McCannel, CA 34, 267 

McCannel, TA 229 

McCann, N 16 

McCarus, CL 136, 137 

McChesney, C 281, 296 

McCluskey, PJ 25 

McColgin, A 119 

McCormick, GJ 25, 54, 79 

McCracken, MS 92, 95, 123 

McCulley, JP 146 

McDonald, J 180 

McDonald, MB 74, 103, 132, 191 

McGetrick, JJ 124 

McGhee, C 34, 72, 75, 76, 77, 133, 182 

McGowan, HD 28, 212 

McGwin, G 16, 25, 174 

McKelvie, J 182 

McKeown, CA 107 

McLauchlan, R 244 

McLendon, BF 262 

McLeod, J 206 

McLeod, SD 135 

McNamara, TR 174 

McPhee, TJ xxv 

McVinney, D 34 

Mehta, JS 28, 70, 75, 127, 187, 

188, 193 

Meldrum-Aaberg, ML 124 

Melende, RF 16 

Melendez, R 258 

Melendez, RF xix, 56, 117, 142, 266 

Melicher Larson, JS 34, 95, 98, 124, 

125 

Melki, SA 68 

Melles, GR 157, 188, 194 

Melson, MR 215, 259 

Menda, S 202 

Mendonca, A 252 

Meng, Q 178 

Menke, AM 101 

Menon, V 222 

Merle, HR 210, 211 

Merritt, JH xxv, 126 

Mertens, EL 25 

Mesa Gutierrez, JC 202, 216 

Mesplie, N 195 

Metlapally, R 201 

Mets, MB 221 

Meunier, IA 229 

Meyer, CH 109 

Meyer, DR 16, 96, 123 

Mian, S 115 

Mian, SI xxv, 33, 74, 118, 192, 193 

Michelson, J 155 

Michelson, MA 56, 62, 115 

Mieler, WF 63, 106, 108, 109, 111, 

112, 262 

Milbratz, GH 214 

Milka, MP 187 

Millan-Velasco, S 228 

Miller, AE xxv 

Miller, AM 16 

Miller-Ballard, DM 34 

Miller-Ballard, M 288 

Miller, BJ 135 

Miller, CA 116, 117 

Miller, D 138, 172, 185 

Miller, EG 82, 142 

Miller-Ellis, EG xxv 

Miller, JW 129 

Miller, KM 16, 33, 34, 52, 61, 62, 65, 

66, 92, 115, 117, 139, 145, 173, 262 

Miller, L 294 

Miller, MT 14 

Miller, NR 55, 89 

Mills, MD 25, 94 

Mills, RP xix, 16, 81, 120 

Milman, T 212 

Minckler, DS 122 

Min, LC 184 

Mintz-Hittner, H 100 

Miranda, A xxv 

Miri, A 186 

Mirshahi, A 165, 213 

Mirza, S 233 

328


Mirza, SK 201 

Mishra, A 202 

Mitchell, P 147, 170, 241 

Mitchell, RJ 206 

Mitra, S 64, 162, 206, 239 

Mitry, D 232 

Mittal, A 235 

Mittal, V 167 

Mittra, RA 106 

Miura, M 227 

Miyake, M 230, 232, 236, 237 

Miyamoto, K 168, 242 

Miyamoto, N 230 

Miyata, K 177 

Mizoguchi, T 198, 201 

Mmukherje JR, S 202 

Mobilia, TA 289 

Mocherla, S 247 

Mock, D 199 

Modak, JM 178 

Modarres, M 28 

Mogk, LG 132 

Mohamed, JY 220 

Mohan, S 177 

Mohapatra, S 252 

Moin, M 93 

Mondino, BJ 144 

Monsalve, B 203, 204 

Montahai, T 241 

Montalban, R 178 

Montalvo, J 255 

Monteiro, SG 181 

Montes, JR 94 

Montoya, M 68 

Moon, N 220 

Moore, GH 203 

Moradi, A 241 

Moradian, S 245 

Morales-Canton, V 166 

Morales, E 199 

Morales, J 82, 202, 208, 228 

Morara, M 231, 244 

Moreira, CA 25 

Morgenstern, KE 124 

Mori, K 201 

Morishita, S 241 

Morlet, N 183 

Moroi, SE 74 

Morris, CL 123 

Morrison, DG 136, 137 

Morrison, JC 120, 184 

Morris, RJ 233 

Morris, T 191 

Morschbacher, R 214 

Morse, C 16 

Morse, CL 79, 149 

Morton III, A 97, 123, 124, 125 

Morton III, AD xxv 

Morton, RL xxv 

Mosaed, S 84, 120, 122 

Moscato, EE 123, 124, 125, 145 

Moshfeghi, AA 117, 173 

Moshfeghi, DM 143 

Moshirfar, M 222 

Mosier, SK 25, 140 

Moss, RF 233 

Moster, M 130 

Moster, ML 52, 86, 89 

Moster, MR 80, 86, 142, 147, 161, 251 

Moster, S 164, 210 

Mota, SHD 28 

Motley, WW 53 

Motukupally, SR 239 

Mourad, MS 158 

Moutray, TN 229 

Moya, FJ 161 

Mruthyunjaya, P 165, 167, 236 

Muccioli, C 88, 208 

Mudumbai, R 25, 83, 85 

Mudvari, SS 128 

Mukkamala, S 241 

Mulay, KB 211, 243 

Munier, FL 25 

Munoz, B 174, 183 

Murakami, T 242 

Murakami, Y 205 

Muralidhar, NS 239 

Muramatsu, D 228 

Muraoka, Y 242 

Murta, JN 250 

Murthy, H 239 

Murthy, SI 180, 189, 224 

Musa, F 157, 194 

Musch, DC 198, 205 

Mutapcic, L 236 

Mwanza, J 201 

Myer, RA 149 

Myers, JP 226 

Myers, JS 120, 121 

Myint, S 123 

N 

Nabili, S 28 

Nading, E 201 

Nagai, T 171 

Nagarsheth, MH 149 

Nagpal, M 61, 108, 110, 244, 254 

Nagy, N 154 

Naik, MN 216 

Nair, UK 202 

Na, J 200 

Nakagawa, S 238 

Nakamura, K 241 

Nakamura, M 89 

Nakamura, T 169 

Nakanishi, H 232, 236, 237 

Nakao, S 209 

Nakao, T 248 

Nakata, I 232, 236, 237 

Nakazawa, T 199 

Nakra, T 25, 94, 123, 124, 126 

Namperumalsamy, P 11 

Nanavaty, MA 118, 192 

Nan, B 205 

Naor, J 163 

Naranjo-Tackman, R 70 

Nardin, G xxv 

Narvaez, J 180 

Naseri, A 116, 202 

Naseripour, M 215 

Nasir, MA 233 

Nassaralla, BA 203 

Nassaralla, JJ 203 

Nassim, HM 28 

Nassiri, N 225 

Natarajan, S 144, 256 

Nathenson, AL 25 

Navas, A 28, 222 

Navea-Tejerina, A 228, 233 

Naveiras Torres-Quiroga, ML 194 

Nawrocki, J 115 

Nayaka T E , A 218 

Neamtu, VA 220 

Nechiporenko, PA 236 

Neelakantan, A 81, 85, 162 

Neff, KD 68, 118, 119 

Negi, A 171 

Nehemy, MB 138, 237 

Neigel, JM 123, 124 

Neimkin, MG 172 

Nelson, CC 91, 134 

Nemi, A 285 

Nemoto, R 227 

Nerad, JA xix, 16, 95, 96, 124, 125, 130 

Netland, P 81, 85, 86, 161, 201 

Netland, PA 173 

Neto, GH 214 

Neubauer, AS 237 

Nevyas, HJ 115 

Nevyas-Wallace, A 60, 115, 155 

Newman-Casey, PA 205 

Newman, NJ 89 

Newman, SA 16, 57, 90 

Nezgoda, JT 142 

Ng, E 175, 184 

Ng, JD 94, 124, 130 

Ng, JQ 183, 207 

Ngo, W 203, 242 

Nguyen, Q 109, 241 

Nguyen, QD 20, 163 

Nguyen, QH 85, 122, 162 

Nichamin, LD 54, 61, 62, 63, 66, 116, 

117, 139, 177 

Nichols, B 116, 117 

Nicolela, MT 202 

Nieto, JC 155, 196 

Nigam, D 178, 228 

Nihalani Gangwani, BK 100, 220 

Nijm, L 25, 127 

Nirankari, VS 159, 191, 193 

Nischal, KK 100 

Nishida, K 177, 248 

Nittala, MG 160 

Nixon, D 116, 175 

Nizam, A 167 

Niziol, LM 198 

Noble, J 234 

Noecker, RJ 69, 107, 121 

Noel, LP 140 

Nomoto, Y 209 

Nordlund, M 119 

Nottage, JM 159, 191, 193 

Nouri-Mahdavi, K 199 

Nouri-Mahdavi, K. 142 

Nourinia, R 209 

Nowilaty, SR 28, 105, 229, 231 

Nozaki, M 206 

Nrusimhadevara, R 180 

Nucci, P 179, 230, 231 

Nuijts, R 25, 70 

Numata, S 210 

Nunery, WR 93, 94, 97, 123, 124, 125 

Nussenblatt, RB xxv, 88, 163 

O 

O’Brart, DP 223 

O’Brien, TP 65 

O’Connell, RV 237 

O’Conner, MS 53 

O’Connor, A 135 

O’Day, DM 16 

Oellerich, S 188 

Oellers, PR 186 

Oeth, P 171 

Oetting, TA 13, 16, 60, 61, 62, 66, 115, 

116, 139, 144 

Ogino, K 238, 242 

Ogino, N 201 

Ogura, Y 206 

Oguz, H 213 

O’Hara, MA 16 

Oh, H 171 

Ohji, M 106, 110 

Ohkubo, S 204, 229 

Ohno-Matsui, K 109 

Ohr, MP 242 

Oh, S 95 

Oie, Y 248 

Oishi, A 171, 230, 232, 238 

Okada, AA 135 

Okada, M 154 

O’Keeffe, M 100 

Okunuki, Y 228 

Olindo, S 211 

Oliva, MS 262 

Oliver, SC 34, 132 

Olivier, M 141 

Olivier, MMG 20, 142, 262 

Ollerton, A 155, 177 

Olsakovsky, LA 201 

Olsen, KR xxv 

Olsen, TW 145, 262 

Olson, JL 178 

Olson, LM 227 

Olson, RJ 61, 62, 66, 139 

Omar, N 184 

Ong-Tone, L 116 

Onizuka, N 240 

Ono, H 199 

Ooto, S 231, 232 

Opremcak, E 88 

Orengo-Nania, SD 20, 81 

Orive, A 214 

Orjuela, MDP 28 

Orlin, SE 194 

Ormonde, SE 72, 77 

Orr, MG 116 

Ortega, P 178 

Orzechowska-Wylegala, B 191 

Osher, RH 63, 65, 66, 67, 134, 139, 247 

Oshima, Y 108, 110, 226 

Oslar, S 34 

Osman, EE 161, 197 

Osmanovic, S 82 

Osmond, L 260 

Othman, IS 190 

Otin, S 203 

Ou, J 182 

Oum, B 250, 256 

Ou, Y 190 

Oyamada, H 240 

Ozaki, M 198, 201 

Öztürk, B 203 

P 

Pablo, LE 203, 204 

Packard, RB 61 

Packer, M 20, 58, 65, 66, 67, 68, 102, 

130, 139, 160 

Packo, KH 58, 108, 111 

Padhi, TR 207 

Padmanabhan, P 250 

Padovese, TJ 259 

Page, S 266 

Page, TP 141 

Pahuja, S 185, 194 

Pajarin, AB 203, 204 

Pakravan, M 209 

Paladino, T 171 

Pallikaris, IG 181, 195 

Palmberg, PF 120, 142 

Palmer, JD 226 

Palmon, FE 115, 118 

Pamel, G 71, 104, 127, 249 

Panagopoulou, S 195 

Pan, CK 229 

Panda, A 28, 119 

Panday, M 197 

Panday, VA 168, 223 

Pandey, N 233 

Pandit, RT 25, 115 

Pandolfo, K 220 

Pandya, HK 118 

Pang, CC 105, 140 

Pan, X 160 

Papadopoulos, R 118 

Papageorgiou, E 136 

Papageorgiou, K 126 

Papavasileiou, E 156, 233 

Pappuru, RR 110, 239 

Paques, M 226 

Paranjpe, GS 244, 254 

Parbhu, KC 123 

Parel, J 188, 195, 198 

Parikh, R 87, 207 

Parkar, AR 28 

Parke, DW 142 

Parke II, DW xiii, xix, 129, 148 

Parker, J 188, 194 

Parke Sr, DW 16 

Parkhurst, G 127 

Park, J 170, 233 

Park, K 83, 84, 87, 200, 201, 203, 205, 

233, 243 

Park, KH 25 

Park, S 221, 233, 243, 256 

Parks, MM 3 

Park, SS 57 

Parlitsis, GJ 240 

Parrish II, R 198 

Parshall, MJ 284 

Parshina, V 225 

Partamian, LG 80 

Pasol, J 79 

Pasquale, LR 198, 199, 205 

Pastora, N 221 

Pataky, CR 135 

Patel, A 73 

Patel, AK 71 

Patel, BC 124 

Patel, K 166 

Patel, N 239 

Patel, NM 264 

Patel, P 223, 258 

Patel, PS 53, 110 

Patel, RD 285 

Patel, SM 123, 124 

Patel, VR 90 

Pathak, AK 115 

Patil, S 206, 219 

Patton, N 244 

Patty Daskivich, L 136 

Patz, A 3 

Paulin Hueria, J 176 

Pavlin, CJ 212 

Paysse, EA 99 

Peace, JH 174 

Peckar, CO 83, 121 

Peeler, CE 146 

Pego, PM 238 

Pelaez, CAR 137 

Pelayes, DE 138 

Pelton, RW 52, 79, 142 

Pena, F 141 

Peña, P 155 

Penha, FM 79, 109, 234 

Pepin, SM 90, 130 

Pepose, JS 65, 156, 177, 182, 185, 263 

Peralta, J 221 

Pereira, FJ 214 

Perera, S 84, 86, 160 

Perez, G 195, 196, 224 

Perez, M 249 

Pérez, P 228 

Perez Soto, N 215 

Perez, VL 69, 73, 158, 185 

Pericak-Vance, MA 227 

Perkins, TW 121 

Perlee, L 171 

Perman, K 124 

Perossini, T 244 

Perry, A 124 

Perry, HD 70, 71 

Perry, JD 33 

Peters, C 198 

Peters, JD 25 

Petrillo, J 170 

Petsoglou, C 159 

Petty, JH 116 

Petzold, G 28 

Pfeiffer, N 162, 165, 198, 213 

Pflugfelder, SC 140 

Phairas, DL 53, 287, 289, 292 

Pham, R 92, 97, 123 

Phillips, PH 53, 167 

Phillips, PM 25, 119 

Pichi, F 230, 231, 244 

Pieramici, D 34, 58, 104, 128, 233, 237 

Pignatari, AC 191 

Pikey, KP 120 

Pillai, VS 185 

Pillunat, LE 202 

Piltz-Seymour, JR 52 

Pina-Hurtado, E 28 

Pineda II, R 56, 68, 73, 79, 115, 187 

Pineles, SL 99 

Piovella, M 62, 65, 102 

Piracha, AR 115, 127 

Pires, J 181 

Pitz, S 165 

Piva, AP 97 

Plager, DA 100, 101, 145 

Plaza, A 178 

Polat, U 213 

Polkinghorne, PJ 180 

Pollack, JS 104, 127, 128 

Pollard, J 231 

Polonski, L 116 

Pomeranz, HD 33 

Ponto, KA 165, 213 

Poon, AC 193 

Poon, DY 197 


329



Pop-Busui, R 192 

Pop, M 127 

Porciatti, V 164 

Porco, T 226 

Portaliou, DM 181 

Potsaid, B 231 

Potter, S 210 

Powell, C 201 

Pradhan, K 225 

Prakash, G 71 

Pramanik, S 194 

Prasad, S 61, 64, 67, 156, 233, 248 

Prasad, V 256 

Pratzer, K 183 

Praud, D 195 

Praveen, M 217, 255 

Preece, DA 285, 291 

Preising, M 210 

Prenner, J 235, 245 

Price Jr, FW 70, 72, 73, 118, 136, 168 

Price, MJ xxv 

Price, MO 73, 168 

Prinzi, R 228 

Probst, L 213 

Pruett, PB 115 

Prussian, MM 34 

Prywes, AS xxv 

Puaud, CM 241 

Puech, B 229 

Pujari, SS 184 

Pula, J 122 

Puliafito, CA 107, 149 

Pulido, JS 91, 233 

Punja, KG 95, 124 

Puthiyapurayil Manjandavida, F 211, 

216, 243, 253 

Pyott, DE 25 

Q 

Qazi, MA 25, 156, 182, 185 

Qazi, Y 186 

Qiang, W 235 

Qiao, L 213 

Quadrado, M 250 

Quigley, HA 149 

Quilendrino, MM 188 

Quinn, GE 264 

Quinones, RA xxv, 160 

Quiros, PA 90, 141 

Quiroz-Mercado, H 111, 170 

R 

Raab, EL 34 

Rabena, MD 233, 237 

Raber, IM 118, 119 

Rabinowitz, YS 104 

Rabsilber, TM 247 

Radcliffe, NM 130 

Radwan, AE 207 

Rafaty, M 34 

Rafuse, PE xxv 

Rahimy, E 146 

Rahmani, B 221 

Rahmathullah, R 87 

Raina, UK 219 

Raizman, MB 194 

Raj, A 188, 247 

Rajan, M 177 

Raje, D 162 

Raj, N 256 

Rajpal, RK 34, 168, 176 

Raj, S 247, 255 

Raju, VK 119 

Ramachandran, IT 222 

Ramachandran, S 190 

Ramakrishnaiah, RH 167 

Ramappa, M 99, 187, 194, 217, 247 

Ramchandran, RS 245 

Rameu, N 126 

Ramey, NA 124 

Ramezani, A 26, 241 

Ramirez-Luquin, T 222 

Ramirez, MA 122, 162, 198 

Ramirez-Miranda, AJ 176, 222 

Ram, J 241 

Ramos, IO 189 

Ramsey, DJ 197 

Ramsey, JE 16, 20 

Randleman, J 63, 101, 132 

Randleman, JB 132 

Rao, A 204 

Rao, AP 28 

Rao, HB 218 

Rao, KS 239 

Rao, NA 88 

Raoof-Daneshvar, DA 188, 192 

Rao, PK 26 

Rao, RC 232 

Rao, SA 207 

Rao, X 244 

Rapuano, C 16, 69, 134, 194, 254 

Rathi, V 189 

Rathi, VM 224 

Rathod, RR 34, 254 

Rath, S 252 

Raval, N 192 

Ravichandran, A 201 

Ravindran, RD 179 

Ravin, JG 18, 92, 134 

Raviv, T 116 

Rawlings, L 171 

Rayess, H 227 

Razeghinejad, M 251 

Read-Brown, S 184 

Read, RW 57, 130 

Realini, AD 26 

Recchia, FM 237 

Reddy, AK xxv 

Reddy, H 125 

Reddy, JC 249, 254, 263 

Reddy, S 117 

Reddy, UP 92, 123 

Reddy, VP 216, 243 

Redenbo, EF 190 

Reeves, S 258 

Reeves, SW 102, 127 

Regatieri, CV 79 

Regiatieri, CV 239 

Regillo, CD 54, 104, 108, 143, 169, 227 

Reilly, B 243 

Reilly, GS 232 

Reinstein, DZ 101, 102, 104, 225 

Relhan, N 239 

Repka, M. X. 282 

Repka, MX xix, 140, 143, 262 

Restelli, E 231 

Restrepo Pelaez, CA 137 

Reuser, TT 215 

Reynolds, AC xxv 

Rezaei, K 111 

Rhea. M 34 

Rhee, DJ 34, 122, 130, 147, 199 

Rhodes, LA 258 

Rho, S 200, 216 

Riabenko, OI 225 

Riadh, M 234 

Riaziesfahani, H 185, 189 

Ribeiro, SF 214 

Richard, GW 138 

Richer, R 210, 211 

Rich III, WL xix 

Richman, J 204 

Rich, WL 16, 140, 148 

Riedel, PJ 120 

Riemann, CD 65, 67, 108 

Ringel, DM xxv 

Rishi, P 192, 234 

Rishi, PP 255 

Ritch, R 83, 204, 211, 289 

Ritterband, DC 69 

Rivas, AJ 28 

Rivera-Narvaez, M 222 

Rivera, RP 115 

Rizzo, JL 211 

Rizzuto, PR xix, 16, 144 

Roberts, C 26, 103, 155 

Robin, AL 179 

Robinet-perrin, A 195 

Roca, JA xiii 

Rocha Cardoso, A 238, 250 

Rocha, KM 26, 127 

Rockwood, EJ 56 

Rodrigues, EB 79, 109, 234 

Rodriguez, FJ 111 

Rodriguez Torres, L 158 

Roe, J 223 

Rofagha, S 171 

Rogers, DL 135 

Roh, YJ 233 

Rojanapongpun, P 84, 87, 139, 140 

Rojanaporn, D 212, 243 

Romano, A 79 

Romano, MR 181 

Romansky, MA 55, 57 

Rootman, DB 126 

Rootman, DS 68, 72, 75 

Roper, G 115, 117 

Roper-Hall, G 99 

Rosa, AM 250 

Rosa, N 189 

Rose, GE 96, 97 

Rose Jr, JG 124 

Rose, L 71, 74 

Rosenberg, KI 211 

Rosenberg, LF 161 

Rosenberg, PR 117 

Rosenberg, R 296 

Rosenberg. R 296 

Rosenblatt, MI 175 

Rosencrance, D 34 

Rosenfeld, PJ 79, 109, 136, 143, 149 

Rosenfeld, SR 16 

Rosen, LM 157 

Rosen, R 145, 230 

Rosenthal, KJ 60, 62, 64, 66, 116, 

117, 139 

Rosenwasser, GD 73, 119, 194 

Rosenwasser, L 194 

Ross, A 229 

Rossini, P 255 

Ross, J 190 

Ross, K 282 

Ross, KM 288 

Ross, KW 193 

Roth, DB 54, 235, 245 

Roth, ZJ 220 

Rougier, M 226, 241 

Rowen, S 62 

Roy, AK 251 

Roy Choudhury, S 222 

Roy, SL 190 

Rozen, S 201 

Rozot, P 176 

Rozsival, P 28 

Rubenstein, JB xiii, xix, 16, 17, 33, 63, 

69, 117, 129 

Rubinfeld, R 195, 196 

Rubin, MR 202 

Rubin, PD 71, 97, 125 

Rubio, RG 231 

Rucker, JC 141 

Ruggeri, M 188, 195 

Ruiz-Garcia, H 160 

Rundle, A 170 

Rusell, SR 16 

Russo, C 188 

Rutnin, N 251 

Ryan, E 109 

Ryan, S. J. 2 

Ryan, SJ 129 

Rychwalski, P 98 

Ryu, I 224 

S 

Saad, A 168 

Saad, HA 175 

Sacco, R 210 

Sachdeva, V 167 

Sachdev, MS 60 

Sadda, SR 34, 54, 110, 160, 169, 

171, 231 

Sadun, AA 141, 146, 263 

Saeed, HN 214 

Safieh, LA 229 

Safi, S 225 

Sahasrabudhe, M 219 

Sahel, JA 226, 240 

Said, D 186 

Saini, A 259 

Saito, M 237 

Sakabayashi, S 186 

Sakai, R 164 

Sakurai, M 229 

Salamat Rad, A 189 

Salcedo, K 28 

Salim, S xxv, 82, 83, 85, 139, 140, 

160, 161 

Salinas, J 28 

Salisbury, T 156 

Salle, M 28 

Sallum, JM 239 

Salomao, MQ 189 

Salom, D 102 

Saluja, RK 92, 123 

Salvato, C 294 

Salz, JJ 66 

Samaras, K 118 

Sambursky, R 74 

Samples, JR 82, 86 

Samson, CA 184 

Samuel, MA 236, 239 

Samuelson, TV 34 

Samuelson, TW 80, 81, 120, 130, 142, 

147, 162, 198 

Sanchez, JG 137 

Sanders, DS 184 

Sanders, RJ 26 

Sandler, JR xxv 

Sangave, A 245 

San Giovanni, JP 178 

Sangtam, T 182 

Sangwan, VS 73, 75, 76, 159, 184, 185, 

186, 189, 190 

Sanjari, N 209 

San, K 224 

Sankar, PS 82, 83 

Santana, P 207 

Santangelo, M 87 

Santilli, J 268 

Santorum, P 188, 249 

Santos, AB 240 

Santos, OR 166 

Saperstein, DA 56 

Saran, R 186, 195 

Sarici, AM 243 

Sarkisian, SR 33, 115, 161 

Sarnicola, V 71, 118, 119 

Sarraf, D 106, 110 

Sar, S 205 

Satake, Y 193 

Sati, A 224 

Sato, M 98 

Sato, MT 229 

Savage, JA 54, 85 

Savar, L 95, 123, 125 

Savatovsky, E 201 

Savino, PJ 141, 263 

Saxena, R 222 

Say, ET 243 

Schaal, S 105, 242 

Schaap-Fogler, M 180 

Schachat, AP xiii, xix, 16, 88, 109 

Schallhorn, SC 62, 104, 137, 145, 168 

Scharioth, GB 162, 198 

Schatz, MP 34 

Scheiner, AJ 92, 123 

Schein, OD 183 

Schemmer, GB xxv 

Schepens, CL 3 

Schiffman, J 79, 122 

Schiffman, JC 163, 164, 201, 218 

Schiffman, JS 20 

Schmidt-Erfurth, UM 133 

Schmidt, ME 293 

Schneider, S 179 

Schoenberg, E 170 

Schoonewolff III, F 166 

Schrader, WF 142 

Schrier, A 179 

Schubert, HD 16 

Schultze, RL 33, 119, 159, 224 

Schultz, JS 121 

Schultz, T 154 

Schuman, JS xxv, 84, 85, 107, 121, 149 

Schwab, IR 18, 71, 92, 146 

Schwarcz, RM 26, 93, 94, 123, 124 

Schwartz, CE 172 

Schwartz, DM 133 

Schwartz, GF 205 

Schwartz, GS 34, 115, 145 

Schwartz, SD 20, 104, 245 

Schwartz, SG xxv, 112, 227 

Schwartz, TL 112 

Schweitzer, C 176 

Scorcia, V 26, 71 

Scorsetti, DH 28, 119 

Scott, IU 16, 147 

Scott, W 227 

Scruggs, J 123 

Seah, L 93, 94 

Sebiloane, SR 248 

Sedghipour, MR 193 

Sedky, AN 56 

Seel, PC 292 

See, RF 233 

Seibel, BS 61 

Seibold, LK 197 

Seider, MI 205 

Seiff, SR 94, 124, 125, 130 

Seiler, T 103, 135, 149 

Sekiryu, T 237, 240 

Self, CA xxv 

Selvadurai, A 228 

Sen, HN 88, 163 

Sen, S 210 

Seo, H 200, 216 

Sepah, YJ 163, 228, 231, 241 

Serbecic, N 63 

Seregard, S 26, 138 

Sergott, RC 204, 210 

Serle, JB 160 

Serrano, LA 183, 225 

Setabutr, P 69 

Seth, A 219 

Sethi, G 208 

Seymenoglu, G 203 

Shady, P 219 

Shafik Shaheen, M 104 

Shah, AA 215 

Shah, AK 119 

Shah, GK 109, 128, 232 

Shah-Heidari, M 209 

Shah, M 219 

Shah, MV 199 

Shah, PK 221 

Shah, PR 117 

Shah, RM 215 

Shah, S 28, 154, 215, 243 

Shah, SK 217 

Shah, VA 117, 118, 209, 267 

Shah, VC 118 

Shaikh, O 163 

Shalchi, Z 223 

Shamie, N 33, 76, 119 

Shamis, DJ 26 

Shamsi, FA 209 

Shams, N 163 

Shapiro, BL 190 

Shapiro, H 228 

Shapiro, M 100 

Shareef, SR 160 

Sharma, A 28, 191, 209, 221 

Sharma Jr, S 164 

Sharma, K 209 

Sharma, N 70, 72, 76, 174, 206, 

249, 250 

Sharma, S 207, 219, 227, 235 

Sharma, T 28, 192, 234, 250, 255 

Sharma, V 180 

Shastri, L 247 

Shatterjee Sr, S 204 

Shatz, AC 127 

Shayegani, A 115 

330


Sheffield, VM 141 

Sheibani, K 225 

Shekhar, H 206 

Shelton, JB 167 

Shemesh, G 199 

Shenoy, BH 167, 254 

Shen, Y 223 

Sheppard, JD 145 

Sheraly, A 178 

Sherman, DD 92, 123 

Sherwood, MB 16, 81, 86, 120, 161 

Sheth, SJ 28 

Shetlar, DJ 20 

Shetty, R 63, 164, 189, 190, 250 

Shibui, H 209 

Shields, CL 69, 91, 108, 111, 165, 167, 

170, 211, 212, 215, 243, 252, 253 

Shields, JA 69, 91, 108, 111, 112, 165, 

170, 211, 212, 243, 252, 253 

Shields, MB 142 

Shih, CY 115, 157, 194, 196 

Shih, GC 178 

Shikari, HT 186 

Shima MD, C 218 

Shimazaki, J 193 

Shimizu, K 26 

Shimmura, S 70, 71, 118 

Shimomura, Y 218 

Shindler, KS 89, 90 

Shingleton, BJ 52, 81, 147 

Shin, S 245 

Shiohara, T 186 

Shiokawa, N 229 

Shiokawa SR, A 229 

Shiraga, F 145 

Shirakata, Y 186 

Shiuey, Y 196 

Shivanna, Y 250 

Shi, W 218 

Shorr, N 97, 126 

Shovlin, JP 124 

Shrestha, JK 221 

Shriver, E 95, 124 

Shriver, EM 33, 165 

Shtein, RM 26, 68, 74, 188, 192, 193 

Shuba, LM 202 

Shukla, SY 167, 170, 212, 243 

Shuler, MF 226 

Shulman, DG 20 

Siatkowski, RM 34, 132, 133 

Siddique, SS 184, 207 

Sidik MD, M 89 

Sidoti, PA 81, 120, 122 

Siegfried, CJ 16, 33, 79, 85, 122, 161 

Siegfried,CJ 33 

Sielert, L 209 

Sieving, PC 100 

Sikder, S 115 

Sikorski, BL 233 

Silbert, DI 217, 219 

Silbert, JE 26, 123 

Silkiss, RZ 20, 55, 123, 124, 125, 134 

Silva, ED 238 

Silva, F 238 

Silva, PS 238 

Silva, R 240 

Silverstone, D 267, 268 

Silverstone, DE 77, 121 

Simmons, ST 81 

Simon, DP 225 

Simon, JW 53, 220 

Simor, A 172 

Simpson, E 212 

Singer, MA 231 

Singerman, LJ 144, 145 

Singh, A 26, 85, 86, 159, 217 

Singh, AD 106, 108 

Singh, D 222 

Singh, G 235 

Singh, J 232 

Singh, K 81, 120, 130, 147, 178, 

201, 205 

Singh Sr, A 219 

Singleton, IC 174 

Singman, EL 219 

Sinha, R 174, 190, 222 

Sinha, TK 244 

Siou-Mermet, R 176 

Sippel, KC 71, 72, 73 

Sippy, BD xxv, 227 

Sirisha, S 251 

Sit, AJ 26, 85, 122 

Sitaraman SR, C 202 

Sivak-Callcott, JA 93, 96, 125, 126 

Skeens, HM 118, 119 

Skuta, GL xiii, xix, 16, 17 

Skuta, JL 145 

Slade, SG 66, 67, 102, 103, 145 

Slomovic, A 73 

Slomovic, AR 26 

Slonim, CB 123 

Smedowski, AP 186, 199 

Smiddy, WE 79 

Smith, BT 232 

Smith, G 227 

Smith, JM 256 

Smith, JR xxv, 130 

Smith, LEH 26 

Smith, LH 107 

Smith, R 240 

Smith, RE xix, 16, 88 

Smith, RT 26, 127 

Sneed, SR 108 

Snyder, ME 56, 64, 67, 249 

Sobel, RK 216 

Soheilian, M 241, 245 

Soler, V 159 

Soliman, SE 165 

Solish, AM 120 

Solish, S 20, 52, 140 

Solomon, KD 139 

Solomon, SD 26, 34, 143, 144, 173 

Soloway, BD 224 

Soltau, JB 120 

Soma, T 248 

Sommer, A 132, 148 

Sommer, A. 3 

Son, B 216 

Song, A 123, 125 

Song, CD 115 

Song, J 123 

Soni, A 99 

Soni, M 67 

Sonty, S 81 

SooHoo, JR 197 

Soong, H 192 

Soper, M 73 

Sophie, R 231, 241 

Soto-Pedre, E 228 

Sotozono, C 186 

Souka, A 165 

Soukiasian, SH 88 

Sousa, L 54, 70, 117, 119 

Souza, AW 208 

Spaeth, GL 56, 81, 120, 204, 251, 263 

Spaide, RF 107, 109, 110, 112, 128, 241 

Spencer, MS 26, 120 

Spigelman, A 117 

Spirn, MJ 180 

Sponsel, W 198 

Springs, CL 115 

Sprunger, DT xxv, 17 

Srikumaran, D 159 

Srinivasan, B 192, 234, 250 

Srinivasan, M 72, 138 

Srinivasan, S 67, 175, 176 

Srivastava, S 247, 255 

Srivastava, SK 88, 208, 234, 242 

Stacey, AW 215 

Stahl, ED 26, 127 

Stahl, JE 101, 126, 127 

Stalmans, PW 111, 128 

Stamper, RL 142, 173, 202 

Stanciu, NA 123 

Standefer, J 141 

Stanfield, M 202 

Stanga, PE 244 

Stark, WJ 66, 139, 142, 183 

Starr, CE 130 

Stasior, GO 126 

Stechschulte, JR xiii 

Steel, DR 256 

Stegmann, R 83, 121 

Steinemann, TL 74 

Steinemann,TL xxv 

Steinert, RF 62, 139, 145, 158 

Stein, JD 198, 205 

Steinle, NC 233 

Steinsapir, K 123, 124 

Stephenson, PG 115 

Sterkin, A 213 

Sterling, RB 55, 290 

Sternberg Jr, P 129 

Sternberg, P xiii 

Stern, GA 16, 18 

Sterns, GK 16, 18, 112, 146, 148, 149 

Stern, WH 226 

Stevens, JD 137 

Stewart, MW xxv 

Stieger, K 210 

Stiles, MC 120, 122 

Stinnett, S 167, 217 

Stodtmeister, R 202 

Stonecipher, KG 34, 67, 168 

Stone, EM 135 

Storey, P 174 

Straatsma, BR 3 

Straiko, MD 76, 119, 189, 193, 194 

Straka, DG 215 

Strassman, E 196 

Stratton, S 34 

Strauss, DS 241 

Strauss, EC 171 

Strenk, L 155 

Strenk, S 155 

Strohmayr, E 210 

Strominger, MB 26 

Strouthidis, NG 136 

Strube, Y 98, 126 

Struck, MC 94 

Studer, HP 155 

Stulting, R 71, 117 

Stulting, RD 135, 137, 263 

Subramanian, PS 33, 90 

Suchecki, J 26, 122 

Su, CS 97 

Su, D 204, 211 

Sudhalkar, AA 211, 239 

Suelves-Cogollos, A 207 

Sugai, M 28 

Sugano, Y 240 

Sugar, A 192, 193 

Sugar, J 16, 117, 146 

Sugiyama, K 83, 204, 229 

Suh, J 200 

Suh, LH 142, 186 

Suh, S 221 

Suh, Y 216 

Suk, KK 236 

Sullivan, T 204 

Sullivan, TJ 94, 96, 97, 134 

Summerfield, ME 58 

Summers, CG 20, 135, 140 

Sun, G 57, 138 

Sung, K 149, 200, 201, 204 

Sung, KR 26 

Sun, JK 145, 238 

Sunness, JS 20, 132, 146 

Sun, Y 182 

Superstein, R 234 

Suthar, TN 157 

Sutphin, JE xxv 

Suzuki, K 197 

Suzuma, K 183, 227, 230, 240, 243 

Swanson, CL 181, 182 

Swarup, R 74, 158 

Swink, D 289, 293 

Syed, NA 148, 211, 216 

Syrogiannis, A 232 

Szkulmowski, M 233 

T 

Taban, M 126 

Tabbara, KF 88, 184 

Tabin, GC 61, 62, 116 

Tabin. GC 139 

Tada, R 208 

Tahija, SG 111 

Tai, TT 120 

Takada, Y 177 

Takagi, S 235 

Takai, N 208 

Takayama, K 231 

Takeda, S 208 

Taketani, Y 209 

Talajic, JC 119, 189, 194 

Talamo, JH 103, 195 

Talley-Rostov, AR 20, 115 

Talwar, N 205 

Tamayo, GE 102, 103 

Tamesis, JM 89 

Tamhankar, MA 89, 90 

Tamura, H 232 

Tan, CS 26, 203, 231, 242 

Tan, D 20, 70, 71, 72, 75, 77, 118, 146, 

187, 188, 193 

Tandon, R 174, 190 

Taneja, M 189, 224 

Taneri, S 127 

Tang, J 100 

Tang, RA 122 

Tan, J 213 

Tanji, TM 122 

Tanna, AP 117, 141, 142 

Tan, NW 242 

Tao, JP 53, 97, 125 

Tapia-Ramirez, R 28 

Tappin, M 118 

Taravella, MJ 118 

Tarnawska, D 186 

Tauber, J 75 

Tauber, S 27, 127 

Taylor, HJF xiii 

Taylor, HR 134 

Taylor, RJ 16 

Taylor, SR 163 

Tedeschi, G 210 

Telezhina, AN 236 

Tello, C 81, 120 

Teng, CC 204 

Tennant, BB 193 

Tenzing, C 87 

Teoh, SC 229 

Terry, MA 68, 72, 73, 76, 77, 119, 189, 

193, 194 

Tesha, PE 28 

Tessler, HH 130 

Tetz, M 162, 198 

Tewari, A 109, 128 

Tezel, TH 27, 105, 242 

Thakker, MM 124 

Tham, CC 83, 84, 87, 203 

Tham, CCY 34 

Tham,CCY 84 

Tham, CY 120 

Theron, J 176 

Thiagarajah, CK 27 

Thomas, JK 205 

Thomley, M 172 

Thompson, GM 233 

Thompson, JT xxv, 33, 34, 136, 171 

Thompson, LS 126 

Thompson, V 127 

Thompson, VM 21 

Thorne, JE 130 

Thungappa, KS 250 

Thurber, C 243 

Ticona SR, F 255 

Tilahun, Y 187 

Tims, JS 118 

Tinageros, NF 28 

Tipperman, R 65, 130, 139 

Titiyal, JS 174, 190, 249 

Tjia, KF 62 

Tobon SR, CA 255 

To, E 200 

Toffaha, BT 155 

Toker, l 176 

Tomidokoro, A 204 

Tomita, G 235 

Tomita, M 101, 127, 169 

Tomkins, O 163 

Tomlins, PJ 215 

Tong, M 206 

Topiwala, P 167 

Topping, T 149 

Topping, TM 262 

Tornambe, PE 109, 128 

Torrazza, C 244 

Tortori, A 189 

Toth, CA 104, 107, 128, 226, 237 

Totsuka, K 209 

Touboul, D 159, 176, 195 

Toussaint, BW 146 

Townley, JR 168, 223 

Toy, B 178, 243 

Toyoda, H 197 

Toyokawa, N 198 

Trabelsi, A 141 

Traboulsi, EI 98 

Traish, AS 111, 119 

Trakos, N 97 

Tran, D 115 

Tran, DB 103 

Tran, THC 28 

Tran-Viet, K 201 

Trattler, WB 34, 66, 67, 74, 101, 195, 

196, 224 

Trese, MT 105, 107, 136 

Trinidad, M 186 

Trivedi, RH 100, 167, 217, 219, 220 

Trubnik, V 251 

Trudo, EW 185 

Tsai, JC xxv 

Tsai, JH 34, 117, 119 

Tsai, L 175 

Tsai, LM xiii, 115 

Tsang, SH 229, 238 

Tse, DT 165 

Tseng, SG 72, 74, 76, 119, 192, 251 

Tsubota, K 136 

Tsuiki, E 183, 227, 230, 243 

Tsujikawa, A 230, 237, 242 

Tsujikawa, M 248 

Tucker, NA 27, 94, 134 

Tucker, SM 94 

Tu, DC 184 

Tu, E 75, 111, 118, 146 

Tuft, SJ 159 

Tuli, SS 69, 76 

Tuncer, S 233 

Tuomi, L 228 

Turalba, AV 198, 199 

Turbin, RE 55, 164 

Turco, DA 228 

Turk, A 210 

Turner, G 244 

Turner, R 210 

Turpcu, A 232 

U 

Udagawa, S 204 

Udaondo, P 102 

Udell, IJ 157, 194, 196 

Ueda-Arakawa, N 231 

Ueda, S 212 

Ueki, R 243 

Uematsu, M 171, 183, 240 

Ueno, M 201 

Ueta, M 186 

Ugurbas, S 175 

Ugurbas, SC 175 

Uhler, TA 16 

Uji, A 242 

Ulbig, MW 237 

Umana, JC 28 

Unal, M 176 

Ung, C 205 

Uram, M 121 

Urcelay, JL 203 

Ursea, R 115 

Usui, Y 210, 212, 228 

Uttley, SA 117 


331



Uy, HS 27, 154, 179 

Uysal, Y 199 

V 

Vaddavalli, P 27 

Vaddavalli, PK 68, 72, 74, 99, 158, 

188, 189, 194, 195 

Vagefi, M 124 

Vajaranant, T 69, 252 

Vajaya, L 210 

Vajpayee, RB 70, 74, 76, 206, 249, 250 

Vakharia, MR 117 

Valdez, JE 28 

Vallejo Garcia, J 221 

Vandenbroucke, R 164, 201 

vanderStraaten, D 154 

VanderVeen, DK 27, 100, 167, 220 

van der Wees, J 188 

van Dijk, K 157, 194 

Van Gelder, RN xiii, xxv, 21, 88 

Van Meter, WS 63, 67, 70, 117, 118 

Van Rij, G 16 

Van Stavern, GP 27 

Vaphiades, MS 21, 122 

Vargas Galveia, JN 252 

Vargas, JM 196 

Varley, GA 33 

Varma, DK 87 

Varma, R 149, 232 

Vasavada, AR 21, 61, 62, 65, 66, 100, 

116, 134, 217, 247, 255, 263 

Vasavada, VA 217, 247, 255 

Vasconcelos-Santos, DV 130 

Vass, C 162, 198 

Vasseur, V 240 

Vassileva, PI 141 

Vatavuk, Z 200 

Vega, A 158 

Veiga, A 229 

Velazquez, AJ 127 

Veloso, C 237 

Vemuganti, G 243 

Venkatapathy, N 221 

Venkatesh, P 242 

Venkatesh, R 179 

Venter, JA 27, 168 

Verdet, R 229 

Verdier, DD 118, 119, 130, 194 

Verghese, A 129 

Verma, GL 28 

Veronese, C 244 

Vicchrilli, S 258, 267, 282 

Vicchrilli, SJ 132, 288 

Vichitvejpaisal, P 182 

Vickers, LA 167 

Victoria Moreno, DA 222 

Videkar, R 254 

Villani, E 179 

Villanueva, L 191 

Vinciguerra, P 101, 102 

Virasch, VV 117 

Vitale, AT 88, 105 

Vitale, L 231 

Vitali, M 181 

Viti, AJ xxv 

Vize, CJ 28 

Vohra, R 242 

Vold, SD 27, 65, 120, 122, 161 

Volpe, MJ 146 

Volpe, NJ 89, 90, 122, 146, 221 

von Bischhoffsha, FB 141 

Vora, MM 196 

Vo, RC 180 

Vrabec, M 127 

Vroman, DT 60, 63, 72, 117, 118 

Vukich, J 101 

Vukich, JA 34, 130, 137 

W 

Wachter, B 34, 78 

Wada, T 229 

Waddell, AM 182 

Wadde, M 283 

Waddle, M 283, 287, 292 

Wadekar, BR 176 

Wade, RA 284, 286, 287, 289, 292 

Wadia, KN 164, 189, 250 

Waedlich, R. 267 

Wagner, AL 16 

Wagner, RS 21 

Waheed, NK 239 

Wajnsztajn, D 196 

Wakabayashi, Y 228 

Wakiyama, H 201, 227 

Walker, JD 27 

Wallace, DK 20, 21 

Wallace III, RB 154 

Wallace, R 52, 103, 117, 127 

Wallace, RB 139 

Wall, M 211 

Walsh, AC 110 

Walsh, M 33 

Walsh, MK 62, 116 

Walter, KA 72, 118 

Walters, TR 174 

Walton Muir, K 217 

Waltz, K 116, 175 

Wand, M 142 

Wang, A 89 

Wang, D 177 

Wang, E 182 

Wang, G 227 

Wang, MY 146 

Wang, N 84, 115, 213, 244 

Wang, SY 178, 201, 205 

Wang, W 213, 235 

Wang, Y 163 

Wan, L 233 

Wanumkarng, N 95 

Wan, X 213 

Waring, GO 101, 127 

Waring III, GO 16 

Warn, AA xiii, xxv 

Warrak, EL 180 

Warren, KA 60, 109, 115, 128, 130 

Washburn, E 34 

Watanabe, A 197, 214 

Watanabe, M 122 

Watson, SL 133 

Watters, AL 163 

Watts, PO 133 

Weatherhead, RG 134 

Wedemeyer, L 78 

Wee, S 220 

Weglarz, B 199 

Weichel, ED 232 

Weikert, MP 33, 103, 149, 173 

Weinberg, RS 197 

Weinreb, RN 85, 203 

Weinstock, RJ 65, 68, 116, 117, 262 

Weinstock, SM 68 

Weisbrod, D 172 

Weisenthal, RW 75, 194 

Weiss, JS 173 

Wells III, JA 227 

Wells, JR 115 

Werner, JS 190 

Werner, L 155 

Wesley, RE 134 

Westfield, KC 174 

Westhouse, SJ 54 

West, SW 144, 174 

Whipple, KM 252 

Whitaker, S 175 

Whitcup, SM 21 

Whitecross, S 137 

Whiteside-de Vos, J 82, 120, 121 

Whitman, J 115 

Whitson, J 205 

Whitson, JT 33 

Whittaker, TJ 78 

Whittington Jr, CD xxv 

Wickham, LJ 112, 233 

Wiedemann, P 111 

Wieland, MR 226 

Wiggins, DA 127 

Wiggins Jr, RE 34 

Wiggins, RE 27, 283, 290, 294 

Wiley, W 65, 127 

Williams, A 204 

Williams, BJ 221 

Williams, C 186 

Williams, DF 108, 135, 171 

Williams, GA xiii, 62, 104, 106, 108, 

109, 138 

Williams, JM 205 

Williams, RD xiii, 129, 258 

Willoughby, BJ 216 

Wilson, J 164 

Wilson Jr, ME 52, 55, 100, 220 

Wilson, MD 211 

Wilson, MW 33, 212 

Wilson, SE 103 

Wilson, SM 148 

Winn, BJ 123 

Winterling, S 283, 290, 291 

Wisnicki, HJ 267, 268 

Witt, IR 34 

Wizov, SS 204 

Wladis, E 123, 124, 165 

Wojtkowski, M 233 

Wolfe, JD 62 

Wolff, B 240 

Wolford, R 292 

Wollstein, G 54, 149 

Wong, A 290, 292, 293 

Wong, AM 90 

Wong, D 110 

Wong, DS 179 

Wong, J 126 

Wong, K 107, 128 

Wong, P 170 

Wong, RV 258, 293 

Wong, SC 107, 254 

Wong, T 106, 147 

Wong, TT 188 

Wong, TY 34, 147 

Wong, WT 228, 243 

Wong, Y 205 

Woodke, EJ 53, 288, 290, 291 

Woodke, J 282 

Woodley, B 155 

Wood, P 267 

Woodward, JA 55, 92, 123, 165 

Woodward, MA 62, 68, 74, 115, 188, 

192, 193 

Woo, K 93, 94, 97, 216, 252 

Woo, R 155 

Woo, S 233 

Wowra, B 191 

Wright, A 232 

Wright, KW 98, 101, 126 

Wright, MM 33, 120, 121 

Wroblewska-Czajka, E 186 

Wu, HK 60, 115, 116, 117 

Wu, L 52, 111 

Wulc, AE 94, 124 

Wu, W 244 

Wylegala, EA 27, 187, 191, 199 

Xing, W 159 

Xu, D 227, 234 

Xu, H 223 

Xu, Y 197 

Xu, Z 177 

X 

Y 

Yackel, T 184 

Yadav, NK 208 

Yagev, R 199 

Yagi, F 235 

Yamada, R 237 

Yamada, Y 227, 230, 240 

Yamagishi, T 236 

Yamamoto, T 27, 84 

Yamane, S 244 

Yamashiro, K 230, 232, 236, 237 

Yamazaki, T 236 

Yanai, D 239 

Yang, H 218 

Yang, MB 217 

Yannuzzi, LA 112, 240, 241 

Yanovitch, TL 201 

Yapur, ES 28 

Yarian, DL 235 

Yaseri, M 209, 241 

Yau, L 227, 231 

Ye, C 200 

Yee Melgar, M 87 

Yehezkel, O 213 

Yeh, R 194 

Yeilding, R 215 

Yen, KG 99 

Yen, M 89 

Yen, MT 94, 95 

Yeu, E 34, 127, 168 

Yeung, IY 179 

Yeung, L 244 

Yick, DW 205 

Yi, J 227 

Yin, VT 172 

Yip, C 94, 97, 126, 182 

Yip, CC 28 

Yip, VC 231 

Yoder, J 190 

Yoganathan, P 233 

Yohannan, J 241 

Yokoi, N 214 

Yokoyama, T 98 

Yoo, DK xxv 

Yoon, C 204, 221 

Yoon, HH 221 

Yoon, HS 233, 243 

Yoon, JS 216 

Yoon, Y 201, 228, 233, 242, 243 

Yoo, S 232 

Yoo, SH 34, 58, 65, 68, 70, 72, 103, 

104, 130, 132, 137, 158, 168, 

188, 195 

Yoo, Y 204 

Yorston, DB 232 

Yoshida, M 206 

Yoshikawa, H 201 

Yoshimura, N 231, 236, 238, 242 

Young, M 296 

Young, TL 33, 99, 166, 201 

Young, WO 57 

Youssef, OH 215 

Yuan, A 234 

Yuen, CY 205 

Yu, F 199 

Yukawa, S 169 

Yu, M 200 

Yung, C 115, 182 

Yunker, J 172 

Yun, S 200 

Yu, S 107, 230 

Yu, Y 217 

Z 

Zacchia, RS 207 

Zacks, CM xiii, 54 

Zahn, S 210 

Zaidman, GW 140, 194 

Zaldivar, R 70, 145 

Zalta, AH 21, 80, 81, 82 

Zambarakji, HJ 255 

Zambrano, AI 183 

Zandi, S 209 

Zanke, BW 236 

Zanlonghi, X 229 

Zaouali, S 234 

Zebardast, N 203 

Zegans, ME 88 

Zegarra, H 233 

Zeid, JL 221 

Zein, WM 100 

Zelt, RP 27 

Zevnovaty-Braun, Y 28 

Zhai, C 224 

Zhang, C 177 

Zhang, E 205 

Zhang, J 170, 224, 231, 239 

Zhang, K 171, 237 

Zhang, X 89 

Zhang, Y 213 

Zhang, Z 160 

Zhao, J 223 

Zhao, L 237 

Zheng, Y 231 

Zhou, M 228 

Zhou, X 223 

Zhou, Y 224 

Ziaei, A 193 

Zimmer-Galler, IE 245 

Zimmerman, LE 3 

Zink, H 148, 149 

Zloty, P 52, 72 

Zobal-Ratner, JL 99, 220 

Zoric Geber, M 200 

Zoumalan, CI 123 

Zou, X 177 

Zou, Y 177 

Zwiener, I 213 

332

Participant Financial Disclosure Index 

The Academy’s Board of Trustees has determined that a financial 

relationship should not restrict expert scientific, clinical, or 

non-clinical presentation or publication, provided that appropriate 

disclosure of such relationship is made. Similarly, it should not 

restrict participation in AAO leadership or governance, so long as 

appropriate disclosure is made. As an ACCME accredited provider 

of CME, the Academy seeks to ensure balance, independence, 

objectivity, and scientific rigor in all individual or jointly sponsored 

CME activities. 

All contributors to Academy educational and leadership activities 

must disclose significant financial relationships (defined below) 

to the Academy annually. The ACCME requires the Academy to 

disclose the following to participants prior to the activity: 

• Any known financial relationships a meeting presenter, author, 

contributor or reviewer has reported with manufacturers of 

commercial ophthalmic products or providers of commercial 

ophthalmic services within the past 12 months 

• Meeting presenters, authors, contributors or reviewers who 

report they have no known financial relationships to disclose 

The Academy will request disclosure information from meeting 

presenters, authors, contributors or reviewers, committee members, 

Board of Trustees, and others involved in Academy leadership 

activities (“Contributors”) annually. Disclosure information will 

be kept on file and used during the calendar year in which it was 

collected for all Academy activities. Updates to the disclosure 

information file should be made whenever there is a change. At 

the time of submission of a Journal article or materials for an 

educational activity or nomination to a leadership position, each 

Contributor should specifically review his/her statement on file and 

notify the Academy of any changes to his/her financial disclosures. 

These requirements apply to relationships that are in place at the 

time of or were in place 12 months preceding the presentation, 

publication submission, or nomination to a leadership position. 

(defined as spouse, domestic partner, parent, child or spouse of 

child, or sibling or spouse of sibling of the Contributor) by: 

• Direct or indirect compensation; 

• Ownership of stock in the producing company; 

• Stock options and/or warrants in the producing company, 

even if they have not been exercised or they are not currently 

exercisable; 

• Financial support or funding to the investigator, including 

research support from government agencies (e.g., NIH), device 

manufacturers, and\or pharmaceutical companies; or 

• Involvement with any for-profit corporation that is likely to 

become involved in activities directly impacting the Academy 

where the Contributor or the Contributor’s family is a director or 

recipient of a grant from said entity, including consultant fees, 

honoraria, and funded travel. 

Description of Financial Interests 

Category Code Description 

Consultant / 

Advisor 

C 

Consultant fee, paid advisory boards or fees for 

attending a meeting (for the past 1 year) 

Employee E Employed by a commercial entity 

Lecture Fees L Lecture fees (honoraria), travel fees or 

reimbursements when speaking at the 

invitation of a commercial sponsor (for the past 

1 year) 

Equity Owner O Equity ownership/stock options (publicly or 

privately traded firms, excluding mutual funds) 

Patents / 

Royalty 

P Patents and/or royalties that might be viewed 

as creating a potential conflict of interest 

Grant Support S Grant support for the past year (all sources) 

and all sources used for this project if this form 

is an update for a specific talk or manuscript 

with no time limitation 

Financial Relationship Disclosure 

For purposes of this disclosure, a known financial relationship 

is defined as any financial gain or expectancy of financial gain 

brought to the Contributor or the Contributor’s immediate family 






Participant Financial 

Disclosure Index 

A 

Thomas M Aaberg Jr MD 

Allergan; L 

Synergetics, Inc.; C 

Tarek Abdel Wahab MD 

Bausch + Lomb; L 

Gary W Abrams MD 

Alcon Laboratories, Inc.; C 

Nisha Acharya MD 

Bausch + Lomb; S 

GlaxoSmithKline; C 

National Eye Institute; S 

Research to Prevent Blindness; 

S 

Xoma; C 

Stacey L Ackerman MD 

ACIEX; C 

Allergan; C 

Bausch + Lomb; C 

QLT Phototherapeutics, Inc; C 

Sun Pharma; C 

Anthony P Adamis MD 

GENENTECH; E,O 

Natalie A Afshari MD 



S 

Amar Agarwal MD 

Abbott Medical Optics; C 

Bausch & Lomb Surgical; C 

Dr. Agarwal’s Pharma; O 

SLACK, Incorporated; P 

STAAR Surgical; C 

Thieme Medical Publishers; P 

Anita Agarwal MD 

AMD genetics licensed to 

Arctic Dx; P 

Athiya Agarwal MD 

Dr. Agarwal’s Pharma; O 

Iqbal K Ahmed MD 

Abbott Medical Optics; L 

Alcon Laboratories, Inc.; C,L,S 

Allergan, Inc.; C,L,S 

Aquesys; C,S 

Carl Zeiss Meditec; C,L,S 

Clarity; C,S 

Endo Optiks, Inc.; C 

Glaukos Corporation; C,S 

IRIDEX; C 

Ivantis; C,L,S 

Merck; C,L,S 

Neomedix; L 

New World Medical Inc; L 

Pfizer, Inc.; C,L,S 

Transcend Medical; C 

Lloyd P Aiello MD PhD 


Allergan, Inc.; L 

Eli Lilly & Company; C,L 

GENENTECH; C 

Genzyme; C 

Kalvista; C,O 

Novartis Pharmaceuticals 

Corporation; C 

Optos, Inc.; S 

Pfizer, Inc.; C 

Thrombogenetics; C 

Makoto Aihara MD PhD 

Alcon Laboratories, Inc.; L,S 

Merck & Co., Inc.; L 

Pfizer, Inc.; L,S 

Santen, Inc.; L,S 

Senju; L,S 

Esen K Akpek MD 

Alcon Laboratories, Inc.; S 

Allergan, Inc.; S 

Daniel M Albert MD FACS 


Thomas A Albini MD 

Alcon Laboratories, Inc.; C,L 

Allergan, Inc.; C 

Bausch & Lomb Surgical; L 

Anthony J Aldave MD 

Alcon Laboratories, Inc.; L 

Allergan; C 

Merck & Co., Inc.; C 

Eduardo C Alfonso MD 


Bio-Tissue, Inc.; C 

InSite Vision, Inc.; C 

Jorge L Alio MD PhD 

Abbott Medical Optics; S 

AcuFocus, Inc.; S 

Akkolens ; C,S 


Bausch Lomb Surgical; C,S 

Carl Zeiss Meditec; S 

Hanita Lenses; C 

Mediphacos; C 

Novagali; S 

Nulens; C,O 

Oculentis; C,S 

Physiol; C 

Presbia; C 

Santen, Inc.; C 

SCHWIND eye-tech-solutions; 

L,S 

SLACK, Incorporated; C 

Springer Verlag; P 

Tedec Meiji; C 

Tekia, Inc.; P 

Thea; S 

Topcon; C 

Vissum Corporation ; E, O 

Daniel Aliseda MD 


Corporation; S 

Norma Allemann MD 

Quantel Medical; L 

Noel A Alpins MD FACS 

ASSORT; P 

Michael M Altaweel MD 

GlaxoSmithKline; S 


Regeneron; S 

Griffith Altmann 

Bausch Lomb; E 

Renato Ambrosio Jr MD 



Allergan, Inc.; L, 

Bausch Lomb; L 

Carl Zeiss Inc; L 

Mediphacos; L 

Oculus, Inc.; C,L 

David Ammar 


Francisco Amparo MD 


Douglas R Anderson MD, 

FARVO 

Carl Zeiss Meditec; C 

Richard L Anderson MD FACS 

Allergan, Inc.; O 

Jose Andonegui MD 



Robert Edward T Ang MD 

AcuFocus, Inc.; C,L 

Allergan, Inc.; C,L 

Bausch & Lomb Surgical; C,L,S 

Carl Zeiss Meditec; L 

Andrew N Antoszyk MD 


GENENTECH; C 

Regeneron; C 

James V Aquavella MD 

Bausch & Lomb Surgical; S 

Johnson & Johnson Consumer 

& Personal Products Worldwide; 

S 


S 

Maria C Arbelaez MD 


L 

Steve A Arshinoff MD 


Alcon Laboratories, Inc.; C, 

Arctic Dx; C 

Bausch Lomb; C 

Penny A Asbell MD FACS 

Alcon Laboratories, Inc.; C,S 

Bausch & Lomb Surgical; C,S 

Merck & Co., Inc.; C,L 


Corporation; C,L 

Pfizer, Inc.; S 

Santen, Inc.; C,L 

Amin Ashrafzadeh MD 


Sanjay G Asrani MD 


Heidelberg Engineering; L 

ICare Finland; L 

Lumenis, Inc.; L 


Kerry K Assil MD 

Abbott Medical Optics; C,L,S 

Gerd U Auffarth MD 

Abbott Medical Optics; C,S 



Carl Zeiss Meditec; C,S 

Rayner Intraocular Lenses 

Ltd; C,S 


C 

Technolas; L,S 

Tin Aung, FRCS PhD 


Allergan; L 

Carl Zeiss Meditec; L,S 

Ellex; L,S 


Pfizer, Inc.; L 

Santen, Inc.; L 

Robert L Avery MD 



GENENTECH; C,L,S 

IRIDEX; C 

iScience; C 


Corporation; C,O 

Ophthotech; C 


Replenish; C,O,P 

SKS Ocular; O 

Richard M Awdeh MD 




Cirle; C,O 

iDoc, Inc; C,O 

Inspire Pharmaceuticals, 

Inc.; C,L 

Ista Pharmacuticals; C 

Sarcode; C 

Carl C Awh MD 

Arctic DX; C,O 

Bausch & Lomb Surgical; C,L 


Katalyst; C 

Neovista; C,O 

Notal Vision, Ltd.; C 


Synergetics, Inc.; C,O,P 

Volk Optical; C 

William Ayliffe MBBS 


Brandon Ayres MD 





Dimitri T Azar MD 

ForSight Labs; C,O 


Corporation; C,O 

B 

Darron A Bacal MD 


George Baerveldt MD 

Advanced Medical Optics; P 

NeoMedix Corporation; C,L,P 

Georges D Baikoff MD 

Optovue; C 

Clare Bailey MD FRCOPHTH 

Bayer; C,S 


Corporation; C,L,S 

Quark pharmaceuticals; S 

James W Bainbridge, MA PhD 

FRCOphth 

Gene Signal; C 

Oxford Biomedica; C 

Carl W Baker MD 


Brock K Bakewell MD 


Sophie J Bakri MD 


GENENTECH; C 

Francesco M Bandello MD, 

FEBO 


Alimera Sciences Inc; C 



Bayer Schering Pharma; C 

Farmila-Thea Pharmaceuticals; 

C 

GENENTECH; C 




Sanofi Aventis; C 

Thrombogenics; C 

Michael R Banitt MD 


Innovia; L 


Aruna T Bansal 

Sequenom Inc.; C 

Pascale Barberger-Gateau, 

PhD 

Danone; S 

Lesieur; L 

THEA; S 

Vifor Pharma; C 

Howard Barnebey MD 


Allergan; L 

iScience; C,L 


Scott D Barnes MD 


STAAR Surgical; L 

Edward M Barnett MD PhD 



Neal P Barney MD 


Rafael I Barraquer Compte MD 



IMEX (Spain); L,P 

Medical Mix (Spain); L 

John M Barrows, MPH 


Keith Barton MD 



Amakem; C 

Aquesys; C,O 

Glaukos Corporation; C 

Ivantis; C 

Kowa; C 

Merck & Co., Inc.; C,L,S 

New World Medical Inc; S 

Ophthalmic Implants PTE ; O 


Refocus Group, Inc.; C 

Thea Labritories; C 

Samar K 

Basak MD FRCS MBBS 


Allergan; C 

Surendra Basti MBBS 



Juan F Batlle MD 

Innovia; C 

Optimedica; C 

Reflow Biomedical Technologies 

; C 


Srilaxmi Bearelly MD 


GENENTECH; C 

Kaplen Foundation; S 

Hilary A Beaver MD 

Genzyme; L 

Nikolaos E Bechrakis MD 


Allergan; S 


Corporation; C,S 

Bruce B Becker MD 

Armadillo Biomedical LLC; O 

Quest Medical, Inc.; P 

334 

The presenters above have a financial interest. See page 333 for Description of Financial Interests key.


Paul M Beer MD 

Z Lens LLC; O,P 

George Beiko MD 


Rubens Belfort Jr MD PhD 



Bayer; C 

Michael W Belin MD 


Darren J Bell MD 



GENENTECH; S 

Neovista; S 

Regeneron; S 

Salim Ben Yahia MD 

Bausch Lomb; C,L 

Goran Bencic 


Susan C Benes MD 

Lundbeck; L 


John P Berdahl MD 




Gregg J Berdy MD 





QLT Phototherapeutics, Inc; C,L 

Brian B Berger MD 


Allergan; C,S 

GENENTECH; S 


Heidelberg Engineering; C 

Lpath Inc.; S 


Daniel M Bernick JD 

Health Care Group; C,E,O 

Maria H Berrocal MD 


Abdhish R Bhavsar MD 

Allergan, Inc.; C,S 

Eyetech, Inc.; C 

GENENTECH; S 

Regeneron; C,S 

Perry S Binder MD 

Abbott Medical Optics; C,L 

AcuFocus, Inc.; C,L,O 

Outcomes Analysis Software, 

Inc; P 

Stroma; C 

Christopher L Blanton MD 


Allergan; C,L 

Mark H Blecher MD 



Allergan; L 

Kevin J Blinder MD 


GENENTECH; C,L 

iScience; C 



C 



Ocusoft; S 

Regeneron; S 


Mark S Blumenkranz MD 

Avalanche Biotechnology; O,P 

Digisight; O 

Ista Pharmaceuticals; C 

Optimedica; O,P 

Vantage Surgical; C,O 

Bahram Bodaghi MD PhD 



Lux Biosciences; S 



Xoma; C 

Michael V Boland MD PhD 

Allergan; C 


J Brent Bond MD 


Navaneet S C Borisuth MD 

PhD 




Ista Pharmacuticals; C,L 

Shyamanga Borooah 

Wellcome Trust; S 

Francesco Boscia MD 





David S Boyer MD 


Allegro; C 


Bayer; C 




GSK; C 

iCo Therapeutics; C 

Neurotech; C 



Optos, Inc.; C 

ORA; C 

Pfizer, Inc.; C,L 

QLT, Inc.; C 

Regeneron; C 

Spire; C 

Rosa Braga-Mele MD 



Allergan; C,L 

James D Brandt MD 



Apple Computer, Inc.; O 



Glaukos Corporation; C,O 



Periklis Brazitikos MD 




Neil M Bressler MD 

Abbott Medical Optics Inc.; S 

Alimera Sciences; S 

Allergan USA; S 

Bausch & Lomb Incorporated; S 

Bristol-Meyers Squibb 

Company; S 

Carl Zeiss Meditec, Inc.; S 

DIAGNOS INC; S 

ForSight Labs, LLC; S 

Genentech, Inc.; S 

Genzyme Corporation; S 

Lumenis, Inc.; S 

Notal Vision; S 

Novartis Pharma AG; S 


Regeneron Pharmaceuticals, 

Inc.; S 

Steba Biotech S.A.; S 

The EMMES Corporation; S 

ThromboGenics; S 

Susan B Bressler MD 

Allergan; S 


GENENTECH; S 





Thrombogenics; S 

Detlev R H Breyer, MD 


Mitchell Brigell PhD 


Corporation; E 

Stephen F Brint MD 


Wave Tec; C 

Jefferey T Brockette 



Regeneron; C,L 

Systeem Medical Information 

Systems; C,O 

David M Brown MD 


Alimera; C 


Bayer Pharmaceuticals; C 


GENENTECH; C,S 

Heidelberg Engineering; C,L 

Molecular Partners; C 



Paloma; C 



Steba Biotech; C 


Michael D Brown 

Health Care Economics, Inc.; C 

Reay H Brown MD 


Ivantis; C 

LifeSynch; P 

Rhein Medical, Inc.; P 

Alexander J Brucker MD 

Escalon Medical Corp; O 

GENENTECH; S 



Neurovision; O 

Ophthotech; C,O 

Optimedica; O 

Donald L Budenz MD MPH 


Alimera; C 




Camille J R Budo MD 

Carl Zeiss Meditec; C,L 

OPHTEC, BV; C,L 

Philippe Buechler 

NCCR Co-Me of the Swiss 

National Science; S 

Swiss Innovation Promotion 

Agency; S 

Brandon G Busbee MD 

Akorn Inc.; P 

Alimera; C 

Elan; C 


Regeneron; L 



Massimo Busin MD 

MORIA; L,P 

Carlos Buznego MD 





CXL; O 

Glaukos Corporation; C,O,S 

RPS; O 

TEAR SCIENCE; S 

C 

Peter Calabresi 

Abbot; S 

Bayer; S 

Biogen Inc; C,S 


Genzyme; C 

Johnson & Johnson; L 




Serono; C,S 

Vaccinex; C 

Vertex; C,S 

David G Callanan MD 




Jorge G Camara MD 

Allergan; L 

Fabrizio I Camesasca MD 


Peter A Campochiaro MD 

Aerpio; C 

Alimera; C,S 

Elan; C 

Gene Signal; C 


Genzyme; S 

GlaxoSmithKline; C,S 

Norvox; C 

Oxford BioMedica; C,S 

Regeneron; C 

Mauro S Campos MD 


Antonio Capone Jr MD 


Alimera Sciences; C 


FocusROP, LLC; O,P 



Ophthotec; S 

Retinal Solutions, LLC; O,P 

Thrombogenics; S 

Joseph Caprioli, MD, FACS 



Allergan; C,L,S 


Alan N Carlson MD 

Tear Science; O 

Francesco Carones MD 

Alcon Laboratories, Inc.; C,L, 

SLACK, Incorporated; C, 

WaveLight AG; L 

Cesar C Carriazo E, MD 

MORIA; P 


P 

Jean D Carruthers MD 

Allergan; C, R 

Kythera; C, R 

Merz; C, R 

Alessandro A Castellarin MD 

Alcon Laboratories, Inc.; O 



QLT Phototherapeutics, Inc; 

C,L,S 

Usha Chakravarthy MBBS PhD 



Neovista Inc; C 



Oraya Therapeutics; C,L 


Angela Chambers, RN MBA 


Eyetech Ltd; C 

EYLEA; C 


Wallace Chamon MD 

Corneal Biomechanincs; P 

Crosslinking; P 

Wavefront Systems; P 

Clara C Chan MD 




Tat-Keong Chan MD FRCS 

FRCOphth 






The presenters above have a financial interest. See page 333 for Description of Financial Interests key. 

335




Daniel H Chang, MD 







Calhoun Vision Inc; O 


Clarity; C,O 

Eyemaginations Inc; P 

Glaukos Corporation; S 

ICON bioscience; O 


LensAR; C,O 

PowerVision Inc; O 

Revital Vision; O 


Transcend Medical; C,O 

John So-Min Chang, MD 


Technolas Perfect Vision; L 

Robert T Chang MD 


Stanley Chang MD 



Steven T Charles MD 

Alcon Laboratories, Inc.; C, P 

Topcon Medical Systems; C, P 

Imran Chaudry 

Covidien/EV3; C 

Microvention; L 

Arturo S Chayet MD 

Calhoun Vision, Inc.; C 

Nidek, Inc.; C 

Soon-Phaik Chee MD 


HOYA Medical Singapore Pte. 

Ltd; C,L 

Technolas Singapore Pte 

Ltd; C,L 

Philip P Chen MD 

Allergan; C 

Sherleen Huang Chen MD 


David H Cherwek MD 

Alcon Laboratories, Inc.; E 

Michael F Chiang MD 

Clarity Medical Systems 

(unpaid Board); C 


Stephanie Chiu 

Duke Eye Center; P 

James Chodosh MD MPH 



National Eye Institute; C,S 

N H Victor Chong, MD 



Bayer; C,L 

IRIDEX; C 




Neil T Choplin MD 


Optovue, Inc.; C,L 

Vikas Chopra MD 

Allergan; C 

Bennett Chotiner MD 


David R Chow MD 

Arctic Dx; C 


Katalyst; C 


Corporation; L 


David S Chu MD 


Analysis Group Inc; C 

Eyegate; S 

Lux Bioscience; S 



Richard C Chu DO 








Lifeguard Health; C 

Ocular Therapeutix; C 

Ocusoft; C 

Powervision; C 

Revision Optics; C 

Alice Z Chuang PhD 


Mina Chung MD 

Lowy Medical Research 

Institute; S 


Rochester CTSI; S 

thome foundation; S 

George A Cioffi MD 


Robert J Cionni MD 


Morcher GmbH; P 

WaveTec Vision; C 

Carl C Claes MD 


William S Clifford MD 

Transcend Medical; S 

David K Coats MD 

I am providing consulting 

services; C 

Kimberly Cockerham MD 

FACS 

Acktivatek; C 

Department of Defense; S 

FanMinder; C 


Elisabeth J Cohen MD 

Merck & Co., Inc.; S 

John S Cohen MD 


Marc S Cohen MD 

Allergan; C,L 

Medicis; L 

Kathryn A Colby MD PhD 



Vision Care Inc.; C 

Joseph Colin MD 


Addition Technology; C 


Shoshana Colman PhD 

GENENTECH; E 

D. Michael Colvard MD 



OASIS Medical, Inc.; P 

Robin Cook MD 

Penquin-Putnam and Berkely 

Publishers; P 

Cheryl Coon PHD 



Kevin J Corcoran 

Corcoran Consulting Group; 

C,E,L,O 

Borja F Corcostegui MD 


Bayer; L 



Vital Paulino Costa MD 



New World Medical Inc; L,S 


Anastasios P Costarides MD 

PhD 

Allergan; S 


Elizabeth D Cottle CPC OCS 

AAO CodeQuest instructor; L 

Casey Eye Institute-OHSU; E 

Private consulting; C 

Cristobal A Couto MD 

Allergan; L 

Stephen S Couvillion MD 

GENENTECH; C 

Alan S Crandall MD 



AqueSys; C 

ASICO; C 

eSinomed; C 

Glaucoma Today; C 


iScience; C 

IVANTIS, Inc.; C 

Journal Cataract Refractive 

Surgery; C 

Mastel Surgical; C 

Ocular Surgery News; L 

Omeros Corporation; C 


Vimetrics; C 

E Randy Craven MD 



Compulink Business Systems, 

Inc.; C 


Haag Streit; C 

Ivantis; C 



Mary Ann Croft 

Z Lens LLC; L,S 

Karl G Csaky MD 

Acucela; C 

Allergan; C,S 



IRIDEX; S 




Ophthotech; C,O 


William W Culbertson MD 




Hoya Surgical Optics; C 

Optimedica; C,O,P 

Arthur B Cummings MD 


WaveLight AG; C,L 

Jose G Cunha-Vaz MD PhD 


Allergan; C 

F. Hoffmann - La Roche; C 

Fovea Pharmaceuticals; C 

GeneSignal; C 



Christine Curcio PhD 


GENENTECH; L 

Global Sight Network; E 


Claus Cursiefen MD 




Gene Signal, France; C 


Oscar E Cuzzani MD PhD 

Abbott Laboratories; E,O 

D 

Donald J. D’Amico MD 

Lux Biosciences, Inc.; C 

Ophthotech, Inc.; C,O 

Optimedica, Inc.; C,O 

Roger A Dailey MD 

Biologic Aqua; O 

Jose Dalma MD 

Sanofi; C 

Reza Dana MD MSc MPH 




Eleven Biotherapeutics; C,O 

GENENTECH; C 


Google; C 

InSite Vision, Inc.; C 

Novabay; C 

Novaliq; C 


Rigel; C 

Sanofi/Fovea; C 

Sarcode; C 

Mark Danese 


Jean-Francois Dartigues PhD 

Eisai; S 

Ipsen; L,S 

Merck-Serono; L 



Arup Das MD PhD 


Jonathan M Davidorf MD 



Richard S Davidson MD 


Elizabeth A Davis MD 





Refractec; O 

SARcode Bioscience; C 

Janet Louise Davis MD 

Santen, Inc.; S 

Michael J Davis MD 



David Lee Davis-Boozer MPH 

Fischer Surgical, Inc.; S 

James A Davison MD 


Sheraz M Daya MD 


Physiol; C 


Technolas Perfect Vision; C,L 

Zeiss Acritec; C 

Eugene De Juan Jr MD 

Bausch & Lomb Surgical; P 

ForSight Labs; E,O 

GENENTECH; P 

IRIDEX; O,P 

NexisVision; C,O 

OneFocus Ventures LLC; E 

Second Sight; C,O,P 

Synergetics, Inc.; P 

Transcend Medical ; C,O 

Vision 4; C,O 

Vision 5; C,O 

Marc Dominique De Smet, MD 

PHD FRCSC FRCOPHTH 


Arnhem Ophthalmic Research; 

O,P 

Bayer Pharmaceuticals; C 

Centocor, Inc.; C,S 

Thrombogenics Inc; C,L,P,S 

Cecile Delcourt PhD 


Laboratoires Thea (France); 

C,L,S 



Steven J Dell MD 




Bausch & Lomb Surgical; C,O,P 


Optical Express; C 

Tracey Technologies, Corp.; C,O 

Marie-Noelle Delyfer, MD 

PHD 

Thea Laboratories; C 

336 



Joseph L Demer MD PhD 

Eye Sight Foundation of 

Alabama; C 

U.S. Public Health Service; C,S 

Sophie X Deng MD PhD 

California Institute of Regenerative 

Med; S 

Uday Devgan MD 

Accutome Inc; L,P 

Alcon Laboratories, Inc.; L,O 



Haag-Streit; L 

Hoya Surgical Optics; C,L 

Ista Pharmacuticals; C,L,O 

SLACK, Incorporated; L 

Specialty Surgical; O 

Storz Instruments from Bausch 

& Lomb; C 

Steven H Dewey MD 


Microsurgical Technology; P 

Felipe E Dhawahir-Scala 


VisionCare Ophthalmic Technologies; 

C 

Narendra Dhingra, MBBS 



Andrew D Dick MD 



Burkhard Dick MD 





Ocular Surgery News; C 

Oculus, Inc.; P 

Diana V Do MD 


GENENTECH; S 

Heidelberg Engineering; S 


Regeneron; S 


Andrew P Doan MD PhD 

Credential Protection, LLC; O 

FEP International, Inc.; O 

John F Doane MD 

Bausch & Lomb Surgical; L,O,S, 

Calhoun Vision Inc; S, 

Carl Zeiss Meditec; S, 

I-Therapeutixs; S 

LenSx; C 

Revision Optics; O,S, 

Claes H Dohlman MD PhD 

Massachusetts Eye & Ear 

Infirmary; E 

Sean P Donahue MD PhD 

Diopsys Corporation; C, 

iScreen; C 

PlusOptix; C 

REBIscan; C 

Eric D Donnenfeld MD 


AcuFocus, Inc.; C 



Aquesys; C 


CRST; C 


Inspire Pharmaceuticals 

Inc; C,P 

Lensx; C 

Odyssey; C 



TLC Laser Eye Centers; L,O 

truevision; C,O 

Wavetec; C 

Peter C Donshik MD 

Osuka; C 

Vistakon Johnson & Johnson 

Visioncare, Inc.; S 

Paul J Dougherty, MD 

Lenstec, Inc.; C,L,O 

Nidek, Inc.; L 

Revision Inc.; C 


Arlene V Drack MD 

Foundation Fighting Blindness; 

S 

Hope for Vision; S 

Vision for Tomorrow; S 

Kimberly A Drenser MD PhD 

FocusROP; O 

Retinal Solutions; O 


John H Drouilhet MD FACS 

Acucela; S 


Pravin U Dugel MD 




ArticDx; C,O 

GENENTECH; C 

Macusight; C,O 

Neovista; C,O 



Ora; C 

ThromboGenics; C 

Jay S Duker MD 



EMD/Serono; C 

EyeNETRA; C,O 

GENENTECH; C 

Hemera Biosciences; O 

Neovista; C 



Ophthotech; O 

OptoVue; S 

Paloma Pharmaceuticals; C 



Topcon Medical Systems; S 

William J Dupps, MD PhD 

Avedro; S 

Cleveland Clinic Innovations; P 

Ziemer; C 

Vikram D Durairaj MD 

Kaneka; C 

OnPharma; E 

Stryker Corp/Medical Division; 

L, 

Daniel S Durrie MD 


Accelerated Vision; C,L,O 


Alcon Laboratories, Inc.; 

C,L,O,S 

Allergan; L 

Avedro; L,O 

NexisVision; C,L,O,S 

Revital Vision; O 

Wavetec; C,L,O,P 

Ziemer; C,L 

E 

Ralph Eagle, MD 

Children’s Oncology Group; S 

Merck & Co., Inc.; O 

Claus Eckardt MD 


Ophthalmic, USA; P 

Jeffrey P Edelstein MD 

Alkermes; O 

American World Clinics; O 

Coviden; O 

CVS; O 

Express Scripts; O 

Gilead Sciences; O 

Insulet; O 


Pfizer, Inc.; O 

Siemans; O 

Teva Pharmaceutical Industries, 

Ltd.; O 

Robert A Eden MD 

Allergan; L 

Inspire Pharmaceuticals Inc; L 

Jane C Edmond MD 


Keith Edwards 

LensAR Inc; E 

Eric Eggenberger DO 

Acorda; C 

Berlex, Inc; C,L 

Biogen Inc; C,L,S 



Serono; C,S 


Ltd.; C,L,S 

Aitor Eguzkiza 



Jason S Ehrlich MD 


Yosuf El Shabrawi MD 

Allergan; C 


Mays A El-Dairi MD 

Prana pharmaceuticals; C 

Alaa M Eldanasoury, MD 



Dean Eliott MD 

Alimera; C 

Arctic; C 


GENENTECH; C 


Ophthotech; C 


Victor M Elner Ph.D. , MD 

OcuSciences, Inc.; O,P 

Alice T Epitropoulos MD FACS 

Alice Epitropoulos MD/Epico, 

LLC; O,P 

Allergan; C 


K David Epley MD 


Randy J Epstein MD 


Tear Sciences, Inc.; C 

Michael Erlanger MD 

University of Colorado; P 

F 

Dale Fajardo 

Gilead Sciences; O 


Daniel H Farkas, PHD 

Sequenom Center for Molecular 

Medicine; E 

Sina Farsiu PhD 

American Health Associattion 

Foundation; S 

Duke Eye Center; P 

Jean-Luc Febbraro MD 



Robert D Fechtner MD FACS 





Robert S Feder MD 


Leonard Feiner MD 

GENENTECH; C 

Robert M Feldman MD 


Allergan; S 

Lux Biosc iences; S 



Steven E Feldon MD 


Excubator, LLC; P 


S 

Rafael Feliz MD 

Optimedica; C 

Ronald Leigh Fellman MD OCS 


iScience; S 

SOLX; S 

Transcend; S 

Zeiss-Meditec; S 

Alberto Ferreira 

Novartis Pharma AG; E 

Antonio Ferreras, MD PhD 





Instituto de Salud Carlos III; S 


Frederick L Ferris, MD 

Bausch + Lomb; P 

Philip J Ferrone MD 



Arctic DX; C,O 



Regeneron; C,L,S 

John P Fezza MD 


Q-Med; L 

Marta Figueroa MD 





Oliver Findl, MD 



Carl Ziess Meditec; C 

Croma; C 

Howard F Fine MD MHS 

Allergan; C 

Auris Surgical Robotics; C,O,P 



Jennifer Fine 


Mitchell S Fineman MD 

PRN; C,S 

Paul T Finger MD 

Liberty Vision Corporation; O 

The Eye Cancer Foundation, 

Inc.; L,S 

Zoraida Fiol-Silva MD 

CIBA Vision, a Novartis 

Company; C 

William J Fishkind, MD FACS 

Abbott Medical Optics; C, 

LensAR; C, 

Thieme Medical Publishers; P, 

Brian W Fleck MBChB 

i2Eyediagnostics; O 

Brian E Flowers MD 


iScience; L 


Transcend Medical, Inc.; C 

Harry W Flynn Jr., MD 

Alimera; C 



William J Flynn MD 


Altheos; S 

Bausch Lomb; S 

Ocular Therapeutix; S 

Omeros Corporation ; S 

QLT Phototherapeutics, Inc; S 

Alice Fong 

GENENTECH; E 




337




Kenneth C S Fong MD 

Allergan; L 

Bayer pharmaceuticals ; C,L 



Quantel Medical; L 

S Lance Forstot MD FACS 



Eleven Biotherapeutics; C 

C Stephen Foster MD 




Eyegate Pharmaceuticals, 

Inc; O,S 

Lux Biosciences, Inc; C,S 



Jill Annette Foster MD FACS 

Allergan, Inc.; C,L, 

Merz; C,L 

Paul J Foster FRCS 


Allergan; L 


Tamara R Fountain MD 


Insurance Company; C 

Amy M Fowler MD 

Ellman International; C,L 

Merz aesthetic; C 

Brian A Francis MD 



Lumenis, Inc.; L,S 


NeoMedix Corporation; C 

Alan J Franklin MD PhD 

Eyetech Inc.; C 

Frederick T Fraunfelder MD 


Jeffrey Freedman MB.Bch PhD 

IOP; L 

Sharon F Freedman MD 


James F Freeman MD 



L Neal Freeman MD MBA 

FACS 

Private consulting; C 

Melvin I Freeman MD FACS 

Elsevier, Inc.; P 

JaypeeHighlights Medical 

Publishers; P 

William R Freeman MD 

Allergan; C 

OD-OS Retina Care Unlimited; 

C 

K Bailey Freund MD 



Regeneron; C 

Thomas R Friberg MD 


GENENTECH; C 



David S Friedman MD MPH 

PhD 






Quark; C 

Zeiss Meditec; S 

Deborah I Friedman MD 

Allergan; L 

Amplatzer; S 

MAP Pharmaceuticals; C,S 

Merck & Co., Inc.; C,S 


Neurology Reviews; C 

Quark Pharmaceuticals; S 

Neil J Friedman MD 


Allergan; L 


digiSight; C,O 

OptiMedica; C,O 

Oraya; C,O 

Scott M Friedman MD 



Michel Friesenhahn 

GENENTECH; E 

Luther Fry MD 


Arthur D Fu MD 

GENENTECH; L 

James Fujimoto PhD 

Carl Zeiss Meditec; P 

Optovue; O,P 

Hiroshi Fujishima MD 


Allergan; C 

Santen, Inc.; L,S 

Senju; L,S 

Anne E Fung MD 





Sequenom; C 


G 

Steven L Galetta MD 

Biogen Inc; C 


Ltd.; C 

Brenda L Gallie MD 

Solutions by Sequence; O 

Antonio Gallo 

Biogen Inc; C,L 



Serono; C,L 


Ltd.; C,L 

Anat Galor MD 

Veterans Affairs Medical 

Center; S 

Parag Gandhi MD 

Synthes CMF; L 

Prashant Garg MD 


NovaBay Pharmaceutical Inc; C 

Sunir J Garg MD FACS 



GENENTECH; S 

Lux; S 

Neovista; S 

Chandra Shekhar Garudadri 

MD 


Allergan; C 


David F Garway-Heath MD 

FRCOphth 




Forsight; C 



Moorfields Motion Detection 

Test; P 

OptoVue; S 


Quark; C 

Ronald N Gaster MD FACS 

Abbott Medical Optics; O 


Damien Gatinel MD 

AcuFocus, Inc.; L 


Chibret International; L 

Nidek, Inc.; C,L 

Reichert Ophthalmic Instruments; 

L 

Technolab; L 

Alain Gaudric MD 



Bayer; S 



Susan A Gauthier 

Biogen Inc; C,S 



Serono; C,S 


Ltd.; L 

Matthew D Gearinger MD 

Lundbeck; L 

Steven J Gedde MD 

Lumenis, Inc.; C 


David I Geffen OD 



Allergan; L 


Vmax; C,L 

Karen Marie Gehrs MD 

Abbott Pharmaceuticals; C 


Allergan; C 

Sequenom; C 

Lawrence Geller MBA 

Medical Management Associates, 

Inc.; E 

Ronnie Jacob George MD 

Allergan; L 

CWCF Chennai; S 


SJ Feike Gerbrandy, MD 

ellex; L 

JoAnn A Giaconi MD 

Allergan; C 

James P Gills MD 



Lenstec, Inc.; O 

Joseph P Gira MD 

Allergan; L 


Michelle Gleeson 

GENENTECH; C 

Christopher C Glisson, DO 


Damien Goldberg MD 

Alcon Laboratories, Inc.; C, L 

Allergan; C, L 


lexitas; C 

QLT; C 

Ivan Goldberg MBBS 

FRANZCO 



Forsight; S 



Dafna Goldenberg MD 

Forsight Labs ltd; C 

Notal Vision; C 

David A Goldman MD 





Debra A Goldstein MD 

Abbott pharmaceuticals; C 



Michael H Goldstein MD 

Eleven Biotherapeutics; C,O 

Karl C Golnik MD 


Andre V Gomes MD 


Ophthalmic, USA; C 



Volk; C 

Jose Gomes MD 





Fumi Gomi, MD PhD 



HOYA Corporation; C,L 



Christine R Gonzales MD 

Alimera; C 

Allergan; L 

Iconic Therapeutics; S 

Lpath Inc.; S 

OPHTEC; S 


Regeneron; S 

Javier Gonzalez 

Optimedica; E 

Victor H Gonzalez MD 


Eyetech, Inc.; C,S 


Iconics; S 



Regeneron; S 

Lynn K Gordon MD PhD 

VentiRx Pharmaceuticals, Inc. 

Seattle,WA; C 

James A Gow MD 

Bausch Lomb; E,O,S 

Raj K Goyal MD MPH 


Gunther Grabner MD 


AcuFocus, Inc.; L,S 

Polytech; C 

Evangelos S Gragoudas MD 

QLT Phototherapeutics, Inc; P 

David B Granet MD 

Alcon Laboratories; C 

Jeff Grant 

Compulink Business Systems, 

Inc.; C,L 

David S Greenfield MD 

Allergan; C 

Biometric Imaging; C,O 


Merz; C 


Optovue; S 

Quark; C 

Senju; C 

SOLX; C,O 

Vivienne C Greenstein PhD 


Darren G Gregory MD 

Bio-Tissue, Inc.; L 

Salvatore Grisanti 

Alimera; C 

Allergan; C 

Bayer; S 




Lewis R Groden MD 


LCA ; O 

Ronald L Gross MD 






Cynthia L Grosskreutz MD PhD 



Davinder S Grover MD 

Allergan; C 

Sandeep Grover MD 

Scyfix LLC; C 

Andrzej Grzybowski MD 


Croma; C,L 

Jose L Guell MD PhD 



Carl Zeiss Inc; C 

OPHTEC, BV; C 

Preeya K Gupta MD 


338 



Sunil Gupta MD 

Alcon Laboratories, Inc.; C, L 

Allergan, Inc.; C, L 

GENENTECH; C, L 

Rainer Guthoff, MD 



David L Guyton MD 

Hartwell Foundation; S 


Patents on fixation detection 

technology; P 

H 

Nabil E Habib MD 

Allergan; C 

Farhad Hafezi, MD PhD 


C 

Ziemer Ophthalmics; C 

Gregory S Hageman PhD 

Sequenom; C 

Julia A Haller MD 

Advanced Cell Technology; C 


GENENTECH; C 

Optimedica; O 

Regeneron; C 


M Bowes Hamill MD 

OPHTEC; S 

D Rex Hamilton MD 



Reichert, Inc; L 

Ziemer; L 

Pedram Hamrah MD 


Allergan; C 

Fovea Pharmaceuticals; C 



Dennis P Han MD 


GENENTECH; S 

Ophthotech; S 

Regeneron; S 

Masaaki Hanebuchi 

Nidek, Inc.; E 

Masanori Hangai MD 

CANON; S 





Topcon Medical Systems, 

Inc.; C 

David R Hardten MD 




Bio-Tissue, Inc.; C 

Calhoun Vision Inc; S 

ESI, Inc.; C 

Oculus, Inc.; L 

TLC Vision; C 


Christos Haritoglou MD 

Allergan; L 



Alon Harris PhD 



Sucampo; C 

Andrew R Harrison MD 

Merz Pharmaceuticals; C 

Mary Elizabeth Hartnett MD 

FACS 

Axikin Pharmaceuticals; C 


Paul J Harton Jr MD 

Lenstec, Inc.; L 


Morris E Hartstein MD 

Springer; P 



Lenstec, Inc.; C 


TLC Laser Eye Centers; O 

Tarek S Hassan MD 

Artic DX; C,L,O 



Genentech, Inc.; C,L 

Insight Instruments; C,L 

Optimedica; C,O 

Regeneron, QLT; C 

Synergetics Inc.; L 

Abdallah K Hassouna MD 





Jeffrey S Heier, MD 

Acucela; C 


Alimera; S 



Bayer Healthcare; C 


Forsight Labs; C 

Fovea; C,S 


Genzyme; C,S 




Kato Pharmaceuticals; C 

Lpath Inc.; C 

NeoVista, Inc.; C,S 

Neurotech, Inc.; S 

Notal Vision; C,S 



Ophthotech; S 

Oraya Therapeutics; C 

Paloma, Inc.; C,S 

QLT Ophthalmics; C 

QLT Therapeutics; C 

QLT, Inc.; C 

Quark Pharmaceuticals; C 


Sequenom; C 

Heinrich Heimann MD 



Peter C Heiner MBBS 


Bonnie A Henderson MD 




Massachusetts Eye and Ear 

Infirmary; P 

Leon W Herndon MD 


Reichert; L 

Sight Sciences; C 

Peter S Hersh MD 

Addition Technology; S 


AVEDRO, INC.; C 

Synergeyes Inc; S 

Dale K Heuer MD 

Aerie Pharmaceuticals; C 





Elenza; C 

Haag-Streit; C 

LensAR; C 

Oculus, Inc.; C 


Akito Hirakata MD 



Lawrence W Hirst, MD MBBS 

MPH DO FRACO FRACS 

owner of trademark 

P.E.R.F.E.C.T. ; P 

Jesper Hjortdal, MD 


Allen C Ho MD 



Janssen; C,L,S 


NEI / NIH; S 

Ophthotech; C,S 

PRN; C,O,S 

Regeneron; C,L,S 

Second Sight; S 

Thrombogenics; C,L 

Ching Lin Ho, FRCS, MBBS 


Allergan; L 

Kenneth J Hoffer, MD FACS 

Haag-Streit ; P 

Oculus, Inc.; P 


Ziemer; P 

Richard S Hoffman MD 

Microsurgical Technology; C 

John Bryan Holds MD 

Allergan; C 

Merz Pharmaceuticals; C 


Jack T Holladay, MD MSEE 

FACS 




Carl Zeiss Inc; C 


Wavetec; C 

Edward J Holland MD 


Advanced Vision Research, 

Inc; C 




QLT Phototherapeutics, Inc; C,S 

Senju Pharmaceutical Co., 

LTD.; C 

Wavetec Vision Systems, 

Inc; C,S 

Simon P Holland MD 


Allergan; L 


David Hollander MD 

Allergan, Inc.; E,O 

Jonathan M Holmes MD 


Frank G Holz MD 

Acucela; C 

Bayer Healthcare; C,L 

Carl Zeiss Meditec; C,S 


Heidelberg Engineering; C,L,S 



Ophthotec; C 



Mike P Holzer MD 




Ltd; L,S 

Technolas Perfect Vision 

GmbH; C,L,S 

Donald C Hood PhD 


J Jill Hopkins MD 

GENENTECH; E 

Yuichi Hori MD 

Grants for Scientific Research 

(Japan); S 

H Dunbar Hoskins Jr., MD 

FACS 

AcuMems; O 

Transcend; C,O 

John A Hovanesian MD 

Abbott Medical Optics; C,L,O,P 


Bausch & Lomb Surgical; C,L,O 

Essex Woodlands Health 

Ventures; C,L 


IOP Inc; C,L,S 


Ivantis; C 

Ocular Therapeutix; C,L,O,S 

ReVision Optics; C 

Sight Sciences; C,O 


Visiogen, Inc.; C,L,S 

Vista Research; C 


Visioncare, Inc.; C,P,S 

Michael J Howcroft MD 

GENENTECH; L 

Genentech Inc.; L 

Andrew J W Huang MD MPH 



David Huang MD PhD 


Optovue, Inc; C,L,O,P,S 

John J Huang MD 

Allergan; C 

Suber S Huang MD, MBA 



i2i Innovative Ideas, Inc.; O 


Retinal Diseases Image 

Analysis Reading Center 

(REDIARC); C,L 

Sequenom; C 

Jean-Pierre Hubschman MD 


Susan M Hughes MD FACS 

Allergan; L 

Mark S Humayun MD PhD 


Bausch & Lomb Surgical; 

C,L,O,P,S 

REPLENISH; C,O,P,S 

Second Sight; C,L,O,P,S 

David G Hunter MD PhD 

Children’s Hospital Boston; P 

Johns Hopkins University; P 

REBIScan, Inc; C,O 

Cindy M Hutnik MD PhD 


Allergan; C,L 

Bausch + Lomb; C,L 


Jeong-Min Hwang MD 

Korean Min Health & Welfare 

A102065-24; S 

I 

Tsontcho Ianchulev MD 

Corinthian Ophthalmics; O 

Transcend Medical; E 

wavetec; C,O 

Osama I Ibrahim MD PhD 


Michele Iester 


Allergan; L 



Tomohiro Iida MD 


Bernie Iliakis 

SightLife; P 

Makoto Inoue MD 




Michael S Ip MD 


Eye Technology Ltd.; C 

GENENTECH; C 

NicOx; C 



Regeneron; C 

Sirion; C 




339




Andrew George Iwach, MD 

Acumems; C,O 



Clarity Medical Systems; C 

IRIDEX; C,L 

Ista Pharmacuticals; L 

Lumenis, Inc.; C,L 



J 

Nada S Jabbur MD 


Douglas A Jabs MD MBA 

Abbott Laboratories; C 


Allergan Pharmaceutical 


Applied Genetic Technologies 


Corcept Therapeutics; C 

GENENTECH; C 

Genzyme Corporation; C 





Inc; C 

Roche Pharmaceuticals; C 

Kent L Jackson 

Outpatient Ophthalmic Surgery 

Society ; C 

Timothy L Jackson MBChB 



Ophthalmic, USA; L 

NeoVista; C,L,S 



Oraya; S 

Thrombogenics; C,L 

W. Bruce Jackson, MD, FRCSC 

Allergan Inc; C,L,S 

AMO/VISX, Inc.; S 

Glenn J Jaffe MD 



Neurotech USA; C 

SurModics, Inc; C 

Martine J Jager MD 

Aeon Astron; S 

Subhadra Jalali MS 

Allergan; C 

Sun pharmaceuticals, India; C 

Andrew Charles James PhD 

Seeing Machines; P 

Lee M Jampol MD 

Baxter BioScience; C 

Jaeb Center/DRCR; C 

Stem Cell Organization/ 

Quintiles; C 

Bennie H Jeng MD 

Kedrion; C 


Thomas John MD 



iScience; C 


Marco; L 

Nidek, Inc.; L 


Visioncare, Inc.; C,L 

Mark W Johnson MD 


Ophthotech; C 

Oraya; C 

Regeneron; S 

Murray A Johnstone MD 

Allergan; C,P 

Cascade Ophthalmics; E 

Healionics; E 

Ivantis; C 

Jost B Jonas MD 


Bayer Co; C,L 

CellMed Alzenau; P,S 

Heidelberg Engineering; L,S 


Morphosys AG, Munich; C 

SOOFT SpA Montegiorgio, 

Italy; C,L 

Zeiss-Meditec; S 

Jason J Jones MD 


OptiMedica; C 

K 

Malik Y Kahook MD 





Innovative Laser Solutions 

LLC; O,P 

IVANTIS; C 

Merck & Co., Inc.; C,S 

Shape Ophthalmics LLC; C,O,P 

ShapeTech LLC; O,P 

Peter K Kaiser MD 


ArcticDx; C 

Bayer; C 





SKS Ocular LLC; C,O 

Richard S Kaiser MD 

Neovista; C,O, 

Ophthotech; C,O, 

Stephen A Kamenetzky MD 

OCS 

ANTHEM BCBS; E 

Ganesha R Kandavel MD 





Avedro; C 

KeraMed, Inc.; L 

WaveLight AG; L 

Paul C Kang MD 





Henry J Kaplan MD 

Advanced Ocular Technology; 

O,P 


Assenti; O 

Caremark; C 


RegenaSight; O,P 


Hampar Karageozian 

Allegro Ophthalmics, LLC; O 

Lisa Karageozian 

Allegro Ophthalmics, LLC; O 

Vicken H Karageozian MD 

Allegro Ophthalmics LLC; O 

Randy H Kardon MD PhD 

Acorda Pharmaceutical; C 

Department of Defense 

TATRC; S 




Veterans Administration; S 

Zeiss Meditec; C 

Tomoyuki Kashima, MD 

Ohtsuka.pharm; L 


Douglas A Katsev MD 



Allergan; S 


Isis Pharmaceuticals; C 

James A Katz MD 


Ocular Therapeutix, Inc; S 

Refocus Group, Inc.; S 

TrueVision Systems, Inc.; C,O 

Visiogen, Inc.; S 

L Jay Katz MD 

Aerie Pharmaceutical; C,S 






Merck & Co., Inc.; L,S 

Robert A Kaufer MD 


Hoya; C 

Paul L Kaufman MD 



Altheos, Inc; C,L 

Amakem Therapeutics; C,L 




C,L 

Lens AR, Inc; S 


Nu-Lens; S 


QLT Phototherapeutics, Inc; C,L 

Santen, Inc.; C,L,S 

Univ of Florida; L 

WARF; P,S 

Z lens, LLC; S 

Stephen C Kaufman MD PhD 

IOP Ophthalmics; C 

Simon P Kelly FRCOphth 

Alimera Sciences ; C 

Bayer; C 



John H Kempen MD 



Celtic; C 

Eyegate; S 

Food and Drug Administration; 

S 

Harbor; C 

Lux Biosciences; C 

Mackall Foundation; S 



S 

University of Pennsylvania; E 

Xoma; C 

Kenneth R Kenyon MD 

KEERA, s.r.l.; O 

Marcus Kernt, MD 


Allergan; L 



Optos, Inc.; C, L 

Peter J Kertes MD 

Allergan; C,S 

ArcticDx; C,O 


Bayer; C,L,S 



Regeneron; S 

Mounir A Khalifa MD 


Yousuf M Khalifa MD 



Baseer U Khan MD 

Abbott Medical Optics; L,S 





Refocus Group, Inc.; C,L,S 

Solx; S 

Hamza N Khan MD FACS 





Albert S Khouri MD 


Allergan; L 

Rahul Khurana MD 



iScience; C 

Regeneron; C 

Jeremy Z Kieval MD 


Allergan; L 


Ivana K Kim MD 


Regeneron; C 

Judy E Kim MD 




Stella K Kim MD 

Eli Lilly & Company; C 

Seattle Genetics; C 

Tae-Woo Kim, MD, PHD 

Allergan; L 


Terry Kim MD 




Ocular Systems Inc; C 

Ocular Therapeutix; C,O 

Powervision; C,O 


Alan E Kimura MD 

GENENTECH; C 

Sequenom; C 

Shigeru Kinoshita MD 


Acucela; C 


HOYA; C,L 


Otsuka Pharmaceutical Co.; 

C,L,S 


Santen, Inc.; C,L,P,S 

Senju Paharmaceutical Co.; 

C,L,P,S 

Marc Kirshbaum 

Allegro Ophthalmics, LLC; E,O 

Szilard Kiss MD 

Alimera; C,L 



Optos, Inc.; C,L,S 

John W Kitchens MD 


mywhitecoat.com; O 

Optos, Inc.; C,L 


Synergetics, Inc.; C,L 

Sharon M Klier, MD 

Ista Pharmacuticals; E 

Stephen D Klyce PhD 


Acufocus; C 


Clinical Research Consultants; 

C 

LensAR; C 

NEXIS VISION; C 


NTK Enterprises; C 

Ocularis Pharma; C 

Topcon Medical Systems; C 

Michael C Knorz MD 


FourSight Labs LLC; C,O 

LenSx Inc.; C,O 

Optical Express Inc.; C 





NuLens; C 

Optimedica; O 

Ziemer; S 

340 



Paul S Koch MD 

Allergan; L 

Anew Optics; P 

Cynacon/Ocusoft; O,P 

Hoya Surgical; C 

iScience; O 

Noble Vision; O 

ScienceBased Health; C 

STAAR Surgical; O 

Robert K Koenekoop MD PhD 


Bruce H Koffler MD 


Aton Pharma; L 



Adrian H Koh MD 

Allergan; C 

Carl Ziess Meditec; C,L 

Heidelberg Engineering; C,L 



Shizuka Koh MD 

Japanese MEXT; S 



Thomas Kohnen MD, PhD, 

FEBO 


Bausch & Lomb Surgical; L,S 

Hoya; L,S 

Neoptics; S 


Ltd; C,L,S 


C,L,S 

Gregg T Kokame MD 

Allergan; C 

GENENTECH; S 






Maria Kolic 

Seeingmachines ; E 

Aaleya F Koreishi MD 


Bobby S Korn, MD PhD FACS 



Jean-Francois Korobelnik MD 




Lab Bayer; C 

Lab THEA; C 



Richard C Koval, MPA, CMPE 

The BSM Consulting Group; 

E,O 

Regis Kowalski MS 


Inspire Pharmaceuticals, Inc.; C 

Rempex; S 

Manus C Kraff MD 

STAAR Surgical; O 

Assaf Kratz MD 


Howard R Krauss MD 

Eli Lilly & Company; S 

Quark, Inc,; S 

Florian T A Kretz MD 

A.R.C. Laser Corporation; S 




Dr. Schmidt Intraocularlinsen; 

L,S 

Eyesense; S 

NuLens; S 

Oculentis; L,S 

PhysIOL; L 

Powervision; S 


Ltd; L,S 

Technolas Perfect Vision; L,S 

Rohit Krishna MD 


Cloud Nine Development; O 

Mark E Kropiewnicki, JD, LLM 

Health Care Group; C,E,O 

Ronald R Krueger MD 

Alcon Laboratories, Inc.; CL 


Clarity Medical; C 

LensAR; O 

Presbia, Inc.; C 

Balakrishna V Kumar MBBS 




Anthony N Kuo MD 


Baruch D Kuppermann MD 

PhD 

Alimera; C,S 

Allegro Ophthalmics LLC; C 


Fovea; C 




NeoVista; C 

Neurotech; C 

Novagali; C 



Ophthotech; C,L 

Regeneron; S 

Thromobogenics; C,S 

Yasuo Kurimoto MD PhD 


HOYA Surgical Optics; L 





Shunji Kusaka MD 

HOYA Inc.; L 

Ministry of Science and 

Technology,Japan; S 


Young H Kwon MD PhD 

Allergan; C 

Free Educational Publications 

Inc.; O 

Steven M Kymes PhD 



Pfizer, Inc.; C,S 

L 

Chi-Chun Lai MD 

Allergan; L 

Bayer; S 



Phillip C Lai, MD 


Timothy Y Lai MD, FRCOphth, 

FRCS 

Allergan; C,L 

Bayer Healthcare; C,L,S 




OXiGENE Inc.; S 


Wico W Lai MD FACS 




Byron L Lam MD 

Advanced Cell Technology; S 

Allergan; C 

Bikam, Inc.; C 

CDC; S 

Department of Defense; S 

Foundation for Fighting Blindness; 

S 



Quark; S 

Wai-Ching Lam MD 



Bayers; C 




Scott R Lambert MD 


Lions International; C 


Stephen S Lane MD 



Bausch + Lomb; C,L,S 



Ocular Therapeutics; C 

PowerVision; C 

SARcode; C 

SMI; C 

SRxA; C 

TearScience; C 


C 

WaveTec; C 

Mark A Latina MD 


IOP Inc; L 

Lumenis, Inc.; C,L,P,S 


Andreas K Lauer MD 


Simon K Law MD 

Allergan, Inc.; L,S 

Michael A Lawless MD 


David E Lederer MD 

Optos, Inc.; L 


CredentialProtection; E 

David A Lee MD 


Jimmy K Lee MD 




Inspire Pharmaceuticals Inc; C 


Joo Yong Lee MD 

Allergan; S 

Korean Retina Society; S 

Michael S Lee MD 

Merz Pharmaceuticals; C,S 



Quark Pharmaceutical; S 


Ltd.; S 

Paul P Lee MD JD 

Duke University; E 

GENENTECH; C 

GlaxoSmithKline; O 

Medco; O 


Pfizer, Inc.; C,O 

Quorum Consulting; C 

University of Michigan Medical 

School; E 

Vitaspring Health Technologies; 

O 

Richard K Lee MD 

American Glaucoma Society; S 



Thomas C Lee MD 

Endo Optiks, Inc.; L 

Wendy W Lee MD 



Cutera; S 

Elizabeth Arden; C 

Medcompare; C,O 

Medicis Aesthetics; L 

Reliant Technologies; S 

William Barry Lee MD 




Won Ki Lee MD 

Allergan; L 

Bayer; L 



Martha Motuz Leen MD 


Phuc Lehoang MD PhD 




Santen, Inc.; C,S 

Richard A Lehrer MD 



Yannek I Leiderman MD PhD 


Christopher Kai-shun Leung 

MD MBChB 





Leonard A Levin MD PhD 


Inotek; C 

Merz; C 

Quark; C 

Wisconsin Alumni Research 

Foundation; P 

Elise Levine, MA, CRC, OCS 

Transitions Optical, Inc.; C,L 

Richard A Lewis MD 

Aerie; C 


Xiaoxin Li MD 



Jeffrey M Liebmann MD 




Diopsys Corporation; C,S 



Merz Pharmaceuticals, Inc.; C 


New York Glaucoma Research 

Institute; S 

Optovue, Inc.; C,S 

Quark Pharmaceuticals, Inc.; C 

SOLX, Inc.; S 


Susan L Lightman FRCOphth 

FRCP PhD 



Jennifer Irene Lim MD 

icon bioscience; S, 

Quark; C 



Tock H Lim MBBS FRCSE 




Kristie L Lin MD 

Johnson & Johnson; C 


Shan C Lin MD 


Allergan; C 





341




Richard L Lindstrom MD 

3D Vision Systems; C,O 


AcuFocus, Inc.; C,O 


Bausch & Lomb Surgical; C,P 

BioSyntrx; C,O 

Calhoun Vision Inc; C,O 

Clarity Ophthalmics; C 

Clear Sight ; C,O 

CoDa Therapeutics ; C,O 

Confluence Acquisition 

Partners I, Inc. ; O 

Curveright, LLC; C 

EBV Partners ; C,O 

EGG Basket Ventures ; C,O 

Encore; C,O 

Evision; C,O 

Eyemaginations; C,O 

Foresight Venture Fund; C,O 

Fziomed; C,O 


Healthcare Transaction 

Services ; O 

HEAVEN Fund ; O 

High Performance Optics ; C,O 


Improve Your Vision ; C,O 


LensAR, Inc.; C,O 

LenSX; C 

Life Guard Health; C,O 

Lumineyes,Inc.; C 

Minnesota Eye Consultants; 

C,O 

NuLens, Ltd.; C,O 

Ocular Optics; C,O 



Omega Eye Health; C,O 


Pixel Optics; C,O 

Qwest; C,O,P 

Refractec Inc; C,O 

Revision Optics; O 

SRxA; C 

William Link, PhD 

AcuFocus, Inc.; O 

Glaukos Corporation; O 

Neurotech, Forsight, Neovista,; 

O 

Nexis Vision; O 

Second Sight; O 

WaveTec; O 

Isaac Lipshitz MD 

OptoLight Vision Technology; 

O,P 

Brian C Little MD 


Eyemovies Ltd; P 

James C Loden MD 


iCataract; O,P 


Omerous Corporation; C 

Nils A Loewen MD 

NeoMedix Corporation; L 

Anat Loewenstein MD 


Forsightlabs; C 

Lumenis, Inc.; C,L 

Notal Vision, Ltd.; C, 



Orabio; C 

John I Loewenstein MD 


Infirmary; P 

Stephanie J Loomis 

NIH; S 

Ron K Lord MD 

Cloud Nine Development; O 

Careen Yen Lowder MD PhD 

Allergan; C 

Anthony J Lubniewski MD 

Mid America Transplant 

Services Eye Bank; C 

Jodi I Luchs MD 


Allergan; C,L 


Eyegate Pharma; C 

Inspire Pharmaceuticals, 

Inc.; C,L 

NiCox; C 


Brandon J Lujan MD 



Michael J Lynn 


M 

Mathew W MacCumber MD 

PhD 

ArcticDx; S 




Regeneron; C 

Sequenom; S 


Ian M MacDonald MD 



Susan M MacDonald MD 


Scott M MacRae MD 



Technolas ; C 

Marian Sue Macsai-Kaplan 

MD 




Inspire Pharmaceuticals Inc; L 


Visiogen, Inc.; C 

Ted Maddess PhD 


Naoyuki Maeda MD 



CIBA Vision, a Novartis 

Company; L 




Tomey Corp.; L 

Topcon Corp; S 

Maureen G Maguire PhD 

Inspire Pharmaceuticals Inc; S 


Francis S Mah MD 

Alcon Laboratories, Inc.; C, S 


Shaam Mahasneh 

Society to Prevent Blindness. 

NY, NY; S 

Parag A Majmudar MD 




Ista Pharmacuticals; C,S 

Mobius Therapeutics; C 

Rapid Pathogen Screening; O 

Tear Science; C,S 

Ranjan P Malhotra MD 


Allergan; L 



Andrew Maller MBA 

Allergan; C 

Bruce S Maller 


Robert K Maloney MD 



Calhoun Vision Inc; C,L,O 

Presbia Corp.; C 

STROMA Medical Corporation; 

O 

Boris Malyugin MD PhD 



MST; P 

Nick Mamalis MD 



Allergan; S 

ANew; C,S 



Medennium, Inc.; S 

NuView, Inc; S 

optimedica; C 

powervision; S 

Zaid Mammo, MD 


Edward E Manche MD 

Best Doctors, Inc.; C 


Guidepoint; C 

Ophthonix, Inc.; O 

Seros Medical, LLC; O 

Michiko Mandai 



Efrem D Mandelcorn, MD 

FRCSC 


Steven L Mansberger MD 

MPH 

Allergan; C, L 


Merck ; S 


Sam Edward Mansour MD 

IRIDEX; C,L 


Kaweh Mansouri MD 

Sensimed AG; C 

Anand V Mantravadi MD 

Allergan; L 


John A Marasco 

Marasco & Associates, 

Healthcare Architects & 

Consultants; E,O 

Michael F Marmor MD 

Basilea; C 

Comentis; C,O 

Corcept; C 


Merck; C 

QLT; C 


John Marshall PhD 

Alcon Laboratories, Inc.; C,L,O 

Avedro; C,L,O 

Ellex; L,O,P 

Nexisvision; C,O 

OPKO; C,P 


L 

John Joseph Martin, MD 

medicis; C 

Keith R Martin MD 

Allergan; L 





Ocular Theraputix; C,O 

PowerVision; C 

Zeiss; L 

Mina Massaro-Giordano MD 

Daylan Sciences; O 

Cynthia Mattox MD FACS 

AHRQ; S 



Transcend; S 

Martine Mauget-Faysse MD 



Vincenzo Maurino MRCOPHTH 



Louise A Mawn MD 

NIH; S 


S 

Dennis G McCafferty, COE, 

MBA 

Visual Clinic, LLC; E,O 

Mary Ellen McCann MD 

NIH; S 

Colin A McCannel MD 

GENENTECH; S 

Savvient, Inc.; C,O 

James P McCulley, MD, FACS, 

FRCOPHTH 


Marguerite B McDonald MD 




Bausch and Lomb Pharma; C 

Essilor; C 

FOCUS Laboratories; C 

Inspire Pharmaceuticals Inc; C 


NexisVision; C 

Ocularis Pharma; C 




Charles McGhee, PhD 

FRCOphth FRANZCO 

CoDa Therapeutics; O 

Felipe A Medeiros MD 


Allergan; C,L 


Jodhbir S Mehta, FRCS, 

FRCOPHTH 



UK Network Medical; P 

Robert F Melendez, MD MBA 


Jill S Melicher Larson MD 

Merz Pharm., Investigator, 

Indirect Comp; S 

Samir A Melki MD PhD 

qualsight; C 

Gerrit RJ Melles MD PhD 



Shannath Louise Merbs MD 

PhD 



C 

Marilyn B Mets MD 

Astrazenica; O 



O 


Corporation; O 

Shahzad I Mian, MD 


Marc A Michelson MD 


William F Mieler, MD 



GENENTECH; C 

Eydie G Miller-Ellis MD 




Joan W Miller MD 



Corporation; O 

QLT Phototherapeutics, Inc; P 




Hoya Surgical Optics; S 

Physical Optics Corporation; S 

Neil R Miller MD 


Quark Pharmaceuticals; C 

342 



Donald S Minckler MD 

NeoMedix Corporation; C 

Alireza Mirshahi MD 

Alimera; C 


Corporation; L,S 


Elisabetta Miserocchi MD 

Abbott immunology; C 

Allergan; C 


Paul Mitchell MD PhD 



Bayer Pharmaceuticals; C,L 




Lylas G Mogk MD 

Random House; P 


C 

Virgilio Morales-Canton MD 

oraya therapeutics; C,L 

Kenneth E Morgenstern MD 

MTF; L 

Kazuhiko Mori MD 

Ocular Instruments Inc; P 

Nigel Morlet MBBS 

NH&MRC; S 

OzSonotek; C,O,P 

Sayoko E Moroi MD PhD 

Lippincott; P 


Timothy W Morris 

Bausch Lomb; E 

Christie L Morse MD 

AAPOS EVP; S 

Asa Dan Morton III MD 


Excaliard; C 

Renovo; C 

Andrew A Moshfeghi MD, 

MBA 



Allergan; C 


GENENTECH; C 

Palm Beach Community Trust 

Fund; S 

RAM Corporate Consulting; E 

Realm Global, LLC; O 

RetinaSense, LLC; C,O 

Synergetics, Inc.; C,O 

Thrombogenics, Inc.; C,S 

Darius M Moshfeghi MD 

Convene, LLC; O,P 

Genentech, Inc.; C 

Grand Legend Technology, 

LTD; C,O 

InSitu Therapeutics, Inc.; C,O,P 

MyWhiteCoat; C,O 

OcuBell; C,O 

Oraya Therapeutics, Inc.; C,O 



VersaVision; O,P 

Mark L Moster MD 

Acorda Therapeutics; C 

Biogen Inc; L 

Marlene R Moster MD 




GENENTECH; S 

iScience; L 



Solx; L 

TissueTech, Inc.; S 

Timothy G Murray, MD MBA 


ThromboGenics Inc; C 

David C Musch PhD 


AqueSys, Inc.; C 

ClinReg Consulting Services, 

Inc.; C 

DigiSight Technologies, Inc.; C 


InnFocus, LLC; C 

Ivantis, Inc.; C 


Neurotech USA, Inc.; C 

Oraya Therapeutics, Inc.; C 

Research to Prevent Blindness, 

Inc.; S 

Revision Therapeutics, Inc.; C 

Jonathan S Myers MD 



Aquesys; S 

Aton Pharma Inc.; C 

Diopsys, Inc.; S 


Haag Streit; L 

Inotek; C,S 


Sucampo Pharma Americas 

Inc.; C 

N 

Manish Nagpal MD 



Zoltan Nagy MD 


LenSx Lasers, Inc.; C 

Ramon Naranjo-Tackman MD 


Lensar; L,O 

Ayman Naseri MD 


Miguel L Naveiras Torres- 

Quiroga MD 

Fundaci?n de Investigaci?n 

Oftalmol?gica; S 

Arvind Neelakantan MD 


Allergan; C,L 


Kristiana D Neff MD 


Marcio B Nehemy MD 


Bayer Shering Pharma; C 



Janet M Neigel MD 

Allergan; C,L 

Peter Andreas Netland MD 

PhD 


Solx; S 

Marcelo V Netto MD 

Allergan; C 

Aljoscha S Neubauer MD 

AstraZeneca; C 

ODOS; C 

Anita Nevyas-Wallace MD 

Varitronics, Inc.; O 

Edmund Ng 


John D Ng MD 

Bio-Logic Aqua; C,O 

Jonathon Q Ng MBBS 

Australian National Health and 

Medical Research Council; S 

Australian Research Council; S 

Quan Dong Nguyen MD 

Abbott Pharmaceuticals, Inc.; S 

Bausch & Lomb Surgical; C, 

GENENTECH; S, 

Heidelberg Engineering; S, 

Lux Biosciences, Inc.; S 


Pfizer, Inc.; S, 


Inc.; S, 

Santen, Inc.; C,S 

Quang H Nguyen MD 




Louis D Skip Nichamin, MD 

3D Vision Systems; C,O 




Eyeonics, Inc.; C,O 

Foresight Biotherapeutics; C 


Harvest Precision Components; 

O 

iScience; C,O 

LensAR; C,O 

PowerVision; C,O 

RevitalVision, LLC; C,O 

SensoMotoric Instruments; C 

WaveTec Vision System; C,O 

Marcelo T Nicolela MD 


Allergan; C,L 



Kanwal K Nischal MBBS 

CLARITY INC; L 

Donald R Nixon MD 

Advanced Medical Optics; C,L 




Oculus, Inc.; C,L,P 

Azhar Nizam 

NIH Grant; S 

Robert J Noecker MD, MBA 







Ocular Therapeutics; C 

Paradigm Medical Industries, 

Inc.; L 

Valeant ; C 

Zeiss; S 

Michael L Nordlund MD 




Rudy Nuijts MD 


ASICO; P 


SMI; C,L 

O 

Terrence P O’Brien MD 



AMO/VISX (ABBOTT); C 



Yuichiro Ogura MD PhD 


Bayer Schering Pharma; C 




Masahito Ohji MD 


Allergan; C 






Sanwa Kagaku Kenkyusho; C 

Shionogi; C 

Shinji Ohkubo MD PhD 



Annabelle A Okada MD 

Mitsubishi Tanabe Pharma; L,S 

Novartis Pharma Japan; L 



Pfizer Japan; L 

XOMA; C 

Mildred M G Olivier MD 





Timothy W Olsen MD 

Dobbs Foundation; S 

Emtech Biotechnology Development 

Grant; S 

Georgia Research Alliance; S 

Johnson & Johnson; S 

NIH/NEI; S 

NIH/NIA; S 


S 

Jeffrey L Olson MD 

Shape Memory Alloy Clip; P 

Lindsay Ong-Tone MD 


Silvia D Orengo-Nania MD 



Stephen E Orlin MD 


Michael G Orr MD 


Robert H Osher MD 




Beaver-Visitec International, 

Inc.; C 


Clarity; C 


SMI; C 

Video Journal of Cataract & 

Refrac Surg; O 

Yusuke Oshima MD 






Synergetics, Inc.; C,L 


Yvonne Ou MD 

American Health Assistance 

Foundation; C 

P 

Richard B Packard MD 




Mark Packer MD 


Advanced Vision Science; C 

Allergan; C 

Auris Surgical Robotics; C 


Corinthian Opthalmic; C,O 

GE Healthcare; C 


Ivantis; C 

LensAR; C,O 

mTuitive; C,O 

NewSee; C,O 


Ltd; C 

SurgiView; C,O 

Transcend Medical; C,O 

TrueVision; C,O 

VisionCare; C 

WaveTec; C,O 

Kirk H Packo MD 


Alimera Sciences; C,S 

Allergan; S 

GENENTECH; S 

Lumenis, Inc.; S 

OD-OS, Inc; C,S 


Thrombogenics; L,S 

Vision Care Inc.; C,S 

Timothy P Page MD 


Toni Paladino 

Sequenom; E 




343




Ioannis G Pallikaris MD 

Presby Corp.; C 

Paul F Palmberg MD PhD 


AqueSys; C 

Aurolab (unpaid consultant); C 

Innovia; C 

Rahul T Pandit MD 



Jean-Marie Parel PhD FARVO 

University of Miami; P 

Ki Ho Park MD, PhD 





Kyu-Hyung Park, MD 



Susanna S Park MD PhD 


GENENTECH; S 

Healthnet; C 




Gregory D Parkhurst MD 


Richard K Parrish II MD 

Alimera Sciences, Inc; C 

AqueSys; C,O 



InnFocus, Inc; O 

Innolene LLC; O 


QLT, Inc; C 

Michael J Parshall 

Michael J. Parshall HCC, LLC; 

C,E,O 

Leon G Partamian 

IOSensor, LLC; O,P 

Louis R Pasquale MD 

Allergan; S 

Alzheimer’s Association; S 

Margolis Fund; S 



Anjali K Pathak MD 


Niall Patton MBChB 


Clive O Peckar MD 

iScience; C 

David E Pelayes MD 




Fernando Yaacov Pena MD 

LCIF - Sight First; C 

Fernando M Penha, MD 

Allergan; C 




Jay Stuart Pepose MD PhD 

1-800-Doctors; C,O 


AcuFocus, Inc.; O,S 

Bausch + Lomb; C,S 


Elenza; C,O 

TearLab; C,O 

Shamira Perera MBBS 

Allergan; L 


Victor L Perez MD 



Margaret A Pericak-Vance 

PhD 

Glide Artic Dx; O,P 

Todd W Perkins MD 

Emmes Corporation; C 

Lorah Perlee 

Sequenom, Inc.; E,O 

Arthur C Perry MD 

Integrated Orbital Implants, 

Inc. (IOI); O,P 

Medtronic; C 

Henry D Perry MD 



Julian D Perry MD 


Colleen Peters 

GENENTECH; G 

Genzyme; G 

Medwin Consulting; C 

Pfizer, Inc.; G 

Stephen C Pflugfelder MD 

Allergan; C,S 




Dante Pieramici MD 

Alimera; C 

Allergan; S 


regeneron; S 


Jody R Piltz-Seymour MD 





Matteo Piovella MD 

Aaren Scientific; L 



Inc.; C 


Ocular Therapeutic; L 


Soleko ; L 

David A Plager MD 



Uri Polat PHD 

Ucansi Inc.; E,O 

Philip J Polkinghorne MD 


John S Pollack MD 


Alimera; C 

Clarus Acuity Group; O 

Covalent Medical; O 

Benjamin Potsaid 

Optovue, Inc; P 

Thorlabs, Inc.; E 

Somdutt Prasad MS FRCSEd 

FRCOphth FACS 




Bayer; C 

NeoVista; S 




Thrombogenics Inc; C 

Derek A Preece MBA 

Allergan, Inc.; C,O 

Jonathan L Prenner MD 

GENENTECH; C 

Neovista; C,O 

Ophthotech; C,L,O 

Panoptica; C 

Regeneron; C 

Francis W Price Jr MD 




MORIA; L 


OPHTEC, BV; C,L 

ReVital Vision; O 

TearLab; O 

Marianne O Price, PhD 



Ista Pharmaceuticals; C 

MORIA; L 


OPHTEC; C,L 

ReVital Vision; O 

TearLab; O 

Louis E Probst MD 


TLC Vision; C 

John Pula MD 

Lundbeck, Bayer; L 

Carmen A Puliafito MD MBA 

Humphrey Zeiss; P 

Q 

Mujtaba A Qazi MD 




TearScience; C 

Harry A Quigley MD 


GENENTECH; C 


Ono, Inc.; C 

sensimed; C 

sucampo; C 

Graham E Quinn MD 


Hugo Quiroz-Mercado MD 

Allegro Ophthalmics LLC; O 

R 

Melvin D Rabena MD 

GENENTECH; L,S 

Tanja M Rabsilber MD 


Ltd; L 

Nathan M Radcliffe MD 



Carl Ziess Meditec; C,L 

IRIDEX; C 


Ophthalmic Imaging Systems; 

C,O 

Raheem Rahmathullah, BS 


Michael B Raizman MD 




Avedro; C,O,S 

Bausch Lomb; C,S 

Boston Eye Surgery & Laser 

Center; O 

Eleven Biotherapeutics; C 

EyeGate; C,O,S 


Ocular Therapeutix; C,O,S 

Ophthalmic Consultants- 

Boston; E 


RPS; C 

SAR Code; C 

Rajesh K Rajpal MD 



Allergan, Inc.; C,L,S, 

Avedro; C,L,O,S 


Ista Pharmacuticals; C,L,S 

Harsha BL Rao MD 

Allergan; C 

Christopher J Rapuano MD 


Allergan; C,L 



Rapid Pathogen Screening; O 

Tal Raviv MD 



Lyle Rawlings 

Sequenom Center for Molecular 

Medicine ; E 

Russell W Read MD PhD 

EyeSight Foundation of 

Alabama; S, 

International Retinal Research 

Foundatio; S 


S, 

Franco M Recchia MD 


GENENTECH; L 


Sherman W Reeves MD MPH 


Carl D Regillo MD FACS 


Allergan; C,S 






Second Sight; S 

Dan Z Reinstein MD 

Arcscan Inc, Morrison, 

Colorado; O,P 


Michael X Repka, MD MBA 

American Academy of Ophthalmology; 

S 


Carlos Alberto Restrepo 

Pelaez MD 

Allergan; L 

Kourous Rezaei MD 



BMC; C 

GENENTECH; L,S 

Michael Rhea 

Roche Group; E 

Douglas J Rhee MD 





Jesse Richman MD 

SPARCS; P 

Christopher D Riemann MD 

IRIDEX; L 

MaCor Industries; O,P 

MedOne; C,P 

Robert Ritch MD FACS 

Aeon Astron; C 

iSonic Medical; C 


Ocular Instruments, Inc.; P 


David C Ritterband MD 

Bausch + Lomb; C,S 

Robert P Rivera MD 



Endo Optiks, Inc.; L 

Escalon Medical Corp; L 

STAAR Surgical; C,L,O 

Cynthia Roberts PhD 



Ziemer Ophthalmic Systems 

AG; C,L,P 

Alan L Robin MD 

Aerie Pharmaceuticals; C,O 

Allergan; C,L 




Sucampo; C 

Edward J Rockwood MD 


Francisco J Rodriguez MD 


Allergan; C,L 

Bayer; C,L 



Prin Rojanapongpun, MD 



Pfizer Ophthalmics; L 

Andre Correa de Oliveira 

Romano MD 

Optovue, Inc; C,L 

Mario R Romano 


David S Rootman MD 


344 



Gerald J Roper MD 


Inc.; C 


Linda Rose MD PhD 

GENENTECH; S 

Emanuel S Rosen MD 

Neoptics AG; C 

Richard B Rosen MD 

Allergan; S 

Clarity; C 

GENENTECH; S 



C 

OD-OS; L 

Ophthalmic Technologies, 

Inc.; C 


Topcon Medical Systems; L 

Ron Rosenberg, PA MPH 

Practice Management 

Resource Group; C,O 

Mark I Rosenblatt MD PhD 

Omeros Inc.; C 

Sarentis Ophthalmic; C,O,P,S 

Sarentis Therapeutics; C,O,P,S 

Philip J Rosenfeld MD PhD 

Acucela; C 

Advanced Cell Technology; S 

Alexion; S 

Boehringer Ingelheim; C 

Canon, Inc.; C 


Chengdu Kanghong Biotech; C 

Digisight; O 


Oraya; C 

Sucampo; C 


Steven I Rosenfeld MD FACS 


Modernizing Medicine; C 

Kenneth J Rosenthal MD FACS 








C 

Microsurgical Technologies; C 

OPHTEC, BV; C,L,S 

George O D Rosenwasser MD 

Accutome; C 

Allergan, Inc.; C,L, 

Inspire Pharmaceuticals Inc; L, 

Katena Products, Inc; C 

Konan; C 

Sharppoint/Angiotech; S 


Visioncare, Inc.; L, 

Daniel B Roth MD 

Allergan; C 


QLT Phototherapeutics, Inc; L 

Marie-Benedicte Rougier MD 

Allergan; C 


Biogen Inc; L 

Kemin Food L.C.; C 

Sheri Rowen MD 

ACE VISION GROUP; C,L 





Pascal Rozot MD 


Hoya; C 



Allergan; C 


Peter A D Rubin MD 

Allergan; C 

Porex Surgical, Inc.; P 

Roy Scott Rubinfeld MD 

CurveRight; E,L,O,P 

CXL USA; E,O 

Alan J Ruby MD 

GENENTECH; L 

Marco Ruggeri 

Bioptigen, Inc. ; S 

Amy Rundle, MA 


Edwin Hurlbut Ryan Jr MD 

Alcon Laboratories, Inc.; P 

S 

Alain Saad MD 


Mahipal S Sachdev, MBBS 


Srinivas R Sadda MD 



GENENTECH; C, 



Optovue, Inc.; S 

Regeneron; C 

Topcon Medical Systems; P 

Alfredo A Sadun MD PhD 

Edison Pharmaceutical; S 

Pfizer Ophthalmics; C 

Jose A Sahel MD 

Aventis; C 

Maite Sainz de la Maza MD 


Allergan; L 


Sarwat Salim MD 



Raminder K Saluja MD 

Cynosure; C 


Carolyn Salvato 

BSM Consulting; C,O 

James J Salz MD 


NTK Enterprises, Inc.; C 

Robert Sambursky MD 

Allergan; C 

Foresight Therapeutics; C 

NovaBay Pharmaceuticals; C 

Rapid Pathogen Screening, 

Inc; E,O,P 

John R Samples MD 



Aquasys; C 

Eyegenetix; C 

Ivantis; C 


Optic Nerve Regeneration 

Technologies; C 


Refocus Group, Inc.; C 

Transcend; C,S 

C Michael A Samson MD 

CLS Pharmaceuticals; C,E,O 

Lux Biosciences; C 

PCAsso; O 

Michael A Samuel MD 

Centocor, Inc.; C 

iScience; C 



C 

Thomas W Samuelson MD 


AcuMems; C 



AqueSys; C 



Ivantis; C 



QLT Phototherapeutics, Inc; C,O 



David A Saperstein MD 


C,L,O,P 

Retinagenix, LLC; O,P 

Steven R Sarkisian, MD 





iScience; C,S 

Ivantis; C 

Optous; C 

Transcend; S 

David Sarraf MD 

GENENTECH; S 

James A Savage MD 

Allergan; L 

Steven C Schallhorn MD 


Allergan; C 


Gabor Bernd Scharioth MD 



Ophthalmic, USA; C,L,P 

Oliver Douglas Schein MD 





Adam J Scheiner MD 


Bio-form; L 

Obagi; C 

Sciton; L 

Joyce C Schiffman MS 




Ursula M Schmidt-Erfurth MD 


BayerHealthcare; C,L 



Wolfgang F Schrader MD 





Jeffrey S Schultz MD 



Robert L Schultze MD 



Joel S Schuman MD 




Vindico, Inc.; C 

Carol E Schwartz MD 



Gail F Schwartz MD 


Tissue Banks International; L 

Stephen G Schwartz, MD MBA 

Alimera; C 



IC Labs; P 


Steven D Schwartz MD 




Genentech, Inc.; C,L 

OptiMedica; C,L,O 


Ingrid U Scott MD MPH 


William Scott 

Licensed to ArcticDx; P 

NIH grant support EY12118; S 

Paul Christian Seel MD MBA 

Sophrona Solutions; E,O 

Barry S Seibel MD 

Bausch + Lomb; P 

Calhoun Vision Inc; C,O 

Neuroptics, Inc; C 


Rhein Medical; P 


Theo Seiler MD PhD 

IROC, Inc.; O 

WaveLight AG; C,L 

Robert C Sergott MD 

BioClinica; C 



Lundbeck; C,L 


MerckSerono; C,L 



Paragon Pharmaceuticals; C 

Questcor; C,L 

Roche Diagnostics; C 


United States Department of 

Defense; C 

Luis Serrano 



Gaurav K Shah MD 






iScience; C 

Neovista; C 

Sunil Shah MD 


Allergan, Inc.; P 


CustomVis; O 

Lenstec, Inc.; C 


Ltd; S 


Vinay A Shah MD 

Cloud Nine Development, 

LLC; O 

Neda Shamie MD 



Howard Shapiro PhD 

Genentech, Inc.; E 

Andrew C Shatz MD 


Victoria M Sheffield 


Deborah D Sherman MD 

Allergan; C,L 

Medicis; C,L 

Mark B Sherwood MD 


BioVascular Inc; S 


EyeIC; S 

IOPtima; C 


Optonol; S 

Sensimed; C 

M Bruce Shields MD 

OPKO Health; C 

Hasanain T Shikari, MD 


Kenneth S Shindler MD PhD 

Allergan; L 

Bradford J Shingleton MD 




iScience; C 






345




Yichieh Shiuey MD 

KeraMed, Inc.; E,O,P 

Roni M Shtein MD 


Lesya M Shuba MD 


Allergan; L 


R Michael Siatkowski MD 


Paul A Sidoti MD 


Carla J Siegfried MD 

HDI, Inc.; O 



Shameema Sikder MD 

Allergan; C 

David I Silbert MD 

iScreen; C,S 

Kaneka; C 

Quest Medical, Inc.; C 

Tear Science; C 

Rufino Silva 



THEA international; C 

Michael A Singer MD 



Eli Lilly & Company; S 


Lawrence J Singerman MD 




GENENTECH; S 


Lux Biosciencse; S 

MacTel; S 





Ophthotech; C 

Opko; O 

Kuldev Singh MD MPH 




iScience; C 

Ivantis; C 


Transcend; C 

Rishi P Singh MD 



GENENTECH; C 

Kimberly C Sippel MD 

Ophthotec, Inc.; O 

OptiMedica; O 

Brian D Sippy MD PhD 

Regeneron, Inc.; S 

Arthur J Sit MD 

AcuMEMS; C 


Allergan; C 


Sensimed AG; C 

Stephen G Slade MD FACS 


AMO; C,L 

ForeSight Labs; C 

LenSx; C,O 

RVO; C 

Technolas; C 

Jason S Slakter MD 

Acucela; C,S 


Alimera; S 


Bayer HealthCare; S 

Centocor, Inc.; S 

Corcept; S 

Fovea/SanofiAventis; S 

GENENTECH; S 


KangHong Biotech; S 

Lpath Inc.; C,S 

NeoVista; S 

Novagali; S 

Oraya Therapeutics; C,S 

OxiGene; C,S 


QLT, Inc.; S 

Regeneron Pharmaceuticals; 

L,S 

ReVision; C,S 

Sanofi-Aventis; S 

SKS Ocular, LLC; O 

Allan R Slomovic MD 





Charles B Slonim MD FACS 

Bausch & Lomb Surgical; C, L 

Justine R Smith MD 

Collins Medical Trust; S 


Ronald E Smith MD 


Clarity Vision; O 

Lacrimal gland device; P 

Michael E Snyder MD 


Dr. Schmidt Intraocularlinsen; 

C, 

Haag Streit; L, 

Alfred M Solish MD 




Kerry D Solomon MD 


Advanced Vision Research; 

C,L,S 





Nidek, Inc.; S 


C,O,S 

Barrie D Soloway MD 

Refocus Group, Inc.; C,L 

Joern B Soltau MD 

CVS Caremark; C 

Sriram Sonty MD FACS 


Mark Soper 

CPTS; C 

Indiana Lions Eye Bank; E 

Gisele Soubrane MD PhD 


Chibret International; C 



Luciene B Sousa MD 




George L Spaeth MD FACS 


Allergan; L,S 



Richard F Spaide MD 

GENENTECH; S 

Thombogenics; C 

Topcon Medical Systems; P 

William Eric Sponsel MD 

Ono Pharmaceutical; C 

Clark L Springs MD 




Tear Science; C,L 

Sathish Srinivasan, MBBS 



Ltd; C 

Sunil K Srivastava MD 

Allergan; S 




Erin D Stahl MD 



TrueVision; C 

Peter W Stalmans MD PhD 




Ellex; L 


Thrombogenics; L 

Robert L Stamper MD 


iScience; O,P 

SightSciences Inc; C,O 

Transcend Inc; C 

Walter J Stark MD 

VueCare Media; O 

Giovanni Staurenghi MD 



Bayer; C 

Canon; C 



Ocular Instruments, Inc.; P 

OD-OS; C 


Optovue; S 



Zeiss; S 

David R W Steel MBBS 




Thomas L Steinemann MD 

Bayer Laboratories; C 

Roger F Steinert MD 


OptiMedica; C 

ReVision Optics; C 

Rhein Medical, Inc.; P 

Kenneth David Steinsapir MD 

Kenneth D. Steinsapir, M.D., 

Inc.; P 

P Dee G Stephenson MD FACS 

Aaren Scientific; C 


WaveTec Vision; L 

Ron Sterling 

Abbott ; L 

Julian D Stevens, DO 

Abbot Medical Optics Inc.; C 

Oculentis AG; C 

OptiMedica Inc.; C 

Revision Optics Inc.; C 

Michael C Stiles MD 



iScience; C 




Pavel Stodulka MD PHD 


TPV; L 

Karl G Stonecipher MD 


Alcon; C,L,S 



Endure Medical; L 


LaserACE; C 

Nexis; C,S 

Nidek; C,L,S 

Oasis Medical Inc; C,L 

Refocus Group, Inc.; C,S 


TLC Laser Eye Centers; E 

Michael D Straiko MD 


Erich C Strauss MD 


Lawrence Strenk 

MRI Research, Inc.; E,O 


Susan Strenk 

MRI Research, Inc.; E,O 


Harald Patrik Studer PHD 

Integrated Scientific Services; 

E 

R Doyle Stulting MD PhD 



Allergan; L 

Calhoun Vision Inc; C 

NuLens; C 



C 

Prem S Subramanian MD PhD 

Lundbeck, Inc.; S 


Leejee H Suh MD 

Allergan; C 


Eric Suhler MD 

Abbott Pharmaceuticals; C,S 

Bristol-Myers Squibb; S 

EyeGate; S 

GENENTECH; S 

LUX BIO; C,S 



C Gail Summers, MD 

BioMarin Pharmaceutical 

Inc.; L 

McKesson; C 

NOAH (Natl Org for Albinism & 

Hypopigmen; S 

Jennifer K Sun MD 






Ivan J Suner MD 




Regeneron; L 

Janet S Sunness MD 

Acucela; C 


Cell Cure; C 

GENENTECH; C 


Neurotech; C 



Ophthotech; C 


Potentia; C 

ReVision; C 

Shire; C 

SUCAMPO; C 

David Swink 

Medical Management Associates, 

Inc.; E 

T 

Khalid F Tabbara MD 

ALCON INTERNATIONAL; L 

Jonathan H Talamo MD 




Ikona; C,P 

Nexis Vision; C,O 

Ocular Therapeutics; S 


Wavetec ; C,S 

Audrey R Talley-Rostov MD 

Addition Technology; L 



Gustavo E Tamayo MD 

Abbott Medical Optics; C,L,O,P 

AVEDRO; L 

Cellular Bioengineering; C 

Presbia Corp.; C 

Donald Tan MD FRCS 

FRCOphth 





Network Medical Products; P 


346 



Nikolle WH Tan MBBS 

Bayer; C 



Oxigene; S 

Suphi Taneri MD 


Technolas; L 

Rosa A Tang MD MPH MBA 

Bayer; L 

Eisai; C 

Serono; L 


Ltd.; L 

Angelo P Tanna MD 


Apotex, Inc.; C 


Sandoz, Inc.; C 

Watson Laboratories, Inc.; C 

Jeremiah P Tao MD 


L 

Joseph Tauber MD 



Biolase; C 

Eleven Bio; C 


Shachar Tauber MD 

Alcon Laboratories, Inc.; C,E 



Ocugenics; O 

Hugh R Taylor MD FRANZCO 


Simon RJ Taylor MA PhD 

FHEA FRCOphth 

Allergan; C,L 




Celso Tello MD 



Diopsys Corporation; C 

Stephen C Teoh MBBS FRCS 

National Research Medical 

Council (SGP); S 

Mark A Terry MD 


Bausch & Lomb Surgical; P 

Optovue; O 

Howard H Tessler MD 


Asheesh Tewari MD 


Clement C Y Tham MBBS 

Aeon Astron Corporation; S 





Santen Pharmaceutical Co., 

Ltd.; C,S 

John T Thompson MD 

GENENTECH; S 


Regeneron; S 

Vance Michael Thompson MD 




Avedro; C 


Calhoun Vision Inc; C 

Euclid Systems; C 

Forsight; C 

Wavetec; C 

Jennifer E Thorne MD PhD 

Allergan; C 



S 

Xoma; C 

Richard Tipperman MD 


Humphrey Zeiss; L, 

Marco; C 

Piezo Resonance Innovations 

Incorporated; C, 

Khiun F Tjia MD 


Mustafa I Toker MD 

Zaraccom lenses; C 

Goji Tomita MD 


Ministry of ECST of the Jpn 

Government; S 

MSD; L 



Minoru Tomita MD PhD 


Zimmer; C 

Trexler M Topping MD 

Boston Eye Surgery & Laser 

Center; O 



Insurance Company; E 

Paul E Tornambe MD 



Humphrey Zeiss; C,L 


Cynthia A Toth MD 

Alcon Laboratories, Inc.; P 

Bioptigen, Inc.; S 

Genentech, Inc.; S 


Physical Sciences Incorporated; 

C,S 

Elias I Traboulsi MD 

Oxford Biomedica; C 

Sanofi; C 

Dan B Tran MD 



ReVision Optics Inc.; C,O 

WaveTec Vision Systems, 

Inc.; C,O 

William B Trattler MD 



Aton pharmaceuticals; C 


CXLUSA; C 

EyeGate; C 

Inspire Pharmaceuticals Inc; 

C,L,S 

Ista Pharmacuticals; S 

LensAR; C 


Rapid Pathogen Screenings; S 

Tear Science; C 

Michael T Trese MD 

Focus ROP; C,O 

GENENTECH; C 

Nu-Vue Technologies, Inc.; C,O 

Retinal Solutions LLC; C,O 

Synergetics, Inc.; P 

ThromboGenics Inc.; C,O 

Rupal H Trivedi MBBS MS 

Springer; P 

Linda M Tsai MD 


Linda Tsai MA 

Abbott Medical Optics; E 

David T Tse MD FACS 

Innovia; O,P 

Scheffer C G Tseng MD PhD 

Bio-Tissue, Inc.; C,O,P 


TissueTech, Inc.; E,O,P,S 

Kazuo Tsubota MD 


Allergan; S 


CEPT Company; P 

Functional visual acuity 

meter; P 

Japanese Ministry of Education, 

etc.; S 

Jin; P 

Kissei; S 

Kowa; S 

Nateglinide Memorial Toyoshima 

Research ; S 


Ophtecs; S 

Otsuka Pharmaceuticals; S 


Rainbow Optical; P 

Santen, Inc.; C,L,S 

Suntory; S 

Wakasa Seikatsu Co., Ltd; S 

Akitaka Tsujikawa MD PhD 




Daniel C Tu, MD PhD 


S 

Roger E Turbin MD 

Lundbeck; C,L 


George S Turner MBBS 




Raymond Turner 

Blockade Medical; C,L,O 

Canebreak Medical; C,E,L,O,P 

Covidien; C,L 

Johnson & Johnson; C,L 

Medtronic; C,L 

Microvention; C,L 

Penumbra; C,L 


C,L 

U 

Ira J Udell MD 


Michael W Ulbig MD 

Allergan; L 




Martin Uram MD 

Endo Optiks, Inc.; O 

Harvey S Uy MD 


LensAR; L 

V 

Pravin Vaddavalli MD 

Allergan; L 

Thasarat S Vajaranant MD 

NIH K12HD055892; S 



Chromologic, LLC; S 

PanOptica; C 

Photoswitch therapeutics; S 

Jan C Van Meurs MD 


Ophthalmic, USA; P 

Luk H Vandenberghe Ph.D. 

GenSight Biologics; O 

GlaxoSmithKline; P 

National Eye Institute; L 

ReGenX Biosciences; P 

Jose M Vargas MD 

KeraMed, Inc.; C 

Tekia, Inc.; C 

Devesh K Varma MD 






Rohit Varma MD MPH 


Aquesys; C 




Replenish, Inc.; C,S 

Abhay Raghukant Vasavada 

MBBS FRCS 


Viraj A Vasavada MD 


Clemens Vass Vass MD 


Allergan; C 



Linda Villanueva COT 

Allergan; E 

Paolo Vinciguerra MD 



Albert T Vitale MD 

Aciont Inc.; C 


Steven D. Vold MD 

Aeon; S 



AqueSys; C,S 


Forsight Labs; C,S 


InnFocus; C 

IRIDEX; C,L,P 

iScience; C,L,S 

Ivantis; C,S 


NeoMedix Corporation; C,L,S 

Ocunetics; C,O 

OptiMedica; C 


SOLX; S 

Transcend Medical; C,S 

TrueVision Systems; C,S 

Michael P Vrabec MD 



David T Vroman MD 

Alcon Laboratories, Inc.; C,O 


John Allan Vukich MD 



Carl Zeiss Meditec; C, 


STAAR Surgical; C, 

W 

Maureen Waddle, MBA 

BSM Consulting; C 

David K Wallace MD MPH 

Allergan; C 


S 

R Bruce Wallace, MD 




LensAR; C 

Alexander C Walsh MD 

Envision Diagnostics; E,O,P 

Keith A Walter MD 



Ocular Systems; C,P,S 

Kevin Lee Waltz MD 


AcuFocus, Inc.; O,S 

Allergan; S 


Hoya Surgical Optics; C,L 

Ista Pharmacuticals; S 


Ltd; L 

Tracey Technologies; O 

Nan Wang MD PhD 


Sophia Ying Wang 

NIH/NCRR/OD UCSF-CTSI TL1 

RR024129; S 




347




George O Waring III, MD FACS 

A.R.C. Laser Corporation; C 



AskLasikDocs.com; O 


George O Waring IV MD 

Accelerated Vision; C 


Focal Point, Asia; C 

Gerson Lehrman Group; C 


RevitalVision, LLC; C,L,O 

Topcon Medical Systems; C,L 

Keith A Warren MD 



Ophthalmic, USA; C,L 

Mitchell P Weikert MD 


Zeimer; L 

Robert N Weinreb MD 



Altheos; C 



Humphrey Zeiss; C,L 


National Eye Institute; L,S 




Optovue; C,S 

Othera Pharmaceuticals Inc; C 

Sensimed; C 

Solx; C 

Topcon Medical Systems; C,S 

Robert J Weinstock MD 




Truevision; C,O 

Wavetec; C,O 

John A Wells III MD 

DRCR Network; S 

Eyetech, Inc.; C,L 

GENENTECH; S 

Iconic Therapeutics; S 

LPath Inc; S 



Ophthotech Corporation; S 


Regeneron ; S 

Steba SA; S 

Liliana Werner MD PhD 

Aaren Scientific; S 


Advanced Vision Science; S 


Anew Optics; S 



Innovia; S 

MRI Research; C 

Powervision; C 


Ltd; S 

Visiogen, Inc.; C 

Steve Whitaker, MD 

Omeros Corporation; E,O 

Julia Whiteside, MD MPH 


Jeffrey Whitman MD OCS 




Jess Thomas Whitson MD 

FACS 




Louisa J Wickham MBBS 

NIHR Biomedical Research 

Centre; S 

Peter Wiedemann MD 




GENENTECH; S 




Robert E Wiggins, MD MHA 

Medflow/Allscripts; C 



William F Wiley MD 


Hoya; C 

WaveTec; C,O 

David F Williams MD 

GENENTECH; C 

George A Williams MD 



ForSight; C,O 

Neurotech; C,S 

Nu-Vue Technologies, Inc.; O,P 


Insurance Company; E 



Julia M Williams, BS 

Allergan; E 

M Edward Wilson Jr MD 


Springer book publishers; P 

Steven E Wilson MD 


Edward J Wladis MD 

Lions Eye Foundation; S 

National Rosacea Society; S 

Gadi Wollstein MD 


Amy Wong 

Medical Marketing Enterprises, 

LLC; O 

Doric Wong FRCS(ED) 


Bayer; C 



Keye Luc Wong MD 

GENENTECH; C 

Pamela Wong 

GENENTECH; E 

Randall V Wong MD 

Medical Marketing Enterprises, 

LLC; O 

Tien Yin Wong MBBS 

Allergan Singapore Pte Ltd; C 


Bayer Healthcare Company 

Limited; C 

Bayer Healthcare Pharmaceuticals 

Inc.; C 

Novartis Pharma AG; C 

Yat Hin Ian Wong MBBS 

Bayer; C 

Raymond Woo 

Optimedica; E 

E. Joy Woodke, COE, OCS 

Private Consulting; C 

Bruce Woodley 

Optimedica Inc.; E 

Julie A Woodward MD 

Lutronic; C 

Medicis; L 

Merz; L 

Skin Ceuticals; C 

Kenneth W Wright MD 

Springer Publisher; P 

Titan Surgical; P 

Helen K Wu MD 

Iop inc; L 


Lihteh Wu MD 


Allan E Wulc MD FACS 

Apogee Aesthetic Technologies; 

O 

Medicis; C,L,O 

Y 

Tetsuya Yamamoto MD 


Kowa; C 

Otsuka; C 



Senju; C,L 

Linda Yau 


Elizabeth Yeu MD 

Allergan; C 



Vivian T Yin MD 



Physician Services Inc. Foundation; 

S 

Norihiko Yokoi MD PhD 


House Foods Cooperation; P 

Kissai Pharmaceutical Co. 

Ltd; C 

Kowa Company. Ltd.; P 

Otsuka Pharmaceuticals Co., 

Ltd.; C 

Rhoto Pharmaceutical Co., 

Ltd.; C 

Santen Pharmatheutical Co., 

Ltd.; L,S 

Sonia H Yoo MD 





GENENTECH; S 

Optimedica; C 

SLACK, Incorporated; L 

Transcend; C 

Young Hee Yoon, MD 


Allergan; L,S 

Bayer; L 

Nagahisa Yoshimura MD PhD 

Canon, Inc; S 

Nidek, Inc.; C,S 

Topcon Medical; C,S 

Martha Land Young 

Practice Development Consultant; 

C 

Terri L Young MD 


Z 

David N Zacks MD PhD 


Infirmary; P 

ONL Therapeutics, LLC; O 

University of Michigan; P 

Roberto Zaldivar MD 



Tracey Technologies; C 

Brent Walter Zanke 

ArcticDx; C,O 

Michael E Zegans MD 

LEK consulitng; C 


Jiameng Zhang 

GENENTECH; E 

Kang Zhang MD PhD 

Accucela; C 


NIH; S 

Manfred Zierhut MD 

Abbott Pharmaceutical Co; L 

Allergan; L 


Ingrid E Zimmer-Galler MD 

EyeTel Imaging, Inc.; C 

Harry A Zink MD 


Insurance Company; C,L 

Peter Zloty MD 


Mia Zoric Geber, MD 


Allergan; L 

348 


CME & CE Credit 

CME Mission Statement 

The purpose of the American Academy of Ophthalmology’s Continuing 

Medical Education (CME) program is to present ophthalmologists 

with the highest quality lifelong learning opportunities 

that promote improvement and change in physician practices, 

performance or competence, thus enabling such physicians to 

maintain or improve the competence and professional performance 

needed to provide the best possible eye care for their 

patients. 

The American Medical Association has determined that non– 

U.S. licensed physicians who participate in this CME activity are 

eligible for AMA PRA Category 1 Credits . 

Attendees registered as exhibitors, spouses or guests are not 

eligible to receive CME credit. 

2012 Joint Meeting CME Credit 

The American Academy of Ophthalmology is accredited by the 

Accreditation Council for Continuing Medical Education to provide 

continuing medical education for physicians. 

The American Academy of Ophthalmology designates this live 

activity for a maximum of 33 AMA PRA Category 1 Credits . Physicians 

should claim only the credit commensurate with the extent 

of their participation in the activity. 

Portions of the meeting identified for credit include Joint Meeting 

scientific sessions, instruction courses, Skills Transfer courses, 

Breakfast With the Experts, AAOE Saturday Program, Scientific 

Papers and Posters, the Video Program, and the Jackson Memorial 

Lecture at the Opening Session. 

Portions of the meeting not eligible for credit include, but are 

not limited to, committee meetings, viewing exhibits, attending 

Special Meetings & Events, the AAOE General Session, social 

networking and any affiliate event. 

2012 Joint Meeting Learning 

Objectives 

Upon completion of this activity, participants should be able to: 

• Identify recent advances in the diagnosis and treatment of eye 

diseases. 

• Identify major advances in key areas of cutting-edge research 

and technology in ophthalmology. 

• Incorporate skills and techniques from the hands-on Skills 

Transfer courses into their daily practice. 

• Integrate practice management strategies to address critical 

business and operational tasks in the ophthalmologist’s 

practice. 

• Develop strategies to identify and address their own individual 

professional practice gaps. 

2012 Joint Meeting Target Audience 

This activity has been designed to meet the educational needs of 

ophthalmologists, nurses, ophthalmic technicians and other allied 

health personnel who are engaged in the diagnosis and treatment 

of eye diseases, as well as business managers responsible for 

managing the business aspects of an ophthalmic practice. 

2012 Subspecialty Day CME Credit 




Subspecialty Day Activities for Retina and Refractive 

Surgery: 





Subspecialty Day Activities for Cornea, Glaucoma, 

Oculofacial Plastic Surgery, Pediatric Ophthalmology and 

Uveitis: 





2012 AAOE Coding CME Credit 




Coding Activities for Coding SOS and Coding Camp: 











Scientific Integrity and Disclosure of 

Financial Interest 

The American Academy of Ophthalmology is committed to ensuring 

that all continuing medical education (CME) information is 

based on the application of research findings and the implementation 

of evidence-based medicine. It seeks to promote balance, objectivity 

and absence of commercial bias in its content. All persons 

in a position to control the content of this activity must disclose 

any and all financial interests. The Academy has mechanisms in 

place to resolve all conflicts of interest prior to an educational 

activity being delivered to the learners. 

Attendance Verification for CME 

Reporting 

Before processing your requests for CME credit, the Academy 

must verify your attendance at Subspecialty Day and/or the Joint 

Meeting. In order to be verified for CME or auditing purposes, you 

must either: 

• Register in advance, receive materials in the mail and turn in 

the Final Program and/or Subspecialty Day Syllabus exchange 

voucher(s) onsite; 

• Register in advance and pick up your badge onsite if materials 

did not arrive before you traveled to the meeting; 

• Register onsite; or 

• Use your ExpoCard at the meeting. 

CME Credit Reporting 

Grand Concourse, Level 2.5 and Academy Resource Center, 

Booth 508 

Attendees whose attendance has been verified at the 2012 Joint 

Meeting can claim their CME credit online during the meeting. 

Registrants will receive an e-mail during the meeting with the link 

and instructions on how to claim credit. Onsite, you may report 

credits earned during Subspecialty Day and/or the Joint Meeting 

at the CME Credit Reporting booth. 

Academy Members: 

The CME credit reporting receipt is not a CME transcript. CME 

transcripts that include 2012 Joint Meeting credits entered onsite 

will be available to Academy members on the Academy’s website 

beginning Dec. 3, 2012. 

NOTE: CME credits must be reported by Jan. 16, 2013. After the 2012 

Joint Meeting, credits can be claimed at www.aao.org/cme. 

The Academy transcript cannot list individual course attendance. 

It will list only the overall credits spent in educational activities at 

Subspecialty Day and/or the Joint Meeting. 

Nonmembers: 

The Academy will provide nonmembers with verification of credits 

earned and reported for a single Academy-sponsored CME activity, 

but it does not provide CME credit transcripts. To obtain a printed 

record of your credits, you must report your CME credits onsite at 

the CME Credit Reporting booths. 

Proof of Attendance 

The following types of attendance verification will be available 

during the Joint Meeting and Subspecialty Day for those who 

need it for reimbursement or hospital privileges, or for nonmembers 

who need it to report CME credit: 

• CME credit reporting/proof-of-attendance letters 

• Onsite Registration 

• Instruction Course Verification 

Visit the Academy’s website for detailed CME reporting 

information. 

AAPC Continuing Education Credit 

The American Academy of Professional Coders (AAPC) reviews 

and selects courses towards the maintenance of CPC, CPC-H and 

CPC-P certification. Approved courses are identified in the Joint 

Meeting programs with a C . Granting of prior approval in no way 

constitutes endorsement by the AAPC of the program content or 

the program sponsor. A certificate of completion is included in 

the Coding Camp Workbook for AAPC and JCAHPO attendance 

verification. Visit www.aapc.com for more information. 

NOTE: AAPC credits cannot be claimed on the Academy’s online CME 

system. Retain the proof-of-attendance portion of the course evaluation 

form for reporting purposes. 

NBCOE Continuing Education Credit 

The National Board for the Certification of Ophthalmic Executives 

(NBCOE) reviews the American Academy of Ophthalmic Executives 

(AAOE) Saturday program for COE Category A credit hours. 

Approved courses are identified in the Joint Meeting programs 

by a A . All Category A activities yield a 1:1 credit ratio for hours 

spent to hours earned. Visit www.asoa.org for more information. 

JCAHPO Continuing Education Credit 

The Joint Commission on Allied Health Personnel in Ophthalmology 

(JCAHPO) reviews courses for continuing education credit 

toward certification or recertification in ophthalmic medical 

assisting for COA, COT and COMT levels. Approved courses are 

designated in the Joint Meeting programs by a J and classified as 

either Group A or Group B. Though JCAHPO may award continuing 

education credit for specified courses, JCAHPO does not sponsor 

these or any other review course. A certificate of completion is 

included in the Coding Camp Workbook for AAPC and JCAHPO attendance 

verification. Visit www.jcahpo.org for more information. 

NOTE: JCAHPO credits cannot be claimed on the Academy’s online 

CME system. Credit must be claimed directly with JCAHPO when you 

are ready to recertify. Retain the proof-of-attendance portion of the 

course evaluation form for reporting purposes. 

350

CME Credit Statement 

116th Joint Meeting of the American Academy of Ophthalmology 

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing 

medical education for physicians. 

The American Academy of Ophthalmology designates this live activity for a maximum of 33 AMA PRA Category 1 Credits .Physicians 

should claim only the credit commensurate with the extent of their participation in the activity. 

ID Number 

Full Name 

Address 

I hereby certify that I have participated in Scientific Sessions, Instruction 

Courses, Skills Transfer Courses, Breakfast With the Experts, AAOE Saturday 

Program, Scientific Posters, Papers and/or the Video Program at the 2012 Joint 

Meeting, and that I have earned the indicated number of credits. 

Signature 

Date 

Please fill in the following hours: 


(up to 6 credits may be claimed) 







Ethics Credits 

(Ethics credits may be entered separately; however 

the total number of credits may not exceed 33.) 

Pain Management Credits 

(Pain Management credits may be entered separately; 

however, the toal number of credits may not exceed 33.) 

Total Number of Credits Earned 

Note: CME Credit for Subspecialty Day and the AAOE Coding Camp is 

reported separately. 

Request for CME Credit must be submitted before January 16, 2013. 

You may return your credit statement to the Academy Resource Center (Booth 508) onsite or mail to: 

American Academy of Ophthalmology 

Attn: Meetings/CME 

PO Box 7424 

San Francisco, CA 94120-7424 

After the 2012 Joint Meeting, credits can also be claimed at www.aao.org/cme. 

FOR ACADEMY MEMBERS ONLY: The Academy maintains a cumulative record of all Academy-sponsored category 1 CME credits 

earned by its members for a ten-year period. Transcripts, including Annual Meeting credits entered onsite, will be available on the Academy’s 

website, www.aao.org, beginning December 3, 2012. 

IMPORTANT: This form should be used for reporting AMA PRA Category 1 Credits only. Teaching instruction courses, or delivering a 

scientific paper or poster are not AMA PRA Category 1 Credit activities and should not be included when calculating your total AMA PRA 

Category 1 Credits. Presenters may claim AMA PRA Category 1 Credits through the American Medical Association. Please contact the 

AMA to obtain an application form at www.ama-assn.org. 

The Academy does not keep any records of attendance or provide CME verification for individual courses. Course attendance verification 

can serve as proof of attendance when reporting credits to local agencies. 


351

Future Annual Meeting Dates and Locations 

2013 Annual Meeting & Subspecialty Day 

New Orleans 

November 15 – 19 

2014 Joint Meeting & Subspecialty Day with the European 

Society of Ophthalmology (SOE) 

Chicago 

Oct. 17 – 21 

2015 Annual Meeting & Subspecialty Day 

Las Vegas 

November 14 - 17 

352

The moment you realize that 

we are there when you need us. 

This is the moment we work for. 

// CUSTOMER CARE 

MADE BY CARL ZEISS 

Carl Zeiss Customer Care: Your Partner for Success 

• A deep level of dedication. 

• A track record of continuous improvement. 

• A commitment to the lifetime value of your investment 

through extraordinary service and support. 

Visit us at booth 534. 

Carl Zeiss Meditec, Inc. 800-342-9821 www.meditec.zeiss.com/us/customercare 

COR.4591 © 2012 Carl Zeiss Meditec, Inc. 0912

FINAL PROGRAM - Imo

Create successful ePaper yourself

Delete template?

Save as template?